FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Dominitz, JA
Spiegel, B
AF Dominitz, Jason A.
Spiegel, Brennan
TI On the Quality of Quality Metrics: Rethinking What Defines a Good
Colonoscopy
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Editorial Material
ID ADENOMA DETECTION RATE; SCREENING COLONOSCOPY; COLORECTAL-CANCER;
WITHDRAWAL TIME; INTERVAL CANCER; DETECTION RATES; RISK; INDICATORS;
POLYP
AB The colonoscopy quality assurance movement has focused on a variety of process metrics, including the adenoma detection rate (ADR). However, the ADR only ascertains whether or not at least one adenoma is identified. Supplemental measures that quantify all neoplasia have been proposed. In this issue of the American Journal of Gastroenterology, Aniwan and colleagues performed tandem screening colonoscopies to determine the adenoma miss rate among high-ADR endoscopists. This permitted validation of supplemental colonoscopy quality metrics. This study highlights potential limitations of ADR and the need for further refinement of colonoscopy quality metrics, although logistic challenges abound.
C1 [Dominitz, Jason A.] Univ Washington, VA Puget Sound Hlth Care Syst, Sch Med, Seattle, WA 98195 USA.
[Spiegel, Brennan] Cedars Sinai Hlth Syst, CS CORE, Dept Hlth Serv Res, Los Angeles, CA USA.
RP Dominitz, JA (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way 111 Gastro, Seattle, WA 98108 USA.
EM jason.dominitz@va.gov
NR 18
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD MAY
PY 2016
VL 111
IS 5
BP 730
EP 732
DI 10.1038/ajg.2016.103
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DO2BH
UT WOS:000377584000027
PM 27151122
ER
PT J
AU Shields, RK
Clancy, CJ
Press, EG
Nguyen, MH
AF Shields, Ryan K.
Clancy, Cornelius J.
Press, Ellen G.
Nguyen, M. Hong
TI Aminoglycosides for Treatment of Bacteremia Due to Carbapenem-Resistant
Klebsiella pneumoniae
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID SEQUENCE TYPE 258; COMBINATION THERAPY; GENTAMICIN THERAPY; PEAK
CONCENTRATION; INFECTIONS; COLISTIN; MORTALITY; DORIPENEM; STRAINS;
TRACT
AB Aminoglycoside treatment of carbapenem-resistant (CR) Klebsiella pneumoniae bacteremia was associated with a 70% rate (23/33) of 30-day survival. Successful treatment was associated with sources of bacteremia amenable to reliable aminoglycoside pharmacokinetics (P = 0.037), acute physiology and chronic health evaluation II (APACHE II) scores of <20 (P = 0.16), and nonfatal underlying diseases (P = 0.015). Success rates were 78% and 100% if >= 2 and all 3 factors were present, respectively. Clinicians may consider the use of aminoglycosides against CR K. pneumoniae bacteremia if strains are susceptible and the sources of infection are amenable to reliable pharmacokinetics.
C1 [Shields, Ryan K.; Clancy, Cornelius J.; Press, Ellen G.; Nguyen, M. Hong] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
[Shields, Ryan K.; Clancy, Cornelius J.; Nguyen, M. Hong] Univ Pittsburgh, Med Ctr, XDR Pathogen Lab, Pittsburgh, PA USA.
[Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Clancy, CJ (reprint author), Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.; Clancy, CJ (reprint author), Univ Pittsburgh, Med Ctr, XDR Pathogen Lab, Pittsburgh, PA USA.; Clancy, CJ (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
EM cjc76@pitt.edu
FU HHS \ NIH \ National Institute of Allergy and Infectious Diseases
(NIAID) [K08AI114883, R21AI111037]
FX This work, including the efforts of Ryan K. Shields, was funded by HHS
vertical bar NIH vertical bar National Institute of Allergy and
Infectious Diseases (NIAID) (K08AI114883). This work, including the
efforts of Cornelius J. Clancy, was funded by HHS vertical bar NIH
vertical bar National Institute of Allergy and Infectious Diseases
(NIAID) (R21AI111037).
NR 34
TC 2
Z9 2
U1 2
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD MAY
PY 2016
VL 60
IS 5
BP 3187
EP 3192
DI 10.1128/AAC.02638-15
PG 6
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA DN4NX
UT WOS:000377045600078
PM 26926642
ER
PT J
AU Buehrle, DJ
Shields, RK
Chen, L
Hao, B
Press, EG
Alkrouk, A
Potoski, BA
Kreiswirth, BN
Clancy, CJ
Nguyen, MH
AF Buehrle, Deanna J.
Shields, Ryan K.
Chen, Liang
Hao, Binghua
Press, Ellen G.
Alkrouk, Ammar
Potoski, Brian A.
Kreiswirth, Barry N.
Clancy, Cornelius J.
Nguyen, M. Hong
TI Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and
Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas
aeruginosa Isolates
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID BETA-LACTAM RESISTANCE; BLOOD-STREAM INFECTIONS; GRAM-NEGATIVE
ORGANISMS; US MEDICAL-CENTERS; CARBAPENEM RESISTANCE;
KLEBSIELLA-PNEUMONIAE; MEDITERRANEAN COUNTRIES; CXA-101 FR264205;
MECHANISMS; ENTEROBACTERIACEAE
AB We compared ceftazidime-avibactam, ceftolozane-tazobactam, ceftazidime, cefepime, and piperacillin-tazobactam MICs for 38 meropenem-resistant Pseudomonas aeruginosa isolates. No isolates harbored carbapenemases; 74% were oprD mutants. Ceftazidime-avibactam and ceftolozane-tazobactam were active against 92% of the isolates, including 80% that were resistant to all three beta-lactams. Forty-three percent of ceftazidime-avibactam-susceptible isolates and 6% of ceftolozane-tazobactam-susceptible isolates exhibited MICs at the respective breakpoints. Ceftolozane-tazobactam and ceftazidime-avibactam are therapeutic options for meropenem-resistant P. aeruginosa infections that should be used judiciously to preserve activity.
C1 [Buehrle, Deanna J.; Potoski, Brian A.] Univ Pittsburgh, Dept Pharm & Therapeut, Pittsburgh, PA USA.
[Shields, Ryan K.; Press, Ellen G.; Alkrouk, Ammar; Clancy, Cornelius J.; Nguyen, M. Hong] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
[Shields, Ryan K.; Hao, Binghua; Clancy, Cornelius J.; Nguyen, M. Hong] Univ Pittsburgh, Med Ctr, XDR Pathogen Lab, Pittsburgh, PA USA.
[Chen, Liang] Rutgers State Univ, Sch Med, Newark, NJ 07102 USA.
[Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Clancy, CJ (reprint author), Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.; Clancy, CJ (reprint author), Univ Pittsburgh, Med Ctr, XDR Pathogen Lab, Pittsburgh, PA USA.; Clancy, CJ (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
EM cjc76@pitt.edu
FU HHS \ National Institutes of Health (NIH) [K08AI114883]; NIH
[R21AI222037]
FX This work, including the efforts of Ryan K Shields, was funded by HHS
vertical bar National Institutes of Health (NIH) (K08AI114883). This
work, including the efforts of Cornelius J. Clancy, was funded by NIH
(R21AI222037).
NR 25
TC 6
Z9 6
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD MAY
PY 2016
VL 60
IS 5
BP 3227
EP 3231
DI 10.1128/AAC.02969-15
PG 5
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA DN4NX
UT WOS:000377045600088
PM 26976862
ER
PT J
AU Moyer, CE
Erickson, SL
Fish, KN
Thiels, E
Penzes, P
Sweet, RA
AF Moyer, Caitlin E.
Erickson, Susan L.
Fish, Kenneth N.
Thiels, Edda
Penzes, Peter
Sweet, Robert A.
TI Developmental Trajectories of Auditory Cortex Synaptic Structures and
Gap-Prepulse Inhibition of Acoustic Startle Between Early Adolescence
and Young Adulthood in Mice
SO CEREBRAL CORTEX
LA English
DT Article
DE dendritic spines; GAD65; kalirin; spinophilin; VGluT1
ID DENDRITIC SPINE DENSITY; GLUTAMIC-ACID DECARBOXYLASE; MONKEY PREFRONTAL
CORTEX; VISUAL-CORTEX; CEREBRAL-CORTEX; POSTNATAL-DEVELOPMENT;
SOMATOSENSORY CORTEX; HEARING-LOSS; HOMEOSTATIC PLASTICITY; EXCITATORY
SYNAPSES
AB Cortical excitatory and inhibitory synapses are disrupted in schizophrenia, the symptoms of which often emerge during adolescence, when cortical excitatory synapses undergo pruning. In auditory cortex, a brain region implicated in schizophrenia, little is known about the development of excitatory and inhibitory synapses between early adolescence and young adulthood, and how these changes impact auditory cortex function. We used immunohistochemistry and quantitative fluorescence microscopy to quantify dendritic spines and GAD65-expressing inhibitory boutons in auditory cortex of early adolescent, late adolescent, and young adult mice. Numbers of spines decreased between early adolescence and young adulthood, during which time responses increased in an auditory cortex-dependent sensory task, silent gap-prepulse inhibition of the acoustic startle reflex (gap-PPI). Within-bouton GAD65 protein and GAD65-expressing bouton numbers decreased between late adolescence and young adulthood, a delay in onset relative to spine and gap-PPI changes. In mice lacking the spine protein kalirin, there were no significant changes in spine number, within-bouton GAD65 protein, or gap-PPI between adolescence and young adulthood. These results illustrate developmental changes in auditory cortex spines, inhibitory boutons, and auditory cortex function between adolescence and young adulthood, and provide insights into how disrupted adolescent neurodevelopment could contribute to auditory cortex synapse pathology and auditory impairments.
C1 [Moyer, Caitlin E.; Fish, Kenneth N.; Thiels, Edda; Sweet, Robert A.] Univ Pittsburgh, Sch Med, Ctr Neurosci, Pittsburgh, PA USA.
[Moyer, Caitlin E.; Erickson, Susan L.; Fish, Kenneth N.; Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Psychiat, Translat Neurosci Program, Pittsburgh, PA USA.
[Thiels, Edda] Univ Pittsburgh, Sch Med, Dept Neurobiol, Pittsburgh, PA USA.
[Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA.
[Penzes, Peter] Northwestern Univ, Feinberg Sch Med, Dept Physiol, Chicago, IL 60611 USA.
[Penzes, Peter] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA.
[Sweet, Robert A.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA.
RP Sweet, RA (reprint author), Biomed Sci Tower,Rm W-1645,3811 OHara St, Pittsburgh, PA 15213 USA.; Sweet, RA (reprint author), Biomed Sci Tower,Rm W-1645,Lothrop & Terrace St, Pittsburgh, PA 15213 USA.
EM sweetra@upmc.edu
RI Penzes, Peter/L-3987-2016
OI Penzes, Peter/0000-0001-5449-1640
FU National Institute of Health [MH 096985, DA 027679, MH 071316, MH
097216, MH 071533]
FX This work was supported by the National Institute of Health (MH 096985
to K.N.F., DA 027679 to E.T., MH 071316 and MH 097216 to P.P., and MH
071533 to R.A.S.).
NR 81
TC 1
Z9 1
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1047-3211
EI 1460-2199
J9 CEREB CORTEX
JI Cereb. Cortex
PD MAY
PY 2016
VL 26
IS 5
BP 2115
EP 2126
DI 10.1093/cercor/bhv040
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA DO0LD
UT WOS:000377469500023
PM 25759333
ER
PT J
AU Rocco, BR
Sweet, RA
Lewis, DA
Fish, KN
AF Rocco, Brad R.
Sweet, Robert A.
Lewis, David A.
Fish, Kenneth N.
TI GABA-Synthesizing Enzymes in Calbindin and Calretinin Neurons in Monkey
Prefrontal Cortex
SO CEREBRAL CORTEX
LA English
DT Article
DE GAD65; GAD67; glutamic acid decarboxylase; somatostatin; vasoactive
intestinal peptide
ID GLUTAMIC-ACID DECARBOXYLASE; IMMUNOREACTIVE AXON TERMINALS; LOCAL
CIRCUIT NEURONS; GENE-EXPRESSION; CEREBRAL-CORTEX; GABAERGIC NEURONS;
MONOCLONAL-ANTIBODIES; CORTICAL INTERNEURONS; DENDRITIC INHIBITION;
MICROARRAY ANALYSIS
AB Non-overlapping groups of cortical gamma-aminobutyric acid-releasing (GABAergic) neurons are identifiable by the presence of calbindin (CB), calretinin (CR), or parvalbumin (PV). Boutons from PV neuron subtypes are also distinguishable by differences in protein levels of the GABA-synthesizing enzymes GAD65 and GAD67. Multilabel fluorescence microscopy was used to determine if this diversity extends to boutons of CB and CR neurons in monkey prefrontal cortex. CB and CR neurons gave rise to 3 subpopulations of GAD-containing boutons: GAD65+, GAD67+, and GAD65/GAD67+. Somatostatin and vasoactive intestinal peptide-expressing neurons, subtypes of CB and CR neurons, respectively, also gave rise to these distinct bouton subpopulations. At the transcript level, CB and CR neurons contained mRNA encoding GAD67-only or both GADS. Thus, the distinct subpopulations of CB/GAD+ and CR/GAD+ boutons arise from 2 unique subtypes of CB and CR neurons. The different CB and CR GAD-expressing neurons targeted the same projection neurons and neuronal structures immunoreactive for PV, CR, or CB. These findings suggest that GABA synthesis from CB/GAD67+ and CR/GAD67+ neurons would presumably be more vulnerable to disease-associated deficits in GAD67 expression, such as in schizophrenia, than neurons that also contain GAD65.
C1 [Rocco, Brad R.; Sweet, Robert A.; Lewis, David A.; Fish, Kenneth N.] Univ Pittsburgh, Sch Med, Dept Psychiat, Biomed Sci Tower,Room W1651, Pittsburgh, PA 15213 USA.
[Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Neurol, Biomed Sci Tower,Room W1651, Pittsburgh, PA 15213 USA.
[Lewis, David A.] Univ Pittsburgh, Sch Med, Dept Neurosci, Biomed Sci Tower,Room W1651, Pittsburgh, PA 15213 USA.
[Sweet, Robert A.] VA Pittsburgh Healthcare Syst, Educ & Clin Ctr MIRECC, VISN Mental Illness Res 4, Pittsburgh, PA 15213 USA.
RP Fish, KN (reprint author), Univ Pittsburgh, Sch Med, Dept Psychiat, Biomed Sci Tower,Room W1651, Pittsburgh, PA 15213 USA.; Fish, KN (reprint author), Univ Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat, Biomed Sci Tower,Room W1651, Pittsburgh, PA USA.
EM fishkn@upmc.edu
OI Lewis, David/0000-0002-3225-6778
FU NSF [DGE-0549352]; NIMH [MH071533, MH051234, MH096985]
FX This work was supported by the NSF (DGE-0549352 to B.R.R.) and NIMH
(MH071533 to R.A.S.; MH051234 to D.A.L.; MH096985 to K.N.F.).
NR 67
TC 2
Z9 2
U1 1
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1047-3211
EI 1460-2199
J9 CEREB CORTEX
JI Cereb. Cortex
PD MAY
PY 2016
VL 26
IS 5
BP 2191
EP 2204
DI 10.1093/cercor/bhv051
PG 14
WC Neurosciences
SC Neurosciences & Neurology
GA DO0LD
UT WOS:000377469500029
PM 25824535
ER
PT J
AU Gilley, RP
Gonzalez-Juarbe, N
Shenoy, AT
Reyes, LF
Dube, PH
Restrepo, MI
Orihuela, CJ
AF Gilley, Ryan P.
Gonzalez-Juarbe, Norberto
Shenoy, Anukul T.
Reyes, Luis F.
Dube, Peter H.
Restrepo, Marcos I.
Orihuela, Carlos J.
TI Infiltrated Macrophages Die of Pneumolysin-Mediated Necroptosis
following Pneumococcal Myocardial Invasion
SO INFECTION AND IMMUNITY
LA English
DT Article
ID MIXED LINEAGE KINASE; STREPTOCOCCUS-PNEUMONIAE; INFLAMMATORY RESPONSE;
CARDIOVASCULAR EVENTS; GENOME SEQUENCE; DOMAIN-LIKE; MORTALITY;
NECROSIS; ASSOCIATION; RECEPTOR
AB Streptococcus pneumoniae (the pneumococcus) is capable of invading the heart. Herein we observed that pneumococcal invasion of the myocardium occurred soon after development of bacteremia and was continuous thereafter. Using immunofluorescence microscopy (IFM), we observed that S. pneumoniae replication within the heart preceded visual signs of tissue damage in cardiac tissue sections stained with hematoxylin and eosin. Different S. pneumoniae strains caused distinct cardiac pathologies: strain TIGR4, a serotype 4 isolate, caused discrete pneumococcus-filled microscopic lesions (microlesions), whereas strain D39, a serotype 2 isolate, was, in most instances, detectable only using IFM and was associated with foci of cardiomyocyte hydropic degeneration and immune cell infiltration. Both strains efficiently invaded the myocardium, but cardiac damage was entirely dependent on the pore-forming toxin pneumolysin only for D39. Early microlesions caused by TIGR4 and microlesions formed by a TIGR4 pneumolysin-deficient mutant were infiltrated with CD11b(+) and Ly6G-positive neutrophils and CD11b(+) and F4/80positive (F4/80(+)) macrophages. We subsequently demonstrated that macrophages in TIGR4-infected hearts died as a result of pneumolysin-induced necroptosis. The effector of necroptosis, phosphorylated mixed-lineage kinase domain-like protein (MLKL), was detected in CD11b(+) and F4/80(+) cells associated with microlesions. Likewise, treatment of infected mice and THP-1 macrophages in vitro with the receptor-interacting protein 1 kinase (RIP1) inhibitor necrostatin-5 promoted the formation of purulent microlesions and blocked cell death, respectively. We conclude that pneumococci that have invaded the myocardium are an important cause of cardiac damage, pneumolysin contributes to cardiac damage in a bacterial strain-specific manner, and pneumolysin kills infiltrated macrophages via necroptosis, which alters the immune response.
C1 [Gilley, Ryan P.; Gonzalez-Juarbe, Norberto; Shenoy, Anukul T.; Reyes, Luis F.; Dube, Peter H.; Orihuela, Carlos J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA.
[Gonzalez-Juarbe, Norberto; Shenoy, Anukul T.; Orihuela, Carlos J.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA.
[Reyes, Luis F.; Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm Dis & Crit Care Med, San Antonio, TX 78229 USA.
[Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, Div Pulm Dis & Crit Care Med, San Antonio, TX USA.
RP Orihuela, CJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA.; Orihuela, CJ (reprint author), Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA.
EM corihuel@uab.edu
FU HHS \ National Institutes of Health (NIH) [R01AI114800]; American Heart
Association (AHA) [13IRG14560023]
FX This work, including the efforts of Carlos J Orihuela, was funded by HHS
vertical bar National Institutes of Health (NIH) (R01AI114800). This
work, including the efforts of Carlos J Orihuela, was funded by American
Heart Association (AHA) (13IRG14560023).
NR 45
TC 2
Z9 3
U1 3
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
EI 1098-5522
J9 INFECT IMMUN
JI Infect. Immun.
PD MAY
PY 2016
VL 84
IS 5
BP 1457
EP 1469
DI 10.1128/IAI.00007-16
PG 13
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DN5KT
UT WOS:000377106600020
PM 26930705
ER
PT J
AU Fouad, NA
Ghosh, A
Chang, WH
Figueiredo, C
Bachhuber, T
AF Fouad, Nadya A.
Ghosh, Arpita
Chang, Wen-hsin
Figueiredo, Catia
Bachhuber, Thomas
TI Career Exploration Among College Students
SO JOURNAL OF COLLEGE STUDENT DEVELOPMENT
LA English
DT Article
ID PSYCHOMETRIC PROPERTIES; CONSTRUCTION
C1 [Fouad, Nadya A.] Univ Wisconsin, Educ Psychol, Milwaukee, WI 53201 USA.
[Ghosh, Arpita] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Womens Hlth, Madison, WI USA.
[Ghosh, Arpita] Univ Wisconsin, Ctr Womens Hlth Res, Madison, WI USA.
[Chang, Wen-hsin; Figueiredo, Catia] Univ Wisconsin, Counseling Psychol, Milwaukee, WI 53201 USA.
[Bachhuber, Thomas] Univ Wisconsin, Career Dev Ctr, Milwaukee, WI 53201 USA.
RP Fouad, NA (reprint author), Univ Wisconsin, Educ Psychol, Milwaukee, WI 53201 USA.
FU Advanced Fellowship in Women's Health at the William S. Middleton
Memorial Veterans Hospital, Madison, WI
FX Research supported by the Advanced Fellowship in Women's Health at the
William S. Middleton Memorial Veterans Hospital, Madison, WI. The
contents do not represent the views of the U.S. Department of Veterans
Affairs or the United States Government.
NR 18
TC 0
Z9 0
U1 3
U2 10
PU JOHNS HOPKINS UNIV PRESS
PI BALTIMORE
PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD
21218-4363 USA
SN 0897-5264
EI 1543-3382
J9 J COLL STUDENT DEV
JI J. Coll. Stud. Dev.
PD MAY
PY 2016
VL 57
IS 4
BP 460
EP 464
PG 5
WC Education & Educational Research; Psychology, Applied
SC Education & Educational Research; Psychology
GA DN9TB
UT WOS:000377422500008
ER
PT J
AU Matlock, DD
Yamashita, TE
Min, SJ
Smith, AK
Kelley, AS
Fischer, SM
AF Matlock, Daniel D.
Yamashita, Traci E.
Min, Sung-Joon
Smith, Alexander K.
Kelley, Amy S.
Fischer, Stacy M.
TI How US Doctors Die: A Cohort Study of Healthcare Use at the End of Life
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE end of life; hospice; physicians; Medicare
ID TREATMENT INTENSITY; CANCER CARE; PHYSICIANS; PREFERENCES; GROWTH;
TRENDS; COSTS
AB ObjectivesTo compare healthcare use in the last months of life between physicians and nonphysicians in the United States.
DesignA retrospective observational cohort study.
SettingUnited States.
ParticipantsFee-for-service Medicare beneficiaries: decedent physicians (n = 9,947) and a random sample of Medicare decedents (n = 192,006).
MeasurementsMedicare Part A claims data from 2008 to 2010 were used to measure days in the hospital and proportion using hospice in the last 6 months of life as primary outcome measures adjusted for sociodemographic characteristics and regional variations in health care.
ResultsInpatient hospital use in the last 6 months of life was no different between physicians and nonphysicians, although more physicians used hospice and for longer (using the hospital: odds ratio (OR) = 0.98, 95% confidence interval (CI) = 0.93-1.04; hospital days: mean difference 0.26, P = .14); dying in the hospital: OR = 0.99, 95% CI = 0.95-1.04; intensive care unit (ICU) or critical care unit (CCU) days: mean difference 0.35 more days for physicians, P < .001); using hospice: OR = 1.23, 95% CI = 1.18-1.29; number of days in hospice: mean difference 2.06, P < .001).
ConclusionThis retrospective, observational study is subject to unmeasured confounders and variation in coding practices, but it provides preliminary evidence of actual use. U.S. physicians were more likely to use hospice and ICU- or CCU-level care. Hospitalization rates were similar.
C1 [Matlock, Daniel D.] Univ Colorado, Div Geriatr, Sch Med, Acad Off 1,12631 E 17th Ave Campus Box B-179, Aurora, CO 80045 USA.
[Yamashita, Traci E.] Univ Colorado, Undergrad Med Educ, Sch Med, Aurora, CO 80045 USA.
[Min, Sung-Joon] Univ Colorado, Div Hlth Care Policy & Res, Sch Med, Aurora, CO 80045 USA.
[Smith, Alexander K.] Univ Calif San Francisco, Div Geriatr, Dept Med, San Francisco, CA 94143 USA.
[Kelley, Amy S.] Icahn Sch Med Mt Sinai, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA.
[Kelley, Amy S.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA.
[Fischer, Stacy M.] Univ Colorado, Div Gen Internal Med, Sch Med, Aurora, CO 80045 USA.
RP Matlock, DD (reprint author), Univ Colorado, Div Geriatr, Sch Med, Acad Off 1,12631 E 17th Ave Campus Box B-179, Aurora, CO 80045 USA.
EM daniel.matlock@ucdenver.edu
FU Department of Medicine at the University of Colorado; National Institute
on Aging [K23AG040696, K23AG028957, K23AG040772, K23AG040774]; American
Federation for Aging Research
FX This project was supported by the Department of Medicine at the
University of Colorado. Drs. Matlock (K23AG040696), Fischer
(K23AG028957), Smith (K23AG040772), and Kelley (K23AG040774) were all
supported by the National Institute on Aging and the American Federation
for Aging Research.
NR 28
TC 0
Z9 0
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
IS 5
BP 1061
EP 1067
DI 10.1111/jgs.14112
PG 7
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DO1FD
UT WOS:000377523000016
PM 27195936
ER
PT J
AU Rajagopalan, S
Yoshikawa, TT
AF Rajagopalan, Shobita
Yoshikawa, Thomas T.
TI Norovirus Infections in Long-Term Care Facilities
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE norovirus; aging; long-term care
ID UNITED-STATES; ACUTE GASTROENTERITIS; HEALTH-CARE; EXCESS MORTALITY;
RT-PCR; OUTBREAKS; CONTAMINATION; PREVENTION; GUIDELINE; DIAGNOSIS
AB Noroviruses have emerged as one of the leading causes of viral gastroenteritis worldwide, affecting community-dwelling and institutionalized older adults. Recent global epidemics present a growing challenge to the healthcare system and to long-term care facilities. Noroviruses spread readily and rapidly through multiple routes (e.g., person-to-person contact, contact with contaminated surfaces, airborne dissemination of vomitus) and thus are able to sustain an epidemic efficiently and successfully. Although norovirus gastroenteritis is a short self-limited illness in healthy immunocompetent individuals, it can result in significant morbidity and mortality in vulnerable compromised persons such as frail elderly persons and older residents of nursing homes. Diagnosis is made by clinical assessment and confirmed primarily by stool evaluation using polymerase chain reaction. Treatment is confined to supportive measures. Public health prevention and control strategies provide guidance regarding surveillance and the necessary steps to curb the clinical effect and spread of norovirus infections in various settings, including long-term care.
C1 [Rajagopalan, Shobita] Dept Publ Hlth, Los Angeles, CA USA.
[Rajagopalan, Shobita] Charles R Drew Univ Med & Sci, 1621 E 120th St, Los Angeles, CA 90059 USA.
[Yoshikawa, Thomas T.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Vet Affairs, Los Angeles, CA USA.
[Yoshikawa, Thomas T.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Rajagopalan, S (reprint author), 123 W Manchester Blvd,Suite 220C, Inglewood, CA 90301 USA.
EM srajagopalan@ph.lacounty.gov
NR 43
TC 1
Z9 1
U1 5
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
IS 5
BP 1097
EP 1103
DI 10.1111/jgs.14085
PG 7
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DO1FD
UT WOS:000377523000022
PM 27225361
ER
PT J
AU Boockvar, KS
Teresi, JA
Inouye, SK
AF Boockvar, Kenneth S.
Teresi, Jeanne A.
Inouye, Sharon K.
TI Preliminary Data: An Adapted Hospital Elder Life Program to Prevent
Delirium and Reduce Complications of Acute Illness in Long-Term Care
Delivered by Certified Nursing Assistants
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE nursing homes; delirium; nosocomial infection; intervention
ID MULTICOMPONENT INTERVENTION; HOME RESIDENTS; INDIVIDUALS; CONFUSION;
SEVERITY; SYMPTOMS
AB Nursing home (NH) residents have a high prevalence of delirium risk factors, experience two to four acute medical conditions (e.g., infections) each year, and have an incidence of delirium during these conditions similar to that of hospitalized older adults. Many NH residents with delirium do not return to their prior level of cognitive function. They are more likely to die, be hospitalized, and less likely to be discharged home than those without delirium. Research on the prevention or treatment of delirium in NHs is limited. This article describes the development and pilot testing of a multicomponent delirium prevention intervention in the NH setting adapted from the Hospital Elder Life Program (HELP-LTC). Activities to reduce the risk of delirium that were appropriate for functionally impaired NH residents were developed and delivered during treatment for and recovery from acute illness, a novel resident-targeting approach. Expertly trained certified nursing assistants (CNAs a total of 1.4 full-time equivalent (FTE) positions) visited residents throughout the facility and delivered the activities. The current study reports on incident delirium, delirium remission, cognitive and physical function change, hospitalization, and death associated with acute medical conditions as ascertained by a program coordinator. The integration and acceptance of the CNAs' activities by residents and staff are also reported on. Hospitalization and death were ascertained in a nonintervention comparison group. Findings support a test of the intervention in a controlled trial. The potential effect is great; there are approximately 1.4 million NH residents in the United States and an estimated 1 million with dementia or cognitive impairment, an important delirium risk factor. An intervention would be broadly adoptable if a reduction in healthcare costs through prevention of hospitalization offset the cost of the program's CNAs.
C1 [Boockvar, Kenneth S.] New Jewish Home, New York, NY USA.
[Boockvar, Kenneth S.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
[Boockvar, Kenneth S.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
[Teresi, Jeanne A.] Hebrew Home Riverdale, Div Res, Bronx, NY USA.
[Teresi, Jeanne A.] Columbia Univ, New York State Psychiat Inst, Stroud Ctr, New York, NY USA.
[Teresi, Jeanne A.] Weill Cornell Div Geriatr & Palliat Care, New York, NY USA.
[Inouye, Sharon K.] Hebrew SeniorLife, Aging Brain Ctr, Boston, MA USA.
[Inouye, Sharon K.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02115 USA.
RP Boockvar, KS (reprint author), Jewish Home Lifecare, 120 West 106th St, New York, NY 10025 USA.
EM kenneth.boockvar@mssm.edu
OI Boockvar, Kenneth/0000-0003-1165-5558
FU Fan Fox and Leslie R. Samuels Foundation; National Institute on Aging
[P30 AG028741, K07AG041835]; Jewish Home Lifecare Parkinson's Research
Fund; HELP; Greenwall Foundation
FX Financial support for the study was provided by the Fan Fox and Leslie
R. Samuels Foundation, the National Institute on Aging (P30 AG028741;
K07AG041835), the Jewish Home Lifecare Parkinson's Research Fund, and
HELP. Dr. Boockvar is supported by the Greenwall Foundation. Dr. Inouye
holds the Milton and Shirley F. Levy Family Chair. This work was
supported with resources and the use of facilities at the James J.
Peters Veterans Affairs Medical Center, Bronx, New York. The contents do
not represent the views of the U.S. Department of Veterans Affairs or
the U.S. government.
NR 20
TC 0
Z9 0
U1 2
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
IS 5
BP 1108
EP 1113
DI 10.1111/jgs.14091
PG 6
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DO1FD
UT WOS:000377523000024
PM 27160212
ER
PT J
AU O'Kula, SS
Gottesman, E
Jones, S
Signor, D
Hung, WW
Boockvar, KS
AF O'Kula, Susanna S.
Gottesman, Eve
Jones, Shatice
Signor, Daniel
Hung, William W.
Boockvar, Kenneth S.
TI Transitional Care Outcomes in Older Spanish-English Bilingual Veterans
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Letter
ID QUALITY
C1 [O'Kula, Susanna S.; Hung, William W.; Boockvar, Kenneth S.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
[Gottesman, Eve; Jones, Shatice; Signor, Daniel; Hung, William W.; Boockvar, Kenneth S.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
RP O'Kula, SS (reprint author), Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
OI Boockvar, Kenneth/0000-0003-1165-5558
NR 8
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
IS 5
BP 1132
EP 1133
DI 10.1111/jgs.14116
PG 2
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DO1FD
UT WOS:000377523000029
PM 27225364
ER
PT J
AU Hawkins, EJ
Malte, CA
AF Hawkins, Eric J.
Malte, Carol A.
TI Prioritizing the reach and patient-centeredness of substance use-related
care
SO AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE
LA English
DT Editorial Material
ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; ALCOHOL-USE
DISORDERS; SMOKING-CESSATION; ADDICTION TREATMENT; COLLABORATIVE CARE;
QUALITY CARE; HEALTH-CARE; FOLLOW-UP; MANAGEMENT
C1 [Hawkins, Eric J.; Malte, Carol A.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev HSR&D Seattle Ctr Innovat Vet, Seattle, WA USA.
[Hawkins, Eric J.; Malte, Carol A.] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA.
[Hawkins, Eric J.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
RP Hawkins, EJ (reprint author), VA Puget Sound Hlth Care Syst, Seattle Div, S116ATC,1660 S Columbian Way, Seattle, WA 98108 USA.
EM Eric.Hawkins@va.gov
NR 37
TC 0
Z9 0
U1 5
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0095-2990
EI 1097-9891
J9 AM J DRUG ALCOHOL AB
JI Am. J. Drug Alcohol Abuse
PD MAY
PY 2016
VL 42
IS 3
BP 245
EP 249
DI 10.3109/00952990.2016.1147568
PG 5
WC Psychology, Clinical; Substance Abuse
SC Psychology; Substance Abuse
GA DN5FB
UT WOS:000377090800001
PM 27088963
ER
PT J
AU Folmer, RL
AF Folmer, Robert L.
TI Reply to: Psychometric properties of the Tinnitus Functional Index
(TFI): Assessment in a UK research volunteer population
SO HEARING RESEARCH
LA English
DT Letter
C1 [Folmer, Robert L.] Natl Ctr Rehabil Auditory Res, Portland, OR USA.
[Folmer, Robert L.] Med Ctr, Portland, OR USA.
[Folmer, Robert L.] Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA.
[Folmer, Robert L.] Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, 3710 SW US Vet Hosp Rd NCRAR, Portland, OR 97239 USA.
RP Folmer, RL (reprint author), Natl Ctr Rehabil Auditory Res, Portland, OR USA.; Folmer, RL (reprint author), Med Ctr, Portland, OR USA.; Folmer, RL (reprint author), Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA.; Folmer, RL (reprint author), Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, 3710 SW US Vet Hosp Rd NCRAR, Portland, OR 97239 USA.
EM Robert.Folmer@va.gov
NR 3
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5955
EI 1878-5891
J9 HEARING RES
JI Hear. Res.
PD MAY
PY 2016
VL 335
BP 236
EP 236
DI 10.1016/j.heares.2016.02.011
PG 1
WC Audiology & Speech-Language Pathology; Neurosciences;
Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Neurosciences & Neurology;
Otorhinolaryngology
GA DM9VN
UT WOS:000376713900023
PM 26900071
ER
PT J
AU Balbale, SN
Etingen, B
Malhiot, A
Miskevics, S
LaVela, SL
AF Balbale, Salva N.
Etingen, Bella
Malhiot, Alex
Miskevics, Scott
LaVela, Sherri L.
TI Perceptions of Chronic Illness Care Among Veterans With Multiple Chronic
Conditions
SO MILITARY MEDICINE
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; HEALTH-CARE; PATIENT ASSESSMENT; OLDER
PERSONS; GUIDED CARE; QUALITY; MULTIMORBIDITY; COSTS; COMORBIDITY;
OUTCOMES
AB Objectives: Given the burden of multiple chronic conditions (MCCs) in the Veterans Affairs (VA) Health Care System, understanding perspectives of Veterans with MCC is essential to evaluate chronic care and ensure that care and quality improvement efforts align with patient needs. The purpose of this study was to use the Patient Assessment of Chronic Illness Care (PACIC) instrument to examine perceptions of chronic care among Veterans with MCC. Methods: We conducted a nation-wide, cross-sectional mailed survey. Study inclusion criteria were Veteran patients with MCC who receive care from eight VA facilities. The survey included questions on patient demographics, recent hospital or doctor visits, and the PACIC instrument. Chronic condition and health care utilization data were extracted from VA administrative databases. Results: The sample (n = 3,519) was mostly male; average age was 68.1 years. Mean PACIC summary score was 3.05 (standard deviation [SD] = 1.12). Respondents achieved higher scores (favorable perceptions) in the Delivery System Design and Patient Activation subscales, and lowest scores (unfavorable perceptions) in the Follow-up/Coordination subscale. Characteristics associated with higher scores included non-white race, recent VA doctor visit, and high school or less education. Conclusions: Perceptions of chronic care were high; however, quality improvements are needed to enhance care continuity and coordination.
C1 [Balbale, Salva N.; Etingen, Bella; Malhiot, Alex; Miskevics, Scott; LaVela, Sherri L.] US Dept Vet Affairs, Ctr Evaluat Practices & Experiences Patient Ctr C, 5000 South 5th Ave,151H, Hines, IL 60141 USA.
[Balbale, Salva N.; Etingen, Bella; Malhiot, Alex; Miskevics, Scott; LaVela, Sherri L.] Edward Hines Jr VA Hosp, Ctr Innovat Complex Chron Healthcare, 5000 South 5th Ave,151H, Hines, IL 60141 USA.
[Balbale, Salva N.; LaVela, Sherri L.] Northwestern Univ, Feinberg Sch Med, Inst Publ Hlth & Med, Ctr Healthcare Studies, 633 North St Clair St, Chicago, IL 60611 USA.
RP Balbale, SN (reprint author), US Dept Vet Affairs, Ctr Evaluat Practices & Experiences Patient Ctr C, 5000 South 5th Ave,151H, Hines, IL 60141 USA.; Balbale, SN (reprint author), Edward Hines Jr VA Hosp, Ctr Innovat Complex Chron Healthcare, 5000 South 5th Ave,151H, Hines, IL 60141 USA.; Balbale, SN (reprint author), Northwestern Univ, Feinberg Sch Med, Inst Publ Hlth & Med, Ctr Healthcare Studies, 633 North St Clair St, Chicago, IL 60611 USA.
FU Department of VA, Office of Patient Centered Care & Cultural
Transformation and Office of Research & Development, Health Services
Research & Development, Quality Enhancement Research Initiative
[PEC-13-002]
FX This work was supported by the Department of VA, Office of Patient
Centered Care & Cultural Transformation and Office of Research &
Development, Health Services Research & Development, Quality Enhancement
Research Initiative (PEC-13-002).
NR 32
TC 0
Z9 0
U1 2
U2 2
PU ASSOC MILITARY SURG US
PI BETHESDA
PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA
SN 0026-4075
EI 1930-613X
J9 MIL MED
JI Milit. Med.
PD MAY
PY 2016
VL 181
IS 5
BP 439
EP 444
DI 10.7205/MILMED-D-15-00207
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA DN5MZ
UT WOS:000377114400009
PM 27136650
ER
PT J
AU Yan, GW
AF Yan, Grace W.
TI The Invisible Wound: Moral Injury and Its Impact on the Health of
Operation Enduring Freedom/Operation Iraqi Freedom Veterans
SO MILITARY MEDICINE
LA English
DT Article
ID MAJOR DEPRESSIVE DISORDER; SERVICE MEMBERS; MENTAL-ILLNESS; WAR
VETERANS; PTSD; CARE; SPIRITUALITY; AFGHANISTAN; DEPLOYMENT; SYMPTOMS
AB Many veterans are now returning from Operation Enduring Freedom and Operation Iraqi Freedom (OEF/OIF) deployments with physical and mental health problems. However, there are few studies that examine the impact of moral injury on both physical and mental well-being. This study examines the impact of moral injury on self-reported general physical health, general mental health, post-traumatic stress disorder symptoms, and depression symptoms. Cross-sectional data were collected at as part of a pilot study at the New Jersey Veteran Affairs. 100 OEF/OIF veterans recruited at the New Jersey Veteran Affairs completed the paper questionnaire. We found that moral injury and combat experiences positively predicted post-traumatic stress disorder scores. Seeing the aftermath of battle and moral injury were negatively associated with mental well-being and positively associated with depression. Physical health status was negatively associated with depression. Spirituality and moral injury were negatively associated with physical health, whereas age was positively associated with physical health. Moral injury plays an important role in both physical and mental health outcomes for OEF/OIF veterans, but it is often not addressed in health care. These results underline the need for an approach to veterans' health care that includes discussion of existential and moral issues since they may impact health outcomes for many service members.
C1 [Yan, Grace W.] US Dept Vet Affairs, Ctr Hlth & Wellness, 385 Tremont Ave,Bldg 17 MS11C, E Orange, NJ 07018 USA.
RP Yan, GW (reprint author), US Dept Vet Affairs, Ctr Hlth & Wellness, 385 Tremont Ave,Bldg 17 MS11C, E Orange, NJ 07018 USA.
FU Department of Veterans Affairs, Office of Patient-Centered Care and
Cultural Transformation
FX We would like to thank the faculty and staff of the War Related Illness
and Injury Study Center at the New Jersey VA Health Care System for
their support. We would also like to thank Dr. Ilysa Michelson and Rev.
Thomas Malek-Jones for their comments and feedback on this manuscript.
This study was supported by a grant from the Department of Veterans
Affairs, Office of Patient-Centered Care and Cultural Transformation.
NR 42
TC 0
Z9 0
U1 3
U2 8
PU ASSOC MILITARY SURG US
PI BETHESDA
PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA
SN 0026-4075
EI 1930-613X
J9 MIL MED
JI Milit. Med.
PD MAY
PY 2016
VL 181
IS 5
BP 451
EP 458
DI 10.7205/MILMED-D-15-00103
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA DN5MZ
UT WOS:000377114400011
PM 27136652
ER
PT J
AU Pugh, MJ
Jaramillo, CA
Leung, KW
Faverio, P
Fleming, N
Mortensen, E
Amuan, ME
Wang, CP
Eapen, B
Restrepo, M
Morris, MJ
AF Pugh, Mary Jo
Jaramillo, Carlos A.
Leung, Kar-wei
Faverio, Paola
Fleming, Nicholas
Mortensen, Eric
Amuan, Megan E.
Wang, Chen-Pin
Eapen, Blessen
Restrepo, Marcos
Morris, Michael J.
TI Increasing Prevalence of Chronic Lung Disease in Veterans of the Wars in
Iraq and Afghanistan
SO MILITARY MEDICINE
LA English
DT Article
ID US MILITARY PERSONNEL; OPERATION ENDURING FREEDOM; RESPIRATORY SYMPTOMS;
PARTICULATE MATTER; SOUTHWEST ASIA; DEPLOYMENT; HEALTH; SOLDIERS;
INJURY; PNEUMONIA
AB Research from the wars in Afghanistan and Iraq have focused on traumatic brain injury (TBI) and mental health conditions; however, it is becoming clear that other health concerns, such as respiratory illnesses, warrant further scientific inquiry. Early reports from theater and postdeployment health assessments suggested an association with deployment-related exposures (e.g., sand, burn pits, chemical, etc.) and new-onset respiratory symptoms. We used data from Veterans Affairs medical encounters between fiscal years 2003 and 2011 to identify trends in chronic obstructive pulmonary disease, asthma, and interstitial lung disease in veterans. We used data from Veterans Affairs and Department of Defense sources to identify sociodemographic (age, sex, race), military (e.g., service branch, multiple deployments) and clinical characteristics (TBI, smoking) of individuals with and without chronic lung diseases. Generalized estimating equations found significant increases over time for chronic obstructive pulmonary disease and asthma in both unadjusted and adjusted analyses. Trends for interstitial lung disease were significant only in adjusted analyses. Age, smoking, and TBI were also significantly associated with chronic lung diseases; however, multiple deployments were not associated. Research is needed to identify which characteristics of deployment-related exposures are linked with chronic lung disease.
C1 [Pugh, Mary Jo; Jaramillo, Carlos A.; Eapen, Blessen; Restrepo, Marcos] South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.
[Pugh, Mary Jo; Jaramillo, Carlos A.; Leung, Kar-wei; Fleming, Nicholas; Wang, Chen-Pin; Eapen, Blessen; Restrepo, Marcos] Univ Texas Hlth Sci Ctr San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
[Faverio, Paola] Univ Milano Bicocca, AO San Gerardo, Clin Pneumol, Dept Hlth Sci, Via Pergolesi 22, Monza, Italy.
[Mortensen, Eric] North Texas Vet Hlth Care Syst, 4500 South Lancaster Rd, Dallas, TX 75216 USA.
[Amuan, Megan E.] Edith Nourse Rogers VA Med Ctr, 200 Springs Rd, Bedford, MA 01730 USA.
[Morris, Michael J.] Uniformed Serv Univ Hlth Sci, Brooke Army Med Ctr, 3551 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA.
RP Pugh, MJ (reprint author), South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.; Pugh, MJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
OI Pugh, Mary Jo/0000-0003-4196-7763; Mortensen, Eric/0000-0002-3880-5563
FU VA Health Services Research and Development Service [DHI 09-237]
FX Data were obtained with the assistance of the VA Office of Environmental
Epidemiology for the Operation Enduring Freedom/Operation Iraqi Freedom
Roster file. This study was funded by the VA Health Services Research
and Development Service (DHI 09-237). The content, of this article is
solely the responsibility of the authors and does not necessarily
reflect the official views of the Veterans' Health Administration or the
Department of Defense. The funding organizations had no role in the
design and conduct of die study; the collection, management, analysis,
and interpretation of the data; or the preparation, review, or approval
of the manuscript. This retrospective data study received approval
including a waiver of informed consent and Health Insurance Portability
and Accountability Act authorization by the institutional review boards
of the University of Texas Health Science Center San Antonio and the
Edith Nourse Rogers Memorial VA Hospital.
NR 27
TC 0
Z9 0
U1 1
U2 2
PU ASSOC MILITARY SURG US
PI BETHESDA
PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA
SN 0026-4075
EI 1930-613X
J9 MIL MED
JI Milit. Med.
PD MAY
PY 2016
VL 181
IS 5
BP 476
EP 481
DI 10.7205/MILMED-D-15-00035
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA DN5MZ
UT WOS:000377114400015
PM 27136656
ER
PT J
AU Brill, AL
Wisinski, JA
Cadena, MT
Thompson, MF
Fenske, RJ
Brar, HK
Schaid, MD
Pasker, RL
Kimple, ME
AF Brill, Allison L.
Wisinski, Jaclyn A.
Cadena, Mark T.
Thompson, Mary F.
Fenske, Rachel J.
Brar, Harpreet K.
Schaid, Michael D.
Pasker, Renee L.
Kimple, Michelle E.
TI Synergy Between G alpha(z) Deficiency and GLP-1 Analog Treatment in
Preserving Functional beta-Cell Mass in Experimental Diabetes
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article
ID GLUCAGON-LIKE PEPTIDE-1; EPIDERMAL-GROWTH-FACTOR; COMBINATION THERAPY;
RESTORES NORMOGLYCEMIA; INSULIN-SECRETION; GLUCOSE-TOLERANCE; HUMAN
ISLETS; NOD MICE; APOPTOSIS; RATS
AB A defining characteristic of type 1 diabetes mellitus ( T1DM) pathophysiology is pancreatic beta-cell death and dysfunction, resulting in insufficient insulin secretion to properly control blood glucose levels. Treatments that promote beta-cell replication and survival, thus reversing the loss of beta-cell mass, while also preserving beta-cell function, could lead to a real cure for T1DM. The alpha-subunit of the heterotrimeric G(z) protein, G alpha(z), is a tonic negative regulator of adenylate cyclase and downstream cAMP production. cAMP is one of a few identified signaling molecules that can simultaneously have a positive impact on pancreatic islet beta-cell proliferation, survival, and function. The purpose of our study was to determine whether mice lacking G alpha(z) might be protected, at least partially, from beta-cell loss and dysfunction after streptozotocin treatment. We also aimed to determine whether G alpha(z) might act in concert with an activator of the cAMP-stimulatory glucagon-like peptide 1 receptor, exendin-4 ( Ex4). Without Ex4 treatment, G alpha(z)-null mice still developed hyperglycemia, albeit delayed. The same finding held true for wild-type mice treated with Ex4. With Ex4 treatment, G alpha(z)-null mice were protected from developing severe hyperglycemia. Immunohistological studies performed on pancreas sections and in vitro apoptosis, cytotoxicity, and survival assays demonstrated a clear effect of G alpha(z) signaling on pancreatic beta-cell replication and death; beta-cell function was also improved in G alpha(z)-null islets. These data support our hypothesis that a combination of therapies targeting both stimulatory and inhibitory pathways will be more effective than either alone at protecting, preserving, and possibly regenerating beta-cell mass and function in T1DM.
C1 [Brill, Allison L.; Wisinski, Jaclyn A.; Cadena, Mark T.; Thompson, Mary F.; Brar, Harpreet K.; Pasker, Renee L.; Kimple, Michelle E.] Univ Wisconsin, Dept Med, Div Endocrinol Diabet & Metab, Madison, WI 53705 USA.
[Kimple, Michelle E.] Univ Wisconsin, Dept Cell & Regenerat Biol, Madison, WI 53705 USA.
[Fenske, Rachel J.; Schaid, Michael D.; Kimple, Michelle E.] Univ Wisconsin, Interdisciplinary Grad Program Nutr Sci, Madison, WI 53705 USA.
[Brill, Allison L.; Wisinski, Jaclyn A.; Cadena, Mark T.; Thompson, Mary F.; Fenske, Rachel J.; Brar, Harpreet K.; Schaid, Michael D.; Kimple, Michelle E.] William S Middleton Mem Vet Adm Med Ctr, Res Serv, Madison, WI 53705 USA.
RP Kimple, ME (reprint author), Univ Wisconsin, Dept Med, Div Endocrinol, 4148 Univ Wisconsin Med Fdn Centennial Bldg, Madison, WI 53705 USA.
EM mkimple@medicine.wisc.edu
FU JDRF [17-2011-608]; National Institutes of Health/National Institute of
Diabetes and Digestive and Kidney Diseases [R01 DK102598]; American
Diabetes Association [1-14-BS-115]; University of Wisconsin-Madison;
American Society of Pharmacology and Experimental Therapeutics
FX This work was supported by the JDRF Grant 17-2011-608 (to M.E.K.), the
National Institutes of Health/National Institute of Diabetes and
Digestive and Kidney Diseases Grant R01 DK102598 (to M.E.K.), the
American Diabetes Association Grant 1-14-BS-115 (to M.E.K.), and the
University of Wisconsin-Madison (M.E.K.). A.L.B. was funded in part
through a Summer Undergraduate Research Fellowship from the American
Society of Pharmacology and Experimental Therapeutics. M.T.C. was funded
in part through a Minority Undergraduate Internship Award from the
American Diabetes Association. H.K.B. was funded in part through a
Hilldale Undergraduate/Faculty Research Award from the University of
Wisconsin-Madison. This material is the result of work supported in part
with the resources and use of facilities at the William S. Middleton
Memorial Veterans Hospital, Madison, WI.
NR 57
TC 1
Z9 1
U1 2
U2 2
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0888-8809
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD MAY
PY 2016
VL 30
IS 5
BP 543
EP 556
DI 10.1210/me.2015-1164
PG 14
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DN6TT
UT WOS:000377209900006
PM 27049466
ER
PT J
AU Bramoweth, AD
Renqvist, JG
Germain, A
Buysse, DJ
Gentili, A
Kochersberger, G
Rodriguez, E
Rossi, MI
Weiner, DK
AF Bramoweth, Adam D.
Renqvist, Jenna G.
Germain, Anne
Buysse, Daniel J.
Gentili, Angela
Kochersberger, Gary
Rodriguez, Eric
Rossi, Michelle I.
Weiner, Debra K.
TI Deconstructing Chronic Low Back Pain in the Older Adult-Step by Step
Evidence and Expert-Based Recommendations for Evaluation and Treatment:
Part VII: Insomnia
SO PAIN MEDICINE
LA English
DT Article
DE Low Back Pain; Chronic Pain; Chronic Low Back Pain; Insomnia; Sleep
Disorders; Elderly; Older Adults
ID COGNITIVE-BEHAVIORAL THERAPY; QUALITY-OF-LIFE; RANDOMIZED
CONTROLLED-TRIAL; DOUBLE-BLIND; SLEEP-ONSET; HEALTHY-VOLUNTEERS;
SEVERITY INDEX; 6 MG; EFFICACY; ZOLPIDEM
AB Objective. To present the seventh in a series of articles designed to deconstruct chronic low back pain ( CLBP) in older adults. This article focuses on insomnia and presents a treatment algorithm for managing insomnia in older adults, along with a representative clinical case.
Methods.aEuro integral A modified Delphi process was used to develop the algorithm and supportive materials. A multidisciplinary expert panel representing expertise in health psychology and sleep medicine developed the algorithm and supporting documents that were subsequently refined through an iterative process of input from a primary care provider panel.
Results.aEuro integral We present an illustrative clinical case and an algorithm to help guide the care of older adults with insomnia, an important contributor to CLBP and disability. Multicomponent cognitive behavioral therapy for insomnia (CBTI) and similar treatments (e.g., brief behavioral treatment for insomnia [BBTI]) are the recommended first-line treatment. Medications should be considered only if BBTI/CBTI is suboptimal or not effective and should be prescribed at the lowest effective dose for short periods of time (< 90 days).
Conclusions.aEuro integral Insomnia is commonly comorbid with CLBP in older adults and should be routinely evaluated and treated because it is an important contributor to pain and disability. The algorithm presented was structured to assist primary care providers in planning treatment for older adults with CLBP and insomnia.
C1 [Bramoweth, Adam D.; Renqvist, Jenna G.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA.
[Bramoweth, Adam D.; Germain, Anne; Buysse, Daniel J.; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA.
[Gentili, Angela] Hunter Holmes McGuire VA Med Ctr, Richmond, VA USA.
[Gentili, Angela] Virginia Commonwealth Univ Hlth Syst, Richmond, VA USA.
[Kochersberger, Gary] VA Med Ctr, Canandaigua, NY USA.
[Kochersberger, Gary] Univ Rochester, Div Geriatr, Rochester, NY 14627 USA.
[Rossi, Michelle I.; Weiner, Debra K.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
[Rodriguez, Eric; Rossi, Michelle I.; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr Med, Pittsburgh, PA 15213 USA.
[Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA.
[Weiner, Debra K.] Univ Pittsburgh, Sch Med, Clin & Translat Sci Inst, Pittsburgh, PA USA.
RP Weiner, DK (reprint author), Pittsburgh Healthcare Syst, Univ Dr,Bldg 30,00GR, Pittsburgh, PA 15240 USA.
EM debra.weiner@va.gov
FU Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development, Rehabilitation Research and Development
Service
FX This material is based on work supported by the Department of Veterans
Affairs, Veterans Health Administration, Office of Research and
Development, Rehabilitation Research and Development Service.
NR 73
TC 2
Z9 2
U1 4
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1526-2375
EI 1526-4637
J9 PAIN MED
JI Pain Med.
PD MAY
PY 2016
VL 17
IS 5
BP 851
EP 863
DI 10.1093/pm/pnw063
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA DM8ZW
UT WOS:000376654000007
PM 27173512
ER
PT J
AU Jackson, JC
Jutte, JE
Hunter, CH
Ciccolella, N
Warrington, H
Sevin, C
Bienvenu, OJ
AF Jackson, James C.
Jutte, Jennifer E.
Hunter, Cashuna Huddleston
Ciccolella, Nancy
Warrington, Hillary
Sevin, Carla
Bienvenu, Oscar J.
TI Posttraumatic Stress Disorder (PTSD) After Critical Illness: A
Conceptual Review of Distinct Clinical Issues and Their Implications
SO REHABILITATION PSYCHOLOGY
LA English
DT Review
DE critical care; posttraumatic stress disorders; intensive care units;
psychosocial rehabilitation
ID INTENSIVE-CARE-UNIT; ACUTE LUNG INJURY; QUALITY-OF-LIFE;
RESPIRATORY-DISTRESS-SYNDROME; TRAUMATIC BRAIN-INJURY; PSYCHOLOGICAL
DISTRESS; ILL PATIENTS; PHYSICAL REHABILITATION; MECHANICAL VENTILATION;
PROLONGED EXPOSURE
AB Purpose/Objective: Posttraumatic stress disorder (PTSD) that develops after critical care may be marked by a unique constellation of symptoms that differ, for example, from the symptoms that develop in response to more traditional traumas such as combat or assault. Research Method/Design: We describe ways in which symptoms of PTSD after critical illness can be clinically engaged, drawing from literature pointing to "best treatment" practices in other settings. And, we discuss the relevance of intensive care unit (ICU) related PTSD to rehabilitation psychologists and explain why rehabilitation psychologists are well suited to identify and treat ICU-related PTSD. Results: In this conceptual review, drawing from both empirical findings and theoretical models, we surmise that traumatized survivors of critical illness demonstrate 2 central clinical features-avoidance and reexperiencing. Conclusions/Implications: The potentially unique clinical profile of ICU-related PTSD likely requires unique assessment and treatment practices. These services may be best provided by providers with expertise in providing coordinated care, such as rehabilitation psychologists. Next steps should include empirical study to determine whether practices that are empirically supported in other settings may be translated to the ICU and post-ICU hospitalization for critical illness survivors.
C1 [Jackson, James C.] Vanderbilt Univ, Sch Med, Div Allergy Pulm Crit Care Med, Ctr Hlth Serv Res, Nashville, TN 37232 USA.
[Jackson, James C.] Vanderbilt Univ, Sch Med, Dept Psychiat, Nashville, TN 37232 USA.
[Jackson, James C.] Vet Affairs Tennessee Valley Geriatr Res Educ & C, Nashville, TN USA.
[Jutte, Jennifer E.] Univ Washington, Dept Rehabil Med, Sch Med, Harborview Med Ctr, Seattle, WA 98195 USA.
[Hunter, Cashuna Huddleston] Houston Vet Affairs Med Ctr, Houston, TX USA.
[Ciccolella, Nancy] Temple Univ, Dept Phys Med & Rehabil, Philadelphia, PA 19122 USA.
[Warrington, Hillary] Baylor Univ, Dept Psychol, Waco, TX 76798 USA.
[Sevin, Carla] Vanderbilt Univ, Sch Med, Div Allergy Pulm Crit Care Med, Nashville, TN 37232 USA.
[Bienvenu, Oscar J.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21218 USA.
RP Jackson, JC (reprint author), Vanderbilt Univ, Ctr Hlth Serv Res, 6100 Med Ctr East, Nashville, TN 37232 USA.
EM james.c.jackson@vanderbilt.edu
NR 87
TC 1
Z9 1
U1 4
U2 7
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 0090-5550
EI 1939-1544
J9 REHABIL PSYCHOL
JI Rehabil. Psychol.
PD MAY
PY 2016
VL 61
IS 2
BP 132
EP 140
DI 10.1037/rep0000085
PG 9
WC Psychology, Clinical; Rehabilitation
SC Psychology; Rehabilitation
GA DN2XS
UT WOS:000376926900003
PM 27196856
ER
PT J
AU Wahl, ER
Yazdany, J
AF Wahl, Elizabeth R.
Yazdany, Jinoos
TI Challenges and Opportunities in Using Patient-reported Outcomes in
Quality Measurement Rheumatology
SO RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
LA English
DT Article
DE Patient-reported outcomes; Quality measures; Performance measures;
Outcome measures; Health care quality; Rheumatology
ID OF-CARE; HEALTH-CARE; CLINICAL-PRACTICE; EUMUSC.NET-PROJECT; INDICATOR
SET; PERFORMANCE; ARTHRITIS; IMPROVEMENT; RECOMMENDATIONS; EUROPE
AB Use of patient-reported outcome measures (PROs) in rheumatology research is widespread, but use of PRO data to evaluate the quality of.rheumatologic care delivered is less well established. This article reviews the use of PROs in assessing health care quality, and highlights challenges and opportunities specific to their use in rheumatology quality measurement. It first explores other countries' experiences collecting and evaluating national PRO data to assess quality of care. It describes the current use of PROs as quality measures in rheumatology, and frames an agenda for future work supporting development of meaningful quality measures based on PROs.
C1 [Wahl, Elizabeth R.] San Francisco VA Med Ctr, Div Rheumatol, VA Qual Scholars Program, 4150 Clement St,Bldg 1,Room 207-1, San Francisco, CA 94121 USA.
[Yazdany, Jinoos] Univ Calif San Francisco, Dept Internal Med, Div Rheumatol, 1001 Potrero Ave,Bldg SFGH 30,Room 3301,Box 0811, San Francisco, CA 94110 USA.
RP Yazdany, J (reprint author), Univ Calif San Francisco, Dept Internal Med, Div Rheumatol, 1001 Potrero Ave,Bldg SFGH 30,Room 3301,Box 0811, San Francisco, CA 94110 USA.
EM jinoos.yazdany@ucsf.edu
FU NIAMS [K23 AR060259]; Russell/Engleman Rheumatology Research Center;
Robert L. Kroc Endowed Chair in Rheumatic and Connective Tissue Diseases
at the University of California, San Francisco; VA Quality Scholars
Fellowship through the VA Office of Academic Affiliations
FX J. Yazdany is supported by NIAMS K23 AR060259, the Russell/Engleman
Rheumatology Research Center, and the Robert L. Kroc Endowed Chair in
Rheumatic and Connective Tissue Diseases at the University of
California, San Francisco. E. Wahl supported by a VA Quality Scholars
Fellowship through the VA Office of Academic Affiliations.
NR 35
TC 1
Z9 1
U1 2
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-857X
EI 1558-3163
J9 RHEUM DIS CLIN N AM
JI Rheum. Dis. Clin. North Am.
PD MAY
PY 2016
VL 42
IS 2
BP 363
EP +
DI 10.1016/j.rdc.2016.01.008
PG 15
WC Rheumatology
SC Rheumatology
GA DN0YO
UT WOS:000376793200013
PM 27133495
ER
PT J
AU Hirsch, J
Generoso, JR
Latoures, R
Acar, Y
Fidler, RL
AF Hirsch, Jan
Generoso, Jose R.
Latoures, Renee
Acar, Yahya
Fidler, Richard L.
TI Simulation Manikin Modifications for High-Fidelity Training of Advanced
Airway Procedures
SO A & A CASE REPORTS
LA English
DT Article
ID INTUBATION
AB Thoracic anesthesia procedures are challenging to master during anesthesia training. A Laerdal ALS Simulator (R) manikin was modified by adding a bronchial tree module to create fidelity to the fourth generation. After modification, placement of endotracheal tubes up to 8.0 mm is possible by direct laryngoscopy, video laryngoscopy, and fiberoptically; in addition, it allows fiberoptically guided insertion of endobronchial blockers. Insertion of left and right 35-Fr double-lumen tubes permits double-and single-lung ventilation with continuous positive airway pressure and positive end-expiratory pressure. This anatomical modification created a high-fidelity training tool for thoracic anesthesia that has been incorporated into educational curricula for anesthesia.
C1 Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA.
San Francisco VA Med Ctr, Simulat Ctr, San Francisco, CA USA.
RP Hirsch, J (reprint author), San Francisco VA Med Ctr, Anesthesia Serv, Mail 129,4150 Clement St, San Francisco, CA 94121 USA.
EM jan.hirsch@ucsf.edu
NR 6
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2325-7237
J9 A A CASE REP
JI A A Case Rep.
PD MAY 1
PY 2016
VL 6
IS 9
BP 268
EP 271
DI 10.1213/XAA.0000000000000278
PG 4
WC Anesthesiology
SC Anesthesiology
GA DN0SZ
UT WOS:000376776100002
PM 26752178
ER
PT J
AU Stall, R
Matthews, DD
Friedman, MR
Kinsky, S
Egan, JE
Coulter, RWS
Blosnich, JR
Markovic, N
AF Stall, Ron
Matthews, Derrick D.
Friedman, M. Reuel
Kinsky, Suzanne
Egan, James E.
Coulter, Robert W. S.
Blosnich, John R.
Markovic, Nina
TI The Continuing Development of Health Disparities Research on Lesbian,
Gay, Bisexual, and Transgender Individuals
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Editorial Material
ID SEXUAL ORIENTATION; MENTAL-HEALTH
C1 [Stall, Ron; Matthews, Derrick D.; Friedman, M. Reuel; Kinsky, Suzanne; Egan, James E.; Coulter, Robert W. S.; Blosnich, John R.; Markovic, Nina] Univ Pittsburgh, Grad Sch Publ Hlth, Ctr LGBT Hlth Res, 130 De Soto St, Pittsburgh, PA 15261 USA.
[Stall, Ron; Kinsky, Suzanne; Egan, James E.; Coulter, Robert W. S.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA 15261 USA.
[Matthews, Derrick D.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Infect Dis & Microbiol, Pittsburgh, PA 15261 USA.
[Blosnich, John R.] US Dept Vet Affairs, VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Markovic, Nina] Univ Pittsburgh, Sch Dent Med, Dept Dent Publ Hlth, Pittsburgh, PA 15261 USA.
RP Stall, R (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Ctr LGBT Hlth Res, 130 De Soto St, Pittsburgh, PA 15261 USA.; Stall, R (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Sci Dept Behav & Community Hlth Sci, 130 De Soto St, Pittsburgh, PA 15261 USA.
EM rstall@pitt.edu
OI Friedman, M. Reuel/0000-0001-6191-9799; Coulter,
Robert/0000-0001-8350-0075
NR 9
TC 2
Z9 2
U1 0
U2 3
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD MAY
PY 2016
VL 106
IS 5
BP 787
EP 789
DI 10.2105/AJPH.2016.303183
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DM2ME
UT WOS:000376180100025
PM 27049415
ER
PT J
AU Ge, L
Wu, YF
Soleimani, M
Khazalpour, M
Takaba, K
Tartibi, M
Zhang, ZH
Acevedo-Bolton, G
Saloner, DA
Wallace, AW
Mishra, R
Grossi, EA
Guccione, JM
Ratcliffe, MB
AF Ge, Liang
Wu, Yife
Soleimani, Mehrdad
Khazalpour, Michael
Takaba, Kiyoaki
Tartibi, Mehrzad
Zhang, Zhihong
Acevedo-Bolton, Gabriel
Saloner, David A.
Wallace, Arthur W.
Mishra, Rakesh
Grossi, Eugene A.
Guccione, Julius M.
Ratcliffe, Mark B.
TI Moderate Ischemic Mitral Regurgitation After Posterolateral Myocardial
Infarction in Sheep Alters Left Ventricular Shear but Not Normal Strain
in the Infarct and Infarct Borderzone
SO ANNALS OF THORACIC SURGERY
LA English
DT Article
ID MATRIX METALLOPROTEINASE-2; TRANSMURAL STRAINS; SURGICAL-TREATMENT;
OVINE MODEL; MR-IMAGES; ECHOCARDIOGRAPHY; DYSFUNCTION; INDUCTION;
EXPANSION; OCCLUSION
AB Background. Chronic ischemic mitral regurgitation (CIMR) is associated with poor outcome. Left ventricular (LV) strain after posterolateral myocardial infarction (MI) may drive LV remodeling. Although moderate CIMR has been previously shown to affect LV remodeling, the effect of CIMR on LV strain after posterolateral MI remains unknown. We tested the hypothesis that moderate CIMR alters LV strain after posterolateral MI.
Methods. Posterolateral MI was created in 10 sheep. Cardiac magnetic resonance imaging with tags was performed 2 weeks before and 2, 8, and 16 weeks after MI. The left and right ventricular volumes were measured, and regurgitant volume indexed to body surface area (regurgitant volume index) was calculated as the difference between left ventricle and right ventricle stroke volumes divided by body surface area. Three-dimensional strain was calculated.
Results. Circumferential strain (E-cc) and longitudinal strain (E-ll) were reduced in the infarct proper, MI borderzone, and remote myocardium 16 weeks after MI. In addition, radial circumferential (E-rc) and radial longitudinal (E-rl) shear strains were reduced in remote myocardium but increased in the infarct and borderzone 16 weeks after MI. Of all strain components, however, only E-rc was affected by regurgitant volume index (p = 0.0005). There was no statistically significant effect of regurgitant volume index on E-cc, E-ll, E-rl, or circumferential longitudinal shear strain (E-cl).
Conclusions. Moderate CIMR alters radial circumferential shear strain after posterolateral MI in sheep. Further studies are needed to determine the effect of shear strain on myocyte hypertrophy and the effect of mitral repair on myocardial strain. (C) 2016 by The Society of Thoracic Surgeons
C1 Univ Calif San Francisco, Dept Surg, San Francisco, CA USA.
Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA USA.
Univ Calif San Francisco, Dept Bioengn, San Francisco, CA 94143 USA.
Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA.
Vet Affairs Med Ctr, San Francisco, CA 94121 USA.
NYU, Sch Med, Dept Cardiothorac Surg, New York, NY USA.
RP Ratcliffe, MB (reprint author), San Francisco VA Med Ctr, Surg Serv 112, 4150 Clement St, San Francisco, CA 94121 USA.
EM mark.ratcliffe@va.gov
OI GROSSI, eugene/0000-0002-2066-7035
FU NIH [R01-HL-084431, R01-HL-077921]
FX This study was supported by NIH grants R01-HL-084431 (Dr Ratcliffe) and
R01-HL-077921 (Dr Guccione).
NR 40
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD MAY
PY 2016
VL 101
IS 5
BP 1691
EP 1699
DI 10.1016/j.athoracsur.2015.10.083
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA DL8CY
UT WOS:000375868500027
PM 26857634
ER
PT J
AU Scott, GD
Sauer, DA
Woolf, KM
Sukumar, MS
Tieu, BH
AF Scott, Gregory D.
Sauer, David A.
Woolf, Kirsten M.
Sukumar, Mithran S.
Tieu, Brandon H.
TI Presumed Second Focus of Lung Immunoglobulin G4-Related Disease Found to
be Adenocarcinoma
SO ANNALS OF THORACIC SURGERY
LA English
DT Editorial Material
ID IGG4-RELATED DISEASE
AB We describe a patient presenting with bilateral radiologically similar lung lesions initially diagnosed as immunoglobulin (Ig) G4-related disease from biopsy of one lesion, but radiographic changes 6 months later prompted biopsy of the second lesion and showed adenocarcinoma. No case of lung IgG4-related disease and a distant lung malignancy has been previously reported. This is notable because lung IgG4-related disease often manifests in multiple thoracic locations but is diagnosed from a representative biopsy specimen. (C) 2016 by The Society of Thoracic Surgeons
C1 Oregon Hlth & Sci Univ, MD PhD Program, Portland, OR 97201 USA.
Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA.
Portland VA Med Ctr, Dept Pathol Lab, Portland, OR USA.
Oregon Hlth & Sci Univ, Div Cardiothorac Surg, Portland, OR 97201 USA.
RP Tieu, BH (reprint author), Cardiothorac Surg Div, Dept Surg, Mail Code L353,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM tieub@ohsu.edu
NR 5
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD MAY
PY 2016
VL 101
IS 5
BP 1965
EP 1967
DI 10.1016/j.athoracsur.2015.07.041
PG 4
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA DL8CY
UT WOS:000375868500066
PM 27106428
ER
PT J
AU Perera, T
George, MS
Grammer, G
Janicak, PG
Pascual-Leone, A
Wirecki, TS
AF Perera, Tarique
George, Mark S.
Grammer, Geoffrey
Janicak, Philip G.
Pascual-Leone, Alvaro
Wirecki, Theodore S.
TI The Clinical TMS Society Consensus Review and Treatment Recommendations
for TMS Therapy for Major Depressive Disorder
SO BRAIN STIMULATION
LA English
DT Article
DE Depression; TMS; Review; Guidelines
ID TRANSCRANIAL MAGNETIC STIMULATION; SHAM-CONTROLLED TRIALS;
TREATMENT-RESISTANT DEPRESSION; RANDOMIZED CONTROLLED-TRIAL;
QUALITY-OF-LIFE; DOUBLE-BLIND; ELECTROCONVULSIVE-THERAPY; ANTIDEPRESSANT
EFFICACY; OPEN-LABEL; RTMS
AB Background: Prefrontal Transcranial Magnetic Stimulation (TMS) therapy repeated daily over 4-6 weeks (20-30 sessions) is US Food and Drug Administration (FDA) approved for treating Major Depressive Disorder in adults who have not responded to prior antidepressant medications. In 2011, leading TMS clinical providers and researchers created the Clinical TMS Society (cTMSs) (www.clinicaltmssociety.org, Greenwich, CT, USA), incorporated in 2013.
Methods: This consensus review was written by cTMSs leaders, informed by membership polls, and approved by the governing board. It summarizes current evidence for the safety and efficacy of the use of TMS therapy for treating depression in routine clinical practice. Authors systematically reviewed the published TMS antidepressant therapy clinical trials. Studies were then assessed and graded on their strength of evidence using the Levels of Evidence framework published by the University of Oxford Centre for Evidence Based Medicine. The authors then summarize essentials for using TMS therapy in routine clinical practice settings derived from discussions and polls of cTMSs members. Finally, each summary clinical recommendation is presented with the substantiating peer-reviewed, published evidence supporting that recommendation. When the current published clinical trial evidence was insufficient or incomplete, expert opinion was included when sufficient consensus was available from experienced clinician users among the membership of the cTMSs, who were polled at the Annual Meetings in 2014 and 2015.
Conclusions: Daily left prefrontal TMS has substantial evidence of efficacy and safety for treating the acute phase of depression in patients who are treatment resistant or intolerant. Following the clinical recommendations in this document should result in continued safe and effective use of this exciting new treatment modality. (C) 2016 The Authors. Published by Elsevier Inc.
C1 [Perera, Tarique] Contemporary Care, Greenwich, CT USA.
[George, Mark S.] Med Univ S Carolina, Dept Psychiat, Brain Stimulat Div, Charleston, SC 29425 USA.
[George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Grammer, Geoffrey] TMS NeuroHlth, Mclean, VA USA.
[Janicak, Philip G.] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA.
[Pascual-Leone, Alvaro] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Berenson Allen Ctr Noninvas Brain Stimulat, Boston, MA 02215 USA.
[Wirecki, Theodore S.] TMS Ctr Colorado, Denver, CO USA.
RP George, MS (reprint author), Med Univ S Carolina, Dept Psychiat, Brain Stimulat Div, Charleston, SC 29425 USA.; George, MS (reprint author), Ralph H Johnson VA Med Ctr, Charleston, SC USA.
EM georgem@musc.edu
NR 71
TC 7
Z9 7
U1 8
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1935-861X
EI 1876-4754
J9 BRAIN STIMUL
JI Brain Stimul.
PD MAY-JUN
PY 2016
VL 9
IS 3
BP 336
EP 346
DI 10.1016/j.brs.2016.03.010
PG 11
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DM6KQ
UT WOS:000376461400004
PM 27090022
ER
PT J
AU Luetkemeyer, AF
Firnhaber, C
Kendall, MA
Wu, XY
Mazurek, GH
Benator, DA
Arduino, R
Fernandez, M
Guy, E
Johnson, P
Metchock, B
Sattler, F
Telzak, E
Wang, YF
Weiner, M
Swindells, S
Sanne, IM
Havlir, DV
Grinsztejn, B
Alland, D
AF Luetkemeyer, Anne F.
Firnhaber, Cynthia
Kendall, Michelle A.
Wu, Xingye
Mazurek, Gerald H.
Benator, Debra A.
Arduino, Roberto
Fernandez, Michel
Guy, Elizabeth
Johnson, Pamela
Metchock, Beverly
Sattler, Fred
Telzak, Edward
Wang, Yun F.
Weiner, Marc
Swindells, Susan
Sanne, Ian M.
Havlir, Diane V.
Grinsztejn, Beatriz
Alland, David
CA AIDS Clinical Trials Grp A5295
TB Trials Consortium Study 34 Team
TI Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify
Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low
and Higher Prevalence Settings
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE Xpert MTB/RIF; tuberculosis diagnosis; respiratory isolation;
nontuberculous mycobacteria; HIV/tuberculosis coinfection
ID DETECTING MYCOBACTERIUM-TUBERCULOSIS; UNITED-STATES; ASSAY
AB Background. The Xpert MTB/RIF (Xpert) assay is a rapid nucleic acid amplification test widely used in settings of high tuberculosis prevalence to detect tuberculosis as well as rpoB mutations associated with rifampin resistance. Data are needed on the diagnostic performance of Xpert in lower-prevalence settings to inform appropriate use for both tuberculosis detection and the need for respiratory isolation.
Methods. Xpert was compared to 2 sputum samples, each evaluated with acid-fast bacilli (AFB) smear and mycobacterial culture using liquid and solid culture media, from participants with suspected pulmonary tuberculosis from the United States, Brazil, and South Africa.
Results. Of 992 participants enrolled with evaluable results, 22% had culture-confirmed tuberculosis. In 638 (64%) US participants, 1 Xpert result demonstrated sensitivity of 85.2% (96.7% in participants with AFB smear-positive [AFB(+)] sputum, 59.3% with AFB smear-negative [AFB(-)] sputum), specificity of 99.2%, negative predictive value (NPV) of 97.6%, and positive predictive value of 94.9%. Results did not differ between higher-and low-prevalence settings. A second Xpert assay increased overall sensitivity to 91.1% (100% if AFB(+), 71.4% if AFB(-)), with specificity of 98.9%. In US participants, a single negative Xpert result predicted the absence of AFB(+)/culture-positive tuberculosis with an NPV of 99.7%; NPV of 2 Xpert assays was 100%, suggesting a role in removing patients from airborne infection isolation. Xpert detected tuberculosis DNA and mutations associated with rifampin resistance in 5 of 7 participants with rifampin-resistant, culture-positive tuberculosis. Specificity for rifampin resistance was 99.5% and NPV was 98.9%.
Conclusions. In the United States, Xpert testing performed comparably to 2 higher-tuberculosis-prevalence settings. These data support the use of Xpert in the initial evaluation of tuberculosis suspects and in algorithms assessing need for respiratory isolation.
C1 [Luetkemeyer, Anne F.; Havlir, Diane V.] Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV Infect Dis & Global Med, Box 0874,Bldg 80,995 Potrero Ave, San Francisco, CA 94110 USA.
[Firnhaber, Cynthia] Univ Witwatersrand, Fac Hlth Sci, Clin HIV Res Unit, Dept Internal Med, ZA-2050 Johannesburg, South Africa.
[Firnhaber, Cynthia; Sanne, Ian M.] Right Care, Johannesburg, South Africa.
[Kendall, Michelle A.; Wu, Xingye] Harvard Univ, TH Chan Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA.
[Mazurek, Gerald H.; Metchock, Beverly] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA.
[Benator, Debra A.] Vet Affairs Med Ctr, Infect Dis Sect, 50 Irving St NW, Washington, DC 20422 USA.
[Benator, Debra A.] George Washington Univ, Washington, DC USA.
[Arduino, Roberto] Univ Texas Hlth Sci Ctr Houston, Div Infect Dis, Dept Internal Med, Houston, TX 77030 USA.
[Fernandez, Michel] Univ N Texas, Hlth Sci Ctr, Tarrant Cty Hlth Dept, Ft Worth, TX USA.
[Guy, Elizabeth] Baylor Coll Med, Ben Taub Gen Hosp, Sect Pulm Crit Care & Sleep Med, Houston, TX 77030 USA.
[Johnson, Pamela] Cepheid, Sunnyvale, CA USA.
[Sattler, Fred] Univ So Calif, Keck Sch Med, Div Infect Dis, Los Angeles, CA 90033 USA.
[Telzak, Edward] Albert Einstein Coll Med, St Barnabus Hosp Hlth Syst, Bronx, NY 10467 USA.
[Wang, Yun F.] Emory Univ, Sch Med, Grady Mem Hosp, Atlanta, GA USA.
[Weiner, Marc] Univ Texas Hlth Sci Ctr San Antonio, Vet Adm Med Ctr, Dept Med, San Antonio, TX 78229 USA.
[Swindells, Susan] Univ Nebraska Med Ctr, Internal Med Infect Dis, Lincoln, NE USA.
[Sanne, Ian M.] Univ Witwatersrand, Fac Hlth Sci, Dept Internal Med, Johannesburg, South Africa.
[Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas Fiocruz, Dept Infect Dis, Rio De Janeiro, Brazil.
[Alland, David] Rutgers New Jersey Med Sch, Div Infect Dis, Newark, NJ USA.
RP Luetkemeyer, AF (reprint author), Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV Infect Dis & Global Med, Box 0874,Bldg 80,995 Potrero Ave, San Francisco, CA 94110 USA.
EM annie.luetkemeyer@ucsf.edu
RI Kendall, Michelle/B-7665-2016
OI Kendall, Michelle/0000-0001-9160-4544
FU National Institute of Allergy and Infectious Diseases through the ACTG
[AI068634, U01AI068636, UM1 AI106701]; CDC through the TBTC; Division of
Tuberculosis Elimination; National Center for HIV; Viral Hepatitis; STD;
TB Prevention; National Institute of Mental Health; National Institute
of Dental and Craniofacial Research
FX This work was supported by the National Institute of Allergy and
Infectious Diseases through the ACTG (grant numbers AI068634,
U01AI068636, and UM1 AI106701); the CDC through the TBTC and the
Division of Tuberculosis Elimination, National Center for HIV, Viral
Hepatitis, STD, and TB Prevention; the National Institute of Mental
Health, and the National Institute of Dental and Craniofacial Research.
NR 15
TC 5
Z9 5
U1 1
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAY 1
PY 2016
VL 62
IS 9
BP 1081
EP 1088
DI 10.1093/cid/ciw035
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DM5IO
UT WOS:000376381800004
PM 26839383
ER
PT J
AU Ford, BK
Ingersoll-Dayton, B
Burgio, K
AF Ford, Bryan Keith
Ingersoll-Dayton, Berit
Burgio, Kathryn
TI Care Transition Experiences of Older Veterans and Their Caregivers
SO HEALTH & SOCIAL WORK
LA English
DT Article
DE caregiving; care transitions; health care; veterans
ID FOLLOW-UP; QUALITY; INFORMATION; TECHNOLOGY; ELDERS
AB This study's main objective was to examine care transition experiences of older veterans and their caregivers. Fifty patients age 65 years and older, discharged from a Veterans Affairs Medical Center hospital, completed the Care Transitions Measure-15 (TM) survey three to four weeks postdischarge. Seven patients and six caregivers participated in semistructured interviews. Overall, the quality of care transitions was rated as good; however, some items were indicated as problematic for veterans. Themes that emerged included agreeableness, frustration with complex information, caregiver education, and the timing and methods of information delivery. These findings have implications for all clinical staff working with veterans, and particularly for social workers facilitating care transitions for veterans and their caregivers.
C1 [Ford, Bryan Keith] Birmingham VA Med Ctr, Mental Hlth Intens Case Management Program, 700 South 19th St, Birmingham, AL 35233 USA.
[Ford, Bryan Keith; Burgio, Kathryn] Birmingham VA Med Ctr, GRECC, 700 South 19th St, Birmingham, AL 35233 USA.
[Ingersoll-Dayton, Berit] Univ Michigan, Sch Social Work, Joint Doctoral Program Social Work & Social Sci, Ann Arbor, MI 48109 USA.
RP Ford, BK (reprint author), Birmingham VA Med Ctr, Mental Hlth Intens Case Management Program, 700 South 19th St, Birmingham, AL 35233 USA.; Ford, BK (reprint author), Birmingham VA Med Ctr, GRECC, 700 South 19th St, Birmingham, AL 35233 USA.
EM bryanford@uabmc.edu
NR 40
TC 0
Z9 0
U1 3
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0360-7283
EI 1545-6854
J9 HEALTH SOC WORK
JI Health Soc. Work
PD MAY
PY 2016
VL 41
IS 2
BP 129
EP 138
DI 10.1093/hsw/hlw009
PG 10
WC Social Work
SC Social Work
GA DM5PJ
UT WOS:000376401800009
PM 27263203
ER
PT J
AU Hanson, L
VandeVusse, L
Jerme, M
Abad, CL
Safdar, N
AF Hanson, Lisa
VandeVusse, Leona
Jerme, Martha
Abad, Cybele L.
Safdar, Nasia
TI Probiotics for Treatment and Prevention of Urogenital Infections in
Women: A Systematic Review
SO JOURNAL OF MIDWIFERY & WOMENS HEALTH
LA English
DT Review
DE probiotics; urogenital; infections; women's health; systematic review
ID VULVO-VAGINAL CANDIDIASIS; LACTOBACILLUS-RHAMNOSUS GR-1;
PLACEBO-CONTROLLED TRIAL; BACTERIAL VAGINOSIS; DOUBLE-BLIND;
METRONIDAZOLE THERAPY; ORAL USE; VAGINITIS; TABLETS; ANTIBIOTICS
AB Introduction: Probiotics are a complementary and integrative therapy useful in the treatment and prevention of urogenital infections in women. This study extends the work of researchers who systematically investigated the scientific literature on probiotics to prevent or treat urogenital infections.
Methods: A systematic review was conducted to determine the efficacy of probiotics for prevention and/or treatment of urogenital infections in adult women from January 1, 2008, through June 30, 2015. We searched in CINAHL, MEDLINE, Cochrane Central Register of Controlled Trials, Web of Science, Dissertations and Theses, and Alt-HealthWatch. After removing duplicates and studies that did not meet inclusion criteria, 20 studies were reviewed. All included at least one species of Lactobacillus probiotic as an intervention for treatment or prevention of urogenital infections. Data extracted included samples, settings, study designs, intervention types, reported outcomes, follow-up periods, and results. We evaluated all randomized controlled trials for risk of bias and made quality appraisals on all studies.
Results: Fourteen of the studies focused on bacterial vaginosis (BV), 3 on urinary tract infections (UTIs), 2 on vulvovaginal candidiasis, and one on human papillomavirus (HPV) as identified on Papanicolaou test. Studies were heterogeneous in terms of design, intervention, and outcomes. Four studies were of good quality, 9 of fair, and 7 poor. Probiotic interventions were effective for treatment and prevention of BV, prevention of recurrences of candidiasis and UTIs, and clearing HPV lesions. No study reported significant adverse events related to the probiotic intervention.
Discussion: The quality of the studies in this systematic review varied. Although clinical practice recommendations were limited by the strength of evidence, probiotic interventions were effective in treatment and prevention of urogenital infections as alternatives or co-treatments. More good quality research is needed to strengthen the body of evidence needed for application by clinicians. (C) 2016 by the American College of Nurse-Midwives.
C1 [Hanson, Lisa] Marquette Univ, Coll Nursing, Midwifery Program, Milwaukee, WI 53233 USA.
[Hanson, Lisa] Aurora Midwifery & Wellness Ctr, Milwaukee, WI 53233 USA.
[VandeVusse, Leona] Marquette Univ, Coll Nursing, Milwaukee, WI 53233 USA.
[Jerme, Martha] Marquette Univ, Raynor Mem Lib, Milwaukee, WI 53233 USA.
[Abad, Cybele L.] Univ Philippines, Philippine Gen Hosp, Manila, Philippines.
[Safdar, Nasia] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med & Infect Dis, Madison, WI USA.
[Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Res, Madison, WI 53705 USA.
RP Hanson, L (reprint author), Marquette Univ, Coll Nursing, Nurse Midwifery Program, 530 N 16th St, Milwaukee, WI 53201 USA.
EM lisa.hanson@mu.edu
NR 45
TC 2
Z9 2
U1 5
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1526-9523
EI 1542-2011
J9 J MIDWIFERY WOM HEAL
JI J. Midwifery Women Health
PD MAY-JUN
PY 2016
VL 61
IS 3
SI SI
BP 339
EP 355
DI 10.1111/jmwh.12472
PG 17
WC Nursing
SC Nursing
GA DM7AC
UT WOS:000376503200006
PM 27218592
ER
PT J
AU Garrido, MM
Prigerson, HG
Bao, YH
Maciejewski, PK
AF Garrido, Melissa M.
Prigerson, Holly G.
Bao, Yuhua
Maciejewski, Paul K.
TI Chemotherapy Use in the Months Before Death and Estimated Costs of Care
in the Last Week of Life
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
DE Chemotherapy; end of life; advanced cancer; costs of care; financial
toxicity
ID CANCER-PATIENTS END; OF-LIFE; CLINICAL ONCOLOGY; AMERICAN SOCIETY;
MEDICARE BENEFICIARIES; PROSPECTIVE COHORT; ASSOCIATIONS; PREFERENCES;
STATEMENT; TOXICITY
AB Context. Considerable attention has been paid to the disproportionately high costs of care for patients nearing death, yet little is known about the costs associated with chemotherapy use among end-stage cancer patients.
Objectives. To compare costs of care other than chemotherapy in the last week of life based on whether cancer patients were using chemotherapy in the months just before death.
Methods. A total of 311 patients with advanced cancer who died between 2002 and 2008 were studied. Data included medical records, patient baseline surveys (median four months before death), and postmortem interviews of caregivers and clinicians. Costs of care were estimated based on reports of death site and services other than chemotherapy received in the week before death (e.g., resuscitation). We tested whether end-of-life (EOL) care preferences, do-not-resuscitate order completion, or EOL discussions accounted for relationships between chemotherapy use and estimated care costs.
Results. Half (50.5%) of patients were receiving chemotherapy at baseline. Estimated EOL care costs for patients with baseline chemotherapy use (median = $2681) were significantly higher than for patients without baseline chemotherapy use (median = $1092) (P = 0.003). This relationship persisted after adjusting for sociodemographic and clinical characteristics in a generalized linear model (mean incremental cost = $2681, 95% confidence interval $611-$4751, P = 0.01). None of the psychosocial variables accounted for the relationship between chemotherapy use and estimated care costs.
Conclusion. Chemotherapy for end-stage cancer patients is associated with higher estimated EOL care costs. Given evidence of limited benefit and potential harm of chemotherapy for end-stage cancer patients, the cost-effectiveness of such care is questioned and further study warranted. (C) 2016 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.
C1 [Garrido, Melissa M.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
[Garrido, Melissa M.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
[Prigerson, Holly G.; Bao, Yuhua; Maciejewski, Paul K.] Weill Cornell Med Coll, New York, NY USA.
RP Prigerson, HG (reprint author), Weill Cornell Med Coll, New York Presbyterian Hosp, Ctr Res End Life Care, 525 East 68th St,Box 39,1404 Baker Pavil, New York, NY 10065 USA.
EM hgp2001@med.cornell.edu
OI Garrido, Melissa/0000-0002-8986-3536
FU HSRD VA [CDP 12-255]; NCI NIH HHS [R01 CA106370, R35 CA197730, U54
CA156732]; NIA NIH HHS [P30 AG028741]; NIMH NIH HHS [R01 MH063892];
NIMHD NIH HHS [R01 MD007652]
NR 42
TC 4
Z9 4
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD MAY
PY 2016
VL 51
IS 5
BP 875
EP +
DI 10.1016/j.jpainsymman.2015.12.323
PG 9
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA DM7CJ
UT WOS:000376510700014
PM 26899821
ER
PT J
AU Soban, LM
Finley, EP
Miltner, RS
AF Soban, Lynn M.
Finley, Erin P.
Miltner, Rebecca S.
TI Identifying Patterns in Implementation of Hospital Pressure Ulcer
Prevention Programs A Multisite Qualitative Study
SO JOURNAL OF WOUND OSTOMY AND CONTINENCE NURSING
LA English
DT Article
DE Nursing; Organization and delivery of care; Pressure ulcer prevention;
Qualitative evaluation
ID HEALTH-CARE
AB PURPOSE: To describe the presence or absence of key components of hospital pressure ulcer (PU) prevention programs in 6 acute care hospitals.
DESIGN: Multisite comparative case study.
SUBJECTS AND SETTING: Using purposeful selection based on PU rates (high vs low) and hospital size, 6 hospitals within the Veterans Health Administration health care system were invited to participate. Key informant interviews (n = 48) were conducted in each of the 6 participating hospitals among individuals playing key roles in PU prevention: senior nursing leadership (n = 9), nurse manager (n = 7), wound care specialist (n = 6), frontline RNs (n = 26).
METHODS: Qualitative data were collected during face-to-face, semistructured interviews. Interview protocols were tailored to each interviewee's role with a core set of common questions covering 3 major content areas: (1) practice environment (eg, policies and wound care specialists), (2) current prevention practices (eg, conduct of PU risk assessment and skin inspection), and (3) barriers to PU prevention. We conducted structured coding of 5 key components of PU prevention programs and cross-case analysis to identify patterns in operationalization and implementation of program components across hospitals based on facility size and PU rates (low vs high).
RESULTS: All hospitals had implemented all PU prevention program components. Component operationalization varied considerably across hospitals. Wound care specialists were integral to the operationalization of the 4 other program components examined; however, staffing levels and work assignments of wound care specialists varied widely. Patterns emerged among hospitals with low and high PU rates with respect to wound care specialist staffing, data monitoring, and staff education.
CONCLUSION: We found hospital-level variations in PU prevention programs. Wound care specialist staffing may represent a potential point of leverage in achieving other PU program components, particularly performance monitoring and staff education.
C1 [Soban, Lynn M.] Cedars Sinai Med Ctr, Nursing Res & Dev, 8700 Beverly Blvd,Ste 2021, Los Angeles, CA 90048 USA.
[Soban, Lynn M.] Vet Affairs Greater Los Angeles Healthcare Syst, VA HSR&D Ctr Study Healthcare Innovat Implementat, North Hills, CA USA.
[Finley, Erin P.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Finley, Erin P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Finley, Erin P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
[Miltner, Rebecca S.] Univ Alabama, Dept Family Community & Hlth Syst, Sch Nursing, Birmingham, W Midlands, England.
RP Soban, LM (reprint author), Cedars Sinai Med Ctr, Nursing Res & Dev, 8700 Beverly Blvd,Ste 2021, Los Angeles, CA 90048 USA.
EM lynn.soban@cshs.org
OI Miltner, Rebecca/0000-0002-4653-0328; Finley, Erin/0000-0003-4497-7721
FU VA HSRD [NRI 10-124-2, CDA 06-301]
FX This work was supported by VA HSR&D (Project # NRI 10-124-2). At the
time of this work, Dr Soban was supported by a Career Development Award
from the VA HSR&D Service (Project # CDA 06-301).
NR 19
TC 1
Z9 1
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1071-5754
EI 1528-3976
J9 J WOUND OSTOMY CONT
JI J. Wound Ostomy Cont. Nurs.
PD MAY-JUN
PY 2016
VL 43
IS 3
BP 248
EP 253
DI 10.1097/WON.0000000000000228
PG 6
WC Nursing
SC Nursing
GA DM6KL
UT WOS:000376460800005
PM 27167318
ER
PT J
AU Park, LG
Beatty, A
Stafford, Z
Whooley, MA
AF Park, Linda G.
Beatty, Alexis
Stafford, Zoey
Whooley, Mary A.
TI Mobile Phone Interventions for the Secondary Prevention of
Cardiovascular Disease
SO PROGRESS IN CARDIOVASCULAR DISEASES
LA English
DT Review
DE Cardiovascular disease; Mobile health; Text messaging; Mobile
applications; Mobile phone; Systematic review
ID RANDOMIZED CONTROLLED-TRIAL; CORONARY-HEART-DISEASE; IMPROVE MEDICATION
ADHERENCE; TEXT MESSAGING INTERVENTION; CARDIAC REHABILITATION; FAILURE
PATIENTS; PHYSICAL-ACTIVITY; SELF-MANAGEMENT; ARTERY-DISEASE; RISK
REDUCTION
AB Mobile health in the form of text messaging and mobile applications provides an innovative and effective approach to promote prevention and management of cardiovascular disease (CVD); however, the magnitude of these effects is unclear. Through a comprehensive search of databases from 2002-2016, we conducted a quantitative systematic review. The selected studies were critically evaluated to extract and summarize pertinent characteristics and outcomes. A large majority of studies (22 of 28, 79%) demonstrated text messaging, mobile applications, and telemonitoring via mobile phones were effective in improving outcomes. Some key factors associated with successful interventions included personalized messages with tailored advice, greater engagement (2-way text messaging, higher frequency of messages), and use of multiple modalities. Overall, text messaging appears more effective than smartphone-based interventions. Incorporating principles of behavioral activation will help promote and sustain healthy lifestyle behaviors in patients with CVD that result in improved clinical outcomes. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Park, Linda G.] Univ Calif San Francisco, Dept Community Hlth Syst, 2 Koret Way,Box 0608, San Francisco, CA 94143 USA.
[Beatty, Alexis] Vet Affairs Puget Sound Med Ctr, Cardiol Sect, Seattle, WA USA.
[Beatty, Alexis] Univ Washington, Dept Med, Seattle, WA 98195 USA.
[Stafford, Zoey] Univ Calif San Francisco, Dept Social & Behav Sci, San Francisco, CA 94143 USA.
[Whooley, Mary A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Whooley, Mary A.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA.
RP Park, LG (reprint author), Univ Calif San Francisco, Dept Community Hlth Syst, 2 Koret Way,Box 0608, San Francisco, CA 94143 USA.
EM Linda.Park@ucsf.edu; beattya@uw.edu; Zoey.Stafford@ucsf.edu;
Mary.Whooley@ucsf.edu
RI Emchi, Karma/Q-1952-2016
FU National Center for Advancing Translational Sciences of the NIH
[KL2TR000143]
FX Research reported in this publication was supported by the National
Center for Advancing Translational Sciences of the NIH under Award
Number KL2TR000143. Its contents are solely the responsibility of the
authors and do not necessarily represent the official views of the NIH.
NR 54
TC 1
Z9 1
U1 4
U2 14
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0033-0620
EI 1873-1740
J9 PROG CARDIOVASC DIS
JI Prog. Cardiovasc. Dis.
PD MAY-JUN
PY 2016
VL 58
IS 6
BP 639
EP 650
DI 10.1016/j.pcad.2016.03.002
PG 12
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DM7PJ
UT WOS:000376552200009
PM 27001245
ER
PT J
AU Horan, WP
Jimenez, AM
Lee, J
Wynn, JK
Eisenberger, NI
Green, MF
AF Horan, William P.
Jimenez, Amy M.
Lee, Junghee
Wynn, Jonathan K.
Eisenberger, Naomi I.
Green, Michael F.
TI Pain empathy in schizophrenia: an fMRI study
SO SOCIAL COGNITIVE AND AFFECTIVE NEUROSCIENCE
LA English
DT Article
DE empathy; schizophrenia; self-related processing; pain; affective
empathy; social cognition
ID PSYCHIATRIC RATING-SCALE; PERSPECTIVE-TAKING; SOCIAL-NEUROSCIENCE;
EMOTION REGULATION; PREFRONTAL CORTEX; COGNITIVE EMPATHY; BRAIN
ACTIVATION; SELF; METAANALYSIS; DYSFUNCTION
AB Although it has been proposed that schizophrenia is characterized by impaired empathy, several recent studies found intact neural responses on tasks measuring the affective subdomain of empathy. This study further examined affective empathy in 21 schizophrenia outpatients and 21 healthy controls using a validated pain empathy paradigm with two components: (i) observing videos of people described as medical patients who were receiving a painful sound stimulation treatment; (ii) listening to the painful sounds (to create regions of interest). The observing videos component incorporated experimental manipulations of perspective taking (instructions to imagine 'Self' vs 'Other' experiencing pain) and cognitive appraisal (information about whether treatment was 'Effective' vs 'Not Effective'). When considering activation across experimental conditions, both groups showed similar dorsal anterior cingulate cortex (dACC) and anterior insula (AI) activation while merely observing others in pain. However, there were group differences associated with perspective taking: controls showed relatively greater dACC and AI activation for the Self vs Other contrast whereas patients showed relatively greater activation in these and additional regions for the Other vs Self contrast. Although patients demonstrated grossly intact neural activity while observing others in pain, they showed more subtle abnormalities when required to toggle between imagining themselves vs others experiencing pain.
C1 [Horan, William P.; Jimenez, Amy M.; Lee, Junghee; Wynn, Jonathan K.; Green, Michael F.] VA Greater Angeles Healthcare Syst, MIRECC 210A,Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
[Horan, William P.; Jimenez, Amy M.; Lee, Junghee; Wynn, Jonathan K.; Eisenberger, Naomi I.; Green, Michael F.] Univ Calif Los Angeles, MIRECC 210A,Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
RP Horan, WP (reprint author), VA Greater Angeles Healthcare Syst, MIRECC 210A,Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.; Horan, WP (reprint author), Univ Calif Los Angeles, MIRECC 210A,Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM horan@ucla.edu
RI Lee, Junghee/C-5226-2014
OI Lee, Junghee/0000-0001-9567-8700
FU VA Career Development Award; NIMH [MH065707, MH43292]
FX Support for this study came from a VA Career Development Award (William
P. Horan, PhD.) and NIMH Grants MH065707 and MH43292 (Michael F. Green,
PhD).
NR 68
TC 1
Z9 1
U1 5
U2 14
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1749-5016
EI 1749-5024
J9 SOC COGN AFFECT NEUR
JI Soc. Cogn. Affect. Neurosci.
PD MAY
PY 2016
VL 11
IS 5
BP 783
EP 792
DI 10.1093/scan/nsw002
PG 10
WC Neurosciences; Psychology; Psychology, Experimental
SC Neurosciences & Neurology; Psychology
GA DM9AH
UT WOS:000376655100010
PM 26746181
ER
PT J
AU Schenning, KJ
Murchison, CF
Mattek, NC
Silbert, LC
Kaye, JA
Quinn, JF
AF Schenning, Katie J.
Murchison, Charles F.
Mattek, Nora C.
Silbert, Lisa C.
Kaye, Jeffrey A.
Quinn, Joseph F.
TI Surgery is associated with ventricular enlargement as well as cognitive
and functional decline
SO ALZHEIMERS & DEMENTIA
LA English
DT Article
DE Epidemiology; Anesthesia; Surgery; Cognitive decline; Postoperative;
Apolipoprotein E epsilon 4; Alzheimer's disease; Cohort study;
Volumetric MRI
ID ILLNESS RATING-SCALE; ALZHEIMERS-DISEASE; ANESTHESIA; DEMENTIA;
DYSFUNCTION; POPULATION; PROGRESSION; IMPAIRMENT; RISK; OLD
AB Introduction: In preclinical studies, surgery/anesthesia contribute to cognitive decline and enhance neuropathologic changes underlying Alzheimer's disease (AD). Nevertheless, the link between surgery, anesthesia, apolipoprotein E epsilon 4 (APOE epsilon 4), and AD remains unclear.
Methods: We performed a retrospective cohort analysis of two prospective longitudinal aging studies. Mixed-effects statistical models were used to assess the relationship between surgical/anesthetic exposure, the APOE genotype, and rate of change in measures of cognition, function, and brain volumes.
Results: The surgical group (n = 182) experienced a more rapid rate of deterioration compared with the nonsurgical group (n = 345) in several cognitive, functional, and brain magnetic resonance imaging measures. Furthermore, there was a significant synergistic effect of anesthesia/surgery exposure and presence of the APOE epsilon 4 allele in the decline of multiple cognitive and functional measures.
Discussion: These data provide insight into the role of surgical exposure as a risk factor for cognitive and functional decline in older adults. (C) 2015 Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
C1 [Schenning, Katie J.] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA.
[Murchison, Charles F.; Kaye, Jeffrey A.; Quinn, Joseph F.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.
[Mattek, Nora C.; Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, Oregon Ctr Aging & Technol, Portland, OR 97201 USA.
[Silbert, Lisa C.; Kaye, Jeffrey A.; Quinn, Joseph F.] Portland VA Med Ctr, Dept Neurol, Portland, OR USA.
[Silbert, Lisa C.; Kaye, Jeffrey A.; Quinn, Joseph F.] Oregon Hlth & Sci Univ, Layton Aging & Alzheimers Dis Ctr, Portland, OR 97201 USA.
RP Schenning, KJ (reprint author), Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA.
EM malcore@ohsu.edu
OI Schenning, Katie/0000-0002-1784-0749
FU Agency for Healthcare Research and Quality [K12 HD 043488]; National
Institutes of Health [P30AG024978, R01AG024059, P30AG008017,
1U10NS077350-01, R01AG036772, R01AG043398]; Merit Review Grant from U.S.
Department of Veterans Affairs
FX This study was funded in part by an Agency for Healthcare Research and
Quality-funded BIRCWH K12 award (K12 HD 043488) and by grants from the
National Institutes of Health (P30AG024978, R01AG024059, P30AG008017,
1U10NS077350-01, R01AG036772, and R01AG043398) and a Merit Review Grant
from the U.S. Department of Veterans Affairs. The authors thank Kirk
Hogan, for reviewing drafts of the article.
NR 25
TC 6
Z9 6
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1552-5260
EI 1552-5279
J9 ALZHEIMERS DEMENT
JI Alzheimers. Dement.
PD MAY
PY 2016
VL 12
IS 5
BP 590
EP 597
DI 10.1016/j.jalz.2015.10.004
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA DM0RT
UT WOS:000376054200008
PM 26610898
ER
PT J
AU Mathews, R
Fonarow, GC
Li, S
Peterson, ED
Rumsfeld, JS
Heidenreich, PA
Roe, MT
Oetgen, WJ
Jollis, JG
Cannon, CP
de Lemos, JA
Wang, TY
AF Mathews, Robin
Fonarow, Gregg C.
Li, Shuang
Peterson, Eric D.
Rumsfeld, John S.
Heidenreich, Paul A.
Roe, Matthew T.
Oetgen, William J.
Jollis, James G.
Cannon, Christopher P.
de Lemos, James A.
Wang, Tracy Y.
CA Natl Cardiovasc Data Registry
TI Comparison of performance on Hospital Compare process measures and
patient outcomes between hospitals that do and do not participate in
Acute Coronary Treatment and Intervention Outcomes Network Registry-Get
With The Guidelines
SO AMERICAN HEART JOURNAL
LA English
DT Article
ID ACUTE MYOCARDIAL-INFARCTION; MORTALITY-RATES; PROGRAM; ASSOCIATION;
MANAGEMENT
AB Background Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines (ACTION Registry-GWTG) was designed to measure and improve the treatment and outcomes of patients with acute myocardial infarction (AMI), yet it is unknown whether performance of Medicare Hospital Compare metrics and outcomes differ between hospitals participating versus those not participating in the registry.
Methods Using 2007 to 2010 Hospital Compare data, we matched participating to nonparticipating hospitals based on teaching status, size, percutaneous coronary intervention capability, and baseline (2007) Hospital Compare AMI process measure performance/We used linear mixed modeling to compare 2010 Hospital Compare process measure adherence, 30-day risk-adjusted mortality, and readmission rates/We repeated these analyses after stratification according to baseline performance level.
Results Compared with nonparticipating hospitals, those participating were larger (median 288 vs 139 beds, P < .0001), more often teaching hospitals (18.8% vs 6.3%, P < .0001), and more likely had interventional catheterization lab capabilities (85.7% vs 34.0%, P < .0001)/Among 502 matched pairs of participating and nonparticipating hospitals, we found high levels of process measure adherence in both 2007 and 2010, with minimal differences between them/Rates of 30-day mortality and readmission in 2010 were also similar between both groups/Results were consistent across strata of baseline performance level.
Conclusions In this observational analysis, there were no significant differences in the performance of Hospital Compare process measures or outcomes between hospitals in Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines and other hospitals not in the registry/However, baseline performance on the Hospital Compare process measures was very high in both groups, suggesting the need for new quality improvement foci to further improve patient outcomes.
C1 [Mathews, Robin; Li, Shuang; Peterson, Eric D.; Roe, Matthew T.; Jollis, James G.; Wang, Tracy Y.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA.
[Fonarow, Gregg C.] Univ Calif Los Angeles, Ahmanson UCLA Cardiomyopathy Ctr, Los Angeles, CA USA.
[Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA.
[Heidenreich, Paul A.] VA Palo Alto Hlth Syst, Palo Alto, CA USA.
[Oetgen, William J.] Amer Coll Cardiol, Washington, DC USA.
[Cannon, Christopher P.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
[de Lemos, James A.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
RP Mathews, R (reprint author), Duke Univ, Med Ctr, 2400 Pratt St, Durham, NC 27705 USA.
EM robin.mathews@duke.edu
FU American College of Cardiology; American Heart Association; Eli Lilly
Company; Janssen Pharmaceutical Products; Society of Thoracic Surgeons;
KAI Pharmaceuticals; Sanofi-Aventis; AstraZeneca; Gilead; Lilly;
Medicines Company; Canyon Pharmaceuticals; American College of
Cardiology Foundation's NCDR; Society of Cardiovascular Patient Care;
American College of Emergency Physicians; Society of Hospital Medicine
FX Dr Peterson reports research funding from the American College of
Cardiology, the American Heart Association, Eli Lilly & Company, Janssen
Pharmaceutical Products, and the Society of Thoracic Surgeons
(significant), and consulting for Merck & Co (modest), Boehringer
Ingelheim, Genentech, Janssen Pharmaceutical Products, and
Sanofi-Aventis (significant).; Dr Roe reports research funding from Eli
Lilly & Company, KAI Pharmaceuticals, and Sanofi-Aventis; educational
activities from Astra Zeneca and Janssen Pharmaceuticals (both modest);
consulting for Bristol Myers Squibb, Eli Lilly & Company, Glaxo Smith
Kline, and Regeneron (all modest) and Merck & Company, Janssen
Pharmaceuticals, and Daiichi-Sankyo (all significant).; Dr Wang reports
research funding from AstraZeneca, Gilead, Lilly, The Medicines Company,
and Canyon Pharmaceuticals (all significant); educational activities or
lectures (generates money for Duke) for AstraZeneca (modest); consulting
(including CME) for Medco (modest) and American College of Cardiology
(significant).; This research was supported by the American College of
Cardiology Foundation's NCDR. The views expressed in this manuscript
represent those of the author(s) and do not necessarily represent the
official views of the NCDR or its associated professional societies
identified at www.ncdr.com.; ACTION Registry-GWTG is an initiative of
the American College of Cardiology Foundation and the American Heart
Association, with partnering support from the Society of Cardiovascular
Patient Care, the American College of Emergency Physicians, and the
Society of Hospital Medicine.
NR 19
TC 0
Z9 0
U1 1
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
EI 1097-5330
J9 AM HEART J
JI Am. Heart J.
PD MAY
PY 2016
VL 175
BP 1
EP 8
DI 10.1016/j.ahj.2016.01.008
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DL5CP
UT WOS:000375655200002
PM 27179718
ER
PT J
AU Reed, BN
Fox, ER
Konig, M
Jackevicius, CA
Masoudi, FA
Rabinstein, AA
Page, RL
AF Reed, Brent N.
Fox, Erin R.
Konig, Madeleine
Jackevicius, Cynthia A.
Masoudi, Frederick A.
Rabinstein, Alejandro A.
Page, Robert L., II
TI The impact of drug shortages on patients with cardiovascular disease:
causes, consequences, and a call to action
SO AMERICAN HEART JOURNAL
LA English
DT Article
ID HEALTH; CRISIS
AB Shortages of cardiovascular drugs have become increasingly common, representing an ongoing public health crisis. Given few therapeutic alternatives to many of the drugs in short supply, these shortages also pose a major challenge for cardiovascular care professionals. Although changes in the regulatory environment have led to some improvements in recent years, problems involving manufacturing processes remain the most common underlying cause. Because of the complex nature of drug shortages, sustainable solutions to prevent and mitigate them will require collaboration between regulatory agencies, drug manufacturers, and other key stakeholder groups. In this report, we describe the scope of the cardiovascular drug shortage crisis in the United States, including its underlying causes and the efforts currently being made to address it. Furthermore, we provide specific recommendations for how cardiovascular care professionals can be involved in efforts to limit the impact of drug shortages on patient care as well as policy changes aimed at preventing and mitigating them.
C1 [Reed, Brent N.] Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA.
[Fox, Erin R.] Univ Utah Hlth Care, Salt Lake City, UT USA.
[Konig, Madeleine] Amer Heart Assoc, Dallas, TX USA.
[Jackevicius, Cynthia A.] Western Univ Hlth Sci, Pomona, CA USA.
[Jackevicius, Cynthia A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Jackevicius, Cynthia A.] Univ Toronto, Inst Clin Evaluat Sci, Toronto, ON, Canada.
[Jackevicius, Cynthia A.] Univ Hlth Network, Toronto, ON, Canada.
[Masoudi, Frederick A.] Univ Colorado, Anschuts Med Campus, Aurora, CO USA.
[Rabinstein, Alejandro A.] Mayo Clin, Rochester, MN USA.
[Page, Robert L., II] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Aurora, CO USA.
RP Reed, BN (reprint author), Univ Maryland, Sch Pharm, Dept Pharm Practice & Sci, BCPS AQ Cardiol, 20 N Pine St,Off S428, Baltimore, MD 21201 USA.
EM breed@rx.umaryland.edu
NR 41
TC 1
Z9 1
U1 1
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
EI 1097-5330
J9 AM HEART J
JI Am. Heart J.
PD MAY
PY 2016
VL 175
BP 130
EP 141
DI 10.1016/j.ahj.2016.02.004
PG 12
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DL5CP
UT WOS:000375655200016
PM 27179732
ER
PT J
AU Lum, HD
Sudore, RL
AF Lum, Hillary D.
Sudore, Rebecca L.
TI Advance Care Planning and Goals of Care Communication in Older Adults
with Cardiovascular Disease and Multi-Morbidity
SO CLINICS IN GERIATRIC MEDICINE
LA English
DT Article
DE Advance care planning; Goals of care; Patient-doctor relationship;
Communication; Older adults; Cardiovascular disease; Multi-morbidity
ID RANDOMIZED CONTROLLED-TRIAL; SURROGATE DECISION-MAKING; OF-LIFE CARE;
HEART-FAILURE; ELDERLY-PATIENTS; HOSPITALIZED-PATIENTS; SERIOUS ILLNESS;
DIRECTIVES; END; ASSOCIATION
AB This article provides an approach to advance care planning (ACP) and goals of care communication in older adults with cardiovascular disease and multi-morbidity. The goal of ACP is to ensure that the medical care patients receive is aligned with their values and preferences. In this article, the authors outline common benefits and challenges to ACP for older adults with cardiovascular disease and multimorbidity. Recognizing that these patients experience diverse disease trajectories and receive care in multiple health care settings, the authors provide practical steps for multidisciplinary teams to integrate ACP into brief clinic encounters.
C1 [Lum, Hillary D.] VA Eastern Colorado Geriatr Res Educ & Clin Ctr G, 1055 Clermont St, Denver, CO 80220 USA.
[Lum, Hillary D.] Univ Colorado, Sch Med, Dept Med, Div Geriatr Med, 12631 East 17th Ave,B-179, Aurora, CO 80045 USA.
[Sudore, Rebecca L.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Med, Div Geriatr, SFVAMC 4150 Clement St 151R, San Francisco, CA 94121 USA.
RP Lum, HD (reprint author), 12631 East 17th Ave,B-179, Aurora, CO 80045 USA.
EM Hillary.Lum@ucdenver.edu
FU National Palliative Care Research Center (NPCRC)
FX The authors do not have commercial or financial conflicts of interest to
disclose. This work was supported in by part by a Junior Faculty Career
Development Award from the National Palliative Care Research Center
(NPCRC).
NR 38
TC 0
Z9 0
U1 4
U2 7
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0749-0690
EI 1879-8853
J9 CLIN GERIATR MED
JI Clin. Geriatr. Med.
PD MAY
PY 2016
VL 32
IS 2
BP 247
EP +
DI 10.1016/j.cger.2016.01.011
PG 15
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA DM2XZ
UT WOS:000376212700004
PM 27113144
ER
PT J
AU Hennig, S
Svensson, EM
Niebecker, R
Fourie, PB
Weiner, MH
Bonora, S
Peloquin, CA
Gallicano, K
Flexner, C
Pym, A
Vis, P
Olliaro, PL
McIlleron, H
Karlsson, MO
AF Hennig, Stefanie
Svensson, Elin M.
Niebecker, Ronald
Fourie, P. Bernard
Weiner, Marc H.
Bonora, Stefano
Peloquin, Charles A.
Gallicano, Keith
Flexner, Charles
Pym, Alex
Vis, Peter
Olliaro, Piero L.
McIlleron, Helen
Karlsson, Mats O.
TI Population pharmacokinetic drug-drug interaction pooled analysis of
existing data for rifabutin and HIV PIs
SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
LA English
DT Article
ID DIAGNOSED PULMONARY TUBERCULOSIS; ACQUIRED RIFAMYCIN RESISTANCE; EARLY
BACTERICIDAL ACTIVITY; VIRUS-INFECTED PATIENTS; SPUTUM VIABLE COUNTS;
HEALTHY-VOLUNTEERS; ANTIRETROVIRAL THERAPY; RIFAMPICIN; RITONAVIR;
LOPINAVIR/RITONAVIR
AB Extensive but fragmented data from existing studies were used to describe the drug-drug interaction between rifabutin and HIV PIs and predict doses achieving recommended therapeutic exposure for rifabutin in patients with HIV-associated TB, with concurrently administered PIs.
Individual-level data from 13 published studies were pooled and a population analysis approach was used to develop a pharmacokinetic model for rifabutin, its main active metabolite 25-O-desacetyl rifabutin (des-rifabutin) and drug-drug interaction with PIs in healthy volunteers and patients who had HIV and TB (TB/HIV).
Key parameters of rifabutin affected by drug-drug interaction in TB/HIV were clearance to routes other than des-rifabutin (reduced by 76%-100%), formation of the metabolite (increased by 224% in patients), volume of distribution (increased by 606%) and distribution to the peripheral compartment (reduced by 47%). For des-rifabutin, clearance was reduced by 35%-76% and volume of distribution increased by 67%-240% in TB/HIV. These changes resulted in overall increased exposure to rifabutin in TB/HIV patients by 210% because of the effects of PIs and 280% with ritonavir-boosted PIs.
Given together with non-boosted or ritonavir-boosted PIs, rifabutin at 150 mg once daily results in similar or higher exposure compared with rifabutin at 300 mg once daily without concomitant PIs and may achieve peak concentrations within an acceptable therapeutic range. Although 300 mg of rifabutin every 3 days with boosted PI achieves an average equivalent exposure, intermittent doses of rifamycins are not supported by current guidelines.
C1 [Hennig, Stefanie] Univ Queensland, Sch Pharm, Brisbane, Qld, Australia.
[Hennig, Stefanie; Svensson, Elin M.; Niebecker, Ronald; Karlsson, Mats O.] Uppsala Univ, Dept Pharmaceut Biosci, Uppsala, Sweden.
[Fourie, P. Bernard] Univ Pretoria, Dept Med Microbiol, ZA-0002 Pretoria, South Africa.
[Weiner, Marc H.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Weiner, Marc H.] Vet Adm Med Ctr, San Antonio, TX USA.
[Bonora, Stefano] Univ Turin, Dept Med Sci, Unit Infect Dis, Turin, Italy.
[Peloquin, Charles A.] Univ Florida, Coll Pharm, Gainesville, FL USA.
[Peloquin, Charles A.] Univ Florida, Emerging Pathogens Inst, Gainesville, FL USA.
[Gallicano, Keith] Novum Pharmaceut Res Serv, Murrieta, CA USA.
[Flexner, Charles] Johns Hopkins Adult AIDS Clin Trials Unit, Div Clin Pharmacol, Baltimore, MD USA.
[Pym, Alex] MRC, TB Res Unit, Durban, South Africa.
[Pym, Alex] KwaZulu Natal Res Inst TB & HIV K RITH, Durban, South Africa.
[Vis, Peter] Janssen Infect Dis BVBA, Beerse, Belgium.
[Olliaro, Piero L.] WHO, Special Programme Res & Training Trop Dis TDR, CH-1211 Geneva, Switzerland.
[McIlleron, Helen] Univ Cape Town, Dept Med, Div Clin Pharmacol, ZA-7925 Cape Town, South Africa.
RP Hennig, S (reprint author), Univ Queensland, Pharm Australia Ctr Excellence, Sch Pharm, 20 Cornwall St, Woolloongabba, Qld 4102, Australia.
EM s.hennig@uq.edu.au
RI Hennig, Stefanie/E-4426-2011
OI Hennig, Stefanie/0000-0001-5972-3711; Pym,
Alexander/0000-0002-6260-8180; McIlleron, Helen/0000-0002-0982-6226
FU Special Programme for Research and Training in Tropical Diseases (TDR)
of the World Health Organization (WHO); National Research Foundation of
South Africa [90729]; National Institute of Allergy and Infectious
Diseases, National Institute of Mental Health (NIMH) [U01AI068636];
National Institute of Dental and Craniofacial Research (NIDCR); United
States Government Division of Tuberculosis Elimination, National Center
for HIV, Viral Hepatitis, STD, and TB Prevention; Centers for Disease
Control and Prevention [AI69464]; Swedish Research Council
[521-2011-3442]; Australian Centre of Pharmacometrics
FX This project was supported by the Special Programme for Research and
Training in Tropical Diseases (TDR) of the World Health Organization
(WHO). H. M. was supported in part by the National Research Foundation
of South Africa (Grant Number 90729). Support for one
dataset37 that contributed data to this study received
funding (Award Number U01AI068636) from the National Institute of
Allergy and Infectious Diseases, National Institute of Mental Health
(NIMH), and National Institute of Dental and Craniofacial Research
(NIDCR); two other datasets contributing data were supported by the
United States Government Division of Tuberculosis Elimination, National
Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for
Disease Control and Prevention. AIDS CTU Grant # AI69464, or the NCT
(National Clinical Trials) number for ACTG 365, NCT00000877.; E. M. S.
and M. O. K. were supported by the Swedish Research Council (Grant
Number 521-2011-3442). The NONMEM license used was supported in part by
the Australian Centre of Pharmacometrics. A portion of the computations
was performed on resources provided by the Swedish National
Infrastructure for Computing (SNIC) at UPPMAX.
NR 75
TC 1
Z9 1
U1 5
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-7453
EI 1460-2091
J9 J ANTIMICROB CHEMOTH
JI J. Antimicrob. Chemother.
PD MAY
PY 2016
VL 71
IS 5
BP 1330
EP 1340
DI 10.1093/jac/dkv470
PG 11
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA DM4BT
UT WOS:000376291300027
PM 26832753
ER
PT J
AU Samantaray, S
Das, A
Matzelle, DC
Yu, SP
Wei, L
Varma, A
Ray, SK
Banik, NL
AF Samantaray, Supriti
Das, Arabinda
Matzelle, Denise C.
Yu, Shan P.
Wei, Ling
Varma, Abhay
Ray, Swapan K.
Banik, Naren L.
TI Administration of low dose estrogen attenuates persistent inflammation,
promotes angiogenesis, and improves locomotor function following chronic
spinal cord injury in rats
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article
DE angiogenesis; axonal protection; chronic spinal cord injury; locomotor
function; low dose estrogen; neuroprotection
ID PRIMARY CORTICAL-NEURONS; APOPTOTIC CELL-DEATH; KAPPA-B ACTIVATION;
CALPAIN INHIBITOR; SECONDARY INJURY; CONTROLLED-TRIAL; RECEPTOR-ALPHA;
FIBROTIC SCAR; BRAIN-INJURY; BLOOD-FLOW
AB Spinal cord injury (SCI) causes loss of neurological function and, depending upon the severity of injury, may lead to paralysis. Currently, no FDA-approved pharmacotherapy is available for SCI. High-dose methylprednisolone is widely used, but this treatment is controversial. We have previously shown that low doses of estrogen reduces inflammation, attenuates cell death, and protects axon and myelin in SCI rats, but its effectiveness in recovery of function is not known. Therefore, the goal of this study was to investigate whether low doses of estrogen in post-SCI would reduce inflammation, protect cells and axons, and improve locomotor function during the chronic phase of injury. Injury (40g.cm force) was induced at thoracic 10 in young adult male rats. Rats were treated with 10 or 100 mu g 17 beta-estradiol (estrogen) for 7days following SCI and compared with vehicle-treated injury and laminectomy (sham) controls. Histology (H&E staining), immunohistofluorescence, Doppler laser technique, and Western blotting were used to monitor tissue integrity, gliosis, blood flow, angiogenesis, the expression of angiogenic factors, axonal degeneration, and locomotor function (Basso, Beattie, and Bresnahan rating) following injury. To assess the progression of recovery, rats were sacrificed at 7, 14, or 42days post injury. A reduction in glial reactivity, attenuation of axonal and myelin damage, protection of cells, increased expression of angiogenic factors and microvessel growth, and improved locomotor function were found following estrogen treatment compared with vehicle-treated SCI rats. These results suggest that treatment with a very low dose of estrogen has significant therapeutic implications for the improvement of locomotor function in chronic SCI.
C1 [Samantaray, Supriti; Das, Arabinda; Matzelle, Denise C.; Varma, Abhay; Banik, Naren L.] Med Univ S Carolina, Dept Neurol & Neurosurg, 96 Jonathan Lucas St, Charleston, SC 29425 USA.
[Yu, Shan P.; Wei, Ling] Emory Univ, Sch Med, Dept Anesthesia, Atlanta, GA 30322 USA.
[Ray, Swapan K.] Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29208 USA.
[Banik, Naren L.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA.
RP Banik, NL (reprint author), Med Univ S Carolina, Dept Neurol & Neurosurg, 96 Jonathan Lucas St, Charleston, SC 29425 USA.; Banik, NL (reprint author), Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA.
EM baniknl@musc.edu
FU NIH [R01-NS31622, R01-NS45967]; Veterans Administration [1IOBX00126,
1IOBX002349]; South Carolina State Spinal Cord Research Fund
[SCIRF-2015P-01, SCIRF-2015P-04, SCIRF-2015-I-01]; Department of
Neurosurgery, MUSC; MUSC-CTSA program
FX This work was supported in part by funding from NIH (R01-NS31622,
R01-NS45967); Veterans Administration (1IOBX00126; 1IOBX002349); South
Carolina State Spinal Cord Research Fund (SCIRF-2015P-01;
SCIRF-2015P-04; SCIRF-2015-I-01); Department of Neurosurgery, MUSC; and
MUSC-CTSA program. We also thank Dr. M. Kelly Guyton for her valuable
contribution to this work. The authors declare no conflict of interest.
NR 74
TC 4
Z9 4
U1 2
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
EI 1471-4159
J9 J NEUROCHEM
JI J. Neurochem.
PD MAY
PY 2016
VL 137
IS 4
BP 604
EP 617
DI 10.1111/jnc.13610
PG 14
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA DL9YX
UT WOS:000376000500011
PM 26998684
ER
PT J
AU Li, XF
Shorter, D
Kosten, TR
AF Li, Xiaofan
Shorter, Daryl
Kosten, Thomas R.
TI Buprenorphine Prescribing: To Expand or Not to Expand
SO JOURNAL OF PSYCHIATRIC PRACTICE
LA English
DT Review
DE buprenorphine; prescription opioids; abuse; diversion; regulation;
policy
ID EXTENDED-RELEASE OXYCODONE; PRESCRIPTION MONITORING PROGRAMS;
SUBSTANCE-ABUSE TREATMENT; OFFICE-BASED TREATMENT; OPIOID DEPENDENCE;
UNITED-STATES; NONMEDICAL USE; PRIMARY-CARE; MAINTENANCE THERAPY;
TREATMENT-SEEKING
AB As a result of the prescription opioid epidemic in the United States, there has been an increasing need for effective treatment interventions, both pharmacological and nonpharmacological. Buprenorphine has emerged as a critical component of the treatment of opioid use disorder, yet its adoption has not been without some concerns. This article first reviews the pharmacology, clinical use, and US legislative action related to buprenorphine, followed by a discussion of the misuse and diversion of buprenorphine in the United States as well as internationally. We then explore the impact of buprenorphine abuse as well as discussing strategies for its reduction, including changes in policy, prescription and pharmacy monitoring, and continuing medical education for guiding and improving clinical practice.
C1 [Li, Xiaofan; Shorter, Daryl; Kosten, Thomas R.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, 2002 Holcombe Blvd,Bldg 121,Off 121-137, Houston, TX 77030 USA.
[Shorter, Daryl; Kosten, Thomas R.] Michael E DeBakey VA Med Ctr, Houston, TX USA.
RP Shorter, D (reprint author), Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, 2002 Holcombe Blvd,Bldg 121,Off 121-137, Houston, TX 77030 USA.; Shorter, D (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Res Serv Line, 2002 Holcombe Blvd,Bldg 121,Off 121-137, Houston, TX 77030 USA.
EM shorter@bcm.edu
FU VA CSRD [I01BX007080]; NIH/NIDA [P50 DA018197]
FX D.S. received support from VA CSR&D I01BX007080. T.R.K. received support
from NIH/NIDA P50 DA018197. X.L. declares no conflicts of interest.
NR 66
TC 1
Z9 1
U1 2
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1527-4160
EI 1538-1145
J9 J PSYCHIATR PRACT
JI J. Psychiatr. Pract.
PD MAY
PY 2016
VL 22
IS 3
BP 183
EP 192
DI 10.1097/PRA.0000000000000154
PG 10
WC Psychiatry
SC Psychiatry
GA DM0CM
UT WOS:000376010200004
PM 27123798
ER
PT J
AU Chavez, LJ
Williams, EC
Lapham, GT
Rubinsky, AD
Kivlahan, DR
Bradley, KA
AF Chavez, Laura J.
Williams, Emily C.
Lapham, Gwen T.
Rubinsky, Anna D.
Kivlahan, Daniel R.
Bradley, Katharine A.
TI Changes in Patient-Reported Alcohol-Related Advice Following Veterans
Health Administration Implementation of Brief Alcohol Interventions
SO JOURNAL OF STUDIES ON ALCOHOL AND DRUGS
LA English
DT Article
ID PRIMARY-CARE SETTINGS; AFFAIRS PRIMARY-CARE; SERVICES-TASK-FORCE;
BEHAVIORAL-COUNSELING INTERVENTIONS; VA PRIMARY-CARE; FINANCIAL
INCENTIVES; MEDICAL HOME; AUDIT-C; DRINKING; QUALITY
AB Objective: Brief alcohol interventions are recommended for primary care patients who screen positive for alcohol misuse, but implementation is challenging. The U.S. Veterans Health Administration (Veterans Affairs [VA]) implemented brief interventions for patients with alcohol misuse in 2008, and rates of brief interventions documented in the electronic medical record increased from 24% to 78% (2008-2011). This study examined whether an independent measure of brief interventions-patient-reported alcohol-related advice-also increased among VA outpatients who screened positive for alcohol misuse on a mailed survey. Method: This retrospective cross-sectional study included VA outpatient respondents to the VA's Survey of Healthcare Experiences of Patients (SHEP; 2007-2011) who reported past-year alcohol use and answered a question about alcohol-related advice. Alcohol-related advice was defined as a report of past-year advice from a VA clinician to abstain from or reduce drinking. The adjusted prevalence of alcohol related advice among patients who screened positive for alcohol misuse (SHEP AUDIT-C >= 5) was estimated for each year. Results: Among patients with alcohol misuse (n = 61,843), the adjusted prevalence of alcohol-related advice increased from 40.4% (95% CI [39.3%, 41.5%]) in 2007 to 55.5% (95% CI [53.3%, 57.8%]) in 2011. Rates of alcohol related advice increased significantly each year except the last. Conclusions: The VA's efforts to implement brief interventions were associated with increased patient-reported alcohol-related advice over time, with a majority of patients with alcohol misuse reporting its receipt. Other systems considering similar approaches to implementation may benefit from collecting patient-reported measures of brief interventions for an additional perspective on implementation.
C1 [Chavez, Laura J.; Williams, Emily C.; Lapham, Gwen T.; Rubinsky, Anna D.; Kivlahan, Daniel R.; Bradley, Katharine A.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1660 S Columbian Way S-152, Seattle, WA 98108 USA.
[Williams, Emily C.; Bradley, Katharine A.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Lapham, Gwen T.; Bradley, Katharine A.] Grp Hlth Res Inst, Seattle, WA USA.
[Rubinsky, Anna D.; Kivlahan, Daniel R.; Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA.
[Kivlahan, Daniel R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA USA.
RP Chavez, LJ (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1660 S Columbian Way S-152, Seattle, WA 98108 USA.
EM ljchavez@uw.edu
FU Veteran's Affairs (VA) Substance Use Disorders Quality Enhancement
Research Initiative (SUD QUERI); National Institutes of Health Agency
for Healthcare Research and Quality (AHRQ) Dissertation Grant [NIH
1R36HS022800-01]; Career Development Award from VA Health Services
Research Development [CDA 12-276]; Group Health Research Institute; VA's
Seattle Center of Excellence for Substance Abuse Teaching and Education
FX This study was supported by the Veteran's Affairs (VA) Substance Use
Disorders Quality Enhancement Research Initiative (SUD QUERI). Dr.
Chavez was supported by a National Institutes of Health Agency for
Healthcare Research and Quality (AHRQ) Dissertation Grant (NIH
1R36HS022800-01). Dr. Williams is supported by a Career Development
Award from VA Health Services Research & Development (CDA 12-276). Dr.
Bradley's support for this project was from Group Health Research
Institute and the VA's Seattle Center of Excellence for Substance Abuse
Teaching and Education. Views expressed in this article are those of the
authors and do not necessarily represent the views of the Department of
Veterans Affairs, the University of Washington, or Group Health Research
Institute. Laura J. Chavez, Emily C. Williams, Gwen T. Lapham, Anna D.
Rubinsky, Daniel R. Kivlahan, and Katharine A. Bradley do not have any
conflicts of interest to disclose.
NR 51
TC 0
Z9 0
U1 2
U2 3
PU ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV
PI PISCATAWAY
PA C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA
SN 1937-1888
EI 1938-4114
J9 J STUD ALCOHOL DRUGS
JI J. Stud. Alcohol Drugs
PD MAY
PY 2016
VL 77
IS 3
BP 500
EP 508
PG 9
WC Substance Abuse; Psychology
SC Substance Abuse; Psychology
GA DL9NH
UT WOS:000375969500017
PM 27172583
ER
PT J
AU Cohen, NL
Heinz, AJ
Ilgen, M
Bonn-Miller, MO
AF Cohen, Nicole L.
Heinz, Adrienne J.
Ilgen, Mark
Bonn-Miller, Marcel O.
TI Pain, Cannabis Species, and Cannabis Use Disorders
SO JOURNAL OF STUDIES ON ALCOHOL AND DRUGS
LA English
DT Article
ID EXPERIENCES; EXTRACTS; MEMORY; THC
AB Objective: The purpose of this study was to examine whether individuals who used medical cannabis for chronic pain were at increased risk for cannabis use problems compared with individuals who used medical cannabis for other reasons (e.g., anxiety, insomnia, and muscle spasms). An additional aim was to determine whether individuals who used cannabis for chronic pain, as well as those who reported greater within-group pain levels, demonstrated a species preference (i.e., sativa, indica, hybrids) and the extent to which species preference was associated with cannabis use problems. Method: Participants were 163 medical cannabis users (77% male), recruited from a medical marijuana dispensary in California, who completed assessments of medical cannabis use motives, history, preferences (species type), and problems, as well as current pain level. Results: Individuals who used cannabis to manage chronic pain experienced fewer cannabis use problems than those who did not use it for pain; among those who used it for pain, the average pain level in the past week was not associated with cannabis use problems. Furthermore, individuals who used cannabis for chronic pain were more likely to use indica over sativa. Preference for indica was associated with fewer cannabis use problems than preference for hybrid species. Conclusions: Individuals who use cannabis to manage chronic pain may be at a lower risk for cannabis use problems, relative to individuals who use it for other indications, potentially as a function of their species preference.
C1 [Cohen, Nicole L.; Heinz, Adrienne J.; Bonn-Miller, Marcel O.] Vet Affairs Palo Alto Hlth Care Syst, Natl Ctr PTSD, 795 Willow Rd 152-MPD, Menlo Pk, CA 94025 USA.
[Heinz, Adrienne J.; Bonn-Miller, Marcel O.] Vet Affairs Palo Alto Hlth Care Syst, Ctr Innovat Implementat, Menlo Pk, CA 94025 USA.
[Ilgen, Mark] Vet Affairs Ctr Clin Management Res, Ann Arbor, MI USA.
[Ilgen, Mark] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA.
[Bonn-Miller, Marcel O.] Philadelphia VA Med Ctr, Ctr Excellence Subst Abuse Treatment & Educ, Philadelphia, PA USA.
[Bonn-Miller, Marcel O.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Bonn-Miller, MO (reprint author), Vet Affairs Palo Alto Hlth Care Syst, Natl Ctr PTSD, 795 Willow Rd 152-MPD, Menlo Pk, CA 94025 USA.
EM Marcel.Bonn-Miller@va.gov
FU San Francisco Patient and Resource Center
FX This work was supported by a donation to Marcel O. Bonn-Miller from the
San Francisco Patient and Resource Center, and a Department of Veterans
Affairs Rehabilitation Research and Development Career Development
Award-2 awarded to Adrienne J. Heinz. The expressed views do not
necessarily represent those of the Department of Veterans Affairs.
NR 19
TC 1
Z9 1
U1 11
U2 17
PU ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV
PI PISCATAWAY
PA C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA
SN 1937-1888
EI 1938-4114
J9 J STUD ALCOHOL DRUGS
JI J. Stud. Alcohol Drugs
PD MAY
PY 2016
VL 77
IS 3
BP 515
EP 520
PG 6
WC Substance Abuse; Psychology
SC Substance Abuse; Psychology
GA DL9NH
UT WOS:000375969500019
PM 27172585
ER
PT J
AU Hsu, JJ
Katz, R
Chirinos, JA
Jacobs, DR
Duprez, DA
Peralta, CA
AF Hsu, Jeffrey J.
Katz, Ronit
Chirinos, Julio A.
Jacobs, David R., Jr.
Duprez, Daniel A.
Peralta, Carmen A.
TI Arterial wave reflections and kidney function decline among persons with
preserved estimated glomerular filtration rate: the Multi-Ethnic Study
of Atherosclerosis
SO JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION
LA English
DT Article
DE Arterial wave reflections; kidney function; reflection magnitude; pulse
pressure amplification
ID STAGE RENAL-DISEASE; ALL-CAUSE MORTALITY; CARDIOVASCULAR EVENTS;
HYPERTENSIVE PATIENTS; AORTIC STIFFNESS; PULSE PRESSURE; BLOOD-PRESSURE;
OLDER-ADULTS; VELOCITY; PROGRESSION
AB Differences in arterial wave reflections have been associated with increased risk for heart failure and mortality. Whether these measures are also associated with kidney function decline is not well established. Reflection magnitude (RM, defined as the ratio of the backward wave [P-b] to that of the forward wave [P-f], augmentation index (AIx), and pulse pressure amplification (PPA) were derived from radial tonometry measures among 5232 participants free of cardiovascular disease who were enrolled in the Multiethnic Study of Atherosclerosis. Kidney function was estimated by creatinine and cystatin C measurements, as well as albumin-to-creatinine ratio. We evaluated the associations of P-b, P-f, RM, AIx, and PPA with annualized estimated glomerular filtration rate (eGFR) change and rapid kidney function decline over 5 years, using generalized linear mixed models and logistic regression, respectively. Of the study participants, 48% were male, mean age was 62 years, mean eGFR and median albumin-to-creatinine ratio at baseline were 84 mL/min/1.73 m(2) and 5.3 mg/g, respectively. In demographically adjusted models, both Pb and Pf had similarly strong associations with kidney function decline; compared to those in the lowest tertiles, the persons in the highest tertiles of P-b and P-f had a 1.01 and 0.99 mL/min/1.73 m(2)/year faster eGFR decline, respectively (P < .05). However, these associations were attenuated after adjustment for systolic blood pressure. We found no significant associations between RM, AIx, or PPA and kidney function decline. In conclusion, the reflected and forward wave components were similarly associated with kidney function decline, and these associations were explained by differences in systolic blood pressure. (C) 2016 American Society of Hypertension. All rights reserved.
C1 [Hsu, Jeffrey J.; Peralta, Carmen A.] Univ Calif San Francisco, Dept Med, San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Katz, Ronit] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA.
[Chirinos, Julio A.] Univ Penn, Dept Med, Div Cardiovasc, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Chirinos, Julio A.] Univ Ghent, Div Cardiol, B-9000 Ghent, Belgium.
[Jacobs, David R., Jr.] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA.
[Duprez, Daniel A.] Univ Minnesota, Sch Med, Div Cardiol, Minneapolis, MN 55455 USA.
RP Peralta, CA (reprint author), Univ Calif San Francisco, Gen Internal Med Sect, VA Med Ctr, 111A1,4150 Clement St, San Francisco, CA 94121 USA.
EM Carmenalicia.peralta@ucsf.edu
FU National Heart, Lung, and Blood Institute [N01-HC-95159, N01-HC-95169,
R01-HL-098382]; National Insitute of Diabetes and Digestive and Kidney
Diseases [R03DK095877]; National Institutes of Health
[1R56HL124073-01A1, 1R01HL121510-01A1]; American Heart Association
[5R21AG043802-02]; Robert Wood Johnson Harold Amos Award; National
Institutes of Health; Veterans Affairs Administration; American College
of Radiology Imaging Network; Bristol-Myers Squibb; Fukuda Denshi
FX This research was supported by contracts N01-HC-95159 through
N01-HC-95169, grant R01-HL-098382 from the National Heart, Lung, and
Blood Institute, grant R03DK095877 from the National Insitute of
Diabetes and Digestive and Kidney Diseases, grants 1R56HL124073-01A1 and
1R01HL121510-01A1 from the National Institutes of Health, and grant
5R21AG043802-02 from the American Heart Association. C.A. Peralta is
supported by a Robert Wood Johnson Harold Amos Award. Dr. Chirinos
receives research funding from the National Institutes of Health,
Veterans Affairs Administration, the American College of Radiology
Imaging Network, Bristol-Myers Squibb, and Fukuda Denshi.
NR 35
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1933-1711
EI 1878-7436
J9 J AM SOC HYPERTENS
JI J. Am. Soc. Hypertens.
PD MAY
PY 2016
VL 10
IS 5
BP 438
EP 446
DI 10.1016/j.jash.2016.02.014
PG 9
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA DM3CF
UT WOS:000376223700014
PM 27085205
ER
PT J
AU Townsend, RR
Rosendorff, C
Nichols, WW
Edwards, DG
Chirinos, JA
Fernhall, B
Cushman, WC
AF Townsend, Raymond R.
Rosendorff, Clive
Nichols, Wilmer W.
Edwards, David G.
Chirinos, Julio A.
Fernhall, Bo
Cushman, William C.
TI Comment on ASH position article on central blood pressure and waveform
analysis Response
SO JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION
LA English
DT Letter
ID CARDIOVASCULAR EVENTS; ARTERY
C1 [Townsend, Raymond R.; Chirinos, Julio A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Rosendorff, Clive] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
[Rosendorff, Clive] James J Peters VA Med Ctr, Bronx, NY USA.
[Nichols, Wilmer W.] Univ Florida, Coll Med, Dept Med, Div Med, Gainesville, FL USA.
[Nichols, Wilmer W.] Univ Florida, Div Cardiovasc Med, Gainesville, FL USA.
[Edwards, David G.] Univ Delaware, Dept Kinesiol & Appl Physiol, Coll Hlth Sci, Newark, DE USA.
[Fernhall, Bo] Univ Illinois, Coll Appl Hlth Sci, Chicago, IL USA.
[Cushman, William C.] Univ Tennessee, Coll Med, Memphis, TN USA.
[Cushman, William C.] Univ Tennessee, Vet Affairs Med Ctr, Memphis, TN USA.
RP Townsend, RR (reprint author), Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
NR 7
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1933-1711
EI 1878-7436
J9 J AM SOC HYPERTENS
JI J. Am. Soc. Hypertens.
PD MAY
PY 2016
VL 10
IS 5
BP 470
EP 471
DI 10.1016/j.jash.2016.03.181
PG 2
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA DM3CF
UT WOS:000376223700019
PM 27085206
ER
PT J
AU Kluger, BM
Herlofson, K
Chou, KL
Lou, JS
Goetz, CG
Lang, AE
Weintraub, D
Friedman, J
AF Kluger, Benzi M.
Herlofson, Karen
Chou, Kelvin L.
Lou, Jau-Shin
Goetz, Christopher G.
Lang, Anthony E.
Weintraub, Daniel
Friedman, Joseph
TI Parkinson's disease-related fatigue: A case definition and
recommendations for clinical research
SO MOVEMENT DISORDERS
LA English
DT Review
DE Parkinson's disease; fatigue; case definition; clinical research
ID CANCER-RELATED FATIGUE; MULTIPLE-SCLEROSIS; MENTAL FATIGUE; PHYSICAL
FATIGUE; MUSCLE FATIGUE; RATING-SCALES; IMPACT SCALE; DEPRESSION; MOTOR;
MAGNETOENCEPHALOGRAPHY
AB Fatigue is one of the most common and disabling symptoms in Parkinson's disease (PD). Since fatigue was first described as a common feature of PD 20 years ago, little progress has been made in understanding its causes or treatment. Importantly, PD patients attending the 2013 World Parkinson Congress voted fatigue as the leading symptom in need of further research. In response, the Parkinson Disease Foundation and ProjectSpark assembled an international team of experts to create recommendations for clinical research to advance this field. The working group identified several areas in which shared standards would improve research quality and foster progress including terminology, diagnostic criteria, and measurement. Terminology needs to (1) clearly distinguish fatigue from related phenomena (eg, sleepiness, apathy, depression); (2) differentiate subjective fatigue complaints from objective performance fatigability; and (3) specify domains affected by fatigue and causal factors. We propose diagnostic criteria for PD-related fatigue to guide participant selection for clinical trials and add rigor to mechanistic studies. Recommendations are made for measurement of subjective fatigue complaints, performance fatigability, and neurophysiologic changes. We also suggest areas in which future research is needed to address methodological issues and validate or optimize current practices. Many limitations in current PD-related fatigue research may be addressed by improving methodological standards, many of which are already being successfully applied in clinical fatigue research in other medical conditions (eg, cancer, multiple sclerosis). (c) 2016 International Parkinson and Movement Disorder Society
C1 [Kluger, Benzi M.] Univ Colorado, Sch Med, Dept Neurol, Aurora, CO 80045 USA.
[Herlofson, Karen] Sorlandet Hosp Arendal, Dept Neurol, Arendal, Norway.
[Chou, Kelvin L.] Univ Michigan, Sch Med, Dept Neurol, Ann Arbor, MI USA.
[Chou, Kelvin L.] Univ Michigan, Sch Med, Dept Neurosurg, Ann Arbor, MI USA.
[Lou, Jau-Shin] Univ N Dakota, Sch Med & Hlth Sci, Dept Neurol, Dept Neurol,Sanford Hlth, Fargo, ND USA.
[Goetz, Christopher G.] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA.
[Lang, Anthony E.] Toronto Western Hosp, Morton & Gloria Shulman Movement Disorders Clin, Toronto, ON M5T 2S8, Canada.
[Lang, Anthony E.] Toronto Western Hosp, Edmond J Safra Program Parkinsons Dis, Toronto, ON M5T 2S8, Canada.
[Weintraub, Daniel] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Weintraub, Daniel] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis & Mental Illness Res Educ & Clin C, Philadelphia, PA USA.
[Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, MIRECC, Philadelphia, PA USA.
[Friedman, Joseph] Brown Univ, Butler Hosp, Alpert Med Sch, Providence, RI 02912 USA.
RP Kluger, BM (reprint author), Univ Colorado, Dept Neurol, Mail Stop B-185,12631 East 17th Ave, Aurora, CO 80045 USA.
EM benzi.kluger@ucdenver.edu
FU NINDS NIH HHS [K02 NS080885, P50 NS091856]
NR 61
TC 7
Z9 8
U1 5
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
EI 1531-8257
J9 MOVEMENT DISORD
JI Mov. Disord.
PD MAY
PY 2016
VL 31
IS 5
BP 625
EP 631
DI 10.1002/mds.26511
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA DL9CR
UT WOS:000375939500005
PM 26879133
ER
PT J
AU Siu, AL
Bibbins-Domingo, K
Grossman, DC
Baumann, LC
Davidson, KW
Ebell, M
Garcia, FAR
Gillman, M
Herzstein, J
Kemper, AR
Krist, AH
Kurth, AE
Owens, DK
Phillips, WR
Phipps, MG
Pignone, MP
AF Siu, Albert L.
Bibbins-Domingo, Kirsten
Grossman, David C.
Baumann, Linda Ciofu
Davidson, Karina W.
Ebell, Mark
Garcia, Francisco A. R.
Gillman, Matthew
Herzstein, Jessica
Kemper, Alex R.
Krist, Alex H.
Kurth, Ann E.
Owens, Douglas K.
Phillips, William R.
Phipps, Maureen G.
Pignone, Michael P.
CA USPSTF
TI Screening for Depression in Adults: US Preventive Services Task Force
Recommendation Statement EDITORIAL COMMENT
SO OBSTETRICAL & GYNECOLOGICAL SURVEY
LA English
DT Editorial Material
C1 [Siu, Albert L.] Mt Sinai Sch Med, New York, NY USA.
[Siu, Albert L.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
[Bibbins-Domingo, Kirsten] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Grossman, David C.] Grp Hlth Res Inst, Seattle, WA USA.
[Baumann, Linda Ciofu] Univ Wisconsin, Madison, WI USA.
[Davidson, Karina W.] Columbia Univ, New York, NY USA.
[Ebell, Mark] Univ Georgia, Athens, GA 30602 USA.
[Garcia, Francisco A. R.] Pima Cty Dept Hlth, Tucson, AZ USA.
[Gillman, Matthew] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Gillman, Matthew] Harvard Pilgrim Hlth Care Inst, Boston, MA USA.
[Kemper, Alex R.] Duke Univ, Durham, NC USA.
[Krist, Alex H.] Fairfax Family Practice, Fairfax, VA USA.
[Krist, Alex H.] Virginia Commonwealth Univ, Richmond, VA USA.
[Kurth, Ann E.] NYU, New York, NY USA.
[Owens, Douglas K.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA.
[Owens, Douglas K.] Stanford Univ, Stanford, CA 94305 USA.
[Phillips, William R.] Univ Washington, Seattle, WA 98195 USA.
[Phipps, Maureen G.] Brown Univ, Providence, RI 02912 USA.
[Pignone, Michael P.] Univ N Carolina, Chapel Hill, NC USA.
RP Siu, AL (reprint author), Mt Sinai Sch Med, New York, NY USA.; Siu, AL (reprint author), James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0029-7828
EI 1533-9866
J9 OBSTET GYNECOL SURV
JI Obstet. Gynecol. Surv.
PD MAY
PY 2016
VL 71
IS 5
BP 283
EP 285
PG 3
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DM3VL
UT WOS:000376274700011
ER
PT J
AU Ruzek, JI
Eftekhari, A
Rosen, CS
Crowley, JJ
Kuhn, E
Foa, EB
Hembree, EA
Karlin, BE
AF Ruzek, Josef I.
Eftekhari, Afsoon
Rosen, Craig S.
Crowley, Jill J.
Kuhn, Eric
Foa, Edna B.
Hembree, Elizabeth A.
Karlin, Bradley E.
TI Effects of a Comprehensive Training Program on Clinician Beliefs About
and Intention to Use Prolonged Exposure Therapy for PTSD
SO PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY
LA English
DT Article
DE cognitive-behavioral; exposure therapy; Prolonged Exposure; PTSD;
treatment
ID POSTTRAUMATIC-STRESS-DISORDER; AFFAIRS-HEALTH-CARE; IMPLEMENTATION;
DISSEMINATION; TRIAL; FRAMEWORK; TRENDS
AB Objective: Evidence for treatment efficacy does not guarantee adoption in clinical practice. Attitudinal "buy-in" from clinicians is also important. This study examines evaluation data from a national training program in an evidence-based treatment for PTSD, Prolonged Exposure (PE) therapy, to assess changes in clinician beliefs related to the importance of specific treatment goals, PE outcome expectations, self-efficacy to deliver PE, perceived time and emotional burdens associated with delivering PE, and intentions to use PE. Method: Training included both an interactive workshop and posttraining telephone consultation. Participants were 943 licensed mental health clinicians who treated veterans with PTSD. They completed questionnaires before and after the workshop, and after consultation. Results: Results indicated that workshop participation was associated with significant increases in perceptions of the importance of helping patients improve by employing PE, expectations that patients would benefit from PE, and self-efficacy to deliver PE, and with reduced expectations of negative patient outcomes and concerns about distressing patients. The workshop alone had little impact on expected clinician emotional burden and no impact on anticipated time burden. Participation in ongoing case consultation was associated with additional increases in expected positive patient outcomes and clinician self-efficacy and further reductions in concerns about distressing patients and negative patient outcomes. Unlike the workshop, consultation was associated with decreased expectancies that PE would take too much time and would be emotionally burdensome to provide. Conclusion: Overall, the results suggest that the combination of workshop and ongoing consultation can significantly improve beliefs likely to affect treatment adoption.
C1 [Ruzek, Josef I.; Eftekhari, Afsoon; Rosen, Craig S.; Crowley, Jill J.; Kuhn, Eric] VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, Disseminat & Training Div, 795 Willow Rd, Menlo Pk, CA 94025 USA.
[Foa, Edna B.; Hembree, Elizabeth A.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Karlin, Bradley E.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mental Hlth, US Dept Vet Affairs,Mental Hlth Serv,Cent Off, Baltimore, MD 21218 USA.
RP Ruzek, JI (reprint author), VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, Disseminat & Training Div, 795 Willow Rd, Menlo Pk, CA 94025 USA.
EM Josef.Ruzek@va.gov
NR 33
TC 4
Z9 4
U1 3
U2 4
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1942-9681
EI 1942-969X
J9 PSYCHOL TRAUMA-US
JI Psychol. Trauma
PD MAY
PY 2016
VL 8
IS 3
BP 348
EP 355
DI 10.1037/tra0000004
PG 8
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA DM2VJ
UT WOS:000376205900012
PM 26524541
ER
PT J
AU Gupta, PK
Ramanan, B
Grossman, L
Gupta, H
Fang, X
MacTaggart, JN
Lynch, TG
Baxter, BT
Pipinos, II
AF Gupta, Prateek K.
Ramanan, Bala
Grossman, Leonid
Gupta, Himani
Fang, Xiang
MacTaggart, Jason N.
Lynch, Thomas G.
Baxter, B. Timothy
Pipinos, Iraklis I.
TI Outcomes of Aortic Surgery for Abdominal Aortic Graft Infections
SO VASCULAR AND ENDOVASCULAR SURGERY
LA English
DT Article
DE aortic; graft; infection; resection
ID VASCULAR SURGICAL-PROCEDURES; ANEURYSM REPAIR; RISK CALCULATOR; VOLUME;
REPLACEMENT; VALIDATION; MANAGEMENT; REMOVAL
AB Background: Literature on postoperative outcomes following aortic surgery for aortic graft infection (AGI) is limited by relatively small sample sizes, resulting in lack of national benchmarks for quality of care. We report in-hospital outcomes following abdominal aortic surgery for AGI and identify factors associated with postoperative complications using the Nationwide Inpatient Sample (NIS) database.
Methods: Patients who underwent aortic graft resection for AGI were identified from the 2002 to 2008 NIS database, a multicenter database capturing 20% of all US admissions. Multivariable logistic regression analyses were performed.
Results: Among 394 patients (men: 73.4%) who underwent abdominal aortic surgery for AGI, 53% of the admissions were emergent/urgent. A significant trend for decreasing number of abdominal aortic surgery for AGIs per year was observed (Pearson r correlation: -.96; P = .0006). Over the same time span, a significant correlation was also seen with decrease in open and increase in endovascular aortic aneurysm repairs in the NIS database. In-hospital rates of overall postoperative morbidity and mortality were 68.3% and 19.8%, respectively. In-hospital rates of postoperative respiratory failure, renal failure, and cardiac arrest were 35.5%, 14.2%, and 8.9%, respectively. Median length of stay was 26 days, with median hospital charges being US$184 162. On multivariable analysis, increase in age per year (odds ratio [OR] 1.07; 95% confidence interval [CI]: 1.03-1.12) was independently associated with postoperative morbidity, while higher hospital volume for this procedure was protective (OR: 0.71; 95% CI: 0.56-0.89). No preoperative factors were independently associated with postoperative mortality.
Conclusion: Incidence of abdominal aortic surgery for AGI has progressively declined over the span of our study in association with decreased open and increased endovascular aortic aneurysm repairs. Aortic surgery for AGI is associated with very high morbidity and mortality rates along with prolonged lengths of stay and elevated hospital charges. The outcomes of operations for AGI are better in younger patients and higher volume hospitals.
C1 [Gupta, Prateek K.] Univ Tennessee, Hlth Sci Ctr, Dept Surg, 1325 Eastmoreland Ave,Ste 310, Memphis, TN 38104 USA.
[Gupta, Prateek K.] Methodist Le Bonheur Healthcare, Dept Surg, Memphis, TN USA.
[Ramanan, Bala] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA.
[Grossman, Leonid; MacTaggart, Jason N.; Baxter, B. Timothy; Pipinos, Iraklis I.] Univ Nebraska Med Ctr, Dept Surg, Omaha, NE USA.
[Gupta, Himani] William S Middleton Mem Vet Adm Med Ctr, Dept Med, Madison, WI USA.
[Fang, Xiang] Creighton Univ, Biostat Core, Omaha, NE 68178 USA.
[Lynch, Thomas G.] Vet Hlth Adm, Washington, DC USA.
[Pipinos, Iraklis I.] VA Nebraska Western Iowa Hlth Care Syst, Dept Surg, Omaha, NE USA.
RP Gupta, PK (reprint author), Univ Tennessee, Hlth Sci Ctr, Dept Surg, 1325 Eastmoreland Ave,Ste 310, Memphis, TN 38104 USA.; Gupta, PK (reprint author), Methodist Le Bonheur Healthcare, 1325 Eastmoreland Ave,Ste 310, Memphis, TN 38104 USA.
EM pgupta5@uthsc.edu
FU Charles and Mary Heider Fund for Excellence in Vascular Surgery; NIH
[R01 AG034995]
FX The author(s) disclosed receipt of the following financial support for
the research, authorship, and/or publication of this article: This work
was supported in part by the Charles and Mary Heider Fund for Excellence
in Vascular Surgery and in part by the NIH grant R01 AG034995.
NR 32
TC 0
Z9 0
U1 0
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1538-5744
EI 1938-9116
J9 VASC ENDOVASC SURG
JI Vasc. Endovasc. Surg.
PD MAY
PY 2016
VL 50
IS 4
BP 256
EP 260
DI 10.1177/1538574416637443
PG 5
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA DM3NO
UT WOS:000376253400009
PM 27102873
ER
PT J
AU Jovanovich, A
Chonchol, M
Smits, G
Ginde, A
AF Jovanovich, Anna
Chonchol, Michel
Smits, Gerard
Ginde, Adit
TI FIBROBLAST GROWTH FACTOR 23 AND RISK OF INFECTION AMONG OLDER ADULTS
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Meeting Abstract
CT Spring Clinical Meetings of the National-Kidney Foundation
CY APR 27-MAY 01, 2016
CL Boston, MA
SP Natl Kidney Fdn
C1 [Jovanovich, Anna] Denver VA Med Ctr, Denver, CO USA.
[Jovanovich, Anna; Chonchol, Michel; Smits, Gerard; Ginde, Adit] Univ Colorado, Sch Med, Aurora, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
EI 1523-6838
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD MAY
PY 2016
VL 67
IS 5
MA 162
BP A59
EP A59
PG 1
WC Urology & Nephrology
SC Urology & Nephrology
GA DK3WZ
UT WOS:000374849400163
ER
PT J
AU Jovanovich, A
Chonchol, M
Smits, G
Ginde, A
AF Jovanovich, Anna
Chonchol, Michel
Smits, Gerard
Ginde, Adit
TI FALLS ARE NOT ASSOCIATED WITH FIBROBLAST GROWTH FACTOR 23 LEVELS AMONG
OLDER ADULTS
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Meeting Abstract
CT Spring Clinical Meetings of the National-Kidney Foundation
CY APR 27-MAY 01, 2016
CL Boston, MA
SP Natl Kidney Fdn
C1 [Jovanovich, Anna] Denver VA Med Ctr, Denver, CO USA.
[Jovanovich, Anna; Chonchol, Michel; Smits, Gerard; Ginde, Adit] Univ Colorado, Sch Med, Aurora, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
EI 1523-6838
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD MAY
PY 2016
VL 67
IS 5
MA 161
BP A59
EP A59
PG 1
WC Urology & Nephrology
SC Urology & Nephrology
GA DK3WZ
UT WOS:000374849400162
ER
PT J
AU Crabbe, JC
Schlumbohm, JP
Hack, W
Barkley-Levenson, AM
Metten, P
Lattal, KM
AF Crabbe, John C.
Schlumbohm, Jason P.
Hack, Wyatt
Barkley-Levenson, Amanda M.
Metten, Pamela
Lattal, K. Matthew
TI Fear conditioning in mouse lines genetically selected for binge-like
ethanol drinking
SO ALCOHOL
LA English
DT Article
DE Ethanol binge drinking; Conditioned fear; Selective breeding; Drinking
in the dark; Mouse; Genetics
ID POSTTRAUMATIC-STRESS-DISORDER; ANIMAL-MODEL; DBA/2 MICE; PTSD;
GLUCOCORTICOIDS; INTOXICATION; EXTINCTION; AMYGDALA; C57BL/6; WOMEN
AB The comorbidity of substance- and alcohol-use disorders (AUD) with other psychiatric conditions, especially those related to stress such as post-traumatic stress disorder (PTSD), is well-established. Binge-like intoxication is thought to be a crucial stage in the development of the chronic relapsing nature of the addictions, and self-medication through binge-like drinking is commonly seen in PTSD patients. We have selectively bred two separate High Drinking in the Dark (HDID-1 and HDID-2) mouse lines to reach high blood ethanol concentrations (BECs) after a 4-h period of access to 20% ethanol starting shortly after the onset of circadian dark. As an initial step toward the eventual goal of employing binge-prone HDID mice to study PTSD-like behavior including alcohol binge drinking, we sought first to determine their ability to acquire conditioned fear. We asked whether these mice acquired, generalized, or extinguished conditioned freezing to a greater or lesser extent than unselected control HS/Npt mice. In two experiments, we trained groups of 16 adult male mice in a standard conditioned fear protocol. Mice were tested for context-elicited freezing, and then, in a novel context, for cue-induced freezing. After extinction tests, renewal of conditioned fear was tested in the original context. Mice of all three genotypes showed typical fear responding. Context paired with shock elicited freezing behavior in a control experiment, but cue unpaired with shock did not. These studies indicate that fear learning per se does not appear to be influenced by genes causing predisposition to binge drinking, suggesting distinct neural mechanisms. However, HDID mice are shown to be a suitable model for studying the role of conditioned fear specifically in binge-like drinking. Published by Elsevier Inc.
C1 [Crabbe, John C.; Schlumbohm, Jason P.; Hack, Wyatt; Barkley-Levenson, Amanda M.; Metten, Pamela] VA Portland Hlth Care Syst, Portland Alcohol Res Ctr, Portland, OR 97239 USA.
[Crabbe, John C.; Schlumbohm, Jason P.; Hack, Wyatt; Barkley-Levenson, Amanda M.; Metten, Pamela; Lattal, K. Matthew] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA.
RP Crabbe, JC (reprint author), Portland VA Med Ctr, Res R&D 12, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM crabbe@ohsu.edu
FU NIH-NIAAA [AA010760, AA013519, AA020245]; Department of Veterans Affairs
[101BX000313]; Department of the Army/DoD-TATRC grant [10245005.05]
FX These studies were supported by Grants AA010760, AA013519, and AA020245
from the NIH-NIAAA; by Grant #101BX000313 the Department of Veterans
Affairs; and by the Department of the Army/DoD-TATRC grant 10245005.05.
We thank Stephanie E. Spence and Lawrence C. Huang for maintaining the
colonies and supplying the mice for these experiments.
NR 34
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-8329
EI 1873-6823
J9 ALCOHOL
JI Alcohol
PD MAY
PY 2016
VL 52
BP 25
EP 32
DI 10.1016/j.alcohol.2016.01.004
PG 8
WC Substance Abuse; Pharmacology & Pharmacy; Toxicology
SC Substance Abuse; Pharmacology & Pharmacy; Toxicology
GA DL7JA
UT WOS:000375815800003
PM 27139234
ER
PT J
AU Klaustermeyer, WB
Choi, SH
AF Klaustermeyer, William B.
Choi, Soo H.
TI A perspective on systemic corticosteroid therapy in severe bronchial
asthma in adults
SO ALLERGY AND ASTHMA PROCEEDINGS
LA English
DT Article
ID SLOW RESPONSE; STEROID RESPONSIVENESS; ORAL CORTICOSTEROIDS; AIRWAY
INFLAMMATION; VETERAN POPULATION; CIGARETTE-SMOKING; REFRACTORY ASTHMA;
PULMONARY-DISEASE; DEPENDENT ASTHMA; EXACERBATIONS
AB Background: Systemic corticosteroids have been used in the treatment of asthma since 1950 and are still required for the treatment of acute severe asthma and corticosteroid dependent asthma.
Objective: To provide an updated overview of clinical considerations of systemic corticosteroids use in severe adult bronchial asthma.
Methods: PubMed searches were undertaken of studies published between 1950 and 2015.
Results: In this review the following concepts are discussed. 1) The onset of action of intravenous methylprednisone is 1-2 hours with a peak at 4-6 hours and duration of 12-30 hours. 2) Each patient should serve as their own control, using their best flow rates in the previous 6 months to 2 years. 3) The individual response to corticosteroid relates to the degree of obstruction at the time of onset of steroid treatment. 4) The pattern of response is variable but tends to be consistent for an individual patient. 5) In monitoring response to steroids frequent measures of peak expiratory flow rate and forced expiratory flow in 1 second are more useful than complete spirometric and lung mechanic tests measured less often. 6) In most cases oral steroids are as effective as parenteral regimens. 7) Patients usually respond in 3 days to 40 to 100 mg of methylprednisolone equivalent. 8) In corticosteroid resistant asthma consider compliance issues, allergen sensitivity, concomitant conditions, psychiatric factors and drug interactions. 9) Corticosteroid toxicity relates to the total lifetime dosage and serious side effects are usually not observed until a total dosage of 6.8 grams of prednisone equivalent.
Conclusion: Until we have a better understanding of the mechanisms of action of glucocorticoids, we will continue to rely on currently available systemic corticosteroids in severe asthma. The intrapatient consistency as discussed in this review, should guide therapy.
C1 [Klaustermeyer, William B.; Choi, Soo H.] Vet Affairs Greater Los Angeles Healthcare Syst U, Los Angeles, CA USA.
RP Klaustermeyer, WB (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd 111R, Los Angeles, CA 90073 USA.
EM william.klaustermeyer@va.gov
NR 79
TC 2
Z9 2
U1 0
U2 3
PU OCEAN SIDE PUBLICATIONS INC
PI PROVIDENCE
PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA
SN 1088-5412
EI 1539-6304
J9 ALLERGY ASTHMA PROC
JI Allergy Asthma Proc.
PD MAY-JUN
PY 2016
VL 37
IS 3
BP 192
EP 198
DI 10.2500/aap.2016.37.3941
PG 7
WC Allergy
SC Allergy
GA DL6AG
UT WOS:000375718500005
PM 27178888
ER
PT J
AU Roose, SP
Rutherford, BR
Wall, MM
Thase, ME
AF Roose, Steven P.
Rutherford, Bret R.
Wall, Melanie M.
Thase, Michael E.
TI Practising evidence-based medicine in an era of high placebo response:
number needed to treat reconsidered
SO BRITISH JOURNAL OF PSYCHIATRY
LA English
DT Article
ID LATE-LIFE DEPRESSION; ANTIDEPRESSANT EFFICACY; CLINICAL-SIGNIFICANCE;
TRIALS; METAANALYSIS; PSYCHOTHERAPY; EXPECTANCY; FREQUENCY; CONTACT;
THERAPY
AB The number needed to treat (NNT) statistic was developed to facilitate the practice of evidence-based medicine. Placebo was assumed to be therapeutically inert when the NNT was originally conceived, but more recent data for conditions such as major depressive disorder (MDD) suggest that the placebo control condition can have considerable therapeutic effects. Complications arise because the NNT calculated from randomised controlled trials (RCTs) reflects a comparison between medication plus clinical management and placebo plus clinical management, whereas, in the clinical setting, physicians choose between prescribing open medication, observing a patient over time with a supportive approach, and doing nothing. Thus, NNTs derived from clinical trials are not directly relevant to clinical decision-making, because they are based on control conditions that do not exist in standard practice. Additional difficulties may arise when using NNTs to compare alternative treatments for MDD, such as medication and psychotherapy, since these comparisons require the control conditions upon which the respective NNTs are based to be similar.Whereas pill placebo conditions include intensive clinical management and elicit expectations of improvement, attention control conditions for psychotherapy research are less well developed. Often the effects of psychotherapy are gauged against a wait-list control condition, which has substantially fewer therapeutic components than a pill placebo control condition. To improve the clinical utility of NNTs for the treatment of MDD, we advocate effectiveness studies that include treatment conditions resembling actual clinical practice, rather than using placebo-controlled RCTs for this purpose. Until such studies are performed, the effect of bias in comparing NNTs across treatments can be controlled by ensuring that the RCT control conditions upon which the NNTs are based are comparable.
C1 [Roose, Steven P.; Rutherford, Bret R.; Wall, Melanie M.] Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, 1051 Riverside Dr,Box 98, New York, NY 10032 USA.
[Thase, Michael E.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
[Thase, Michael E.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA.
RP Roose, SP (reprint author), Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, 1051 Riverside Dr,Box 98, New York, NY 10032 USA.
EM spr2@cumc.columbia.edu
FU National Institute of Mental Health [K23 MH085236, T32 MH015144]
FX This work was supported by National Institute of Mental Health grants
K23 MH085236 (BRR) and T32 MH015144 (SPR).
NR 28
TC 1
Z9 1
U1 4
U2 4
PU ROYAL COLLEGE OF PSYCHIATRISTS
PI LONDON
PA BRITISH JOURNAL OF PSYCHIATRY 17 BELGRAVE SQUARE, LONDON SW1X 8PG,
ENGLAND
SN 0007-1250
EI 1472-1465
J9 BRIT J PSYCHIAT
JI Br. J. Psychiatry
PD MAY
PY 2016
VL 208
IS 5
BP 416
EP 420
DI 10.1192/bjp.bp.115.163261
PG 5
WC Psychiatry
SC Psychiatry
GA DL3DZ
UT WOS:000375515700004
PM 27143006
ER
PT J
AU Armstrong, EJ
Chhatriwalla, AK
Szerlip, M
Swaminathan, RV
Patel, RAG
AF Armstrong, Ehrin J.
Chhatriwalla, Adnan K.
Szerlip, Molly
Swaminathan, Rajesh V.
Patel, Rajan A. G.
TI Late Breaking Trials of 2015 in Structural Heart Disease and Peripheral
Artery Disease: Commentary Covering ACC, EuroPCR, SCAI, TCT, VIVA, ESC,
and AHA
SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
LA English
DT Article
ID DRUG-COATED BALLOON; AORTIC-VALVE-REPLACEMENT; TRANSCATHETER; OUTCOMES;
REGISTRY; THERAPY; SFA
AB With the large number of late breaking clinical trials presented at major meetings, it is often difficult to stay current with advances in interventional cardiology. Therefore, the SCAI Publications Committee summarizes and provides editorial commentary on the most important structural heart and peripheral artery disease late-breaking trials from 2015. (C) 2016 Wiley Periodicals, Inc.
C1 [Armstrong, Ehrin J.] Univ Colorado, Boulder, CO 80309 USA.
[Armstrong, Ehrin J.] Denver VA Med Ctr, Denver, CO USA.
[Chhatriwalla, Adnan K.] St Lukes Mid Amer Heart Inst, Kansas City, MO USA.
[Szerlip, Molly] Heart Hosp Baylor Plano, Plano, TX USA.
[Swaminathan, Rajesh V.] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA.
[Patel, Rajan A. G.] Ochsner Med Ctr, New Orleans, LA USA.
RP Armstrong, EJ (reprint author), Univ Colorado, Sch Med, Div Cardiol, VA Eastern Colorado Healthcare Syst, Boulder, CO 80309 USA.
EM ehrin.armstrong@gmail.com
FU Edwards Lifesciences; Medtronic; St Jude Medical; Abbott Vascular
FX EJA is a consultant for Abbott Vascular, Medtronic, Merck, Pfizer, and
Spectranetics. AKC reports travel reimbursement from Edwards
Lifesciences, Medtronic, St Jude Medical and Abbott Vascular. MS is a
speaker for Edwards LifeSciences and Abbott Vascular. RVS has ownership
of stock in Boston Scientific Corp. RP none.
NR 14
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1522-1946
EI 1522-726X
J9 CATHETER CARDIO INTE
JI Catheter. Cardiovasc. Interv.
PD MAY
PY 2016
VL 87
IS 6
BP 1020
EP 1026
DI 10.1002/ccd.26473
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DL8MT
UT WOS:000375896800008
PM 26947260
ER
PT J
AU Toledo, RA
Qin, YJ
Cheng, ZM
Gao, Q
Iwata, S
Silva, GM
Prasad, ML
Ocal, IT
Rao, S
Aronin, N
Barontini, M
Bruder, J
Reddick, RL
Chen, YD
Aguiar, RCT
Dahia, PLM
AF Toledo, Rodrigo A.
Qin, Yuejuan
Cheng, Zi-Ming
Gao, Qing
Iwata, Shintaro
Silva, Gustavo M.
Prasad, Manju L.
Ocal, I. Tolgay
Rao, Sarika
Aronin, Neil
Barontini, Marta
Bruder, Jan
Reddick, Robert L.
Chen, Yidong
Aguiar, Ricardo C. T.
Dahia, Patricia L. M.
TI Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors
in Pheochromocytomas and Paragangliomas
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID GIANT-CELL TUMOR; PEDIATRIC GLIOBLASTOMA; RET PROTOONCOGENE; SOMATIC
MUTATIONS; DRIVER MUTATIONS; HISTONE H3.3; CANCER; GERMLINE; FAMILY;
SUSCEPTIBILITY
AB Purpose: Pheochromocytomas and paragangliomas (PPGL) are genetically heterogeneous tumors of neural crest origin, but the molecular basis of most PPGLs is unknown.
Experimental Design: We performed exome or transcriptome sequencing of 43 samples from 41 patients. Avalidation set of 136 PPGLs was used for amplicon-specific resequencing. In addition, a subset of these tumors was subjected to microarray-based transcription, protein expression, and histone methylation analysis by Western blotting or immunohistochemistry. In vitro analysis of mutants was performed in cell lines.
Results: We detected mutations in chromatin-remodeling genes, including histone-methyltransferases, histone-demethylases, and histones in 11 samples from 8 patients (20%). In particular, we characterized a new cancer syndrome involving PPGLs and giant cell tumors of bone (GCT) caused by a postzygotic G34W mutation of the histone 3.3 gene, H3F3A. Furthermore, mutations in kinase genes were detected in samples from 15 patients (37%). Among those, a novel germline kinase domain mutation of MERTK detected in a patient with PPGL and medullary thyroid carcinoma was found to activate signaling downstream of this receptor. Recurrent germline and somatic mutations were also detected in MET, including a familial case and sporadic PPGLs. Importantly, in each of these three genes, mutations were also detected in the validation group. In addition, a somatic oncogenic hotspot FGFR1 mutation was found in a sporadic tumor.
Conclusions: This study implicates chromatin-remodeling and kinase variants as frequent genetic events in PPGLs, many of which have no other known germline driver mutation. MERTK, MET, and H3F3A emerge as novel PPGL susceptibility genes. (C) 2015 AACR.
C1 [Toledo, Rodrigo A.; Qin, Yuejuan; Cheng, Zi-Ming; Gao, Qing; Bruder, Jan; Aguiar, Ricardo C. T.; Dahia, Patricia L. M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr,MC 7880, San Antonio, TX 78229 USA.
[Iwata, Shintaro] Chiba Canc Ctr, Dept Orthoped Surg, 666-2 Nitonacho, Chiba 2608717, Japan.
[Silva, Gustavo M.] NYU, Dept Biol, Ctr Genom & Syst Biol, New York, NY 10003 USA.
[Prasad, Manju L.] Yale Univ, Dept Pathol, New Haven, CT USA.
[Ocal, I. Tolgay] Mayo Clin Arizona, Dept Lab Med & Pathol, Scottsdale, AZ USA.
[Rao, Sarika; Aronin, Neil] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA.
[Barontini, Marta] Ctr Endocrinol Invest CEDIE, Buenos Aires, DF, Argentina.
[Reddick, Robert L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Chen, Yidong] Univ Texas Hlth Sci Ctr San Antonio, Dept Biostat, San Antonio, TX 78229 USA.
[Aguiar, Ricardo C. T.] Audie Murphy VA Hosp, South Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Dahia, Patricia L. M.] Univ Texas Hlth Sci Ctr San Antonio, CTRC, San Antonio, TX 78229 USA.
RP Dahia, PLM (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr,MC 7880, San Antonio, TX 78229 USA.
EM Dahia@uthscsa.edu
FU Max and Minnie Voelcker Fund; Greehey Children's Cancer Research
Institute (GCCRI); National Council for Scientific and Technological
Development (CNPq); UTHSCSA; NIH-NCI [P30 CA54174]
FX This study was supported by grants from the Max and Minnie Voelcker
Fund, and Greehey Children's Cancer Research Institute (GCCRI; to P.L.M.
Dahia). R.A. Toledo was a recipient of a research fellowship from the
National Council for Scientific and Technological Development (CNPq).
The CTRC Pathology tumor bank and GCCRI Next Generation Sequencing core
are supported by UTHSCSA, NIH-NCI P30 CA54174.
NR 49
TC 5
Z9 5
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAY 1
PY 2016
VL 22
IS 9
BP 2301
EP 2310
DI 10.1158/1078-0432.CCR-15-1841
PG 10
WC Oncology
SC Oncology
GA DL0NG
UT WOS:000375329100026
PM 26700204
ER
PT J
AU Fleming, JN
Taber, DJ
Pilch, NA
McGillicuddy, JW
Srinivas, TR
Baliga, PK
Chavin, KD
Bratton, CF
AF Fleming, James N.
Taber, David J.
Pilch, Nicole A.
McGillicuddy, John W.
Srinivas, Titte R.
Baliga, Prabhakar K.
Chavin, Kenneth D.
Bratton, Charles F.
TI A randomized, prospective comparison of transition to sirolimus-based
CNI-minimization or withdrawal in African American kidney transplant
recipients
SO CLINICAL TRANSPLANTATION
LA English
DT Article
DE kidney; mammalian target of rapamycin; minimization; transplant;
withdrawal
ID RENAL-ALLOGRAFT SURVIVAL; MYCOPHENOLATE-MOFETIL; CALCINEURIN INHIBITORS;
IMMUNOSUPPRESSION; REGIMENS; TACROLIMUS; OUTCOMES; COMBINATION;
CONVERSION; TRIAL
AB BackgroundThere is a lack of conclusive evidence to suggest if calcineurin inhibitor (CNI) withdrawal or minimization with sirolimus is the best strategy for African Americans.
MethodsThis was a randomized, prospective, open-label, pilot study comparing the two mammalian target of rapamycin (mTOR) transition strategies in adult African Americans between six and 24 wk post-transplant. The primary outcome was a comparison of the eGFR at one yr after conversion.
ResultsForty patients were randomized and analyzed in an intent-to-treat fashion. Median day of transition was day 96 (withdrawal) and 68 (minimization). Patients in the CNI-withdrawal group (n = 23) had significantly higher eGFR at one yr compared to the CNI-minimization group (n = 17, 73 vs. 56 mL/min, p = 0.03), as well as a significantly larger increase in eGFR from baseline (12 vs. 5 mL/min, p = 0.03). There were no differences in infections, acute rejection, death, or graft loss. Both regimens were constrained by disproportionately high discontinuation rates despite modest toxicity profiles.
ConclusionIn spite of considerable withdrawal rate across both study arms, African American kidney transplant recipients who underwent early transition to a sirolimus-based CNI-withdrawal regimen had significantly better graft function at one yr compared to those transitioned to a sirolimus-based CNI-minimization regimen. Clinicaltrials.gov identifier: NCT01005706.
C1 [Fleming, James N.; Pilch, Nicole A.] Med Univ S Carolina, Dept Pharm Serv, Charleston, SC 29425 USA.
[Taber, David J.; McGillicuddy, John W.; Baliga, Prabhakar K.; Chavin, Kenneth D.; Bratton, Charles F.] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA.
[Taber, David J.] Med Univ S Carolina, Ralph H Johnson VAMC, Dept Pharm, Charleston, SC 29425 USA.
[Srinivas, Titte R.] Med Univ S Carolina, Dept Nephrol, Charleston, SC 29425 USA.
RP Fleming, JN (reprint author), Med Univ S Carolina, Solid Organ Transplant, 150 Ashley Ave, Charleston, SC 29425 USA.; Fleming, JN (reprint author), South Carolina Coll Pharm, 150 Ashley Ave, Charleston, SC 29425 USA.
EM fleminj@musc.edu
FU Pfizer
FX This study was funded by an unrestricted research grant from Pfizer.
NR 20
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0902-0063
EI 1399-0012
J9 CLIN TRANSPLANT
JI Clin. Transplant.
PD MAY
PY 2016
VL 30
IS 5
BP 528
EP 533
DI 10.1111/ctr.12718
PG 6
WC Surgery; Transplantation
SC Surgery; Transplantation
GA DL4LA
UT WOS:000375606100006
PM 26914542
ER
PT J
AU Sonnenberg, A
AF Sonnenberg, Amnon
TI Short article: Gastrointestinal bleeding in multiorgan failure
SO EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
LA English
DT Article
DE endoscopic hemostasis; gastrointestinal bleeding; Markov chain; medical
decision analysis; modeling
AB Background and aimsGastrointestinal bleeding (GIB) may present as complication of multiorgan failure (MOF). The study aims to analyze the reasons for the limited success of hemostasis of GIB in MOF.MethodsUsing a Markov process, GIB is modeled as one of several complications associated with multiorgan breakdown to study how the reversal of GIB affects clinical outcome.ResultsAlthough endoscopic hemostasis can delay mortality in patients with severe systemic disease, its overall influence on survival is relatively small. In patients with a time-limited transition through an acute phase of increased mortality risk secondary to MOF, endoscopic hemostasis may substantially prolong survival in absolute terms. However, its relative contribution to overall survival still remains relatively small even in the scenario of transient risk only. The benefit of endoscopy is largest, if GIB is a major contributor to morbidity and mortality in comparison with all other disease complications.ConclusionBecause disease outcome in MOF is ultimately determined by other complications than GIB alone, the influence of endoscopic hemostasis on patient survival often remains disappointingly small. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.
C1 [Sonnenberg, Amnon] Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
[Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM sonnenbe@ohsu.edu
NR 7
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0954-691X
EI 1473-5687
J9 EUR J GASTROEN HEPAT
JI Eur. J. Gastroenterol. Hepatol.
PD MAY
PY 2016
VL 28
IS 5
BP 543
EP 545
DI 10.1097/MEG.0000000000000589
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DK2QP
UT WOS:000374759800008
PM 26849464
ER
PT J
AU Cristancho, MA
Thase, ME
AF Cristancho, Mario A.
Thase, Michael E.
TI Critical appraisal of selegiline transdermal system for major depressive
disorder
SO EXPERT OPINION ON DRUG DELIVERY
LA English
DT Review
DE Selegiline; Transdermal; Depression; Treatment
ID HEALTHY-SUBJECTS; SHORT-TERM; INHIBITORS; EFFICACY; TRIALS;
ANTIDEPRESSANTS; PHARMACOLOGY; METAANALYSIS; (-)DEPRENYL; SYMPTOMS
AB Introduction: Although safer and easier to use antidepressants (ie.,SSRIs/SNRIs) have largely displaced MAOIs, these medications still have a role in difficult to treat conditions. Efforts to improve MAOIs benefit-risk profile resulted on the reversible MAOI and in the first antidepressant patch (selegiline transdermal delivery system-STS). The later had been available in the US since 2006. Thus a review on its safety profile and comparative efficacy is timely.Areas covered: This review provides an overview of STS's clinical pharmacology and summarizes what has been learned across nearly a decade of experience. Product labels and the search engine PubMed were used to obtain relevant information.Expert opinion: STS remains a unique treatment option. It is the only FDA-approved antidepressant for patients with significant problems ingesting, tolerating, or absorbing oral medications. It remains the only MAOI that can be initiated without dietary restrictions at a therapeutic dose and has a low incidence of side effects when compared to other MAOIs. STS also provides an interesting option for depressed patients suffering from Parkinson's disease. However these advantages are counterweighted by drawbacks including the need for wash-out periods and the lack of convincing data illustrating its utility for treatment of more severe, treatment refractory depression.
C1 [Cristancho, Mario A.; Thase, Michael E.] Univ Penn, Dept Psychiat, Mood & Anxiety Disorders Treatment & Res Program, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Dept Psychiat, Philadelphia, PA USA.
RP Thase, ME (reprint author), Univ Penn, Perelman Sch Med, Penn Behav Hlth, Psychiat, 3535 Market St 4th Floor, Philadelphia, PA 19104 USA.
EM thase@mail.med.upenn.edu
NR 27
TC 0
Z9 0
U1 3
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1742-5247
EI 1744-7593
J9 EXPERT OPIN DRUG DEL
JI Expert Opin. Drug Deliv.
PD MAY
PY 2016
VL 13
IS 5
BP 659
EP 665
DI 10.1517/17425247.2016.1140145
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DK1TA
UT WOS:000374696000006
PM 26837935
ER
PT J
AU Sendelweck, MA
Bell, E
Anderson, AM
Ashack, K
Pindyck, T
Townley, C
Dellavalle, RP
AF Sendelweck, Myra A.
Bell, Eric
Anderson, Amy Marie
Ashack, Kurt
Pindyck, Talia
Townley, Cate
Dellavalle, Robert P.
TI Associations Between Indoor Tanning and Substance Use Among Colorado
High School Students
SO JAMA DERMATOLOGY
LA English
DT Letter
ID UNITED-STATES
C1 [Sendelweck, Myra A.] Univ Colorado, Sch Med, Aurora, CO USA.
[Bell, Eric; Anderson, Amy Marie; Townley, Cate] Colorado Dept Publ Hlth & Environm, Denver, CO USA.
[Ashack, Kurt] Michigan State Univ, Coll Human Med, Grand Rapids, MI USA.
[Pindyck, Talia] Univ Colorado, Colorado Sch Publ Hlth, Aurora, CO USA.
[Dellavalle, Robert P.] Univ Colorado, Sch Med, Dept Dermatol, Aurora, CO USA.
[Dellavalle, Robert P.] Univ Colorado, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA.
[Dellavalle, Robert P.] Denver Vet Affairs Med Ctr, Dermatol Serv, 1055 Clermont St,Mail Stop 165, Denver, CO 80220 USA.
RP Dellavalle, RP (reprint author), Denver Vet Affairs Med Ctr, Dermatol Serv, 1055 Clermont St,Mail Stop 165, Denver, CO 80220 USA.
EM robert.dellavalle@ucdenver.edu
OI Bell, Eric/0000-0002-8187-7298
NR 6
TC 1
Z9 1
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6068
EI 2168-6084
J9 JAMA DERMATOL
JI JAMA Dermatol.
PD MAY
PY 2016
VL 152
IS 5
BP 575
EP 577
DI 10.1001/jamadermatol.2015.5663
PG 4
WC Dermatology
SC Dermatology
GA DL7BU
UT WOS:000375795400023
PM 26791966
ER
PT J
AU Armstrong, AW
Aldredge, L
Yamauchi, PS
AF Armstrong, April W.
Aldredge, Lakshi
Yamauchi, Paul S.
TI Managing Patients With Psoriasis in the Busy Clinic: Practical Tips for
Health Care Practitioners
SO JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
LA English
DT Review
DE psoriasis; biologics; TNF inhibitor; cyclosporine; methotrexate
ID SEVERE PLAQUE PSORIASIS; RHEUMATOID-ARTHRITIS; UNITED-STATES;
MULTINATIONAL ASSESSMENT; PEDIATRIC PSORIASIS; MONOCLONAL-ANTIBODY;
BIOLOGICS REGISTER; TOPICAL THERAPIES; ALPHA-INHIBITORS;
CONTROLLED-TRIAL
AB Psoriasis is a common inflammatory disease with significant comorbidities, whose management can be challenging given the variety of treatment options. It is critical for nurse practitioners, physician assistants, general practitioners, and dermatology trainees to have useful information about the treatment and monitoring of patients with psoriasis. Although certain aspects of care apply to all patients, each therapeutic agent has its own nuances in terms of assessments, dosing, and monitoring. The most appropriate treatment is based not only on disease severity but also on comorbid conditions and concomitant medications. These practitioners are vital in facilitating patient care by thorough understanding of systemic agents, selection criteria, dosing, and recommended monitoring. This article provides high-yield practical pearls on managing patients with moderate to severe psoriasis. It includes case-based discussions illustrating considerations for special populations, such as pregnant women, children, and patients with comorbidities (eg, human immunodeficiency virus infection, hepatitis C, hepatitis B, and history of malignancy).
C1 [Armstrong, April W.] Univ Colorado Denver, Dept Dermatol, Aurora, CO USA.
[Aldredge, Lakshi] Portland VA Med Ctr, Dept Dermatol, Portland, OR USA.
[Yamauchi, Paul S.] Dermatol Inst & Skin Care Ctr, Santa Monica, CA USA.
[Yamauchi, Paul S.] Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Los Angeles, CA 90095 USA.
[Armstrong, April W.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
RP Armstrong, AW (reprint author), Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
EM aprilarmstrong@post.harvard.edu
FU AbbVie by Complete Publication Solutions, LLC (North Wales, PA, USA);
AbbVie
FX The author( s) disclosed receipt of the following financial support for
the research, authorship, and/ or publication of this article: AbbVie
funded development of the publication by Complete Publication Solutions,
LLC (North Wales, PA, USA). AbbVie had no role in content development of
the publication. All decisions regarding content were made by the
authors. This support was funded by AbbVie.
NR 67
TC 0
Z9 0
U1 2
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1203-4754
EI 1615-7109
J9 J CUTAN MED SURG
JI J. Cutan. Med. Surg.
PD MAY-JUN
PY 2016
VL 20
IS 3
BP 196
EP 206
DI 10.1177/1203475415623508
PG 11
WC Dermatology
SC Dermatology
GA DJ8TK
UT WOS:000374485900002
PM 26712930
ER
PT J
AU Gaither, JR
Goulet, JL
Becker, WC
Crystal, S
Edelman, EJ
Gordon, K
Kerns, RD
Rimland, D
Skanderson, M
Justice, AC
Fiellin, DA
AF Gaither, Julie R.
Goulet, Joseph L.
Becker, William C.
Crystal, Stephen
Edelman, E. Jennifer
Gordon, Kirsha
Kerns, Robert D.
Rimland, David
Skanderson, Melissa
Justice, Amy C.
Fiellin, David A.
TI The Association Between Receipt of Guideline-Concordant Long-Term Opioid
Therapy and All-Cause Mortality
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE Opioid analgesics; practice guideline; quality of health care;
mortality; pain
ID CHRONIC NONCANCER PAIN; SUBSTANCE USE DISORDER; VETERANS AGING COHORT;
CLINICAL GUIDELINES; OLDER-ADULTS; ANTIRETROVIRAL THERAPY; PRESCRIBING
PRACTICES; UNINFECTED VETERANS; COMPARATIVE SAFETY; AMERICAN ACADEMY
AB For patients receiving long-term opioid therapy (LtOT), the impact of guideline-concordant care on important clinical outcomes-notably mortality-is largely unknown, even among patients with a high comorbidity and mortality burden (e.g., HIV-infected patients). Our objective was to determine the association between receipt of guideline-concordant LtOT and 1-year all-cause mortality.
Among HIV-infected and uninfected patients initiating LtOT between 2000 and 2010 through the Department of Veterans Affairs, we used Cox regression with time-updated covariates and propensity-score matched analyses to examine the association between receipt of guideline-concordant care and 1-year all-cause mortality.
Of 17,044 patients initiating LtOT between 2000 and 2010, 1048 patients (6%) died during 1 year of follow-up. Patients receiving psychotherapeutic co-interventions (hazard ratio [HR] 0.62; 95% confidence interval [CI] 0.51-0.75; P < 0.001) or physical rehabilitative therapies (HR 0.81; 95% CI 0.67-0.98; P = 0.03) had a decreased risk of all-cause mortality compared to patients not receiving these services, whereas patients prescribed benzodiazepines concurrent with opioids had a higher risk of mortality (HR 1.39; 95% CI 1.12-1.66; P < 0.001). Among patients with a current substance use disorder (SUD), those receiving SUD treatment had a lower risk of mortality than untreated patients (HR 0.47; 95% CI 0.32-0.68; P = < 0.001). No association was found between all-cause mortality and primary care visits (HR 1.12; 95% CI 0.90-1.26; P = 0.32) or urine drug testing (HR 0.96; 95% CI 0.78-1.17; P = 0.67).
Providers should use caution in initiating LtOT in conjunction with benzodiazepines and untreated SUDs. Patients receiving LtOT may benefit from multi-modal treatment that addresses chronic pain and its associated comorbidities across multiple disciplines.
C1 [Gaither, Julie R.; Justice, Amy C.; Fiellin, David A.] Yale Univ, Sch Publ Hlth, New Haven, CT USA.
[Gaither, Julie R.; Goulet, Joseph L.; Becker, William C.; Gordon, Kirsha; Kerns, Robert D.; Justice, Amy C.] VA Connecticut Healthcare Syst, 950 Campbell Ave, West Haven, CT 06516 USA.
[Gaither, Julie R.; Justice, Amy C.] Yale Univ, Sch Med, Yale Ctr Med Informat, New Haven, CT USA.
[Gaither, Julie R.; Edelman, E. Jennifer; Fiellin, David A.] Yale Univ, Sch Publ Hlth, Ctr Interdisciplinary Res AIDS, New Haven, CT USA.
[Goulet, Joseph L.; Kerns, Robert D.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
[Becker, William C.; Edelman, E. Jennifer; Justice, Amy C.; Fiellin, David A.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA.
[Crystal, Stephen] Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, 30 Coll Ave, New Brunswick, NJ 08903 USA.
[Rimland, David] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA USA.
[Rimland, David] Atlanta VA Med Ctr, Decatur, GA USA.
[Skanderson, Melissa] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Gaither, JR (reprint author), VA Connecticut Healthcare Syst, 950 Campbell Ave, West Haven, CT 06516 USA.
EM julie.gaither@yale.edu
OI Justice, Amy/0000-0003-0139-5502; Fiellin, David/0000-0002-4006-010X;
Goulet, Joseph/0000-0002-0842-804X
FU National Institute on Drug Abuse [F31DA035567, K12DA033312]; National
Institute on Alcohol Abuse and Alcoholism [U10AA013566, U01AA020790,
U24AA020794]; National Institute of Mental Health [P30MH062294]; VA
Health Services Research and Development Center of Innovation [CIN
13-047]; Agency for Healthcare Research and Quality [U19HS21112]
FX Research reported in this paper was supported by grants from the
National Institute on Drug Abuse (F31DA035567; K12DA033312), National
Institute on Alcohol Abuse and Alcoholism (U10AA013566; U01AA020790;
U24AA020794), National Institute of Mental Health (P30MH062294), VA
Health Services Research and Development Center of Innovation (CIN
13-047), and the Agency for Healthcare Research and Quality
(U19HS21112). These organizations had no role in the design, conduct, or
reporting of this study.
NR 67
TC 5
Z9 5
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD MAY
PY 2016
VL 31
IS 5
BP 492
EP 501
DI 10.1007/s11606-015-3571-4
PG 10
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA DJ8KO
UT WOS:000374461400012
PM 26847447
ER
PT J
AU Radomski, TR
Zhao, XH
Thorpe, CT
Thorpe, JM
Good, CB
Mor, MK
Fine, MJ
Gellad, WF
AF Radomski, Thomas R.
Zhao, Xinhua
Thorpe, Carolyn T.
Thorpe, Joshua M.
Good, Chester B.
Mor, Maria K.
Fine, Michael J.
Gellad, Walid F.
TI VA and Medicare Utilization Among Dually Enrolled Veterans with Type 2
Diabetes: A Latent Class Analysis
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE utilization; diabetes; Veterans; Medicare; health services research
ID AFFAIRS HEALTH-CARE; GLYCEMIC CONTROL; AMBULATORY-CARE; SYSTEM;
SERVICES; MELLITUS; MEDICATIONS; PERFORMANCE; VALIDATION; MORTALITY
AB Many Veterans treated within the VA Healthcare System (VA) are also enrolled in fee-for-service (FFS) Medicare and receive treatment outside the VA. Prior research has not accounted for the multiple ways that Veterans receive services across healthcare systems.
We aimed to establish a typology of VA and Medicare utilization among dually enrolled Veterans with type 2 diabetes.
This was a retrospective cohort.
316,775 community-dwelling Veterans age a parts per thousand yen 65 years with type 2 diabetes who were dually enrolled in the VA and FFS Medicare in 2008-2009.
Using latent class analysis, we identified classes of Veterans based upon their probability of using VA and Medicare diabetes care services, including patient visits, laboratory tests, glucose test strips, and medications. We compared the amount of healthcare use between classes and identified factors associated with class membership using multinomial regression.
We identified four distinct latent classes: class 1 (53.9 %) had high probabilities of VA use and low probabilities of Medicare use; classes 2 (17.2 %), 3 (21.8 %), and 4 (7.0 %) had high probabilities of VA and Medicare use, but differed in their Medicare services used. For example, Veterans in class 3 received test strips exclusively through Medicare, while Veterans in class 4 were reliant on Medicare for medications. Living a parts per thousand yen 40 miles from a VA predicted membership in classes 3 (OR 1.1, CI 1.06-1.15) and 4 (OR 1.11, CI 1.04-1.18), while Medicaid eligibility predicted membership in class 4 (OR 4.30, CI 4.10-4.51).
Veterans with diabetes can be grouped into four distinct classes of dual health system use, representing a novel way to characterize how patients use multiple services across healthcare systems. This classification has applications for identifying patients facing differential risk from care fragmentation.
C1 [Radomski, Thomas R.; Good, Chester B.; Fine, Michael J.; Gellad, Walid F.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA.
[Radomski, Thomas R.; Zhao, Xinhua; Thorpe, Carolyn T.; Thorpe, Joshua M.; Good, Chester B.; Mor, Maria K.; Fine, Michael J.; Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Univ Dr 151C, Pittsburgh, PA 15240 USA.
[Thorpe, Carolyn T.; Thorpe, Joshua M.; Good, Chester B.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA USA.
[Good, Chester B.] US Dept Vet Affairs, Pharm Benefits Management Serv, Hines, IL USA.
[Mor, Maria K.] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA.
RP Gellad, WF (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Univ Dr 151C, Pittsburgh, PA 15240 USA.
EM walid.gellad@va.gov
FU U.S. Department of Veterans Affairs [CDA 09-207]; National Research
Service Award from the Health Resources and Services Administration
[T32HP22240]; Department of Veterans Affairs, Veterans Health
Administration, Office of Research and Development, Health Services
Research and Development, VA Information Resource Center [SDR 02-237,
98-004]
FX This study was supported by a Career Development Award (CDA 09-207) from
the U.S. Department of Veterans Affairs and a National Research Service
Award from the Health Resources and Services Administration
(T32HP22240). Support for VA/CMS data is provided by the Department of
Veterans Affairs, Veterans Health Administration, Office of Research and
Development, Health Services Research and Development, VA Information
Resource Center (Project Numbers SDR 02-237 and 98-004).
NR 39
TC 0
Z9 0
U1 3
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD MAY
PY 2016
VL 31
IS 5
BP 524
EP 531
DI 10.1007/s11606-016-3631-4
PG 8
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA DJ8KO
UT WOS:000374461400016
PM 26902242
ER
PT J
AU Breslau, ES
Gorin, SS
Edwards, HM
Schonberg, MA
Saiontz, N
Walter, LC
AF Breslau, Erica S.
Gorin, Sherri Sheinfeld
Edwards, Heather M.
Schonberg, Mara A.
Saiontz, Nicole
Walter, Louise C.
TI An Individualized Approach to Cancer Screening Decisions in Older
Adults: A Multilevel Framework
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Review
DE Individualized screening; Shared decisionmaking; Geriatric; Multilevel;
Framework
ID SERVICES TASK-FORCE; WOMEN AGED 80; PREVENTIVE SERVICES;
COLORECTAL-CANCER; BREAST-CANCER; RECOMMENDATION STATEMENT; LIFE
EXPECTANCY; CHRONIC ILLNESS; NATIONAL-SURVEY; HEALTH-CARE
AB Guidelines for optimal cancer screening in older adults remain unclear, particularly for adults over the age of 75. While cancer screening in older adults may benefit some in good health, it may cause unnecessary burdens in others with limited life expectancy. Thus, a systematic approach to enable individualized cancer screening decisions in older adults is needed. We suggest a framework that guides such decisions through evidence-based approaches from multiple interactions, and that involves the patient, clinician, and healthcare system. An individualized approach considers differences in disease risk rather than the chronological age of the patient. This paper presents a comprehensive framework that depicts the independent and converging levels of influences on individualized cancer screening decisions in older adults. This Individualized Decisions for Screening (IDS) framework recognizes the reality of these interrelationships, including the tensions that arise when behaviors and outcomes are valued differently at the patient, clinician, and healthcare organization levels. Person-centered approaches are essential to advancing multilevel research of individualized cancer screening decisions among older adults.
C1 [Breslau, Erica S.] NCI, Healthcare Delivery Res Program, Div Canc Control & Populat Sci, 9609 Med Ctr Dr, Rockville, MD 20850 USA.
[Gorin, Sherri Sheinfeld] Leidos Biomed Res Inc, Frederick Natl Lab Canc Res, Frederick, MD USA.
[Gorin, Sherri Sheinfeld] Herbert Irving Comprehens Canc Ctr, New York Phys Canc, New York, NY USA.
[Edwards, Heather M.] Patient Ctr Outcomes Res Inst, Washington, DC USA.
[Schonberg, Mara A.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Gen Med & Primary Care, Boston, MA 02215 USA.
[Saiontz, Nicole] NCI, Off Director, Div Canc Control & Populat Sci, Rockville, MD 20850 USA.
[Walter, Louise C.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA.
[Walter, Louise C.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Breslau, ES (reprint author), NCI, Healthcare Delivery Res Program, Div Canc Control & Populat Sci, 9609 Med Ctr Dr, Rockville, MD 20850 USA.
EM breslaue@mail.nih.gov
FU National Cancer Institute, National Institutes of Health
[HHSN261200800001E]; National Institute on Aging, National Institutes of
Health [K24AG041180]
FX Disclaimer for Drs. Edwards and Sheinfeld Gorin: This project has been
funded in whole or in part with federal funds from the National Cancer
Institute, National Institutes of Health, under Contract No.
HHSN261200800001E (HME). Dr. Walter was funded by the National Institute
on Aging, National Institutes of Health under grant number K24AG041180.
The content of this publication does not necessarily reflect the views
or policies of the Department of Health and Human Services, nor does the
mention of trade names, commercial products, or organizations imply
endorsement by the U.S. government.
NR 55
TC 0
Z9 0
U1 2
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD MAY
PY 2016
VL 31
IS 5
BP 539
EP 547
DI 10.1007/s11606-016-3629-y
PG 9
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA DJ8KO
UT WOS:000374461400024
PM 26941042
ER
PT J
AU Braithwaite, D
Walter, LC
Izano, M
Kerlikowske, K
AF Braithwaite, Dejana
Walter, Louise C.
Izano, Monika
Kerlikowske, Karla
TI Benefits and Harms of Screening Mammography by Comorbidity and Age: A
Qualitative Synthesis of Observational Studies and Decision Analyses
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Review
DE breast cancer screening; comorbidity; aging
ID STAGE RENAL-DISEASE; BREAST-CANCER; OLDER WOMEN; COST-EFFECTIVENESS;
LIFE EXPECTANCY; COMMUNITY PRACTICE; UNITED-STATES; ELDERLY-WOMEN;
ADULTS; MODEL
AB We conducted a systematic review to assess the quality and limitations of published studies examining benefits and harms of screening mammography in relation to comorbidity and age.
We searched MEDLINE and EMBASE from January 1980 through June 2013 for studies that examined benefits or harms of screening mammography in women aged 65 years or older in relation to comorbidity. For each study, we extracted data regarding setting, design, quality, screening schedule, measure of comorbidity, and estimates of benefits and/or harms. We reviewed 1760 titles, identifying 7 articles that met the inclusion criteria: prospective cohort (two studies), retrospective cohort (two studies), and decision analyses (three studies). No randomized controlled trials were identified.
At least one measure of life expectancy or reduction in the risk of breast cancer death as a marker of benefit was examined in four studies, whereas three studies addressed the harms of screening mammography, including false-positive results. Both cohort studies and decision analyses showed that screening benefits decreased with increasing age and comorbidity burden.
The limited evidence currently available suggests that, apart from older women with severe comorbidity, women 65 and older may experience improvements in life expectancy from screening. Given the potential for harm, it is unclear whether the magnitude of the benefit is sufficient to warrant regular screening. Women, clinicians and policymakers should consider these factors in deciding whether continue screening.
C1 [Braithwaite, Dejana; Izano, Monika; Kerlikowske, Karla] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Walter, Louise C.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA.
[Walter, Louise C.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Izano, Monika] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA.
[Kerlikowske, Karla] Univ Calif San Francisco, Div Gen Internal Med, VA Med Ctr, San Francisco, CA 94143 USA.
RP Braithwaite, D (reprint author), Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
EM DBraithwaite@epi.ucsf.edu
FU American Cancer Society [121891-MRSG-12-007-01-CPHPS]
FX This research was supported by grant no. 121891-MRSG-12-007-01-CPHPS
from the American Cancer Society (to Dr. Braithwaite). We thank Min-Lin
Fang, MLS, and Gloria Won, MLS, for their assistance with the literature
search, and Jisu Shin for administrative assistance. We are also
grateful to Iris Lansdorp-Vogelaar, PhD, for her helpful comments on an
earlier version of this manuscript.
NR 55
TC 2
Z9 2
U1 3
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD MAY
PY 2016
VL 31
IS 5
BP 561
EP 572
DI 10.1007/s11606-015-3580-3
PG 12
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA DJ8KO
UT WOS:000374461400026
PM 26831305
ER
PT J
AU Braun, K
Erickson, M
Utech, A
List, R
Garcia, JM
AF Braun, Katie
Erickson, Megan
Utech, Anne
List, Riesa
Garcia, Jose M.
TI Evaluation of Veterans MOVE! Program for Weight Loss
SO JOURNAL OF NUTRITION EDUCATION AND BEHAVIOR
LA English
DT Article
DE weight management; obesity; nutrition education; veteran
ID OBESITY; OVERWEIGHT; BURDEN; PREVALENCE; SUCCESS
AB Objective: To evaluate the degree of weight loss in subjects enrolled in the Veterans Affairs weight management program (MOVE!).
Design: Retrospective cohort design.
Setting: Tertiary care US veterans hospital, July, 2007 to September, 2008, using a retrospective database.
Participants: Adult veterans (n = 1,659), mostly men (85%).
Intervention: Encounters with existing nutrition education classes were collected and outcomes were assessed.
Main Outcome Measures: Primary outcome was weight change; the predictor was visits or encounters.
Analysis: One-way ANOVA.
Results: In this sample, >= 3 nutrition education encounters were associated with significantly more body weight loss compared with 1-2 encounters or no education (-1.62%, 0.2%, and -0.23%, respectively; P =.01).
Conclusions and Implications: Three or more nutrition education encounters within the MOVE! weight management program at the Michael E. DeBakey Veterans Affairs Medical Center are associated with modest weight loss. Future prospective studies are needed to determine causality and confirm these findings.
C1 [Braun, Katie; Utech, Anne] Michael E DeBakey VA Med Ctr, Nutr & Food Serv, Dept Vet Affairs, Houston, TX 77030 USA.
[Braun, Katie; Erickson, Megan] Texas Womans Univ, Houston, TX USA.
[List, Riesa] Edwards Hines Jr Vet Affairs Med Ctr, Nutr & Food Serv, Dept Vet Affairs, Hines, IL USA.
[Garcia, Jose M.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
[Garcia, Jose M.] Univ Washington, Sch Med, Seattle, WA USA.
[Garcia, Jose M.] Michael E DeBakey VA Med Ctr, Ctr Translat Res Inflammatory Dis, Houston, TX 77030 USA.
[Garcia, Jose M.] Baylor Coll Med, Huffington Ctr Aging, Dept Med & Mol & Cell Biol, Houston, TX 77030 USA.
RP Braun, K (reprint author), Michael E DeBakey VA Med Ctr, Nutr & Food Serv, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM Katie.Braun@va.gov
FU Department of Veterans Affairs [I01-BX000507, I01 CX000174]; Department
of Veterans Affairs (National Institute on Aging) [T32AG000183,
AG040583]; Department of Veterans Affairs, Veterans Health
Administration, Office of Research and Development
FX Dr Garcia received research support from the Department of Veterans
Affairs (MERIT grants: I01-BX000507 and I01 CX000174 and National
Institute on Aging T32AG000183 and AG040583). This material is based
upon work supported (or supported in part) by the Department of Veterans
Affairs, Veterans Health Administration, Office of Research and
Development. The views expressed here are those of the authors and do
not necessarily reflect the position or policy of the Department of
Veterans Affairs or the United States government. The authors also
acknowledge the following individuals for their technical and written
contributions to the original works from which this project stems: Dr
Charles Wright, Karen Moreland, Caroline Nelson, Rose Bush, John
Radcliffe, and Mary Watson. The Institutional Review Boards at Baylor
College of Medicine, the Michael E. DeBakey Veterans Affairs Medical
Center, and Texas Woman's University approved this protocol.
NR 20
TC 1
Z9 1
U1 3
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1499-4046
EI 1878-2620
J9 J NUTR EDUC BEHAV
JI J. Nutr. Educ. Behav.
PD MAY
PY 2016
VL 48
IS 5
BP 299
EP +
DI 10.1016/j.jneb.2016.02.012
PG 6
WC Education, Scientific Disciplines; Nutrition & Dietetics
SC Education & Educational Research; Nutrition & Dietetics
GA DL4DQ
UT WOS:000375584100003
PM 27169639
ER
PT J
AU Ornstein, KA
Aldridge, MD
Mair, CA
Gorges, R
Siu, AL
Kelley, AS
AF Ornstein, Katherine A.
Aldridge, Melissa D.
Mair, Christine A.
Gorges, Rebecca
Siu, Albert L.
Kelley, Amy S.
TI Spousal Characteristics and Older Adults' Hospice Use: Understanding
Disparities in End-of-Life Care
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Article
ID DECISION-MAKING; MENTAL-HEALTH; UNITED-STATES; ENROLLMENT; QUALITY;
MEDICARE; CANCER; DEATH; ASSOCIATION; FAMILIES
AB Background: Hospice use has been shown to benefit quality of life for patients with terminal illness and their families, with further evidence of cost savings for Medicare and other payers. While disparities in hospice use by patient diagnosis, race, and region are well documented and attention to the role of family members in end-of-life decision-making is increasing, the influence of spousal characteristics on the decision to use hospice is unknown.
Objectives: To determine the association between spousal characteristics and hospice use.
Design: We used data from the Health and Retirement Study (HRS), a prospective cohort study, linked to the Dartmouth Atlas of Health Care and Medicare claims.
Setting: National study of 1567 decedents who were married or partnered at the time of death (2000-2011).
Measures: Hospice use at least 1 day in the last year of life as measured via Medicare claims data. Spousal factors (e.g., education and health status) measured via survey.
Results: In multivariate models controlling for patient factors and regional variation, spouses with lower educational attainment than their deceased spouse had decreased likelihood of hospice use (odds ratio [OR]=0.58; 95% confidence interval [CI]=0.40-0.82). Health of the spouse was not significantly associated with likelihood of decedent hospice use in adjusted models.
C1 [Ornstein, Katherine A.; Aldridge, Melissa D.; Siu, Albert L.; Kelley, Amy S.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, Box 1070,One Gustave Levy Pl, New York, NY 10029 USA.
[Ornstein, Katherine A.] Icahn Sch Med Mt Sinai, Inst Translat Epidemiol, New York, NY 10029 USA.
[Siu, Albert L.; Kelley, Amy S.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
[Mair, Christine A.] Univ Maryland, Dept Sociol & Anthropol, Baltimore, MD 21201 USA.
[Gorges, Rebecca] Univ Chicago, Harris Sch Publ Policy, Chicago, IL 60637 USA.
RP Ornstein, KA (reprint author), Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, Box 1070,One Gustave Levy Pl, New York, NY 10029 USA.
EM Katherine.ornstein@mssm.edu
FU National Institute on Aging [K01AG047923]
FX The research was supported by: National Institute on Aging K01AG047923
(Dr. Ornstein).
NR 43
TC 0
Z9 0
U1 2
U2 7
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
EI 1557-7740
J9 J PALLIAT MED
JI J. Palliat. Med.
PD MAY
PY 2016
VL 19
IS 5
BP 509
EP 515
DI 10.1089/jpm.2015.0399
PG 7
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA DL8DZ
UT WOS:000375871600011
PM 26991831
ER
PT J
AU Lam, CA
Sherbourne, C
Tang, LQ
Belin, TR
Williams, P
Young-Brinn, A
Miranda, J
Wells, KB
AF Lam, Christine A.
Sherbourne, Cathy
Tang, Lingqi
Belin, Thomas R.
Williams, Pluscedia
Young-Brinn, Angela
Miranda, Jeanne
Wells, Kenneth B.
TI The Impact of Community Engagement on Health, Social, and Utilization
Outcomes in Depressed, Impoverished Populations: Secondary Findings from
a Randomized Trial
SO JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE
LA English
DT Article
DE Depression; Health Care Disparities; Homelessness; Populations;
Underserved; Social Determinants of Health
ID FALSE DISCOVERY RATE; QUALITY IMPROVEMENT; COLLABORATIVE CARE; TREATING
DEPRESSION; MINORITY WOMEN; SCREENING-TEST; DSM-IV; CLUSTER; LIFE;
INTERVENTIONS
AB Background: Disparities in depression care exist among the poor. Community Partners in Care (CPIC) compared a community coalition model with technical assistance to improve depression services in under-resourced communities. We examine effects on health, social, and utilization outcomes among the poor and, non-poor depressed, and poor subgroups.
Methods: This study analyzed clients living above (n = 268) and below (n = 750) the federal-poverty level and, among the poor, 3 nonoverlapping subgroups: justice-involved (n = 158), homeless and not justice- involved (n = 298), and other poor (n = 294). Matched programs (n = 93) from health and community sectors were randomly assigned to community engagement and planning (CEP) or resources for services (RS). Primary outcomes were poor mental health-related quality of life and 8-item Patient Health Questionnaire scores, whereas community-prioritized and utilization outcomes were secondary. Effects were scrutinized using false discovery rate-adjusted P values to account for multiple comparisons.
Results: In the impoverished group, CEP and RS clients of participating study programs did not differ in primary outcomes, but CEP more than RS improved mental wellness among the depressed poor (unadjusted P = .004) while providing suggestive evidence for other secondary outcomes. Within the poor subgroups, evidence favoring CEP was only suggestive but was strongest among justice-involved clients.
Conclusions: A coalition approach to improving outcomes for low-income clients with depression, particularly those involved in the justice system, may offer additional benefits over standard technical assistance programs.
C1 [Lam, Christine A.] Vet Adm Greater Los Angeles Healthcare Syst, Vet Adm Hlth Serv Res & Dev Ctr Study Healthcare, Sepulveda, CA USA.
[Lam, Christine A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Belin, Thomas R.; Wells, Kenneth B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Lam, Christine A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Sherbourne, Cathy; Wells, Kenneth B.] RAND Corp, Santa Monica, CA USA.
[Tang, Lingqi; Miranda, Jeanne; Wells, Kenneth B.] Univ Calif Los Angeles, Ctr Hlth Serv & Soc, Los Angeles, CA USA.
[Belin, Thomas R.] Univ Calif Los Angeles, Jonathan & Karin Fielding Sch Publ Hlth, Dept Biostat, Los Angeles, CA USA.
[Wells, Kenneth B.] Univ Calif Los Angeles, Jonathan & Karin Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA.
[Williams, Pluscedia] Hlth African Amer Families II, Los Angeles, CA USA.
[Williams, Pluscedia] Charles R Drew Univ Med & Sci, Dept Res, 1621 E 120th St, Los Angeles, CA 90059 USA.
[Young-Brinn, Angela] JD Pacada Fdn, Los Angeles, CA USA.
RP Lam, CA (reprint author), VA Greater Angeles Healthcare Syst, 11301 Wilshire Blvd 111G,Room 3233, Los Angeles, CA 90073 USA.
EM christinealam@mednet.ucla.edu
FU National Institute on Minority Health and Health Disparities
[R01MH078853]; Patient-Centered Outcomes Research Institute [1845];
National Institute of Mental Health [R01MH078853, P30MH082760,
P30MH068639]; Robert Wood Johnson Foundation [64244]; California
Community Foundation [CMCH-12-97088]; National Library of Medicine
[G08LM011058]; National Institutes of Health/National Center For
Advancing Translational Science UCLA CTSI [UL1TR000124]; VA Quality
Scholars program
FX These analyses of Community Partners in Care data were supported by the
National Institute on Minority Health and Health Disparities (grant no.
R01MH078853; P.I.s JM, KBW) and the Patient-Centered Outcomes Research
Institute (award no. 1845; P.I. KBW). The parent study was funded by the
National Institute of Mental Health (award no. R01MH078853, P30MH082760,
and P30MH068639); the Robert Wood Johnson Foundation (award no. 64244),
the California Community Foundation (award no. CMCH-12-97088), the
National Library of Medicine (award no. G08LM011058), and the National
Institutes of Health/National Center For Advancing Translational Science
UCLA CTSI (award no. UL1TR000124). CAL is supported by the VA Quality
Scholars program.
NR 50
TC 1
Z9 1
U1 8
U2 11
PU AMER BOARD FAMILY MEDICINE
PI LEXINGTON
PA 2228 YOUNG DR, LEXINGTON, KY 40505 USA
SN 1557-2625
EI 1558-7118
J9 J AM BOARD FAM MED
JI J. Am. Board Fam. Med.
PD MAY-JUN
PY 2016
VL 29
IS 3
BP 325
EP +
DI 10.3122/jabfm.2016.03.150306
PG 20
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA DL6NT
UT WOS:000375756600007
PM 27170790
ER
PT J
AU Arevalo-Flechas, LC
Murray, A
May, L
Frausto, E
Sanchez-Reilly, S
Ross, J
AF Arevalo-Flechas, L. C.
Murray, A.
May, L.
Frausto, E.
Sanchez-Reilly, S.
Ross, J.
TI The Fall: A Cultural and Linguistic Adaptation of a Fall Prevention
Program for Community Dwelling Older Hispanics
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Arevalo-Flechas, L. C.; Sanchez-Reilly, S.; Ross, J.] South Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA.
[Arevalo-Flechas, L. C.; Murray, A.; May, L.; Frausto, E.; Sanchez-Reilly, S.; Ross, J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
FU University of Texas Patient Safety Medical Education Grant Award
FX Supported By: University of Texas Patient Safety Medical Education Grant
Award
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA C104
BP S186
EP S186
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800515
ER
PT J
AU Arevalo-Flechas, LC
Noel, P
Rottman-Sagebiel, R
Cupples, N
Conde, A
Sanchez-Reilly, S
Powers, B
Espinoza, S
AF Arevalo-Flechas, L. C.
Noel, P.
Rottman-Sagebiel, R.
Cupples, N.
Conde, A.
Sanchez-Reilly, S.
Powers, B.
Espinoza, S.
TI Presence of a Caregiver Associated with Increased Odds of Readmission in
a Cohort of Older Adults Included in a Transitional Care Intervention
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Arevalo-Flechas, L. C.; Noel, P.; Rottman-Sagebiel, R.; Cupples, N.; Conde, A.; Sanchez-Reilly, S.; Powers, B.; Espinoza, S.] South Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA.
[Arevalo-Flechas, L. C.; Noel, P.; Rottman-Sagebiel, R.; Cupples, N.; Conde, A.; Sanchez-Reilly, S.; Powers, B.; Espinoza, S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
FU Veterans Administration T21 Non-Institutional Long Term Care Initiative;
Office of Rural Health
FX Supported By: Veterans Administration T21 Non-Institutional Long Term
Care Initiative and Office of Rural Health
NR 0
TC 0
Z9 0
U1 2
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA B149
BP S141
EP S141
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800386
ER
PT J
AU Arevalo-Flechas, LC
Flores, BP
Martinez, M
Cleveland, L
AF Arevalo-Flechas, L. C.
Flores, B. P.
Martinez, M.
Cleveland, L.
TI If they are taken away I will die: Hispanic Abuelas as custodial
"caregivers"
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Arevalo-Flechas, L. C.] South Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA.
[Arevalo-Flechas, L. C.; Flores, B. P.; Martinez, M.; Cleveland, L.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
FU Center for Research to Advance Community Health (ReACH); University of
Texas Health Science Center at San Antonio
FX Center for Research to Advance Community Health (ReACH). The University
of Texas Health Science Center at San Antonio
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA A112
BP S56
EP S57
PG 2
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800156
ER
PT J
AU Binkley, C
Davila, AE
Sanchez-Reilly, S
Lee, S
AF Binkley, C.
Davila, A. E.
Sanchez-Reilly, S.
Lee, S.
TI Advance Care Planning among Homeless Older Adults: How Can We Facilitate
the Process?
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Binkley, C.; Davila, A. E.; Sanchez-Reilly, S.] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, San Antonio, TX 78229 USA.
[Davila, A. E.; Sanchez-Reilly, S.; Lee, S.] South Texas Vet Hlth Care Syst, GEC GRECC, San Antonio, TX USA.
FU MSTAR/AFAR
FX Supported By: MSTAR/AFAR
NR 0
TC 0
Z9 0
U1 3
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA D26
BP S226
EP S226
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800629
ER
PT J
AU Blanchard, E
Castle, S
Ines, E
Morey, M
Deberry, J
Humecky, T
Obar, F
Lee, CC
AF Blanchard, E.
Castle, S.
Ines, E.
Morey, M.
Deberry, J.
Humecky, T.
Obar, F.
Lee, C. C.
TI Delivering a clinical exercise program to rural Veterans via clinical
video telehealth
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Blanchard, E.; Castle, S.; Ines, E.; Humecky, T.; Obar, F.; Lee, C. C.] VA Greater Los Angeles, GRECC, Los Angeles, CA USA.
[Castle, S.; Lee, C. C.] Univ Calif Los Angeles, David Geffen Sch Med, Internal Med Geriatr, Los Angeles, CA 90095 USA.
[Morey, M.; Deberry, J.] VHA Durham, GRECC, Durham, NC USA.
FU VA Office of Geriatrics and Extended Care Transformational Patient
Centered Alternatives to Institutional Care program; VHA Office of Rural
Health
FX Supported By: 1) VA Office of Geriatrics and Extended Care
Transformational Patient Centered Alternatives to Institutional Care
program; 2) VHA Office of Rural Health
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA C167
BP S208
EP S208
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800578
ER
PT J
AU Bready, E
Shi, Y
Shu, Z
Xue, X
Kamat, A
AF Bready, E.
Shi, Y.
Shu, Z.
Xue, X.
Kamat, A.
TI Beta2-Adrenergic Receptor Activation In Vivo Induces Hepatic Steatosis
in Rodents
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Bready, E.; Shi, Y.; Shu, Z.; Xue, X.; Kamat, A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Shi, Y.; Shu, Z.; Xue, X.; Kamat, A.] South Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA.
FU VA Merit Award [1I01BX001744]; Kronos Longevity Research Institute;
AFAR/MSTAR
FX Supported By: VA Merit Award (1I01BX001744), Kronos Longevity Research
Institute, and AFAR/MSTAR
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA B131
BP S134
EP S134
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800368
ER
PT J
AU Brown, R
Komaiko, K
Fung, K
Shi, Y
Au-Yeung, A
Jacob, R
Steinman, M
AF Brown, R.
Komaiko, K.
Fung, K.
Shi, Y.
Au-Yeung, A.
Jacob, R.
Steinman, M.
TI Bringing functional status into a Big Data world: Validation of national
Veterans Affairs functional status data
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Brown, R.; Komaiko, K.; Fung, K.; Shi, Y.; Au-Yeung, A.; Jacob, R.; Steinman, M.] UCSF, Div Geriatr, San Francisco VA Med Ctr, San Francisco, CA USA.
FU National Center for Advancing Translational Sciences, National
Institutes of Health through UCSF-Clinical and Translational Sciences
Institute [KL2TR000143]; National Institute on Aging at the National
Institutes of Health [K23AG045290, P30AG044281, K23AG030999,
K24AG049057]; Tideswell at UCSF
FX Supported By: 1. National Center for Advancing Translational Sciences,
National Institutes of Health, through UCSF-Clinical and Translational
Sciences Institute (KL2TR000143); 2. National Institute on Aging at the
National Institutes of Health (K23AG045290, P30AG044281, K23AG030999,
K24AG049057); 3. Tideswell at UCSF
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA B64
BP S109
EP S109
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800301
ER
PT J
AU Brown, R
Ahalt, C
Rivera, J
Casadei, M
Williams, B
AF Brown, R.
Ahalt, C.
Rivera, J.
Casadei, M.
Williams, B.
TI Good Cop, Better Cop: Evaluation of a Geriatrics Training Program for
Police
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Brown, R.; Ahalt, C.; Rivera, J.; Casadei, M.; Williams, B.] UCSF Div Geriatr, San Francisco, CA USA.
[Brown, R.] San Francisco VA Med Ctr, San Francisco, CA USA.
FU Tideswell at UCSF; Jacob and Valeria Langeloth Foundation; National
Center for Advancing Translational Sciences, National Institutes of
Health, through UCSF-Clinical and Translational Sciences Institute
[KL2TR000143]; National Institute on Aging at the National Institutes of
Health [K23AG045290, P30AG044281]
FX Supported By: 1. Tideswell at UCSF; 2. Jacob and Valeria Langeloth
Foundation; 3. National Center for Advancing Translational Sciences,
National Institutes of Health, through UCSF-Clinical and Translational
Sciences Institute (KL2TR000143); 4. National Institute on Aging at the
National Institutes of Health (K23AG045290, P30AG044281)
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA P8
BP S3
EP S3
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800009
ER
PT J
AU Burke, RE
Whitfield, E
Levy, C
AF Burke, R. E.
Whitfield, E.
Levy, C.
TI Improving transitions to post-acute care facilities
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Burke, R. E.; Whitfield, E.; Levy, C.] Denver VA Med Ctr, Denver, CO USA.
FU Hartford Foundation/Jahnigen Center of Excellence at the University of
Colorado
FX Supported By: Drs. Burke and Whitfield were funded by the Hartford
Foundation/Jahnigen Center of Excellence at the University of Colorado.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA C114
BP S189
EP S190
PG 2
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800525
ER
PT J
AU Fathi, R
Patel, K
Houston, T
Ritchie, C
AF Fathi, R.
Patel, K.
Houston, T.
Ritchie, C.
TI Life-Space Assessment as a predictor of readmission and mobility in
hospitalized older adults
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Fathi, R.; Patel, K.; Ritchie, C.] UCSF, Geriatr, San Francisco, CA USA.
[Fathi, R.] San Francisco VA Med Ctr, Geriatr, San Francisco, CA USA.
[Houston, T.] Univ Massachusetts, Sch Med, Worcester, MA USA.
FU [1 R18 HS017786]
FX Supported By: The project described was supported by grant number 1 R18
HS017786.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA A56
BP S37
EP S37
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800100
ER
PT J
AU Hagiwara, Y
Lee, S
Garza, G
Huang, C
Sanchez-Reilly, S
AF Hagiwara, Y.
Lee, S.
Garza, G.
Huang, C.
Sanchez-Reilly, S.
TI The Gateway to Geriatrics: Impact of an Innovative Early Exposure
Geriatrics Curriculum For First Year College Students
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Lee, S.; Huang, C.; Sanchez-Reilly, S.] South Texas Vet Hlth Care Syst, GEC GRECC, San Antonio, TX USA.
[Garza, G.] St Marys Univ, San Antonio, TX USA.
[Hagiwara, Y.; Sanchez-Reilly, S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
FU Hartford CoE Award, HRSA
FX Supported By: Hartford CoE Award, HRSA
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA A71
BP S42
EP S42
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800115
ER
PT J
AU Hagiwara, Y
Healy, J
Ghannam, S
Lee, S
Sanchez-Reilly, S
AF Hagiwara, Y.
Healy, J.
Ghannam, S.
Lee, S.
Sanchez-Reilly, S.
TI The Family Meeting OSCE Assessment Tool: Development and Validation of a
Novel Assessment Tool
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Hagiwara, Y.; Healy, J.; Sanchez-Reilly, S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Lee, S.; Sanchez-Reilly, S.] South Texas Vet Hlth Care Syst, GEC GRECC, San Antonio, TX USA.
[Ghannam, S.] Univ Texas San Antonio, San Antonio, TX USA.
FU Hartford CoE Award, HRSA
FX Supported By: Hartford CoE Award, HRSA
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA A70
BP S41
EP S42
PG 2
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800114
ER
PT J
AU Harris, J
Hagiwara, Y
Kasbarian, C
Lee, S
Ross, J
AF Harris, J.
Hagiwara, Y.
Kasbarian, C.
Lee, S.
Ross, J.
TI Geri-SAFE: An Educational Intervention to Aid Students in the Prevention
& Assessment of Falls in the Elderly
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Harris, J.; Hagiwara, Y.; Kasbarian, C.; Lee, S.; Ross, J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Harris, J.; Hagiwara, Y.; Kasbarian, C.; Lee, S.; Ross, J.] South Texas Vet Hlth Care Syst, GEC GRECC, San Antonio, TX USA.
FU MSTAR/AFAR; University of Texas System Patient Safety Medical Education
Award
FX Supported By: Supported by: MSTAR/AFAR and The University of Texas
System Patient Safety Medical Education Award
NR 0
TC 0
Z9 0
U1 3
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA B71
BP S111
EP S111
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800308
ER
PT J
AU Harrison, KL
Smith, AK
AF Harrison, K. L.
Smith, A. K.
TI Advance care planning in older adults: wide disparities, no difference
by health
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Harrison, K. L.; Smith, A. K.] Univ Calif San Francisco, Geriatr, San Francisco, CA 94143 USA.
[Harrison, K. L.; Smith, A. K.] San Francisco VA Med Ctr, San Francisco, CA USA.
FU National Institute of Aging [T32-AG000212]
FX Supported By: National Institute of Aging T32-AG000212
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA B79
BP S114
EP S114
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800316
ER
PT J
AU Hsu, A
Gan, S
Stijacic-Cenzer, I
Lee, S
AF Hsu, A.
Gan, S.
Stijacic-Cenzer, I.
Lee, S.
TI Glycemic control and functional status in residents of VA Community
Living Centers (CLC)
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Hsu, A.; Stijacic-Cenzer, I.; Lee, S.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Hsu, A.; Gan, S.; Stijacic-Cenzer, I.; Lee, S.] San Francisco VA Med Ctr, San Francisco, CA USA.
FU Beeson Career Development program from National Institute on Aging
[K23AG040779]; American Federation of Aging Research
FX Supported By: This work was supported with resources from and the use of
facilities at the San Francisco VA Medical Center. S.J.L was supported
by the Beeson Career Development program from the National Institute on
Aging (K23AG040779) and the American Federation of Aging Research.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA C56
BP S169
EP S170
PG 2
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800467
ER
PT J
AU Jang, M
Davis, D
Edes, T
Makineni, R
Kinosian, B
AF Jang, M.
Davis, D.
Edes, T.
Makineni, R.
Kinosian, B.
TI How Many Independence at Home Qualified (IAH-Q) Veterans do Home Based
Primary Care (HBPC) Programs Think Need HBPC?
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Jang, M.; Kinosian, B.] Philadelphia VAMC, GEC DAC, Philadelphia, PA USA.
[Davis, D.; Edes, T.] US Dept Vet Affairs, Washington, DC USA.
[Makineni, R.] Providence VAMC, GEC DAC, Providence, RI USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA B109
BP S126
EP S126
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800346
ER
PT J
AU Joseph, M
Higbea, A
Thorpe, C
Coley, K
McGiveny, M
Klatt, P
Schleiden, L
Zaharoff, J
Cox-Vance, L
Corbo, J
Balestrino, V
Sakely, H
AF Joseph, M.
Higbea, A.
Thorpe, C.
Coley, K.
McGiveny, M.
Klatt, P.
Schleiden, L.
Zaharoff, J.
Cox-Vance, L.
Corbo, J.
Balestrino, V.
Sakely, H.
TI Surveys of older adult's medication-related self-efficacy and adherence:
Pharmacist-led InterVentions On Transitions of Seniors (PIVOTS)
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Joseph, M.; Klatt, P.; Balestrino, V.; Sakely, H.] UPMC St Margaret, Pittsburgh, PA USA.
[Thorpe, C.; Coley, K.; McGiveny, M.; Schleiden, L.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA.
[Thorpe, C.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Zaharoff, J.] Presbyterian Senior Care, Pittsburgh, PA USA.
[Cox-Vance, L.] Chillicothe VA Med Ctr, Chillicothe, OH USA.
[Higbea, A.] Texas Tech Univ, Sch Pharm, Lubbock, TX 79409 USA.
[Corbo, J.] South Texas VA Hlth Syst, San Antonio, TX USA.
FU ASHP Research and Education Foundation; Jewish Healthcare Foundation
FX Supported By: ASHP Research and Education Foundation; Jewish Healthcare
Foundation
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA D113
BP S257
EP S257
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800715
ER
PT J
AU Kennelty, KA
Jensen, L
Gehring, M
Gilmore-Bykovskyi, A
Roiland, R
Hager, DR
Kind, A
AF Kennelty, K. A.
Jensen, L.
Gehring, M.
Gilmore-Bykovskyi, A.
Roiland, R.
Hager, D. R.
Kind, A.
TI Development of the Preventing Opioid Theft and Ensuring Secure Transfer
of Personal Health Information (PROTECT PHI) Intervention when Patients
Transition from the Hospital to a Nursing Home
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Kennelty, K. A.; Jensen, L.; Gehring, M.; Gilmore-Bykovskyi, A.; Roiland, R.; Kind, A.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
[Kennelty, K. A.; Gehring, M.; Gilmore-Bykovskyi, A.; Roiland, R.; Kind, A.] Univ Wisconsin, Madison, WI USA.
[Hager, D. R.] UW Hlth, Madison, WI USA.
FU National Institute on Aging Beeson Career Development Award
[K23AG034551]; National Institute on Aging Beeson Career Development
Award (National Institute on Aging); National Institute on Aging Beeson
Career Development Award (American Federation for Aging Research);
National Institute on Aging Beeson Career Development Award (John A.
Hartford Foundation); National Institute on Aging Beeson Career
Development Award (Atlantic Philanthropies); National Institute on Aging
Beeson Career Development Award (Starr Foundation); National Institute
on Aging [2P50AG033514-06]; University of Wisconsin School of Medicine
and Public Health from the Wisconsin Partnership Program;
Community-Academic Partnerships core of the University of Wisconsin
Institute for Clinical and Translational Research (UW ICTR),
[1UL1RR025011]
FX Supported By: This material is the result of work supported with
resources at the William S. Middleton Memorial Veterans Hospital,
Madison, WI. The contents do not represent views of the Dept. of
Veterans Affairs or the United States Government. Dr. Kind was supported
by a National Institute on Aging Beeson Career Development Award
(K23AG034551 [PI Kind], National Institute on Aging, The American
Federation for Aging Research, The John A. Hartford Foundation, The
Atlantic Philanthropies and The Starr Foundation); National Institute on
Aging 2P50AG033514-06. Dr. Kind's time was also partially supported by
the University of Wisconsin School of Medicine and Public Health from
the Wisconsin Partnership Program. Additional support was provided by
the Community-Academic Partnerships core of the University of Wisconsin
Institute for Clinical and Translational Research (UW ICTR), grant
1UL1RR025011 from the Clinical and Translational Science Award (CTSA)
program of the National Center for Research Resources, National
Institutes of Health.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA B146
BP S140
EP S140
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800383
ER
PT J
AU Kennelty, KA
Gilmore-Bykovskyi, A
Kind, A
AF Kennelty, K. A.
Gilmore-Bykovskyi, A.
Kind, A.
TI Absence of warfarin discharge communication components increases risk of
30-day rehospitalization and/or death in stroke and hip fracture
patients discharged to sub-acute care
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Kennelty, K. A.; Gilmore-Bykovskyi, A.; Kind, A.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
[Kennelty, K. A.; Gilmore-Bykovskyi, A.; Kind, A.] Univ Wisconsin, Madison, WI USA.
FU National Institute on Aging Beeson Career Development Award
[K23AG034551]; National Institute on Aging Beeson Career Development
Award (National Institute on Aging, The American Federation for Aging
Research); National Institute on Aging Beeson Career Development Award
(The John A. Hartford Foundation); National Institute on Aging Beeson
Career Development Award (The Atlantic Philanthropies); National
Institute on Aging Beeson Career Development Award (Starr Foundation);
National Institute on Aging [2P50AG033514-06]; University of Wisconsin
School of Medicine and Public Health from the Wisconsin Partnership
Program; Community-Academic Partnerships core of the University of
Wisconsin Institute for Clinical and Translational Research (UW ICTR)
[1UL1RR025011]
FX Supported By: This material is the result of work supported with
resources at the William S. Middleton Memorial Veterans Hospital,
Madison, WI. The contents do not represent views of the Dept. of
Veterans Affairs or the United States Government. Dr. Kind was supported
by a National Institute on Aging Beeson Career Development Award
(K23AG034551 [PI Kind], National Institute on Aging, The American
Federation for Aging Research, The John A. Hartford Foundation, The
Atlantic Philanthropies and The Starr Foundation); National Institute on
Aging 2P50AG033514-06. Dr. Kind's time was also partially supported by
the University of Wisconsin School of Medicine and Public Health from
the Wisconsin Partnership Program. Additional support was provided by
the Community-Academic Partnerships core of the University of Wisconsin
Institute for Clinical and Translational Research (UW ICTR), grant
1UL1RR025011 from the Clinical and Translational Science Award (CTSA)
program of the National Center for Research Resources, National
Institutes of Health.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA B81
BP S115
EP S115
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800318
ER
PT J
AU Lin, A
Brook, J
Grill, J
Teng, E
AF Lin, A.
Brook, J.
Grill, J.
Teng, E.
TI Participant-Informant Relationship Affects Quality of Life Ratings in
Incipient and Clinical Alzheimer's Disease
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Lin, A.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
[Brook, J.] Univ Calif Los Angeles, David Geffen Sch Med, Med, Los Angeles, CA 90095 USA.
[Grill, J.] UCI, Inst Memory Impairments & Neurol Disorders, Irvine, CA USA.
[Teng, E.] Univ Calif Los Angeles, David Geffen Sch Med, Neurol, Los Angeles, CA 90095 USA.
[Teng, E.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
FU National Institute on Aging [T35 AG026736, P50 AG16570]; Alzheimer's
Disease Research Centers of California; Sidell-Kagan Foundation
FX National Institute on Aging (T35 AG026736 [UCLA Medical Student Training
in Aging Research Program], P50 AG16570 [UCLA Alzheimer's Disease
Research Center]), Alzheimer's Disease Research Centers of California,
and the Sidell-Kagan Foundation
NR 0
TC 0
Z9 0
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA B119
BP S130
EP S130
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800356
ER
PT J
AU Linden, J
Stowers, KH
Veeder, H
Lee, S
Sanchez-Reilly, S
AF Linden, J.
Stowers, K. H.
Veeder, H.
Lee, S.
Sanchez-Reilly, S.
TI Protecting our Vulnerable: Mistreatment in Palliative Care
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Linden, J.] Univ Hawaii Manoa, JABSOM, Honolulu, HI 96822 USA.
[Stowers, K. H.; Sanchez-Reilly, S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Veeder, H.] VITAS Hosp, San Antonio, TX USA.
[Lee, S.; Sanchez-Reilly, S.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA D153
BP S271
EP S271
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800755
ER
PT J
AU Lum, H
Jones, J
Sudore, R
Schwartz, R
Levy, C
Kutner, JD
AF Lum, H.
Jones, J.
Sudore, R.
Schwartz, R.
Levy, C.
Kutner, J. D.
TI A Group Visit Intervention Improves Advance Care Planning Readiness,
Conversations, and Documentation
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Lum, H.; Schwartz, R.; Levy, C.; Kutner, J. D.] Univ Colorado, Sch Med, Aurora, CO USA.
[Lum, H.; Schwartz, R.] VA Eastern Colorado GRECC, Denver, CO USA.
[Jones, J.] Univ Colorado, Coll Nursing, Aurora, CO USA.
[Sudore, R.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Sudore, R.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
FU Colorado Health Foundation; University of Colorado Hospital/University
of Colorado Denver/University Physicians, Inc. Primary Care Strategic
Initiative Fund
FX The Colorado Health Foundation; University of Colorado
Hospital/University of Colorado Denver/University Physicians, Inc.
Primary Care Strategic Initiative Fund
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA B100
BP S122
EP S123
PG 2
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800337
ER
PT J
AU Mireles, C
Murray, A
Pagan-Ferrer, J
Arevalo-Flechas, LC
Ross, J
AF Mireles, C.
Murray, A.
Pagan-Ferrer, J.
Arevalo-Flechas, L. C.
Ross, J.
TI Determining the Efficacy of Clinical Novelas as a Teaching Tool for Fall
Prevention in the Geriatric Population
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Mireles, C.; Murray, A.; Pagan-Ferrer, J.; Arevalo-Flechas, L. C.; Ross, J.] Univ Texas Hlth Sci Ctr San Antonio, Hlth Sci Ctr, San Antonio, TX 78229 USA.
[Mireles, C.; Murray, A.; Pagan-Ferrer, J.; Arevalo-Flechas, L. C.; Ross, J.] South Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA.
FU University of Texas System Patient Safety Medical Education Award
FX Supported By: University of Texas System Patient Safety Medical
Education Award
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA C165
BP S207
EP S208
PG 2
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800576
ER
PT J
AU Miura, L
Onitsuka, J
Srikantom, S
Delmar, J
Blehm, R
AF Miura, L.
Onitsuka, J.
Srikantom, S.
Delmar, J.
Blehm, R.
TI Preliminary Outcomes of a Fall Assessment Clinic
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Miura, L.; Onitsuka, J.; Srikantom, S.; Delmar, J.; Blehm, R.] Portland VA Med Ctr, Med, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA A178
BP S80
EP S80
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800222
ER
PT J
AU Nakano, C
Chen, R
Bell, C
Robbins, J
Ross, G
Abbott, R
Petrovitch, H
Masaki, K
AF Nakano, C.
Chen, R.
Bell, C.
Robbins, J.
Ross, G.
Abbott, R.
Petrovitch, H.
Masaki, K.
TI Dysphagia as a Predictor of All-Cause Mortality: The Honolulu-Asia Aging
Study
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Nakano, C.; Bell, C.; Ross, G.; Abbott, R.; Petrovitch, H.; Masaki, K.] Univ Hawaii, Geriatr Med, Honolulu, HI 96822 USA.
[Chen, R.; Masaki, K.] Kuakini Med Ctr, Honolulu, HI USA.
[Ross, G.; Petrovitch, H.] Vet Affairs Pacific Islands Hlth Care Syst, Honolulu, HI USA.
[Abbott, R.] Shiga Univ Med Sci, Ctr Epidemiol Res Asia, Otsu, Shiga 52021, Japan.
[Robbins, J.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
[Robbins, J.] Univ Wisconsin, Madison, WI USA.
FU John A. Hartford Foundation Center of Excellence in Geriatrics;
Department of Geriatric Medicine, University of Hawaii; John A. Burns
School of Medicine, University of Hawaii; Kuakini Medical Center;
National Institutes of Health (NIH) from National Institute on Aging
[N01-AG-4-2149, U01 AG019349, R01AG027060, R01AG038707]; National
Institutes of Health (NIH) from National Heart, Lung, and Blood
Institute [N01-HC-05102]; Hawaii Community Foundation [2004-0463];
Office for Research and Development, Department of Veterans Affairs
FX Supported By: This study was supported by the John A. Hartford
Foundation Center of Excellence in Geriatrics, Department of Geriatric
Medicine, John A. Burns School of Medicine, University of Hawaii; the
Kuakini Medical Center; the National Institutes of Health (NIH)
(Contract N01-AG-4-2149, Grants U01 AG019349, R01AG027060, and
R01AG038707 from the National Institute on Aging, and Contract
N01-HC-05102 from the National Heart, Lung, and Blood Institute); Hawaii
Community Foundation grant 2004-0463; and the Office for Research and
Development, Department of Veterans Affairs. The views expressed in this
abstract do not necessarily represent those of the federal government.
The funding sources had no role in the analysis.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA B63
BP S108
EP S108
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800300
ER
PT J
AU Niemiec, SS
Halle, A
Sarkisian, C
AF Niemiec, S. Schepens
Halle, A.
Sarkisian, C.
TI Knowledge and anxiety about aging and negative bias toward older adults
in White and Asian occupational therapy students
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Niemiec, S. Schepens; Halle, A.] Univ So Calif, Div Occupat Sci & Occupat Therapy, Los Angeles, CA USA.
[Sarkisian, C.] GRECC, VA Greater Angeles Healthcare Syst, Los Angeles, CA USA.
[Sarkisian, C.] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, Los Angeles, CA 90095 USA.
FU NIH--NCMRR [K12 HD055929]; NINDS; Midcareer Award in Patient-Oriented
Community-Academic Partnered Aging Research [1K24AG047899-01]
FX Supported By: Dr. Schepens Niemiec is supported by K12 HD055929
NIH--NCMRR and NINDS. Dr. Sarkisian is supported by 1K24AG047899-01
Midcareer Award in Patient-Oriented Community-Academic Partnered Aging
Research.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA C79
BP S177
EP S178
PG 2
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800490
ER
PT J
AU Nirkhe, S
Rhea, EM
Banks, WA
AF Nirkhe, S.
Rhea, E. M.
Banks, W. A.
TI Effects of Intranasal Insulin on Brain Insulin Signaling in an Aged
Mouse Model of Alzheimer's Disease
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Nirkhe, S.; Rhea, E. M.; Banks, W. A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Nirkhe, S.] Univ Washington, Sch Med, Seattle, WA USA.
[Rhea, E. M.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
[Banks, W. A.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA.
FU Medical Student Training in Aging Research Program, National Institute
on Aging
FX Supported By: Medical Student Training in Aging Research Program,
National Institute on Aging
NR 0
TC 0
Z9 0
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA D122
BP S260
EP S260
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800724
ER
PT J
AU Obal, L
Tubbesing, SA
Vega, A
Nelson, S
Toy, S
Brazier, J
Bai, J
Dhanani, S
AF Obal, L.
Tubbesing, S. A.
Vega, A.
Nelson, S.
Toy, S.
Brazier, J.
Bai, J.
Dhanani, S.
TI Using Geographic Information Systems to Improve Practitioner Travel
Efficiency in Home Based Primary Care
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Brazier, J.] VA Greater Angeles Healthcare Syst, Adm Med, Los Angeles, CA USA.
[Tubbesing, S. A.] Univ Calif Los Angeles, David Geffen Sch Med, Internal Med Geriatr, Los Angeles, CA 90095 USA.
[Dhanani, S.] VA Southern Oregon Rehabil Ctr & Clin, White City, OR USA.
[Bai, J.] Vet Emergency Management Evaluat Ctr, Los Angeles, CA USA.
[Toy, S.] VA Greater Angeles Healthcare Syst, Geriatr & Rehabil Care, Los Angeles, CA USA.
[Nelson, S.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.
[Vega, A.] Univ Penn, NewCourtland Ctr Transit & Hlth, Philadelphia, PA 19104 USA.
[Obal, L.; Tubbesing, S. A.] VA Greater Angeles Healthcare Syst, Geriatr & Extended Care, Los Angeles, CA USA.
FU VA Office of Geriatrics and Extended Care
FX Supported By: VA Office of Geriatrics and Extended Care
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA C117
BP S191
EP S191
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800528
ER
PT J
AU Pang, M
Bartholomew, A
Castle, S
Lee, CC
AF Pang, M.
Bartholomew, A.
Castle, S.
Lee, C. C.
TI Maintaining Diabetes Prevention Behaviors using a Social Cognitive
Health Coaching Approach Within the Construct of GEROFIT
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Pang, M.; Bartholomew, A.; Castle, S.; Lee, C. C.] VA Greater Los Angeles, GRECC, Los Angeles, CA USA.
[Castle, S.; Lee, C. C.] Univ Calif Los Angeles, David Geffen Sch Med, Internal Med Geriatr, Los Angeles, CA 90095 USA.
FU VA Office of Geriatrics and Extended Care Transformative
Non-Institutional Long Term Care Program; VHA Office of Rural Health
FX Supported By: 1) VA Office of Geriatrics and Extended Care
Transformative Non-Institutional Long Term Care Program; 2) VHA Office
of Rural Health
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA D142
BP S267
EP S267
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800744
ER
PT J
AU Phibbs, C
Intrator, O
Kinosian, B
Scott, W
Dally, S
Shay, K
AF Phibbs, C.
Intrator, O.
Kinosian, B.
Scott, W.
Dally, S.
Shay, K.
TI Cost of Care for Veterans Receiving Primary Care in Patient Aligned Care
Teams (PACT) vs. Geriatric PACT
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Phibbs, C.] Stanford Univ, Stanford, CA 94305 USA.
[Phibbs, C.; Scott, W.; Dally, S.] VA Palo Alto Healthcare Syst, GECDAC & HERC, Palo Alto, CA USA.
[Intrator, O.] Canandaigua VA Med Ctr, GECDAC, Canandaigua, NY USA.
[Intrator, O.] Univ Rochester, Rochester, NY USA.
[Kinosian, B.] Philadelphia VA Med Ctr, GECDAC, Philadelphia, PA USA.
[Kinosian, B.] Univ Penn, Philadelphia, PA 19104 USA.
[Shay, K.] Geriatr & Extended Care VA, Washington, DC USA.
FU Veterans Affairs Office of Geriatrics and Extended Care Service
FX Supported By: Veterans Affairs Office of Geriatrics and Extended Care
Service
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA P17
BP S7
EP S7
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800018
ER
PT J
AU Ritchey, KC
Olney, A
Wojtowicz, M
Howard, I
Phelan, EA
Matsumoto, AM
AF Ritchey, K. C.
Olney, A.
Wojtowicz, M.
Howard, I.
Phelan, E. A.
Matsumoto, A. M.
TI The Relationship between Self-Report and Performance-Based Measures of
Mobility in Persons with Osteoporosis
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Ritchey, K. C.; Wojtowicz, M.; Matsumoto, A. M.] VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA.
[Ritchey, K. C.; Phelan, E. A.; Matsumoto, A. M.] Univ Washington, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA.
[Olney, A.; Howard, I.] VA Puget Sound Hlth Care Syst, RCS, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA C170
BP S209
EP S209
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800581
ER
PT J
AU Rodriguez, JC
Alessi, C
Martin, JL
Hays, R
Dzierzewski, J
Col, N
Patterson, E
Jouldjian, S
Josephson, K
Song, Y
Fung, CH
AF Rodriguez, J. C.
Alessi, C.
Martin, J. L.
Hays, R.
Dzierzewski, J.
Col, N.
Patterson, E.
Jouldjian, S.
Josephson, K.
Song, Y.
Fung, C. H.
TI Association Between Pain And Difficulty Setting Up Positive Airway
Pressure Devices Among Older Adults With Sleep-Disordered Breathing
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Rodriguez, J. C.; Alessi, C.; Martin, J. L.; Hays, R.; Dzierzewski, J.; Fung, C. H.] Univ Calif Los Angeles, Med, Los Angeles, CA USA.
[Rodriguez, J. C.; Alessi, C.; Martin, J. L.; Dzierzewski, J.; Jouldjian, S.; Josephson, K.; Song, Y.; Fung, C. H.] Vet Affairs Greater Los Angeles, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA.
[Col, N.] Univ New England, Main, ME USA.
[Patterson, E.] Ohio State Univ, Columbus, OH 43210 USA.
FU National Institute On Aging of the National Institutes of Health
[K23AG045937]; Beeson Career Development in Aging Research Award
Program; NIA; AFAR; John A. Hartford Foundation; Atlantic Philanthropies
FX Supported By: Research reported in this publication was supported by the
National Institute On Aging of the National Institutes of Health under
Award Number K23AG045937 and The Beeson Career Development in Aging
Research Award Program (supported by NIA, AFAR, The John A. Hartford
Foundation, and The Atlantic Philanthropies). The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the National Institutes of Health or the Department of
Veterans Affairs.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA D59
BP S238
EP S238
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800662
ER
PT J
AU Vandenberg, AE
Vaughan, C
Stevens, M
Hastings, SN
Powers, J
Markland, AD
Hwang, U
Hung, W
Echt, K
AF Vandenberg, A. E.
Vaughan, C.
Stevens, M.
Hastings, S. N.
Powers, J.
Markland, A. D.
Hwang, U.
Hung, W.
Echt, K.
TI Evaluating use of a clinical decision support tool to improve quality of
geriatric prescribing in the ED
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Vandenberg, A. E.; Vaughan, C.; Stevens, M.; Echt, K.] Birmingham & Atlanta VAMC, GRECC, Atlanta, GA USA.
[Vandenberg, A. E.; Vaughan, C.; Stevens, M.; Echt, K.] Emory Univ, Med, Atlanta, GA 30322 USA.
[Hastings, S. N.] Durham VAMC, GRECC, Durham, NC USA.
[Hastings, S. N.] Duke Univ, Med, Durham, NC USA.
[Powers, J.] Tennessee Valley VAMC, GRECC, Nashville, TN USA.
[Powers, J.] Vanderbilt Univ, Med, 221 Kirkland Hall, Nashville, TN 37235 USA.
[Markland, A. D.] Birmingham & Atlanta VAMC, GRECC, Birmingham, AL USA.
[Markland, A. D.] Univ Alabama Birmingham, Med, Birmingham, AL USA.
[Hwang, U.; Hung, W.] James J Peters VAMC, GRECC, Bronx, NY USA.
FU VA Office of Geriatrics and Extended Care; VA office of Rural Health;
John A. Hartford Foundation; Emory University Department of Medicine
FX Supported By: Funding provided by the VA Office of Geriatrics and
Extended Care, VA office of Rural Health, John A. Hartford Foundation,
and Emory University Department of Medicine
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA C109
BP S188
EP S188
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800520
ER
PT J
AU Zullo, AR
Lee, Y
Daiello, LA
Mor, V
Boscardin, W
Steinman, M
AF Zullo, A. R.
Lee, Y.
Daiello, L. A.
Mor, V.
Boscardin, W.
Steinman, M.
TI Effect of Beta Blocker Use on Daily Functioning, Rehospitalization, and
Death After Myocardial Infarction Among Older Nursing Home Residents.
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 19-21, 2016
CL Long Beach, CA
SP Amer Geriatr Soc
C1 [Zullo, A. R.; Lee, Y.; Daiello, L. A.; Mor, V.] Brown Univ, Hlth Serv Policy & Practice, North Kingstown, RI USA.
[Boscardin, W.; Steinman, M.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
[Boscardin, W.; Steinman, M.] San Francisco VA Med Ctr, San Francisco, CA USA.
FU NIH [5R01HL111032-03]; AHRQ [5K12HS022998-02]
FX Supported By: NIH (5R01HL111032-03) and AHRQ (5K12HS022998-02)
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2016
VL 64
SU 1
SI SI
MA P25
BP S10
EP S10
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK2SD
UT WOS:000374763800025
ER
PT J
AU Friedman, CP
Donaldson, KM
Vantsevich, AV
AF Friedman, Charles P.
Donaldson, Katherine M.
Vantsevich, Anna V.
TI Educating medical students in the era of ubiquitous information
SO MEDICAL TEACHER
LA English
DT Article
ID HEALTH-CARE; TECHNOLOGY; ERROR
AB Health care around the world is going digital. This inexorable trend will result in: (1) routine documentation of care in digital form and emerging national infrastructures for sharing data that allow progress toward a learning health system; and (2) a biomedical knowledge cloud that is fully integrated into practice environments and accessible to both providers and consumers of healthcare. Concurrently, medical students will be complete digital natives who have literally grown up with the Internet and will enter practice early in the next decade when the projected changes in practice approach maturity. This essay describes three competencies linked to this evolving information environment(1) knowing what you do and don't know, (2) ability to ask a good question, and (3) skills in evaluating and weighing evidenceand suggests educational approaches to promote student mastery of each competency. Shifting medical education to address these competencies will call into question many current methods but may be essential to fully prepare trainees for optimal practice in the future.
C1 [Friedman, Charles P.] Univ Michigan, Sch Med, Dept Learning Hlth Sci, Ann Arbor, MI 48109 USA.
[Friedman, Charles P.] Univ Michigan, Sch Informat, Sch Publ Hlth, Ann Arbor, MI 48109 USA.
[Donaldson, Katherine M.] Univ Chicago, NORC, Hlth Sci, Bethesda, MD USA.
[Vantsevich, Anna V.] Mental Hlth Serv, San Francisco VA Med Ctr, San Francisco, CA USA.
RP Friedman, CP (reprint author), Univ Michigan, Sch Med, 209 Victor Vaughan Bldg,SPC 2054, Ann Arbor, MI 48109 USA.
EM cpfried@umich.edu
NR 29
TC 0
Z9 0
U1 6
U2 10
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0142-159X
EI 1466-187X
J9 MED TEACH
JI Med. Teach.
PD MAY
PY 2016
VL 38
IS 5
BP 504
EP 509
DI 10.3109/0142159X.2016.1150990
PG 6
WC Education, Scientific Disciplines; Health Care Sciences & Services
SC Education & Educational Research; Health Care Sciences & Services
GA DL7YD
UT WOS:000375855400010
PM 27027546
ER
PT J
AU Duong, HA
Le, KT
Soulema, AL
Yueh, RH
Scheuner, MT
Holick, MF
Christensen, R
Tajima, TL
Leung, AM
Mallya, SM
AF Duong, Hannah A.
Le, Karen T.
Soulema, Albert L.
Yueh, Ronald H.
Scheuner, Maren T.
Holick, Michael F.
Christensen, Russell
Tajima, Tracey L.
Leung, Angela M.
Mallya, Sanjay M.
TI Gnathodiaphyseal dysplasia: report of a family with a novel mutation of
the ANO5 gene
SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY
LA English
DT Article
ID FIBROOSSEOUS LESIONS; BONE; OSTEONECROSIS; PROTEIN; JAW
AB Gnathodiaphyseal dysplasia (GDD) is a rare autosomal dominant disorder characterized by florid osseous dysplasia of the jaws, bone fragility, and diaphyseal cortical thickening and bowing of long bones. We present a family with previously undiagnosed GDD. The disorder was identified by the characteristic gnathic and skeletal manifestations in the father. Clinical and radiologic examination of the patient's son also revealed the characteristic features of GDD. Gene sequencing revealed a novel mutation (c. 1067 G>A, p. Cys356 Tyr) in the ANO5 gene, which is causative for GDD. This mutation was predicted to be detrimental by computational analyses and by structural modeling of the protein. The implications for recognition and management of this disease are discussed.
C1 [Duong, Hannah A.; Mallya, Sanjay M.] Univ Calif Los Angeles, Sch Dent, Sect Oral & Maxillofacial Radiol, Los Angeles, CA 90024 USA.
[Le, Karen T.; Leung, Angela M.] VA Greater Los Angeles Healthcare Syst, Div Endocrinol, Los Angeles, CA USA.
[Le, Karen T.] Cedars Sinai Med Ctr, Div Endocrinol, Los Angeles, CA 90048 USA.
[Soulema, Albert L.; Tajima, Tracey L.] VA Greater Los Angeles Healthcare Syst, Dept Dent, Los Angeles, CA USA.
[Yueh, Ronald H.] VA Greater Los Angeles Healthcare Syst, Oral & Maxillofacial Surg, Dent Serv, Sepulveda Campus, Los Angeles, CA USA.
[Scheuner, Maren T.] VA Greater Los Angeles Healthcare Syst, Div Med Genet, Los Angeles, CA USA.
[Scheuner, Maren T.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Holick, Michael F.] Boston Univ, Sch Med, Sect Endocrinol Diabet & Nutr, Boston, MA 02118 USA.
[Christensen, Russell] Univ Calif Los Angeles, Sch Dent, Sect Oral & Maxillofacial Pathol, Los Angeles, CA 90024 USA.
[Leung, Angela M.] Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol, Los Angeles, CA 90095 USA.
RP Mallya, SM (reprint author), Univ Calif Los Angeles, Sch Dent, 53-068 CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA.
EM Smallya@ucla.edu
FU Eunice Kennedy Shriver National Institute of Child Health & Human
Development of the National Institutes of Health [K23 HD068552]
FX AML was supported, in part, by the Eunice Kennedy Shriver National
Institute of Child Health & Human Development of the National Institutes
of Health under award number K23 HD068552. The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the National Institutes of Health.
NR 21
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 2212-4403
EI 1528-395X
J9 OR SURG OR MED OR PA
JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol.
PD MAY
PY 2016
VL 121
IS 5
BP E123
EP E128
DI 10.1016/j.oooo.2016.01.014
PG 6
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA DL4LN
UT WOS:000375608100005
PM 27068316
ER
PT J
AU Suri, P
Pearson, AM
Scherer, EA
Zhao, WY
Lurie, JD
Morgan, TS
Weinstein, JN
AF Suri, Pradeep
Pearson, Adam M.
Scherer, Emily A.
Zhao, Wenyan
Lurie, Jon D.
Morgan, Tamara S.
Weinstein, James N.
TI Recurrence of Pain After Usual Nonoperative Care for Symptomatic Lumbar
Disk Herniation: Analysis of Data From the Spine Patient Outcomes
Research Trial
SO PM&R
LA English
DT Article
ID LOW-BACK-PAIN; RISK-FACTORS; LONGITUDINAL ASSESSMENT; NONSURGICAL
TREATMENT; GENERAL-POPULATION; SPORT; SCIATICA; COHORT; PREDICTORS;
DISABILITY
AB Objective: To determine risks and predictors of recurrent leg and low back pain (LBP) after unstructured, usual nonoperative care for subacute/chronic symptomatic lumbar disk herniation (LDH).
Design: Secondary analysis of data from a concurrent randomized trial and observational cohort study.
Setting: Thirteen outpatient spine practices.
Participants: A total of 199 participants with resolution of leg pain and 142 participants with resolution of LBP from among 478 participants receiving usual nonoperative care for symptomatic LDH.
Assessment of Risk Factors: Potential predictors of recurrence included time to initial symptom resolution, sociodemographics, clinical characteristics, work-related factors, imaging-detected herniation characteristics, and baseline pain bothersomeness.
Main Outcome Measurements: Leg pain and LBP bothersomeness were assessed by the use of a 0-6 numerical scale at up to 4 years of follow-up. For individuals with initial resolution of leg pain, we defined recurrent leg pain as having leg pain, receiving lumbar epidural steroid injections, or undergoing lumbar surgery subsequent to initial leg pain resolution. We calculated cumulative risks of recurrence by using Kaplan-Meier survival plots and examined predictors of recurrence using Cox proportional hazards models. We used similar definitions for LBP recurrence.
Results: One-and 3-year cumulative recurrence risks were 23% and 51% for leg pain, and 28% and 70% for LBP, respectively. Early leg pain resolution did not predict future leg pain recurrence. Complete leg pain resolution (adjusted hazard ratio [aHR] 0.47, 95% confidence interval [CI] 0.31-0.72) and posterolateral herniation location (aHR 0.61; 95% CI 0.39-0.97) predicted a lower risk of leg pain recurrence, and joint problems (aHR 1.89; 95% CI 1.16-3.05) and smoking (aHR 1.81; 95% CI 1.07-3.05) predicted a greater risk of leg pain recurrence. For participants with complete initial resolution of pain, recurrence risks at 1 and 3 years were 16% and 41% for leg pain and 24% and 59% for LBP, respectively.
Conclusions: Recurrence of pain is common after unstructured, usual nonsurgical care for LDH. These risk estimates depend on the specific definitions applied, and the predictors identified require replication in future studies.
C1 [Suri, Pradeep] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr ERIC, S-152 ERIC,1660 S Columbian Way, Seattle, WA USA.
[Suri, Pradeep] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA.
[Pearson, Adam M.; Zhao, Wenyan] Dartmouth Hitchcock Med Ctr, Geisel Sch Med, Dept Orthopaed, Hanover, NH USA.
[Scherer, Emily A.] Dartmouth Hitchcock Med Ctr, Geisel Sch Med, Dept Med, Hanover, NH USA.
[Lurie, Jon D.] Dartmouth Hitchcock Med Ctr, Geisel Sch Med, Dartmouth Inst Hlth Policy & Clin Practice, Dept Med, Hanover, NH USA.
[Morgan, Tamara S.; Weinstein, James N.] Dartmouth Hitchcock Med Ctr, Geisel Sch Med, Dartmouth Inst Hlth Policy & Clin Practice, Hanover, NH USA.
RP Suri, P (reprint author), VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr ERIC, S-152 ERIC,1660 S Columbian Way, Seattle, WA USA.; Suri, P (reprint author), Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA.
EM pradeep.suri@va.gov
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases
(NIAMS) [U01-AR45444]; Office of Research on Women's Health; National
Institutes of Health; National Institute of Occupational Safety and
Health; Centers for Disease Control and Prevention; NIAMS [P60-AR048094,
P60-AR062799]; VA Puget Sound Health Care System
FX Supported by the National Institute of Arthritis and Musculoskeletal and
Skin Diseases (NIAMS; U01-AR45444) and the Office of Research on Women's
Health, the National Institutes of Health, and the National Institute of
Occupational Safety and Health, the Centers for Disease Control and
Prevention. The Multidisciplinary Clinical Research Center in
Musculoskeletal Diseases is funded by NIAMS (P60-AR048094 and
P60-AR062799). Dr. Suri's participation is this study was funded by VA
Puget Sound Health Care System. The authors report no financial
arrangements that may represent a possible conflict of interest with the
work presented.
NR 36
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1934-1482
EI 1934-1563
J9 PM&R
JI PM&R
PD MAY
PY 2016
VL 8
IS 5
BP 405
EP 414
DI 10.1016/j.pmrj.2015.10.016
PG 10
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA DL6LA
UT WOS:000375749500002
PM 26548963
ER
PT J
AU Glaser, J
Reeves, ST
Stoll, WD
Epperson, TI
Hilbert, M
Madan, A
George, MS
Borckardt, JJ
AF Glaser, John
Reeves, Scott T.
Stoll, William David
Epperson, Thomas I.
Hilbert, Megan
Madan, Alok
George, Mark S.
Borckardt, Jeffrey J.
TI Motor/Prefrontal Transcranial Direct Current Stimulation (tDCS)
Following Lumbar Surgery Reduces Postoperative Analgesia Use
SO SPINE
LA English
DT Article
DE back pain; brain stimulation; lumbar surgery; motor cortex; opioid use;
pain; prefrontal cortex; transcranial direct current stimulation
ID MOTOR CORTEX STIMULATION; CHRONIC NEUROPATHIC PAIN; SPINAL-CORD-INJURY;
PREFRONTAL CORTEX; FIBROMYALGIA; RTMS; ELECTROACUPUNCTURE; REPLACEMENT;
PERCEPTION; BRAIN
AB Design. Randomized, controlled pilot trial.
Objective. The present study is the first randomized, double-blind, sham-controlled pilot clinical trial of transcranial direct current stimulation (tDCS) for pain and patient-controlled analgesia (PCA) opioid usage among patients receiving spine surgery.
Summary of Background Data. Lumbar spinal surgeries are common, and while pain is often a complaint that precedes surgical intervention, the procedures themselves are associated with considerable postoperative pain lasting days to weeks. Adequate postoperative pain control is an important factor in determining recovery and new analgesic strategies are needed that can be used adjunctively to existing strategies potentially to reduce reliance on opioid analgesia. Several novel brain stimulation technologies including tDCS are beginning to demonstrate promise as treatments for a variety of pain conditions.
Methods. Twenty-seven patients undergoing lumbar spine procedures at Medical University of South Carolina were randomly assigned to receive four 20-minute sessions of real or sham tDCS during their postsurgical hospital stay. Patient-administered hydromorphone usage was tracked along with numeric rating scale pain ratings.
Results. The effect of tDCS on the slope of the cumulative PCA curve was significant (P < 0.001) and tDCS was associated with a 23% reduction in PCA usage. In the real tDCS group a 31% reduction was observed in pain-at-its-least ratings from admission to discharge (P = 0.027), but no other changes in numeric rating scale pain ratings were significant in either group.
Conclusion. The present pilot trial is the first study to demonstrate an opioid sparing effect of tDCS after spine surgical procedures. Although this was a small pilot trial in a heterogeneous sample of spinal surgery patients, a moderate effect-size was observed for tDCS, suggesting that future work in this area is warranted.
C1 [Glaser, John] Med Univ S Carolina, Dept Orthoped Surg, Charleston, SC 29425 USA.
[Reeves, Scott T.; Stoll, William David; Epperson, Thomas I.; Hilbert, Megan; Borckardt, Jeffrey J.] Med Univ S Carolina, Dept Anesthesia & Perioperat Med, Charleston, SC 29425 USA.
[Madan, Alok] Menninger Clin, Houston, TX USA.
[Madan, Alok] Baylor Coll Med, Houston, TX 77030 USA.
[George, Mark S.; Borckardt, Jeffrey J.] Med Univ S Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA.
[George, Mark S.; Borckardt, Jeffrey J.] Ralph H Johnson VAMC, Charleston, SC USA.
RP Borckardt, JJ (reprint author), Inst Psychiat MSC 861, 507 North,67 President St, Charleston, SC 29425 USA.
EM borckard@musc.edu
FU National Association for Spine Surgery (NASS)
FX National Association for Spine Surgery (NASS) grant funds were received
in support of this work.
NR 30
TC 2
Z9 2
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0362-2436
EI 1528-1159
J9 SPINE
JI SPINE
PD MAY
PY 2016
VL 41
IS 10
BP 835
EP 839
DI 10.1097/BRS.0000000000001525
PG 5
WC Clinical Neurology; Orthopedics
SC Neurosciences & Neurology; Orthopedics
GA DL4RZ
UT WOS:000375626200013
PM 26909844
ER
PT J
AU Callon, W
Saha, S
Korthuis, PT
Wilson, IB
Moore, RD
Cohn, J
Beach, MC
AF Callon, Wynne
Saha, Somnath
Korthuis, P. Todd
Wilson, Ira B.
Moore, Richard D.
Cohn, Jonathan
Beach, Mary Catherine
TI Which Clinician Questions Elicit Accurate Disclosure of Antiretroviral
Non-adherence When Talking to Patients?
SO AIDS AND BEHAVIOR
LA English
DT Article
DE HIV/AIDS; Antiretrovirals; Adherence; Physician-patient communication
ID HIV-INFECTED PATIENTS; MEDICATION ADHERENCE; SELF-REPORT; PROVIDER
COMMUNICATION; THERAPY; CARE; INSTRUMENTS; BEHAVIOR; OUTCOMES; COHORT
AB This study evaluated how clinicians assess antiretroviral (ARV) adherence in clinical encounters, and which questions elicit accurate responses. We conducted conversation analysis of audio-recorded encounters between 34 providers and 58 patients reporting ARV non-adherence in post-encounter interviews. Among 42 visits where adherence status was unknown by providers, 4 providers did not discuss ARVs (10 %), 6 discussed ARVs but did not elicit non-adherence disclosure (14 %), and 32 discussed ARVs which prompted disclosure (76 %). Questions were classified as: (1) clarification of medication ("Are you still taking the Combivir?"); (2) broad ("How's it going with your meds?"); (3) positively-framed ("Are you taking your medications regularly?"); (4) negatively-framed ("Have you missed any doses?"). Clinicians asked 75 ARV-related questions: 23 clarification, 12 broad, 17 positively-framed, and 23 negatively-framed. Negatively-framed questions were 3.8 times more likely to elicit accurate disclosure than all other question types (p < 0.0001). Providers can improve disclosure probability by asking directly about missed doses.
C1 [Callon, Wynne; Moore, Richard D.; Beach, Mary Catherine] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Saha, Somnath] Portland VA Med Ctr, Portland, OR USA.
[Saha, Somnath; Korthuis, P. Todd] Oregon Hlth & Sci Univ, Dept Med, Portland, OR USA.
[Wilson, Ira B.] Brown Univ, Sch Publ Hlth, Dept Hlth Serv Policy & Practice, Providence, RI 02912 USA.
[Cohn, Jonathan] Wayne State Univ, Dept Med, Detroit, MI 48202 USA.
RP Callon, W (reprint author), Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
EM wcallon1@jhmi.edu
FU Health Resources Service Administration; Agency for Healthcare Research
and Quality [AHRQ 290-01-0012]; National Institute of Drug Abuse [K23
DA019809, K24 DA037804]; Department of Veterans Affairs
FX This research was supported by a contract from the Health Resources
Service Administration and the Agency for Healthcare Research and
Quality (AHRQ 290-01-0012). In addition, Dr. Korthuis was supported by
the National Institute of Drug Abuse (K23 DA019809). Dr. Saha was
supported by the Department of Veterans Affairs, Dr. Beach was supported
by the National Institute of Drug Abuse (K24 DA037804). None of the
funders had a role in the design and conduct of this analysis, nor was
it subject to their final approval. None of the authors have any
relevant financial conflicts of interest.
NR 29
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD MAY
PY 2016
VL 20
IS 5
BP 1108
EP 1115
DI 10.1007/s10461-015-1231-7
PG 8
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA DK3XM
UT WOS:000374850700017
PM 26499336
ER
PT J
AU Yaffe, K
AF Yaffe, Kristine
TI Moving Beyond Dualism to Advance Geriatric Neuropsychiatry
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Editorial Material
ID DEPRESSION
C1 [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA.
[Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA.
[Yaffe, Kristine] Univ Calif San Francisco, Box 181,4150 Clement St, San Francisco, CA 94121 USA.
RP Yaffe, K (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.; Yaffe, K (reprint author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.; Yaffe, K (reprint author), Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA.; Yaffe, K (reprint author), San Francisco VA Med Ctr, San Francisco, CA USA.; Yaffe, K (reprint author), Univ Calif San Francisco, Box 181,4150 Clement St, San Francisco, CA 94121 USA.
EM kristine.yaffe@ucsf.edu
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD MAY
PY 2016
VL 24
IS 5
BP 339
EP 341
DI 10.1016/j.jagp.2016.01.137
PG 3
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA DK6SF
UT WOS:000375054800001
PM 27066734
ER
PT J
AU Epstein, AE
Olshansky, B
Naccarelli, GV
Kennedy, JI
Murphy, EJ
Goldschlager, N
AF Epstein, Andrew E.
Olshansky, Brian
Naccarelli, Gerald V.
Kennedy, John I., Jr.
Murphy, Elizabeth J.
Goldschlager, Nora
TI Practical Management Guide for Clinicians Who Treat Patients with
Amiodarone
SO AMERICAN JOURNAL OF MEDICINE
LA English
DT Review
DE Adverse drug reactions; Amiodarone; Atrial fibrillation; Ventricular
fibrillation; Ventricular tachycardia
ID CONGESTIVE-HEART-FAILURE; ANTIARRHYTHMIC-DRUG-THERAPY; LEFT-VENTRICULAR
DYSFUNCTION; ACUTE MYOCARDIAL-INFARCTION; ONSET ATRIAL-FIBRILLATION;
SUDDEN CARDIAC DEATH; LOW-DOSE AMIODARONE; PULMONARY TOXICITY;
RANDOMIZED-TRIAL; INTRAVENOUS AMIODARONE
AB Amiodarone, an iodinated benzofuran derivative with Class I, II, III, and IV antiarrhythmic properties, is the most commonly used antiarrhythmic drug used to treat supraventricular and ventricular arrhythmias. Appropriate use of this drug, with its severe and potentially life-threatening adverse effects, requires an essential understanding of its risk-benefit properties in order to ensure safety. The objective of this review is to afford clinicians who treat patients receiving amiodarone an appropriate management strategy for its safe use. The authors of this consensus management guide have thoroughly reviewed and evaluated the existing literature on amiodarone and apply this information, along with the collective experience of the authors, in its development. Provided are management guides on the intravenous and oral dosing of amiodarone, appropriate outpatient follow-up of patients taking the drug, its recognized adverse effects, and recommendations on when to consult specialists to help in patient management. All clinicians must be cognizant of the appropriate use, follow-up, and adverse reactions of amiodarone. The responsibility incurred by those treating such patients cannot be overemphasized. Published by Elsevier Inc.
C1 [Epstein, Andrew E.] Univ Penn, Dept Med, Electrophysiol Sect, Cardiovasc Div, Philadelphia, PA 19104 USA.
[Olshansky, Brian] Mercy Hosp North Iowa, Mason City, PA USA.
[Naccarelli, Gerald V.] Penn State Univ, Penn State Heart & Vasc Inst, Hershey, PA USA.
[Kennedy, John I., Jr.] Univ Alabama Birmingham, Dept Med, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA.
[Kennedy, John I., Jr.] Birmingham VA Med Ctr, Dept Med, Birmingham, AL USA.
[Murphy, Elizabeth J.; Goldschlager, Nora] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Murphy, Elizabeth J.] San Francisco Gen Hosp, Dept Med, Div Endocrinol, San Francisco, CA 94110 USA.
[Goldschlager, Nora] San Francisco Gen Hosp, Dept Med, Div Cardiol, San Francisco, CA 94110 USA.
RP Epstein, AE (reprint author), Univ Penn, Cardiovasc Div, Electrophysiol Sect, 3400 Spruce St,9 Founders, Philadelphia, PA 19104 USA.
EM andrew.epstein@uphs.upenn.edu
NR 64
TC 7
Z9 7
U1 4
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9343
EI 1555-7162
J9 AM J MED
JI Am. J. Med.
PD MAY
PY 2016
VL 129
IS 5
BP 468
EP 475
DI 10.1016/j.amjmed.2015.08.039
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA DK7YZ
UT WOS:000375144600023
PM 26497904
ER
PT J
AU Brondfield, S
Feingold, KR
AF Brondfield, Sam
Feingold, Kenneth R.
TI Symptomatic Graves' Disease After Autoimmune Hypothyroidism
SO AMERICAN JOURNAL OF MEDICINE
LA English
DT Letter
C1 [Brondfield, Sam; Feingold, Kenneth R.] Univ Calif San Francisco, Dept Med, 505 Parnassus Ave,Rm 987, San Francisco, CA 94143 USA.
[Brondfield, Sam; Feingold, Kenneth R.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA.
RP Brondfield, S (reprint author), Univ Calif San Francisco, Dept Med, 505 Parnassus Ave,Rm 987, San Francisco, CA 94143 USA.
EM sam.brondfield@ucsf.edu
NR 5
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9343
EI 1555-7162
J9 AM J MED
JI Am. J. Med.
PD MAY
PY 2016
VL 129
IS 5
BP E19
EP E20
DI 10.1016/j.amjmed.2015.12.017
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA DK7YZ
UT WOS:000375144600008
PM 26772649
ER
PT J
AU Yarar-Fisher, C
Bickel, CS
Kelly, NA
Stec, MJ
Windham, ST
McLain, AB
Oster, RA
Bamman, MM
AF Yarar-Fisher, Ceren
Bickel, C. Scott
Kelly, Neil A.
Stec, Michael J.
Windham, Samuel T.
McLain, Amie B.
Oster, Robert A.
Bamman, Marcas M.
TI Heightened TWEAK-NF-kappa B signaling and inflammation-associated
fibrosis in paralyzed muscles of men with chronic spinal cord injury
SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
LA English
DT Article
DE TNF-like weak inducer of apoptosis; nuclear factor
kappa-light-chain-enhancer of activated B cells
ID SKELETAL-MUSCLE; APOPTOSIS TWEAK; WEAK INDUCER; GLUCOSE-TOLERANCE;
OLDER-ADULTS; ATROPHY; EXERCISE; MICE; INDIVIDUALS; ACTIVATION
AB Individuals with long-standing spinal cord injury (SCI) often present with extreme muscle atrophy and impaired glucose metabolism at both the skeletal muscle and whole body level. Persistent inflammation and increased levels of proinflammatory cytokines in the skeletal muscle are potential contributors to dysregulation of glucose metabolism and atrophy; however, to date no study has assessed the effects of long-standing SCI on their expression or intracellular signaling in the paralyzed muscle. In the present study, we assessed the expression of genes (TNF alpha R, TNF alpha, IL-6R, IL-6, TWEAK, TWEAK R, atrogin-1, and MuRF1) and abundance of intracellular signaling proteins (TWEAK, TWEAK R, NF-kappa B, and p-p65/p-50/105) that are known to mediate inflammation and atrophy in skeletal muscle. In addition, based on the effects of muscle inflammation on promotion of skeletal muscle fibrosis, we assessed the degree of fibrosis between myofibers and fascicles in both groups. For further insight into the distribution and variability of muscle fiber size, we also analyzed the frequency distribution of SCI fiber size. Resting vastus lateralis (VL) muscle biopsy samples were taken from 11 men with long-standing SCI (approximate to 22 yr) and compared with VL samples from 11 able-bodied men of similar age. Our results demonstrated that chronic SCI muscle has heightened TNF alpha R and TWEAK R gene expression and NF-kappa B signaling (higher TWEAK R and phospho-NF-kappa B p65) and fibrosis, along with substantial myofiber size heterogeneity, compared with able-bodied individuals. Our data suggest that the TWEAK/TWEAK R/NF-kappa B signaling pathway may be an important mediator of chronic inflammation and fibrotic adaptation in SCI muscle.
C1 [Yarar-Fisher, Ceren; McLain, Amie B.] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL 35294 USA.
[Kelly, Neil A.; Stec, Michael J.; Bamman, Marcas M.] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL 35294 USA.
[Bickel, C. Scott] Univ Alabama Birmingham, Dept Phys Therapy, Birmingham, AL 35294 USA.
[Windham, Samuel T.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA.
[Oster, Robert A.; Bamman, Marcas M.] Univ Alabama Birmingham, Dept Med, Div Prevent Med, Birmingham, AL 35294 USA.
[Yarar-Fisher, Ceren; Bickel, C. Scott; Kelly, Neil A.; Stec, Michael J.; Windham, Samuel T.; McLain, Amie B.] Univ Alabama Birmingham, UAB Ctr Exercise Med, 966 McCallum Basic Hlth Sci Bldg, Birmingham, AL 35294 USA.
[Bamman, Marcas M.] Birmingham Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Birmingham, AL USA.
RP Bamman, MM (reprint author), Univ Alabama Birmingham, UAB Ctr Exercise Med, 966 McCallum Basic Hlth Sci Bldg, Birmingham, AL 35294 USA.
EM mbamman@uab.edu
FU Veterans Affairs Merit Award; UAB Center for Exercise Medicine,
Department of Physical Medicine and Rehabilitation [5T32-DK-62710]; UAB
Center for Clinical and Translational Science [UL1-TR-000165]
FX This work was supported by a Veterans Affairs Merit Award (M. M.
Bamman), the UAB Center for Exercise Medicine, Department of Physical
Medicine and Rehabilitation, 5T32-DK-62710, and the UAB Center for
Clinical and Translational Science (UL1-TR-000165).
NR 45
TC 3
Z9 4
U1 0
U2 1
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193-1849
EI 1522-1555
J9 AM J PHYSIOL-ENDOC M
JI Am. J. Physiol.-Endocrinol. Metab.
PD MAY 1
PY 2016
VL 310
IS 9
BP E754
EP E761
DI 10.1152/ajpendo.00240.2015
PG 8
WC Endocrinology & Metabolism; Physiology
SC Endocrinology & Metabolism; Physiology
GA DK9FC
UT WOS:000375235200005
PM 26931128
ER
PT J
AU Leonpacher, AK
Peters, ME
Drye, LT
Makino, KM
Newell, JA
Devanand, DP
Frangakis, C
Munro, CA
Mintzer, JE
Pollock, BG
Rosenberg, PB
Schneider, LS
Shade, DM
Weintraub, D
Yesavage, J
Lyketsos, CG
Porsteinsson, AP
AF Leonpacher, Anne K.
Peters, Matthew E.
Drye, Lea T.
Makino, Kelly M.
Newell, Jeffery A.
Devanand, D. P.
Frangakis, Constantine
Munro, Cynthia A.
Mintzer, Jacobo E.
Pollock, Bruce G.
Rosenberg, Paul B.
Schneider, Lon S.
Shade, David M.
Weintraub, Daniel
Yesavage, Jerome
Lyketsos, Constantine G.
Porsteinsson, Anton P.
CA CitAD Res Grp
TI Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's
Dementia: Evidence From the CitAD Study
SO AMERICAN JOURNAL OF PSYCHIATRY
LA English
DT Article
ID PLACEBO-CONTROLLED TRIALS; BEHAVIORAL DISTURBANCES; ANTIPSYCHOTIC-DRUGS;
PSYCHOTIC SYMPTOMS; NURSING-HOMES; CACHE COUNTY; RISK-FACTORS; DISEASE;
AGITATION; HEALTH
AB Objective: Citalopram has been shown to improve agitation in patients with Alzheimer's disease. The authors evaluated whether other neuropsychiatric symptoms improve with citalopram treatment compared with placebo.
Method: In this planned secondary analysis of the Citalopram for Agitation in Alzheimer's Disease study, the authors evaluated the effect of citalopram on the 12 neuropsychiatric symptom domains assessed by the Neuropsychiatric Inventory (NPI). They compared caregiver-reported NPI scores at week 9 in patients receiving citalopram(30 mg/day) or placebo with regard to both the presence or absence of individual neuropsychiatric symptoms and individual domain scores (reflecting severity) in participants who had symptoms at week 9.
Results: At week 9, participants treated with citalopram were significantly less likely to be reported as showing delusions (odds ratio=0.40), anxiety (odds ratio=0.43), and irritability/lability (odds ratio=0.38). A comparison of median scores of participants with symptoms present at week 9 showed significant differences favoring citalopram for hallucinations and favoring placebo for sleep/nighttime behavior disorders.
Conclusions: While dosage constraints must be considered because of citalopram's adverse effect profile, this agent's overall therapeutic effects in patients with Alzheimer's disease and agitation, in addition to efficacy for agitation/aggression, included reductions in the frequency of irritability, anxiety, and delusions; among patients who had these symptoms at week 9, they included a reduction in the severity of hallucinations but an increase in the severity of sleep/nighttime behavior disorders.
C1 [Porsteinsson, Anton P.] Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA.
Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
Univ Rochester, Sch Med & Dent, Alzheimers Dis Care Res & Educ Program, Rochester, NY USA.
Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA.
New York State Psychiat Inst & Hosp, Dept Psychiat, Div Geriatr Psychiat, New York, NY 10032 USA.
Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.
Roper St Francis Healthcare, Clin Biotechnol Res Inst, Charleston, SC USA.
Ralph H Johnson VA Med Ctr, Dept Psychiat, Charleston, SC USA.
Ctr Addict & Mental Hlth, Campbell Inst, Toronto, ON, Canada.
Univ Toronto, Dept Psychiat, Toronto, ON, Canada.
Univ So Calif, Keck Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90033 USA.
Univ So Calif, Keck Sch Med, Dept Neurol, Los Angeles, CA 90033 USA.
Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Porsteinsson, AP (reprint author), Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA.
EM anton_porsteinsson@urmc.rochester.edu
FU National Institute on Aging (NIA); NIMH [R01AG031348]; NIH
[P50-AG05142]; Avanir; NIA; Office of the Federal Public Defender; U.S.
Attorney's Office; Avanir Pharmaceuticals; Transition Therapeutics;
Insys Therapeutics; Takeda Global Research and Development Center;
Pfizer; Genentech; Merck; Accera; Elan; Hoffmann-La Roche; Novartis;
Baxter; Eli Lilly; Wyeth; Janssen Alzheimer Initiative; Alzheimer's
Assocation; Functional Neuromodulation; Abbott; AstraZeneca;
Bristol-Myers Squibb; GlaxoSmithKline; Johnson Johnson; Lundbeck; Roche;
AbbVie; ACImmune; Forest Laboratories; Forum; Merz; Orion; Otsuka;
Servier; Takeda; Toyama/FujiFilm; Zinfandel; Michael J. Fox Foundation
for Parkinson's Research; Department of Veterans Affairs; Avid
Radiopharmaceuticals; Alzheimer's Disease Cooperative Study;
International Parkinson; Movement Disorder Society; Associated Jewish
Federation of Baltimore; Weinberg Foundation; Forest; Eisai;
Ortho-McNeil; National Football League; Biogen; EnVivo; Genentech/Roche;
Medivation; MerckPfizer; Toyama; Department of Defense
FX Supported by National Institute on Aging (NIA) and NIMH grant
R01AG031348, and in part by NIH grant P50-AG05142 (to University of
Southern California and Dr. Schneider).; Dr. Devanand has received
research support from Avanir and has served on scientific advisory
boards for AbbVie, Astellas, and Lundbeck and as a consultant for
Intracellular Therapies. Dr. Munro has received grant funding (to her
institution) from NIA, NIH, and NIMH and has received payment for expert
testimony from various law firms, from the Office of the Federal Public
Defender, and from the U.S. Attorney's Office, as well as payment for
lectures for Episcopal Ministries. Dr. Mintzer has received grant
support from and served as a consultant for Avanir Pharmaceuticals,
Transition Therapeutics, and Insys Therapeutics; he has received support
for travel to meetings from NIA and NIMH; he has received grants (to his
institution) from NIA, NIH, Takeda Global Research and Development
Center, Pfizer, Genentech, Merck, Accera, Elan, Avanir, Hoffmann-La
Roche, Novartis, Baxter, Eli Lilly, Wyeth, and Janssen Alzheimer
Initiative; he has been employed by NeuroQuest and is founder of
BioPharma Connex. Dr. Pollock has received a grant (to his institution)
from NIA and NIMH; he has served on a board for Lundbeck Canada and as a
consultant for Wyeth; and he has received travel and accommodation
support from Lundbeck International Neuroscience Foundation. Dr.
Rosenberg has received grant support from the Alzheimer's Assocation,
Eli Lilly, Functional Neuromodulation, Merck, NIA, and Novartis; he has
served as a consultant to AbbVie, Abide, Insys, Janssen, and Merck; and
he has received travel support from Eli Lilly. Dr. Schneider has
received grant and clinical trial support from Abbott, AstraZeneca,
Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson,
Lundbeck, Merck, NIH, Novartis, Pfizer, and Roche and consultancy fees,
including for data monitoring committees and adjudication committees,
from Abbott, AbbVie, ACImmune, AstraZeneca, Baxter, Bristol-Myers
Squibb, Elan, Eli Lilly, Forest Laboratories, Forum, GlaxoSmithKline,
Johnson & Johnson, Lundbeck, Merck, Merz, Novartis, Orion, Otsuka,
Pfizer, Roche, Servier, Takeda, Toyama/FujiFilm, and Zinfandel. Dr.
Weintraub has received research funding or support from the Michael J.
Fox Foundation for Parkinson's Research, NIH, Novartis, the Department
of Veterans Affairs, Avid Radiopharmaceuticals, the Alzheimer's Disease
Cooperative Study, and the International Parkinson and Movement Disorder
Society; honoraria from AbbVie, Acadia, Biotie, Clintrex, Novartis, Teva
Pharmaceuticals, UCB, and the CHDI Foundation; license fee payments from
the University of Pennsylvania for the QUIP and QUIP-RS; royalties from
Wolters Kluwer; and fees for legal consultation for a lawsuit related to
antipsychotic prescribing in a patient with Parkinson's disease. Dr.
Lyketsos has received grant support (for research or CME) from NIMH,
NIA, the Associated Jewish Federation of Baltimore, the Weinberg
Foundation, Forest, GlaxoSmithKline, Eisai, Pfizer, AstraZeneca, Eli
Lilly, Ortho-McNeil, Bristol-Myers Squibb, Novartis, the National
Football League, Elan, and Functional Neuromodulation; he has served as
a consultant or adviser to AstraZeneca, GlaxoSmithKline, Eisai,
Novartis, Forest, Supernus, Adlyfe, Takeda, Wyeth, Lundbeck, Merz, Eli
Lilly, Pfizer, Genentech, Elan, the NFL Players Association, the NFL
Benefits Office, Avanir, Zinfandel, Bristol-Myers Squibb, AbbVie,
Janssen, Orion, Otsuka, and Astellas; and he has received honoraria or
travel support from Pfizer, Forest, GlaxoSmithKline, and Health Monitor.
Dr.; Porsteinsson has received grants (to his institution) from
AstraZeneca, Avanir, Baxter, Biogen, Bristol-Myers Squibb, Eisai, Elan,
EnVivo, Genentech/Roche, the Janssen Alzheimer Initiative, Medivation,
Merck, Pfizer, Toyama, Transition Therapeutics, NIH, NIMH, NIA, and the
Department of Defense; he has served as a consultant for Elan, the
Janssen Alzheimer Initiative, Lundbeck, Pfizer, and TransTech Pharma;
and he has been amember on data safety and monitoring boards for
Quintiles, Functional Neuromodulation, and the New York State
Psychiatric Institute, participated on a speakers bureau for Forest, and
participated in the development of educational presentations for CME,
Inc., and PVI. The other authors report no financial relationships with
commercial interests.
NR 38
TC 4
Z9 4
U1 7
U2 12
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0002-953X
EI 1535-7228
J9 AM J PSYCHIAT
JI Am. J. Psychiat.
PD MAY
PY 2016
VL 173
IS 5
BP 473
EP 480
DI 10.1176/appi.ajp.2016.15020248
PG 8
WC Psychiatry
SC Psychiatry
GA DK9ZS
UT WOS:000375291500010
PM 27032628
ER
PT J
AU Kurzbard-Roach, N
Lewis, M
Chow, K
Masih, S
Modaressi, S
AF Kurzbard-Roach, Nicole
Lewis, Michael
Chow, Kira
Masih, Sulabh
Modaressi, Shahla
TI Stewart-Bluefarb syndrome
SO APPLIED RADIOLOGY
LA English
DT Editorial Material
C1 [Kurzbard-Roach, Nicole] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol, Los Angeles, CA 90024 USA.
[Lewis, Michael] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Pathol, Los Angeles, CA USA.
[Chow, Kira] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Radiol, Los Angeles, CA USA.
[Masih, Sulabh; Modaressi, Shahla] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA.
RP Kurzbard-Roach, N (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol, Los Angeles, CA 90024 USA.
NR 9
TC 0
Z9 0
U1 0
U2 0
PU ANDERSON PUBLISHING, INC
PI SCOTCH PLAINS
PA 180 GLENSIDE AVE, SCOTCH PLAINS, NJ 07076 USA
SN 0160-9963
EI 1879-2898
J9 APPL RADIOL
JI Appl. Radiol.
PD MAY
PY 2016
VL 45
IS 5
BP 42
EP 45
PG 4
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA DK9EK
UT WOS:000375233400010
ER
PT J
AU Wells, JM
Morrison, JB
Bhatt, SP
Nath, H
Dransfield, MT
AF Wells, J. Michael
Morrison, Joshua B.
Bhatt, Surya P.
Nath, Hrudaya
Dransfield, Mark T.
TI Pulmonary Artery Enlargement Is Associated With Cardiac Injury During
Severe Exacerbations of COPD
SO CHEST
LA English
DT Article
DE acute exacerbation of COPD; COPD; CT scan; enzymes (cardiology);
pulmonary circulation
ID CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; COMPUTED-TOMOGRAPHY;
PROGNOSTIC-VALUE; TROPONIN-T; HYPERTENSION; MORTALITY; PREDICTORS; RISK;
DYSFUNCTION
AB BACKGROUND: Relative pulmonary arterial enlargement, defined by a pulmonary artery to aorta (PA/A) ratio > 1 on CT scanning, predicts hospitalization for acute exacerbations of COPD (AECOPD). However, it is unclear how AECOPD affect the PA/A ratio. We hypothesized that the PA/A ratio would increase at the time of AECOPD and that a ratio > 1 would be associated with worse clinical outcomes.
METHODS: Patients discharged with an International Classification of Diseases, Ninth Revision, diagnosis of AECOPD from a single center over a 5-year period were identified. Patients were included who had a CT scan performed during the stable period prior to the index AECOPD episode as well as a CT scan at the time of hospitalization. A subset of patients also underwent postexacerbation CT scans. The pulmonary arterial diameter, ascending aortic diameter, and the PA/A ratio were measured on CT scans. Demographic data, comorbidities, troponin level, and hospital outcome data were analyzed.
RESULTS: A total of 134 patients were included in the study. They had a mean age of 65 +/- 10 years, 47% were male, and 69% were white; overall, patients had a mean FEV1 of 47% +/- 19%. The PA/A ratio increased from baseline at the time of exacerbation (0.97 +/- 0.15 from 0.91 +/- 0.17; P < .001). Younger age and known pulmonary hypertension were independently associated with an exacerbation PA/A ratio > 1. Patients with PA/A ratio > 1 had higher troponin values. Those with a PA/A ratio > 1 and troponin levels > 0.01 ng/mL had increased acute respiratory failure, ICU admission, or inpatient mortality compared with those without both factors (P = .0028). The PA/A ratio returned to baseline values following AECOPD.
CONCLUSIONS: The PA/A ratio increased at the time of severe AECOPD and a ratio > 1 predicted cardiac injury and a more severe hospital course.
C1 [Wells, J. Michael; Morrison, Joshua B.; Bhatt, Surya P.; Dransfield, Mark T.] Univ Alabama Birmingham, Div Pulm Allergy & Crit Care, Birmingham, AL USA.
[Wells, J. Michael; Morrison, Joshua B.; Bhatt, Surya P.; Dransfield, Mark T.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
[Wells, J. Michael; Bhatt, Surya P.; Dransfield, Mark T.] Univ Alabama Birmingham, Lung Hlth Ctr, Birmingham, AL USA.
[Nath, Hrudaya] Univ Alabama Birmingham, Dept Radiol, Div Cardiothorac Imaging, Birmingham, AL USA.
[Wells, J. Michael; Dransfield, Mark T.] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Wells, JM (reprint author), 1900 Univ Blvd,THT 422, Birmingham, AL 35294 USA.
EM jmwells@uab.edu
FU National Institutes of Health/National Heart, Lung, and Blood Institute
[K08HL123940]; University of Alabama at Birmingham
FX The funding for this study came from the National Institutes of
Health/National Heart, Lung, and Blood Institute (K08HL123940) and the
Walter B. Frommeyer Jr. Fellowship in Investigational Medicine from the
University of Alabama at Birmingham (to Dr Wells).
NR 47
TC 1
Z9 1
U1 0
U2 3
PU AMER COLL CHEST PHYSICIANS
PI GLENVIEW
PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA
SN 0012-3692
J9 CHEST
JI Chest
PD MAY
PY 2016
VL 149
IS 5
BP 1197
EP 1204
DI 10.1378/chest.15-1504
PG 8
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA DL2TH
UT WOS:000375487600023
PM 26501747
ER
PT J
AU Ebert, N
Delanaye, P
Shlipak, M
Jakob, O
Martus, P
Bartel, J
Gaedeke, J
van der Giet, M
Schuchardt, M
Cavalier, E
Schaeffner, E
AF Ebert, Natalie
Delanaye, Pierre
Shlipak, Michael
Jakob, Olga
Martus, Peter
Bartel, Jan
Gaedeke, Jens
van der Giet, Markus
Schuchardt, Mirjam
Cavalier, Etienne
Schaeffner, Elke
TI Cystatin C standardization decreases assay variation and improves
assessment of glomerular filtration rate
SO CLINICA CHIMICA ACTA
LA English
DT Article
DE Cystatin C; Renal biomarkers; Assay standardization; Glomerular
filtration rate
ID CHRONIC KIDNEY-DISEASE; SERUM CREATININE; MULTICENTRIC EVALUATION;
RENAL-DISEASE; EQUATIONS; CALIBRATION; IMPACT; IMMUNOASSAY; VALIDATION;
PREDICTION
AB Background: Cystatin C is increasingly used in glomerular filtration rate (GFR) estimation equations. The dependence of cystatin C results upon the analytical method has been a major source of controversy.
Methods: Cystatin C was measured with non-standardized turbidimetric Roche Generation 1 and standardized nephelometric Siemens assays in 3666 and additionally with standardized Roche Generation 2 and Siemens in 567 blood samples of the Berlin Initiative Study. Cystatin C-based GFR was assessed with CKD-EPIcys (Chronic Kidney Disease Epidemiology) and CAPA (Caucasian, Asian, Pediatric, Adult) equations and the impact of the assays on GFR estimation was determined. Equation performance compared to measured GFR was evaluated.
Results: Concordance of Roche Gen2 and Siemens was high with median difference of 0.003 +/- 0.13 mg/L (limits of agreement: -0.12 to 0.12) and Passing Bablok correlation was essentially perfect. Roche Gen1 assay showed worse concordance with Siemens: median difference was 0.08 +/- 0.13 mg/L (limits of agreement: -0.18 to 034) and correlation was inferior. Mean difference (+/-SD) of estimated GFR(CKD-EPIcys) was 0 +/- 4 mL/min/1.73 m(2) for Gen2 and Siemens compared to -5 +/- 8 with Gen1. Performance of GFR estimating equations was not influenced by the choice of Siemens or Gen2 assays.
Conclusions: Standardization of Roche Gen2 assay improved accuracy of cystatin C measurement compared to Siemens. It suggests only negligible method bias and results in equal performance of both assays when estimating GFR indicating that successful calibration has led to major progress in cystatin C analysis. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Ebert, Natalie; Schaeffner, Elke] Charite, Inst Publ Hlth, Campus Virchow,Seestr 73, D-13347 Berlin, Germany.
[Delanaye, Pierre] Ctr Hosp Univ Sart Tilman, Div Nephrol, Liege, Belgium.
[Shlipak, Michael] San Francisco VA Med Ctr, San Francisco, CA USA.
[Shlipak, Michael] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Jakob, Olga] Charite, Inst Biostat & Clin Epidemiol, Berlin, Germany.
[Martus, Peter] Univ Tubingen, Inst Clin Epidemiol & Med Biostat, Tubingen, Germany.
[Bartel, Jan] Limbach Lab, Heidelberg, Germany.
[Gaedeke, Jens] Charite, Div Nephrol, Campus Mitte, D-13347 Berlin, Germany.
[van der Giet, Markus; Schuchardt, Mirjam] Charite, Div Nephrol, Campus Benjamin Franklin, D-13347 Berlin, Germany.
[Cavalier, Etienne] Ctr Hosp Univ Sart Tilman, Dept Clin Chem, Liege, Belgium.
RP Ebert, N (reprint author), Charite, Inst Publ Hlth, Campus Virchow,Seestr 73, D-13347 Berlin, Germany.
EM natalie.ebert@charite.de
OI Bartel, Jan/0000-0001-7602-7224
FU Kuratorium fur Dialyse und Nierentransplantation (KfH) Foundation of
Preventive Medicine; Stiftung fur Pathobiochemie und Molelculare
Diagnostik
FX By the Kuratorium fur Dialyse und Nierentransplantation (KfH) Foundation
of Preventive Medicine and the Stiftung fur Pathobiochemie und
Molelculare Diagnostik.
NR 35
TC 2
Z9 2
U1 3
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0009-8981
EI 1873-3492
J9 CLIN CHIM ACTA
JI Clin. Chim. Acta
PD MAY 1
PY 2016
VL 456
BP 115
EP 121
DI 10.1016/j.cca.2016.03.002
PG 7
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA DL0YG
UT WOS:000375357900020
PM 26947968
ER
PT J
AU Acierno, R
Gros, DF
Ruggiero, KJ
Hernandez-Tejada, BMA
Knapp, RG
Lejuez, CW
Muzzy, W
Frueh, CB
Egede, LE
Tuerk, PW
AF Acierno, Ron
Gros, Daniel F.
Ruggiero, Kenneth J.
Hernandez-Tejada, B. Melba A.
Knapp, Rebecca G.
Lejuez, Carl W.
Muzzy, Wendy
Frueh, Christopher B.
Egede, Leonard E.
Tuerk, Peter W.
TI BEHAVIORAL ACTIVATION AND THERAPEUTIC EXPOSURE FOR POSTTRAUMATIC STRESS
DISORDER: A NONINFERIORITY TRIAL OF TREATMENT DELIVERED IN PERSON VERSUS
HOME-BASED TELEHEALTH
SO DEPRESSION AND ANXIETY
LA English
DT Article
DE PTSD; major depression; telehealth; telemedicine; telemental health;
psychotherapy; home-based
ID MENTAL-HEALTH PROBLEMS; PTSD; DEPRESSION; VETERANS; AFGHANISTAN;
SERVICE; IRAQ; PSYCHOTHERAPY; TELEMEDICINE; MILITARY
AB ObjectiveCombat veterans returning to society with impairing mental health conditions such as PTSD and major depression (MD) report significant barriers to care related to aspects of traditional psychotherapy service delivery (e.g., stigma, travel time, and cost). Hence, alternate treatment delivery methods are needed. Home-based telehealth (HBT) is one such option; however, this delivery mode has not been compared to in person, clinic-based care for PTSD in adequately powered trials. The present study was designed to compare relative noninferiority of evidence-based psychotherapies for PTSD and MD, specifically Behavioral Activation and Therapeutic Exposure (BA-TE), when delivered via HBT versus in person, in clinic delivery.
MethodA repeated measures (i.e., baseline, posttreatment, 3-, 6-month follow-up) randomized controlled design powered for noninferiority analyses was used to compare PTSD and MD symptom improvement in response to BA-TE delivered via HBT versus in person, in clinic conditions. Participants were 232 veterans diagnosed with full criteria or predefined subthreshold PTSD.
ResultsPTSD and MD symptom improvement following BA-TE delivered by HBT was comparable to that of BA-TE delivered in person at posttreatment and at 3- and 12-month follow-up.
ConclusionEvidence-based psychotherapy for PTSD and depression can be safely and effectively delivered via HBT with clinical outcomes paralleling those of clinic-based care delivered in person. HBT, thereby, addresses barriers to care related to both logistics and stigma.
C1 [Acierno, Ron; Gros, Daniel F.; Ruggiero, Kenneth J.; Hernandez-Tejada, B. Melba A.; Knapp, Rebecca G.; Muzzy, Wendy; Egede, Leonard E.; Tuerk, Peter W.] Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC 29401 USA.
[Acierno, Ron; Ruggiero, Kenneth J.; Hernandez-Tejada, B. Melba A.; Muzzy, Wendy] Med Univ S Carolina, Coll Nursing, Charleston, SC 29425 USA.
[Gros, Daniel F.; Knapp, Rebecca G.; Egede, Leonard E.; Tuerk, Peter W.] Med Univ S Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA.
[Lejuez, Carl W.] Univ Maryland, Ctr Addict Personal & Emot Res, College Pk, MD 20742 USA.
[Frueh, Christopher B.] Univ Hawaii, Dept Psychol, Hilo, HI 96720 USA.
RP Acierno, R (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA.
EM acierno@musc.edu
FU Department of Veteran Affairs Clinical Sciences Research and Development
Career Development Award [CX000845]
FX Several authors are core and affiliate members of the Ralph H. Johnson
VAMC Center of Innovation (CIN 13-418; PI: Egede), the Health Equity and
Rural Outreach Innovation Center (HEROIC). Dr. Gros is funded by
Department of Veteran Affairs Clinical Sciences Research and Development
Career Development Award CX000845 (PI: Gros). The views expressed in
this article are those of the authors and do not necessarily reflect the
position or policy of the Department of Veterans Affairs or the United
States government. There are no conflicts of interest to disclose. There
are no conflicts of interest for any of the authors.
NR 27
TC 5
Z9 5
U1 3
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1091-4269
EI 1520-6394
J9 DEPRESS ANXIETY
JI Depress. Anxiety
PD MAY
PY 2016
VL 33
IS 5
BP 415
EP 423
DI 10.1002/da.22476
PG 9
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA DK8CM
UT WOS:000375154800008
PM 26864655
ER
PT J
AU Nayak, BK
Shanmugasundaram, K
Friedrichs, WE
Cavaglierii, RC
Patel, M
Barnes, J
Block, K
AF Nayak, Bijaya K.
Shanmugasundaram, Karthigayan
Friedrichs, William E.
Cavaglierii, Rita C.
Patel, Mandakini
Barnes, Jeffrey
Block, Karen
TI HIF-1 Mediates Renal Fibrosis in OVE26 Type 1 Diabetic Mice
SO DIABETES
LA English
DT Article
ID HYPOXIA-INDUCIBLE FACTORS; RAT MESANGIAL CELLS; FACTOR-I; FACTOR
1-ALPHA; TGF-BETA; NEPHROPATHY; EXPRESSION; MECHANISMS; HIF-1-ALPHA;
DISEASE
AB Hypoxia-inducible factor (HIF)-1 mediates hypoxia- and chronic kidney disease-induced fibrotic events. Here, we assessed whether HIF-1 blockade attenuates the manifestations of diabetic nephropathy in a type 1 diabetic animal model, OVE26. YC-1 [3-(5-hydroxymethyl-2-furyl)-1-benzyl indazole], an HIF-1 inhibitor, reduced whole kidney glomerular hypertrophy, mesangial matrix expansion, extracellular matrix accumulation, and urinary albumin excretion as well as NOX4 protein expression and NADPH-dependent reactive oxygen species production, while blood glucose levels remained unchanged. The role of NOX oxidases in HIF-1-mediated extracellular matrix accumulation was explored in vitro using glomerular mesangial cells. Through a series of genetic silencing and adenoviral overexpression studies, we have defined GLUT1 as a critical downstream target of HIF-1 mediating high glucose-induced matrix expression through the NADPH oxidase isoform, NOX4. Together, our data suggest that pharmacological inhibition of HIF-1 may improve clinical manifestations of diabetic nephropathy.
C1 [Nayak, Bijaya K.; Shanmugasundaram, Karthigayan; Friedrichs, William E.; Cavaglierii, Rita C.; Patel, Mandakini; Barnes, Jeffrey; Block, Karen] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Barnes, Jeffrey; Block, Karen] South Texas Vet Hlth Care Syst, Audie L Murphy Mem VA Hosp Div, San Antonio, TX USA.
RP Block, K (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.; Block, K (reprint author), South Texas Vet Hlth Care Syst, Audie L Murphy Mem VA Hosp Div, San Antonio, TX USA.
EM block@uthscsa.edu
FU U.S. Department of Veterans Affairs Merit Award; JDRF; National
Institute of Diabetes and Digestive and Kidney Diseases [DK-033665]
FX This work was supported by the U.S. Department of Veterans Affairs Merit
Award (grant to K.B.), a multi-project grant from JDRF (to K.B.), and
the National Institute of Diabetes and Digestive and Kidney Diseases
(DK-033665 to K.B.).
NR 44
TC 4
Z9 4
U1 4
U2 8
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
EI 1939-327X
J9 DIABETES
JI Diabetes
PD MAY
PY 2016
VL 65
IS 5
BP 1387
EP 1397
DI 10.2337/db15-0519
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DK6JA
UT WOS:000375028000028
PM 26908870
ER
PT J
AU Maria, MMMS
Baker, NL
McRae-Clark, AL
Prisciandaro, JJ
Brady, KT
AF Maria, M. M. Moran-Santa
Baker, N. L.
McRae-Clark, A. L.
Prisciandaro, J. J.
Brady, K. T.
TI Effects of yohimbine and drug cues on impulsivity and attention in
cocaine-dependent men and women and sex-matched controls
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article
DE Cocaine; Sex differences; Yohimbine; Executive control; Stress;
Drug-cues
ID COGNITIVE-BEHAVIORAL THERAPY; INDUCED REINSTATEMENT; INHIBITORY CONTROL;
STRESS; INDIVIDUALS; ADDICTION; DEFICITS; SEEKING; USERS; ENHANCEMENT
AB Background: Deficits in executive function have been associated with risk for relapse. Data from previous studies suggest that relapse may be triggered by stress and drug-paired cues and that there are significant sex differences in the magnitude of these responses. The aim of this study was to examine the impact of the pharmacological stressor and alpha-2 adrenergic receptor antagonist yohimbine and cocaine cues on executive function in cocaine-dependent men and women.
Methods: In a double-blind placebo controlled cross-over study, cocaine-dependent men (n = 12), cocaine dependent women (n = 27), control men (n = 31) and control women (n=25) received either yohimbine or placebo prior to two cocaine cue exposure sessions. Participants performed the Connors' Continuous Performance Test II prior to medication/placebo administration and immediately after each cue exposure session
Results: Healthy controls had a significant increase in commission errors under the yohimbine condition [RR (95% CI)=1.1 (1.0-1.3), chi(2)(1)=2.0, p = 0.050]. Cocaine-dependent individuals exhibited a significant decrease in omission errors under the yohimbine condition [RR (95% CI) = 0.6 (0.4-0.8), chi(2)(1)=8.6, p = 0.003]. Cocaine-dependent women had more omission errors as compared to cocaine-dependent men regardless of treatment [RR (95% CI)= 7.2 (3.6-14.7), chi(2)(1) =30.1, p<0.001]. Cocaine-dependent women exhibited a slower hit reaction time as compared to cocaine-dependent men [Female 354 +/- 13 vs. Male 415 +/- 14; t(89) = 2.6, p = 0.012].
Conclusions: These data add to a growing literature demonstrating significant sex differences in behaviors associated with relapse in cocaine-dependent individuals. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Maria, M. M. Moran-Santa; McRae-Clark, A. L.; Prisciandaro, J. J.; Brady, K. T.] Med Univ S Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA.
[Baker, N. L.] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA.
[Brady, K. T.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA.
RP Maria, MMMS (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Addict Sci Div, 125 Doughty St, Charleston, SC 29425 USA.
EM moranm@musc.edu
FU Forest Pharmaceuticals
FX Authors Moran-Santa Maria, Baker, and Prisciandaro declare no conflict
of interest. Kathleen Brady lists: Consultant AstraZeneca
Pharmaceuticals. Aimee McRae lists: Forest Pharmaceuticals medication
provided for separate NIH grant.
NR 44
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0376-8716
EI 1879-0046
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD MAY 1
PY 2016
VL 162
BP 56
EP 63
DI 10.1016/j.drugalcdep.2016.02.021
PG 8
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA DK8GK
UT WOS:000375165000007
ER
PT J
AU Saunders, GH
Frederick, MT
Silverman, SC
Nielsen, C
Laplante-Levesque, A
AF Saunders, Gabrielle H.
Frederick, Melissa T.
Silverman, ShienPei C.
Nielsen, Claus
Laplante-Levesque, Ariane
TI Description of Adults Seeking Hearing Help for the First Time According
to Two Health Behavior Change Approaches: Transtheoretical Model (Stages
of Change) and Health Belief Model
SO EAR AND HEARING
LA English
DT Article
DE Health behavior; Health care seeking behavior; Motivation; Patient
acceptance of health care; Rehabilitation of hearing impaired
ID OLDER-ADULTS; AID; IMPAIRMENT; ATTITUDES; ADOPTION; PEOPLE; STIGMA
AB Objectives: Several models of health behavior change are commonly used in health psychology. This study applied the constructs delineated by two models-the transtheoretical model (in which readiness for health behavior change can be described with the stages of precontemplation, contemplation and action) and the health belief model (in which susceptibility, severity, benefits, barriers, self-efficacy, and cues to action are thought to determine likelihood of health behavior change)-to adults seeking hearing help for the first time.
Design: One hundred eighty-two participants (mean age: 69.5 years) were recruited following an initial hearing assessment by an audiologist. Participants' mean four-frequency pure-tone average was 35.4 dB HL, with 25.8% having no hearing impairment, 50.5% having a slight impairment, and 23.1% having a moderate or severe impairment using the World Health Organization definition of hearing loss. Participants' hearing-related attitudes and beliefs toward hearing health behaviors were examined using the University of Rhode Island Change Assessment (URICA) and the health beliefs questionnaire (HBQ), which assess the constructs of the transtheoretical model and the health belief model, respectively. Participants also provided demographic information, and completed the hearing handicap inventory (HHI) to assess participation restrictions, and the psychosocial impact of hearing loss (PIHL) to assess the extent to which hearing impacts competence, self-esteem, and adaptability.
Results: Degree of hearing impairment was associated with participation restrictions, perceived competence, self-esteem and adaptability, and attitudes and beliefs measured by the URICA and the HBQ. As degree of impairment increased, participation restrictions measured by the HHI, and impacts of hearing loss, as measured by the PIHL, increased. The majority of first-time help seekers in this study were in the action stage of change. Furthermore, relative to individuals with less hearing impairment, individuals with more hearing impairment were at more advanced stages of change as measured by the URICA (i.e., higher contemplation and action scores relative to their precontemplation score), and they perceived fewer barriers and more susceptibility, severity, benefits and cues to action as measured by the HBQ. Multiple regression analyses showed participation restrictions (HHI scores) to be a highly significant predictor of stages of change explaining 30% to 37% of the variance, as were duration of hearing difficulty, and perceived benefits, severity, self-efficacy and cues to action assessed by the HBQ.
Conclusions: The main predictors of stages of change in first-time help seekers were reported participation restrictions and duration of hearing difficulty, with constructs from the health belief model also explaining some of the variance in stages of change scores. The transtheoretical model and the health belief model are valuable for understanding hearing health behaviors and can be applied when developing interventions to promote help seeking.
C1 [Saunders, Gabrielle H.; Frederick, Melissa T.; Silverman, ShienPei C.] Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Portland, OR USA.
[Saunders, Gabrielle H.] Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA.
[Nielsen, Claus; Laplante-Levesque, Ariane] Oticon AS, Eriksholm Res Ctr, Snekkersten, Denmark.
[Laplante-Levesque, Ariane] Linkoping Univ, Dept Behav Sci & Learning, Linkoping, Sweden.
RP Saunders, GH (reprint author), VA Portland Hlth Care Syst, Natl Ctr Rehabilitat Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM gabrielle.saunders@va.gov
FU Oticon Foundation; VA Rehabilitation Research and Development Center of
Excellence [C9230C]
FX This study was supported financially by the Oticon Foundation, with
additional support from a VA Rehabilitation Research and Development
Center of Excellence award #C9230C.
NR 39
TC 3
Z9 3
U1 7
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0196-0202
EI 1538-4667
J9 EAR HEARING
JI Ear Hear.
PD MAY-JUN
PY 2016
VL 37
IS 3
BP 324
EP 333
DI 10.1097/AUD.0000000000000268
PG 10
WC Audiology & Speech-Language Pathology; Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Otorhinolaryngology
GA DK8BM
UT WOS:000375151900016
PM 26765286
ER
PT J
AU Freudenberg, C
Jones, RA
Livingston, G
Goetsch, V
Schaffner, A
Buchanan, L
AF Freudenberg, Cara
Jones, Rebecca A.
Livingston, Genvieve
Goetsch, Virginia
Schaffner, Angela
Buchanan, Linda
TI Effectiveness of individualized, integrative outpatient treatment for
females with anorexia nervosa and bulimia nervosa
SO EATING DISORDERS
LA English
DT Article
ID COGNITIVE-BEHAVIORAL THERAPY; BINGE-EATING DISORDER; RANDOMIZED
CONTROLLED-TRIALS; 3 PSYCHOLOGICAL TREATMENTS; NATURAL COURSE;
PREDICTORS; INVENTORY; 5-YEAR; CARE
AB The effectiveness of an individualized outpatient program was investigated in the treatment of bulimia nervosa (BN) and anorexia nervosa (AN). Participants included 151 females who received outpatient eating disorder treatment in the partial hospitalization program, the intensive outpatient program, or a combination of the two programs. Outcome measures included the Eating Disorder Inventory (EDI-2), Beck Depression Inventory (BDI-II), frequency of binge eating and purging, and mean body weight. Findings included significant increases in weight for the AN group, reductions in binge eating frequency for the BN group, and reductions in EDI-2 and BDI-II scores and purging frequency for both groups. This study provides preliminary support for the efficacy of a multimodal program for the treatment of both anorexia nervosa and bulimia nervosa.
C1 [Freudenberg, Cara] Tennessee Valley Healthcare Syst, US Dept Vet Affairs, Murfreesboro, TN USA.
[Jones, Rebecca A.; Livingston, Genvieve; Goetsch, Virginia] Argosy Univ, Georgia Sch Profess Psychol, 980 Hammond Dr, Atlanta, GA 30328 USA.
[Schaffner, Angela] Richmont Grad Univ, Atlanta Ctr Eating Disorders, Atlanta, GA USA.
[Schaffner, Angela] Richmont Grad Univ, Sch Counseling, Atlanta, GA USA.
[Buchanan, Linda] Atlanta Ctr Eating Disorders, Atlanta, GA USA.
RP Jones, RA (reprint author), Argosy Univ, Georgia Sch Profess Psychol, 980 Hammond Dr, Atlanta, GA 30328 USA.
EM rjones@argosy.edu
NR 60
TC 0
Z9 0
U1 6
U2 11
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1064-0266
EI 1532-530X
J9 EAT DISORD
JI Eat. Disord
PD MAY-JUN
PY 2016
VL 24
IS 3
BP 240
EP 254
DI 10.1080/10640266.2015.1090868
PG 15
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA DL3UE
UT WOS:000375558100003
PM 26467107
ER
PT J
AU Santos, GM
Coffin, P
Santos, D
Huffaker, S
Matheson, T
Euren, J
DeMartini, A
Rowe, C
Hahn, JA
Vlahov, D
Vittinghoff, E
Batki, SL
AF Santos, Glenn-Milo
Coffin, Phillip
Santos, Deirdre
Huffaker, Shannon
Matheson, Tim
Euren, Jason
DeMartini, Anna
Rowe, Christopher
Hahn, Judith A.
Vlahov, David
Vittinghoff, Eric
Batki, Steven L.
TI Feasibility, Acceptability, and Tolerability of Targeted Naltrexone for
Nondependent Methamphetamine-Using and Binge-Drinking Men Who Have Sex
with Men
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE methamphetamine; alcohol; HIV; men who have sex with men; HIV
prevention; pharmacotherapy
ID HIV BEHAVIORAL SURVEILLANCE; RANDOMIZED CONTROLLED-TRIAL; MESSENGER-RNA
EXPRESSION; MU-OPIOID RECEPTOR; SUBSTANCE USE; GAY MEN; RISK BEHAVIORS;
DRUG-USE; AMPHETAMINE DEPENDENCE; TESTING BEHAVIORS
AB Background: There are no effective pharmacologic strategies for nondependent methamphetamine (meth)-using and binge-drinking men who have sex with men (MSM) at high-risk for HIV. We sought to determine the feasibility of enrolling and retaining this population in a pharmacologic trial; the acceptability of pharmacotherapy study procedures; and the tolerability of targeted naltrexone versus placebo.
Methods: Thirty meth-using and binge-drinking MSM were randomly assigned 1: 1 to 50 mg naltrexone or placebo for 8 weeks for targeted administration (ie, during craving or in anticipation of meth or alcohol use). Substance use counseling and behavioral assessments were conducted every 2 weeks. Medication use was measured using WisePill dispensers.
Results: Trial completion was 93%; visit completion rate was 95%. Mean weekly number of medication pills taken was 2.1 and was similar between arms. Participant satisfaction rate was 96%. There were neither serious adverse events nor differences in adverse event rates between arms. In exploratory intention-to-treat analyses, there were no differences in meth use and drinking. Naltrexone participants had greater reductions in serodiscordant receptive anal intercourse [incident rate ratio (IRR) = 0.15; 95% CI = 0.05 to 0.42] and serodiscordant condomless receptive anal intercourse (IRR = 0.11; 95% CI = 0.03 to 0.37), compared with placebo. In subgroup analyses among frequent meth users, naltrexone participants had greater reductions in meth-using days (IRR = 0.78; 95% CI = 0.62 to 0.99). In as-treated analyses, frequent study medication users in the naltrexone arm had greater reductions in binge drinking days (IRR = 0.72; 95% CI = 0.54 to 0.97).
Conclusions: Targeted naltrexone is a feasible, acceptable, and tolerable intervention strategy for nondependent meth-using and binge-drinking MSM. Naltrexone was associated with significant sexual risk reductions; and for some individuals, naltrexone was associated with meth and binge-drinking reductions.
C1 [Santos, Glenn-Milo; Coffin, Phillip; Santos, Deirdre; Huffaker, Shannon; Matheson, Tim; Euren, Jason; DeMartini, Anna; Rowe, Christopher] San Francisco Dept Publ Hlth, Ctr Publ Hlth, Res Branch, San Francisco, CA USA.
[Santos, Glenn-Milo; Vlahov, David] Univ Calif San Francisco, Sch Nursing, Dept Community Hlth Syst, San Francisco, CA 94143 USA.
[Coffin, Phillip; Hahn, Judith A.] Univ Calif San Francisco, Sch Med, Div HIV AIDS, San Francisco, CA USA.
[Hahn, Judith A.] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA USA.
[Vlahov, David; Vittinghoff, Eric] Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, San Francisco, CA USA.
[Batki, Steven L.] Univ Calif San Francisco, Sch Med, Dept Psychiat, San Francisco, CA 94143 USA.
[Batki, Steven L.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Santos, GM (reprint author), Univ Calif San Francisco, San Francisco Dept Publ Hlth, San Francisco, CA 94107 USA.
EM glenn-milo.santos@ucsf.edu
FU National Institutes of Drug Abuse (NIDA) [R36DA035109]; [K24AA022586]
FX This study was funded by the National Institutes of Drug Abuse (NIDA),
grant number R36DA035109. JAH was funded by K24AA022586.
NR 83
TC 0
Z9 0
U1 5
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD MAY 1
PY 2016
VL 72
IS 1
BP 21
EP 30
PG 10
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DK6WY
UT WOS:000375067600013
PM 26674372
ER
PT J
AU Bhattacharya, D
Tseng, CH
Tate, JP
Lo Re, V
Gibert, CL
Butt, AA
Brown, ST
Lim, JK
Rodriguez-Barradas, MC
Rimland, D
Kaufman, E
Justice, AC
Goetz, MB
AF Bhattacharya, Debika
Tseng, Chi-hong
Tate, Janet P.
Lo Re, Vincent, III
Gibert, Cynthia L.
Butt, Adeel A.
Brown, Sheldon T.
Lim, Joseph K.
Rodriguez-Barradas, Maria C.
Rimland, David
Kaufman, Erica
Justice, Amy C.
Goetz, Matthew Bidwell
TI Isolated Hepatitis B Core Antibody is Associated With Advanced Hepatic
Fibrosis in HIV/HCV Infection But Not in HIV Infection Alone
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Letter
ID SIMPLE NONINVASIVE INDEX; VIRUS INFECTION; LIVER-DISEASE; COINFECTION;
PREVALENCE; COHORT; PREDICT; DNA
C1 [Bhattacharya, Debika; Goetz, Matthew Bidwell] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Bhattacharya, Debika; Tseng, Chi-hong; Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Tate, Janet P.; Lim, Joseph K.; Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven, CT USA.
[Tate, Janet P.; Lim, Joseph K.; Justice, Amy C.] Yale Univ, Sch Med, New Haven, CT USA.
[Lo Re, Vincent, III] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Lo Re, Vincent, III] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Gibert, Cynthia L.] Washington DC VA Med Ctr, Washington, DC USA.
[Gibert, Cynthia L.] George Washington Univ, Med Ctr, Washington, DC 20037 USA.
[Butt, Adeel A.] Hamad Healthcare Qual Inst, Doha, Qatar.
[Butt, Adeel A.] Hamad Med Corp, Doha, Qatar.
[Butt, Adeel A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Brown, Sheldon T.] James J Peters VA Med Ctr, Bronx, NY USA.
[Rodriguez-Barradas, Maria C.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
[Rodriguez-Barradas, Maria C.] Michael E DeBakey VA Med Ctr, Houston, TX USA.
[Rodriguez-Barradas, Maria C.] Baylor Coll Med, Houston, TX 77030 USA.
[Rimland, David] Atlanta VA Med Ctr, Atlanta, GA USA.
[Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA.
[Kaufman, Erica] St Louis Univ, Sch Med, St Louis, MO USA.
RP Bhattacharya, D (reprint author), VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.; Bhattacharya, D (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
FU NIAAA NIH HHS [U01 AA020790, U10 AA013566, U24 AA020794]; NIDDK NIH HHS
[P30 DK034989]
NR 17
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD MAY 1
PY 2016
VL 72
IS 1
BP E14
EP E17
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DK6WY
UT WOS:000375067600005
PM 26829660
ER
PT J
AU Au, DH
AF Au, David H.
TI Screening for Chronic Obstructive Pulmonary Disease D Is the New F
SO JAMA INTERNAL MEDICINE
LA English
DT Editorial Material
ID COPD
C1 [Au, David H.] VA Puget Sound Hlth Care Syst, Ctr Innovat Veteran Centered & Value Driven Care, 1660 S Columbian Way,MS 152, Seattle, WA 98101 USA.
[Au, David H.] Univ Washington, Div Pulm & Crit Care Med, 1660 S Columbian Way,MS 152, Seattle, WA 98101 USA.
RP Au, DH (reprint author), VA Puget Sound Hlth Care Syst, Ctr Innovat Veteran Centered & Value Driven Care, 1660 S Columbian Way,MS 152, Seattle, WA 98101 USA.; Au, DH (reprint author), Univ Washington, Div Pulm & Crit Care Med, 1660 S Columbian Way,MS 152, Seattle, WA 98101 USA.
EM dau@uw.edu
NR 6
TC 0
Z9 0
U1 1
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD MAY
PY 2016
VL 176
IS 5
BP 601
EP 602
DI 10.1001/jamainternmed.2016.1115
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA DL0AC
UT WOS:000375292500011
PM 27046674
ER
PT J
AU Keyhani, S
Cheng, EM
Naseri, A
Halm, EA
Williams, LS
Johanning, J
Madden, E
Rofagha, S
Woodbridge, A
Abraham, A
Ahn, R
Saba, S
Eilkhani, E
Hebert, P
Bravata, DM
AF Keyhani, Salomeh
Cheng, Eric M.
Naseri, Ayman
Halm, Ethan A.
Williams, Linda S.
Johanning, Jason
Madden, Erin
Rofagha, Soraya
Woodbridge, Alexandra
Abraham, Ann
Ahn, Rosa
Saba, Susan
Eilkhani, Elnaz
Hebert, Paul
Bravata, Dawn M.
TI Common Reasons That Asymptomatic Patients Who Are 65 Years and Older
Receive Carotid Imaging
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID ENDARTERECTOMY; STROKE; STENOSIS; TRIAL; APPROPRIATENESS; PREVENTION
AB IMPORTANCE National guidelines do not agree on the role of carotid screening in asymptomatic patients (ie, patients who have not had a stroke or transient ischemic attack). Recently, several physician organizations participating in the Choosing Wisely campaign have identified carotid imaging in selected asymptomatic populations as being of low value. However, the majority of patients who are evaluated for carotid stenosis and subsequently revascularized are asymptomatic.
OBJECTIVE To better understand why asymptomatic patients who undergo revascularization receive initial carotid imaging.
DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study of 4127 Veterans Health Administration patients 65 years and older undergoing carotid revascularization for asymptomatic carotid stenosis between 2005 and 2009.
MAIN OUTCOMES AND MEASURES Indications for carotid ultrasounds were extracted using trained abstractors. Frequency of indications and appropriateness of initial carotid ultrasound imaging for patients within each rating category after the intervention were reported.
RESULTS The mean (SD) age of this cohort of 4127 patients was 73.6 (5.9) years; 4014 (98.8%) were male. Overall, there were 5226 indications for 4063 carotid ultrasounds. The most common indications listed were carotid bruit (1578 [30.2% of indications]) and follow-up for carotid disease (stenosis/history of carotid disease) in patients who had previously documented carotid stenosis (1087 [20.8% of indications]). Multiple vascular risk factors were the next most common indication listed. Rates of appropriate, uncertain, and inappropriate imaging were 5.4%(227 indications), 83.4%(3387 indications), and 11.3%(458 indications), respectively. Among the most common inappropriate indications were dizziness/vertigo and syncope. Among the 4063 patients, 3373 (83.0%) received a carotid endarterectomy. Overall, 663 procedures were performed in patients 80 years and older.
CONCLUSIONS AND RELEVANCE Carotid bruit and follow-up for carotid disease accounted for approximately half of all indications provided by physicians for carotid testing. Strong consideration should be given to improving the evidence base around carotid testing, especially around monitoring stenosis over long periods and evaluating carotid bruits. Targeting carotid ultrasound ordering with decision support tools may also be an important step in reducing use of low-value imaging.
C1 [Keyhani, Salomeh; Naseri, Ayman; Madden, Erin; Rofagha, Soraya; Woodbridge, Alexandra; Abraham, Ann; Ahn, Rosa; Saba, Susan; Eilkhani, Elnaz] San Francisco VA Med Ctr, San Francisco, CA USA.
[Keyhani, Salomeh; Rofagha, Soraya] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA 94143 USA.
[Cheng, Eric M.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Neurol, Los Angeles, CA USA.
[Cheng, Eric M.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.
[Naseri, Ayman] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA.
[Williams, Linda S.; Bravata, Dawn M.] Richard L Roudebush Vet Affairs Med Ctr, Ctr Excellence Implementing Evidence Based Practi, Vet Hlth Adm, Hlth Serv Res & Dev Serv, 1481 W 10th St, Indianapolis, IN 46202 USA.
[Williams, Linda S.] Indiana Univ Sch Med, Dept Neurol, Indianapolis, IN 46202 USA.
[Bravata, Dawn M.] Indiana Univ Sch Med, Dept Internal Med, Indianapolis, IN 46202 USA.
[Halm, Ethan A.] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA.
[Johanning, Jason] Univ Nebraska Med Ctr, Dept Surg, Omaha, NE USA.
[Johanning, Jason] Omaha Vet Affairs Nebraska Western Iowa Hlth Care, Omaha, NE USA.
[Hebert, Paul] Puget Sound Vet Affairs Med Ctr, Seattle, WA USA.
[Hebert, Paul] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA.
RP Keyhani, S (reprint author), 4150 Clement St, San Francisco, CA 94121 USA.
EM salomeh.keyhani@ucsf.edu
FU National Institutes of Health/National Heart, Lung, and Blood Institute
[RO1 HL114563-01A1]
FX The project reported was supported by National Institutes of
Health/National Heart, Lung, and Blood Institute grant RO1
HL114563-01A1.
NR 16
TC 1
Z9 1
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD MAY
PY 2016
VL 176
IS 5
BP 626
EP 633
DI 10.1001/jamainternmed.2016.0678
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA DL0AC
UT WOS:000375292500016
PM 27088224
ER
PT J
AU Schonberg, MA
Smith, AK
AF Schonberg, Mara A.
Smith, Alexander K.
TI Discussing Long-term Prognosis in Primary Care Hard but Necessary
SO JAMA INTERNAL MEDICINE
LA English
DT Editorial Material
ID SURVIVAL; ADULTS
C1 [Schonberg, Mara A.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Gen Med & Primary Care, Boston, MA 02215 USA.
[Smith, Alexander K.] Univ Calif San Francisco, Dept Med, Div Geriatr, 4150 Clement St,181G, San Francisco, CA 94121 USA.
[Smith, Alexander K.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Smith, AK (reprint author), Univ Calif San Francisco, Dept Med, Div Geriatr, 4150 Clement St,181G, San Francisco, CA 94121 USA.
EM aksmith@ucsf.edu
FU NCI NIH HHS [R01 CA181357]; NIA NIH HHS [K23 AG040772]
NR 10
TC 0
Z9 0
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD MAY
PY 2016
VL 176
IS 5
BP 678
EP 680
DI 10.1001/jamainternmed.2016.0972
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA DL0AC
UT WOS:000375292500026
PM 27064576
ER
PT J
AU Weintraub, D
Chiang, C
Kim, HM
Wilkinson, J
Marras, C
Stanislawski, B
Mamikonyan, E
Kales, HC
AF Weintraub, Daniel
Chiang, Claire
Kim, Hyungjin Myra
Wilkinson, Jayne
Marras, Connie
Stanislawski, Barbara
Mamikonyan, Eugenia
Kales, Helen C.
TI Association of Antipsychotic Use With Mortality Risk in Patients With
Parkinson Disease
SO JAMA NEUROLOGY
LA English
DT Article
ID OLDER-ADULTS; LEWY BODIES; DEMENTIA; MANAGEMENT; SYMPTOMS; PSYCHOSIS;
MEDICATIONS; PATTERNS; DISORDER; FRACTURE
AB IMPORTANCE As many as 60% of patients with Parkinson disease (PD) experience psychosis, 80% develop dementia, and the use of antipsychotics (APs) in the population with PD is common. The use of APs by patients with dementia in the general population is associated with increased mortality, but whether this risk extends to patients with PD remains unknown.
OBJECTIVE To determine whether AP use in patients with PD is associated with increased mortality.
DESIGN, SETTING, AND PARTICIPANTS This retrospective matched-cohort study used data from a Veterans Health Administration database from fiscal years 1999 to 2010 to examine the risk associated with AP use in a cohort of patients with idiopathic PD and recent stable physical health. The rates of 180-day mortality were compared in 7877 patients initiating AP therapy and 7877 patients who did not initiate AP therapy (matched for age +/- 2.5 years, sex, race, index year, presence and duration of dementia, PD duration, delirium, hospitalization, Charlson Comorbidity Index, and new nonpsychiatric medications). Data were analyzed from October 19, 2012, to September 21, 2015.
MAIN OUTCOMES AND MEASURES Mortality rates at 180 days in those patients who initiated AP therapy compared with matched patients who did not use APs. Cox proportional hazards regression models were used with intent-to-treat (ITT) and exposure-only analyses.
RESULTS The study population included 7877 matched pairs of patients with PD (65 women [0.8%] and 7812 men [99.2%] in each cohort; mean [SD] age, 76.3 [7.7] years for those who initiated AP therapy and 76.4 [7.6] years for those who did not). Antipsychotic use was associated with more than twice the hazard ratio (HR) of death compared with nonuse (ITT HR, 2.35; 95% CI, 2.08-2.66; P < .001). The HR was significantly higher for patients who used typical vs atypical APs (ITT HR, 1.54; 95% CI, 1.24-1.91; P < .001). Among the atypical APs used, HRs relative to nonuse of APs in descending order were 2.79 (95% CI, 1.97-3.96) for olanzapine, 2.46 (95% CI, 1.94-3.12) for risperidone, and 2.16 (95% CI, 1.88-2.48) for quetiapine fumarate.
CONCLUSIONS AND RELEVANCE Use of APs is associated with a significantly increased mortality risk in patients with PD, after adjusting for measurable confounders. This finding highlights the need for cautious use of APs in patients with PD. Future studies should examine the role of nonpharmacologic strategies in managing psychosis in PD. In addition, new pharmacologic treatments that do not increase mortality in patients with neurodegenerative diseases need to be developed.
C1 [Weintraub, Daniel; Wilkinson, Jayne] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA.
[Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA.
[Weintraub, Daniel; Wilkinson, Jayne; Mamikonyan, Eugenia] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19014 USA.
[Weintraub, Daniel; Wilkinson, Jayne; Mamikonyan, Eugenia] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19014 USA.
[Chiang, Claire; Kim, Hyungjin Myra; Stanislawski, Barbara; Kales, Helen C.] US Dept Vet Affairs, Hlth Serv Res & Dev, Ctr Clin Management Res, Ann Arbor, MI USA.
[Kim, Hyungjin Myra] Univ Michigan, Ctr Stat Consultat & Res, Ann Arbor, MI 48109 USA.
[Marras, Connie] Univ Toronto, Toronto Western Hosp, Edmond J Safra Program Parkinsons Dis, Morton & Gloria Shulman Movement Disorder Ctr, Toronto, ON M5T 2S8, Canada.
[Kales, Helen C.] Vet Affairs Ann Arbor Healthcare Syst, Geriatr Res Educ & Clin Ctr, Ann Arbor, MI USA.
[Kales, Helen C.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA.
RP Weintraub, D (reprint author), Univ Penn, Perelman Sch Med, 3615 Chestnut St,Ste 330, Philadelphia, PA 19014 USA.
EM daniel.weintraub@uphs.upenn.edu
FU Veterans Health Administration [IIR 12-144-2]; Department of Veterans
Affairs, Veterans Health Administration, Office of Research and
Development, Health Services Research and Development, VA Information
Resource Center [SDR 02-237, 98-004]
FX This study was supported by merit review award IIR 12-144-2 from the
Veterans Health Administration. Support for the Veterans Administration
and Centers for Medicare & Medicaid data is provided by the Department
of Veterans Affairs, Veterans Health Administration, Office of Research
and Development, Health Services Research and Development, VA
Information Resource Center (project SDR 02-237 and 98-004).
NR 34
TC 14
Z9 14
U1 3
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6149
EI 2168-6157
J9 JAMA NEUROL
JI JAMA Neurol.
PD MAY
PY 2016
VL 73
IS 5
BP 535
EP 541
DI 10.1001/jamaneurol.2016.0031
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA DL2JW
UT WOS:000375461900015
PM 26999262
ER
PT J
AU Yehuda, R
Hoge, CW
AF Yehuda, Rachel
Hoge, Charles W.
TI The Meaning of Evidence-Based Treatments for Veterans With Posttraumatic
Stress Disorder
SO JAMA PSYCHIATRY
LA English
DT Editorial Material
ID PTSD
C1 [Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Dept Psychiat, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
[Yehuda, Rachel] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
[Hoge, Charles W.] Walter Reed Army Inst Res, Silver Spring, MD USA.
RP Yehuda, R (reprint author), James J Peters Vet Affairs Med Ctr, Dept Psychiat, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM rachel.yehuda@mssm.edu
NR 7
TC 8
Z9 8
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-622X
EI 2168-6238
J9 JAMA PSYCHIAT
JI JAMA Psychiatry
PD MAY
PY 2016
VL 73
IS 5
BP 433
EP 434
DI 10.1001/jamapsychiatry.2015.2878
PG 2
WC Psychiatry
SC Psychiatry
GA DL2KD
UT WOS:000375462600002
PM 26886229
ER
PT J
AU Sherva, R
Wang, Q
Kranzler, H
Zhao, HY
Koesterer, R
Herman, A
Farrer, LA
Gelernter, J
AF Sherva, Richard
Wang, Qian
Kranzler, Henry
Zhao, Hongyu
Koesterer, Ryan
Herman, Aryeh
Farrer, Lindsay A.
Gelernter, Joel
TI Genome-wide Association Study of Cannabis Dependence Severity, Novel
Risk Variants, and Shared Genetic Risks
SO JAMA PSYCHIATRY
LA English
DT Article
ID PSYCHIATRIC-DISORDERS; NICOTINE DEPENDENCE; EUROPEAN-AMERICANS;
AFRICAN-AMERICANS; LINKAGE ANALYSIS; DRUG-USE; SCHIZOPHRENIA; LOCI;
SUSCEPTIBILITY; IDENTIFICATION
AB IMPORTANCE Cannabis dependence (CAD) is a serious problem worldwide and is of growing importance in the United States because cannabis is increasingly available legally. Although genetic factors contribute substantially to CAD risk, at present no well-established specific genetic risk factors for CAD have been elucidated.
OBJECTIVE To report findings for DSM-IV CAD criteria from association analyses performed in large cohorts of African American and European American participants from 3 studies of substance use disorder genetics.
DESIGN, SETTING, AND PARTICIPANTS This genome-wide association study for DSM-IV CAD criterion count was performed in 3 independent substance dependence cohorts (the Yale-Penn Study, Study of Addiction: Genetics and Environment [SAGE], and International Consortium on the Genetics of Heroin Dependence [ICGHD]). A referral sample and volunteers recruited in the community and from substance abuse treatment centers included 6000 African American and 8754 European American participants, including some from small families. Participants from the Yale-Penn Study were recruited from 2000 to 2013. Data were collected for the SAGE trial from 1990 to 2007 and for the ICGHD from 2004 to 2009. Data were analyzed from January 2, 2013, to November 9, 2015.
MAIN OUTCOMES AND MEASURES Criterion count for DSM-IV CAD.
RESULTS Among the 14 754 participants, 7879 were male, 6875 were female, and the mean (SD) age was 39.2 (10.2) years. Three independent regions with genome-wide significant single-nucleotide polymorphism associations were identified, considering the largest possible sample. These included rs143244591 (beta = 0.54, P = 4.32 x 10(-10) for the meta-analysis) in novel antisense transcript RP11-206M11.7; rs146091982 (beta = 0.54, P = 1.33 x 10(-9) for the meta-analysis) in the solute carrier family 35 member G1 gene (SLC35G1); and rs77378271 (beta = 0.29, P = 2.13 x 10(-8) for the meta-analysis) in the CUB and Sushi multiple domains 1 gene (CSMD1). Also noted was evidence of genome-level pleiotropy between CAD and major depressive disorder and for an association with single-nucleotide polymorphisms in genes associated with schizophrenia risk. Several of the genes identified have functions related to neuronal calcium homeostasis or central nervous system development.
CONCLUSIONS AND RELEVANCE These results are the first, to our knowledge, to identify specific CAD risk alleles and potential genetic factors contributing to the comorbidity of CAD with major depression and schizophrenia.
C1 [Sherva, Richard; Koesterer, Ryan; Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Med, Sect Biomed Genet, Boston, MA 02118 USA.
[Wang, Qian; Zhao, Hongyu] Yale Univ, Program Computat Biol & Bioinformat, New Haven, CT USA.
[Kranzler, Henry] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Kranzler, Henry] Philadelphia VA Med Ctr, Vet Affairs VA Stars & Stripes Healthcare Network, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA.
[Zhao, Hongyu] Yale Univ, Sch Med, Dept Genet, West Haven, CT 06516 USA.
[Zhao, Hongyu] Yale Univ, Sch Publ Hlth, Dept Biostat, New Haven, CT USA.
[Zhao, Hongyu; Gelernter, Joel] VA Cooperat Studies Program Coordinating Ctr, West Haven, CT USA.
[Herman, Aryeh; Gelernter, Joel] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
[Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.
[Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA.
[Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
[Gelernter, Joel] Yale Univ, Sch Med, VA Connecticut Healthcare Ctr, Dept Psychiat, West Haven, CT 06516 USA.
[Gelernter, Joel] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT USA.
RP Gelernter, J (reprint author), Yale Univ, Sch Med, Vet Affairs Connecticut Healthcare Ctr, Dept Psychiat, 116A2,950 Campbell Ave, West Haven, CT 06516 USA.
EM joel.gelernter@yale.edu
RI Wang, Qian/Q-4664-2016
OI Wang, Qian/0000-0002-5615-4506
FU National Institutes of Health (NIH) [RC2 DA028909, R01 DA12690, R01
DA12849, R01 DA18432, R01 AA11330, R01 AA017535]; Veterans Affairs
Connecticut Healthcare Center; Philadelphia Veterans Affairs Mental
Illness Research, Education and Clinical Center; NIH Genes, Environment
and Health Initiative [U01 HG004422, U01HG004438]; Gene Environment
Association Studies under the Genes, Environment and Health Initiative;
National Institute on Alcohol Abuse and Alcoholism [HHSN268200782096C];
National Institute on Drug Abuse, NIH; NIH [HHSN268200782096C, U10
AA008401, P01 CA089392, R01 DA013423, HHSN268201100011I]
FX This study was supported by grants RC2 DA028909, R01 DA12690, R01
DA12849, R01 DA18432, R01 AA11330, and R01 AA017535 from the National
Institutes of Health (NIH), the Veterans Affairs Connecticut Healthcare
Center, and the Philadelphia Veterans Affairs Mental Illness Research,
Education and Clinical Center. Funding support for the Study of
Addiction: Genetics and Environment (SAGE) was provided by grant U01
HG004422 from the NIH Genes, Environment and Health Initiative. SAGE is
one of the genome-wide association studies funded as part of the Gene
Environment Association Studies under the Genes, Environment and Health
Initiative. The portion of the genotyping that was performed at the
Johns Hopkins University Center for Inherited Disease Research was
supported by grant U01HG004438 from the NIH Genes, Environment and
Health Initiative, and by contract HHSN268200782096C (High Throughput
Genotyping for Studying the Genetic Contributions to Human Disease) from
the National Institute on Alcohol Abuse and Alcoholism, the National
Institute on Drug Abuse, NIH. Support for collection of datasets and
samples was provided by grant U10 AA008401 (Collaborative Study on the
Genetics of Alcoholism), grant P01 CA089392 (Collaborative Genetic Study
of Nicotine Dependence), and grant R01 DA013423 (Family Study of Cocaine
Dependence) from the NIH. The International Consortium on the Genetics
of Heroin Dependence (principal investigator, Elliot Nelson, MD) was
funded by HHSN268200782096C (NIH contract: High Throughput Genotyping
for Studying the Genetic Contributions to Human Disease) and
HHSN268201100011I (NIH contract: High Throughput Genotyping for Studying
the Genetic Contributions to Human Disease).
NR 50
TC 11
Z9 11
U1 1
U2 17
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-622X
EI 2168-6238
J9 JAMA PSYCHIAT
JI JAMA Psychiatry
PD MAY
PY 2016
VL 73
IS 5
BP 472
EP 480
DI 10.1001/jamapsychiatry.2016.0036
PG 9
WC Psychiatry
SC Psychiatry
GA DL2KD
UT WOS:000375462600012
PM 27028160
ER
PT J
AU Kaup, AR
Byers, AL
Falvey, C
Simonsick, EM
Satterfield, S
Ayonayon, HN
Smagula, SF
Rubin, SM
Yaffe, K
AF Kaup, Allison R.
Byers, Amy L.
Falvey, Cherie
Simonsick, Eleanor M.
Satterfield, Suzanne
Ayonayon, Hilsa N.
Smagula, Stephen F.
Rubin, Susan M.
Yaffe, Kristine
TI Trajectories of Depressive Symptoms in Older Adults and Risk of Dementia
SO JAMA PSYCHIATRY
LA English
DT Article
ID MILD COGNITIVE IMPAIRMENT; LATE-LIFE DEPRESSION; ALZHEIMERS-DISEASE;
BODY-COMPOSITION; PRIMARY-CARE; HEALTH ABC; DECLINE; WOMEN; ASSOCIATION;
PREDICTORS
AB IMPORTANCE Depression has been identified as a risk factor for dementia. However, most studies have measured depressive symptoms at only one time point, and older adults may show different patterns of depressive symptoms over time.
OBJECTIVE To investigate the association between trajectories of depressive symptoms and risk of dementia in older adults.
DESIGN, SETTING, AND PARTICIPANTS This was a prospective cohort investigation of black and white community-dwelling older adults in the Health, Aging, and Body Composition study. Participants were enrolled between May 1997 and June 1998 and followed up through 2001-2002. The dates of this analysis were September 2014 to December 2015. The setting was community research centers in Memphis, Tennessee, and Pittsburgh, Pennsylvania. Trajectories of depressive symptoms were assessed from baseline to year 5. Symptoms were measured with the Center for Epidemiologic Studies Depression Scale Short Form, and trajectories were calculated using latent class growth curve analysis.
MAIN OUTCOMES AND MEASURES Incident dementia through year 11, determined by dementia medication use, hospital records, or significant cognitive decline (>= 1.5 SD race-specific decline on the Modified Mini-Mental State Examination). We examined the association between depressive symptom trajectories and dementia incidence using Cox proportional hazards regression models adjusted for demographics, health factors that differed between groups, and cognition during the depressive symptom assessment period (baseline to year 5).
RESULTS The analytic cohort included 2488 black and white older adults with repeated depressive symptom assessments from baseline to year 5 who were free of dementia throughout that period. Their mean (SD) age at baseline was 74.0 (2.8) years, and 53.1% (n = 1322) were female. The following 3 depressive symptom trajectories were identified: consistently minimal symptoms (62.0% [n = 1542] of participants), moderate and increasing symptoms (32.2%[n = 801] of participants), and high and increasing symptoms (5.8% [n = 145] of participants). Compared with the consistently minimal trajectory, having a high and increasing depressive symptom trajectory was associated with significantly increased risk of dementia (fully adjusted hazard ratio, 1.94; 95% CI, 1.30-2.90), while the moderate and increasing trajectory was not associated with risk of dementia after full adjustment. Sensitivity analyses indicated that the high and increasing trajectory was associated with dementia incidence, while depressive symptoms at individual time points were not.
CONCLUSIONS AND RELEVANCE Older adults with a longitudinal pattern of high and increasing depressive symptoms are at high risk for dementia. Individuals' trajectory of depressive symptoms may inform dementia risk more accurately than one-time assessment of depressive symptoms.
C1 [Kaup, Allison R.; Byers, Amy L.] San Francisco VA Med Ctr, Res Serv, 4150 Clement St,Mail Code 116H, San Francisco, CA 94121 USA.
[Kaup, Allison R.; Byers, Amy L.; Falvey, Cherie; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Simonsick, Eleanor M.] NIA, Intramural Res Program, Baltimore, MD 21224 USA.
[Satterfield, Suzanne] Univ Tennessee, Hlth Sci Ctr, Dept Prevent Med, Memphis, TN USA.
[Ayonayon, Hilsa N.; Rubin, Susan M.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Smagula, Stephen F.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
RP Kaup, AR (reprint author), San Francisco VA Med Ctr, Res Serv, 4150 Clement St,Mail Code 116H, San Francisco, CA 94121 USA.
EM allison.kaup@ucsf.edu
FU National Institute on Aging [N01-AG-6-2101, N01-AG-6-2103,
N01-AG-6-2106, R01-AG028050, K24AG031155]; National Institute for
Nursing Research [R01-NR012459]; Intramural Research Program of the
National Institute on Aging; US Department of Veterans Affairs,
Rehabilitation Research and Development Service [1IK2RX001629]; National
Institute of Mental Health [T32 MH019986]; Department of Veterans
Affairs Office of Academic Affiliations Advanced Fellowship Program in
Mental Illness Research and Treatment; Medical Research Service of the
San Francisco Veterans Affairs Medical Center; Department of Veterans
Affairs Sierra-Pacific Mental Illness Research, Education, and Clinical
Center
FX This research was supported by contracts N01-AG-6-2101, N01-AG-6-2103,
and N01-AG-6-2106 from the National Institute on Aging; by grant
R01-AG028050 from the National Institute on Aging; by grant R01-NR012459
from the National Institute for Nursing Research; and in part by the
Intramural Research Program of the National Institute on Aging. The
research described herein was also supported in part by Career
Development Award 1IK2RX001629 from the US Department of Veterans
Affairs, Rehabilitation Research and Development Service (Dr Kaup); by
research training grant T32 MH019986 from the National Institute of
Mental Health (Dr Smagula); by grant K24AG031155 from the National
Institute on Aging (Dr Yaffe); and by the Department of Veterans Affairs
Office of Academic Affiliations Advanced Fellowship Program in Mental
Illness Research and Treatment, the Medical Research Service of the San
Francisco Veterans Affairs Medical Center, and the Department of
Veterans Affairs Sierra-Pacific Mental Illness Research, Education, and
Clinical Center.
NR 35
TC 5
Z9 5
U1 3
U2 9
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-622X
EI 2168-6238
J9 JAMA PSYCHIAT
JI JAMA Psychiatry
PD MAY
PY 2016
VL 73
IS 5
BP 525
EP 531
DI 10.1001/jamapsychiatry.2016.0004
PG 7
WC Psychiatry
SC Psychiatry
GA DL2KD
UT WOS:000375462600018
PM 26982217
ER
PT J
AU Horan, WP
Wynn, JK
Hajcak, G
Altshuler, L
Green, MF
AF Horan, William P.
Wynn, Jonathan K.
Hajcak, Greg
Altshuler, Lori
Green, Michael F.
TI Distinct Patterns of Dysfunctional Appetitive and Aversive Motivation in
Bipolar Disorder Versus Schizophrenia: An Event-Related Potential Study
SO JOURNAL OF ABNORMAL PSYCHOLOGY
LA English
DT Article
DE schizophrenia; bipolar disorder; event-related potentials; psychological
distance; motivation
ID BEHAVIORAL ACTIVATION SYSTEM; RATING-SCALE; EMOTIONAL PICTURES; CORTICAL
ACTIVITY; NEGATIVE EMOTION; REWARD; ANTICIPATION; IMPULSIVITY;
DEPRESSION; SPECTRUM
AB Schizophrenia and bipolar disorder are associated with different clinical profiles of disturbances in motivation, yet few studies have compared the neurophysiological correlates of such disturbances. Outpatients with schizophrenia (n = 34), or bipolar disorder I (n = 33), and healthy controls (n = 31) completed a task in which the late positive potential (LPP), an index of motivated attention, was assessed along motivational gradients determined by apparent distance from potential rewards or punishments. Sequences of cues signaling possible monetary gains or losses appeared to loom progressively closer to the viewer; a reaction time (RT) task after the final cue determined the outcome. Controls showed the expected pattern with LPPs for appetitive and aversive cues that were initially elevated, smaller during intermediate positions, and escalated just prior to the RT task. The clinical groups showed different patterns in the final positions just prior to the RT task: the bipolar group's LPPs to both types of cues peaked relatively early during looming sequences and subsequently decreased, whereas the schizophrenia group showed relatively small LPP escalations, particularly for aversive cues. These distinct patterns suggest that the temporal unfolding of attentional resource allocation for motivationally significant events may qualitatively differ between these disorders.
C1 [Horan, William P.; Wynn, Jonathan K.; Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA.
[Horan, William P.; Wynn, Jonathan K.; Green, Michael F.] Univ Calif Los Angeles, Dept Psychiat, MIRECC 210A,Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90024 USA.
[Hajcak, Greg] SUNY Stony Brook, Dept Psychol, Stony Brook, NY USA.
[Altshuler, Lori] Univ Calif Los Angeles, Los Angeles, CA USA.
RP Horan, WP (reprint author), Univ Calif Los Angeles, Dept Psychiat, MIRECC 210A,Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90024 USA.; Horan, WP (reprint author), VA Greater Los Angeles Healthcare Syst, MIRECC 210A,Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM horan@ucla.edu
FU National Institute of Mental Health [MH091468, MH065707, MH43292];
Amgen; Forum
FX Support for this study came from a National Institute of Mental Health
Grants MH091468 (William P. Horan) and MH065707 and MH43292 (Michael F.
Green). We thank Amanda Bender, Michelle Dolinsky, Crystal Gibson, Cory
Tripp, and Katherine Weiner for assistance in data collection. Michael
F. Green has been a consultant to AbbVie, DSP, Forum, and Takeda, and he
is on the scientific advisory board of Mnemosyne. He has received
research funds from Amgen and Forum. The rest of the authors report no
biomedical financial interests or potential conflicts of interest.
NR 57
TC 1
Z9 1
U1 1
U2 4
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0021-843X
EI 1939-1846
J9 J ABNORM PSYCHOL
JI J. Abnorm. Psychol.
PD MAY
PY 2016
VL 125
IS 4
BP 576
EP 587
DI 10.1037/abn0000142
PG 12
WC Psychology, Clinical; Psychology, Multidisciplinary
SC Psychology
GA DK8ZJ
UT WOS:000375218300011
PM 26845261
ER
PT J
AU Chimote, AA
Hajdu, P
Kottyan, LC
Harley, JB
Yun, YH
Conforti, L
AF Chimote, Ameet A.
Hajdu, Peter
Kottyan, Leah C.
Harley, John B.
Yun, Yeoheung
Conforti, Laura
TI Nanovesicle-targeted Kv1.3 knockdown in memory T cells suppresses CD40L
expression and memory phenotype
SO JOURNAL OF AUTOIMMUNITY
LA English
DT Article
DE Autoimmunity; T cell; Kv1.3 ion channel; CD40 ligand; Lipid
nanoparticles; Ca2+ signaling
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS;
INFLAMMATORY-BOWEL-DISEASE; ION CHANNELS; MULTIPLE-SCLEROSIS; POTASSIUM
CHANNELS; K+ CHANNELS; LYMPHOCYTES; ACTIVATION; CALCINEURIN
AB Ca2+ signaling controls activation and effector functions of T lymphocytes. Ca2+ levels also regulate NFAT activation and CD40 ligand (CD40L) expression in T cells. CD40L in activated memory T cells binds to its cognate receptor, CD40, on other cell types resulting in the production of antibodies and pro inflammatory mediators. The CD40L/CD40 interaction is implicated in the pathogenesis of autoimmune disorders and CD40L is widely recognized as a therapeutic target. Ca2+ signaling in T cells is regulated by Kv1.3 channels. We have developed lipid nanoparticles that deliver Kv1.3 siRNAs (Kv1.3-NPs) selectively to CD45RO(+) memory T cells and reduce the activation-induced Ca2+ influx. Herein we report that Kv1.3-NPs reduced NFAT activation and CD40L expression exclusively in CD45RO(+) T cells. Furthermore, Kv1.3-NPs suppressed cytokine release and induced a phenotype switch of T cells from predominantly memory to naive. These findings indicate that Kv1.3-NPs operate as targeted immune suppressive agents with promising therapeutic potentials. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Chimote, Ameet A.; Hajdu, Peter; Conforti, Laura] Univ Cincinnati, Div Nephrol, Dept Internal Med, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.
[Kottyan, Leah C.; Harley, John B.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Ctr Autoimmune Genom & Etiol, Cincinnati, OH 45267 USA.
[Yun, Yeoheung] N Carolina Agr & Tech State Univ, Biol & Bioengn Dept, Greensboro, NC 27411 USA.
[Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA.
RP Conforti, L (reprint author), Univ Cincinnati, Div Nephrol, Dept Internal Med, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.
EM Laura.Conforti@uc.edu
RI Chimote, Ameet/R-5357-2016
OI Kottyan, Leah/0000-0003-3979-2220
FU NIH [R21AR060966, R01CA095286]; Dialysis Clinic, Inc.
FX This project was funded in part by NIH grants R21AR060966, R01CA095286
and a research grant from Dialysis Clinic, Inc. to LC. All flow
cytometry experiments were performed at the Research Flow Cytometry Core
in the Division of Rheumatology at Cincinnati Children's Hospital
Medical Center and Shriner's Hospital for Children Flow Cytometry Core,
Cincinnati OH. We thank Dr. Heather Duncan for her assistance with IRB
regulatory affairs and Dr. Giovanni Pauletti for making the Zetasizer
Nano ZS instrument available to us. We are also grateful to Dr. Judith
Heiny and Dr. Christy Holland for the use of the lyophilizer. All
authors discussed the results and commented on the manuscript.
NR 42
TC 1
Z9 1
U1 2
U2 6
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0896-8411
EI 1095-9157
J9 J AUTOIMMUN
JI J. Autoimmun.
PD MAY
PY 2016
VL 69
BP 86
EP 93
DI 10.1016/j.jaut.2016.03.004
PG 8
WC Immunology
SC Immunology
GA DK4WB
UT WOS:000374919900009
PM 26994905
ER
PT J
AU Schopfer, DW
Priano, S
Allsup, K
Helfrich, CD
Ho, PM
Rumsfeld, JS
Forman, DE
Whooley, MA
AF Schopfer, David W.
Priano, Susan
Allsup, Kelly
Helfrich, Christian D.
Ho, P. Michael
Rumsfeld, John S.
Forman, Daniel E.
Whooley, Mary A.
TI Factors Associated With Utilization of Cardiac Rehabilitation Among
Patients With Ischemic Heart Disease in the Veterans Health
Administration A QUALITATIVE STUDY
SO JOURNAL OF CARDIOPULMONARY REHABILITATION AND PREVENTION
LA English
DT Article
DE cardiac rehabilitation; program delivery; qualitative; utilization
ID CORONARY-ARTERY-DISEASE; MYOCARDIAL-INFARCTION; EXERCISE; CARE;
PREDICTORS; PREVENTION; CARDIOLOGY; MORTALITY; PROGRAM; SYSTEM
AB BACKGROUND: Cardiac rehabilitation (CR) programs reduce morbidity and mortality in patients with ischemic heart disease but are vastly underutilized in the United States, including the Veterans Health Administration (VA) Healthcare System. Numerous barriers affecting utilization have been identified in other health care systems, but the specific factors affecting Veterans are unknown. We sought to identify barriers and facilitators associated with utilization of CR in VA facilities.
METHODS: We performed a qualitative study of 56 VA patients, providers, and CR program managers at 30 VA facilities across the United States. We conducted semistructured interviews with key informants to explore their attitudes and knowledge toward CR. Interviews were conducted until thematic saturation occurred. Analyses using grounded theory to identify key themes were conducted using the qualitative data analysis package ATLAS.ti.
RESULTS: We identified 6 themes as barriers and 5 as facilitators. The most common barriers to participation in CR were patient transportation issues (68%), lack of patient willingness to participate (41%), and no access to a nearby VA hospital with a CR program (30%). The most common facilitators were involvement of a dedicated provider or "clinical champion" (50%), provider knowledge of or experience with CR (48%), and patient desire for additional medical support (32%).
CONCLUSIONS: Our findings suggest that addressing access issues and educating and activating providers on CR may increase utilization of CR programs. Targeting these specific factors may improve utilization of CR programs.
C1 [Schopfer, David W.; Whooley, Mary A.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA.
[Schopfer, David W.; Whooley, Mary A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Priano, Susan] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA.
[Allsup, Kelly; Forman, Daniel E.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
[Helfrich, Christian D.] Vet Affairs Puget Sound Healthcare Syst, Northwest Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA.
[Ho, P. Michael; Rumsfeld, John S.] Denver Vet Affairs Med Ctr, Div Cardiol, Denver, CO USA.
[Ho, P. Michael; Rumsfeld, John S.] Univ Colorado, Hlth Sci Ctr, Div Cardiol, Dept Med, Denver, CO 80262 USA.
[Forman, Daniel E.] Univ Pittsburgh, Med Ctr, Geriatr Cardiol Sect, Pittsburgh, PA USA.
[Forman, Daniel E.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
[Whooley, Mary A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
RP Schopfer, DW (reprint author), 4150 Clement St 111A1, San Francisco, CA 94121 USA.
EM david.schopfer@gmail.com
OI Schopfer, David/0000-0002-7244-9857
FU Department of Veterans Affairs (Health Services Research RRP) [12-232];
National Center for Advancing Translational Sciences of the NIH
[KL2TR000143]
FX This study was supported by a grant from the Department of Veterans
Affairs (Health Services & Research RRP #12-232). Dr Schopfer is
supported by the National Center for Advancing Translational Sciences of
the NIH under Award Number KL2TR000143.
NR 38
TC 2
Z9 2
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1932-7501
EI 1932-751X
J9 J CARDIOPULM REHABIL
JI J. Cardiopulm. Rehabil. Prev.
PD MAY-JUN
PY 2016
VL 36
IS 3
BP 167
EP 173
DI 10.1097/HCR.0000000000000166
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DK7QH
UT WOS:000375120300003
PM 27115074
ER
PT J
AU Lee, J
Fei, P
Packard, RRS
Kang, H
Xu, H
Baek, KI
Jen, N
Chen, JJ
Yen, H
Kuo, CCJ
Chi, NC
Ho, CM
Li, RS
Hsiai, TK
AF Lee, Juhyun
Fei, Peng
Packard, Rene R. Sevag
Kang, Hanul
Xu, Hao
Baek, Kyung In
Jen, Nelson
Chen, Junjie
Yen, Hilary
Kuo, C-C Jay
Chi, Neil C.
Ho, Chih-Ming
Li, Rongsong
Hsiai, Tzung K.
TI 4-Dimensional light-sheet microscopy to elucidate shear stress
modulation of cardiac trabeculation
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID VENTRICULAR NONCOMPACTION CARDIOMYOPATHY; ZEBRAFISH HEART; IN-VIVO;
MESENCHYMAL TRANSITION; BLOOD-VESSELS; NADPH OXIDASE; NOTCH; EMBRYOS;
FORCE; PROLIFERATION
AB Hemodynamic shear forces are intimately linked with cardiac development, during which trabeculae form a network of branching outgrowths from the myocardium. Mutations that alter Notch signaling also result in trabeculation defects. Here, we assessed whether shear stress modulates trabeculation to influence contractile function. Specifically, we acquired 4D (3D + time) images with light sheets by selective plane illumination microscopy (SPIM) for rapid scanning and deep axial penetration during zebrafish morphogenesis. Reduction of blood viscosity via gata1a morpholino oligonucleotides (MO) reduced shear stress, resulting in downregulation of Notch signaling and attenuation of trabeculation. Arrest of cardiomyocyte contraction either by troponin T type 2a (tnnt2a) MO or in weak atrium(m58) (wea) mutants resulted in reduced shear stress and downregulation of Notch signaling and trabeculation. Integrating 4D SPIM imaging with synchronization algorithm demonstrated that coinjection of neuregulin1 mRNA with gata1 MO rescued trabeculation to restore contractile function in association with upregulation of Notch-related genes. Crossbreeding of Tg(flk:mCherry) fish, which allows visualization of the vascular system with the Tg(tp1:gfp) Notch reporter line, revealed that shear stress-mediated Notch activation localizes to the endocardium. Deleting endocardium via the cloche(sk4) mutants downregulated Notch signaling, resulting in nontrabeculated ventricle. Subjecting endothelial cells to pulsatile flow in the presence of the ADAM10 inhibitor corroborated shear stress-activated Notch signaling to modulate trabeculation.
C1 [Lee, Juhyun; Baek, Kyung In; Jen, Nelson; Chen, Junjie; Yen, Hilary; Hsiai, Tzung K.] Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA USA.
[Fei, Peng] Huazhong Univ Sci & Technol, Sch Opt & Elect Informat, Wuhan 430074, Peoples R China.
[Fei, Peng; Ho, Chih-Ming] Univ Calif Los Angeles, Dept Mech Engn, Los Angeles, CA USA.
[Packard, Rene R. Sevag; Kang, Hanul; Li, Rongsong; Hsiai, Tzung K.] Univ Calif Los Angeles, Dept Med, Div Cardiol, Los Angeles, CA 90024 USA.
[Kang, Hanul; Li, Rongsong; Hsiai, Tzung K.] Vet Affairs Greater Los Angeles Healthcare Syst, Div Cardiol, Los Angeles, CA USA.
[Xu, Hao; Kuo, C-C Jay] Univ So Calif, Dept Elect Engn, Los Angeles, CA 90089 USA.
[Chi, Neil C.] UCSD, Dept Med, Inst Genom Med, La Jolla, CA USA.
[Hsiai, Tzung K.] Univ Calif Los Angeles, Calif NanoSyst Inst, Los Angeles, CA USA.
RP Hsiai, TK (reprint author), Univ Calif Los Angeles, Dept Med Cardiol & Bioengn, 10833 Le Conte,CHS 17-054, Los Angeles, CA 90095 USA.
EM thsiai@mednet.ucla.edu
OI Packard, Rene/0000-0002-8520-5843
FU NIH [HL118650, HL083015, HD069305, HL111437, HL129727, T32HL007895];
American Heart Association [15PRE21400019]
FX The authors would like to express gratitude to William Talbot from
Stanford University for providing the human Nrg1 plasmid and to Deborah
Yelon from UCSD for providing the wea mutants. In addition, the authors
also thank David Traver at UCSD and Nathan Lawson at the University of
Massachusetts Medical School (Worcester, Massachusetts, USA) for
generously providing the Tg(tp1:gfp) line. This study was supported by
grants NIH HL118650 (to T.K. Hsiai), HL083015 (to T.K. Hsiai), HD069305
(to N.C. Chi and T.K. Hsiai.), HL111437 (to T.K. Hsiai and N.C. Chi),
HL129727 (to T.K. Hsiai), T32HL007895 (to R.R. Sevag Packard), and
American Heart Association Pre-Doctoral Fellowship 15PRE21400019 (to J.
Lee).
NR 71
TC 3
Z9 3
U1 1
U2 10
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD MAY
PY 2016
VL 126
IS 5
BP 1679
EP 1690
DI 10.1172/JCI83496
PG 12
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA DK8MX
UT WOS:000375182100010
PM 27018592
ER
PT J
AU Szkudlinska, MA
von Frankenberg, AD
Utzschneider, KM
AF Szkudlinska, Magdalena A.
von Frankenberg, Anize D.
Utzschneider, Kristina M.
TI The antioxidant N-Acetylcysteine does not improve glucose tolerance or
beta-cell function in type 2 diabetes
SO JOURNAL OF DIABETES AND ITS COMPLICATIONS
LA English
DT Article
DE N-Acetylcysteine; beta-cell function; Antioxidant; Oxidative stress;
Supplement
ID CHRONIC OXIDATIVE STRESS; ENDOTHELIAL ACTIVATION; TOXICITY; GLUTATHIONE;
DYSFUNCTION; MECHANISM; MELLITUS; CYSTEINE
AB Hyperglycemia induces oxidative stress and thereby may exacerbate beta-cell dysfunction in type 2 diabetes (T2DM). Notably, glutathione (GSH), synthesized from N-Acetylcysteine (NAC), neutralizes reactive oxygen species within cells and is low in individuals with diabetes.
Aim: Determine if NAC supplementation improves beta-cell function and glucose tolerance by decreasing oxidative stress in T2DM.
Methods: Thirteen subjects (6 M/7 F) with T2DM (duration: 0-13 years, median: 2 years), treated with diet/exercise alone (n = 7) or metformin (n = 6), underwent a 2-h oral glucose tolerance test (OGTT) at baseline, after 2 weeks supplementation with 600 mg NAC orally twice daily, and again after 2 weeks supplementation with 1200 mg NAC twice daily. The following measurements were made: fasting glucose and fructosamine for glycemic control, incremental AUC glucose (0-120 min) for glucose tolerance, and A insulin/Delta, glucose (0-30 min) for the early insulin response to glucose. Fasting erythrocyte GSH and GSSG (oxidized glutathione) levels, plasma thiobarbituric acid reactive substances (TBARS), and urine F2 alpha isoprostanes were measured to assess oxidative status.
Results: Subjects were middle aged (mean +/- SEM: 53.9 +/- 32 years), obese (BMI 373 +/- 2.8 kg/m(2)), and relatively well-controlled (HbA1c 6.7 +/- 03%, 50 mmol/mol). Glycemic control, glucose tolerance, insulin release, and oxidative markers did not change with either dose of NAC.
Conclusions: Based on the lack of any short-term benefit from NAC supplementation on markers of glucose metabolism, beta-cell response, and oxidative status, it is unlikely to be a valuable therapeutic approach for treatment of type 2 diabetes. Published by Elsevier Inc.
C1 [Szkudlinska, Magdalena A.; Utzschneider, Kristina M.] VA Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Seattle, WA USA.
[Szkudlinska, Magdalena A.; Utzschneider, Kristina M.] Univ Washington, Seattle, WA 98195 USA.
[von Frankenberg, Anize D.] Univ Fed Rio Grande do Sul, Sch Med, Postgrad Endocrinol Program, Porto Alegre, RS, Brazil.
RP Szkudlinska, MA (reprint author), VA Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Seattle, WA USA.; Szkudlinska, MA (reprint author), Univ Washington, Seattle, WA 98195 USA.
EM magda3@u.washington.edu; anize.frankenberg@gmail.com;
kutzschn@u.washington.edu
FU Department of Veteran Affairs; Diabetes Research Center [P30DK017047]
FX We are grateful to the study participants for their contribution and
time. This study was supported by funding and resources from the
Department of Veteran Affairs and the Diabetes Research Center
(P30DK017047). The NAC supplement was generously provided free of charge
from Twin Labs.
NR 25
TC 0
Z9 0
U1 3
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1056-8727
EI 1873-460X
J9 J DIABETES COMPLICAT
JI J. Diabetes Complications
PD MAY-JUN
PY 2016
VL 30
IS 4
BP 618
EP 622
DI 10.1016/j.jdiacomp.2016.02.003
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DK4UQ
UT WOS:000374916200010
PM 26922582
ER
PT J
AU Lopes-Virella, MF
Hunt, KJ
Baker, NL
Virella, G
AF Lopes-Virella, Maria F.
Hunt, Kelly J.
Baker, Nathaniel L.
Virella, Gabriel
CA VADT Grp Investigators
TI High levels of AGE-LDL, and of IgG antibodies reacting with MDA-lysine
epitopes expressed by oxLDL and MDA-LDL in circulating immune complexes
predict macroalbuminuria in patients with type 2 diabetes
SO JOURNAL OF DIABETES AND ITS COMPLICATIONS
LA English
DT Article
DE Nephropathy; Albuminuria; Modified LDL immune complexes; Modified LDL
antibodies; AGE- LDL; MDA-LDL
ID LOW-DENSITY-LIPOPROTEIN; GLYCATION END-PRODUCTS; EURODIAB PROSPECTIVE
COMPLICATIONS; INTIMA-MEDIA THICKNESS; OXIDIZED LDL; CARDIOVASCULAR
EVENTS; OXIDATIVE STRESS; GLYCEMIC CONTROL; MODIFIED FORMS; RISK-FACTORS
AB Background: Circulating immune complexes (IC) containing modified forms of LDL (mLDL) are strongly pro-inflammatory and when present in high levels are associated with the development of diabetic complications.
Objective: We investigated whether levels of oxidized LDL (oxLDL), malondialdehyde-LDL (MDA-LDL) and advanced glycation end products-LDL (AGE-LDL) as well as IgG and IgM antibodies reacting with MDA-lysine epitopes expressed by oxLDL and MDA-LDL isolated from circulating IC were associated with progression to macroalbuminuria in type 2 diabetes (VADT cohort).
Methods: Levels of mLDL in IC were measured in 905 patients, a median of two years after entry into the study. Participants were followed for an average of 3.7 years for renal outcomes. Generalized logistic regression models were used to quantify the association of increased levels of biomarkers and development of abnormal albuminuria. Normal, persistent micro-(ACR >= 30), incident micro-(ACR >= 30) and incident macroalbuminuria (ACR >= 300) were the outcomes of interest.
Results and conclusions: Patients with macro (n = 78) or non-persistent microalbuminuria (n = 81) at baseline were excluded. Odds ratios for endpoints in relation to high versus low (defined using a median split) biomarker levels are found in Fig. 1. Our study demonstrates that high levels of AGE-LDL as well as of IgG antibodies (but not IgM antibodies) reacting with MDA-LDL lysine epitopes in circulating IC predict the development of macroalbuminuria in patients with type 2 diabetes. These data support the pathogenic role of modified LDL IgG antibodies but not the protective role of modified LDL IgM antibodies. Published by Elsevier Inc.
C1 [Lopes-Virella, Maria F.] Med Univ S Carolina, Dept Med & Lab Serv, Charleston, SC 29425 USA.
[Lopes-Virella, Maria F.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Hunt, Kelly J.; Baker, Nathaniel L.] Med Univ S Carolina, Dept Publ Hlth Serv, Charleston, SC 29425 USA.
[Virella, Gabriel] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.
RP Lopes-Virella, MF (reprint author), 114 Doughty St, Charleston, SC 29425 USA.
EM virellam@musc.edu
FU Cooperative Studies Program of the Department of Veterans Affairs Office
of Research and Development; National Institutes of Health (NIH),
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
[R01-DK099177]
FX This work was supported in part by the Cooperative Studies Program of
the Department of Veterans Affairs Office of Research and Development.
This work was also supported by a program project funded by the National
Institutes of Health (NIH), National Institute of Diabetes and Digestive
and Kidney Diseases (NIDDK) Grants R01-DK099177. The contents of this
article do not represent the views of the Department of Veterans Affairs
or the United States Government. M. L.-V. is the guarantor of this work
and, as such, had full access to all the data in the study and takes
responsibility for the integrity of the data and the accuracy of the
data analysis.
NR 46
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1056-8727
EI 1873-460X
J9 J DIABETES COMPLICAT
JI J. Diabetes Complications
PD MAY-JUN
PY 2016
VL 30
IS 4
BP 693
EP 699
DI 10.1016/j.jdiacomp.2016.01.012
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DK4UQ
UT WOS:000374916200021
PM 26861948
ER
PT J
AU Gallegos, AM
Streltzov, NA
Stecker, T
AF Gallegos, Autumn M.
Streltzov, Nicholas A.
Stecker, Tracy
TI Improving Treatment Engagement for Returning Operation Enduring Freedom
and Operation Iraqi Freedom Veterans With Posttraumatic Stress Disorder,
Depression, and Suicidal Ideation
SO JOURNAL OF NERVOUS AND MENTAL DISEASE
LA English
DT Article
DE OEF/OIF veterans; posttraumatic stress disorder; suicidal ideation;
treatment engagement
ID MENTAL-HEALTH TREATMENT; AFGHANISTAN; CARE; PREDICTORS; SERVICES;
BARRIERS; SAMPLE; PTSD; RISK; WAR
AB Posttraumatic stress disorder (PTSD) is associated with increased risk of suicidal ideation among veterans of Operation Enduring Freedom and Operation Iraqi Freedom. This report examined the effectiveness of a brief phone-based cognitive-behavioral intervention on treatment seeking among suicidal and nonsuicidal Operation Enduring Freedom and Operation Iraqi Freedom veterans who screened positive for PTSD. Participants were randomized to the intervention or control conditions. We found that suicidal participants, regardless of condition, were twice as likely to attend treatment as nonsuicidal participants. Participants assigned to the control condition who did not indicate suicidality at baseline were less likely to attend treatment at both the 1- and 6-month follow-up interviews. Qualitative findings of the suicidal participants indicated PTSD and depressive symptoms, low social support, and infrequent positive coping mechanisms. Our finding indicates the effectiveness of an intervention to motivate veterans with PTSD to initiate and remain in treatment. The intervention might be particularly useful prior to experiencing a psychological crisis.
C1 [Gallegos, Autumn M.] Univ Rochester, Med Ctr, Dept Psychiat, 300 Crittenden Blvd, Rochester, NY 14642 USA.
[Streltzov, Nicholas A.] Geisel Sch Med Dartmouth, Dartmouth Psychiat Res Ctr, Lebanon, NH USA.
[Stecker, Tracy] Med Univ S Carolina, Coll Nursing, Charleston, SC 29425 USA.
[Stecker, Tracy] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Gallegos, AM (reprint author), Univ Rochester, Med Ctr, Dept Psychiat, 300 Crittenden Blvd, Rochester, NY 14642 USA.
EM autumn_gallegos@urmc.rochester.edu
FU National Institute of Mental Health [R01 MH086939]
FX This research was funded by grant R01 MH086939 from the National
Institute of Mental Health.
NR 26
TC 0
Z9 0
U1 1
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0022-3018
EI 1539-736X
J9 J NERV MENT DIS
JI J. Nerv. Ment. Dis.
PD MAY
PY 2016
VL 204
IS 5
BP 339
EP 343
DI 10.1097/NMD.0000000000000489
PG 5
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA DK4LL
UT WOS:000374889700002
PM 26894313
ER
PT J
AU La Fountaine, MF
Toda, M
Testa, A
Bauman, WA
AF La Fountaine, Michael F.
Toda, Michita
Testa, Anthony
Bauman, William A.
TI Suppression of Serum Prolactin Levels after Sports Concussion with
Prompt Resolution Upon Independent Clinical Assessment To Permit
Return-to-Play
SO JOURNAL OF NEUROTRAUMA
LA English
DT Article
DE adult brain injury; head trauma; hypopituitarism
ID TRAUMATIC BRAIN-INJURY; SLEEP; HYPOPITUITARISM; DYSFUNCTION; STATEMENT;
SECRETION; HORMONE
AB A significant outflow of neurotransmitters and metabolites with associated enhanced cortical excitation occurs after concussive head trauma. Cellular changes in the acute post-injury period cannot be observed directly in humans, and as such, require indirect evidence from systems sufficiently sensitive to central neuronal cellular excitation. Dopamine is a neurotransmitter with numerous targets in the central and peripheral nervous system. Changes to central dopaminergic tone result in reciprocal responses to the level of serum prolactin (PRL). Thus, a concussion may lead to abnormal dopaminergic tone, resulting in dynamic perturbations in the serum PRL concentration. To determine the effect of concussion on serum PRL concentrations, venipuncture was performed in the morning in four male intercollegiate athletes (age, 20 +/- 1 years; height, 71 +/- 5 inches; weight, 174 +/- 21 pounds) within 48 h of concussion and again at 7 and 14 days post-injury. Serum PRL concentrations for each visit were categorized by quartile within the normal range. In all athletes, serum PRL concentrations increased from the lower quartiles in samples obtained closer to the time of injury to the higher quartiles at 14 days post-injury. These serum PRL changes accompanied the resolution of symptoms and the clinical decision to permit return-to-play. It may be postulated that transient augmentation of central dopaminergic tone resulted in inhibition of PRL secretion early after concussion and that disinhibition of PRL release occurred when central dopaminergic tone subsequently returned to baseline levels. This novel observation provides evidence for dopaminergic dysfunction after concussion that may be tracked by determination of serum PRL levels.
C1 [La Fountaine, Michael F.] Seton Hall Univ, Sch Hlth & Med Sci, 400 South Orange Ave, S Orange, NJ 07079 USA.
[La Fountaine, Michael F.] Seton Hall Univ, Inst Adv Study Rehabil & Sports Sci, S Orange, NJ 07079 USA.
[Testa, Anthony] Seton Hall Univ, Dept Athlet, S Orange, NJ 07079 USA.
[La Fountaine, Michael F.; Bauman, William A.] James J Peters VA Med Ctr, VA Rehabil Res & Dev Natl Ctr Excellence Med Cons, Bronx, NY USA.
[Toda, Michita] Univ Wisconsin, Dept Athlet, Madison, WI USA.
[Bauman, William A.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA.
[Bauman, William A.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA.
RP La Fountaine, MF (reprint author), Seton Hall Univ, Sch Hlth & Med Sci, 400 South Orange Ave, S Orange, NJ 07079 USA.
EM lafounmi@shu.edu
NR 20
TC 0
Z9 0
U1 1
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
EI 1557-9042
J9 J NEUROTRAUM
JI J. Neurotrauma
PD MAY 1
PY 2016
VL 33
IS 9
BP 904
EP 906
DI 10.1089/neu.2015.3968
PG 3
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA DK7SA
UT WOS:000375124800012
PM 26159360
ER
PT J
AU Waltz, P
Carchman, E
Gomez, H
Zuckerbraun, B
AF Waltz, Paul
Carchman, Evie
Gomez, Hernando
Zuckerbraun, Brian
TI Sepsis results in an altered renal metabolic and osmolyte profile
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
DE Sepsis; CLP; Acute kidney injury; Metabolomics
ID ACUTE KIDNEY INJURY; EPIDEMIOLOGY; MULTICENTER; DYSFUNCTION; UREA
AB Background: Sepsis remains a major health-care burden and source of morbidity and mortality. Acute kidney injury and failure frequently accompanies severe sepsis and contributes to this burden. Despite a great deal of research, the exact mechanisms underlying renal failure in sepsis are poorly understood. This study aims to further understand metabolic changes in renal tissue during sepsis.
Materials and methods: Experimental sepsis was induced by cecal ligation and puncture (CLP) in C57BL/6 mice. Serum and organs were harvested 8 h after CLP. Markers of renal function including serum creatinine, blood urea nitrogen, and cystatin C were measured. Whole kidneys were analyzed for a global biochemical profile via liquid chromatography/tandem mass spectrometry by Metabolon.
Results: CLP induced renal injury as evidenced by elevated serum creatinine, blood urea nitrogen, and cystatin C. Global energetic profile in sepsis showed an increase in glycolytic intermediates with decreased flux through the tricarboxylic acid (TCA) cycle. Multiple inflammatory markers were elevated in response to CLP. Levels of osmotic regulators varied, with an overall increase in pinitol, urea, and taurine in response to CLP.
Conclusions: CLP resulted in dramatic changes in the renal macromolecular milieu. There appears to be an increased dependence on glycolysis and diminished flush through the TCA cycle. In addition, changes in renal osmolytes including pinitol, urea, and taurine were observed, perhaps uncovering an additional change with implications on renal function during sepsis. Published by Elsevier Inc.
C1 [Waltz, Paul; Carchman, Evie; Zuckerbraun, Brian] Univ Pittsburgh, Dept Surg, F1267PUH,200 Lothrop St, Pittsburgh, PA 15213 USA.
[Gomez, Hernando] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15213 USA.
[Zuckerbraun, Brian] VA Pittsburgh Healthcare Syst, Univ Dr C, Pittsburgh, PA USA.
RP Zuckerbraun, B (reprint author), Univ Pittsburgh, Dept Surg, F1267PUH,200 Lothrop St, Pittsburgh, PA 15213 USA.
EM zuckerbraunbs@upmc.edu
FU NIH [GM113816]
FX This work was funded by NIH grant GM113816.
NR 14
TC 2
Z9 2
U1 2
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
EI 1095-8673
J9 J SURG RES
JI J. Surg. Res.
PD MAY 1
PY 2016
VL 202
IS 1
BP 8
EP 12
DI 10.1016/j.jss.2015.12.011
PG 5
WC Surgery
SC Surgery
GA DK5OR
UT WOS:000374969800002
PM 27083942
ER
PT J
AU Veenstra, CM
Vachani, A
Ciunci, CA
Zafar, HM
Epstein, AI
Paulson, EC
AF Veenstra, Christine M.
Vachani, Anil
Ciunci, Christine A.
Zafar, Hanna M.
Epstein, Andrew I.
Paulson, E. Carter
TI Trends in the Use of F-18-Fluorodeoxyglucose PET Imaging in Surveillance
of Non-Small-Cell Lung and Colorectal Cancer
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Article; Proceedings Paper
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
DE Positron emission tomographic imaging; surveillance; colorectal cancer;
non-small-cell lung cancer; Choosing Wisely; FDG-PET
ID MEDICARE BENEFICIARIES; FOLLOW-UP; CLINICAL ONCOLOGY; AMERICAN SOCIETY;
TOMOGRAPHY
AB Purpose: Surveillance PET after curative-intent treatment of non small-cell lung cancer (NSCLC) or colorectal cancer (CRC) is not clearly supported by available evidence or the Choosing Wisely campaign. However, the frequency of PET imaging during the surveillance period is relatively unknown.
Methods: Using Surveillance, Epidemiology, and End Results Medicare data, 65,748 patients aged 66 years or older who were diagnosed with stage I to IIIA NSCLC or stage I to III CRC from 2001 through 2009 and who underwent surgical resection were identified. Trends in "any PET" or "PET-only" use 6 to 18 months postoperatively were assessed.
Results: Any PET use more than doubled over the study period. Eleven percent of patients with NSCLC and 4% of those with CRC diagnosed in 2001 received any PET, compared with 25% of patients with NSCLC and 13% of those with CRC in 2009 (P < .001 for both). Higher stage disease was correlated with higher PET utilization and faster growth in use over the study period. PET-only use also increased over the study period, especially in higher stage disease. Fewer than 2% of patients diagnosed with stage IIIA NSCLC in 2001 received PET only, compared with 15% of patients diagnosed in 2009 (P = .014). Similarly, 1% of patients diagnosed with stage III CRC in 2001 received PET only, compared with 8% of patients diagnosed in 2009 (P < .001).
Conclusions: PET utilization during the surveillance period increased between 2001 and 2009. Further research is needed to determine the factors driving use of surveillance PET and to examine relationships between PET and patient outcomes.
C1 [Veenstra, Christine M.] Univ Michigan, Dept Internal Med, North Ingalls Bldg,3A22,300 North Ingalls, Ann Arbor, MI 48109 USA.
[Veenstra, Christine M.] Univ Michigan, Inst Healthcare Policy & Innovat, North Ingalls Bldg,3A22,300 North Ingalls, Ann Arbor, MI 48109 USA.
[Vachani, Anil; Ciunci, Christine A.; Epstein, Andrew I.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
[Zafar, Hanna M.] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA.
[Zafar, Hanna M.; Epstein, Andrew I.; Paulson, E. Carter] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Vachani, Anil; Epstein, Andrew I.; Paulson, E. Carter] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Paulson, E. Carter] Univ Penn, Div Colon & Rectal Surg, Philadelphia, PA 19104 USA.
RP Veenstra, CM (reprint author), Univ Michigan, North Ingalls Bldg,3A22,300 North Ingalls, Ann Arbor, MI 48109 USA.
EM cveenstr@med.umich.edu
FU NCI NIH HHS [P30 CA016520]
NR 13
TC 1
Z9 1
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD MAY
PY 2016
VL 13
IS 5
BP 491
EP 496
DI 10.1016/j.jacr.2015.11.016
PG 6
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA DL0YE
UT WOS:000375357700004
PM 26774883
ER
PT J
AU Berian, JR
Paruch, JL
Cohen, ME
Merkow, RP
Dahlke, AR
Ko, CY
Bilimoria, KY
AF Berian, Julia R.
Paruch, Jennifer L.
Cohen, Mark E.
Merkow, Ryan P.
Dahlke, Allison R.
Ko, Clifford Y.
Bilimoria, Karl Y.
TI Does Performance Vary Within the Same Hospital When Separately Examining
Different Patient Subgroups?
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Article
ID QUALITY IMPROVEMENT PROGRAM; BODY-MASS INDEX; SURGICAL QUALITY;
AMERICAN-COLLEGE; SURGERY; OUTCOMES; CANCER; RISK; MORTALITY; NSQIP
AB BACKGROUND: Surgical quality programs, such as the American College of Surgeons NSQIP, provide reports based on specialty or procedure, with patients aggregated together. It is unknown whether hospital performance differs by patient subgroup (eg cancer vs noncancer patients), masking opportunities for improvement. Our objectives were to determine whether performance differs within a given hospital for 6 contrasting patient subgroups and to identify the percentage of hospitals with greater than chance differences in performance.
STUDY DESIGN: Using the American College of Surgeons NSQIP data, adults undergoing lung resection, esophagectomy, hepatectomy, pancreatectomy, colectomy, and proctectomy (2005 through 2012) were divided into 6 contrasting subgroups (elderly vs nonelderly, white vs nonwhite, obese vs nonobese, renal insufficiency vs normal renal function, cancer vs noncancer, emergency vs nonemergency). The main end point was serious morbidity or mortality. Observed to expected ratios were constructed using hierarchical models and compared using paired t-tests (eg observed to expected for cancer cases compared with noncancer). Variation in performance differences was assessed using a randomization test and z-tests for proportions.
RESULTS: From 433 hospitals, 221,518 patients were included. Overall quality differed for elderly vs nonelderly, renal insufficiency vs normal renal function patients, cancer vs noncancer, and emergency vs nonemergency (p < 0.05). Variation in within-hospital performance differences exceeded chance expectations for renal insufficiency vs normal renal function in 31.1% of hospitals, cancer vs noncancer in 40.8%, and emergency vs nonemergency patients in 55.4% (p < 0.001).
CONCLUSIONS: Hospital performance within a given hospital varies by patient subgroup. Quality programs can consider separate reports for these subgroups to identify opportunities for quality improvement. (C) 2016 by the American College of Surgeons. Published by Elsevier Inc. All rights reserved.
C1 [Berian, Julia R.; Paruch, Jennifer L.; Cohen, Mark E.; Merkow, Ryan P.; Ko, Clifford Y.; Bilimoria, Karl Y.] Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St,22nd Floor, Chicago, IL 60611 USA.
[Berian, Julia R.; Paruch, Jennifer L.; Merkow, Ryan P.] Univ Chicago, Med Ctr, Dept Surg, Chicago, IL 60637 USA.
[Berian, Julia R.; Merkow, Ryan P.; Dahlke, Allison R.; Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Surg Outcomes & Qual Improvement, Dept Surg, Chicago, IL 60611 USA.
[Berian, Julia R.; Merkow, Ryan P.; Dahlke, Allison R.; Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Northwestern Inst Comparat Effectiveness Res Onco, Chicago, IL 60611 USA.
[Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA.
[Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA.
RP Berian, JR (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St,22nd Floor, Chicago, IL 60611 USA.
EM jberian@facs.org
FU Agency for Healthcare Research and Quality [R21 HS21857-01]; American
Cancer Society [280521]; American College of Surgeons Clinical Scholars
in Residence Program, University of Chicago Medical Center, Northwestern
University; John A Hartford Foundation; American College of Surgeons,
the University of Chicago, Northwestern University; Genentech
FX This work was supported in part by the Agency for Healthcare Research
and Quality (R21 HS21857-01; Principal Investigator: Dr Bilimoria) and
American Cancer Society (280521; Principal Investigator: Dr Bilimoria).
Dr Berian's fellowship position at the American College of Surgeons as a
Clinical Scholar in Residence is supported by the American College of
Surgeons Clinical Scholars in Residence Program, University of Chicago
Medical Center, Northwestern University, and a grant from the John A
Hartford Foundation. Dr Paruch's American College of Surgeons Clinical
Scholars in Residence fellowship was supported by the American College
of Surgeons, the University of Chicago, Northwestern University, and an
unrestricted educational grant from Genentech, which had no input on the
selection of the recipient, research topic, research direction, or the
content of any resulting report, presentation, or publication.
NR 27
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1072-7515
EI 1879-1190
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD MAY
PY 2016
VL 222
IS 5
BP 790
EP +
DI 10.1016/j.jamcollsurg.2016.01.057
PG 9
WC Surgery
SC Surgery
GA DK7UD
UT WOS:000375130300012
PM 27016904
ER
PT J
AU Sharath, SE
Kougias, P
Pisimisis, G
Barshes, NR
AF Sharath, Sherene E.
Kougias, Panos
Pisimisis, George
Barshes, Neal R.
TI The impact of clinical, psychological, behavioral, social, and
environmental factors on self-perceived symptom severity in a male
cohort with intermittent claudication
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Article
ID PERIPHERAL ARTERIAL-DISEASE; WALKING IMPAIRMENT QUESTIONNAIRE;
ANKLE-BRACHIAL INDEX; QUALITY-OF-LIFE; LOW-BACK-PAIN; PHYSICAL-ACTIVITY;
D PERSONALITY; EXERCISE; VALIDATION; THERAPY
AB Objective: To understand the relationship between self-perceived severity of intermittent claudication and various associated nonclinical factors, we examined how correlates in domains of physical activity (ie, clinical, psychological, behavioral, social, and environmental factors) relate to exertional limb symptoms.
Methods: A survey was administered to individuals with intermittent claudication during their initial outpatient assessment. The subjects' self-reported exertional limb symptom severity and classic -versus -atypical claudication classification was based on the Walking Impairment Questionnaire (WIQ) and San Diego Claudication Questionnaire (SDCQ), respectively. We evaluated psychosocial and environmental factors, osteoarthritis symptoms, health, behaviors, and beliefs. Logistic and linear regressions identified factors with a strong independent association with total WIQ scores and the SDCQs.
Results: A cohort of 102 subjects (99.0% male) was enrolled in the study. The median age was 65 years with a median ankle -brachial index of 0.69. Forty-three subjects (43%) had "typical" claudication per SDCQs. Individuals with atypical claudication were more likely to report higher Aberdeen Clinical Back Pain Questionnaire scores (odds ratio, 1.04; P = .04) and no depressive symptoms (odds ratio, 8.30; P = .03). Exertional limb symptom severity among the entire cohort was significantly associated with increasing osteoarthritis symptoms (P <001), age (P = .02), a reserved personality (P = .008), and the belief that an exercise regimen would not improve symptoms (P = .005), self -perceived levels of boredom (P = .002), and the belief that exercise (P = .002) was the best way to improve symptoms were associated with decreased symptom severity. When restricted to those with atypical pain, significant factors associated with increasing exertional symptom severity included age greater than 60 years (P = .005), osteoarthritis (P = .02), alcohol use (P = .01), belief that exercise would not improve walking (P = .03), and difficulty walking around the neighborhood (P = .02). When restricted to those with classic claudication, significant factors associated with increasing exertional limb symptom severity included frequent pain or aching in the calves while walking or sitting (P = .03 [walking]; P = .01 [sitting]) and occasional morning joint stiffness (P = .007). Exertional limb symptom severity was also associated with high limitations at home (P = .003) and a belief that exercise would not improve walking (P = .005) among those with classic claudication.
Conclusions: Symptom severity and type of pain are associated with a number of nonclinical factors. A multidomain approach, as indicated by the models above, would benefit the continuum of care for intermittent claudication, where management is integrated and coordinated among multiple lines of care.
C1 [Sharath, Sherene E.] Michael E DeBakey VA Med Ctr, Hlth Serv & Res Dev, Houston, TX USA.
[Kougias, Panos; Pisimisis, George; Barshes, Neal R.] Baylor Coll Med, Michael E DeBakey Dept Surg, Div Vasc Surg & Endovasc Therapy, Michael E DeBakey Vet Affairs Med Ctr, 2002 Holcombe Blvd OCL 112, Houston, TX 77030 USA.
RP Barshes, NR (reprint author), Baylor Coll Med, Michael E DeBakey Dept Surg, Div Vasc Surg & Endovasc Therapy, Michael E DeBakey Vet Affairs Med Ctr, 2002 Holcombe Blvd OCL 112, Houston, TX 77030 USA.
EM nbarshes@bcm.tmc.edu
NR 38
TC 0
Z9 0
U1 1
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD MAY
PY 2016
VL 63
IS 5
BP 1296
EP U483
DI 10.1016/j.jvs.2015.11.040
PG 13
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA DK8YN
UT WOS:000375216000025
PM 26821592
ER
PT J
AU Ankri-Eliahoo, G
Weitz, K
Cox, TC
Tang, GL
AF Ankri-Eliahoo, Galit
Weitz, Kevin
Cox, Timothy C.
Tang, Gale L.
TI p27(kip1) Knockout enhances collateralization in response to hindlimb
ischemia
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Article
ID MUSCLE-CELL MIGRATION; SINGLE NUCLEOTIDE POLYMORPHISM; MATRIX
METALLOPROTEINASES; THERAPEUTIC ANGIOGENESIS; PROLIFERATION;
CONTRACTION; INHIBITORS; GROWTH; MMP-9; CYCLE
AB Objective: The natural response to arterial occlusive disease is enlargement of collaterals; however, the molecular factors that control collateralization are not well understood. The gene p27(Kipl) (p27) affects human response to arterial injury. Previous studies have shown that overexpression of p27 inhibits vascular endothelial and vascular smooth muscle cell (VSMC) proliferation and angiogenesis. To test the hypothesis that knockout of p27 would improve collateralization in reaction to ischemia, we performed in vivo and in vitro experiments using p27 knockout (p27(-/-)) and wild-type (wt) mice.
Methods: Hindlimb ischemia was induced by left femoral artery ligation in p27(-/-) and wt (C57BL/6) female mice. The mice underwent weekly laser Doppler perfusion imaging of the footpads until sacrifice on postoperative day 28 followed by microcomputed tomography scanning of both hindlimbs VSMCs were isolated from p27 /and wt mice and used in migration and gel contraction assays in the absence and presence of the nonspecific matrix metalloproteinase (M1VIP) inhibitor BB94. MMP-2 and MMP-9 messenger RNA (mRNA) expression was measured by quantitative reverse transcription-polymerase chain reaction in p27 /and wt VSMCs.
Results: p27 /mice reperfused more effectively than wt mice by laser Doppler starting from day 7 (ischemic/nonischemic ratio, 0.33 +/- 0.02 vs 0.25 +/- 0.02; P<.05) and continuing through day 28 (0.45 +/- 0.04 vs +/- 0.31 0.04; P<.05). The gracilis collateral diameter was similar for the nonischemic hindlimbs of the p27 /and wt mice, and this collateral pathway increased similarly after ischemia as assessed by microcomputed tomography. However, the p27 /mice significantly enlarged a novel collateral pathway that bridged directly between the femoral artery proximal to the ligation site and the saphenous or popliteal artery distal to the ligation site more than wt mice (158 18.3 vs 82 22 m; P<.001). p27 /VSMCs migrated more (79% 5% vs 56% 6%; P<.05) and caused more gel contraction (18% 5% of the initial area vs 43% 4%; P<.05) than wt cells. Migration and collagen contraction were abolished in p27 /and wt cells by MMP inhibition. p27 /cells expressed significantly more MMP-2 mRNA than wt cells did.
Conclusions: Knockout of p27 enhances arterial collateralization in response to hindlimb ischemia through enlargement of a new collateral pathway. In vitro, knockout of p27 increases collagen gel contraction in addition to stimulating VSMC migration. We speculate that p27 may affect collateralization through its role in regulating MMP-2 expression. (J Vasc Surg 2016;63:1351-9.)
Clinical Relevance: Atherosclerosis is the leading cause of mortality and morbidity in the United States. _ENREF_2 The adaptive response to the progressive occlusion of arteries is collateralization (arteriogenesis). As many patients with severe atherosclerosis are not good candidates for angioplasty or surgical bypass, therapies directed toward improving collateralization are needed. The molecular pathways controlling collateralization, however, are not well understood. The human response to arterial injury is affected by a genetic polymorphism in the gene CDKNIB (p27K'P1 or p27). We demonstrate that knockout of p27 improves collateralization. Study of the molecular partners of p27 will identify therapeutic candidates to enhance this process for patients.
C1 [Ankri-Eliahoo, Galit; Weitz, Kevin; Tang, Gale L.] Univ Washington, Div Vasc Surg, Seattle, WA 98195 USA.
[Cox, Timothy C.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA.
[Cox, Timothy C.] Seattle Childrens Res Inst, Ctr Dev Biol & Regenerat Med, Seattle, WA USA.
[Tang, Gale L.] VA Puget Sound Hlth Care Syst, Dept Surg, Div Vasc Surg, Seattle, WA USA.
RP Tang, GL (reprint author), Univ Washington, Dept Surg, Div Vasc Surg, Surg Serv 112, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM gtang@uw.edu
FU University of Washington Royalty Research Fund
FX This work was supported with the facilities and resources of the VA
Puget Sound Health Care System, the Seattle Institute for Biomedical and
Clinical Research, the University of Washington Royalty Research Fund,
the Vascular Cures Foundation, and the Laurel Foundation.
NR 29
TC 0
Z9 0
U1 1
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD MAY
PY 2016
VL 63
IS 5
BP 1351
EP 1359
DI 10.1016/j.jvs.2015.12.047
PG 9
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA DK8YN
UT WOS:000375216000032
PM 25701497
ER
PT J
AU Zaidi, M
Iqbal, J
AF Zaidi, Mone
Iqbal, Jameel
TI Closing the loop on the bone-resorbing osteoclast
SO NATURE MEDICINE
LA English
DT Editorial Material
AB A new study shows in mice that tumor necrosis factor (TNF) superfamily member 11 (TNFSF11, also known as RANKL), which stimulates osteoclasts to remove bone, binds to the G-protein-coupled receptor LGR4 to prevent excessive bone removal. In mouse models of osteoporosis, a recombinant LGR4 ectodomain reduces bone loss.
C1 [Zaidi, Mone] Icahn Sch Med Mt Sinai, Mt Sinai Bone Program, New York, NY 10029 USA.
[Iqbal, Jameel] Los Angeles VA Med Ctr, Dept Pathol, Los Angeles, CA USA.
RP Zaidi, M (reprint author), Icahn Sch Med Mt Sinai, Mt Sinai Bone Program, New York, NY 10029 USA.
EM Mone.zaidi@mssm.edu
NR 12
TC 1
Z9 1
U1 5
U2 6
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD MAY
PY 2016
VL 22
IS 5
BP 460
EP 461
PG 2
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
Medicine
GA DL3DI
UT WOS:000375514000006
PM 27149217
ER
PT J
AU Amini, A
Jasem, J
Jones, BL
Robin, TP
McDermott, JD
Bhatia, S
Raben, D
Jimeno, A
Bowles, DW
Karam, SD
AF Amini, Arya
Jasem, Jagar
Jones, Bernard L.
Robin, Tyler P.
McDermott, Jessica D.
Bhatia, Shilpa
Raben, David
Jimeno, Antonio
Bowles, Daniel W.
Karam, Sana D.
TI Predictors of overall survival in human papillomavirus-associated
oropharyngeal cancer using the National Cancer Data Base
SO ORAL ONCOLOGY
LA English
DT Article
DE Human papillomavirus (HPV); National Cancer Data Base (NCDB); Oropharynx
cancer; Survival outcomes; Chemoradiation; Head and neck squamous cell
carcinoma
ID SQUAMOUS-CELL CARCINOMA; LOCALLY ADVANCED HEAD; DISTANT METASTASIS;
REGIONAL CONTROL; DE-ESCALATION; LYMPH-NODES; NECK-CANCER; HIGH-RISK;
RADIOTHERAPY; CHEMOTHERAPY
AB Objectives: This study identifies clinical characteristics associated with HPV-positive oropharynx squamous cell carcinoma (OPSCC) and evaluates predictors of overall survival (OS) in HPV-positive patients undergoing definitive treatment within the National Cancer Data Base (NCDB).
Material and methods: The NCDB was queried for patients P18 years old with OPSCC and known HPV status who underwent definitive treatment: surgery, radiation (RT), chemotherapy-RT (CRT), surgery + RT, surgery + CRT (S-CRT). Cox proportional hazards model was used for multivariate analysis (MVA) to evaluate predictors of OS by HPV status.
Results: 3952 patients were included: 2454 (62%) were HPV-positive. Median follow up was 23.7 months (range, 1.0-54.5). Unadjusted 2-year OS rates for HPV-positive vs. negative were 93.1% vs. 77.8% (p < 0.001) with an adjusted hazard ratio of 0.44 (95% CI, 0.36-0.53; p < 0.001). MVA identified multimodality treatment including CRT (HR, 0.42; p = 0.024) and S-RT (HR, 0.30; p = 0.024), but not S-CRT (HR, 0.51; p = 0.086), as predictors for improved OS in HPV-positive stage III-IVB disease. Multimodality treatment including S-CRT was associated with longer OS in HPV-negative OPSCC. Nodal stage was poorly associated with OS in HPV-positive cancers. The presence of positive margins and/or extracapsular extension was associated with worse OS in HPV-negative (HR, 2.11; p = 0.008) but not HPV positive OPSCC (HR, 1.61; p = 0.154).
Conclusion: The established demographic and clinical features of HPV-positive OPSCC were corroborated in the NCDB. Population analysis suggests that AJCC staging is poorly associated with OS in HPV-positive cancer, and traditional high-risk features may be less impactful. Bimodality therapy appears beneficial in HPV-positive HNSCC. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Amini, Arya; Jones, Bernard L.; Robin, Tyler P.; Bhatia, Shilpa; Raben, David; Karam, Sana D.] Univ Colorado, Sch Med, Dept Radiat Oncol, 1665 Aurora Court,Room 1032, Aurora, CO 80045 USA.
[Jasem, Jagar] Univ Colorado, Sch Med, Dept Med, Aurora, CO 80045 USA.
[McDermott, Jessica D.; Bowles, Daniel W.] Eastern Colorado Hlth Care Syst, Denver Vet Affairs Med Ctr, Denver, CO USA.
[McDermott, Jessica D.; Jimeno, Antonio; Bowles, Daniel W.] Univ Colorado, Sch Med, Dept Med, Div Med Oncol, Aurora, CO 80045 USA.
RP Karam, SD (reprint author), Univ Colorado, Sch Med, Dept Radiat Oncol, 1665 Aurora Court,Room 1032, Aurora, CO 80045 USA.
EM arya.amini@ucdenver.edu; sana.karam@ucdenver.edu
OI Jones, Bernard/0000-0001-7169-559X
NR 31
TC 6
Z9 6
U1 2
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1368-8375
EI 1879-0593
J9 ORAL ONCOL
JI Oral Oncol.
PD MAY
PY 2016
VL 56
BP 1
EP 7
DI 10.1016/j.oraloncology.2016.02.011
PG 7
WC Oncology; Dentistry, Oral Surgery & Medicine
SC Oncology; Dentistry, Oral Surgery & Medicine
GA DK3VF
UT WOS:000374844800008
PM 27086480
ER
PT J
AU Melton, DW
Lei, XF
Gelfond, JAL
Shireman, PK
AF Melton, David W.
Lei, XiuFen
Gelfond, Jonathan A. L.
Shireman, Paula K.
TI Dynamic macrophage polarization-specific miRNA patterns reveal increased
soluble VEGF receptor 1 by miR-125a-5p inhibition
SO PHYSIOLOGICAL GENOMICS
LA English
DT Article
DE microRNAs; temporal; M1; M2a; M2c; VEGF
ID ENDOTHELIAL GROWTH-FACTOR; TUMOR-ASSOCIATED MACROPHAGES; IN-VIVO;
INFLAMMATORY RESPONSE; ACTIVATED MACROPHAGES; HUMAN MONOCYTES;
EXPRESSION; MICRORNAS; ANGIOGENESIS; FLT-1
AB Dynamic, epigenetic mechanisms can regulate macrophage phenotypes following exposure to different stimulating conditions and environments. However, temporal patterns of microRNAs (miRNAs or miRs) across multiple macrophage polarization phenotypes have not been defined. We determined miRNA expression in bone marrow-derived murine macrophages over multiple time points (0.5, 1, 3, 24 h) following exposure to cytokines and/or LPS. We hypothesized that dynamic changes in miRNAs regulate macrophage phenotypes. Changes in macrophage polarization markers were detected as early as 0.5 and as late as 24 h; however, robust responses for most markers occurred within 3 h. In parallel, many polarization-specific miRNAs were also changed by 3 h and expressed divergent patterns between M1 and M2a conditions, with increased expression in M1 (miR-155, 199a-3p, 214-3p, 455-3p, and 125a) or M2a (miR-511 and 449a). Specifically, miR-125a-5p exhibited divergent patterns: increased at 12-24 h in M1 macrophages and decreasing trend in M2a. VEGF in the culture media of macrophages was dependent upon the polarization state, with greatly diminished VEGF in M2a compared with M1 macrophage culture media despite similar VEGF in cell lysates. Inhibition of miR-125a-5p in media-only controls (MO) and M1 macrophages greatly increased expression and secretion of soluble VEGF receptor-1 (sVEGFR1) leading to diminished VEGF in the culture media, partially converting MO and M1 into an M2a phenotype. Thus, the divergent expression patterns of polarization-specific miRNAs led to the identification and demonstrated the regulation of a specific macrophage polarization phenotype, sVEGFR1 by inhibition of miR-125a-5p.
C1 [Melton, David W.; Lei, XiuFen; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, 7703 Floyd Curl Dr,MC 7741, San Antonio, TX 78229 USA.
[Gelfond, Jonathan A. L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
[Melton, David W.; Gelfond, Jonathan A. L.; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
[Melton, David W.; Lei, XiuFen; Shireman, Paula K.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Shireman, PK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, 7703 Floyd Curl Dr,MC 7741, San Antonio, TX 78229 USA.
EM shireman@uthscsa.edu
FU National Heart, Lung, and Blood Institute Grants [HL-074236, HL-110743];
Veterans Administration Merit Review [1I01BX001186]; Institute for the
Integration of Medicine and Science [UL1 TR001120]
FX This study was supported in part by National Heart, Lung, and Blood
Institute Grants HL-074236 and HL-110743, the Veterans Administration
Merit Review (1I01BX001186), and the Institute for the Integration of
Medicine and Science, UL1 TR001120.
NR 88
TC 2
Z9 2
U1 0
U2 1
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1094-8341
EI 1531-2267
J9 PHYSIOL GENOMICS
JI Physiol. Genomics
PD MAY 1
PY 2016
VL 48
IS 5
BP 345
EP 360
DI 10.1152/physiolgenomics.00098.2015
PG 16
WC Cell Biology; Genetics & Heredity; Physiology
SC Cell Biology; Genetics & Heredity; Physiology
GA DK7SS
UT WOS:000375126600003
PM 26884460
ER
PT J
AU Halpin, DMG
Vogelmeier, C
Pieper, MP
Metzdorf, N
Richard, F
Anzueto, A
AF Halpin, David M. G.
Vogelmeier, Claus
Pieper, Michael P.
Metzdorf, Norbert
Richard, Frank
Anzueto, Antonio
TI Effect of tiotropium on COPD exacerbations: A systematic review
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Anticholinergic; Antimuscarinic; COPD; Long-acting muscarinic antagonist
ID OBSTRUCTIVE PULMONARY-DISEASE; RANDOMIZED-TRIAL; HEALTH OUTCOMES;
PARALLEL-GROUP; LUNG-FUNCTION; UPLIFT TRIAL; EFFICACY; SAFETY;
SALMETEROL; BRONCHODILATOR
AB Background: Exacerbation frequency is related to disease progression, quality of life, and prognosis in COPD. Earlier diagnosis, along with interventions aimed at preventing exacerbations and delaying progression, may help reduce the global burden of disease. Long-acting inhaled bronchodilators are effective at maintaining symptom relief and are recommended as first-choice therapy for more symptomatic patients and those at risk of exacerbation.
Methods: As prevention of exacerbations is a priority goal in COPD management and a number of different long-acting bronchodilators are available, we conducted a systematic review of exacerbation data from randomized controlled trials (published January 2000 to May 2014) comparing the effect of tiotropium versus placebo and/or other maintenance therapies.
Results: Exacerbations were a primary endpoint in 12 publications (five studies: four comparing tiotropium with placebo; one with active comparator) and a secondary endpoint in 17 publications (seven studies: six comparing tiotropium with placebo; one with active comparator). Overall, tiotropium was associated with a longer time to first exacerbation event and fewer exacerbations (including severe exacerbations/hospitalizations) compared with placebo and long-acting beta(2)-agonists. Tiotropium also showed similar efficacy to glycopyrronium and a fixed long-acting muscarinic antagonist/long-acting beta(2)-agonist combination (glycopyrronium/indacaterol), although not all studies were powered to demonstrate differences in exacerbation outcomes. Exacerbation outcomes were comparable with both formulations of tiotropium (HandiHaler (R) 18 mu g/Respimat (R) 5 mu g).
Conclusions: The results of this comprehensive systematic review demonstrate tiotropium is beneficial in reducing exacerbation risk versus placebo or other maintenance treatments. (C) 2016 The Authors. Published by Elsevier Ltd.
C1 [Halpin, David M. G.] Univ Exeter, Sch Med, Royal Devon & Exeter Hosp, Exeter, Devon, England.
[Vogelmeier, Claus] Univ Marburg, Univ Med Ctr Giessen & Marburg, German Ctr Lung Res, Dept Med Pulm & Crit Care Med, Marburg, Germany.
[Pieper, Michael P.] Boehringer Ingelheim Pharma GmbH & Co KG, Resp Dis Res, Biberach, Germany.
[Metzdorf, Norbert; Richard, Frank] Boehringer Ingelheim Pharma GmbH Co KG, Ingelheim, Germany.
[Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Pulm Dis, Crit Care Med, San Antonio, TX 78229 USA.
[Anzueto, Antonio] Audie L Murphy Mem Vet Hosp Div, South Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Halpin, DMG (reprint author), Royal Devon & Exeter Hosp, Dept Resp Med, Barrack Rd, Exeter EX2 5DW, Devon, England.
EM d.halpin@nhs.net
OI Richard, Frank/0000-0003-1027-3814
FU Boehringer Ingelheim
FX Writing assistance was provided by Leigh Prevost and Natalie Dennis from
PAREXEL, which was funded by Boehringer Ingelheim.
NR 53
TC 0
Z9 1
U1 3
U2 3
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAY
PY 2016
VL 114
BP 1
EP 8
DI 10.1016/j.rmed.2016.02.012
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA DK8WJ
UT WOS:000375209000001
PM 27109805
ER
PT J
AU Schure, MB
Borson, S
Nguyen, HQ
Trittschuh, EH
Thielke, SM
Pike, KC
Adams, SG
Fan, VS
AF Schure, Mark B.
Borson, Soo
Nguyen, Huong Q.
Trittschuh, Emily H.
Thielke, Stephen M.
Pike, Kenneth C.
Adams, Sandra G.
Fan, Vincent S.
TI Associations of cognition with physical functioning and health-related
quality of life among COPD patients
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Cognition; COPD; Physical functioning; Quality of life; Physical
activity; Affective symptoms; Motor strength
ID OBSTRUCTIVE PULMONARY-DISEASE; OLDER MEXICAN-AMERICANS;
CONSTRUCT-VALIDITY; SURVEY SF-36; PART-B; IMPAIRMENT; TRAIL; FRAILTY;
PHENOTYPE; OUTCOMES
AB Background: Neurocognitive impairment has been described in COPD patients, but little is known about its relationship with physical functioning and health-related quality of life (HRQL) in this chronically ill patient group.
Methods: 301 stable COPD patients completed the Trail Making Test (TMT-A: psychomotor speed and TMT-B: executive control); 198 patients completed the Memory Impairment Screen (MIS). Standardization of TMT-A and TMT-B scores to a normative population yielded classifications of normal, borderline, or impaired cognitive status. Using multivariable regression, we examined the relationship between the TMT-A, TMT-B, and MIS with physical functioning (physical activity, 6-min walk test, and grip strength) and health-related quality of life (HRQL) measured with the Chronic Respiratory Questionnaire and the SF-36.
Results: Nearly 30% of patients had either borderline or impaired cognition on the TMT-A or TMT-B. Adjusted models indicated that those with either borderline or impaired cognitive functioning had weaker grip strength (TMT-A borderline: beta = -2.9, P < 0.05; TMT-B borderline: beta = -3.0, P < 0.05; TMT-B impaired: beta = -2.5, P < 0.05) and lower scores on the mental health component summary score (MCS-SF-36 HRQOL) measure (TMT-A impaired: beta = -4.7, P < 0.01). No adjusted significant associations were found for other physical functioning measures or the other HRQL measures. Impaired memory showed a significant association only with the MCS scale.
Conclusions: Cognitive function was not associated with most standard indicators of physical function or most measures of HRQL in COPD patients. Both TMT-A and TMT-B were associated with weaker grip strength, and the TMT-A and MIS with poorer mental health. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Schure, Mark B.] Montana State Univ, Dept Hlth & Human Dev, POB 173540, Bozeman, MT 59717 USA.
[Borson, Soo; Trittschuh, Emily H.; Thielke, Stephen M.] Univ Washington, Dept Psychiat & Behav Sci, Sch Med, Box 356560, Seattle, WA 98195 USA.
[Nguyen, Huong Q.] Kaiser Permanente So Calif, 100 S Los Robies, Pasadena, CA 91101 USA.
[Nguyen, Huong Q.; Thielke, Stephen M.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, 1660 S Columbian Way, Seattle, WA 98108 USA.
[Pike, Kenneth C.] Univ Washington, Off Nursing Res, 1959 NE Pacific St, Seattle, WA 98195 USA.
[Adams, Sandra G.] Univ Texas Hlth Sci Ctr San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
[Adams, Sandra G.] South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.
[Fan, Vincent S.] Ctr Innovat VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1660 S Columbian Way, Seattle, WA 98108 USA.
[Fan, Vincent S.] Univ Washington, Dept Med, 1959 NE Pacific St, Seattle, WA 98195 USA.
RP Schure, MB (reprint author), 305 Herrick Hall,POB 173540, Bozeman, MT 59717 USA.
EM mark.schure@montana.edu
FU National Heart, Lung, and Blood Institute (NHLBI) [R01HL093146]
FX This grant was funded by grant R01HL093146 from the National Heart,
Lung, and Blood Institute (NHLBI). The views expressed in this article
are those of the authors and do not necessarily reflect the position or
policy of the VA.
NR 47
TC 0
Z9 0
U1 4
U2 5
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAY
PY 2016
VL 114
BP 46
EP 52
DI 10.1016/j.rmed.2016.03.005
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA DK8WJ
UT WOS:000375209000006
PM 27109810
ER
PT J
AU Ponce, AN
Aosved, AC
Cornish, JAE
AF Ponce, Allison N.
Aosved, Allison C.
Cornish, Jennifer A. Erickson
TI Parental Leave During Internship and Postdoctoral Psychology Training:
APPIC Guidelines Revisited
SO TRAINING AND EDUCATION IN PROFESSIONAL PSYCHOLOGY
LA English
DT Article
DE parental leave; maternity leave; paternity leave; psychology; training
ID MATERNITY LEAVE; HEALTH; CHILD
AB This article introduces the updated Association of Psychology Postdoctoral and Internship Centers' (APPIC) APPIC Guidelines for Parental Leave During Internship and Postdoctoral Training and provides recommendations for addressing the complex issue of supporting parental leave during the course of a doctoral internship or postdoctoral training year.
C1 [Ponce, Allison N.] Yale Univ, Sch Med, Dept Psychiat, 34 Pk St, New Haven, CT 06519 USA.
[Aosved, Allison C.] VA Puget Sound, Amer Lake Div, Tacoma, WA USA.
[Cornish, Jennifer A. Erickson] Univ Denver, Clin Training & Internship Consortium, Grad Sch Profess Psychol, Denver, CO 80208 USA.
RP Ponce, AN (reprint author), Yale Univ, Sch Med, Dept Psychiat, 34 Pk St, New Haven, CT 06519 USA.
EM allison.ponce@yale.edu
NR 18
TC 1
Z9 1
U1 0
U2 1
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1931-3918
EI 1931-3926
J9 TRAIN EDUC PROF PSYC
JI Train. Educ. Prof. Psychol.
PD MAY
PY 2016
VL 10
IS 2
BP 71
EP 77
DI 10.1037/tep0000109
PG 7
WC Psychology, Educational
SC Psychology
GA DK3DL
UT WOS:000374796200002
ER
PT J
AU Abdul-Ghani, M
Del Prato, S
Chilton, R
DeFronzo, RA
AF Abdul-Ghani, Muhammad
Del Prato, Stefano
Chilton, Robert
DeFronzo, Ralph A.
TI SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the
EMPA-REG OUTCOME Study
SO DIABETES CARE
LA English
DT Article
ID TYPE-2 DIABETES-MELLITUS; RANDOMIZED CONTROLLED-TRIAL; PIOGLITAZONE
CLINICAL-TRIAL; INSULIN SENSITIVITY; GLYCEMIC CONTROL; GLUCOSE CONTROL;
BLOOD-PRESSURE; MICROVASCULAR OUTCOMES; MYOCARDIAL-INFARCTION;
MACROVASCULAR EVENTS
AB Although cardiovascular (CV) mortality is the principal cause of death in individuals with type 2 diabetes (T2DM), reduction of plasma glucose concentration has little effect on CV disease (CVD) risk. Thus, novel strategies to reduce CVD risk in T2DM patients are needed. The recently published BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) study demonstrated that in T2DM patients with high CVD risk empagliflozin reduced the primary major adverse cardiac event end point (CV death, nonfatal myocardial infarction, nonfatal stroke) by 14%. This beneficial effect was driven by a 38% reduction in CV mortality with no significant decrease in nonfatal myocardial infarction or stroke. Empagliflozin also caused a 35% reduction in hospitalization for heart failure without affecting hospitalization for unstable angina. Although sodium-glucose cotransporter 2 inhibitors exert multiple metabolic benefits (decreases in HbA(1c), body weight, and blood pressure and an increase in HDL cholesterol), all of which could reduce CVD risk, it is unlikely that the reduction in CV mortality can be explained by empagliflozin's metabolic effects. More likely, hemodynamic effects, specifically reduced blood pressure and decreased extracellular volume, are responsible for the reduction in CV mortality and heart failure hospitalization. In this Perspective, we will discuss possible mechanisms for these beneficial effects of empagliflozin and their implications for the care of T2DM patients.
C1 [Abdul-Ghani, Muhammad; DeFronzo, Ralph A.] Univ Texas San Antonio, Hlth Sci Ctr, Div Diabet, San Antonio, TX USA.
[Abdul-Ghani, Muhammad] Hamad Gen Hosp, Diabet & Obes Clin Res Ctr, Dept Med, Doha, Qatar.
[Del Prato, Stefano] Univ Pisa, Sch Med, Dept Clin & Expt Med, I-56100 Pisa, Italy.
[Chilton, Robert] Univ Texas San Antonio, Div Cardiol, Hlth Sci Ctr, San Antonio, TX USA.
[Chilton, Robert] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Abdul-Ghani, M; DeFronzo, RA (reprint author), Univ Texas San Antonio, Hlth Sci Ctr, Div Diabet, San Antonio, TX USA.; Abdul-Ghani, M (reprint author), Hamad Gen Hosp, Diabet & Obes Clin Res Ctr, Dept Med, Doha, Qatar.
EM abdulghani@uthscsa.edu; albarado@uthscsa.edu
RI Del Prato, Stefano/K-3405-2016
OI Del Prato, Stefano/0000-0002-5388-0270
FU Qatar Foundation [NPRP 4-248-3-076]; National Institutes of Health [R01
DK097554-01, 5R01DK24093]; South Texas Veterans Health Care System
FX M.A.-G. receives grant support from the Qatar Foundation (NPRP
4-248-3-076). M.A.-G. (R01 DK097554-01) and R.A.D. (5R01DK24093) have
received grant support from the National Institutes of Health. The
salary of R.A.D. is partially supported by the South Texas Veterans
Health Care System.
NR 56
TC 26
Z9 26
U1 4
U2 7
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD MAY
PY 2016
VL 39
IS 5
BP 717
EP 725
DI 10.2337/dc16-0041
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DK6MU
UT WOS:000375039000012
PM 27208375
ER
PT J
AU Azad, N
Bahn, GD
Emanuele, NV
Agrawal, L
Ge, L
Reda, D
Klein, R
Reaven, PD
Hayward, R
AF Azad, Nasrin
Bahn, Gideon D.
Emanuele, Nicholas V.
Agrawal, Lily
Ge, Ling
Reda, Dominic
Klein, Ronald
Reaven, Peter D.
Hayward, Rodney
CA VADT Study Grp
TI Association of Blood Glucose Control and Lipids With Diabetic
Retinopathy in the Veterans Affairs Diabetes Trial (VADT)
SO DIABETES CARE
LA English
DT Article
ID RISK-FACTORS; SERUM-LIPIDS; HARD EXUDATE; COMPLICATIONS; PROGRESSION;
MELLITUS; PREVALENCE; DIAGNOSIS; THERAPY
AB OBJECTIVE
This study examined whether lipids modify the relationship between intensive glucose control (INT) and diabetic retinopathy (DR).
RESEARCH DESIGN AND METHODS
The incidence and progression of DR were assessed in 858 of 1,791 participants with 7-field stereoscopic fundus photographs at baseline and 5 years later.
RESULTS
Odds of DR progression were lower by similar to 40% in those with baseline total cholesterol (TC) >= 200 mg/dL (P = 0.007), LDL-C >= 120 mg/dL (P < 0.02), or HDL-C >= 40 mg/dL (P < 0.007) in the INT arm versus standard glycemic treatment. Odds of DR progression were reduced by similar to 40% in those who had TC <= 140 mg/dL (P <= 0.024), triglycerides (TG) <= 120 mg/dL (P = 0.004), or HDL-C >= 45 mg/dL (P = 0.01) at the fifth year. Odds of DR progression were lower by similar to 40-50% with reductions of TC by >= 40 mg/dL (P < 0.0001), of LDL-C of >= 40 mg/dL (P < 0.004), and of TG by >= 60 mg/dL (P = 0.004) at the fifth year. Odds of DR progression increased by 80% with increases in TC of >= 20 mg/dL (P < 0.0001) and by 180% with increases in LDL-C by >= 60 mg/dL (P < 0.004). After adjusting for covariants, those with higher TC at baseline and lower TC during and at the fifth year and higher HDL-C throughout study had significantly decreased odds of DR progression in INT.
CONCLUSIONS
INT was associated with decreased odds of progression but not with onset of retinopathy in those with worse lipid levels at baseline and more improved lipid levels during the study. Higher HDL-C was consistently associated with better response to INT throughout the study.
C1 [Azad, Nasrin; Emanuele, Nicholas V.; Agrawal, Lily] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Endocrinol Sect, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA.
[Bahn, Gideon D.; Ge, Ling; Reda, Dominic] Coordinating Ctr, Cooperat Studies Program, Hines, IL USA.
[Klein, Ronald] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
[Reaven, Peter D.] Carl T Hayden VA Med Ctr, Endocrinol Sect, Phoenix, AZ USA.
[Hayward, Rodney] Ann Arbor VA Healthcare Syst, Ann Arbor, MI USA.
RP Azad, N (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Endocrinol Sect, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA.
EM nasrin.azad@va.gov
FU Cooperative Studies Program of the Department of Veterans Affairs Office
of Research and Development; National Eye Institute; Sanofi;
GlaxoSmithKline; Novo Nordisk; Roche; Kos Pharmaceuticals; Merck; Amylin
FX The study was sponsored by the Cooperative Studies Program of the
Department of Veterans Affairs Office of Research and Development. There
was also generous support from the National Eye Institute.; Medications
and financial support were provided by Sanofi, GlaxoSmithKline, Novo
Nordisk, Roche, Kos Pharmaceuticals, Merck, and Amylin. These companies
had no role in the design of the study, in the accrual or analysis of
the data, or in the preparation or approval of the manuscript.
NR 37
TC 0
Z9 0
U1 2
U2 2
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD MAY
PY 2016
VL 39
IS 5
BP 816
EP 822
DI 10.2337/dc15-1897
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DK6MU
UT WOS:000375039000026
PM 27006510
ER
PT J
AU Baksh, SN
Gellad, WF
Alexander, GC
AF Baksh, Sheriza N.
Gellad, Walid F.
Alexander, G. Caleb
TI Maximizing the Post-Approval Safety of Flibanserin: A Role for
Regulators, Clinicians, and Patients
SO DRUG SAFETY
LA English
DT Article
ID SEXUAL DESIRE DISORDER; PREMENOPAUSAL WOMEN EFFICACY
AB In August 2015, the US Food and Drug Administration (FDA) made the controversial decision to approve flibanserin (Addyi((R))) for women experiencing hypoactive sexual desire disorder. A number of factors contributed to disagreements regarding the FDA's decision, including the product's two prior failed FDA reviews, the unmet need of women with this disorder, extensive advocacy and politicization surrounding the product's relevance to women and sexual health, the potential for widespread off-label use, and the product's tenuous risk/benefit profile. Despite that, attention now shifts to maximizing the safe use of the product, including the optimal means to avoid numerous drug-drug interactions as well as the concomitant use of alcohol, both of which potentiate the risks of dizziness, hypotension, and syncope. Although the FDA has implemented a comprehensive Risk Evaluation and Mitigation Strategies program to maximize the product's safe use, patients, clinicians, and regulators must exhibit heightened vigilance early in the product's post-market life.
C1 [Baksh, Sheriza N.; Alexander, G. Caleb] Johns Hopkins Univ, Ctr Drug Safety & Effectiveness, Baltimore, MD 21205 USA.
[Baksh, Sheriza N.; Alexander, G. Caleb] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St W6035, Baltimore, MD 21205 USA.
[Gellad, Walid F.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA 15261 USA.
[Gellad, Walid F.] Univ Pittsburgh, Ctr Pharmaceut Policy & Prescribing, Pittsburgh, PA 15261 USA.
[Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA 15261 USA.
[Alexander, G. Caleb] Johns Hopkins Med, Dept Med, Div Gen Internal Med, Baltimore, MD 21205 USA.
RP Alexander, GC (reprint author), Johns Hopkins Univ, Ctr Drug Safety & Effectiveness, Baltimore, MD 21205 USA.; Alexander, GC (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St W6035, Baltimore, MD 21205 USA.; Alexander, GC (reprint author), Johns Hopkins Med, Dept Med, Div Gen Internal Med, Baltimore, MD 21205 USA.
EM galexan9@jhmi.edu
NR 21
TC 1
Z9 2
U1 0
U2 1
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0114-5916
EI 1179-1942
J9 DRUG SAFETY
JI Drug Saf.
PD MAY
PY 2016
VL 39
IS 5
BP 375
EP 380
DI 10.1007/s40264-015-0389-2
PG 6
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
Toxicology
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
Toxicology
GA DJ6NM
UT WOS:000374330200002
PM 26798050
ER
PT J
AU Braley, TJ
Boudreau, EA
AF Braley, Tiffany J.
Boudreau, Eilis Ann
TI Sleep Disorders in Multiple Sclerosis
SO CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS
LA English
DT Review
DE Obstructive sleep apnea; Restless leg syndrome; Insomnia; Fatigue;
Multiple sclerosis
ID RESTLESS LEGS SYNDROME; QUALITY-OF-LIFE; COGNITIVE-BEHAVIORAL THERAPY;
RANDOMIZED CONTROLLED-TRIAL; PERIODIC LIMB MOVEMENTS; FATIGUE IMPACT
SCALE; HEART HEALTH; CLINICAL-PRACTICE; RISK-FACTOR; APNEA
AB Recent studies suggest that individuals with multiple sclerosis (MS) are at increased risk for sleep disturbances and that sleep disturbances contribute to fatigue and other chronic symptoms in MS. Although fatigue occurs commonly in people with MS, this symptom is often attributed to MS-specific pathology. Consequently, sleep disorders are often unrecognized and untreated in this population. Timely diagnosis and treatment of sleep problems in MS offer a new opportunity to ameliorate some of the daytime fatigue experienced by patients with MS. To increase this opportunity, the practitioner should be comfortable performing basic screening for common sleep complaints among patients with MS. The objectives of this review are to summarize the latest relevant data on sleep disorders in MS and offer a helpful approach to the identification and workup of the most common sleep problems in this population. Unexplored research avenues and opportunities to address important questions at the interface of sleep and MS are also discussed.
C1 [Braley, Tiffany J.] Univ Michigan, Dept Neurol, Multiple Sclerosis Ctr, 1500 E Med Ctr Dr,C728 Med Inn Bldg, Ann Arbor, MI USA.
[Braley, Tiffany J.] Univ Michigan, Dept Neurol, Sleep Disorders Ctr, 1500 E Med Ctr Dr,C728 Med Inn Bldg, Ann Arbor, MI USA.
[Boudreau, Eilis Ann] Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd L226, Portland, OR 97239 USA.
[Boudreau, Eilis Ann] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, 3181 SW Sam Jackson Pk Rd L226, Portland, OR 97239 USA.
[Boudreau, Eilis Ann] Portland VA Med Ctr, P3-ECOE,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
RP Boudreau, EA (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd L226, Portland, OR 97239 USA.; Boudreau, EA (reprint author), Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, 3181 SW Sam Jackson Pk Rd L226, Portland, OR 97239 USA.; Boudreau, EA (reprint author), Portland VA Med Ctr, P3-ECOE,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM tbraley@med.umich.edu; boudreau@ohsu.edu
FU National Multiple Sclerosis Society; American Sleep Medicine Foundation;
Michigan Translation and Commercialization (MTRAC) for Life Sciences
Program; Biogen; Genzyme-Sanofi; Genentech-Roche
FX Tiffany J. Braley receives grant support from the National Multiple
Sclerosis Society, the American Sleep Medicine Foundation, and the
Michigan Translation and Commercialization (MTRAC) for Life Sciences
Program to conduct her research. She is principal investigator on a
clinical trial that receives material support, but no financial support,
from Biogen. She is site principal investigator for several
industry-funded studies of MS immunotherapeutics at the University of
Michigan (sponsors include Genzyme-Sanofi and Genentech-Roche) but
receives no direct compensation for any of this work.
NR 79
TC 4
Z9 4
U1 4
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1528-4042
EI 1534-6293
J9 CURR NEUROL NEUROSCI
JI Curr. Neurol. Neurosci. Rep.
PD MAY
PY 2016
VL 16
IS 5
AR 50
DI 10.1007/s11910-016-0649-2
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DJ5NO
UT WOS:000374255800009
PM 27068547
ER
PT J
AU Karimkhani, C
Wanga, V
Coffeng, LE
Naghavi, P
Dellavalle, RP
Naghavi, M
AF Karimkhani, Chante
Wanga, Valentine
Coffeng, Luc E.
Naghavi, Paria
Dellavalle, Robert P.
Naghavi, Mohsen
TI Global burden of cutaneous leishmaniasis: a cross-sectional analysis
from the Global Burden of Disease Study 2013
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID LIFE YEARS DALYS; INFECTION; INJURIES; ISFAHAN; IRAN
AB Background High-quality epidemiological studies evaluating the burden of cutaneous leishmaniasis worldwide are lacking. We compared the burden of cutaneous leishmaniasis in each country to the overall global burden and assessed the equality of cutaneous leishmaniasis burden across different countries and regions.
Methods Data were extracted from scientific literature, hospital sources, country reports, and WHO sources on the prevalence of sequalae of both acute and chronic cutaneous leishmaniasis. Prevalence data were combined with a disability weight to yield years lived with disability. Disability-adjusted life-years (DALYs) are a sum of the years lived with disability and years of life lost (or mortality, assumed to be zero). We compared DALYs due to cutaneous leishmaniasis for 152 countries using standard Z score analysis with Bonferroni correction (p<0.003) and generation of Lorenz curves with a Gini coefficient.
Findings In 2013, the global mean age-standardised DALYs for cutaneous leishmaniasis was 0.58 per 100 000 people. Nine countries had significantly greater DALYs from cutaneous leishmaniasis than the mean: Afghanistan (87.0), Sudan (20.2), Syria (9.2), Yemen (6.2), Iraq (6.0), Burkina Faso (4.8), Bolivia (4.6), Haiti (4.1), and Peru (4.0). The Gini coefficient was 0.89. Andean Latin America, North Africa and Middle East, western sub-Saharan Africa, and south Asia had the highest DALYs from cutaneous leishmaniasis. Among males, Palestine had the highest incidence rates (616.2 cases per 100 000 people) followed by Afghanistan (566.4), Syria (357.1), and Nicaragua (354.8). Among females, Afghanistan had the highest incidence rates (623.9) followed by Syria (406.3), Palestine (222.1), and Nicaragua (180.8). Similar proportions of males and females had cutaneous leishmaniasis in most countries with a high incidence.
Interpretation The burden from cutaneous leishmaniasis mainly falls on countries in Africa and the Middle East. Global and national data on the burden of cutaneous leishmaniasis disease are pivotal to promote field studies and initiate behavioural change.
C1 [Karimkhani, Chante] Case Western Reserve Univ, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA.
[Wanga, Valentine; Coffeng, Luc E.; Naghavi, Paria; Naghavi, Mohsen] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA.
[Coffeng, Luc E.] Erasmus MC Univ Med Ctr Rotterdam, Dept Publ Hlth, Ca Rotterdam, Netherlands.
[Dellavalle, Robert P.] Univ Colorado, Dept Dermatol, Anschutz Med Campus, Aurora, CO USA.
[Dellavalle, Robert P.] Eastern Colorado Hlth Care Syst, Dermatol Serv, US Dept Vet Affairs, Denver, CO USA.
[Dellavalle, Robert P.] Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA.
RP Karimkhani, C (reprint author), Univ Hosp Case Western Med Ctr, Dept Med, 408 W St Clair Ave,Unit 317, Cleveland, OH 44113 USA.
EM ck2525@caa.columbia.edu
OI Naghavi, Paria/0000-0002-8908-7952
FU Bill & Melinda Gates Foundation
FX Bill & Melinda Gates Foundation.
NR 31
TC 7
Z9 8
U1 5
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD MAY
PY 2016
VL 16
IS 5
BP 584
EP 591
DI 10.1016/S1473-3099(16)00003-7
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA DJ5TL
UT WOS:000374272900029
PM 26879176
ER
PT J
AU Lo-Ciganic, WH
Gellad, WF
Gordon, AJ
Cochran, G
Zemaitis, MA
Cathers, T
Kelley, D
Donohue, JM
AF Lo-Ciganic, Wei-Hsuan
Gellad, Walid F.
Gordon, Adam J.
Cochran, Gerald
Zemaitis, Michael A.
Cathers, Terri
Kelley, David
Donohue, Julie M.
TI Association between trajectories of buprenorphine treatment and
emergency department and in-patient utilization
SO ADDICTION
LA English
DT Article
DE Buprenorphine; group-based trajectory models; Medicaid; opioid agonist
therapy; Opioid use disorders; trajectories; treatment duration;
treatment patterns
ID OFFICE-BASED TREATMENT; PRESCRIPTION OPIOID DEPENDENCE;
HEALTH-CARE-SYSTEM; MEDICATION-ADHERENCE; MAINTENANCE THERAPY; AGONIST
TREATMENT; USE DISORDER; HOSPITALIZATION; METHADONE; NONADHERENCE
AB Background and aimsUncertainty about optimal treatment duration for buprenorphine opioid agonist therapy may lead to substantial variation in provider and payer decision-making regarding treatment course. We aimed to identify distinct trajectories of buprenorphine use and examine outcomes associated with these trajectories to guide health system interventions regarding treatment length.
DesignRetrospective cohort study.
SettingUS Pennsylvania Medicaid.
PatientsA total of 10945 enrollees aged 18-64years initiating buprenorphine treatment between 2007 and 2012.
MeasurementsGroup-based trajectory models were used to identify trajectories based on monthly proportion of days covered with buprenorphine in the 12months post-treatment initiation. We used separate multivariable Cox proportional hazard models to examine associations between trajectories and time to first all-cause hospitalization and emergency department (ED) visit within 12months after the first-year treatment.
FindingsSix trajectories [Bayesian information criterion (BIC)=-86246.70] were identified: 24.9% discontinued buprenorphine <3months, 18.7% discontinued between 3 and 5months, 12.4% discontinued between 5 and 8months, 13.3% discontinued >8months, 9.5% refilled intermittently and 21.2% refilled persistently for 12months. Persistent refill trajectories were associated with an 18% lower risk of all-cause hospitalizations [hazard ratio (HR)=0.82, 95% confidence interval (CI)=0.70-0.95] and 14% lower risk of ED visits (HR=0.86, 95% CI=0.78-0.95) in the subsequent year, compared with those discontinuing between 3 and 5months.
ConclusionsSix distinct buprenorphine treatment trajectories were identified in this population-based low-income Medicaid cohort in Pennsylvania, USA. There appears to be an association between persistent use of buprenorphine for 12months and lower risk of all-cause hospitalizations/emergency department visits.
C1 [Lo-Ciganic, Wei-Hsuan] Univ Arizona, Coll Pharm, Dept Pharm Practice & Sci, Drachman Hall,Room 307E,1295 N Martin Ave, Tucson, AZ 85719 USA.
[Lo-Ciganic, Wei-Hsuan; Gellad, Walid F.; Gordon, Adam J.; Cochran, Gerald; Zemaitis, Michael A.; Donohue, Julie M.] Univ Pittsburgh, Ctr Pharmaceut Policy & Prescribing, Hlth Policy Inst, Pittsburgh, PA USA.
[Gellad, Walid F.; Gordon, Adam J.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA.
[Gellad, Walid F.; Gordon, Adam J.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Cochran, Gerald] Univ Pittsburgh, Sch Social Work, Pittsburgh, PA 15260 USA.
[Zemaitis, Michael A.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA.
[Cathers, Terri; Kelley, David] Penn Dept Human Serv, Harrisburg, PA USA.
[Donohue, Julie M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA USA.
RP Lo-Ciganic, WH (reprint author), Univ Arizona, Coll Pharm, Dept Pharm Practice & Sci, Drachman Hall,Room 307E,1295 N Martin Ave, Tucson, AZ 85719 USA.
EM lociganic@pharmacy.arizona.edu
OI Donohue, Julie/0000-0003-2418-6017
FU University of Pittsburgh Health Policy Institute, Center for
Pharmaceutical Policy and Prescribing; Pennsylvania Department of Human
Services; University of Pittsburgh; VA HSR&D Career Development Award
FX We thank Dr. Bobby Jones for his assistance on performing group-based
trajectory models. W.-H.L.-C. was funded by a post-doctoral fellowship
through the University of Pittsburgh Health Policy Institute, Center for
Pharmaceutical Policy and Prescribing. This work was supported in part
by an intergovernmental agreement between the Pennsylvania Department of
Human Services and the University of Pittsburgh. W.F.G. was supported by
a VA HSR&D Career Development Award.
NR 58
TC 2
Z9 2
U1 4
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0965-2140
EI 1360-0443
J9 ADDICTION
JI Addiction
PD MAY
PY 2016
VL 111
IS 5
BP 892
EP 902
DI 10.1111/add.13270
PG 11
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA DJ3HO
UT WOS:000374095600019
PM 26662858
ER
PT J
AU Sidani, JE
Shensa, A
Shiffman, S
Switzer, GE
Primack, BA
AF Sidani, J. E.
Shensa, A.
Shiffman, S.
Switzer, G. E.
Primack, B. A.
TI Public health implications of waterpipe tobacco use in the United States
warrant initial steps towards assessing dependence
SO ADDICTION
LA English
DT Letter
ID INTERMITTENT SMOKERS; PUFF TOPOGRAPHY; YOUNG-ADULTS; SMOKING; EXPOSURE
C1 [Sidani, J. E.; Shensa, A.; Primack, B. A.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med,UPMC Montefiore Hosp, Pittsburgh, PA 15213 USA.
[Sidani, J. E.; Shensa, A.; Primack, B. A.] Univ Pittsburgh, Ctr Res Media Technol & Hlth, Pittsburgh, PA USA.
[Shiffman, S.] Pinney Associates, Pittsburgh, PA USA.
[Switzer, G. E.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Switzer, G. E.] Univ Pittsburgh, Dept Med Psychiat Clin & Translat Sci, Pittsburgh, PA USA.
[Primack, B. A.] Univ Pittsburgh, Sch Med, Dept Pediat, Div Adolescent Med, Pittsburgh, PA 15261 USA.
RP Sidani, JE (reprint author), Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med,UPMC Montefiore Hosp, Pittsburgh, PA 15213 USA.
FU NCI NIH HHS [R01 CA140150, R21 CA185767]
NR 16
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0965-2140
EI 1360-0443
J9 ADDICTION
JI Addiction
PD MAY
PY 2016
VL 111
IS 5
BP 937
EP 938
DI 10.1111/add.13316
PG 2
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA DJ3HO
UT WOS:000374095600024
PM 26987303
ER
PT J
AU Ren, XY
Tu, V
Bischoff, D
Weisgerber, DW
Lewis, MS
Yamaguchi, DT
Miller, TA
Harley, BAC
Lee, JC
AF Ren, Xiaoyan
Tu, Victor
Bischoff, David
Weisgerber, Daniel W.
Lewis, Michael S.
Yamaguchi, Dean T.
Miller, Timothy A.
Harley, Brendan A. C.
Lee, Justine C.
TI Nanoparticulate mineralized collagen scaffolds induce in vivo bone
regeneration independent of progenitor cell loading or exogenous growth
factor stimulation
SO BIOMATERIALS
LA English
DT Article
DE Bone regeneration; Biomimetic material; Nanoparticulate mineralization
ID MESENCHYMAL STEM-CELLS; OSTEOGENIC DIFFERENTIATION; MORPHOGENETIC
PROTEINS; SIGNALING PATHWAYS; CROSS-LINKING; DEFECT MODEL; GAG SCAFFOLD;
FAMILY; RHBMP-2; FUSION
AB Current strategies for skeletal regeneration often require co-delivery of scaffold technologies, growth factors, and cellular material. However, isolation and expansion of stem cells can be time consuming, costly, and requires an additional procedure for harvest. Further, the introduction of supraphysiologic doses of growth factors may result in untoward clinical side effects, warranting pursuit of alternative methods for stimulating osteogenesis. In this work, we describe a nanoparticulate mineralized collagen glycosaminoglycan scaffold that induces healing of critical-sized rabbit cranial defects without addition of expanded stem cells or exogenous growth factors. We demonstrate that the mechanism of osteogenic induction corresponds to an increase in canonical BMP receptor signalling secondary to autogenous production of BMP-2 and -9 early and BMP-4 later during differentiation. Thus, nanoparticulate mineralized collagen glycosaminoglycan scaffolds may provide a novel growth factor-free and ex vivo progenitor cell culture-free implantable method for bone regeneration. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Ren, Xiaoyan; Tu, Victor; Miller, Timothy A.; Lee, Justine C.] Univ Calif Los Angeles, David Geffen Sch Med, Div Plast & Reconstruct Surg, 200 UCLA Med Plaza,Suite 465, Los Angeles, CA 90095 USA.
[Ren, Xiaoyan; Tu, Victor; Miller, Timothy A.; Lee, Justine C.] Greater Los Angeles VA Healthcare Syst, Div Plast & Reconstruct Surg, Los Angeles, CA 90073 USA.
[Ren, Xiaoyan; Tu, Victor; Bischoff, David; Yamaguchi, Dean T.; Lee, Justine C.] Greater Los Angeles VA Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA.
[Weisgerber, Daniel W.; Harley, Brendan A. C.] Univ Illinois, Inst Genom Biol, Dept Chem & Biomol Engn, Urbana, IL 61801 USA.
[Lewis, Michael S.] Greater Los Angeles VA Healthcare Syst, Dept Pathol, Los Angeles, CA 90073 USA.
RP Lee, JC (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Plast & Reconstruct Surg, 200 UCLA Med Plaza,Suite 465, Los Angeles, CA 90095 USA.
EM justine@ucla.edu
OI Harley, Brendan/0000-0001-5458-154X
FU US Department of Veterans Affairs [IK2 BX002442-01A2,
1I01BX001367-01A2]; Aramont Foundation; Jean Perkins Foundation;
National Institute of Arthritis and Musculoskeletal and Skin Diseases of
the National Institutes of Health [R21 AR063331]; AO Foundation,
Switzerland [S-14-54H]; National Science Foundation (NSF) IGERT:
Training the Next Generation of Researchers in Cellular & Molecular
Mechanics and BioNanotechnology [0965918]
FX This work was supported by the US Department of Veterans Affairs under
award numbers IK2 BX002442-01A2 (JCL) and 1I01BX001367-01A2 (TAM), the
Aramont Foundation (TAM), and the Jean Perkins Foundation (JCL).
Research reported in this publication was also supported by the National
Institute of Arthritis and Musculoskeletal and Skin Diseases of the
National Institutes of Health under award number R21 AR063331 (BACH).
The content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institutes of
Health. Additional support was provided by project number S-14-54H by AO
Foundation, Switzerland (BACH). DWW was funded at UIUC from National
Science Foundation (NSF) Grant 0965918 IGERT: Training the Next
Generation of Researchers in Cellular & Molecular Mechanics and
BioNanotechnology.
NR 48
TC 3
Z9 3
U1 7
U2 39
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD MAY
PY 2016
VL 89
BP 67
EP 78
DI 10.1016/j.biomaterials.2016.02.020
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA DJ2YY
UT WOS:000374072500006
PM 26950166
ER
PT J
AU Rugge, M
Genta, RM
Graham, DY
Di Mario, F
Coelho, LGV
Kim, N
Malfertheiner, P
Sugano, K
Tsukanov, V
Correa, P
AF Rugge, Massimo
Genta, Robert M.
Graham, David Y.
Di Mario, Francesco
Coelho, Luiz Gonzaga Vaz
Kim, Nayoung
Malfertheiner, Peter
Sugano, Kentaro
Tsukanov, Vladislav
Correa, Pelayo
TI Chronicles of a cancer foretold: 35 years of gastric cancer risk
assessment
SO GUT
LA English
DT Article
ID HELICOBACTER-PYLORI INFECTION; CHRONIC ATROPHIC GASTRITIS; INTESTINAL
METAPLASIA; EPITHELIAL-DYSPLASIA; PRECANCEROUS LESIONS; MAGNIFYING
ENDOSCOPY; MALT LYMPHOMA; CLASSIFICATION; MANAGEMENT; OLGA
C1 [Rugge, Massimo] Univ Padua, Dept Med DIMED, Pathol & Cytopathol Unit, Padua, Italy.
[Rugge, Massimo] Tumor Registry Veneto Reg, Padua, Italy.
[Genta, Robert M.] Miraca Life Sci Res Inst, Irving, TX USA.
[Genta, Robert M.] Univ Texas Southwestern Med Sch, Dallas, TX USA.
[Graham, David Y.] Michael E De Bakey Vet Affairs Med Ctr, Dept Med, Houston, TX USA.
[Graham, David Y.] Baylor Coll Med, Houston, TX 77030 USA.
[Di Mario, Francesco] Univ Parma, Dept Clin & Expt Med, I-43100 Parma, Italy.
[Coelho, Luiz Gonzaga Vaz] Univ Fed Minas Gerais, Inst Alfa Gastroenterol, Belo Horizonte, MG, Brazil.
[Kim, Nayoung] Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Songnam, Gyeonggi Do, South Korea.
[Malfertheiner, Peter] Univ Med Ctr Magdeburg, Otto Von Guericke Univ, Dept Gastroenterol Hepatol & Infect Dis, Magdeburg, Germany.
[Sugano, Kentaro] Jichi Med Univ, Dept Med, Shimotsuke, Tochigi, Japan.
[Tsukanov, Vladislav] Russian Acad Med Sci, State Sci Med Res Inst, Northern Problems Siberian Div, Krasnoyarsk, Russia.
[Correa, Pelayo] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, 221 Kirkland Hall, Nashville, TN 37235 USA.
RP Rugge, M (reprint author), Univ Padua, Surg Pathol & Cytopathol Unit, Dept Med DIMED, Via A Gabelli 61, I-35121 Padua, Italy.
EM massimo.rugge@unipd.it
RI Rugge, Massimo/K-7525-2016; Tsukanov, Vladislav/E-6638-2015
FU Italian Association for Cancer Research (AIRC) [6421]; Healthy Stomach
Initiative (HSI)
FX This work was partly supported by a grant from the Italian Association
for Cancer Research (AIRC Regional grant 2008 N. 6421). This study was
conducted under the cooperative auspices of the Healthy Stomach
Initiative (HSI).
NR 50
TC 3
Z9 3
U1 1
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD MAY
PY 2016
VL 65
IS 5
BP 721
EP +
DI 10.1136/gutjnl-2015-310846
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DJ3QA
UT WOS:000374119400001
PM 26927528
ER
PT J
AU Nasti, TH
Cochran, JB
Tsuruta, Y
Yusuf, N
McKay, KM
Athar, M
Timares, L
Elmets, CA
AF Nasti, Tahseen H.
Cochran, J. Barry
Tsuruta, Yuko
Yusuf, Nabiha
McKay, Kristopher M.
Athar, Mohammad
Timares, Laura
Elmets, Craig A.
TI A murine model for the development of melanocytic nevi and their
progression to melanoma
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE carcinogenesis; melanocyte; nevi; Ras
ID CELL-CYCLE ARREST; ULTRAVIOLET-RADIATION; CUTANEOUS MELANOMA;
MALIGNANT-MELANOMA; TUMOR PROMOTION; KNOCKOUT MICE; GROWTH-FACTOR; MOUSE
MODEL; IN-VIVO; SKIN
AB Acquired melanocytic nevi are commonly found in sun exposed and unexposed human skin, but the potential for their transformation into invasive melanoma is not clear. Therefore, a mouse model of nevus initiation and progression was developed in C3H/HeN mice using a modified chemical carcinogenesis protocol. Nevi develop due to DNA damage initiated by dimethylbenz(a) anthracene (DMBA) followed by chronic promotion with 12-O-tetradecanoyl-phorbol-13-acetate (TPA). Dysplastic pigmented skin lesions appeared in 7-9wk with 100% penetrance. Nests of melanocytic cells appeared in a subset of skin draining lymph nodes (dLN) by 25wk, but not in age matched controls. Immunohistochemistry, real-time PCR, and flow cytometric analyses confirmed their melanocytic origin. Transformed cells were present in a subset of nevi and dLNs, which exhibited anchorage-independent growth, tumor development, and metastasis in nude mice. Approximately 50% of the cell lines contained H-Ras mutations and lost tumor suppressor p16(Ink4a) expression. While most studies of melanoma focus on tumor progression in transgenic mouse models where the mutations are present from birth, our model permits investigation of acquired mutations at the earliest stages of nevus initiation and promotion of nevus cell transformation. This robust nevus/melanoma model may prove useful for identifying genetic loci associated with nevus formation, novel oncogenic pathways, tumor targets for immune-prevention, screening therapeutics, and elucidating mechanisms of immune surveillance and immune evasion. (c) 2015 The Authors. Molecular Carcinogenesis, published by Wiley Periodicals, Inc.
C1 [Nasti, Tahseen H.; Cochran, J. Barry; Tsuruta, Yuko; Yusuf, Nabiha; McKay, Kristopher M.; Athar, Mohammad; Timares, Laura; Elmets, Craig A.] Univ Alabama Birmingham, Sch Med, Dept Dermatol, Birmingham, AL USA.
[Tsuruta, Yuko; Yusuf, Nabiha; Athar, Mohammad; Timares, Laura; Elmets, Craig A.] Univ Alabama Birmingham, Skin Dis Res Ctr, Sch Med, Birmingham, AL USA.
[Yusuf, Nabiha; Timares, Laura; Elmets, Craig A.] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Timares, L (reprint author), Univ Alabama Birmingham, Dept Dermatol, 1720 2nd Ave S, Birmingham, AL 35294 USA.
FU UAB Skin Diseases Research Center Core [P30 AR05094]; NIH NCI [R01
CA138988]; Heflin Center Genomic Core and Cancer Center Core
[P30CA13148-40]; UAB Comprehensive Flow Cytometry Core of the Rheumatic
Diseases Core Center [P30AR048311, P30AI27667]
FX Grant sponsor: UAB Skin Diseases Research Center Core; Grant number: P30
AR05094; Grant sponsor: NIH NCI; Grant number: R01 CA138988; Grant
sponsor: Heflin Center Genomic Core and Cancer Center Core; Grant
number: P30CA13148-40; Grant sponsor: UAB Comprehensive Flow Cytometry
Core of the Rheumatic Diseases Core Center; Grant numbers: P30AR048311;
P30AI27667
NR 58
TC 2
Z9 2
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0899-1987
EI 1098-2744
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD MAY
PY 2016
VL 55
IS 5
BP 646
EP 658
DI 10.1002/mc.22310
PG 13
WC Biochemistry & Molecular Biology; Oncology
SC Biochemistry & Molecular Biology; Oncology
GA DJ3IA
UT WOS:000374096800020
PM 25788145
ER
PT J
AU Gutzmer, K
Ludwig-Barron, NT
Wyatt, GE
Hamilton, AB
Stockman, JK
AF Gutzmer, Kyle
Ludwig-Barron, Natasha T.
Wyatt, Gail E.
Hamilton, Alison B.
Stockman, Jamila K.
TI "Come on Baby. You Know I Love You": African American Women's
Experiences of Communication with Male Partners and Disclosure in the
Context of Unwanted Sex
SO ARCHIVES OF SEXUAL BEHAVIOR
LA English
DT Article
DE Unwanted sex; Partner communication; Disclosure; African American women
ID INTIMATE PARTNER; HELP-SEEKING; DATING PARTNERS; VIOLENCE; COERCION;
HEALTH; ASSAULT; MEN; VICTIMIZATION; BEHAVIOR
AB We examined African American women's experiences of communication with their male intimate partners a couple of hours before and after an incident of unwanted sex. We also examined women's experiences of disclosure following an incident of unwanted sex. Semi-structured qualitative interviews were conducted with a community-based sample of sexually active African American women (n = 19) reporting at least one incident of sexual coercion (i.e., being pressured into unwanted sex without consent) by an intimate male partner since the age of 18. Our analysis was guided by "the sexual division of power" from Connell's (1987) theory of gender and power. Data were analyzed inductively by examining the interviews for common themes in the following domains: communication before the unwanted sex, communication after the unwanted sex, and disclosure to others. Men pressured partners for unwanted sex through verbal and non-verbal tactics, ranging from pestering and blunt requests for sex to verbal bullying and violence. Many women responded by clearly saying no. However, many women also described eventually ceasing to resist their partners and engaging in unwanted sex. After the unwanted sex, men actively and passively avoided discussing the incident. Although many women discussed the unwanted sex with family and friends, less women disclosed to trained professionals. In some cases, women did not discuss the incident with anyone at all. These findings indicate that, when addressing sexual violence against women, there is a need to target men as well as the norms of masculinity that underpin physical and sexual violence against women.
C1 [Gutzmer, Kyle] Univ Calif San Diego, Dept Family Med & Publ Hlth, 9500 Gilman Dr,MC 0507, La Jolla, CA 92093 USA.
[Gutzmer, Kyle] San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USA.
[Ludwig-Barron, Natasha T.; Stockman, Jamila K.] Univ Calif San Diego, Dept Med, Div Global Publ Hlth, 9500 Gilman Dr,MC 0507, La Jolla, CA 92093 USA.
[Wyatt, Gail E.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Hamilton, Alison B.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Stockman, JK (reprint author), Univ Calif San Diego, Dept Med, Div Global Publ Hlth, 9500 Gilman Dr,MC 0507, La Jolla, CA 92093 USA.
EM jstockman@ucsd.edu
FU National Institute of Mental Health [R25MH080665, R25MH080664]; National
Institute on Drug Abuse [K01DA031593]; National Institute on Minority
Health and Health Disparities [L60MD003701]; Eunice Kennedy Shriver
National Institute of Child Health and Human Development [R01HD077891]
FX We gratefully acknowledge the contributions of study participants and
study staff to this research. This study was supported by the National
Institute of Mental Health (Grant #R25MH080665 and Grant #R25MH080664),
the National Institute on Drug Abuse (Grant #K01DA031593), the National
Institute on Minority Health and Health Disparities (Grant#L60MD003701),
and the Eunice Kennedy Shriver National Institute of Child Health and
Human Development (Grant #R01HD077891). The views expressed are those of
the authors and not necessarily those of the National Institutes of
Health.
NR 42
TC 0
Z9 0
U1 5
U2 11
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0004-0002
EI 1573-2800
J9 ARCH SEX BEHAV
JI Arch. Sex. Behav.
PD MAY
PY 2016
VL 45
IS 4
BP 807
EP 819
DI 10.1007/s10508-015-0688-9
PG 13
WC Psychology, Clinical; Social Sciences, Interdisciplinary
SC Psychology; Social Sciences - Other Topics
GA DI6WH
UT WOS:000373640400011
PM 26892099
ER
PT J
AU Guerrero-Berroa, E
Ravona-Springer, R
Heymann, A
Schmeidler, J
Hoffman, H
Preiss, R
Koifmann, K
Greenbaum, L
Levy, A
Silverman, JM
Leroith, D
Sano, M
Schnaider-Beeri, M
AF Guerrero-Berroa, Elizabeth
Ravona-Springer, Ramit
Heymann, Anthony
Schmeidler, James
Hoffman, Hadas
Preiss, Rachel
Koifmann, Keren
Greenbaum, Lior
Levy, Andrew
Silverman, Jeremy M.
Leroith, Derek
Sano, Mary
Schnaider-Beeri, Michal
TI Ethnicity/culture modulates the relationships of the haptoglobin (Hp)
1-1 phenotype with cognitive function in older individuals with type 2
diabetes
SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE cognitive function; cognitive domains; diabetes; haptoglobin;
ethnicity/culture; older adults
ID SMALL VESSEL DISEASE; NEUROPSYCHOLOGICAL BATTERY; ALZHEIMERS-DISEASE;
CARDIOVASCULAR-DISEASE; DEMENTIA; RISK; SUSCEPTIBILITY; CERAD;
POLYMORPHISM; EDUCATION
AB Objective: The haptoglobin (Hp) genotype has been associated with cognitive function in type 2 diabetes. Because ethnicity/culture has been associated with both cognitive function and Hp genotype frequencies, we examined whether it modulates the association of Hp with cognitive function.
Methods: This cross-sectional study evaluated 787 cognitively normal older individuals (> 65 years of age) with type 2 diabetes participating in the Israel Diabetes and Cognitive Decline study. Interactions in two-way analyses of covariance compared Group (Non-Ashkenazi versus Ashkenazi Jews) on the associations of Hp phenotype (Hp 1-1 versus non-Hp 1-1) with five cognitive outcome measures. The primary control variables were age, gender, and education.
Results: Compared with Ashkenazi Jews, non-Ashkenazi Jews with the Hp 1-1 phenotype had significantly poorer cognitive function than non-Hp 1-1 in the domains of Attention/Working Memory (p= 0.035) and Executive Function (p= 0.023), but not in Language/Semantic Categorization (p= 0.432), Episodic Memory (p= 0.268), or Overall Cognition (p= 0.082). After controlling for additional covariates (type 2 diabetes-related characteristics, cardiovascular risk factors, Mini-mental State Examination, and extent of depressive symptoms), Attention/Working Memory (p= 0.038) and Executive Function (p= 0.013) remained significant.
Conclusions: Older individuals from specific ethnic/cultural backgrounds with the Hp 1-1 phenotype may benefit more from treatment targeted at decreasing or halting the detrimental effects of Hp 1-1 on the brain. Future studies should examine differential associations of Hp 1-1 and cognitive impairment, especially for groups with high prevalence of both, such as African-Americans and Hispanics. Copyright (C) 2015 John Wiley & Sons, Ltd.
C1 [Guerrero-Berroa, Elizabeth; Schmeidler, James; Silverman, Jeremy M.; Sano, Mary; Schnaider-Beeri, Michal] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.
[Guerrero-Berroa, Elizabeth; Silverman, Jeremy M.; Sano, Mary] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA.
[Ravona-Springer, Ramit; Koifmann, Keren; Greenbaum, Lior; Schnaider-Beeri, Michal] Chaim Sheba Med Ctr, Joseph Sagol Neurosci Ctr, Ramat Gan, Israel.
[Ravona-Springer, Ramit; Heymann, Anthony] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel.
[Heymann, Anthony; Hoffman, Hadas; Preiss, Rachel] Maccabi Healthcare Serv, Tel Aviv, Israel.
[Levy, Andrew] Technion Israel Inst Technol, Technion Fac Med, Haifa, Israel.
[Leroith, Derek] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA.
RP Guerrero-Berroa, E (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.; Guerrero-Berroa, E (reprint author), James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA.
EM elizabeth.guerrero-berroa@mssm.edu
FU NIA [R01 AG034087, P50 AG05138]; Helen Bader Foundation; Leroy Schecter
Foundation; Irma T. Hirschl Scholar award; Alzheimer's Association
[MNIRGD-14-321113]
FX This study was supported by NIA grants R01 AG034087 to Dr. Beeri and P50
AG05138 to Dr. Sano; the Helen Bader Foundation, the Leroy Schecter
Foundation, and the Irma T. Hirschl Scholar award to Dr. Beeri; and the
Alzheimer's Association grant MNIRGD-14-321113 to Dr. Guerrero-Berroa.
NR 45
TC 0
Z9 0
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-6230
EI 1099-1166
J9 INT J GERIATR PSYCH
JI Int. J. Geriatr. Psychiatr.
PD MAY
PY 2016
VL 31
IS 5
BP 494
EP 501
DI 10.1002/gps.4354
PG 8
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA DI8RA
UT WOS:000373767400006
PM 26388309
ER
PT J
AU Barnett, MD
Williams, BR
Tucker, RO
AF Barnett, Michael D.
Williams, Beverly R.
Tucker, Rodney O.
TI Sudden Advanced Illness: An Emerging Concept Among Palliative Care and
Surgical Critical Care Physicians
SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE
LA English
DT Article
DE critical care; surgery; palliative care; prognostication; decision
making; caregiver issues
ID OF-LIFE CARE; INTENSIVE-CARE; UNIT; END; TRAUMA; SERVICES; ICU; PROJECT;
MODELS
AB Background: End-of-life discussions in critically-ill patients with acute surgical conditions may be rushed and occur earlier during hospitalization. This study explores the concept of sudden advanced illness (SAI) and its relevance to patients requiring Palliative and Surgical Critical Care.
Methods: Semi-structured interviews were completed with 16 physicians, querying each about (1) definitional components, (2) illustrative cases, and (3) comfort with SAI. Analysis was done by grounded theory.
Results: SAI was characterized as unforeseen, emerging abruptly and producing devastating injury, often in healthy, younger patients. There is (1) prognostic uncertainty, (2) loss of capacity, and (3) unprepared surrogate decision-making. Cases are emotionally-charged and often personal.
Conclusion: The emerging concept of SAI is important for understanding how Palliative Care can enhance care for this subset of patients.
C1 [Barnett, Michael D.; Williams, Beverly R.; Tucker, Rodney O.] Univ Alabama Birmingham, Ctr Palliat & Support Care, 1720 2nd Ave S,CH19 219, Birmingham, AL 35294 USA.
[Barnett, Michael D.; Williams, Beverly R.; Tucker, Rodney O.] Univ Alabama Birmingham, Div Geriatr Gerontol & Palliat Care, Birmingham, AL USA.
[Barnett, Michael D.] Univ Alabama Birmingham, Div Gen Pediat & Adolescent Med, Birmingham, AL USA.
[Williams, Beverly R.] Birmingham VA Med Ctr, Birmingham Atlanta VA Geriatr Res Educ & Clin Ctr, Birmingham, AL USA.
RP Barnett, MD (reprint author), Univ Alabama Birmingham, Ctr Palliat & Support Care, 1720 2nd Ave S,CH19 219, Birmingham, AL 35294 USA.
EM mbarnett@peds.uab.edu
NR 23
TC 0
Z9 0
U1 2
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1049-9091
EI 1938-2715
J9 AM J HOSP PALLIAT ME
JI Am. J. Hosp. Palliat. Med.
PD MAY
PY 2016
VL 33
IS 4
BP 321
EP 326
DI 10.1177/1049909114565108
PG 6
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA DH6CX
UT WOS:000372879700002
PM 25548391
ER
PT J
AU Hutt, E
Whitfield, E
Min, SJ
Jones, J
Weber, M
Albright, K
Levy, C
O'Toole, T
AF Hutt, Evelyn
Whitfield, Emily
Min, Sung-Joon
Jones, Jacqueline
Weber, Mary
Albright, Karen
Levy, Cari
O'Toole, Thomas
TI Challenges of Providing End-of-Life Care for Homeless Veterans
SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE
LA English
DT Article
DE veteran; palliative care; homelessness
ID DEATH; ADULTS; BOSTON
AB Objective: To describe challenges of caring for homeless veterans at end of life (EOL) as perceived by Veterans Affairs Medical Center (VAMC) homeless and EOL care staff.
Design: E-mail survey.
Setting/participants: Homelessness and EOL programs at VAMCs.
Measurements: Programs and their ratings of personal, structural, and clinical care challenges were described statistically. Homelessness and EOL program responses were compared in unadjusted analyses and using multivariable models.
Results: Of 152 VAMCs, 50 (33%) completed the survey. The VAMCs treated an average of 6.5 homeless veterans at EOL annually. Lack of appropriate housing was the most critical challenge. The EOL programs expressed somewhat more concern about lack of appropriate care site and care coordination than did homelessness programs.
Conclusions: Personal, clinical, and structural challenges face care providers for veterans who are homeless at EOL. Deeper understanding of these challenges will require qualitative study of homeless veterans and care providers.
C1 [Hutt, Evelyn; Whitfield, Emily; Levy, Cari] Denver Vet Affairs Med Ctr VAMC, Denver, CO USA.
[Hutt, Evelyn; Whitfield, Emily; Min, Sung-Joon; Albright, Karen; Levy, Cari] Univ Colorado, Sch Med, Dept Med, Denver, CO USA.
[Jones, Jacqueline; Weber, Mary] Univ Colorado, Coll Nursing, Denver, CO USA.
[O'Toole, Thomas] Providence Vet Affairs Med Ctr, Providence, RI USA.
[O'Toole, Thomas] Brown Univ, Alpert Med Sch, Dept Med, Providence, RI 02912 USA.
RP Hutt, E (reprint author), Denver VA Med Ctr, Res, 1055 Clermont St,Mail Code A151, Denver, CO 80220 USA.
EM evelyn.hutt@ucdenver.edu
FU Department of Veterans Affairs [10-322]
FX The authors disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: The funding
for this study was provided by Merit Award 10-322 from the Department of
Veterans Affairs. The funding sources had no role in the study design;
in the collection, analysis, and interpretation of data; in the writing
of the report; and in the decision to submit the article for
publication.
NR 12
TC 0
Z9 0
U1 2
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1049-9091
EI 1938-2715
J9 AM J HOSP PALLIAT ME
JI Am. J. Hosp. Palliat. Med.
PD MAY
PY 2016
VL 33
IS 4
BP 381
EP 389
DI 10.1177/1049909115572992
PG 9
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA DH6CX
UT WOS:000372879700011
PM 25701660
ER
PT J
AU Egede, LE
Bishu, KG
Walker, RJ
Dismuke, CE
AF Egede, Leonard E.
Bishu, Kinfe G.
Walker, Rebekah J.
Dismuke, Clara E.
TI Impact of diagnosed depression on healthcare costs in adults with and
without diabetes: United States, 2004-2011
SO JOURNAL OF AFFECTIVE DISORDERS
LA English
DT Article
DE Diabetes; Depression; Cost; Comorbidities; Expenditures
ID COMORBID DEPRESSION; MEDICAL COSTS; PREVALENCE; COMPLICATIONS;
EXPENDITURES; BURDEN; MODELS
AB Objective: This study used the Medical Expenditures Panel Survey (MEPS) to estimate the cost of diabetes, depression, and comorbid diabetes and depression over 8 years.
Methods: An 8-year pooled dataset was created using the household and medical provider components of MEPS. Medical expenditures were adjusted to a common 2014 dollar value. Analyses used responses of 147,095 individuals > 18 years of age for the years 2004-2011. The dependent variable in this study was total healthcare expenditure and the primary independent variables were diabetes and depression status. A two-part (probit/GLM) model was used to estimate the annual medical spending and marginal effects were calculated for incremental cost.
Results: In the pooled sample, after adjusting for socio-demographic factors, comorbidities and time trend covariates, the incremental cost of depression only was $2654 (95% CI 2343-2966), diabetes was $2692 (95% CI 2338-3046), and both was $6037 (CI 95% 5243-6830) when compared to patients with none. Based on the unadjusted mean, annual average aggregate cost of depression only was estimated at $238.3 billion, diabetes only $150.1 billion and depression and diabetes together was $77.6 billion.
Conclusion: Costs at both the individual and aggregate level are significant, with comorbid diagnoses resulting in higher incremental costs than the sum of the costs for each diagnosis alone. In addition, while the cost of depression increased over time, the cost of diabetes decreased over time, much due to decreased inpatient costs. This study highlights the tremendous cost savings possible through more aggressive screening, diagnosis, and treatment of depression. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Egede, Leonard E.; Bishu, Kinfe G.; Walker, Rebekah J.; Dismuke, Clara E.] Med Univ S Carolina, Dept Med, Ctr Hlth Dispar Res, Charleston, SC 29425 USA.
[Egede, Leonard E.; Bishu, Kinfe G.; Walker, Rebekah J.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Dept Med, Charleston, SC 29425 USA.
[Egede, Leonard E.; Walker, Rebekah J.; Dismuke, Clara E.] Ralph H Johnson Vet Affairs Med Ctr, HEROIC, Charleston, SC USA.
RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280G, Charleston, SC 29425 USA.
EM egedel@musc.edu
FU National Institute of Diabetes and Digestive and Kidney Disease
[K24DK093699-01]
FX This study was supported by Grant K24DK093699-01 from The National
Institute of Diabetes and Digestive and Kidney Disease (PI: Leonard
Egede).
NR 40
TC 2
Z9 2
U1 4
U2 18
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-0327
EI 1573-2517
J9 J AFFECT DISORDERS
JI J. Affect. Disord.
PD MAY
PY 2016
VL 195
BP 119
EP 126
DI 10.1016/j.jad.2016.02.011
PG 8
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA DF3PP
UT WOS:000371257400014
PM 26890289
ER
PT J
AU Morris, JN
Howard, EP
Steel, K
Berg, K
Tchalla, A
Munankarmi, A
David, D
AF Morris, John N.
Howard, Elizabeth P.
Steel, Knight
Berg, Katherine
Tchalla, Achille
Munankarmi, Amy
David, Daniel
TI Strategies to reduce the risk of falling: Cohort study analysis with
1-year follow-up in community dwelling older adults
SO BMC GERIATRICS
LA English
DT Article
DE Strategies to reduce risk of falls; Community-dwelling older adults;
interRAI assessment
ID RANDOMIZED CONTROLLED-TRIAL; PHYSICAL FUNCTION; ELDERLY-PEOPLE;
VISUAL-ACUITY; REHABILITATION; HEALTH; ASSOCIATIONS; PREVENTION;
POPULATION; PREDICTORS
AB Background: According to the CDC, falls rank among the leading causes of accidental death in the United States, resulting in significant health care costs annually. In this paper we present information about everyday lifestyle decisions of the older adult that may help reduce the risk of falling. We pursued two lines of inquiry: first, we identify and then test known mutable fall risk factors and ask how the resolution of such problems correlates with changes in fall rates. Second, we identify a series of everyday lifestyle options that persons may follow and then ask, does such engagement (e.g., engagement in exercise programs) lessen the older adult's risk of falling and if it does, will the relationship hold as the count of risk factors increases?
Methods: Using a secondary analysis of lifestyle choices and risk changes that may explain fall rates over one year, we drew on a data set of 13,623 community residing elders in independent housing sites from 24 US states. All older adults were assessed at baseline, and a subset assessed one year later (n = 4,563) using two interRAI tools: the interRAI Community Health Assessment and interRAI Wellness Assessment.
Results: For the vast majority of risk measures, problem resolution is followed by lower rate of falls. This is true for physical measures such as doing housework, meal preparation, unsteady gait, transferring, and dressing the lower body. Similarly, this pattern is observed for clinical measures such as depression, memory, vision, dizziness, and fatigue. Among the older adults who had a falls risk at the baseline assessment, about 20 % improve, that is, they had a decreased falls rate when the problem risk improved. This outcome suggests that improvement of physical or clinical states potentially may result in a decreased falls rate. Additionally, physical exercise and cognitive activities are associated with a lower rate of falls.
Conclusions: The resolution of risk problems and physical and cognitive lifestyle choices are related to lower fall rates in elders in the community. The results presented here point to specific areas, that when targeted, may reduce the risk of falls. In addition, when there is problem resolution for specific clinical conditions, a decreased risk for falls also may occur.
C1 [Morris, John N.] Hebrew SeniorLife, Inst Aging Res, 1200 Ctr St, Boston, MA 02131 USA.
[Howard, Elizabeth P.] Northeastern Univ, Sch Nursing, 360 Huntington Ave, Boston, MA 02115 USA.
[Steel, Knight] Hackensack Univ, Med Ctr, 30 Prospect Ave, Hackensack, NJ 07601 USA.
[Berg, Katherine] Univ Toronto, Dept Phys Therapy, 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada.
[Berg, Katherine] Univ Toronto, Rehabil Sci Inst, 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada.
[Tchalla, Achille] Univ Limoges, Dept Geriatr Med, IFR Geist 145, F-87025 Limoges, France.
[Tchalla, Achille] CHU Limoges, EA HAVAE 6310, F-87025 Limoges, France.
[Munankarmi, Amy] Northeastern Univ, 360 Huntington Ave, Boston, MA 02115 USA.
[David, Daniel] San Francisco VA Med Ctr, VA Qual Scholar Geriatr Palliat & Extended Care S, San Francisco, CA 94121 USA.
RP Howard, EP (reprint author), Northeastern Univ, Sch Nursing, 360 Huntington Ave, Boston, MA 02115 USA.
EM e.howard@neu.edu
FU COLLAGE
FX Financial support was provided partially by COLLAGE with the remainder
being self-supported.
NR 51
TC 0
Z9 0
U1 9
U2 15
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2318
J9 BMC GERIATR
JI BMC Geriatr.
PD APR 29
PY 2016
VL 16
AR 92
DI 10.1186/s12877-016-0267-5
PG 10
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DK7IT
UT WOS:000375099100001
PM 27129303
ER
PT J
AU Vergidis, P
Clancy, CJ
Shields, RK
Park, SY
Wildfeuer, BN
Simmons, RL
Nguyen, MH
AF Vergidis, Pascalis
Clancy, Cornelius J.
Shields, Ryan K.
Park, Seo Young
Wildfeuer, Brett N.
Simmons, Richard L.
Nguyen, M. Hong
TI Intra-Abdominal Candidiasis: The Importance of Early Source Control and
Antifungal Treatment
SO PLOS ONE
LA English
DT Article
ID INTENSIVE-CARE-UNIT; INVASIVE CANDIDIASIS; ABDOMINAL CANDIDIASIS;
SURGICAL-PATIENTS; NONCULTURE DIAGNOSTICS; RISK-FACTORS; PERITONITIS;
INFECTIONS; MANAGEMENT; MORTALITY
AB Intra-abdominal candidiasis (IAC) is poorly understood compared to candidemia. We described the clinical characteristics, microbiology, treatment and outcomes of IAC, and identified risk factors for mortality. We performed a retrospective study of adults diagnosed with IAC at our center in 2012-2013. Risk factors for mortality were evaluated using multivariable logistic regression. We identified 163 patients with IAC, compared to 161 with candidemia. Types of IAC were intra-abdominal abscesses (55%), secondary peritonitis (33%), primary peritonitis (5%), infected pancreatic necrosis (5%), and cholecystitis/cholangitis (3%). Eighty-three percent and 66% of secondary peritonitis and abscesses, respectively, stemmed from gastrointestinal (GI) tract sources. C. albicans (56%) and C. glabrata (24%) were the most common species. Bacterial co-infections and candidemia occurred in 67% and 6% of patients, respectively. Seventy-two percent of patients underwent an early source control intervention (within 5 days) and 72% received early antifungal treatment. 100-day mortality was 28%, and highest with primary (88%) or secondary (40%) peritonitis. Younger age, abscesses and early source control were independent predictors of survival. Younger age, abscesses and early antifungal treatment were independently associated with survival for IAC stemming from GI tract sources. Infectious diseases (ID) consultations were obtained in only 48% of patients. Consulted patients were significantly more likely to receive antifungal treatment. IAC is a common disease associated with heterogeneous manifestations, which result in poor outcomes. All patients should undergo source control interventions and receive antifungal treatment promptly. It is important for the ID community to become more engaged in treating IAC.
C1 [Vergidis, Pascalis; Clancy, Cornelius J.; Shields, Ryan K.; Wildfeuer, Brett N.; Nguyen, M. Hong] Univ Pittsburgh, Sch Med, Dept Med, Div Infect Dis, Pittsburgh, PA 15213 USA.
[Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Park, Seo Young] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA.
[Simmons, Richard L.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA.
RP Vergidis, P (reprint author), Univ Pittsburgh, Sch Med, Dept Med, Div Infect Dis, Pittsburgh, PA 15213 USA.
EM vergidisp@upmc.edu
FU National Institutes of Health (NIH) [R21AI107290]; National Center for
Advancing Translational Sciences of the NIH [KL2TR000146]; NIH
[K08AI114883]
FX The study was supported, in part, by award R21AI107290 (M.H.N.) from the
National Institutes of Health (NIH). P.V. is supported by the National
Center for Advancing Translational Sciences of the NIH under Award
Number KL2TR000146. R.K.S is supported by the NIH under award number
K08AI114883. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
NR 40
TC 4
Z9 4
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 28
PY 2016
VL 11
IS 4
AR e0153247
DI 10.1371/journal.pone.0153247
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DK8XE
UT WOS:000375211700013
PM 27123857
ER
PT J
AU Reddy, AT
Lakshmi, SP
Muchumarri, RR
Reddy, RC
AF Reddy, Aravind T.
Lakshmi, Sowmya P.
Muchumarri, Ramamohan R.
Reddy, Raju C.
TI Nitrated Fatty Acids Reverse Cigarette Smoke-Induced Alveolar Macrophage
Activation and Inhibit Protease Activity via Electrophilic S-Alkylation
SO PLOS ONE
LA English
DT Article
ID OBSTRUCTIVE PULMONARY-DISEASE; HUMAN CATHEPSIN-S; EPITHELIAL-CELLS;
NITROLINOLEIC ACID; PPAR-GAMMA; INFLAMMATION; TRANSDUCTION; REPERFUSION;
MECHANISMS; ISCHEMIA
AB Nitrated fatty acids (NFAs), endogenous products of nonenzymatic reactions of NO-derived reactive nitrogen species with unsaturated fatty acids, exhibit substantial anti-inflammatory activities. They are both reversible electrophiles and peroxisome proliferator-activated receptor gamma (PPAR gamma) agonists, but the physiological implications of their electrophilic activity are poorly understood. We tested their effects on inflammatory and emphysema-related biomarkers in alveolar macrophages (AMs) of smoke-exposed mice. NFA (10-nitro-oleic acid or 12-nitrolinoleic acid) treatment downregulated expression and activity of the inflammatory transcription factor NF-kappa B while upregulating those of PPAR gamma. It also downregulated production of inflammatory cytokines and chemokines and of the protease cathepsin S (Cat S), a key mediator of emphysematous septal destruction. Cat S downregulation was accompanied by decreased AM elastolytic activity, a major mechanism of septal destruction. NFAs downregulated both Cat S expression and activity in AMs of wild-type mice, but only inhibited its activity in AMs of PPAR. knockout mice, pointing to a PPAR gamma-independent mechanism of enzyme inhibition. We hypothesized that this mechanism was electrophilic S-alkylation of target Cat S cysteines, and found that NFAs bind directly to Cat S following treatment of intact AMs and, as suggested by in silico modeling and calculation of relevant parameters, elicit S-alkylation of Cys25 when incubated with purified Cat S. These results demonstrate that NFAs' electrophilic activity, in addition to their role as PPAR. agonists, underlies their protective effects in chronic obstructive pulmonary disease (COPD) and support their therapeutic potential in this disease.
C1 [Reddy, Aravind T.; Lakshmi, Sowmya P.; Muchumarri, Ramamohan R.; Reddy, Raju C.] Univ Pittsburgh, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA.
[Reddy, Aravind T.; Lakshmi, Sowmya P.; Muchumarri, Ramamohan R.; Reddy, Raju C.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA.
RP Reddy, RC (reprint author), Univ Pittsburgh, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA.; Reddy, RC (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA.
EM reddyrc@upmc.edu
FU U.S. Department of Veterans Affairs; National Institutes of Health
[HL093196]
FX This work was supported by a Merit Review award from the U.S. Department
of Veterans Affairs and National Institutes of Health grant HL093196 to
RCR. The funder had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 28
TC 1
Z9 1
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 27
PY 2016
VL 11
IS 4
AR e0153336
DI 10.1371/journal.pone.0153336
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DK5QZ
UT WOS:000374976200022
PM 27119365
ER
PT J
AU Kim, JE
Scherzer, R
Estrella, MM
Ix, JH
Shlipak, MG
AF Kim, Julie E.
Scherzer, Rebecca
Estrella, Michelle M.
Ix, Joachim H.
Shlipak, Michael G.
TI Tenofovir exposure alters associations of serum bicarbonate with chronic
kidney disease risk in HIV-infected veterans
SO AIDS
LA English
DT Article
DE tenofovir; HIV; chronic kidney disease; bicarbonate
ID ANTIRETROVIRAL THERAPY; COHORT; PROGRESSION; ACIDOSIS; OUTCOMES; HEALTH;
CARE; CKD
AB Objective:
Among HIV-infected persons, tenofovir disoproxil fumarate (TDF) use is associated with higher risk of developing chronic kidney disease (CKD). Because lower serum bicarbonate concentrations may precede CKD onset, this study investigated the associations between TDF use and bicarbonate concentrations, and between bicarbonate with CKD risk among TDF users and nonusers.
Methods:
Retrospective cohort study of 16 070 HIV-infected US veterans who initiated antiretroviral therapy between 1997-2011. The association between TDF use with longitudinal bicarbonate concentrations and associations between bicarbonate with incident CKD stratified by TDF use (never, initial, and later user) were evaluated.
Results:
Compared with TDF users, never users had faster declines in bicarbonate concentrations: change in bicarbonate -0.11 mmol/l per year (95% confidence interval -0.16, -0.05), compared with -0.04 mmol/l per year (-0.06, 0.05) in initial users and -0.02 mmol/l per year (-0.05, 0.01) in later users. Low baseline bicarbonate (<22 mmol/l) was significantly associated with CKD risk among TDF never users (1.80; 1.21, 2.68), but not among TDF users (0.98; 0.69, 1.38). Similarly, declining bicarbonate concentrations were associated with higher CKD risk among never users (hazard ratio 1.67 per mmol/l; 1.34, 2.08), but not among TDF users (1.09; 0.98, 1.22). Interactions were highly significant for both analyses (P value = 0.001).
Conclusion:
Despite associations with nephrotoxicity, TDF use was associated with higher serum bicarbonate concentrations longitudinally. Additionally, TDF use obscured the strong associations of bicarbonate with CKD risk in HIV-infected persons. Therefore, the role of bicarbonate concentrations as a tool to monitor kidney health in HIV-infected persons may be limited in the setting of TDF use.
C1 [Kim, Julie E.; Scherzer, Rebecca; Estrella, Michelle M.; Ix, Joachim H.; Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Shlipak, MG (reprint author), San Francisco VA Med Ctr, San Francisco, CA USA.
EM michael.shlipak@ucsf.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases
[1K23DK081317]; American Heart Association [14EIA18560026]; National
Institute of Aging [R01AG034853]
FX R.S. received honorarium from Merck for participating in a Renal Expert
Input Forum in June 2014; this honorarium was donated to NCIRE to
support kidney research. M.E. was supported by grant 1K23DK081317 from
the National Institute of Diabetes and Digestive and Kidney Diseases.
J.I. was supported by an Established Investigator Award 14EIA18560026
from the American Heart Association. M.S. was supported by grant
R01AG034853 from the National Institute of Aging.
NR 25
TC 0
Z9 0
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD APR 24
PY 2016
VL 30
IS 7
BP 1049
EP 1057
DI 10.1097/QAD.0000000000001023
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA DI1AW
UT WOS:000373229400001
PM 26760455
ER
PT J
AU Krager, SC
Prochazka, AV
AF Krager, Steven C.
Prochazka, Allan V.
TI Review: In women 50 to 69 y of age at average risk, mammography
screening reduces breast cancer mortality
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Editorial Material
ID FORCE RECOMMENDATION STATEMENT; TRIAL
C1 [Krager, Steven C.; Prochazka, Allan V.] Denver VA Med Ctr, Denver, CO USA.
RP Krager, SC (reprint author), Denver VA Med Ctr, Denver, CO USA.
NR 7
TC 0
Z9 0
U1 3
U2 4
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD APR 19
PY 2016
VL 164
IS 8
BP JC38
EP JC39
DI 10.7326/ACPJC-2016-164-8-038
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA DJ5OH
UT WOS:000374257900001
PM 27089086
ER
PT J
AU Prochazka, AV
AF Prochazka, Allan V.
TI Varenicline increased smoking cessation at 24 weeks in patients
hospitalized with ACS and motivated to quit
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Editorial Material
C1 [Prochazka, Allan V.] Denver VA Med Ctr, Denver, CO USA.
RP Prochazka, AV (reprint author), Denver VA Med Ctr, Denver, CO USA.
NR 4
TC 0
Z9 0
U1 0
U2 0
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD APR 19
PY 2016
VL 164
IS 8
BP JC43
EP JC43
DI 10.7326/ACPJC-2016-164-6-043
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA DJ5OH
UT WOS:000374257900005
PM 27089093
ER
PT J
AU Baek, JI
Kwon, SH
Zuo, XF
Choi, SY
Kim, SH
Lipschutz, JH
AF Baek, Jeong-In
Kwon, Sang-Ho
Zuo, Xiaofeng
Choi, Soo Young
Kim, Seok-Hyung
Lipschutz, Joshua H.
TI Dynamin Binding Protein (Tuba) Deficiency Inhibits Ciliogenesis and
Nephrogenesis in Vitro and in Vivo
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE CDC42; cilia; guanine nucleotide exchange factor (GEF); kidney; membrane
trafficking
ID NUCLEOTIDE EXCHANGE FACTORS; EPITHELIAL-CELLS; CDC42 GEF; ZEBRAFISH
PRONEPHROS; PRIMARY CILIUM; FACIOGENITAL DYSPLASIA; INDUCED
TUBULOGENESIS; EXTRACELLULAR-MATRIX; SPINDLE ORIENTATION; ACTIN
CYTOSKELETON
AB Dysfunction of renal primary cilia leads to polycystic kidney disease. We previously showed that the exocyst, a protein trafficking complex, is essential for ciliogenesis and regulated by multiple Rho and Rab family GTPases, such as Cdc42. Cdc42 deficiency resulted in a disruption of renal ciliogenesis and a polycystic kidney disease phenotype in zebrafish and mice. Here we investigate the role of Dynamin binding protein (also known as Tuba), a Cdc42-specific guanine nucleotide exchange factor, in ciliogenesis and nephrogenesis using Tuba knockdown Madin-Darby canine kidney cells and tuba knockdown in zebrafish. Tuba depletion resulted in an absence of cilia, with impaired apical polarization and inhibition of hepatocyte growth factor-induced tubulogenesis in Tuba knockdown Madin-Darby canine kidney cell cysts cultured in a collagen gel. In zebrafish, tuba was expressed in multiple ciliated organs, and, accordingly, tuba start and splice site morphants showed various ciliary mutant phenotypes in these organs. Co-injection of tuba and cdc42 morpholinos at low doses, which alone had no effect, resulted in genetic synergy and led to abnormal kidney development with highly disorganized pronephric duct cilia. Morpholinos targeting two other guanine nucleotide exchange factors not known to be in the Cdc42/ciliogenesis pathway and a scrambled control morpholino showed no phenotypic effect. Given the molecular nature of Cdc42 and Tuba, our data strongly suggest that tuba and cdc42 act in the same ciliogenesis pathway. Our study demonstrates that Tuba deficiency causes an abnormal renal ciliary and morphogenetic phenotype. Tuba most likely plays a critical role in ciliogenesis and nephrogenesis by regulating Cdc42 activity.
C1 [Baek, Jeong-In; Kwon, Sang-Ho; Zuo, Xiaofeng; Choi, Soo Young; Kim, Seok-Hyung; Lipschutz, Joshua H.] Med Univ S Carolina, Dept Med, Clin Sci Bldg 829,96 Jonathan Lucas St, Charleston, SC 29425 USA.
[Lipschutz, Joshua H.] Ralph H Johnson Vet Affairs Med Ctr, Dept Med, Charleston, SC 29401 USA.
RP Lipschutz, JH (reprint author), Med Univ S Carolina, Dept Med, Clin Sci Bldg 829,96 Jonathan Lucas St, Charleston, SC 29425 USA.
EM Lipschut@musc.edu
FU Department of Veterans Affairs Merit Award [2I01BX000820]; National
Institutes of Health [2P30DK074038]; PKD Foundation fellowship award
FX This work was supported in part by Department of Veterans Affairs Merit
Award 2I01BX000820 (to J. H. L.), National Institutes of Health Grant
2P30DK074038 (to J. H. L.), and a PKD Foundation fellowship award (to J.
I. B.). The authors declare that they have no conflicts of interest with
the contents of this article. The content is solely the responsibility
of the authors and does not necessarily represent the official views of
the National Institutes of Health.
NR 74
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 15
PY 2016
VL 291
IS 16
BP 8632
EP 8643
DI 10.1074/jbc.M115.688663
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DK2VT
UT WOS:000374773200026
PM 26895965
ER
PT J
AU Ferrario, CM
VonCannon, J
Jiao, Y
Ahmad, S
Bader, M
Dell'Italia, LJ
Groban, L
Varagic, J
AF Ferrario, Carlos M.
VonCannon, Jessica
Jiao, Yan
Ahmad, Sarfaraz
Bader, Michael
Dell'Italia, Louis J.
Groban, Leanne
Varagic, Jasmina
TI Cardiac angiotensin-(1-12) expression and systemic hypertension in rats
expressing the human angiotensinogen gene
SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
LA English
DT Article
DE angiotensin converting enzyme inhibitors; angiotensin II;
angiotensinogen; cardiac angiotensins; chymase; angiotensin-(1-12);
renin
ID CONVERTING ENZYME; HUMAN RENIN; BLOOD-PRESSURE; II GENERATION; CHYMASE;
HEART; INTRACRINE; PROANGIOTENSIN-12; IDENTIFICATION; METABOLISM
AB Angiotensin-(1-12) [ANG-(1-12)] is processed into ANG II by chymase in rodent and human heart tissue. Differences in the amino acid sequence of rat and human ANG-(1-12) render the human angiotensinogen (hAGT) protein refractory to cleavage by renin. We used transgenic rats harboring the hAGT gene [TGR(hAGT)L1623] to assess the non-renin-dependent effects of increased hAGT expression on heart function and arterial pressure. Compared with Sprague-Dawley (SD) control rats (n = 11), male homozygous TGR(hAGT)L1623 (n = 9) demonstrated sustained daytime and nighttime hypertension associated with no changes in heart rate but increased heart rate lability. Increased heart weight/tibial length ratio and echocardiographic indexes of cardiac hypertrophy were associated with modest reduction of systolic function in hAGT rats. Robust human ANG-(1-12) immunofluorescence within myocytes of TGR(hAGT) L1623 rats was associated with a fourfold increase in cardiac ANG II content. Chymase enzymatic activity, using the rat or human ANG-(1-12) as a substrate, was not different in the cardiac tissue of SD and hAGT rats. Since both cardiac angiotensin-converting enzyme (ACE) and ACE2 activities were not different among the two strains, the changes in cardiac structure and function, blood pressure, and left ventricular ANG II content might be a product of an increased cardiac expression of ANG II generated through a non-renin-dependent mechanism. The data also underscore the existence in the rat of alternate enzymes capable of acting on hAGT protein. Homozygous transgenic rats expressing the hAGT gene represent a novel tool to investigate the contribution of human relevant renin-independent cardiac ANG II formation and function.
C1 [Ferrario, Carlos M.; VonCannon, Jessica; Jiao, Yan; Varagic, Jasmina] Wake Forest Sch Med, Dept Surg, Winston Salem, NC USA.
[VonCannon, Jessica; Ahmad, Sarfaraz; Groban, Leanne; Varagic, Jasmina] Wake Forest Sch Med, Hypertens & Vasc Res Ctr, Winston Salem, NC USA.
[Bader, Michael] Max Delbruck Ctr Mol Med MDC, Berlin, Germany.
[Dell'Italia, Louis J.] Univ Alabama Birmingham, Div Cardiovasc Dis, Birmingham, AL 35294 USA.
[Dell'Italia, Louis J.] Birmingham Vet Affairs Med Ctr, Dept Vet Affairs, Birmingham, AL USA.
[Groban, Leanne] Wake Forest Sch Med, Dept Anesthesiol, Winston Salem, NC USA.
[Ferrario, Carlos M.; Varagic, Jasmina] Wake Forest Sch Med, Dept Med Nephrol, Winston Salem, NC USA.
[Ferrario, Carlos M.; Varagic, Jasmina] Wake Forest Sch Med, Dept Physiol Pharmacol, Winston Salem, NC USA.
RP Varagic, J (reprint author), Wake Forest Sch Med, Hypertens & Vasc Res Ctr, Div Surg Sci, Med Ctr Blvd, Winston Salem, NC 27157 USA.
EM jvaragic@wakehealth.edu
FU National Heart, Lung, and Blood Institute [P01-HL-051952]; Wake Forest
University TSC-Reynolda Grant [U01079]
FX This research was supported by National Heart, Lung, and Blood Institute
Grant P01-HL-051952 (to C. M. Ferrario) and Wake Forest University
TSC-Reynolda Grant U01079 (to J. Varagic).
NR 39
TC 2
Z9 2
U1 2
U2 5
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6135
EI 1522-1539
J9 AM J PHYSIOL-HEART C
JI Am. J. Physiol.-Heart Circul. Physiol.
PD APR 15
PY 2016
VL 310
IS 8
BP H995
EP H1002
DI 10.1152/ajpheart.00833.2015
PG 8
WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular
Disease
SC Cardiovascular System & Cardiology; Physiology
GA DJ3IY
UT WOS:000374099500005
PM 26873967
ER
PT J
AU Liu, H
Rose, ME
Culver, S
Ma, XC
Dixon, CE
Graham, SH
AF Liu, Hao
Rose, Marie E.
Culver, Sherman
Ma, Xiecheng
Dixon, C. Edward
Graham, Steven H.
TI Rosiglitazone attenuates inflammation and CA3 neuronal loss following
traumatic brain injury in rats
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Traumatic brain injury; PPAR gamma; Inflammation; Rosiglitazone;
Behavioral; Cell survival
ID SPINAL-CORD-INJURY; PPAR-GAMMA; STROKE; AGONIST; DYSFUNCTION;
MECHANISMS; THERAPIES; DEFICITS; TARGET; DAMAGE
AB Rosiglitazone, a potent peroxisome proliferator-activated receptor (PPAR)-gamma agonist, has been shown to confer neuroprotective effects in stroke and spinal cord injury, but its role in the traumatic brain injury (TBI) is still controversial. Using a controlled cortical impact model in rats, the current study was designed to determine the effects of rosiglitazone treatment (6 mg/kg at 5 min, 6 h and 24 h post injury) upon inflammation and histological outcome at 21 d after TBI. In addition, the effects of rosiglitazone upon inflammatory cytokine transcription, vestibulomotor behavior and spatial memory function were determined at earlier time points (24 h, 1-5 d, 14-20 d post injury, respectively). Compared with the vehicle-treated group, rosiglitazone treatment suppressed production of TNF alpha at 24 h after TBI, attenuated activation of microglia/macrophages and increased survival of CA3 neurons but had no effect on lesion volume at 21 d after TBI. Rosiglitazone-treated animals had improved performance on beam balance testing, but there was no difference in spatial memory function as determined by Morris water maze. In summary, this study indicates that rosiglitazone treatment in the first 24 h after TBI has limited anti-inflammatory and neuroprotective effects in rat traumatic injury. Further study using an alternative dosage paradigm and more sensitive behavioral testing may be warranted. Published by Elsevier Inc.
C1 [Liu, Hao; Rose, Marie E.; Culver, Sherman; Ma, Xiecheng; Dixon, C. Edward; Graham, Steven H.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
[Liu, Hao; Rose, Marie E.; Graham, Steven H.] Univ Pittsburgh, Dept Neurol, Sch Med, Pittsburgh, PA 15260 USA.
[Culver, Sherman; Ma, Xiecheng; Dixon, C. Edward] Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15216 USA.
[Culver, Sherman; Ma, Xiecheng; Dixon, C. Edward] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15216 USA.
RP Graham, SH (reprint author), VA Pittsburgh Healthcare Ctr Res, Geriatr Res Educ & Clin Ctr, Off Bldg 30,Mail Code 151, Pittsburgh, PA 15240 USA.
EM Steven.Graham@va.gov
FU Veteran's Affairs Rehabilitation Research and Development Merit Review
Program Award [I01RX000310]
FX This work was supported by the Veteran's Affairs Rehabilitation Research
and Development Merit Review Program Award I01RX000310 (S.H.G.).
NR 26
TC 2
Z9 2
U1 1
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD APR 15
PY 2016
VL 472
IS 4
BP 648
EP 655
DI 10.1016/j.bbrc.2016.03.003
PG 8
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA DI8LX
UT WOS:000373753600013
PM 26947332
ER
PT J
AU Liu, SJ
Nowakowski, TJ
Pollen, AA
Lui, JH
Horlbeck, MA
Attenello, FJ
He, D
Weissman, JS
Kriegstein, AR
Diaz, AA
Lim, DA
AF Liu, Siyuan John
Nowakowski, Tomasz J.
Pollen, Alex A.
Lui, Jan H.
Horlbeck, Max A.
Attenello, Frank J.
He, Daniel
Weissman, Jonathan S.
Kriegstein, Arnold R.
Diaz, Aaron A.
Lim, Daniel A.
TI Single-cell analysis of long non-coding RNAs in the developing human
neocortex
SO GENOME BIOLOGY
LA English
DT Article
DE lncRNA; Single-cell RNA-seq; Developing brain; CRISPRi
ID EMBRYONIC STEM-CELLS; GENOME-WIDE ANALYSIS; CEREBRAL-CORTEX;
MOUSE-BRAIN; IN-VIVO; REVEALS; GENE; EXPRESSION; SEQ; TRANSCRIPTOME
AB Background: Long non-coding RNAs (lncRNAs) comprise a diverse class of transcripts that can regulate molecular and cellular processes in brain development and disease. LncRNAs exhibit cell type-and tissue-specific expression, but little is known about the expression and function of lncRNAs in the developing human brain. Furthermore, it has been unclear whether lncRNAs are highly expressed in subsets of cells within tissues, despite appearing lowly expressed in bulk populations.
Results: We use strand-specific RNA-seq to deeply profile lncRNAs from polyadenylated and total RNA obtained from human neocortex at different stages of development, and we apply this reference to analyze the transcriptomes of single cells. While lncRNAs are generally detected at low levels in bulk tissues, single-cell transcriptomics of hundreds of neocortex cells reveal that many lncRNAs are abundantly expressed in individual cells and are cell type-specific. Notably, LOC646329 is a lncRNA enriched in single radial glia cells but is detected at low abundance in tissues. CRISPRi knockdown of LOC646329 indicates that this lncRNA regulates cell proliferation.
Conclusion: The discrete and abundant expression of lncRNAs among individual cells has important implications for both their biological function and utility for distinguishing neural cell types.
C1 [Liu, Siyuan John; Attenello, Frank J.; He, Daniel; Diaz, Aaron A.; Lim, Daniel A.] Univ Calif San Francisco, Dept Neurol Surg, Ray & Dagmar Dolby Regenerat Med Bldg, San Francisco, CA 94143 USA.
[Liu, Siyuan John; Nowakowski, Tomasz J.; Pollen, Alex A.; Lui, Jan H.; Attenello, Frank J.; He, Daniel; Kriegstein, Arnold R.; Diaz, Aaron A.; Lim, Daniel A.] Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, San Francisco, CA 94143 USA.
[Nowakowski, Tomasz J.; Pollen, Alex A.; Lui, Jan H.; Kriegstein, Arnold R.] Dept Neurol, San Francisco, CA 94143 USA.
[Horlbeck, Max A.; Weissman, Jonathan S.] Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA.
[Horlbeck, Max A.; Weissman, Jonathan S.] Howard Hughes Med Inst, San Francisco, CA 94143 USA.
[Horlbeck, Max A.; Weissman, Jonathan S.] Calif Inst Quantitat Biomed Res, San Francisco, CA 94143 USA.
[Horlbeck, Max A.; Weissman, Jonathan S.] Ctr RNA Syst Biol, San Francisco, CA 94143 USA.
[Liu, Siyuan John; Nowakowski, Tomasz J.; Pollen, Alex A.; Lui, Jan H.; Horlbeck, Max A.; Attenello, Frank J.; He, Daniel; Weissman, Jonathan S.; Kriegstein, Arnold R.; Diaz, Aaron A.; Lim, Daniel A.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Lim, Daniel A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Lui, Jan H.] Stanford Univ, Dept Biol, Stanford, CA 94305 USA.
[Lui, Jan H.] Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA.
RP Diaz, AA; Lim, DA (reprint author), Univ Calif San Francisco, Dept Neurol Surg, Ray & Dagmar Dolby Regenerat Med Bldg, San Francisco, CA 94143 USA.
EM Aaron.Diaz@ucsf.edu; Daniel.Lim@ucsf.edu
FU VA [5I01 BX000252-06]; NIH [1R01NS091544-01A1, U01 MH105989, F30
NS092319-01]; NIH SPORE DRP; Shurl and Kay Curci Foundation; Hana
Jabsheh Initiative; UCSF-CTSI [UL1 TR000004]; Damon Runyon Cancer
Research Foundation [DRG-2166-13]
FX This project was supported by VA 5I01 BX000252-06, NIH
1R01NS091544-01A1, NIH SPORE DRP, the Shurl and Kay Curci Foundation,
and the Hana Jabsheh Initiative (to DAL), UCSF-CTSI UL1 TR000004 (to
AAD), and NIH U01 MH105989 to ARK. SJL is supported by NIH F30
NS092319-01. AAP is supported by a Damon Runyon Cancer Research
Foundation postdoctoral fellowship (DRG-2166-13).
NR 59
TC 17
Z9 17
U1 3
U2 25
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1465-6906
EI 1474-760X
J9 GENOME BIOL
JI Genome Biol.
PD APR 14
PY 2016
VL 17
AR 67
DI 10.1186/s13059-016-0932-1
PG 17
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA DJ5WK
UT WOS:000374281300001
PM 27081004
ER
PT J
AU Aras, MA
Teerlink, JR
AF Aras, Mandar A.
Teerlink, John R.
TI Lung ultrasound: a 'B-line' to the prediction of decompensated heart
failure
SO EUROPEAN HEART JOURNAL
LA English
DT Editorial Material
ID PULMONARY CONGESTION; REHOSPITALIZATION
C1 [Aras, Mandar A.; Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
[Teerlink, John R.] San Francisco VA Med Ctr, Sect Cardiol, 111C Bldg 203,Room 2A-49,4150 Clement St, San Francisco, CA 94121 USA.
RP Teerlink, JR (reprint author), San Francisco VA Med Ctr, Sect Cardiol, 111C Bldg 203,Room 2A-49,4150 Clement St, San Francisco, CA 94121 USA.
EM john.teerlink@ucsf.edu
NR 11
TC 4
Z9 4
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
EI 1522-9645
J9 EUR HEART J
JI Eur. Heart J.
PD APR 14
PY 2016
VL 37
IS 15
BP 1252
EP 1254
DI 10.1093/eurheartj/ehw094
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DJ1TC
UT WOS:000373985800018
PM 27080198
ER
PT J
AU He, BK
Nohara, K
Park, N
Park, YS
Guillory, B
Zhao, ZY
Garcia, JM
Koike, N
Lee, CC
Takahashi, JS
Yoo, SH
Chen, Z
AF He, Baokun
Nohara, Kazunari
Park, Noheon
Park, Yong-Sung
Guillory, Bobby
Zhao, Zhaoyang
Garcia, Jose M.
Koike, Nobuya
Lee, Cheng Chi
Takahashi, Joseph S.
Yoo, Seung-Hee
Chen, Zheng
TI The Small Molecule Nobiletin Targets the Molecular Oscillator to Enhance
Circadian Rhythms and Protect against Metabolic Syndrome
SO CELL METABOLISM
LA English
DT Article
ID ORPHAN NUCLEAR RECEPTOR; REV-ERB-ALPHA; HIGH-FAT DIET;
INSULIN-RESISTANCE; ROR-ALPHA; CITRUS FLAVONOIDS; LIPID-METABOLISM;
GENE-EXPRESSION; T-CELLS; CLOCK
AB Dysregulation of circadian rhythms is associated with metabolic dysfunction, yet it is unclear whether enhancing clock function can ameliorate metabolic disorders. In an unbiased chemical screen using fibroblasts expressing PER2::Luc, we identified Nobiletin (NOB), a natural polymethoxylated flavone, as a clock amplitude-enhancing small molecule. When administered to diet-induced obese (DIO) mice, NOB strongly counteracted metabolic syndrome and augmented energy expenditure and locomotor activity in a Clock gene-dependent manner. In db/db mutant mice, the clock is also required for the mitigating effects of NOB on metabolic disorders. In DIO mouse liver, NOB enhanced clock protein levels and elicited pronounced gene expression remodeling. We identified retinoid acid receptor-related orphan receptors as direct targets of NOB, revealing a pharmacological intervention that enhances circadian rhythms to combat metabolic disease via the circadian gene network.
C1 [He, Baokun; Nohara, Kazunari; Park, Yong-Sung; Zhao, Zhaoyang; Lee, Cheng Chi; Yoo, Seung-Hee; Chen, Zheng] Univ Texas Hlth Sci Ctr Houston, Dept Biochem & Mol Biol, 6431 Fannin St, Houston, TX 77030 USA.
[Park, Noheon; Takahashi, Joseph S.] Univ Texas SW Med Ctr Dallas, Dept Neurosci, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
[Guillory, Bobby; Garcia, Jose M.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Ctr Translat Res Inflammatory Dis, MCL,Div Endocrinol Diabet & Metab, Houston, TX 77030 USA.
[Guillory, Bobby; Garcia, Jose M.] Baylor Coll Med, Huffington Ctr Aging, Dan L Duncan Canc Ctr, Dept Med & Mol & Cell Biol, Houston, TX 77030 USA.
[Koike, Nobuya] Kyoto Prefectural Univ Med, Dept Physiol & Syst Biosci, Kyoto 6028566, Japan.
[Takahashi, Joseph S.] Univ Texas SW Med Ctr Dallas, Howard Hughes Med Inst, Dallas, TX 75390 USA.
[Garcia, Jose M.] Univ Washington, VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, 1660 South Columbian Way S-182-GRECC, Seattle, WA 98108 USA.
RP Chen, Z (reprint author), Univ Texas Hlth Sci Ctr Houston, Dept Biochem & Mol Biol, 6431 Fannin St, Houston, TX 77030 USA.
EM zheng.chen.1@uth.tmc.edu
OI Takahashi, Joseph/0000-0003-0384-8878
FU Welch Foundation [AU-1731]; American Heart Association [11SDG7600045];
NIH/National Institute on Aging [R01AG045828]; NIH/National Institute of
General Medical Sciences [R01 GM114424]; Texas Medical Center Digestive
Disease Center P/F Awards (National Institute of Diabetes and Digestive
and Kidney Diseases) [P30-DK056338]; U.S.A. Department of Veterans
Affairs [BX000507, CX000174]; NIH [AG040583, T32AG000183, NIH/DP1
OD000895]; JSPS [26293048]; Uehara Memorial Foundation
FX We thank C. Lee for reagent; C. Stephan, E. Song, C. Ayoub, and T.M.
Tran for technical support; and S. McKnight, C. Green, M. Bogdanov, G.
Lee, D. Marshak, C. Wu, P. Griffin, R. Garcia-Ordonez, and G. Gloston
for helpful advice and/or critical reading of the manuscript. This work
is supported in part by The Welch Foundation (AU-1731), the American
Heart Association (11SDG7600045), and the NIH/National Institute on
Aging (R01AG045828) to Z.C., NIH/National Institute of General Medical
Sciences (R01 GM114424) to S.-H.Y., Texas Medical Center Digestive
Disease Center P/F Awards (National Institute of Diabetes and Digestive
and Kidney Diseases Center Grant P30-DK056338) to S.-H.Y. and Z.C.,
U.S.A. Department of Veterans Affairs, BX000507 and CX000174; and NIH
AG040583 to J.M.G., T32AG000183 to B.G., NIH/DP1 OD000895 to C.C.L., and
JSPS KAKENHI (26293048) and the Uehara Memorial Foundation to N.K.
J.S.T. is an Investigator in the Howard Hughes Medical Institute.
NR 85
TC 15
Z9 15
U1 9
U2 15
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1550-4131
EI 1932-7420
J9 CELL METAB
JI Cell Metab.
PD APR 12
PY 2016
VL 23
IS 4
BP 610
EP 621
DI 10.1016/j.cmet.2016.03.007
PG 12
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA DJ3RL
UT WOS:000374123200010
PM 27076076
ER
PT J
AU Garrido, MM
AF Garrido, Melissa M.
TI Covariate Adjustment and Propensity Score
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
C1 [Garrido, Melissa M.] James J Peters VA Med Ctr, 130 W Kingsbridge Rd,4A-17J, Bronx, NY USA.
RP Garrido, MM (reprint author), James J Peters VA Med Ctr, 130 W Kingsbridge Rd,4A-17J, Bronx, NY USA.
EM melissa.garrido@mssm.edu
NR 3
TC 0
Z9 0
U1 3
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD APR 12
PY 2016
VL 315
IS 14
BP 1521
EP 1522
DI 10.1001/jama.2015.19081
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA DJ0EE
UT WOS:000373873800026
PM 27115275
ER
PT J
AU Inohara, T
Kohsaka, S
Miyata, H
Ueda, I
Maekawa, Y
Fukuda, K
Cohen, DJ
Kennedy, KF
Rumsfeld, JS
Spertus, JA
AF Inohara, Taku
Kohsaka, Shun
Miyata, Hiroaki
Ueda, Ikuko
Maekawa, Yuichiro
Fukuda, Keiichi
Cohen, David J.
Kennedy, Kevin F.
Rumsfeld, John S.
Spertus, John A.
TI Performance and Validation of the US NCDR Acute Kidney Injury Prediction
Model in Japan
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE external validation; percutaneous coronary intervention; risk model;
serum creatinine
ID PERCUTANEOUS CORONARY INTERVENTION; CONTRAST-INDUCED NEPHROPATHY;
RENAL-FAILURE; APPROPRIATENESS; DATABASE; OUTCOMES; REGISTRY
AB BACKGROUND Stratifying patient risk for acute kidney injury (AKI) prior to percutaneous coronary intervention (PCI) can enable clinicians to tailor their approach to minimize AKI. The National Cardiovascular Data Registry (NCDR) CathPCI Registry recently developed 2 prediction models: for AKI and AKI requiring dialysis (AKI-D).
OBJECTIVES This study sought to externally validate the NCDR AKI and AKI-D models in a Japanese population. Determining the generalizability of the U.S. model could support quality improvement efforts in Japan.
METHODS The NCDR prediction models were applied to 11,041 consecutive patients in the Japanese multicenter PCI registry. AKI was defined as an absolute increase >= 0.3 mg/dL or a relative increase of 50% in serum creatinine, in accordance with the definition of AKI Network criteria; AKI-D was defined as initiation of dialysis after PCI. Discrimination and calibration of the NCDR models were tested in the Japanese cohort. If the model was perfectly calibrated, the slope and intercept would equal 1.0 and 0.0, respectively.
RESULTS In the Japanese PCI cohort, AKI and AKI-D occurred in 10.5% and 1.5% of patients, respectively. The NCDR AKI prediction model showed good discrimination (c-statistic = 0.76) and calibration (slope = 0.93 and intercept = -0.10) in both acute and nonacute PCI. The AKI-D prediction model had good discrimination (c-statistic = 0.92), but while the calibration slope was good (1.04), the intercept was significantly underestimated (0.96). However, this was corrected with recalibration (slope = 1.04 and intercept = -0.087).
CONCLUSIONS In a Japanese population, the NCDR AKI models validly predict post-procedural AKI and, with recalibration, AKI-D. Prospective use of these models to inform clinical decision making should be tested as a means of reducing AKI after PCI in Japan. (C) 2016 by the American College of Cardiology Foundation.
C1 [Inohara, Taku; Kohsaka, Shun; Ueda, Ikuko; Maekawa, Yuichiro; Fukuda, Keiichi] Keio Univ, Sch Med, Dept Cardiol, Tokyo 1608582, Japan.
[Inohara, Taku] Hiratsuka City Hosp, Dept Cardiol, Hiratsuka, Kanagawa, Japan.
[Miyata, Hiroaki] Keio Univ, Sch Med, Dept Hlth Policy & Management, Tokyo 1608582, Japan.
[Cohen, David J.; Kennedy, Kevin F.; Spertus, John A.] Univ Missouri, Sch Med, St Lukes Mid Amer Heart Inst, Kansas City, MO 64108 USA.
[Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA.
RP Kohsaka, S (reprint author), Keio Univ, Sch Med, Dept Cardiol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM kohsaka@cpnet.med.keio.ac.jp
RI Fukuda, Keiichi/L-3777-2013
OI Kohsaka, Shun/0000-0003-3779-2972
FU Japan Society for the Promotion of Science [25460630, 80571398]; Pfizer
Health Research Foundation; Pfizer Japan, Inc.; Bayer Pharmaceutical
Co., Ltd.
FX The present study was funded by the Grants-in-Aid for Scientific
Research from Japan Society for the Promotion of Science (Grant Nos.
25460630, 80571398) and Pfizer Health Research Foundation. The funders
had no role in the conduct of the study; in the collection, management,
analysis, and interpretation of the data; or in the preparation or
approval of the manuscript. Dr. Kohsaka has received unrestricted
research grants for the Department of Cardiology, Keio University School
of Medicine, from Pfizer Japan, Inc. and Bayer Pharmaceutical Co., Ltd.
Dr. Rumsfeld is the Chief Science Officer of the National Cardiovascular
Data Registry. Dr. Spertus is the principal investigator of a contract
from the American College of Cardiology Foundation to analyze the
National Cardiovascular Data Registry data; and has an equity interest
in Health Outcomes Sciences. All other authors have reported that they
have no relationships relevant to the contents of this paper to
disclose. Peter A. McCullough, MD, served as Guest Editor for this
paper.
NR 26
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
EI 1558-3597
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD APR 12
PY 2016
VL 67
IS 14
BP 1715
EP 1722
DI 10.1016/j.jacc.2016.01.049
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DI3LP
UT WOS:000373400500009
PM 27056778
ER
PT J
AU Coronado-Montoya, S
Levis, AW
Kwakkenbos, L
Steele, RJ
Turner, EH
Thombs, BD
AF Coronado-Montoya, Stephanie
Levis, Alexander W.
Kwakkenbos, Linda
Steele, Russell J.
Turner, Erick H.
Thombs, Brett D.
TI Reporting of Positive Results in Randomized Controlled Trials of
Mindfulness-Based Mental Health Interventions
SO PLOS ONE
LA English
DT Article
ID QUALITY-OF-LIFE; COGNITIVE THERAPY; STRESS REDUCTION; PUBLICATION BIAS;
EXCESS SIGNIFICANCE; PRIMARY OUTCOMES; METAANALYSIS; DEPRESSION;
ANXIETY; PREVENTION
AB Background
A large proportion of mindfulness-based therapy trials report statistically significant results, even in the context of very low statistical power. The objective of the present study was to characterize the reporting of "positive" results in randomized controlled trials of mindfulness-based therapy. We also assessed mindfulness-based therapy trial registrations for indications of possible reporting bias and reviewed recent systematic reviews and meta-analyses to determine whether reporting biases were identified.
Methods
CINAHL, Cochrane CENTRAL, EMBASE, ISI, MEDLINE, PsycInfo, and SCOPUS databases were searched for randomized controlled trials of mindfulness-based therapy. The number of positive trials was described and compared to the number that might be expected if mindfulness-based therapy were similarly effective compared to individual therapy for depression. Trial registries were searched for mindfulness-based therapy registrations. CINAHL, Cochrane CENTRAL, EMBASE, ISI, MEDLINE, PsycInfo, and SCOPUS were also searched for mindfulness-based therapy systematic reviews and meta-analyses.
Results
108 (87%) of 124 published trials reported >= 1 positive outcome in the abstract, and 109 (88%) concluded that mindfulness-based therapy was effective, 1.6 times greater than the expected number of positive trials based on effect size d = 0.55 (expected number positive trials = 65.7). Of 21 trial registrations, 13 (62%) remained unpublished 30 months post-trial completion. No trial registrations adequately specified a single primary outcome measure with time of assessment. None of 36 systematic reviews and meta-analyses concluded that effect estimates were overestimated due to reporting biases.
Conclusions
The proportion of mindfulnessbased therapy trials with statistically significant results may overstate what would occur in practice.
C1 [Coronado-Montoya, Stephanie; Levis, Alexander W.; Kwakkenbos, Linda; Steele, Russell J.; Thombs, Brett D.] McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada.
[Coronado-Montoya, Stephanie; Kwakkenbos, Linda; Thombs, Brett D.] McGill Univ, Dept Psychiat, Montreal, PQ, Canada.
[Steele, Russell J.; Thombs, Brett D.] McGill Univ, Dept Math & Stat, Montreal, PQ, Canada.
[Turner, Erick H.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA.
[Turner, Erick H.] Portland VA Med Ctr, Dept Psychiat, Portland, OR USA.
[Thombs, Brett D.] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada.
[Thombs, Brett D.] McGill Univ, Dept Med, Montreal, PQ, Canada.
[Thombs, Brett D.] McGill Univ, Dept Educ & Counselling Psychol, Montreal, PQ, Canada.
[Thombs, Brett D.] McGill Univ, Dept Psychol, Montreal, PQ, Canada.
[Thombs, Brett D.] McGill Univ, Sch Nursing, Montreal, PQ, Canada.
RP Thombs, BD (reprint author), McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada.; Thombs, BD (reprint author), McGill Univ, Dept Psychiat, Montreal, PQ, Canada.; Thombs, BD (reprint author), McGill Univ, Dept Math & Stat, Montreal, PQ, Canada.; Thombs, BD (reprint author), McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada.; Thombs, BD (reprint author), McGill Univ, Dept Med, Montreal, PQ, Canada.; Thombs, BD (reprint author), McGill Univ, Dept Educ & Counselling Psychol, Montreal, PQ, Canada.; Thombs, BD (reprint author), McGill Univ, Dept Psychol, Montreal, PQ, Canada.; Thombs, BD (reprint author), McGill Univ, Sch Nursing, Montreal, PQ, Canada.
EM brett.thombs@mcgill.ca
RI Steele, Russell/G-6926-2017
NR 71
TC 2
Z9 2
U1 6
U2 25
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 8
PY 2016
VL 11
IS 4
AR e0153220
DI 10.1371/journal.pone.0153220
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DI6JK
UT WOS:000373604800022
PM 27058355
ER
PT J
AU Kozlenkov, A
Wang, MH
Roussos, P
Rudchenko, S
Barbu, M
Bibikova, M
Klotzle, B
Dwork, AJ
Zhang, B
Hurd, YL
Koonin, EV
Wegner, M
Dracheva, S
AF Kozlenkov, Alexey
Wang, Minghui
Roussos, Panos
Rudchenko, Sergei
Barbu, Mihaela
Bibikova, Marina
Klotzle, Brandy
Dwork, Andrew J.
Zhang, Bin
Hurd, Yasmin L.
Koonin, Eugene V.
Wegner, Michael
Dracheva, Stella
TI Substantial DNA methylation differences between two major neuronal
subtypes in human brain
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID EMBRYONIC STEM-CELLS; HUMAN HOUSEKEEPING GENES; RETT-SYNDROME; GABAERGIC
INTERNEURONS; EPIGENETIC MEMORY; PREFRONTAL CORTEX; SITE RESOLUTION;
MECP2 BINDS; RNA-SEQ; SCHIZOPHRENIA
AB The brain is built from a large number of cell types which have been historically classified using location, morphology and molecular markers. Recent research suggests an important role of epigenetics in shaping and maintaining cell identity in the brain. To elucidate the role of DNA methylation in neuronal differentiation, we developed a new protocol for separation of nuclei from the two major populations of human prefrontal cortex neurons-GABAergic interneurons and glutamatergic (GLU) projection neurons. Major differences between the neuronal subtypes were revealed in CpG, non-CpG and hydroxymethylation (hCpG). A dramatically greater number of undermethylated CpG sites in GLU versus GABA neurons were identified. These differences did not directly translate into differences in gene expression and did not stem from the differences in hCpG methylation, as more hCpG methylation was detected in GLU versus GABA neurons. Notably, a comparable number of undermethylated non-CpG sites were identified in GLU and GABA neurons, and non-CpG methylation was a better predictor of subtype-specific gene expression compared to CpG methylation. Regions that are differentially methylated in GABA and GLU neurons were significantly enriched for schizophrenia risk loci. Collectively, our findings suggest that functional differences between neuronal subtypes are linked to their epigenetic specification.
C1 [Kozlenkov, Alexey; Roussos, Panos; Dracheva, Stella] James J Peters VA Med Ctr, Bronx, NY 10468 USA.
[Kozlenkov, Alexey; Roussos, Panos; Hurd, Yasmin L.; Dracheva, Stella] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA.
[Kozlenkov, Alexey; Roussos, Panos; Hurd, Yasmin L.; Dracheva, Stella] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.
[Wang, Minghui; Roussos, Panos; Zhang, Bin] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA.
[Rudchenko, Sergei; Barbu, Mihaela] Hosp Special Surg, New York, NY 10021 USA.
[Bibikova, Marina; Klotzle, Brandy] Illumina Inc, San Diego, CA 92122 USA.
[Dwork, Andrew J.] Columbia Univ, Dept Psychiat, New York, NY 10032 USA.
[Koonin, Eugene V.] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA.
[Wegner, Michael] Univ Erlangen Nurnberg, Emil Fischer Zentrum, Inst Biochem, D-91054 Erlangen, Germany.
RP Dracheva, S (reprint author), James J Peters VA Med Ctr, Bronx, NY 10468 USA.; Dracheva, S (reprint author), Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA.; Dracheva, S (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.
EM Stella.Dracheva@mssm.edu
RI Roussos, Panos/J-7090-2013
OI Roussos, Panos/0000-0002-4640-6239
FU National Institute of Mental Health [R21MH103877]; U.S. Department of
Veterans Affairs [BX001829]; U.S. Department of Health and Human
Services; National Institute of Health
FX National Institute of Mental Health [R21MH103877 that is a part of the
PsychENCODE consortium to S.D.]; U.S. Department of Veterans Affairs
[Merit Review Award BX001829 to S.D.]; Intramural funds of the U.S.
Department of Health and Human Services to National Library of Medicine
(to E.V.K.). Funding for open access charge: National Institute of
Health.
NR 96
TC 7
Z9 7
U1 4
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD APR 7
PY 2016
VL 44
IS 6
BP 2593
EP 2612
DI 10.1093/nar/gkv1304
PG 20
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DJ9YW
UT WOS:000374570500020
PM 26612861
ER
PT J
AU Callahan, A
Abeyruwan, SW
Al-Ali, H
Sakurai, K
Ferguson, AR
Popovich, PG
Shah, NH
Visser, U
Bixby, JL
Lemmon, VP
AF Callahan, Alison
Abeyruwan, Saminda W.
Al-Ali, Hassan
Sakurai, Kunie
Ferguson, Adam R.
Popovich, Phillip G.
Shah, Nigam H.
Visser, Ubbo
Bixby, John L.
Lemmon, Vance P.
TI RegenBase: a knowledge base of spinal cord injury biology for
translational research
SO DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION
LA English
DT Article
ID GROWTH-FACTOR RECEPTOR; KINASE INHIBITOR SELECTIVITY; THROUGHPUT
SCREENING DATA; ACTIVATED PROTEIN-KINASE; BIOASSAY ONTOLOGY BAO; AXON
REGENERATION; NEURITE OUTGROWTH; PHENOTYPE ONTOLOGY; GENOME DATABASE;
DRUG TARGETS
AB Spinal cord injury (SCI) research is a data-rich field that aims to identify the biological mechanisms resulting in loss of function and mobility after SCI, as well as develop therapies that promote recovery after injury. SCI experimental methods, data and domain knowledge are locked in the largely unstructured text of scientific publications, making large scale integration with existing bioinformatics resources and subsequent analysis infeasible. The lack of standard reporting for experiment variables and results also makes experiment replicability a significant challenge. To address these challenges, we have developed RegenBase, a knowledge base of SCI biology. RegenBase integrates curated literature-sourced facts and experimental details, raw assay data profiling the effect of compounds on enzyme activity and cell growth, and structured SCI domain knowledge in the form of the first ontology for SCI, using Semantic Web representation languages and frameworks. RegenBase uses consistent identifier schemes and data representations that enable automated linking among RegenBase statements and also to other biological databases and electronic resources. By querying RegenBase, we have identified novel biological hypotheses linking the effects of perturbagens to observed behavioral outcomes after SCI. RegenBase is publicly available for browsing, querying and download.
C1 [Callahan, Alison; Shah, Nigam H.] Stanford Univ, Stanford Ctr Biomed Informat Res, Stanford, CA 94305 USA.
[Abeyruwan, Saminda W.; Visser, Ubbo] Univ Miami, Dept Comp Sci, Coral Gables, FL 33146 USA.
[Al-Ali, Hassan; Sakurai, Kunie; Bixby, John L.; Lemmon, Vance P.] Univ Miami, Miami Project Cure Paralysis, Sch Med, Miami, FL 33136 USA.
[Ferguson, Adam R.] Univ Calif San Francisco, Dept Neurol Surg, Brain & Spinal Injury Ctr BASIC, San Francisco, CA 94143 USA.
[Ferguson, Adam R.] San Francisco VA Med Ctr, San Francisco, CA 94143 USA.
[Popovich, Phillip G.] Ohio State Univ, Ctr Brain & Spinal Cord Repair, Columbus, OH 43210 USA.
[Popovich, Phillip G.] Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA.
[Bixby, John L.; Lemmon, Vance P.] Univ Miami, Ctr Computat Sci, Coral Gables, FL 33146 USA.
[Bixby, John L.] Univ Miami, Dept Cellular & Mol Pharmacol, Sch Med, Miami, FL 33136 USA.
RP Lemmon, VP (reprint author), Univ Miami, Miami Project Cure Paralysis, Sch Med, Miami, FL 33136 USA.; Lemmon, VP (reprint author), Univ Miami, Ctr Computat Sci, Coral Gables, FL 33146 USA.
EM vlemmon@miami.edu
OI Lemmon, Vance/0000-0003-3550-7576
FU National Institute of Child Health and Human Development [HD057632];
National Institute of Neurological Disorders and Stroke [NS080145];
University of Miami Center for Computational Science; Miami Project to
Cure Paralysis
FX National Institute of Child Health and Human Development (HD057632);
National Institute of Neurological Disorders and Stroke (NS080145);
University of Miami Center for Computational Science and the Miami
Project to Cure Paralysis.
NR 73
TC 1
Z9 1
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1758-0463
J9 DATABASE-OXFORD
JI Database
PD APR 7
PY 2016
AR baw040
DI 10.1093/database/baw040
PG 13
WC Mathematical & Computational Biology
SC Mathematical & Computational Biology
GA DJ3GZ
UT WOS:000374094100001
ER
PT J
AU Tagge, I
O'Connor, A
Chaudhary, P
Pollaro, J
Berlow, Y
Chalupsky, M
Bourdette, D
Woltjer, R
Johnson, M
Rooney, W
AF Tagge, Ian
O'Connor, Audrey
Chaudhary, Priya
Pollaro, Jim
Berlow, Yosef
Chalupsky, Megan
Bourdette, Dennis
Woltjer, Randy
Johnson, Mac
Rooney, William
TI Spatio-Temporal Patterns of Demyelination and Remyelination in the
Cuprizone Mouse Model
SO PLOS ONE
LA English
DT Article
ID CENTRAL-NERVOUS-SYSTEM; CORPUS-CALLOSUM; MAGNETIZATION-TRANSFER;
SUBVENTRICULAR ZONE; MULTIPLE-SCLEROSIS; WHITE-MATTER; IN-VIVO; REGIONAL
HETEROGENEITY; BRAIN; MRI
AB Cuprizone administration in mice provides a reproducible model of demyelination and spontaneous remyelination, and has been useful in understanding important aspects of human disease, including multiple sclerosis. In this study, we apply high spatial resolution quantitative MRI techniques to establish the spatio-temporal patterns of acute demyelination in C57BL/6 mice after 6 weeks of cuprizone administration, and subsequent remyelination after 6 weeks of post-cuprizone recovery. MRI measurements were complemented with Black Gold II stain for myelin and immunohistochemical stains for associated tissue changes. Gene expression was evaluated using the Allen Gene Expression Atlas. Twenty-five C57BL/6 male mice were split into control and cuprizone groups; MRI data were obtained at baseline, after 6 weeks of cuprizone, and 6 weeks post-cuprizone. High-resolution (100 mu m isotropic) whole-brain coverage magnetization transfer ratio (MTR) parametric maps demonstrated concurrent caudal-to-rostral and medial-to-lateral gradients of MTR decrease within corpus callosum (CC) that correlated well with demyelination assessed histologically. Our results show that demyelination was not limited to the midsagittal line of the corpus callosum, and also that opposing gradients of demyelination occur in the lateral and medial CC. T-2-weighted MRI gray/white matter contrast was strong at baseline, weak after 6 weeks of cuprizone treatment, and returned to a limited extent after recovery. MTR decreases during demyelination were observed throughout the brain, most clearly in callosal white matter. Myelin damage and repair appear to be influenced by proximity to oligodendrocyte progenitor cell populations and exhibit an inverse correlation with myelin basic protein gene expression. These findings suggest that susceptibility to injury and ability to repair vary across the brain, and whole-brain analysis is necessary to accurately characterize this model. Whole-brain parametric mapping across time is essential for gaining a real understanding of disease processes in-vivo. MTR increases in healthy mice throughout adolescence and adulthood were observed, illustrating the need for appropriate age-matched controls. Elucidating the unique and site-specific demyelination in the cuprizone model may offer new insights into in mechanisms of both damage and repair in human demyelinating diseases.
C1 [Tagge, Ian; O'Connor, Audrey; Pollaro, Jim; Berlow, Yosef; Rooney, William] Oregon Hlth & Sci Univ, Adv Imaging Res Ctr, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
[Tagge, Ian; Rooney, William] Oregon Hlth & Sci Univ, Biomed Engn, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
[Chaudhary, Priya; Bourdette, Dennis; Rooney, William] Oregon Hlth & Sci Univ, Neurol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
[Chalupsky, Megan; Woltjer, Randy] Oregon Hlth & Sci Univ, Pathol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
[Bourdette, Dennis] Portland VA Med Ctr, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
[Johnson, Mac] Vertex Pharmaceut Inc, 50 Northern Ave, Boston, MA 02210 USA.
RP Tagge, I; Rooney, W (reprint author), Oregon Hlth & Sci Univ, Adv Imaging Res Ctr, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM taggei@ohsu.edu; rooneyw@ohsu.edu
OI Tagge, Ian/0000-0002-5260-7117
FU Vertex Pharmaceuticals, Inc.; NIA [P30 AG008017]
FX The primary funder, Vertex Pharmaceuticals, Inc., provided a grant to
investigate MRI biomarkers of myelination which supported experimental
costs and partial salary support for authors AO'C, JP, IT, and WR, but
did not have any additional role in the study design, data collection
and analysis, decision to publish, or preparation of the manuscript. The
specific roles of these authors are articulated in the 'author
contributions' section. MJ, on behalf of Vertex Pharmaceuticals, Inc.,
contributed to study design insofar as suggesting the use of cuprizone
in mice to validate MRI biomarkers of myelin content in-vivo. The
funders had no role in data acquisition, processing, or analysis. MJ
reviewed the paper prior to submission and offered comments on
presentation, but otherwise did not have a role in the decision to
publish.; Evan Calkins, Danielle Galipeau, and David Clark provided
excellent technical support in histological processing. We would like to
express our thanks to the Advanced Light Microscopy Core (P30 NS061800)
Facility at the Oregon Health & Science University. Immunohistochemical
studies were performed in the laboratory of the Oregon Brain Bank and
the Oregon Alzheimer's Disease Center (supported by NIA P30 AG008017).
NR 60
TC 4
Z9 4
U1 3
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 7
PY 2016
VL 11
IS 4
AR e0152480
DI 10.1371/journal.pone.0152480
PG 24
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DI6KO
UT WOS:000373608000021
PM 27054832
ER
PT J
AU Garg, A
Sharma, A
Krishnamoorthy, P
Bagae, S
Mukherjee, D
AF Garg, Aakash
Sharma, Abhishek
Krishnamoorthy, Parasuram
Bagae, Solomon
Mukherjee, Debabrata
TI ROLE OF NIACIN IN CURRENT CLINICAL PRACTICE: A SYSTEMATIC REVIEW AND
META-ANALYSIS OF RANDOMIZED CONTROL TRIALS
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Meeting Abstract
CT 65th Annual Scientific Session and Expo of the
American-College-of-Cardiology (ACC)
CY APR 02-04, 2016
CL Chicago, IL
SP Amer Coll Cardiol
C1 [Garg, Aakash; Sharma, Abhishek; Krishnamoorthy, Parasuram; Bagae, Solomon; Mukherjee, Debabrata] James J Peters VA Hosp, Bronx, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
EI 1558-3597
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD APR 5
PY 2016
VL 67
IS 13
SU S
MA 1271-383
BP 2025
EP 2025
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DK8PH
UT WOS:000375188702871
ER
PT J
AU Psotka, M
Schiller, N
Whooley, M
Mishra, R
AF Psotka, Mitchell
Schiller, Nelson
Whooley, Mary
Mishra, Rakesh
TI ASSOCIATION OF FIVE-YEAR CHANGE IN N-TERMINAL FRAGMENT OF THE PROHORMONE
BRAIN-TYPE NATRIURETIC PEPTIDE WITH CHANGE IN LEFT VENTRICULAR MASS AND
INCIDENT HYPERTROPHY IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE:
THE HEART AND SOUL STUDY
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Meeting Abstract
CT 65th Annual Scientific Session and Expo of the
American-College-of-Cardiology (ACC)
CY APR 02-04, 2016
CL Chicago, IL
SP Amer Coll Cardiol
C1 Univ Calif San Francisco, San Francisco, CA 94143 USA.
San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
EI 1558-3597
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD APR 5
PY 2016
VL 67
IS 13
SU S
MA 1124M-09
BP 2084
EP 2084
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DK8PH
UT WOS:000375188702930
ER
PT J
AU Valle, J
Graham, L
Thiruvoipati, T
Armstrong, E
Hawn, MT
Maddox, T
Bradley, S
AF Valle, Javier
Graham, Laura
Thiruvoipati, Thejasvi
Armstrong, Ehrin
Hawn, Mary T.
Maddox, Thomas
Bradley, Steven
TI IS PREOPERATIVE STRESS TESTING ASSOCIATED WITH 30-DAY POSTOPERATIVE
MORTALITY IN PATIENTS PRIOR PCI UNDERGOING NONCARDIAC SURGERY: INSIGHTS
FROM THE VETERANS AFFAIRS HEALTH CARE SYSTEM
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Meeting Abstract
CT 65th Annual Scientific Session and Expo of the
American-College-of-Cardiology (ACC)
CY APR 02-04, 2016
CL Chicago, IL
SP Amer Coll Cardiol
C1 Vet Affairs Eastern Colorado Hlth Care Syst, Denver, CO USA.
Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
EI 1558-3597
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD APR 5
PY 2016
VL 67
IS 13
SU S
MA 912-04
BP 2110
EP 2110
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DK8PH
UT WOS:000375188702956
ER
PT J
AU Xu, RJ
Wang, K
Mileva, I
Hannun, YA
Obeid, LM
Mao, CG
AF Xu, Ruijuan
Wang, Kai
Mileva, Izolda
Hannun, Yusuf A.
Obeid, Lina M.
Mao, Cungui
TI Alkaline ceramidase 2 and its bioactive product sphingosine are novel
regulators of the DNA damage response
SO ONCOTARGET
LA English
DT Article
DE ceramide; Golgi; p53; programmed cell death; reactive oxygen species
ID RADIATION-INDUCED APOPTOSIS; INDUCED CELL-DEATH; CANCER-CELLS;
MITOCHONDRIAL PATHWAY; CONFERS RESISTANCE; OXIDATIVE STRESS;
UP-REGULATION; HELA-CELLS; ACID; SPHINGOSINE-1-PHOSPHATE
AB Human cells respond to DNA damage by elevating sphingosine, a bioactive sphingolipid that induces programmed cell death (PCD) in response to various forms of stress, but its regulation and role in the DNA damage response remain obscure. Herein we demonstrate that DNA damage increases sphingosine levels in tumor cells by upregulating alkaline ceramidase 2 (ACER2) and that the upregulation of the ACER2/sphingosine pathway induces PCD in response to DNA damage by increasing the production of reactive oxygen species (ROS). Treatment with the DNA damaging agent doxorubicin increased both ACER2 expression and sphingosine levels in HCT116 cells in a dose-dependent manner. ACER2 overexpression increased sphingosine in HeLa cells whereas knocking down ACER2 inhibited the doxorubicin-induced increase in sphingosine in HCT116 cells, suggesting that DNA damage elevates sphingosine by upregulating ACER2. Knocking down ACER2 inhibited an increase in the apoptotic and necrotic cell population and the cleavage of poly ADP ribose polymerase (PARP) in HCT116 cells in response to doxorubicin as well as doxorubicin-induced release of lactate dehydrogenase (LDH) from these cells. Similar to treatment with doxorubicin, ACER2 overexpression induced an increase in the apoptotic and necrotic cell population and PARP cleavage in HeLa cells and LDH release from cells, suggesting that ACER2 upregulation mediates PCD in response to DNA damage through sphingosine. Mechanistic studies demonstrated that the upregulation of the ACER2/sphingosine pathway induces PCD by increasing ROS levels. Taken together, these results suggest that the ACER2/sphingosine pathway mediates PCD in response to DNA damage through ROS production.
C1 [Xu, Ruijuan; Wang, Kai; Hannun, Yusuf A.; Obeid, Lina M.; Mao, Cungui] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA.
[Xu, Ruijuan; Wang, Kai; Hannun, Yusuf A.; Obeid, Lina M.; Mao, Cungui] SUNY Stony Brook, Stony Brook Canc Ctr, Stony Brook, NY 11794 USA.
[Mileva, Izolda] SUNY Stony Brook, Lipid Core Facil, Stony Brook, NY 11794 USA.
[Obeid, Lina M.] Ralph H Johnson Vet Adm Hosp, Stony Brook, NY 11794 USA.
RP Mao, CG (reprint author), SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA.; Mao, CG (reprint author), SUNY Stony Brook, Stony Brook Canc Ctr, Stony Brook, NY 11794 USA.
EM cungui.mao@stonybrook.edu
FU National Institutes of Health Grants [R01CA104834, R01CA163825,
P20RR017677, P01CA097132]
FX This work was supported, in whole or in part, by National Institutes of
Health Grants R01CA104834 (to C.M.), R01CA163825 (to C.M), P20RR017677
(to L.M.O.), and P01CA097132 (to Y.A.H).
NR 54
TC 2
Z9 3
U1 0
U2 2
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD APR 5
PY 2016
VL 7
IS 14
BP 18440
EP 18457
PG 18
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA DL5TE
UT WOS:000375699000091
PM 26943039
ER
PT J
AU Downs, JR
O'Malley, PG
AF Downs, John R.
O'Malley, Patrick G.
TI Management of Dyslipidemia for Cardiovascular Disease Risk Reduction
RESPONSE
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Letter
C1 [Downs, John R.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
[O'Malley, Patrick G.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA.
RP Downs, JR (reprint author), South Texas Vet Hlth Care Syst, San Antonio, TX USA.
NR 4
TC 0
Z9 0
U1 2
U2 4
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD APR 5
PY 2016
VL 164
IS 7
BP 509
EP 510
DI 10.7326/L15-0522
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA DI6QP
UT WOS:000373625300018
PM 27043985
ER
PT J
AU Weisbord, SD
Palevsky, PM
AF Weisbord, Steven D.
Palevsky, Paul M.
TI Prevention Strategies for Contrast-Induced Nephropathy
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Letter
ID ASSOCIATION TASK-FORCE; PRACTICE GUIDELINES
C1 [Weisbord, Steven D.; Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Weisbord, SD (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
OI Palevsky, Paul/0000-0002-7334-5400
NR 5
TC 0
Z9 0
U1 0
U2 1
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD APR 5
PY 2016
VL 164
IS 7
BP 511
EP 511
DI 10.7326/L16-0098
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA DI6QP
UT WOS:000373625300021
PM 27043990
ER
PT J
AU Siu, AL
Bibbins-Domingo, K
Grossman, DC
Davidson, KW
Epling, JW
Garcia, FAR
Gillman, M
Kemper, AR
Krist, AH
Kurth, AE
Landefeld, CS
Mangione, CM
Harper, DM
Phillips, WR
Phipps, MG
Pignone, MP
AF Siu, Albert L.
Bibbins-Domingo, Kirsten
Grossman, David C.
Davidson, Karina W.
Epling, John W., Jr.
Garcia, Francisco A. R.
Gillman, Matthew
Kemper, Alex R.
Krist, Alex H.
Kurth, Ann E.
Landefeld, C. Seth
Mangione, Carol M.
Harper, Diane M.
Phillips, William R.
Phipps, Maureen G.
Pignone, Michael P.
CA USPSTF
TI Screening for Chronic Obstructive Pulmonary Disease US Preventive
Services Task Force Recommendation Statement
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; SMOKING-CESSATION; COPD; QUESTIONNAIRE;
SPIROMETRY; SMOKERS
AB IMPORTANCE About 14% of US adults aged 40 to 79 years have chronic obstructive pulmonary disease (COPD), and it is the third leading cause of death in the United States. Persons with severe COPD are often unable to participate in normal physical activity due to deterioration of lung function.
OBJECTIVE To update the 2008 US Preventive Services Task Force (USPSTF) recommendation on screening for COPD in asymptomatic adults.
EVIDENCE REVIEW The USPSTF reviewed the evidence on whether screening for COPD in asymptomatic adults (those who do not recognize or report respiratory symptoms) improves health outcomes. The USPSTF reviewed the diagnostic accuracy of screening tools (including prescreening questionnaires and spirometry); whether screening for COPD improves the delivery and uptake of targeted preventive services, such as smoking cessation or relevant immunizations; and the possible harms of screening for and treatment of mild to moderate COPD.
FINDINGS Similar to 2008, the USPSTF did not find evidence that screening for COPD in asymptomatic persons improves health-related quality of life, morbidity, or mortality. The USPSTF determined that early detection of COPD, before the development of symptoms, does not alter the course of the disease or improve patient outcomes. The USPSTF concludes with moderate certainty that screening for COPD in asymptomatic persons has no net benefit.
CONCLUSIONS AND RECOMMENDATION The USPSTF recommends against screening for COPD in asymptomatic adults. (D recommendation)
C1 [Siu, Albert L.] Mt Sinai Sch Med, New York, NY USA.
[Siu, Albert L.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
[Bibbins-Domingo, Kirsten] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Grossman, David C.] Grp Hlth Res Inst, Seattle, WA USA.
[Davidson, Karina W.] Columbia Univ, New York, NY USA.
[Epling, John W., Jr.] SUNY Upstate Med Univ, Syracuse, NY 13210 USA.
[Garcia, Francisco A. R.] Pima Cty Dept Hlth, Tucson, AZ USA.
[Gillman, Matthew] Harvard Univ, Sch Med, Boston, MA USA.
[Gillman, Matthew] Harvard Pilgrim Hlth Care Inst, Boston, MA USA.
[Kemper, Alex R.] Duke Univ, Durham, NC USA.
[Krist, Alex H.] Fairfax Family Practice, Fairfax, VA USA.
[Krist, Alex H.] Virginia Commonwealth Univ, Richmond, VA 23284 USA.
[Kurth, Ann E.] Yale Univ, Sch Nursing, West Haven, CT USA.
[Landefeld, C. Seth] Univ Alabama Birmingham, Birmingham, AL USA.
[Mangione, Carol M.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Harper, Diane M.] Univ Louisville, Louisville, KY 40292 USA.
[Phillips, William R.] Univ Washington, Seattle, WA 98195 USA.
[Phipps, Maureen G.] Brown Univ, Providence, RI 02912 USA.
[Pignone, Michael P.] Univ N Carolina, Chapel Hill, NC USA.
RP Siu, AL (reprint author), Mt Sinai Sch Med, New York, NY USA.
OI Epling, John W/0000-0001-9445-8669; Phillips,
William/0000-0003-2802-4349
NR 18
TC 11
Z9 11
U1 1
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD APR 5
PY 2016
VL 315
IS 13
BP 1372
EP 1377
DI 10.1001/jama.2016.2638
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA DI3EP
UT WOS:000373381500021
ER
PT J
AU Huber, BR
Meabon, JS
Hoffer, ZS
Zhang, J
Hoekstra, JG
Pagulayan, KF
McMillan, PJ
Mayer, CL
Banks, WA
Kraemer, BC
Raskind, MA
McGavern, DB
Peskind, ER
Cook, DG
AF Huber, B. R.
Meabon, J. S.
Hoffer, Z. S.
Zhang, J.
Hoekstra, J. G.
Pagulayan, K. F.
McMillan, P. J.
Mayer, C. L.
Banks, W. A.
Kraemer, B. C.
Raskind, M. A.
McGavern, D. B.
Peskind, E. R.
Cook, D. G.
TI BLAST EXPOSURE CAUSES DYNAMIC MICROGLIAL/MACROPHAGE RESPONSES AND
MICRODOMAINS OF BRAIN MICROVESSEL DYSFUNCTION
SO NEUROSCIENCE
LA English
DT Article
DE blood-brain barrier; two-photon microscopy; neuropathology; microglia;
macrophages
ID CHRONIC TRAUMATIC ENCEPHALOPATHY; IN-VIVO; MICROGLIAL ACTIVATION;
WHITE-MATTER; MOUSE MODEL; INJURY; BLOOD; BARRIER; CORTEX; IMPACT
AB Exposure to blast overpressure (BOP) is associated with behavioral, cognitive, and neuroimaging abnormalities. We investigated the dynamic responses of cortical vasculature and its relation to microglia/macrophage activation in mice using intravital two-photon microscopy following mild blast exposure. We found that blast caused vascular dysfunction evidenced by microdomains of aberrant vascular permeability. Microglial/macrophage activation was specifically associated with these restricted microdomains, as evidenced by rapid microglial process retraction, increased ameboid morphology, and escape of blood-borne Q-dot tracers that were internalized in microglial/macrophage cell bodies and phagosome-like compartments. Microdomains of cortical vascular disruption and microglial/macrophage activation were also associated with aberrant tight junction morphology that was more prominent after repetitive (3 x) blast exposure. Repetitive, but not single, BOPs also caused TNF alpha elevation two weeks post-blast. In addition, following a single BOP we found that aberrantly phosphorylated tau rapidly accumulated in perivascular domains, but cleared within four hours, suggesting it was removed from the perivascular area, degraded, and/or dephosphorylated. Taken together these findings argue that mild blast exposure causes an evolving CNS insult that is initiated by discrete disturbances of vascular function, thereby setting the stage for more protracted and more widespread neuro-inflammatory responses. Published by Elsevier Ltd. on behalf of IBRO.
C1 [Huber, B. R.] Boston Univ, VA Jamaica Plain, Dept Neurol, Sch Med, Jamaica Plain, MA USA.
[Meabon, J. S.; Pagulayan, K. F.; McMillan, P. J.; Mayer, C. L.; Raskind, M. A.; Peskind, E. R.] VA Puget Sound Healthcare Syst, Northwest Network Mental Illness Res Educ & Clin, Seattle, WA USA.
[Meabon, J. S.; Pagulayan, K. F.; McMillan, P. J.; Mayer, C. L.; Raskind, M. A.; Peskind, E. R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98108 USA.
[Hoffer, Z. S.] US Army, Madigan Army Med Ctr, Joint Base Lewis Mcchord, WA USA.
[Zhang, J.; Hoekstra, J. G.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98108 USA.
[Banks, W. A.; Kraemer, B. C.; Cook, D. G.] Vet Affairs Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA.
[Banks, W. A.; Kraemer, B. C.; Cook, D. G.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98108 USA.
[McGavern, D. B.] NINDS, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
[Cook, D. G.] Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98108 USA.
RP Cook, DG (reprint author), Univ Washington, VA Puget Sound Hlth Care Syst, Dept Med, 1660 South Columbian Way, Seattle, WA 98108 USA.
EM dgcook@u.washington.edu
OI Hoekstra, Jake/0000-0001-6597-5878
FU Department of Veterans Affairs Office of Research and Development
Medical Research Service; VA Rehabilitation Research and Development
Service; University of Washington Royalty Research Fund [R01AG046619];
Northwest Network Mental Illness Research, Education and Clinical
Center; Office of Academic Affiliations, Advanced Fellowship Program in
Mental Illness Research and Treatment, Department of Veterans Affairs;
NIH [T32 AG000258]; VA CSR&D Career Development Award [IK2 CX00516]
FX This work was supported by the Department of Veterans Affairs Office of
Research and Development Medical Research Service (D.G.C., B.C.K.), VA
Rehabilitation Research and Development Service (E.R.P.), University of
Washington Royalty Research Fund (D.G.C.); R01AG046619 (W.A.B.);
Northwest Network Mental Illness Research, Education and Clinical Center
(E.R.P., B.R.H., J.S.M., K.F.P., P.J.M., C.L.M.), Office of Academic
Affiliations, Advanced Fellowship Program in Mental Illness Research and
Treatment, Department of Veterans Affairs (B.R.H.); NIH T32 AG000258
(J.S.M.), VA CSR&D Career Development Award Program #IK2 CX00516
(K.F.P.). We thank Dr. Gerard Schellenberg (Univ. Pennsylvania) for
providing Tau knock-out samples.
NR 41
TC 3
Z9 3
U1 2
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
EI 1873-7544
J9 NEUROSCIENCE
JI Neuroscience
PD APR 5
PY 2016
VL 319
BP 206
EP 220
DI 10.1016/j.neuroscience.2016.01.022
PG 15
WC Neurosciences
SC Neurosciences & Neurology
GA DD9RD
UT WOS:000370262400019
PM 26777891
ER
PT J
AU Yetish, G
Kaplan, H
Gurven, M
Wood, B
Pontzer, H
Manger, PR
Wilson, C
McGregor, R
Siegel, JM
AF Yetish, Gandhi
Kaplan, Hillard
Gurven, Michael
Wood, Brian
Pontzer, Herman
Manger, Paul R.
Wilson, Charles
McGregor, Ronald
Siegel, Jerome M.
TI Ancestral sleep Response
SO CURRENT BIOLOGY
LA English
DT Letter
C1 [Yetish, Gandhi; Kaplan, Hillard] Univ New Mexico, Dept Anthropol, MSC01-1040, Albuquerque, NM 87131 USA.
[Gurven, Michael] Univ Calif Santa Barbara, Dept Anthropol, 1210 Cheadle Hall, Santa Barbara, CA 93106 USA.
[Wood, Brian] Yale Univ, Dept Anthropol, 10 Sachem St, New Haven, CT 06511 USA.
[Pontzer, Herman] CUNY Hunter Coll, Dept Anthropol, 695 Pk Ave, New York, NY 10065 USA.
[Manger, Paul R.] Univ Witwatersrand, Sch Anat Sci, 7 York Rd, ZA-2193 Johannesburg, South Africa.
[Wilson, Charles] Univ Calif Los Angeles, Dept Neurol, 10833 Conte Ave, Los Angeles, CA 90095 USA.
[Wilson, Charles; Siegel, Jerome M.] Univ Calif Los Angeles, Brain Res Inst, 10833 Conte Ave, Los Angeles, CA 90095 USA.
[McGregor, Ronald; Siegel, Jerome M.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Siegel, Jerome M.] VA Greater Angeles Healthcare Syst, 16111 Plummer St, Los Angeles, CA 91343 USA.
RP Siegel, JM (reprint author), Univ Calif Los Angeles, Brain Res Inst, 10833 Conte Ave, Los Angeles, CA 90095 USA.; Siegel, JM (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.; Siegel, JM (reprint author), VA Greater Angeles Healthcare Syst, 16111 Plummer St, Los Angeles, CA 91343 USA.
EM jsiegel@ucla.edu
NR 10
TC 0
Z9 0
U1 4
U2 10
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0960-9822
EI 1879-0445
J9 CURR BIOL
JI Curr. Biol.
PD APR 4
PY 2016
VL 26
IS 7
BP R273
EP R274
PG 2
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA DI1RP
UT WOS:000373273600008
PM 27046810
ER
PT J
AU Braquehais, MD
Eiroa-Orosa, FJ
Holmes, KM
Lusilla, P
Bravo, M
Mozo, X
Mezzatesta, M
Casanovas, M
Pujol, T
Sher, L
AF Dolores Braquehais, Maria
Eiroa-Orosa, Francisco Jose
Holmes, Kristin M.
Lusilla, Pilar
Bravo, Maria
Mozo, Xulian
Mezzatesta, Marcela
Casanovas, Marta
Pujol, Tania
Sher, Leo
TI Differences in Physicians' and Nurses' Recent Suicide Attempts: An
Exploratory Study
SO ARCHIVES OF SUICIDE RESEARCH
LA English
DT Article
DE suicide attempts; nurses; physicians
ID DOCTORS; RISK; DEPRESSION; IDEATION; GENDER; RATES
AB The aim of this study was to examine the characteristics of physicians' and nurses' suicide attempts (SA). A retrospective review of 493 medical records of physicians and nurses admitted to an inpatient unit for health professionals; 36 patients had a recent SA. Depression, cluster B and C personality disorders, and a history of previous SA were more prevalent in patients with a recent SA compared to those without it. Both professional groups preferred drug overdose as a suicide method. Physicians made more lethal attempts and had a history of more previous stressors than nurses. Depression, cluster B and C personality disorders, and previous SA should be appropriately screened and treated in order to prevent SA amongst physicians and nurses.
C1 [Dolores Braquehais, Maria; Bravo, Maria; Mozo, Xulian; Pujol, Tania] Generalitat Catalonia, Dept Hlth, Galatea Clin, Integral Care Program Sick Hlth Care Profess, Barcelona, Spain.
[Dolores Braquehais, Maria; Bravo, Maria; Mozo, Xulian; Pujol, Tania] Coll Metges Barcelona, Galatea Fdn, Barcelona, Spain.
[Dolores Braquehais, Maria; Lusilla, Pilar] Univ Autonoma Barcelona, CIBERSAM, Vall dHebron Univ Hosp, Dept Psychiat & Legal Med, E-08193 Barcelona, Spain.
[Eiroa-Orosa, Francisco Jose] Univ E London, Sch Psychol, Water Lane, Stratford, England.
[Holmes, Kristin M.; Sher, Leo] James J Peters Vet Adm Med Ctr, Dept Psychiat, New York, NY USA.
[Holmes, Kristin M.; Sher, Leo] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
[Mezzatesta, Marcela] Fundacio Salut & Comunitat, Fundacio Orienta, Child & Adolescent Mental Hlth Unit, Barcelona, Spain.
[Casanovas, Marta] Univ London Imperial Coll Sci Technol & Med, Ctr Mental Hlth, Hammersmith Hosp Campus, London, England.
RP Braquehais, MD (reprint author), Galatea Fdn, Integral Care Program Sick Hlth Care Profess, Inpatient Psychiat Unit Hlth Profess, Galatea Clin, Passeig Bonanova 47, Barcelona 08017, Spain.
EM mdbraquehais.paimm@comb.cat
RI Eiroa Orosa, Francisco Jose/D-2510-2012
OI Eiroa Orosa, Francisco Jose/0000-0002-4163-6545
NR 17
TC 0
Z9 0
U1 0
U2 4
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1381-1118
EI 1543-6136
J9 ARCH SUICIDE RES
JI Arch. Suicide Res.
PD APR 2
PY 2016
VL 20
IS 2
BP 273
EP 279
DI 10.1080/13811118.2014.996693
PG 7
WC Psychiatry; Psychology; Psychology, Multidisciplinary
SC Psychiatry; Psychology
GA DJ0PG
UT WOS:000373905800013
PM 25517040
ER
PT J
AU Gunnery, SD
Ruben, MA
AF Gunnery, Sarah D.
Ruben, Mollie A.
TI Perceptions of Duchenne and non-Duchenne smiles: A meta-analysis
SO COGNITION & EMOTION
LA English
DT Article
DE Duchenne smile; Non-Duchenne smile; Smile perceptions
ID NON-ENJOYMENT SMILES; DETECTING HAPPINESS; NONENJOYMENT SMILES; FAKE
SMILES; AUTHENTICITY; SENSITIVITY; EXPRESSIONS; CHILDRENS; GENUINE;
MARKER
AB A meta-analysis was conducted to compare perceptions of Duchenne smiles, smiles that include activation of the cheek raiser muscle that creates crow's feet around the eyes, with perceptions of non-Duchenne smiles, smiles without cheek raiser activation. In addition to testing the overall effect, moderator analyses were conducted to test how methodological, stimulus-specific and perceiver-specific differences between studies predicted the overall effect size. The meta-analysis found that, overall, Duchenne smiles and people producing Duchenne smiles are rated more positively (i.e., authentic, genuine, real, attractive, trustworthy) than non-Duchenne smiles and people producing non-Duchenne smiles. The difference between Duchenne and non-Duchenne smiles was greater when the stimuli were videos rather than photographs, when smiles were elicited naturally rather than through posing paradigms and when Duchenne and non-Duchenne smiles were not matched for intensity of the lip corner puller in addition to other perceiver and methodological moderators.
C1 [Gunnery, Sarah D.] Tufts Univ, Dept Occupat Therapy, 26 Winthrop St, Medford, MA 02155 USA.
[Ruben, Mollie A.] US Dept Vet Affairs, Ctr Healthcare Org & Implementat Res, Boston, MA USA.
RP Gunnery, SD (reprint author), Tufts Univ, Dept Occupat Therapy, 26 Winthrop St, Medford, MA 02155 USA.
EM sarah.gunnery@tufts.edu
NR 36
TC 1
Z9 1
U1 6
U2 22
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 0269-9931
EI 1464-0600
J9 COGNITION EMOTION
JI Cogn. Emot.
PD APR 2
PY 2016
VL 30
IS 3
BP 501
EP 515
DI 10.1080/02699931.2015.1018817
PG 15
WC Psychology, Experimental
SC Psychology
GA DB7VA
UT WOS:000368723500008
PM 25787714
ER
PT J
AU Walker, RH
AF Walker, Ruth H.
TI The non-Huntington disease choreas Five new things
SO NEUROLOGY-CLINICAL PRACTICE
LA English
DT Review
ID FAMILIAL DYSKINESIA; FACIAL MYOKYMIA; NEUROFERRITINOPATHY; MOVEMENT;
SLEEP; ANTIBODIES; DISORDER; MUTATION
AB Purpose of review: Chorea can be due to a wide variety of causes. In this review, I provide updates on several recently identified genetic and autoimmune causes of chorea, and review evidence supporting the use of deep brain stimulation in chorea. Recent findings: New genes that may cause chorea include ADCY5 (encoding for adenylate cyclase 5) C9ORF72 (in addition to amyotrophic lateral sclerosis and frontotemporal dementia), and those responsible for the neurodegeneration with brain iron accumulation disorders. Novel autoantibodies are increasingly being identified as associated with a variety of neurologic syndromes, including chorea, in both paraneoplastic and non-paraneoplastic settings. Deep brain stimulation can be a useful intervention in patients with chorea who do not respond to oral medications, whether due to neurodegenerative or nondegenerative causes. Summary: New causes of chorea continue to be identified. Correct diagnosis is essential for prognostication and treatment.
C1 [Walker, Ruth H.] James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY 10468 USA.
[Walker, Ruth H.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
EM ruth.walker@mssm.edu
NR 20
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2163-0402
EI 2163-0933
J9 NEUROL-CLIN PRACT
JI Neurol.-Clin. Pract.
PD APR
PY 2016
VL 6
IS 2
BP 150
EP 156
DI 10.1212/CPJ.0000000000000236
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA EI6JT
UT WOS:000392602400014
ER
PT J
AU Koval, RD
Mcdonagh, J
Grubaugh, A
Young, W
Corcoran, B
Lee, A
Dumas, B
Edlund, B
AF Koval, Renee D.
Mcdonagh, James
Grubaugh, Anouk
Young, Wendy
Corcoran, Beth
Lee, Angela
Dumas, Bonnie
Edlund, Barbara
TI Implementation of Recovery Programming on an Inpatient Acute Psychiatric
Unit and Its Impact on Readmission
SO JOURNAL OF ADDICTIONS NURSING
LA English
DT Article
DE mental health; readmissions; recovery; veterans
ID ILLNESS MANAGEMENT
AB Background: Recovery-oriented models of care are evidence based and have been shown to improve patient satisfaction and outcomes as well as decrease the percentage of readmissions to inpatient psychiatric units.
Methods: This quality improvement project was implemented on a 16-bed inpatient adult mental health unit in a Veterans Affairs Medical Center. Percentages of readmissions were compared throughout the course of implementation of the recovery model. Readmissions during the months of July-September were tabulated over 3 subsequent years and compared readmission percentages before recovery implementation, during the early stage of recovery implementation, and finally, during ongoing recovery implementation.
Results: A decrease in readmission percentages was seen with implementation of recovery-oriented care when comparing the same 3-month period over 3 years.
Conclusion: After implementation of recovery-oriented care measures, there was a decrease in percentage of readmissions to the unit. In addition, this decrease was sustained and was shown to improve over time as recovery-oriented programming was further developed on the unit. These data suggest that Veterans Affairs Medical Centers should consider adding tools and procedures to successfully implement recovery programming on inpatient units and efforts should include direct involvement of patients in their own recovery journey, revision of policies and procedures to reflect the importance of recovery, thorough training of frontline staff regarding recovery principles, and transfer of recovery information directly from inpatient units to outpatient providers.
C1 [Koval, Renee D.] Med Univ South Carolina, Coll Nursing, Charleston, SC USA.
[Mcdonagh, James; Grubaugh, Anouk; Young, Wendy] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Corcoran, Beth] Lehigh Valley Hlth Network, LVPG Consultat Liaison Psychiat, Allentown, PA USA.
[Lee, Angela] Multnomah Cty Hlth Dept Correct Hlth, Portland, OR USA.
[Dumas, Bonnie; Edlund, Barbara] Med Univ South Carolina, Coll Nursing, Charleston, SC USA.
RP Koval, RD (reprint author), 650 Enterprise Blvd Apt 1304, Charleston, SC 29492 USA.
EM rkdnp15@gmail.com
FU (Office of Academic Affiliations), at a south eastern VAMC; American
Psychiatric Nurses Association
FX The authors acknowledge the assistance of Dr. Christopher Pelic, MD, in
preparation of the manuscript. In addition, the authors would also like
to acknowledge the Psychiatric Nurse Practitioner Residency Program
Directed by Dr. Janet York, PhD, PMHCS-BC, FAAN (funded by the Office of
Academic Affiliations), at a south eastern VAMC and the American
Psychiatric Nurses Association's Recovery to Practice training without
which this project would not have been possible.
NR 15
TC 1
Z9 1
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1088-4602
EI 1548-7148
J9 J ADDICT NURS
JI J. Addict. Nurs.
PD APR-JUN
PY 2016
VL 27
IS 2
BP 101
EP 108
DI 10.1097/JAN.0000000000000121
PG 8
WC Substance Abuse; Nursing
SC Substance Abuse; Nursing
GA EF0TO
UT WOS:000390039100007
PM 27272994
ER
PT J
AU Aliberti, S
Lonni, S
Dore, S
McDonnell, MJ
Goeminne, PC
Dimakou, K
Fardon, TC
Rutherford, R
Pesci, A
Restrepo, MI
Sotgiu, G
Chalmers, JD
AF Aliberti, Stefano
Lonni, Sara
Dore, Simone
McDonnell, Melissa J.
Goeminne, Pieter C.
Dimakou, Katerina
Fardon, Thomas C.
Rutherford, Robert
Pesci, Alberto
Restrepo, Marcos I.
Sotgiu, Giovanni
Chalmers, James D.
TI Clinical phenotypes in adult patients with bronchiectasis
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Article
ID OBSTRUCTIVE PULMONARY-DISEASE; CYSTIC FIBROSIS BRONCHIECTASIS;
CLUSTER-ANALYSIS; SYSTEMIC INFLAMMATION; COPD PHENOTYPES; VALIDATION;
EMPHYSEMA; AIRWAY
AB Bronchiectasis is a heterogeneous disease. This study aimed at identifying discrete groups of patients with different clinical and biological characteristics and long-term outcomes.
This was a secondary analysis of five European databases of prospectively enrolled adult outpatients with bronchiectasis. Principal component and cluster analyses were performed using demographics, comorbidities, and clinical, radiological, functional and microbiological variables collected during the stable state. Exacerbations, hospitalisations and mortality during a 3-year follow-up were recorded. Clusters were externally validated in an independent cohort of patients with bronchiectasis, also investigating inflammatory markers in sputum.
Among 1145 patients (median age 66 years; 40% male), four clusters were identified driven by the presence of chronic infection with Pseudomonas aeruginosa or other pathogens and daily sputum: "Pseudomonas" (16%), "Other chronic infection" (24%), "Daily sputum" (33%) and "Dry bronchiectasis" (27%). Patients in the four clusters showed significant differences in terms of quality of life, exacerbations, hospitalisations and mortality during follow-up. In the validation cohort, free neutrophil elastase activity, myeloperoxidase activity and interleukin-1 beta levels in sputum were significantly different among the clusters.
Identification of four clinical phenotypes in bronchiectasis could favour focused treatments in future interventional studies designed to alter the natural history of the disease.
C1 [Aliberti, Stefano; Lonni, Sara; Pesci, Alberto] Univ Milano Bicocca, Sch Med & Surg, AO San Gerardo, Via Pergolesi 33, I-20052 Monza, Italy.
[Dore, Simone; Sotgiu, Giovanni] Univ Sassari Res, Dept Biomed Sci, Med Educ & Profess Dev Unit, Clin Epidemiol & Med Stat Unit,AOU Sassari, Sassari, Italy.
[McDonnell, Melissa J.; Rutherford, Robert] Galway Univ Hosp, Dept Resp Med, Galway, Ireland.
[Goeminne, Pieter C.] Univ Hosp Gasthuisberg, Dept Resp Med, Leuven, Belgium.
[Goeminne, Pieter C.] UZ Leuven, Dept Resp Med, Leuven, Belgium.
[Dimakou, Katerina] Sotiria Chest Hosp, Dept Pulm 5, Athens, Greece.
[Fardon, Thomas C.; Chalmers, James D.] Univ Dundee, Tayside Resp Res Grp, Dundee, Scotland.
[Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, Div Pulm Dis & Crit Care, San Antonio, TX USA.
[Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
RP Aliberti, S (reprint author), Univ Milano Bicocca, Sch Med & Surg, AO San Gerardo, Via Pergolesi 33, I-20052 Monza, Italy.
EM stefano.aliberti@unimib.it
OI Aliberti, Stefano/0000-0002-0090-4531
FU European Multicentre Bronchiectasis Audit and Research Collaboration
(EMBARC); European Respiratory Society; Bayer HealthCare; Aradigm
Corporation; Medical Research Council; Wellcome Trust; European
Respiratory Society/European Lung Foundation; Health Research Board,
Ireland; National Heart, Lung and Blood Institute [K23HL096054]
FX This study was supported by the European Multicentre Bronchiectasis
Audit and Research Collaboration (EMBARC; www.bronchiectasis.eu). EMBARC
is a European Respiratory Society Clinical Research Collaboration and
has received funding from the European Respiratory Society, Bayer
HealthCare and Aradigm Corporation. J.D. Chalmers acknowledges
fellowship support from the Medical Research Council and the Wellcome
Trust. M.J. McDonnell acknowledges fellowship support from the European
Respiratory Society/European Lung Foundation and Health Research Board,
Ireland. M.I. Restrepo's time is partially protected by Award Number
K23HL096054 from the National Heart, Lung and Blood Institute. The
content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Heart, Lung and
Blood Institute or the National Institutes of Health. The funding
agencies had no role in the preparation, review or approval of the
manuscript. The views expressed in this article are those of the authors
and do not necessarily represent the views of the Department of Veterans
Affairs.
NR 25
TC 26
Z9 25
U1 0
U2 1
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
EI 1399-3003
J9 EUR RESPIR J
JI Eur. Resp. J.
PD APR
PY 2016
VL 47
IS 4
BP 1113
EP 1122
DI 10.1183/13993003.01899-2015
PG 10
WC Respiratory System
SC Respiratory System
GA DZ6EW
UT WOS:000385955400018
PM 26846833
ER
PT J
AU Jackevicius, CA
Tu, JV
Krumholz, HM
Austin, PC
Ross, JS
Stukel, TA
Koh, M
Chong, A
Ko, DT
AF Jackevicius, Cynthia A.
Tu, Jack V.
Krumholz, Harlan M.
Austin, Peter C.
Ross, Joseph S.
Stukel, Therese A.
Koh, Maria
Chong, Alice
Ko, Dennis T.
TI Comparative Effectiveness of Generic Atorvastatin and Lipitor (R) in
Patients Hospitalized with an Acute Coronary Syndrome
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE acute coronary syndrome; comparative effectiveness; statin
ID BRAND-NAME STATINS; CARDIOVASCULAR-DISEASE; PROPENSITY SCORE; KOREAN
ADULTS; DRUGS; TOLERABILITY; PERCEPTIONS; MEDICATIONS; EQUIVALENCE;
MULTICENTER
AB Background-Although generic medications are approved based on bioequivalence with brand-name medications, there remains substantial concern regarding their clinical effectiveness and safety. Lipitor (R), available as generic atorvastatin, is one of the most commonly prescribed statins. Therefore, we compared the effectiveness of generic atorvastatin products and Lipitor (R).
Methods and Results-We conducted a population-based cohort study, using propensity score matching to minimize potential confounding of patients >= 65 years, discharged alive after acute coronary syndrome (ACS) hospitalization between 2008 and 2012 in Ontario, Canada, who were prescribed Lipitor (R) or generic atorvastatin within 7 days of discharge. The primary outcome was 1-year death/recurrent ACS hospitalization. Secondary outcomes included hospitalization for heart failure, stroke, new-onset diabetes, rhabdomyolysis, and renal failure. In the 7863 propensity-matched pairs (15 726 patients), mean age was 76.9 years, 56.3% were male, 87.6% had myocardial infarction, and all patients had complete follow-up. At 1 year, 17.7% of those prescribed generic atorvastatin and 17.7% of those prescribed Lipitor (R) experienced death or recurrent ACS (hazard ratio, 1.00; 95% CI, 0.93-1.08; P= 0.94). No significant differences in rates of secondary outcomes between groups were observed. Prespecified subgroup analyses by age, sex, diabetes, atorvastatin dose, or admission diagnosis found no outcome difference between groups.
Conclusions-Among older adults discharged alive after ACS hospitalization, we found no significant difference in cardiovascular outcomes or serious, infrequent side effects in patients prescribed generic atorvastatin compared with those prescribed Lipitor (R) at 1 year. Our findings support the use of generic atorvastatin in ACS, which could lead to substantial cost saving for patients and health care plans without diminishing population clinical effectiveness.
C1 [Jackevicius, Cynthia A.] Western Univ Hlth Sci, Coll Pharm, Dept Pharm Practice & Adm, Pomona, CA USA.
[Jackevicius, Cynthia A.; Tu, Jack V.; Austin, Peter C.; Stukel, Therese A.; Koh, Maria; Chong, Alice; Ko, Dennis T.] Inst Clin Evaluat Sci, Toronto, ON, Canada.
[Jackevicius, Cynthia A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Jackevicius, Cynthia A.; Tu, Jack V.; Austin, Peter C.; Stukel, Therese A.; Ko, Dennis T.] Univ Toronto, Fac Med, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada.
[Tu, Jack V.; Ko, Dennis T.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Schulich Heart Ctr, Div Cardiol, Toronto, ON, Canada.
[Jackevicius, Cynthia A.] Univ Hlth Network, Toronto, ON, Canada.
[Krumholz, Harlan M.] Yale Univ, Dept Med, Sect Cardiovasc Med, New Haven, CT 06520 USA.
[Krumholz, Harlan M.; Ross, Joseph S.] Yale Univ, Yale New Haven Hosp, Sch Med, Ctr Outcomes Res & Evaluat, New Haven, CT USA.
[Krumholz, Harlan M.] Yale Univ, Dept Epidemiol & Publ Hlth, Sect Hlth Policy & Adm, New Haven, CT 06520 USA.
[Krumholz, Harlan M.] Robert Wood Johnson Clin Scholars Program, New Haven, CT USA.
[Ross, Joseph S.] Yale Univ, Dept Med, Gen Internal Med Sect, New Haven, CT 06520 USA.
RP Jackevicius, CA (reprint author), Western Univ Hlth Sci, Coll Pharm, 309 E Second St, Pomona, CA 91766 USA.
EM cjackevicius@westernu.edu
FU Heart and Stroke Foundation (HSF) [G-14-0005977]; Ontario Ministry of
Health and Long-Term Care (MOHLTC)
FX This study was funded by a grant (G-14-0005977) from the Heart and
Stroke Foundation (HSF). The Institute for Clinical Evaluative Sciences
(ICES) is funded by an annual grant from the Ontario Ministry of Health
and Long-Term Care (MOHLTC). The opinions, results, and conclusions
reported in this article are those of the authors and are independent
from the funding sources. Furthermore, design and conduct of the study;
collection, management, analysis, and interpretation of the data;
preparation, review, or approval of the manuscript; and decision to
submit the manuscript for publication were also independent from the
funding sources. No endorsement by ICES, the MOHLTC, or the HSF is
intended or should be inferred.
NR 39
TC 1
Z9 1
U1 4
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD APR
PY 2016
VL 5
IS 4
AR e003350
DI 10.1161/JAHA.116.003350
PG 18
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DZ1PI
UT WOS:000385609900033
PM 27098970
ER
PT J
AU Nettiksimmons, J
Tranah, G
Evans, DS
Yokoyama, JS
Yaffe, K
AF Nettiksimmons, Jasmine
Tranah, Gregory
Evans, Daniel S.
Yokoyama, Jennifer S.
Yaffe, Kristine
TI Gene-based aggregate SNP associations between candidate AD genes and
cognitive decline
SO AGE
LA English
DT Article
DE SNP associations; Candidate AD genes; Cognitive decline
ID GENOME-WIDE ASSOCIATION; ALZHEIMERS-DISEASE; OSTEOPOROTIC FRACTURES;
COMMON VARIANTS; CD33; SIGLECS; RISK; EXPRESSION; ROLES; BRAIN
AB Single nucleotide polymorphisms (SNPs) in and near ABCA7, BIN1, CASS4, CD2AP, CD33, CELF1, CLU, complement receptor 1 (CR1), EPHA1, EXOC3L2, FERMT2, HLA cluster (DRB5-DQA), INPP5D, MEF2C, MS4A cluster (MS4A3-MS4A6E), NME8, PICALM, PTK2B, SLC24A4, SORL1, and ZCWPW1 have been associated with Alzheimer's disease (AD) in large meta-analyses. We aimed to determine whether established AD-associated genes are associated with longitudinal cognitive decline by examining aggregate variation across these gene regions. In two single-sex cohorts of older, community-dwelling adults, we examined the association between SNPs in previously implicated gene regions and cognitive decline (age-adjusted person-specific cognitive slopes) using a Sequence Kernel Association Test (SKAT). In regions which showed aggregate significance, we examined the univariate association between individual SNPs in the region and cognitive decline. Only two of the original AD-associated SNPs were significantly associated with cognitive decline in our cohorts. We identified significant aggregate-level associations between cognitive decline and the gene regions BIN1, CD33, CELF1, CR1, HLA cluster, and MEF2C in the allfemale cohort and significant associations with ABCA7, HLA cluster, MS4A6E, PICALM, PTK2B, SLC24A4, and SORL1 in the all-male cohort. We also identified a block of eight correlated SNPs in CD33 and several blocks of correlated SNPs in CELF1 that were significantly associated with cognitive decline in univariate analysis in the all-female cohort.
C1 [Nettiksimmons, Jasmine] Univ Calif San Francisco, Dept Psychiat, 4150 Clement St,Box VAMC-116H, San Francisco, CA 94121 USA.
[Tranah, Gregory] Univ Calif San Francisco, Dept Epidemiol & Biostat, Calif Pacific Med Ctr, Res Inst, Mission Hall Global Hlth & Clin Sci Bldg, San Francisco, CA 94158 USA.
[Evans, Daniel S.] Calif Pacific Med Ctr, Res Inst, Mission Hall Global Hlth & Clin Sci Bldg, San Francisco, CA 94158 USA.
[Yokoyama, Jennifer S.] Univ Calif San Francisco, Memory & Aging Ctr, Sandler Neurosci Ctr, 675 Nelson Rising Lane,Suite 190, San Francisco, CA 94143 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco Vet Affairs Med Ctr, 4150 Clement St,Box 181, San Francisco, CA 94121 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco Vet Affairs Med Ctr, 4150 Clement St,Box 181, San Francisco, CA 94121 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco Vet Affairs Med Ctr, 4150 Clement St,Box 181, San Francisco, CA 94121 USA.
RP Nettiksimmons, J (reprint author), Univ Calif San Francisco, Dept Psychiat, 4150 Clement St,Box VAMC-116H, San Francisco, CA 94121 USA.
EM jasminen@gmail.com; GTranah@psg.ucsf.edu; DEvans@psg.ucsf.edu;
jyokoyama@memory.ucsf.edu; kristine.yaffe@ucsf.edu
FU National Institutes of Health; National Institute on Aging (NIA) [R01
AG005407, R01 AR35582, R01 AR35583, R01 AR35584, R01 AG005394, R01
AG027574, R01 AG027576]; National Institute of Arthritis and
Musculoskeletal and Skin Diseases (NIAMS); National Center for Advancing
Translational Sciences (NCATS); NIH Roadmap for Medical Research [U01
AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01
AG042145, U01 AG042168, U01 AR066160, UL1 TR000128]; NIAMS [RC2
AR058973, R01 AR051124]; National Institute of Aging [K24AG031155];
Larry L. Hillblom Foundation [2012-A-015-FEL]; National Institute on
Aging [K01 AG049152]; Diversity Supplement [P50 AG023501]; AFTD Susan
Marcus Memorial Fund Clinical Research Grant
FX The Study of Osteoporotic Fractures (SOF) is supported by the National
Institutes of Health funding. The National Institute on Aging (NIA)
provides support under the following grant numbers: R01 AG005407, R01
AR35582, R01 AR35583, R01 AR35584, R01 AG005394, R01 AG027574, and R01
AG027576. The Osteoporotic Fractures in Men (MrOS) Study is supported by
the National Institutes of Health funding. The following institutes
provide support: the National Institute on Aging (NIA), the National
Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),
the National Center for Advancing Translational Sciences (NCATS), and
NIH Roadmap for Medical Research under the following grant numbers: U01
AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01
AG042145, U01 AG042168, U01 AR066160, and UL1 TR000128. The NIAMS
provides funding for the MrOS ancillary study "GWAS in MrOS and SOF"
under the grant number RC2 AR058973. TheNIAMS provides funding for the
MrOS ancillary study "Replication of candidate gene associations and
bone strength phenotype in MrOS" under the grant number R01 AR051124.
Dr. Yaffe is supported in part by a National Institute of Aging Grant
(K24AG031155). Dr. Yokoyama is supported in part by Larry L. Hillblom
Foundation 2012-A-015-FEL, National Institute on Aging K01 AG049152 and
Diversity Supplement to P50 AG023501, and AFTD Susan Marcus Memorial
Fund Clinical Research Grant.
NR 33
TC 4
Z9 4
U1 3
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0161-9152
EI 1574-4647
J9 AGE
JI Age
PD APR
PY 2016
VL 38
IS 2
AR 41
DI 10.1007/s11357-016-9885-2
PG 10
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA DX9SM
UT WOS:000384735400001
PM 27005436
ER
PT J
AU Schlosser, D
Campellone, T
Kim, D
Truong, B
Vergani, S
Ward, C
Vinogradov, S
AF Schlosser, Danielle
Campellone, Timothy
Kim, Daniel
Truong, Brandy
Vergani, Silvia
Ward, Charlie
Vinogradov, Sophia
TI Feasibility of PRIME: A Cognitive Neuroscience-Informed Mobile App
Intervention to Enhance Motivated Behavior and Improve Quality of Life
in Recent Onset Schizophrenia
SO JMIR RESEARCH PROTOCOLS
LA English
DT Article
DE schizophrenia; mobile app; smartphone; motivation; technology-based
intervention; social networking; coaching; negative symptoms; quality of
life
ID NEGATIVE SYMPTOMS; ENVIRONMENTAL SUPPORTS; PHYSICAL-ACTIVITY; RECOVERY;
OUTCOMES; PEOPLE; METAANALYSIS; OUTPATIENTS; DISORDERS; DEFICITS
AB Background: Despite improvements in treating psychosis, schizophrenia remains a chronic and debilitating disorder that affects approximately 1% of the US population and costs society more than depression, dementia, and other medical illnesses across most of the lifespan. Improving functioning early in the course of illness could have significant implications for long-term outcome of individuals with schizophrenia. Yet, current gold-standard treatments do not lead to clinically meaningful improvements in outcome, partly due to the inherent challenges of treating a population with significant cognitive and motivational impairments. The rise of technology presents an opportunity to develop novel treatments that may circumvent the motivational and cognitive challenges observed in schizophrenia.
Objective: The purpose of this study was two-fold: (1) to evaluate the feasibility and acceptability of implementing a Personalized Real-Time Intervention for Motivation Enhancement (PRIME), a mobile app intervention designed to target reward-processing impairments, enhance motivation, and thereby improve quality of life in recent onset schizophrenia, and (2) evaluate the empirical benefits of using an iterative, user-centered design (UCD) process.
Methods: We conducted two design workshops with 15 key stakeholders, followed by a series of in-depth interviews in collaboration with IDEO, a design and innovation firm. The UCD approach ultimately resulted in the first iteration of PRIME, which was evaluated by 10 RO participants. Results from the Stage 1 participants were then used to guide the next iteration that is currently being evaluated in an ongoing RCT. Participants in both phases were encouraged to use the app daily with a minimum frequency of 1/week over a 12-week period.
Results: The UCD process resulted in the following feature set: (1) delivery of text message (short message service, SMS)-based motivational coaching from trained therapists, (2) individualized goal setting in prognostically important psychosocial domains, (3) social networking via direct peer-to-peer messaging, and (4) community "moments feed" to capture and reinforce rewarding experiences and goal achievements. Users preferred an experience that highlighted several of the principles of self-determination theory, including the desire for more control of their future (autonomy and competence) and an approach that helps them improve existing relationships (relatedness). IDEO, also recommended an approach that was casual, friendly, and nonstigmatizing, which is in line with the recovery model of psychosis. After 12-weeks of using PRIME, participants used the app, on average, every other day, were actively engaged with its various features each time they logged in and retention and satisfaction was high (20/20, 100% retention, high satisfaction ratings). The iterative design process lead to a 2- to 3-fold increase in engagement from Stage 1 to Stage 2 in almost each aspect of the platform.
Conclusions: These results indicate that the neuroscience-informed mobile app, PRIME, is a feasible and acceptable intervention for young people with schizophrenia.
C1 [Schlosser, Danielle; Kim, Daniel; Truong, Brandy; Ward, Charlie; Vinogradov, Sophia] Univ Calif San Francisco, Dept Psychiat, 401 Parnassus Ave, San Francisco, CA 94134 USA.
[Campellone, Timothy] Univ Calif Berkeley, Berkeley, CA 94720 USA.
[Vergani, Silvia] IDEO, Palo Alto, CA USA.
[Vinogradov, Sophia] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Schlosser, D (reprint author), Univ Calif San Francisco, Dept Psychiat, 401 Parnassus Ave, San Francisco, CA 94134 USA.
EM danielle.schlosser@ucsf.edu
RI Emchi, Karma/Q-1952-2016
OI Schlosser, Danielle/0000-0001-7652-0924
FU NCATS NIH HHS [UL1 TR000004]; NIMH NIH HHS [K23 MH097795, R34 MH100399]
NR 41
TC 0
Z9 0
U1 12
U2 15
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA
SN 1929-0748
J9 JMIR RES PROTOC
JI JMIR RES. Protoc.
PD APR-JUN
PY 2016
VL 5
IS 2
AR e77
DI 10.2196/resprot.5450
PG 13
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA DT1AH
UT WOS:000381213600043
PM 27125771
ER
PT J
AU Li, L
Shelton, RC
Chassan, RA
Hammond, JC
Gower, BA
Garvey, TW
AF Li, Li
Shelton, Richard Charles
Chassan, Rachel Ann
Hammond, John Charles
Gower, Barbara Ann
Garvey, Timothy W.
TI Impact of Major Depressive Disorder on Prediabetes by Impairing Insulin
Sensitivity
SO JOURNAL OF DIABETES & METABOLISM
LA English
DT Article
DE Insulin sensitivity; Prediabetes; Atherosclerosis; Phosphorylation;
Cardiovascular diseases; Glucose tolerance test
ID TYPE-2 DIABETES-MELLITUS; ORAL GLUCOSE-TOLERANCE; RISK-FACTOR;
PLASMA-GLUCOSE; DSM-IV; RESISTANCE; METABOLISM; ADIPOSITY; DISEASE;
HEALTH
AB Reports regarding the associations between major depressive disorder (MDD) and diabetes remain heterogeneous. Our aim was to investigate whether glucose homeostasis and insulin sensitivity were impaired in the MDD patients and its mechanisms. A total of 30 patients with MDD and 30 matched controls were recruited. The oral glucose tolerance test and dual-energy X-ray absorptiometry scan were performed in each participant. Insulin signaling in postmortem brain tissues from other depressive patients and controls (obtained from Alabama brain bank) was examined. Insulin sensitivity was reduced substantially in the MDD patients, however, the fasting and 2-h glucose concentrations remained within the normal range through compensatory insulin secretion. Despite increased insulin secretion, 1-h glucose concentrations in the MDD patients were significantly elevated compared with the controls. MDD patients had greater visceral fat mass but lower adiponectin levels compared with the controls. Furthermore, phosphorylated-AKT levels in insulin signaling were decreased in postmortem brain tissues in patients with MDD. These results suggest that MDD patients are at a greater risk for diabetes due to decreased insulin sensitivity, reduced disposition index, and impaired glucose tolerance as manifested by elevated 1-h glucose concentrations following an oral glucose challenge. Mechanistic studies reveal that decreased insulin sensitivity is associated with increased visceral fat mass, lower adiponectin levels and impaired insulin action in postmortem brain tissues in the MDD patients. Our findings emphasize the importance of screening depressive patients to identify susceptible individuals for developing future diabetes with the hope of improving their health outcomes.
C1 [Li, Li; Shelton, Richard Charles; Chassan, Rachel Ann; Hammond, John Charles] Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, 1720 Univ Blvd, Birmingham, AL 35294 USA.
[Gower, Barbara Ann; Garvey, Timothy W.] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA.
[Garvey, Timothy W.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA.
RP Li, L (reprint author), Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, 1720 Univ Blvd, Birmingham, AL 35294 USA.
EM lili978@uab.edu
NR 30
TC 0
Z9 0
U1 3
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 2155-6156
J9 J DIABETES METAB
JI J. Diabetes Metab.
PD APR
PY 2016
VL 7
IS 4
AR UNSP 664
DI 10.4172/2155-6156.1000664
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DX6BB
UT WOS:000384466000003
ER
PT J
AU Hermayer, KL
AF Hermayer, Kathie L.
TI The Diabetes Initiative of South Carolina Celebrates Over 20 Years of
Professional Diabetes Education
SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES
LA English
DT Article
DE Diabetes mellitus; South Carolina; Symposium; Education; Program
AB Background: Diabetes is a major public health problem in South Carolina; however, the Diabetes Initiative of South Carolina (DSC) provides a realistic mechanism to address issues on a statewide basis.
Methods: The Diabetes Center of Excellence in the DSC provides oversight for developing and supervising professional education programs for health care workers of all types in South Carolina to increase their knowledge and ability to care for people with diabetes. The DSC has developed many programs for the education of a variety of health professionals about diabetes and its complications.
Results: The DSC has sponsored 21 Annual Diabetes Fall Symposia for primary health care professionals featuring education regarding many aspects of diabetes mellitus. The intent of the program is to enhance the lifelong learning process of physicians, advanced practice providers, nurses, pharmacists, dietitians, laboratorians and other health care professionals, by providing educational opportunities and to advance the quality and safety of patient care. The symposium is an annual 2-day statewide program that supplies both a comprehensive diabetes management update to all primary care professionals and an opportunity for attendees to obtain continuing education credits at a low cost.
Conclusion: The overarching goal of the DSC is that the programs it sponsors and the development of new targeted initiatives will lead to continuous improvements in the care of people at risk and with diabetes along with a decrease in morbidity, mortality and costs of diabetes and its complications in South Carolina and elsewhere.
C1 [Hermayer, Kathie L.] Med Univ South Carolina, Qual Dept, Charleston, SC USA.
[Hermayer, Kathie L.] Med Univ South Carolina, Dept Med, Div Endocrinol, Charleston, SC USA.
[Hermayer, Kathie L.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
RP Hermayer, KL (reprint author), Med Univ South Carolina, 96 Jonathan Lucas St,CSB 938,MSC 624, Charleston, SC 29425 USA.
EM hermayer@musc.edu
NR 1
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9629
EI 1538-2990
J9 AM J MED SCI
JI Am. J. Med. Sci.
PD APR
PY 2016
VL 351
IS 4
BP 325
EP 326
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA DV1FJ
UT WOS:000382665400001
PM 27079336
ER
PT J
AU Walker, RJ
Williams, JS
Egede, LE
AF Walker, Rebekah J.
Williams, Joni Strom
Egede, Leonard E.
TI Influence of Race, Ethnicity and Social Determinants of Health on
Diabetes Outcomes
SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES
LA English
DT Article
DE Social determinants of health; Diabetes; Health disparities;
Psychosocial factors; Neighborhood factors
ID SELF-CARE BEHAVIORS; NUTRITION EXAMINATION SURVEY; IMPROVE GLYCEMIC
CONTROL; HISPANIC WHITE ADULTS; NEIGHBORHOOD FACTORS; UNITED-STATES;
CARDIOVASCULAR-DISEASE; SOCIOECONOMIC-STATUS; RACIAL DISPARITIES;
AFRICAN-AMERICANS
AB Background: There is strong evidence that race, ethnicity and social determinants of health significantly influence outcomes for patients with diabetes. A better understanding of the mechanisms of these relationships or associations would improve development of cost-effective, culturally tailored programs for patients with diabetes.
Methods: This article reviews the current state of the literature on the influence of race and ethnicity and social determinants of health on process of care, quality of care and outcomes for diabetes, with particular emphasis on the rural South to give an overview of the state of the literature.
Results: The literature review shows that racial or ethnic differences in the clinical outcomes for diabetes, including glycemic, blood pressure (BP) and lipid control, continue to persist. In addition, the literature review shows that the role of social determinants of health on outcomes, and the possible role these determinants play in disparities have largely been ignored. Psychosocial factors, such as self-efficacy, depression, social support and perceived stress, show consistent associations with self-care, quality of life and glycemic control. Neighborhood factors, such as food insecurity, social cohesion and neighborhood esthetics have been associated with glycemic control. Perceived discrimination has also been associated with self-care and the psychological component of quality of life.
Conclusion: Healthcare professionals need to be skilled in assessing social determinants of health and taking them into consideration in clinical care. In addition, more research is needed to identify the separate and combined influence of race and ethnicity and social determinants of health on process of care, quality of care and outcomes in diabetes, especially in the South, where the burden of disease is particularly high.
C1 [Walker, Rebekah J.; Williams, Joni Strom; Egede, Leonard E.] Med Univ South Carolina, Ctr Hlth Dispar Res, Dept Med, 135 Rutledge Ave,Room 280G, Charleston, SC 29425 USA.
[Walker, Rebekah J.; Williams, Joni Strom; Egede, Leonard E.] Med Univ South Carolina, Div Gen Internal Med & Geriatr, Dept Med, Charleston, SC USA.
[Walker, Rebekah J.; Williams, Joni Strom; Egede, Leonard E.] Ralph H Johnson Vet Affairs Med Ctr, HEROIC, Charleston, SC USA.
RP Egede, LE (reprint author), Med Univ South Carolina, Ctr Hlth Dispar Res, Dept Med, 135 Rutledge Ave,Room 280G, Charleston, SC 29425 USA.
EM egedel@musc.edu
FU HSRD VA [I50 HX001229]; NIDDK NIH HHS [K24 DK093699, R01 DK098529]
NR 69
TC 4
Z9 4
U1 10
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9629
EI 1538-2990
J9 AM J MED SCI
JI Am. J. Med. Sci.
PD APR
PY 2016
VL 351
IS 4
BP 366
EP 373
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA DV1FJ
UT WOS:000382665400007
PM 27079342
ER
PT J
AU Shearer, JE
Jenkins, CH
Magwood, GS
Pope, CA
AF Shearer, Jennifer E.
Jenkins, Carolyn H.
Magwood, Gayenell S.
Pope, Charlene A.
TI Contested Ownership of Disease and Ambulatory-Sensitive Emergency
Department Visits for Type 2 Diabetes
SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES
LA English
DT Article
DE Type 2 diabetes; Emergency departmentuse; Ambulatory-sensitive
conditions; Qualitative research; Grounded theory with dimensional
analysis
ID ILLNESS SELF-MANAGEMENT; AFRICAN-AMERICANS; GROUNDED THEORY; CARE;
MODEL; PATIENT; LIFE
AB Background: Approximately 21 million persons have diabetes and account for 11.9% of all emergency department (ED) visits for a total cost of $14.1 billion. Nonemergent visits for ambulatory-sensitive conditions that could be managed by the primary care provider make up almost one-third of the ED visits. African Americans comprise approximately 30% of South Carolina's population but make up approximately 50% of the ED visits for diabetes. The purpose of the research was to explore the experiences of 20 African-American adults with diabetes with ambulatory-sensitive ED use.
Research Design and Methods: The research design for this study is grounded theory with dimensional analysis methods. Following ethics approval and informed consent, interviews were conducted, recorded and transcribed verbatim, and themes were analyzed to form the explanatory framework or matrix for ED use. The framework of context, conditions, processes and consequences provides a key for understanding the themes of the story embedded in the descriptive narratives.
Results: The contested ownership of diabetes was the overarching perspective--"doing what I got to do," "it's always on mind wishing not to be a diabetic" and "it's a constant burden." And handling diabetes involved taking decisions "into your hands." The context of perceived urgency of symptoms included all the reasons that precipitated ED visit--personal experience, primary care access and services and social network support for decisions--influenced ownership of these decisions.
C1 [Shearer, Jennifer E.; Jenkins, Carolyn H.] Charleston Southern Univ, Coll Nursing, Charleston, SC USA.
[Jenkins, Carolyn H.; Magwood, Gayenell S.; Pope, Charlene A.] Med Univ South Carolina, Coll Nursing, 99 Jonathan Lucas St,MSC 160, Charleston, SC 29425 USA.
[Pope, Charlene A.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Jenkins, CH (reprint author), Med Univ South Carolina, Coll Nursing, 99 Jonathan Lucas St,MSC 160, Charleston, SC 29425 USA.
EM Jenkins@musc.edu
FU NINR NIH HHS [R15 NR009486]
NR 35
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9629
EI 1538-2990
J9 AM J MED SCI
JI Am. J. Med. Sci.
PD APR
PY 2016
VL 351
IS 4
BP 400
EP 406
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA DV1FJ
UT WOS:000382665400011
PM 27079346
ER
PT J
AU Larsen, BA
Wassel, CL
Kritchevsky, SB
Strotmeyer, ES
Criqui, MH
Kanaya, AM
Fried, LF
Schwartz, AV
Harris, TB
Ix, JH
AF Larsen, Britta A.
Wassel, Christina L.
Kritchevsky, Stephen B.
Strotmeyer, Elsa S.
Criqui, Michael H.
Kanaya, Alka M.
Fried, Linda F.
Schwartz, Ann V.
Harris, Tamara B.
Ix, Joachim H.
CA Hlth ABC Study
TI Association of Muscle Mass, Area, and Strength With Incident Diabetes in
Older Adults: The Health ABC Study
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID SKELETAL-MUSCLE; INSULIN SENSITIVITY; GLUCOSE-TOLERANCE;
BODY-COMPOSITION; ADIPOSE-TISSUE; WOMEN; RESISTANCE; MORTALITY; MEN;
OVERWEIGHT
AB Context: Skeletal muscle plays a key role in glucose regulation, yet the association between muscle quantity or quality and the risk of developing type 2 diabetes has not been explored.
Objective: The objective of the study was to assess the association between muscle quantity and strength and incident diabetes and to explore whether this association differs by body mass index (BMI) category.
Design and Setting: Participants were 2166 older adults in the Health, Aging, and Body Composition Study who were free of diabetes at baseline (1997-1998). Computed tomography and dual-energy x-ray absorptiometry were used to measure abdominal and thigh muscle area and total body lean mass, respectively. Strength was quantified by grip and knee extensions.
Main Outcome Measure: Incident diabetes, defined as fasting glucose of 126 mg/dL or greater, a physician's diagnosis, and/or the use of hypoglycemic medication were measured.
Results: After a median 11.3 years of follow-up, there were 265 incident diabetes cases (12.2%). In fully adjusted models, no association was found between muscle or strength measures and incident diabetes (for all, P > .05). For women, there was a significant interaction with BMI category for both abdominal and thigh muscle, such that greater muscle predicted lower risk of incident diabetes for normal-weight women(hazard ratio 0.37 [0.17-0.83] and 0.58 [0.27-1.27] per SD, respectively) and a greater risk for overweight and obese women(hazard ratio 1.23 [0.98-1.54] and 1.28 [1.00-1.64], respectively). No significant interactions by BMI category existed for strength measures or any measures for men (for all, P > .05).
Conclusions: Greater muscle area is associated with a lower risk of incident diabetes for older normal-weight women but not for men or overweight women.
C1 [Larsen, Britta A.; Criqui, Michael H.; Ix, Joachim H.] Univ Calif San Diego, Dept Family Med & Publ Hlth, 9500 Gilman Dr, San Diego, CA 92093 USA.
[Ix, Joachim H.] Univ Calif San Diego, Dept Med, San Diego, CA 92093 USA.
[Wassel, Christina L.] Univ Vermont, Coll Med, Dept Pathol & Lab Med, Burlington, VT 05446 USA.
[Kritchevsky, Stephen B.] Wake Forest Univ, Winston Salem, NC 27157 USA.
[Kritchevsky, Stephen B.] Sch Med, Winston Salem, NC 27157 USA.
[Strotmeyer, Elsa S.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15219 USA.
[Schwartz, Ann V.] Univ Calif San Francisco, Div Gen Internal Med, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Fried, Linda F.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15261 USA.
[Fried, Linda F.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA.
[Harris, Tamara B.] NIA, Bethesda, MD 20892 USA.
RP Larsen, BA (reprint author), Univ Calif San Diego, Dept Family Med & Publ Hlth, 9500 Gilman Dr, San Diego, CA 92093 USA.
EM blarsen@ucsd.edu
FU National Institute on Aging [N01-AG-6-2101, N01-AG-6-2103,
N01-AG-6-2106, R01-AG028050]; National Institute of Nursing Research
Grant [R01-NR012459]; Intramural Research Program of the National
Institute on Aging; Career Development Grant from National Institute of
Diabetes and Digestive and Kidney Diseases [K01 DK101650]; Established
Investigator Award from American Heart Association [14EIA18560026]
FX This work was supported Contracts N01-AG-6-2101, N01-AG-6-2103, and
N01-AG-6-2106 from the National Institute on Aging, National Institute
on Aging Grant R01-AG028050 and National Institute of Nursing Research
Grant R01-NR012459. This research was also supported in part by the
Intramural Research Program of the National Institute on Aging. B.L. was
supported by Career Development Grant K01 DK101650 from the National
Institute of Diabetes and Digestive and Kidney Diseases. J.I. was
supported by an Established Investigator Award from the American Heart
Association (14EIA18560026).
NR 26
TC 1
Z9 1
U1 0
U2 0
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD APR
PY 2016
VL 101
IS 4
BP 1847
EP 1855
DI 10.1210/jc.2015-3643
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DU0YP
UT WOS:000381931400060
PM 26930180
ER
PT J
AU Hjelmeland, A
Zhang, JH
AF Hjelmeland, Anita
Zhang, Jianhua
TI Metabolic, autophagic, and mitophagic activities in cancer initiation
and progression
SO BIOMEDICAL JOURNAL
LA English
DT Review
DE Autophagy; Cancer; Mitochondria; Mitophagy; Oxidative stress; Reactive
species
ID TUMOR-SUPPRESSOR GENE; POSITRON-EMISSION-TOMOGRAPHY; FACTOR-INDEPENDENT
SURVIVAL; TRANSCRIPTION FACTOR NRF2; PYRUVATE-KINASE M2; NITRIC-OXIDE;
REACTIVE OXYGEN; BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; THERAPEUTIC
TARGET
AB Cancer is a complex disease marked by uncontrolled cell growth and invasion. These processes are driven by the accumulation of genetic and epigenetic alterations that promote cancer initiation and progression. Contributing to genome changes are the regulation of oxidative stress and reactive species-induced damage to molecules and organelles. Redox regulation, metabolic plasticity, autophagy, and mitophagy play important and interactive roles in cancer hallmarks including sustained proliferation, activated invasion, and replicative immortality. However, the impact of these processes can differ depending on the signaling pathways altered in cancer, tumor type, tumor stage, and/or the differentiation state. Here, we highlight some of the representative studies on the impact of oxidative and nitrosative activities, mitochondrial bioenergetics, metabolism, and autophagy and mitophagy in the context of tumorigenesis. We discuss the implications of these processes for cellular activities in cancer for anti-cancer-based therapeutics.
C1 [Hjelmeland, Anita] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL USA.
[Hjelmeland, Anita; Zhang, Jianhua] Univ Alabama Birmingham, Ctr Free Radical Biol, Birmingham, AL USA.
[Zhang, Jianhua] Univ Alabama Birmingham, Dept Pathol, Biomed Res Bldg 2,901 19th St South, Birmingham, AL 35294 USA.
[Zhang, Jianhua] Birmingham VA Med Ctr, Dept Vet Affairs, Birmingham, AL USA.
RP Zhang, JH (reprint author), Univ Alabama Birmingham, Dept Pathol, Biomed Res Bldg 2,901 19th St South, Birmingham, AL 35294 USA.
EM zhanja@uab.edu
NR 168
TC 7
Z9 7
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2319-4170
EI 2320-2890
J9 BIOMED J
JI Biomed. J.
PD APR
PY 2016
VL 39
IS 2
BP 98
EP 106
DI 10.1016/j.bj.2015.10.002
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DS3VN
UT WOS:000380710900003
PM 27372165
ER
PT J
AU Russell, DW
Gaggar, A
Solomon, GM
AF Russell, Derek W.
Gaggar, Amit
Solomon, George M.
TI Neutrophil Fates in Bronchiectasis and Alpha-1 Antitrypsin Deficiency
SO ANNALS OF THE AMERICAN THORACIC SOCIETY
LA English
DT Article
AB The neutrophil is a powerful cellular defender of the vulnerable interface between the environment and pulmonary tissues. This cell's potent weapons are carefully calibrated in the healthy state to maximize effectiveness in fighting pathogens while minimizing tissue damage and allowing for repair of what damage does occur. The three related chronic airway disorders of cystic fibrosis, non-cystic fibrosis bronchiectasis, and alpha-1 antitrypsin deficiency all demonstrate significant derangements of this homeostatic system that result in their respective pathologies. An important shared feature among them is the inefficient resolution of chronic inflammation that serves as a central means for neutrophil-driven lung damage resulting in disease progression. Examining the commonalities and divergences between these diseases in the light of their immunopathology is informative and may help guide us toward future therapeutics designed to modulate the neutrophil's interplay with the pulmonary environment.
C1 [Russell, Derek W.; Gaggar, Amit; Solomon, George M.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
[Gaggar, Amit; Solomon, George M.] Univ Alabama Birmingham, Gregory Fleming James Cyst Fibrosis Res Ctr, Birmingham, AL USA.
[Russell, Derek W.; Gaggar, Amit] Univ Alabama Birmingham, Program Protease & Matrix Biol, Birmingham, AL USA.
[Gaggar, Amit] Birmingham Vet Affairs Med Ctr, Med Serv, Birmingham, AL USA.
RP Solomon, GM (reprint author), 1900 Univ Blvd,THT 422, Birmingham, AL 35294 USA.
EM msolomon@uab.edu
FU NIH [HL102371, HL126596]; Veterans Administration [1 I01 BX001756];
Cystic Fibrosis Foundation [CLANCY09Y0, SORSCH15RO]
FX Supported by the NIH (HL102371 and HL126596 to A.G.), the Veterans
Administration (1 I01 BX001756 to A.G.), and the Cystic Fibrosis
Foundation (CLANCY09Y0 and SORSCH15RO to G.M.S.).
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1546-3222
EI 2325-6621
J9 ANN AM THORAC SOC
JI Ann. Am. Thoracic Society
PD APR
PY 2016
VL 13
SU 2
BP S123
EP S129
DI 10.1513/AnnalsATS.201512-805KV
PG 7
WC Respiratory System
SC Respiratory System
GA DR7QM
UT WOS:000380094800005
PM 27115946
ER
PT J
AU Bunch, PM
Sheehan, SE
Dyer, GS
Sodickson, A
Khurana, B
AF Bunch, Paul M.
Sheehan, Scott E.
Dyer, George S.
Sodickson, Aaron
Khurana, Bharti
TI A biomechanical approach to distal radius fractures for the emergency
radiologist
SO EMERGENCY RADIOLOGY
LA English
DT Review
DE Radius; Fracture; Trauma; Wrist; Biomechanical; Mechanism
ID TRIANGULAR FIBROCARTILAGE COMPLEX; RADIOULNAR JOINT SUBLUXATION;
COMPUTED-TOMOGRAPHY; RADIOGRAPHIC EVALUATION; INTRAOBSERVER
REPRODUCIBILITY; INTEROBSERVER RELIABILITY; INTRAARTICULAR FRACTURES;
INTERNAL-FIXATION; EXTERNAL FIXATION; COLLES FRACTURES
AB Distal radius fractures are the most common upper extremity fracture and account for approximately one sixth of all fractures treated in US emergency departments. These fractures are associated with significant morbidity and have a major economic impact. Radiographic evaluation of distal radius fractures is frequently performed in the emergency department setting, has a profound impact on initial management, and is essential to assessing the quality and relative success of the initial reduction. While the most appropriate definitive management of distal radius fractures remains controversial, overarching treatment principles reflect distal radius injury mechanisms and biomechanics. An intuitive understanding of the biomechanics of the distal radius and of common mechanisms of injury informs and improves the emergency radiologist's ability to identify key imaging findings with important management implications and to communicate the critical information that emergency physicians and orthopedic surgeons need to best manage distal radius fractures.
C1 [Bunch, Paul M.; Sodickson, Aaron; Khurana, Bharti] Harvard Med Sch, Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA.
[Sheehan, Scott E.] William S Middleton Mem Vet Adm Med Ctr, Dept Radiol, 2500 Overlook Terrace, Madison, WI 53705 USA.
[Dyer, George S.] Harvard Med Sch, Brigham & Womens Hosp, Dept Orthoped Surg, 75 Francis St, Boston, MA 02115 USA.
RP Bunch, PM (reprint author), Harvard Med Sch, Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA.
EM paul.m.bunch@gmail.com
NR 73
TC 2
Z9 2
U1 2
U2 4
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1070-3004
EI 1438-1435
J9 EMERG RADIOL
JI Emerg. Radiol.
PD APR
PY 2016
VL 23
IS 2
BP 175
EP 185
DI 10.1007/s10140-015-1363-0
PG 11
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA DR1BI
UT WOS:000379640600012
PM 26564022
ER
PT J
AU Gibson, C
Thurston, R
Matthews, K
AF Gibson, Carolyn
Thurston, Rebecca
Matthews, Karen
TI DAILY ASSOCIATIONS BETWEEN DIARY-REPORTED HOT FLASHES AND CORTISOL
SO PSYCHOSOMATIC MEDICINE
LA English
DT Meeting Abstract
CT 74th Annual Meeting of the American-Psychosomatic-Society
CY MAR 09-12, 2015
CL Denver, CO
SP Amer Psychosomat Soc
C1 [Gibson, Carolyn] San Francisco VA Med Ctr, San Francisco, CA USA.
[Thurston, Rebecca; Matthews, Karen] Univ Pittsburgh, Psychol, Psychiat, Epidemiol, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0033-3174
EI 1534-7796
J9 PSYCHOSOM MED
JI Psychosom. Med.
PD APR
PY 2016
VL 78
IS 3
MA 1079
BP A47
EP A47
PG 1
WC Psychiatry; Psychology; Psychology, Multidisciplinary
SC Psychiatry; Psychology
GA DJ1FX
UT WOS:000373949800149
ER
PT J
AU Harris, KM
Anderson, DR
Landers, JD
Emery, CF
AF Harris, Kristie M.
Anderson, Derek R.
Landers, Jacob D.
Emery, Charles F.
TI COPING STYLE AND DESIRE FOR TREATMENT AMONG PATIENTS IN OUTPATIENT
CARDIAC REHABILITATION
SO PSYCHOSOMATIC MEDICINE
LA English
DT Meeting Abstract
CT 74th Annual Meeting of the American-Psychosomatic-Society
CY MAR 09-12, 2015
CL Denver, CO
SP Amer Psychosomat Soc
C1 [Harris, Kristie M.; Landers, Jacob D.; Emery, Charles F.] Ohio State Univ, Psychol, Columbus, OH 43210 USA.
[Anderson, Derek R.] Vet Affairs Puget Sound Healthcare Syst, Rehabil Care Serv, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0033-3174
EI 1534-7796
J9 PSYCHOSOM MED
JI Psychosom. Med.
PD APR
PY 2016
VL 78
IS 3
MA 1292
BP A57
EP A57
PG 1
WC Psychiatry; Psychology; Psychology, Multidisciplinary
SC Psychiatry; Psychology
GA DJ1FX
UT WOS:000373949800176
ER
PT J
AU Walsh, CM
Patel, N
Walker, K
Ruoff, L
Varbel, J
Wynn, M
Miller, BL
Neylan, TC
Kramer, JH
AF Walsh, Christine M.
Patel, Nihar
Walker, Kathleen
Ruoff, Leslie
Varbel, Jonathan
Wynn, Matthew
Miller, Bruce L.
Neylan, Thomas C.
Kramer, Joel H.
TI The cognitive effects of disrupted sleep in healthy older adults
SO PSYCHOSOMATIC MEDICINE
LA English
DT Meeting Abstract
CT 74th Annual Meeting of the American-Psychosomatic-Society
CY MAR 09-12, 2015
CL Denver, CO
SP Amer Psychosomat Soc
C1 [Walsh, Christine M.; Patel, Nihar; Walker, Kathleen; Wynn, Matthew; Miller, Bruce L.; Kramer, Joel H.] Univ Calif San Francisco, Neurol, San Francisco, CA 94143 USA.
[Ruoff, Leslie; Varbel, Jonathan; Neylan, Thomas C.] San Francisco VA Med Ctr, Stress & Hlth Res, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0033-3174
EI 1534-7796
J9 PSYCHOSOM MED
JI Psychosom. Med.
PD APR
PY 2016
VL 78
IS 3
MA 1442
BP A18
EP A19
PG 2
WC Psychiatry; Psychology; Psychology, Multidisciplinary
SC Psychiatry; Psychology
GA DJ1FX
UT WOS:000373949800064
ER
PT J
AU Redmann, M
Darley-Usmar, V
Zhang, JH
AF Redmann, Matthew
Darley-Usmar, Victor
Zhang, Jianhua
TI The Role of Autophagy, Mitophagy and Lysosomal Functions in Modulating
Bioenergetics and Survival in the Context of Redox and Proteotoxic
Damage: Implications for Neurodegenerative Diseases
SO AGING AND DISEASE
LA English
DT Review
DE oxidative stress; reductive stress; mitochondrial dysfunction; prions;
alpha-synuclein; neurodegenerative diseases
ID EXTENDS LIFE-SPAN; LIPOFUSCINOSES BATTEN-DISEASE; MITOCHONDRIAL
QUALITY-CONTROL; CUZN-SUPEROXIDE-DISMUTASE; D-DEFICIENT MICE; OXIDATIVE
STRESS; PARKINSONS-DISEASE; ALPHA-SYNUCLEIN; ALZHEIMERS-DISEASE;
REACTIVE OXYGEN
AB Redox and proteotoxic stress contributes to age-dependent accumulation of dysfunctional mitochondria and protein aggregates, and is associated with neurodegeneration. The free radical theory of aging inspired many studies using reactive species scavengers such as alpha-tocopherol, ascorbate and coenzyme Q to suppress the initiation of oxidative stress. However, clinical trials have had limited success in the treatment of neurodegenerative diseases. We ascribe this to the emerging literature which suggests that the oxidative stress hypothesis does not encompass the role of reactive species in cell signaling and therefore the interception with reactive species with antioxidant supplementation may result in disruption of redox signaling. In addition, the accumulation of redox modified proteins or organelles cannot be reversed by oxidant intercepting antioxidants and must then be removed by alternative mechanisms. We have proposed that autophagy serves this essential function in removing damaged or dysfunctional proteins and organelles thus preserving neuronal function and survival. In this review, we will highlight observations regarding the impact of autophagy regulation on cellular bioenergetics and survival in response to reactive species or reactive species generating compounds, and in response to proteotoxic stress.
C1 [Redmann, Matthew; Darley-Usmar, Victor; Zhang, Jianhua] Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL 35294 USA.
[Redmann, Matthew; Darley-Usmar, Victor; Zhang, Jianhua] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
[Zhang, Jianhua] Birmingham VA Med Ctr, Dept Vet Affairs, Birmingham, AL 35294 USA.
RP Zhang, JH (reprint author), Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
EM zhanja@uab.edu
FU [NIHR01-NS064090]
FX This work was supported by NIHR01-NS064090 (to JZ).
NR 149
TC 8
Z9 8
U1 4
U2 12
PU INT SOC AGING & DISEASE
PI FORT WORTH
PA EDITORIAL OFF, 3400 CAMP BOWIE BLVD, FORT WORTH, TX 76106 USA
SN 2152-5250
J9 AGING DIS
JI Aging Dis.
PD APR
PY 2016
VL 7
IS 2
BP 150
EP 162
DI 10.14336/AD.2015.0820
PG 13
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA DO5BD
UT WOS:000377797700006
PM 27114848
ER
PT J
AU Yamada, A
Sato, KK
Kinuhata, S
Uehara, S
Endo, G
Hikita, Y
Fujimoto, WY
Boyko, EJ
Hayashi, T
AF Yamada, Akiko
Sato, Kyoko K.
Kinuhata, Shigeki
Uehara, Shinichiro
Endo, Ginji
Hikita, Yonezo
Fujimoto, Wilfred Y.
Boyko, Edward J.
Hayashi, Tomoshige
TI Association of Visceral Fat and Liver Fat With Hyperuricemia
SO ARTHRITIS CARE & RESEARCH
LA English
DT Article
ID URIC-ACID LEVEL; X-RAY ABSORPTIOMETRY; HIGH BLOOD-PRESSURE;
INSULIN-RESISTANCE; COMPUTED-TOMOGRAPHY; METABOLIC SYNDROME;
HEART-DISEASE; METAANALYSIS; GOUT; MEN
AB Objective. To examine cross-sectionally whether intraabdominal fat area (IAFA), i.e., visceral fat, and liver fat assessed by computed tomography (CT) are independently associated with hyperuricemia.
Methods. Subjects were 801 Japanese men not taking antidiabetic, antihypertensive, or urate-lowering medications, without any history of renal disease, cardiovascular disease, or cancer, and with serum creatinine <1.5 mg/dl. Abdominal, thoracic, and thigh fat areas were measured by CT. Total fat area (TFA) was the sum of these fat areas. Total subcutaneous fat area (TSFA) was TFA minus IAFA. Liver fat was assessed by liver-to-spleen (L/S) ratio measured by CT. Hyperuricemia was defined as serum uric acid level >7.0 mg/dl. Its association with adiposity was tested using logistic regression.
Results. The prevalence of hyperuricemia was 19.6% (157 men). Both greater IAFA and lower L/S ratio were independently associated with hyperuricemia in models that simultaneously included IAFA and L/S ratio: multiple-adjusted odds ratios of hyperuricemia for quintiles 3, 4, and 5 of IAFA were 2.16 (95% confidence interval [95% CI] 1.02-4.59), 2.41 (95% CI 1.13-5.16), and 4.00 (95% CI 1.81-8.85), respectively, compared to quintile 1, and the L/S ratios for quintiles 3, 2, and 1 were 2.34 (95% CI 1.16-4.75), 2.15 (95% CI 1.06-4.34), and 2.79 (95% CI 1.35-5.76), respectively, compared to quintile 5. Both IAFA and L/S ratio remained significant even after adjusting for abdominal subcutaneous fat area, TFA, TSFA, body mass index, or waist circumference. Of all fat measurements, IAFA had the strongest association with hyperuricemia by Akaike's information criteria.
Conclusion. Greater amounts of both visceral fat and liver fat were independently associated with hyperuricemia.
C1 [Yamada, Akiko; Sato, Kyoko K.; Kinuhata, Shigeki; Uehara, Shinichiro; Endo, Ginji; Hayashi, Tomoshige] Osaka City Univ, Grad Sch Med, Osaka 558, Japan.
[Hikita, Yonezo] Ohtori Hlth Promot Ctr, Sakai, Osaka, Japan.
[Fujimoto, Wilfred Y.; Boyko, Edward J.; Hayashi, Tomoshige] Univ Washington, Seattle, WA 98195 USA.
[Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA.
RP Hayashi, T (reprint author), Osaka City Univ, Grad Sch Med, Dept Prevent Med & Environm Hlth, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan.
EM thayashi@med.osaka-cu.ac.jp
OI Boyko, Edward/0000-0002-3695-192X
FU Ministry of Education, Culture, Sports, Science and Technology
[17390177, 20390187, 23390177]; VA Puget Sound Health Care System
FX Supported by Grants-in-Aid for Scientific Research (17390177, 20390187,
23390177) from the Ministry of Education, Culture, Sports, Science and
Technology, and by the Ohtori Health Promotion Center, which provided
facilities and services.; Dr. Boyko's work was supported by the VA Puget
Sound Health Care System.
NR 41
TC 1
Z9 2
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2151-464X
EI 2151-4658
J9 ARTHRIT CARE RES
JI Arthritis Care Res.
PD APR
PY 2016
VL 68
IS 4
BP 553
EP 561
DI 10.1002/acr.22729
PG 9
WC Rheumatology
SC Rheumatology
GA DO6OG
UT WOS:000377902400017
PM 26414410
ER
PT J
AU Myers, EA
Smith, DA
Allen, SR
Kaplan, LJ
AF Myers, Elizabeth A.
Smith, David A.
Allen, Steven R.
Kaplan, Lewis J.
TI Post-ICU syndrome: Rescuing the undiagnosed
SO JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS
LA English
DT Review
DE ICU; critical illness; post-traumatic stress disorder; delirium;
postintensive care syndrome; PICS
ID INTENSIVE CARE SYNDROME; LONG-TERM-OUTCOMES; CRITICAL ILLNESS;
SURVIVORSHIP
AB Survivors of critical illness may develop postintensive care syndrome (PICS), a spectrum of conditions that include persistent cognitive dysfunction, acquired weakness, and intrusive memories akin to post-traumatic stress disorder. Relatively few ICU survivors are routinely followed in the outpatient setting by intensivists, but are regularly evaluated by primary care physicians and physician assistants in their practices. Specific and focused education about the key features of PICS, its effect on patients as well as family members, and potential therapeutic interventions may increase recognition of PICS and reduce its effect on survivors of critical illness.
C1 [Myers, Elizabeth A.] Medstar Southern Maryland Hosp Ctr, Emergency Med, Clinton, MD USA.
[Smith, David A.] Salus Univ, PA Program, Elkins Pk, PA USA.
[Smith, David A.] VA Med Ctr, Crit Care Med Surg ICU, Philadelphia, PA USA.
[Allen, Steven R.] Penn States Hershey Med Ctr, Hershey, PA USA.
[Kaplan, Lewis J.] Philadelphia VA Med Ctr, Surg Crit Care, Philadelphia, PA USA.
[Kaplan, Lewis J.] Philadelphia VA Med Ctr, Surg, Philadelphia, PA USA.
[Kaplan, Lewis J.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Myers, EA (reprint author), Medstar Southern Maryland Hosp Ctr, Emergency Med, Clinton, MD USA.
NR 13
TC 0
Z9 0
U1 2
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1547-1896
EI 0893-7400
J9 JAAPA-J AM ACAD PHYS
JI JAAPA-J. Am. Acad. Physician Assist.
PD APR
PY 2016
VL 29
IS 4
BP 34
EP 37
DI 10.1097/01.JAA.0000481401.21841.32
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA DO6FZ
UT WOS:000377880000014
PM 27023654
ER
PT J
AU Byers, AL
Lai, AX
Arean, P
Nelson, JC
Yaffe, K
AF Byers, Amy L.
Lai, Amy X.
Arean, Patricia
Nelson, J. Craig
Yaffe, Kristine
TI Mental Health Service Use Across the Life Course Among Adults With
Psychiatric Disorders and Prior Suicidal Behavior
SO PSYCHIATRIC SERVICES
LA English
DT Article
ID PERCEIVED NEED; CARE
AB Objective: Little is known about mental health service use by adults with prior suicidal behavior and current mood or anxiety disorders. This study determined nationally representative prevalence estimates of current mental health service use by these adults, examining racial-ethnic, age, and gender differences.
Methods: Service use across the life course was examined with Collaborative Psychiatric Epidemiology Survey data from 1,139 adults with a history of suicidal behavior and current mood or anxiety disorders.
Results: Overall service use was 47.3%. Across the life course, African Americans showed increasing service use that paralleled use by non-Hispanic whites, Hispanics, and others, whereas use by these three groups decreased in the latter half of the life course (p interaction = .01).
Conclusions: Adults with prior suicidal behavior and current mood or anxiety disorders have low mental health service use. Findings of racial-ethnic disparities in use can help identify those in need of care.
C1 [Byers, Amy L.; Nelson, J. Craig; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Byers, Amy L.; Lai, Amy X.; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Arean, Patricia] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
RP Byers, AL (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.; Byers, AL (reprint author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
EM amy.byers@ucsf.edu
FU National Institute on Aging [AG031155]; Avid; [MD007019]
FX Dr. Byers is supported by R01 award MD007019, administered by the
Northern California Institute for Research and Education, and by
resources from the San Francisco Veterans Affairs Medical Center and the
National Institutes of Health, National Institute on Minority Health and
Health Disparities. Dr. Yaffe is partially supported by K24 midcareer
investigator award AG031155 from the National Institute on Aging.; Dr.
Nelson reports receiving lecture honoraria from Bristol-Myers Squibb,
Genentech, and Otsuka; consulting for Corcept, Lundbeck, and Otsuka;
serving on the advisory board for Genentech and Otsuka; receiving
research support from Avid; and owning stock in Atossa. Dr. Yaffe
reports that she serves on data and safety monitoring boards for Takeda
and DIAN. The other authors report no financial relationships with
commercial interests.
NR 15
TC 0
Z9 0
U1 0
U2 2
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
EI 1557-9700
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD APR
PY 2016
VL 67
IS 4
BP 452
EP 455
DI 10.1176/appi.ps.201500019
PG 4
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA DO4TY
UT WOS:000377778300019
PM 26766753
ER
PT J
AU Timko, C
Gupta, S
Schultz, N
Harris, AHS
AF Timko, Christine
Gupta, Shalini
Schultz, Nicole
Harris, Alex H. S.
TI Veterans' Service Utilization Patterns After Alcohol and Opioid
Detoxification in VHA Care
SO PSYCHIATRIC SERVICES
LA English
DT Article
ID SUBSTANCE-ABUSE TREATMENT; INPATIENT; OUTCOMES
AB Objective: This study aimed to examine detoxification-related service utilization in the Veterans Health Administration (VHA).
Methods: VHA data for 266,908 patients were used to examine rates and predictors of receiving detoxification, attending post-detoxification appointments, and entering specialty treatment. Multilevel, mixed-effects logistic regressions were used to examine associations between patient and facility characteristics and service utilization.
Results: Nationally, 8.0% of VHA patients with alcohol or opiate dependence received detoxification in fiscal year 2013 (facility range=.1% 220.4%); 43.1% of detoxified patients received follow-up (11.1% 276.4%), and 49.9% entered specialty treatment (13.0%-77.2%). In adjusted analyses, detoxification was more likely among male, younger, white, and homeless patients with documented alcohol or opiate disorders and comorbid general medical conditions but without previous addiction treatment. Detoxification was also more likely in facilities with fewer vacant addiction therapist positions. Follow-up and specialty treatments were more likely among younger, healthier homeless patients with previous addiction treatment and a documented alcohol use disorder.
Conclusions: Detoxification-related service utilization was highly variable across the VHA. Interventions are needed to optimize use.
C1 [Timko, Christine; Gupta, Shalini; Schultz, Nicole; Harris, Alex H. S.] US Dept Vet Affairs, Hlth Serv Res & Dev, Menlo Pk, CA 94025 USA.
RP Timko, C (reprint author), US Dept Vet Affairs, Hlth Serv Res & Dev, Menlo Pk, CA 94025 USA.
EM christine.timko@va.gov
FU HSR&D Quality Enhancement Research Initiative [RRP 12-525]; HSRD [RCS
00-001, RCS 14-232]
FX This work was supported by grant RRP 12-525 from HSR&D Quality
Enhancement Research Initiative. Dr. Timko was supported by grant RCS
00-001 and Dr. Harris was supported by grant RCS 14-232, both from
HSR&D.
NR 17
TC 1
Z9 1
U1 0
U2 0
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
EI 1557-9700
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD APR
PY 2016
VL 67
IS 4
BP 460
EP 464
DI 10.1176/appi.ps.201400579
PG 5
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA DO4TY
UT WOS:000377778300021
PM 26766752
ER
PT J
AU Brennan, L
Siderowf, A
Rubright, JD
Rick, J
Dahodwala, N
Duda, JE
Hurtig, H
Stern, M
Xie, SX
Rennert, L
Karlawish, J
Shea, JA
Trojanowski, JQ
Weintraub, D
AF Brennan, Laura
Siderowf, Andrew
Rubright, Jonathan D.
Rick, Jacqueline
Dahodwala, Nabila
Duda, John E.
Hurtig, Howard
Stern, Matthew
Xie, Sharon X.
Rennert, Lior
Karlawish, Jason
Shea, Judy A.
Trojanowski, John Q.
Weintraub, Daniel
TI The Penn Parkinson's Daily Activities Questionnaire-15: Psychometric
properties of a brief assessment of cognitive instrumental activities of
daily living in Parkinson's disease
SO PARKINSONISM & RELATED DISORDERS
LA English
DT Article
DE Parkinson's disease; Instrumental activities of daily living; Cognition
ID SOCIETY TASK-FORCE; ALZHEIMERS-DISEASE; IMPAIRMENT; DEMENTIA; AGREEMENT;
PATIENT
AB Introduction: To describe the psychometric properties of the Penn Parkinson's Daily Activities Questionnaire-15 (PDAQ-15), a 15-item measure of cognitive instrumental activities of daily living for Parkinson's disease (PD) patients derived from the original 50-item PDAQ.
Methods: PDAQ-15 items were chosen by expert consensus. Knowledgeable informants of PD participants (n-= 161) completed the PDAQ-15. Knowledgeable informants were defined as an individual having regular contact with the PD participant. PD participants were assigned a diagnosis of normal cognition, mild cognitive impairment, or dementia based on expert consensus.
Results: PDAQ-15 scores correlated strongly with global cognition (Dementia Rating Scale-2, r = 0.71, p < 0.001) and a performance-based functional measure (Direct Assessment of Functional Status, r = 0.83; p < 0.001). PDAQ-15 scores accurately discriminated between non-demented PD participants (normal cognition/mild cognitive impairment) and PD with dementia (ROC curve area = 0.91), participants with and without any cognitive impairment (normal cognition versus mild cognitive impairment/dementia, ROC curve area = 0.85) and between participants with mild cognitive impairment and dementia (ROC curve area = 0.84).
Conclusions: The PDAQ-15 shows good discriminant validity across cognitive stages, correlates highly with global cognitive performance, and appears suitable to assess daily cognitive functioning in PD. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Brennan, Laura] Drexel Univ, Coll Med, Drexel Neurosci Inst, 245 N 15th St,7102 NCB, Philadelphia, PA 19102 USA.
[Brennan, Laura; Weintraub, Daniel] Univ Penn, Sch Med, Dept Psychiat, 3615 Chestnut St,330, Philadelphia, PA 19104 USA.
[Siderowf, Andrew] Avid Radiopharmaceut, 3711 Market St 7, Philadelphia, PA 19104 USA.
[Rubright, Jonathan D.] Natl Board Med Examiners, 3750 Market St, Philadelphia, PA 19104 USA.
[Rick, Jacqueline; Dahodwala, Nabila; Duda, John E.; Hurtig, Howard; Stern, Matthew; Trojanowski, John Q.; Weintraub, Daniel] Univ Penn, Sch Med, Dept Neurol, 330 S 9th St, Philadelphia, PA 19107 USA.
[Duda, John E.; Rennert, Lior; Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, 3900 Woodland Ave, Philadelphia, PA 19104 USA.
[Xie, Sharon X.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, 8th Floor Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
[Karlawish, Jason] PENN CMU Roybal Ctr Behav Econ & Hlth, LDI Ctr Hlth Incent, Dept Med Eth & Med, 3401 Market St,Suite 320, Philadelphia, PA 19104 USA.
[Karlawish, Jason] Alzheimers Dis Ctr, 3401 Market St,Suite 320, Philadelphia, PA 19104 USA.
[Shea, Judy A.] Univ Penn, Sch Med, Dept Med, 3400 Civ Ctr Blvd,Bldg 421, Philadelphia, PA 19104 USA.
[Rubright, Jonathan D.] Amer Inst Certified Publ Accountants, Durham, NC USA.
RP Weintraub, D (reprint author), 3615 Chestnut St,330, Philadelphia, PA 19104 USA.
EM daniel.weintraub@uphs.upenn.edu
FU Morris K. Udall Parkinson's Disease Research Center of Excellence grant
from NINDS [NS-053488]; Department of Health of the Commonwealth of
Pennsylvania from the Tobacco Master Settlement Agreement
[SAP4100027296]
FX This study was funded by a Morris K. Udall Parkinson's Disease Research
Center of Excellence grant from NINDS (NS-053488) and by SAP4100027296,
a health research grant awarded by the Department of Health of the
Commonwealth of Pennsylvania from the Tobacco Master Settlement
Agreement under Act 2001-77.
NR 25
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1353-8020
EI 1873-5126
J9 PARKINSONISM RELAT D
JI Parkinsonism Relat. Disord.
PD APR
PY 2016
VL 25
BP 21
EP 26
DI 10.1016/j.parkreldis.2016.02.020
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA DK0QD
UT WOS:000374616400004
PM 26923524
ER
PT J
AU Trikamji, B
Thomas, M
Hathout, G
Mishra, S
AF Trikamji, Bhavesh
Thomas, Mariam
Hathout, Gasser
Mishra, Shrikant
TI An unusual case of cerebral autosomal-dominant arteriopathy with
subcortical infarcts and leukoencephalopathy with occipital lobe
involvement
SO ANNALS OF INDIAN ACADEMY OF NEUROLOGY
LA English
DT Article
DE Cerebral autosomal-dominant arteriopathy with subcortical infarcts and
leukoencephalopathy (CADASIL); dementia; migraine; magnetic resonance
imaging (MRI); occipital lobe; seizures
ID CADASIL; PATTERNS
AB Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an autosomal dominant angiopathy caused by a mutation in the notch 3 gene on chromosome 19. Clinically, patients may be asymptomatic or can present with recurrent ischemic episodes and strokes leading to dementia, depression, pseudobulbar palsy, and hemi-or quadraplegia. Additional manifestations that have been described include migraine (mostly with aura), psychiatric disturbances, and epileptic seizures. Neuroimaging is essential to the diagnosis of CADASIL. On imaging CADASIL is characterized by symmetric involvement by confluent lesions located subcortically in the frontal and temporal lobes as well as in the insula, periventricularly, in the centrum semiovale, in the internal and external capsule, basal ganglia, and brain stem; with relative sparing of the fronto-orbital and the occipital subcortical regions. We describe a 49 year old male with CADASIL with absence of temporal lobe findings on MRI but predominant lesions within the periventricular white matter, occipital lobes with extension into the subcortical frontal lobes, corpus callosum and cerebellar white matter. Although CADASIL characteristically presents with anterior temporal lobe involvement, these findings may be absent and our case addresses the atypical imaging findings in CADASIL.
C1 [Trikamji, Bhavesh; Thomas, Mariam; Hathout, Gasser; Mishra, Shrikant] Olive View UCLA Med Ctr, Dept Neurol, 14445 Olive View Dr, Sylmar, CA 91342 USA.
[Trikamji, Bhavesh; Hathout, Gasser; Mishra, Shrikant] VA Greater Los Angeles Healthcare Syst, Dept Radiol, Los Angeles, CA USA.
[Hathout, Gasser; Mishra, Shrikant] Univ Calif Los Angeles, Los Angeles, CA USA.
[Mishra, Shrikant] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
RP Mishra, S (reprint author), 16111 Plummer St, North Hills, CA 91343 USA.
EM smishra@usc.edu
NR 7
TC 0
Z9 0
U1 0
U2 0
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
INDIA
SN 0972-2327
EI 1998-3549
J9 ANN INDIAN ACAD NEUR
JI Ann. Indian Acad. Neurol.
PD APR-JUN
PY 2016
VL 19
IS 2
BP 272
EP 274
DI 10.4103/0972-2327.173403
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA DN0BE
UT WOS:000376728600023
PM 27293347
ER
PT J
AU Parajuli, S
Lockridge, JB
Langewisch, ED
Norman, DJ
Kujovich, JL
AF Parajuli, Sandesh
Lockridge, Joseph B.
Langewisch, Eric D.
Norman, Douglas J.
Kujovich, Jody L.
TI Hypercoagulability in Kidney Transplant Recipients
SO TRANSPLANTATION
LA English
DT Review
ID FACTOR-V-LEIDEN; RENAL GRAFT THROMBOSIS; ANTIPHOSPHOLIPID ANTIBODY
SYNDROME; MOLECULAR-WEIGHT HEPARIN; PROTEIN-S DEFICIENCY; ALLOGRAFT
THROMBOSIS; RISK-FACTORS; SINGLE-CENTER; VASCULAR COMPLICATIONS;
SURGICAL COMPLICATIONS
AB Thrombosis remains an important complication after kidney transplantation. Outcomes for graft and deep vein thrombosis are not favorable. The majority of early kidney transplant failure in adults is due to allograft thrombosis. Risk stratification, early diagnosis, and appropriate intervention are critical to the management of thrombotic complications of transplant. In patients with end-stage renal disease, the prevalence of acquired risk factors for thrombosis is significantly high. Because of hereditary and acquired risk factors, renal transplant recipients manifest features of a chronic prothrombotic state. Identification of hereditary thrombotic risk factors before transplantation may be a useful tool for selecting appropriate candidates for thrombosis prophylaxis immediately after transplantation. Short-term anticoagulation may be appropriate for all patients after kidney transplantation.
C1 [Parajuli, Sandesh] Univ Wisconsin, Sch Med & Publ Hlth, Univ Wisconsin Hosp & Clin, Div Nephrol,Dept Med, Madison, WI USA.
[Parajuli, Sandesh; Lockridge, Joseph B.; Langewisch, Eric D.; Norman, Douglas J.] Oregon Hlth & Sci Univ, Dept Med, Div Nephrol, 2611 SW 3rd Ave,Ste 360, Portland, OR 97201 USA.
[Lockridge, Joseph B.; Langewisch, Eric D.; Norman, Douglas J.] Portland VA Med Ctr, Portland, OR USA.
[Kujovich, Jody L.] Oregon Hlth & Sci Univ, Dept Med, Div Hematol & Med Oncol, Portland, OR 97201 USA.
RP Norman, DJ (reprint author), Oregon Hlth & Sci Univ, Dept Med, Div Nephrol, 2611 SW 3rd Ave,Ste 360, Portland, OR 97201 USA.
EM normand@ohsu.edu
NR 100
TC 2
Z9 2
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0041-1337
EI 1534-6080
J9 TRANSPLANTATION
JI Transplantation
PD APR
PY 2016
VL 100
IS 4
BP 719
EP 726
DI 10.1097/TP.0000000000000887
PG 8
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA DN5QR
UT WOS:000377125700015
PM 26413991
ER
PT J
AU Lockhart, SR
Fothergill, AW
Iqbal, N
Bolden, CB
Grossman, NT
Garvey, EP
Brand, SR
Hoekstra, WJ
Schotzinger, RJ
Ottinger, E
Patterson, TF
Wiederhold, NP
AF Lockhart, Shawn R.
Fothergill, Annette W.
Iqbal, Naureen
Bolden, Carol B.
Grossman, Nina T.
Garvey, Edward P.
Brand, Stephen R.
Hoekstra, William J.
Schotzinger, Robert J.
Ottinger, Elizabeth
Patterson, Thomas F.
Wiederhold, Nathan P.
TI The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent
In Vitro Activity against Cryptococcus neoformans and Cryptococcus
gattii
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID ANTIFUNGAL SUSCEPTIBILITIES
AB The in vitro activities of the novel fungal Cyp51 inhibitor VT-1129 were evaluated against a large panel of Cryptococcus neoformans and Cryptococcus gattii isolates. VT-1129 demonstrated potent activities against both Cryptococcus species as demonstrated by low MIC50 and MIC90 values. For C. gattii, the in vitro potency was maintained against all genotypes. In addition, significantly lower geometric mean MICs were observed for VT-1129 than for fluconazole against C. neoformans, including isolates with reduced fluconazole susceptibility.
C1 [Lockhart, Shawn R.; Iqbal, Naureen; Bolden, Carol B.; Grossman, Nina T.] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA.
[Fothergill, Annette W.; Patterson, Thomas F.; Wiederhold, Nathan P.] Univ Texas San Antonio, Hlth Sci Ctr, San Antonio, TX USA.
[Garvey, Edward P.; Brand, Stephen R.; Hoekstra, William J.; Schotzinger, Robert J.] Viamet Pharmaceut Inc, Durham, NC USA.
[Ottinger, Elizabeth] NIH, Therapeut Rare & Neglected Dis Bethesda, Bldg 10, Bethesda, MD 20892 USA.
[Patterson, Thomas F.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Wiederhold, NP (reprint author), Univ Texas San Antonio, Hlth Sci Ctr, San Antonio, TX USA.
EM wiederholdn@uthscsa.edu
FU National Institutes of Health National Institute of Allergy and
Infectious Diseases [N01-AI-25475]; National Institutes of Health,
National Center for Advancing Translational Sciences, Therapeutics for
Rare and Neglected Diseases (TRND) Program; Viamet Pharmaceuticals, Inc.
FX This project was funded by the National Institutes of Health National
Institute of Allergy and Infectious Diseases under contract no.
N01-AI-25475 (Thomas F. Patterson), the National Institutes of Health,
National Center for Advancing Translational Sciences, Therapeutics for
Rare and Neglected Diseases (TRND) Program (Shawn R. Lockhart), and
Viamet Pharmaceuticals, Inc. (Nathan P. Wiederhold). VT-1129 powder was
provided by Viamet Pharmaceuticals, Inc.
NR 18
TC 3
Z9 3
U1 2
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD APR
PY 2016
VL 60
IS 4
BP 2528
EP 2531
DI 10.1128/AAC.02770-15
PG 4
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA DM6XL
UT WOS:000376496100072
PM 26787697
ER
PT J
AU Yung, M
Iafe, N
Sarraf, D
AF Yung, Madeline
Iafe, Nicholas
Sarraf, David
TI Optical coherence tomography angiography of a retinal astrocytic
hamartoma
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Letter
C1 [Yung, Madeline; Iafe, Nicholas; Sarraf, David] Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Los Angeles, CA 90095 USA.
[Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA.
RP Sarraf, D (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Los Angeles, CA 90095 USA.; Sarraf, D (reprint author), Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA.
EM dsarraf@ucla.edu
NR 6
TC 0
Z9 0
U1 1
U2 1
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD APR
PY 2016
VL 51
IS 2
BP E62
EP E64
DI 10.1016/j.jcjo.2015.11.005
PG 4
WC Ophthalmology
SC Ophthalmology
GA DM7BR
UT WOS:000376508400010
PM 27085280
ER
PT J
AU Ranard, BL
Werner, RM
Antanavicius, T
Schwartz, HA
Smith, RJ
Meisel, ZF
Asch, DA
Ungar, LH
Merchant, RM
AF Ranard, Benjamin L.
Werner, Rachel M.
Antanavicius, Tadas
Schwartz, H. Andrew
Smith, Robert J.
Meisel, Zachary F.
Asch, David A.
Ungar, Lyle H.
Merchant, Raina M.
TI Yelp Reviews Of Hospital Care Can Supplement And Inform Traditional
Surveys Of The Patient Experience Of Care
SO HEALTH AFFAIRS
LA English
DT Review
ID SOCIAL MEDIA; PERFORMANCE; QUALITY; RATINGS
AB Little is known about how real-time online rating platforms such as Yelp may complement the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey, which is the US standard for evaluating patients' experiences after hospitalization. We compared the content of Yelp narrative reviews of hospitals to the topics in the HCAHPS survey, called domains in HCAHPS terminology. While the domains included in Yelp reviews covered the majority of HCAHPS domains, Yelp reviews covered an additional twelve domains not found in HCAHPS. The majority of Yelp topics that most strongly correlate with positive or negative reviews are not measured or reported by HCAHPS. The large collection of patient- and caregiver-centered experiences found on Yelp can be analyzed with natural language processing methods, identifying for policy makers the measures of hospital quality that matter most to patients and caregivers. The Yelp measures and analysis can also provide actionable feedback for hospitals.
C1 [Ranard, Benjamin L.] Univ Penn, Med, Philadelphia, PA 19104 USA.
[Ranard, Benjamin L.; Smith, Robert J.; Asch, David A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Werner, Rachel M.] Univ Penn, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA.
[Werner, Rachel M.] Univ Penn, Perelman Sch Med, Med, Philadelphia, PA 19104 USA.
[Antanavicius, Tadas] Univ Penn, Philadelphia, PA 19104 USA.
[Schwartz, H. Andrew] SUNY Stony Brook, Dept Comp Sci, Stony Brook, NY 11794 USA.
[Meisel, Zachary F.] Hosp Univ Penn, Emergency Med, Philadelphia, PA 19104 USA.
[Asch, David A.] Univ Penn, Ctr Hlth Care Innovat, Philadelphia, PA 19104 USA.
[Asch, David A.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA.
[Asch, David A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Ungar, Lyle H.] Univ Penn, Dept Comp & Informat Sci, Philadelphia, PA 19104 USA.
[Merchant, Raina M.] Univ Penn, Penn Social Media & Hlth Innovat Lab, Philadelphia, PA 19104 USA.
[Merchant, Raina M.] Univ Penn, Emergency Med, Philadelphia, PA 19104 USA.
RP Ranard, BL (reprint author), Univ Penn, Med, Philadelphia, PA 19104 USA.
EM Raina.merchant@uphs.upenn.edu
OI Smith, Robert James/0000-0001-9746-1230
FU National Institutes of Health [K23-10714038, K24-AG047908]
FX Funding and support were provided by the National Institutes of Health,
Grant No. K23-10714038 (for Raina M. Merchant) and Grant No.
K24-AG047908 (for Rachel M. Werner). The study sponsors had no role in
the design and conduct of the study; collection, management, analysis,
and interpretation of the data; preparation, review, or approval of the
article; or decision to submit the article for publication. The authors
thank Judith A. Long (Perelman School of Medicine, University of
Pennsylvania) for her review of the article and her insightful comments.
She received no financial compensation. The opinions expressed are those
of the authors and not the Department of Veterans Affairs.
NR 36
TC 4
Z9 4
U1 4
U2 9
PU PROJECT HOPE
PI BETHESDA
PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA
SN 0278-2715
J9 HEALTH AFFAIR
JI Health Aff.
PD APR
PY 2016
VL 35
IS 4
BP 697
EP 705
DI 10.1377/hlthaff.2015.1030
PG 9
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA DK2SG
UT WOS:000374764100020
PM 27044971
ER
PT J
AU Maleki-Yazdi, M
Singh, D
Anzueto, A
Tombs, L
Naya, I
Harris, S
Iqbal, A
Rolke, M
AF Maleki-Yazdi, M.
Singh, D.
Anzueto, A.
Tombs, L.
Naya, I.
Harris, S.
Iqbal, A.
Rolke, M.
TI Clinically relevant Deterioration in COPD Patients under treatment with
Umeclidinium/Vilanterol, Tiotropium or Placebo: Pooled Data
SO INTERNIST
LA German
DT Meeting Abstract
C1 [Maleki-Yazdi, M.] Univ Toronto, Womens Coll Hosp, Div Resp Med, Toronto, ON, Canada.
[Singh, D.] Univ Manchester, Med Evaluat Unit, Manchester, Lancs, England.
[Anzueto, A.] Audie L Murphy Hosp, San Antonio, TX USA.
[Tombs, L.; Naya, I.] GlaxoSmithKline, Resp Med Dev Ctr, Stockley Pk, Uxbridge, Middx, England.
[Harris, S.; Iqbal, A.] GlaxoSmithKline, Resp & Immunoinflammat Res, Res Triangle Pk, NC USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0020-9554
EI 1432-1289
J9 INTERNIST
JI Internist
PD APR
PY 2016
VL 57
SU 1
MA P038
BP S25
EP S25
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA DL1UG
UT WOS:000375417500045
ER
PT J
AU Woodell, A
Jones, BW
Williamson, T
Schnabolk, G
Tomlinson, S
Atkinson, C
Rohrer, B
AF Woodell, Alex
Jones, Bryan W.
Williamson, Tucker
Schnabolk, Gloriane
Tomlinson, Stephen
Atkinson, Carl
Rohrer, Baerbel
TI A Targeted Inhibitor of the Alternative Complement Pathway Accelerates
Recovery From Smoke-Induced Ocular Injury
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE alternative complement pathway; CR2-fH; knockout mouse; smoke exposure;
mitochondria; Bruch's membrane deposits; dry age-related macular
degeneration
ID RETINAL-PIGMENT EPITHELIUM; CAUSES OXIDATIVE DAMAGE; AGE-RELATED
MACULOPATHY; MACULAR DEGENERATION; CIGARETTE-SMOKE; CHOROIDAL
NEOVASCULARIZATION; MEDIATED INJURY; RPE CELLS; STRESS; ACTIVATION
AB PURPOSE. Morphologic and genetic evidence exists that an overactive complement system driven by the complement alternative pathway (AP) is involved in pathogenesis of age-related macular degeneration (AMD). Smoking is the only modifiable risk factor for AMD. As we have shown that smoke-related ocular pathology can be prevented in mice that lack an essential activator of AP, we ask here whether this pathology can be reversed by increasing inhibition in AP.
METHODS. Mice were exposed to either cigarette smoke (CS) or filtered air (6 hours/day, 5 days/week, 6 months). Smoke-exposed animals were then treated with the AP inhibitor (CR2-fH) or vehicle control (PBS) for the following 3 months. Spatial frequency and contrast sensitivity were assessed by optokinetic response paradigms at 6 and 9 months; additional readouts included assessment of retinal morphology by electron microscopy (EM) and gene expression analysis by quantitative RT-PCR.
RESULTS. The CS mice treated with CR2-fH showed significant improvement in contrast threshold compared to PBS-treated mice, whereas spatial frequency was unaffected by CS or pharmacologic intervention. Treatment with CR2-fH in CS animals reversed thinning of the retina observed in PBS-treated mice as analyzed by spectral-domain optical coherence tomography, and reversed most morphologic changes in RPE and Bruch's membrane seen in CS animals by EM.
CONCLUSIONS. Taken together, these findings suggest that AP inhibitors not only prevent, but have the potential to accelerate the clearance of complement-mediated ocular injury. Improving our understanding of the regulation of the AP is paramount to developing novel treatment approaches for AMD.
C1 [Woodell, Alex; Rohrer, Baerbel] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
[Jones, Bryan W.] Univ Utah, Moran Eye Ctr, Salt Lake City, UT USA.
[Williamson, Tucker; Tomlinson, Stephen; Atkinson, Carl] Med Univ S Carolina, Dept Microbiol & Immunol, 173 Ashley Ave, Charleston, SC 29425 USA.
[Schnabolk, Gloriane; Tomlinson, Stephen; Rohrer, Baerbel] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC USA.
[Atkinson, Carl] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA.
[Rohrer, Baerbel] Med Univ S Carolina, Dept Ophthalmol, 167 Ashley Ave, Charleston, SC 29425 USA.
RP Atkinson, C (reprint author), Med Univ S Carolina, Dept Microbiol & Immunol, 173 Ashley Ave, Charleston, SC 29425 USA.; Rohrer, B (reprint author), Med Univ S Carolina, Dept Ophthalmol, 167 Ashley Ave, Charleston, SC 29425 USA.
EM atkinsoc@musc.edu; rohrer@musc.edu
FU National Institutes of Health (NIH) [R01EY019320, R01 NHLBI 091944, NIH
EY015128, NIH EY02576, EY014800]; Department of Veterans Affairs [I01
RX000444]; Research to Prevent Blindness (RPB), Inc., New York, New
York, United States; Vision Core from Research to Prevent Blindness;
Edward N. and Della L. Thome Memorial Foundation; NIH [C06 RR015455]
FX Supported in part by National Institutes of Health (NIH) Grants
R01EY019320, R01 NHLBI 091944, NIH EY015128, NIH EY02576, and EY014800;
Department of Veterans Affairs I01 RX000444; an unrestricted grant to
the Medical University of South Carolina from Research to Prevent
Blindness (RPB), Inc., New York, New York, United States; Vision Core,
an unrestricted grant from Research to Prevent Blindness to the Moran
Eye Center; Edward N. and Della L. Thome Memorial Foundation grant for
Age-Related Macular Degeneration Research. Animal studies were conducted
in a facility constructed with support from the NIH (C06 RR015455). CA,
ST, and BR are patent holders for the use of CR2-fH in
complement-dependent diseases. This patent is licensed to Alexion
Therapeutics.
NR 46
TC 0
Z9 0
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2016
VL 57
IS 4
BP 1728
EP 1737
DI 10.1167/iovs.15-18471
PG 10
WC Ophthalmology
SC Ophthalmology
GA DL8XY
UT WOS:000375926700027
PM 27064393
ER
PT J
AU Bradshaw, AD
AF Bradshaw, Amy D.
TI The role of secreted protein acidic and rich in cysteine (SPARC) in
cardiac repair and fibrosis: Does expression of SPARC by macrophages
influence outcomes?
SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
LA English
DT Article
DE Matricellular; Inflammation; Collagen; Extracellular matrix;
Osteonectin; BM40
ID FIBRILLAR COLLAGEN CONTENT; DIASTOLIC FUNCTION ROLE;
EXTRACELLULAR-MATRIX; MYOCARDIAL-INFARCTION; INFLAMMATION; DEPOSITION;
CARCINOMA; LEUKOCYTE; MONOCYTE; DERMIS
AB Secreted protein acidic and rich in cysteine (SPARC) is a matricellular, collagen-binding protein. Matricellular proteins are described as extracellular matrix-associated proteins that do not serve classical structural roles in the matrix such as those ascribed to laminins and collagens. The family of matricellular proteins modulates cell:extracellular matrix interactions and is actively expressed during tissue remodeling. Functional activities attributed to SPARC in cultured cells include regulation of cell adhesion, cytoskeletal rearrangement, proliferation, and matrix assembly. The primary phenotype characteristic of SPARC-null mice is a deficit in amounts of fibrillar collagen and fibril morphology. Strikingly, SPARC-null mice demonstrate a blunted fibrotic response in a number of different tissue settings. The role of monocyte/macrophages as an important component of tissue fibrosis is becoming increasingly appreciated. Expression of SPARC by bone marrow derived inflammatory cells raises the interesting proposition that SPARC produced by infiltrating leukocytes might contribute to the course of inflammation and tissue fibrosis in the heart. This review will summarize results from studies defining the function of SPARC in myocardial repair and fibrosis and results from other non-cardiac tissues that shed light onto possible consequences of SPARC expression by monocyte/macrophages in the setting of heart disease. (C) 2015 Published by Elsevier Ltd.
C1 [Bradshaw, Amy D.] Med Univ S Carolina, Gazes Cardiac Res Inst, Div Cardiol, Dept Med, MSC 773, Charleston, SC 29425 USA.
[Bradshaw, Amy D.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA.
RP Bradshaw, AD (reprint author), Med Univ S Carolina, Gazes Cardiac Res Inst, Div Cardiol, Dept Med, MSC 773, Charleston, SC 29425 USA.; Bradshaw, AD (reprint author), Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA.
EM bradshad@musc.edu
OI Bradshaw, Amy/0000-0002-9202-3044
FU Veterans Affairs Merit Award [BX001385]; American Heart Association
Award [12GRNT12060193]
FX This work was supported by a Veterans Affairs Merit Award (BX001385) and
an American Heart Association Award (12GRNT12060193).
NR 32
TC 4
Z9 4
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0022-2828
EI 1095-8584
J9 J MOL CELL CARDIOL
JI J. Mol. Cell. Cardiol.
PD APR
PY 2016
VL 93
BP 156
EP 161
DI 10.1016/j.yjmcc.2015.11.014
PG 6
WC Cardiac & Cardiovascular Systems; Cell Biology
SC Cardiovascular System & Cardiology; Cell Biology
GA DM1ZL
UT WOS:000376145300020
PM 26582465
ER
PT J
AU Fidler, R
Johnson, M
AF Fidler, Richard
Johnson, Meshell
TI Human Factors Approach to Comparative Usability of Hospital Manual
Defibrillators
SO RESUSCITATION
LA English
DT Article
DE Defibrillator; Resuscitation equipment; Simulation; AED; Transcutaneous
pacing; Synchronized cardioversion
ID CARDIAC-ARREST; UNITED-STATES; SURVIVAL
AB Introduction: Equipment-related issues have recently been cited as a significant contributor to the suboptimal outcomes of resuscitation management. A systematic evaluation of the human-device interface was undertaken to evaluate the intuitive nature of three different defibrillators. Devices tested were the Physio-Control LifePak 15, the Zoll R Series Plus, and the Philips MRx.
Methods: A convenience sample of 73 multidisciplinary health care providers from 5 different hospitals participated in this study. All subjects' performances were evaluated without any training on the devices being studied to assess the intuitiveness of the user interface to perform the functions of delivering an Automated External Defibrillator (AED) shock, a manual defibrillation, pacing to achieve 100% capture, and synchronized cardioversion on a rhythm simulator.
Results: Times to deliver an AED shock were fastest with the Zoll, whereas the Philips had the fastest times to deliver a manual defibrillation. Subjects took the least time to attain 100% capture for pacing with the Physio-Control device. No differences in performance times were seen with synchronized cardioversion among the devices. Human factors issues uncovered during this study included a preference for knobs over soft keys and a desire for clarity in control panel design. This study demonstrated no clearly superior defibrillator, as each of the models exhibited strengths in different areas. When asked their defibrillator preference, 67% of subjects chose the Philips.
Conclusions: This comparison of user interfaces of defibrillators in simulated situations allows the assessment of usability that can provide manufacturers and educators with feedback about defibrillator implementation for these critical care devices. Published by Elsevier Ireland Ltd
C1 [Fidler, Richard; Johnson, Meshell] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA.
[Johnson, Meshell] Univ Calif San Francisco, Northern Calif Inst Res & Educ, San Francisco, CA 94121 USA.
[Fidler, Richard] Univ Calif San Francisco, Sch Nursing, Dept Anesthesia, San Francisco, CA 94121 USA.
[Fidler, Richard] Univ Calif San Francisco, Sch Nursing, Dept Perioperat Med, San Francisco, CA 94121 USA.
[Johnson, Meshell] Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA.
RP Fidler, R (reprint author), San Francisco VA Med Ctr, Dept Anesthesia, 4150 Clement St, San Francisco, CA 94121 USA.; Fidler, R (reprint author), San Francisco VA Med Ctr, Dept Perioperat Med, 4150 Clement St, San Francisco, CA 94121 USA.
EM richard.fidler@ucsf.edu
FU San Francisco Department of Veterans Affairs Medical Center
FX The San Francisco Department of Veterans Affairs Medical Center
supported this work. Philips Healthcare, Physio-Control, and Zoll
Medical provided equipment support.
NR 10
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0300-9572
J9 RESUSCITATION
JI Resuscitation
PD APR
PY 2016
VL 101
BP 71
EP 76
DI 10.1016/j.resuscitation.2016.01.029
PG 6
WC Critical Care Medicine; Emergency Medicine
SC General & Internal Medicine; Emergency Medicine
GA DL8HR
UT WOS:000375882300025
PM 26868076
ER
PT J
AU Bourguignon, LYW
AF Bourguignon, Lilly Y. W.
TI Matrix Hyaluronan Promotes Specific MicroRNA Upregulation Leading to
Drug Resistance and Tumor Progression
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE hyaluronan (HA); CD44; microRNA (miRNA); cancer stem cells (CSCs);
signaling; chemoresistance; tumor progression
ID BREAST-CANCER CELLS; EMBRYONIC STEM-CELLS; CYTOSKELETON ACTIVATION;
HOMING RECEPTOR; MARKER NANOG; ACID BINDING; EXPRESSION; CD44; INVASION;
METASTASIS
AB Solid tumor invasion, metastasis and therapeutic drug resistance are the common causes for serious morbidity and cancer recurrence in patients. A number of research studies have searched for malignancy-related biomarkers and drug targets that are closely linked to tumor cell properties. One of the candidates is matrix hyaluronan (HA), which is known as one of the major extracellular matrix (ECM) components. HA serves as a physiological ligand for surface CD44 molecule and also functions as a bio-regulator. The binding of HA to CD44 has been shown to stimulate concomitant activation of a number of oncogenic pathways and abnormal cellular processes in cancer cells and cancer stem cells (CSCs). MicroRNAs (miRNAs) belong to a class of small RNAs containing similar to 20-25 nucleotides and are known to promote aberrant cellular functions in cancer cells. In this article, I have focused on the role of HA interaction with CD44 and several important signaling molecules in the regulation of unique miRNAs (e. g., miR-21, miR-302 and miR-10b) and their downstream targets leading to multiple tumor cell-specific functions (e. g., tumor cell growth, drug resistance and metastasis) and cancer progression. This new knowledge could provide the groundwork necessary for establishing new tumor markers and developing important, novel drugs targeted against HA/CD44-associated tumor progression, which can be utilized in the therapeutic treatment of metastatic cancer patients.
C1 [Bourguignon, Lilly Y. W.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Med, 4150 Clement St, San Francisco, CA 94121 USA.
[Bourguignon, Lilly Y. W.] Endocrine Unit 111N2, 4150 Clement St, San Francisco, CA 94121 USA.
RP Bourguignon, LYW (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Med, 4150 Clement St, San Francisco, CA 94121 USA.; Bourguignon, LYW (reprint author), Endocrine Unit 111N2, 4150 Clement St, San Francisco, CA 94121 USA.
EM lilly.bourguignon@ucsf.edu
OI Bourguignon, Lilly/0000-0003-3172-9251
FU Veterans Affairs (VA) Merit Review Awards [RR & D-1I01 RX000601, BLR &
D-5I01 BX000628]; United States Public Health [R01 CA66163]; DOD
(Department of Defense)
FX This work was supported by Veterans Affairs (VA) Merit Review Awards (RR
& D-1I01 RX000601 and BLR & D-5I01 BX000628), United States Public
Health grants (R01 CA66163) and DOD (Department of Defense) grant Lilly
Y.W. Bourguignon is a VA Senior Research Career Scientist.
NR 65
TC 3
Z9 3
U1 2
U2 11
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD APR
PY 2016
VL 17
IS 4
AR 517
DI 10.3390/ijms17040517
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA DK0EL
UT WOS:000374585300096
PM 27070574
ER
PT J
AU Hoang, B
Shi, YJ
Frost, PJ
Mysore, V
Bardeleben, C
Lichtenstein, A
AF Hoang, Bao
Shi, Yijiang
Frost, Patrick J.
Mysore, Veena
Bardeleben, Carolyne
Lichtenstein, Alan
TI SGK Kinase Activity in Multiple Myeloma Cells Protects against ER Stress
Apoptosis via a SEK-Dependent Mechanism
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID PRECLINICAL MODELS; PATHWAY; GENE; INHIBITOR; SERUM; AKT; SURVIVAL;
RECEPTOR; GROWTH; PHOSPHORYLATION
AB To assess the role of the serum and glucocorticoid-regulated kinase (SGK) kinase in multiple myeloma, we ectopically expressed wild type or a phosphomimetic version of SGK into multiple myeloma cell lines. These cells were specifically resistant to the ER stress inducers tunicamycin, thapsigargin, and bortezomib. In contrast, there was no alteration of sensitivity to dexamethasone, serum starvation, or mTORC inhibitors. Mining of genomic data from a public database indicated that low baseline SGK expression in multiple myeloma patients correlated with enhanced ability to undergo a complete response to subsequent bortezomib treatment and a longer time to progression and overall survival following treatment. SGK overexpressing multiple myeloma cells were also relatively resistant to bortezomib in a murine xenograft model. Parental/control multiple myeloma cells demonstrated a rapid upregulation of SGK expression and activity (phosphorylation of NDRG-1) during exposure to bortezomib and an SGK inhibitor significantly enhanced bortezomib-induced apoptosis in cell lines and primary multiple myeloma cells. In addition, a multiple myeloma cell line selected for bortezomib resistance demonstrated enhanced SGK expression and SGK activity. Mechanistically, SGK overexpression constrained an ER stress-induced JNK proapoptotic pathway and experiments with a SEK mutant supported the notion that SGK's protection against bortezomib was mediated via its phosphorylation of SEK (MAP2K4) which abated SEK/JNK signaling. These data support a role for SGK inhibitors in the clinical setting for myeloma patients receiving treatment with ER stress inducers like bortezomib.
Implications: Enhanced SGK expression and activity in multiple myeloma cells contributes to resistance to ER stress, including bortezomib challenge. Mol Cancer Res; 14(4); 397-407. (C) 2016 AACR.
C1 [Hoang, Bao; Shi, Yijiang; Frost, Patrick J.; Mysore, Veena; Bardeleben, Carolyne; Lichtenstein, Alan] UCLA Med Ctr, Johnsson Comprehens Canc Ctr, Div Hematol Oncol, Greater Los Angeles VA Healthcare Ctr,Dept Med, Los Angeles, CA 90073 USA.
RP Lichtenstein, A (reprint author), UCLA Med Ctr, West Los Angeles VA Med Center, 11301 Wilshire Blvd,Bldg 304,Room E1-115, Los Angeles, CA 90073 USA.
EM alan.lichtenstein@med.va.gov
FU NIH [RO1CA168700, 2RO1CA111448, R21CA168491]; Veteran's Administration;
Multiple Myeloma Research Foundation; CURE grant [P30 DK041301]
FX This work was supported by NIH grants RO1CA168700, 2RO1CA111448, and
R21CA168491 as well as research funds of the Veteran's Administration
and Multiple Myeloma Research Foundation. The UCLA Vector Core Lab was
supported by CURE grant P30 DK041301.
NR 29
TC 0
Z9 0
U1 0
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1541-7786
EI 1557-3125
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD APR
PY 2016
VL 14
IS 4
BP 397
EP 407
DI 10.1158/1541-7786.MCR-15-0422
PG 11
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA DL7WX
UT WOS:000375852200009
PM 26869290
ER
PT J
AU Kopacz, MS
Nieuwsma, JA
Jackson, GL
Rhodes, JE
Cantrell, WC
Bates, MJ
Meador, KG
AF Kopacz, Marek S.
Nieuwsma, Jason A.
Jackson, George L.
Rhodes, Jeffrey E.
Cantrell, William C.
Bates, Mark J.
Meador, Keith G.
TI Chaplains' Engagement with Suicidality among Their Service Users:
Findings from the VA/DoD Integrated Mental Health Strategy
SO SUICIDE AND LIFE-THREATENING BEHAVIOR
LA English
DT Article
ID UNITED-STATES; ACTIVE-DUTY; VETERANS; RISK; ATTENDANCE; PERSONNEL;
CHURCH; CARE
AB Chaplains play an important role in supporting the mental health of current and former military personnel; in this study, the engagement of Department of Veterans Affairs (VA), Army, Navy, and Air Force chaplains with suicidality among their service users were examined. An online survey was used to collect data from 440 VA and 1,723 Department of Defense (DoD) chaplains as part of the VA/DoD Integrated Mental Health Strategy. Differences were noted for demographics, work setting characteristics, encountering suicidality, and self-perceived preparation for dealing with suicidality. Compared to DoD chaplains, VA chaplains encounter more at-risk service users, yet feel less prepared for dealing with suicidality.
C1 [Kopacz, Marek S.] US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, 400 Ft Hill Ave, Canandaigua, NY 14424 USA.
[Nieuwsma, Jason A.; Cantrell, William C.; Meador, Keith G.] Mid Atlantic Mental Illness Res Educ & Clin Ctr, Dept Vet Affairs, Mental Hlth & Chaplaincy, Durham, NC USA.
[Nieuwsma, Jason A.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA.
[Jackson, George L.] Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA.
[Jackson, George L.] Duke Univ, Med Ctr, Div Gen Internal Med, Durham, NC 27710 USA.
[Rhodes, Jeffrey E.; Bates, Mark J.] Def Ctr Excellence Psychol Hlth & Traumat Brain I, Deployment Hlth Clin Ctr, Psychol Hlth Promot, Silver Spring, MD USA.
[Meador, Keith G.] Vanderbilt Univ, Ctr Biomed Eth & Soc, Dept Psychiat, 221 Kirkland Hall, Nashville, TN 37235 USA.
[Meador, Keith G.] Vanderbilt Univ, Ctr Biomed Eth & Soc, Dept Hlth Policy, 221 Kirkland Hall, Nashville, TN 37235 USA.
[Meador, Keith G.] Vanderbilt Univ, Grad Dept Relig, 221 Kirkland Hall, Nashville, TN 37235 USA.
RP Kopacz, MS (reprint author), US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, 400 Ft Hill Ave, Canandaigua, NY 14424 USA.
EM marek.kopacz@va.gov
FU VISN 2 Center of Excellence for Suicide Prevention in Canandaigua, New
York
FX The views expressed are those of the authors and do not reflect the
official policy or position of the US Department of Veterans Affairs,
the US Department of Defense, or the US Government. This work was
funded, in part, by the VISN 2 Center of Excellence for Suicide
Prevention in Canandaigua, New York.
NR 23
TC 3
Z9 3
U1 2
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0363-0234
EI 1943-278X
J9 SUICIDE LIFE-THREAT
JI Suicide Life-Threat. Behav.
PD APR
PY 2016
VL 46
IS 2
BP 206
EP 212
DI 10.1111/sltb.12184
PG 7
WC Psychiatry; Psychology, Multidisciplinary
SC Psychiatry; Psychology
GA DK1TC
UT WOS:000374696200007
PM 26255592
ER
PT J
AU Greenwood, TA
Light, GA
Swerdlow, NR
Calkins, ME
Green, MF
Gur, RE
Gur, RC
Lazzeroni, LC
Nuechterlein, KH
Olincy, A
Radant, AD
Seidman, LJ
Siever, LJ
Silverman, JM
Stone, WS
Sugar, CA
Tsuang, DW
Tsuang, MT
Turetsky, BI
Freedman, R
Braff, DL
AF Greenwood, Tiffany A.
Light, Gregory A.
Swerdlow, Neal R.
Calkins, Monica E.
Green, Michael F.
Gur, Raquel E.
Gur, Ruben C.
Lazzeroni, Laura C.
Nuechterlein, Keith H.
Olincy, Ann
Radant, Allen D.
Seidman, Larry J.
Siever, Larry J.
Silverman, Jeremy M.
Stone, William S.
Sugar, Catherine A.
Tsuang, Debby W.
Tsuang, Ming T.
Turetsky, Bruce I.
Freedman, Robert
Braff, David L.
TI Gating Deficit Heritability and Correlation With Increased Clinical
Severity in Schizophrenia Patients With Positive Family History
SO AMERICAN JOURNAL OF PSYCHIATRY
LA English
DT Article
ID SCHIZOTYPAL PERSONALITY-DISORDER; EVOKED RESPONSE SUPPRESSION; PREPULSE
INHIBITION; P50 SUPPRESSION; ACOUSTIC STARTLE; CONSORTIUM; RELATIVES;
GENETICS; RISK; ENDOPHENOTYPES
AB Objective: The Consortium on the Genetics of Schizophrenia Family Study evaluated 12 primary and other supplementary neurocognitive and neurophysiological endophenotypes in schizophrenia probands and their families. Previous analyses of prepulse inhibition (PPI) and P50 gating measures in this sample revealed heritability estimates that were lower than expected based on earlier family studies. Here the authors investigated whether gating measures were more heritable in multiply affected families with a positive family history compared with families with only a single affected proband (singleton).
Method: A total of 296 nuclear families consisting of a schizophrenia proband, at least one unaffected sibling, and both parents underwent a comprehensive endophenotype andclinical characterization. The Family Interview for Genetic Studies was administered to all participants and used to obtain convergent psychiatric symptom information for additional first-degree relatives. Among the families, 97 were multiply affected, and 96 were singletons.
Results: Both PPI and P50 gating displayed substantially increased heritability in the 97 multiply affected families (47% and 36%, respectively) compared with estimates derived from the entire sample of 296 families (29% and 20%, respectively). However, no evidence for heritability was observed for either measure in the 96 singleton families. Schizophrenia probands derived from the multiply affected families also displayed a significantly increased severity of clinical symptoms compared with those from singleton families.
Conclusions: PPI and P50 gating measures demonstrate substantially increased heritability in schizophrenia families with a higher genetic vulnerability for illness, providing further support for the commonality of genes underlying both schizophrenia and gating measures.
C1 [Greenwood, Tiffany A.] UCSanDiego, Ctr Behav Genom, Dept Psychiat, La Jolla, CA USA.
[Greenwood, Tiffany A.] UCSanDiego, Inst Genom Med, La Jolla, CA USA.
VA San Diego Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 22, San Diego, CA USA.
Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA.
VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA.
Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA.
Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
VA Puget Sound Hlth Care Syst, Seattle, WA USA.
Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
Harvard Inst Psychiat Epidemiol & Genet, Boston, MA USA.
Beth Israel Deaconess Med Ctr, Massachusetts Mental Hlth Ctr, Div Publ Psychiat, Boston, MA 02215 USA.
Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.
James J Peters VA Med Ctr, New York, NY USA.
RP Greenwood, TA (reprint author), UCSanDiego, Ctr Behav Genom, Dept Psychiat, La Jolla, CA USA.; Greenwood, TA (reprint author), UCSanDiego, Inst Genom Med, La Jolla, CA USA.
EM tgreenwood@ucsd.edu
RI Tsuang, Debby/L-7234-2016
OI Tsuang, Debby/0000-0002-4716-1894; Greenwood,
Tiffany/0000-0002-6080-6503
FU NIMH [R01-MH065571, R01-MH065588, R01-MH065562, R01-MH065707,
R01-MH065554, R01-MH065578, R01-MH065558, R01 MH86135, K01-MH087889];
Amgen; Brain Plasticity; Genentech; Janssen Scientific Affairs
FX Supported by NIMH grants R01-MH065571, R01-MH065588, R01-MH065562,
R01-MH065707, R01-MH065554, R01-MH065578, R01-MH065558, R01 MH86135, and
K01-MH087889.; Dr. Freedman has a patent through the VA on DNA sequences
in CHRNA7. Dr. Green has been a consultant to AbbVie, Biogen, DSP,
EnVivo/Forum, and Roche; he is on the scientific advisory board of
Mnemosyne; and he has received research funds from Amgen. Dr. R.E. Gur
has served as a consultant for Otsuka. Dr. Lazzeroni is an inventor on a
patent application filed by Stanford University on genetic polymorphisms
associated with depression. Dr. Light has served as a consultant for
Astellas, Forum, and Neuroverse. Dr. Nuechterlein has received research
support from Brain Plasticity, Genentech, and Janssen Scientific
Affairs, and has served as a consultant for Brain Plasticity, Genentech,
Janssen, and Otsuka. Dr. Swerdlow has served as a consultant for Genco
Sciences. The other authors report no financial relationships with
commercial interests.
NR 60
TC 3
Z9 3
U1 3
U2 4
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0002-953X
EI 1535-7228
J9 AM J PSYCHIAT
JI Am. J. Psychiat.
PD APR
PY 2016
VL 173
IS 4
BP 385
EP 391
DI 10.1176/appi.ajp.2015.15050605
PG 7
WC Psychiatry
SC Psychiatry
GA DK9ZH
UT WOS:000375290400013
PM 26441157
ER
PT J
AU Mandal, R
Duvvuri, U
Ferris, RL
Kaffenberger, TM
Choby, GW
Kim, S
AF Mandal, Rajarsi
Duvvuri, Umamaheswar
Ferris, Robert L.
Kaffenberger, Thomas M.
Choby, Garret W.
Kim, Seungwon
TI Analysis of post-transoral robotic-assisted surgery hemorrhage:
Frequency, outcomes, and prevention
SO HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND
NECK
LA English
DT Article
DE transoral robotic-assisted surgery (TORS); TORS hemorrhage; TORS
bleeding; TORS complications; prophylactic arterial ligation
ID OBSTRUCTIVE SLEEP-APNEA; ASCENDING PHARYNGEAL ARTERY; SQUAMOUS-CELL
CARCINOMA; FUNCTIONAL OUTCOMES; PARAPHARYNGEAL SPACE;
CLINICAL-EXPERIENCE; HYPOPNEA SYNDROME; CAROTID-ARTERY; FEASIBILITY;
OROPHARYNX
AB Background. Transoral robotic-assisted surgery (TORS) carries a small, but not insignificant, risk of life-threatening postsurgical hemorrhage. The purpose of this study was to analyze all post-TORS hemorrhagic events at our institution to establish preventative recommendations.
Methods. We conducted a retrospective review of 224 consecutive patients who underwent TORS for any indication at a single tertiary care institution.
Results. Twenty-two patients (n = 22; 9.82%) had varying degrees of postoperative bleeding. An impaired ability to protect the airway at the time of hemorrhage increased the rate of severe complications. Prophylactic transcervical arterial ligation did not significantly decrease overall postoperative bleeding rates (9.1% vs 9.9%; p = 1.00); however, there was a trend toward decreased hemorrhage severity in prophylactically ligated patients (3.0% vs 7.3%; p = .7040).
Conclusion. Prophylactic transcervical arterial ligation may reduce the incidence of severe bleeding following TORS. Post-TORS patients displaying an inability to protect the airway should be strongly considered for prophylactic tracheostomy to assist airway protection. (C) 2015 Wiley Periodicals, Inc.
C1 [Mandal, Rajarsi; Duvvuri, Umamaheswar; Ferris, Robert L.; Choby, Garret W.; Kim, Seungwon] Univ Pittsburgh, Dept Otolaryngol, Med Ctr, Pittsburgh, PA 15260 USA.
[Duvvuri, Umamaheswar] Vet Affairs Pittsburgh Hlth Syst, Pittsburgh, PA USA.
[Kaffenberger, Thomas M.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
RP Kim, S (reprint author), Eye & Ear Inst Pittsburgh, Suite 500,203 Lothrop St, Pittsburgh, PA 15213 USA.
EM kimsw2@upmc.edu
NR 25
TC 6
Z9 6
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1043-3074
EI 1097-0347
J9 HEAD NECK-J SCI SPEC
JI Head Neck-J. Sci. Spec. Head Neck
PD APR
PY 2016
VL 38
SU 1
BP E776
EP E782
DI 10.1002/hed.24101
PG 7
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA DK7OU
UT WOS:000375116400093
PM 25916790
ER
PT J
AU Scales, CD
Moin, T
Fink, A
Berry, SH
Afsar-Manesh, N
Mangione, CM
Kerfoot, BP
AF Scales, Charles D., Jr.
Moin, Tannaz
Fink, Arlene
Berry, Sandra H.
Afsar-Manesh, Nasim
Mangione, Carol M.
Kerfoot, B. Price
TI A randomized, controlled trial of team-based competition to increase
learner participation in quality-improvement education
SO INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE
LA English
DT Article
DE graduate medical education; randomized controlled trial; quality
improvement; spaced education
ID INTERACTIVE SPACED-EDUCATION; WEIGHT-LOSS; MEMORY; ENVIRONMENT;
INCENTIVES; RETENTION; RETRIEVAL; PROGRAM; IMPACT; SAFETY
AB Several barriers challenge resident engagement in learning quality improvement (QI). We investigated whether the incorporation of team-based game mechanics into an evidence-based online learning platform could increase resident participation in a QI curriculum.
Randomized, controlled trial.
Tertiary-care medical center residency training programs.
Resident physicians (n = 422) from nine training programs (anesthesia, emergency medicine, family medicine, internal medicine, ophthalmology, orthopedics, pediatrics, psychiatry and general surgery) randomly allocated to a team competition environment (n = 200) or the control group (n = 222).
Specialty-based team assignment with leaderboards to foster competition, and alias assignment to de-identify individual participants.
Participation in online learning, as measured by percentage of questions attempted (primary outcome) and additional secondary measures of engagement (i.e. response time). Changes in participation measures over time between groups were assessed with a repeated measures ANOVA framework.
Residents in the intervention arm demonstrated greater participation than the control group. The percentage of questions attempted at least once was greater in the competition group (79% [SD +/- 32] versus control, 68% [SD +/- 37], P= 0.03). Median response time was faster in the competition group (P= 0.006). Differences in participation continued to increase over the duration of the intervention, as measured by average response time and cumulative percent of questions attempted (each P < 0.001).
Team competition increases resident participation in an online course delivering QI content. Medical educators should consider game mechanics to optimize participation when designing learning experiences.
C1 [Scales, Charles D., Jr.; Fink, Arlene; Mangione, Carol M.] Univ Calif Los Angeles, Robert Wood Johnson Fdn, US Dept Vet Affairs, Clin Scholars Program, Los Angeles, CA USA.
[Scales, Charles D., Jr.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA.
[Scales, Charles D., Jr.; Moin, Tannaz; Fink, Arlene; Afsar-Manesh, Nasim; Mangione, Carol M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Scales, Charles D., Jr.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA.
[Moin, Tannaz] Vet Affairs Greater Los Angeles Healthcare Syst, HSR&D Ctr Excellence Study Healthcare Innovat Imp, Los Angeles, CA USA.
[Fink, Arlene; Mangione, Carol M.] Univ Calif Los Angeles, Dept Hlth Policy & Management, Fielding Sch Publ Hlth, Los Angeles, CA USA.
[Berry, Sandra H.] RAND Corp, Santa Monica, CA USA.
[Afsar-Manesh, Nasim] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA.
[Kerfoot, B. Price] Vet Affairs Boston Healthcare Syst, Boston, MA USA.
[Kerfoot, B. Price] Harvard Univ, Sch Med, Boston, MA USA.
[Scales, Charles D., Jr.] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA.
[Scales, Charles D., Jr.] Duke Univ, Sch Med, Div Urol Surg, Durham, NC USA.
RP Scales, CD (reprint author), Duke Clin Res Inst, DUMC 3707, Durham, NC 27710 USA.; Scales, CD (reprint author), Div Urol Surg, DUMC 3707, Durham, NC 27710 USA.
EM chuck.scales@duke.edu
NR 30
TC 4
Z9 4
U1 2
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1353-4505
EI 1464-3677
J9 INT J QUAL HEALTH C
JI Int. J. Qual. Health Care
PD APR 1
PY 2016
VL 28
IS 2
BP 227
EP 232
DI 10.1093/intqhc/mzw008
PG 6
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA DK7GU
UT WOS:000375094000011
PM 26857941
ER
PT J
AU Li, XL
Wilson, M
Nylander, W
Smith, T
Lynn, M
Gunnar, W
AF Li, Xinli
Wilson, Mark
Nylander, William
Smith, Tracy
Lynn, Marilyn
Gunnar, William
TI Analysis of Morbidity and Mortality Outcomes in Postoperative
Clostridium difficile Infection in the Veterans Health Administration
SO JAMA SURGERY
LA English
DT Article
ID RISK-FACTORS; TRANSPLANT RECIPIENTS; SURGERY; PROPHYLAXIS; OUTBREAK;
DIARRHEA; COLITIS; IMPACT
AB IMPORTANCE This study analyzes and reports Clostridium difficile infection (CDI) rates, risk factors, and associations with postoperative outcomes in the Veterans Health Administration (VHA).
OBJECTIVE To report 30-day postoperative CDI rates and outcomes and identify associated risks by surgical procedures and preoperative patient demographics in a large integrated health care system.
DESIGN, SETTING, AND PARTICIPANTS In a retrospective observational study conducted from September 2014 to April 2015, the Veterans Affairs Surgical Quality Improvement Program database and the Decision Support System pharmacy database were linked to analyze the association of postoperative CDI with patients' demographics, preoperative comorbidities, operative characteristics, and preoperative medications. The Veterans Affairs Surgical Quality Improvement Program assessments from October 1, 2009, to September 30, 2013, were investigated. The study was conducted at 134 VHA surgery programs, and the study population represents 12 surgical specialties: general, gynecological, neurosurgical, oral, orthopedics, otolaryngologic, plastic, podiatric, thoracic, transplant, urologic, and peripheral vascular.
MAIN OUTCOMES AND MEASURES Thirty-day postoperative CDI rates, risk factors of CDI, and association of CDI with postoperative morbidity and mortality.
RESULTS Among 468 386 surgical procedures, the postoperative CDI rate was 0.4% per year and varied by the VHA Surgery Program (0.0% to 1.4%) and surgical specialty (0.0% to 2.4%). Thirty-day CDI rates were higher in emergency procedures, procedures with greater complexity and higher relative value units, and those with a contaminated/ infected wound classification. Patients with postoperative CDI were significantly older, more frequently hospitalized after surgery (59.9% vs 15.4%), had longer preoperative hospital stays (9.1 days vs 1.9 days), and had received 3 or more classes of antibiotics (1.5% vs 0.3% for a single antibiotic class) (all P < .001). Patients with CDI had higher rates of other postoperative morbidity (86.0% vs 7.1%), 30-day mortality (5.3% vs 1.0%), and longer postoperative hospital stays (17.9 days vs 3.6 days). Independent risk factors for CDI included commonly identified patient factors (albumin, functional class, and weight loss), procedural characteristics (complexity, relative value units, emergency, and wound classification), surgical program complexity, the number of preoperative antibiotic classes, and length of preoperative hospital stay.
CONCLUSIONS AND RELEVANCE The number and class of antibiotics administered after surgery, preoperative length of stay, procedural characteristics, surgical program complexity, and patient comorbidities are associated with postoperative CDI in the VHA.
C1 [Li, Xinli; Wilson, Mark; Nylander, William; Smith, Tracy; Lynn, Marilyn; Gunnar, William] Vet Hlth Adm, Natl Surg Off, Washington, DC USA.
[Wilson, Mark] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Wilson, Mark] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA.
[Gunnar, William] George Washington Univ, Washington, DC USA.
RP Li, XL (reprint author), Vet Hlth Adm, Natl Surg Off, 4100 E Mississippi Ave,Ste 310, Glendale, CO 80246 USA.
EM xinli.li2@va.gov
NR 24
TC 6
Z9 6
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6254
EI 2168-6262
J9 JAMA SURG
JI JAMA Surg.
PD APR
PY 2016
VL 151
IS 4
BP 314
EP 322
DI 10.1001/jamasurg.2015.4263
PG 9
WC Surgery
SC Surgery
GA DJ7SE
UT WOS:000374411000004
PM 26606675
ER
PT J
AU Waltz, PK
Zuckerbraun, BS
AF Waltz, Paul K.
Zuckerbraun, Brian S.
TI The High Stakes of Postoperative Clostridium difficile Infection
SO JAMA SURGERY
LA English
DT Editorial Material
C1 [Waltz, Paul K.; Zuckerbraun, Brian S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Waltz, Paul K.; Zuckerbraun, Brian S.] Univ Pittsburgh, 200 Lothrop St,F1200 PUH, Pittsburgh, PA 15213 USA.
RP Zuckerbraun, BS (reprint author), Univ Pittsburgh, 200 Lothrop St,F1200 PUH, Pittsburgh, PA 15213 USA.
EM zuckerbraunbs@upmc.edu
NR 1
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6254
EI 2168-6262
J9 JAMA SURG
JI JAMA Surg.
PD APR
PY 2016
VL 151
IS 4
BP 322
EP 322
DI 10.1001/jamasurg.2015.4254
PG 1
WC Surgery
SC Surgery
GA DJ7SE
UT WOS:000374411000005
PM 26606279
ER
PT J
AU Lamming, DW
Cummings, NE
Apelo, SA
Neuman, JC
Schmidt, B
Merrins, M
Kimple, M
Fontana, L
AF Lamming, D. W.
Cummings, N. E.
Apelo, S. Arriola
Neuman, J. C.
Schmidt, B.
Merrins, M.
Kimple, M.
Fontana, L.
TI IMPROVING GLYCEMIC CONTROL THROUGH REDUCTION OF SPECIFIC DIETARY AMINO
ACIDS
SO JOURNAL OF INVESTIGATIVE MEDICINE
LA English
DT Meeting Abstract
CT Midwestern Regional Meeting of the
American-Federation-for-Medical-Research (AFMR)
CY APR 21, 2016
CL Chicago, IL
SP Amer Federat Med Res
C1 [Lamming, D. W.; Cummings, N. E.; Apelo, S. Arriola; Neuman, J. C.; Schmidt, B.; Merrins, M.; Kimple, M.] Univ Wisconsin, Med, Madison, WI USA.
[Lamming, D. W.; Cummings, N. E.; Apelo, S. Arriola; Neuman, J. C.; Schmidt, B.; Merrins, M.; Kimple, M.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
[Fontana, L.] Washington Univ, Geriatr & Nutr Sci, St Louis, MO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1081-5589
EI 1708-8267
J9 J INVEST MED
JI J. Invest. Med.
PD APR
PY 2016
VL 64
IS 4
MA 78
BP 926
EP 926
DI 10.1136/jim-2016-000120.32
PG 1
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA DK3CI
UT WOS:000374792900047
ER
PT J
AU Apelo, SA
Pumper, CP
Baar, EL
Cummings, NE
Brar, HK
Kimple, ME
Lamming, DW
Neuman, JC
AF Apelo, S. Arriola
Pumper, C. P.
Baar, E. L.
Cummings, N. E.
Brar, H. K.
Kimple, M. E.
Lamming, D. W.
Neuman, J. C.
TI ALTERNATIVE RAPAMYCIN TREATMENT REGIMENS MITIGATE THE IMPACT OF
RAPAMYCIN ON GLUCOSE HOMEOSTASIS AND THE IMMUNE SYSTEM, AND EXTENDS
LIFESPAN
SO JOURNAL OF INVESTIGATIVE MEDICINE
LA English
DT Meeting Abstract
CT Midwestern Regional Meeting of the
American-Federation-for-Medical-Research (AFMR)
CY APR 21, 2016
CL Chicago, IL
SP Amer Federat Med Res
C1 [Apelo, S. Arriola; Pumper, C. P.; Baar, E. L.; Cummings, N. E.; Brar, H. K.; Kimple, M. E.; Lamming, D. W.] Univ Wisconsin, Div Endocrinol Diabet & Metab, Med, Madison, WI USA.
[Neuman, J. C.] Univ Wisconsin, Interdisciplinary Grad Program Nutr Sci, Madison, WI USA.
[Apelo, S. Arriola; Pumper, C. P.; Baar, E. L.; Cummings, N. E.; Brar, H. K.; Kimple, M. E.; Lamming, D. W.; Neuman, J. C.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1081-5589
EI 1708-8267
J9 J INVEST MED
JI J. Invest. Med.
PD APR
PY 2016
VL 64
IS 4
MA 21
DI 10.1136/jim-2016-000120.45
PG 2
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA DK3CI
UT WOS:000374792900060
ER
PT J
AU Graves, MC
Harris, JR
Kohn, M
Hannon, PA
Lichiello, PA
Martin, DP
Ahmed, F
AF Graves, Meredith C.
Harris, Jeffrey R.
Kohn, Marlana
Hannon, Peggy A.
Lichiello, Patricia A.
Martin, Diane P.
Ahmed, Faruque
TI Employers' Views on Influenza and Tetanus-Diphtheria-Pertussis
Vaccination in the Workplace
SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE
LA English
DT Letter
ID UNITED-STATES; ADULTS; COSTS
C1 [Harris, Jeffrey R.; Kohn, Marlana; Hannon, Peggy A.; Lichiello, Patricia A.; Martin, Diane P.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA.
[Harris, Jeffrey R.; Kohn, Marlana; Hannon, Peggy A.] Univ Washington, Hlth Promot Res Ctr, Ctr Dis Control & Prevent, Res Ctr, Seattle, WA 98195 USA.
[Graves, Meredith C.] VA Puget Sound Healthcare Syst, Seattle, WA USA.
[Ahmed, Faruque] Ctr Dis Control & Prevent CDC, Atlanta, GA USA.
RP Graves, MC (reprint author), VA Puget Sound Healthcare Syst, Seattle, WA USA.
NR 11
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1076-2752
EI 1536-5948
J9 J OCCUP ENVIRON MED
JI J. Occup. Environ. Med.
PD APR
PY 2016
VL 58
IS 4
BP E157
EP E158
DI 10.1097/JOM.0000000000000693
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DK4ME
UT WOS:000374891600009
PM 27058495
ER
PT J
AU Lee, LY
Foley, DP
AF Lee, Lung-Yi
Foley, David P.
TI Technical Aspects of Orthotopic Liver Transplantation for Hepatocellular
Carcinoma
SO SURGICAL CLINICS OF NORTH AMERICA
LA English
DT Article
DE Liver transplantation; Surgery; Hepatocellular carcinoma; Piggyback
technique; Portal vein thrombosis
ID TRANSARTERIAL CHEMOEMBOLIZATION; BILIARY COMPLICATIONS; CANCER
STATISTICS; HEPATIC-ARTERY; SURVIVAL; EXPERIENCE; CIRRHOSIS
AB Hepatocellular carcinoma (HCC) remains a significant malignancy and is the second leading cause of cancer death worldwide. Multiple therapeutic strategies exist for patients with HCC including locoregional therapy, liver resection, and liver transplantation. In many instances locoregional therapy is used to decrease tumor burden and "bridge" patients to liver transplant. Surgical technique during liver transplantation may need to be altered in light of these preoperative therapies used for treating HCC. In this review, we discuss the technical aspects of liver transplantation and how they are impacted in patients with HCC.
C1 [Lee, Lung-Yi; Foley, David P.] Univ Wisconsin, Dept Surg, Ctr Clin Sci, Sch Med & Publ Hlth, H4-766,600 Highland Ave, Madison, WI 53792 USA.
[Foley, David P.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, 2500 Overlook Terrace, Madison, WI 53705 USA.
RP Foley, DP (reprint author), Univ Wisconsin, Ctr Clin Sci, H4-766,600 Highland Ave, Madison, WI 53792 USA.
EM foley@surgery.wisc.edu
NR 28
TC 0
Z9 0
U1 4
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0039-6109
EI 1558-3171
J9 SURG CLIN N AM
JI Surg. Clin.-North Am.
PD APR
PY 2016
VL 96
IS 2
BP 269
EP +
DI 10.1016/j.suc.2015.11.004
PG 15
WC Surgery
SC Surgery
GA DK6GR
UT WOS:000375021200011
PM 27017864
ER
PT J
AU Musher, DM
AF Musher, Daniel M.
TI Quantitative Molecular Approach to Diagnosing Pneumonia
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Editorial Material
DE community-acquired pneumonia; etiology; sputum; Gram stain
ID COMMUNITY-ACQUIRED PNEUMONIA; ADULTS
C1 [Musher, Daniel M.] Baylor Coll Med, Houston, TX 77030 USA.
[Musher, Daniel M.] Michael E DeBakey VA Med Ctr, Infect Dis Sect, Med Care Line, Houston, TX USA.
RP Musher, DM (reprint author), VA Med Ctr, 2002 Holcombe, Houston, TX 77030 USA.
EM daniel.musher@va.gov
NR 11
TC 4
Z9 4
U1 2
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD APR 1
PY 2016
VL 62
IS 7
BP 824
EP 825
DI 10.1093/cid/civ1216
PG 2
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DJ5LD
UT WOS:000374248700002
PM 26747824
ER
PT J
AU Fox, GJ
Mitnick, CD
Benedetti, A
Chan, ED
Becerra, M
Chiang, CY
Keshavjee, S
Koh, WJ
Shiraishi, Y
Viiklepp, P
Yim, JJ
Pasvol, G
Robert, J
Shim, TS
Shin, SS
Menzies, D
AF Fox, Gregory J.
Mitnick, Carole D.
Benedetti, Andrea
Chan, Edward D.
Becerra, Mercedes
Chiang, Chen-Yuan
Keshavjee, Salmaan
Koh, Won-Jung
Shiraishi, Yuji
Viiklepp, Piret
Yim, Jae-Joon
Pasvol, Geoffrey
Robert, Jerome
Shim, Tae Sun
Shin, Sonya S.
Menzies, Dick
CA Collaborative Grp Meta-Anal Indivi
TI Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis:
An Individual Patient Data Metaanalysis
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE multidrug resistant tuberculosis; thoracic surgery; pneumonectomy;
metaanalysis; individual patient data
ID TREATMENT OUTCOMES
AB Background. Medical treatment for multidrug-resistant (MDR)-tuberculosis is complex, toxic, and associated with poor outcomes. Surgical lung resection may be used as an adjunct to medical therapy, with the intent of reducing bacterial burden and improving cure rates. We conducted an individual patient data metaanalysis to evaluate the effectiveness of surgery as adjunctive therapy for MDR-tuberculosis.
Methods. Individual patient data, was obtained from the authors of 26 cohort studies, identified from 3 systematic reviews of MDR-tuberculosis treatment. Data included the clinical characteristics and medical and surgical therapy of each patient. Primary analyses compared treatment success (cure and completion) to a combined outcome of failure, relapse, or death. The effects of all forms of resection surgery, pneumonectomy, and partial lung resection were evaluated.
Results. A total of 4238 patients from 18 surgical studies and 2193 patients from 8 nonsurgical studies were included. Pulmonary resection surgery was performed on 478 patients. Partial lung resection surgery was associated with improved treatment success (adjusted odds ratio [aOR], 3.0; 95% confidence interval [CI], 1.5-5.9; I-R(2), 11.8%), but pneumonectomy was not (aOR, 1.1; 95% CI,.6-2.3; I-R(2), 13.2%). Treatment success was more likely when surgery was performed after culture conversion than before conversion (aOR, 2.6; 95% CI, 0.9-7.1; I-R(2), 0.2%).
Conclusions. Partial lung resection, but not pneumonectomy, was associated with improved treatment success among patients with MDR-tuberculosis. Although improved outcomes may reflect patient selection, partial lung resection surgery after culture conversion may improve treatment outcomes in patients who receive optimal medical therapy.
C1 [Fox, Gregory J.; Benedetti, Andrea; Menzies, Dick] McGill Univ, Montreal Chest Inst, Montreal, PQ H3A 2T5, Canada.
[Mitnick, Carole D.; Becerra, Mercedes; Keshavjee, Salmaan] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA 02115 USA.
[Chan, Edward D.] Denver Vet Affairs Med Ctr, Dept Med, Denver, CO USA.
[Chan, Edward D.] Denver Vet Affairs Med Ctr, Dept Acad Affairs, Denver, CO USA.
[Chiang, Chen-Yuan] Taipei Med Univ, Wan Fang Hosp, Taipei, Taiwan.
[Koh, Won-Jung] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea.
[Shiraishi, Yuji] Fukujuji Hosp, Sect Chest Surg, Tokyo, Japan.
[Viiklepp, Piret] Natl Inst Hlth Dev, Estonian TB Registry, Tallinn, Estonia.
[Yim, Jae-Joon] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 151, South Korea.
[Pasvol, Geoffrey] Univ London Imperial Coll Sci Technol & Med, Dept Infect & Trop Med, London, England.
[Robert, Jerome] Univ Paris 06, Lab Bacteriol Hyg, Paris, France.
[Shim, Tae Sun] Univ Ulsan, Coll Med, Dept Pulm & Crit Care Med, Asan Med Ctr, Seoul, South Korea.
[Shin, Sonya S.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.
RP Menzies, D (reprint author), 2155 Guy St, Montreal, PQ H3H 2R9, Canada.
EM dick.menzies@mcgill.ca
RI Koh, Won Jung/C-9595-2011
OI Hollm-Delgado, Maria-Graciela/0000-0003-1067-8520; ROBERT,
JEROME/0000-0002-9380-0570
FU CJ Martin post-doctoral fellowship [APP1054107]; Australian National
Health and Medical Research Council
FX This work was supported by a CJ Martin post-doctoral fellowship
(APP1054107) to G. J. F. from the Australian National Health and Medical
Research Council.
NR 17
TC 7
Z9 7
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD APR 1
PY 2016
VL 62
IS 7
BP 887
EP 895
DI 10.1093/cid/ciw002
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DJ5LD
UT WOS:000374248700011
PM 26757804
ER
PT J
AU Ovchinnikova, ES
Schmitter, D
Vegter, EL
ter Maaten, JM
Valente, MAE
Liu, LCY
van der Harst, P
Pinto, YM
de Boer, RA
Meyer, S
Teerlink, JR
O'Connor, CM
Metra, M
Davison, BA
Bloomfield, DM
Cotter, G
Cleland, JG
Mebazaa, A
Laribi, S
Givertz, MM
Ponikowski, P
van der Meer, P
van Veldhuisen, DJ
Voors, AA
Berezikov, E
AF Ovchinnikova, Ekaterina S.
Schmitter, Daniela
Vegter, Eline L.
ter Maaten, Jozine M.
Valente, Mattia A. E.
Liu, Licette C. Y.
van der Harst, Pim
Pinto, Yigal M.
de Boer, Rudolf A.
Meyer, Sven
Teerlink, John R.
O'Connor, Christopher M.
Metra, Marco
Davison, Beth A.
Bloomfield, Daniel M.
Cotter, Gadi
Cleland, John G.
Mebazaa, Alexandre
Laribi, Said
Givertz, Michael M.
Ponikowski, Piotr
van der Meer, Peter
van Veldhuisen, Dirk J.
Voors, Adriaan A.
Berezikov, Eugene
TI Signature of circulating microRNAs in patients with acute heart failure
SO EUROPEAN JOURNAL OF HEART FAILURE
LA English
DT Article
DE Heart failure; Circulating microRNAs; Biomarkers
ID DILATED CARDIOMYOPATHY; EJECTION FRACTION; CANDIDATE MARKERS;
HYPERTROPHY; EXPRESSION; MIRNAS; BIOMARKERS; CARDIOMYOCYTES; MECHANISM;
DIAGNOSIS
AB AimsOur aim was to identify circulating microRNAs (miRNAs) associated with acute heart failure (AHF).
Methods and resultsPlasma miRNA profiling included 137 patients with AHF from 3 different cohorts, 20 with chronic heart failure (CHF), 8 with acute exacerbation of COPD, and 41 healthy controls. Levels of circulating miRNAs were measured using quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Plasma levels of miRNAs in patients with AHF were decreased compared with CHF patients or healthy subjects, whereas no significant changes were observed between acute COPD patients and controls. Fifteen miRNAs found in the discovery phase to differ most significantly between healthy controls and patients with AHF were further investigated in an extended cohort of 100 AHF patients at admission and a separate cohort of 18 AHF patients at different time points. Out of these 15 miRNAs, 12 could be confirmed in an additional AHF validation cohort and 7 passed the Bonferroni correction threshold (miR-18a-5p, miR-26b-5p, miR-27a-3p, miR-30e-5p, miR-106a-5p, miR-199a-3p, and miR-652-3p, all P < 0.00005). A further drop in miRNA levels within 48 h after AHF admission was associated with an increased risk of 180-day mortality in a subset of the identified miRNAs.
ConclusionsDeclining levels of circulating miRNAs were associated with increasing acuity of heart failure. Early in-hospital decreasing miRNA levels were predictive for mortality in a subset of miRNAs in patients with AHF. The discovered miRNA panel may serve as a launch-pad for molecular pathway studies to identify new pharmacological targets and miRNA-based therapies.
C1 [Ovchinnikova, Ekaterina S.; Vegter, Eline L.; ter Maaten, Jozine M.; Valente, Mattia A. E.; Liu, Licette C. Y.; van der Harst, Pim; de Boer, Rudolf A.; Meyer, Sven; van der Meer, Peter; van Veldhuisen, Dirk J.; Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, AB31,Hanzepl 1, NL-9713 GZ Groningen, Netherlands.
[Ovchinnikova, Ekaterina S.; Berezikov, Eugene] Univ Groningen, Univ Med Ctr Groningen, European Res Inst Biol Ageing, Groningen, Netherlands.
[Schmitter, Daniela] Momentum Res Inc, Allschwil, Switzerland.
[Pinto, Yigal M.] Univ Amsterdam, Amsterdam, Netherlands.
[Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA.
[O'Connor, Christopher M.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA.
[Metra, Marco] Univ Brescia, Dept Med & Surg Specialties Radiol Sci & Publ Hlt, Cardiol, Brescia, Italy.
[Davison, Beth A.; Cotter, Gadi] Momentum Res, Durham, NC USA.
[Bloomfield, Daniel M.] Merck Res Labs, Rahway, NJ USA.
[Cleland, John G.] Univ London Imperial Coll Sci Technol & Med, Royal Brompton & Harefield Hosp, Natl Heart & Lung Inst, London, England.
[Mebazaa, Alexandre] Univ Paris Diderot, St Louis Lariboisiere Univ Hosp, AP HP,INSERM,U942, Dept Anesthesiol & Crit Care, Paris, France.
[Mebazaa, Alexandre] Univ Paris Diderot, St Louis Lariboisiere Univ Hosp, AP HP,INSERM,U942, Burn Unit, Paris, France.
[Laribi, Said] St Louis Lariboisiere Univ Hosp, AP HP, INSERM,U942, Dept Emergency Med, Paris, France.
[Givertz, Michael M.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA.
[Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland.
RP Voors, AA (reprint author), Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, AB31,Hanzepl 1, NL-9713 GZ Groningen, Netherlands.
EM a.a.voors@umcg.nl
RI Laribi, said/S-3693-2016; Ponikowski, Piotr/O-6454-2015
OI Ponikowski, Piotr/0000-0002-3391-7064; Berezikov,
Eugene/0000-0002-1145-2884; Cleland, John/0000-0002-1471-7016
FU Dutch Heart Foundation: Approaching Heart Failure By Translational
Research of RNA Mechanisms (ARENA); NovaCardia, a subsidiary of Merck;
Netherlands Heart Foundation [2000Z003]; Biosite France SAS;
Jouy-en-Josas, France (BNP); Roche Diagnostics Nederland BV, Venlo, The
Netherlands (NT-proBNP); Novartis Pharma BV, Arnhem, The Netherlands
FX This study was supported by a Grant from the Dutch Heart Foundation:
Approaching Heart Failure By Translational Research of RNA Mechanisms
(ARENA). The PROTECT trial was supported by NovaCardia, a subsidiary of
Merck. COACH was supported by grant 2000Z003 from the Netherlands Heart
Foundation and by additional unrestricted grants from Biosite France
SAS, Jouy-en-Josas, France (BNP), Roche Diagnostics Nederland BV, Venlo,
The Netherlands (NT-proBNP), and Novartis Pharma BV, Arnhem, The
Netherlands.
NR 44
TC 13
Z9 13
U1 1
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1388-9842
EI 1879-0844
J9 EUR J HEART FAIL
JI Eur. J. Heart Fail.
PD APR
PY 2016
VL 18
IS 4
BP 414
EP 423
DI 10.1002/ejhf.332
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DJ6GK
UT WOS:000374308700012
PM 26345695
ER
PT J
AU Samsky, MD
Dunning, A
DeVore, AD
Schulte, PJ
Starling, RC
Tang, WHW
Armstrong, PW
Ezekowitz, JA
Butler, J
McMurray, JJ
Teerlink, JR
Voors, AA
Metra, M
Mentz, RJ
O'Connor, CM
Patel, CB
Hernandez, AF
AF Samsky, Marc D.
Dunning, Allison
DeVore, Adam D.
Schulte, Phillip J.
Starling, Randall C.
Tang, W. H. Wilson
Armstrong, Paul W.
Ezekowitz, Justin A.
Butler, Javed
McMurray, John J.
Teerlink, John R.
Voors, Adrian A.
Metra, Marco
Mentz, Robert J.
O'Connor, Christopher M.
Patel, Chetan B.
Hernandez, Adrian F.
TI Liver function tests in patients with acute heart failure and associated
outcomes: insights from ASCEND-HF
SO EUROPEAN JOURNAL OF HEART FAILURE
LA English
DT Article
DE Heart failure; Liver function tests; Outcomes
ID FUNCTION ABNORMALITIES; PROGNOSTIC-SIGNIFICANCE; HYPOXIC HEPATITIS;
VENOUS-PRESSURE; RENAL-FUNCTION; TASK-FORCE; DYSFUNCTION; PREVALENCE;
CONGESTION; GUIDELINES
AB AimsWe aimed to characterize abnormal liver function tests in patients with heart failure (HF), as they are commonly encountered yet poorly defined.
Methods and resultsWe used data from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) to characterize associations with baseline liver function tests (LFTs). Each LFT was analysed as both a continuous and dichotomous variable [normal vs. abnormal; bilirubin >1.0mg/dL; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >35mmol/L]. Logistic regression assessed the association of LFTs and 30-day all-cause mortality and HF rehospitalization, and Cox proportional hazards assessed the association with 180-day all-cause mortality among patients alive at a 30-day landmark. In ASCEND-HF, 4228 (59%) had complete admission LFT data. Of these, 42% had abnormal bilirubin, 22% had abnormal ALT, and 30% had abnormal AST. Patients with abnormal LFTs were younger, had lower body mass index, and lower left ventricular ejection fraction. In multivariable models, increased total bilirubin was associated with increased 30-day mortality or HF rehospitalization [hazard ratio (HR) 1.17 per 1mg/dL increase, 95% confidence interval (CI) 1.04, 1.32; P=0.012], but not with an increase in 180-day mortality (HR 1.10, 95% CI 0.97, 1.25; P=0.13) per 1mg/dl increase. Compared with normal bilirubin levels, abnormal bilirubin was associated with increased 30-day mortality or HF rehospitalization (HR 1.24, 95% CI 1.00, 1.54; P=0.048) and 180-day mortality (HR 1.32, 95% CI 1.08, 1.62; P=0.007). We found no association with AST or ALT and outcomes.
ConclusionGreater than 40% of patients hospitalized with acute HF had abnormal LFTs. After multivariable adjustment, only elevated bilirubin was independently associated with worse clinical outcomes and may represent an important prognostic variable.
C1 [Samsky, Marc D.; DeVore, Adam D.; Mentz, Robert J.; O'Connor, Christopher M.; Patel, Chetan B.; Hernandez, Adrian F.] Duke Univ, Durham, NC USA.
[Dunning, Allison; DeVore, Adam D.; Schulte, Phillip J.; Mentz, Robert J.; O'Connor, Christopher M.; Patel, Chetan B.; Hernandez, Adrian F.] Duke Clin Res Inst, Durham, NC USA.
[Starling, Randall C.; Tang, W. H. Wilson] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA.
[Armstrong, Paul W.] Canadian VIGOUR Ctr, Edmonton, AB, Canada.
[Armstrong, Paul W.; Ezekowitz, Justin A.] Univ Alberta, Edmonton, AB, Canada.
[Butler, Javed] Stony Brook Univ Hosp, Stony Brook, NY USA.
[McMurray, John J.] Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland.
[McMurray, John J.] Univ Glasgow, Glasgow, Lanark, Scotland.
[Teerlink, John R.] Univ Calif San Francisco, San Francisco VA Hosp, San Francisco, CA 94143 USA.
[Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Voors, Adrian A.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands.
[Metra, Marco] Univ Brescia, Brescia, Italy.
RP Samsky, MD (reprint author), Duke Univ, Med Ctr, Duke North Hosp, Room 8254,2301 Erwin Rd, Durham, NC 27710 USA.
EM marc.samsky@dm.duke.edu
OI DeVore, Adam/0000-0002-4679-2221; mcmurray, john/0000-0002-6317-3975
FU Johnson and Johnson
FX The ASCEND-HF trial was supported by Johnson and Johnson.
NR 36
TC 6
Z9 6
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1388-9842
EI 1879-0844
J9 EUR J HEART FAIL
JI Eur. J. Heart Fail.
PD APR
PY 2016
VL 18
IS 4
BP 424
EP 432
DI 10.1002/ejhf.440
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DJ6GK
UT WOS:000374308700013
PM 26707029
ER
PT J
AU Linnemann, AK
Davis, DB
AF Linnemann, Amelia K.
Davis, Dawn Belt
TI Glucagon-like peptide-1 and cholecystokinin production and signaling in
the pancreatic islet as an adaptive response to obesity
SO JOURNAL OF DIABETES INVESTIGATION
LA English
DT Article
DE Cholecystokinin; Glucagon-like peptide-1; Pancreatic islet
ID BETA-CELL MASS; FAT-FED MICE; TRANSCRIPTION FACTORS; GENE-TRANSCRIPTION;
INSULIN-SECRETION; GLP-1 RECEPTORS; MOUSE MODELS; DOUBLE-BLIND;
ALPHA-CELLS; IN-VITRO
AB Precise control of blood glucose is dependent on adequate -cell mass and function. Thus, reductions in -cell mass and function lead to insufficient insulin production to meet demand, and result in diabetes. Recent evidence suggests that paracrine signaling in the islet might be important in obesity, and disruption of this signaling could play a role in the pathogenesis of diabetes. For example, we recently discovered a novel islet incretin axis where glucagon-like peptide-1 regulates -cell production of another classic gut hormone, cholecystokinin. This axis is stimulated by obesity, and plays a role in enhancing -cell survival. In the present review, we place our observations in the wider context of the literature on incretin regulation in the islet, and discuss the potential for therapeutic targeting of these pathways.
C1 [Linnemann, Amelia K.; Davis, Dawn Belt] Univ Wisconsin, Dept Med, Div Endocrinol, Madison, WI USA.
[Davis, Dawn Belt] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
RP Linnemann, AK (reprint author), Univ Wisconsin, Dept Med, Div Endocrinol, Madison, WI USA.
EM alinnemann@medicine.wisc.edu
FU BLRD VA [I01 BX001880]; NIDDK NIH HHS [K01 DK102492]
NR 50
TC 1
Z9 1
U1 2
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2040-1116
EI 2040-1124
J9 J DIABETES INVEST
JI J. Diabetes Investig.
PD APR
PY 2016
VL 7
SU 1
SI SI
BP 44
EP 49
DI 10.1111/jdi.12465
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DK1HN
UT WOS:000374663200009
PM 27186355
ER
PT J
AU Watanabe, C
Komoto, S
Tomita, K
Hokari, R
Tanaka, M
Hirata, I
Hibi, T
Kaunitz, JD
Miura, S
AF Watanabe, Chikako
Komoto, Shunsuke
Tomita, Kengo
Hokari, Ryota
Tanaka, Masanori
Hirata, Ichiro
Hibi, Toshifumi
Kaunitz, Jonathan D.
Miura, Soichiro
TI Endoscopic and clinical evaluation of treatment and prognosis of
Cronkhite-Canada syndrome: a Japanese nationwide survey
SO JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Acquired gastrointestinal polyposis syndrome; Malnutrition; Gastric
cancer; Colon cancer
ID INTRAMUCOSAL GASTRIC-CANCER; GASTROINTESTINAL POLYPOSIS; COLON-CANCER;
REMISSION; MANAGEMENT; DIAGNOSIS; PATHOLOGY; ALOPECIA
AB Background First reported in 1955, Cronkhite-Canada syndrome (CCS), a rare syndrome characterized by ectodermal abnormalities and inflammatory changes of the gastrointestinal tract mucosa, has been associated with a poor prognosis and life-threatening malignant complications. In a large population survey, we endeavored to characterize the course and treatment outcome of CCS through clinical and endoscopic assessment, and to explore its optimal treatment and surveillance strategy.
Methods A retrospective analysis of 210 patients with CCS was conducted via a questionnaire-based nationwide survey of 983 teaching hospitals located throughout Japan. We assessed clinical features, endoscopic findings, treatments used, and short-and long-term outcomes.
Results The average age at diagnosis was 63.5 years. In all cases, upper or lower gastrointestinal tract polyposis was confirmed, accompanied by characteristic ectodermal abnormalities. Of the treatments used, oral corticosteroids (30-49 mg/day) were the most effective treatment for active disease, with adjunctive nutritional support considered beneficial. With corticosteroid treatment, abdominal symptoms were relieved within a few months, whereas polyp regression often required more than 6 months. Maintenance of endoscopic remission with or without steroids for 3 years significantly lowered the development of CCS-related cancer, compared with relapsers or nonresponders, underscoring the importance of sustained endoscopic remission for cancer prevention.
Conclusions The prognosis of CCS has greatly improved through the use of improved medical treatment. Although CCS continues to be relentlessly progressive, carrying a high cancer risk, a sufficient dose and duration of corticosteroid therapy accompanied by nutritional support and periodic endoscopic surveillance appears to improve its natural history.
C1 [Watanabe, Chikako; Komoto, Shunsuke; Tomita, Kengo; Hokari, Ryota; Miura, Soichiro] Natl Def Med Coll, Dept Internal Med, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan.
[Tanaka, Masanori] Hirosaki City Hosp, Dept Pathol & Lab Med, Aomori, Japan.
[Hirata, Ichiro] Fujita Hlth Univ, Dept Gastroenterol, Toyoake, Aichi, Japan.
[Hibi, Toshifumi] Kitasato Inst Hosp, Ctr Adv IBD Res & Treatment, Tokyo, Japan.
[Kaunitz, Jonathan D.] Univ Calif Los Angeles, David Geffen Sch Med, Greater Los Angeles VA Med Ctr, Los Angeles, CA 90095 USA.
[Kaunitz, Jonathan D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Kaunitz, Jonathan D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA.
RP Watanabe, C (reprint author), Natl Def Med Coll, Dept Internal Med, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan.
EM chikakow@ndmc.ac.jp
FU Ministry of Health, Labour and Welfare of Japan; Japanese Ministry of
Education, Culture, Sports, Science and Technology
FX This study was supported by a Grant-in-Aid for the Intractable Disease
Project of the Ministry of Health, Labour and Welfare of Japan, and by
Grants-in-Aid for Scientific Research from the Japanese Ministry of
Education, Culture, Sports, Science and Technology. The authors thank
the following institutions for replying to the questionnaires in the
first and second surveys: Asahikawa Medical University, Sapporo Medical
University Hospital, Hokkaido University Hospital, Kushiro Rosai
Hospital, KKR Sapporo Medical Center, National Hospital Organization
Hokkaido Medical Center, Sapporo Higashi Tokushukai Hospital, Sunagawa
City Medical Center, Iwate Medical University, Tohoku University
Hospital, Akita University Hospital, Nakadori General Hospital, Tokyo
Medical University Ibaraki Medical Center, Jichi Medical University
Hospital, Isesaki Municipal Hospital, Saitama Medical University
Hospital, Dokkyo Medical University Koshigaya Hospital, Saiseikai
Kawaguchi General Hospital, Saitama Medical Center Jichi Medical
University, Sekishindo Hospital, Chiba University Hospital, Funabashi
Municipal Medical Center, The University of Tokyo Hospital, Kyorin
University Hospital, Keio University Hospital, Tokyo Medical University
Hachioji Medical Center, Tokyo Women's Medical University Hospital,
Nihon University Itabashi Hospital, NTT Medical Center Tokyo, The Cancer
Institute Hospital of JFCR, Hiratsuka GI Hospital, Kitasato University
Kitasato Institute Hospital, Sanno Hospital, Shiseikai Daini Hospital,
Toho University Ohashi Medical Center, Mishuku Hospital, Kitasato
University Hospital, Showa University Fujigaoka Hospital, St. Marianna
University School of Medicine, Yokohama City Seibu Hospital, Yokosuka
Kyosai Hospital, Saiseikai Yokohamashi Nanbu Hospital, Nihon Koukan
Hospital, Yokohama Sakae Kyosai Hospital, Federation of National Public
Service Personnel Mutual Associations, National Hospital Organization
Shinshu Ueda Medical Center, Niigata City General Hospital, Kanazawa
University Hospital, Public Central Hospital of Matto Ishikawa, Toyama
Rosai Hospital, Gifu Municipal Hospital, Nagano Chuo Hospital, Toki
General Hospital, Juntendo Hospital Shizuoka Hospital, Hamamatsu Medical
Center, Hamamatsu South Hospital, Nagoya City University Hospital,
Fujita Health University Hospital, Aichi Cancer Center Hospital,
Japanese Red Cross Nagoya Daiichi Hospital, Kainan Hospital, Daiyukai
General Hospital, Saiseikai Matsusaka General Hospital, Japanese Red
Cross Society Nagahama Hospital, Mitsubishi Kyoto Hospital, Osaka City
University Hospital, Osaka Medical College Hospital, Kinki University
Hospital, Osaka General Medical Center, Osaka Red Cross Hospital, Kitano
Hospital, Osaka Saiseikai Nakatsu Hospital, Ishikiriseikikai Hospital,
Sakai City Hospital, Yodogawa Christian Hospital, Maki Hospital, Kobe
University Hospital, Hyogo College of Medicine, Takarazuka City
Hospital, St.; Mary's Hospital, Miki-Sanyo Hospital, Yamato Takada
Municipal Hospital, Wakayama Medical University Hospital, Shimane
University Hospital, Masuda Red Cross Hospital, Okayama University
Hospital, Kawasaki Medical School Hospital, Hiroshima City Hiroshima
Citizens Hospital, Hiroshima General Hospital of West Japan Railway
Company, Hiroshima City Asa Hospital, Yamaguchi University Hospital,
Tokuyama Central Hospital, Yamaguchi Red Cross Hospital, Tokushima
Prefecture Naruto Hospital, Tokushima Red Cross Hospital, Uwajima City
Hospital, Matsuyama Red Cross Hospital, National Hospital Organization
Kochi National Hospital, Takamatsu Municipal Hospital, Kurume University
Hospital, Kitakyushu Municipal Medical Center, Tagawa Hospital, Kyushu
Central Hospital, Fukuoka Higashi Medical Center, Nagata Hospital,
Wakamatsu Hospital, University of Occupational and Environmental Health,
Japan, Saga University Hospital, Kumamoto University Hospital, Beppu
Medical Center, Nakatsu Municipal Hospital, Nakagami Hospital, Kyushu
University Graduate School of Medical Sciences, Yame General Hospital,
Fukuoka Sanno Hospital, University of Miyazaki Hospital, Iizuka
Hospital, Kyoto University, Sapporo-Kosei General Hospital, Sannno
Hospital, Nanbu Medical Center/Nanbu Child Medical Center, Jikei
University, Jikei University Kashiwa Hospital, Jikei University
Katsushika Medical Center, Nagoya Handa City Hospital, Tsuchiura Kyodo
General Hospital, Yokohama Municipal Citizen's Hospital, Sano General
Hospital, and National Defense Medical College.
NR 47
TC 4
Z9 5
U1 2
U2 4
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
JAPAN
SN 0944-1174
EI 1435-5922
J9 J GASTROENTEROL
JI J. Gastroenterol.
PD APR
PY 2016
VL 51
IS 4
BP 327
EP 336
DI 10.1007/s00535-015-1107-7
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DK1JT
UT WOS:000374669000003
PM 26216651
ER
PT J
AU Salinsky, M
Parko, K
Rutecki, P
Boudreau, E
Storzbach, D
AF Salinsky, Martin
Parko, Karen
Rutecki, Paul
Boudreau, Eilis
Storzbach, Daniel
TI Attributing seizures to TBI: Validation of a brief patient questionnaire
SO EPILEPSY & BEHAVIOR
LA English
DT Article
DE Psychogenic seizures; Epilepsy; TBI; Veterans
ID TRAUMATIC BRAIN-INJURY; PSYCHOGENIC NONEPILEPTIC SEIZURES; VETERANS
AB Puipose: Traumatic brain injury (TBI) is an important cause of epilepsy and has also been associated with psychogenic nonepileptic seizures (PNES). We designed a brief questionnaire assessing patient beliefs regarding TBI as the cause of their seizures (Patient Seizure Etiology Questionnaire; PSEQ). This study reports content validity for the PSEQ
Methods: Ninety Veterans undergoing comprehensive evaluation at 3 VA epilepsy centers completed the PSEQ a series of questions regarding possible causes for their seizures, including TB1. The PSEQ was scored as YES vs. NO for TBI as the proposed cause of seizures. For each patient, two expert reviewers independently completed a structured chart review to determine whether TBI was the proposed cause of seizures (n = 180 reviews). Kappa statistic was used to assess agreement between the PSEQ and each chart review and between the PSEQ and combined chart reviews where both reviewers agreed on a TBI seizure etiology.
Results: The PSEQ scored higher overall rates for a TBI seizure etiology than did expert chart reviews (40% vs. 28%; p < 0.001). The PSEQ agreed with 82% of 180 independent chart reviews (sensitivity 88%; specificity 79%). Kappa statistic for agreement was 0.60. The two reviewers agreed on a probable TB1 seizure etiology for SR of chart reviews. The PSEQ sensitivity increased to 100% when both reviewers were in agreement.
Conclusion: The PSEQ provides a direct, standardized measure of patient beliefs regarding TBlas the cause of their seizures and has moderate-substantial agreement with expert chart reviews. Published by Elsevier Inc.
C1 [Salinsky, Martin; Boudreau, Eilis; Storzbach, Daniel] Portland VA Med Ctr, Portland, OR USA.
[Salinsky, Martin; Boudreau, Eilis] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Parko, Karen] San Francisco VA Med Ctr, San Francisco, CA USA.
[Rutecki, Paul] William S Middleton Vet Affairs Med Ctr, Madison, WI USA.
RP Salinsky, M (reprint author), Portland VAMC Epilepsy Ctr Excellence, 3710 SW US Vet Hosp Rd P3ECOE, Portland, OR 97239 USA.
EM Salinsky@ohsu.edu
FU Department of Veterans Affairs [5101CX000721-04]
FX The authors thank S. Chen FNP, R. Kotloski MD PhD, and C. Evrard FNP for
their participation in this project. This work was supported by grant #
5101CX000721-04 from the Department of Veterans Affairs.
NR 13
TC 0
Z9 0
U1 2
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1525-5050
EI 1525-5069
J9 EPILEPSY BEHAV
JI Epilepsy Behav.
PD APR
PY 2016
VL 57
BP 141
EP 144
DI 10.1016/j.yebeh.2016.02.003
PN A
PG 4
WC Behavioral Sciences; Clinical Neurology; Psychiatry
SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry
GA DJ5NW
UT WOS:000374256700024
PM 26953843
ER
PT J
AU Pugh, MJ
AF Pugh, Mary Jo
TI Clinical decision rules for epilepsy care: The case for thinking big
SO EPILEPSY & BEHAVIOR
LA English
DT Editorial Material
ID PREDICTION; VALIDATION; GUIDELINES; MANAGEMENT; STANDARDS; MEDICINE;
SEIZURE; ADULTS; RISK
C1 [Pugh, Mary Jo] STVHCS, VA Epilepsy Ctr Excellence, San Antonio, TX USA.
[Pugh, Mary Jo] UTHSCSA, Dept Epidemiol & Biostat, San Antonio, TX USA.
[Pugh, Mary Jo] South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.
RP Pugh, MJ (reprint author), STVHCS, VA Epilepsy Ctr Excellence, San Antonio, TX USA.; Pugh, MJ (reprint author), UTHSCSA, Dept Epidemiol & Biostat, San Antonio, TX USA.; Pugh, MJ (reprint author), South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.
EM Pughm@uthscsa.edu
OI Pugh, Mary Jo/0000-0003-4196-7763
FU NCCIH NIH HHS [1R01AT008422-01]
NR 18
TC 0
Z9 0
U1 1
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1525-5050
EI 1525-5069
J9 EPILEPSY BEHAV
JI Epilepsy Behav.
PD APR
PY 2016
VL 57
BP 220
EP 221
DI 10.1016/j.yebeh.2016.02.034
PN A
PG 2
WC Behavioral Sciences; Clinical Neurology; Psychiatry
SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry
GA DJ5NW
UT WOS:000374256700037
PM 26979764
ER
PT J
AU Dullard, B
Saunders, GH
AF Dullard, Brittney
Saunders, Gabrielle H.
TI Documentation of Dual Sensory Impairment in Electronic Medical Records
SO GERONTOLOGIST
LA English
DT Article
DE Hearing impairment; Vision impairment; Interdisciplinary communication;
Electronic medical records; Sensory disorders
ID CONCURRENT HEARING; VISUAL IMPAIRMENT; VISION IMPAIRMENT; HEALTH-CARE;
EXPERIENCES; PREVALENCE; PHYSICIANS; NEEDS
AB Purpose of the Study: To examine the documentation of sensory impairment in the electronic medical records (EMRs) of Veterans with both hearing and vision losses (dual sensory impairment [DSI]).
Design and Methods: A retrospective chart review of the EMRs of 20 patients with DSI was conducted. Providers' documentation of the presence of sensory impairment, the use of assistive technology during clinical appointments, and the content of notes mentioning communication issues were extracted from each chart note in the EMR for the prior 6 years.
Results: Primary care providers documented DSI in 50% of EMRs, vision loss alone in 40%, and hearing loss alone in 10% of EMRs. Audiologists documented vision loss in 50% of cases, whereas ophthalmologists/optometrists documented hearing loss in 15% of cases. Examination of two selected cases illustrates that care can be compromised when providers do not take note of sensory impairments during planning and provision of clinical care.
Implications: Sensory impairment is poorly documented by most providers in EMRs. This is alarming because vision and hearing affect patient-physician communication and the use of medical interventions. The results of this study raise awareness about the need to document the presence of sensory impairments and use the information when planning treatment for individuals with DSI.
C1 [Dullard, Brittney] Univ Connecticut, Speech Language & Hearing Sci, Mansfield, CT 06250 USA.
[Saunders, Gabrielle H.] Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Portland, OR USA.
RP Dullard, B (reprint author), Univ Connecticut, Speech Language & Hearing Sci, Mansfield, CT 06250 USA.
EM Brittney.Dullard@uconn.edu
FU Portland VA Research Foundation; Department of Veterans Affairs
Rehabilitation Research and Development [C9230C]
FX This work was supported by a Portland VA Research Foundation Summer
Fellowship and by the Department of Veterans Affairs Rehabilitation
Research and Development (C9230C).
NR 19
TC 3
Z9 3
U1 1
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
EI 1758-5341
J9 GERONTOLOGIST
JI Gerontologist
PD APR
PY 2016
VL 56
IS 2
BP 313
EP 317
DI 10.1093/geront/gnu032
PG 5
WC Gerontology
SC Geriatrics & Gerontology
GA DJ5BA
UT WOS:000374220600017
PM 24846883
ER
PT J
AU Felker, P
Bunch, R
Leung, AM
AF Felker, Peter
Bunch, Ronald
Leung, Angela M.
TI Concentrations of thiocyanate and goitrin in human plasma, their
precursor concentrations in brassica vegetables, and associated
potential risk for hypothyroidism
SO NUTRITION REVIEWS
LA English
DT Review
DE broccoli; Chinese cabbage; glucosinolate; glucoraphanin; indole; kale;
phase II enzymes
ID PHASE-II ENZYMES; BRUSSELS-SPROUTS; FROZEN BROCCOLI; THIOL OXIDATION;
FRESH BROCCOLI; BREAST-CANCER; IN-VIVO; SULFORAPHANE; ISOTHIOCYANATES;
EXPRESSION
AB Brassica vegetables are common components of the diet and have beneficial as well as potentially adverse health effects. Following enzymatic breakdown, some glucosinolates in brassica vegetables produce sulforaphane, phenethyl, and indolylic isothiocyanates that possess anticarcinogenic activity. In contrast, progoitrin and indolylic glucosinolates degrade to goitrin and thiocyanate, respectively, and may decrease thyroid hormone production. Radioiodine uptake to the thyroid is inhibited by 194 mu mol of goitrin, but not by 77 mu mol of goitrin. Collards, Brussels sprouts, and some Russian kale (Brassica napus) contain sufficient goitrin to potentially decrease iodine uptake by the thyroid. However, turnip tops, commercial broccoli, broccoli rabe, and kale belonging to Brassica oleracae contain less than 10 mu mol of goitrin per 100-g serving and can be considered of minimal risk. Using sulforaphane plasma levels following glucoraphanin ingestion as a surrogate for thiocyanate plasma concentrations after indole glucosinolate ingestion, the maximum thiocyanate contribution from indole glucosinolate degradation is estimated to be 10 mu M, which is significantly lower than background plasma thiocyanate concentrations (40-69 mu M). Thiocyanate generated from consumption of indole glucosinolate can be assumed to have minimal adverse risks for thyroid health.
C1 [Felker, Peter; Bunch, Ronald] DArrigo Bros Co Calif, 21777 Harris Rd, Salinas, CA 93908 USA.
[Leung, Angela M.] VA Greater Angeles Healthcare Syst, Div Endocrinol, Los Angeles, CA USA.
[Leung, Angela M.] Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol, Los Angeles, CA 90095 USA.
RP Felker, P (reprint author), DArrigo Bros Co Calif, 21777 Harris Rd, Salinas, CA 93908 USA.
EM Peter.Felker@darrigo.com
FU National Institutes of Health [K23HD068552]
FX The study was supported in part by National Institutes of Health
K23HD068552 (A.M.L.).
NR 66
TC 1
Z9 1
U1 6
U2 21
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0029-6643
EI 1753-4887
J9 NUTR REV
JI Nutr. Rev.
PD APR
PY 2016
VL 74
IS 4
BP 248
EP 258
DI 10.1093/nutrit/nuv110
PG 11
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA DJ4OD
UT WOS:000374184800003
PM 26946249
ER
PT J
AU Hogaboom, NS
Diehl, JA
Oyster, ML
Koontz, AM
Boninger, ML
AF Hogaboom, Nathan S.
Diehl, Jessica A.
Oyster, Michelle L.
Koontz, Alicia M.
Boninger, Michael L.
TI Ultrasonographic Median Nerve Changes After Repeated Wheelchair
Transfers in Persons With Paraplegia: Relationship With Subject
Characteristics and Transfer Skills
SO PM&R
LA English
DT Article
ID CARPAL-TUNNEL-SYNDROME; SPINAL-CORD-INJURY; UPPER EXTREMITY PAIN;
SHOULDER PAIN; USERS; PREVALENCE; SONOGRAPHY; DIAGNOSIS; INDIVIDUALS;
POPULATION
AB Background: Wheelchair users with spinal cord injuries are susceptible to peripheral neuropathies from overuse, yet no studies have established a relationship between median neuropathy and wheelchair transfers. A more thorough understanding of how transfers and technique contribute to pathologic conditions may guide interventions that curtail its development.
Objective: To evaluate the effects of repeated transfers on ultrasound markers for carpal tunnel syndrome (CTS) in people with spinal cord injuries and to relate changes to subject characteristics and transfer skills.
Design: Cross-sectional, repeated measures.
Setting: Research laboratory and national wheelchair sporting events.
Participants: A convenience sample of 30 wheelchair users with nonprogressive paraplegia were recruited via research registries and at the 2013 National Veterans Wheelchair Games and 2014 Paralyzed Veterans of America Buckeye Games. Participants were older than 18 years and could complete transfers independently within 30 seconds without use of their leg muscles.
Methods: Demographic questionnaires and physical examinations for CTS were completed. Quantitative ultrasound techniques were used to measure changes in the median nerve after a repeated-transfers protocol. The Transfer Assessment Instrument (TAI) was completed to quantify transfer ability.
Main Outcome Measurements: Median nerve cross-sectional area at the level of the pisiform (PCSA) and swelling ratio (SR), transfer quality, and skills via the TAI.
Results: PCSA increased after repeated transfers (P < .025). Participants who used safe hand positions had a lower baseline SR (beta = -0.728; P < .01). Participants with a higher body weight had a lower baseline SR provided they performed higher quality transfers. Participants who scooted to the front of the seat prior to transferring (TAI item 7; beta = 0.144; P < .05) and who weighed more (beta = 0.142; P < .05) exhibited greater increases in PCSA in response to transfers.
Conclusions: An acute increase was observed in median nerve CSA at the pisiform after repeated wheelchair transfers. Changes were greater in persons with higher body weight and in persons who did not perform certain transfer skills correctly (according to the TAI). It is possible that these factors contribute to chronic injury and possibly CTS.
C1 [Hogaboom, Nathan S.; Oyster, Michelle L.; Koontz, Alicia M.; Boninger, Michael L.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 6425 Penn Ave,Suite 400, Pittsburgh, PA 15206 USA.
[Hogaboom, Nathan S.; Oyster, Michelle L.; Koontz, Alicia M.; Boninger, Michael L.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA.
[Diehl, Jessica A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
RP Boninger, ML (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 6425 Penn Ave,Suite 400, Pittsburgh, PA 15206 USA.; Boninger, ML (reprint author), Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA.
EM boninger@pitt.edu
OI Hogaboom, Nathan/0000-0002-0601-5751; Boninger,
Michael/0000-0001-6966-919X
FU National Institute on Disability and Rehabilitation Research, Office of
Special Education and Rehabilitation Services, U. S. Department of
Education [H133N110011]; National Science Foundation Graduate Research
Fellowship [1247842]
FX This article is the result of work supported with resources and the use
of facilities at the Human Engineering Research Laboratories, VA
Pittsburgh Healthcare System. This project was supported by the National
Institute on Disability and Rehabilitation Research, Office of Special
Education and Rehabilitation Services, U. S. Department of Education
(H133N110011). This article is based on work supported by the National
Science Foundation Graduate Research Fellowship (grant #1247842). Any
opinion, findings, and conclusions or recommendations expressed in this
material are those of the authors and do not necessarily reflect the
view of the National Science Foundation. The contents of this paper do
not represent the views of the Department of Veterans Affairs or the
United States Government.
NR 40
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1934-1482
EI 1934-1563
J9 PM&R
JI PM&R
PD APR
PY 2016
VL 8
IS 4
BP 305
EP 313
DI 10.1016/j.pmrj.2015.08.001
PG 9
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA DJ4LE
UT WOS:000374176100002
PM 26265431
ER
PT J
AU Sebastian, A
Jung, P
Neuhoff, J
Wibral, M
Fox, PT
Lieb, K
Fries, P
Eickhoff, SB
Tuscher, O
Mobascher, A
AF Sebastian, Alexandra
Jung, Patrick
Neuhoff, Jonathan
Wibral, Michael
Fox, Peter T.
Lieb, Klaus
Fries, Pascal
Eickhoff, Simon B.
Tuescher, Oliver
Mobascher, Arian
TI Dissociable attentional and inhibitory networks of dorsal and ventral
areas of the right inferior frontal cortex: a combined task-specific and
coordinate-based meta-analytic fMRI study
SO BRAIN STRUCTURE & FUNCTION
LA English
DT Article
DE Attentional capture; Functional magnetic resonance imaging;
Meta-analytic connectivity modeling; Right inferior frontal cortex;
Right inferior frontal junction; Stop signal task
ID TEMPORO-PARIETAL JUNCTION; RESPONSE-INHIBITION; FUNCTIONAL CONNECTIVITY;
COGNITIVE CONTROL; HUMAN BRAIN; MODEL; ACTIVATIONS; RELEVANCE; CONTEXT;
CHOICE
AB The right inferior frontal cortex (rIFC) is frequently activated during executive control tasks. Whereas the function of the dorsal portion of rIFC, more precisely the inferior frontal junction (rIFJ), is convergingly assigned to the attention system, the functional key role of the ventral portion, i.e., the inferior frontal gyrus (rIFG), is hitherto controversially debated. Here, we used a two-step methodical approach to clarify the differential function of rIFJ and rIFG. First, we used event-related functional magnetic resonance imaging (fMRI) during a modified stop signal task with an attentional capture condition (acSST) to delineate attentional from inhibitory motor processes (step 1). Then, we applied coordinate-based meta-analytic connectivity modeling (MACM) to assess functional connectivity profiles of rIFJ and rIFG across various paradigm classes (step 2). As hypothesized, rIFJ activity was associated with the detection of salient stimuli, and was functionally connected to areas of the ventral and dorsal attention network. RIFG was activated during successful response inhibition even when controlling for attentional capture and revealed the highest functional connectivity with core motor areas. Thereby, rIFJ and rIFG delineated largely independent brain networks for attention and motor control. MACM results attributed a more specific attentional function to rIFJ, suggesting an integrative role between stimulus-driven ventral and goal-directed dorsal attention processes. In contrast, rIFG was disclosed as a region of the motor control but not attention system, being essential for response inhibition. The current study provides decisive evidence regarding a more precise functional characterization of rIFC subregions in attention and inhibition.
C1 [Sebastian, Alexandra; Jung, Patrick; Neuhoff, Jonathan; Lieb, Klaus; Tuescher, Oliver; Mobascher, Arian] Johannes Gutenberg Univ Mainz, Med Ctr Mainz, Dept Psychiat & Psychotherapy, Focus Program Translat Neurosci FTN, Untere Zahlbacher Str 8, D-55131 Mainz, Germany.
[Wibral, Michael] Goethe Univ Frankfurt, Brain Imaging Ctr, MEG Unit, D-60054 Frankfurt, Germany.
[Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.
[Fox, Peter T.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Fries, Pascal] Max Planck Gesell, Ernst Strungmann Inst ESI Neurosci Cooperat, Frankfurt, Germany.
[Eickhoff, Simon B.] Univ Dusseldorf, Inst Clin Neurosci & Med Psychol, Dusseldorf, Germany.
[Eickhoff, Simon B.] Forschungszentrum Julich, Inst Neurosci & Med INM 1, D-52425 Julich, Germany.
[Tuescher, Oliver] Univ Freiburg, Med Ctr Freiburg, Dept Neurol, Hugstetter Str 55, D-79106 Freiburg, Germany.
[Tuescher, Oliver] Univ Freiburg, Med Ctr Freiburg, Dept Psychiat, Hugstetter Str 55, D-79106 Freiburg, Germany.
RP Jung, P (reprint author), Johannes Gutenberg Univ Mainz, Med Ctr Mainz, Dept Psychiat & Psychotherapy, Focus Program Translat Neurosci FTN, Untere Zahlbacher Str 8, D-55131 Mainz, Germany.
EM patrjung@uni-mainz.de
RI Fries, Pascal/E-3196-2010
OI Fries, Pascal/0000-0002-4270-1468; Wibral, Michael/0000-0001-8010-5862
FU MAIFOR program; Johannes Gutenberg University Medical Center Mainz,
Germany; NIH/NIMH [R01 MH074457]
FX This work was supported by internal grants of the MAIFOR program and the
research focus translational neurosciences (FTN) of the Johannes
Gutenberg University Medical Center Mainz, Germany. Comprehensive access
to the BrainMap database was authorized by a collaborative-use license
agreement, provided to Simon Eickhoff by the University of Texas Health
Science Center at San Antonio. BrainMap is supported by NIH/NIMH R01
MH074457. Findings presented in this study are part of the doctoral
thesis of Jonathan Neuhoff.
NR 51
TC 4
Z9 4
U1 4
U2 12
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1863-2653
EI 1863-2661
J9 BRAIN STRUCT FUNCT
JI Brain Struct. Funct.
PD APR
PY 2016
VL 221
IS 3
BP 1635
EP 1651
DI 10.1007/s00429-015-0994-y
PG 17
WC Anatomy & Morphology; Neurosciences
SC Anatomy & Morphology; Neurosciences & Neurology
GA DI9DK
UT WOS:000373801400027
PM 25637472
ER
PT J
AU Wehner, MR
Linos, E
Boscardin, WJ
Chren, MM
AF Wehner, Mackenzie R.
Linos, Eleni
Boscardin, W. John
Chren, Mary-Margaret
TI Competing Risk of Death in Kaplan-Meier Curves When Analyzing Subsequent
Keratinocyte Cancer Reply
SO JAMA DERMATOLOGY
LA English
DT Letter
C1 [Wehner, Mackenzie R.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA.
[Linos, Eleni; Chren, Mary-Margaret] Univ Calif San Francisco, Dept Dermatol, 2340 Sutter St,Rm N412,POB 0808, San Francisco, CA 94143 USA.
[Boscardin, W. John] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Chren, Mary-Margaret] San Francisco VA Med Ctr, Dermatol Serv, San Francisco, CA USA.
RP Chren, MM (reprint author), Univ Calif San Francisco, Dept Dermatol, 2340 Sutter St,Rm N412,POB 0808, San Francisco, CA 94143 USA.
EM chrenm@derm.ucsf.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6068
EI 2168-6084
J9 JAMA DERMATOL
JI JAMA Dermatol.
PD APR
PY 2016
VL 152
IS 4
BP 494
EP 495
DI 10.1001/jamadermatol.2015.5153
PG 2
WC Dermatology
SC Dermatology
GA DJ0TF
UT WOS:000373916600039
PM 27074364
ER
PT J
AU Isakova, T
Cai, X
Lee, J
Katz, R
Cauley, JA
Fried, LF
Hoofnagle, AN
Satterfield, S
Harris, TB
Shlipak, MG
Sarnak, MJ
Ix, JH
AF Isakova, Tamara
Cai, Xuan
Lee, Jungwha
Katz, Ronit
Cauley, Jane A.
Fried, Linda F.
Hoofnagle, Andrew N.
Satterfield, Suzanne
Harris, Tamara B.
Shlipak, Michael G.
Sarnak, Mark J.
Ix, Joachim H.
CA Hlth ABC Study
TI Associations of FGF23 With Change in Bone Mineral Density and Fracture
Risk in Older Individuals
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE FIBROBLAST GROWTH FACTOR 23; BONE MINERAL DENSITY; FRACTURE; CHRONIC
KIDNEY DISEASE
ID FIBROBLAST GROWTH FACTOR-23; CHRONIC KIDNEY-DISEASE; VITAMIN-D
METABOLISM; OSTEOPOROTIC FRACTURES; CARDIOVASCULAR HEALTH; DIETARY
PHOSPHATE; HIP-FRACTURES; FGF-23; MEN; FIBROBLAST-GROWTH-FACTOR-23
AB Elevated levels of the phosphate-regulating hormone fibroblast growth factor 23 (FGF23) have been linked to greater risk of fractures in some studies, especially among individuals with chronic kidney disease (CKD). We evaluated FGF23 as a risk factor for bone loss and fractures in the Health, Aging, and Body Composition (Health ABC) study, which is a prospective biracial cohort of well-functioning adults aged 70 to 79 years recruited at two clinical centers in the United States. The sample for the bone mineral density (BMD) analyses consisted of 2234 participants who had at least two serial total hip areal BMD measures. The fracture analyses included 2786 participants, 567 of whom sustained a fracture during a median follow up of 4.95 years. Linear mixed-effects models were used for longitudinal measurements of total hip areal BMD and the proportional subdistribution hazard regression model subject to competing risks of death was used for risk of fracture. The median FGF23 was 46.7 (interquartile range [IQR] 36.7 to 60.2) pg/mL. The mean annualized percent change in total hip areal BMD did not vary significantly according to FGF23 quartile in all participants (p for trend=0.70), but the effect was modified by CKD status (adjusted p for interaction <0.001). Among participants with CKD, the unadjusted mean annualized percent change in total hip areal BMD was greater with higher levels of FGF23 (unadjusted p for trend=0.02), but the trend was attenuated with adjustment for estimated glomerular filtration rate and parathyroid hormone (adjusted p for trend=0.30). FGF23 was not significantly associated with fracture risk in crude (hazard ratio [HR] per doubling of FGF23, 0.97; 95% CI, 0.85 to 1.12) or adjusted models (HR per doubling of FGF23, 1.02; 95% CI, 0.86 to 1.22), and these findings were not modified by gender or CKD status. FGF23 levels are not associated with bone loss or fracture risk in older adults with low prevalence of CKD. (c) 2015 American Society for Bone and Mineral Research.
C1 [Isakova, Tamara] Northwestern Univ Feinberg, Sch Med, Dept Med, Div Nephrol & Hypertens, Chicago, IL USA.
[Isakova, Tamara; Cai, Xuan] Northwestern Univ Feinberg, Sch Med, Inst Publ Hlth & Med, Ctr Translat Metab & Hlth, Chicago, IL USA.
[Lee, Jungwha] Northwestern Univ Feinberg, Sch Med, Dept Preventat Med, Div Biostat, Chicago, IL USA.
[Katz, Ronit; Hoofnagle, Andrew N.] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA.
[Cauley, Jane A.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA.
[Fried, Linda F.] Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA.
[Hoofnagle, Andrew N.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA.
[Satterfield, Suzanne] Univ Tennessee, Dept Prevent Med, Memphis, TN USA.
[Harris, Tamara B.] NIA, Lab Epidemiol & Populat Sci, NIH, Rockville, MD USA.
[Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol Biostat & Med, San Francisco, CA 94143 USA.
[Shlipak, Michael G.] San Francisco VA Med Ctr, Dept Gen Internal Med, San Francisco, CA USA.
[Sarnak, Mark J.] Tufts Med Ctr, Dept Med, Div Nephrol, Boston, MA USA.
[Ix, Joachim H.] Univ Calif San Diego, Vet Affairs San Diego Healthcare Syst, Nephrol Sect, San Diego, CA 92103 USA.
[Ix, Joachim H.] Univ Calif San Diego, Div Nephrol & Prevent Med, San Diego, CA 92103 USA.
RP Isakova, T (reprint author), 633 N St Clair St, Chicago, IL 60611 USA.
EM tamara.isakova@northwestern.edu
RI Cauley, Jane/N-4836-2015
OI Cauley, Jane/0000-0003-0752-4408
FU Carl W. Gottschalk Research Scholar Grant from the American Society of
Nephrology Foundation for Kidney Research; National Institutes on Aging
[R01AG027002]; National Institute on Aging (NIA) [N01-AG-6-2101,
N01-AG-6-2103, N01-AG-6-2106, R01-AG028050]; NINR [R01-NR012459]; NIH,
National Institute on Aging; [K23DK087858]
FX TI was supported by K23DK087858 and by the Carl W. Gottschalk Research
Scholar Grant from the American Society of Nephrology Foundation for
Kidney Research. MGS, MS, and JHI and the FGF23 measurements were
supported by a grant from the National Institutes on Aging
(R01AG027002). The Health ABC Study was supported by the National
Institute on Aging (NIA) Contracts N01-AG-6-2101; N01-AG-6-2103;
N01-AG-6-2106; NIA grant R01-AG028050, and NINR grant R01-NR012459. This
research was supported in part by the Intramural Research Program of the
NIH, National Institute on Aging.
NR 45
TC 3
Z9 3
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0884-0431
EI 1523-4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD APR
PY 2016
VL 31
IS 4
BP 742
EP 748
DI 10.1002/jbmr.2750
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DJ2BH
UT WOS:000374008200006
PM 26590361
ER
PT J
AU Melzer, AC
Feemster, LC
Collins, MP
Au, DH
AF Melzer, Anne C.
Feemster, Laura C.
Collins, Margaret P.
Au, David H.
TI Utilization and effectiveness of pharmacotherapy for Tobacco use
following admission for exacerbation of COPD
SO JOURNAL OF HOSPITAL MEDICINE
LA English
DT Article
DE Tobacco; smoking; pulmonary disease; chronic obstructive; nicotine
replacement therapy
ID OBSTRUCTIVE PULMONARY-DISEASE; RANDOMIZED CLINICAL-TRIAL;
SMOKING-CESSATION; MYOCARDIAL-INFARCTION; DOUBLE-BLIND;
HOSPITALIZED-PATIENTS; NICOTINE REPLACEMENT; STOP SMOKING; INTERVENTION;
VARENICLINE
AB BACKGROUNDPatients admitted for chronic obstructive pulmonary disease (COPD) commonly continue to smoke. The utilization and effectiveness of tobacco cessation medications after discharge is largely unknown. We sought to examine whether pharmacologic treatment of tobacco use following admission for COPD was associated with smoking cessation at 6 to 12 months.
METHODSMultivariable logistic regression analysis of a cohort of 1334 smokers, discharged from hospital with a COPD exacerbation between 2005 and 2012, identified administratively within the Veterans Affairs Veterans Integrated Service Network-20, adjusted for variables chosen a priori. Our primary exposure was treatment with any 1 or combination of smoking cessation medications within 90 days of discharge determined from pharmacy records, with the outcome of smoking cessation at 6 to 12 months after discharge.
MEASUREMENTS AND MAIN RESULTSFour hundred fifty (33.7%) of the patients were dispensed a smoking cessation medication, with 53.4% receiving a nicotine patch alone. Overall, 19.8% of patients reported quitting smoking at 6 to 12 months. Compared to those not receiving medications, the odds of quitting were not greater among patients dispensed any single or combination of smoking cessation medications within 90 days of discharge (odds ratio [OR]: 0.88, 95% confidence interval [CI]: 0.74-1.04). Among patients treated with medications compared to nicotine patch alone, varenicline (OR: 2.44, 95% CI: 1.48-4.05) was associated with increased odds of cessation, and short-acting nicotine replacement therapy alone (OR: 0.66, 95% CI: 0.51-0.85) was associated with decreased odds of cessation.
CONCLUSIONSTreatment was provided to a minority of subjects and was not associated with cessation, with potential differences observed in effectiveness between medications. Systems-based changes may improve delivery of this key intervention. Journal of Hospital Medicine 2016;11:257-263. (c) 2015 Society of Hospital Medicine
C1 [Melzer, Anne C.; Feemster, Laura C.; Au, David H.] Univ Washington, Div Pulm & Crit Care, Seattle, WA 98195 USA.
[Melzer, Anne C.; Feemster, Laura C.; Collins, Margaret P.; Au, David H.] VA Puget Sound, Ctr Innovat Veteran Centered & Value Driven Care, Seattle, WA USA.
RP Melzer, AC (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM acmelzer@uw.edu
FU Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development; University of Washington Department of
Pulmonary and Critical Care [HL007287-36]; National Institutes of
Health, National Heart, Lung, and Blood Institute [HL111116]; Gilead
Sciences; VA Health Services Research and Development
FX Dr. Melzer conceived of the research question and performed background
reading, analyses, primary drafting, and final revision of the
manuscript. Drs. Collins and Feemster participated in finalizing the
research question, developing the cohort, performing data collection,
and revising the manuscript. Dr. Au provided the database for analysis,
helped finalize the research question, and assisted in interpretation of
the data and revision of the manuscript. Dr. Au has personally reviewed
the data, understands the statistical methods employed, and confirms an
understanding of this analysis, that the methods are clearly described,
and that they are a fair way to report the results. This material is
based upon work supported in part by the Department of Veterans Affairs,
Veterans Health Administration, Office of Research and Development, who
provided access to data, office space, and programming and data
management. The views expressed in this article are those of the authors
and do not necessarily reflect the position or policy of the Department
of Veterans Affairs, the United States government, or the National
Institutes of Health. Dr. Au is an unpaid research consultant for
Analysis Group. None of the other authors have any conflicts of interest
to disclose. Dr. Melzer is supported by an institutional F-32
(HL007287-36) through the University of Washington Department of
Pulmonary and Critical Care. Dr. Feemster is supported by an National
Institutes of Health, National Heart, Lung, and Blood Institute, K23
Mentored Career Development Award (HL111116). Partial support of this
project was provided by Gilead Sciences with research funding to the
Seattle Institute for Biomedical and Clinical Research. Additional
support was received through the VA Health Services Research and
Development. A portion of this work was presented in abstract form at
the American Thoracic Society International Meeting, May 2015, in
Denver, Colorado.
NR 47
TC 1
Z9 1
U1 3
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1553-5592
EI 1553-5606
J9 J HOSP MED
JI J. Hosp. Med.
PD APR
PY 2016
VL 11
IS 4
BP 257
EP 263
DI 10.1002/jhm.2519
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA DJ0TE
UT WOS:000373916500003
PM 26663891
ER
PT J
AU Rocque, GB
Taylor, RA
Acemgil, A
Li, XL
Pisu, M
Kenzik, K
Jackson, BE
Halilova, KI
Demark-Wahnefried, W
Meneses, K
Li, YF
Martin, MY
Chambless, C
Lisovicz, N
Fouad, M
Partridge, EE
Kvale, EA
AF Rocque, Gabrielle B.
Taylor, Richard A.
Acemgil, Aras
Li, Xuelin
Pisu, Maria
Kenzik, Kelly
Jackson, Bradford E.
Halilova, Karina I.
Demark-Wahnefried, Wendy
Meneses, Karen
Li, Yufeng
Martin, Michelle Y.
Chambless, Carol
Lisovicz, Nedra
Fouad, Mona
Partridge, Edward E.
Kvale, Elizabeth A.
CA Patient Care Connect Grp
TI Guiding Lay Navigation in Geriatric Patients With Cancer Using a
Distress Assessment Tool
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Article
ID PSYCHOLOGIC DISTRESS; OLDER PATIENTS; BREAST-CANCER; THERMOMETER;
VALIDATION; CARE; INTERVENTION; WOMEN
AB Background: There is growing interest in psychosocial care and evaluating distress in patients with cancer. As of 2015, the Commission on Cancer requires cancer centers to screen patients for distress, but the optimal approach to implementation remains unclear. Methods: We assessed the feasibility and impact of using distress assessments to frame lay navigator interactions with geriatric patients with cancer who were enrolled in navigation between January 1, 2014, and December 31, 2014. Results: Of the 5,121 patients enrolled in our lay patient navigation program, 4,520 (88%) completed at least one assessment using a standardized distress tool (DT). Navigators used the tool to structure both formal and informal distress assessments. Of all patients, 24% reported distress scores of 4 or greater and 5.5% reported distress scores of 8 or greater. The most common sources of distress at initial assessment were pain, balance/mobility difficulties, and fatigue. Minority patients reported similar sources of distress as the overall program population, with increased relative distress related to logistical issues, such as transportation and financial/insurance questions. Patients were more likely to ask for help with questions about insurance/financial needs (79%), transportation (76%), and knowledge deficits about diet/nutrition (76%) and diagnosis (66%) when these items contributed to distress. Conclusions: Lay navigators were able to routinely screen for patient distress at a high degree of penetration using a structured distress assessment.
C1 [Rocque, Gabrielle B.; Taylor, Richard A.; Acemgil, Aras; Pisu, Maria; Halilova, Karina I.; Demark-Wahnefried, Wendy; Meneses, Karen; Li, Yufeng; Chambless, Carol; Lisovicz, Nedra; Fouad, Mona; Partridge, Edward E.; Kvale, Elizabeth A.] Univ Alabama Birmingham, Birmingham Comprehens Canc Ctr, Birmingham, AL USA.
[Rocque, Gabrielle B.] Univ Alabama Birmingham, Birmingham Sch Med, Div Hematol & Oncol, Birmingham, AL USA.
[Acemgil, Aras; Li, Xuelin; Pisu, Maria; Kenzik, Kelly; Jackson, Bradford E.; Li, Yufeng; Martin, Michelle Y.; Lisovicz, Nedra; Fouad, Mona] Univ Alabama Birmingham, Birmingham Sch Med, Div Prevent Med, Birmingham, AL USA.
[Taylor, Richard A.; Meneses, Karen] Univ Alabama Birmingham, Birmingham Sch Nursing, Birmingham, AL USA.
[Kvale, Elizabeth A.] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Rocque, GB (reprint author), Univ Alabama Birmingham, Sch Med, 1824 6th Ave South,WTI 240E, Birmingham, AL 35294 USA.
EM grocque@uabmc.edu
FU Walter B. Frommeyer, Jr., Fellowship in Investigative Medicine;
Department of Health and Human Services, Centers for Medicare & Medicaid
Services [1C1CMS331023]
FX Dr. Rocque is supported by a Walter B. Frommeyer, Jr., Fellowship in
Investigative Medicine. This funding source had no role in the design
and conduct of the study; collection, management, analysis, or
interpretation of the data; and preparation, review, or approval of the
manuscript for publication. Dr. Kvale has disclosed that she is the
Palliative Care Medical Director for Aspire Healthcare. The remaining
authors have disclosed that they have no financial interests,
arrangements, affiliations, or commercial interests with the
manufacturers of any products discussed in this article or their
competitors.; This publication was made possible by grant no.
1C1CMS331023 from the Department of Health and Human Services, Centers
for Medicare & Medicaid Services. The contents of this publication are
solely the responsibility of the authors and do not necessarily
represent the official views of the US Department of Health and Human
Services or any of its agencies.
NR 37
TC 1
Z9 1
U1 0
U2 2
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
EI 1540-1413
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD APR
PY 2016
VL 14
IS 4
BP 407
EP 414
PG 8
WC Oncology
SC Oncology
GA DJ3CL
UT WOS:000374082300005
PM 27059189
ER
PT J
AU Byne, W
AF Byne, William
TI Regulations Restrict Practice of Conversion Therapy
SO LGBT HEALTH
LA English
DT Editorial Material
DE continuing medical education; gender identity; legislation; LGBT
conversion therapy; reparative therapy; sexual orientation
ID GENDER DYSPHORIA; DISORDERS; GAY
C1 [Byne, William] James J Peters VA Med Ctr, Bronx, NY USA.
[Byne, William] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.
RP Byne, W (reprint author), James J Peters VA Med Ctr, Bronx, NY USA.; Byne, W (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.
EM william.byne@mssm.edu
NR 22
TC 0
Z9 0
U1 7
U2 10
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2325-8292
EI 2325-8306
J9 LGBT HEALTH
JI LGBT Health
PD APR
PY 2016
VL 3
IS 2
BP 97
EP 99
DI 10.1089/lgbt.2016.0015
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DJ0ZE
UT WOS:000373932100001
PM 26990275
ER
PT J
AU Mizukami, K
Akatsu, H
Abrahamson, EE
Mi, ZP
Ikonomovic, MD
AF Mizukami, Katsuyoshi
Akatsu, Hiroyasu
Abrahamson, Eric E.
Mi, Zhiping
Ikonomovic, Milos D.
TI Immunohistochemical analysis of hippocampal butyrylcholinesterase:
Implications for regional vulnerability in Alzheimer's disease
SO NEUROPATHOLOGY
LA English
DT Article
DE alzheimer's disease; amyloid; butyrylcholinesterase; hippocampus; tau
ID SENILE PLAQUES; HYDROLYZE ACETYLCHOLINE; DYSTROPHIC NEURITES; AMYLOID
PLAQUES; CEREBRAL-CORTEX; CHOLINESTERASES; BRAIN; PATHOLOGY; PROTEIN;
BETA
AB Studies of acetylcholine degrading enzymes acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) in Alzheimer's disease (AD) have suggested their potential role in the development of fibrillar amyloid- (A) plaques (amyloid plaques). A recent genome-wide association study analysis identified a novel association between genetic variations in the BCHE locus and amyloid burden. We studied BChE immunoreactivity in hippocampal tissue sections from AD and control cases, and examined its relationship with amyloid plaques, neurofibrillary tangles (NFT), dystrophic neurites (DN) and neuropil threads (NT). Compared to controls, AD cases had greater BChE immunoreactivity in hippocampal neurons and neuropils in CA2/3, but not in the CA1, CA4 and dentate gyrus. The majority of amyloid plaques (>80%, using a pan-amyloid marker X-34) contained discrete neuritic clusters which were dual-labeled with antibodies against BChE and phosphorylated tau (clone AT8). There was no association between overall regional BChE immunoreaction intensity and amyloid plaque burden. In contrast to previous reports, BChE was localized in only a fraction (similar to 10%) of classic NFT (positive for X-34). A similar proportion of BChE-immunoreactive pyramidal cells were AT8 immunoreactive. Greater NFT and DN loads were associated with greater BChE immunoreaction intensity in CA2/3, but not in CA1, CA4 and dentate gyrus. Our results demonstrate that in AD hippocampus, BChE accumulates in neurons and plaque-associated neuritic clusters, but only in a small proportion of NFT. The association between greater neurofibrillary pathology burden and markedly increased BChE immunoreactivity, observed selectively in CA2/3 region, could reflect a novel compensatory mechanism. Since CA2/3 is generally considered more resistant to AD pathology, BChE upregulation could impact the cholinergic modulation of glutamate neurotransmission to prevent/reduce neuronal excitotoxicity in AD hippocampus.
C1 [Mizukami, Katsuyoshi] Univ Tsukuba, Fac Hlth & Sport Sci, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.
[Mizukami, Katsuyoshi] Univ Tsukuba, Grad Sch Comprehens Human Sci, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.
[Akatsu, Hiroyasu] Nagoya City Univ, Grad Sch Med, Dept Community Based Med, Nagoya, Aichi, Japan.
[Akatsu, Hiroyasu] Fukushimura Hosp, Choju Med Inst, Toyohashi, Aichi, Japan.
[Abrahamson, Eric E.; Mi, Zhiping; Ikonomovic, Milos D.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA.
[Ikonomovic, Milos D.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA.
[Abrahamson, Eric E.; Ikonomovic, Milos D.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
RP Mizukami, K (reprint author), Univ Tsukuba, Grad Sch Comprehens Human Sci, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.
EM kmizukam@taiiku.tsukuba.ac.jp
FU NIH [NIA AG014449, AG025204]; Japanese Ministry of Education, Culture,
Sports, Science and Technology
FX We are indebted to the subjects from Choju Medical Institute,
Fukushimura Hospital and Ishizaki Hospital in this study. This work was
supported by NIH grants NIA AG014449 and AG025204 (MDI), and by a
Grant-in-Aid for Scientific Research from the Japanese Ministry of
Education, Culture, Sports, Science and Technology (KM). Ms. Lan Shao,
Ms. Natsuko Kato and Ms. Megumi Mitani provided expert technical
assistance.
NR 39
TC 1
Z9 1
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0919-6544
EI 1440-1789
J9 NEUROPATHOLOGY
JI Neuropathology
PD APR
PY 2016
VL 36
IS 2
BP 135
EP 145
DI 10.1111/neup.12241
PG 11
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA DJ2AT
UT WOS:000374006800003
PM 26293308
ER
PT J
AU Floyd, JS
Blondon, M
Moore, KP
Boyko, EJ
Smith, NL
AF Floyd, James S.
Blondon, Marc
Moore, Kathryn P.
Boyko, Edward J.
Smith, Nicholas L.
TI Validation of methods for assessing cardiovascular disease using
electronic health data in a cohort of Veterans with diabetes
SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
LA English
DT Article
DE validation; electronic health data; diabetes mellitus; myocardial
infarction; smoking; pharmacoepidemiology
ID ACUTE MYOCARDIAL-INFARCTION; ADMINISTRATIVE DATA; DATA ALGORITHMS;
DATABASES; EVENTS; CODES; RISK
AB BackgroundElectronic health data are routinely used to conduct studies of cardiovascular disease in the setting of the Veterans Health Administration (VA). Previous studies have estimated the positive predictive value (PPV) of International Classification of Disease, Ninth Revision (ICD-9) codes for acute myocardial infarction (MI), but the sensitivity of these codes for all true events and the accuracy of coding algorithms for prevalent disease status at baseline are largely unknown.
MethodsWe randomly sampled 180 Veterans from the VA Puget Sound Health Care System who initiated diabetes treatment. The full electronic medical record was reviewed to identify prevalent conditions at baseline and acute MI events during follow-up. The accuracy of various coding algorithms was assessed.
ResultsAlgorithms for previous acute events at baseline had high PPV (previous MI: 97%; previous stroke: 81%) but low sensitivity (previous MI: 38%; previous stroke: 52%). Algorithms for chronic conditions at baseline had high PPV (heart failure: 72%; coronary heart disease [CHD]: 85%) and high sensitivity (heart failure: 90%, CHD: 84%). For current smoking status at baseline, ICD-9 codes with pharmacy data had a PPV of 77% and sensitivity of 73%. The coding algorithm for acute MI events during follow-up had high PPV (80%) and sensitivity (89%)
ConclusionsICD-9 codes for acute MI events during follow-up had high PPV and sensitivity. The sensitivity of ICD-9 codes for previous acute events at baseline was low, but a composite variable for baseline CHD had good accuracy. Copyright (c) 2015 John Wiley & Sons, Ltd.
C1 [Floyd, James S.; Smith, Nicholas L.] Univ Washington, Cardiovasc Hlth Res Unit, 1730 Minor Ave,Suite 1360, Seattle, WA 98101 USA.
[Smith, Nicholas L.] Univ Washington, Dept Epidemiol, Seattle, WA 98101 USA.
[Floyd, James S.; Boyko, Edward J.] Univ Washington, Med, Seattle, WA 98101 USA.
[Moore, Kathryn P.; Boyko, Edward J.; Smith, Nicholas L.] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA.
[Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Gen Med Serv, Seattle, WA USA.
[Smith, Nicholas L.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA.
[Blondon, Marc] Univ Hosp Geneva, Div Angiol & Haemostasis, Geneva, Switzerland.
[Blondon, Marc] Fac Med, Geneva, Switzerland.
RP Floyd, JS (reprint author), Univ Washington, Cardiovasc Hlth Res Unit, 1730 Minor Ave,Suite 1360, Seattle, WA 98101 USA.
EM jfloyd@uw.edu
RI Floyd, James/G-7563-2015
OI Boyko, Edward/0000-0002-3695-192X
FU NHLBI NIH HHS [K08 HL116640, K08HL116640]; NIDDK NIH HHS [P30 DK017047]
NR 16
TC 4
Z9 4
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1053-8569
EI 1099-1557
J9 PHARMACOEPIDEM DR S
JI Pharmacoepidemiol. Drug Saf.
PD APR
PY 2016
VL 25
IS 4
BP 467
EP 471
DI 10.1002/pds.3921
PG 5
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
GA DJ1ZI
UT WOS:000374003100016
PM 26555025
ER
PT J
AU Smits, JAJ
Zvolensky, MJ
Davis, ML
Rosenfield, D
Marcus, BH
Church, TS
Powers, MB
Frierson, GM
Otto, MW
Hopkins, LB
Brown, RA
Baird, SO
AF Smits, Jasper A. J.
Zvolensky, Michael J.
Davis, Michelle L.
Rosenfield, David
Marcus, Bess H.
Church, Timothy S.
Powers, Mark B.
Frierson, Georita M.
Otto, Michael W.
Hopkins, Lindsey B.
Brown, Richard A.
Baird, Scarlett O.
TI The Efficacy of Vigorous-Intensity Exercise as an Aid to Smoking
Cessation in Adults With High Anxiety Sensitivity: A Randomized
Controlled Trial
SO PSYCHOSOMATIC MEDICINE
LA English
DT Article
DE smoking; smoking cessation; intervention; randomized controlled trial;
exercise; aerobic exercise; anxiety; anxiety sensitivity
ID PHYSICAL-ACTIVITY; AEROBIC EXERCISE; DAILY SMOKERS; WITHDRAWAL SYMPTOMS;
CIGARETTE CRAVINGS; DEPRESSION; METAANALYSIS; VALIDATION; DIMENSIONS;
CHALLENGE
AB Objectives: High anxiety sensitivity predicts poor smoking cessation outcomes. Aerobic exercise reduces anxiety sensitivity and aspects of the risk conferred by anxiety sensitivity. In the current study, we examined whether exercise can aid smoking cessation in adults with high anxiety sensitivity.
Methods: Participants were sedentary and low-activity adult daily smokers (n = 136) with elevated prescreen anxiety sensitivity. Participants received 15 weeks of standard smoking cessation treatment (ST; cognitive behavioral therapy plus nicotine replacement therapy). In addition, participants were simultaneously randomized to 15 weeks of either an exercise intervention (ST + EX; n = 72) or a wellness education control condition (ST + CTRL; n = 64). Self-reported smoking abstinence was assessed weekly during the intervention, at the end of treatment (10 weeks after the target quit date), and at 4 and 6 months after the target quit date. Abstinence was verified by expired carbon monoxide readings and saliva cotinine.
Results: Results indicated that point prevalence abstinence (PPA) and prolonged abstinence (PA) rates were significantly higher for ST + EX than for ST + CTRL at each of the major end points among persons with high anxiety sensitivity (PPA: b = -0.91, standard error [SE] = 0.393, t(1171) = -2.33, p = .020; PA: b = -0.98, SE = 0.346, t(132) = -2.84, p = .005), but not among those with low anxiety sensitivity (PPA: b = -0.23, SE = 0.218, t(1171) = -1.06, p = .29; PA: b = -0.31, SE = 0.306, t(132) = -1.01, p = .32).
Conclusions: The present results suggest that exercise facilitates the odds of quit success for smokers with high levels of anxiety sensitivity and therefore may be a useful therapeutic tactic for this high-risk segment of the smoking population.
C1 [Smits, Jasper A. J.; Davis, Michelle L.; Powers, Mark B.; Baird, Scarlett O.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA.
[Smits, Jasper A. J.; Davis, Michelle L.; Powers, Mark B.; Baird, Scarlett O.] Univ Texas Austin, Mental Hlth Res Inst, Austin, TX 78712 USA.
[Zvolensky, Michael J.] Univ Houston, Dept Psychol, Houston, TX USA.
[Zvolensky, Michael J.] Univ Texas MD Anderson Canc Ctr, Dept Behav Sci, Houston, TX 77030 USA.
[Rosenfield, David] So Methodist Univ, Dept Psychol, Dallas, TX 75275 USA.
[Marcus, Bess H.] Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA.
[Church, Timothy S.] Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA.
[Frierson, Georita M.] Howard Univ, Dept Psychol, Washington, DC 20059 USA.
[Otto, Michael W.] Boston Univ, Dept Psychol, 64 Cummington St, Boston, MA 02215 USA.
[Otto, Michael W.] Boston Univ, Dept Psychol & Brain Sci, Boston, MA 02215 USA.
[Hopkins, Lindsey B.] San Francisco VA Med Ctr, Stress & Hlth Res Program, San Francisco, CA USA.
[Brown, Richard A.] Univ Texas Austin, Sch Nursing, Austin, TX 78712 USA.
RP Smits, JAJ (reprint author), Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA.; Smits, JAJ (reprint author), Univ Texas Austin, Mental Hlth Res Inst, Austin, TX 78712 USA.
EM smits@utexas.edu
OI Hopkins, Lindsey/0000-0002-0577-2961; Powers, Mark/0000-0001-7898-073X
FU National Institute on Drug Abuse [R01DA027533]
FX The authors have declared that no competing interests exist. This study
was funded by a grant from the National Institute on Drug Abuse
(R01DA027533). The National Institute on Drug Abuse plays no role in
approving the publications.
NR 52
TC 4
Z9 4
U1 4
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0033-3174
EI 1534-7796
J9 PSYCHOSOM MED
JI Psychosom. Med.
PD APR
PY 2016
VL 78
IS 3
BP 354
EP 364
DI 10.1097/PSY.0000000000000264
PG 11
WC Psychiatry; Psychology; Psychology, Multidisciplinary
SC Psychiatry; Psychology
GA DJ1FY
UT WOS:000373949900012
PM 26513517
ER
PT J
AU Tipps, ME
Raybuck, JD
Kozell, LB
Lattal, KM
Buck, KJ
AF Tipps, Megan E.
Raybuck, Jonathan D.
Kozell, Laura B.
Lattal, K. Matthew
Buck, Kari J.
TI G Protein-Gated Inwardly Rectifying Potassium Channel Subunit 3
Knock-Out Mice Show Enhanced Ethanol Reward
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE GIRK Channels; Reward; Conditioned Place Preference; Fear Conditioning;
Ethanol
ID CONDITIONED PLACE PREFERENCE; VENTRAL TEGMENTAL AREA; NULL MUTANT MICE;
GIRK CHANNELS; ALCOHOL ADDICTION; DOPAMINE SYSTEM; DRUG-ADDICTION; K+
CHANNELS; HYBRID MICE; NEURONS
AB BackgroundG protein-gated inwardly rectifying potassium (GIRK) channels contribute to the effects of a number of drugs of abuse, including ethanol. However, the roles of individual subunits in the rewarding effects of ethanol are poorly understood.
MethodsWe compare conditioned place preference (CPP) in GIRK3 subunit knock-out (GIRK3(-/-)), heterozygote (GIRK3(+/-)), and wild-type (WT) mice. In addition, the development of locomotor tolerance/sensitization and the effects of EtOH intoxication on associative learning (fear conditioning) are also assessed.
ResultsOur data show significant EtOH CPP in GIRK3(-/-) and GIRK3(+/-) mice, but not in the WT littermates. In addition, we demonstrate that these effects are not due to differences in EtOH metabolism, the development of EtOH tolerance/sensitivity, or associative learning abilities. While there were no consistent genotype differences in the fear conditioning assay, our data do show a selective sensitization of the impairing effects of EtOH intoxication on contextual learning, but no effect on cued learning.
ConclusionsThese findings suggest that GIRK3 plays a role in EtOH reward. Furthermore, the selectivity of this effect suggests that GIRK channels could be an effective therapeutic target for the prevention and/or treatment of alcoholism.
C1 [Tipps, Megan E.; Kozell, Laura B.; Buck, Kari J.] Portland VA Med Ctr, Portland Alcohol Res Ctr, Portland, OR USA.
[Tipps, Megan E.; Raybuck, Jonathan D.; Kozell, Laura B.; Lattal, K. Matthew; Buck, Kari J.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, 3181 SW Sam Jackson Pk Rd,Mail Code L470, Portland, OR 97239 USA.
RP Tipps, ME (reprint author), Oregon Hlth & Sci Univ, Dept Behav Neurosci, 3181 SW Sam Jackson Pk Rd,Mail Code L470, Portland, OR 97239 USA.
EM metipps@gmail.com
OI Kozell, Laura/0000-0003-3059-2046
FU NIH [F32 AA022011, T32 AA07468, F32DA031537, T32 DA07262, R01 AA011114,
P60 AA10760, R24 AA020245, R01 DA005228, R01 DA025922]; VA; U.S.
Department of the Army/DOD-TATRC [W81XWH-12-2-0048]
FX This work was supported by NIH F32 AA022011 and T32 AA07468 (MET); NIH
F32DA031537 and T32 DA07262 (JDR); NIH R01 AA011114, P60 AA10760, R24
AA020245, R01 DA005228, and the VA (KJB); NIH R01 DA025922 and U.S.
Department of the Army/DOD-TATRC: W81XWH-12-2-0048 (KML).
NR 52
TC 3
Z9 3
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD APR
PY 2016
VL 40
IS 4
BP 857
EP 864
DI 10.1111/acer.13012
PG 8
WC Substance Abuse
SC Substance Abuse
GA DI8GK
UT WOS:000373739300023
PM 27012303
ER
PT J
AU Rosendorff, C
AF Rosendorff, Clive
CA Writing Comm
TI Treatment of Hypertension in Patients with Coronary Artery Disease. A
Case-Based Summary of the 2015 AHA/ACC/ASH Scientific Statement
SO AMERICAN JOURNAL OF MEDICINE
LA English
DT Review
DE Acute Coronary Syndrome; Coronary Artery Disease; Heart Failure;
Hypertension; Myocardial Infarction; Stable Angina; Unstable Angina
ID COLLEGE-OF-CARDIOLOGY; LEFT-VENTRICULAR DYSFUNCTION;
CONVERTING-ENZYME-INHIBITOR; ACUTE MYOCARDIAL-INFARCTION;
AMERICAN-HEART-ASSOCIATION; PREVENTIVE-CARDIOVASCULAR-NURSES;
BLOOD-PRESSURE CONTROL; HIGH-RISK PATIENTS; RANDOMIZED-TRIAL; PRACTICE
GUIDELINES
AB The 2015 American Heart Association/American College of Cardiology/American Society of Hypertension Scientific Statement "Treatment of Hypertension in Patients with Coronary Artery Disease" is summarized in the context of a clinical case. The Statement deals with target blood pressures, and the optimal agents for the treatment of hypertension in patients with stable angina, in acute coronary syndromes, and in patients with ischemic heart failure. In all cases, the recommended blood pressure target is < 140/90 mm Hg, but < 130/80 mm Hg may be appropriate, especially in those with a history of a previous myocardial infarction or stroke, or at high risk for developing either. These numbers may need to be revised after the publication of the SPRINT data. Appropriate management should include beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and in the case of heart failure, aldosterone antagonists. Thiazide or thiazide-like (chlorthalidone) diuretics and calcium channel blockers can be used for the management of hypertension, but the evidence for improved outcomes compared with other agents in hypertension with coronary artery disease is meager. Loop diuretics should be reserved for patients with New York Heart Association Class III and IV heart failure or with a glomerular filtration rate of < 30 mL/min. Published by Elsevier Inc.
C1 Mt Sinai Heart, New York, NY USA.
Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA.
James J Peters VA Med Ctr, Bronx, NY 10468 USA.
RP Rosendorff, C (reprint author), James J Peters VA Med Ctr, Med 111, 130 West Kingsbridge Rd, Bronx, NY 10468 USA.
EM clive.rosendorff@va.gov
OI Allison, Matthew/0000-0003-0777-8272
NR 37
TC 2
Z9 2
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9343
EI 1555-7162
J9 AM J MED
JI Am. J. Med.
PD APR
PY 2016
VL 129
IS 4
BP 372
EP 378
DI 10.1016/j.amjmed.2015.10.045
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA DI4RH
UT WOS:000373486500021
PM 26655222
ER
PT J
AU Kempen, JH
Gewaily, DY
Newcomb, CW
Liesegang, TL
Kacmaz, RO
Levy-Clarke, GA
Nussenblatt, RB
Rosenbaum, JT
Sen, HN
Suhler, EB
Thorne, JE
Foster, CS
Jabs, DA
Payal, A
Fitzgerald, TD
AF Kempen, John H.
Gewaily, Dina Y.
Newcomb, Craig W.
Liesegang, Teresa L.
Kacmaz, R. Oktay
Levy-Clarke, Grace A.
Nussenblatt, Robert B.
Rosenbaum, James T.
Sen, H. Nida
Suhler, Eric B.
Thorne, Jennifer E.
Foster, C. Stephen
Jabs, Douglas A.
Payal, Abhishek
Fitzgerald, Tonetta D.
CA Systemic Immunosuppressive Therapy
TI Remission of Intermediate Uveitis: Incidence and Predictive Factors
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PARS-PLANA VITRECTOMY; OCULAR INFLAMMATORY DISEASES; CLINICAL-FEATURES;
PLANITIS; THERAPY; PANUVEITIS; POSTERIOR; OUTCOMES; RISK; EYE
AB PURPOSE: To evaluate the incidence of remission among patients with intermediate uveitis; to identify factors potentially predictive of remission.
DESIGN: Retrospective cohort study.
METHODS: Involved eyes of patients with primary noninfectious intermediate uveitis at 4 academic ocular inflammation subspecialty practices, followed sufficiently long to meet the remission outcome definition, were studied retrospectively by standardized chart review data. Remission of intermediate uveitis was defined as a lack of inflammatory activity at >= 2 visits spanning >= 90 days in the absence of any corticosteroid or immunosuppressant medications. Factors potentially predictive of intermediate uveitis remission were evaluated using survival analysis.
RESULTS: Among 849 eyes (of 510 patients) with intermediate uveitis followed over 1934 eye-years, the incidence of intermediate uveitis remission was 8.6/100 eye-years (95% confidence interval [CI], 7.4-10.1). Factors predictive of disease remission included prior pars plana vitrectomy (PPV) (hazard ratio [HR] [vs no PPV] = 2.39; 95% CI, 1.42-4.00), diagnosis of intermediate uveitis within the last year (HR [vs diagnosis >5 years ago] = 3.82; 95% CI, 1.91-7.63), age >= 45 years (HR [vs age <45 years] = 1.79; 95% CI, 1.03-3.11), female sex (HR = 1.61; 95% CI, 1.04-2.49), and Hispanic race/ethnicity (HR [vs white race] = 2.81; 95% CI, 1.23-6.41). Presence/absence of a systemic inflammatory disease, laterality of uveitis, and smoking status, were not associated with differential incidence.
CONCLUSIONS: Our results suggest that intermediate uveitis is a chronic disease with an overall low rate of remission. Recently diagnosed patients and older, female, and Hispanic patients were more likely to remit. With regard to management, pars plana vitrectomy was associated with increased probability of remission. (C) 2016 by Elsevier Inc. All rights reserved.
C1 [Kempen, John H.; Gewaily, Dina Y.; Payal, Abhishek; Fitzgerald, Tonetta D.] Univ Penn, Perelman Sch Med, Dept Ophthalmol, Philadelphia, PA 19104 USA.
[Kempen, John H.; Newcomb, Craig W.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
[Kempen, John H.; Newcomb, Craig W.] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Gewaily, Dina Y.] Deglin & Greene Retinal Ctr, Wynnewood, PA USA.
[Liesegang, Teresa L.; Rosenbaum, James T.; Suhler, Eric B.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Portland, OR 97201 USA.
[Rosenbaum, James T.; Payal, Abhishek] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA.
[Kacmaz, R. Oktay; Foster, C. Stephen] Massachusetts Eye Res & Surg Inst, Waltham, MA USA.
[Kacmaz, R. Oktay] Allergan Pharmaceut Inc, Dublin, Ireland.
[Levy-Clarke, Grace A.; Nussenblatt, Robert B.; Sen, H. Nida] NEI, Immunol Lab, Bldg 10, Bethesda, MD 20892 USA.
[Levy-Clarke, Grace A.] Tampa Bay Uveitis Ctr, Tampa, FL USA.
[Rosenbaum, James T.] Devers Eye Inst, Portland, OR USA.
[Suhler, Eric B.; Payal, Abhishek] Portland VA Med Ctr, Portland, OR USA.
[Thorne, Jennifer E.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA.
[Thorne, Jennifer E.; Jabs, Douglas A.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Foster, C. Stephen] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
[Jabs, Douglas A.] Icahn Sch Med Mt Sinai, Dept Ophthalmol, New York, NY USA.
[Jabs, Douglas A.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA.
RP Kempen, JH (reprint author), Univ Penn, Dept Ophthalmol, Ctr Prevent Ophthalmol & Biostat, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA.
EM john.kempen@uphs.upenn.edu
OI Payal, Abhishek/0000-0002-4484-8279
FU NATIONAL EYE INSTITUTE (BETHESDA, MD, USA) [EY014943]; Research to
Prevent Blindness (New York, NY, USA); Paul and Evanina Mackall
Foundation (New York, NY, USA); Lois Pope Life Foundation (New York, NY,
USA); Veteran's Affairs Administration (Washington, DC, USA); National
Eye Institute; Research to Prevent Blindness
FX SUPPORTED PRIMARILY BY NATIONAL EYE INSTITUTE (BETHESDA, MD, USA) GRANT
EY014943 (JOHN H. Kempen). Additional support was provided by Research
to Prevent Blindness (New York, NY, USA), the Paul and Evanina Mackall
Foundation (New York, NY, USA), and the Lois Pope Life Foundation (New
York, NY, USA). During the course of the study, John H. Kempen was a
Research to Prevent Blindness James S. Adams Special Scholar Award
recipient, Jennifer E. Thorne was a Research to Prevent Blindness
Harrington Special Scholar Award recipient, and Douglas A. Jabs and
James T. Rosenbaum were Research to Prevent Blindness Senior Scientific
Investigator Award recipients. Eric B. Suhler receives support from the
Veteran's Affairs Administration (Washington, DC, USA). Grace A.
Levy-Clarke was previously supported by and Robert B. Nussenblatt and H.
Nida Sen continue to be supported by intramural funds of the National
Eye Institute. The funding organizations had no role in the design or
conduct of this research.
NR 34
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2016
VL 164
BP 110
EP 117
DI 10.1016/j.ajo.2015.12.034
PG 8
WC Ophthalmology
SC Ophthalmology
GA DI7CS
UT WOS:000373657300014
PM 26772874
ER
PT J
AU Capurso, NA
Petrakis, I
AF Capurso, Noah A.
Petrakis, Ismene
TI Dyslipidemia associated with heavy alcohol use
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Article
ID CORONARY-HEART-DISEASE; SEVERE HYPERTRIGLYCERIDEMIA; LIPOPROTEIN-LIPASE;
RISK; CONSUMPTION; MEN; MORTALITY; DRINKING
AB Background and ObjectivesAlcohol has many effects on lipid metabolism and has been associated with elevated triglycerides. The purpose of this paper is to report a case of globally dysregulated lipids secondary to alcohol use and to describe the natural history of this phenomenon after drinking cessation.
MethodsWe present a case of an otherwise healthy patient (N=1) who was admitted to our facility for alcohol detoxification and found to have extreme lipid dysregulation. He was treated with benzodiazepines for alcohol withdrawal but no hypolipidemic agents were given.
ResultsLipid indices self-corrected and were found to be normal following just several weeks of sobriety in the absence of treatment with any hypolipidemic agents.
DiscussionThe literature regarding the effects of alcohol on lipid metabolism is briefly reviewed followed by a discussion of how these findings might apply to this patient in particular as well as implications for broader clinical practice.
Conclusion and Scientific SignificanceAlcohol has the ability to dysregulate several lipid indices in addition to elevating triglycerides. The rapid resolution of dyslipidemia suggests that additional treatment may not be necessary for patients who are able to abstain from alcohol but that hypolipidemic agents may be indicated for those patients who continue to drink. Additionally, clinicians should consider checking lipid panels in patients who present with alcohol intoxication and are found to have other laboratory abnormalites or those who have risk factors for hyperlipidemia. (Am J Addict 2016;25:188-190)
C1 [Capurso, Noah A.; Petrakis, Ismene] Yale Univ, Sch Med, Dept Psychiat, 300 George St,Suite 901, New Haven, CT 06511 USA.
[Petrakis, Ismene] VA Connecticut Healthcare Syst, US Dept Vet Affairs, West Haven, CT USA.
RP Capurso, NA (reprint author), Yale Univ, Sch Med, Dept Psychiat, 300 George St,Suite 901, New Haven, CT 06511 USA.
EM noah.capurso@yale.edu
NR 19
TC 0
Z9 0
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1055-0496
EI 1521-0391
J9 AM J ADDICTION
JI Am. J. Addict.
PD APR
PY 2016
VL 25
IS 3
BP 188
EP 190
DI 10.1111/ajad.12347
PG 3
WC Substance Abuse
SC Substance Abuse
GA DI5UA
UT WOS:000373564800002
PM 26991470
ER
PT J
AU Emery, MJ
Groves, CC
Kruse, TN
Shi, C
Terman, GW
AF Emery, Michael J.
Groves, Chase C.
Kruse, Timothy N.
Shi, Chen
Terman, Gregory W.
TI Ventilation and the Response to Hypercapnia after Morphine in
Opioid-naive and Opioid-tolerant Rats
SO ANESTHESIOLOGY
LA English
DT Article
ID INDUCED RESPIRATORY DEPRESSION; ADMINISTERED MORPHINE;
POSTNATAL-DEVELOPMENT; RECURRENT HYPOXIA; CHRONIC PAIN; RECEPTORS;
SLEEP; OVERDOSE; MECHANISMS; ANALGESIA
AB Background: Opioid-related deaths are a leading cause of accidental death, with most occurring in patients receiving chronic pain therapy. Respiratory arrest is the usual cause of death, but mechanisms increasing that risk with increased length of treatment remain unclear. Repeated administration produces tolerance to opioid analgesia, prompting increased dosing, but depression of ventilation may not gain tolerance to the same degree. This study addresses differences in the degree to which chronic morphine (1) produces tolerance to ventilatory depression versus analgesia and (2) alters the magnitude and time course of ventilatory depression.
Methods: Juvenile rats received subcutaneous morphine for 3 days (n = 116) or vehicle control (n = 119) and were then tested on day 4 following one of a range of morphine doses for (a) analgesia by paw withdraw from heat or (b) respiratory parameters by plethysmography-respirometry.
Results: Rats receiving chronic morphine showed significant tolerance to morphine sedation and analgesia (five times increased ED50). When sedation was achieved for all animals in a dose group (lowest effective doses: opioid-tolerant, 15 mg/kg; opioid-naive, 3 mg/kg), the opioid-tolerant showed similar magnitudes of depressed ventilation (-41.4 7.0%, mean +/- SD) and hypercapnic response (-80.9 +/- 15.7%) as found for morphine-naive (-35.5 +/- 16.9% and -67.7 +/- 15.1%, respectively). Ventilation recovered due to tidal volume without recovery of respiratory rate or hypercapnic sensitivity and more slowly in morphine-tolerant.
Conclusions: In rats, gaining tolerance to morphine analgesia does not reduce ventilatory depression effects when sedated and may inhibit recovery of ventilation.
C1 [Emery, Michael J.; Groves, Chase C.; Kruse, Timothy N.; Shi, Chen; Terman, Gregory W.] Univ Washington, Sch Med, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA.
[Emery, Michael J.] Vet Affairs Puget Sound Hlth Care Syst, Pulm & Crit Care Med, Seattle, WA USA.
RP Emery, MJ (reprint author), Univ Washington, Sch Med, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA.
EM mjemery@u.washington.edu
FU University of Washington Alcohol and Drug Abuse Institute (Seattle,
Washington)
FX This study was supported by the University of Washington Alcohol and
Drug Abuse Institute (Seattle, Washington).
NR 56
TC 2
Z9 2
U1 3
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-3022
EI 1528-1175
J9 ANESTHESIOLOGY
JI Anesthesiology
PD APR
PY 2016
VL 124
IS 4
BP 945
EP 957
DI 10.1097/ALN.0000000000000997
PG 13
WC Anesthesiology
SC Anesthesiology
GA DI2TO
UT WOS:000373352000027
PM 26734964
ER
PT J
AU Park, M
Shlipak, MG
Thiessen-Philbrook, H
Garg, AX
Koyner, JL
Coca, SG
Parikh, CR
AF Park, Meyeon
Shlipak, Michael G.
Thiessen-Philbrook, Heather
Garg, Amit X.
Koyner, Jay L.
Coca, Steven G.
Parikh, Chirag R.
CA TRIBE-AKI Consortium
TI Association of Peak Changes in Plasma Cystatin C and Creatinine With
Death After Cardiac Operations
SO ANNALS OF THORACIC SURGERY
LA English
DT Article
ID GLOMERULAR-FILTRATION-RATE; ACUTE KIDNEY INJURY; SERUM CREATININE;
CARDIOTHORACIC SURGERY; RISK; BIOMARKERS; EQUATION; FAILURE; MARKER
AB Background. Acute kidney injury is a risk factor for death in cardiac surgical patients. Plasma cystatin C and creatinine have different temporal profiles in the postoperative setting, but the associations of simultaneous changes in both filtration markers compared with change in only one marker with prognosis after hospital discharge are not well described.
Methods. This is a longitudinal study of 1,199 high-risk adult cardiac surgical patients in the TRIBE-AM (Translational Research Investigating Biomarker Endpoints for Acute Kidney Injury) Consortium who survived hospitalization. We examined in-hospital peak changes of cystatin C and creatinine in the 3 days after cardiac operations. We evaluated associations of these filtration markers with death, adjusting for demographics, operative characteristics, medical comorbidities, preoperative estimated glomerular filtration rate, preoperative urinary albumin-to-creatinine ratio, and site.
Results. During the first 3 days of hospitalization, nearly twice as many patients had a 25% or higher rise in creatinine (30%) compared with a 25% or higher peak rise in cystatin C (15%). The risk of death was higher in those with elevations in cystatin C (adjusted hazard ratio [HR], 1.83; 95% confidence interval [CI], 1.4 to 2.37) or creatinine (adjusted HR, 1.90; 95% CI, 1.32 to 2.72) compared with patients who experienced a postoperative decrease in either filtration marker. Patients who had simultaneous elevations of 25% or higher in cystatin C and creatinine were at similar adjusted risk for 3-year mortality (HR, 1.79; 95% CI, 1.03 to 3.1) as those with a 25% or higher increase in cystatin C alone (HR, 2.2; 95% CI, 1.09 to 4.47).
Conclusions. Elevations in creatinine postoperatively are more common than elevations in cystatin C. However, elevations in cystatin C appeared to be associated with a higher risk of death after hospital discharge. (C) 2016 by The Society of Thoracic Surgeons
C1 Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA.
Univ Calif San Francisco, Div Gen Internal Med, San Francisco VA Med Ctr, San Francisco, CA 94143 USA.
Univ Western Ontario, Dept Med, Div Nephrol, London, ON, Canada.
Inst Clin Evaluat Sci, Toronto, ON, Canada.
Univ Chicago, Dept Med, Nephrol Sect, 5841 S Maryland Ave, Chicago, IL 60637 USA.
Mt Sinai Sch Med, Div Nephrol, New York, NY USA.
Yale Univ, Sch Med, Nephrol Sect, New Haven, CT USA.
RP Park, M (reprint author), 521 Parnassus Ave,C443,Box 0532, San Francisco, CA 94143 USA.
EM meyeon.park@ucsf.edu
FU Institute for Clinical Evaluative Sciences; Ontario Ministry of Health
and Long-Term Care; National Institutes of Health (NIH) [R01-HL085757];
NIH National Institute of Diabetes and Digestive and Kidney Diseases
[K23-DK099238]; Adam Linton Chair in Kidney Health Analytics; NIH
[K23-DK081616, K23-DK080132, K24-DK090203, U01-DK082185]; Abbott
Diagnostics; Sekisui Diagnostics Inc
FX This study was supported by the Institute for Clinical Evaluative
Sciences, funded by an annual grant from the Ontario Ministry of Health
and Long-Term Care. The opinions, results, and conclusions reported in
this paper are those of the authors and are independent from the funding
sources. No endorsement by Institute for Clinical Evaluative Sciences or
the Ontario Ministry of Health and Long-Term Care is intended or should
be inferred. This study was supported by National Institutes of Health
(NIH) (R01-HL085757 C.R.P.) to fund the TRIBE-AKI Consortium to study
novel biomarkers of AKI in cardiac surgery. Other support: NIH National
Institute of Diabetes and Digestive and Kidney Diseases grant
K23-DK099238 (M.P.), Adam Linton Chair in Kidney Health Analytics
(A.X.G.), and NIH K23-DK081616 (J.L.K.), K23-DK080132 (S.G.C.), and
K24-DK090203 (C.R.P.). S.G.C., A.X.G., and C.R.P. are also members of
the NIH-sponsored Assess, Serial Evaluation, and Subsequent Sequelae in
Acute Kidney Injury Consortium (U01-DK082185). The granting agencies,
Abbott Diagnostics and Sekisui Diagnostics Inc, did not participate in
the design or conduct of the study, collection, management, analysis,
interpretation of data, or preparation, review, or approval of the
manuscript.
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD APR
PY 2016
VL 101
IS 4
BP 1395
EP 1401
DI 10.1016/j.athoracsur.2015.12.010
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA DH1CT
UT WOS:000372522700034
PM 26921980
ER
PT J
AU Balasubramanian, CK
Li, CY
Bowden, MG
Duncan, PW
Kautz, SA
Velozo, CA
AF Balasubramanian, Chitralakshmi K.
Li, Chih-Ying
Bowden, Mark G.
Duncan, Pamela W.
Kautz, Steven A.
Velozo, Craig A.
TI Dimensionality and Item-Difficulty Hierarchy of the Lower Extremity
Fugl-Meyer Assessment in Individuals With Subacute and Chronic Stroke
SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
LA English
DT Article
DE Lower extremity; Rehabilitation; Stroke
ID ASSESSMENT SCALE; HEMIPLEGIC PATIENT; OUTCOME MEASURES; MOTOR RECOVERY;
PERFORMANCE; POSTSTROKE; WALKING; REHABILITATION; COORDINATION;
RELIABILITY
AB Objective: To investigate the dimensionality and item-difficulty hierarchy of the Fugl-Meyer Assessment of the lower extremity (FMA-LE).
Design: Secondary analyses of data pooled from 4 existing datasets: a phase III randomized controlled trial investigating the effectiveness of body weight support and a treadmill for rehabilitation of walking poststroke, and 3 cross-sectional studies investigating the link between impaired motor performance poststroke and walking.
Setting: University research centers and rehabilitation centers.
Participants: A pooled sample of individuals with a stroke (N=535, men = 313; mean age +/- SD, 61.91 +/- 12.42y).
Interventions: Not applicable.
Main Outcome Measures: Confirmatory factor analyses (CFA) and Rasch residual principal component analysis (PCA) investigated the dimensionality of the FMA-LE. The Rasch analysis rating scale model investigated item-difficulty hierarchy of the FMA-LE.
Results: The CFA showed adequate fit of a 3-factor model, with 2 out of 3 indices (CFA=.95; Tucker-Lewis Index=.94; root mean square error of approximation=.124) showing good model fit. Rasch PCA showed that removal of the reflex and coordination items explained 90.8% of variance in the data, suggesting that the abnormal synergy items contributed to the measurement of a unidimensional construct. However, rating scale model results revealed deviations in the item-difficulty hierarchy of the unidimensional abnormal synergy items from the originally proposed stepwise sequence of motor recovery.
Conclusions: Our findings suggest that the FMA-LE might represent a multidimensional construct, challenging the use of a total score of the FMA-LE to predict lower extremity motor recovery. Removal of the misfit items resulted in creation of a unidimensional scale composed of the abnormal synergy items. However, this unidimensional scale deviates from the originally proposed hierarchical ordering. (C) 2016 by the American Congress of Rehabilitation Medicine
C1 [Balasubramanian, Chitralakshmi K.] Univ N Florida, Dept Clin & Appl Movement Sci, 1 UNF Dr, Jacksonville, FL 32224 USA.
[Li, Chih-Ying; Bowden, Mark G.; Kautz, Steven A.] Med Univ S Carolina, Coll Hlth Profess, Dept Hlth Sci & Res, Charleston, SC 29425 USA.
[Li, Chih-Ying; Bowden, Mark G.; Kautz, Steven A.] Med Univ S Carolina, Coll Hlth Profess, Div Phys Therapy, Charleston, SC 29425 USA.
[Bowden, Mark G.; Kautz, Steven A.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Duncan, Pamela W.] Wake Forest Univ, Dept Neurol, Winston Salem, NC 27109 USA.
[Velozo, Craig A.] Med Univ S Carolina, Coll Hlth Profess, Div Occupat Therapy, Charleston, SC 29425 USA.
RP Balasubramanian, CK (reprint author), Univ N Florida, Dept Clin & Appl Movement Sci, 1 UNF Dr, Jacksonville, FL 32224 USA.
EM c.k-balasubramanian@unf.edu
FU National Institute of Neurologic Diseases and Stroke; National Center
for Medical Rehabilitation Research [RO1 NS050506]; National Institutes
of Health [HD46820]; Rehabilitation Research and Development Service of
the U.S. Department of Veterans Affairs [B2748R]; Institutional
Development Award from the National Institute of General Medical
Sciences of the National Institutes of Health [P20-GM109040]
FX Support for study 1 by the National Institute of Neurologic Diseases and
Stroke and the National Center for Medical Rehabilitation Research
(grant no. RO1 NS050506); for study 2, by the National Institutes of
Health (grant no. HD46820); for study 3, by the Rehabilitation Research
and Development Service of the U.S. Department of Veterans Affairs
(grant no. B2748R); and for study 4, by an Institutional Development
Award from the National Institute of General Medical Sciences of the
National Institutes of Health (grant no. P20-GM109040).
NR 47
TC 1
Z9 1
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0003-9993
EI 1532-821X
J9 ARCH PHYS MED REHAB
JI Arch. Phys. Med. Rehabil.
PD APR
PY 2016
VL 97
IS 4
BP 582
EP 589
DI 10.1016/j.apmr.2015.12.012
PG 8
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA DI5EM
UT WOS:000373521700012
PM 26740065
ER
PT J
AU Johansen, KL
Dalrymple, LS
Glidden, D
Delgado, C
Kaysen, GA
Grimes, B
Chertow, GM
AF Johansen, Kirsten L.
Dalrymple, Lorien S.
Glidden, David
Delgado, Cynthia
Kaysen, George A.
Grimes, Barbara
Chertow, Glenn M.
TI Association of Performance-Based and Self-Reported Function-Based
Definitions of Frailty with Mortality among Patients Receiving
Hemodialysis
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID MAINTENANCE HEMODIALYSIS; CONSENSUS; DIALYSIS; DISEASE; HEALTH; OLDER
AB Background and objectives Frailty is common among patients on dialysis and increases vulnerability to dependency and death.
Design, setting, participants, & measurements We examined the predictive ability of frailty on the basis of physical performance and self-reported function in participants of a US Renal Data System special study that enrolled a convenience sample of 771 prevalent patients on hemodialysis from 14 facilities in the Atlanta and northern California areas from 2009 to 2011. Performance-based frailty was assessed using direct measures of grip strength (weakness) and gait speed along with weight loss, exhaustion, and low physical activity; poor self reported function was substituted for weakness and slow gait speed in the self reported function based definition. For both definitions, patients meeting three or more criteria were considered frail.
Results The mean age of 762 patients included in analyses was 57.1 +/- 14.2 years old; 240 patients (31%) met the physical performance-based definition of frailty, and 396 (52%) met the self reported function-based definition. There were 106 deaths during 1.7 (interquartile range, 1.4-2.4) years of follow-up. After adjusting for demographic and clinical characteristics, the hazard ratio (HR) for mortality for the performance-based definition (2.16; 95% confidence interval [95% CI], 1.41 to 3.29) was slightly higher than that of the self reported function based definition (HR, 1.93; 95% CI, 1.24 to 3.00). Patients who met the self-report based definition but not the physical performance definition of frailty (n=192) were not at statistically significantly higher risk of mortality than those who were not frail by either definition (n=330; HR, 1.41; 95% CI, 0.81 to 2.45), but those who met both definitions of frailty (n=204) were at significantly higher risk (HR, 2.46; 95% CI, 1.51 to 4.01).
Conclusions Frailty, defined using either direct tests of physical performance or self reported physical function, was associated with higher mortality among patients receiving hemodialysis. Future studies are needed to determine the utility of assessing frailty in clinical practice.
C1 [Johansen, Kirsten L.; Delgado, Cynthia] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA.
[Johansen, Kirsten L.; Glidden, David; Grimes, Barbara] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Johansen, Kirsten L.; Delgado, Cynthia] San Francisco VA Med Ctr, Nephrol Sect, 111J,4150 Clement St, San Francisco, CA 94121 USA.
[Dalrymple, Lorien S.; Kaysen, George A.] Univ Calif Davis, Div Nephrol, Davis, CA 95616 USA.
[Chertow, Glenn M.] Stanford Univ, Sch Med, Div Nephrol, Stanford, CA 94305 USA.
RP Johansen, KL (reprint author), San Francisco VA Med Ctr, Nephrol Sect, 111J,4150 Clement St, San Francisco, CA 94121 USA.
EM Kirsten.johansen@ucsf.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
[N01-DK-7-005, K24DK085153, K23DK093584, K24DK085446]; Career
Development Award from US Department of Veterans Affairs [1K2CX000527];
Clinical Research and Development Program; National Center for Advancing
Translational Sciences, National Institutes of Health through University
of California; San Francisco-Clinical & Translational Science Institute
grant [UL1 TR000004]
FX This work was supported by National Institute of Diabetes and Digestive
and Kidney Diseases (NIDDK) Contract N01-DK-7-005 and NIDDK Grants
K24DK085153 (to K.L.J.), K23DK093584 (to L.S.D.), and K24DK085446 (to
G.M.C.). In addition, C.D. was supported by Career Development Award
1K2CX000527 from the US Department of Veterans Affairs, Clinical
Research and Development Program. This publication was supported by the
National Center for Advancing Translational Sciences, National
Institutes of Health through University of California, San
Francisco-Clinical & Translational Science Institute grant UL1 TR000004.
NR 20
TC 3
Z9 3
U1 1
U2 3
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
EI 1555-905X
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD APR
PY 2016
VL 11
IS 4
BP 626
EP 632
DI 10.2215/CJN.03710415
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA DI5EV
UT WOS:000373522600013
PM 26792529
ER
PT J
AU Bitzer, C
AF Bitzer, Carolynn
TI Evidence-Based Practice Research on Pole- vs Patient-Mounted Transducer
Placement
SO CRITICAL CARE NURSE
LA English
DT Meeting Abstract
C1 [Bitzer, Carolynn] Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CRITICAL CARE NURSES
PI ALISO VIEJO
PA 101 COLUMBIA, ALISO VIEJO, CA 92656 USA
SN 0279-5442
EI 1940-8250
J9 CRIT CARE NURSE
JI Crit. Care Nurse
PD APR
PY 2016
VL 36
IS 2
MA EB66
BP E27
EP E28
PG 2
WC Critical Care Medicine; Nursing
SC General & Internal Medicine; Nursing
GA DI4CQ
UT WOS:000373448300030
ER
PT J
AU Justice, AC
McGinnis, KA
Tate, JP
Braithwaite, RS
Bryant, KJ
Cook, RL
Edelman, EJ
Fiellin, LE
Freiberg, MS
Gordon, AJ
Kraemer, KL
Marshall, BDL
Williams, EC
Fiellin, DA
AF Justice, Amy C.
McGinnis, Kathleen A.
Tate, Janet P.
Braithwaite, R. Scott
Bryant, Kendall J.
Cook, Robert L.
Edelman, E. Jennifer
Fiellin, Lynn E.
Freiberg, Matthew S.
Gordon, Adam J.
Kraemer, Kevin L.
Marshall, Brandon D. L.
Williams, Emily C.
Fiellin, David A.
TI Risk of mortality and physiologic injury evident with lower alcohol
exposure among HIV infected compared with uninfected men
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article
DE Alcohol; Mortality; Morbidity; VACS Index; AUDIT-C; Veteran; HIV
ID VETERANS AGING COHORT; ALL-CAUSE MORTALITY; J-SHAPED CURVE;
ANTIRETROVIRAL THERAPY; PRIMARY-CARE; AUDIT-C; MEDICATION ADHERENCE;
ADMINISTRATIVE DATA; SCREENING SCORES; PROBLEM DRINKING
AB Background: HIV infected (HIV+) individuals may be more susceptible to alcohol-related harm than uninfected individuals.
Methods: We analyzed data on HIV+ and uninfected individuals in the Veterans Aging Cohort Study (VACS) with an Alcohol Use Disorders Identification Test-Consumption AUDIT-C score from 2008 to 2012. We used Cox proportional hazards models to examine the association between alcohol exposure and mortality through July, 2014; and linear regression models to assess the association between alcohol exposure and physiologic injury based on VACS Index Scores. Models were adjusted for age, race/ethnicity, smoking, and hepatitis C infection.
Results: The sample included 18,145 HIV+ and 42,228 uninfected individuals. Among HIV+ individuals, 76% had undetectable HIV-1 RNA (<500 copies/ml). The threshold for an association of alcohol use with mortality and physiologic injury differed by HIV status. Among HIV+ individuals, AUDIT-C score >= 4 (hazard ratio [HR] 1.25, 95% CI 1.09-1.44) and >= 30 drinks per month (HR, 1.30, 95% CI 1.14-1.50) were associated with increased risk of mortality. Among uninfected individuals, AUDIT-C score >= 5 (HR, 1.19, 95% CI 1.07-1.32) and >= 70 drinks per month (HR 1.13, 95% CI 1.00-1.28) were associated with increased risk. Similarly, AUDIT-C threshold scores of 5-7 were associated with physiologic injury among HIV+ individuals (beta 0.47, 95% CI 0.22, 0.73) and a score of 8 or more was associated with injury in uninfected (beta 0.29, 95% CI 0.16, 0.42) individuals.
Conclusions: Despite antiretroviral therapy, HIV+ individuals experienced increased mortality and physiologic injury at lower levels of alcohol use compared with uninfected individuals. Alcohol consumption limits should be lower among HIV+ individuals. Published by Elsevier Ireland Ltd.
C1 [Justice, Amy C.; Tate, Janet P.; Edelman, E. Jennifer; Fiellin, David A.] West Haven VA Healthcare Syst, Vet Aging Cohort Study Coordinating Ctr, 950 Campbell Ave, West Haven, CT 06516 USA.
[Justice, Amy C.; Tate, Janet P.; Edelman, E. Jennifer; Fiellin, Lynn E.; Fiellin, David A.] Yale Univ, Yale Sch Med, Dept Internal Med, 367 Cedar St, New Haven, CT 06510 USA.
[Justice, Amy C.; Tate, Janet P.; Edelman, E. Jennifer; Fiellin, Lynn E.; Fiellin, David A.] Yale Univ, Yale Sch Med, CIRA, 367 Cedar St, New Haven, CT 06510 USA.
[McGinnis, Kathleen A.; Gordon, Adam J.; Kraemer, Kevin L.] VA Pittsburgh Healthcare Syst, Univ Dr C, Pittsburgh, PA 15240 USA.
[Braithwaite, R. Scott] NYU, Sch Med, Dept Populat Hlth, 227 East 30th St, New York, NY 10016 USA.
[Bryant, Kendall J.] NIAAA, 5635 Fishers Lane,MSC 9304, Bethesda, MD 20892 USA.
[Cook, Robert L.] Univ Florida, Dept Epidemiol, POB 100231, Gainesville, FL USA.
[Freiberg, Matthew S.] Vanderbilt Univ, Sch Med, Div Cardiovasc Med, Nashville, TN 37212 USA.
[Freiberg, Matthew S.] Vet Affairs Tennessee Valley Healthcare Syst, Geriatr Res Educ & Clin Ctr, 2525 West End Ave, Nashville, TN USA.
[Gordon, Adam J.; Kraemer, Kevin L.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Suite 600,230 McKee Pl, Pittsburgh, PA 15213 USA.
[Marshall, Brandon D. L.] Brown Univ, Sch Publ Hlth, Dept Epidemiol, 121 South Main St, Providence, RI 02912 USA.
[Williams, Emily C.] Univ Washington, Sch Publ Hlth, 325 Ninth Ave,Box 359762, Seattle, WA 98195 USA.
RP Justice, AC (reprint author), Yale Univ, Sch Med, VA Connecticut Healthcare Syst, 950 Campbell Ave,Bldg 35a Room 2-212 11 ACSLG, West Haven, CT 06516 USA.
EM amy.Justice2@va.gov
OI Fiellin, David/0000-0002-4006-010X; Justice, Amy/0000-0003-0139-5502
FU NHLBI NIH HHS [R01 HL090342, R01 HL095136, R01-HL090342, R01-HL095136,
RC1 HL100347, RCI-HL100347]; NIA NIH HHS [R01-AG029154, R01 AG029154];
NIAAA NIH HHS [U10 AA013566, U10-AA13566, U13 AA022864, U24 AA022000,
U24 AA022002, U24AA02002]; PHS HHS [U01-A1069918]
NR 60
TC 13
Z9 13
U1 3
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0376-8716
EI 1879-0046
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD APR 1
PY 2016
VL 161
BP 95
EP 103
DI 10.1016/j.drugalcdep.2016.01.017
PG 9
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA DI3SP
UT WOS:000373419100013
PM 26861883
ER
PT J
AU Okita, K
Ghahremani, DG
Payer, DE
Robertson, CL
Dean, AC
Mandelkern, MA
London, ED
AF Okita, Kyoji
Ghahremani, Dara G.
Payer, Doris E.
Robertson, Chelsea L.
Dean, Andy C.
Mandelkern, Mark A.
London, Edythe D.
TI Emotion dysregulation and amygdala dopamine D2-type receptor
availability in methamphetamine users
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article
DE Methamphetamine; Amygdala; Emotion dysregulation; Dopamine;
[F-18]Fallypride; PET
ID BORDERLINE PERSONALITY-DISORDER; REFERENCE TISSUE MODEL; HUMAN BRAIN;
NEURAL MECHANISMS; IMPULSE CONTROL; ABSTINENCE; DEPENDENCE; CORTEX;
DIFFICULTIES; INHIBITION
AB Background: Individuals who use methamphetamine chronically exhibit emotional and dopaminergic neurochemical deficits. Although the amygdala has an important role in emotion processing and receives dopaminergic innervation, little is known about how dopamine transmission in this region contributes to emotion regulation. This investigation aimed to evaluate emotion regulation in subjects who met DSM-IV criteria for methamphetamine dependence, and to test for a relationship between self-reports of difficulty in emotion regulation and D2-type dopamine receptor availability in the amygdala.
Method: Ninety-four methamphetamine-using and 102 healthy-control subjects completed the Difficulties in Emotion Regulation Scale (DERS); 33 of those who used methamphetamine completed the Addiction Severity Index (ASI). A subset of 27 methamphetamine-group and 20 control-group subjects completed positron emission tomography with [F-18]fallypride to assay amygdala D2-type dopamine receptor availability, measured as binding potential (BPND).
Results: The methamphetamine group scored higher than the control group on the DERS total score (p < 0.001), with DERS total score positively correlated with the Drug Composite Score on the ASI (p = 0.02) in the methamphetamine group. The DERS total score was positively correlated with amygdala BPND in both groups and the combined group of participants (combined: r= 0.331, p= 0.02), and the groups did not differ in this relationship.
Conclusion: These findings highlight problems with emotion regulation linked to methamphetamine use, possibly contributing to personal and interpersonal behavioral problems. They also suggest that D2-type dopamine receptors in the amygdala contribute to emotion regulation in both healthy and methamphetamine-using subjects. (c) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Okita, Kyoji; Ghahremani, Dara G.; Dean, Andy C.; London, Edythe D.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Robertson, Chelsea L.; London, Edythe D.] Dept Mol & Med Pharmacol, Los Angeles, CA 90024 USA.
[London, Edythe D.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA.
[Payer, Doris E.] Ctr Addict & Mental Hlth, Addict Imaging Res Grp, Toronto, ON M5T 1R8, Canada.
[Payer, Doris E.] Univ Toronto, Dept Psychiat, Toronto, ON M5T 1R8, Canada.
[Okita, Kyoji; Robertson, Chelsea L.; Mandelkern, Mark A.; London, Edythe D.] VA Greater Los Angeles Healthcare Syst, Dept Res, Los Angeles, CA 90073 USA.
[Mandelkern, Mark A.] Univ Calif Irvine, Dept Phys, Irvine, CA 92697 USA.
RP London, ED (reprint author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, 760 Westwood Plaza,POB 175919, Los Angeles, CA 90095 USA.
EM elondon@mednet.ucla.edu
OI Payer, Doris/0000-0001-9313-2587
FU National Institute on Drug Abuse [R01 DA015179, R01 DA020726, P20
DA022539, T32 DA024635, K23 DA027734, R21 DA034928]; National Center for
Research Resources [M01 RR00865]; Thomas P and Katherine K Pike Chair in
Addiction Studies; Marjorie M Greene Trust; Department of Psychiatry,
Chiba University, DOMONKAI fund
FX This research was supported, in part, by grants from the National
Institute on Drug Abuse (R01 DA015179, R01 DA020726, P20 DA022539, T32
DA024635, EDL; K23 DA027734, R21 DA034928, ACD) and the National Center
for Research Resources (M01 RR00865), and endowments from the Thomas P
and Katherine K Pike Chair in Addiction Studies and the Marjorie M
Greene Trust. KO was partly supported by Department of Psychiatry, Chiba
University, DOMONKAI fund.
NR 68
TC 1
Z9 1
U1 8
U2 14
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0376-8716
EI 1879-0046
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD APR 1
PY 2016
VL 161
BP 163
EP 170
DI 10.1016/j.drugalcdep.2016.01.029
PG 8
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA DI3SP
UT WOS:000373419100021
PM 26880595
ER
PT J
AU Chavez, LJ
Bradley, K
Tefft, N
Liu, CF
Hebert, P
Devine, B
AF Chavez, Laura J.
Bradley, Katharine
Tefft, Nathan
Liu, Chuan-Fen
Hebert, Paul
Devine, Beth
TI Preference weights for the spectrum of alcohol use in the US Population
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article
DE Alcohol consumption; Health-related quality of life; preference weights
ID QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; REPORTED HEALTH-STATUS;
USE DISORDER SEVERITY; UNITED-STATES; GENERAL-POPULATION; PRIMARY-CARE;
SCREENING SCORES; RISK-FACTORS; AUDIT-C
AB Background: Little is known about the cost-utility of population-based alcohol interventions. One barrier to research has been the lack of preference weights needed to calculate Quality Adjusted Life Years (QALYs). Preference weights can be estimated from measures of health-related quality of life (HRQOL). The objective of this study was to describe preference weights for the full spectrum of alcohol use.
Methods: This cross-sectional study included participants in both the National Health Interview Survey (NHIS; 1999-2002) and the Medical Expenditure Panel Survey (MEPS; 2000-2003). The AUDIT-C alcohol screen was derived from NHIS with scores categorized into 6 groups (0,1-3, 4-5, 6-7, 8-9,10-12 points), ranging from nondrinking (0) to very severe unhealthy alcohol use (10-12). AUDIT-C scores were mapped to EQ-5D and SF-6D preference weights using the linked datasets and analyses adjusted for demographics.
Results: Among 17,440 participants, mean EQ-5D and SF-6D preference weights were 0.82 (95% CI 0.82-0.83) and 0.79 (95% CI 0.79-0.80), respectively. Adjusted EQ-5D preference weights for nondrinking (0.80; 95% CI 0.79-0.81) and moderate unhealthy drinking (0.85; 95% CI 0.84-0.86) were significantly different from low-risk drinking (0.83; 95% CI 0.83-0.84), but no other differences were significant. Results for the SF-GD were similar.
Conclusions: This study provides EQ-5D and SF-6D preference weights for various alcohol use categories in a representative U.S. adult sample. However, neither measure suggested meaningful differences in HRQOL based on AUDIT-C categories. Self-reported alcohol consumption may not be associated with preference weights or generic instruments may not capture alcohol-related differences in HRQOL. (c) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Chavez, Laura J.; Bradley, Katharine; Liu, Chuan-Fen; Hebert, Paul] Vet Affairs Puget Sound Hlth Care Syst, Seattle Ctr Innovat Vet Ctr & Value Driven Care, Hlth Serv Res & Dev, 1660 S Columbian Way, Seattle, WA 98108 USA.
[Bradley, Katharine] Vet Affairs Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, 1660 S Columbian Way, Seattle, WA 98108 USA.
[Chavez, Laura J.; Bradley, Katharine; Liu, Chuan-Fen; Hebert, Paul; Devine, Beth] Univ Washington, Dept Hlth Serv, 1959 NE Pacific St,Box 357660, Seattle, WA 98195 USA.
[Bradley, Katharine] Univ Washington, Dept Med, 1959 NE Pacific St, Seattle, WA 98195 USA.
[Devine, Beth] Univ Washington, Dept Pharm, 1959 NE Pacific St, Seattle, WA 98195 USA.
[Tefft, Nathan] Bates Coll, 2 Andrews Rd, Lewiston, ME 04240 USA.
[Bradley, Katharine] Grp Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.
RP Chavez, LJ (reprint author), Univ Washington, Dept Hlth Serv, 1959 NE Pacific St,Box 357660, Seattle, WA 98195 USA.
EM ljchavez@u.washington.edu
OI Bradley, Katharine/0000-0003-1933-4425; Tefft,
Nathan/0000-0002-2758-8700
FU Agency for Healthcare Research and Quality (AHRQ) [NIH 1R36HS022800-01];
University of Washington Center of Excellence in Comparative
Effectiveness Research; Pharmaceutical Researcher and Manufacturer's
Association (PhRMA) Foundation
FX Ms. Chavez's work on this study was supported by an Agency for
Healthcare Research and Quality (AHRQ) Dissertation Grant (NIH
1R36HS022800-01) and a predoctoral fellowship from the University of
Washington Center of Excellence in Comparative Effectiveness Research,
sponsored by the Pharmaceutical Researcher and Manufacturer's
Association (PhRMA) Foundation. Dr. Bradley's time on this study was
supported by the Center of Excellence for Substance Abuse Treatment and
Education (CESATE) at VA Puget Sound.
NR 50
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0376-8716
EI 1879-0046
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD APR 1
PY 2016
VL 161
BP 206
EP 213
DI 10.1016/j.drugalcdep.2016.02.004
PG 8
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA DI3SP
UT WOS:000373419100026
PM 26900145
ER
PT J
AU Adappa, ND
Workman, AD
Hadjiliadis, D
Dorgan, DJ
Frame, D
Brooks, S
Doghramji, L
Palmer, JN
Mansfield, C
Reed, DR
Cohen, NA
AF Adappa, Nithin D.
Workman, Alan D.
Hadjiliadis, Denis
Dorgan, Daniel J.
Frame, Danielle
Brooks, Steven
Doghramji, Laurel
Palmer, James N.
Mansfield, Corrine
Reed, Danielle R.
Cohen, Noam A.
TI T2R38 genotype is correlated with sinonasal quality of life in
homozygous F508 cystic fibrosis patients
SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY
LA English
DT Article
DE chronic rhinosinusitis; cystic fibrosis; T2R38; SNOT-22; bitter taste
receptor; genetics
ID TASTE RECEPTOR T2R38; SINUS SURGERY; CHRONIC RHINOSINUSITIS;
PSEUDOMONAS-AERUGINOSA; PARANASAL SINUSES; INFECTION; DISEASE; NASAL;
MECHANISMS; PHENOTYPE
AB BackgroundChronic rhinosinusitis (CRS) is very prevalent in the cystic fibrosis (CF) patient population, and leads to high morbidity and markedly decreased quality of life (QOL). Identification of genetic markers that contribute to CRS symptoms in these patients can allow for risk stratification and tailoring of medical and surgical treatments. T2R38 is a bitter taste receptor expressed in the sinonasal tract, and nonfunctional alleles of this receptor have been implicated in treatment-refractory CRS in non-CF patients. The purpose of this study is to investigate the significance of T2R38 genotype in the variability of sinonasal QOL and CRS disease severity in a sample of CF patients.
MethodsF508 homozygous CF patients were recruited from the University of Pennsylvania Cystic Fibrosis Center and were genotyped for the TAS2R38 locus. To assess sinonasal symptom severity, a 22-item Sino-Nasal Outcome Test (SNOT-22) was collected from each patient. Additional demographic and medical history data was obtained at the time of patient enrollment.
ResultsA total of 49 F508 homozygous CF patients aged 18 to 32 years were included in the final SNOT-22 score analysis. Individuals with 2 functional T2R38 alleles (PAV/PAV) had significantly lower SNOT-22 scores (n = 49, p < 0.05). On further breakdown of SNOT-22 subcategories, rhinologic symptoms specifically were less severe in PAV/PAV patients than patients with other genotypes (n = 47, p < 0.05).
ConclusionOur investigation indicates that T2R38 genotype correlates both with SNOT-22 scores and rhinologic-specific QOL in F508 homozygous CF patients.
C1 [Adappa, Nithin D.; Workman, Alan D.; Brooks, Steven; Doghramji, Laurel; Palmer, James N.; Cohen, Noam A.] Univ Penn, Perelman Sch Med, Dept Otorhinolaryngol Head & Neck Surg, 5th Floor Ravdin Bldg,3400 Spruce St, Philadelphia, PA 19104 USA.
[Hadjiliadis, Denis; Dorgan, Daniel J.; Frame, Danielle] Univ Penn, Dept Med, Perelman Sch Med, Paul Harron Jr Lung Ctr, 5th Floor Ravdin Bldg,3400 Spruce St, Philadelphia, PA 19104 USA.
[Mansfield, Corrine; Reed, Danielle R.; Cohen, Noam A.] Monell Smell & Taste Ctr, Philadelphia, PA USA.
[Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Adappa, ND (reprint author), Univ Penn, Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, 5th Floor Ravdin Bldg,3400 Spruce St, Philadelphia, PA 19104 USA.
EM Nithin.Adappa@uphs.upenn.edu
FU American Rhinology Society; Cystic Fibrosis Foundation
FX American Rhinology Society (to N.D.A.); Cystic Fibrosis Foundation (to
N.D.A.).
NR 31
TC 6
Z9 6
U1 1
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2042-6976
EI 2042-6984
J9 INT FORUM ALLERGY RH
JI Int. Forum Allergy Rhinol.
PD APR
PY 2016
VL 6
IS 4
BP 356
EP 361
DI 10.1002/alr.21675
PG 6
WC Otorhinolaryngology
SC Otorhinolaryngology
GA DI6OH
UT WOS:000373618500003
PM 26678226
ER
PT J
AU Reeves, GR
Forman, DE
AF Reeves, Gordon R.
Forman, Daniel E.
TI Gait Speed: Stepping Towards Improved Assessment of Heart Failure
Patients
SO JACC-HEART FAILURE
LA English
DT Editorial Material
DE frailty; gait speed; heart failure; hospitalization; prognosis
ID PRESERVED EJECTION FRACTION; CARDIOVASCULAR HEALTH; ELDERLY-PATIENTS;
OLDER PERSONS; RISK-FACTORS; ADULTS; OUTCOMES; IMPACT; CARE
C1 [Reeves, Gordon R.] Thomas Jefferson Univ, Dept Med, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA.
[Forman, Daniel E.] Univ Pittsburgh, Med Ctr, Geriatr Cardiol Sect, Div Cardiol, Pittsburgh, PA 15213 USA.
[Forman, Daniel E.] Univ Pittsburgh, Med Ctr, Geriatr Cardiol Sect, Div Geriatr, Pittsburgh, PA 15213 USA.
[Forman, Daniel E.] VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA.
[Forman, Daniel E.] Univ Pittsburgh, Dept Med, 930 Scaife Hall, Pittsburgh, PA 15213 USA.
RP Forman, DE (reprint author), Univ Pittsburgh, Geriatr Cardiol Sect, 3471 Fifth Ave,Suite 500, Pittsburgh, PA 15213 USA.
EM formand@pitt.edu
NR 16
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2213-1779
EI 2213-1787
J9 JACC-HEART FAIL
JI JACC-Heart Fail.
PD APR
PY 2016
VL 4
IS 4
BP 299
EP 300
DI 10.1016/j.jchf.2016.02.002
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DI8KT
UT WOS:000373750600010
PM 27033017
ER
PT J
AU Atkins, D
Kansagara, D
AF Atkins, David
Kansagara, Devan
TI Reducing Readmissions-Destination or Journey?
SO JAMA INTERNAL MEDICINE
LA English
DT Editorial Material
ID CARE TRANSITIONS; RATES
C1 [Atkins, David] US Dept Vet Affairs, Off Res & Dev, Hlth Serv Res & Dev, 10P9H,810 Vermont Ave NW, Washington, DC 20420 USA.
[Kansagara, Devan] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA.
[Kansagara, Devan] Vet Affairs Portland Healthcare Syst, Portland, OR USA.
RP Atkins, D (reprint author), US Dept Vet Affairs, Off Res & Dev, Hlth Serv Res & Dev, 10P9H,810 Vermont Ave NW, Washington, DC 20420 USA.
EM David.atkins@va.gov
NR 8
TC 1
Z9 1
U1 1
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD APR
PY 2016
VL 176
IS 4
BP 493
EP 495
DI 10.1001/jamainternmed.2015.8603
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA DI3EG
UT WOS:000373380600018
PM 26954103
ER
PT J
AU McIlvennan, CK
Jones, J
Allen, LA
Swetz, KM
Nowels, C
Matlock, DD
AF McIlvennan, Colleen K.
Jones, Jacqueline
Allen, Larry A.
Swetz, Keith M.
Nowels, Carolyn
Matlock, Daniel D.
TI Bereaved Caregiver Perspectives on the End-of-Life Experience of
Patients With a Left Ventricular Assist Device
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID DESTINATION THERAPY; SUPPORT
AB IMPORTANCE For patients and their loved ones, decisions regarding the end of life in the setting of chronic progressive illness are among the most complex in health care. Complicating these decisions are increasingly available, invasive, and potentially life-prolonging technologies such as the left ventricular assist device (LVAD).
OBJECTIVE To understand the experience of bereaved caregivers and patients at the end of life who have an LVAD.
DESIGN, SETTING, AND PARTICIPANTS Semistructured, in-depth interviews were conducted between September 10 and November 21, 2014, with 8 bereaved caregivers of patients with an LVAD who were recruited from a single institution. Data were analyzed from December 13, 2014, to February 18, 2015, using a mixed inductive and deductive approach.
MAIN OUTCOMES AND MEASURES Themes from semistructured interviews.
RESULTS The 8 caregivers (6 females) described 3 main themes that coalesced around feelings of confusion in the final weeks with their loved ones: (1) the process of death with an LVAD, (2) the legal and ethically permissible care of patients with an LVAD approaching death, and (3) fragmented integration of palliative and hospice care.
CONCLUSIONS AND RELEVANCE Despite increasing use of LVADs in patients with advanced heart failure, bereaved caregivers of patients with an LVAD describe a high level of confusion at the end of life. There remains a need for the health care community to develop clear guidance on the management of patients with an LVAD at the end of life. Future work will focus on the educational process and the ideal timing and reiteration of such information to patients and families.
C1 [McIlvennan, Colleen K.; Allen, Larry A.] Univ Colorado, Sch Med, Div Cardiol, Sect Adv Heart Failure & Transplantat, 12631 E 17th Ave,Mail Code B130, Aurora, CO 80045 USA.
[McIlvennan, Colleen K.; Allen, Larry A.; Matlock, Daniel D.] Univ Colorado, Sch Med, Colorado Cardiovasc Outcomes Res Consortium, 12631 E 17th Ave,Mail Code B130, Aurora, CO 80045 USA.
[Jones, Jacqueline] Univ Colorado, Sch Nursing, 12631 E 17th Ave,Mail Code B130, Aurora, CO 80045 USA.
[Nowels, Carolyn; Matlock, Daniel D.] Univ Colorado, Sch Med, Div Gen Internal Med, 12631 E 17th Ave,Mail Code B130, Aurora, CO 80045 USA.
[Swetz, Keith M.] Birmingham VA Med Ctr, Dept Vet Affairs, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Birmingham, AL USA.
[Swetz, Keith M.] Univ Alabama Birmingham, Ctr Palliat & Support Care, Birmingham, AL USA.
RP McIlvennan, CK (reprint author), Univ Colorado, Sch Med, Div Cardiol, Sect Adv Heart Failure & Transplantat, 12631 E 17th Ave,Mail Code B130, Aurora, CO 80045 USA.
EM colleen.mcilvennan@ucdenver.edu
NR 28
TC 5
Z9 5
U1 1
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD APR
PY 2016
VL 176
IS 4
BP 534
EP 539
DI 10.1001/jamainternmed.2015.8528
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA DI3EG
UT WOS:000373380600026
PM 26998594
ER
PT J
AU Kerlikowske, K
AF Kerlikowske, Karla
TI Progress Toward Consensus on Breast Cancer Screening Guidelines and
Reducing Screening Harms Reply
SO JAMA INTERNAL MEDICINE
LA English
DT Letter
ID WOMEN
C1 [Kerlikowske, Karla] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Kerlikowske, Karla] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Kerlikowske, Karla] Univ Calif San Francisco, Dept Vet Affairs, Gen Internal Med Sect, San Francisco, CA 94143 USA.
RP Kerlikowske, K (reprint author), San Francisco VA Med Ctr, Gen Internal Med Sect, 4150 Clement St,111A1, San Francisco, CA 94121 USA.
EM karla.kerlikowske@ucsf.edu
FU NCI NIH HHS [P01 CA154292, P01CA154292]
NR 6
TC 0
Z9 0
U1 2
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD APR
PY 2016
VL 176
IS 4
BP 562
EP 563
DI 10.1001/jamainternmed.2016.0225
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA DI3EG
UT WOS:000373380600043
PM 27043108
ER
PT J
AU Hauberg, ME
Roussos, P
Grove, J
Borglum, AD
Mattheisen, M
AF Hauberg, Mads Engel
Roussos, Panos
Grove, Jakob
Borglum, Anders Dupont
Mattheisen, Manuel
CA Psychiat Genomics Consortium
TI Analyzing the Role of MicroRNAs in Schizophrenia in the Context of
Common Genetic Risk Variants
SO JAMA PSYCHIATRY
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; SYNAPTIC PLASTICITY; TARGET GENES; BRAIN; LOCI;
NEUROGENESIS; ARCHITECTURE; ENRICHMENT; DATABASE; DISEASE
AB IMPORTANCE The recent implication of 108 genomic loci in schizophrenia marked a great advancement in our understanding of the disease. Against the background of its polygenic nature there is a necessity to identify how schizophrenia risk genes interplay. As regulators of gene expression, microRNAs (miRNAs) have repeatedly been implicated in schizophrenia etiology. It is therefore of interest to establish their role in the regulation of schizophrenia risk genes in disease-relevant biological processes.
OBJECTIVE To examine the role of miRNAs in schizophrenia in the context of disease-associated genetic variation.
DESIGN, SETTING, AND PARTICIPANTS The basis of this study was summary statistics from the largest schizophrenia genome-wide association study meta-analysis to date (83 550 individuals in a meta-analysis of 52 genome-wide association studies) completed in 2014 along with publicly available data for predicted miRNA targets. We examined whether schizophrenia risk genes were more likely to be regulated by miRNA. Further, we used gene set analyses to identify miRNAs that are regulators of schizophrenia risk genes.
MAIN OUTCOMES AND MEASURES Results from association tests for miRNA targetomes and related analyses.
RESULTS In line with previous studies, we found that similar to other complex traits, schizophrenia risk genes were more likely to be regulated by miRNAs (P < 2 x 10(-16)). Further, the gene set analyses revealed several miRNAs regulating schizophrenia risk genes, with the strongest enrichment for targets of miR-9-5p (P = .0056 for enrichment among the top 1% most-associated single-nucleotide polymorphisms, corrected for multiple testing). It is further of note that MIR9-2 is located in a genomic region showing strong evidence for association with schizophrenia (P = 7.1 x 10(-8)). The second and third strongest gene set signals were seen for the targets of miR-485-5p and miR-137, respectively.
CONCLUSIONS AND RELEVANCE This study provides evidence for a role of miR-9-5p in the etiology of schizophrenia. Its implication is of particular interest as the functions of this neurodevelopmental miRNA tie in with established disease biology: it has a regulatory loop with the fragile X mental retardation homologue FXR1 and regulates dopamine D-2 receptor density.
C1 [Hauberg, Mads Engel; Grove, Jakob; Borglum, Anders Dupont; Mattheisen, Manuel] Aarhus Univ, Dept Biomed, iPSYCH, Wilhelm Meyers Alle 1, DK-8000 Aarhus C, Denmark.
[Hauberg, Mads Engel; Grove, Jakob; Borglum, Anders Dupont; Mattheisen, Manuel] Lundbeck Fdn Initiat Integrat Psychiat Res, iPSYCH, Lundbeck, Denmark.
[Hauberg, Mads Engel; Grove, Jakob; Borglum, Anders Dupont; Mattheisen, Manuel] Aarhus Univ, Ctr Integrat Sequencing, iPSYCH, DK-8000 Aarhus C, Denmark.
[Roussos, Panos] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.
[Roussos, Panos] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA.
[Roussos, Panos] Icahn Sch Med Mt Sinai, Inst Genom & Multiscale Biol, New York, NY 10029 USA.
[Roussos, Panos] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA.
[Roussos, Panos] James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA.
[Grove, Jakob] Aarhus Univ, Bioinformat Res Ctr, DK-8000 Aarhus C, Denmark.
[Borglum, Anders Dupont] Aarhus Univ Hosp, Res Dept P, iPSYCH, Risskov, Denmark.
[Borglum, Anders Dupont] Aarhus Univ, Dept Clin Med, Translat Neuropsychiat Unit, iPSYCH, DK-8000 Aarhus C, Denmark.
RP Mattheisen, M (reprint author), Aarhus Univ, Dept Biomed, iPSYCH, Wilhelm Meyers Alle 1, DK-8000 Aarhus C, Denmark.
EM mm@biomed.au.dk
RI Roussos, Panos/J-7090-2013
OI Roussos, Panos/0000-0002-4640-6239; Grove, Jakob/0000-0003-2284-5744
FU Lundbeck Foundation; Centre for Integrative Sequencing, Aarhus
University; Faculty of Health, Aarhus University
FX This work was supported by the Lundbeck Foundation; the Centre for
Integrative Sequencing, Aarhus University; and the Faculty of Health,
Aarhus University.
NR 47
TC 5
Z9 5
U1 1
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-622X
EI 2168-6238
J9 JAMA PSYCHIAT
JI JAMA Psychiatry
PD APR
PY 2016
VL 73
IS 4
BP 369
EP 377
DI 10.1001/jamapsychiatry.2015.3018
PG 9
WC Psychiatry
SC Psychiatry
GA DI4BI
UT WOS:000373444700012
PM 26963595
ER
PT J
AU Painter, JM
Kring, AM
AF Painter, Janelle M.
Kring, Ann M.
TI Toward an Understanding of Anticipatory Pleasure Deficits in
Schizophrenia: Memory, Prospection, and Emotion Experience
SO JOURNAL OF ABNORMAL PSYCHOLOGY
LA English
DT Article
DE schizophrenia; memory; prospection; emotion; narratives
ID MENTAL TIME-TRAVEL; AUTOBIOGRAPHICAL MEMORY; NEGATIVE SYMPTOMS;
COGNITIVE NEUROSCIENCE; AFFECTIVE REACTIVITY; FUTURE; IMAGINE; THINKING;
EVENTS; BRAIN
AB Anticipatory pleasure deficits have been observed in people with schizophrenia. Less is known about the extent to which interrelated processes that comprise anticipatory pleasure, including memory, prospection, and emotion experience are disrupted. We asked people with (n = 32) and without (n = 29) schizophrenia or schizoaffective disorder to provide memory and prospection narratives in response to specific cues. Half of the prospections followed a memory task, and half followed a control task. People with schizophrenia generated memories similar in content and experience as controls even as they described them less clearly. However, people with schizophrenia were less likely to explicitly reference the past in their prospections, and their prospections were less detailed and richly experienced than controls, regardless of the task completed before prospection. People with schizophrenia reported similar levels of positive emotion (current and predicted) in positive prospections that followed the memory task, but less positive emotion than controls in positive prospections that followed the control task. Taken together, these results suggest that people with schizophrenia experience difficulties drawing from past experiences and generating detailed prospections. However, asking people with schizophrenia to recall and describe memories prior to prospection may increase the likelihood of drawing from the past in prospections, and may help boost current and predicted pleasure.
C1 [Painter, Janelle M.; Kring, Ann M.] Univ Calif Berkeley, Berkeley, CA 94720 USA.
[Painter, Janelle M.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Painter, JM (reprint author), Vet Affairs Puget Sound Hlth Care Syst, 1660 South Columbian Way S-116, Seattle, WA 98108 USA.
EM janelle.painter@va.gov
FU National Institutes of Health Grant [1R01MH082890]
FX This study was supported in part by National Institutes of Health Grant
1R01MH082890 to Ann M. Kring.
NR 46
TC 0
Z9 0
U1 4
U2 5
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0021-843X
EI 1939-1846
J9 J ABNORM PSYCHOL
JI J. Abnorm. Psychol.
PD APR
PY 2016
VL 125
IS 3
BP 442
EP 452
DI 10.1037/abn0000151
PG 11
WC Psychology, Clinical; Psychology, Multidisciplinary
SC Psychology
GA DI7XE
UT WOS:000373714500012
PM 26950753
ER
PT J
AU Rudd-Barnard, G
Walbom, A
Pangarkar, S
Baria, A
AF Rudd-Barnard, G.
Walbom, A.
Pangarkar, S.
Baria, A.
TI A case study investigating opioid medication utilization in patients
with complex regional pain syndrome before and after ketamine infusion
therapy
SO JOURNAL OF PAIN
LA English
DT Meeting Abstract
C1 [Rudd-Barnard, G.; Walbom, A.; Pangarkar, S.; Baria, A.] Univ Calif Los Angeles, Greater Los Angeles VA Hlth Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1526-5900
J9 J PAIN
JI J. Pain
PD APR
PY 2016
VL 17
IS 4
SU 1
MA 406
BP S76
EP S76
PG 1
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DI5EZ
UT WOS:000373523000305
PM 28162651
ER
PT J
AU Rudd-Barnard, G
Pangarkar, S
Moaleji, N
Glassman, P
AF Rudd-Barnard, G.
Pangarkar, S.
Moaleji, N.
Glassman, P.
TI Epidemiology of naloxone use for opioid overdose in a tertiary care
medical center
SO JOURNAL OF PAIN
LA English
DT Meeting Abstract
C1 [Rudd-Barnard, G.; Pangarkar, S.; Moaleji, N.; Glassman, P.] Greater Los Angeles VA Hlth Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1526-5900
J9 J PAIN
JI J. Pain
PD APR
PY 2016
VL 17
IS 4
SU 1
MA 141
BP S11
EP S11
PG 1
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DI5EZ
UT WOS:000373523000043
PM 28162348
ER
PT J
AU Stegner, A
Cook, D
AF Stegner, A.
Cook, D.
TI Resistance exercise training in Gulf War Veterans with chronic
unexplained muscle pain: impact on pain, fatigue, mood and global
impression of change
SO JOURNAL OF PAIN
LA English
DT Meeting Abstract
C1 [Stegner, A.; Cook, D.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1526-5900
J9 J PAIN
JI J. Pain
PD APR
PY 2016
VL 17
IS 4
SU 1
MA 484
BP S95
EP S96
PG 2
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DI5EZ
UT WOS:000373523000382
PM 28162735
ER
PT J
AU Katz, DA
Stewart, K
Paez, M
Holman, J
Adams, SL
Vander Weg, MW
Battaglia, CT
Joseph, AM
Titler, MG
Ono, S
AF Katz, David A.
Stewart, Kenda
Paez, Monica
Holman, John
Adams, Susan L.
Vander Weg, Mark W.
Battaglia, Catherine T.
Joseph, Anne M.
Titler, Marita G.
Ono, Sarah
TI "Let Me Get You a Nicotine Patch": Nurses' Perceptions of Implementing
Smoking Cessation Guidelines for Hospitalized Veterans
SO MILITARY MEDICINE
LA English
DT Article
ID CONTROLLED-TRIAL; STANDARDIZED PATIENTS; CARE; SERVICE; INTERVENTIONS;
PREVENTION; PROGRAM
AB Many hospitalized smokers do not receive guideline-recommended tobacco treatment, but little is known about the perceptions of inpatient nurses with regard to tobacco treatment. We used a sequential explanatory mixed methods design to help explain the findings of an academic detailing intervention trial on the inpatient medicine units of four Veterans Affairs (VA) hospitals. We surveyed 164 nurses and conducted semistructured interviews in a purposeful sample of 33 nurses with different attitudes toward cessation counseling. Content analysis was used to inductively characterize the issues raised by participants. Emerging themes were categorized using the knowledge-attitudes-behavior framework of guideline adherence. Knowledge-related and attitudinal barriers included perceived lack of skills in cessation counseling and skepticism about the effectiveness of cessation guidelines in hospitalized veterans. Nurses also reported multiple behavioral and organizational barriers to guideline adherence: resistance from patients, insufficient time and resources, the presence of smoking areas on VA premises, and lack of coordination with primary care. VA hospitals should train inpatient staff how to negotiate behavior change, integrate cessation counseling into nurses' workflow, develop alternative referral mechanisms for post-discharge cessation counseling, and adopt hospital policies to promote inpatient abstinence.
C1 [Katz, David A.; Stewart, Kenda; Paez, Monica; Holman, John; Adams, Susan L.; Vander Weg, Mark W.; Ono, Sarah] Iowa City VA Hlth Care Syst, Comprehens Access & Delivery Res & Evaluat CADRE, Iowa City, IA USA.
[Katz, David A.; Vander Weg, Mark W.] Univ Iowa, Dept Med, Iowa City, IA 52242 USA.
[Katz, David A.] Univ Iowa, Dept Epidemiol, Iowa City, IA USA.
[Vander Weg, Mark W.] Univ Iowa, Dept Psychol, Iowa City, IA 52242 USA.
[Battaglia, Catherine T.] VA Eastern Colorado Hlth Care Syst, Dept Med, Denver, CO USA.
[Battaglia, Catherine T.] Denver Seattle Ctr Vet Centr Value Based Res DiSC, Denver, CO USA.
Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA.
[Titler, Marita G.] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA.
[Ono, Sarah] Portland VA Med Ctr, Ctr Improve Vet Involvement Care, Portland, OR USA.
RP Katz, DA (reprint author), Iowa City VA Hlth Care Syst, Comprehens Access & Delivery Res & Evaluat CADRE, Iowa City, IA USA.
FU Veterans Affairs Health Services Research and Development [IIR 07-113]
FX The authors acknowledge Jonathan Thomas for assistance with
transcription of in-depth interviews, George Bailey, MS and Ray Opiola
for assisting with database design and data management, Bonnie
Bootsmiller, PhD and Sue Kieffer for administrative support, and
Jennifer Reed for assistance with manuscript preparation. This work was
funded by the Veterans Affairs Health Services Research and Development
(IIR 07-113).
NR 41
TC 2
Z9 2
U1 4
U2 6
PU ASSOC MILITARY SURG US
PI BETHESDA
PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA
SN 0026-4075
EI 1930-613X
J9 MIL MED
JI Milit. Med.
PD APR
PY 2016
VL 181
IS 4
BP 373
EP 382
DI 10.7205/MILMED-D-15-00101
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA DI3NO
UT WOS:000373405600015
PM 27046185
ER
PT J
AU Mayer, VL
McDonough, K
Seligman, H
Mitra, N
Long, JA
AF Mayer, Victoria L.
McDonough, Kevin
Seligman, Hilary
Mitra, Nandita
Long, Judith A.
TI Food insecurity, coping strategies and glucose control in low-income
patients with diabetes
SO PUBLIC HEALTH NUTRITION
LA English
DT Article
DE Diabetes; Nutrition; Vulnerable populations; Socio-economic factors;
Disease management
ID NUTRITION ASSISTANCE PROGRAM; OF-THE-LITERATURE; GLYCEMIC CONTROL;
DIETARY QUALITY; ADULTS; HEALTH; MANAGEMENT; OBESITY; PARTICIPANTS;
SUFFICIENCY
AB Objective: To examine the relationship between food insecurity and coping strategies (actions taken to manage economic stress) hypothesized to worsen glucose control in patients with diabetes.
Design: Using a cross-sectional telephone survey and clinical data, we compared food-insecure and food-secure individuals in their use of coping strategies. Using logistic regression models, we then examined the association between poor glucose control (glycated Hb, HbA1c >= 8.0 %), food insecurity and coping strategies.
Setting: An urban medical centre, between June and December 2013.
Subjects: Four hundred and seven adults likely to be low income (receiving Medicaid or uninsured and/or residing in a zip code with >30 % of the population below the federal poverty level) with type 2 diabetes.
Results: Of respondents, 40.5 % were food insecure. A significantly higher percentage of the food-insecure group reported use of most examined coping strategies, including foregone medical care, participation in the Supplemental Nutrition Assistance Program (SNAP)) and use of emergency food programmes. Food insecurity was associated with poor glucose control (OR=2.23; 95 % CI 1.22, 4.10); coping strategies that were more common among the food insecure were not associated with poor glucose control. Among the food insecure, receipt of SNAP was associated with lower risk of poor glucose control (OR=0.27; 95 % CI 0.09, 0.80).
Conclusions: While food insecurity was associated with poor glucose control, most examined coping strategies did not explain this relationship. However, receipt of SNAP among food-insecure individuals was associated with better diabetes control, suggesting that such programmes may play a role in improving health.
C1 [Mayer, Victoria L.] Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, 1 Gustave L Levy Pl,Box 1077, New York, NY 10029 USA.
[Mayer, Victoria L.] Icahn Sch Med Mt Sinai, Dept Med, Div Gen Internal Med, New York, NY 10029 USA.
[McDonough, Kevin] Univ Penn, Sch Arts & Sci, Philadelphia, PA 19104 USA.
[Seligman, Hilary] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA.
[Mitra, Nandita] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
[Mitra, Nandita; Long, Judith A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Long, Judith A.] Univ Penn, Dept Med, Perelman Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA.
[Long, Judith A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
RP Mayer, VL (reprint author), Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, 1 Gustave L Levy Pl,Box 1077, New York, NY 10029 USA.; Mayer, VL (reprint author), Icahn Sch Med Mt Sinai, Dept Med, Div Gen Internal Med, New York, NY 10029 USA.
EM victoria.mayer@mountsinai.org
FU Division of General Internal Medicine Matt Slap Award from the Perelman
School of Medicine at the University of Pennsylvania; National
Institutes of Health Institutional Training Grant
[5-T32-HP-100296-20-00]; Empire Clinical Research Investigator Program
FX V.L.M. was supported with funding from the Division of General Internal
Medicine Matt Slap Award from the Perelman School of Medicine at the
University of Pennsylvania and the National Institutes of Health
Institutional Training Grant 5-T32-HP-100296-20-00. She is currently
supported by the Empire Clinical Research Investigator Program
(Investigator Dr Carol Horowitz). The funders had no role in the design,
analysis, or writing of this article.Principal
NR 52
TC 0
Z9 0
U1 3
U2 11
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 1368-9800
EI 1475-2727
J9 PUBLIC HEALTH NUTR
JI Public Health Nutr.
PD APR
PY 2016
VL 19
IS 6
BP 1103
EP 1111
DI 10.1017/S1368980015002323
PG 9
WC Public, Environmental & Occupational Health; Nutrition & Dietetics
SC Public, Environmental & Occupational Health; Nutrition & Dietetics
GA DI7US
UT WOS:000373708100019
PM 26328922
ER
PT J
AU Pierre, JM
Gandal, M
Son, M
AF Pierre, Joseph M.
Gandal, Michael
Son, Maya
TI Cannabis-induced psychosis associated with high potency "wax dabs"
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Marijuana; Tetrahydrocannabinol; Cannabis; Cannabis oil; Cannabis wax;
Cannabis-induced psychosis, catatonia
ID MARIJUANA; DANGERS; RISK
AB With mounting evidence that the risk of cannabis-induced psychosis may be related to both dose and potency of tetrahydrocannbinol (THC), increasing reports of psychosis associated with cannabinoids containing greater amounts of THC are anticipated. We report two cases of emergent psychosis after using a concentrated THC extract known as cannabis "wax," "oil," or "dabs" raising serious concerns about its psychotic liability. Although "dabbing" with cannabis wax is becoming increasingly popular in the US for both recreational and "medicinal" intentions, our cases raise serious concerns about its psychotic liability and highlight the importance of understanding this risk by physicians recommending cannabinoids for purported medicinal purposes. Published by Elsevier B.V.
C1 [Pierre, Joseph M.; Gandal, Michael] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Pierre, Joseph M.] VA Greater Los Angeles Healthcare Syst, Dept Vet Affairs, Los Angeles, CA USA.
[Son, Maya] Univ Vermont, Coll Med, Burlington, VT USA.
RP Pierre, JM (reprint author), 11301 Wilshire Blvd,Bldg 210 Room15, Los Angeles, CA 90073 USA.
EM joseph.pierre2@va.gov
NR 10
TC 2
Z9 2
U1 4
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
EI 1573-2509
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD APR
PY 2016
VL 172
IS 1-3
BP 211
EP 212
DI 10.1016/j.schres.2016.01.056
PG 2
WC Psychiatry
SC Psychiatry
GA DI5GY
UT WOS:000373528100034
PM 26876313
ER
PT J
AU Leung, AM
Korevaar, TIM
Peeters, RP
Zoeller, RT
Kohrle, J
Duntas, LH
Brent, GA
Demeneix, BA
AF Leung, Angela M.
Korevaar, Tim I. M.
Peeters, Robin P.
Zoeller, R. Thomas
Koehrle, Josef
Duntas, Leonidas H.
Brent, Gregory A.
Demeneix, Barbara A.
TI Exposure to Thyroid-Disrupting Chemicals: A Transatlantic Call for
Action
SO THYROID
LA English
DT Editorial Material
C1 [Leung, Angela M.; Brent, Gregory A.] Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol, Los Angeles, CA 90095 USA.
[Leung, Angela M.; Brent, Gregory A.] VA Greater Los Angeles Healthcare Syst, Div Endocrinol, Los Angeles, CA USA.
[Korevaar, Tim I. M.; Peeters, Robin P.] Erasmus MC, Generat R Study Grp, Rotterdam, Netherlands.
[Korevaar, Tim I. M.; Peeters, Robin P.] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
[Korevaar, Tim I. M.; Peeters, Robin P.] Erasmus MC, Rotterdam Thyroid Ctr, Rotterdam, Netherlands.
[Zoeller, R. Thomas] Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA.
[Zoeller, R. Thomas] Univ Massachusetts, Program Mol & Cellular Biol, Amherst, MA 01003 USA.
[Koehrle, Josef] Charite, Inst Expt Endokrinol, D-13353 Berlin, Germany.
[Duntas, Leonidas H.] Univ Athens, Thyroid Unit, Evgenid Hosp, Athens, Greece.
[Demeneix, Barbara A.] Museum Natl Hist Nat, Dept Regulat Dev & Diversite Mol, Evolut Regulat Endocriniennes, F-75231 Paris, France.
RP Leung, AM (reprint author), VA Greater Angeles Healthcare Syst, Div Endocrinol 111D, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM amleung@mednet.ucla.edu
OI Kohrle, Josef/0000-0002-9187-9078
FU NICHD NIH HHS [K23HD068552, K23 HD068552]
NR 4
TC 3
Z9 3
U1 1
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1050-7256
EI 1557-9077
J9 THYROID
JI Thyroid
PD APR 1
PY 2016
VL 26
IS 4
BP 479
EP 480
DI 10.1089/thy.2016.0077
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DI1DY
UT WOS:000373237400001
PM 26906244
ER
PT J
AU Greiman, A
Shah, J
Bhavsar, R
Armeson, K
Caulder, S
Jones, R
Keane, TE
Clarke, HS
Savage, SJ
AF Greiman, Alyssa
Shah, Jaimin
Bhavsar, Robin
Armeson, Kent
Caulder, Susan
Jones, Rabun
Keane, Thomas E.
Clarke, Harry S.
Savage, Stephen J.
TI Six Weeks of Fluoroquinolone Antibiotic Therapy for Patients With
Elevated Serum Prostate-specific Antigen Is Not Clinically Beneficial: A
Randomized Controlled Clinical Trial
SO UROLOGY
LA English
DT Article
ID PSA LEVELS; CANCER; BIOPSY; BENIGN; MARKER
AB OBJECTIVE To evaluate asymptomatic men with elevated serum prostate-specific antigen (PSA) to determine whether a 6-week course of fluoroquinolone antibiotics lowers serum PSA and affects recommendations for prostate biopsy.
MATERIALS AND METHODS A randomized, single-center prospective trial of 150 men with an initial elevated PSA was conducted. Patients were randomized to 6 weeks of ciprofloxacin or observation. Those patients with persistently elevated PSA were recommended to proceed with transrectal ultrasound-guided 12-core biopsy. Those with reduced PSA were offered transrectal ultrasound-guided biopsy but could opt to continue serial digital rectal examination/PSA. Patients were followed an average of 4.6 years to assess trends in PSA and biopsy results.
RESULTS Of 136 men who completed the trial, 63 were in the treatment and 73 were in the observation group. The average PSA change from baseline was borderline statistically significant with a change of -0.68 ng/mL in the treatment arm and 0.01 ng/mL in the observation arm (P = .052). Of those who underwent biopsy, prostate cancer was diagnosed in the first biopsy in 24 (63%) of the treatment vs 27 (52%) of the observation group (P = .60) over follow-up.
CONCLUSION In a cohort of asymptomatic men with elevated PSA, there was only a borderline statistically significant change in serum PSA between patients randomized to a 6-week course of fluoroquinolones vs observation, and there was no difference in positive prostate biopsy results. Our clinical recommendation is one should not treat patients with elevated serum PSA with antibiotics in the absence of clinical symptoms of prostatitis. Published by Elsevier Inc.
C1 [Greiman, Alyssa; Shah, Jaimin; Bhavsar, Robin; Armeson, Kent; Caulder, Susan; Jones, Rabun; Keane, Thomas E.; Clarke, Harry S.; Savage, Stephen J.] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Dept Urol, Urol Sect, 96 Jonathan Lucas St,CSB 644, Charleston, SC 29425 USA.
RP Greiman, A (reprint author), Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Dept Urol, Urol Sect, 96 Jonathan Lucas St,CSB 644, Charleston, SC 29425 USA.
EM greiman@musc.edu
NR 30
TC 1
Z9 1
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0090-4295
EI 1527-9995
J9 UROLOGY
JI Urology
PD APR
PY 2016
VL 90
BP 32
EP 37
DI 10.1016/j.urology.2015.11.046
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA DI4JT
UT WOS:000373466900017
PM 26802800
ER
PT J
AU Vasilevskis, EE
Kripalani, S
Ong, MK
Rosenthal, JT
Longnecker, DE
Harmon, B
Hohmann, SF
Wright, K
Black, JT
AF Vasilevskis, Eduard E.
Kripalani, Sunil
Ong, Michael K.
Rosenthal, J. Thomas
Longnecker, David E.
Harmon, Brian
Hohmann, Samuel F.
Wright, Kelly
Black, Jeanne T.
TI Variability in Implementation of Interventions Aimed at Reducing
Readmissions Among Patients With Heart
SO ACADEMIC MEDICINE
LA English
DT Article
ID HOSPITAL READMISSIONS; 30-DAY READMISSIONS; RANDOMIZED-TRIALS;
TRANSITIONAL CARE; FAILURE PATIENTS; PALLIATIVE CARE; HEALTH-CARE;
FOLLOW-UP; STRATEGIES; RATES
AB Purpose To highlight teaching hospitals' efforts to reduce readmissions by describing interventions implemented to improve care transitions for heart failure (HF) patients and the variability in implemented HF-specific and care transition interventions.
Method In 2012, the authors surveyed a network of 17 teaching hospitals to capture information about the number, type, stage of implementation, and structure of 4 HF-specific and 21 care transition (predischarge, bridging, and postdischarge) interventions implemented to reduce readmissions among patients with HF. The authors summarized data using descriptive statistics, including the mean number of interventions implemented and the frequency and stage of specific interventions, and descriptive plots of the structure of two common interventions (multidisciplinary rounds and follow-up telephone calls).
Results Sixteen hospitals (94%) responded. The number and stage of implementation of the HF-specific and care transition interventions implemented varied across institutions. The mean number of interventions at an advanced stage of implementation (i.e., implemented for 75% of HF patients on the cardiology service or on all services) was 10.9 (standard deviation = 4.3). Overall, predischarge interventions were more common than bridging or postdischarge interventions. There was variability in the personnel involved in multidisciplinary rounds and in the processes/content of follow-up telephone calls.
Conclusions Teaching hospitals have implemented a wide range of interventions aimed at reducing hospital readmissions, but there is substantial variability in the types, stages, and structure of their interventions. This heterogeneity highlights the need for collaborative efforts to improve understanding of intervention effectiveness.
C1 [Vasilevskis, Eduard E.] Vanderbilt Univ, Dept Med, Div Gen Internal Med & Publ Hlth, Med,Sect Hosp Med, Nashville, TN 37232 USA.
[Vasilevskis, Eduard E.] VA Tennessee Valley Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Nashville, TN USA.
[Kripalani, Sunil] Vanderbilt Univ, Dept Med, Div Gen Internal Med & Publ Hlth, Ctr Clin Qual & Implementat Res,Sect Hosp Med, Nashville, TN 37232 USA.
[Ong, Michael K.] Univ Calif Los Angeles, Dept Med, Med, Los Angeles, CA 90024 USA.
[Ong, Michael K.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA.
[Rosenthal, J. Thomas] Univ Calif Los Angeles Hlth Syst, Los Angeles, CA USA.
[Longnecker, David E.] Univ Penn, Anesthesiol, Philadelphia, PA 19104 USA.
[Longnecker, David E.] Coalit Transform Adv Care, Washington, DC USA.
[Harmon, Brian] Childrens Hosp & Clin Minnesota, Minneapolis, MN USA.
[Hohmann, Samuel F.] Univ HealthSyst Consortium, Comparat Data & Informat Res, Chicago, IL USA.
[Hohmann, Samuel F.] Rush Univ, Dept Hlth Syst Management, Chicago, IL 60612 USA.
[Wright, Kelly] Vanderbilt Univ, Div Gen Internal Med & Publ Hlth, Sect Hosp Med, Dept Med, Nashville, TN 37232 USA.
[Black, Jeanne T.] Cedars Sinai Hlth Syst, Hlth Policy & Program Evaluat, Los Angeles, CA USA.
RP Vasilevskis, EE (reprint author), Vanderbilt Univ, Med Ctr, 1215 21st Ave S,6006 Med Ctr East NT, Nashville, TN 37232 USA.
EM eduard.vasilevskis@vanderbilt.edu
FU National Institutes of Health [K23 AG040157]; Tennessee Valley Geriatric
Research, Education and Clinical Center (GRECC); Robert Wood Johnson
Foundation [RWJF 67627]
FX Funding for E.E. Vasilevskis was provided by the National Institutes of
Health (K23 AG040157) and the Tennessee Valley Geriatric Research,
Education and Clinical Center (GRECC). The Variations Collaborative
Study Group additionally received support from the Robert Wood Johnson
Foundation (RWJF 67627).
NR 40
TC 2
Z9 2
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-2446
EI 1938-808X
J9 ACAD MED
JI Acad. Med.
PD APR
PY 2016
VL 91
IS 4
BP 522
EP 529
PG 8
WC Education, Scientific Disciplines; Health Care Sciences & Services
SC Education & Educational Research; Health Care Sciences & Services
GA DH6XW
UT WOS:000372936400027
PM 26579793
ER
PT J
AU Hser, YI
Evans, E
Huang, D
Weiss, R
Saxon, A
Carroll, KM
Woody, G
Liu, D
Wakim, P
Matthews, AG
Hatch-Maillette, M
Jelstrom, E
Wiest, K
McLaughlin, P
Ling, W
AF Hser, Yih-Ing
Evans, Elizabeth
Huang, David
Weiss, Robert
Saxon, Andrew
Carroll, Kathleen M.
Woody, George
Liu, David
Wakim, Paul
Matthews, Abigail G.
Hatch-Maillette, Mary
Jelstrom, Eve
Wiest, Katharina
McLaughlin, Paul
Ling, Walter
TI Long-term outcomes after randomization to buprenorphine/naloxone versus
methadone in a multi-site trial
SO ADDICTION
LA English
DT Article
DE Buprenorphine; methadone; opioid dependence; longitudinal; outcomes;
opioid use; mortality
ID MAINTENANCE THERAPY; OPIOID DEPENDENCE; RETENTION; ADDICTION;
METHAMPHETAMINE; PERSPECTIVES; MEDICATION; HEALTH; ENTRY; USERS
AB AimsTo compare long-term outcomes among participants randomized to buprenorphine or methadone.
Design, Setting and ParticipantsFollow-up was conducted in 2011-14 of 1080 opioid-dependent participants entering seven opioid treatment programs in the United States between 2006 and 2009 and randomized (within each program) to receive open-label buprenorphine/naloxone or methadone for up to 24weeks; 795 participants completed in-person interviews (similar to 74% follow-up interview rate) covering on average 4.5years.
MeasurementsOutcomes were indicated by mortality and opioid use. Covariates included demographics, site, cocaine use and treatment experiences.
FindingsMortality was not different between the two randomized conditions, with 23 (3.6%) of 630 participants randomized to buprenorphine having died versus 26 (5.8%) of 450 participants randomized to methadone. Opioid use at follow-up was higher among participants randomized to buprenorphine relative to methadone [42.8 versus 31.7% positive opioid urine specimens, P<0.01, effect size (h)=0.23 (0.09, 0.38); 5.8days versus 4.4days of past 30-day heroin use, P<0.05, effect size (d)=0.14 (0.00, 0.28)]. Opioid use during the follow-up period by randomization condition was also significant (F-(7,F-39600)=3.16; P<0.001) due mainly to less treatment participation among participants randomized to buprenorphine than methadone. Less opioid use was associated with both buprenorphine and methadone treatment (relative to no treatment); no difference was found between the two treatments. Individuals who are white or used cocaine at baseline responded better to methadone than to buprenorphine.
ConclusionsThere are few differences in long-term outcomes between buprenorphine and methadone treatment for opioid dependence, and treatment with each medication is associated with a strong reduction in opioid use.
C1 [Hser, Yih-Ing; Evans, Elizabeth; Huang, David; Weiss, Robert; Ling, Walter] Univ Calif Los Angeles, Los Angeles, CA USA.
[Saxon, Andrew] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Carroll, Kathleen M.] Yale Univ, Sch Med, New Haven, CT USA.
[Woody, George] Univ Penn, Philadelphia, PA 19104 USA.
[Liu, David; Wakim, Paul] NIDA, Bethesda, MD 20892 USA.
[Matthews, Abigail G.; Jelstrom, Eve] Emmes Corp, Rockville, MD USA.
[Hatch-Maillette, Mary] Univ Washington, Seattle, WA 98195 USA.
[Wiest, Katharina] CODA Inc, Portland, OR USA.
[McLaughlin, Paul] Hartford Dispensary, Hartford, CT USA.
RP Hser, YI (reprint author), Univ Calif Los Angeles, Integrated Subst Abuse Programs, 11075 Santa Monica Blvd,Suite 200, Los Angeles, CA USA.
EM yhser@ucla.edu
FU National Institute on Drug Abuse (NIDA) through the Clinical Trials
Network (CTN) [U10 DA01714, U10 DA 015815, U10 DA13038, U10 DA13043, U10
DA13045]; NIDA [P30DA016383]
FX The corresponding author, Yih-Ing Hser, has full access to all of the
data in the study and takes responsibility for the integrity of the data
and the accuracy of the data analysis. Sincere appreciation to our
participating networks: the Pacific Northwest Node and Evergreen
Treatment Services; the Western States Node and CODA Inc. and Bi-Valley
Medical Clinic; the New England Node and Connecticut Counseling Centers
and Yale and Hartford Dispensary; the Delaware Valley Node and NET
Steps; the Pacific Region Node and Matrix Institute; and the EMMES
Corporation (CCC); the CCTN and NIDA. The main study funding was
provided by the National Institute on Drug Abuse (NIDA) through the
Clinical Trials Network (CTN) through a series of grants provided to
each participating node: the Pacific Northwest Node (U10 DA01714); the
Western States Node (U10 DA 015815); the New England Node (U10 DA13038);
the Delaware Valley Node (U10 DA13043); and he Pacific Region Node (U10
DA13045). Funding was also provided by NIDA through grant number
P30DA016383.
NR 29
TC 2
Z9 2
U1 5
U2 14
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0965-2140
EI 1360-0443
J9 ADDICTION
JI Addiction
PD APR
PY 2016
VL 111
IS 4
BP 695
EP 705
DI 10.1111/add.13238
PG 11
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA DH6NM
UT WOS:000372907400022
PM 26599131
ER
PT J
AU Axon, RN
Gebregziabher, M
Everett, CJ
Heidenreich, P
Hunt, KJ
AF Axon, R. Neal
Gebregziabher, Mulugeta
Everett, Charles J.
Heidenreich, Paul
Hunt, Kelly J.
TI Dual health care system use is associated with higher rates of
hospitalization and hospital readmission among veterans with heart
failure
SO AMERICAN HEART JOURNAL
LA English
DT Article
ID GUIDELINES PROGRAM; AMBULATORY-CARE; MEDICARE; OUTCOMES; INPATIENT;
MORTALITY; ADMISSION; SERVICES; REGRESSION; PATIENT
AB Background Heart failure (HF) frequently causes hospital admission and readmission. Patients receiving care from multiple providers and facilities (dual users) may risk higher health care utilization and worse health outcomes.
Methods To determine rates of emergency department (ED) visits, hospitalizations, and hospital readmissions relative to dual use among HF patients, we analyzed a retrospective cohort of 13,977 veterans with HF hospitalized at the Veterans Affairs (VA) or non-VA facilities from 2007 to 2011; we analyzed rates of acute health care utilization using zero-inflated negative binomial regression.
Results Compared to VA-only users and dual users, individuals receiving all of their ED and hospital care outside the VA tended to be older, more likely to be non-Hispanic white and married, and less likely to have high levels of service connected disability. Compared to VA-only users, dual users had significantly higher rates of ED visits for HF as a primary diagnosis (adjusted rate ratio 1.15, 95% CI 1.04-1.27), hospitalization for HF (adjusted rate ratio 1.4, 95% CI 1.26-1.56), hospital readmission after HF hospitalization (all cause) (1.46, 95% CI 1.30-1.65), and HF-specific hospital readmission after HF hospitalization (1.46, 95% CI 1.31-1.63). With the exception of hospitalization for any primary diagnosis, non-VA-only users had significantly lower rates of ED visits, hospitalization, and readmission compared to VA-only users.
Conclusions Dual use is associated with higher rates of health care utilization among patients with HF. Interventions should be devised to encourage continuity of care where possible and to improve the effectiveness and safety of dual use in instances where it is necessary or desired.
C1 [Axon, R. Neal; Gebregziabher, Mulugeta; Everett, Charles J.; Hunt, Kelly J.] Ralph H Johnson VA Med Ctr, Charleston Hlth Equ & Rural Outreach Innovat Ctr, Charleston, SC USA.
[Axon, R. Neal] Med Univ S Carolina, Dept Med, Div Gen Internal Med, Charleston, SC 29425 USA.
[Gebregziabher, Mulugeta; Hunt, Kelly J.] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA.
[Heidenreich, Paul] Stanford Univ, Med Ctr, Div Cardiol, VA Palo Alto Healthcare Syst, Palo Alto, CA 94304 USA.
RP Axon, RN (reprint author), 109 Bee St,Mail Code 111, Charleston, SC 29401 USA.
EM axon@musc.edu
OI Gebregziabher, Mulugeta/0000-0002-4826-481X
FU VA Health Services Research and Development [IIR 12-331]
FX VA Health Services Research and Development (IIR 12-331, Axon-PI).
NR 40
TC 0
Z9 0
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
EI 1097-5330
J9 AM HEART J
JI Am. Heart J.
PD APR
PY 2016
VL 174
BP 157
EP 163
DI 10.1016/j.ahj.2015.09.023
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DH1IV
UT WOS:000372538500023
PM 26995383
ER
PT J
AU Hill, SY
Jones, BL
Steinhauer, SR
Zezza, N
Stiffler, S
AF Hill, Shirley Y.
Jones, Bobby L.
Steinhauer, Stuart R.
Zezza, Nicholas
Stiffler, Scott
TI Longitudinal predictors of cannabis use and dependence in offspring from
families at ultra high risk for alcohol dependence and in control
families
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS
LA English
DT Article
DE CNR1; D2; cannabis use; cannabis abuse; cannabis dependence
ID RECEPTOR GENE CNR1; EVENT-RELATED POTENTIALS; LINKAGE-PHYSICAL MAP;
SUBSTANCE USE; P300 AMPLITUDE; MARIJUANA USE; DEVELOPMENTAL
TRAJECTORIES; HAPLOTYPE RECONSTRUCTION; GENOTYPE DATA; HUMAN GENOME
AB Cannabis use is common among adolescents. Identification of the factors associated with continued heavy use into young adulthood and development of cannabis abuse and dependence is of considerable importance. The role of familial risk for addiction and an associated endophenotype, P300 amplitude, has not previously been related to cannabis use and dependence. A prospective longitudinal study spanning childhood and young adulthood provided the opportunity for exploring these factors, along with genetic variation, in the cannabis use behaviors of 338 young adult offspring from high and low familial risk for alcohol dependence families (ages 19-30). P300 data were collected multiple times in childhood. The association between young adult patterns of cannabis use or cannabis abuse/dependence was tested with genetic variation in the cannabinoid gene, CNR1, the ANKK1-DRD2 gene, and childhood developmental trajectories of P300. Young adult patterns of cannabis use was characterized by three patterns: (i) no use throughout; (ii) declining use from adolescence through young adulthood; and (iii) frequent use throughout. Following the low P300 trajectory in childhood predicted cannabis abuse and dependence by young adulthood. A four SNP ANKK1-DRD2 haplotype (G-G-G-C) was found to be significantly associated with the frequency of use patterns (P=0.0008). Although CNR1 variation overall was not significantly associated with these patterns, among individuals with cannabis abuse/dependence the presence of one or both copies of the rs806368 A>G minor allele conferred a 5.4-fold increase (P=0.003) in the likelihood that they would be in the frequent and persistent use group rather than the declining use group. (c) 2016 Wiley Periodicals, Inc.
C1 [Hill, Shirley Y.; Jones, Bobby L.; Zezza, Nicholas; Stiffler, Scott] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA.
[Steinhauer, Stuart R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Hill, SY (reprint author), Univ Pittsburgh, Dept Psychiat, Med Ctr, 3811 O Hara St, Pittsburgh, PA 15213 USA.
EM syh50@imap.pitt.edu
FU NIAAA [AA018289, AA05909, AA08082, AA015168]
FX Grant sponsor: NIAAA; Grant numbers: AA018289, AA05909, AA08082,
AA015168.
NR 76
TC 0
Z9 0
U1 5
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4841
EI 1552-485X
J9 AM J MED GENET B
JI Am. J. Med. Genet. B
PD APR
PY 2016
VL 171
IS 3
BP 383
EP 395
DI 10.1002/ajmg.b.32417
PG 13
WC Genetics & Heredity; Psychiatry
SC Genetics & Heredity; Psychiatry
GA DH8FO
UT WOS:000373029100009
PM 26756393
ER
PT J
AU Das, F
Ghosh-Choudhury, N
Mariappan, MM
Kasinath, BS
Choudhury, GG
AF Das, Falguni
Ghosh-Choudhury, Nandini
Mariappan, Meenalakshmi M.
Kasinath, Balakuntalam S.
Choudhury, Goutam Ghosh
TI Hydrophobic motif site-phosphorylated protein kinase C beta II between
mTORC2 and Akt regulates high glucose-induced mesangial cell hypertrophy
SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
LA English
DT Article
DE diabetic nephropathy; signal transduction; mTOR complex; protein kinase
C
ID GROWTH-FACTOR-BETA; DIABETIC-NEPHROPATHY; RENAL HYPERTROPHY; IN-VIVO;
PHOSPHOINOSITIDE 3-KINASE; TRANSPLANT RECIPIENTS; RAPAMYCIN COMPLEXES;
DIACYLGLYCEROL MASS; ENDOTHELIAL-CELLS; BINDING PARTNER
AB PKC beta II controls the pathologic features of diabetic nephropathy, including glomerular mesangial cell hypertrophy. PKC beta II contains the COOH-terminal hydrophobic motif site Ser-660. Whether this hydrophobic motif phosphorylation contributes to high glucose-induced mesangial cell hypertrophy has not been determined. Here we show that, in mesangial cells, high glucose increased phosphorylation of PKC beta II at Ser-660 in a phosphatidylinositol 3-kinase (PI3-kinase)-dependent manner. Using siRNAs to downregulate PKC beta II, dominant negative PKC beta II, and PKC beta II hydrophobic motif phosphorylation-deficient mutant, we found that PKCbII regulates activation of mechanistic target of rapamycin complex 1 (mTORC1) and mesangial cell hypertrophy by high glucose. PKCbII via its phosphorylation at Ser-660 regulated phosphorylation of Akt at both catalytic loop and hydrophobic motif sites, resulting in phosphorylation and inactivation of its substrate PRAS40. Specific inhibition of mTORC2 increased mTORC1 activity and induced mesangial cell hypertrophy. In contrast, inhibition of mTORC2 decreased the phosphorylation of PKC beta II and Akt, leading to inhibition of PRAS40 phosphorylation and mTORC1 activity and prevented mesangial cell hypertrophy in response to high glucose; expression of constitutively active Akt or mTORC1 restored mesangial cell hypertrophy. Moreover, constitutively active PKC beta II reversed the inhibition of high glucose-stimulated Akt phosphorylation and mesangial cell hypertrophy induced by suppression of mTORC2. Finally, using renal cortexes from type 1 diabetic mice, we found that increased phosphorylation of PKC beta II at Ser-660 was associated with enhanced Akt phosphorylation and mTORC1 activation. Collectively, our findings identify a signaling route connecting PI3-kinase to mTORC2 to phosphorylate PKC beta II at the hydrophobic motif site necessary for Akt phosphorylation and mTORC1 activation, leading to mesangial cell hypertrophy.
C1 [Das, Falguni; Mariappan, Meenalakshmi M.; Kasinath, Balakuntalam S.; Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Mail Code 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
[Ghosh-Choudhury, Nandini; Kasinath, Balakuntalam S.; Choudhury, Goutam Ghosh] South Texas Vet Hlth Care Syst, Vet Affairs Res, San Antonio, TX USA.
[Choudhury, Goutam Ghosh] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Res, San Antonio, TX USA.
[Ghosh-Choudhury, Nandini] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
RP Choudhury, GG (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Mail Code 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM choudhuryg@uthscsa.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases
[R01-DK-50190]; Veterans Affairs (VA) Research Service Merit Review
Grant [5I01BX000926]; VA Senior Research Career Scientist Award; VA
Merit Review Grants [5I01BX000150, 5I01BX001340]
FX This work was supported by National Institute of Diabetes and Digestive
and Kidney Diseases Grant R01-DK-50190 and Veterans Affairs (VA)
Research Service Merit Review Grant 5I01BX000926 (to G. G. Choudhury).
G. G. Choudhury is a recipient of VA Senior Research Career Scientist
Award. N. Ghosh-Choudhury and B. S. Kasinath are supported by VA Merit
Review Grants 5I01BX000150 and 5I01BX001340, respectively.
NR 87
TC 1
Z9 1
U1 0
U2 2
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6143
EI 1522-1563
J9 AM J PHYSIOL-CELL PH
JI Am. J. Physiol.-Cell Physiol.
PD APR 1
PY 2016
VL 310
IS 7
BP C583
EP C596
DI 10.1152/ajpcell.00266.2015
PG 14
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA DI1RR
UT WOS:000373273900009
PM 26739493
ER
PT J
AU Wang, J
Han, L
Sinnett-Smith, J
Han, LL
Stevens, JV
Rozengurt, N
Young, SH
Rozengurt, E
AF Wang, Jia
Han, Liang
Sinnett-Smith, James
Han, Li-Li
Stevens, Jan V.
Rozengurt, Nora
Young, Steven H.
Rozengurt, Enrique
TI Positive cross talk between protein kinase D and beta-catenin in
intestinal epithelial cells: impact on beta-catenin nuclear localization
and phosphorylation at Ser552
SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
LA English
DT Article
DE G protein-coupled receptors; angiotensin II; IEC-18 cells; PKA; PKD
family inhibitors; CRT006610; kb NB 142-70; PKD1 transgenic mice
ID ACTIVATION LOOP SER(744); STEM-CELLS; IN-VIVO; ANG-II; G(Q)-COUPLED
RECEPTORS; SIGNALING PATHWAYS; COUPLED RECEPTOR; ANGIOTENSIN-II;
DNA-SYNTHESIS; LYSOPHOSPHATIDIC ACID
AB Given the fundamental role of beta-catenin signaling in intestinal epithelial cell proliferation and the growth-promoting function of protein kinase D1 (PKD1) in these cells, we hypothesized that PKDs mediate cross talk with beta-catenin signaling. The results presented here provide several lines of evidence supporting this hypothesis. We found that stimulation of intestinal epithelial IEC-18 cells with the G protein-coupled receptor (GPCR) agonist angiotensin II (ANG II), a potent inducer of PKD activation, promoted endogenous beta-catenin nuclear localization in a time-dependent manner. A significant increase was evident within 1 h of ANG II stimulation (P < 0.01), peaked at 4 h (P < 0.001), and declined afterwards. GPCR stimulation also induced a marked increase in beta-catenin-regulated genes and phosphorylation at Ser(552) in intestinal epithelial cells. Exposure to preferential inhibitors of the PKD family (CRT006610 or kb NB 142-70) or knockdown of the isoforms of the PKD family prevented the increase in beta-catenin nuclear localization and phosphorylation at Ser(552) in response to ANG II. GPCR stimulation also induced the formation of a complex between PKD1 and beta-catenin, as shown by coimmuno-precipitation that depended on PKD1 catalytic activation, as it was abrogated by cell treatment with PKD family inhibitors. Using transgenic mice that express elevated PKD1 protein in the intestinal epithelium, we detected a marked increase in the localization of beta-catenin in the nucleus of crypt epithelial cells in the ileum of PKD1 transgenic mice, compared with nontransgenic littermates. Collectively, our results identify a novel cross talk between PKD and beta-catenin in intestinal epithelial cells, both in vitro and in vivo.
C1 [Wang, Jia; Han, Liang; Sinnett-Smith, James; Han, Li-Li; Stevens, Jan V.; Young, Steven H.; Rozengurt, Enrique] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Digest Dis, Los Angeles, CA 90095 USA.
[Sinnett-Smith, James; Rozengurt, Nora; Rozengurt, Enrique] Digest Dis Res Ctr, CURE, Los Angeles, CA USA.
[Rozengurt, Enrique] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA.
[Sinnett-Smith, James; Young, Steven H.; Rozengurt, Enrique] Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA.
RP Rozengurt, E (reprint author), Univ Calif Los Angeles, Sch Med, Dept Med, Warren Hall Rm 11-124,900 Vet Ave, Los Angeles, CA 90095 USA.
EM erozengurt@mednet.ucla.edu
FU National Institutes of Health [R01-DK-100405, P30-DK-41301,
P01-CA-163200]; Department of Veterans Affair Grant [1I01BX001473];
Chinese Scholarship Council
FX This work was supported by National Institutes of Health Grants
R01-DK-100405, P30-DK-41301, and P01-CA-163200 and by Department of
Veterans Affair Grant 1I01BX001473 (to E. Rozengurt). L. Han and L.-L.
Han were both supported by a scholarship from the Chinese Scholarship
Council.
NR 85
TC 0
Z9 0
U1 1
U2 3
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6143
EI 1522-1563
J9 AM J PHYSIOL-CELL PH
JI Am. J. Physiol.-Cell Physiol.
PD APR 1
PY 2016
VL 310
IS 7
BP C542
EP C557
DI 10.1152/ajpcell.00302.2015
PG 16
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA DI1RR
UT WOS:000373273900005
PM 26739494
ER
PT J
AU Patterson, RE
Kalavalapalli, S
Williams, CM
Nautiyal, M
Mathew, JT
Martinez, J
Reinhard, MK
McDougall, DJ
Rocca, JR
Yost, RA
Cusi, K
Garrett, TJ
Sunny, NE
AF Patterson, Rainey E.
Kalavalapalli, Srilaxmi
Williams, Caroline M.
Nautiyal, Manisha
Mathew, Justin T.
Martinez, Janie
Reinhard, Mary K.
McDougall, Danielle J.
Rocca, James R.
Yost, Richard A.
Cusi, Kenneth
Garrett, Timothy J.
Sunny, Nishanth E.
TI Lipotoxicity in steatohepatitis occurs despite an increase in
tricarboxylic acid cycle activity
SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
LA English
DT Article
DE steatosis; hepatic insulin resistance; mitochondria; nonalcoholic
steatohepatitis
ID NONALCOHOLIC FATTY LIVER; HEPATIC INSULIN-RESISTANCE; TCA CYCLE;
MITOCHONDRIAL DYSFUNCTION; GLUCOSE-PRODUCTION; AMINO-ACIDS; DISEASE;
METABOLISM; MODEL; GLUCONEOGENESIS
AB The hepatic tricarboxylic acid (TCA) cycle is central to integrating macro-nutrient metabolism and is closely coupled to cellular respiration, free radical generation, and inflammation. Oxidative flux through the TCA cycle is induced during hepatic insulin resistance, in mice and humans with simple steatosis, reflecting early compensatory remodeling of mitochondrial energetics. We hypothesized that progressive severity of hepatic insulin resistance and the onset of nonalcoholic steatohepatitis (NASH) would impair oxidative flux through the hepatic TCA cycle. Mice (C57/BL6) were fed a high-trans-fat high-fructose diet (TFD) for 8 wk to induce simple steatosis and NASH by 24 wk. In vivo fasting hepatic mitochondrial fluxes were determined by C-13-nuclear magnetic resonance (NMR)-based isotopomer analysis. Hepatic metabolic intermediates were quantified using mass spectrometry- based targeted metabolomics. Hepatic triglyceride accumulation and insulin resistance preceded alterations in mitochondrial metabolism, since TCA cycle fluxes remained normal during simple steatosis. However, mice with NASH had a twofold induction (P < 0.05) of mitochondrial fluxes (mu mol/min) through the TCA cycle (2.6 +/- 0.5 vs. 5.4 +/- 0.6), anaplerosis (9.1 +/- 1.2 vs. 16.9 +/- 2.2), and pyruvate cycling (4.9 +/- 1.0 vs. 11.1 +/- 1.9) compared with their age-matched controls. Induction of the TCA cycle activity during NASH was concurrent with blunted ketogenesis and accumulation of hepatic diacylglycerols (DAGs), ceramides (Cer), and long-chain acylcar-nitines, suggesting inefficient oxidation and disposal of excess free fatty acids (FFA). Sustained induction of mitochondrial TCA cycle failed to prevent accretion of "lipotoxic" metabolites in the liver and could hasten inflammation and the metabolic transition to NASH.
C1 [Patterson, Rainey E.; McDougall, Danielle J.; Yost, Richard A.] Univ Florida, Dept Chem, Gainesville, FL 32610 USA.
[Kalavalapalli, Srilaxmi; Nautiyal, Manisha; Mathew, Justin T.; Martinez, Janie; Cusi, Kenneth; Sunny, Nishanth E.] Univ Florida, Dept Med, Div Endocrinol Diabet & Metab, 1600 SW Archer Rd, Gainesville, FL 32610 USA.
[Williams, Caroline M.] Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA.
[Reinhard, Mary K.] Univ Florida, Anim Care Serv, Gainesville, FL 32610 USA.
[Rocca, James R.] Univ Florida, McKnight Brain Inst, Adv Magnet Resonance Imaging & Spect Facil, Gainesville, FL 32610 USA.
[Cusi, Kenneth] Malcom Randall Vet Adm Med Ctr, Div Endocrinol Diabet & Metab, Gainesville, FL USA.
[Cusi, Kenneth] Univ Texas Hlth Sci Ctr San Antonio, Div Diabet, San Antonio, TX 78229 USA.
[Cusi, Kenneth] Audie L Murphy Vet Adm Med Ctr, Div Diabet, San Antonio, TX USA.
[Yost, Richard A.; Garrett, Timothy J.] Univ Florida, Dept Pathol, Gainesville, FL 32610 USA.
RP Sunny, NE (reprint author), Univ Florida, Dept Med, Div Endocrinol Diabet & Metab, 1600 SW Archer Rd, Gainesville, FL 32610 USA.
EM nishanth.sunny@medicine.ufl.edu
FU University of Florida [00089467]; Southeast Center for Integrated
Metabolomics National Institute of Diabetes and Digestive and Kidney
Diseases Grant [U24-DK-097209]; National Center for Research Resources
Clinical and Translational Science Award [UL1-TR-00064]; National
Institutes of Health
FX This work was supported by a University of Florida Research Opportunity
Seed Fund Award (00089467; to N. E. Sunny), a Southeast Center for
Integrated Metabolomics National Institute of Diabetes and Digestive and
Kidney Diseases Grant (U24-DK-097209), and a National Institutes of
Health and National Center for Research Resources Clinical and
Translational Science Award to the University of Florida (UL1-TR-00064).
NR 45
TC 4
Z9 4
U1 2
U2 8
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193-1849
EI 1522-1555
J9 AM J PHYSIOL-ENDOC M
JI Am. J. Physiol.-Endocrinol. Metab.
PD APR 1
PY 2016
VL 310
IS 7
BP E484
EP E494
DI 10.1152/ajpendo.00492.2015
PG 11
WC Endocrinology & Metabolism; Physiology
SC Endocrinology & Metabolism; Physiology
GA DI1RJ
UT WOS:000373272900002
PM 26814015
ER
PT J
AU Blevins, JE
Thompson, BW
Anekonda, VT
Ho, JM
Graham, JL
Roberts, ZS
Hwang, BH
Ogimoto, K
Wolden-Hanson, T
Nelson, J
Kaiyala, KJ
Havel, PJ
Bales, KL
Morton, GJ
Schwartz, MW
Baskin, DG
AF Blevins, James E.
Thompson, Benjamin W.
Anekonda, Vishwanath T.
Ho, Jacqueline M.
Graham, James L.
Roberts, Zachary S.
Hwang, Bang H.
Ogimoto, Kayoko
Wolden-Hanson, Tami
Nelson, Jarrell
Kaiyala, Karl J.
Havel, Peter J.
Bales, Karen L.
Morton, Gregory J.
Schwartz, Michael W.
Baskin, Denis G.
TI Chronic CNS oxytocin signaling preferentially induces fat loss in
high-fat diet-fed rats by enhancing satiety responses and increasing
lipid utilization
SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE
PHYSIOLOGY
LA English
DT Article
DE obesity; food intake; energy expenditure; oxytocin
ID BROWN ADIPOSE-TISSUE; TYPE-2 DIABETIC-PATIENTS; CAUSES WEIGHT-LOSS;
NERVOUS-SYSTEM OUTFLOW; INDUCED OBESE RATS; FOOD-INTAKE;
ENERGY-EXPENDITURE; PARAVENTRICULAR NUCLEUS; METABOLIC SYNDROME;
BODY-WEIGHT
AB Based largely on a number of short-term administration studies, growing evidence suggests that central oxytocin is important in the regulation of energy balance. The goal of the current work is to determine whether long-term third ventricular (3V) infusion of oxytocin into the central nervous system (CNS) is effective for obesity prevention and/or treatment in rat models. We found that chronic 3V oxytocin infusion between 21 and 26 days by osmotic minipumps both reduced weight gain associated with the progression of high-fat diet (HFD)-induced obesity and elicited a sustained reduction of fat mass with no decrease of lean mass in rats with established diet-induced obesity. We further demonstrated that these chronic oxytocin effects result from 1) maintenance of energy expenditure at preintervention levels despite ongoing weight loss, 2) a reduction in respiratory quotient, consistent with increased fat oxidation, and 3) an enhanced satiety response to cholecystokinin-8 and associated decrease of meal size. These weight-reducing effects persisted for approximately 10 days after termination of 3V oxytocin administration and occurred independently of whether sucrose was added to the HFD. We conclude that long-term 3V administration
C1 [Blevins, James E.; Thompson, Benjamin W.; Anekonda, Vishwanath T.; Ho, Jacqueline M.; Roberts, Zachary S.; Hwang, Bang H.; Wolden-Hanson, Tami; Baskin, Denis G.] Vet Affairs Puget Sound Hlth Care Syst, Off Res & Dev Med Res Serv, Dept Vet Affairs Med Ctr, Seattle, WA 98108 USA.
[Blevins, James E.; Ho, Jacqueline M.; Morton, Gregory J.; Schwartz, Michael W.; Baskin, Denis G.] Univ Washington, Sch Med, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA.
[Ogimoto, Kayoko; Nelson, Jarrell; Morton, Gregory J.; Schwartz, Michael W.] Univ Washington, Sch Med, Diabet & Obes Ctr Excellence, Seattle, WA USA.
[Kaiyala, Karl J.] Univ Washington, Sch Dent, Dept Oral Hlth Sci, Seattle, WA 98195 USA.
[Graham, James L.; Havel, Peter J.] Univ Calif Davis, Sch Vet Med, Dept Nutr, Davis, CA 95616 USA.
[Graham, James L.; Havel, Peter J.] Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA.
[Bales, Karen L.] Univ Calif Davis, Dept Psychol, Davis, CA 95616 USA.
RP Blevins, JE (reprint author), VA Puget Sound Hlth Care Syst, Res 151, 1660 South Columbian Way, Seattle, WA 98108 USA.
EM jeblevin@u.washington.edu
FU Office of Research and Development, Medical Research Service, Department
of Veterans Affairs (VA); VA Puget Sound Health Care System Rodent
Metabolic and Behavioral Phenotyping Core; Cellular and Molecular
Imaging Core of the Diabetes Research Center at the University of
Washington; National Institutes of Health (NIH) [P30DK017047, P30
DK035816, P30DK017047-31689, 2T32DK007247]; Energy Balance and Glucose
Metabolism Core of the Nutrition Obesity Research Center at the
University of Washington; Department of Veterans Affairs Biomedical
Laboratory R&D Merit Review Program; NIH [DK-095980, HL-091333,
HL-107256]; University of California Office of the President; VA Senior
Research Career Scientist award
FX This material is based upon work supported by the Office of Research and
Development, Medical Research Service, Department of Veterans Affairs
(VA), the VA Puget Sound Health Care System Rodent Metabolic and
Behavioral Phenotyping Core, and the Cellular and Molecular Imaging Core
of the Diabetes Research Center at the University of Washington. This
study was supported by National Institutes of Health (NIH) Grant
P30DK017047. This work is also supported by the Energy Balance and
Glucose Metabolism Core of the Nutrition Obesity Research Center at the
University of Washington and supported by National Institutes of Health
(NIH) Grant P30 DK035816. The research in our laboratory has been
supported by the Department of Veterans Affairs Biomedical Laboratory
R&D Merit Review Program as well as National Institutes of Health Grants
P30DK017047-31689 and the Diabetes, Obesity, and Metabolism Training
Grant 2T32DK007247. P. J. Havel's research program also receives
research support from NIH Grants DK-095980, HL-091333, HL-107256,
HL-107256 and a Multi-campus grant from the University of California
Office of the President. D. G. Baskin is the recipient of a VA Senior
Research Career Scientist award.
NR 105
TC 8
Z9 8
U1 0
U2 3
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6119
EI 1522-1490
J9 AM J PHYSIOL-REG I
JI Am. J. Physiol.-Regul. Integr. Comp. Physiol.
PD APR 1
PY 2016
VL 310
IS 7
BP R640
EP R658
DI 10.1152/ajpregu.00220.2015
PG 19
WC Physiology
SC Physiology
GA DI1PU
UT WOS:000373268800012
PM 26791828
ER
PT J
AU Morgan, TA
Chandran, S
Burger, IM
Zhang, CA
Goldstein, RB
AF Morgan, T. A.
Chandran, S.
Burger, I. M.
Zhang, C. A.
Goldstein, R. B.
TI Complications of Ultrasound-Guided Renal Transplant Biopsies
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
ID KIDNEY BIOPSY; CORE BIOPSY; SAFETY; NEEDLE; GUN; ALLOGRAFTS; ADEQUACY;
EFFICACY; YIELD; TRIAL
AB Renal transplant biopsies to diagnose transplant pathology are routinely performed using ultrasound guidance. Few large studies have assessed the rate and risk factors of major biopsy complications. This study is a single-center 5-year retrospective cohort analysis of 2514 biopsies. Major complications occurred in 47 of 2514 patients (1.9%) and included hospitalization, transfusion of blood products, operative exploration and interventional radiology procedures. The complication rate among cause biopsies was significantly higher than in protocol biopsies (2.7% vs. 0.33%, p < 0.001). Complications presented on postbiopsy days 0-14, with the majority diagnosed on the same day as the biopsy and manifested by hematocrit drop, although the presence of such delayed presentation of complications occurring >24 h after the biopsy on days 2-14 is previously unreported. Specific patient characteristics associated with increased risk of a complication were increased age and blood urea nitrogen, decreased platelet count, history of prior renal transplant, deceased donor transplant type and use of anticoagulant medications but not aspirin.
The authors review the incidence of major complications associated with ultrasound-guided renal transplant biopsies, including timing, presentation, and association with clinical factors, including patient demographics and prebiopsy laboratory values.
C1 [Morgan, T. A.; Zhang, C. A.; Goldstein, R. B.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA.
[Chandran, S.] Univ Calif San Francisco, Dept Med, Kidney Transplant Serv, Div Nephrol, San Francisco, CA USA.
[Burger, I. M.] Kaiser Permanente Los Angeles, VA Greater Angeles Healthcare Syst, Dept Radiol, Los Angeles, CA USA.
RP Morgan, TA (reprint author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA.
EM tara.morgan@ucsf.edu
NR 25
TC 2
Z9 2
U1 1
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2016
VL 16
IS 4
BP 1298
EP 1305
DI 10.1111/ajt.13622
PG 8
WC Surgery; Transplantation
SC Surgery; Transplantation
GA DH8VQ
UT WOS:000373075400031
PM 26601796
ER
PT J
AU Aplin, AC
Nicosia, RF
AF Aplin, Alfred C.
Nicosia, Roberto F.
TI Hypoxia paradoxically inhibits the angiogenic response of isolated
vessel explants while inducing overexpression of vascular endothelial
growth factor
SO ANGIOGENESIS
LA English
DT Article
DE Endothelial cells; Pericytes; Neovessels; Vascular endothelial growth
factor; Aorta; Vein; Collagen; Neovascularization
ID AORTIC RING MODEL; SOLUBLE VEGF RECEPTOR-1; RAT AORTA; IN-VITRO; OXYGEN;
CELLS; PERMEABILITY; EXPRESSION; SYSTEM; PHOSPHORYLATION
AB This study was designed to investigate how changes in O-2 levels affected angiogenesis in vascular organ culture. Although hypoxia is a potent inducer of angiogenesis, aortic rings cultured in collagen paradoxically failed to produce an angiogenic response in 1-4 % O-2. Additionally, aortic neovessels preformed in atmospheric O-2 lost pericytes and regressed at a faster rate than control when exposed to hypoxia. Aortic explants remained viable in hypoxia and produced an angiogenic response when returned to atmospheric O-2. Hypoxic aortic rings were unresponsive to VEGF, while increased oxygenation of the system dose-dependently enhanced VEGF-induced angiogenesis. Hypoxia-induced refractoriness to angiogenic stimulation was not restricted to the aorta because similar results were obtained with vena cava explants or isolated endothelial cells. Unlike endothelial cells, aorta-derived mural cells were unaffected by hypoxia. Hypoxia downregulated expression in aortic explants of key signaling molecules including VEGFR2, NRP1 and Prkc-beta while upregulating expression of VEGFR1. Medium conditioned by hypoxic cultures exhibited angiostatic and anti-VEGF activities likely mediated by sVEGFr1. Hypoxia reduced expression of VEGFR1 and VEGFR2 in endothelial cells while upregulating VEGFR1 in macrophages and VEGF in both macrophages and mural cells. Thus, changes in O-2 levels profoundly affect the endothelial response to angiogenic stimuli. These results suggest that hypoxia-induced angiogenesis is fine-tuned by complex regulatory mechanisms involving not only production of angiogenic factors including VEGF but also differential regulation of VEGFR expression in different cell types and production of inhibitors of VEGF function such as sVEGFR1.
C1 [Aplin, Alfred C.; Nicosia, Roberto F.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
[Nicosia, Roberto F.] VA Puget Sound Hlth Care Syst, Pathol & Lab Med Serv S Lab 113, Seattle, WA USA.
RP Nicosia, RF (reprint author), Univ Washington, Dept Pathol, Seattle, WA 98195 USA.; Nicosia, RF (reprint author), VA Puget Sound Hlth Care Syst, Pathol & Lab Med Serv S Lab 113, Seattle, WA USA.
EM Roberto.Nicosia@va.gov
FU United States (U.S.) Department of Veterans Affairs Biomedical
Laboratory Research and Development Service; American Heart Association
FX This work was supported in part by a Merit Review Award from the United
States (U.S.) Department of Veterans Affairs Biomedical Laboratory
Research and Development Service. The contents do not represent the
views of the U.S. Department of Veteran Affairs or the United States
Government. In addition, we gratefully acknowledge the support of a
grant-in-aid from the American Heart Association.
NR 55
TC 2
Z9 2
U1 2
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0969-6970
EI 1573-7209
J9 ANGIOGENESIS
JI Angiogenesis
PD APR
PY 2016
VL 19
IS 2
BP 133
EP 146
DI 10.1007/s10456-015-9493-2
PG 14
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA DI0IK
UT WOS:000373178900003
PM 26748649
ER
PT J
AU Domsic, RT
Nihtyanova, SI
Wisniewski, SR
Fine, MJ
Lucas, M
Kwoh, CK
Denton, CP
Medsger, TA
AF Domsic, Robyn T.
Nihtyanova, Svetlana I.
Wisniewski, Stephen R.
Fine, Michael J.
Lucas, Mary
Kwoh, C. Kent
Denton, Christopher P.
Medsger, Thomas A., Jr.
TI Derivation and External Validation of a Prediction Rule for Five-Year
Mortality in Patients With Early Diffuse Cutaneous Systemic Sclerosis
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Article
ID CLINICAL-PREDICTION; EUSTAR DATABASE; SCLERODERMA; SURVIVAL; FEATURES;
DEATH; EMPHASIS; DISEASE; COHORT; MODEL
AB ObjectiveAlthough diffuse cutaneous systemic sclerosis (dcSSc) is associated with a reduction in life expectancy, there are no validated prognostic models for determining 5-year mortality in patients with dcSSc. The objective of this study was to derive and validate a rule for predicting 5-year mortality in patients with early dcSSc.
MethodsWe studied an inception cohort of 388 US Caucasian patients with early dcSSc (<2 years from the appearance of the first symptom). Predefined baseline variables were analyzed in a stepwise logistic regression model in order to identify factors independently associated with 5-year all-cause mortality. We rounded the beta weights to the nearest integer and summed the points assigned to each variable in order to stratify patients into low-risk (<0 points), moderate-risk (1-2 points), and high-risk (3 points) groups. We then applied this rule to an external validation cohort of 144 Caucasian patients with early dcSSc from the Royal Free Hospital cohort and compared stratum-specific 5-year mortality.
ResultsSix independent predictors (rounded beta weight) comprised the model: age at first visit (points allotted: -1, 0, or 1), male sex (points allotted: 0 or 1), tendon friction rubs (points allotted: 0 or 1), gastrointestinal involvement (points allotted: 0 or 1), RNA polymerase III antibodies (points allotted: 0 or 1), and anemia (points allotted: 0 or 1). The 3-level risk stratification model performed well, with no significant differences between the US derivation cohort and the UK validation cohort.
ConclusionWe derived and externally validated, in US and UK cohorts, an easy-to-use 6-variable prediction rule that assigns low-risk, moderate-risk, and high-risk categories for 5-year mortality in patients with early dcSSc. Only history, physical examination, and basic laboratory assessments are required.
C1 [Domsic, Robyn T.; Wisniewski, Stephen R.; Lucas, Mary; Medsger, Thomas A., Jr.] Univ Pittsburgh, Pittsburgh, PA USA.
[Nihtyanova, Svetlana I.; Denton, Christopher P.] UCL, Sch Med, Royal Free Hosp, Mortimer St, London W1N 8AA, England.
[Fine, Michael J.] Univ Pittsburgh, Pittsburgh, PA USA.
[Fine, Michael J.] Vet Affairs Pittsburgh Healthcare, Vet Affairs Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Kwoh, C. Kent] Univ Arizona, Arthrit Ctr, Tucson, AZ USA.
RP Domsic, RT (reprint author), Univ Pittsburgh, S724 Biomed Sci Tower,3500 Terrace St, Pittsburgh, PA 15261 USA.
EM rtd4@pitt.edu
OI Wisniewski, Stephen/0000-0002-3877-9860
FU NIH (National Institute of Arthritis and Musculoskeletal and Skin
Diseases) [K23-AR-057845]
FX Dr. Domsic's work was supported by the NIH (National Institute of
Arthritis and Musculoskeletal and Skin Diseases grant K23-AR-057845).
NR 40
TC 2
Z9 2
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2326-5191
EI 2326-5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
PD APR
PY 2016
VL 68
IS 4
BP 993
EP 1003
DI 10.1002/art.39490
PG 11
WC Rheumatology
SC Rheumatology
GA DH9QH
UT WOS:000373130300026
PM 26554637
ER
PT J
AU Fisher, MB
Belkin, NS
Milby, AH
Henning, EA
Soegaard, N
Kim, M
Pfeifer, C
Saxena, V
Dodge, GR
Burdick, JA
Schaer, TP
Steinberg, DR
Mauck, RL
AF Fisher, Matthew B.
Belkin, Nicole S.
Milby, Andrew H.
Henning, Elizabeth A.
Soeegaard, Nicole
Kim, Minwook
Pfeifer, Christian
Saxena, Vishal
Dodge, George R.
Burdick, Jason A.
Schaer, Thomas P.
Steinberg, David R.
Mauck, Robert L.
TI Effects of Mesenchymal Stem Cell and Growth Factor Delivery on Cartilage
Repair in a Mini-Pig Model
SO CARTILAGE
LA English
DT Article
DE cartilage; repair; mesenchymal stem cells; TGF-3; animal models
ID HYALURONIC-ACID HYDROGELS; AUTOLOGOUS CHONDROCYTE IMPLANTATION;
ENGINEERED CARTILAGE; IN-VIVO; OSTEOCHONDRAL DEFECTS;
ARTICULAR-CARTILAGE; CHONDROGENIC DIFFERENTIATION; ALGINATE
MICROSPHERES; STROMAL CELLS; MATRIX
AB Objective We have recently shown that mesenchymal stem cells (MSCs) embedded in a hyaluronic acid (HA) hydrogel and exposed to chondrogenic factors (transforming growth factor-3 [TGF-3]) produce a cartilage-like tissue in vitro. The current objective was to determine if these same factors could be combined immediately prior to implantation to induce a superior healing response in vivo relative to the hydrogel alone.
Design Trochlear chondral defects were created in Yucatan mini-pigs (6 months old). Treatment groups included an HA hydrogel alone and hydrogels containing allogeneic MSCs, TGF-3, or both. Six weeks after surgery, micro-computed tomography was used to quantitatively assess defect fill and subchondral bone remodeling. The quality of cartilage repair was assessed using the ICRS-II histological scoring system and immunohistochemistry for type II collagen.
Results Treatment with TGF-3 led to a marked increase in positive staining for collagen type II within defects (P < 0.05), while delivery of MSCs did not (P > 0.05). Neither condition had an impact on other histological semiquantitative scores (P > 0.05), and inclusion of MSCs led to significantly less defect fill (P < 0.05). For all measurements, no synergistic interaction was found between TGF-3 and MSC treatment when they were delivered together (P > 0.05).
Conclusions At this early healing time point, treatment with TGF-3 promoted the formation of collagen type II within the defect, while allogeneic MSCs had little benefit. Combination of TGF-3 and MSCs at the time of surgery did not produce a synergistic effect. An in vitro precultured construct made of these components may be required to enhance in vivo repair in this model system.
C1 [Fisher, Matthew B.; Belkin, Nicole S.; Milby, Andrew H.; Henning, Elizabeth A.; Soeegaard, Nicole; Kim, Minwook; Pfeifer, Christian; Saxena, Vishal; Dodge, George R.; Steinberg, David R.; Mauck, Robert L.] Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, McKay Orthopaed Res Lab, Philadelphia, PA 19104 USA.
[Fisher, Matthew B.; Belkin, Nicole S.; Milby, Andrew H.; Henning, Elizabeth A.; Soeegaard, Nicole; Kim, Minwook; Pfeifer, Christian; Saxena, Vishal; Dodge, George R.; Burdick, Jason A.; Steinberg, David R.; Mauck, Robert L.] Philadelphia VA Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA USA.
[Fisher, Matthew B.] Univ N Carolina, Dept Biomed Engn, Chapel Hill, NC USA.
[Fisher, Matthew B.] N Carolina State Univ, Raleigh, NC 27695 USA.
[Pfeifer, Christian] Univ Regensburg, Med Ctr, Dept Trauma Surg, D-93053 Regensburg, Germany.
[Burdick, Jason A.; Mauck, Robert L.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA.
[Schaer, Thomas P.] Univ Penn, Sch Vet Med, Comparat Orthopaed Res Lab, Philadelphia, PA 19104 USA.
RP Mauck, RL (reprint author), Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, 424 Stemmler Hall,36th St & Hamilton Walk, Philadelphia, PA 19104 USA.; Mauck, RL (reprint author), Univ Penn, Perelman Sch Med, Dept Bioengn, 424 Stemmler Hall,36th St & Hamilton Walk, Philadelphia, PA 19104 USA.
EM lemauck@mail.med.upenn.edu
FU National Institutes of Health [R01 EB008722, F32 AR062971]; Department
of Veterans Affairs [I01 RX000700]; AO Foundation; Orthopaedic Research
and Education Foundation
FX The authors thank Liming Bian, Megan Farrell, Tristan Driscoll, Sylvia
Qu, and Marc Bostrom for their technical assistance. This work was
supported by the National Institutes of Health (R01 EB008722 and F32
AR062971), the Department of Veterans Affairs (I01 RX000700), the AO
Foundation, and the Orthopaedic Research and Education Foundation
(Resident Clinician Scientist Training Grant).
NR 52
TC 1
Z9 1
U1 7
U2 19
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1947-6035
EI 1947-6043
J9 CARTILAGE
JI Cartilage
PD APR
PY 2016
VL 7
IS 2
BP 174
EP 184
DI 10.1177/1947603515623030
PG 11
WC Orthopedics
SC Orthopedics
GA DH6LG
UT WOS:000372901500006
PM 27047640
ER
PT J
AU Post, RM
Leverich, GS
Kupka, R
Keck, PE
McElroy, SL
Altshuler, LL
Frye, MA
Rowe, M
Grunze, H
Suppes, T
Nolen, WA
AF Post, Robert M.
Leverich, Gabriele S.
Kupka, Ralph
Keck, Paul E., Jr.
McElroy, Susan L.
Altshuler, Lori L.
Frye, Mark A.
Rowe, Michael
Grunze, Heinz
Suppes, Trisha
Nolen, Willem A.
TI Clinical correlates of sustained response to individual drugs used in
naturalistic treatment of patients with bipolar disorder
SO COMPREHENSIVE PSYCHIATRY
LA English
DT Article
ID LIFE-CHART METHOD; I DISORDER; ANTIDEPRESSANT TREATMENT;
CONTROLLED-TRIAL; DOUBLE-BLIND; EARLY-ONSET; STEP-BD; LITHIUM;
OUTPATIENTS; DEPRESSION
AB Objective: To report use and treatment success rates of medications for bipolar disorder as a function of patients' clinical characteristics.
Method: Outpatients with bipolar illness diagnosed by SCID were rated by research assistants on the NIMH-LCM and those who had an good response for at least 6 months (much or very much improved on the CGI-BP) were considered responders (treatment "success"). Clinical characteristics associated with treatment response in the literature were examined for how often a drug was in a successful regimen when a given characteristic was either present or absent.
Results: Lithium was less successful in those with histories of rapid cycling, substance abuse, or (surprisingly) a positive parental history of mood disorders. Valproate was less successful in those with >= 20 prior episodes. Lamotrigine (LTG) was less successful in those with a parental history of mood disorders or in BP-I compared to BP-II disorder. Antidepressants (ADs) had low success rates, especially in those with a history of anxiety disorders. Benzodiazepines had low success rates in those with child abuse, substance use, or >= 20 episodes. Atypical antipsychotics were less successful in the presence of rapid cycling, >= 20 prior episodes, or a greater number of poor prognosis factors.
Conclusion: Success rates reflect medications used in combination with an average of two other drugs during naturalistic treatment and thus should be considered exploratory. However, the low long-term success rates of drugs (even when used in combination with others) that occurred in the presence of many very common clinical characteristics of bipolar illness speak to the need for the development of alternative treatment strategies. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Post, Robert M.; Leverich, Gabriele S.; Rowe, Michael] Bipolar Collaborat Network, Bethesda, MD USA.
[Post, Robert M.] George Washington Univ, Dept Psychiat & Behav Sci, Washington, DC USA.
[Kupka, Ralph] Vrije Univ Amsterdam, Med Ctr, Dept Psychiat, Amsterdam, Netherlands.
[Keck, Paul E., Jr.] Univ Cincinnati, Coll Med, Dept Psychiat & Behav Neurosci, Cincinnati, OH USA.
[Keck, Paul E., Jr.; McElroy, Susan L.] Lindner Ctr HOPE, Mason, OH USA.
[McElroy, Susan L.] Univ Cincinnati, Coll Med, Biol Psychiat Program, Cincinnati, OH USA.
[Altshuler, Lori L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Altshuler, Lori L.] West Los Angeles Healthcare Ctr, VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA.
[Frye, Mark A.] Mayo Clin, Dept Psychiat, Rochester, MI USA.
[Grunze, Heinz] Newcastle Univ, Acad Psychiat, Inst Neurosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
[Suppes, Trisha] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA.
[Suppes, Trisha] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA.
[Nolen, Willem A.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands.
RP Post, RM (reprint author), Bipolar Collaborat Network, 5415 West Cedar Lane,Suite 201-B, Bethesda, MD 20814 USA.
EM robert.post@speakeasy.net
OI Grunze, Heinz/0000-0003-4712-8979
NR 43
TC 2
Z9 2
U1 2
U2 6
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0010-440X
EI 1532-8384
J9 COMPR PSYCHIAT
JI Compr. Psychiat.
PD APR
PY 2016
VL 66
BP 146
EP 156
DI 10.1016/j.comppsych.2016.01.009
PG 11
WC Psychiatry
SC Psychiatry
GA DH4ML
UT WOS:000372760000020
PM 26995248
ER
PT J
AU Lynch, CP
Williams, JS
Voronca, D
Walker, RJ
Egede, LE
AF Lynch, Cheryl P.
Williams, Joni Strom
Voronca, Delia
Walker, Rebekah J.
Egede, Leonard E.
TI Meaning of Illness and Cardiovascular Risk Factors in Patients With Type
2 Diabetes
SO DIABETES EDUCATOR
LA English
DT Article
ID SELF-MANAGEMENT; DEPRESSION; MELLITUS; ADULTS; HEALTH; QUESTIONNAIRE;
RELIABILITY; ASSOCIATION; DISTRESS; VALIDITY
AB Purpose The purpose of this study was to examine the relationship between meaning of illness and cardiovascular disease risk factors in patients with type 2 diabetes.
Methods The sample population was recruited from primary care clinics in the southeastern United States. The meaning of illness was assessed by a validated questionnaire with 5 subscales. The primary outcomes were cardiovascular disease (CVD) risk factors, assessed by A1C, systolic and diastolic blood pressure (SBP and DBP, respectively), and low-density lipoprotein cholesterol (LDL-C). Multivariate linear regression models investigated associations between the clinical outcomes and the 5 MIQ factors, controlling for possible confounders.
Results The sample comprised 302 black and white participants of whom more than half were elderly (65+ years) and the vast majority were male (98%). Systolic blood pressure was positively associated with non-anticipated vulnerability. Diastolic blood pressure was negatively associated with degree of stress/change in commitments and positively associated with challenge/motivation/hope and non-anticipated vulnerability. Low-density lipoprotein cholesterol was significantly and negatively associated with degree of stress/change in commitments.
Conclusions Meaning of illness had a significant effect on measured outcomes of CVD risk. The specific factor included in the overarching concept of meaning of illness differed in its influence, with more positive views of stress/commitments associated with lower blood pressure and LDL but more positive views of the challenge/hope/motivation and negative views of non-anticipated vulnerability associated with diabetes associated with higher systolic and diastolic blood pressure.
C1 [Lynch, Cheryl P.; Walker, Rebekah J.; Egede, Leonard E.] Ralph H Johnson Vet Affairs Med Ctr, HEROIC, Charleston, SC USA.
[Lynch, Cheryl P.; Williams, Joni Strom; Voronca, Delia; Walker, Rebekah J.; Egede, Leonard E.] Med Univ S Carolina, Dept Med, Ctr Hlth Dispar Res, Charleston, SC 29425 USA.
[Lynch, Cheryl P.; Williams, Joni Strom; Voronca, Delia; Egede, Leonard E.] Med Univ S Carolina, Dept Med, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA.
RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, Hlth Equ & Rural Outreach Innovat Ctr, 135 Rutledge Ave,Room 280G,POB 250593, Charleston, SC 29425 USA.
EM egedel@musc.edu
FU VHA Health Services Research and Development (HSRD) program [TRP 04-038]
FX This study was supported by grant No. TRP 04-038 funded by the VHA
Health Services Research and Development (HSR&D) program. The funding
agency did not participate in the design and conduct of the study;
collection, management, analysis, and interpretation of the data; or
preparation, review, or approval of the manuscript. The manuscript
represents the views of the authors and not those of the VA or HSR&D.
NR 29
TC 0
Z9 0
U1 1
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0145-7217
EI 1554-6063
J9 DIABETES EDUCATOR
JI Diabetes Educ.
PD APR
PY 2016
VL 42
IS 2
BP 220
EP 227
DI 10.1177/0145721716631430
PG 8
WC Endocrinology & Metabolism; Public, Environmental & Occupational Health
SC Endocrinology & Metabolism; Public, Environmental & Occupational Health
GA DH6DV
UT WOS:000372882100007
PM 26879460
ER
PT J
AU Francis, FF
Kulich, SM
Hashash, JG
AF Francis, Fadi F.
Kulich, Scott M.
Hashash, Jana G.
TI Diarrhea, Ascites, and Eosinophilia Image 3: Hypereosinophilic Syndrome
SO GASTROENTEROLOGY
LA English
DT Editorial Material
C1 [Francis, Fadi F.] VA Pittsburgh Hlth Care Syst, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA.
[Francis, Fadi F.; Hashash, Jana G.] Univ Pittsburgh, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA.
[Kulich, Scott M.] VA Pittsburgh Hlth Care Syst, Dept Pathol, Pittsburgh, PA USA.
[Kulich, Scott M.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA.
RP Francis, FF (reprint author), VA Pittsburgh Hlth Care Syst, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA.; Francis, FF (reprint author), Univ Pittsburgh, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA.
NR 3
TC 0
Z9 0
U1 1
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
EI 1528-0012
J9 GASTROENTEROLOGY
JI Gastroenterology
PD APR
PY 2016
VL 150
IS 4
BP E6
EP E8
DI 10.1053/j.gastro.2015.10.019
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DH4BH
UT WOS:000372730000003
PM 26930018
ER
PT J
AU White, PL
Wiederhold, NP
Loeffler, J
Najvar, LK
Melchers, W
Herrera, M
Bretagne, S
Wickes, B
Kirkpatrick, WR
Barnes, RA
Donnelly, JP
Patterson, TF
AF White, P. Lewis
Wiederhold, Nathan P.
Loeffler, Juergen
Najvar, Laura K.
Melchers, Willem
Herrera, Monica
Bretagne, Stephane
Wickes, Brian
Kirkpatrick, William R.
Barnes, Rosemary A.
Donnelly, J. Peter
Patterson, Thomas F.
TI Comparison of Nonculture Blood-Based Tests for Diagnosing Invasive
Aspergillosis in an Animal Model
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID HIGH-RISK HEMATOLOGY; RANDOMIZED CONTROLLED-TRIAL; GUINEA-PIG MODEL;
REAL-TIME PCR; FUNGAL DISEASE; PULMONARY ASPERGILLOSIS; AMPHOTERICIN-B;
FUMIGATUS DNA; GALACTOMANNAN; SERUM
AB The European Aspergillus PCR Initiative (EAPCRI) has provided recommendations for the PCR testing of whole blood (WB) and serum/plasma. It is important to test these recommended protocols on nonsimulated "in vivo" specimens before full clinical evaluation. The testing of an animal model of invasive aspergillosis (IA) overcomes the low incidence of disease and provides experimental design and control that is not possible in the clinical setting. Inadequate performance of the recommended protocols at this stage would require reassessment of methods before clinical trials are performed and utility assessed. The manuscript describes the performance of EAPCRI protocols in an animal model of invasive aspergillosis. Blood samples taken from a guinea pig model of IA were used for WB and serum PCR. Galactomannan and beta-D-glucan detection were evaluated, with particular focus on the timing of positivity and on the interpretation of combination testing. The overall sensitivities for WB PCR, serum PCR, galactomannan, and beta-D-glucan were 73%, 65%, 68%, and 46%, respectively. The corresponding specificities were 92%, 79%, 80%, and 100%, respectively. PCR provided the earliest indicator of IA, and increasing galactomannan and beta-D-glucan values were indicators of disease progression. The combination of WB PCR with galactomannan and beta-D-glucan proved optimal (area under the curve [AUC], 0.95), and IA was confidently diagnosed or excluded. The EAPRCI-recommended PCR protocols provide performance comparable to commercial antigen tests, and clinical trials are warranted. By combining multiple tests, IA can be excluded or confirmed, highlighting the need for a combined diagnostic strategy. However, this approach must be balanced against the practicality and cost of using multiple tests.
C1 [White, P. Lewis] PHW Microbiol, Cardiff, S Glam, Wales.
[Wiederhold, Nathan P.; Najvar, Laura K.; Herrera, Monica; Wickes, Brian; Kirkpatrick, William R.; Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio Ctr Med Mycol, San Antonio, TX 78229 USA.
[Loeffler, Juergen] Univ Wurzburg, D-97070 Wurzburg, Germany.
[Melchers, Willem; Donnelly, J. Peter] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands.
[Bretagne, Stephane] Hop St Louis, Paris, France.
[Barnes, Rosemary A.] Cardiff Univ, UHW, Cardiff CF10 3AX, S Glam, Wales.
[Patterson, Thomas F.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP White, PL (reprint author), PHW Microbiol, Cardiff, S Glam, Wales.
EM lewis.white@wales.nhs.uk
OI Bretagne, Stephane/0000-0001-6870-3800; Wiederhold,
Nathan/0000-0002-2225-5122; Donnelly, J Peter/0000-0002-8521-335X
FU HHS\ NIH\ National Institute of Allergy and Infectious Diseases (NIAID)
[N01-AI-30041]
FX HHS vertical bar NIH vertical bar National Institute of Allergy and
Infectious Diseases (NIAID) provided funding to Nathan P. Wiederhold,
Laura K. Najvar, Monica L. Herrera, Brian L. Wickes, William R.
Kirkpatrick, and Thomas F. Patterson under grant number N01-AI-30041.
NR 30
TC 2
Z9 2
U1 1
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD APR
PY 2016
VL 54
IS 4
BP 960
EP 966
DI 10.1128/JCM.03233-15
PG 7
WC Microbiology
SC Microbiology
GA DI2OX
UT WOS:000373337100015
PM 26791366
ER
PT J
AU Wahbeh, H
Goodrich, E
Goy, E
Oken, BS
AF Wahbeh, Helane
Goodrich, Elena
Goy, Elizabeth
Oken, Barry S.
TI Mechanistic Pathways of Mindfulness Meditation in Combat Veterans With
Posttraumatic Stress Disorder
SO JOURNAL OF CLINICAL PSYCHOLOGY
LA English
DT Article
DE meditation; mindfulness; veteran; combat; posttraumatic stress disorder
ID AUTONOMIC NERVOUS-SYSTEM; HEART-RATE-VARIABILITY; PSYCHOMETRIC
PROPERTIES; CLINICAL-TRIAL; WAR VETERANS; METAANALYSIS; PTSD; SYMPTOMS;
EEG; QUESTIONNAIRE
AB ObjectiveThis study's objective was to evaluate the effect of two common components of meditation (mindfulness and slow breathing) on potential mechanistic pathways.
MethodsA total of 102 combat veterans with posttraumatic stress disorder (PTSD) were randomized to (a) the body scan mindfulness meditation (MM), (b) slow breathing (SB) with a biofeedback device, (c) mindful awareness of the breath with an intention to slow the breath (MM+SB), or (d) sitting quietly (SQ). Participants had 6 weekly one-on-one sessions with 20 minutes of daily home practice. The mechanistic pathways and measures were as follows: (a) autonomic nervous system (hyperarousal symptoms, heart rate [HR], and heart rate variability [HRV]); (b) frontal cortex activity (attentional network task [ANT] conflict effect and event-related negativity and intrusive thoughts); and (c) hypothalamic-pituitary-adrenal axis (awakening cortisol). PTSD measures were also evaluated.
ResultsMeditation participants had significant but modest within-group improvement in PTSD and related symptoms, although there were no effects between groups. Perceived impression of PTSD symptom improvement was greater in the meditation arms compared with controls. Resting respiration decreased in the meditation arms compared with SQ. For the mechanistic pathways, (a) subjective hyperarousal symptoms improved within-group (but not between groups) for MM, MM+SB, and SQ, while HR and HRV did not; (b) intrusive thoughts decreased in MM compared with MM+SB and SB, while the ANT measures did not change; and (c) MM had lower awakening cortisol within-group (but not between groups).
ConclusionTreatment effects were mostly specific to self-report rather than physiological measures. Continued research is needed to further evaluate mindfulness meditation's mechanism in people with PTSD.
C1 [Wahbeh, Helane; Goodrich, Elena; Oken, Barry S.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Wahbeh, Helane] Natl Coll Nat Med, Portland, OR USA.
[Goy, Elizabeth] Portland VA Med Ctr, Portland, OR USA.
RP Wahbeh, H (reprint author), 3181 SW Sam Jackson Pk Rd CR120, Portland, OR 97239 USA.
EM wahbehh@ohsu.edu
FU National Center for Advancing Translational Sciences of the National
Institutes of Health [UL1TR000128]; National Center for Complementary
and Alternative Medicine of the National Institutes of Health
[T32AT002688, K01AT004951, K24AT005121]
FX Research reported in this publication was supported by National Center
for Advancing Translational Sciences of the National Institutes of
Health under award number UL1TR000128 and the National Center for
Complementary and Alternative Medicine of the National Institutes of
Health [grant numbers T32AT002688, K01AT004951, K24AT005121].
NR 81
TC 0
Z9 0
U1 9
U2 22
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9762
EI 1097-4679
J9 J CLIN PSYCHOL
JI J. Clin. Psychol.
PD APR
PY 2016
VL 72
IS 4
BP 365
EP 383
DI 10.1002/jclp.22255
PG 19
WC Psychology, Clinical
SC Psychology
GA DH7KX
UT WOS:000372973800005
PM 26797725
ER
PT J
AU Turner, AP
Hartoonian, N
Sloan, AP
Benich, M
Kivlahan, DR
Hughes, C
Hughes, AJ
Haselkorn, JK
AF Turner, Aaron P.
Hartoonian, Narineh
Sloan, Alicia P.
Benich, Marisa
Kivlahan, Daniel R.
Hughes, Christina
Hughes, Abbey J.
Haselkorn, Jodie K.
TI Improving Fatigue and Depression in Individuals With Multiple Sclerosis
Using Telephone-Administered Physical Activity Counseling
SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY
LA English
DT Article
DE fatigue; depression; physical activity; motivational interviewing;
self-management
ID QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; DISABILITY STATUS SCALE;
SELF-REPORT; MAJOR DEPRESSION; CLINICAL-TRIALS; MENTAL-HEALTH;
PRIMARY-CARE; MS PATIENTS; EXERCISE
AB Objective: To evaluate the impact of a physical activity intervention consisting of telephone counseling with home-based monitoring to improve fatigue and depression in individuals with multiple sclerosis (MS). Method: Single-blind randomized controlled trial. Sixty-four individuals with MS received either telephone counseling (N = 31), or self-directed physical activity education (N = 33). The education condition (EC) consisted of advice to increase physical activity and a DVD with examples of in-home exercises for multiple physical ability levels. The telephone counseling condition (TC) included EC as well as mailed graphic feedback, 6 telephone counseling sessions using principles of motivational interviewing, and telehealth home monitoring to track progress on physical activity goals. Booster sessions were provided when participants indicated they did not meet their goals. Assessment was conducted at baseline, 3-month, and 6-month follow-up. Results: TC participants reported significantly reduced fatigue (d = -.70), reduced depression (d = -.72) and increased physical activity (d =.92) relative to EC participants. Of individuals receiving TC, 33.3% experienced clinically significant improvement in fatigue (vs. 18.2% in EC) and 53.3% experienced clinically significant improvement in depression (vs. 9.1% in EC). Improvements in physical activity mediated improvements in fatigue with a similar trend for depression. TC was highly feasible (participants completed 99.5% of schedule telephone sessions) and well tolerated (100% rated it highly successful). Conclusion: Telephone-based counseling with home monitoring is a promising modality to improve physical activity and treat fatigue and depression.
C1 [Turner, Aaron P.; Benich, Marisa; Hughes, Abbey J.] VA Puget Sound Hlth Care Syst, VA Multiple Sclerosis Ctr Excellence, Seattle, WA USA.
[Turner, Aaron P.; Hughes, Abbey J.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA.
[Hartoonian, Narineh; Sloan, Alicia P.; Haselkorn, Jodie K.] VA Multiple Sclerosis Ctr Excellence West, Seattle, WA USA.
[Kivlahan, Daniel R.] Vet Hlth Adm, Mental Hlth Serv, Washington, DC USA.
[Kivlahan, Daniel R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Haselkorn, Jodie K.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
RP Turner, AP (reprint author), VA Puget Sound Hlth Care Syst, Rehabil Care Serv, S-117 RCS,1660 South Columbian Way, Seattle, WA 98108 USA.
EM Aaron.Turner@med.va.gov
OI Turner, Aaron/0000-0001-6897-8003
FU Department of Veterans Affairs Rehabilitation Research and Development
Service Career Development Award [B4927W]; VA Multiple Sclerosis Center
of Excellence West; VA Center of Excellence for Limb Loss Prevention and
Prosthetic Engineering; VA Center of Excellence in Substance Abuse
Treatment and Education
FX This research was supported by Department of Veterans Affairs
Rehabilitation Research and Development Service Career Development Award
B4927W to Aaron P. Turner. Additional support was provided by the VA
Multiple Sclerosis Center of Excellence West, the VA Center of
Excellence for Limb Loss Prevention and Prosthetic Engineering, and the
VA Center of Excellence in Substance Abuse Treatment and Education.
Trial Registration clinicaltrials.gov Identifier: NCT01198977. Special
thanks to Charles Bombardier who provided mentorship and consultation on
this project.
NR 75
TC 1
Z9 1
U1 12
U2 20
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0022-006X
EI 1939-2117
J9 J CONSULT CLIN PSYCH
JI J. Consult. Clin. Psychol.
PD APR
PY 2016
VL 84
IS 4
BP 297
EP 309
DI 10.1037/ccp0000086
PG 13
WC Psychology, Clinical
SC Psychology
GA DH8PP
UT WOS:000373057100002
PM 26913621
ER
PT J
AU Jarrett, RB
Minhajuddin, A
Vittengl, JR
Clark, LA
Thase, ME
AF Jarrett, Robin B.
Minhajuddin, Abu
Vittengl, Jeffrey R.
Clark, Lee Anna
Thase, Michael E.
TI Quantifying and Qualifying the Preventive Effects of Acute-Phase
Cognitive Therapy: Pathways to Personalizing Care
SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY
LA English
DT Article
DE depression; cognitive therapy; relapse; recurrence; predictors of
outcomes
ID MAJOR DEPRESSIVE DISORDER; ATTRIBUTIONAL STYLE QUESTIONNAIRE; RECURRENT
DEPRESSION; CONTINUATION PHASE; FOLLOW-UP; SOCIAL-ADJUSTMENT;
RANDOMIZED-TRIAL; PILL PLACEBO; SELF-CONTROL; RELAPSE
AB Objective: To determine the extent to which prospectively identified responders to cognitive therapy (CT) for recurrent major depressive disorder (MDD) hypothesized to be lower risk show significantly less relapse or recurrence than treated higher risk counterparts across 32 months. Method: Outpatients (N = 523), aged 18-70, with recurrent MDD received 12-14 weeks of CT. The last 7 consecutive scores from the Hamilton Rating Scale for Depression (HRSD-17) were used to stratify or define responders (n = 290) into lower (7 HRSD-17 scores of less than or equal to 6; n = 49; 17%) and higher risk (n = 241; 83%). The lower risk patients entered the 32-month follow-up. Higher risk patients were randomized to 8 months of continuation-phase CT or clinical management plus double-blind fluoxetine or pill placebo, with a 24-month follow-up. Results: Lower risk patients were significantly less likely to relapse over the first 8 months compared to higher risk patients (Kaplan-Meier [KM] estimates; i.e., 4.9% = lower risk; 22.1% = higher risk; log-rank chi(2) = 6.83, p = .009). This increased risk was attenuated, but not completely neutralized, by active continuation-phase therapy. Over the subsequent 24 months, the lower and higher risk groups did not differ in relapse or recurrence risk. Conclusions: Rapid and sustained acute-phase CT remission identifies responders who do not require continuation-phase treatment to prevent relapse (i.e., return of an index episode). To prevent recurrence (i.e., new episodes), however, strategic allocation and more frequent "dosing" of CT and/or targeted maintenance-phase treatments may be required. Longitudinal follow-up is recommended.
C1 [Jarrett, Robin B.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
[Minhajuddin, Abu] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
[Vittengl, Jeffrey R.] Truman State Univ, Dept Psychol, Kirksville, MO USA.
[Clark, Lee Anna] Univ Notre Dame, Dept Psychol, Notre Dame, IN 46556 USA.
[Thase, Michael E.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Jarrett, RB (reprint author), Univ Texas SW Med Ctr Dallas, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
EM robin.jarrett@utsouthwestern.edu
FU Alkermes; Assurerx; AstraZeneca; Avenir; Eli Lilly and Company; Forest
Laboratories; Janssen/Johnson Johnson; Otsuka; Roche; Agency for
Healthcare Research and Quality; National Institute of Mental Health
(NIMH); NIMH [K24 MH001571, R01 MH058397, R01 MH069619, R01 MH058356,
R01 MH069618]
FX During the past 3 years, Michael E. Thase has consulted with and/or
served on advisory boards for Advir, Alkermes, Allergan, AstraZeneca,
Avenir, Bristol-Myers Squibb Company, Cerecor, Cerenex, Eli Lilly and
Company, Forest Laboratories, Janssen Pharmaceutica, Johnson & Johnson,
Lundbeck, MedAvante, Merck, Moksha8, Naurex, Neuronetics, Novartis,
Otsuka, Nestle (formerly Pamlab), Pfizer Pharmaceuticals, Roche, Shire,
Sunovion, Takeda, and Teva. During this time, he has received grant
support from Alkermes, Assurerx, AstraZeneca, Avenir, Eli Lilly and
Company, Forest Laboratories, Janssen/Johnson & Johnson, Otsuka, and
Roche, as well as funding from the Agency for Healthcare Research and
Quality and the National Institute of Mental Health (NIMH). He has
equity holdings for MedAvante, Inc., and has received royalties from
American Psychiatric Publishing, Inc. (APPI), Guilford Publications,
Herald House, and W. W. Norton & Company, Inc. Two books currently
promoted by the APPI specifically pertain to cognitive therapy. Michael
E. Thase also discloses that his spouse is an employee of Peloton
Advantage, which does business with several pharmaceutical companies
that market medications used to treat depression. Robin B. Jarrett's
medical center collects the payments from the cognitive therapy she
provides to patients. Jarrett is a paid consultant to the NIMH and the
National Institutes of Health (NIH). Robin B. Jarrett and Jeffrey R.
Vittengl are paid reviewers for UpToDate.; This report was supported by
Grants K24 MH001571, R01 MH058397, and R01 MH069619 (to Robin B.
Jarrett) and R01 MH058356 and R01 MH069618 (to Michael E. Thase) from
the NIMH. The content is solely the responsibility of the authors and
does not necessarily represent the official views of the NIMH or the
NIH. We also wish to acknowledge the unrestricted support of Eli Lilly
and Company, which provided fluoxetine and matched pill placebo for the
first 6 years of the study. Thereafter, study materials were purchased
and prepared to appear identical for both sites by the pharmacy at The
University of Texas Southwestern Medical Center. We are grateful to our
patients, research teams, and colleagues at The University of Texas
Southwestern Medical Center, the University of Pittsburgh, and the
University of Pennsylvania who made this trial possible. We appreciate
the assistance of Lauren Singer, M. S. and Joanne Sanders, M. S. for
their research support.
NR 47
TC 1
Z9 1
U1 8
U2 11
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0022-006X
EI 1939-2117
J9 J CONSULT CLIN PSYCH
JI J. Consult. Clin. Psychol.
PD APR
PY 2016
VL 84
IS 4
BP 365
EP 376
DI 10.1037/ccp0000069
PG 12
WC Psychology, Clinical
SC Psychology
GA DH8PP
UT WOS:000373057100008
PM 26654211
ER
PT J
AU Lightner, AL
Shannon, E
Gibbons, MM
Russell, MM
AF Lightner, Amy L.
Shannon, Evan
Gibbons, Melinda Maggard
Russell, Marcia M.
TI Primary Gastrointestinal Non-Hodgkin's Lymphoma of the Small and Large
Intestines: a Systematic Review
SO JOURNAL OF GASTROINTESTINAL SURGERY
LA English
DT Review
DE Lymphoma; Small intestine; Large intestine; Surgery; Outcomes
ID B-CELL LYMPHOMA; PRIMARY COLONIC LYMPHOMA; FOLLICULAR LYMPHOMA;
CLINICAL-FEATURES; CLINICOPATHOLOGICAL ANALYSIS; MALT LYMPHOMA;
POPULATION; MANAGEMENT; RITUXIMAB; TRACT
AB Primary gastrointestinal non-Hodgkin's lymphoma (PGINHL) of small and large intestines is a group of heterogeneous, rare malignancies. Optimal treatment practices remain undefined.
A systematic review (2003-2015) was performed to assess tumor characteristics, treatment practices, and treatment outcomes of PGINHL of small and large intestines.
Twenty-eight studies (1658 patients) were included; five focused on follicular lymphoma subtype. Of the non-follicular patients, 59.3 % presented with abdominal pain, 37.2 % were located in ileocecum, and 53.6 % were diffuse large B cell lymphoma subtype. The majority of patients (60.7 %) were treated with a combination of surgery and chemotherapy. Forty-three percent of studies concluded an overall survival benefit with surgery; none reported increased postoperative morbidity or mortality. Survival outcomes were not typically stratified by emergent versus elective surgery. Multivariate analysis within individual studies associated B cell lymphoma and ileocecum location with higher survival, while advanced stage and B symptoms were associated with poorer survival. Patients with asymptomatic follicular lymphoma had no progression with a watchful waiting approach.
The majority of patients with non-follicular small and large intestinal PGINHLs are treated with both chemotherapy and surgery. Although surgery appears to be an important part of the treatment algorithm, definitive statements regarding its survival benefit remain limited due to lack of patient stratification based on timing and indication for surgery.
C1 [Lightner, Amy L.; Gibbons, Melinda Maggard; Russell, Marcia M.] Univ Calif Los Angeles, Dept Surg, David Geffen Sch Med, 200 1st St SW Rochester, Los Angeles, MN 55905 USA.
[Shannon, Evan] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.
[Russell, Marcia M.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA.
RP Lightner, AL (reprint author), Univ Calif Los Angeles, Dept Surg, David Geffen Sch Med, 200 1st St SW Rochester, Los Angeles, MN 55905 USA.
EM Lightner.amy@mayo.edu
NR 57
TC 2
Z9 2
U1 2
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1091-255X
EI 1873-4626
J9 J GASTROINTEST SURG
JI J. Gastrointest. Surg.
PD APR
PY 2016
VL 20
IS 4
BP 827
EP 839
DI 10.1007/s11605-015-3052-4
PG 13
WC Gastroenterology & Hepatology; Surgery
SC Gastroenterology & Hepatology; Surgery
GA DI0BB
UT WOS:000373158700021
PM 26676930
ER
PT J
AU Harris, AHS
Chen, C
Rubinsky, AD
Hoggatt, KJ
Neuman, M
Vanneman, ME
AF Harris, Alex H. S.
Chen, Cheng
Rubinsky, Anna D.
Hoggatt, Katherine J.
Neuman, Matthew
Vanneman, Megan E.
TI Are Improvements in Measured Performance Driven by Better Treatment or
"Denominator Management"?
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE quality measurement; measurement reactivity; performance contracts
ID PREVENTING UNINTENDED CONSEQUENCES; QUALITY MEASUREMENT; REPORT CARDS;
INFORMATION
AB Process measures of healthcare quality are usually formulated as the number of patients who receive evidence-based treatment (numerator) divided by the number of patients in the target population (denominator). When the systems being evaluated can influence which patients are included in the denominator, it is reasonable to wonder if improvements in measured quality are driven by expanding numerators or contracting denominators.
In 2003, the US Department of Veteran Affairs (VA) based executive compensation in part on performance on a substance use disorder (SUD) continuity-of-care quality measure. The first goal of this study was to evaluate if implementing the measure in this way resulted in expected improvements in measured performance. The second goal was to examine if the proportion of patients with SUD who qualified for the denominator contracted after the quality measure was implemented, and to describe the facility-level variation in and correlates of denominator contraction or expansion.
Using 40 quarters of data straddling the implementation of the performance measure, an interrupted time series design was used to evaluate changes in two outcomes.
All veterans with an SUD diagnosis in all VA facilities from fiscal year 2000 to 2009.
The two outcomes were 1) measured performance-patients retained/patients qualified and 2) denominator prevalence-patients qualified/patients with SUD program contact.
Measured performance improved over time (P < 0.001). Notably, the proportion of patients with SUD program contact who qualified for the denominator decreased more rapidly after the measure was implemented (p = 0.02). Facilities with higher pre-implementation denominator prevalence had steeper declines in denominator prevalence after implementation (p < 0.001).
These results should motivate the development of measures that are less vulnerable to denominator management, and also the exploration of "shadow measures" to monitor and reduce undesirable denominator management.
C1 [Harris, Alex H. S.; Chen, Cheng; Rubinsky, Anna D.; Neuman, Matthew; Vanneman, Megan E.] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, 795 Willow Rd, Menlo Pk, CA 94025 USA.
[Hoggatt, Katherine J.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA.
[Hoggatt, Katherine J.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Vanneman, Megan E.] Stanford Univ, Ctr Hlth Policy Primary Care & Outcomes Res, Sch Med, Stanford, CA 94305 USA.
RP Harris, AHS (reprint author), VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, 795 Willow Rd, Menlo Pk, CA 94025 USA.
EM Alexander.Harris2@va.gov
FU VA Health Services Research and Development (HSRD) Service [IIR
10-370-2]; VA Substance Use Disorder Quality Enhancement Research
Initiative (SUD QUERI) [SUDQ-LIP-1208, SUDQ-LIP-1314]; VA HSR&D/QUERI
Career Development Award; VA HSR&D Postdoctoral Fellowship; VA HSR&D
Research Career Scientist Award [RCS-14-232]
FX This study was funded by the VA Health Services Research and Development
(HSR&D) Service (IIR 10-370-2), VA Substance Use Disorder Quality
Enhancement Research Initiative (SUD QUERI; SUDQ-LIP-1208;
SUDQ-LIP-1314), a VA HSR&D/QUERI Career Development Award to Dr.
Hoggatt, a VA HSR&D Postdoctoral Fellowship to Dr. Vanneman, and a VA
HSR&D Research Career Scientist Award (RCS-14-232) to Dr. Harris. The
views expressed herein are not necessarily those of the Department of
Veterans Affairs.
NR 21
TC 2
Z9 2
U1 3
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD APR
PY 2016
VL 31
SU 1
BP 21
EP 27
DI 10.1007/s11606-015-3558-1
PG 7
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA DI0BN
UT WOS:000373159900006
PM 26951270
ER
PT J
AU Farmer, MM
Rubenstein, LV
Sherbourne, CD
Huynh, A
Chu, K
Lam, CA
Fickel, JJ
Lee, ML
Metzger, ME
Verchinina, L
Post, EP
Chaney, EF
AF Farmer, Melissa M.
Rubenstein, Lisa V.
Sherbourne, Cathy D.
Huynh, Alexis
Chu, Karen
Lam, Christine A.
Fickel, Jacqueline J.
Lee, Martin L.
Metzger, Maureen E.
Verchinina, Lilia
Post, Edward P.
Chaney, Edmund F.
TI Depression Quality of Care: Measuring Quality over Time Using VA
Electronic Medical Record Data
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE performance measurement; depression; Veterans; measurement; quality
assessment
ID RANDOMIZED CONTROLLED-TRIAL; COLLABORATIVE CARE; PERFORMANCE-MEASURES;
CHRONIC DISEASE; MENTAL-HEALTH; IMPROVEMENT; OUTCOMES; IMPACT
AB The Veterans Health Administration (VA) has invested substantially in evidence-based mental health care. Yet no electronic performance measures for assessing the level at which the population of Veterans with depression receive appropriate care have proven robust enough to support rigorous evaluation of the VA's depression initiatives.
Our objectives were to develop prototype longitudinal electronic population-based measures of depression care quality, validate the measures using expert panel judgment by VA and non-VA experts, and examine detection, follow-up and treatment rates over a decade (2000-2010). We describe our development methodology and the challenges to creating measures that capture the longitudinal course of clinical care from detection to treatment.
Data come from the National Patient Care Database and Pharmacy Benefits Management Database for primary care patients from 1999 to 2011, from nine Veteran Integrated Service Networks.
We developed four population-based quality metrics for depression care that incorporate a 6-month look back and 1-year follow-up: detection of a new episode of depression, 84 and 180 day follow-up, and minimum appropriate treatment 1-year post detection. Expert panel techniques were used to evaluate the measure development methodology and results. Key challenges to creating valid longitudinal measures are discussed.
Over the decade, the rates for detection of new episodes of depression remained stable at 7-8 %. Follow-up at 84 and 180 days were 37 % and 45 % in 2000 and increased to 56 % and 63 % by 2010. Minimum appropriate treatment remained relatively stable over the decade (82-84 %).
The development of valid longitudinal, population-based quality measures for depression care is a complex process with numerous challenges. If the full spectrum of care from detection to follow-up and treatment is not captured, performance measures could actually mask the clinical areas in need of quality improvement efforts.
C1 [Farmer, Melissa M.; Rubenstein, Lisa V.; Huynh, Alexis; Chu, Karen; Lam, Christine A.; Fickel, Jacqueline J.; Lee, Martin L.] VA Greater Los Angeles Healthcare Syst, VA HSR&D Ctr Study Healthcare Innovat Implementat, 16111 Plummer St 152, Sepulveda, CA 91343 USA.
[Rubenstein, Lisa V.; Sherbourne, Cathy D.] RAND Corp, Santa Monica, CA USA.
[Rubenstein, Lisa V.; Lee, Martin L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Rubenstein, Lisa V.; Lee, Martin L.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA.
[Metzger, Maureen E.; Verchinina, Lilia; Post, Edward P.] HSR&D Ctr Clin Management Res, VA Ann Arbor, Ann Arbor, MI USA.
[Post, Edward P.] Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA.
[Chaney, Edmund F.] Univ Washington, Sch Med, Seattle, WA 98195 USA.
RP Farmer, MM (reprint author), VA Greater Los Angeles Healthcare Syst, VA HSR&D Ctr Study Healthcare Innovat Implementat, 16111 Plummer St 152, Sepulveda, CA 91343 USA.
EM Melissa.Farmer@va.gov
FU VA Health Services Research Development [IIR 11-326]
FX Funding for this research was supported by a grant from VA Health
Services Research & Development (Project #IIR 11-326; PI: Farmer). We
would like to acknowledge the expert panelists for their contribution as
well as Britney Chow, MPH and Ismelda Canelo, MPA for administrative
support.
NR 33
TC 3
Z9 3
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD APR
PY 2016
VL 31
SU 1
BP 36
EP 45
DI 10.1007/s11606-015-3563-4
PG 10
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA DI0BN
UT WOS:000373159900008
PM 26951274
ER
PT J
AU Saini, SD
Powell, AA
Dominitz, JA
Fisher, DA
Francis, J
Kinsinger, L
Pittman, KS
Schoenfeld, P
Moser, SE
Vijan, S
Kerr, EA
AF Saini, Sameer D.
Powell, Adam A.
Dominitz, Jason A.
Fisher, Deborah A.
Francis, Joseph
Kinsinger, Linda
Pittman, Kathleen S.
Schoenfeld, Philip
Moser, Stephanie E.
Vijan, Sandeep
Kerr, Eve A.
TI Developing and Testing an Electronic Measure of Screening Colonoscopy
Overuse in a Large Integrated Healthcare System
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE performance measurement; colorectal cancer; screening; health services
research
ID SOCIETY TASK-FORCE; COLORECTAL-CANCER; MEDICARE POPULATION; QUALITY
MEASURES; GUIDELINES
AB Most existing performance measures focus on underuse of care, but there is growing interest in identifying and reducing overuse.
We aimed to develop a valid and reliable electronic performance measure of overuse of screening colonoscopy in the Veterans Affairs Health Care System (VA), and to quantify overuse in VA.
This was a cross-sectional study with multiple cross-sections.
U.S. Veterans who underwent screening colonoscopy between 2011 and 2013.
Overuse of screening colonoscopy, using a validated electronic measure developed by an expert workgroup.
Compared to results obtained from manual record review, the electronic measure was highly specific (97 %) for overuse, but not sensitive (20 %). After exclusion of diagnostic and high-risk screening or surveillance procedures, the validated electronic measure identified 88,754 average-risk screening colonoscopies performed in VA during 2013. Of these, 20,530 (23 %) met the definition for probable (17 %) or possible (6 %) overuse. Substantial variation in colonoscopy overuse was noted between Veterans Integrated Care Networks (VISNs) and between facilities, with a nearly twofold difference between the maximum and minimum rates of overuse at the VISN level and a nearly eightfold difference at the facility level. Overuse at the VISN and facility level was relatively stable over time.
Overuse of screening colonoscopy can be measured reliably and with high specificity using electronic data, and is common in a large integrated healthcare system. Overuse measures, such as those we have specified through a consensus workgroup process, could be combined with underuse measures to improve the appropriateness of colorectal cancer screening.
C1 [Saini, Sameer D.; Schoenfeld, Philip; Moser, Stephanie E.; Vijan, Sandeep; Kerr, Eve A.] Vet Affairs Ctr Clin Management Res CCMR, 2215 Fuller Rd,111D, Ann Arbor, MI 48105 USA.
[Saini, Sameer D.; Schoenfeld, Philip; Vijan, Sandeep; Kerr, Eve A.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.
[Saini, Sameer D.; Schoenfeld, Philip; Vijan, Sandeep; Kerr, Eve A.] Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA.
[Powell, Adam A.] Minneapolis VA HealthCare Syst, CCDOR, Minneapolis, MN USA.
[Powell, Adam A.] Anthem Inc, Minneapolis, MN USA.
[Dominitz, Jason A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Fisher, Deborah A.] Durham Vet Affairs Med Ctr, Durham, NC USA.
[Fisher, Deborah A.] Duke Univ, Dept Med, Durham, NC USA.
[Francis, Joseph] VHA Off Analyt & Business Intelligence, Washington, DC USA.
[Kinsinger, Linda; Pittman, Kathleen S.] VHA Natl Ctr Hlth Promot & Dis Prevent, Durham, NC USA.
[Vijan, Sandeep] Univ Michigan, Dept Anesthesiol, Ann Arbor, MI 48109 USA.
RP Saini, SD (reprint author), Vet Affairs Ctr Clin Management Res CCMR, 2215 Fuller Rd,111D, Ann Arbor, MI 48105 USA.
EM sdsaini@umich.edu
FU VA Health Services Research and Development [CDA 09-213-2, RRP 12-184];
Veterans Health Administration (VHA) Office of Informatics and Analytics
(OIA)
FX This work was funded by VA Health Services Research and Development (CDA
09-213-2 and RRP 12-184). Partial funding for this work was provided by
the Veterans Health Administration (VHA) Office of Informatics and
Analytics (OIA). These funding agencies had no role in the design and
conduct of the study. VHA OIA reviewed the manuscript prior to
submission. The opinions expressed in this paper are of the authors and
do not necessarily reflect those of the Department of Veterans Affairs.
NR 22
TC 2
Z9 2
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD APR
PY 2016
VL 31
SU 1
BP 53
EP 60
DI 10.1007/s11606-015-3569-y
PG 8
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA DI0BN
UT WOS:000373159900010
PM 26951277
ER
PT J
AU Kondo, KK
Damberg, CL
Mendelson, A
Motu'apuaka, M
Freeman, M
O'Neil, M
Relevo, R
Low, A
Kansagara, D
AF Kondo, Karli K.
Damberg, Cheryl L.
Mendelson, Aaron
Motu'apuaka, Makalapua
Freeman, Michele
O'Neil, Maya
Relevo, Rose
Low, Allison
Kansagara, Devan
TI Implementation Processes and Pay for Performance in Healthcare: A
Systematic Review
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Review
DE pay for performance; financial incentives; implementation; performance
metrics; systematic review
ID FOR-PERFORMANCE; OUTCOMES-FRAMEWORK; GENERAL PRACTICES; DIABETES CARE;
PRACTICE SIZE; QUALITY; PROGRAM; INCENTIVES; IMPACT; CONTRACT
AB Over the last decade, various pay-for-performance (P4P) programs have been implemented to improve quality in health systems, including the VHA. P4P programs are complex, and their effects may vary by design, context, and other implementation processes. We conducted a systematic review and key informant (KI) interviews to better understand the implementation factors that modify the effectiveness of P4P.
We searched PubMed, PsycINFO, and CINAHL through April 2014, and reviewed reference lists. We included trials and observational studies of P4P implementation. Two investigators abstracted data and assessed study quality. We interviewed P4P researchers to gain further insight.
Among 1363 titles and abstracts, we selected 509 for full-text review, and included 41 primary studies. Of these 41 studies, 33 examined P4P programs in ambulatory settings, 7 targeted hospitals, and 1 study applied to nursing homes. Related to implementation, 13 studies examined program design, 8 examined implementation processes, 6 the outer setting, 18 the inner setting, and 5 provider characteristics. Results suggest the importance of considering underlying payment models and using statistically stringent methods of composite measure development, and ensuring that high-quality care will be maintained after incentive removal. We found no conclusive evidence that provider or practice characteristics relate to P4P effectiveness. Interviews with 14 KIs supported limited evidence that effective P4P program measures should be aligned with organizational goals, that incentive structures should be carefully considered, and that factors such as a strong infrastructure and public reporting may have a large influence.
There is limited evidence from which to draw firm conclusions related to P4P implementation. Findings from studies and KI interviews suggest that P4P programs should undergo regular evaluation and should target areas of poor performance. Additionally, measures and incentives should align with organizational priorities, and programs should allow for changes over time in response to data and provider input.
C1 [Kondo, Karli K.; Motu'apuaka, Makalapua; Freeman, Michele; O'Neil, Maya; Relevo, Rose; Low, Allison; Kansagara, Devan] Evidence Based Synth Program, Portland Vet Affairs Med Ctr, Mailcode RD71,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
[Damberg, Cheryl L.] RAND Corp, Santa Monica, CA USA.
[Kondo, Karli K.; Mendelson, Aaron; O'Neil, Maya; Kansagara, Devan] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
RP Kondo, KK (reprint author), Evidence Based Synth Program, Portland Vet Affairs Med Ctr, Mailcode RD71,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM karli.kondo@va.gov
RI haron, suhaila/E-9360-2017
OI Low, Allison/0000-0003-2088-2429
FU U.S. Department of Veterans Affairs, Veterans Health Administration
(VHA) ESP [05-225]
FX This project was funded by the U.S. Department of Veterans Affairs,
Veterans Health Administration (VHA) ESP Project #05-225.
NR 49
TC 4
Z9 4
U1 11
U2 22
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD APR
PY 2016
VL 31
SU 1
BP 61
EP 69
DI 10.1007/s11606-015-3567-0
PG 9
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA DI0BN
UT WOS:000373159900011
PM 26951276
ER
PT J
AU Oslin, DW
Lynch, KG
Maisto, SA
Lantinga, LJ
Mckay, JR
Possemato, K
Ingram, E
Wierzbicki, M
AF Oslin, David W.
Lynch, Kevin G.
Maisto, Stephen A.
Lantinga, Larry J.
McKay, James R.
Possemato, Kyle
Ingram, Erin
Wierzbicki, Michael
TI A Randomized Clinical Trial of Alcohol Care Management Delivered in
Department of Veterans Affairs Primary Care Clinics Versus Specialty
Addiction Treatment (vol 29, pg 162, 2014)
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Correction
C1 [Oslin, David W.; McKay, James R.; Ingram, Erin] Univ Penn, Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA 19104 USA.
[Oslin, David W.; Lynch, Kevin G.; McKay, James R.] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA.
[Maisto, Stephen A.; Lantinga, Larry J.; Possemato, Kyle] Syracuse Univ, Dept Psychol, Syracuse, NY USA.
[Maisto, Stephen A.; Lantinga, Larry J.; Possemato, Kyle] VISN2, Dept Vet Affairs, Ctr Integrated Healthcare, Syracuse, NY USA.
[Wierzbicki, Michael] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
RP Oslin, DW (reprint author), Univ Penn, Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA 19104 USA.; Oslin, DW (reprint author), Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD APR
PY 2016
VL 31
IS 4
BP 449
EP 449
DI 10.1007/s11606-015-3419-y
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA DI0BR
UT WOS:000373160300023
PM 26055225
ER
PT J
AU Ghosh, A
Leahy, KP
Singhal, S
Einhorn, E
Howlett, P
Cohen, NA
Mirza, N
AF Ghosh, A.
Leahy, K. P.
Singhal, S.
Einhorn, E.
Howlett, P.
Cohen, N. A.
Mirza, N.
TI A murine model of subglottic granulation
SO JOURNAL OF LARYNGOLOGY AND OTOLOGY
LA English
DT Article
DE Subglottic Stenosis, Acquired; Airway Obstruction; Granulation Tissue;
Animal Model
ID RABBIT MODEL; STENOSIS; INJURY
AB Objective: This study aimed to develop a functional model of subglottic stenosis by inducing direct airway irritation in transplanted mouse laryngotracheal complexes.
Methods: Laryngotracheal complexes from C57BL/6 mice were harvested and divided into three groups: uninjured, mechanically injured and chemically injured. Donor laryngotracheal complexes from each group were placed in dorsal subcutaneous pockets of recipient mice. Each week, the transplanted laryngotracheal complexes were harvested, and tissues were fixed, sectioned, and stained with haematoxylin and eosin. Representative slides were reviewed by a blinded pathologist, to determine the formation of granulation tissue, and graded as to the degree of granulation formation.
Results: Direct airway irritation induced granulation tissue formation under the disrupted epithelium of airway mucosa; this was seen as early as two weeks after chemical injury.
Conclusion: Results indicate that granulation tissue formation in a murine model may be an efficient tool for investigating the development and treatment of subglottic stenosis.
C1 [Ghosh, A.; Leahy, K. P.; Cohen, N. A.; Mirza, N.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, 3400 Spruce St,5 Ravdin, Philadelphia, PA 19104 USA.
[Singhal, S.] Univ Penn, Dept Thorac Surg, 3400 Spruce St,5 Ravdin, Philadelphia, PA 19104 USA.
[Einhorn, E.; Howlett, P.] Philadelphia Vet Affairs Med Ctr, Dept Pathol, Philadelphia, PA USA.
RP Ghosh, A (reprint author), Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, 3400 Spruce St,5 Ravdin, Philadelphia, PA 19104 USA.
EM ankona.ghosh@uphs.upenn.edu
OI Cohen, Noam/0000-0002-9462-3932
NR 9
TC 0
Z9 0
U1 0
U2 1
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0022-2151
EI 1748-5460
J9 J LARYNGOL OTOL
JI J. Laryngol. Otol.
PD APR
PY 2016
VL 130
IS 4
BP 380
EP 387
DI 10.1017/S0022215116000049
PG 8
WC Otorhinolaryngology
SC Otorhinolaryngology
GA DH9PJ
UT WOS:000373127800013
PM 26991876
ER
PT J
AU Schreibeis-Baum, HC
Xenakis, LE
Chen, EK
Hanson, M
Ahluwalia, S
Ryan, G
Lorenz, KA
AF Schreibeis-Baum, Hannah C.
Xenakis, Lea E.
Chen, Emily K.
Hanson, Mark
Ahluwalia, Sangeeta
Ryan, Gery
Lorenz, Karl A.
TI A Qualitative Inquiry on Palliative and End-of-Life Care Policy Reform
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Article
ID TOBACCO CONTROL; HEALTH; OPPORTUNITIES; SMOKING
AB Background: There is increasing recognition of the role of palliative care (PC) in health care delivery, but priorities for state and federal policy to support PC are unclear and have sometimes engendered controversy. We canvassed experts to shed light on general recommendations for improving PC.
Objective: The study objective was to identify challenges to and potential solutions for promoting, adopting, and implementing policies that would support or expand high-quality PC.
Methods: Semistructured telephone interviews were used to solicit challenges to and potential solutions for promoting, adopting, and implementing policies that would support or expand high-quality PC. Interviews were analyzed using qualitative methods. The subjects were a purposive sample of 22 professional state and federal-level advocates who work in the field of aging and/or PC.
Results: Respondents identified four central challenges to advancing PC policies: (1) knowledge about PC in the health care setting, (2) cultural beliefs about PC, (3) payment/reimbursement for PC services, and (4) public understanding of PC. Of the wide range of solutions proposed by respondents, we present the eight most frequently discussed solutions to these challenges targeted towards policymakers, health care professionals, research, and the general public. Respondents' understanding of the relationships between problems and solutions revealed many dependencies and interconnectedness.
Conclusions: A qualitative approach of querying experts identified multiple significant challenges to improving and expanding PC, most of which are acknowledged in existing consensus statements. Proposed solutions were more numerous and diffuse than descriptions of the problems, signaling the need for further consensus building around actionable policy, and better understanding of how to advance a PC policy agenda.
C1 [Schreibeis-Baum, Hannah C.] VA Greater Angeles, Ctr Healthcare Innovat Implementat & Policy, Hlth Serv Res & Dev, Los Angeles, CA USA.
[Xenakis, Lea E.; Chen, Emily K.; Hanson, Mark; Ahluwalia, Sangeeta; Ryan, Gery; Lorenz, Karl A.] RAND Corp, RAND Hlth, Santa Monica, CA USA.
[Lorenz, Karl A.] VA Palo Alto, Ctr Innovat Implementat Ci2i, Palo Alto, CA USA.
[Lorenz, Karl A.] Stanford Univ, Sch Med, Sect Palliat Med, Stanford, CA 94305 USA.
RP Lorenz, KA (reprint author), Stanford Univ, Sch Med, Div Gen Med Disciplines, Sch Med, Off Bldg,1265 Welch Rd,Room X3c46,MC 5411, Stanford, CA 94305 USA.
EM kalorenz@stanford.edu
FU National Institute of Nursing Research [NINR R01NR013372]; California
Healthcare Foundation [CHCF 17173]
FX The Trajectories and Palliation Study (TAPS) was funded by a grant from
the National Institute of Nursing Research (NINR R01NR013372), and the
TAPS Policy Project was funded by the California Healthcare Foundation
(CHCF 17173).
NR 22
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
EI 1557-7740
J9 J PALLIAT MED
JI J. Palliat. Med.
PD APR 1
PY 2016
VL 19
IS 4
BP 400
EP 407
DI 10.1089/jpm.2015.0296
PG 8
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA DI1DZ
UT WOS:000373237500013
PM 27035522
ER
PT J
AU Sadeghi, B
Walling, AM
Romano, PS
Ahluwalia, SC
Ong, MK
AF Sadeghi, Bahman
Walling, Anne M.
Romano, Patrick S.
Ahluwalia, Sangeeta C.
Ong, Michael K.
TI A Hospital-Based Advance Care Planning Intervention for Patients with
Heart Failure: A Feasibility Study
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; LIFE-SUSTAINING TREATMENT; DECISION-MAKING;
PREFERENCES; ADULTS
AB Background: Early discussions about advance care planning (ACP) have been associated with improved patient and caregiver outcomes for patients with serious illness. Many patients with heart failure (HF) may benefit from more timely ACP, in part due to the unpredictable trajectory of the disease.
Objectives: The purpose of this study was to evaluate the feasibility of implementing a multiple-component hospital-based intervention on completion of ACP forms among HF patients.
Methods: A brief hospital-based ACP intervention was led by a nonclinician health educator that included (1) an educational video about shared decision making and (2) a protocol to engage HF providers in patients' ACP decision making after the hospitalization. We surveyed patients regarding attitudes toward the ACP intervention and studied completion rates of advance directives (ADs) or physician orders for life sustaining treatment (POLST) forms six months following discharge.
Results: The educational video component of this intervention was considered helpful by 92% of participants, and 70% said they were more likely to talk with their physician about their end-of-life preferences after watching the video and interacting with the health educator. Of 37 participants, 49% had evidence of completion of an AD or POLST in their medical records six months after the index hospitalization compared to 32% before the intervention. The number of patients having a signed scanned POLST form increased from 10 (27%) before the intervention to 16 (43%) six months after the intervention (p = 0.03).
Conclusions: A hospital-based ACP intervention using nonclinician health educators is feasible to implement and has the potential to facilitate the ACP process.
C1 [Sadeghi, Bahman; Walling, Anne M.; Ong, Michael K.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med & Hlth Serv Res, 10940 Wilshire Blvd, Los Angeles, CA 90024 USA.
[Walling, Anne M.; Ong, Michael K.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA.
[Romano, Patrick S.] Univ Calif Davis, Dept Internal Med, Davis, CA 95616 USA.
[Romano, Patrick S.] Univ Calif Davis, Dept Pediat, Davis, CA 95616 USA.
[Ahluwalia, Sangeeta C.] RAND Corp, Santa Monica, CA USA.
[Ahluwalia, Sangeeta C.] Univ Calif Los Angeles, UCLA Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA 90024 USA.
RP Ong, MK (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med & Hlth Serv Res, 10940 Wilshire Blvd, Los Angeles, CA 90024 USA.
EM mong@mednet.ucla.edu
FU California Healthcare Foundation [15666]; Agency for Healthcare Research
and Quality [R01 HS019311]; NIH National Center for Advancing
Translational Science UCLA Clinical and Translational Science Institute
(CTSI) [UL1TR000124]; NIH Loan Repayment Program; Foundation for
Informed Medical Decision Making
FX This study was supported by a grant from the California Healthcare
Foundation (#15666). The authors would like to acknowledge the work of
Kymberly Aoki, Jennifer Matsui, Wern Ong, and Matt Tiacharoen at the
UCLA Medical Center and Mauricio Rodriguez and Meghan Soulsby at the UCD
Medical Center. We acknowledge the support we received for the patient
screening process from the BEAT-HF study funded by a grant from the
Agency for Healthcare Research and Quality (#R01 HS019311). Dr. Walling
was also supported by the NIH National Center for Advancing
Translational Science UCLA Clinical and Translational Science Institute
(CTSI) (#UL1TR000124) and the NIH Loan Repayment Program. We appreciate
the support from the Foundation for Informed Medical Decision Making
with regards to the videos used in this study.
NR 15
TC 1
Z9 1
U1 3
U2 7
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
EI 1557-7740
J9 J PALLIAT MED
JI J. Palliat. Med.
PD APR 1
PY 2016
VL 19
IS 4
BP 451
EP 455
DI 10.1089/jpm.2015.0269
PG 5
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA DI1DZ
UT WOS:000373237500019
PM 26862682
ER
PT J
AU Bekelman, DB
Rabin, BA
Nowels, CT
Sahay, A
Heidenreich, PA
Fischer, SM
Main, DS
AF Bekelman, David B.
Rabin, Borsika A.
Nowels, Carolyn T.
Sahay, Anju
Heidenreich, Paul A.
Fischer, Stacy M.
Main, Deborah S.
TI Barriers and Facilitators to Scaling Up Outpatient Palliative Care
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Article
ID CHRONIC HEART-FAILURE; RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE;
IMPLEMENTATION SCIENCE; INTERVENTION; CONSULTATION; PROGRAMS; OUTCOMES;
FRAMEWORK; ADOPTION
AB Background: The Institute of Medicine recommends people with serious advanced illness have access to skilled palliative care. However, the predominant delivery model of nonhospice palliative care is inpatient, consultative care focused on the end of life, with a small specialist palliative care workforce.
Objective: The study objective was to understand organizational factors that could influence the adoption and scale-up of outpatient palliative care in chronic advanced illness, using the example of heart failure.
Methods: This was a cross-sectional qualitative study. Participants were 17 health care providers and local, regional, and national health system leaders from the Veterans Health Administration (VHA) who were considering whether and how to adopt and sustain outpatient palliative care. Individual interviews using semistructured questions assessed domains of the Consolidated Framework for Implementation Science.
Results: Most providers and leaders perceived outpatient palliative care as high priority in the VHA given its patient-centeredness and potential to decrease health care use and costs associated with conditions like heart failure. They also supported a collaborative care team model of outpatient palliative care delivery where a palliative care specialist collaborates with medical nurses and social workers. They reported lack of performance measures/incentives for patient-centered care processes and outcomes as a potential barrier to implementation. Features of outpatient palliative care viewed as important for successful adoption and scale-up included coordination and communication with other providers, ease of integration into existing programs, and evidence of improving quality of care while not substantially increasing overall health care costs.
Conclusion: Incentives such as performance measures and collaboration with local VHA providers and leaders could improve adoption and scale-up of outpatient palliative care.
C1 [Bekelman, David B.] Eastern Colorado Hlth Care Syst, Dept Vet Affairs, Denver, CO USA.
[Bekelman, David B.; Nowels, Carolyn T.; Fischer, Stacy M.] Univ Colorado, Sch Med, Dept Med, Anschutz Med Campus, Aurora, CO USA.
[Rabin, Borsika A.] Univ Colorado, Sch Med, Dept Family Med, Anschutz Med Campus, Aurora, CO USA.
[Rabin, Borsika A.] Univ Colorado, Sch Med, Colorado Hlth Outcomes Program, Anschutz Med Campus, Aurora, CO USA.
[Sahay, Anju; Heidenreich, Paul A.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA.
[Main, Deborah S.] Univ Colorado, Dept Hlth & Behav Sci, Denver, CO 80202 USA.
RP Bekelman, DB (reprint author), Denver VA Med Ctr, 1055 Clermont St,Res 151, Denver, CO 80220 USA.
EM david.bekelman@va.gov
FU VA HSR&D Quality Enhancement Research Initiative (QUERI) Rapid Response
Project [11-239]
FX This study was funded by VA HSR&D Quality Enhancement Research
Initiative (QUERI) Rapid Response Project #11-239. The views expressed
in this article are those of the authors and do not necessarily reflect
the position or policy of the Department of Veterans Affairs or the
United States government.
NR 28
TC 2
Z9 2
U1 5
U2 10
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
EI 1557-7740
J9 J PALLIAT MED
JI J. Palliat. Med.
PD APR 1
PY 2016
VL 19
IS 4
BP 456
EP 459
DI 10.1089/jpm.2015.0280
PG 4
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA DI1DZ
UT WOS:000373237500020
PM 26974489
ER
PT J
AU Kougias, P
Tiwari, V
Berger, DH
AF Kougias, Panos
Tiwari, Vikram
Berger, David H.
TI Use of simulation to assess a statistically driven surgical scheduling
system
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
DE Simulation; Statistical modeling; Effectiveness
ID OPERATING-ROOM EFFICIENCY; TIMES; EXPENDITURES; VARIABILITY; PREDICTION;
SURGERY; THEATER; LENGTH; MODEL
AB Background: To maximize operating room (OR) utilization, better estimates of case duration lengths are needed. We used computerized simulation to determine whether scheduling OR cases using a statistically driven system that incorporates patient and surgery-specific factors in the process of case duration prediction improves OR throughput and utilization.
Methods: We modeled surgical and anesthetic length of vascular surgical procedures as a function of patient and operative characteristics using a multivariate linear regression approach (Predictive Modeling System [PMS]). Mean historical operative time per surgeon (HMS) and mean anesthetic time were also calculated for each procedure type. A computerized simulation of scheduling in a single OR performing vascular operations was then created using either the PMS or the HMS.
Results: Compared to HMS, scheduling the operating room using the PMS increased throughput by a minimum of 15% (99.8% cumulative probability, P < 0.001). The PMS was slightly more likely to lead to overtime (mean 13% versus 11% of operative days during a calendar year, P < 0.001). However, the overtime lasted longer in the HMS group (mean 140 versus 95 min per day of overtime, P < 0.001). PMS was associated with lower OR underutilization rate (mean 23% versus 34% of operative days, P < 0.001) and less lengthy OR underutilization (mean 120 versus 193 min per day of underutilization, P < 0.001).
Conclusions: This computerized simulation demonstrates that using the PMS for scheduling in a single operating room increases throughput and other measures of surgical efficiency. Published by Elsevier Inc.
C1 [Kougias, Panos; Berger, David H.] Michael E DeBakey VA Med Ctr, Houston, TX USA.
[Kougias, Panos] Baylor Coll Med, Div Vasc Surg, Houston, TX 77030 USA.
[Kougias, Panos; Berger, David H.] Ctr Innovat Qual Effectiveness & Safety, Houston, TX USA.
[Tiwari, Vikram] Vanderbilt Univ, Dept Anesthesiol, 221 Kirkland Hall, Nashville, TN 37235 USA.
[Berger, David H.] Baylor Coll Med, Dept Surg, Houston, TX 77030 USA.
RP Kougias, P (reprint author), Houston VAMC, Michael E DeBakey Dept Surg, 2002 Holcombe Blvd OCL 112, Houston, TX 77030 USA.
EM pkougias@bcm.edu
NR 17
TC 2
Z9 2
U1 4
U2 8
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
EI 1095-8673
J9 J SURG RES
JI J. Surg. Res.
PD APR
PY 2016
VL 201
IS 2
BP 306
EP 312
DI 10.1016/j.jss.2015.10.043
PG 7
WC Surgery
SC Surgery
GA DH8VS
UT WOS:000373075600010
PM 27020812
ER
PT J
AU Friedlander, AH
Chang, TI
Aghazadehsanai, N
Graves, LL
AF Friedlander, Arthur H.
Chang, Tina I.
Aghazadehsanai, Nona
Graves, Lindsay L.
TI COST-EFFECTIVENESS OF ANTIBIOTIC PROPHYLAXIS
SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION
LA English
DT Letter
C1 [Friedlander, Arthur H.] Vet Affairs Greater Los Angeles Healthcare Syst, Grad Med Educ, Los Angeles, CA USA.
[Friedlander, Arthur H.] Ronald Reagan UCLA Med Ctr, Hosp Dent Serv, Qual Assurance, Los Angeles, CA USA.
[Friedlander, Arthur H.; Chang, Tina I.] Univ Calif Los Angeles, Sch Dent, Dept Oral & Maxillofacial Surg, Los Angeles, CA 90024 USA.
[Chang, Tina I.] Vet Affairs Greater Los Angeles Healthcare Syst, Inpatient Oral & Maxillofacial Surg, Los Angeles, CA USA.
[Aghazadehsanai, Nona; Graves, Lindsay L.] Vet Affairs Greater Los Angeles Healthcare Syst, Oral & Maxillofacial Surg Sect, Dent Serv, Los Angeles, CA USA.
RP Friedlander, AH (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Grad Med Educ, Los Angeles, CA USA.; Friedlander, AH (reprint author), Ronald Reagan UCLA Med Ctr, Hosp Dent Serv, Qual Assurance, Los Angeles, CA USA.; Friedlander, AH (reprint author), Univ Calif Los Angeles, Sch Dent, Dept Oral & Maxillofacial Surg, Los Angeles, CA 90024 USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU AMER DENTAL ASSOC
PI CHICAGO
PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA
SN 0002-8177
EI 1943-4723
J9 J AM DENT ASSOC
JI J. Am. Dent. Assoc.
PD APR
PY 2016
VL 147
IS 4
BP 229
EP 230
DI 10.1016/j.adaj.2016.02.004
PG 3
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA DH9LD
UT WOS:000373116700003
PM 27017589
ER
PT J
AU Wrocklage, KM
Schweinsburg, BC
Krystal, JH
Trejo, M
Roy, A
Weisser, V
Moore, TM
Southwick, SM
Scott, JC
AF Wrocklage, Kristen M.
Schweinsburg, Brian C.
Krystal, John H.
Trejo, Marcia
Roy, Alicia
Weisser, Valerie
Moore, Tyler M.
Southwick, Steven M.
Scott, J. Cobb
TI Neuropsychological Functioning in Veterans with Posttraumatic Stress
Disorder: Associations with Performance Validity, Comorbidities, and
Functional Outcomes
SO JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY
LA English
DT Article
DE Posttraumatic stress disorder; Neuropsychology; Cognitive abilities;
Memory; Executive functions; Quality of life; Occupational functioning
ID TRAUMATIC BRAIN-INJURY; TERM BENZODIAZEPINE USE; MEMORY PERFORMANCE;
COMBAT EXPOSURE; VERBAL MEMORY; ARMY SOLDIERS; WAR VETERANS; FOLLOW-UP;
PTSD; HEALTH
AB Objectives: Numerous studies have shown that individuals with posttraumatic stress disorder (PTSD) display reduced performances on neuropsychological tests, although most prior research has not adequately accounted for comorbidities or performance validity concerns that are common in this population and could partially account for the observed neurocognitive findings. Moreover, few studies have examined the functional implications of neuropsychological results in PTSD. Methods: We examined neuropsychological functioning in 44 veterans with PTSD and 40 veteran trauma comparison (TC) participants with combat exposure and no PTSD. Results: After excluding four veterans with PTSD for performance validity concerns, multivariate analyses of variance by neurocognitive domain revealed significantly worse performance by the PTSD group in the domains of speed of information processing (p = .035) and executive functions (p = .017), but no group differences in attention/working memory, verbal/language functioning, visuoconstruction, or episodic memory. Group differences by PTSD status were still present after covarying for depression, a history of head injuries, and substance use disorders. Executive functioning performance was associated with poorer self-reported occupational functioning and physical health-related quality of life, while speed of information processing performance was associated with poorer physical health-related quality of life. Discussion: These results are generally consistent with a fronto-limbic conceptualization of PTSD-associated neuropsychological dysfunction and show that cognitive functioning may be associated with critical functional outcomes. Taken together, results suggest that consideration of neurocognitive functioning may enhance the clinical management of individuals with PTSD.
C1 [Wrocklage, Kristen M.; Schweinsburg, Brian C.; Krystal, John H.; Trejo, Marcia; Roy, Alicia; Weisser, Valerie; Southwick, Steven M.] Natl Ctr PTSD, Clin Neurosci Div, West Haven, CT USA.
[Wrocklage, Kristen M.; Schweinsburg, Brian C.; Krystal, John H.; Trejo, Marcia; Roy, Alicia; Weisser, Valerie; Southwick, Steven M.] VA Connecticut Healthcare Syst, West Haven, CT USA.
[Schweinsburg, Brian C.; Krystal, John H.; Roy, Alicia; Southwick, Steven M.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
[Krystal, John H.] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT USA.
[Krystal, John H.] Yale New Haven Med Ctr, Psychiat Serv, 20 York St, New Haven, CT 06504 USA.
[Moore, Tyler M.; Scott, J. Cobb] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Scott, J. Cobb] Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr VISN4, Philadelphia, PA 19104 USA.
RP Scott, JC (reprint author), Philadelphia VA Med Ctr, MIRECC 116, 3900 Woodland Ave, Philadelphia, PA 19104 USA.
EM scott1@upenn.edu
FU Department of Veterans Affairs Career Development Award [IK2CX000772];
National Center for PTSD (NCPTSD); National Center for Advancing
Translational Science [1UH2TR000960-01]; Department of Veterans Affairs
(NCPTSD); National Institute on Alcohol Abuse and Alcoholism
[P50AA12870, M01RR00125]; Yale Center for Clinical Investigation [UL1
RR024139]
FX This work was supported by a Department of Veterans Affairs Career
Development Award (IK2CX000772) to Dr. Scott, as well as the National
Center for PTSD (NCPTSD). Dr. Krystal's participation was supported by
the National Center for Advancing Translational Science
(1UH2TR000960-01), the Department of Veterans Affairs (NCPTSD), the
National Institute on Alcohol Abuse and Alcoholism (P50AA12870,
M01RR00125), and the Yale Center for Clinical Investigation (UL1
RR024139). Portions of this research were presented at the 2014 Annual
Meeting of the American Psychological Association (APA). The views
expressed in this article are those of the authors and do not
necessarily reflect the position or policy of the Department of Veterans
Affairs. The authors declare no conflicts of interest.
NR 92
TC 5
Z9 5
U1 6
U2 12
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1355-6177
EI 1469-7661
J9 J INT NEUROPSYCH SOC
JI J. Int. Neuropsychol. Soc.
PD APR
PY 2016
VL 22
IS 4
BP 399
EP 411
DI 10.1017/S1355617716000059
PG 13
WC Clinical Neurology; Neurosciences; Psychiatry; Psychology
SC Neurosciences & Neurology; Psychiatry; Psychology
GA DI1ZK
UT WOS:000373295300003
PM 26892753
ER
PT J
AU Sorensen, MD
AF Sorensen, Mathew D.
TI A Prospective Randomized Controlled Trial of the Efficacy of External
Physical Vibration Lithecbole after Extracorporeal Shock Wave
Lithotripsy for a Lower Pole Renal Stone Less Than 2 cm EDITORIAL
COMMENT
SO JOURNAL OF UROLOGY
LA English
DT Editorial Material
C1 [Sorensen, Mathew D.] Univ Washington, Dept Urol, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
RP Sorensen, MD (reprint author), Univ Washington, Dept Urol, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
EI 1527-3792
J9 J UROLOGY
JI J. Urol.
PD APR
PY 2016
VL 195
IS 4
BP 970
EP 970
PN 1
PG 1
WC Urology & Nephrology
SC Urology & Nephrology
GA DI3LW
UT WOS:000373401200048
PM 26812396
ER
PT J
AU Kikuchi, S
Kenagy, RD
Gao, L
Wight, TN
Azuma, N
Sobel, M
Clowes, AW
AF Kikuchi, Shinsuke
Kenagy, Richard D.
Gao, Lu
Wight, Thomas N.
Azuma, Nobuyoshi
Sobel, Michael
Clowes, Alexander W.
TI Surgical marking pen dye inhibits saphenous vein cell proliferation and
migration in saphenous vein graft tissue
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Article
ID LOWER-EXTREMITY BYPASS; SMOOTH-MUSCLE; INTIMAL HYPERPLASIA;
RANDOMIZED-TRIAL; PROGENITOR CELLS; METHYLENE-BLUE; NEOINTIMA; INSITU;
MYOFIBROBLASTS; APOPTOSIS
AB Objective: Markers containing dyes such as crystal violet (CAS 548-62-9) are routinely used on the adventitia of vein bypass grafts to avoid twisting during placement. Because little is known about how these dyes affect vein graft healing and function, we determined the effect of crystal violet on cell migration and proliferation, which are responses to injury after grafting.
Methods: Fresh human saphenous veins were obtained as residual specimens from leg bypass surgeries. Portions of the vein that had been surgically marked with crystal violet were analyzed separately from those that had no dye marking. In the laboratory, they were split into easily dissected inner and outer layers after removal of endothelium. This cleavage plane was within the circular muscle layer of the media. Cell migration from explants was measured daily as either (1) percentage of migration-positive explants, which exclusively measures migration, or (2) number of cells on the plastic surrounding each explant, which measures migration plus proliferation. Cell proliferation and apoptosis (Ki67 and TUNEL staining, respectively) were determined in dye-marked and unmarked areas of cultured vein rings. The dose-dependent effects of crystal violet were measured for cell migration from explants as well as for proliferation, migration, and death of cultured outer layer cells. Dye was extracted from explants with ethanol and quantified by spectrophotometry.
Results: There was significantly less cell migration from visibly blue compared with unstained outer layer explants by both methods. There was no significant difference in migration from inner layer explants adjacent to blue-stained or unstained sections of vein because dye did not penetrate to the inner layer. Ki67 staining of vein in organ culture, which is a measure of proliferation, progressively increased up to 6 days in nonblue outer layer and was abolished in the blue outer layer. Evidence of apoptosis (TUNEL staining) was present throughout the wall and not different in blue-stained and unstained vein wall segments. Blue outer layer explants had 65.9 +/- 8.0 ng dye/explant compared with 2.1 +/- 1.3 for nonblue outer layer explants. Dye applied in vitro to either outer or inner layer explants dose dependently inhibited migration (IC50 similar to 10 ng/explant). The IC(50)s of crystal violet for outer layer cell proliferation and migration were 0.1 and 1.2 mg/mL, whereas the EC50 for death was between 1 and 10 mg/mL.
Conclusions: Crystal violet inhibits venous cell migration and proliferation, indicating that alternative methods should be considered for marking vein grafts.
C1 [Kikuchi, Shinsuke; Kenagy, Richard D.; Gao, Lu; Sobel, Michael; Clowes, Alexander W.] Univ Washington, Dept Surg, Seattle, WA 98195 USA.
[Kikuchi, Shinsuke; Azuma, Nobuyoshi] Asahikawa Med Univ, Dept Vasc Surg, Asahikawa, Hokkaido, Japan.
[Wight, Thomas N.] Virginia Mason, Benaroya Res Inst, Matrix Biol Program, Seattle, WA USA.
[Sobel, Michael] VA Puget Sound Hlth Care Syst, Div Vasc Surg, Seattle, WA USA.
[Sobel, Michael] Univ Washington, Seattle, WA 98195 USA.
RP Kenagy, RD (reprint author), Univ Washington, Ctr Cardiovasc Biol, POB 358050,850 Republican St, Seattle, WA 98109 USA.
EM rkenagy@u.washington.edu
FU CSRD VA [I01 CX000712]; NHLBI NIH HHS [R41 HL106967, R01 HL030946, R01
HL30946]
NR 34
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD APR
PY 2016
VL 63
IS 4
BP 1044
EP 1050
DI 10.1016/j.jvs.2014.10.017
PG 7
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA DH7FR
UT WOS:000372958200031
PM 25935273
ER
PT J
AU Bates, SE
Fojo, T
AF Bates, Susan E.
Fojo, Tito
TI New drug for pancreatic cancer highlights the dual effect of regulatory
approvals
SO NATURE REVIEWS CLINICAL ONCOLOGY
LA English
DT Editorial Material
ID PACLITAXEL PLUS GEMCITABINE; FOLFIRINOX; TRIALS
AB The recent FDA approval of MM-398 as a second-line treatment of metastatic pancreatic cancer, based on a 1.9-month overall survival benefit observed in the NAPOLI-1 trial, adds a new therapeutic option for this notoriously difficult-to-treat disease; however, by discouraging clinical trial enrolment, this approval might have negative consequences for the development of novel agents, which remain an essential unmet need.
C1 [Bates, Susan E.; Fojo, Tito] Columbia Univ, Med Ctr, Dept Med, Div Hematol Oncol, Herbert Irving Pavil,9th Floor, New York, NY 10032 USA.
[Bates, Susan E.; Fojo, Tito] James J Peters VA Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA.
RP Bates, SE (reprint author), Columbia Univ, Med Ctr, Dept Med, Div Hematol Oncol, Herbert Irving Pavil,9th Floor, New York, NY 10032 USA.; Bates, SE (reprint author), James J Peters VA Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA.
EM seb2227@cumc.columbia.edu
NR 9
TC 0
Z9 0
U1 1
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-4774
EI 1759-4782
J9 NAT REV CLIN ONCOL
JI Nat. Rev. Clin. Oncol.
PD APR
PY 2016
VL 13
IS 4
BP 205
EP 206
DI 10.1038/nrclinonc.2016.22
PG 2
WC Oncology
SC Oncology
GA DH4DF
UT WOS:000372735000002
PM 26902963
ER
PT J
AU Banks, WA
AF Banks, William A.
TI From blood-brain barrier to blood-brain interface: new opportunities for
CNS drug delivery
SO NATURE REVIEWS DRUG DISCOVERY
LA English
DT Review
ID AMYLOID-BETA-PROTEIN; CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE
ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS;
MICROVASCULAR ENDOTHELIAL-CELLS; RECEPTOR-RELATED PROTEIN-1;
CEREBRAL-ARTERY OCCLUSION; NECROSIS-FACTOR-ALPHA; SPINAL-CORD BARRIER;
ALZHEIMERS-DISEASE
AB One of the biggest challenges in the development of therapeutics for central nervous system (CNS) disorders is achieving sufficient blood-brain barrier (BBB) penetration. Research in the past few decades has revealed that the BBB is not only a substantial barrier for drug delivery to the CNS but also a complex, dynamic interface that adapts to the needs of the CNS, responds to physiological changes, and is affected by and can even promote disease. This complexity confounds simple strategies for drug delivery to the CNS, but provides a wealth of opportunities and approaches for drug development. Here, I review some of the most important areas that have recently redefined the BBB and discuss how they can be applied to the development of CNS therapeutics.
C1 [Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, 1660 S Columbian Way, Seattle, WA 98108 USA.
[Banks, William A.] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, 1660 S Columbian Way, Seattle, WA 98108 USA.
RP Banks, WA (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, 1660 S Columbian Way, Seattle, WA 98108 USA.; Banks, WA (reprint author), Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM wabanks1@uw.edu
FU US Department of Veterans Affairs; US National Institute on Aging [R01
AG046619]
FX The author is supported by the US Department of Veterans Affairs and a
grant from the US National Institute on Aging (grant R01 AG046619).
NR 174
TC 20
Z9 20
U1 22
U2 54
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1474-1776
EI 1474-1784
J9 NAT REV DRUG DISCOV
JI Nat. Rev. Drug Discov.
PD APR
PY 2016
VL 15
IS 4
BP 275
EP +
DI 10.1038/nrd.2015.21
PG 18
WC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy
SC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy
GA DI0ZM
UT WOS:000373225800017
PM 26794270
ER
PT J
AU McCarthy, MS
Warren, M
Roberts, PR
AF McCarthy, Mary S.
Warren, Malissa
Roberts, Pamela R.
TI Recent Critical Care Nutrition Trials and the Revised Guidelines: Do
They Reconcile?
SO NUTRITION IN CLINICAL PRACTICE
LA English
DT Editorial Material
ID SUPPLEMENTAL PARENTERAL-NUTRITION; IMMUNE-MODULATING NUTRIENTS; OIL
LIPID EMULSIONS; ILL PATIENT SOCIETY; ACUTE LUNG INJURY; CLINICAL-TRIAL;
GASTROINTESTINAL SURGERY; ENTERAL NUTRITION; RANDOMIZED-TRIAL;
NOSOCOMIAL INFECTIONS
C1 [McCarthy, Mary S.] Madigan Army Med Ctr, Ctr Nursing Sci & Clin Inquiry, 9040 Jackson Ave, Tacoma, WA 98431 USA.
[Warren, Malissa] Portland VA Med Ctr, Portland, OR USA.
[Roberts, Pamela R.] Univ Oklahoma, Coll Med, Dept Anesthesiol, Oklahoma City, OK 73190 USA.
RP McCarthy, MS (reprint author), Madigan Army Med Ctr, Ctr Nursing Sci & Clin Inquiry, 9040 Jackson Ave, Tacoma, WA 98431 USA.
EM Mary.s.mccarthy1.civ@mail.mil
NR 34
TC 1
Z9 1
U1 1
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0884-5336
EI 1941-2452
J9 NUTR CLIN PRACT
JI Nutr. Clin. Pract.
PD APR
PY 2016
VL 31
IS 2
BP 150
EP 154
DI 10.1177/0884533616630301
PG 5
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA DH6LS
UT WOS:000372902700002
PM 26915509
ER
PT J
AU Curtis, CS
Busch, RA
Crass, RL
Webb, AP
Kudsk, KA
AF Curtis, Caitlin S.
Busch, Rebecca A.
Crass, Ryan L.
Webb, Aaron P.
Kudsk, Kenneth A.
TI Use of Premixed Parenteral Nutrition During a Phosphate Shortage in a
Non-Critically Ill Population
SO NUTRITION IN CLINICAL PRACTICE
LA English
DT Article
DE parenteral nutrition; nutritional support; dietary phosphorus;
phosphates
ID DRUG SHORTAGES; IMPACT
AB Background: Drug shortages pose prescribing problems to clinicians. During fiscal year (FY) 2014, an acute shortage of intravenous potassium phosphate (K-Phos IV), a common supplement in parenteral nutrition (PN), prompted the use of premixed instead of individualized PN to conserve K-Phos IV. Here we quantify the K-Phos IV conserved by using premixed PN and the associated cost differences. Materials and Methods: Costs of preparing premixed PN vs individualized PN of equivalent composition were calculated for FY 2014 at a single-center tertiary care facility. Quantity and cost of K-Phos IV saved were calculated based on the number of premixed PN prescriptions. Costs for FY 2015 were projected based on drug costs from July 2014. Results: During FY 2014, prescribing premixed in lieu of individualized PN conserved 16,440 mmol K-Phos IV but increased the cost of PN by $4080.45. However, increases in K-Phos IV cost at the end of FY 2014 resulted in premixed PN as a relatively less expensive therapy than individualized PN for our institution. Cost savings of $7092.20 due to use of premixed PN is projected for FY 2015. Conclusions: Prescribing premixed PN conserves K-Phos IV during shortages, but it increased direct drug spending in non-critically ill patients at our institution during FY 2014. Persistent shortages can drive market costs of K-Phos IV, however, necessitating frequent reconsideration of resource utilization.
C1 [Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Veteran Adm Surg Serv, Madison, WI USA.
[Curtis, Caitlin S.; Webb, Aaron P.] Univ Wisconsin Hosp & Clin, Dept Pharm, Madison, WI 53792 USA.
[Busch, Rebecca A.; Kudsk, Kenneth A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI USA.
[Crass, Ryan L.] Univ Wisconsin, Sch Pharm, 425 N Charter St, Madison, WI 53706 USA.
RP Kudsk, KA (reprint author), G5 341 Clin Sci Ctr, 600 Highland Ave, Madison, WI 53792 USA.
EM kudsk@surgery.wisc.edu
FU Surgical Oncology Research Training Program [T32 CA090217]; William S.
Middleton Memorial Veterans Hospital, Madison, Wisconsin
FX This material is the result of work supported with the resources and use
of facilities at the William S. Middleton Memorial Veterans Hospital,
Madison, Wisconsin. The contents of this article do not represent the
views of the Department of Veterans Affairs or the United States
government. The project described was supported in part by the Surgical
Oncology Research Training Program T32 CA090217.
NR 9
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0884-5336
EI 1941-2452
J9 NUTR CLIN PRACT
JI Nutr. Clin. Pract.
PD APR
PY 2016
VL 31
IS 2
BP 218
EP 222
DI 10.1177/0884533615583093
PG 5
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA DH6LS
UT WOS:000372902700012
PM 25896971
ER
PT J
AU Holland, CL
Rubio, D
Rodriguez, KL
Kraemer, KL
Day, N
Arnold, RM
Tarr, JA
Chang, JC
AF Holland, Cynthia L.
Rubio, Doris
Rodriguez, Keri L.
Kraemer, Kevin L.
Day, Nancy
Arnold, Robert M.
Tarr, Jill A.
Chang, Judy C.
TI Obstetric Health Care Providers' Counseling Responses to Pregnant
Patient Disclosures of Marijuana Use
SO OBSTETRICS AND GYNECOLOGY
LA English
DT Article; Proceedings Paper
CT International Conference on Communication in Healthcare
CY OCT 25-28, 2015
CL New Orleans, LA
ID EXPOSURE; ATTENTION; BEHAVIOR; ALCOHOL; ABUSE; DRUG; AGE
AB OBJECTIVE:
To describe obstetric health care providers' responses and counseling approaches to patients' disclosures of marijuana use during first prenatal visits.
METHODS:
We performed a content analysis of audio-recorded patient-health care provider first prenatal visits for obstetrics health care providers' responses to patients' disclosure of marijuana use. The study was conducted at five urban outpatient clinics located in Pittsburgh, Pennsylvania.
RESULTS:
Among 468 audio-recorded first obstetric encounters, 90 patients (19%) disclosed marijuana use to 47 health care providers; mean number of recoded encounters containing marijuana disclosures for participating health providers was 1.8 +/- 1.4. In 48% of these 90 visits, obstetric health care providers did not respond to marijuana use disclosures or offer counseling. When counseling was offered, it consisted of general statements without specific information on the risks or outcomes related to marijuana use in pregnancy, discussions regarding the need for urine toxicology testing, and warnings that use detected at the time of delivery would initiate child protective services involvement.
CONCLUSION:
Obstetric health care provider responses to disclosure of marijuana use occurred in approximately half of patient encounters when marijuana use was disclosed and focused on legal and procedural consequences with less focus on health or medical implications. Our results suggest a need for health care provider training on potential consequences of perinatal marijuana use and communication skills for counseling patients about perinatal marijuana.
C1 Magee Womens Res Inst, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA.
Univ Pittsburgh, Dept Internal Med, Ctr Res Hlth Care, Div Gen Internal Med,Clin & Translat Sci Inst, Pittsburgh, PA USA.
Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA.
Ctr Res Hlth Care, Inst Enhance Palliat Care, Sect Palliat Care & Med Eth, Inst Doctor Patient Commun, Pittsburgh, PA USA.
RP Chang, JC (reprint author), 300 Halket St, Pittsburgh, PA 15213 USA.
EM jchang@mail.magee.edu
RI Day, Nancy/H-3171-2016
FU NCATS NIH HHS [UL1 TR000005, UL1TR000005]; NIDA NIH HHS
[1R01DA026410-01A1, R01 DA026410]
NR 24
TC 2
Z9 2
U1 2
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0029-7844
J9 OBSTET GYNECOL
JI Obstet. Gynecol.
PD APR
PY 2016
VL 127
IS 4
BP 681
EP 687
DI 10.1097/AOG.0000000000001343
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DH4YF
UT WOS:000372791000009
PM 26959210
ER
PT J
AU McCarrier, KP
Deal, LS
Abraham, L
Blum, SI
Bush, EN
Martin, ML
Thase, ME
Coons, SJ
AF McCarrier, Kelly P.
Deal, Linda S.
Abraham, Lucy
Blum, Steven I.
Bush, Elizabeth Nicole
Martin, Mona L.
Thase, Michael E.
Coons, Stephen Joel
CA PRO Consortium's Depression Workin
TI Patient-Centered Research to Support the Development of the Symptoms of
Major Depressive Disorder Scale (SMDDS): Initial Qualitative Research
SO PATIENT-PATIENT CENTERED OUTCOMES RESEARCH
LA English
DT Article
ID OUTCOMES PRO INSTRUMENTS; RATING-SCALE; INTERRATER RELIABILITY;
SELF-REPORT; MELANCHOLIA; VALIDATION; SEVERITY
AB Content valid, patient-reported outcome (PRO) measures of major depressive disorder (MDD) symptoms are needed to assess MDD treatment benefit. While a range of questionnaires are currently available to evaluate aspects of depression from the patient's perspective, their comprehensiveness and qualitative development histories are unclear.
The objective of this study was to describe the process and results of the preliminary qualitative development of a new symptom-based PRO measure intended to assess treatment benefit in MDD clinical trials.
Qualitative interviews were conducted with adult MDD patients in the USA who recently experienced a major depressive episode. Experienced interviewers conducted concept elicitation (CE) and cognitive interviews using semi-structured interview guides. The CE interview guide was used to elicit spontaneous reports of symptom experiences along with probing to further explore and confirm concepts. The cognitive interview guide was developed to evaluate concept relevance, understandability, and structure of the draft items, and to facilitate further instrument refinement.
Forty patients participated in the CE interviews. A total of 3022 symptom codes, representing 84 different concepts were derived from the transcripts. Data from the CE interviews were considered alongside existing literature and clinical expert opinion during an item-generation process, leading to development of a preliminary version of the Symptoms of Major Depressive Disorder Scale (SMDDS). Fifteen patients participated in three waves of cognitive interviews, during which the SMDDS was further refined.
The SMDDS is a 35-item PRO measure intended for use as an endpoint in MDD clinical trials to support medical product labeling. The SMDDS uses a 7-day recall period and verbal rating scales. It was developed in accordance with the US Food and Drug Administration (FDA)'s PRO Guidance and best practices. Qualitative interviews have provided evidence for content validity. Future quantitative studies will confirm the SMDDS's measurement properties and support FDA qualification.
C1 [McCarrier, Kelly P.; Martin, Mona L.] Hlth Res Associates Inc, 6505 216th St SW Suite 105, Mountlake Terrace, WA 98043 USA.
[Deal, Linda S.] Shire, Clin Outcomes Assessment, Wayne, PA USA.
[Abraham, Lucy] Pfizer Ltd, Outcomes & Evidence, Tadworth, Surrey, England.
[Blum, Steven I.] GlaxoSmithKline, Patient Reported Outcomes, King Of Prussia, PA USA.
[Bush, Elizabeth Nicole] Eli Lilly & Co, PRO Ctr Expertise, Indianapolis, IN 46285 USA.
[Thase, Michael E.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Coons, Stephen Joel] Crit Path Inst, Patient Reported Outcome Consortium, Tucson, AZ USA.
RP McCarrier, KP (reprint author), Hlth Res Associates Inc, 6505 216th St SW Suite 105, Mountlake Terrace, WA 98043 USA.
EM mccarrier@hrainc.net
FU AbbVie; Bristol-Myers Squibb; Eli Lilly and Company; Forest Research
Institute; Janssen; Pfizer; Roche Products Limited; Shire; Sunovion;
Takeda; United States Food and Drug Administration [U01FD003865]
FX This research was funded by the following members of the PRO Consortium:
AbbVie, Bristol-Myers Squibb, Eli Lilly and Company, Forest Research
Institute, Janssen, Pfizer, Roche Products Limited, Shire, Sunovion, and
Takeda. The PRO Consortium receives support through Grant U01FD003865
from the United States Food and Drug Administration to the Critical Path
Institute.
NR 28
TC 1
Z9 1
U1 0
U2 1
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1178-1653
EI 1178-1661
J9 PATIENT
JI Patient
PD APR
PY 2016
VL 9
IS 2
BP 117
EP 134
DI 10.1007/s40271-015-0132-1
PG 18
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA DH6EL
UT WOS:000372883700003
PM 26113249
ER
PT J
AU Berg, AT
Baca, CB
Rychlik, K
Vickrey, BG
Caplan, R
Testa, FM
Levy, SR
AF Berg, Anne T.
Baca, Christine B.
Rychlik, Karen
Vickrey, Barbara G.
Caplan, Rochelle
Testa, Francine M.
Levy, Susan R.
TI Determinants of Social Outcomes in Adults With Childhood-onset Epilepsy
SO PEDIATRICS
LA English
DT Article
ID LONG-TERM PROGNOSIS; ABSENCE EPILEPSY; 2 DECADES; CHILDREN; SEIZURES;
DIAGNOSIS; BEHAVIOR; DUTCH
AB BACKGROUND: Adults with childhood-onset epilepsy experience poorer adult social outcomes than their peers. The relative roles of seizures over time versus learning and psychiatric problems are unclear.
METHODS: We examined independent influences of psychiatric and learning disorders and of seizure course in 241 young adults (22-35 years old) with uncomplicated epilepsy in a longitudinal community-based cohort study. Social outcomes were ascertained throughout the study. A history of psychiatric and learning problems was ascertained similar to 9 years after study entry. Seizure course was: "Excellent," no seizures after the first year, in complete remission at last contact (N = 95, 39%); " Good, " seizures occurred 1 to 5 years after diagnosis, in complete remission at last contact (N = 56, 23%); " Fluctuating, " more complicated trajectories, but never pharmacoresistant (N = 70, 29%); " Pharmacoresistant, " long-term pharmacoresistant (N = 20, 8%). Multiple logistic regression was used to identify contributors to each social outcome.
RESULTS: Better seizure course predicted college completion, being either employed or pursuing a degree, and driving, but was not substantially associated with other social outcomes. Poorer seizure course was associated with a greater likelihood of having offspring, particularly in women without partners. Learning problems, psychiatric disorders, or both negatively influenced all but 2 of the social outcomes.
CONCLUSIONS: In young adults with uncomplicated epilepsy, the course of seizures contributed primarily to education, employment, and driving. A history of learning problems and psychiatric disorders adversely influenced most adult outcomes. These findings identify potential reasons for vocational and social difficulties encountered by young adults with childhood epilepsy and areas to target for counseling and transition planning.
C1 [Berg, Anne T.] Ann & Robert H Lurie Childrens Hosp Chicago, Epilepsy Ctr, Box 29,225 East Chicago Ave, Chicago, IL 60611 USA.
[Rychlik, Karen] Ann & Robert H Lurie Childrens Hosp Chicago, Stanley Manne Childrens Res Inst, Biostat Res Core, Chicago, IL 60611 USA.
[Berg, Anne T.] Northwestern Feinberg Sch Med, Dept Pediat, Chicago, IL USA.
[Baca, Christine B.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Dept Neurol, Los Angeles, CA 90024 USA.
[Caplan, Rochelle] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, David Geffen Sch Med, Los Angeles, CA 90024 USA.
[Baca, Christine B.] VA Greater Los Angeles Hlth Care Syst, Dept Neurol, Los Angeles, CA USA.
[Vickrey, Barbara G.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA.
[Testa, Francine M.; Levy, Susan R.] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA.
[Testa, Francine M.; Levy, Susan R.] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA.
RP Berg, AT (reprint author), Ann & Robert H Lurie Childrens Hosp Chicago, Epilepsy Ctr, Box 29,225 East Chicago Ave, Chicago, IL 60611 USA.
EM atberg@luriechildrens.org
FU National Institute of Neurologic Disorders and Stroke [R37-NS31146];
National Institutes of Health (NIH)
FX This study was funded by grant R37-NS31146 from the National Institute
of Neurologic Disorders and Stroke. Funded by the National Institutes of
Health (NIH).
NR 37
TC 2
Z9 2
U1 1
U2 4
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD APR
PY 2016
VL 137
IS 4
AR e20153944
DI 10.1542/peds.2015-3944
PG 10
WC Pediatrics
SC Pediatrics
GA DI0OU
UT WOS:000373197500049
ER
PT J
AU Kittiskulnam, P
Chertow, GM
Kaysen, GA
Delgado, C
Dalrymple, LS
Johansen, KL
AF Kittiskulnam, Piyawan
Chertow, Glenn M.
Kaysen, George A.
Delgado, Cynthia
Dalrymple, Lorien S.
Johansen, Kirsten L.
TI Misclassification of Obesity by Body Mass Index Among Patients Receiving
Hemodialysis
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Letter
ID WAIST CIRCUMFERENCE; DIAGNOSING OBESITY; POPULATION; MORTALITY; DISEASE
C1 [Kittiskulnam, Piyawan; Delgado, Cynthia; Johansen, Kirsten L.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Kittiskulnam, Piyawan; Delgado, Cynthia; Johansen, Kirsten L.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Kittiskulnam, Piyawan] Chulalongkorn Univ, Bangkok, Thailand.
[Kittiskulnam, Piyawan] King Chulalongkorn Mem Hosp, Thai Red Cross Soc, Bangkok, Thailand.
[Chertow, Glenn M.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[Kaysen, George A.; Dalrymple, Lorien S.] Univ Calif Davis, Sacramento, CA 95817 USA.
[Johansen, Kirsten L.] Univ Calif San Francisco, US Renal Data Syst Nutr Special Studies Ctr, San Francisco, CA 94143 USA.
RP Johansen, KL (reprint author), Univ Calif San Francisco, San Francisco, CA 94143 USA.; Johansen, KL (reprint author), San Francisco VA Med Ctr, San Francisco, CA USA.; Johansen, KL (reprint author), Univ Calif San Francisco, US Renal Data Syst Nutr Special Studies Ctr, San Francisco, CA 94143 USA.
EM kirsten.johansen@ucsf.edu
FU CSRD VA [IK2 CX000527]; NIDDK NIH HHS [K24DK085153, N01-DK-7-0005,
K23DK093584]; PHS HHS [KD-7-5004]
NR 10
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
EI 1523-6838
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD APR
PY 2016
VL 67
IS 4
BP 709
EP 711
DI 10.1053/j.ajkd.2015.09.028
PG 3
WC Urology & Nephrology
SC Urology & Nephrology
GA DH3XO
UT WOS:000372720300027
PM 26612278
ER
PT J
AU Thomas, KM
Wright, AGC
Lukowitsky, MR
Donnellan, MB
Hopwood, CJ
AF Thomas, Katherine M.
Wright, Aidan G. C.
Lukowitsky, Mark R.
Donnellan, M. Brent
Hopwood, Christopher J.
TI Correction to "Evidence for the Criterion Validity and Clinical Utility
of the Pathological Narcissism Inventory"
SO ASSESSMENT
LA English
DT Article
DE correction; narcissism; validity; clinical utility
AB In our article Evidence for the Criterion Validity and Clinical Utility of the Pathological Narcissism Inventory (2012), we provided incorrect values for the r(contrast-cv) coefficients we presented in Table 1. In the current report, we provide correct r(contrast-cv) values in Table 1 and discuss the implications of our updated results, particularly with respect to how these results differ from our initial report.
C1 [Thomas, Katherine M.; Hopwood, Christopher J.] Michigan State Univ, E Lansing, MI 48824 USA.
[Thomas, Katherine M.] San Francisco VA Med Ctr, Bldg 8 Behav Hlth, San Francisco, CA 94118 USA.
[Wright, Aidan G. C.] Univ Pittsburgh, Pittsburgh, PA USA.
[Lukowitsky, Mark R.] Albany Med Ctr, Albany, NY USA.
[Donnellan, M. Brent] Texas A&M Univ, College Stn, TX USA.
RP Thomas, KM (reprint author), San Francisco VA Med Ctr, Bldg 8 Behav Hlth, San Francisco, CA 94118 USA.
EM thomas.kate.m@gmail.com
NR 5
TC 1
Z9 1
U1 0
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1073-1911
EI 1552-3489
J9 ASSESSMENT
JI Assessment
PD APR
PY 2016
VL 23
IS 2
BP 262
EP 263
DI 10.1177/1073191115584971
PG 2
WC Psychology, Clinical
SC Psychology
GA DG8CO
UT WOS:000372310200011
PM 26019298
ER
PT J
AU Shahid, H
Singh, JA
AF Shahid, Hania
Singh, Jasvinder A.
TI Racial/Ethnic Disparity in Rates and Outcomes of Total Joint
Arthroplasty
SO CURRENT RHEUMATOLOGY REPORTS
LA English
DT Article
DE Total joint arthroplasty (TJA); Race; Ethnicity; Disparity; Total joint
replacement (TJR); Total knee arthroplasty (TKA); Total hip arthroplasty
(THA); Total ankle arthroplasty (TAA); Total elbow arthroplasty (TEA);
Total shoulder arthroplasty (TSA); Osteoarthritis (OA); Rheumatoid
arthritis (RA); White; Caucasian; African American (AA); Black; Hispanic
ID TOTAL KNEE REPLACEMENT; TOTAL HIP-REPLACEMENT; STATES MEDICARE
POPULATION; CLINICAL DECISION-MAKING; QUALITY-OF-LIFE; RACIAL
DISPARITIES; UNITED-STATES; AFRICAN-AMERICANS; SHOULDER ARTHROPLASTY;
PATIENT EXPECTATIONS
AB Racial/ethnic disparity in total joint arthroplasty (TJA) has grown over the last two decades as studies have documented the widening gap between Blacks and Whites in TJA utilization rates despite the known benefits of TJA. Factors contributing to this disparity have been explored and include demographics, socioeconomic status, patient knowledge, patient preference, willingness to undergo TJA, patient expectation of post-arthroplasty outcome, religion/spirituality, and physician-patient interaction. Improvement in patient knowledge by effective physician-patient communication and other methods can possibly influence patient's perception of the procedure. Such interventions can provide patient-relevant data on benefits/risks and dispel myths related to benefits/risks of arthroplasty and possibly reduce this disparity. This review will summarize the literature on racial/ethnic disparity on TJA utilization and outcomes and the factors underlying this disparity.
C1 [Shahid, Hania] Rawalpindi Med Coll, Dept Med, Rawalpindi, Pakistan.
[Shahid, Hania; Singh, Jasvinder A.] UAB, Sch Med, Dept Med, Birmingham, AL USA.
[Singh, Jasvinder A.] UAB, Sch Publ Hlth, Div Epidemiol, Birmingham, AL USA.
[Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA.
[Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA.
RP Singh, JA (reprint author), UAB, Sch Med, Dept Med, Birmingham, AL USA.; Singh, JA (reprint author), UAB, Sch Publ Hlth, Div Epidemiol, Birmingham, AL USA.; Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA.; Singh, JA (reprint author), Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA.
EM Jasvinder.md@gmail.com
FU UAB Division of Rheumatology
FX This material is the result of work supported by research funds from UAB
Division of Rheumatology and the resources and use of facilities at the
Birmingham VA Medical Center.
NR 90
TC 0
Z9 0
U1 5
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3774
EI 1534-6307
J9 CURR RHEUMATOL REP
JI Curr. Rheumatol. Rep.
PD APR
PY 2016
VL 18
IS 4
AR 20
DI 10.1007/s11926-016-0570-3
PG 13
WC Rheumatology
SC Rheumatology
GA DH2DO
UT WOS:000372594600003
PM 26984804
ER
PT J
AU Pugliese, A
Boulware, D
Yu, LP
Babu, S
Steck, AK
Becker, D
Rodriguez, H
DiMeglio, L
Evans-Molina, C
Harrison, LC
Schatz, D
Palmer, JP
Greenbaum, C
Eisenbarth, GS
Sosenko, JM
AF Pugliese, Alberto
Boulware, David
Yu, Liping
Babu, Sunanda
Steck, Andrea K.
Becker, Dorothy
Rodriguez, Henry
DiMeglio, Linda
Evans-Molina, Carmella
Harrison, Leonard C.
Schatz, Desmond
Palmer, Jerry P.
Greenbaum, Carla
Eisenbarth, George S.
Sosenko, Jay M.
CA Type 1 Diabet TrialNet Study Grp
TI HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 Haplotype Protects
Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the
Stages of Disease Progression
SO DIABETES
LA English
DT Article
ID CLASS-II MOLECULES; GLUTAMIC-ACID DECARBOXYLASE; TRIALNET
NATURAL-HISTORY; 1ST DEGREE RELATIVES; DOMINANT PROTECTION; IMPROVE
PREDICTION; ISLET AUTOIMMUNITY; HLA; MELLITUS; INSULIN
AB The HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 haplotype is linked to protection from the development of type 1 diabetes (T1D). However, it is not known at which stages in the natural history of T1D development this haplotype affords protection. We examined a cohort of 3,358 auto antibody -positive relatives of T1D patients in the Pathway to Prevention (PTP) Study of the Type 1 Diabetes Trial Net. The PTP study examines risk factors for T1D and disease progression in relatives. HLA typing revealed that 155 relatives carried this protective haplotype. A comparison with 60 autoantibody-negative relatives suggested protection from autoantibody development. Moreover, the relatives with DRB1*15:01-D0A1*01:02-DQB1*06:02 less frequently expressed autoantibodies associated with higher T1D risk, were less likely to have multiple autoantibodies at baseline, and rarely converted from single to multiple autoantibody positivity on follow-up. These relatives also had lower frequencies of metabolic abnormalities at baseline and exhibited no overall metabolic worsening on follow-up. Ultimately, they had a very low 5-year cumulative incidence of T1D. In conclusion, the protective influence of DRB1*15:01-DQA1*01:02-DQB1*06:02 spans from autoantibody development through all stages of progression, and relatives with this allele only rarely develop T1D.
C1 [Pugliese, Alberto; Sosenko, Jay M.] Univ Miami, Diabet Res Inst, Miller Sch Med, Miami, FL USA.
[Pugliese, Alberto] Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL USA.
[Boulware, David] Univ Miami, Div Endocrinol Metab & Diabet, Dept Med, Miller Sch Med, Miami, FL USA.
[Yu, Liping; Babu, Sunanda; Steck, Andrea K.; Eisenbarth, George S.] Univ S Florida, Div Bioinformat & Biostat, Tampa, FL USA.
[Becker, Dorothy] Univ Colorado, Barbara Davis Ctr Childhood Diabet, Anschutz Med Campus, Aurora, CO USA.
[Rodriguez, Henry] Univ Pittsburgh, Med Ctr, Dept Pediat, Childrens Hosp Pittsburgh, Pittsburgh, PA USA.
[DiMeglio, Linda] Univ S Florida, Dept Pediat, Morsani Coll Med, Tampa, FL USA.
[Evans-Molina, Carmella] Indiana Univ Hlth, Riley Hosp Children, Dept Pediat Endocrinol, Indianapolis, IN USA.
[Harrison, Leonard C.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA.
[Harrison, Leonard C.] Richard L Roudebush VA Med Ctr, Indianapolis, IN USA.
[Schatz, Desmond] Univ Melbourne, Dept Med Biol, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3052, Australia.
[Palmer, Jerry P.] Univ Florida, Dept Pediat, Gainesville, FL USA.
[Greenbaum, Carla] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Greenbaum, Carla] Univ Washington, Seattle, WA 98195 USA.
[Sosenko, Jay M.] Benaroya Res Inst, Seattle, WA USA.
RP Pugliese, A (reprint author), Univ Miami, Diabet Res Inst, Miller Sch Med, Miami, FL USA.; Pugliese, A (reprint author), Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL USA.
EM apuglies@med.miami.edu
FU National Institutes of Health_(NIH) through the National Institute of
Diabetes and Digestive and Kidney Diseases; National Institute of
Allergy and Infectious Diseases; Eunice Kennedy Shriver National
Institute of Child Health and Human Development [U01 DK061010, U01
DK061034, U01 DK061042, U01 DK061058, U01 DK085465, U01 DK085453, U01
DK085461, U01 DK085463, U01 DK085466, U01 DK085499, U01 DK085504, U01
DK085505, U01 DK085509, U01 DK103180, U01 DK103153, U01 DK085476, U01
DK103266]; JDRF
FX The sponsor of the trial was the Type 1 Diabetes TrialNet Pathway to
Prevention Study Group. Type 1 Diabetes TrialNet Pathway to Prevention
Study Group is a clinical trials network funded by the National
Institutes of Health_(NIH) through the National Institute of Diabetes
and Digestive and Kidney Diseases, the National Institute of Allergy and
Infectious Diseases, and the Eunice Kennedy Shriver National Institute
of Child Health and Human Development through the cooperative agreements
U01 DK061010, U01 DK061034, U01 DK061042, U01 DK061058, U01 DK085465,
U01 DK085453, U01 DK085461, U01 DK085463, U01 DK085466, U01 DK085499,
U01 DK085504, U01 DK085505, U01 DK085509, U01 DK103180, U01 DK103153,
U01 DK085476, and U01 DK103266. The study group is also funded by JDRF.
NR 48
TC 0
Z9 0
U1 1
U2 3
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
EI 1939-327X
J9 DIABETES
JI Diabetes
PD APR
PY 2016
VL 65
IS 4
BP 1109
EP 1119
DI 10.2337/db15-1105
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DH5VC
UT WOS:000372859200028
PM 26822082
ER
PT J
AU Vindigni, SM
Kaz, AM
AF Vindigni, Stephen M.
Kaz, Andrew M.
TI Universal Screening of Colorectal Cancers for Lynch Syndrome: Challenges
and Opportunities
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Review
DE Lynch syndrome; Hereditary non-polyposis colorectal cancer; HNPCC;
Universal screening; Universal testing; Colorectal cancer screening;
Genetic testing
ID REVISED BETHESDA GUIDELINES; COST-EFFECTIVENESS ANALYSIS; GENETIC
TESTING STRATEGIES; MSH6 GERMLINE MUTATIONS; MICROSATELLITE-INSTABILITY;
COLON-CANCER; FOLLOW-UP; IDENTIFICATION; IMMUNOHISTOCHEMISTRY;
INDIVIDUALS
AB Lynch syndrome (LS) is the most common heritable colorectal cancer (CRC) syndrome, accounting for approximately 3 % of CRC cases in the USA each year. LS results from a genetic mutation in one of the four mismatch repair genes, and clinically LS is associated with CRC and other gastrointestinal and extra-gastrointestinal malignancies. In this review, we describe the various clinical criteria utilized for the identification of LS patients and the inherent flaws with these criteria. We discuss the concept of universal testing for LS in all cases of newly diagnosed CRC, along with the potential benefits and challenges of universal testing. Several studies have shown that universal tumor testing is cost-effective and identifies cases of LS that are missed using traditional clinical criteria, which may result in reduced cancer mortality for probands and their families. Yet the full benefits of universal tumor testing may be limited by the availability and patient acceptance of genetic testing, and by logistical obstacles affecting the implementation of universal testing programs. Lastly, we comment on developing technologies such as massively parallel next-generation sequencing, which permits simultaneous sequencing of multiple genes involved in LS and other inherited colon cancer syndromes.
C1 [Vindigni, Stephen M.; Kaz, Andrew M.] Univ Washington, Div Gastroenterol, Sch Med, 1959 NE Pacific St,Box 356424, Seattle, WA 98105 USA.
[Kaz, Andrew M.] VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S 111 Gastro, Seattle, WA 98108 USA.
RP Kaz, AM (reprint author), Univ Washington, Div Gastroenterol, Sch Med, 1959 NE Pacific St,Box 356424, Seattle, WA 98105 USA.; Kaz, AM (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S 111 Gastro, Seattle, WA 98108 USA.
EM vindigni@uw.edu; Andrew.kaz@va.gov
NR 52
TC 1
Z9 1
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
EI 1573-2568
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD APR
PY 2016
VL 61
IS 4
BP 969
EP 976
DI 10.1007/s10620-015-3964-6
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DG7ZJ
UT WOS:000372301900008
PM 26602911
ER
PT J
AU Muehe, AM
Feng, D
Eyben, R
Luna-Fineman, S
Link, MP
Muthig, T
Huddleston, AE
Neuwelt, EA
Daldrup-Link, HE
AF Muehe, Anne M.
Feng, Dan
von Eyben, Rie
Luna-Fineman, Sandra
Link, Michael P.
Muthig, Travis
Huddleston, Amy E.
Neuwelt, Edward A.
Daldrup-Link, Heike E.
TI Safety Report of Ferumoxytol for Magnetic Resonance Imaging in Children
and Young Adults
SO INVESTIGATIVE RADIOLOGY
LA English
DT Article
DE pediatric; ferric compounds; ferumoxytol; adverse events/adverse
effects; safety; toxicity; contrast media
ID IRON-OXIDE NANOPARTICLES; HEMODIALYSIS-PATIENTS; DEFICIENCY ANEMIA;
ADVERSE-REACTIONS; KIDNEY-DISEASE; CONTRAST AGENT; LIFE-SUPPORT; MRI;
THERAPY; MANAGEMENT
AB Objective
The aim of this study was to assess the safety profile of ferumoxytol as an intravenous magnetic resonance imaging contrast agent in children.
Materials and Methods
We prospectively evaluated the safety of ferumoxytol administrations as an "off-label" contrast agent for magnetic resonance imaging in nonrandomized phase 4 clinical trials at 2 centers. From September 2009 to February 2015, 49 pediatric patients (21 female and 28 male, 5-18 years) and 19 young adults (8 female and 11 male, 18-25 years) were reported under an investigator-initiated investigational new drug investigation with institutional review board approval, in health insurance portability and accountability act compliance, and after written informed consent of the child's legal representative or the competent adult patient was obtained. Patients received either a single dose (5 mg Fe/kg) or up to 4 doses of ferumoxytol (0.7-4 mg Fe/kg) intravenously, which were approximately equivalent to one third of the dose for anemia treatment. We monitored vital signs and adverse events directly for up to 1 hour after injection. In addition, we examined weekly vitals, hematologic, renal, and liver serum panels for 1 month after injection in over 20 pediatric patients. At fixed time points before and after ferumoxytol injection, data were evaluated for significant differences by a repeated measures linear mixed model.
Results
Four mild adverse events, thought to be related to ferumoxytol, were observed within 1 hour of 85 ferumoxytol injections: 2 episodes of mild hypotension and 1 case of nausea in 65 injections in pediatric patients without related clinical symptoms. One young adult patient developed warmness and erythema at the injection site. All adverse events were self-resolving. No spontaneous serious adverse events were reported. At a dose of 5 mg Fe/kg or lower, intravenous ferumoxytol injection had no clinical relevance or statistically significant effect (P > 0.05) on vital signs, hematological parameters, kidney function, or liver enzymes within 1 month of the injection.
Conclusions
Ferumoxytol was overall well tolerated among 49 pediatric and 19 young adult patients experiencing various tumors or kidney transplants without major adverse events or signs of hematologic and kidney impairment or liver toxicity. Larger studies are needed to determine the incidence of anaphylactic reactions.
C1 [Muehe, Anne M.; Feng, Dan; Daldrup-Link, Heike E.] Stanford Univ, Mol Imaging Program Stanford, Dept Radiol, Stanford, CA 94305 USA.
[Muehe, Anne M.; Feng, Dan; Daldrup-Link, Heike E.] Stanford Univ, Lucile Packard Childrens Hosp, Stanford, CA 94305 USA.
[von Eyben, Rie] Stanford Univ, Dept Radiat Oncol, Stanford, CA 94305 USA.
[Luna-Fineman, Sandra; Link, Michael P.] Stanford Univ, Sect Pediat Hematol & Oncol, Dept Pediat, Stanford, CA 94305 USA.
[Muthig, Travis] Univ S Carolina, Sch Med, Columbia, SC USA.
[Huddleston, Amy E.; Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.
[Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurosurg, Portland, OR 97201 USA.
[Neuwelt, Edward A.] Portland VA Med Ctr, Portland, OR USA.
RP Daldrup-Link, HE (reprint author), Stanford Sch Med, Dept Radiol, 725 Welch Rd, Stanford, CA 94305 USA.
EM H.E.Daldrup-Link@stanford.edu
RI Daldrup-Link, Heike/D-9829-2012
OI Daldrup-Link, Heike/0000-0002-4929-819X
FU National Institute of Child Health and Human Development [R01
HD081123A]; Translational Research and Applied Medicine Program at
Stanford University; National Institute of Health [CA137488]; Walter S.
and Lucienne Driskill Foundation; Stanford Medical Scholars Fellowship
Program
FX Supported by R01 HD081123A from the National Institute of Child Health
and Human Development, a grant from the Translational Research and
Applied Medicine Program at Stanford University (H.E.D.L. and D.F.), by
National Institute of Health grant CA137488, and by the Walter S. and
Lucienne Driskill Foundation to Oregon Health & Science University
(E.A.N.). D.F. was supported by a stipend from the Stanford Medical
Scholars Fellowship Program.
NR 41
TC 10
Z9 10
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0020-9996
EI 1536-0210
J9 INVEST RADIOL
JI Invest. Radiol.
PD APR
PY 2016
VL 51
IS 4
BP 221
EP 227
DI 10.1097/RLI.0000000000000230
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA DH0CX
UT WOS:000372451200002
PM 26656202
ER
PT J
AU Einstein, AJ
Lloyd, SG
Chaudhry, FA
AlJaroudi, WA
Hage, FG
AF Einstein, Andrew J.
Lloyd, Steven G.
Chaudhry, Farooq A.
AlJaroudi, Wael A.
Hage, Fadi G.
TI Multi-modality Imaging: Bird's eye view from the 2015 American Heart
Association Scientific Sessions
SO JOURNAL OF NUCLEAR CARDIOLOGY
LA English
DT Article
DE AHA; cardiac computed tomography; CMRI
ID CORONARY FLOW RESERVE
AB Multiple novel studies were presented at the 2015 American Heart Association Scientific Sessions which was considered a successful conference at many levels. In this review, we will summarize key studies in nuclear cardiology, cardiac magnetic resonance, echocardiography, and cardiac computed tomography that were presented at the Sessions. We hope that this bird's eye view will keep readers updated on the newest imaging studies presented at the meeting whether or not they were able to attend the meeting.
C1 [Einstein, Andrew J.] Columbia Univ, New York Presbyterian Hosp, Med Ctr, New York, NY USA.
[Lloyd, Steven G.; Hage, Fadi G.] Univ Alabama Birmingham, Lyons Harrison Res Bldg 314,1900 Univ BLVD, Birmingham, AL 35294 USA.
[Lloyd, Steven G.; Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Chaudhry, Farooq A.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
[AlJaroudi, Wael A.] Clemenceau Med Ctr, Beirut, Lebanon.
RP Hage, FG (reprint author), Univ Alabama Birmingham, Lyons Harrison Res Bldg 314,1900 Univ BLVD, Birmingham, AL 35294 USA.
EM fadihage@uab.edu
OI Hage, Fadi/0000-0002-1397-4942
FU Astellas Pharma
FX Dr Hage reports grant support from Astellas Pharma.
NR 35
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1071-3581
EI 1532-6551
J9 J NUCL CARDIOL
JI J. Nucl. Cardiol.
PD APR
PY 2016
VL 23
IS 2
BP 235
EP 243
DI 10.1007/s12350-016-0404-8
PG 9
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA DG7UR
UT WOS:000372289700008
PM 26818142
ER
PT J
AU Harmon, JL
Wills, LP
McOmish, CE
Demireva, EY
Gingrich, JA
Beeson, CC
Schnellmann, RG
AF Harmon, Jennifer L.
Wills, Lauren P.
McOmish, Caitlin E.
Demireva, Elena Y.
Gingrich, Jay A.
Beeson, Craig C.
Schnellmann, Rick G.
TI 5-HT2 Receptor Regulation of Mitochondrial Genes: Unexpected
Pharmacological Effects of Agonists and Antagonists
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID ACUTE KIDNEY INJURY; PROXIMAL TUBULES; OXIDATIVE STRESS; CHOROID-PLEXUS;
ANIMAL-MODELS; SB 242084; BIOGENESIS; DYSFUNCTION; PGC-1-ALPHA; CELLS
AB In acute organ injuries, mitochondria are often dysfunctional, and recent research has revealed that recovery of mitochondrial and renal functions is accelerated by induction of mitochondrial biogenesis (MB). We previously reported that the nonselective 5-HT2 receptor agonist DOI [1-(4-iodo-2,5-dimethoxyphenyl) propan-2-amine] induced MB in renal proximal tubular cells (RPTCs). The goal of this study was to determine the role of 5-HT2 receptors in the regulation of mitochondrial genes and oxidative metabolism in the kidney. The 5-HT2C receptor agonist CP-809,101 [2-[(3-chlorophenyl)methoxy]-6-(1-piperazinyl)pyrazine] and antagonist SB-242,084 [6-chloro-2,3-dihydro-5-methyl-N-[6-[(2-methyl-3-pyridinyl)oxy]-3-pyridinyl]-1H-indole-1-carboxyamide dihydrochloride] were used to examine the induction of renal mitochondrial genes and oxidative metabolism in RPTCs and in mouse kidneys in the presence and absence of the 5-HT2C receptor. Unexpectedly, both CP-809,101 and SB-242,084 increased RPTC respiration and peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha) mRNA expression in RPTCs at 1-10 nM. In addition, CP-809,101 and SB-242,084 increased mRNA expression of PGC-1 alpha and the mitochondrial proteins NADH dehydrogenase subunit 1 and NADH dehydrogenase (ubiquinone) beta subcomplex 8 in mice. These compounds increased mitochondrial genes in RPTCs in which the 5-HT2C receptor was downregulated with small interfering RNA and in the renal cortex of mice lacking the 5-HT2C receptor. By contrast, the ability of these compounds to increase PGC-1 alpha mRNA and respiration was blocked in RPTCs treated with 5-HT2A receptor small interfering RNA or the 5-HT2A receptor antagonist eplivanserin. In addition, the 5-HT2A receptor agonist NBOH-2C-CN [4-[2-[[(2-hydroxyphenyl)methyl]amino]ethyl]-2,5-dimethoxybenzonitrile] increased RPTC respiration at 1-100 nM. These results suggest that agonism of the 5-HT2A receptor induces MB and that the classic 5-HT2C receptor agonist CP-809,101 and antagonist SB-242,084 increase mitochondrial genes and oxidative metabolism through the 5-HT2A receptor. To our knowledge, this is the first report that links 5-HT2A receptor agonism to mitochondrial function.
C1 [Harmon, Jennifer L.; Wills, Lauren P.; Beeson, Craig C.; Schnellmann, Rick G.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, 280 Calhoun St,MSC140, Charleston, SC 29425 USA.
[McOmish, Caitlin E.; Demireva, Elena Y.; Gingrich, Jay A.] Columbia Univ, Dept Psychiat, Sackler Inst Dev Psychobiol, New York, NY USA.
[McOmish, Caitlin E.] Univ Melbourne, Div Mol Psychiat, Florey Inst Neurosci & Mental Hlth, Melbourne Brain Ctr, Parkville, Vic 3052, Australia.
[Demireva, Elena Y.; Gingrich, Jay A.] New York State Psychiat Inst & Hosp, Div Dev Neurosci, New York, NY 10032 USA.
[Schnellmann, Rick G.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA.
RP Schnellmann, RG (reprint author), Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, 280 Calhoun St,MSC140, Charleston, SC 29425 USA.
EM schnell@musc.edu
FU National Institutes of Health National Institute of Diabetes and
Digestive and Kidney Diseases [F30DK091107, T32DK083262]; National
Health and Medical Research Council; Brain and Behavior Research
Foundation; National Institutes of Health National Institute of Mental
Health [R21MH099458, R01MH080116]; National Institutes of Health
National Institute of General Medical Sciences [R01GM084147,
P20GM103542-02]; National Institutes of Health National Center for
Research Resources [UL1RR029882, C06RR015455]; Biomedical Laboratory
Research and Development Program of the U.S. Department of Veterans
Affairs [5I01 BX-000851]; South Carolina Clinical and Translational
Research Institute at the Medical University of South Carolina
FX This research was supported in part by the National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases [Grants
F30DK091107 and T32DK083262 (to J.L.H.)]; the National Health and
Medical Research Council [C.J. Martin Overseas Biomedical Fellowship (to
C.E.M.)]; the Brain and Behavior Research Foundation [Young Investigator
Award (to C.E.M.)]; the National Institutes of Health National Institute
of Mental Health [Grants R21MH099458 and R01MH080116 (to J.A.G.)]; the
National Institutes of Health National Institute of General Medical
Sciences [Grants R01GM084147 (to R.G.S) and P20GM103542-02 (to South
Carolina COBRE in Oxidants, Redox Balance, and Stress Signaling)]; the
National Institutes of Health National Center for Research Resources
[Grant UL1RR029882]; the Biomedical Laboratory Research and Development
Program of the U.S. Department of Veterans Affairs [Grant 5I01 BX-000851
(to R.G.S.)]; and the South Carolina Clinical and Translational Research
Institute at the Medical University of South Carolina. Animal facilities
were funded by the National Institutes of Health National Center for
Research Resources [Grant C06RR015455].
NR 44
TC 1
Z9 1
U1 1
U2 3
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0022-3565
EI 1521-0103
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD APR
PY 2016
VL 357
IS 1
BP 1
EP 9
DI 10.1124/jpet.115.228395
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DG5TX
UT WOS:000372142800001
PM 26787771
ER
PT J
AU Keating, JJ
Okusanya, OT
De Jesus, E
Judy, R
Jiang, J
Deshpande, C
Nie, S
Low, P
Singhal, S
AF Keating, Jane J.
Okusanya, Olugbenga T.
De Jesus, Elizabeth
Judy, Ryan
Jiang, Jack
Deshpande, Charuhas
Nie, Shuming
Low, Philip
Singhal, Sunil
TI Intraoperative Molecular Imaging of Lung Adenocarcinoma Can Identify
Residual Tumor Cells at the Surgical Margins
SO MOLECULAR IMAGING AND BIOLOGY
LA English
DT Article
DE Surgical oncology; Molecular imaging; Lung cancer; Thoracic surgery;
Folate receptor alpha
ID FOLATE RECEPTOR-ALPHA; FLUORESCENCE-GUIDED SURGERY; TARGETED
IMMUNOTHERAPY; INFLAMMATORY DISEASES; PANCREATIC-CANCER; MOUSE MODELS;
RESECTION; THERAPY; CHEMOTHERAPY; ANTIBODY
AB Purpose: During lung surgery, identification of surgical margins is challenging. We hypothesized that molecular imaging with a fluorescent probe to pulmonary adenocarcinomas could enhance residual tumor during resection.
Procedures: Mice with flank tumors received a contrast agent targeting folate receptor alpha. Optimal dose and time of injection was established. Margin detection was compared using traditional methods versus molecular imaging. A pilot study was then performed in three humans with lung adenocarcinoma.
Results: The peak tumor-to-background ratio (TBR) of murine tumors was 3.9. Fluorescence peaked at 2 h and was not improved beyond 0.1 mg/kg. Traditional inspection identified 30 % of mice with positive margins. Molecular imaging identified an additional 50 % of residual tumor deposits (p < 0.05). The fluorescent probe visually enhanced all human tumors with a mean TBR of 3.5.
Conclusions: Molecular imaging is an important adjunct to traditional inspection to identify surgical margins after tumor resection.
C1 [Keating, Jane J.; Okusanya, Olugbenga T.; De Jesus, Elizabeth; Judy, Ryan; Jiang, Jack; Singhal, Sunil] Univ Penn, Dept Surg, Div Thorac Surg, Philadelphia, PA 19104 USA.
[Keating, Jane J.; Okusanya, Olugbenga T.; De Jesus, Elizabeth; Judy, Ryan; Jiang, Jack; Singhal, Sunil] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Deshpande, Charuhas] Univ Penn, Perelman Sch Med, Dept Pathol, Philadelphia, PA 19104 USA.
[Nie, Shuming] Emory Univ, Dept Biomed Engn, Atlanta, GA 30322 USA.
[Nie, Shuming] Emory Univ, Dept Chem, Atlanta, GA 30322 USA.
[Low, Philip] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.
[Singhal, Sunil] Univ Penn, Sch Med, Div Thorac Surg, 6 White Bldg,3400 Spruce St, Philadelphia, PA 19104 USA.
RP Singhal, S (reprint author), Univ Penn, Dept Surg, Div Thorac Surg, Philadelphia, PA 19104 USA.; Singhal, S (reprint author), Philadelphia VA Med Ctr, Philadelphia, PA USA.; Singhal, S (reprint author), Univ Penn, Sch Med, Div Thorac Surg, 6 White Bldg,3400 Spruce St, Philadelphia, PA 19104 USA.
EM sunil.singhal@uphs.upenn.edu
OI Low, Philip/0000-0001-9042-5528
FU National Institutes of Health [RO1CA163256]
FX This work was supported by the National Institutes of Health
RO1CA163256.
NR 30
TC 6
Z9 6
U1 2
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1536-1632
EI 1860-2002
J9 MOL IMAGING BIOL
JI Mol. Imaging. Biol.
PD APR
PY 2016
VL 18
IS 2
BP 209
EP 218
DI 10.1007/s11307-015-0878-9
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA DG7JP
UT WOS:000372260900007
PM 26228697
ER
PT J
AU Friedlander, AH
Giaconi, JA
Tsui, I
Aghazadehsanai, N
Chang, TI
Garrett, NR
AF Friedlander, Arthur H.
Giaconi, JoAnn A.
Tsui, Irena
Aghazadehsanai, Nona
Chang, Tina I.
Garrett, Neal R.
TI Meaningful correlation between asymptomatic retinal arteriole emboli and
calcified carotid plaque found on panoramic dental imaging of males with
diabetes
SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY
LA English
DT Article
ID BEAVER DAM EYE; CHOLESTEROL EMBOLI; RADIOGRAPHY; DISEASE; ATHEROMA;
STROKE; RISK; CALCIFICATIONS; DUPLEX; AID
AB Objective. There is ongoing controversy with regard to the stability of calcified carotid artery plaques (CCAPs) seen in the bifurcation area on panoramic images (PIs). Therefore, we sought to evaluate the possibility of these plaques shedding emboli by observing their relationship with ipsilateral retinal emboli.
Study Design. The study group included 50 neurologically and visually asymptomatic males with diabetes, with PIs that incidentally demonstrated CCAPs (CCAP+) and contemporaneous digital retinal images that had been obtained for evaluation of diabetic retinopathy. The control group consisted of 50 males with diabetes who were matched for age and body mass index and had undergone both imaging studies and whose PIs were devoid of carotid plaques (CCAP-). The presence of retinal emboli was determined by two ophthalmologists blinded to the patients' medical histories, and the prevalence rates for the two groups were calculated.
Results. The presence of asymptomatic retinal arteriolar emboli was found in the eye ipsilateral to the radiographically observed carotid atheroma in 10 of 50 (20%) of the patients in the CCAP+ group, compared with 2 of 50 (4%) in the CCAP- group, and this difference was statistically significant (Fisher's exact P <.03).
Conclusions. Some male patients with diabetes mellitus type II having calcified carotid artery atheromas in the bifurcation area, as visualized on PIs, may have significant sequelae as evidenced by retinal artery emboli.
C1 [Friedlander, Arthur H.] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Grad Med Educ, Los Angeles, CA USA.
[Friedlander, Arthur H.] Univ Calif Los Angeles, Ronald Reagan UCLA Med Ctr, Hosp Dent Serv, Qual Assurance, Los Angeles, CA USA.
[Friedlander, Arthur H.] Univ Calif Los Angeles, Sch Dent, Oral & Maxillofacial Surg, Los Angeles, CA 90024 USA.
[Giaconi, JoAnn A.] Vet Affairs Greater Los Angeles Healthcare Syst, Ophthalmol, Los Angeles, CA USA.
[Giaconi, JoAnn A.; Tsui, Irena] Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA USA.
[Tsui, Irena] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Aghazadehsanai, Nona] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Chang, Tina I.] Univ Calif Los Angeles, Sch Dent, Vet Affairs Greater Los Angeles Healthcare Syst, Res Fellowship & Inpatient Oral & Maxillofacial S, Los Angeles, CA 90024 USA.
[Chang, Tina I.] Univ Calif Los Angeles, Sch Dent, Oral & Maxillofacial Surg, Los Angeles, CA 90024 USA.
[Garrett, Neal R.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA.
RP Friedlander, AH (reprint author), VA Greater Los Angeles Healthcare Syst, Grad Med Educ, 11301 Wilshire Blvd 14, Los Angeles, CA 90073 USA.
EM Arthur.friedlander@va.gov
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 2212-4403
EI 1528-395X
J9 OR SURG OR MED OR PA
JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol.
PD APR
PY 2016
VL 121
IS 4
BP 434
EP 440
DI 10.1016/j.oooo.2015.12.005
PG 7
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA DG3UU
UT WOS:000371996800018
PM 26972542
ER
PT J
AU Wen, JC
Jiang, FG
Yeh, CK
Sun, YY
AF Wen, Jianchuan
Jiang, Fuguang
Yeh, Chih-Ko
Sun, Yuyu
TI Controlling fungal biofilms with functional drug delivery denture
biomaterials
SO COLLOIDS AND SURFACES B-BIOINTERFACES
LA English
DT Article
DE Denture; Grafting; Drug delivery; Fungal; Biofilm-controlling
ID IN-VITRO; BIOMEDICAL APPLICATIONS; SILVER NANOPARTICLES; SURFACE
MODIFICATION; ANTIFUNGAL ACTIVITY; MICONAZOLE-NITRATE; CANDIDA-ALBICANS;
STOMATITIS; PLASMA; ETIOLOGY
AB Candida-associated denture stomatitis (CADS), caused by colonization and biofilm-formation of Candida species on denture surfaces, is a significant clinical concern. We show here that modification of conventional denture materials with functional groups can significantly increase drug binding capacity and control drug release rate of the resulting denture materials for potentially managing CADS. In our approach, poly(methyl methacrylate) (PMMA)-based denture resins were surface grafted with three kinds of polymers, poly(1-vinyl-2-pyrrolidinone) (PNVP), poly(methacrylic acid) (PMAA), and poly(2-hydroxyethyl methacrylate) (PHEMA), through plasma-initiated grafting polymerization. With a grafting yield as low as 2 wt%, the three classes of new functionalized denture materials showed significantly higher drug binding capacities toward miconazole, a widely used antifungal drug, than the original PMMA denture resin control, leading to sustained drug release and potent biofilm-controlling effects against Candida. Among the three classes of functionalized denture materials, PNVP-grafted resin provided the highest miconazole binding capability and the most powerful antifungal and biofilm-controlling activities. Drug binding mechanisms were studied. These results demonstrated the importance of specific interactions between drug molecules and functional groups on biomaterials, shedding lights on future design of CADS-managing denture materials and other related devices for controlled drug delivery. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Wen, Jianchuan; Jiang, Fuguang; Sun, Yuyu] Univ Massachusetts, Dept Chem, Lowell, MA 01854 USA.
[Yeh, Chih-Ko] South Texas Vet Hlth Care Syst, Audie L Murphy Div, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA.
[Yeh, Chih-Ko] Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, San Antonio, TX 78229 USA.
RP Sun, YY (reprint author), Univ Massachusetts, Dept Chem, Lowell, MA 01854 USA.
EM yuyu_sun@uml.edu
FU NIDCR, NIH [R01 DE021084]; VA Merit Review [1I01BX001103]
FX This study was supported by NIDCR, NIH (R01 DE021084) and VA Merit
Review (1I01BX001103).
NR 51
TC 3
Z9 3
U1 8
U2 26
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7765
EI 1873-4367
J9 COLLOID SURFACE B
JI Colloid Surf. B-Biointerfaces
PD APR 1
PY 2016
VL 140
BP 19
EP 27
DI 10.1016/j.colsurfb.2015.12.028
PG 9
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
SC Biophysics; Chemistry; Materials Science
GA DF6DG
UT WOS:000371445500003
PM 26731194
ER
PT J
AU Kaz, AM
Anwar, A
O'Neill, DR
Dominitz, JA
AF Kaz, Andrew M.
Anwar, Asma
O'Neill, Darby Robinson
Dominitz, Jason A.
TI Use of a novel polyp "ruler snare" improves estimation of colon polyp
size
SO GASTROINTESTINAL ENDOSCOPY
LA English
DT Article
ID SOCIETY-TASK-FORCE; COLORECTAL-CANCER; COLONOSCOPY SURVEILLANCE;
POLYPECTOMY; ACCURATE; GUIDELINE
AB Background and Aims: Prior studies have demonstrated that endoscopists' estimates of polyp size are imprecise. The aim of this study was to determine whether a modified polypectomy "ruler snare" improves the accuracy of assessment of polyp size in real time without the use of additional devices.
Methods: Ten artificial polyps of predetermined sizes (4 to 25 mm) were affixed to the inside of a colon model. A standard polypectomy snare was modified by adding 5-mm graduated markings to the distal end of the plastic sheath. Study participants estimated the sizes of the artificial polyps during simulated colonoscopies, first using a standard snare and then with the modified ruler snare.
Results: Thirty-four private practice and academic gastroenterologists participated in the study. Endoscopists' ability to accurately classify polyps by size (diminutive, small, or large) improved from 48.5% to 60.3% with the ruler snare (P = .002). The greatest improvement in precision was seen among the large polyps, where accuracy increased from 35.9% to 58.2% with use of the ruler snare (P < .0001). Participants underestimated polyp size by a mean of 3.6 mm (interquartile range, -5 to -2 mm) with the standard snare and 1.8 mm (interquartile range, -3 to 0 mm) with the ruler snare, which corresponded to a 44.2% improvement in accuracy with the ruler snare (P < .05).
Conclusions: The modified ruler snare improved polyp size assessment compared with a standard snare, particularly with large polyps. Overall, although size estimation continues to be imprecise, the addition of calibrated markings to a polypectomy snare is a simple and likely low-cost means to improve neoplasia surveillance recommendations.
C1 [Kaz, Andrew M.; Dominitz, Jason A.] VA Puget Sound Hlth Care Syst, Gastroenterol Sect, Seattle, WA USA.
[Kaz, Andrew M.; Anwar, Asma; Dominitz, Jason A.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
[O'Neill, Darby Robinson] Everett Clin, Gastroenterol & Liver Dis, Everett, WA USA.
RP Dominitz, JA (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-111 Gastro, Seattle, WA 98108 USA.
OI Dominitz, Jason/0000-0002-8070-7086
NR 16
TC 1
Z9 1
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0016-5107
EI 1097-6779
J9 GASTROINTEST ENDOSC
JI Gastrointest. Endosc.
PD APR
PY 2016
VL 83
IS 4
BP 812
EP 816
DI 10.1016/j.gie.2015.08.082
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DG2JX
UT WOS:000371894300023
PM 26382052
ER
PT J
AU Ashack, KA
Burton, KA
Johnson, TR
Currie, DW
Comstock, RD
Dellavalle, RP
AF Ashack, Kurt A.
Burton, Kyle A.
Johnson, Teresa R.
Currie, Dustin W.
Comstock, R. Dawn
Dellavalle, Robert P.
TI Skin infections among US high school athletes: A national survey
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Article
DE athletes; competition; high school; injury; prevention; skin infections;
sports
ID HERPES GLADIATORUM; COMPETITIVE SPORTS; DISEASE OUTBREAKS; INJURIES
AB Background: Skin infections have long been a reported problem among high school athletes, particularly wrestlers. There has yet to be a national study describing the epidemiology of skin infections across multiple high school sports.
Objective: We sought to report the epidemiology of skin infections among US high school athletes.
Methods: High school sports-related skin infections resulting in time loss were reported by a convenience sample of US high schools from 2009/2010 through 2013/2014 via High School Reporting Information Online.
Results: During the study, 474 skin infections were reported among 20,858,781 athlete exposures, a rate of 2.27 per 100,000 athlete exposures. The largest number of skin infections occurred in wrestling (73.6%) followed by football (17.9%). The most common infections were bacterial (60.6%) and tinea (28.4%) infections. Body parts most often affected were the head/face (25.3%) followed by the forearm (12.7%). Limitations: The study included only high schools with National Athletic Trainers' Associationeaffiliated athletic trainers, which may limit generalizability. However, using athletic trainers as data reporters improved data quality.
Conclusions: Skin infections are an important subset of high school sports-related adverse events. An understanding of the epidemiology of sports-related skin infections should promote awareness and drive evidence-based prevention efforts.
C1 [Ashack, Kurt A.] Michigan State Univ, Coll Human Med, Grand Rapids, MI USA.
[Johnson, Teresa R.] Univ Cent Florida, Coll Med, Dept Med Educ, Orlando, FL 32816 USA.
[Burton, Kyle A.] Univ Cent Florida, Coll Med, Orlando, FL 32816 USA.
[Currie, Dustin W.; Comstock, R. Dawn; Dellavalle, Robert P.] Univ Colorado, Colorado Sch Publ Hlth, Dept Epidemiol, Anschutz Med Campus, Aurora, CO USA.
[Comstock, R. Dawn] Univ Colorado, Dept Pediat Emergency Med, Anschutz Med Campus, Aurora, CO USA.
[Dellavalle, Robert P.] Univ Colorado, Dept Dermatol, Anschutz Med Campus, Aurora, CO USA.
[Dellavalle, Robert P.] US Dept Vet Affairs, Dermatol Serv, Eastern Colorado Hlth Care Syst, Denver, CO USA.
RP Dellavalle, RP (reprint author), US Dept Vet Affairs, Dermatol Serv, 1055 Clermont St,Box 165, Denver, CO 80220 USA.
EM robert.dellavalle@ucdenver.edu
FU Centers for Disease Control and Prevention [R49/CE000674-01,
R49/CE001172-01]; National Federation of State High School Associations;
National Operating Committee on Standards for Athletic Equipment; DonJoy
Orthotics; EyeBlack
FX The content of this report representing data collection by the National
High School Sports-Related Injury Surveillance Study (High School
Reporting Information Online) was funded in part by the Centers for
Disease Control and Prevention grants R49/CE000674-01 and
R49/CE001172-01. We also acknowledge the generous research funding
contributions of the National Federation of State High School
Associations, the National Operating Committee on Standards for Athletic
Equipment, DonJoy Orthotics, and EyeBlack. The content of this report is
solely the responsibility of the authors and does not necessarily
represent the official views of the Centers for Disease Control and
Prevention or any of the other institutions that provided financial
support for this research.
NR 21
TC 0
Z9 0
U1 3
U2 6
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD APR
PY 2016
VL 74
IS 4
BP 679
EP U156
DI 10.1016/j.jaad.2015.10.042
PG 7
WC Dermatology
SC Dermatology
GA DG0ZM
UT WOS:000371794800021
PM 26850656
ER
PT J
AU Minzenberg, MJ
Yoon, JH
Cheng, YA
Carter, CS
AF Minzenberg, Michael J.
Yoon, Jong H.
Cheng, Yaoan
Carter, Cameron S.
TI Sustained Modafinil Treatment Effects on Control-Related Gamma
Oscillatory Power in Schizophrenia
SO NEUROPSYCHOPHARMACOLOGY
LA English
DT Article
ID INDEPENDENT COMPONENT ANALYSIS; COGNITIVE CONTROL; PREFRONTAL CORTEX;
LOCUS-COERULEUS; RULE SELECTION; WORKING-MEMORY; IN-VITRO; MODULATION;
DOPAMINE; NOREPINEPHRINE
AB Control-related cognitive processes such as rule selection and maintenance are associated with cortical oscillations in the gamma range, and modulated by catecholamine neurotransmission. Control-related gamma power is impaired in schizophrenia, and an understudied treatment target. It remains unknown whether pro-catecholamine pharmacological agents augment control-related gamma oscillations in schizophrenia. We tested the effects of 4-week fixed-dose daily adjunctive modafinil (MOD) 200 mg, in a randomized double-blind, placebo-controlled, parallel-groups design. Twenty-seven stable schizophrenia patients performed a cognitive control task during EEG, at baseline and after 4 weeks of treatment. EEG data underwent time-frequency decomposition with Morlet wavelets to determine power of 4-80 Hz oscillations. The modafinil group (n = 14), relative to placebo group (n = 13), exhibited enhanced oscillatory power associated with high-control rule selection in the gamma range after treatment, with additional effects during rule maintenance in gamma and sub-gamma ranges. MOD-treated patients who exhibited improved task performance with treatment also showed greater treatment-related delay period gamma compared with MOD-treated patients without improved performance. This is the first evidence in schizophrenia of augmentation of cognition-related gamma oscillations by an FDA-approved agent with therapeutic potential. Gamma oscillations represent a novel treatment target in this disorder, and modulation of catecholamine signaling may represent a viable strategy at this target.
C1 [Minzenberg, Michael J.; Cheng, Yaoan] Univ Calif San Francisco, Sch Med, Dept Psychiat, San Francisco, CA 94143 USA.
[Minzenberg, Michael J.; Cheng, Yaoan] San Francisco VA Med Ctr, San Francisco, CA USA.
[Yoon, Jong H.] Stanford Univ, Sch Med, Dept Psychiat, Palo Alto, CA 94304 USA.
[Yoon, Jong H.] Palo Alto Vet Affairs Med Ctr, Palo Alto, CA USA.
[Carter, Cameron S.] Univ Calif Davis, Sch Med, Dept Psychiat, Sacramento, CA 95817 USA.
[Carter, Cameron S.] Univ Calif Davis, Ctr Neurosci, Program Neurosci, Davis, CA 95616 USA.
RP Minzenberg, MJ (reprint author), UCSF, Psychiat, Outpatient Mental Hlth Serv, San Francisco Vet Affairs Ctr, 116C,4150 Clement St, San Francisco, CA 94121 USA.
EM Michael.minzenberg@ucsf.edu
OI Cheng, Yaoan/0000-0001-5858-6161
FU Clinical Scientist Development Award from the Doris Duke Charitable
Foundation; Young Investigator award from NARSAD (Brain and Behavior
Foundation)
FX This work was supported by Clinical Scientist Development Award from the
Doris Duke Charitable Foundation, and a Young Investigator award from
NARSAD (Brain and Behavior Foundation), to MJM. The authors declare no
conflict of interest.
NR 60
TC 1
Z9 1
U1 1
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0893-133X
EI 1740-634X
J9 NEUROPSYCHOPHARMACOL
JI Neuropsychopharmacology
PD APR
PY 2016
VL 41
IS 5
BP 1231
EP 1240
DI 10.1038/npp.2015.271
PG 10
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA DG1BW
UT WOS:000371801200006
PM 26329382
ER
PT J
AU Crossley, NA
Fox, PT
Bullmore, ET
AF Crossley, N. A.
Fox, P. T.
Bullmore, E. T.
TI Meta-connectomics: human brain network and connectivity meta-analyses
SO PSYCHOLOGICAL MEDICINE
LA English
DT Review
DE Connectome; cytoarchitectonics; gene expression; graph theory;
neuroimaging
ID RICH-CLUB ORGANIZATION; FUNCTIONAL CONNECTIVITY; CEREBRAL-CORTEX;
COACTIVATION PATTERNS; PREFRONTAL CORTEX; SCHIZOPHRENIA; FMRI;
DISORDERS; MODEL; HETEROGENEITY
AB Abnormal brain connectivity or network dysfunction has been suggested as a paradigm to understand several psychiatric disorders. We here review the use of novel meta-analytic approaches in neuroscience that go beyond a summary description of existing results by applying network analysis methods to previously published studies and/or publicly accessible databases. We define this strategy of combining connectivity with other brain characteristics as meta-connectomics'. For example, we show how network analysis of task-based neuroimaging studies has been used to infer functional co-activation from primary data on regional activations. This approach has been able to relate cognition to functional network topology, demonstrating that the brain is composed of cognitively specialized functional subnetworks or modules, linked by a rich club of cognitively generalized regions that mediate many inter-modular connections. Another major application of meta-connectomics has been efforts to link meta-analytic maps of disorder-related abnormalities or MRI lesions' to the complex topology of the normative connectome. This work has highlighted the general importance of network hubs as hotspots for concentration of cortical grey-matter deficits in schizophrenia, Alzheimer's disease and other disorders. Finally, we show how by incorporating cellular and transcriptional data on individual nodes with network models of the connectome, studies have begun to elucidate the microscopic mechanisms underpinning the macroscopic organization of whole-brain networks. We argue that meta-connectomics is an exciting field, providing robust and integrative insights into brain organization that will likely play an important future role in consolidating network models of psychiatric disorders.
C1 [Crossley, N. A.] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychosis Studies, London WC2R 2LS, England.
[Crossley, N. A.] P Catholic Univ Chile, Inst Biol & Med Engn, Sch Med, Santiago, Chile.
[Crossley, N. A.] P Catholic Univ Chile, Sch Biol Sci & Engn, Santiago, Chile.
[Crossley, N. A.] P Catholic Univ Chile, Sch Med, Dept Psychiat, Santiago, Chile.
[Fox, P. T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.
[Fox, P. T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA.
[Fox, P. T.] South Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX USA.
[Bullmore, E. T.] Univ Cambridge, Dept Psychiat, Behav & Clin Neurosci Inst, Cambridge, England.
[Bullmore, E. T.] Cambridgeshire & Peterborough NHS Fdn Trust, Cambridge, England.
[Bullmore, E. T.] GlaxoSmithKline, ImmunoPsychiat Alternat Discovery & Dev, Cambridge, England.
RP Crossley, NA (reprint author), Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychosis Studies, London WC2R 2LS, England.
EM nicolas.crossley@kcl.ac.uk
OI Bullmore, Edward/0000-0002-8955-8283; Crossley,
Nicolas/0000-0002-3060-656X
FU National Institute of Health (NIH) [R01MH074457]
FX PTF is supported by a National Institute of Health (NIH) award
(R01MH074457).
NR 70
TC 4
Z9 5
U1 3
U2 24
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0033-2917
EI 1469-8978
J9 PSYCHOL MED
JI Psychol. Med.
PD APR
PY 2016
VL 46
IS 5
BP 897
EP 907
DI 10.1017/S0033291715002895
PG 11
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA DF8PQ
UT WOS:000371620700001
PM 26809184
ER
PT J
AU Dasari, M
Borrero, S
Akers, AY
Sucato, GS
Dick, R
Hicks, A
Miller, E
AF Dasari, Mohini
Borrero, Sonya
Akers, Aletha Y.
Sucato, Gina S.
Dick, Rebecca
Hicks, Angela
Miller, Elizabeth
TI Barriers to Long-Acting Reversible Contraceptive Uptake Among Homeless
Young Women
SO JOURNAL OF PEDIATRIC AND ADOLESCENT GYNECOLOGY
LA English
DT Article
DE Contraception; LARC; IUD; Implant; Homelessness; Mixed-methods
ID ADOLESCENT; ATTITUDES; PERSPECTIVES; YOUTH; LARC
AB Study Objective: To identify barriers to long-acting reversible contraception (LARC) uptake among homeless young women.
Design: In this mixed methods study surveys and guided interviews were used to explore women's contraceptive and reproductive experiences, interactions with the health care system, and their histories of homelessness.
Setting: All surveys and interviews were conducted at a homeless drop-in center or shelter.
Participants: Fifteen women between 18 and 24 years of age with a past year history of homelessness.
Interventions: None.
Main Outcome Measures: Perceived barriers to contraceptive use, including knowledge and access barriers and interactions with the health care system around reproductive health.
Results: Confusion about the possibility of early termination of LARC, and the perception that providers deliberately withhold selective information about contraceptive options to bias contraceptive decision-making, were 2 key new findings. Women also reported interest in visual aids accompanying verbal contraceptive counseling. Pregnancy attitudes and history of reproductive and sexual coercion also influenced contraceptive decision-making and reported interest in LARC methods.
Conclusion: Comprehensive counseling about all contraceptive options, including LARC, are important for targeting the perceived gaps in contraceptive education and care among homeless young women.
C1 [Dasari, Mohini] Univ Pittsburgh, Sch Med, M240 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.
[Borrero, Sonya] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA 15261 USA.
[Borrero, Sonya] VA Pittsburgh Healthcare Syst, CHERP, Pittsburgh, PA USA.
[Akers, Aletha Y.] Childrens Hosp Philadelphia, Craig Dalsimer Div Adolescent Med, Philadelphia, PA 19104 USA.
[Sucato, Gina S.] Seattle Childrens Hosp, Adolescent Hlth, Grp Hlth Cooperat, Seattle, WA USA.
[Dick, Rebecca; Hicks, Angela; Miller, Elizabeth] Univ Pittsburgh, Med Ctr, Childrens Hosp Pittsburgh, Div Adolescent & Young Adult Med, Pittsburgh, PA 15261 USA.
[Miller, Elizabeth] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA.
RP Dasari, M (reprint author), Univ Pittsburgh, Sch Med, M240 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.
EM mod13@pitt.edu
NR 26
TC 0
Z9 0
U1 5
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-3188
EI 1873-4332
J9 J PEDIATR ADOL GYNEC
JI J. Pediatr Adolesc. Gynecol.
PD APR
PY 2016
VL 29
IS 2
BP 104
EP 110
DI 10.1016/j.jpag.2015.07.003
PG 7
WC Obstetrics & Gynecology; Pediatrics
SC Obstetrics & Gynecology; Pediatrics
GA DF2SA
UT WOS:000371192900006
PM 26210293
ER
PT J
AU Pope, CA
Escobar-Gomez, M
Davis, BH
Roberts, JR
O'Brien, ES
Hinton, E
Darden, PM
AF Pope, C. A.
Escobar-Gomez, M.
Davis, B. H.
Roberts, J. R.
O'Brien, E. S.
Hinton, E.
Darden, P. M.
TI The challenge of tetradic relationships in medically interpreted
pediatric primary care visits: A descriptive study of communication
practices
SO PATIENT EDUCATION AND COUNSELING
LA English
DT Article
DE Adolescent; Primary care; Healthcare disparities; Communication
barriers; Linguistics; Hispanic Americans
ID LIMITED ENGLISH PROFICIENCY; OF-THE-LITERATURE; LANGUAGE SERVICES;
HEALTH-CARE; CONSULTATIONS; FAMILIES
AB Objective: To examine spoken interactions between pediatricians and community-based interpreters speaking with adolescents and parents with Limited English proficiency (LEP) in primary care to identify the challenges of interpreting in a four-person or tetradic visit, its sources of co-constructed errors, and specific practices for educational intervention.
Methods: As part of a larger study of vaccine decision-making at six clinical sites in two states, this descriptive study used discourse analysis to examine 20 routine primary care visits in a Latino Clinic in interactions between adolescents, parents, community-based interpreters, and pediatricians. Specific patterns of communication practices were identified that contributed to inaccuracies in medical interpretation
Results: Practices needing improvement were tallied for simple frequencies and included: omissions; false fluency; substitutions; editorializing; added clarification, information, or questions; medical terminology; extra explanation to mother; and, cultural additions. Of these speaking practices, omissions were the most common (123 out of 292 total) and the most affected by pediatricians.
Conclusion: The dynamics of both pediatricians and interpreters contributed to identification of areas for improvement, with more adolescent participation in bilingual than monolingual visits. Practice implications: These observations provide opportunities for mapping a communication skills training intervention based on observations for future testing of an evidence-based curriculum. Published by Elsevier Ireland Ltd.
C1 [Pope, C. A.] Med Univ S Carolina, Coll Nursing, 99 Jonathan Lucas St SN511,MSC 160, Charleston, SC 29425 USA.
[Pope, C. A.] Ralph H Johnson Vet Affairs VA Med Ctr, Charleston, SC 29401 USA.
[Davis, B. H.] Univ N Carolina, Dept English, Charlotte, NC 28223 USA.
[Roberts, J. R.; O'Brien, E. S.; Hinton, E.] Med Univ S Carolina, Coll Med, Dept Pediat, Charleston, SC 29425 USA.
[Darden, P. M.] Univ Oklahoma, Hlth Sci Ctr, Gen & Community Pediat, Oklahoma City, OK 73104 USA.
[Escobar-Gomez, M.] Bilingo LLC, Goose Creek, SC USA.
RP Pope, CA (reprint author), Med Univ S Carolina, Coll Nursing, 99 Jonathan Lucas St SN511,MSC 160, Charleston, SC 29425 USA.
EM popec@musc.edu; eskobarm@gmail.com; bdavis@uncc.edu; robertsj@musc.edu;
obriene@musc.edu; HintonE@musc.edu; paul-darden@ouhsc.edu
FU South Carolina Pediatric Practice Research Network; Oklahoma Child
Health Research Network; Department of Health and Human Services, Health
Resources and Services Administration, Maternal and Child Health
Research Program [R40 MC 21522]
FX This research was supported by funding from the R40 MC 21522 through the
Department of Health and Human Services, Health Resources and Services
Administration, Maternal and Child Health Research Program, Principal
Investigator, Dr. Paul Darden. We are grateful to the adolescents,
parents, and pediatric practices that allowed us to record and learn
from their encounters and the support of the South Carolina Pediatric
Practice Research Network and the Oklahoma Child Health Research
Network.
NR 31
TC 0
Z9 0
U1 6
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0738-3991
J9 PATIENT EDUC COUNS
JI Patient Educ. Couns.
PD APR
PY 2016
VL 99
IS 4
BP 542
EP 548
DI 10.1016/j.pec.2015.10.032
PG 7
WC Public, Environmental & Occupational Health; Social Sciences,
Interdisciplinary
SC Public, Environmental & Occupational Health; Social Sciences - Other
Topics
GA DH7IE
UT WOS:000372965900008
PM 26796067
ER
PT J
AU Lee, JD
Friedmann, PD
Kinlock, TW
Nunes, EV
Boney, TY
Hoskinson, RA
Wilson, D
McDonald, R
Rotrosen, J
Gourevitch, MN
Gordon, M
Fishman, M
Chen, DT
Bonnie, RJ
Cornish, JW
Murphy, SM
O'Brien, CP
AF Lee, Joshua D.
Friedmann, Peter D.
Kinlock, Timothy W.
Nunes, Edward V.
Boney, Tamara Y.
Hoskinson, Randall A., Jr.
Wilson, Donna
McDonald, Ryan
Rotrosen, John
Gourevitch, Marc N.
Gordon, Michael
Fishman, Marc
Chen, Donna T.
Bonnie, Richard J.
Cornish, James W.
Murphy, Sean M.
O'Brien, Charles P.
TI Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal
Justice Offenders
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID RANDOMIZED CLINICAL-TRIAL; METHADONE-MAINTENANCE; BUPRENORPHINE;
DEPENDENCE; TIME; PROBATIONERS; POSTRELEASE; ADDICTION; SEVERITY;
PAROLEES
AB BACKGROUND
Extended-release naltrexone, a sustained-release monthly injectable formulation of the full mu-opioid receptor antagonist, is effective for the prevention of relapse to opioid dependence. Data supporting its effectiveness in U.S. criminal justice populations are limited.
METHODS
In this five-site, open-label, randomized trial, we compared a 24-week course of extended-release naltrexone (Vivitrol) with usual treatment, consisting of brief counseling and referrals for community treatment programs, for the prevention of opioid relapse among adult criminal justice offenders (i.e., persons involved in the U.S. criminal justice system) who had a history of opioid dependence and a preference for opioid-free rather than opioid maintenance treatments and who were abstinent from opioids at the time of randomization. The primary outcome was the time to an opioid-relapse event, which was defined as 10 or more days of opioid use in a 28-day period as assessed by self-report or by testing of urine samples obtained every 2 weeks; a positive or missing sample was computed as 5 days of opioid use. Post-treatment follow-up occurred at weeks 27, 52, and 78.
RESULTS
A total of 153 participants were assigned to extended-release naltrexone and 155 to usual treatment. During the 24-week treatment phase, participants assigned to extended-release naltrexone had a longer median time to relapse than did those assigned to usual treatment (10.5 vs. 5.0 weeks, P<0.001; hazard ratio, 0.49; 95% confidence interval [CI], 0.36 to 0.68), a lower rate of relapse (43% vs. 64% of participants, P<0.001; odds ratio, 0.43; 95% CI, 0.28 to 0.65), and a higher rate of opioid-negative urine samples (74% vs. 56%, P<0.001; odds ratio, 2.30; 95% CI, 1.48 to 3.54). At week 78 (approximately 1 year after the end of the treatment phase), rates of opioid-negative urine samples were equal (46% in each group, P = 0.91). The rates of other prespecified secondary outcome measures - self-reported cocaine, alcohol, and intravenous drug use, unsafe sex, and reincarceration - were not significantly lower with extended-release naltrexone than with usual treatment. Over the total 78 weeks observed, there were no overdose events in the extended-release naltrexone group and seven in the usual-treatment group (P = 0.02).
CONCLUSIONS
In this trial involving criminal justice offenders, extended-release naltrexone was associated with a rate of opioid relapse that was lower than that with usual treatment. Opioid-use prevention effects waned after treatment discontinuation.
C1 [Lee, Joshua D.; McDonald, Ryan; Gourevitch, Marc N.] NYU, Dept Populat Hlth, 227 E 30th St, New York, NY 10016 USA.
[Lee, Joshua D.] NYU, Dept Med, Div Gen Internal Med & Clin Innovat, New York, NY USA.
[Rotrosen, John] NYU, Dept Psychiat, New York, NY USA.
[Nunes, Edward V.] Columbia Univ, Coll Phys & Surg, New York State Psychiat Inst, New York, NY USA.
[Friedmann, Peter D.; Hoskinson, Randall A., Jr.; Wilson, Donna] Rhode Isl Hosp, Div Gen Internal Med, Dept Med, Providence, RI USA.
[Friedmann, Peter D.; Hoskinson, Randall A., Jr.; Wilson, Donna] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA.
[Kinlock, Timothy W.; Gordon, Michael; Fishman, Marc] Univ Baltimore, Sch Criminal Justice, Friends Res Inst, Baltimore, MD 21201 USA.
[Fishman, Marc] Maryland Treatment Ctr, Baltimore, MD USA.
[Boney, Tamara Y.; Cornish, James W.; O'Brien, Charles P.] Univ Penn, Philadelphia, PA 19104 USA.
[Cornish, James W.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
[Chen, Donna T.] Univ Virginia, Ctr Biomed Eth & Humanities, Sch Med, Charlottesville, VA USA.
[Bonnie, Richard J.] Univ Virginia, Sch Law, Charlottesville, VA USA.
[Murphy, Sean M.] Washington State Univ, Spokane, WA USA.
RP Lee, JD (reprint author), NYU, Dept Populat Hlth, 227 E 30th St, New York, NY 10016 USA.
EM joshua.lee@nyumc.org
OI Gourevitch, Marc/0000-0001-6865-2126
FU National Institute on Drug Abuse
FX Funded by the National Institute on Drug Abuse
NR 24
TC 14
Z9 14
U1 4
U2 10
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAR 31
PY 2016
VL 374
IS 13
BP 1232
EP 1242
DI 10.1056/NEJMoa1505409
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA DH8ZM
UT WOS:000373085500006
PM 27028913
ER
PT J
AU Coughlin, B
Schnabolk, G
Joseph, K
Raikwar, H
Kunchithapautham, K
Johnson, K
Moore, K
Wang, Y
Rohrer, B
AF Coughlin, Beth
Schnabolk, Gloriane
Joseph, Kusumam
Raikwar, Himanshu
Kunchithapautham, Kannan
Johnson, Krista
Moore, Kristi
Wang, Yi
Rohrer, Baerbel
TI Connecting the innate and adaptive immune responses in mouse choroidal
neovascularization via the anaphylatoxin C5a and gamma delta T-cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; COMPLEMENT-MEDIATED INJURY; FACTOR-H
POLYMORPHISM; MACULAR DEGENERATION; OXIDATIVE STRESS; RISK-FACTORS;
MONOCLONAL-ANTIBODY; FACTOR-B; ACTIVATION; DRUSEN
AB Neovascular age-related macular degeneration (AMD) is characterized by choroidal neovascularization (CNV). An overactive complement system is associated with AMD pathogenesis, and serum proinflammatory cytokines, including IL-17, are elevated in AMD patients. IL-17 is produced by complement C5a-receptor-expressing T-cells. In murine CNV, infiltrating gamma delta T-rather than Th17-cells produce the IL-17 measurable in lesioned eyes. Here we asked whether C5a generated locally in response to CNV recruits IL-17-producing T-cells to the eye. CNV lesions were generated using laser photocoagulation and quantified by imaging; T-lymphocytes were characterized by QRT-PCR. CNV resulted in an increase in splenic IL-17-producing gamma delta T- and Th17-cells; yet in the CNV eye, only elevated levels of gamma delta T-cells were observed. Systemic administration of anti-C5- or anti-C5a-blocking antibodies blunted the CNV-induced production of splenic Th17- and gamma delta T-cells, reduced CNV size and eliminated ocular gamma delta T-cell infiltration. In ARPE-19 cell monolayers, IL-17 triggered a pro-inflammatory state; and splenocyte proliferation was elevated in response to ocular proteins. Thus, we demonstrated that CNV lesions trigger a systemic immune response, augmenting local ocular inflammation via the infiltration of IL-17-producing gamma delta T-cells, which are presumably recruited to the eye in a C5a-dependent manner. Understanding the complexity of complement-mediated pathological mechanisms will aid in the development of an AMD treatment.
C1 [Coughlin, Beth; Joseph, Kusumam; Raikwar, Himanshu; Kunchithapautham, Kannan; Rohrer, Baerbel] Med Univ S Carolina, Dept Ophthalmol, 171 Ashley Ave, Charleston, SC 29425 USA.
[Schnabolk, Gloriane; Rohrer, Baerbel] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC 29401 USA.
[Johnson, Krista; Moore, Kristi; Wang, Yi] Alex Pharmaceut, 352 Knotter Dr, Cheshire, CT 06410 USA.
[Raikwar, Himanshu] Pandit Bhagwat Dayal Sharma Post Grad Inst Med Sc, Rohtak, Haryana, India.
RP Rohrer, B (reprint author), Med Univ S Carolina, Dept Ophthalmol, 171 Ashley Ave, Charleston, SC 29425 USA.; Rohrer, B (reprint author), Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC 29401 USA.
EM rohrer@musc.edu
FU National Institutes of Health (NIH) [R01EY019320, C06 RR015455];
Department of Veterans Affairs [I01 RX000444]; Foundation Fighting
Blindness; Alexion Therapeutics; Research to Prevent Blindness (RPB),
Inc., New York, NY
FX Supported in part by the National Institutes of Health (NIH)
(R01EY019320), Department of Veterans Affairs (I01 RX000444), Foundation
Fighting Blindness, an unrestricted grant to MUSC from Research to
Prevent Blindness (RPB), Inc., New York, NY and a sponsored research
agreement by Alexion Therapeutics to BR. Animal studies were conducted
in a facility constructed with support from the NIH (C06 RR015455).
NR 84
TC 2
Z9 2
U1 2
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 31
PY 2016
VL 6
AR 23794
DI 10.1038/srep23794
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DI0ET
UT WOS:000373168600001
PM 27029558
ER
PT J
AU Lee, MH
Appleton, KM
Strungs, EG
Kwon, JY
Morinelli, TA
Peterson, YK
Laporte, SA
Luttrell, LM
AF Lee, Mi-Hye
Appleton, Kathryn M.
Strungs, Erik G.
Kwon, Joshua Y.
Morinelli, Thomas A.
Peterson, Yuri K.
Laporte, Stephane A.
Luttrell, Louis M.
TI The conformational signature of beta-arrestin2 predicts its trafficking
and signalling functions
SO NATURE
LA English
DT Article
ID COUPLED RECEPTOR ACTIVATION; BETA-ARRESTIN; G-PROTEIN;
CRYSTAL-STRUCTURE; CLATHRIN ADAPTER; BIASED AGONISM; LIVING CELLS;
ENDOCYTOSIS; MECHANISM; PHOSPHORYLATION
AB Arrestins are cytosolic proteins that regulate G-protein-coupled receptor (GPCR) desensitization, internalization, trafficking and signalling(1,2). Arrestin recruitment uncouples GPCRs from heterotrimeric G proteins, and targets the proteins for internalization via clathrin-coated pits(3,4). Arrestins also function as ligand-regulated scaffolds that recruit multiple non-G-protein effectors into GPCR-based 'signalsomes'(5,6). Although the dominant function(s) of arrestins vary between receptors, the mechanism whereby different GPCRs specify these divergent functions is unclear. Using a panel of intramolecular fluorescein arsenical hairpin (FlAsH) bioluminescence resonance energy transfer (BRET) reporters(7) to monitor conformational changes in beta-arrestin2, here we show that GPCRs impose distinctive arrestin 'conformational signatures' that reflect the stability of the receptor-arrestin complex and role of a-arrestin2 in activating or dampening downstream signalling events. The predictive value of these signatures extends to structurally distinct ligands activating the same GPCR, such that the innate properties of the ligand are reflected as changes in beta-arrestin2 conformation. Our findings demonstrate that information about ligand-receptor conformation is encoded within the population average a-arrestin2 conformation, and provide insight into how different GPCRs can use a common effector for different purposes. This approach may have application in the characterization and development of functionally selective GPCR ligands(8,9) and in identifying factors that dictate arrestin conformation and function.
C1 [Lee, Mi-Hye; Appleton, Kathryn M.; Strungs, Erik G.; Kwon, Joshua Y.; Morinelli, Thomas A.; Luttrell, Louis M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Peterson, Yuri K.] Med Univ S Carolina, Coll Pharm, Dept Pharmaceut & Biomed Sci, Charleston, SC 29425 USA.
[Laporte, Stephane A.] McGill Univ, Res Inst, Ctr Hlth, Dept Med, Quebec City, PQ H4A 3J1, Canada.
[Laporte, Stephane A.] McGill Univ, Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada.
[Laporte, Stephane A.] McGill Univ, Anat & Cell Biol, Quebec City, PQ H3A 0C7, Canada.
[Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA.
RP Luttrell, LM (reprint author), Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.; Luttrell, LM (reprint author), Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA.
EM luttrell@musc.edu
FU National Institutes of Health [DK055524, GM095497, RR027777]; Dialysis
Clinics, Inc.; Research Service of the Charleston, SC Veterans Affairs
Medical Center; Canadian Institutes of Health [MOP-74603]
FX This work was supported by National Institutes of Health grants DK055524
(L.M.L.) and GM095497 (L.M.L.), funds provided by Dialysis Clinics, Inc.
(T.A.M), and the Research Service of the Charleston, SC Veterans Affairs
Medical Center (L.M.L.). Supported by Canadian Institutes of Health
Research operating grant MOP-74603 (S.A.L.). National Institutes of
Health grant RR027777 (L.M.L.) supported the FLIPRTETRA
facility. The contents of this article do not represent the views of the
Department of Veterans Affairs or the United States Government.
NR 33
TC 21
Z9 21
U1 8
U2 23
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD MAR 31
PY 2016
VL 531
IS 7596
BP 665
EP +
DI 10.1038/nature17154
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DH8EX
UT WOS:000373027400044
PM 27007854
ER
PT J
AU Yuan, GD
Zhang, BX
Yang, SZ
Jin, L
Datta, A
Bae, S
Chen, XP
Datta, PK
AF Yuan, Guandou
Zhang, Bixiang
Yang, Shanzhong
Jin, Lin
Datta, Arunima
Bae, Sejong
Chen, Xiaoping
Datta, Pran K.
TI Novel role of STRAP in progression and metastasis of colorectal cancer
through Wnt/beta-catenin signaling
SO ONCOTARGET
LA English
DT Article
DE STRAP; beta-catenin; CRC; metastasis; tissue microarray
ID RECEPTOR-ASSOCIATED PROTEIN; BETA-CATENIN; DESTRUCTION COMPLEX; KINASE;
EXPRESSION; INHIBITION; APC; IDENTIFICATION; ACTIVATION; GSK3-BETA
AB Serine-Threonine Kinase Receptor-Associated Protein (STRAP) interacts with a variety of proteins and influences a wide range of cellular processes. Aberrant activation of Wnt/beta-catenin signaling has been implicated in the development of colorectal cancer (CRC). Here, we show the molecular mechanism by which STRAP induces CRC metastasis by promoting beta-catenin signaling through its stabilization. We have genetically engineered a series of murine and human CRC and lung cancer cell lines to investigate the effects of STRAP on cell migration and invasion in vitro, and on tumorigenicity and metastasis in vivo. Downregulation of STRAP inhibits invasion, tumorigenicity, and metastasis of CRC cells. Mechanistically, STRAP binds with GSK-3 beta and reduces the phosphorylation, ubiquitylation, and degradation of beta-catenin through preventing its binding to the destruction complex. This leads to an inhibition of Wnt/beta-catenin signaling and reduction in the expression of downstream targets, such as Cyclin D1, matrix metalloproteinases 2 and 9, and beta-TrCP. In human CRC specimens, higher STRAP expression correlates significantly with beta-catenin expression with increased nuclear levels (R = 0.696, p < .0001, n = 128). Together, these results suggest that STRAP increases invasion and metastasis of CRC partly through inhibiting ubiquitin-dependent degradation of beta-catenin and promoting Wnt/beta-catenin signaling.
C1 [Yuan, Guandou; Yang, Shanzhong; Jin, Lin; Datta, Arunima; Datta, Pran K.] Univ Alabama Birmingham, Dept Med, UAB Comprehens Canc Ctr, Div Hematol & Oncol, Birmingham, AL 35294 USA.
[Datta, Pran K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Yuan, Guandou; Zhang, Bixiang; Chen, Xiaoping] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, Wuhan 430074, Peoples R China.
[Bae, Sejong] Univ Alabama Birmingham, Div Prevent Med, Birmingham, AL USA.
RP Datta, PK (reprint author), Univ Alabama Birmingham, Dept Med, UAB Comprehens Canc Ctr, Div Hematol & Oncol, Birmingham, AL 35294 USA.; Datta, PK (reprint author), Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.; Chen, XP (reprint author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, Wuhan 430074, Peoples R China.
EM chenxpchenxp@163.com; prandatta@uabmc.edu
FU National Cancer Institute [R01 CA95195]; Veterans Affairs Merit Review
Award; UAB Comprehensive Cancer Center [P30 CA013148]
FX This study was supported by National Cancer Institute R01 CA95195,
Veterans Affairs Merit Review Award, and a Faculty Development Award
from UAB Comprehensive Cancer Center, P30 CA013148 (to PK Datta).
NR 46
TC 3
Z9 3
U1 1
U2 1
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAR 29
PY 2016
VL 7
IS 13
BP 16023
EP 16037
PG 15
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA DL5QW
UT WOS:000375692900057
PM 26910283
ER
PT J
AU Maron, BA
Hess, E
Maddox, TM
Opotowsky, AR
Tedford, RJ
Lahm, T
Joynt, KE
Kass, DJ
Stephens, T
Stanislawski, MA
Swenson, ER
Goldstein, RH
Leopold, JA
Zamanian, RT
Elwing, JM
Plomondon, ME
Grunwald, GK
Baron, AE
Rumsfeld, JS
Choudhary, G
AF Maron, Bradley A.
Hess, Edward
Maddox, Thomas M.
Opotowsky, Alexander R.
Tedford, Ryan J.
Lahm, Tim
Joynt, Karen E.
Kass, Daniel J.
Stephens, Thomas
Stanislawski, Maggie A.
Swenson, Erik R.
Goldstein, Ronald H.
Leopold, Jane A.
Zamanian, Roham T.
Elwing, Jean M.
Plomondon, Mary E.
Grunwald, Gary K.
Baron, Anna E.
Rumsfeld, John S.
Choudhary, Gaurav
TI Association of Borderline Pulmonary Hypertension With Mortality and
Hospitalization in a Large Patient Cohort: Insights From the Veterans
Affairs Clinical Assessment, Reporting, and Tracking Program
SO CIRCULATION
LA English
DT Article
DE pulmonary hypertension; pulmonary heart disease; outcome assessment
ID REDUCED EJECTION FRACTION; ARTERY SYSTOLIC PRESSURE; HEART-FAILURE;
AFRICAN-AMERICANS; DIAGNOSIS; CLASSIFICATION
AB Background- Pulmonary hypertension (PH) is associated with increased morbidity across the cardiopulmonary disease spectrum. Based primarily on expert consensus opinion, PH is defined by a mean pulmonary artery pressure (mPAP) >= 25 mm Hg. Although mPAP levels below this threshold are common among populations at risk for PH, the relevance of mPAP < 25 mm Hg to clinical outcome is unknown. Methods and Results- We analyzed retrospectively all US veterans undergoing right heart catheterization (2007-2012) in the Veterans Affairs healthcare system (n=21 727; 908-day median follow-up). Cox proportional hazards models were used to evaluate the association between mPAP and outcomes of all-cause mortality and hospitalization, adjusted for clinical covariates. When treating mPAP as a continuous variable, the mortality hazard increased beginning at 19 mm Hg (hazard ratio [HR]=1.183; 95% confidence interval [CI], 1.004-1.393) relative to 10 mm Hg. Therefore, patients were stratified into 3 groups: (1) referent (<= 18 mm Hg; n=4 207); (2) borderline PH (19-24 mm Hg; n=5 030); and (3) PH (>= 25 mm Hg; n=12 490). The adjusted mortality hazard was increased for borderline PH (HR=1.23; 95% CI, 1.12-1.36; P < 0.0001) and PH (HR=2.16; 95% CI, 1.96-2.38; P < 0.0001) compared with the referent group. The adjusted hazard for hospitalization was also increased in borderline PH (HR=1.07; 95% CI, 1.01-1.12; P=0.0149) and PH (HR=1.15; 95% CI, 1.09-1.22; P < 0.0001). The borderline PH cohort remained at increased risk for mortality after excluding the following high-risk subgroups: (1) patients with pulmonary artery wedge pressure > 15 mm Hg; (2) pulmonary vascular resistance >= 3.0 Wood units; or (3) inpatient status at the time of right heart catheterization. Conclusions- These data illustrate a continuum of risk according to mPAP level and that borderline PH is associated with increased mortality and hospitalization. Future investigations are needed to test the generalizability of our findings to other populations and study the effect of treatment on outcome in borderline PH.
C1 [Maron, Bradley A.; Goldstein, Ronald H.] Vet Affairs Boston Healthcare Syst, West Roxbury, MA 02132 USA.
[Maron, Bradley A.; Opotowsky, Alexander R.; Stephens, Thomas; Leopold, Jane A.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
[Maron, Bradley A.; Opotowsky, Alexander R.; Stephens, Thomas; Leopold, Jane A.] Harvard Univ, Sch Med, Boston, MA USA.
[Hess, Edward; Maddox, Thomas M.; Stanislawski, Maggie A.; Plomondon, Mary E.; Grunwald, Gary K.; Baron, Anna E.; Rumsfeld, John S.] Vet Affairs Eastern Colorado Hlth Care Syst, Denver, CO USA.
[Maddox, Thomas M.] Univ Colorado, Sch Med, Boulder, CO 80309 USA.
[Opotowsky, Alexander R.] Boston Childrens Hosp, Boston, MA USA.
[Tedford, Ryan J.] Johns Hopkins Sch Med, Div Cardiol, Dept Med, Baltimore, MD USA.
[Lahm, Tim] Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
[Lahm, Tim] Richard L Roudebush Vet Affairs Med Ctr, 1481 W 10th St, Indianapolis, IN 46202 USA.
[Joynt, Karen E.] US Dept HHS, Off Assistant Secretary Planning & Evaluat, Washington, DC 20201 USA.
[Kass, Daniel J.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Swenson, Erik R.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Swenson, Erik R.] Univ Washington, Seattle, WA 98195 USA.
[Zamanian, Roham T.] Stanford Univ, Sch Med, Vera Moulton Wall Ctr Pulm Vasc Dis, Stanford, CA 94305 USA.
[Elwing, Jean M.] Cincinnati Vet Affairs Med Ctr, Cincinnati, OH USA.
[Elwing, Jean M.] Univ Cincinnati, Cincinnati, OH 45221 USA.
[Choudhary, Gaurav] Brown Univ, Providence Vet Affairs Med Ctr, Providence, RI 02912 USA.
[Choudhary, Gaurav] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA.
RP Maron, BA (reprint author), Vet Affairs Boston Healthcare Syst, Div Cardiol, Dept Med, 1400 VFW Pkwy, West Roxbury, MA 02132 USA.
EM Bradley.Maron@va.gov
FU National Institutes of Health (NIH) [1K08HL11207-01A1]; American Heart
Association [15GRNT25080016]; Pulmonary Hypertension Association;
Cardiovascular Medical Research and Education Fund; Klarman Foundation
at Brigham and Women's Hospital; Gilead Young Scholars Foundation
(Gilead Sciences); Veterans Affairs Health Services Research and
Development Career Development Award [CDA 08-021]; Dunlevie Family Fund;
Office of Research and Development: Biomedical Laboratory Research and
Development Service (MERIT Review Award) [1I01BX002042-01A2,
IBX000711A]; Department of Veterans Affairs, Veterans Health
Administration; Catherine and Lowe Berger and Pauline L. Ford
Scholarship in Pulmonary Medicine; Department of Medicine, Indiana
University; VA Merit Award from the Department of Veterans Affairs,
Veterans Health Administration; Office of Research and Development:
Clinical Science Research and Development Service; NIH/National Heart,
Lung, and Blood Institute (NHLBI) [1U01HL125215-01]; Junior Faculty
Endowment by Vera Moulton Wall Center for Pulmonary Vascular Disease;
NIH/NHLBI/National Institute of Allergy and Infectious Diseases [PO1
HL108797, UO1 HL107393, R24 HL123767, N01 HV00242, ASCO1]; Department of
Medicine, Alpert Medical School
FX Dr Maron was supported by National Institutes of Health (NIH) Grant
1K08HL11207-01A1, American Heart Association Grant 15GRNT25080016, the
Pulmonary Hypertension Association, the Cardiovascular Medical Research
and Education Fund, the Klarman Foundation at Brigham and Women's
Hospital, and Gilead Young Scholars Foundation (Gilead Sciences). Dr
Maddox was supported by Veterans Affairs Health Services Research and
Development Career Development Award CDA 08-021. Dr Opotowsky was
supported by the Dunlevie Family Fund. Dr Lahm was supported by
Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development: Biomedical Laboratory Research and
Development Service (MERIT Review Award 1I01BX002042-01A2), and
Catherine and Lowe Berger and Pauline L. Ford Scholarship in Pulmonary
Medicine, Department of Medicine, Indiana University. Dr Goldstein was
supported by VA Merit Award from the Department of Veterans Affairs,
Veterans Health Administration, Office of Research and Development:
Clinical Science Research and Development Service. Dr Leopold was
supported by NIH/National Heart, Lung, and Blood Institute (NHLBI) Grant
1U01HL125215-01. Dr Zamanian was supported by Junior Faculty Endowment
by Vera Moulton Wall Center for Pulmonary Vascular Disease and
NIH/NHLBI/National Institute of Allergy and Infectious Diseases Grants
PO1 HL108797, UO1 HL107393, R24 HL123767, N01 HV00242, and ASCO1. Dr
Choudhary was supported by Department of Veterans Affairs, Veterans
Health Administration, Office of Research and Development: Biomedical
Laboratory Research and Development Service (MERIT Review Award
IBX000711A) and the Department of Medicine, Alpert Medical School.
NR 30
TC 11
Z9 11
U1 2
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD MAR 29
PY 2016
VL 133
IS 13
BP 1240
EP 1248
DI 10.1161/CIRCULATIONAHA.115.020207
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA DH5ST
UT WOS:000372852800004
PM 26873944
ER
PT J
AU Arsalan, M
Szerlip, M
Vemulapalli, S
Holper, EM
Arnold, SV
Li, ZK
DiMaio, MJ
Rumsfeld, JS
Brown, DL
Mack, MJ
AF Arsalan, Mani
Szerlip, Molly
Vemulapalli, Sreekanth
Holper, Elizabeth M.
Arnold, Suzanne V.
Li, Zhuokai
DiMaio, Michael J.
Rumsfeld, John S.
Brown, David L.
Mack, Michael J.
TI Should Transcatheter Aortic Valve Replacement Be Performed in
Nonagenarians? Insights From the STS/ACC TVT Registry
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE centenarians; elderly; quality of life; TAVI; TAVR; transcatheter aortic
valve implantation
ID CITY CARDIOMYOPATHY QUESTIONNAIRE; END-POINT DEFINITIONS;
CARDIAC-SURGERY; IMPLANTATION; STENOSIS; OUTCOMES; MANAGEMENT; VERSION;
RISK; SAFE
AB BACKGROUND Data demonstrating the outcome of transcatheter aortic valve replacement (TAVR) in the very elderly patients are limited, as they often represent only a small proportion of the trial populations.
OBJECTIVES The purpose of this study was to compare the outcomes of nonagenarians to younger patients undergoing TAVR in current practice.
METHODS We analyzed data from the Society of Thoracic Surgeons/American College of Cardiology TVT (Transcatheter Valve Therapy) Registry. Outcomes at 30 days and 1 year were compared between patients >= 90 years versus <90 years of age using cumulative incidence curves. Quality of life was assessed with the 12-item Kansas City Cardiomyopathy Questionnaire.
RESULTS Between November 2011 and September 2014, 24,025 patients underwent TAVR in 329 participating hospitals, of which 3,773 (15.7%) were age >= 90 years. The 30-day and 1-year mortality rates were significantly higher among nonagenarians (age >= 90 years vs. <90 years: 30-day: 8.8% vs. 5.9%; p < 0.001; 1 year: 24.8% vs. 22.0%; p < 0.001, absolute risk: 2.8%, relative risk: 12.7%). However, nonagenarians had a higher mean Society of Thoracic Surgeons Predicted Risk of Operative Mortality score (10.9% vs. 8.1%; p < 0.001) and, therefore, had similar ratios of observed to expected rates of 30-day death (age >= 90 years vs. <90 years: 0.81, 95% confidence interval: 0.70 to 0.92 vs. 0.72, 95% confidence interval: 0.67 to 0.78). There were no differences in the rates of stroke, aortic valve reintervention, or myocardial infarction at 30 days or 1 year. Nonagenarians had lower (worse) median Kansas City Cardiomyopathy Questionnaire scores at 30 days; however, there was no significant difference at 1 year.
CONCLUSIONS In current U.S. clinical practice, approximately 16% of patients undergoing TAVR are >= 90 years of age. Although 30-day and 1-year mortality rates were statistically higher compared with younger patients undergoing TAVR, the absolute and relative differences were clinically modest. TAVR also improves quality of life to the same degree in nonagenarians as in younger patients. These data support safety and efficacy of TAVR in select very elderly patients. (C) 2016 by the American College of Cardiology Foundation.
C1 [Arsalan, Mani; Szerlip, Molly; Holper, Elizabeth M.; DiMaio, Michael J.; Brown, David L.; Mack, Michael J.] Heart Hosp Baylor Plano, 1100 Allied Dr, Plano, TX 75093 USA.
[Arsalan, Mani] Kerckhoff Heart Ctr, Bad Nauheim, Germany.
[Vemulapalli, Sreekanth; Li, Zhuokai] Duke Clin Res Inst, Durham, NC USA.
[Arnold, Suzanne V.] St Lukes Mid Amer Heart Inst, Kansas City, MO USA.
[Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA.
RP Mack, MJ (reprint author), Heart Hosp Baylor Plano, 1100 Allied Dr, Plano, TX 75093 USA.
EM MichaeMa@baylorhealth.edu
RI Li, Zhuokai/F-4681-2017
FU American College of Cardiology's National Cardiovascular Data Registry
(NCDR); Abbott Vascular; Boston Scientific; American College of
Cardiology
FX The Society of Thoracic Surgeons/American College of Cardiology
Transcatheter Valve Therapy (STS/ACC TVT) Registry is an initiative of
the Society of Thoracic Surgeons and the American College of Cardiology.
This research was supported by the American College of Cardiology's
National Cardiovascular Data Registry (NCDR). The views expressed in
this paper represent those of the author(s) and do not necessarily
represent the official views of the NCDR or its associated professional
societies identified at CVQuality.ACC.org/NCDR. Dr. Szerlip has served
as a speaker for Edwards Lifesciences. Dr. Vemulapalli has received
research grants from Abbott Vascular, Boston Scientific, and the
American College of Cardiology. Dr. Holper has been a consultant to
Boston Scientific and Asahi Intecc. Dr. Rumsfeld is Chief Science
Officer of the NCDR. Dr. Mack is an uncompensated member of the
executive committee of the PARTNER (Placement of Aortic Transcatheter
Valve) trial of Edwards Lifesciences. All other authors have reported
that they have no relationships relevant to the contents of this paper
to disclose.
NR 25
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
EI 1558-3597
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD MAR 29
PY 2016
VL 67
IS 12
BP 1387
EP 1395
DI 10.1016/j.jacc.2016.01.055
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DG9NA
UT WOS:000372408500001
PM 27012397
ER
PT J
AU Teerlink, JR
Felker, GM
McMurray, JJV
Ponikowski, P
Metra, M
Filippatos, GS
Ezekowitz, JA
Dickstein, K
Cleland, JGF
Kim, JB
Lei, L
Knusel, B
Wolff, AA
Malik, FI
Wasserman, SM
AF Teerlink, John R.
Felker, G. Michael
McMurray, John J. V.
Ponikowski, Piotr
Metra, Marco
Filippatos, Gerasimos S.
Ezekowitz, Justin A.
Dickstein, Kenneth
Cleland, John G. F.
Kim, Jae B.
Lei, Lei
Knusel, Beat
Wolff, Andrew A.
Malik, Fady I.
Wasserman, Scott M.
CA ATOMIC-AHF Investigators
TI Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in
Acute Heart Failure The ATOMIC-AHF Study
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE arrhythmia; cardiac myosin activator; dyspnea; inotrope
ID CARDIAC MYOSIN ACTIVATOR; MYOCARDIAL OXYGEN-CONSUMPTION; TASK-FORCE;
CONTROLLED TRIAL; ATPASE ACTIVITY; RELAX-AHF; ASCEND-HF; ASSOCIATION;
OUTCOMES; HOSPITALIZATION
AB BACKGROUND Omecamtiv mecarbil (OM) is a selective cardiac myosin activator that increases myocardial function in healthy volunteers and in patients with chronic heart failure.
OBJECTIVES This study evaluated the pharmacokinetics, pharmacodynamics, tolerability, safety, and efficacy of OM in patients with acute heart failure (AHF).
METHODS Patients admitted for AHF with left ventricular ejection fraction <= 40%, dyspnea, and elevated plasma concentrations of natriuretic peptides were randomized to receive a double-blind, 48-h intravenous infusion of placebo or OM in 3 sequential, escalating-dose cohorts.
RESULTS In 606 patients, OM did not improve the primary endpoint of dyspnea relief (3 OM dose groups and pooled placebo: placebo, 41%; OM cohort 1, 42%; cohort 2, 47%; cohort 3, 51%; p = 0.33) or any of the secondary outcomes studied. In supplemental, pre-specified analyses, OM resulted in greater dyspnea relief at 48 h (placebo, 37% vs. OM, 51%; p = 0.034) and through 5 days (p = 0.038) in the high-dose cohort. OM exerted plasma concentration-related increases in left ventricular systolic ejection time (p < 0.0001) and decreases in end-systolic dimension (p < 0.05). The adverse event profile and tolerability of OM were similar to those of placebo, without increases in ventricular or supraventricular tachyarrhythmias. Plasma troponin concentrations were higher in OM-treated patients compared with placebo (median difference at 48 h, 0.004 ng/ml), but with no obvious relationship with OM concentration (p = 0.95).
CONCLUSIONS In patients with AHF, intravenous OM did not meet the primary endpoint of dyspnea improvement, but it was generally well tolerated, it increased systolic ejection time, and it may have improved dyspnea in the high-dose group. (Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure [ATOMIC-AHF]; NCT01300013) (C) 2016 by the American College of Cardiology Foundation.
C1 [Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
[Teerlink, John R.] San Francisco VA Med Ctr, Sect Cardiol, San Francisco, CA 94121 USA.
[Felker, G. Michael] Duke Univ, Sch Med, Div Cardiol, Durham, NC USA.
[McMurray, John J. V.] Univ Glasgow, British Heart Fdn Cardiovasc Res Ctr, Glasgow, Lanark, Scotland.
[Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Dept Heart Dis, Wroclaw, Poland.
[Metra, Marco] Univ Brescia, Div Cardiol, Dept Med & Surg Specialties Radiol Sci & Publ Hlt, Brescia, Italy.
[Filippatos, Gerasimos S.] Univ Athens, Hosp Attikon, Dept Cardiol, Athens, Greece.
[Ezekowitz, Justin A.] Univ Alberta, Canadian VIGOUR Ctr, Edmonton, AB, Canada.
[Dickstein, Kenneth] Univ Bergen, Cardiol Div, Bergen, Norway.
[Dickstein, Kenneth] Stavanger Univ Hosp, Cardiol Div, Stavanger, Norway.
[Cleland, John G. F.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Royal Brompton Hosp, London, England.
[Cleland, John G. F.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Harefield Hosp, London, England.
[Kim, Jae B.; Lei, Lei; Knusel, Beat; Wasserman, Scott M.] Amgen Inc, Thousand Oaks, CA 91320 USA.
[Wolff, Andrew A.; Malik, Fady I.] Cytokinetics Inc, San Francisco, CA USA.
RP Teerlink, JR (reprint author), San Francisco VA Med Ctr, Cardiol, 111C,4150 Clement St, San Francisco, CA 94121 USA.
EM john.teerlink@ucsf.edu
RI Ponikowski, Piotr/O-6454-2015
OI Ponikowski, Piotr/0000-0002-3391-7064; mcmurray,
john/0000-0002-6317-3975
FU Amgen, Inc.; Cytokinetics, Inc.; Amgen; Cytokinetics; Mast Therapeutics;
Novartis; Sorbent; Trevena; Roche Diagnostics; Otsuka; National Heart,
Lung, and Blood Institute; Singulex; Bayer; Servier; Cardiorentis;
Vifor; European Union; Abbott; AstraZeneca; Biotronik; Boston
Scientific; Johnson Johnson; Medtronic; Merck; Pfizer; Sanofi; Sorin;
St. Jude Medical; University of Bergen; Alere; Philips; StealthPeptides
FX The ATOMIC-AHF study was funded by Amgen, Inc. in collaboration with
Cytokinetics, Inc. The design of the study protocols was the
responsibility of the authors, Amgen, Inc., and Cytokinetics, Inc. All
statistical analyses were performed by Amgen, Inc. Dr. Teerlink received
research grants from Amgen, Cytokinetics, Mast Therapeutics, Novartis,
Sorbent, and Trevena; and has served as a consultant to Amgen,
Cytokinetics, Mast Therapeutics, Novartis, and Trevena. Dr. Felker has
received research grants from Amgen, Roche Diagnostics, Novartis,
Otsuka, and the National Heart, Lung, and Blood Institute; and has
served as a consultant for Amgen, Novartis, Roche Diagnostics, Singulex,
Trevena, Celladon, Bristol-Myers Squibb, Merck, and Medtronic. Dr.
McMurray's employer, Glasgow University, has been paid by Cytokinetics
and Amgen for his time spent working on the clinical trial program with
omecamtiv mecarbil. Dr. McMurray has had travel and accommodation costs
paid by Cytokinetics and Amgen in relation to advisory board and
clinical trial meetings about omecamtiv mecarbil. Dr. Ponikowski has
received consultancy and speaker honoraria from Amgen, Bayer,
Cardiorentis, Johnson & Johnson, Novartis, and Servier; and has received
an institutional research grant from Singulex. Dr. Metra has received
consulting fees from Amgen, Bayer, Mast Therapeutics, Novartis, Servier,
and Trevena. Dr. Filippatos has received research grants or consulting
fees, or both, from Bayer, Novartis, Cardiorentis, Vifor, and the
European Union. Dr. Ezekowitz has received research grants or honoraria
from Amgen, Novartis, Trevena, and Cardiorentis. Dr. Dickstein has
received honoraria and research support from Abbott, Amgen, AstraZeneca,
Bayer, Biotronik, Boston Scientific, Johnson & Johnson, Medtronic,
Merck, Novartis, Pfizer, Sanofi, Servier, Sorin, and St. Jude Medical;
and has received a research grant from the University of Bergen. Dr.
Cleland has received research grants from Alere, Amgen, Roche
Diagnostics, Novartis, Philips, Servier, and StealthPeptides; has served
as a consultant for Amgen, Novartis, Philips, Roche Diagnostics, Merck,
Medtronic, Servier, and Zoll; and has received speaker honoraria from
Bayer and Novartis. Dr. Kim is a former employee of and shareholder in
Amgen; and is current employee of and shareholder in MyoKardia. Drs.
Wolff and Malik are employees of and shareholders in Cytokinetics. Drs.
Lei, Knusel, and Wasserman are employees of and shareholders in Amgen.
NR 29
TC 17
Z9 17
U1 3
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
EI 1558-3597
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD MAR 29
PY 2016
VL 67
IS 12
BP 1444
EP 1455
DI 10.1016/j.jacc.2016.01.031
PG 12
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DG9NA
UT WOS:000372408500009
PM 27012405
ER
PT J
AU Bilen, O
Kamal, A
Virani, SS
AF Bilen, Ozlem
Kamal, Ayeesha
Virani, Salim S.
TI Lipoprotein abnormalities in South Asians and its association with
cardiovascular disease: Current state and future directions
SO WORLD JOURNAL OF CARDIOLOGY
LA English
DT Review
DE Dyslipidemia; South Asians; Asian Indians; Cardiovascular disease
ID CORONARY-HEART-DISEASE; LOW-DENSITY-LIPOPROTEIN; INTIMA-MEDIA THICKNESS;
APOLIPOPROTEIN-A-I; RISK-FACTORS; ARTERY-DISEASE; MYOCARDIAL-INFARCTION;
ELEVATED LIPOPROTEIN(A); INDIAN SUBCONTINENT; CHOLESTEROL EFFLUX
AB South Asians have a high prevalence of coronary heart disease (CHD) and suffer from early-onset CHD compared to other ethnic groups. Conventional risk factors may not fully explain this increased CHD risk in this population. Indeed, South Asians have a unique lipid profile which may predispose them to premature CHD. Dyslipidemia in this patient population seems to be an important contributor to the high incidence of coronary atherosclerosis. The dyslipidemia in South Asians is characterized by elevated levels of triglycerides, low levels of high-density lipoprotein (HDL) cholesterol, elevated lipoprotein(a) levels, and a higher atherogenic particle burden despite comparable low-density lipoprotein cholesterol levels compared with other ethnic subgroups. HDL particles also appear to be smaller, dysfunctional, and proatherogenic in South Asians. Despite the rapid expansion of the current literature with better understanding of the specific lipid abnormalities in this patient population, studies with adequate sample sizes are needed to assess the significance and contribution of a given lipid parameter on overall cardiovascular risk in this population. Specific management goals and treatment thresholds do not exist for South Asians because of paucity of data. Current treatment recommendations are mostly extrapolated from Western guidelines. Lastly, large, prospective studies with outcomes data are needed to assess cardiovascular benefit associated with various lipid-lowering therapies (including combination therapy) in this patient population.
C1 [Bilen, Ozlem; Virani, Salim S.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[Kamal, Ayeesha] Aga Khan Univ Hosp, Dept Med, Neurol Sect, Karachi 3500, Pakistan.
RP Virani, SS (reprint author), Baylor Coll Med, Dept Med, Michael E DeBakey Vet Affairs Med Ctr, Hlth Serv Res & Dev 152, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM virani@bcm.edu
OI Virani, Salim/0000-0001-9541-6954
NR 92
TC 2
Z9 2
U1 1
U2 2
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1949-8462
J9 WORLD J CARDIOL
JI World J. Cardiol.
PD MAR 26
PY 2016
VL 8
IS 3
BP 247
EP 257
DI 10.4330/wjc.v8.i3.247
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA DH4LF
UT WOS:000372756800001
PM 27022456
ER
PT J
AU Batth, I
Yun, HY
Hussain, S
Meng, P
Osumulski, P
Huang, THM
Bedolla, R
Profit, A
Reddick, R
Kumar, A
AF Batth, Izhar
Yun, Huiyoung
Hussain, Suleman
Meng, Peng
Osumulski, Powel
Huang, Tim Hui-Ming
Bedolla, Roble
Profit, Amanda
Reddick, Robert
Kumar, Addanki
TI Crosstalk between RON and androgen receptor signaling in the development
of castration resistant prostate cancer
SO ONCOTARGET
LA English
DT Article
DE castrate resistant prostate cancer; apoptosis; FLIP; RON; MSTIR
ID EPITHELIAL-MESENCHYMAL TRANSITION; TYROSINE KINASE; PANCREATIC-CANCER;
DEPRIVATION THERAPY; ALTERED EXPRESSION; TUMOR PROGRESSION;
BREAST-CANCER; C-MET; CELLS; GROWTH
AB Castrate-resistant prostate cancer (CRPC) is the fatal form of prostate cancer. Although reactivation of androgen receptor (AR) occurs following androgen deprivation, the precise mechanism involved is unclear. Here we show that the receptor tyrosine kinase, RON alters mechanical properties of cells to influence epithelial to mesenchymal transition and functions as a transcription factor to differentially regulate AR signaling. RON inhibits AR activation and subset of AR-regulated transcripts in androgen responsive LNCaP cells. However in C4-2B, a castrate-resistant sub-line of LNCaP and AR-negative androgen independent DU145 cells, RON activates subset of AR-regulated transcripts. Expression of AR in PC-3 cells leads to activation of RON under androgen deprivation but not under androgen proficient conditions implicating a role for RON in androgen independence. Consistently, RON expression is significantly elevated in castrate resistant prostate tumors. Taken together our results suggest that RON activation could aid in promoting androgen independence and that inhibition of RON in combination with AR antagonist(s) merits serious consideration as a therapeutic option during hormone deprivation therapy.
C1 [Batth, Izhar; Meng, Peng; Bedolla, Roble; Kumar, Addanki] Dept Urol, San Antonio, TX USA.
[Yun, Huiyoung; Hussain, Suleman; Kumar, Addanki] Univ Texas San Antonio, Hlth Sci Ctr, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.
[Osumulski, Powel; Huang, Tim Hui-Ming; Kumar, Addanki] Dept Mol Med, San Antonio, TX USA.
[Profit, Amanda; Reddick, Robert] Univ Texas San Antonio, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA.
[Huang, Tim Hui-Ming; Kumar, Addanki] Dept Canc Therapy & Res Ctr, San Antonio, TX USA.
[Kumar, Addanki] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Kumar, Addanki] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Meng, Peng] Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA USA.
[Batth, Izhar] Univ Texas MD Anderson Canc Ctr, Dept Pediat, Houston, TX 77030 USA.
RP Kumar, A (reprint author), Dept Urol, San Antonio, TX USA.; Kumar, A (reprint author), Univ Texas San Antonio, Hlth Sci Ctr, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.; Kumar, A (reprint author), Dept Mol Med, San Antonio, TX USA.; Kumar, A (reprint author), Dept Canc Therapy & Res Ctr, San Antonio, TX USA.; Kumar, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.; Kumar, A (reprint author), South Texas Vet Hlth Care Syst, San Antonio, TX USA.
EM kumara3@uthscsa.edu
FU Veterans Affairs-Merit Award [I01 BX 000766-01, 1R01CA135451,
1R01AT007448]; CTRC at UT Health Science Center San Antonio (UTHSCSA)
through the National Cancer Institute [2P30 CA 054174-17]; CTRC 40th
Anniversary Distinguished Professor of Oncology Endowment
FX This work was supported in part by funds from Veterans Affairs-Merit
Award I01 BX 000766-01, 1R01CA135451 and 1R01AT007448 (APK). We
acknowledge support provided by CTRC at UT Health Science Center San
Antonio (UTHSCSA) through the National Cancer Institute support grant
#2P30 CA 054174-17. We acknowledge support provided by the CTRC 40th
Anniversary Distinguished Professor of Oncology Endowment to APK. We
thank Dr. JW Freeman, (UTHSCSA) for the RON-reporter; Dr. A. Lowey,
(UC-San Diego) for the RON expression plasmid; Dr. D. Tindall, (Mayo
Clinic Rochester) for pGL3-PSAARE constructs; and Dr. R. Vadlamudi
(UTHSCSA) for providing PC-3AR cells. We sincerely thank Dr. R. Ghosh,
(UTHSCSA) for critically reading the manuscript.
NR 56
TC 1
Z9 1
U1 0
U2 0
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAR 22
PY 2016
VL 7
IS 12
BP 14048
EP 14063
PG 16
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA DL5OT
UT WOS:000375687200058
PM 26872377
ER
PT J
AU Cong, LL
Muir, ER
Chen, C
Qian, YS
Liu, JW
Biju, KC
Clark, RA
Li, SL
Duong, TQ
AF Cong, Linlin
Muir, Eric R.
Chen, Cang
Qian, Yusheng
Liu, Jingwei
Biju, K. C.
Clark, Robert A.
Li, Senlin
Duong, Timothy Q.
TI Multimodal MRI Evaluation of the MitoPark Mouse Model of Parkinson's
Disease
SO PLOS ONE
LA English
DT Article
ID CEREBRAL-BLOOD-FLOW; DEFICIENT DOPAMINE NEURONS; IRON-DEPOSITION;
COGNITIVE IMPAIRMENT; SUBSTANTIA-NIGRA; ANIMAL-MODELS; BRAIN-TISSUE;
IN-VIVO; DIFFUSION; MICE
AB The MitoPark mouse, a relatively new genetic model of Parkinson's disease (PD), has a dopaminergic neuron-specific knock-out that inactivates the mitochondrial transcription factor A (Tfam), a protein essential for mitochondrial DNA expression and maintenance. This study used multimodal MRI to characterize the neuroanatomical correlates of PD-related deficits in MitoPark mice, along with functional behavioral tests. Compared with age-matched wild-type animals, MitoPark mice at 30 weeks showed: i) reduced whole-brain volume and increased ventricular volume, indicative of brain atrophy, ii) reduced transverse relaxation time (T-2*) of the substantia nigra and striatum, suggestive of abnormal iron accumulation, iii) reduced apparent diffusion coefficient in the substantia nigra, suggestive of neuronal loss, iv) reduced fractional anisotropy in the corpus callosum and substantia nigra, indicative of white-matter damages, v) cerebral blood flow was not significantly affected, and vi) reduced motor activity in open-field tests, reduced memory in novel object recognition tests, as well as decreased mobility in tail suspension tests, an indication of depression. In sum, MitoPark mice recapitulate changes in many MRI parameters reported in PD patients. Multimodal MRI may prove useful for evaluating neuroanatomical correlates of PD pathophysiology in MitoPark mice, and for longitudinally monitoring disease progression and therapeutic interventions for PD.
C1 [Cong, Linlin; Muir, Eric R.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.
[Cong, Linlin] Univ Texas San Antonio, Grad Sch Biomed Sci, San Antonio, TX USA.
[Muir, Eric R.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA.
[Chen, Cang; Qian, Yusheng; Liu, Jingwei; Biju, K. C.; Clark, Robert A.; Li, Senlin] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Clark, Robert A.; Li, Senlin; Duong, Timothy Q.] South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA.
RP Muir, ER; Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.; Muir, ER; Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA.; Duong, TQ (reprint author), South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA.
EM muire@uthscsa.edu; duongt@uthscsa.edu
FU United States (U.S.) Department of Veterans Biomedical Laboratory
Research and Development Service [I01BX000737]; William and Ella Owens
Medical Research Foundation
FX work was supported by Merit Review Award #I01BX000737 from the United
States (U.S.) Department of Veterans Biomedical Laboratory Research and
Development Service and by a grant from the William and Ella Owens
Medical Research Foundation awarded to S.L. The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 56
TC 0
Z9 0
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 22
PY 2016
VL 11
IS 3
AR e0151884
DI 10.1371/journal.pone.0151884
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DH3OX
UT WOS:000372697400053
PM 27003179
ER
PT J
AU Lynch, CP
Williams, JS
Ruggiero, KJ
Knapp, RG
Egede, LE
AF Lynch, Cheryl P.
Williams, Joni S.
Ruggiero, Kenneth J.
Knapp, Rebecca G.
Egede, Leonard E.
TI Tablet-Aided BehavioraL intervention EffecT on Self-management skills
(TABLETS) for Diabetes
SO TRIALS
LA English
DT Article
ID AMERICAN-HEART-ASSOCIATION; DISEASE RISK-FACTORS;
CARDIOVASCULAR-DISEASE; PHYSICAL-ACTIVITY; RANDOMIZED-TRIAL;
ETHNIC-DIFFERENCES; EMPOWERMENT SCALE; GLYCEMIC CONTROL; HEALTH
LITERACY; PEER SUPPORT
AB Background: Multiple randomized controlled trials (RCTs) show that behavioral lifestyle interventions are effective in improving diabetes management and that comprehensive risk factor management improves cardiovascular disease (CVD) outcomes. The role of technology has been gaining strong support as evidence builds of its potential to improve diabetes management; however, evaluation of its impact in minority populations is limited. This study intends to provide early evidence of a theory-driven intervention, Tablet-Aided BehavioraL intervention EffecT on Self-management skills (TABLETS), using real-time videoconferencing for education and skills training. We examine the potential for TABLETS to improve health risk behaviors and reduce CVD risk outcomes among a low-income African American (AA) population with poorly controlled type 2 diabetes.
Methods: The study is a two-arm, pilot controlled trial that randomizes 30 participants to the TABLETS intervention and 30 participants to a usual care group. Blinded outcome assessments will be completed at baseline, 2.5 months (immediate post-intervention), and 6.5 months (follow-up). The TABLETS intervention consists of culturally tailored telephone-delivered diabetes education and skills training delivered via videoconferencing on tablet devices, with two booster sessions delivered via tablet-based videoconferencing at 3 months and 5 months to stimulate ongoing use of the tablet device with access to intervention materials via videoconferencing slides and a manual of supplementary materials. The primary outcomes are physical activity, diet, medication adherence, and self-monitoring behavior, whereas the secondary outcomes are HbA1c, low-density lipoprotein cholesterol (LDL-C), BP, CVD risk, and quality of life.
Discussion: This study provides a unique opportunity to assess the feasibility and efficacy of a theory-driven, tablet-aided behavioral intervention that utilizes real-time videoconferencing technology for education and skills training on self-management behaviors and quality of life among a high-risk, low-income AA population with an uncontrolled dyad or triad of CVD risk factors (diabetes with or without hypertension or hyperlipidemia). The intervention leverages the use of novel technology for education and skill-building to foster improved diabetes self-management. The findings of this study will inform the process of disseminating the intervention to a broader and larger sample of people and can potentially be refined to align with clinical workflows that target a subsample of patients with poor diabetes self-management.
C1 [Lynch, Cheryl P.; Williams, Joni S.; Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Ctr Hlth Dispar Res, 135 Rutledge Ave,MSC 593, Charleston, SC 29425 USA.
[Lynch, Cheryl P.; Ruggiero, Kenneth J.; Knapp, Rebecca G.; Egede, Leonard E.] Ralph H Johnson VAMC, Hlth Equity & Rural Outreach Innovat Ctr, 109 Bee St, Charleston, SC 29401 USA.
[Ruggiero, Kenneth J.] Med Univ S Carolina, Coll Nursing, 19 Hagood Ave,Suite 1002,MSC 160, Charleston, SC 29425 USA.
[Ruggiero, Kenneth J.] Med Univ S Carolina, Dept Psychiat & Behav Sci, 19 Hagood Ave,Suite 1002,MSC 160, Charleston, SC 29425 USA.
[Knapp, Rebecca G.] Med Univ S Carolina, Dept Publ Hlth Sci, 135 Cannon St,MSC 835, Charleston, SC 29425 USA.
RP Lynch, CP (reprint author), Med Univ S Carolina, Div Gen Internal Med & Geriatr, Ctr Hlth Dispar Res, 135 Rutledge Ave,MSC 593, Charleston, SC 29425 USA.; Lynch, CP (reprint author), Ralph H Johnson VAMC, Hlth Equity & Rural Outreach Innovat Ctr, 109 Bee St, Charleston, SC 29401 USA.
EM lynchcp@musc.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK), National Institutes of Health (NIH) [R03DK098489]
FX The study is funded by grant number R03DK098489 from the National
Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),
National Institutes of Health (NIH).
NR 72
TC 1
Z9 1
U1 3
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1745-6215
J9 TRIALS
JI Trials
PD MAR 22
PY 2016
VL 17
AR 157
DI 10.1186/s13063-016-1243-2
PG 12
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA DH2HC
UT WOS:000372604300006
PM 27005766
ER
PT J
AU Leventhal, JS
Ni, J
Osmond, M
Lee, K
Gusella, GL
Salem, F
Ross, MJ
AF Leventhal, Jeremy S.
Ni, Jie
Osmond, Morgan
Lee, Kyung
Gusella, G. Luca
Salem, Fadi
Ross, Michael J.
TI Autophagy Limits Endotoxemic Acute Kidney Injury and Alters Renal
Tubular Epithelial Cell Cytokine Expression
SO PLOS ONE
LA English
DT Article
ID SEPSIS; MICE; PROTECTS; DISEASE; INACTIVATION; APOPTOSIS; PREVENTS;
FAILURE; PLAYS; GENE
AB Sepsis related acute kidney injury (AKI) is a common in-hospital complication with a dismal prognosis. Our incomplete understanding of disease pathogenesis has prevented the identification of hypothesis-driven preventive or therapeutic interventions. Increasing evidence in ischemia-reperfusion and nephrotoxic mouse models of AKI support the theory that autophagy protects renal tubular epithelial cells (RTEC) from injury. However, the role of RTEC autophagy in septic AKI remains unclear. We observed that lipopolysaccharide (LPS), a mediator of gram-negative bacterial sepsis, induces RTEC autophagy in vivo and in vitro through TLR4-initiated signaling. We modeled septic AKI through intraperitoneal LPS injection in mice in which autophagy-related protein 7 was specifically knocked out in the renal proximal tubules (ATG7KO). Compared to control littermates, ATG7KO mice developed more severe renal dysfunction (24hr BUN 100.1mg/dl +/- 14.8 vs 54.6mg/dl +/- 11.3) and parenchymal injury. After injection with LPS, analysis of kidney lysates identified higher IL-6 expression and increased STAT3 activation in kidney lysates from ATG7KO mice compared to controls. In vitro experiments confirmed an altered response to LPS in RTEC with genetic or pharmacological impairment of autophagy. In conclusion, RTEC autophagy protects against endotoxin induced injury and regulates downstream effects of RTEC TLR4 signaling.
C1 [Leventhal, Jeremy S.; Ni, Jie; Osmond, Morgan; Lee, Kyung; Gusella, G. Luca; Ross, Michael J.] Icahn Sch Med Mt Sinai, Dept Med, Div Nephrol, New York, NY 10029 USA.
[Leventhal, Jeremy S.; Ross, Michael J.] James J Peters Bronx VA Med Ctr, Div Renal, Bronx, NY USA.
[Salem, Fadi] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA.
RP Leventhal, JS (reprint author), Icahn Sch Med Mt Sinai, Dept Med, Div Nephrol, New York, NY 10029 USA.; Leventhal, JS (reprint author), James J Peters Bronx VA Med Ctr, Div Renal, Bronx, NY USA.
EM jeremy.leventhal@mssm.edu
FU NIH/NIDDK grant [R01 DK101338, DK108346, K08 DK090217]
FX This research was supported by the NIH/NIDDK grant R01 DK101338 and
DK108346 (MR) and an NIH/NIDDK K08 DK090217 grant (JSL).; This research
was supported by the NIH/NIDDK grant R01 DK101338 and DK108346 (M.R.)
and an NIH/NIDDK K08 DK090217 (J.S.L). Microscopy was performed at the
Microscopy CORE at the Icahn School of Medicine at Mount Sinai.
NR 32
TC 1
Z9 3
U1 1
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 18
PY 2016
VL 11
IS 3
AR e0150001
DI 10.1371/journal.pone.0150001
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DH1ZE
UT WOS:000372582800023
PM 26990086
ER
PT J
AU Baenninger, A
Hernandez, LD
Rieger, K
Ford, JM
Kottlow, M
Koenig, T
AF Baenninger, Anja
Hernandez, Laura Diaz
Rieger, Kathryn
Ford, Judith M.
Kottlow, Mara
Koenig, Thomas
TI Inefficient Preparatory fMRI-BOLD Network Activations Predict Working
Memory Dysfunctions in Patients with Schizophrenia
SO FRONTIERS IN PSYCHIATRY
LA English
DT Article
DE schizophrenia; working memory; temporally coherent networks;
state-dependent information processing; simultaneous EEG-fMRI;
covariance mapping
ID DEFAULT MODE NETWORK; DORSOLATERAL PREFRONTAL CORTEX; CORTICAL
OSCILLATORY ACTIVITY; RESTING-STATE; FUNCTIONAL CONNECTIVITY; BRAIN
NETWORKS; EXECUTIVE NETWORKS; SUBSEQUENT-MEMORY; EEG ABNORMALITIES;
HEALTHY CONTROLS
AB Patients with schizophrenia show abnormal dynamics and structure of temporally coherent networks (TCNs) assessed using fMRI, which undergo adaptive shifts in preparation for a cognitively demanding task. During working memory (WM) tasks, patients with schizophrenia show persistent deficits in TCNs as well as EEG indices of WM. Studying their temporal relationship during WM tasks might provide novel insights into WM performance deficits seen in schizophrenia. Simultaneous EEG-fMRI data were acquired during the performance of a verbal Sternberg WM task with two load levels (load 2 and load 5) in 17 patients with schizophrenia and 17 matched healthy controls. Using covariance mapping, we investigated the relationship of the activity in the TCNs before the memoranda were encoded and EEG spectral power during the retention interval. We assessed four TCNs- default mode network (DMN), dorsal attention network (dAN), left and right working memory networks (WMNs)- and three EEG bands- theta, alpha, and beta. In healthy controls, there was a load-dependent inverse relation between DMN and frontal midline theta power and an anti-correlation between DMN and dAN. Both effects were not significantly detectable in patients. In addition, healthy controls showed a left-lateralized load dependent recruitment of the WMNs. Activation of the WMNs was bilateral in patients, suggesting more resources were recruited for successful performance on the WM task. Our findings support the notion of schizophrenia patients showing deviations in their neurophysiological responses before the retention of relevant information in a verbal WM task. Thus, treatment strategies as neurofeedback targeting prestates could be beneficial as task performance relies on the preparatory state of the brain.
C1 [Baenninger, Anja; Hernandez, Laura Diaz; Kottlow, Mara; Koenig, Thomas] Univ Bern, Univ Hosp Psychiat & Psychotherapy, Translat Res Ctr, Bern, Switzerland.
[Baenninger, Anja; Ford, Judith M.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Hernandez, Laura Diaz; Rieger, Kathryn; Kottlow, Mara; Koenig, Thomas] Univ Bern, Ctr Cognit Learning & Memory, Bern, Switzerland.
[Ford, Judith M.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
RP Baenninger, A (reprint author), Univ Bern, Univ Hosp Psychiat & Psychotherapy, Translat Res Ctr, Bern, Switzerland.; Baenninger, A (reprint author), San Francisco VA Med Ctr, San Francisco, CA USA.
EM anja.baenninger@puk.unibe.ch
RI Koenig, Thomas/F-6454-2010
OI Koenig, Thomas/0000-0002-1472-4638; Baenninger,
Anja/0000-0001-8921-5216; Diaz Hernandez, Laura/0000-0003-3452-8797
NR 87
TC 1
Z9 1
U1 2
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 1664-0640
J9 FRONT PSYCHIATRY
JI Front. Psychiatry
PD MAR 18
PY 2016
VL 7
AR 29
DI 10.3389/fpsyt.2016.00029
PG 15
WC Psychiatry
SC Psychiatry
GA DG8XY
UT WOS:000372368100002
PM 27047395
ER
PT J
AU Downey, JE
Weiss, JM
Muelling, K
Venkatraman, A
Valois, JS
Hebert, M
Bagnell, JA
Schwartz, AB
Collinger, JL
AF Downey, John E.
Weiss, Jeffrey M.
Muelling, Katharina
Venkatraman, Arun
Valois, Jean-Sebastien
Hebert, Martial
Bagnell, J. Andrew
Schwartz, Andrew B.
Collinger, Jennifer L.
TI Blending of brain-machine interface and vision-guided autonomous
robotics improves neuroprosthetic arm performance during grasping
SO JOURNAL OF NEUROENGINEERING AND REHABILITATION
LA English
DT Article
DE Brain-machine interface; Brain-computer interface; Neuroprosthetic;
Shared mode control; Assistive technology
ID SPINAL-CORD-INJURY; COMPUTER INTERFACE; PRIORITIES; USERS
AB Background: Recent studies have shown that brain-machine interfaces (BMIs) offer great potential for restoring upper limb function. However, grasping objects is a complicated task and the signals extracted from the brain may not always be capable of driving these movements reliably. Vision-guided robotic assistance is one possible way to improve BMI performance. We describe a method of shared control where the user controls a prosthetic arm using a BMI and receives assistance with positioning the hand when it approaches an object.
Methods: Two human subjects with tetraplegia used a robotic arm to complete object transport tasks with and without shared control. The shared control system was designed to provide a balance between BMI-derived intention and computer assistance. An autonomous robotic grasping system identified and tracked objects and defined stable grasp positions for these objects. The system identified when the user intended to interact with an object based on the BMI-controlled movements of the robotic arm. Using shared control, BMI controlled movements and autonomous grasping commands were blended to ensure secure grasps.
Results: Both subjects were more successful on object transfer tasks when using shared control compared to BMI control alone. Movements made using shared control were more accurate, more efficient, and less difficult. One participant attempted a task with multiple objects and successfully lifted one of two closely spaced objects in 92 % of trials, demonstrating the potential for users to accurately execute their intention while using shared control.
Conclusions: Integration of BMI control with vision-guided robotic assistance led to improved performance on object transfer tasks. Providing assistance while maintaining generalizability will make BMI systems more attractive to potential users.
C1 [Downey, John E.; Weiss, Jeffrey M.; Schwartz, Andrew B.; Collinger, Jennifer L.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15213 USA.
[Downey, John E.; Schwartz, Andrew B.; Collinger, Jennifer L.] Ctr Neural Basis Cognit, Pittsburgh, PA USA.
[Weiss, Jeffrey M.; Collinger, Jennifer L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA.
[Muelling, Katharina; Venkatraman, Arun; Valois, Jean-Sebastien; Hebert, Martial; Bagnell, J. Andrew] Carnegie Mellon Univ, Inst Robot, Pittsburgh, PA 15213 USA.
[Schwartz, Andrew B.] Univ Pittsburgh, Dept Neurobiol, Pittsburgh, PA 15213 USA.
[Collinger, Jennifer L.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Collinger, Jennifer L.] Univ Pittsburgh, 3520 5th Ave,Suite 300, Pittsburgh, PA 15213 USA.
RP Collinger, JL (reprint author), Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15213 USA.; Collinger, JL (reprint author), Ctr Neural Basis Cognit, Pittsburgh, PA USA.
EM collinger@pitt.edu
OI Downey, John/0000-0002-2992-2848
FU US Food and Drug Administration [NCT01364480, NCT01894802]; Defense
Advanced Research Projects Agency's (DARPA, Arlington, VA, USA)
Revolutionizing Prosthetics program [N66001-10-C-4056]; Autonomous
Robotic Manipulation Software Track (ARM-S) program; National Science
Foundation's NRI Purposeful Prediction program [1227495]; GRF program
[DGE-1252522]
FX This study was done under investigational device exemptions granted by
the US Food and Drug Administration (NCT01364480 and NCT01894802). We
thank Jan Scheuermann and Nathan Copeland for their extraordinary
commitment and effort in relation to this study and insightful
discussions with the study team; Karina Palko for her participation as
an honorary research team member and support of the study; Debbie
Harrington (Physical Medicine and Rehabilitation) for regulatory
management of the study; the University of Pittsburgh Clinical and
Translational Science Institute and the Office of Investigator-Sponsored
Investigational New Drugs and Investigational Device Exemption support
for assistance with protocol development and regulatory reporting and
compliance; the volunteer members of the DSMB for their continued
monitoring of this study; and Blackrock Microsystems (Salt Lake City,
UT, USA) for technical support in relation to this project. This
research was developed with funding from the Defense Advanced Research
Projects Agency's (DARPA, Arlington, VA, USA) Revolutionizing
Prosthetics program (contract number N66001-10-C-4056), and the
Autonomous Robotic Manipulation Software Track (ARM-S) program. National
Science Foundation's NRI Purposeful Prediction program (award no.
1227495) and GRF program (award no. DGE-1252522). The views, opinions,
and/or findings contained in this article are those of the authors and
should not be interpreted as representing the official views or policies
of the Department of Veterans Affairs, Department of Defense, or US
Government.
NR 23
TC 0
Z9 0
U1 4
U2 21
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1743-0003
J9 J NEUROENG REHABIL
JI J. NeuroEng. Rehabil.
PD MAR 18
PY 2016
VL 13
AR 28
DI 10.1186/s12984-016-0134-9
PG 12
WC Engineering, Biomedical; Neurosciences; Rehabilitation
SC Engineering; Neurosciences & Neurology; Rehabilitation
GA DH2DW
UT WOS:000372595400001
PM 26987662
ER
PT J
AU Nicholl, MB
Chen, XH
Qin, CL
Bai, Q
Zhu, ZW
Davis, MR
Fang, YJ
AF Nicholl, Michael B.
Chen, Xuhui
Qin, Chenglu
Bai, Qian
Zhu, Ziwen
Davis, Matthew R.
Fang, Yujiang
TI IL-32 has differential effects on proliferation and apoptosis of human
melanoma cell lines
SO JOURNAL OF SURGICAL ONCOLOGY
LA English
DT Article
DE IL-32; apoptosis; proliferation
ID NATURAL-KILLER-CELLS; NF-KAPPA-B; RHEUMATOID-ARTHRITIS; GASTRIC-CANCER;
T-CELLS; INTERLEUKIN-32; DEATH; EXPRESSION; GROWTH; METASTASIS
AB BackgroundInterleukin-32 (IL-32) is a recently recognized intracellular, proinflammatory cytokine which may play a role in cancer metastasis and patient survival. The role of IL-32 in cancer, especially its direct effect on cancer cells, is not well understood.
Material and MethodsClonogenic assay, PCNA staining, Quick Cell Proliferation assay, TUNEL staining, and caspase-3 activity assay were used to investigate the in vitro role for IL-32 in human melanoma growth. We further investigated the possible molecular mechanisms using RT-PCR and immunohistochemical staining.
ResultsExogenous administration of IL-32 inhibited proliferation of the HTB-72 human melanoma cell line, but had little effect on other melanoma cell lines. Inhibition of proliferation in HTB-72 correlated with increased expression of p21 and p53. IL-32 administration also increased apoptosis in HTB-72. This finding correlated with increased expression of TRAILR1.
ConclusionsThe data presented suggest a direct effect of IL-32 on the growth of human melanoma and give some insight into the mechanisms which may in part govern this effect. J. Surg. Oncol. 2016;113:364-369. (c) 2016 Wiley Periodicals, Inc.
C1 [Nicholl, Michael B.; Chen, Xuhui; Qin, Chenglu; Bai, Qian; Zhu, Ziwen; Davis, Matthew R.; Fang, Yujiang] Univ Missouri, Sch Med, Ellis Fischel Canc Ctr, Columbia, MO USA.
[Nicholl, Michael B.] South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.
[Chen, Xuhui; Qin, Chenglu] Luohu Hosp, Shenzhen, Peoples R China.
[Fang, Yujiang] Des Moines Univ, Des Moines, IA 50312 USA.
RP Nicholl, MB (reprint author), South Texas Vet Hlth Care Syst, Dept Surg, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.; Fang, YJ (reprint author), Des Moines Univ, Coll Osteopath Med, Dept Microbiol Immunol & Pathol, Des Moines, IA 50312 USA.
EM michaelnicholl@gmail.com; yujiang.fang@dmu.edu
RI Zhu, Ziwen/I-1895-2014
OI Zhu, Ziwen/0000-0002-6681-9153
FU University of Missouri; Des Moines University
FX Grant sponsor: University of Missouri; Grant sponsor: Des Moines
University
NR 39
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-4790
EI 1096-9098
J9 J SURG ONCOL
JI J. Surg. Oncol.
PD MAR 15
PY 2016
VL 113
IS 4
BP 364
EP 369
DI 10.1002/jso.24142
PG 6
WC Oncology; Surgery
SC Oncology; Surgery
GA DK1YK
UT WOS:000374711400004
PM 27100023
ER
PT J
AU Cavusoglu, E
Marmur, JD
Kassotis, JT
Yanamadala, S
Chopra, V
Eng, C
AF Cavusoglu, Erdal
Marmur, Jonathan D.
Kassotis, John T.
Yanamadala, Sunitha
Chopra, Vineet
Eng, Calvin
TI Usefulness of Plasma Matrix Metalloproteinase-3 Levels to Predict
Myocardial Infarction in Men With and Without Acute Coronary Syndrome
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID ALL-CAUSE MORTALITY; ATHEROSCLEROTIC PLAQUES; STROMELYSIN-1 MMP-3;
INDEPENDENT PREDICTOR; GENE-EXPRESSION; PROMOTER; MACROPHAGES;
INSTABILITY; PROGRESSION; ACTIVATION
AB Matrix metalloproteinase-3 (MMP-3), or stromelysin-1, is a matrix metalloproteinase which is expressed in atherosclerotic plaques and which has been implicated in the pathogenesis of acute coronary syndrome (ACS). Functional polymorphisms in the promoter region of the human MMP-3 gene resulting in an increased expression of MMP-3 have been shown to predict the risk of incident myocardial infarction (MI). However, there have been no studies that have specifically examined the utility of baseline plasma MMP-3 levels for the prediction of long-term MI. In this study, baseline plasma MMP-3 levels were measured in 355 male patients who were referred for coronary angiography and followed prospectively for the development of enzymatically confirmed MI out to 5 years. After adjustment for a variety of baseline clinical, angiographic, and laboratory parameters, plasma MMP-3 levels were an independent predictor of MI at 5 years (hazards ratio 1.42, 95% CI 1.13 to 1.79; p = 0.0023). Furthermore, in 5 additional multivariate models that included a variety of contemporary biomarkers associated with adverse outcomes and MI, MMP-3 remained an independent predictor of MI at 5 years. Similar results were obtained when the analyses were restricted to the subpopulation of patients presenting with ACS. In conclusion, elevated levels of MMP-3 are associated with an increased risk of long-term MI in patients with and without ACS referred for coronary angiography. Furthermore, this association is independent of a variety of clinical, angiographic, laboratory variables, including biomarkers with established prognostic efficacy for the prediction of MI. (c) 2016 Elsevier Inc. All rights reserved.
C1 [Cavusoglu, Erdal; Chopra, Vineet; Eng, Calvin] Bronx Vet Affairs Med Ctr, Dept Med, Div Cardiol, Bronx, NY USA.
[Cavusoglu, Erdal; Marmur, Jonathan D.; Kassotis, John T.; Yanamadala, Sunitha] Suny Downstate Med Ctr, Dept Med, Div Cardiol, Brooklyn, NY 11203 USA.
RP Cavusoglu, E (reprint author), Bronx Vet Affairs Med Ctr, Dept Med, Div Cardiol, Bronx, NY USA.; Cavusoglu, E (reprint author), Suny Downstate Med Ctr, Dept Med, Div Cardiol, Brooklyn, NY 11203 USA.
EM ECavusoglu@aol.com
NR 30
TC 0
Z9 0
U1 1
U2 1
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
EI 1879-1913
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD MAR 15
PY 2016
VL 117
IS 6
BP 881
EP 886
DI 10.1016/j.amjcard.2015.12.022
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DG5RH
UT WOS:000372135800001
PM 26805660
ER
PT J
AU Giordano, S
Zhao, XM
Xing, D
Hage, F
Oparil, S
Cooke, JP
Lee, J
Nakayama, KH
Huang, NF
Chen, YF
AF Giordano, Samantha
Zhao, Xiangmin
Xing, Daisy
Hage, Fadi
Oparil, Suzanne
Cooke, John P.
Lee, Jieun
Nakayama, Karina H.
Huang, Ngan F.
Chen, Yiu-Fai
TI Targeted delivery of human iPS-ECs overexpressing IL-8 receptors
inhibits neointimal and inflammatory responses to vascular injury in the
rat
SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
LA English
DT Article
DE targeted cell therapy; human induced pluripotent stem cells; endothelial
cells; vascular injury; inflammation vascular injury; restenosis
ID PLURIPOTENT STEM-CELLS; PERIPHERAL ARTERIAL-DISEASE; ENDOTHELIAL
GROWTH-FACTOR; MYOCARDIAL-INFARCTION; CAROTID ARTERIES; BALLOON INJURY;
INTERLEUKIN-8; ESTROGEN; PROLIFERATION; HYPERTENSION
AB Interleukin-8 (IL8) is highly expressed by injured arteries in a variety of diseases and is a chemoattractant for neutrophils which express IL8 receptors IL8RA and RB (IL8RA/B) on their membranes. Neutrophils interact with the damaged endothelium and initiate an inflammatory cascade at the site of injury. We have generated a novel translational targeted cell therapy for acute vascular injury using adenoviral vectors to overexpress IL8RA/B and green fluorescent protein (GFP) on the surface of endothelial cells (ECs) derived from human induced pluripotent stem cells (HiPS-IL8RA/B-ECs). We hypothesize that HiPS-IL8RA/B-ECs transfused intravenously into rats with balloon injury of the carotid artery will target to the injured site and compete with neutrophils, thus inhibiting inflammation and neointima formation. Young adult male Sprague-Dawley rats underwent balloon injury of the right carotid artery and received intravenous transfusion of saline vehicle, 1.5 x 10(6) HiPS-ECs, 1.5 x 10(6) HiPS-Null-ECs, or 1.5 x 10(6) HiPS-IL8RA/B-ECs immediately after endoluminal injury. Tissue distribution of HiPS-IL8RA/B-ECs was analyzed by a novel GFP DNA qPCR method. Cytokine and chemokine expression and leukocyte infiltration were measured in injured and uninjured arteries at 24 h postinjury by ELISA and immunohistochemistry, respectively. Neointimal, medial areas, and reendothelialization were measured 14 days postinjury. HiPS-IL8RA/B-ECs homed to injured arteries, inhibited inflammatory mediator expression and inflammatory cell infiltration, accelerated reendothelialization, and attenuated neointima formation after endoluminal injury while control HiPS-ECs and HiPS-Null-ECs did not. HiPS-IL8RA/B-ECs transfused into rats with endoluminal carotid artery injury target to the injured artery and provide a novel strategy to treat vascular injury.
C1 [Giordano, Samantha; Xing, Daisy; Hage, Fadi; Oparil, Suzanne; Chen, Yiu-Fai] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Vasc Biol & Hypertens Program, Birmingham, AL 35294 USA.
[Zhao, Xiangmin] Univ Illinois, Coll Med, Dept Pulm Crit Care Sleep & Allergy, Chicago, IL USA.
[Hage, Fadi] Birmingham Vet Affairs Med Ctr, Div Cardiol, Birmingham, AL USA.
[Cooke, John P.] Houston Methodist Res Inst, Houston, TX USA.
[Lee, Jieun] Stanford Univ, Div Cardiovasc Med, Stanford, CA 94305 USA.
[Nakayama, Karina H.; Huang, Ngan F.] Stanford Univ, Cardiovasc Inst, Stanford, CA 94305 USA.
[Nakayama, Karina H.; Huang, Ngan F.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA.
[Huang, Ngan F.] Stanford Univ, Dept Cardiothorac Surg, Stanford, CA 94305 USA.
RP Chen, YF (reprint author), Univ Alabama Birmingham, Dept Med, 1008 Zeigler Res Bldg,703 19th St South, Birmingham, AL 35294 USA.
EM yfchen@uab.edu
OI Cooke, John/0000-0003-0033-9138; Hage, Fadi/0000-0002-1397-4942
FU UAB CCVC William W. Featheringill Innovative Award; National Institutes
of Health [RO1-HL-116727, RO1-HL-087980, T32-HL-07457, U01-HL-100397,
RC2-HL-103400, R00-HL-098688]; American Heart Association
[AHA-SDG-0930098N]; Veterans Affairs Biomedical Laboratory Research &
Development Service Merit Award [OMB 4040-0001]
FX This work was supported, in part, by UAB CCVC William W. Featheringill
Innovative Award (Y. F. Chen); by National Institutes of Health Grants
RO1-HL-116727 (Y. F. Chen), RO1-HL-087980 (S. Oparil), T32-HL-07457 (S.
Oparil, S. Giordano); U01-HL-100397 and RC2-HL-103400 (J. P. Cooke), and
R00-HL-098688 (N. F. Huang); by American Heart Association Grant
AHA-SDG-0930098N (F. G. Hage); and by Veterans Affairs Biomedical
Laboratory Research & Development Service Merit Award OMB 4040-0001 (F.
G. Hage).
NR 24
TC 2
Z9 2
U1 0
U2 6
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6135
EI 1522-1539
J9 AM J PHYSIOL-HEART C
JI Am. J. Physiol.-Heart Circul. Physiol.
PD MAR 15
PY 2016
VL 310
IS 6
BP H705
EP H715
DI 10.1152/ajpheart.00587.2015
PG 11
WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular
Disease
SC Cardiovascular System & Cardiology; Physiology
GA DG4ZX
UT WOS:000372082900005
PM 26801304
ER
PT J
AU Finegersh, A
Kulich, S
Duvvuri, U
AF Finegersh, A.
Kulich, S.
Duvvuri, U.
TI DNA Methylation Regulates ANO1 Expression Through Alternate Mechanisms
at 3 Distinct CpG Islands in Head and Neck Squamous Cell Carcinoma
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Meeting Abstract
CT Multidisciplinary Head and Neck Cancer Symposium
CY FEB 18-20, 2016
CL Scottsdale, AZ
SP Amer Head & Neck Soc, Amer Soc Clin Oncol, ASTRO
C1 [Finegersh, A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Kulich, S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Duvvuri, U.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
EI 1879-355X
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD MAR 15
PY 2016
VL 94
IS 4
MA 283
BP 942
EP 942
PG 1
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA DF8BM
UT WOS:000371581900220
ER
PT J
AU Durazzo, TC
Meyerhoff, DJ
Mon, A
Abe, C
Gazdzinski, S
Murray, DE
AF Durazzo, Timothy C.
Meyerhoff, Dieter J.
Mon, Anderson
Abe, Christoph
Gazdzinski, Stefan
Murray, Donna E.
TI Chronic Cigarette Smoking in Healthy Middle-Aged Individuals Is
Associated With Decreased Regional Brain N-acetylaspartate and Glutamate
Levels
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Brain metabolites; Cigarette smoking; Decision making and impulsivity;
Magnetic resonance; Neurocognition; Spectroscopy
ID MAGNETIC-RESONANCE-SPECTROSCOPY; ALCOHOL-DEPENDENT INDIVIDUALS; RISK
TASK BART; EARLY ABSTINENCE; SMOKERS; NEUROCOGNITION; VOLUMES;
IMPULSIVENESS; NEUROBIOLOGY; METABOLITES
AB BACKGROUND: Cigarette smoking is associated with metabolite abnormalities in anterior brain regions, but it is unclear if these abnormalities are apparent in other regions. Additionally, relationships between regional brain metabolite levels and measures of decision making, risk taking, and impulsivity in smokers and nonsmokers have not been investigated.
METHODS: In young to middle-aged (predominately male) nonsmokers (n = 30) and smokers (n = 35), N-acetylaspartate (NAA), choline-containing compounds, creatine-containing compounds (Cr), myo-inositol (mI), and glutamate (Glu) levels in the anterior cingulate cortex and right dorsolateral prefrontal cortex (DLPFC) were compared via 4-tesla proton single volume magnetic resonance spectroscopy. Groups also were compared on NAA, choline-containing compounds, Cr, and mI concentrations in the gray matter and white matter of the four cerebral lobes and subcortical nuclei/regions with 1.5-tesla proton magnetic resonance spectroscopy. Associations of regional metabolite levels with neurocognitive, decision-making, risk-taking, and self-reported impulsivity measures were examined.
RESULTS: Smokers showed lower DLPFC NAA, Cr, mI and Glu concentrations and lower lenticular nuclei NAA level; smokers also demonstrated greater age-related decreases of DLPFC NAA and anterior cingulate cortex and DLPFC Glu levels. Smokers exhibited poorer decision making and greater impulsivity. Across the sample, higher NAA and Glu in the DLPFC and NAA concentrations in multiple lobar gray matter and white matter regions and subcortical nuclei were associated with better neurocognition and lower impulsivity.
CONCLUSIONS: This study provides additional novel evidence that chronic smoking in young and middle-aged individuals is associated with significant age-related neurobiological abnormalities in anterior frontal regions implicated in the development and maintenance of addictive disorders.
C1 San Francisco Vet Adm Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA.
Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA.
RP Durazzo, TC (reprint author), San Francisco Vet Adm Med Ctr, Ctr Imaging Neurodegenerat Dis 114M, 4150 Clement St 114M, San Francisco, CA 94121 USA.
EM timothy.durazzo@ucsf.edu
OI Abe, Christoph/0000-0002-1680-8480
FU National Institutes of Health/National Institute on Drug Abuse Grant
[DA24136]; National Institutes of Health/National Institute on Alcohol
Abuse and Alcoholism Grant [AA10788]
FX This work was supported by National Institutes of Health/National
Institute on Drug Abuse Grant No. DA24136 (to TCD) and National
Institutes of Health/National Institute on Alcohol Abuse and Alcoholism
Grant No. AA10788 (to DJM), with resources and the use of facilities at
the San Francisco Veterans Administration Medical Center, San Francisco
CA.
NR 58
TC 7
Z9 8
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAR 15
PY 2016
VL 79
IS 6
BP 481
EP 488
DI 10.1016/j.biopsych.2015.03.029
PG 8
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA DD6GY
UT WOS:000370023900010
PM 25979621
ER
PT J
AU Maguen, S
Hoerster, KD
Littman, AJ
Klingaman, EA
Evans-Hudnall, G
Holleman, R
Kim, HM
Goodrich, DE
AF Maguen, Shira
Hoerster, Katherine D.
Littman, Alyson J.
Klingaman, Elizabeth A.
Evans-Hudnall, Gina
Holleman, Rob
Kim, H. Myra
Goodrich, David E.
TI Iraq and Afghanistan veterans with PTSD participate less in VA's weight
loss program than those without PTSD
SO JOURNAL OF AFFECTIVE DISORDERS
LA English
DT Article
DE Weight loss; Care engagement; Veterans; Mental health; Comorbidity; Sex;
Obesity
ID MENTAL-HEALTH DISORDERS; SERVICES TASK-FORCE; POSTTRAUMATIC-STRESS;
MILITARY PERSONNEL; OBESITY; CARE; ADULTS; MANAGEMENT; HOME
AB Background: Three-quarters of Iraq and Afghanistan veterans enrolled in Veterans Health Administration (VHA) care are overweight or obese. The VHA MOVE! weight management program can mitigate the risks of obesity-related morbidity. However, many Iraq and Afghanistan veterans experience barriers to VHA services, which may affect participation, especially among those with posttraumatic stress disorder (PTSD) and/or depression. Little is known about MOVE! engagement among recent veterans. We describe a retrospective evaluation of MOVE! participation among Iraq and Afghanistan veterans with and without mental health problems.
Methods: As part of a national VHA mental health evaluation study, we accessed VHA patient care databases to identify Iraq and Afghanistan veterans receiving care from 2008-2013 who had >= 1 MOVE! visit(s) and >= 1 weight measurements (N=24,899). We used logistic regression to determine whether mental health conditions were associated with having 12 visits/year (desirable dose of care), adjusting for demographic, health, and utilization factors.
Results: Among Iraq and Afghanistan veterans enrolled in MOVE!, 4% had a desirable dose of participation. In adjusted models, desirable MOVE! participation was more likely among those without PTSD; those who were older, female, and unmarried; and those who had higher baseline weight, more medical comorbidities, no pain, psychotropic medication use, higher disability ratings, and more mental health visits.
Limitations: We used administrative ICD-9 codes. Sample only included veterans in VHA care.
Conclusions: Iraq and Afghanistan veterans, particularly those with PTSD, had low participation in VHA weight management programming. Correlates of MOVE! participation were identified, highlighting opportunities to tailor MOVE! to improve participation for these veterans. Published by Elsevier B.V.
C1 [Maguen, Shira] San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA.
[Maguen, Shira] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Hoerster, Katherine D.; Littman, Alyson J.] VA Puget Sound Healthcare Syst, Seattle Div, Seattle, WA USA.
[Hoerster, Katherine D.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Littman, Alyson J.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Klingaman, Elizabeth A.] VA Maryland Healthcare Syst, Baltimore, MD USA.
[Klingaman, Elizabeth A.] Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD USA.
[Evans-Hudnall, Gina] Houston VA Med Ctr, Houston, TX USA.
[Holleman, Rob; Kim, H. Myra; Goodrich, David E.] VA Ann Arbor Healthcare Syst, Ctr Clin Management Res, Ann Arbor, MI USA.
RP Maguen, S (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA.
EM Shira.Maguen@va.gov
FU VA Health Services Research and Development Quality Enhancement Research
Initiative (QUERI) [QLP 55-017]; VA Rehabilitation Research &
Development Career Development Award [6982]; VA Health Services Research
& Development Career Development Award [12-263]; Department of Veterans
Affairs Office of Academic Affiliations Advanced Fellowship Program in
Mental Illness Research and Treatment
FX This analysis is part of a larger quality improvement evaluation of
MOVE! requested by the VHA Center for Health Promotion & Disease
Prevention (NCP) and conducted by VA National Serious Mental Illness
Treatment and Evaluation Center (SMITREC). Funding for this study was
provided by VA Health Services Research and Development Quality
Enhancement Research Initiative (QUERI) programs for Diabetes and Mental
Health research as a locally initiated project (QLP 55-017). Dr.
Littman's time was supported in part through a VA Rehabilitation
Research & Development Career Development Award (#6982). Dr. Hoerster's
time was supported in part through a VA Health Services Research &
Development Career Development Award (#12-263). Dr. Klingaman's time was
supported by the Department of Veterans Affairs Office of Academic
Affiliations Advanced Fellowship Program in Mental Illness Research and
Treatment.
NR 24
TC 0
Z9 0
U1 1
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-0327
EI 1573-2517
J9 J AFFECT DISORDERS
JI J. Affect. Disord.
PD MAR 15
PY 2016
VL 193
BP 289
EP 294
DI 10.1016/j.jad.2015.12.078
PG 6
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA DD0BT
UT WOS:000369586000041
PM 26774516
ER
PT J
AU Weinrich, S
Hardin, S
Glaser, D
Barger, M
Bormann, J
Lizarraga, C
Terry, M
Criscenzo, J
Allard, CB
AF Weinrich, Sally
Hardin, Sally
Glaser, Dale
Barger, Mary
Bormann, Jill
Lizarraga, Cabiria
Terry, Micheal
Criscenzo, Jeeni
Allard, Carolyn B.
TI Assessing sexual trauma histories in homeless women
SO JOURNAL OF TRAUMA & DISSOCIATION
LA English
DT Article
DE Homeless women; sexual trauma; military sexual trauma
ID VETERANS; MILITARY; PREVALENCE; ASSAULT
AB Almost 1 out of every 3 homeless women (32%) in the United States, United Kingdom, and Australia has experienced childhood sexual trauma. We assessed lifetime sexual trauma histories among 29 homeless women from three Southern California community sites: one residential safe house and two safe parking areas. More than half of the women (54%) reported a history of sexual trauma. That rate was higher (86%) among women living at the safe home than among women staying at the safe parking sites (only 42%). All four of the women who had served in the military reported having experienced military sexual trauma. The high percentages of sexual trauma found in homeless women highlight the need for effective interventions for sexual trauma.
C1 [Weinrich, Sally; Hardin, Sally; Glaser, Dale; Barger, Mary; Bormann, Jill; Terry, Micheal] Univ San Diego, Hahn Sch Nursing & Hlth Sci, 5998 Alcala Pk, San Diego, CA 92110 USA.
[Weinrich, Sally; Hardin, Sally; Glaser, Dale; Barger, Mary; Bormann, Jill; Terry, Micheal] Univ San Diego, Betty & Bob Beyster Inst Nursing Res Adv Practice, 5998 Alcala Pk, San Diego, CA 92110 USA.
[Bormann, Jill] US Dept Vet Affairs, Ctr Excellence Stress & Mental Hlth, San Diego, CA USA.
[Lizarraga, Cabiria] Sharp Grossmont Hosp, La Mesa, CA USA.
[Criscenzo, Jeeni] Amikas, San Diego, CA USA.
[Allard, Carolyn B.] Univ Calif San Diego, Vet Affairs San Diego Healthcare Syst, Mil Sexual Trauma & Interpersonal Trauma Clin, San Diego, CA 92110 USA.
RP Weinrich, S (reprint author), Univ San Diego, Hahn Sch Nursing & Hlth Sci, 5998 Alcala Pk, San Diego, CA 92110 USA.; Weinrich, S (reprint author), Univ San Diego, Betty & Bob Beyster Inst Nursing Res Adv Practice, 5998 Alcala Pk, San Diego, CA 92110 USA.
EM sallyweinrich@sandiego.edu
FU Jonas Center for Nursing and Veterans Healthcare; University of San
Diego Hahn School of Nursing and Health Science Faculty Research Fund
FX Funding was received from the Jonas Center for Nursing and Veterans
Healthcare and the University of San Diego Hahn School of Nursing and
Health Science Faculty Research Fund.
NR 22
TC 1
Z9 1
U1 1
U2 3
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1529-9732
EI 1529-9740
J9 J TRAUMA DISSOCIATIO
JI J. Trauma Dissociation
PD MAR 14
PY 2016
VL 17
IS 2
BP 237
EP 243
DI 10.1080/15299732.2015.1089968
PG 7
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA DG6MA
UT WOS:000372197700009
PM 26583457
ER
PT J
AU Jimenez, AM
Lee, J
Wynn, JK
Cohen, MS
Engel, SA
Glahn, DC
Nuechterlein, KH
Reavis, EA
Green, MF
AF Jimenez, Amy M.
Lee, Junghee
Wynn, Jonathan K.
Cohen, Mark S.
Engel, Stephen A.
Glahn, David C.
Nuechterlein, Keith H.
Reavis, Eric A.
Green, Michael F.
TI Abnormal Ventral and Dorsal Attention Network Activity during Single and
Dual Target Detection in Schizophrenia
SO FRONTIERS IN PSYCHOLOGY
LA English
DT Article
DE schizophrenia; fMRI; visual attention; RSVP; attentional blink
ID SERIAL VISUAL PRESENTATION; NEGATIVE SYMPTOMS; HUMAN BRAIN; BLINK;
SALIENCE; MEMORY; TASK; FMRI; DEACTIVATION; ENVIRONMENT
AB Early visual perception and attention are impaired in schizophrenia, and these deficits can be observed on target detection tasks. These tasks activate distinct ventral and dorsal brain networks which support stimulus-driven and goal-directed attention, respectively. We used single and dual target rapid serial visual presentation (RSVP) tasks during fMRI with an ROI approach to examine regions within these networks associated with target detection and the attentional blink (AB) in 21 schizophrenia outpatients and 25 healthy controls. In both tasks, letters were targets and numbers were distractors. For the dual target task, the second target (T2) was presented at three different lags after the first target (T1) (lag1 = 100 ms, lag3 = 300 ms, lag7 = 700ms). For both single and dual target tasks, patients identified fewer targets than controls. For the dual target task, both groups showed the expected AB effect with poorer performance at lag 3 than at lags 1 or 7, and there was no group by lag interaction. During the single target task, patients showed abnormally increased deactivation of the temporo-parietal junction (TPJ), a key region of the ventral network. When attention demands were increased during the dual target task, patients showed overactivation of the posterior intraparietal cortex, a key dorsal network region, along with failure to deactivate TPJ. Results suggest inefficient and faulty suppression of salience-oriented processing regions, resulting in increased sensitivity to stimuli in general, and difficulty distinguishing targets from non-targets.
C1 [Jimenez, Amy M.; Lee, Junghee; Wynn, Jonathan K.; Reavis, Eric A.; Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Desert Pacific MIRECC, Los Angeles, CA USA.
[Jimenez, Amy M.; Lee, Junghee; Wynn, Jonathan K.; Cohen, Mark S.; Nuechterlein, Keith H.; Reavis, Eric A.; Green, Michael F.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Engel, Stephen A.] Univ Minnesota, Dept Psychol, Minneapolis, MN USA.
[Glahn, David C.] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA.
RP Jimenez, AM (reprint author), VA Greater Los Angeles Healthcare Syst, Desert Pacific MIRECC, Los Angeles, CA USA.; Jimenez, AM (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
EM amjimenez@ucla.edu
RI Wynn, Jonathan/H-3749-2014; Lee, Junghee/C-5226-2014
OI Wynn, Jonathan/0000-0002-1763-8540; Lee, Junghee/0000-0001-9567-8700
FU NIMH [MH043292]; Brain Mapping Medical Research Organization; Brain
Mapping Support Foundation; Pierson-Lovelace Foundation; Ahmanson
Foundation; William M. and Linda R. Dietel Philanthropic Fund at the
Northern Piedmont Community Foundation; Tamkin Foundation; Jennifer
Jones-Simon Foundation; Capital Group Companies Charitable Foundation;
Robson Family; Northstar Fund
FX This research was supported by NIMH Grant MH043292 (PI: MG). Writing of
this manuscript was supported by the Office of Academic Affiliations,
Advanced Fellowship Program in Mental Illness Research and Treatment,
Department of Veterans Affairs. For generous support, we also thank the
Brain Mapping Medical Research Organization, Brain Mapping Support
Foundation, Pierson-Lovelace Foundation, The Ahmanson Foundation,
William M. and Linda R. Dietel Philanthropic Fund at the Northern
Piedmont Community Foundation, Tamkin Foundation, Jennifer Jones-Simon
Foundation, Capital Group Companies Charitable Foundation, Robson
Family, and Northstar Fund. The funders had no role in the study design,
data collection and analysis, decision to publish, or preparation of the
manuscript.
NR 53
TC 0
Z9 0
U1 4
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 1664-1078
J9 FRONT PSYCHOL
JI Front. Psychol.
PD MAR 8
PY 2016
VL 7
AR 323
DI 10.3389/fpsyg.7015.00323
PG 11
WC Psychology, Multidisciplinary
SC Psychology
GA DF5NF
UT WOS:000371398100001
PM 27014135
ER
PT J
AU Lipska, KJ
Krumholz, H
Soones, T
Lee, SJ
AF Lipska, Kasia J.
Krumholz, Harlan
Soones, Tacara
Lee, Sei J.
TI Polypharmacy in the Aging Patient A Review of Glycemic Control in Older
Adults With Type 2 Diabetes
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Review
ID INTENSIVE GLUCOSE CONTROL; CLINICAL-PRACTICE GUIDELINES; DRUG-DRUG
INTERACTIONS; CARDIOVASCULAR OUTCOMES; RISK-FACTORS; SEVERE
HYPOGLYCEMIA; INSULIN-RESISTANCE; ACCORD TRIAL; FOLLOW-UP; HEMOGLOBIN
A(1C)
AB IMPORTANCE There is substantial uncertainty about optimal glycemic control in older adults with type 2 diabetes mellitus.
OBSERVATIONS Four large randomized clinical trials (RCTs), ranging in size from 1791 to 11 440 patients, provide the majority of the evidence used to guide diabetes therapy. Most RCTs of intensive vs standard glycemic control excluded adults older than 80 years, used surrogate end points to evaluate microvascular outcomes and provided limited data on which subgroups are most likely to benefit or be harmed by specific therapies. Available data from randomized clinical trials suggest that intensive glycemic control does not reduce major macrovascular events in older adults for at least 10 years. Furthermore, intensive glycemic control does not lead to improved patient-centered microvascular outcomes for at least 8 years. Data from randomized clinical trials consistently suggest that intensive glycemic control immediately increases the risk of severe hypoglycemia 1.5-to 3-fold. Based on these data and observational studies, for the majority of adults older than 65 years, the harms associated with a hemoglobin A1c (HbA1c) target lower than 7.5% or higher than 9% are likely to outweigh the benefits. However, the optimal target depends on patient factors, medications used to reach the target, life expectancy, and patient preferences about treatment. If only medications with low treatment burden and hypoglycemia risk (such as metformin) are required, a lower HbA1c targetmay be appropriate. If patients strongly prefer to avoid injections or frequent fingerstick monitoring, a higher HbA1c target that obviates the need for insulin may be appropriate.
CONCLUSIONS AND RELEVANCE High-quality evidence about glycemic treatment in older adults is lacking. Optimal decisions need to be made collaboratively with patients, incorporating the likelihood of benefits and harms and patient preferences about treatment and treatment burden. For the majority of older adults, an HbA1c target between 7.5% and 9% will maximize benefits and minimize harms.
C1 [Lipska, Kasia J.] Yale Univ, Sch Med, Dept Internal Med, Endocrinol Sect, 333 Cedar St,POB 208020, New Haven, CT 06520 USA.
[Krumholz, Harlan] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, 20 York St, New Haven, CT 06504 USA.
[Krumholz, Harlan] Yale Univ, Sch Med, Sect Cardiovasc Med, New Haven, CT 06520 USA.
[Krumholz, Harlan] Yale Univ, Sch Med, Robert Wood Johnson Fdn, Clin Scholars Program, New Haven, CT 06520 USA.
[Krumholz, Harlan] Yale Univ, Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT 06520 USA.
[Soones, Tacara] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, New York, NY 10029 USA.
[Lee, Sei J.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA.
[Lee, Sei J.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Lipska, KJ (reprint author), Yale Univ, Sch Med, Dept Internal Med, Endocrinol Sect, 333 Cedar St,POB 208020, New Haven, CT 06520 USA.
EM kasia.lipska@yale.edu
FU Beeson Career Development Award from the National Institute on Aging;
American Federation of Aging Research [K23AG048359, K23AG040779]; Early
Career Award from the S. D. Bechtel Jr Foundation
FX Dr Lipska's effort on this project was supported through the Beeson
Career Development Award from the National Institute on Aging and the
American Federation of Aging Research (K23AG048359). Dr Lee's effort on
this project was supported through the Beeson Career Development Award
from the National Institute on Aging and the American Federation of
Aging Research (K23AG040779) and an Early Career Award from the S. D.
Bechtel Jr Foundation.
NR 84
TC 16
Z9 16
U1 10
U2 15
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAR 8
PY 2016
VL 315
IS 10
BP 1034
EP 1045
DI 10.1001/jama.2016.0299
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA DF7LW
UT WOS:000371540200016
PM 26954412
ER
PT J
AU Zhang, W
Hartmann, R
Tun, HM
Elson, CO
Khafipour, E
Garvey, WT
AF Zhang, Wei
Hartmann, Riley
Tun, Hein Min
Elson, Charles O.
Khafipour, Ehsan
Garvey, W. Timothy
TI Deletion of the Toll-Like Receptor 5 Gene Per Se Does Not Determine the
Gut Microbiome Profile That Induces Metabolic Syndrome: Environment
Trumps Genotype
SO PLOS ONE
LA English
DT Article
ID INTESTINAL MICROBIOTA; INNATE IMMUNITY; OBESITY; MICE; COMMUNITIES;
DIET; SEQUENCE; SHAPES
AB Over the past decade, emerging evidence has linked alterations in the gut microbial composition to a wide range of diseases including obesity, type 2 diabetes, and cardiovascular disease. Toll-like receptors (TLRs) are the major mediators for the interactions between gut microbiota and host innate immune system, which is involved in the localization and structuring of host gut microbiota. A previous study found that TLR5 deficient mice (TLR5KO1) had altered gut microbial composition which led to the development of metabolic syndrome including hyperlipidemia, hypertension, insulin resistance and increased adiposity. In the current study, a second TLR5-deficient mouse model was studied (TLR5KO2). TLR5 deficient mice did not manifest metabolic abnormalities related to the metabolic syndrome compared with littermate controls maintained on normal chow or after feeding a high fat diet. Analysis of the gut microbial composition of littermate TLR5KO2 and wild type mice revealed no significant difference in the overall microbiota structure between genotypes. However, the TLR5KO2 microbiota was distinctly different from that previously reported for TLR5KO1 mice with metabolic syndrome. We conclude that an altered composition of the microbiota in a given environment can result in metabolic syndrome, but it is not a consequence of TLR5 deficiency per se.
C1 [Zhang, Wei; Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Sch Hlth Profess, Birmingham, AL 35294 USA.
[Hartmann, Riley; Khafipour, Ehsan] Univ Manitoba, Dept Med Microbiol & Infect Dis, Winnipeg, MB, Canada.
[Tun, Hein Min; Khafipour, Ehsan] Univ Manitoba, Dept Anim Sci, Winnipeg, MB R3T 2N2, Canada.
[Elson, Charles O.] Univ Alabama Birmingham, Sch Med, Div Gastroenterol & Hepatol, Birmingham, AL USA.
[Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Garvey, WT (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, Sch Hlth Profess, Birmingham, AL 35294 USA.; Khafipour, E (reprint author), Univ Manitoba, Dept Med Microbiol & Infect Dis, Winnipeg, MB, Canada.; Khafipour, E (reprint author), Univ Manitoba, Dept Anim Sci, Winnipeg, MB R3T 2N2, Canada.; Garvey, WT (reprint author), Birmingham VA Med Ctr, Birmingham, AL USA.
EM Ehsan.Khafipour@umanitoba.ca; garveyt@uab.edu
OI Khafipour, Ehsan/0000-0003-4673-7633
FU UAB Diabetes Research Center (NIDDK) [P60 DK-079626]; National
Institutes of Health [RO1 DK083562, R01 DK-38765]; Merit Review Research
Grant from the Department of Veterans Affairs
FX The authors acknowledge support from UAB Diabetes Research Center
(NIDDK, P60 DK-079626), individual research grants from the National
Institutes of Health (RO1 DK083562; R01 DK-38765), and a Merit Review
Research Grant from the Department of Veterans Affairs. The funders had
no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 47
TC 2
Z9 2
U1 2
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 7
PY 2016
VL 11
IS 3
AR e0150943
DI 10.1371/journal.pone.0150943
PG 21
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DG3SL
UT WOS:000371990100072
PM 26950299
ER
PT J
AU Beste, LA
Moseley, RH
Saint, S
Cornia, PB
AF Beste, Lauren A.
Moseley, Richard H.
Saint, Sanjay
Cornia, Paul B.
TI Too Much of a Good Thing
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
ID PORTAL-HYPERTENSION; HISTORY
C1 [Beste, Lauren A.] Vet Affairs VA Puget Sound Hlth Care Syst, Gen Med Serv, Seattle, WA USA.
[Beste, Lauren A.] Vet Affairs VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
[Beste, Lauren A.; Cornia, Paul B.] Vet Affairs VA Puget Sound Hlth Care Syst, Hosp & Specialty Med Serv, Seattle, WA USA.
[Beste, Lauren A.; Cornia, Paul B.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
[Moseley, Richard H.; Saint, Sanjay] VA Ann Arbor Healthcare Syst, Med Serv, Ann Arbor, MI USA.
[Moseley, Richard H.; Saint, Sanjay] Univ Michigan Hlth Syst, Dept Internal Med, Ann Arbor, MI USA.
RP Beste, LA (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way S-111-GI, Seattle, WA 98108 USA.
EM lab25@uw.edu
FU Doximity; Jvion
FX Dr. Saint reports receiving fees for serving on advisory boards from
Doximity and Jvion. No other potential conflict of interest relevant to
this article was reported.
NR 9
TC 0
Z9 0
U1 1
U2 1
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAR 3
PY 2016
VL 374
IS 9
BP 873
EP 878
DI 10.1056/NEJMcps1405984
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA DF2FT
UT WOS:000371158400013
PM 26962907
ER
PT J
AU Sandford, E
Bird, TD
Li, JZ
Burmeister, M
AF Sandford, Erin
Bird, Thomas D.
Li, Jun Z.
Burmeister, Margit
TI PRICKLE2 Mutations Might Not Be Involved in Epilepsy
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Letter
ID PROGRESSIVE MYOCLONUS; ATAXIA; A467T; POLG
C1 [Sandford, Erin; Burmeister, Margit] Univ Michigan, Mol & Behav Neurosci Inst, Ann Arbor, MI 48109 USA.
[Bird, Thomas D.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
[Bird, Thomas D.] Univ Washington, Dept Med Med Genet, Seattle, WA 98195 USA.
[Bird, Thomas D.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98101 USA.
[Li, Jun Z.; Burmeister, Margit] Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA.
[Li, Jun Z.; Burmeister, Margit] Univ Michigan, Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA.
[Burmeister, Margit] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA.
RP Burmeister, M (reprint author), Univ Michigan, Mol & Behav Neurosci Inst, Ann Arbor, MI 48109 USA.; Burmeister, M (reprint author), Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA.; Burmeister, M (reprint author), Univ Michigan, Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA.; Burmeister, M (reprint author), Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA.
EM margit@umich.edu
FU NINDS NIH HHS [R01 NS078560, R01-NS078560]
NR 10
TC 1
Z9 3
U1 0
U2 0
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 1537-6605
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD MAR 3
PY 2016
VL 98
IS 3
BP 588
EP 589
DI 10.1016/j.ajhg.2016.01.009
PG 2
WC Genetics & Heredity
SC Genetics & Heredity
GA DG9DN
UT WOS:000372383100021
PM 26942291
ER
PT J
AU McGowan, SK
Espejo, EP
Balliett, N
Werdowatz, EA
AF McGowan, Sarah Kate
Espejo, Emmanuel P.
Balliett, Noelle
Werdowatz, Emily A.
TI The Effects of Transdiagnostic Group CBT for Anxiety on Insomnia
Symptoms
SO COGNITIVE BEHAVIOUR THERAPY
LA English
DT Article
DE Anxiety; insomnia; anxious arousal; cognitive behavior therapy
ID COGNITIVE-BEHAVIOR THERAPY; SLEEP DISTURBANCES; PANIC DISORDER;
METAANALYSIS; DEPRESSION; PSYCHOTHERAPY; EPIDEMIOLOGY; EXPOSURE; IMPACT;
MODEL
AB Insomnia is a common feature among individuals with anxiety disorders. Studies of cognitive behavioral therapy (CBT) for anxiety report moderate effects on concomitant insomnia symptoms, but further research is still needed especially toward understanding how CBT for anxiety renders beneficial effects on insomnia. The current study examined changes in insomnia symptoms reported by 51 Veterans who participated in a group-based transdiagnostic CBT for anxiety intervention. In addition, insomnia symptoms were examined in relation to symptoms of general distress (GD), anhedonic depression (AD), and anxious arousal (AA) pre- to post-treatment. Results revealed a small, though statistically significant (p<.05) beneficial effect on insomnia symptoms. When changes in GD, AD, and AA were simultaneously examined in relation to changes in insomnia, change in AA was the only significant predictor of insomnia symptoms. The current study highlights the role of AA in the relationship between anxiety disorders and insomnia and demonstrates that reductions in insomnia during transdiagnostic CBT for anxiety can be largely attributed to changes in AA.
C1 [McGowan, Sarah Kate; Espejo, Emmanuel P.] VA San Diego Healthcare Syst, Psychol Serv, San Diego, CA USA.
[Balliett, Noelle] VA Puget Sound Hlth Care Syst, Psychol, Tacoma, WA USA.
[Werdowatz, Emily A.] VA San Diego Healthcare Syst, Res Serv, San Diego, CA USA.
RP Espejo, EP (reprint author), VA San Diego Healthcare Syst, Psychol Serv, San Diego, CA USA.
EM eespejo@ucsd.edu
FU Clinical Scientist Training Initiative Award
FX Training in transdiagnostic group cognitive-behavioral therapy of
anxiety by Dr. Peter Norton was supported by a Clinical Scientist
Training Initiative Award issued to the VA San Diego Psychology Service
by the Society for a Science of Clinical Psychology. The contents do not
reflect the views of the Department of Veterans Affairs or the United
States Government. There are no conflicts to report. We would like to
thank Dr. Peter Norton for providing training in his transdiagnostic
group cognitive-behavioral therapy of anxiety protocol and for providing
materials to assist in the delivery of the group treatment and the
conduct of this research study. We would also like to thank Natalie
Castriotta, Ph.D., Kim Roser-Kedward, LCSW, Lesley Boutah, LCSW, Kathryn
Seay, M.A., and Alexandrea Harmell, M.A. who assisted with co-leading
the anxiety groups included in this study.
NR 48
TC 0
Z9 0
U1 3
U2 8
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1650-6073
EI 1651-2316
J9 COGN BEHAV THERAPY
JI Cogn. Behav. Ther.
PD MAR 3
PY 2016
VL 45
IS 2
BP 163
EP 175
DI 10.1080/16506073.2015.1134639
PG 13
WC Behavioral Sciences; Psychology, Clinical
SC Behavioral Sciences; Psychology
GA DG4JE
UT WOS:000372037700006
PM 26838091
ER
PT J
AU Pearlman, RA
Foglia, MB
Fox, E
Cohen, JH
Chanko, BL
Berkowitz, KA
AF Pearlman, Robert A.
Foglia, Mary Beth
Fox, Ellen
Cohen, Jennifer H.
Chanko, Barbara L.
Berkowitz, Kenneth A.
TI Ethics Consultation Quality Assessment Tool: A Novel Method for
Assessing the Quality of Ethics Case Consultations Based on Written
Records
SO AMERICAN JOURNAL OF BIOETHICS
LA English
DT Article
DE professional ethics; organizational ethics; clinical ethics; ethics
consultation
ID CLINICAL-ETHICS; SERVICE
AB Although ethics consultation is offered as a clinical service in most hospitals in the United States, few valid and practical tools are available to evaluate, ensure, and improve ethics consultation quality. The quality of ethics consultation is important because poor quality ethics consultation can result in ethically inappropriate outcomes for patients, other stakeholders, or the health care system. To promote accountability for the quality of ethics consultation, we developed the Ethics Consultation Quality Assessment Tool (ECQAT). ECQAT enables raters to assess the quality of ethics consultations based on the written record. Through rigorous development and preliminary testing, we identified key elements of a quality ethics consultation (ethics question, consultation-specific information, ethical analysis, and conclusions and/or recommendations), established scoring criteria, developed training guidelines, and designed a holistic assessment process. This article describes the development of the ECQAT, the resulting product, and recommended future testing and potential uses for the tool.
C1 [Pearlman, Robert A.; Foglia, Mary Beth; Cohen, Jennifer H.; Chanko, Barbara L.; Berkowitz, Kenneth A.] Natl Ctr Eth Hlth Care, Dept Vet Affairs, Zurich, Switzerland.
[Fox, Ellen] Fox Eth Consulting, Zurich, Switzerland.
RP Pearlman, RA (reprint author), VA Puget Sound Hlth Care Syst, Natl Ctr Eth Hlth Care, S-182 GEC,1660 South Columbian Way, Seattle, WA 98108 USA.
EM Robert.Pearlman@va.gov
NR 34
TC 12
Z9 12
U1 5
U2 6
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1526-5161
EI 1536-0075
J9 AM J BIOETHICS
JI Am. J. Bioeth.
PD MAR 3
PY 2016
VL 16
IS 3
BP 3
EP 14
DI 10.1080/15265161.2015.1134704
PG 12
WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical
SC Social Sciences - Other Topics; Medical Ethics; Social Issues;
Biomedical Social Sciences
GA DF7NJ
UT WOS:000371544100002
PM 26913651
ER
PT J
AU Pearlman, RA
Foglia, MB
Cohen, JH
Chanko, BL
Berkowitz, KA
AF Pearlman, Robert A.
Foglia, Mary Beth
Cohen, Jennifer H.
Chanko, Barbara L.
Berkowitz, Kenneth A.
TI Response to Open Peer Commentaries on "Ethics Consultation Quality
Assessment Tool: A Novel Method for Assessing the Quality of Ethics Case
Consultations Based on Written Records"
SO AMERICAN JOURNAL OF BIOETHICS
LA English
DT Letter
C1 [Pearlman, Robert A.; Foglia, Mary Beth; Cohen, Jennifer H.; Chanko, Barbara L.; Berkowitz, Kenneth A.] Natl Ctr Eth Hlth Care, Dept Vet Affairs, Seattle, WA 98108 USA.
RP Pearlman, RA (reprint author), Natl Ctr Eth Hlth Care, VA Puget Sound Hlth Care Syst, S 182-GEC,1660 South Columbian Way, Seattle, WA 98108 USA.
EM Robert.Pearlman@va.gov
NR 2
TC 0
Z9 0
U1 0
U2 0
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1526-5161
EI 1536-0075
J9 AM J BIOETHICS
JI Am. J. Bioeth.
PD MAR 3
PY 2016
VL 16
IS 3
BP W1
EP W2
DI 10.1080/15265161.2016.1150532
PG 2
WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical
SC Social Sciences - Other Topics; Medical Ethics; Social Issues;
Biomedical Social Sciences
GA DF7NO
UT WOS:000371544600001
PM 26913669
ER
PT J
AU Shura, RD
Miskey, HM
Rowland, JA
Yoash-Gantz, RE
Denning, JH
AF Shura, Robert D.
Miskey, Holly M.
Rowland, Jared A.
Yoash-Gantz, Ruth E.
Denning, John H.
TI Embedded Performance Validity Measures with Postdeployment Veterans:
Cross-Validation and Efficiency with Multiple Measures
SO APPLIED NEUROPSYCHOLOGY-ADULT
LA English
DT Article
DE multiple measures; veteran; neuropsychological assessment; Word Memory
Test; performance validity
ID TRAUMATIC BRAIN-INJURY; WORD MEMORY TEST; COMPLEX FIGURE TEST; TEST
FAILURE; MALINGERING DETECTION; EVALUATION CONTEXT; LIKELIHOOD RATIOS;
INADEQUATE EFFORT; SUSPECT EFFORT; RESPONSE BIAS
AB Embedded validity measures support comprehensive assessment of performance validity. The purpose of this study was to evaluate the accuracy of individual embedded measures and to reduce them to the most efficient combination. The sample included 212 postdeployment veterans (average age=35 years, average education=14 years). Thirty embedded measures were initially identified as predictors of Green's Word Memory Test (WMT) and were derived from the California Verbal Learning Test-Second Edition (CVLT-II), Conners' Continuous Performance Test-Second Edition (CPT-II), Trail Making Test, Stroop, Wisconsin Card Sorting Test-64, the Wechsler Adult Intelligence Scale-Third Edition Letter-Number Sequencing, Rey Complex Figure Test (RCFT), Brief Visuospatial Memory Test-Revised, and the Finger Tapping Test. Eight nonoverlapping measures with the highest area-under-the-curve (AUC) values were retained for entry into a logistic regression analysis. Embedded measure accuracy was also compared to cutoffs found in the existing literature. Twenty-one percent of the sample failed the WMT. Previously developed cutoffs for individual measures showed poor sensitivity (SN) in the current sample except for the CPT-II (Total Errors, SN=.41). The CVLT-II (Trials 1-5 Total) showed the best overall accuracy (AUC=.80). After redundant measures were statistically eliminated, the model included the RCFT (Recognition True Positives), CPT-II (Total Errors), and CVLT-II (Trials 1-5 Total) and increased overall accuracy compared with the CVLT-II alone (AUC=.87). The combination of just 3 measures from the CPT-II, CVLT-II, and RCFT was the most accurate/efficient in predicting WMT performance.
C1 [Shura, Robert D.; Miskey, Holly M.; Rowland, Jared A.; Yoash-Gantz, Ruth E.] WG Bill Hefner Vet Affairs Med Ctr, Mid Atlantic Mental Illness Res Educ & Clin Ctr, Salisbury, Wilts, England.
[Shura, Robert D.; Miskey, Holly M.; Rowland, Jared A.; Yoash-Gantz, Ruth E.] WG Bill Hefner Vet Affairs Med Ctr, Mental Hlth & Behav Sci Serv Line, Salisbury, Wilts, England.
[Shura, Robert D.; Miskey, Holly M.; Yoash-Gantz, Ruth E.] Wake Forest Sch Med, Dept Psychiat & Behav Sci, Winston Salem, NC USA.
[Rowland, Jared A.] Wake Forest Sch Med, Dept Psychiat & Behav Sci, Dept Anat & Neurobiol, Winston Salem, NC USA.
[Denning, John H.] Alvin C York Vet Affairs Med Ctr, Tennessee Valley Healthcare Syst, Murfreesboro, TN USA.
[Denning, John H.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Shura, RD (reprint author), Hefner VAMC, 11M-2 MH BS,1601 Brenner Ave, Salisbury, NC 28144 USA.
EM robert.shura2@va.gov
OI Miskey, Holly/0000-0002-5139-4586
FU W. G. "Bill" Hefner Veterans Affairs Medical Center; Mid-Atlantic Mental
Illness Research Education and Clinical Center; Department of Veterans
Affairs Office of Academic Affiliations Advanced Fellowship Program in
Mental Illness Research and Treatment
FX This work was supported by the This research was supported by resources
of the W. G. "Bill" Hefner Veterans Affairs Medical Center, the
Mid-Atlantic Mental Illness Research Education and Clinical Center, and
the Department of Veterans Affairs Office of Academic Affiliations
Advanced Fellowship Program in Mental Illness Research and Treatment..
NR 57
TC 1
Z9 1
U1 2
U2 3
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 2327-9095
EI 2327-9109
J9 APPL NEUROPSYCH-ADUL
JI Appl. Neuropsychol.-Adult
PD MAR 3
PY 2016
VL 23
IS 2
BP 94
EP 104
DI 10.1080/23279095.2015.1014556
PG 11
WC Clinical Neurology; Psychology
SC Neurosciences & Neurology; Psychology
GA DE4TK
UT WOS:000370623000003
PM 26375185
ER
PT J
AU Gaines, KD
Soper, HV
Berenji, GR
AF Gaines, Katy D.
Soper, Henry V.
Berenji, Gholam R.
TI Executive Functioning of Combat Mild Traumatic Brain Injury
SO APPLIED NEUROPSYCHOLOGY-ADULT
LA English
DT Article
DE traumatic brain injury; mild TBI; military; psychology; neuropsychology;
executive
ID HEAD-INJURY; SELF-AWARENESS; DYSFUNCTION; METAANALYSIS; CONCUSSION;
NEUROSCIENCE; COGNITION; SYMPTOMS; RECOVERY; SEQUELAE
AB This study investigates neuropsychological deficits in recently deployed veterans with mild traumatic brain injury (mTBI). Veterans discharged from 2007 to 2012 were recruited from Veterans Affairs clinics. Independent groups of participants with mTBI (n=57) and those without TBI (n=57) were administered the Beck Depression Inventory-II, Combat Exposure Scale, Word Memory Test, and the Self-Awareness of Deficits Interview. Neuropsychological instruments included the Rey-Osterrieth Complex Figure Test, Letter and Category Fluency, Trail-Making Test-Parts A and B, Christiansen H-abbreviated, Soper Neuropsychology Screen, Wechsler Memory Scale subtests Logical Memory I and II, and the Street Completion Test. The mTBI group performed significantly worse on all of the executive and nonexecutive measurements with the exception of Category Fluency, after controlling for age, depression effort, and combat exposure. Depression and combat exposure were greater for the mTBI group. The mTBI group scored poorer on effort, but only the Multiple Choice subtest was significant. The mTBI group had good awareness of their deficits.
C1 [Gaines, Katy D.; Berenji, Gholam R.] Vet Affairs Greater Los Angeles Healthcare Syst, Nucl Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
[Soper, Henry V.] Fielding Grad Univ, Sch Psychol, Santa Barbara, CA USA.
RP Gaines, KD (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Nucl Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM drdgaines@gmail.com
FU Veterans Affairs of Greater Los Angeles Health Care System
[PCC2011-070727]
FX This work was supported by the This work was supported by the Veterans
Affairs of Greater Los Angeles Health Care System [PCC2011-070727]..
NR 79
TC 0
Z9 1
U1 1
U2 16
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 2327-9095
EI 2327-9109
J9 APPL NEUROPSYCH-ADUL
JI Appl. Neuropsychol.-Adult
PD MAR 3
PY 2016
VL 23
IS 2
BP 115
EP 124
DI 10.1080/23279095.2015.1012762
PG 10
WC Clinical Neurology; Psychology
SC Neurosciences & Neurology; Psychology
GA DE4TK
UT WOS:000370623000005
PM 26496530
ER
PT J
AU Fei, P
Lee, J
Packard, RRS
Sereti, KI
Xu, H
Ma, JG
Ding, YC
Kang, H
Chen, H
Sung, K
Kulkarni, R
Ardehali, R
Kuo, CCJ
Xu, XL
Ho, CM
Hsiai, TK
AF Fei, Peng
Lee, Juhyun
Packard, Rene R. Sevag
Sereti, Konstantina-Ioanna
Xu, Hao
Ma, Jianguo
Ding, Yichen
Kang, Hanul
Chen, Harrison
Sung, Kevin
Kulkarni, Rajan
Ardehali, Reza
Kuo, C. -C. Jay
Xu, Xiaolei
Ho, Chih-Ming
Hsiai, Tzung K.
TI Cardiac Light-Sheet Fluorescent Microscopy for Multi-Scale and Rapid
Imaging of Architecture and Function
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PLANE ILLUMINATION MICROSCOPY; RESOLUTION; ZEBRAFISH; HEART; TOMOGRAPHY;
EMBRYOS; FETAL; RECONSTRUCTION; MYOCARDIUM; DIFFUSION
AB Light Sheet Fluorescence Microscopy (LSFM) enables multi-dimensional and multi-scale imaging via illuminating specimens with a separate thin sheet of laser. It allows rapid plane illumination for reduced photo-damage and superior axial resolution and contrast. We hereby demonstrate cardiac LSFM (c-LSFM) imaging to assess the functional architecture of zebrafish embryos with a retrospective cardiac synchronization algorithm for four-dimensional reconstruction (3-D space + time). By combining our approach with tissue clearing techniques, we reveal the entire cardiac structures and hypertrabeculation of adult zebrafish hearts in response to doxorubicin treatment. By integrating the resolution enhancement technique with c-LSFM to increase the resolving power under a large field-of-view, we demonstrate the use of low power objective to resolve the entire architecture of large-scale neonatal mouse hearts, revealing the helical orientation of individual myocardial fibers. Therefore, our c-LSFM imaging approach provides multi-scale visualization of architecture and function to drive cardiovascular research with translational implication in congenital heart diseases.
C1 [Fei, Peng] Huazhong Univ Sci & Technol, Sch Opt & Elect Informat, Wuhan 430074, Peoples R China.
[Fei, Peng; Ho, Chih-Ming] Univ Calif Los Angeles, Dept Mech & Aerosp Engn, Los Angeles, CA USA.
[Lee, Juhyun; Packard, Rene R. Sevag; Chen, Harrison; Sung, Kevin; Hsiai, Tzung K.] Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA USA.
[Packard, Rene R. Sevag; Hsiai, Tzung K.] Univ Calif Los Angeles, Dept Mol Cellular & Integrat Physiol, Los Angeles, CA USA.
[Packard, Rene R. Sevag; Sereti, Konstantina-Ioanna; Ma, Jianguo; Ding, Yichen; Kang, Hanul; Kulkarni, Rajan; Ardehali, Reza; Hsiai, Tzung K.] Univ Calif Los Angeles, Div Cardiol, Los Angeles, CA USA.
[Xu, Hao; Kuo, C. -C. Jay] Univ So Calif, Dept Elect Engn, Los Angeles, CA 90089 USA.
[Kang, Hanul; Hsiai, Tzung K.] Vet Affairs Greater Los Angeles Healthcare Syst, Div Cardiol, Los Angeles, CA USA.
[Xu, Xiaolei] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN USA.
RP Hsiai, TK (reprint author), Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA USA.; Hsiai, TK (reprint author), Univ Calif Los Angeles, Dept Mol Cellular & Integrat Physiol, Los Angeles, CA USA.; Hsiai, TK (reprint author), Univ Calif Los Angeles, Div Cardiol, Los Angeles, CA USA.; Hsiai, TK (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Div Cardiol, Los Angeles, CA USA.
EM THsiai@mednet.ucla.edu
OI Packard, Rene/0000-0002-8520-5843
FU National Institutes of Health [HL083015, HL111437, HL129727, HL81753,
HL127728, T32HL007895]; UCLA STAR Program; AHA Pre-Doctoral Fellowship
[15PRE21400019]
FX This study was supported by National Institutes of Health HL083015
(T.K.H.), HL111437 (T.K.H.), HL129727 (T.K.H.), HL81753 (X.X.), HL127728
(R.A.), T32HL007895 (R.R.S.P.), UCLA STAR Program (R.R.S.P.) and AHA
Pre-Doctoral Fellowship 15PRE21400019 (J.L.).
NR 36
TC 3
Z9 3
U1 2
U2 19
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 3
PY 2016
VL 6
AR 22489
DI 10.1038/srep22489
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DF3FS
UT WOS:000371230000001
PM 26935567
ER
PT J
AU Pursley, AJ
Saunders, GH
AF Pursley, Alyssa J.
Saunders, Gabrielle H.
TI Knowledge, attitudes, behaviors, and noise exposure of baristas
SO INTERNATIONAL JOURNAL OF AUDIOLOGY
LA English
DT Article
DE questionnaires; cafes; Hearing conservation; health belief model;
noise-induced hearing loss
ID HEARING-LOSS PREVENTION; HEALTH PROMOTION MODEL; PROTECTION
AB Objective: To examine the daily noise exposure of baristas working in cafes, and to measure their knowledge, attitudes, and behaviors regarding hearing conservation and perceptions of noise in their work environment. Design: Fifteen baristas from six cafes in Portland completed the Knowledge, Attitudes and Behaviors questionnaire, a sound disturbance survey, and a structured interview to document perceptions of noise in the work environment. To measure daily noise exposure, a subset of eight participants wore a personal dosimeter for three different work shifts. Study sample: A total of 11 females and four males, aged between 19 and 36 years old (mean: 26.3, SD: 4.6) recruited from independently owned cafes in the Portland metro area. Results: Dosimetry measurements revealed Leq measurements between 71 and 83 dBA, with noise doses ranging from 4% to 74%, indicating that baristas are not exposed to sound levels above the regulatory criterion. Questionnaire results indicated that baristas have low awareness about the hazards of noise, are not opposed to hearing conservation, and rarely use hearing protection when engaged in noisy activities. Conclusions: Baristas here lacked the pertinent education and motivation to commit to invaluable hearing conservation practices.
C1 [Pursley, Alyssa J.] Washington Univ, Sch Med, Program Audiol & Commun Sci, 660 S Euclid Ave,Campus Box 8042, St Louis, MO 63110 USA.
[Saunders, Gabrielle H.] Portland VA Med Ctr, NCRAR, Portland, OR USA.
RP Pursley, AJ (reprint author), Washington Univ, Sch Med, Program Audiol & Commun Sci, 660 S Euclid Ave,Campus Box 8042, St Louis, MO 63110 USA.
EM alyssa.pursley@wustl.edu
FU NIH National Institute on Deafness and other Communicative Disorders
Predoctoral Short-term Training Grant [DC008764, T-35]
FX This study was supported by a NIH National Institute on Deafness and
other Communicative Disorders T-35 Predoctoral Short-term Training Grant
(Grant number DC008764). Portions of this work were presented at the
American Auditory Society Annual Conference, Phoenix, USA (March 6,
2015), the Missouri Academy of Audiology Annual Conference, Saint Louis,
USA (September 12, 2014), and the International Hearing Aid Research
Conference, Lake Tahoe, USA (August 14, 2014).
NR 16
TC 0
Z9 0
U1 3
U2 5
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1499-2027
EI 1708-8186
J9 INT J AUDIOL
JI Int. J. Audiol.
PD MAR 3
PY 2016
VL 55
IS 3
BP 184
EP 188
DI 10.3109/14992027.2015.1124295
PG 5
WC Audiology & Speech-Language Pathology; Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Otorhinolaryngology
GA DE5BO
UT WOS:000370646000007
PM 26795371
ER
PT J
AU Williams, NR
Hopkins, TR
Short, EB
Sahlem, GL
Snipes, J
Revuelta, GJ
George, MS
Takacs, I
AF Williams, Nolan R.
Hopkins, Thomas R.
Short, E. Baron
Sahlem, Gregory L.
Snipes, Jonathan
Revuelta, Gonzalo J.
George, Mark S.
Takacs, Istvan
TI Reward circuit DBS improves Parkinson's gait along with severe
depression and OCD
SO NEUROCASE
LA English
DT Article
DE Deep brain stimulation; Parkinson's disease; depression; apathy;
obsessive-compulsive disorder
ID OBSESSIVE-COMPULSIVE DISORDER; DEEP BRAIN-STIMULATION; SUBTHALAMIC
NUCLEUS STIMULATION; DISEASE; STRIATUM
AB A 59-year-old Caucasian man with a past history of Parkinson's disease (PD) status post-bilateral subthalamic nucleus (STN) deep brain stimulation (DBS), who also had treatment-resistant (TR) obsessive-compulsive disorder (OCD), and treatment-resistant depression (TRD), presented for further evaluation and management of his TR OCD. After an unsuccessful attempt to treat his OCD by reprogramming his existing STN DBS, he was offered bilateral ventral capsule/ventral striatum (VC/VS) DBS surgery. In addition to the expected improvement in OCD symptoms, he experienced significant improvement in both PD-related apathy and depression along with resolution of suicidal ideation. Furthermore, the patient's festinating gait dramatically improved. This case demonstrates that DBS of both the STN and VC/VS appears to have an initial signal of safety and tolerability. This is the first instance where both the STN and the VC/VS DBS targets have been implanted in an individual and the first case where a patient with PD has received additional DBS in mood-regulatory circuitry.
C1 [Williams, Nolan R.] Stanford Univ, Dept Psychiat, Stanford, CA 94305 USA.
[Hopkins, Thomas R.; Short, E. Baron; Sahlem, Gregory L.; Snipes, Jonathan; George, Mark S.] Med Univ S Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA.
[Revuelta, Gonzalo J.; George, Mark S.; Takacs, Istvan] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
[George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Williams, NR (reprint author), Stanford Univ, Dept Psychiat, Stanford, CA 94305 USA.
EM nolrywillia@gmail.com
OI Williams, Nolan/0000-0003-4368-3203
FU National Institute of Drug Abuse [R25 DA020537]
FX NRW and TRH are both funded through National Institute of Drug Abuse
[grant number R25 DA020537].
NR 18
TC 3
Z9 3
U1 3
U2 18
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1355-4794
EI 1465-3656
J9 NEUROCASE
JI Neurocase
PD MAR 3
PY 2016
VL 22
IS 2
BP 201
EP 204
DI 10.1080/13554794.2015.1112019
PG 4
WC Clinical Neurology; Psychiatry; Psychology
SC Neurosciences & Neurology; Psychiatry; Psychology
GA DD2RR
UT WOS:000369770400011
PM 26644268
ER
PT J
AU Singh, JA
Yu, SH
AF Singh, Jasvinder A.
Yu, Shaohua
TI Gout-related inpatient utilization: a study of predictors of outcomes
and time trends
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
DE Gout; Inpatient utilization; Hospitalization; Comorbidity; Predictors;
Length of stay; Hospital discharge; Resource utilization; Charges
ID HEALTH-CARE UTILIZATION; HEART-FAILURE; MANAGEMENT; COMORBIDITIES;
PREVALENCE; HOSPITALIZATION; HYPERURICEMIA; POPULATION; COSTS
AB Background: To assess inpatient healthcare burden of gout n the USA after an Emergency Department (ED) visit and the predictors of gout-related hospitalizations.
Method: We used the 2009, 2010 and 2012 US National ED Sample (NEDS) data to examine the time trends in inpatient visits with gout as the primary diagnosis. We used the 2012 NEDS data to assess multivariable-adjusted predictors of length of hospital stay, discharge to home (versus other) and total charges for gout-related inpatient visits.
Results: Of the 205,152 ED visits for gout as the primary diagnosis in 2012, 77 % resulted in hospitalization. In 2009, 2010 and 2012, 63 36, 63 % and 64.5 36 of hospitalized patients were discharged home; respective durations of hospital stay were 4.15, 4.00 and 3.86 days. Older age 50 to <65 years (ref <50), renal failure, heart failure, osteoarthritis and diabetes were associated with a longer hospital stay and self-pay/uninsured status, hospital location in the Midwest or Western USA with a shorter hospital stay for gout. Similar factors were associated with total charges for gout-related admissions. Older age (65 to <80 and >= 80, relative to <50 years), diabetes, self-pay/no charge insurance status, metropolitan area residence, and a longer length of hospital stay were associated with lower odds of discharge to home; and self-pay/no charge (uninsured) status was associated with higher odds of discharge to borne, compared to Medicare coverage.
Conclusions: Using a national sample, we noted declining duration of hospital stay and identified factors associated with the length of hospital stay, discharge to borne and charges for gout hospitalization following an ED visit. Future studies should examine whether better management of comorbidities in patients with gout can further reduce utilization and cost of gout-related hospitalizations.
C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, 700 South 19th St, Birmingham, AL 35233 USA.
[Singh, Jasvinder A.; Yu, Shaohua] Univ Alabama Birmingham, Sch Med, Dept Med, 1705 Univ Blvd, Birmingham, AL 35233 USA.
[Singh, Jasvinder A.; Yu, Shaohua] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, 1705 Univ Blvd, Birmingham, AL 35233 USA.
[Singh, Jasvinder A.] Mayo Clin, Dept Orthoped Surg, Coll Med, 200 1st St SW, Rochester, MN 55905 USA.
RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, 700 South 19th St, Birmingham, AL 35233 USA.; Singh, JA (reprint author), Univ Alabama Birmingham, Sch Med, Dept Med, 1705 Univ Blvd, Birmingham, AL 35233 USA.; Singh, JA (reprint author), Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, 1705 Univ Blvd, Birmingham, AL 35233 USA.; Singh, JA (reprint author), Mayo Clin, Dept Orthoped Surg, Coll Med, 200 1st St SW, Rochester, MN 55905 USA.
EM jassingh@uab.edu
FU Univetsity of Alabama at Birmingham (JAB) Division of Rheumatology;
National Institute of Arthritis, Musculoskeletal and skin Diseases
(NIAMS) [P50 AR060772]
FX This material is the resuIt of work supported by research funds from the
Univetsity of Alabama at Birmingham (JAB) Division of Rheumatology and
the resources and use of facilities at the Birmingham VA Medical Center.
JAS is also suppoqed it grant from the National Institute of Arthritis,
Musculoskeletal and skin Diseases (NIAMS) P50 AR060772.
NR 32
TC 0
Z9 0
U1 1
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1478-6354
EI 1478-6362
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PD MAR 2
PY 2016
VL 18
DI 10.1186/s13075-016-0936-y
PG 10
WC Rheumatology
SC Rheumatology
GA DF3YU
UT WOS:000371285300001
PM 26935737
ER
PT J
AU Gray, NE
Harris, CJ
Quinn, JF
Soumyanath, A
AF Gray, Nora E.
Harris, Christopher J.
Quinn, Joseph F.
Soumyanath, Amala
TI Centella asiatica modulates antioxidant and mitochondrial pathways and
improves cognitive function in mice
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Aging; Cognition; Centella asiatica; Mitochondrial dysfunction; Reactive
oxygen species
ID AMYLOID-BETA TOXICITY; OXIDATIVE STRESS; ALZHEIMERS-DISEASE;
NEURODEGENERATIVE DISEASES; SYNAPTIC PLASTICITY; BRAIN-REGIONS; RATS;
MEMORY; MOUSE; DYSFUNCTION
AB Ethnopharmacological relevance: This study investigates the cognitive enhancing effects of the plant Centella asiatica which is widely used Ayurvedic and traditional Chinese medicine.
Aim of the study: The goal of this study was to determine the effects of a water extract of the medicinal plant Centella asiatica (CAW) on cognitive ability as well as mitochondrial and antioxidant response pathways in vivo.
Materials and methods: Old and young C57BL/6 mice were treated with CAW (2 mg/mL) in their drinking water. Learning and memory was assessed using Morris Water Maze (MWM) and then tissue was collected and gene expression analyzed.
Results: CAW improved performance in the MWM in aged animals and had a modest effect on the performance of young animals. CAW also increased the expression of mitochondria] and antioxidant response genes in the brain and liver of both young and old animals. Expression of synaptic markers was also increased in the hippocampus and frontal cortex, but not in the cerebellum of CAW-treated animals.
Conclusions: These data indicate a cognitive enhancing effect of CAW in healthy mice. The gene expression changes caused by CAW suggest a possible effect on mitochondrial biogenesis, which in conjunction with activation of antioxidant response genes could contribute to cognitive improvement. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Gray, Nora E.; Harris, Christopher J.; Quinn, Joseph F.; Soumyanath, Amala] Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
[Quinn, Joseph F.] Portland VA Med Ctr, Dept Neurol, Portland, OR 97239 USA.
[Quinn, Joseph F.] Portland VA Med Ctr, Parkinsons Dis Res Educ & Clin Care Ctr PADRECC, Portland, OR 97239 USA.
RP Gray, NE (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM grayn@ohsu.edu
FU NIH-NCCAM Grant [R01AT008099]; Oregon Alzheimer's Disease Center (OADC)
[3P30-AG008017 24 S1]; NIH-NCCAM [AT002688]; Department of Veterans
Affairs
FX This work was funded by NIH-NCCAM Grant R01AT008099 (Soumyanath), an
Oregon Alzheimer's Disease Center (OADC) Grant 3P30-AG008017 24 S1
(Soumyanath), a T32 grant on which N. Gray was a trainee from NIH-NCCAM
AT002688, and by a Department of Veterans Affairs Merit Review grant
(Quinn).
NR 40
TC 1
Z9 1
U1 1
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0378-8741
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD MAR 2
PY 2016
VL 180
BP 78
EP 86
DI 10.1016/j.jep.2016.01.013
PG 9
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
Medicine; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
Medicine
GA DF7TN
UT WOS:000371560600010
PM 26785167
ER
PT J
AU Hirano, AA
Liu, X
Boulter, J
Grove, J
Muller, LPD
Barnes, S
Brecha, NC
AF Hirano, Arlene A.
Liu, Xue
Boulter, Jim
Grove, James
Mueller, Luis Perez de Sevilla
Barnes, Steven
Brecha, Nicholas C.
TI Targeted Deletion of Vesicular GABA Transporter from Retinal Horizontal
Cells Eliminates Feedback Modulation of Photoreceptor Calcium Channels
SO ENEURO
LA English
DT Article
DE Ca channels; Cx57-iCre; GABA receptors; inhibitory feedback; retinal
horizontal cells; synaptic vesicles
ID GAMMA-AMINOBUTYRIC-ACID; MOUSE RETINA; MAMMALIAN RETINA; GUINEA-PIG;
INTRACELLULAR CALCIUM; CONE PHOTORECEPTORS; TRANSMITTER RELEASE; ROD
PHOTORECEPTORS; VERTEBRATE RETINA; RABBIT RETINA
AB The cellular mechanisms underlying feedback signaling from horizontal cells to photoreceptors, which are important for the formation of receptive field surrounds of early visual neurons, remain unsettled. Mammalian horizontal cells express a complement of synaptic proteins that are necessary and sufficient for calcium-dependent exocytosis of inhibitory neurotransmitters at their contacts with photoreceptor terminals, suggesting that they are capable of releasing GABA via vesicular release. To test whether horizontal cell vesicular release is involved in feedback signaling, we perturbed inhibitory neurotransmission in these cells by targeted deletion of the vesicular GABA transporter (VGAT), the protein responsible for the uptake of inhibitory transmitter by synaptic vesicles. To manipulate horizontal cells selectively, an iCre mouse line with Cre recombinase expression controlled by connexin57 (Cx57) regulatory elements was generated. In Cx57-iCre mouse retina, only horizontal cells expressed Cre protein, and its expression occurred in all retinal regions. After crossing with a VGAT(flox/flox) mouse line, VGAT was selectively eliminated from horizontal cells, which was confirmed immunohistochemically. Voltage-gated ion channel currents in horizontal cells of Cx57-VGAT(-/-) mice were the same as Cx57-VGAT(+/+) controls, as were the cell responses to the ionotropic glutamate receptor agonist kainate, but the response to the GABA(A) receptor agonist muscimol in Cx57-VGAT(-/-) mice was larger. In contrast, the feedback inhibition of photoreceptor calcium channels, which in control animals is induced by horizontal cell depolarization, was completely absent in Cx57-VGAT(-/-) mice. The results suggest that vesicular release of GABA from horizontal cells is required for feedback inhibition of photoreceptors.
C1 [Hirano, Arlene A.; Liu, Xue; Grove, James; Mueller, Luis Perez de Sevilla; Barnes, Steven; Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA.
[Hirano, Arlene A.; Barnes, Steven; Brecha, Nicholas C.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Boulter, Jim] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Hatos Res Ctr Neuropharmacol,David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Barnes, Steven] Dalhousie Univ, Dept Physiol & Biophys, Halifax, NS B3H 4R2, Canada.
[Barnes, Steven] Dalhousie Univ, Dept Ophthalmol & Visual Sci, Halifax, NS B3H 4R2, Canada.
[Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA.
[Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Liu, Xue] Chongqing Univ Sci & Technol, Biomat & Live Cell Imaging Inst, Chongqing 400044, Peoples R China.
RP Hirano, AA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA.
EM ahirano@mednet.ucla.edu
OI Hirano, Arlene/0000-0001-8842-3582
FU National Institutes of Health [EY-15573]; UCLA Oppenheimer Seed Grant;
Plum Foundation; Veterans Administration Career Scientist Award;
Canadian Institutes of Health Research-Nova Scotia Health Research
Foundation Regional Partnership Program Grant [MOP10968]; Natural
Sciences and Engineering Research Council of Canada Discovery Award
[194640]
FX This research was supported by National Institutes of Health Grant
EY-15573 (N.C.B.), UCLA Oppenheimer Seed Grant (A.A.H., J.B., N.C.B.),
the Plum Foundation (S.B., N.C.B.), a Veterans Administration Career
Scientist Award (N.C.B.), Canadian Institutes of Health Research-Nova
Scotia Health Research Foundation Regional Partnership Program Grant
MOP10968 (S.B.), and Natural Sciences and Engineering Research Council
of Canada Discovery Award 194640 (S.B.).
NR 61
TC 2
Z9 2
U1 0
U2 0
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 2373-2822
J9 ENEURO
JI eNeuro
PD MAR-APR
PY 2016
VL 3
IS 2
AR UNSP e0148-15.2016
DI 10.1523/ENEURO.0148-15.2016
PG 13
WC Neurosciences
SC Neurosciences & Neurology
GA EH7AY
UT WOS:000391926400031
ER
PT J
AU Schwartz, MD
Nguyen, AT
Warrier, DR
Palmerston, JB
Thomas, AM
Morairty, SR
Neylan, TC
Kilduff, TS
AF Schwartz, Michael D.
Nguyen, Alexander T.
Warrier, Deepti R.
Palmerston, Jeremiah B.
Thomas, Alexia M.
Morairty, Stephen R.
Neylan, Thomas C.
Kilduff, Thomas S.
TI Locus Coeruleus and Tuberomammillary Nuclei Ablations Attenuate
Hypocretin/Orexin Antagonist-Mediated REM Sleep
SO ENEURO
LA English
DT Article
DE arousal; hypnotics; insomnia; monoamine; orexin; paradoxical sleep
ID EYE-MOVEMENT SLEEP; ALMOREXANT PROMOTES SLEEP; WAKING CYCLE;
HISTAMINERGIC NEURONS; LATERAL HYPOTHALAMUS; RECEPTOR ANTAGONISTS;
PONTINE CARBACHOL; OREXIN RECEPTOR-1; PARADOXICAL SLEEP; FOS EXPRESSION
AB Hypocretin 1 and 2 (Hcrts; also known as orexin A and B), excitatory neuropeptides synthesized in cells located in the tuberal hypothalamus, play a central role in the control of arousal. Hcrt inputs to the locus coeruleus norepinephrine (LC NE) system and the posterior hypothalamic histaminergic tuberomammillary nuclei (TMN HA) are important efferent pathways for Hcrt-induced wakefulness. The LC expresses Hcrt receptor 1 (HcrtR1), whereas HcrtR2 is found in the TMN. Although the dual Hcrt/orexin receptor antagonist almorexant (ALM) decreases wakefulness and increases NREM and REM sleep time, the neural circuitry that mediates these effects is currently unknown. To test the hypothesis that ALM induces sleep by selectively disfacilitating subcortical wake-promoting populations, we ablated LC NE neurons (LCx) or TMN HA neurons (TMNx) in rats using cell-type-specific saporin conjugates and evaluated sleep/wake following treatment with ALM and the GABAA receptor modulator zolpidem (ZOL). Both LCx and TMNx attenuated the promotion of REM sleep by ALM without affecting ALM-mediated increases in NREM sleep. Thus, eliminating either HcrtR1 signaling in the LC or HcrtR2 signaling in the TMN yields similar effects on ALM-induced REM sleep without affecting NREM sleep time. In contrast, neither lesion altered ZOL efficacy on any measure of sleep-wake regulation. These results contrast with those of a previous study in which ablation of basal forebrain cholinergic neurons attenuated ALM-induced increases in NREM sleep time without affecting REM sleep, indicating that Hcrt neurotransmission influences distinct aspects of NREM and REM sleep at different locations in the sleep-wake regulatory network.
C1 [Schwartz, Michael D.; Nguyen, Alexander T.; Warrier, Deepti R.; Palmerston, Jeremiah B.; Thomas, Alexia M.; Morairty, Stephen R.; Kilduff, Thomas S.] SRI Int, Biosci Div, Ctr Neurosci, 333 Ravenswood Ave, Menlo Pk, CA 94025 USA.
[Neylan, Thomas C.] Univ Calif San Francisco, San Francisco VA Med Ctr, NCIRE, San Francisco, CA 94121 USA.
RP Kilduff, TS (reprint author), SRI Int, 333 Ravenswood Ave, Menlo Pk, CA 94025 USA.
EM thomas.kilduff@sri.com
OI Kilduff, Thomas/0000-0002-6823-0094
FU U.S. Army Medical Research Acquisition Activity [W81XWH-09-2-0081]; NIH
[R01 NS077408]
FX This work was supported by the U.S. Army Medical Research Acquisition
Activity award number W81XWH-09-2-0081 and NIH R01 NS077408 to T.S.K. We
thank Drs Priyattam J. Shiromani and Carlos Blanco-Centurion for
providing Hcrt2-SAP; Tsui-Ming Chen, Alan Wilk, and Dr Simon Fisher for
technical assistance; Dr Ling Jong for synthesis of almorexant; and Drs
Sarah Black and Gregory Parks for helpful comments on data analysis and
the paper.
NR 77
TC 0
Z9 0
U1 0
U2 0
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 2373-2822
J9 ENEURO
JI eNeuro
PD MAR-APR
PY 2016
VL 3
IS 2
AR UNSP e0018-16.2016
DI 10.1523/ENEURO.0018-16.2016
PG 16
WC Neurosciences
SC Neurosciences & Neurology
GA EH7AY
UT WOS:000391926400007
ER
PT J
AU Ellis, C
Hoffman, W
Jaehnert, S
Plagge, J
Loftis, JM
Schwartz, D
Huckans, M
AF Ellis, Carilyn
Hoffman, William
Jaehnert, Sarah
Plagge, Jane
Loftis, Jennifer M.
Schwartz, Daniel
Huckans, Marilyn
TI Everyday Problems With Executive Dysfunction and Impulsivity in Adults
Recovering From Methamphetamine Addiction
SO ADDICTIVE DISORDERS & THEIR TREATMENT
LA English
DT Article
DE methamphetamine; impulsivity; executive function
ID DEPENDENT INDIVIDUALS; ABUSE; USERS; SYMPTOMS; THERAPY
AB Objectives: Compared with nonaddicted controls (CTLs), adults in remission from methamphetamine addiction (MAREM) evidence impairments on objective measures of executive functioning and impulsivity.
Methods: To evaluate the impact of these impairments in MA-REM adults, demographically matched groups (MA-REM, n=30; CTLs, n=24) completed objective and self-report measures of executive functioning and impulsivity.
Results: MA-REMadults demonstrated significantly (P < 0.050) greater objective and subjective problems with executive functioning and impulsivity.
Conclusions: These results suggest that adults in MA-REM are aware of their deficits and that these deficits have significant impact in everyday life.
C1 [Ellis, Carilyn; Hoffman, William; Jaehnert, Sarah; Loftis, Jennifer M.; Schwartz, Daniel; Huckans, Marilyn] Portland VA Med Ctr, Res & Dev Serv, Portland, OR 97239 USA.
[Ellis, Carilyn; Hoffman, William; Jaehnert, Sarah; Plagge, Jane; Huckans, Marilyn] Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR 97239 USA.
[Ellis, Carilyn; Hoffman, William; Jaehnert, Sarah; Loftis, Jennifer M.; Schwartz, Daniel; Huckans, Marilyn] Oregon Hlth & Sci Univ, Sch Med, Methamphetamine Abuse Res Ctr, Portland, OR 97201 USA.
[Hoffman, William; Loftis, Jennifer M.; Schwartz, Daniel; Huckans, Marilyn] Oregon Hlth & Sci Univ, Sch Med, Dept Psychiat, Portland, OR 97201 USA.
[Hoffman, William; Huckans, Marilyn] Oregon Hlth & Sci Univ, Sch Med, Dept Behav Neurosci, Portland, OR 97201 USA.
[Ellis, Carilyn] George Fox Univ, Grad Dept Clin Psychol, Newberg, OR USA.
[Jaehnert, Sarah] Univ Pacific, Sch Profess Psychol, Hillsboro, OR USA.
RP Huckans, M (reprint author), Portland VA Med Ctr, P3MHN,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM marilyn.huckans@va.gov
FU BLRD VA [I01 BX002061]; NIDA NIH HHS [P50 DA018165]
NR 28
TC 1
Z9 1
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1531-5754
EI 1535-1122
J9 ADDICT DISORD TREAT
JI Addict. Disord. Treat.
PD MAR
PY 2016
VL 15
IS 1
BP 1
EP 5
DI 10.1097/ADT.0000000000000059
PG 5
WC Substance Abuse
SC Substance Abuse
GA EE5QZ
UT WOS:000389664100001
PM 27034621
ER
PT J
AU VanEpps, EM
Roberto, CA
Park, S
Economos, CD
Bleich, SN
AF VanEpps, Eric M.
Roberto, Christina A.
Park, Sara
Economos, Christina D.
Bleich, Sara N.
TI Restaurant Menu Labeling Policy: Review of Evidence and Controversies
SO CURRENT OBESITY REPORTS
LA English
DT Review
DE Menu labeling; Calorie labeling; Obesity prevention; Food policy
ID FAST-FOOD RESTAURANTS; OF-THE-LITERATURE; AMERICAN-HEART-ASSOCIATION;
FULL-SERVICE RESTAURANTS; CHAIN RESTAURANTS; SCIENTIFIC STATEMENT;
PHYSICAL-ACTIVITY; CALORIE LABELS; ENERGY-INTAKE; PORTION SIZE
AB In response to high rates of obesity in the USA, several American cities, counties, and states have passed laws requiring restaurant chains to post labels identifying the energy content of items on menus, and nationwide implementation of menu labeling is expected in late 2016. In this review, we identify and summarize the results of 16 studies that have assessed the impact of real-world numeric calorie posting. We also discuss several controversies surrounding the US Food and Drug Administration's implementation of federally mandated menu labeling. Overall, the evidence regarding menu labeling is mixed, showing that labels may reduce the energy content of food purchased in some contexts, but have little effect in other contexts. However, more data on a range of ong-term consumption habits and restaurant responses is needed to fully understand the impact menu labeling laws will have on the US population's diet.
C1 [VanEpps, Eric M.] VA Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Roberto, Christina A.; Park, Sara] Perelman Sch Med, Dept Med Eth & Hlth Policy, 423 Guardian Dr,1105b Blockley Hall, Philadelphia, PA 19104 USA.
[Economos, Christina D.] Tufts Univ, Friedman Sch Nutr Sci & Policy, ChildObesity180, Boston, MA 02111 USA.
[Economos, Christina D.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
[Bleich, Sara N.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA.
RP Roberto, CA (reprint author), Perelman Sch Med, Dept Med Eth & Hlth Policy, 423 Guardian Dr,1105b Blockley Hall, Philadelphia, PA 19104 USA.
EM croberto@mail.med.upenn.edu
FU NIA NIH HHS [P30 AG034546]
NR 47
TC 1
Z9 1
U1 1
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 2162-4968
J9 CURR OBES REP
JI Curr. Obes. Rep.
PD MAR
PY 2016
VL 5
IS 1
BP 72
EP 80
DI 10.1007/s13679-016-0193-z
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA EB0SH
UT WOS:000387055300009
PM 26877095
ER
PT J
AU Dehlendorf, C
Fox, E
Sobel, L
Borrero, S
AF Dehlendorf, Christine
Fox, Edith
Sobel, Lauren
Borrero, Sonya
TI Patient-Centered Contraceptive Counseling: Evidence to Inform Practice
SO CURRENT OBSTETRICS AND GYNECOLOGY REPORTS
LA English
DT Article
DE Contraception; Contraceptive counseling; Patient-centered; Decision
making
ID RANDOMIZED CONTROLLED-TRIAL; DECISION-MAKING; UNINTENDED PREGNANCY;
QUALITATIVE-ANALYSIS; WOMENS PERSPECTIVES; REPRODUCTIVE AGE;
HEALTH-CARE; SERVICES; KNOWLEDGE; ATTITUDES
AB Patient centeredness is an increasingly recognized aspect of quality health care. The application of this framework to contraceptive counseling and care has not been well described. We propose a definition of patient-centered contraceptive counseling that focuses on and prioritizes each patient's individual needs and preferences regarding contraceptive methods and the counseling experience. Guided by this definition, we review recent research that has advanced our understanding of how patient-centered contraceptive counseling can be delivered in practice, focusing on how women decide on a contraceptive method, their preferences for counseling, and their experiences with counseling. This research provides evidence that women have diverse preferences around attributes of their contraceptive methods and value personal, supportive relationships with their family planning providers that focus on their individual preferences. We discuss the implications of this research for practice and review recent interventions that incorporate patient centeredness to varying degrees.
C1 [Dehlendorf, Christine; Fox, Edith] Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA.
[Dehlendorf, Christine] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA USA.
[Dehlendorf, Christine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Sobel, Lauren] Touro Univ Calif Vallejo, Coll Osteopath Med, Vallejo, CA USA.
[Borrero, Sonya] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Borrero, Sonya] VA Pittsburgh Healthcare Syst, VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
RP Fox, E (reprint author), Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA.
EM christine.dehlendorf@ucsf.edu; edith.fox@ucsf.edu; lauren.sobel@tu.edu;
borrsp@upmc.edu
NR 62
TC 3
Z9 3
U1 7
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 2161-3303
J9 CURR OBSTET GYNECOL
JI CURR. OBSTET. GYNECOL. REP.
PD MAR
PY 2016
VL 5
IS 1
BP 55
EP 63
DI 10.1007/s13669-016-0139-1
PG 9
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA EA0DA
UT WOS:000386254400007
ER
PT J
AU Obedin-Maliver, J
Makadon, HJ
AF Obedin-Maliver, Juno
Makadon, Harvey J.
TI Transgender men and pregnancy
SO OBSTETRIC MEDICINE
LA English
DT Review
DE Transgender pregnancy; gender identity; counseling; sexual orientation;
primary care transgender people; obstetrical care of transgender people;
behavioral aspects of transgender pregnancy; testosterone in pregnancy
ID TESTOSTERONE LEVELS; BIRTH
AB Transgender people have experienced significant advances in societal acceptance despite experiencing continued stigma and discrimination. While it can still be difficult to access quality health care, and there is a great deal to be done to create affirming health care organizations, there is growing interest around the United States in advancing transgender health. The focus of this commentary is to provide guidance to clinicians caring for transgender men or other gender nonconforming people who are contemplating, carrying, or have completed a pregnancy. Terms transgender and gender nonconforming specifically refer to those whose gender identity (e.g., being a man) differs from their female sex assigned at birth. Many, if not most transgender men retain their female reproductive organs and retain the capacity to have children. Review of their experience demonstrates the need for preconception counseling that includes discussion of stopping testosterone while trying to conceive and during pregnancy, and anticipating increasing experiences of gender dysphoria during and after pregnancy. The clinical aspects of delivery itself fall within the realm of routine obstetrical care, although further research is needed into how mode and environment of delivery may affect gender dysphoria. Postpartum considerations include discussion of options for chest (breast) feeding, and how and when to reinitiate testosterone. A positive perinatal experience begins from the moment transgender men first present for care and depends on comprehensive affirmation of gender diversity.
C1 [Obedin-Maliver, Juno] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Obedin-Maliver, Juno] San Francisco VA Med Ctr, Dept Gynecol, San Francisco, CA USA.
[Makadon, Harvey J.] Fenway Inst, Natl LGBT Hlth Educ Ctr, 1340 Boylston St, Boston, MA 02215 USA.
[Makadon, Harvey J.] Harvard Med Sch, Boston, MA USA.
RP Makadon, HJ (reprint author), Fenway Inst, Natl LGBT Hlth Educ Ctr, 1340 Boylston St, Boston, MA 02215 USA.
EM hmakadon@fenwayhealth.org
NR 41
TC 1
Z9 1
U1 4
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1753-495X
EI 1753-4968
J9 OBSTET MED
JI Obstet. Med.
PD MAR
PY 2016
VL 9
IS 1
BP 4
EP 8
DI 10.1177/1753495X15612658
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DV7LR
UT WOS:000383118000002
ER
PT J
AU Wong, CA
Ostapovich, G
Kramer-Golinkoff, E
Griffis, H
Asch, DA
Merchant, RM
AF Wong, Charlene A.
Ostapovich, Gabrielle
Kramer-Golinkoff, Emily
Griffis, Heather
Asch, David A.
Merchant, Raina M.
TI How U.S. children's hospitals use social media: A mixed methods study
SO HEALTHCARE-THE JOURNAL OF DELIVERY SCIENCE AND INNOVATION
LA English
DT Article
ID HEALTH RESEARCH; CARE; INFORMATION; FACEBOOK; TWITTER; YOUTUBE; SITES
AB Background: Social media provide new channels for hospitals to engage with communities, a goal of increasing importance as non-profit hospitals face stricter definitions of community benefit under the Affordable Care Act. We describe the variability in social media presence among US children's hospitals and the distribution of their Facebook content curation.
Methods: Social media data from freestanding children's hospitals were extracted from September November 2013. Social media adoption was reviewed for each hospital-generated Facebook, Twitter, YouTube, Google + and Pinterest platform. Facebook page (number of Likes) and Twitter account (number of followers) engagement were examined by hospital characteristics. Facebook posts from each hospital over a 6-week period were thematically characterized.
Results: We reviewed 5 social media platforms attributed to 45 children's hospitals and 2004 associated Facebook posts. All hospitals maintained Facebook and Twitter accounts and most used YouTube (82%), Google+ (53%) and Pinterest (69%). Larger hospitals were more often high performers for Facebook (67% versus 10%, p < 0.01) and Twitter (75% versus 17%, p < 0.05) engagement than small hospitals. The most common Facebook post-themes were hospital promotion 35% (706), education and information 35% (694), community partnership or benefit 24% (474), fundraising 21% (426), and narratives 12% (241). Of health education posts, 73% (509) provided pediatric health supervision and anticipatory guidance.
Conclusions: Social media adoption by US children's hospitals was widespread. Implications: Beyond its traditional marketing role, social media can serve as a conduit for health education, engagement with communities, including community benefit. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Wong, Charlene A.; Asch, David A.; Merchant, Raina M.] Univ Penn, Robert Wood Johnson Fdn, Clin Scholars Program, 1303 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
[Wong, Charlene A.; Ostapovich, Gabrielle; Kramer-Golinkoff, Emily; Griffis, Heather; Asch, David A.; Merchant, Raina M.] Univ Penn, Penn Med Social Media & Hlth Innovat Lab, Penn Med Ctr Hlth Care Innovat, Philadelphia, PA 19104 USA.
[Asch, David A.; Merchant, Raina M.] Univ Penn, Div Gen Internal Med, Philadelphia, PA 19104 USA.
[Asch, David A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
RP Wong, CA (reprint author), Univ Penn, Robert Wood Johnson Fdn, Clin Scholars Program, 1303 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM charwong@upenn.edu
NR 30
TC 0
Z9 0
U1 5
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2213-0764
EI 2213-0772
J9 HEALTHCARE
JI HealthCare
PD MAR
PY 2016
VL 4
IS 1
BP 15
EP 21
DI 10.1016/j.hjdsi.2015.12.004
PG 7
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA DQ5LK
UT WOS:000379246500006
PM 27001094
ER
PT J
AU Mota, N
Tsai, J
Kirwin, PD
Harpaz-Rotem, I
Krystal, JH
Southwick, SM
Pietrzak, RH
AF Mota, Natalie
Tsai, Jack
Kirwin, Paul D.
Harpaz-Rotem, Ilan
Krystal, John H.
Southwick, Steven M.
Pietrzak, Robert H.
TI Late-Life Exacerbation of PTSD Symptoms in US Veterans: Results From the
National Health and Resilience in Veterans Study
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW;
OLDER-ADULTS; CASE SERIES; DSM-IV; TRAUMA; EXPOSURE; ONSET;
INTERVENTIONS; TRAJECTORIES
AB Objective: More than 60% of US military veterans are 55 years or older. Although several case studies have suggested that older age is associated with a higher likelihood of reactivated or delayed-onset posttraumatic stress disorder (PTSD) symptoms in veterans, population-based data on the prevalence and determinants of this phenomenon are lacking.
Method: Using data from the National Health and Resilience in Veterans Study (NHRVS: Wave 1 = October 2011-December 2011; Wave 2 = September 2013), a nationally representative, cohort study of US veterans, we evaluated the prevalence and determinants of exacerbated PTSD symptoms in 1,441 veterans 55 years or older using a DSM-IV-based measure in 2011 and a DSM-5-based measure in 2013. Veterans whose worst trauma occurred at least 5 years prior to Wave 2 of the NHRVS (mean = 28.6 years) and who reported a clinically significant increase (ie, >= 0.5 standard deviation [SD]; mean = 1.27, SD = 0.78) in PTSD symptoms from Wave 1 (lifetime) to Wave 2 (past-month) were identified as having exacerbated PTSD symptoms.
Results: Results revealed that 9.9% of older US veterans experienced exacerbated PTSD symptoms an average of nearly 3 decades after their worst trauma. A multivariable logistic regression model indicated that greater self-reported cognitive difficulties at Wave 1 independently predicted exacerbated PTSD symptoms at Wave 2. Post hoc analysis revealed that this association was driven by greater severity of executive dysfunction (adjusted odds ratio range, 1.27-3.22).
Conclusions: Approximately 1 in 10 older US veterans experiences a clinically significant exacerbation of PTSD symptoms in late life. Executive dysfunction may contribute to risk for exacerbated PTSD symptoms. These results suggest that exacerbated PTSD symptoms are prevalent in US veterans and highlight potential targets for identifying veterans at risk for this phenomenon. (C) Copyright 2016 Physicians Postgraduate Press, Inc.
C1 [Mota, Natalie; Tsai, Jack; Kirwin, Paul D.; Harpaz-Rotem, Ilan; Krystal, John H.; Southwick, Steven M.; Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
[Mota, Natalie; Kirwin, Paul D.; Harpaz-Rotem, Ilan; Krystal, John H.; Southwick, Steven M.; Pietrzak, Robert H.] US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, Clin Neurosci Div, West Haven, CT USA.
[Tsai, Jack] US Dept Vet Affairs, New England Mental Illness Res Educ & Clin Ctr, West Haven, CT USA.
[Mota, Natalie] Univ Manitoba, Dept Clin Hlth Psychol, Winnipeg, MB, Canada.
[Mota, Natalie] Yale Univ, Natl Ctr Posttraumat Stress Disorder, New Haven, CT 06520 USA.
RP Mota, N (reprint author), 817 Bannatyne Ave, Winnipeg, MB R3E 0W2, Canada.
EM natalie.mota@umanitoba.ca
FU US Department of Veterans Affairs National Center for Posttraumatic
Stress Disorder
FX The National Health and Resilience in Veterans Study (NHRVS) was funded
by the US Department of Veterans Affairs National Center for
Posttraumatic Stress Disorder.
NR 40
TC 0
Z9 0
U1 2
U2 4
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
EI 1555-2101
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD MAR
PY 2016
VL 77
IS 3
BP 348
EP 354
DI 10.4088/JCP.15m10101
PG 7
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA DQ5LC
UT WOS:000379245700015
PM 27046308
ER
PT J
AU George, B
Denney, T
Gupta, H
Dell'Italia, L
Aban, I
AF George, Brandon
Denney, Thomas, Jr.
Gupta, Himanshu
Dell'Italia, Louis
Aban, Inmaculada
TI APPLYING A SPATIOTEMPORAL MODEL FOR LONGITUDINAL CARDIAC IMAGING DATA
SO ANNALS OF APPLIED STATISTICS
LA English
DT Article
DE Spatiotemporal; imaging; correlation; separable; summary measures
ID ISOLATED MITRAL REGURGITATION; CARDIOCYTE; BLOCKADE
AB Longitudinal imaging studies have both spatial and temporal correlation among the multiple outcome measurements from a subject. Statistical methods of analysis must properly account for this autocorrelation. In this work we discuss how a linear model with a separable parametric correlation structure could be used to analyze data from such a study. The goal of this paper is to provide an easily understood description of how such a model works and discuss how it can be applied to real data. Model assumptions are discussed and the process of selecting a working correlation structure is thoroughly discussed. The steps necessitating collaboration between statistical and scientific investigators have been highlighted, as have considerations for missing data or uneven follow-up.
The results from a completed longitudinal cardiac imaging study were considered for illustration purposes. The data comes from a clinical trial for medical therapy for patients with mitral regurgitation, with repeated measurements taken at sixteen locations from the left ventricle to measure disease progression. The spatiotemporal correlation model was compared to previously used summary measures to demonstrate improved power as well as increased flexibility in the use of time- and space- varying predictors.
C1 [George, Brandon; Aban, Inmaculada] Univ Alabama Birmingham, Dept Biostat, 1720 2nd Ave S, Birmingham, AL 35233 USA.
[Denney, Thomas, Jr.] Auburn Univ, Dept Elect & Comp Engn, Broun Hall,341 War Eagle Way, Auburn, AL 36849 USA.
[Gupta, Himanshu; Dell'Italia, Louis] Univ Alabama Birmingham, Dept Med, 1808 7th Ave S, Birmingham, AL 35294 USA.
[Gupta, Himanshu; Dell'Italia, Louis] Birmingham Vet Affairs Med Ctr, 700 South 19th St, Birmingham, AL 35233 USA.
RP George, B (reprint author), Univ Alabama Birmingham, Dept Biostat, 1720 2nd Ave S, Birmingham, AL 35233 USA.
EM brgeorge@uab.edu; caban@uab.edu
FU NHLBI [T32HL079888]; National Institutes of Health Specialized Center of
Clinically Oriented Research in Cardiac Dysfunction [P50-HL077100]
FX Predoctoral funding was provided by NHLBI T32HL079888. The UAB SCCOR
study was supported by National Institutes of Health Specialized Center
of Clinically Oriented Research in Cardiac Dysfunction P50-HL077100.
NR 31
TC 0
Z9 0
U1 0
U2 0
PU INST MATHEMATICAL STATISTICS
PI CLEVELAND
PA 3163 SOMERSET DR, CLEVELAND, OH 44122 USA
SN 1932-6157
J9 ANN APPL STAT
JI Ann. Appl. Stat.
PD MAR
PY 2016
VL 10
IS 1
BP 527
EP 548
DI 10.1214/16-AOAS911
PG 22
WC Statistics & Probability
SC Mathematics
GA DO9OU
UT WOS:000378116900022
PM 27087884
ER
PT J
AU Novais, EA
Baumal, CR
Sarraf, D
Freund, KB
Duker, JS
AF Novais, Eduardo A.
Baumal, Caroline R.
Sarraf, David
Freund, K. Bailey
Duker, Jay S.
TI Multimodal Imaging in Retinal Disease: A Consensus Definition
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Editorial Material
ID OPTICAL COHERENCE TOMOGRAPHY; OCCULT MACULAR DYSTROPHY; CHOROIDAL
NEOVASCULARIZATION; ANGIOGRAPHY; DEGENERATION; FUTURE
C1 [Novais, Eduardo A.; Baumal, Caroline R.; Duker, Jay S.] Tufts Med Ctr, New England Eye Ctr, 260 Tremont St,Biewend Bldg,9-11th Floor, Boston, MA 02116 USA.
[Novais, Eduardo A.] Univ Fed Sao Paulo, Sch Med, Sao Paulo, Brazil.
[Sarraf, David] Univ Calif Los Angeles, Stein Eye Inst, Los Angeles, CA USA.
[Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA.
[Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
[Freund, K. Bailey] NYU, Sch Med, Dept Ophthalmol, New York, NY USA.
RP Duker, JS (reprint author), Tufts Med Ctr, New England Eye Ctr, 260 Tremont St,Biewend Bldg,9-11th Floor, Boston, MA 02116 USA.
EM jduker@tuftsmedicalcenter.org
OI Freund, K. Bailey/0000-0002-7888-9773
NR 34
TC 1
Z9 1
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD MAR
PY 2016
VL 47
IS 3
BP 201
EP +
DI 10.3928/23258160-20160229-01
PG 6
WC Ophthalmology; Surgery
SC Ophthalmology; Surgery
GA DP9VF
UT WOS:000378844900001
PM 26985792
ER
PT J
AU Harriff, MJ
Karamooz, E
Burr, A
Grant, WF
Canfield, ET
Sorensen, ML
Moita, LF
Lewinsohn, DM
AF Harriff, Melanie J.
Karamooz, Elham
Burr, Ansen
Grant, Wilmon F.
Canfield, Elizabeth T.
Sorensen, Michelle L.
Moita, Luis F.
Lewinsohn, David M.
TI Endosomal MR1 Trafficking Plays a Key Role in Presentation of
Mycobacterium tuberculosis Ligands to MAIT Cells
SO PLOS PATHOGENS
LA English
DT Article
ID INVARIANT T-CELLS; MHC CLASS-I; CD1 ANTIGEN PRESENTATION;
ENDOPLASMIC-RETICULUM; BACTERIAL-INFECTION; SYNTAXIN 18; Q-SNARE;
RECEPTOR; PATHWAY; INVOLVEMENT
AB Mucosal-Associated Invariant T (MAIT) cells, present in high frequency in airway and other mucosal tissues, have Th1 effector capacity positioning them to play a critical role in the early immune response to intracellular pathogens, including Mycobacterium tuberculosis (Mtb). MR1 is a highly conserved Class I-like molecule that presents vitamin B metabolites to MAIT cells. The mechanisms for loading these ubiquitous small molecules are likely to be tightly regulated to prevent inappropriate MAIT cell activation. To define the intracellular localization of MR1, we analyzed the distribution of an MR1-GFP fusion protein in antigen presenting cells. We found that MR1 localized to endosomes and was translocated to the cell surface upon addition of 6-formyl pterin (6-FP). To understand the mechanisms by which MR1 antigens are presented, we used a lentiviral shRNA screen to identify trafficking molecules that are required for the presentation of Mtb antigen to HLA-diverse T cells. We identified Stx18, VAMP4, and Rab6 as trafficking molecules regulating MR1-dependent MAIT cell recognition of Mtb-infected cells. Stx18 but not VAMP4 or Rab6 knockdown also resulted in decreased 6-FP-dependent surface translocation of MR1 suggesting distinct pathways for loading of exogenous ligands and intracellular mycobacterially-derived ligands. We postulate that endosome-mediated trafficking of MR1 allows for selective sampling of the intracellular environment.
C1 [Harriff, Melanie J.; Karamooz, Elham; Burr, Ansen; Sorensen, Michelle L.; Lewinsohn, David M.] Portland VA Med Ctr, Portland, OR 97239 USA.
[Harriff, Melanie J.; Karamooz, Elham; Grant, Wilmon F.; Canfield, Elizabeth T.; Lewinsohn, David M.] Oregon Hlth & Sci Univ, Pulm & Crit Care Med, Portland, OR 97201 USA.
[Moita, Luis F.] Inst Gulbenkian Ciencias, Oeiras, Portugal.
[Lewinsohn, David M.] Oregon Hlth & Sci Univ, Mol Microbiol & Immunol, Portland, OR 97201 USA.
RP Harriff, MJ (reprint author), Portland VA Med Ctr, Portland, OR 97239 USA.; Harriff, MJ (reprint author), Oregon Hlth & Sci Univ, Pulm & Crit Care Med, Portland, OR 97201 USA.
EM harriffm@ohsu.edu; lewinsod@ohsu.edu
OI Moita, Luis/0000-0003-0707-315X
FU Career Development Award from the U.S. Department of Veterans Affairs
Clinical Sciences Research and Development Program [IK2 CX000538]; U.S.
Department of Veterans Affairs Biomedical Laboratory Research and
Development Program [I01 BX000533]; American Lung Association
[RT-350058]
FX This work was supported in part by Career Development Award #IK2
CX000538 from the U.S. Department of Veterans Affairs Clinical Sciences
Research and Development Program (MJH) and in part by Merit Award #I01
BX000533 from the U.S. Department of Veterans Affairs Biomedical
Laboratory Research and Development Program (DML). EK also received
support from the American Lung Association (RT-350058). The funders had
no role in the study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 34
TC 2
Z9 2
U1 4
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD MAR
PY 2016
VL 12
IS 3
AR e1005524
DI 10.1371/journal.ppat.1005524
PG 19
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA DP0CH
UT WOS:000378154800039
PM 27031111
ER
PT J
AU Bowhay-Carnes, EA
Lee, S
Datta, P
AF Bowhay-Carnes, Elizabeth Ann
Lee, Shuko
Datta, Paromita
TI Evaluation of leukocytosis: Benign or malignant.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT ASCO Quality Care Symposium
CY FEB 26-27, 2016
CL Phoenix, AZ
SP Amer Soc Clin Oncol
C1 Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
South Texas Vet Hlth Care Syst, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2016
VL 34
IS 7
SU S
MA 245
PG 1
WC Oncology
SC Oncology
GA DO9ME
UT WOS:000378109900236
ER
PT J
AU Clarke, CA
Baker, LC
Malin, J
Parker, J
Holliday-Hanson, M
Fong, N
Teleki, S
Lang, L
O'Sullivan, M
AF Clarke, Christina A.
Baker, Laurence C.
Malin, Jennifer
Parker, Joseph
Holliday-Hanson, Merry
Fong, Niya
Teleki, Stephanie
Lang, Lance
O'Sullivan, Maryann
TI Creating an online resource providing hospital cancer surgery volumes in
California.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT ASCO Quality Care Symposium
CY FEB 26-27, 2016
CL Phoenix, AZ
SP Amer Soc Clin Oncol
C1 Canc Prevent Inst Calif, Fremont, CA USA.
Stanford Univ, Palo Alto, CA 94304 USA.
VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
Calif Off Statewide Hlth Planning & Dev, Sacramento, CA USA.
Calif HealthCare Fndtn, Oakland, CA USA.
Calif Qual Collaborat, Berkeley, CA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2016
VL 34
IS 7
SU S
MA 172
PG 1
WC Oncology
SC Oncology
GA DO9ME
UT WOS:000378109900168
ER
PT J
AU Kaplan, MS
Huguet, N
McFarland, BH
Caetano, R
Conner, KR
Nolte, KB
Giesbrecht, N
AF Kaplan, Mark S.
Huguet, Nathalie
McFarland, Bentson H.
Caetano, Raul
Conner, Kenneth R.
Nolte, Kurt B.
Giesbrecht, Norman
TI Heavy Alcohol Use Among Suicide Decedents: Differences in Risk Across
Racial-Ethnic Groups
SO PSYCHIATRIC SERVICES
LA English
DT Editorial Material
ID UNITED-STATES
C1 [Kaplan, Mark S.] Univ Calif Los Angeles, Luskin Sch Publ Affairs, Los Angeles, CA 90095 USA.
[Huguet, Nathalie; McFarland, Bentson H.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Caetano, Raul] Pacific Inst Res & Evaluat, Oakland, CA USA.
[Conner, Kenneth R.] US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, Canandaigua, NY USA.
[Conner, Kenneth R.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA.
[Nolte, Kurt B.] Univ New Mexico, Albuquerque, NM 87131 USA.
[Giesbrecht, Norman] Ctr Addict & Mental Hlth, Toronto, ON, Canada.
RP Kaplan, MS (reprint author), Univ Calif Los Angeles, Luskin Sch Publ Affairs, Los Angeles, CA 90095 USA.
EM kaplanm@luskin.ucla.edu
FU National Institute on Alcohol Abuse and Alcoholism [R01-AA020063]
FX This research was supported by the National Institute on Alcohol Abuse
and Alcoholism (grant R01-AA020063).
NR 2
TC 2
Z9 2
U1 0
U2 0
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
EI 1557-9700
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD MAR
PY 2016
VL 67
IS 3
BP 258
EP 258
DI 10.1176/appi.ps.201500494
PG 1
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA DO4TI
UT WOS:000377776600002
PM 26725300
ER
PT J
AU Harrington, AT
Black, JA
Clarridge, JE
AF Harrington, Amanda T.
Black, Jennifer A.
Clarridge, Jill E., III
TI In Vitro Activity of Retapamulin and Antimicrobial Susceptibility
Patterns in a Longitudinal Collection of Methicillin-Resistant
Staphylococcus aureus Isolates from a Veterans Affairs Medical Center
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID MUPIROCIN RESISTANCE; COLONIZATION; DECOLONIZATION; PLEUROMUTILIN;
EPIDEMIOLOGY; INHIBITION; INFECTION; OINTMENT
AB Mupirocin is a topical antimicrobial used to decolonize patients who carry methicillin-resistant Staphylococcus aureus (MRSA), and the topical agent retapamulin may be a potential alternative therapy. The goal of this study was to determine the in vitro activity of retapamulin as well as a panel of 15 antimicrobial agents, including mupirocin, for 403 MRSA isolates collected longitudinally from a naive population at the Veterans Affairs Puget Sound Health Care System. The MICs for retapamulin had a unimodal distribution, ranging from 0.008 to 0.5 mu g/ml. One isolate had an MIC of > 16 mu g/ml, was also resistant to clindamycin and erythromycin, and was recovered from the nares of a patient undergoing hemodialysis. Twenty-four isolates (6%) and 11 isolates (3%) demonstrated low-level resistance (MICs of 8 to 64 mu g/ml) and high-level resistance (MICs of> 512 mu g/ml), respectively, to mupirocin. Isolates were recovered from 10 patients both before and after mupirocin therapy. Of those, isolates from 2 patients demonstrated MIC changes postmupirocin therapy; in both cases, however, strain typing demonstrated that the pre and postmupirocin strains were different. A total of 386 isolates (96%) had vancomycin MICs of <= 1.0 mu g/ml; 340 isolates (84%) were resistant to levofloxacin, 18 isolates (4.5%) were resistant to trimethoprim-sulfamethoxazole, and 135 isolates (33%) had elevated MICs of 4 mu g/ml for linezolid. The baseline levels of resistance were low for mupirocin (9%) and even lower for retapamulin (0.25%) Although the use of mupirocin is currently the standard therapy for decolonization practices, the activity of retapamulin warrants its consideration as an alternative therapy in MRSA decolonization regimens.
C1 [Harrington, Amanda T.; Clarridge, Jill E., III] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Harrington, Amanda T.; Black, Jennifer A.; Clarridge, Jill E., III] Univ Washington, Seattle, WA 98195 USA.
[Harrington, Amanda T.] Univ Illinois, Chicago, IL USA.
RP Harrington, AT (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA USA.; Harrington, AT (reprint author), Univ Illinois, Chicago, IL USA.
EM harria@uic.edu
FU North Carolina GlaxoSmithKline Foundation
FX North Carolina GlaxoSmithKline Foundation provided funding to Amanda T.
Harrington.
NR 24
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD MAR
PY 2016
VL 60
IS 3
BP 1298
EP 1303
DI 10.1128/AAC.01568-15
PG 6
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA DM6VM
UT WOS:000376490800016
ER
PT J
AU Shields, RK
Nguyen, MH
Press, EG
Cumbie, R
Driscoll, E
Pasculle, AW
Clancy, CJ
AF Shields, Ryan K.
Nguyen, M. Hong
Press, Ellen G.
Cumbie, Richard
Driscoll, Eileen
Pasculle, A. William
Clancy, Cornelius J.
TI Rate of FKS Mutations among Consecutive Candida Isolates Causing
Bloodstream Infection (vol 59, pg 7465, 2015)
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Correction
C1 [Shields, Ryan K.; Nguyen, M. Hong; Press, Ellen G.; Clancy, Cornelius J.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
[Shields, Ryan K.; Nguyen, M. Hong; Clancy, Cornelius J.] Univ Pittsburgh, Med Ctr, XDR Pathogen Lab, Pittsburgh, PA USA.
[Cumbie, Richard; Driscoll, Eileen; Pasculle, A. William] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA.
[Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Shields, RK (reprint author), Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.; Shields, RK (reprint author), Univ Pittsburgh, Med Ctr, XDR Pathogen Lab, Pittsburgh, PA USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD MAR
PY 2016
VL 60
IS 3
BP 1954
EP 1954
DI 10.1128/AAC.00183-16
PG 1
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA DM6VM
UT WOS:000376490800110
PM 26921416
ER
PT J
AU Yao, JK
Dougherty, GG
Gautier, CH
Haas, GL
Condray, R
Kasckow, JW
Kisslinger, BL
Gurklis, JA
Messamore, E
AF Yao, Jeffrey K.
Dougherty, George G., Jr.
Gautier, Clara H.
Haas, Gretchen L.
Condray, Ruth
Kasckow, John W.
Kisslinger, Benjamin L.
Gurklis, John A.
Messamore, Erik
TI Prevalence and Specificity of the Abnormal Niacin Response: A Potential
Endophenotype Marker in Schizophrenia
SO SCHIZOPHRENIA BULLETIN
LA English
DT Article
DE niacin-induced flush response; laser Doppler flowmeter; EC50; maximal
blood flow; bipolar disorder; phospholipid-arachidonate-eicosanoid
signaling
ID SKIN FLUSH RESPONSE; NICOTINIC-ACID; ARACHIDONIC-ACID; FATTY-ACIDS;
PHOSPHOLIPASE-A2 ACTIVITY; LANGERHANS CELLS; ABSENT RESPONSE; TOPICAL
NIACIN; CHALLENGE TEST; PATHWAY
AB The skin flush response to niacin is abnormally blunted among a subset of patients with schizophrenia (SZ), preferentially associates with SZ compared to other mental illnesses, occurs frequently in nonpsychotic members of SZ-affected families, appears heritable, and shows evidence of genetic association. The niacin response abnormality (NRA) may prove to be a useful SZ endophenotype. Using a laser Doppler flowmeter, we undertook this study to estimate the prevalence of NRA in SZ (n = 70), bipolar disorder (BP, n = 59), and healthy control (HC, n = 87) groups, and to estimate its specificity for the illness. From the dose-response curves, we calculated the concentration of methylnicotinate required to elicit a half-maximal blood flow (MBF) response (EC50 value) and MBF value for each subject. The median log(10) EC50 of the SZ was above the third quartile of log(10)EC(50) of either the HC or BP groups, whereas the MBF was significantly lower in the SZ than in the HC or BP groups. With a definition of NRA of having both EC50 above the ninetieth percentile of the control samples and MBF response below the sixtieth percentile for the control range, the NRA predicted SZ with 31% sensitivity and 97% specificity. Moreover, the NRA was not influenced by age, gender, race, and cigarette smoking. In summary, the NRA may define a SZ subtype with a clinically significant phospholipid signaling defect. Understanding its molecular origins may shed light on the pathophysiology of SZ and suggest new tools for its early diagnosis and treatment.
C1 [Yao, Jeffrey K.; Dougherty, George G., Jr.; Gautier, Clara H.; Haas, Gretchen L.; Condray, Ruth; Kasckow, John W.; Kisslinger, Benjamin L.; Gurklis, John A.] VA Pittsburgh Healthcare Syst, Med Res Serv, Pittsburgh, PA 15240 USA.
[Yao, Jeffrey K.; Dougherty, George G., Jr.; Haas, Gretchen L.; Kasckow, John W.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA.
[Yao, Jeffrey K.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA.
[Messamore, Erik] Univ Cincinnati, Dept Psychiat, Cincinnati, OH USA.
[Messamore, Erik] Lindner Ctr Hope, Cincinnati, OH USA.
RP Yao, JK (reprint author), VA Pittsburgh Healthcare Syst, B1-2E-140,Univ Dr C, Pittsburgh, PA 15240 USA.
EM jkyao@pitt.edu
FU Department of Veterans Affairs [1I01CX000110]; Senior Research Career
Scientist Award; VA VISN4 Mental Illness Research, Education and
Clinical Center (MIRECC); VA Pittsburgh Healthcare System
FX This work was supported in part by Department of Veterans Affairs (Merit
Reviews 1I01CX000110 and Senior Research Career Scientist Award to J K
Y); VA VISN4 Mental Illness Research, Education and Clinical Center
(MIRECC Director: D. Oslin; Associate Director: G. Haas); and the VA
Pittsburgh Healthcare System.
NR 36
TC 1
Z9 1
U1 3
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2016
VL 42
IS 2
BP 369
EP 376
DI 10.1093/schbul/sbv130
PG 8
WC Psychiatry
SC Psychiatry
GA DM5PG
UT WOS:000376401500014
PM 26371338
ER
PT J
AU Li, QW
Zhan, M
Chen, W
Zhao, BP
Yang, K
Yang, J
Yi, J
Huang, QH
Mohan, M
Hou, ZY
Wang, J
AF Li, Qiwei
Zhan, Ming
Chen, Wei
Zhao, Benpeng
Yang, Kai
Yang, Jie
Yi, Jing
Huang, Qihong
Mohan, Man
Hou, Zhaoyuan
Wang, Jian
TI Phenylethyl isothiocyanate reverses cisplatin resistance in biliary
tract cancer cells via glutathionylation-dependent degradation of Mcl-1
SO ONCOTARGET
LA English
DT Article
DE biliary tract cancer; PEITC; cisplatin; Mcl-1; glutathionylation
ID SIDE POPULATION CELLS; MILD OXIDATIVE STRESS; MRP1 DOWN-REGULATION;
GALLBLADDER CANCER; MEDIATED MECHANISM; DRUG-RESISTANCE; PLATINUM DRUGS;
LUNG-CANCER; STEM-CELLS; EMODIN
AB Biliary tract cancer (BTC) is a highly malignant cancer. BTC exhibits a low response rate to cisplatin (CDDP) treatment, and therefore, an understanding of the mechanism of CDDP resistance is urgently needed. Here, we show that BTC cells develop CDDP resistance due, in part, to upregulation of myeloid cell leukemia 1 (Mcl-1). Phenylethyl isothiocyanate (PEITC), a natural compound found in watercress, could enhance the efficacy of CDDP by degrading Mcl-1. PEITC-CDDP co-treatment also increased the rate of apoptosis of cancer stem-like side population (SP) cells and inhibited xenograft tumor growth without obvious toxic effects. In vitro, PEITC decreased reduced glutathione (GSH), which resulted in decreased GSH/oxidized glutathione (GSSG) ratio and increased glutathionylation of Mcl-1, leading to rapid proteasomal degradation of Mcl-1. Furthermore, we identified Cys16 and Cys286 as Mcl-1 glutathionylation sites, and mutating them resulted in PEITC-mediated degradation resistant Mcl-1 protein. In conclusion, we demonstrate for the first time that CDDP resistance is partially associated with Mcl-1 in BTC cells and we identify a novel mechanism that PEITC can enhance CDDP-induced apoptosis via glutathionylation-dependent degradation of Mcl-1. Hence, our results provide support that dietary intake of watercress may help reverse CDDP resistance in BTC patients.
C1 [Li, Qiwei; Zhan, Ming; Chen, Wei; Wang, Jian] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Biliary Pancreat Surg, Shanghai 200030, Peoples R China.
[Zhao, Benpeng; Yang, Kai; Yang, Jie; Yi, Jing; Mohan, Man; Hou, Zhaoyuan] Shanghai Jiao Tong Univ, Shanghai Key Lab Tumor Microenvironment & Inflamm, Dept Biochem & Mol Cell Biol, Inst Med Sci,Sch Med, Shanghai 200030, Peoples R China.
[Huang, Qihong] Univ Penn, Wistar Inst, Philadelphia, PA 19104 USA.
[Huang, Qihong] Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Wang, J (reprint author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Biliary Pancreat Surg, Shanghai 200030, Peoples R China.
EM dr_wangjian@126.com
FU National Natural Science Foundation of China [81072011]; National Key
Technology R D Program [2012BAI06B01]; Shanghai Science and Technology
Fund [12XD1403400]; Shanghai Municipal Public Health Bureau, China
[XBR2011035]
FX This work was supported by grants from National Natural Science
Foundation of China (81072011, J. Wang), National Key Technology R & D
Program (2012BAI06B01, J. Wang), Shanghai Science and Technology Fund
(12XD1403400, J. Wang) and Shanghai Municipal Public Health Bureau,
China (XBR2011035, J. Wang).
NR 45
TC 1
Z9 1
U1 0
U2 1
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAR 1
PY 2016
VL 7
IS 9
BP 10271
EP 10282
PG 12
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA DL5JI
UT WOS:000375672900050
PM 26848531
ER
PT J
AU Blosnich, JR
Marsiglio, MC
Gao, SS
Gordon, AJ
Shipherd, JC
Kauth, M
Brown, GR
Fine, MJ
AF Blosnich, John R.
Marsiglio, Mary C.
Gao, Shasha
Gordon, Adam J.
Shipherd, Jillian C.
Kauth, Michael
Brown, George R.
Fine, Michael J.
TI Mental Health of Transgender Veterans in US States With and Without
Discrimination and Hate Crime Legal Protection
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID SEXUAL MINORITY VETERANS; STRUCTURAL STIGMA; BISEXUAL POPULATIONS; CARE
UTILIZATION; UNITED-STATES; GAY; SUICIDE; PEOPLE; VIOLENCE; RISK
AB Objectives. To examine whether indicators of community-and state-level lesbian, gay, bisexual, and transgender equality are associated with transgender veterans' mental health.
Methods. We extracted Veterans Administration data for patients who were diagnosed with gender identity disorder, had at least 1 visit in 2013, and lived in a zip code with a Municipality Equality Index score (n = 1640). We examined the associations of whether a state included transgender status in employment nondiscrimination laws and in hate crimes laws with mood disorders; alcohol, illicit drug, and tobacco use disorders; posttraumatic stress disorder; and suicidal ideation or attempt.
Results. Nearly half (47.3%) of the sample lived in states with employment discrimination protection, and 44.8% lived in states with hate crimes protection. Employment nondiscrimination protection was associated with 26% decreased odds of mood disorders (adjusted odds ratio [AOR] = 0.74; 95% confidence interval [CI] = 0.59, 0.93) and 43% decreased odds of self-directed violence (AOR = 0.57; 95% CI = 0.34, 0.95).
Conclusions. Understanding lesbian, gay, bisexual, and transgender social stressors can inform treatment and care coordination for transgender populations.
C1 [Blosnich, John R.; Gao, Shasha; Gordon, Adam J.; Kauth, Michael] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Univ Dr C 151C U,Bldg 30, Pittsburgh, PA 15240 USA.
[Marsiglio, Mary C.] Portland VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Portland, OR USA.
[Shipherd, Jillian C.; Kauth, Michael] VA Off Patient Care Serv, Dept Vet Affairs, Washington, DC USA.
[Brown, George R.] Mt Home VA Med Ctr, Mountain Home, TN USA.
RP Blosnich, JR (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Univ Dr C 151C U,Bldg 30, Pittsburgh, PA 15240 USA.
EM John.blosnich@va.gov
FU Department of Veterans Affairs (VA) Office of Academic Affiliations;
Center for Health Equity Research and Promotion at the VA Pittsburgh
Healthcare System; VA Health Service Research and Development [LIP
72-077, LIP 72-080]
FX This work was supported by a postdoctoral fellowship through the
Department of Veterans Affairs (VA) Office of Academic Affiliations and
the Center for Health Equity Research and Promotion at the VA Pittsburgh
Healthcare System (to J. R. B) and by the VA Health Service Research and
Development (awards LIP 72-077 and LIP 72-080).
NR 46
TC 0
Z9 0
U1 7
U2 15
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD MAR
PY 2016
VL 106
IS 3
BP 534
EP 540
DI 10.2105/AJPH.2015.302981
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DL2EA
UT WOS:000375444800031
PM 26794162
ER
PT J
AU Hedayati, SS
Daniel, DM
Cohen, S
Comstock, B
Cukor, D
Diaz-Linhart, Y
Dember, LM
Dubovsky, A
Greene, T
Grote, N
Heagerty, P
Katon, W
Kimmel, PL
Kutner, N
Linke, L
Quinn, D
Rue, T
Trivedi, MH
Unruh, M
Weisbord, S
Young, BA
Mehrotra, R
AF Hedayati, S. Susan
Daniel, Divya M.
Cohen, Scott
Comstock, Bryan
Cukor, Daniel
Diaz-Linhart, Yaminette
Dember, Laura M.
Dubovsky, Amelia
Greene, Tom
Grote, Nancy
Heagerty, Patrick
Katon, Wayne
Kimmel, Paul L.
Kutner, Nancy
Linke, Lori
Quinn, Davin
Rue, Tessa
Trivedi, Madhukar H.
Unruh, Mark
Weisbord, Steven
Young, Bessie A.
Mehrotra, Rajnish
TI Rationale and design of A Trial of Sertraline vs. Cognitive Behavioral
Therapy for End-stage Renal Disease Patients with Depression (ASCEND)
SO CONTEMPORARY CLINICAL TRIALS
LA English
DT Article
DE End Stage Renal Disease (ESRD); Hemodialysis; Depression; Engagement
interview; Cognitive behavioral therapy (CBT); Sertraline
ID QUALITY-OF-LIFE; CHRONIC KIDNEY-DISEASE; CHRONIC-HEMODIALYSIS PATIENTS;
INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; PERITONEAL-DIALYSIS PATIENTS;
MAJOR DEPRESSION; PRACTICE PATTERNS; ANTIDEPRESSANT TREATMENT;
PSYCHOSOCIAL FACTORS; NUTRITIONAL-STATUS
AB Major Depressive Disorder (MDD) is highly prevalent in patients with End Stage Renal Disease (ESRD) treated with maintenance hemodialysis (HD). Despite the high prevalence and robust data demonstrating an independent association between depression and poor clinical and patient-reported outcomes, MDD is under-treated when identified in such patients. This may in part be due to the paucity of evidence confirming the safety and efficacy of treatments for depression in this population. It is also unclear whether HD patients are interested in receiving treatment for depression. ASCEND (Clinical Trials Identifier Number NCT02358343),A Trial of Sertraline vs. Cognitive Behavioral Therapy (CBT) for End-stage Renal Disease Patients with Depression, was designed as a multi-center, 12-week, open-label, randomized, controlled trial of prevalent HD patients with comorbid MDD or dysthymia. It will compare (1) a single Engagement Interview vs. a control visit for the probability of initiating treatment for comorbid depression in up to 400 patients; and (2) individual chair-side CBT vs. flexible-dose treatment with a selective serotonin reuptake inhibitor, sertraline, for improvement of depressive symptoms in 180 of the up to 400 patients. The evolution of depressive symptoms will also be examined in a prospective longitudinal cohort of 90 HD patients who choose not to be treated for depression. We discuss the rationale and design of ASCEND, the first large-scale randomized controlled trial evaluating efficacy of non-pharmacologic vs. pharmacologic treatment of depression in HD patients for patient-centered outcomes. Published by Elsevier Inc.
C1 [Hedayati, S. Susan] VA North Texas Hlth Care Syst, Renal Sect, Dallas, TX 75216 USA.
[Hedayati, S. Susan] Univ Texas Southwestern Med Ctr, Div Nephrol, Dallas, TX 75390 USA.
[Daniel, Divya M.; Linke, Lori; Young, Bessie A.; Mehrotra, Rajnish] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA.
[Cohen, Scott] George Washington Univ, Div Nephrol, Washington, DC 20052 USA.
[Comstock, Bryan; Heagerty, Patrick; Rue, Tessa] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA.
[Cukor, Daniel] Suny Downstate Med Ctr, Dept Psychiat, Brooklyn, NY 11203 USA.
[Diaz-Linhart, Yaminette] Boston Univ, Sch Med, Boston Med Ctr, Boston, MA 02215 USA.
[Dember, Laura M.] Univ Penn, Div Nephrol, Philadelphia, PA 19104 USA.
[Dubovsky, Amelia; Katon, Wayne] Univ Washington, Dept Psychiat, Seattle, WA 98195 USA.
[Greene, Tom] Univ Utah, Salt Lake City, UT 84112 USA.
[Grote, Nancy] Univ Washington, Sch Social Work, Seattle, WA 98195 USA.
[Kutner, Nancy] Emory Univ, Atlanta, GA 30322 USA.
[Quinn, Davin] Univ New Mexico, Dept Psychiat, Albuquerque, NM 87131 USA.
[Trivedi, Madhukar H.] Univ Texas Southwestern Med Ctr, Dept Psychiat, Dallas, TX 75390 USA.
[Unruh, Mark] Univ New Mexico, Div Nephrol, Albuquerque, NM 87131 USA.
[Weisbord, Steven] VA Pittsburgh Healthcare Syst, Div Nephrol, Pittsburgh, PA USA.
[Weisbord, Steven] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA.
RP Hedayati, SS (reprint author), VA North Texas Hlth Care Syst, Nephrol Sect, MC 111G1,4500 South Lancaster Rd, Dallas, TX 75216 USA.
EM susan.hedayati@va.gov
FU Dialysis Clinic, Inc.
FX There are no financial disclosures other than listed: Mark Unruh
receives research support from Dialysis Clinic, Inc.
NR 84
TC 4
Z9 4
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1551-7144
EI 1559-2030
J9 CONTEMP CLIN TRIALS
JI Contemp. Clin. Trials
PD MAR
PY 2016
VL 47
BP 1
EP 11
DI 10.1016/j.cct.2015.11.020
PG 11
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA DK0MM
UT WOS:000374606900001
PM 26621218
ER
PT J
AU Marriott, BP
Hibbeln, JR
Killeen, TK
Magruder, KM
Holes-Lewis, K
Tolliver, BK
Turner, TH
AF Marriott, Bernadette P.
Hibbeln, Joseph R.
Killeen, Therese K.
Magruder, Kathryn M.
Holes-Lewis, Kelly
Tolliver, Bryan K.
Turner, Travis H.
CA BRAVO Grp
TI Design and methods for the Better Resiliency Among Veterans and
non-Veterans with Omega-3's (BRAVO) study: A double blind,
placebo-controlled trial of omega-3 fatty acid supplementation among
adult individuals at risk of suicide
SO CONTEMPORARY CLINICAL TRIALS
LA English
DT Article
DE Suicide; Omega-3 fatty acids; Adults
ID FATTY-ACIDS; DIETARY SUPPLEMENTATION; MAJOR DEPRESSION; BEHAVIOR; SCALE;
VALIDATION; MILITARY; DISORDER; IDEATION; ALCOHOL
AB Suicide remains the 10th leading cause of death among adults in the United States (U.S.). Annually, approximately 30 per 100,000 U.S. military Veterans commit suicide, compared to 14 per 100,000 U.S. civilians. Symptoms associated with suicidality can be treatment resistant and proven-effective pharmaceuticals may have adverse side-effects. Thus, a critical need remains to identify effective approaches for building psychological resiliency in at-risk individuals. Omega-3 highly unsaturated fatty acids (n-3 HUFAs) are essential nutrients, which must be consumed in the diet. N-3 HUFAs have been demonstrated to reduce symptoms of depression, anxiety, and impulsivity which are associated with suicide risk. Here we present the design and methods for the Better Resiliency Among Veterans and non-Veterans with Omega-3's (BRAVO) study, which is a double blind, randomized, controlled trial among individuals at risk of suicide of an n-3 HUFA versus placebo supplementation in the form of all natural fruit juice beverages. The BRAVO study seeks to determine if dietary supplementation with n-3 HUFAs reduces the risk for serious suicidal behaviors, suicidal thinking, negative emotions, and symptoms associated with suicide risk. Sub-analyses will evaluate efficacy in reducing depressive symptoms, alcohol, and nicotine use. A sub-study utilizes functional magnetic resonance imaging (JMRI) to evaluate the neuropsychological and neurophysiological effects of n-3 HUFAs. We also outline selection of appropriate proxy outcome measures for detecting response to treatment and collection of ancillary data, such as diet and substance use, that are critical for interpretation of results. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Marriott, Bernadette P.] Med Univ S Carolina, Div Gastroenterol & Hepatol, Dept Med, Nutr Sect,Coll Med, 114 Doughty St,Ste 630D,MSC774, Charleston, SC 29425 USA.
[Marriott, Bernadette P.] Med Univ S Carolina, Mil Div, Dept Psychiat, Coll Med, 114 Doughty St,Ste 630D,MSC774, Charleston, SC 29425 USA.
[Hibbeln, Joseph R.] NIAAA, Sect Nutr Neurosci, LMBB, NIH, 5625 Fishers Lane,Rm 3N-07,MSC 9410, Bethesda, MD 20892 USA.
[Killeen, Therese K.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Addict Sci Div, 67 President St,POB 25086, Charleston, SC 29425 USA.
[Magruder, Kathryn M.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Dept Publ Hlth Sci, Mil Sci Div,Div Epidemiol,Off Res Integr, 109 Bee St, Charleston, SC 29401 USA.
[Holes-Lewis, Kelly] Med Univ S Carolina, Dept Psychiat & Behav Sci, Div Brain Res & Integrat Neuropsychopharmacol, 67 President St, Charleston, SC 29425 USA.
[Tolliver, Bryan K.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Div Addict Sci, 67 President St, Charleston, SC 29425 USA.
[Turner, Travis H.] Ralph H Johnson VAMC, 109 Bee St, Charleston, SC 29410 USA.
[Turner, Travis H.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Dept Neurosci Neurol, 67 President St, Charleston, SC 29425 USA.
RP Marriott, BP (reprint author), Med Univ S Carolina, Div Gastroenterol & Hepatol, Dept Med, 114 Doughty St,Suite 629,MSC 774, Charleston, SC 29425 USA.
EM marriobp@musc.edu
FU Department of Defense (DoD), U.S. Army Medical Research and Materiel
Command (USAMRMC), Congressionally Directed Medical Research Programs
(CDMRP) through the U.S. Army Medical Research Acquisition Authority
(USAMRAA) [W81XWH-13-2-0015]; National Institute on Alcohol Abuse and
Alcoholism
FX The BRAVO study is sponsored by award # W81XWH-13-2-0015 from the
Department of Defense (DoD), U.S. Army Medical Research and Materiel
Command (USAMRMC), Congressionally Directed Medical Research Programs
(CDMRP) through the U.S. Army Medical Research Acquisition Authority
(USAMRAA). The intramural program of the National Institute on Alcohol
Abuse and Alcoholism also provides support for this study. The BRAVO
study team wishes to acknowledge the excellent-support of Samantha Wise
in all aspects of the study. The DoD or its representatives had no role
in the study design; in the collection, analysis and interpretation of
data; in the writing of the report; or in the decision to submit the
article for publication. All views and opinions expressed herein are
those of the authors and do not necessarily reflect the funding agency.
NR 49
TC 1
Z9 1
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1551-7144
EI 1559-2030
J9 CONTEMP CLIN TRIALS
JI Contemp. Clin. Trials
PD MAR
PY 2016
VL 47
BP 325
EP 333
DI 10.1016/j.cct.2016.02.002
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA DK0MM
UT WOS:000374606900042
PM 26855120
ER
PT J
AU VanEpps, EM
Downs, JS
Loewenstein, G
AF VanEpps, Eric M.
Downs, Julie S.
Loewenstein, George
TI Calorie Label Formats: Using Numeric and Traffic Light Calorie Labels to
Reduce Lunch Calories
SO JOURNAL OF PUBLIC POLICY & MARKETING
LA English
DT Article
DE calorie labeling; traffic light labeling; nutrition; online decision
making; field experiment
ID FRONT-OF-PACKAGE; BODY-MASS INDEX; FOOD CHOICE; NUTRITION; INFORMATION;
OBESITY; CONSUMPTION; CONVENIENCE; INTENTIONS; CONSUMERS
AB In a field experiment involving online workplace lunch orders, this study examines the impact of numeric and traffic light calorie labels on calorie intake. Employees of a large corporation ordered lunches through a website of the authors' design, on which they were presented menus with numeric calorie labels, traffic light labels, or both together, and the authors compared the calorie content of the ordered lunches with that of diners randomized to receive no calorie information. Each label type reduced lunch calories by approximately 10%. Nutrition knowledge was not improved by any menu format. Traffic light labels achieved meaningful reductions in calories ordered even in the absence of numeric information, and the authors found no apparent benefit or detriment of combining label types. These findings suggest that consumers may benefit most from help in identifying relatively healthier choices but rely little on information about the exact caloric content of items.
C1 [VanEpps, Eric M.] Univ Penn, VA Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA.
[Downs, Julie S.] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA.
[Loewenstein, George] Carnegie Mellon Univ, Econ & Psychol, Pittsburgh, PA 15213 USA.
RP VanEpps, EM (reprint author), Univ Penn, VA Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA.; Downs, JS (reprint author), Carnegie Mellon Univ, Pittsburgh, PA 15213 USA.; Loewenstein, G (reprint author), Carnegie Mellon Univ, Econ & Psychol, Pittsburgh, PA 15213 USA.
EM vanepps@mail.med.upenn.edu; downs@cmu.edu; gl20@andrew.cmu.edu
NR 52
TC 2
Z9 2
U1 11
U2 18
PU AMER MARKETING ASSOC
PI CHICAGO
PA 311S WACKER DR, STE 5800, CHICAGO, IL 60606-6629 USA
SN 0743-9156
EI 1547-7207
J9 J PUBLIC POLICY MARK
JI J. Public Policy Mark.
PD SPR
PY 2016
VL 35
IS 1
BP 26
EP 36
DI 10.1509/jppm.14.112
PG 11
WC Business
SC Business & Economics
GA DL8EY
UT WOS:000375874600003
ER
PT J
AU Kahi, CJ
Boland, CR
Dominitz, JA
Giardiello, FM
Johnson, DA
Kaltenbach, T
Lieberman, D
Levin, TR
Robertson, DJ
Rex, DK
AF Kahi, Charles J.
Boland, C. Richard
Dominitz, Jason A.
Giardiello, Francis M.
Johnson, David A.
Kaltenbach, Tonya
Lieberman, David
Levin, Theodore R.
Robertson, Douglas J.
Rex, Douglas K.
TI Colonoscopy Surveillance after Colorectal Cancer Resection:
Recommendations of the US Multi-Society Task Force on Colorectal Cancer
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
ID EARLY RECTAL-CANCER; TRANSANAL ENDOSCOPIC MICROSURGERY; COMPUTED
TOMOGRAPHIC COLONOGRAPHY; CONTRAST BARIUM ENEMA; FOLLOW-UP STRATEGIES;
COLLEGE-OF-RADIOLOGY; CURATIVE RESECTION; CT COLONOGRAPHY; LOCAL
EXCISION; RADICAL SURGERY
AB The US Multi-Society Task Force has developed updated recommendations to guide health care providers with the surveillance of patients after colorectal cancer (CRC) resection with curative intent. This document is based on a critical review of the literature regarding the role of colonoscopy, flexible sigmoidoscopy, endoscopic ultrasound, fecal testing and CT colonography in this setting. The document addresses the effect of surveillance, with focus on colonoscopy, on patient survival after CRC resection, the appropriate use and timing of colonoscopy for perioperative clearing and for postoperative prevention of metachronous CRC, specific considerations for the detection of local recurrence in the case of rectal cancer, as well as the place of CT colonography and fecal tests in post-CRC surveillance.
C1 [Kahi, Charles J.] Richard L Roudebush VA Med Ctr, Indianapolis, IN USA.
[Kahi, Charles J.; Rex, Douglas K.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
[Boland, C. Richard] Baylor Univ, Med Ctr Dallas, Dallas, TX USA.
[Dominitz, Jason A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Dominitz, Jason A.] Univ Washington, Sch Med, Seattle, WA USA.
[Giardiello, Francis M.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Johnson, David A.] Eastern VA Med Sch, Norfolk, VA USA.
[Kaltenbach, Tonya] Vet Affairs Palo Alto, Palo Alto, CA USA.
[Kaltenbach, Tonya] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA.
[Lieberman, David] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Levin, Theodore R.] Kaiser Permanente Med Ctr, Walnut Creek, CA USA.
[Robertson, Douglas J.] VA Med Ctr, White River Jct, VT USA.
[Robertson, Douglas J.] Geisel Sch Med Dartmouth, Hanover, NH USA.
RP Kahi, CJ (reprint author), Indiana Univ Sch Med, Richard L Roudebush VA Med Ctr, 1481 W 10th St,111G, Indianapolis, IN 46202 USA.
EM ckahi2@iu.edu
NR 122
TC 1
Z9 1
U1 3
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD MAR
PY 2016
VL 111
IS 3
BP 337
EP 346
DI 10.1038/ajg.2016.22
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DL1OB
UT WOS:000375400500014
PM 26871541
ER
PT J
AU Lowry, EA
Greninger, DA
Porco, TC
Naseri, A
Stamper, RL
Han, Y
AF Lowry, Eugene A.
Greninger, Daniel A.
Porco, Travis C.
Naseri, Ayman
Stamper, Robert L.
Han, Ying
TI A Comparison of Resident-performed Argon and Selective Laser
Trabeculoplasty in Patients With Open-angle Glaucoma
SO JOURNAL OF GLAUCOMA
LA English
DT Article
DE laser trabeculoplasty; resident education; glaucoma; ALT; SLT
ID TRIAL
AB Purpose: To compare intraocular pressure (IOP) reduction and complications of resident-performed argon laser trabeculoplasty (ALT) and selective laser trabeculoplasty (SLT).
Patients and Methods: This was a retrospective, interventional, comparative case series performed at the San Francisco Veterans Affairs Hospital. The study included 77 patients each undergoing 1 resident-performed ALT procedure from April 2006 through November 2009, and 81 patients each undergoing 1 resident-performed SLT procedure from November 2009 through December 2011. Reduction in IOP at 12 months and a longitudinal analysis across 24 months was determined. Secondary outcomes investigated included additional interventions of either repeat trabeculoplasty or trabeculectomy as well as change in eye drop medications.
Results: There was no evidence of a difference between IOP reductions in patients undergoing ALT compared with SLT at 12 months (P=0.41, linear modeling) or across all follow-up appointments (P=0.62, linear-mixed effects regression). Patients undergoing ALT had a significantly increased number of eye drops (+ 0.6 vs. -0.1 drops, P<0.001, Wilcoxon rank-sum test) and trend toward increased rates of additional interventions (P=0.06, Weibull regression). There was no difference in immediate post-procedure IOP rise between the 2 groups (P=0.75, Wilcoxon rank-sum test) or any evidence of change in visual acuity.
Conclusions: We found no difference in IOP reduction between patients undergoing resident-performed ALT compared with SLT. However, patients undergoing ALT had a significant increase in eye drop medications and trend toward additional interventions compared with patients undergoing SLT.
C1 [Lowry, Eugene A.; Greninger, Daniel A.; Porco, Travis C.; Naseri, Ayman; Stamper, Robert L.; Han, Ying] Univ Calif San Francisco, Dept Ophthalmol, 10 Koret Way, San Francisco, CA 94143 USA.
[Porco, Travis C.; Naseri, Ayman; Han, Ying] Univ Calif San Francisco, Francis I Proctor Fdn, 10 Koret Way, San Francisco, CA 94143 USA.
[Porco, Travis C.] Univ Calif San Francisco, Dept Epidemiol & Biostat, Div Prevent Med & Publ Hlth, 10 Koret Way, San Francisco, CA 94143 USA.
[Naseri, Ayman; Stamper, Robert L.; Han, Ying] San Francisco VA Med Ctr, Dept Ophthalmol, San Francisco, CA USA.
[Greninger, Daniel A.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Portland, OR 97201 USA.
RP Han, Y (reprint author), Univ Calif San Francisco, Dept Ophthalmol, 10 Koret Way, San Francisco, CA 94143 USA.
EM ying.han@ucsf.edu
NR 23
TC 1
Z9 1
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1057-0829
EI 1536-481X
J9 J GLAUCOMA
JI J. Glaucoma
PD MAR
PY 2016
VL 25
IS 3
BP E157
EP E161
DI 10.1097/IJG.0000000000000207
PG 5
WC Ophthalmology
SC Ophthalmology
GA DK3MO
UT WOS:000374821000007
PM 25651207
ER
PT J
AU Mitchell, NS
Prochazka, AV
Glasgow, RE
AF Mitchell, Nia S.
Prochazka, Allan V.
Glasgow, Russell E.
TI Time to RE-AIM: Why Community Weight Loss Programs Should Be Included in
Academic Obesity Research
SO PREVENTING CHRONIC DISEASE
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; DIABETES PREVENTION PROGRAM; UNITED-STATES;
INTERVENTION; PREVALENCE; REDUCTION; CHILDHOOD; HEALTH; CARE
AB Despite decades of efficacy-based research on weight loss interventions, the obesity epidemic in the United States persists, especially in underserved populations. We used the RE-AIM (Reach, Efficacy/Effectiveness, Adoption, Implementation, and Maintenance) framework to describe the limitations of the current paradigm of efficacy-based research for weight loss interventions. We also used RE-AIM to propose that existing weight loss interventions (community-based programs) such as Jenny Craig, Take Off Pounds Sensibly (TOPS), and Weight Watchers be studied to supplement the efficacy-based research approaches to achieve population-level impact on obesity.
C1 [Mitchell, Nia S.] Univ Colorado, Div Gen Internal Med, Anschutz Hlth & Wellness Ctr, Adult & Child Consortium Hlth Outcomes Res & Deli, Anschutz Med Campus,Mail Stop C263, Aurora, CO 80045 USA.
[Prochazka, Allan V.] Denver VA Med Ctr, Denver, CO USA.
[Prochazka, Allan V.] Univ Colorado, Anschutz Med Coll, Aurora, CO USA.
[Glasgow, Russell E.] Univ Colorado, Anschutz Med Campus, Aurora, CO USA.
RP Mitchell, NS (reprint author), Univ Colorado, Div Gen Internal Med, Anschutz Hlth & Wellness Ctr, Adult & Child Consortium Hlth Outcomes Res & Deli, Anschutz Med Campus,Mail Stop C263, Aurora, CO 80045 USA.
EM Nia.Mitchell@ucdenver.edu
NR 23
TC 1
Z9 1
U1 0
U2 2
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-1151
J9 PREV CHRONIC DIS
JI Prev. Chronic Dis.
PD MAR
PY 2016
VL 13
AR 150436
DI 10.5888/pcd13.150436
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DK8UG
UT WOS:000375203200008
ER
PT J
AU O'Toole, TP
Johnson, EE
Aiello, R
Kane, V
Pape, L
AF O'Toole, Thomas P.
Johnson, Erin E.
Aiello, Riccardo
Kane, Vincent
Pape, Lisa
TI Tailoring Care to Vulnerable Populations by Incorporating Social
Determinants of Health: the Veterans Health Administration's "Homeless
Patient Aligned Care Team" Program
SO PREVENTING CHRONIC DISEASE
LA English
DT Article
ID EMERGENCY-DEPARTMENT VISITS; MEDICAL-CARE; ADULTS; SERVICES; MODEL;
MORTALITY; ACCESS; BOSTON; COSTS; NEEDS
AB Introduction
Although the clinical consequences of homelessness are well described, less is known about the role for health care systems in improving clinical and social outcomes for the homeless. We described the national implementation of a "homeless medical home" initiative in the Veterans Health Administration (VHA) and correlated patient health outcomes with characteristics of high-performing sites.
Methods
We conducted an observational study of 33 VHA facilities with homeless medical homes and patient-aligned care teams that served more than 14,000 patients. We correlated site-specific health care performance data for the 3,543 homeless veterans enrolled in the program from October 2013 through March 2014, including those receiving ambulatory or acute health care services during the 6 months prior to enrollment in our study and 6 months post-enrollment with corresponding survey data on the Homeless Patient Aligned Care Team (H-PACT) program implementation. We defined high performance as high rates of ambulatory care and reduced use of acute care services.
Results
More than 96% of VHA patients enrolled in these programs were concurrently receiving VHA homeless services. Of the 33 sites studied, 82% provided hygiene care (on-site showers, hygiene kits, and laundry), 76% provided transportation, and 55% had an onsite clothes pantry; 42% had a food pantry and provided on-site meals or other food assistance. Six-month patterns of acute-care use pre-enrollment and post-enrollment for 3,543 consecutively enrolled patients showed a 19.0% reduction in emergency department use and a 34.7% reduction in hospitalizations. Three features were significantly associated with high performance: 1) higher staffing ratios than other sites, 1) integration of social supports and social services into clinical care, and 3) outreach to and integration with community agencies.
Conclusion
Integrating social determinants of health into clinical care can be effective for high-risk homeless veterans.
C1 [O'Toole, Thomas P.] Providence VA Med Ctr, Natl Ctr Homelessness Vet, 830 Chalkstone Ave, Providence, RI 02909 USA.
[Johnson, Erin E.; Aiello, Riccardo; Kane, Vincent; Pape, Lisa] US Dept Vet Affairs, Natl Ctr Homelessness Vet, Off Homeless Programs, Providence, RI USA.
[Kane, Vincent] Lebanon VA Med Ctr, Lebanon, NH USA.
RP O'Toole, TP (reprint author), Providence VA Med Ctr, Natl Ctr Homelessness Vet, 830 Chalkstone Ave, Providence, RI 02909 USA.
EM Thomas.OToole@va.gov
FU VHA National Center on Homelessness Among Veterans
FX The authors report no conflicts of interest. This project was internally
supported by VHA National Center on Homelessness Among Veterans as part
of its ongoing program evaluation efforts. Dr O'Toole is also affiliated
with Warren Alpert Medical School at Brown University and with the
Providence VA Medical Center.
NR 29
TC 2
Z9 2
U1 3
U2 13
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-1151
J9 PREV CHRONIC DIS
JI Prev. Chronic Dis.
PD MAR
PY 2016
VL 13
AR 150567
DI 10.5888/pcd13.150567
PG 12
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DK8UG
UT WOS:000375203200015
ER
PT J
AU Zhao, HS
Carney, KE
Falgoust, L
Pan, JW
Sun, DD
Zhang, ZL
AF Zhao, Hanshu
Carney, Karen E.
Falgoust, Lindsay
Pan, Jullie W.
Sun, Dandan
Zhang, Zhongling
TI Emerging roles of Na+/H+ exchangers in epilepsy and developmental brain
disorders
SO PROGRESS IN NEUROBIOLOGY
LA English
DT Review
DE ADHD; Autism; Excitability; NHE1; NHE6; NHE9
ID CARBONIC-ANHYDRASE-II; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT
HYPERACTIVITY DISORDER; GAMMA-AMINOBUTYRIC-ACID; CENTRAL-NERVOUS-SYSTEM;
COUPLED BICARBONATE TRANSPORTERS; CATION-CHLORIDE COTRANSPORTERS;
CULTURED HIPPOCAMPAL-NEURONS; LINKED MENTAL-RETARDATION; ANGELMAN-LIKE
SYNDROME
AB Epilepsy is a common central nervous system (CNS) disease characterized by recurrent transient neurological events occurring due to abnormally excessive or synchronous neuronal activity in the brain. The CNS is affected by systemic acid-base disorders, and epileptic seizures are sensitive indicators of underlying imbalances in cellular pH regulation. Na+/H+ exchangers (NHEs) are a family of membrane transporter proteins actively involved in regulating intracellular and organellar pH by extruding H+ in exchange for Na+ influx. Altering NHE function significantly influences neuronal excitability and plays a role in epilepsy. This review gives an overview of pH regulatory mechanisms in the brain with a special focus on the NHE family and the relationship between epilepsy and dysfunction of NHE isoforms. We first discuss how cells translocate acids and bases across the membrane and establish pH homeostasis as a result of the concerted effort of enzymes and ion transporters. We focus on the specific roles of the NHE family by detailing how the loss of NHE1 in two NHE mutant mice results in enhanced neuronal excitability in these animals. Furthermore, we highlight new findings on the link between mutations of NHE6 and NHE9 and developmental brain disorders including epilepsy, autism, and attention deficit hyperactivity disorder (ADHD). These studies demonstrate the importance of NHE proteins in maintaining H+ homeostasis and their intricate roles in the regulation of neuronal function. A better understanding of the mechanisms underlying NHE1, 6, and 9 dysfunctions in epilepsy formation may advance the development of new epilepsy treatment strategies. Published by Elsevier Ltd.
C1 [Zhao, Hanshu; Zhang, Zhongling] Harbin Med Univ, Dept Neurol, Affiliated Hosp 1, 23 You Zheng St, Harbin 150001, Heilongjiang Pr, Peoples R China.
[Zhao, Hanshu; Carney, Karen E.; Falgoust, Lindsay; Pan, Jullie W.; Sun, Dandan] Univ Pittsburgh, Dept Neurol, S-598 South Biomed Sci Tower BST,3500 Terrance St, Pittsburgh, PA 15213 USA.
[Sun, Dandan] Ctr Geriatr Res Educ & Clin, Vet Affairs Pittsburgh Hlth Care Syst, Pittsburgh, PA 15213 USA.
RP Zhang, ZL (reprint author), Harbin Med Univ, Dept Neurol, Affiliated Hosp 1, 23 You Zheng St, Harbin 150001, Heilongjiang Pr, Peoples R China.; Sun, DD (reprint author), Univ Pittsburgh, Dept Neurol, S-598 South Biomed Sci Tower BST,3500 Terrance St, Pittsburgh, PA 15213 USA.
EM sund@upmc.edu; zhangzhongling@outlook.com
FU NIH [R01NS048216]
FX The research was supported by NIH R01NS048216 (DS).
NR 227
TC 6
Z9 6
U1 1
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0301-0082
EI 1873-5118
J9 PROG NEUROBIOL
JI Prog. Neurobiol.
PD MAR-MAY
PY 2016
VL 138
BP 19
EP 35
DI 10.1016/j.pneurobio.2016.02.002
PG 17
WC Neurosciences
SC Neurosciences & Neurology
GA DK4VZ
UT WOS:000374919700002
PM 26965387
ER
PT J
AU Gibson, CJ
Gray, KE
Katon, JG
Simpson, TL
Lehavot, K
AF Gibson, Carolyn J.
Gray, Kristen E.
Katon, Jodie G.
Simpson, Tracy L.
Lehavot, Keren
TI Sexual Assault, Sexual Harassment, and Physical Victimization during
Military Service across Age Cohorts of Women Veterans
SO WOMENS HEALTH ISSUES
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH; ADMINISTRATION
OUTPATIENTS; FEMALE VETERANS; TRAUMA; PREVALENCE; RISK; SYMPTOMATOLOGY;
ASSOCIATION; SOLDIERS
AB Objectives: Exposure to sexual and physical trauma during military service is associated with adverse mental and physical health outcomes. Little is known about their prevalence and impact in women veterans across age cohorts.
Methods: Data from a 2013 national online survey of women veterans was used to examine associations between age and trauma during military service, including sexual assault, sexual harassment, and physical victimization. Analyses were conducted using logistic regression, adjusting for service duration and demographic factors. In secondary analyses, the moderating role of age in the relationship between trauma and self-reported health was examined.
Results: The sample included 781 women veterans. Compared with the oldest age group (>= 65), all except the youngest age group had consistently higher odds of reporting trauma during military service. These differences were most pronounced in women aged 45 to 54 years (sexual assault odds ratio [OR], 3.81 [95% CI, 2.77-6.71]; sexual harassment, OR, 3.99 [95% CI, 2.25-7.08]; and physical victimization, OR, 5.72 [95% CI, 3.32-9.85]). The association between trauma during military service and self-reported health status also varied by age group, with the strongest negative impact observed among women aged 45 to 54 and 55 to 64.
Conclusions: Compared with other age groups, women in midlife were the most likely to report trauma during military service, and these experiences were associated with greater negative impact on their self-reported health. Providers should be aware that trauma during military service may be particularly problematic for the cohort of women currently in midlife, who represent the largest proportion of women who use Department of Veterans Affairs health care. Published by Elsevier Inc. on behalf of the Jacobs Institute of Women's Health.
C1 [Gibson, Carolyn J.] San Francisco VA Med Ctr, Med Serv Line, San Francisco, CA USA.
[Gray, Kristen E.; Katon, Jodie G.; Lehavot, Keren] Dept Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
[Gray, Kristen E.; Katon, Jodie G.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA.
[Katon, Jodie G.] Dept Vet Affairs, Vet Hlth Adm, Off Patient Care Serv, Womens Hlth Serv, Washington, DC USA.
[Simpson, Tracy L.; Lehavot, Keren] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Simpson, Tracy L.; Lehavot, Keren] VA Puget Sound Hlth Care Syst, MIRECC, Seattle, WA USA.
[Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, CESATE, Seattle, WA USA.
RP Gibson, CJ (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA.
EM Carolyn.Gibson2@va.gov
FU VSN-20 Mental Illness, Research, Education, and Clinical Center
(MIRECC); VA Career Development Award from CSRD [1K2 CX000867]
FX This research was supported by funding from the VSN-20 Mental Illness,
Research, Education, and Clinical Center (MIRECC) to Drs. Lehavot and
Simpson. Dr. Lehavot was supported by a VA Career Development Award from
CSR&D (1K2 CX000867).
NR 36
TC 1
Z9 1
U1 4
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1049-3867
EI 1878-4321
J9 WOMEN HEALTH ISS
JI Womens Health Iss.
PD MAR-APR
PY 2016
VL 26
IS 2
BP 225
EP 231
DI 10.1016/j.whi.2015.09.013
PG 7
WC Public, Environmental & Occupational Health; Women's Studies
SC Public, Environmental & Occupational Health; Women's Studies
GA DK6TJ
UT WOS:000375058000014
PM 26632005
ER
PT J
AU Cucciare, MA
Lewis, ET
Hoggatt, KJ
Bean-Mayberry, B
Timko, C
Durazo, EM
Jamison, AL
Frayne, SM
AF Cucciare, Michael A.
Lewis, Eleanor T.
Hoggatt, Katherine J.
Bean-Mayberry, Bevanne
Timko, Christine
Durazo, Eva M.
Jamison, Andrea L.
Frayne, Susan M.
TI Factors Affecting Women's Disclosure of Alcohol Misuse in Primary Care:
A Qualitative Study with US Military Veterans
SO WOMENS HEALTH ISSUES
LA English
DT Article
ID SUBSTANCE-ABUSE; PATIENT-RELATIONSHIP; USE DISORDERS; HEALTH;
IMPLEMENTATION; INTERVENTIONS; AFGHANISTAN; DRINKING; THERAPY; AUDIT
AB Background: One in five women veterans screens positive for alcohol misuse. Women may be less likely than men to disclose alcohol use to a primary care provider (PCP), resulting in women being less likely to receive effective interventions. We sought to qualitatively examine factors that may affect women veterans' willingness to disclose alcohol use to a PCP.
Methods: Between October 2012 and May 2013, in-depth interviews were conducted with 30 women veterans at two Department of Veterans Affairs (VA) medical facilities. Qualitative data analyses identified common themes representing factors that influence women's decision to disclose alcohol use to a PCP.
Findings: Nine themes were endorsed by women veterans as influencing their willingness to disclose alcohol use to their PCP. Themes included provider behaviors perceived as encouraging or discouraging disclosure of alcohol misuse, perceived positive relationship with provider, negative emotions such as concerns about being judged or labeled an "alcoholic," health concerns about drinking, non-health-related concerns about drinking, self-appraisal of drinking behavior, social support, and clinic factors.
Conclusions: Our findings demonstrate the importance of social relationships, comfort with one's provider, and education on the potential harms (especially health related) associated with alcohol in encouraging disclosure of alcohol use in women veterans. Our results also support VA national health care efforts, including the provision of brief alcohol counseling and the use of primary care clinics specializing in the care of women veterans. Published by Elsevier Inc. on behalf of the Jacobs Institute of Women's Health.
C1 [Cucciare, Michael A.] Cent Arkansas Vet Affairs Healthcare Syst, Ctr Mental Healthcare & Outcomes Res, Little Rock, AR USA.
[Cucciare, Michael A.] Cent Arkansas Vet Healthcare Syst, VA South Cent VISN Mental Illness Res Educ & Clin, 2200 Ft Roots Dr, Little Rock, AR 72205 USA.
[Cucciare, Michael A.] Univ Arkansas Med Sci, Dept Psychiat, Little Rock, AR 72205 USA.
[Lewis, Eleanor T.; Timko, Christine; Durazo, Eva M.; Jamison, Andrea L.; Frayne, Susan M.] VA Palo Alto Healthcare Syst, Ctr Innovat Implementat, Menlo Pk, CA USA.
[Hoggatt, Katherine J.; Bean-Mayberry, Bevanne] VA Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Innovat Implementat & Policy, Sepulveda, CA USA.
[Hoggatt, Katherine J.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA USA.
[Bean-Mayberry, Bevanne] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Timko, Christine] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA.
[Frayne, Susan M.] VA Palo Alto Hlth Care Syst, Womens Hlth Serv, Palo Alto, CA USA.
[Frayne, Susan M.] Stanford Univ, Sch Med, Div Gen Med Disciplines, Stanford, CA 94305 USA.
RP Cucciare, MA (reprint author), Cent Arkansas Vet Healthcare Syst, Ctr Mental Healthcare & Outcomes Res, 2200 Ft Roots Dr, North Little Rock, AR 72205 USA.
EM macucciare@uams.edu
FU Rapid Response Project by the VA Substance Use Disorder Quality
Enhancement Research Initiative [RRP 11-436]; Department of Veterans
Affairs (VA) Health Services Research and Development (HSRD) Service
[CDA 08-004, RCS 00-001]; VA HSR&D QUERI Career Development Award at the
VA Greater Los Angeles [CDA 11-261]
FX This research was supported by a Rapid Response Project (RRP 11-436) to
Dr. Cucciare by the VA Substance Use Disorder Quality Enhancement
Research Initiative. This research was also supported by a Career
Development Award-2 (CDA 08-004) to Dr. Cucciare, and by a Senior
Research Career Scientist Award (RCS 00-001) to Dr. Timko, by the
Department of Veterans Affairs (VA) Health Services Research and
Development (HSR&D) Service. Dr. Hoggatt is funded through a VA HSR&D
QUERI Career Development Award (CDA 11-261) at the VA Greater Los
Angeles. The views expressed in this article are those of the authors
and do not necessarily reflect the position or policy of the Department
of Veterans Affairs or the United States government. There are no
financial conflicts to disclose.
NR 34
TC 2
Z9 2
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1049-3867
EI 1878-4321
J9 WOMEN HEALTH ISS
JI Womens Health Iss.
PD MAR-APR
PY 2016
VL 26
IS 2
BP 232
EP 239
DI 10.1016/j.whi.2015.07.010
PG 8
WC Public, Environmental & Occupational Health; Women's Studies
SC Public, Environmental & Occupational Health; Women's Studies
GA DK6TJ
UT WOS:000375058000015
PM 26341569
ER
PT J
AU Ellingson, LD
Stegner, AJ
Schwabacher, IJ
Koltyn, KF
Cook, DB
AF Ellingson, Laura D.
Stegner, Aaron J.
Schwabacher, Isaac J.
Koltyn, Kelli F.
Cook, Dane B.
TI Exercise Strengthens Central Nervous System Modulation of Pain in
Fibromyalgia
SO BRAIN SCIENCES
LA English
DT Article
DE modulation; exercise; chronic pain; imaging; fibromyalgia
ID SMOKING-RELATED IMAGES; PHYSICAL-ACTIVITY; HEALTHY-INDIVIDUALS;
CIGARETTE CRAVINGS; ISOMETRIC-EXERCISE; RESPONSE FUNCTION; BRAIN
ACTIVATION; FUNCTIONAL MRI; HEART-RATE; WOMEN
AB To begin to elucidate the mechanisms underlying the benefits of exercise for chronic pain, we assessed the influence of exercise on brain responses to pain in fibromyalgia (FM). Complete data were collected for nine female FM patients and nine pain-free controls (CO) who underwent two functional neuroimaging scans, following exercise (EX) and following quiet rest (QR). Brain responses and pain ratings to noxious heat stimuli were compared within and between groups. For pain ratings, there was a significant (p < 0.05) Condition by Run interaction characterized by moderately lower pain ratings post EX compared to QR (d = 0.39-0.41) for FM but similar to ratings in CO (d = 0.10-0.26), thereby demonstrating that exercise decreased pain sensitivity in FM patients to a level that was analogous to pain-free controls. Brain responses demonstrated a significant within-group difference in FM patients, characterized by less brain activity bilaterally in the anterior insula following QR as compared to EX. There was also a significant Group by Condition interaction with FM patients showing less activity in the left dorsolateral prefrontal cortex following QR as compared to post-EX and CO following both conditions. These results suggest that exercise appeared to stimulate brain regions involved in descending pain inhibition in FM patients, decreasing their sensitivity to pain. Thus, exercise may benefit patients with FM via improving the functional capacity of the pain modulatory system.
C1 [Ellingson, Laura D.] Iowa State Univ, Dept Kinesiol, Ames, IA 50011 USA.
[Stegner, Aaron J.; Schwabacher, Isaac J.; Cook, Dane B.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53706 USA.
[Stegner, Aaron J.; Schwabacher, Isaac J.; Koltyn, Kelli F.; Cook, Dane B.] Univ Wisconsin, Dept Kinesiol, Madison, WI 53706 USA.
RP Ellingson, LD (reprint author), Iowa State Univ, Dept Kinesiol, Ames, IA 50011 USA.
EM ellingl@iastate.edu; astegner@wisc.edu; ischwabacher@wisc.edu;
kelli.koltyn@wisc.edu; dane.cook@wisc.edu
OI Cook, Dane/0000-0002-3992-4820
NR 43
TC 3
Z9 3
U1 2
U2 3
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 2076-3425
EI 2976-3425
J9 BRAIN SCI
JI Brain Sci.
PD MAR
PY 2016
VL 6
IS 1
AR 8
DI 10.3390/brainsci6010008
PG 13
WC Neurosciences
SC Neurosciences & Neurology
GA DJ2QC
UT WOS:000374048900007
ER
PT J
AU Giardina, TD
Sarkar, U
Gourley, G
Modi, V
Meyer, AND
Singh, H
AF Giardina, Traber Davis
Sarkar, Urmimala
Gourley, Gato
Modi, Varsha
Meyer, Ashley N. D.
Singh, Hardeep
TI Online public reactions to frequency of diagnostic errors in US
outpatient care
SO DIAGNOSIS
LA English
DT Article
DE diagnostic error burden; public perceptions
ID PATIENT SAFETY; INTERVENTIONS
AB Background: Diagnostic errors pose a significant threat to patient safety but little is known about public perceptions of diagnostic errors. A study published in BMJ Quality & Safety in 2014 estimated that diagnostic errors affect at least 5% of US adults (or 12 million) per year. We sought to explore online public reactions to media reports on the reported frequency of diagnostic errors in the US adult population.
Methods: We searched the World Wide Web for any news article reporting findings from the study. We then gathered all the online comments made in response to the news articles to evaluate public reaction to the newly reported diagnostic error frequency (n = 241). Two coders conducted content analyses of the comments and an experienced qualitative researcher resolved differences.
Results: Overall, there were few comments made regarding the frequency of diagnostic errors. However, in response to the media coverage, 44 commenters shared personal experiences of diagnostic errors. Additionally, commentary centered on diagnosis-related quality of care as affected by two emergent categories: (1) US health care providers (n = 79; 63 commenters) and (2) US health care reform-related policies, most commonly the Affordable Care Act (ACA) and insurance/reimbursement issues (n = 62; 47 commenters).
Conclusion: The public appears to have substantial concerns about the impact of the ACA and other reform initiatives on the diagnosis-related quality of care. However, policy discussions on diagnostic errors are largely absent from the current national conversation on improving quality and safety. Because outpatient diagnostic errors have emerged as a major safety concern, researchers and policymakers should consider evaluating the effects of policy and practice changes on diagnostic accuracy.
C1 [Giardina, Traber Davis] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr 152, Houston VA HSR&D Ctr Innovat, 2002 Holcombe Blvd, Houston, TX 77030 USA.
[Giardina, Traber Davis; Modi, Varsha; Meyer, Ashley N. D.; Singh, Hardeep] Baylor Coll Med, Sect Hlth Serv Res, Dept Med, 2002 Holcombe Blvd, Houston, TX 77030 USA.
[Sarkar, Urmimala; Gourley, Gato] San Francisco Gen Hosp, UCSF Ctr Vulnerable Populat, San Francisco, CA 94110 USA.
[Sarkar, Urmimala; Gourley, Gato] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Div Gen Internal Med, San Francisco, CA USA.
[Modi, Varsha; Meyer, Ashley N. D.; Singh, Hardeep] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston VA HSR&D Ctr Innovat, Houston, TX 77030 USA.
RP Giardina, TD (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr 152, Houston VA HSR&D Ctr Innovat, 2002 Holcombe Blvd, Houston, TX 77030 USA.; Giardina, TD (reprint author), Baylor Coll Med, Sect Hlth Serv Res, Dept Med, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM Traberd@bcm.edu
FU AHRQ HHS [P30 HS023558, R01 HS022087, R21 HS023602]; NCI NIH HHS [K23
CA125585]
NR 34
TC 0
Z9 0
U1 2
U2 4
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 2194-8011
EI 2194-802X
J9 DIAGNOSIS
JI Diagnosis
PD MAR
PY 2016
VL 3
IS 1
BP 17
EP 22
DI 10.1515/dx-2015-0022
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA DJ3LI
UT WOS:000374106300004
PM 27347474
ER
PT J
AU Fritz, JM
Rundell, SD
Dougherty, P
Gentili, A
Kochersberger, G
Morone, NE
Raja, SN
Rodriguez, E
Rossi, MI
Shega, J
Sowa, G
Weiner, DK
AF Fritz, Julie M.
Rundell, Sean D.
Dougherty, Paul
Gentili, Angela
Kochersberger, Gary
Morone, Natalia E.
Raja, Srinivasa Naga
Rodriguez, Eric
Rossi, Michelle I.
Shega, Joseph
Sowa, Gwendolyn
Weiner, Debra K.
TI Deconstructing Chronic Low Back Pain in the Older Adult-Step by Step
Evidence and Expert-Based Recommendations for Evaluation and Treatment.
Part VI: Lumbar Spinal Stenosis
SO PAIN MEDICINE
LA English
DT Article
DE Aged; Assessment; Lumbar Spinal Stenosis; Spinal Stenosis; Chronic Pain;
Elderly; Low Back Pain; Primary Care; Chronic Low Back Pain
ID UNITED-STATES TRENDS; PHYSICAL-THERAPY; NATURAL-HISTORY; SURGERY;
DIAGNOSIS; OSTEOARTHRITIS; COMPLICATIONS; METAANALYSIS; MANAGEMENT;
INJECTIONS
AB Methods. The evaluation and treatment algorithm, a table articulating the rationale for the individual algorithm components, and stepped-care drug recommendations were developed using a modified Delphi approach. The Principal Investigator, a five-member content expert panel and a nine-member primary care panel were involved in the iterative development of these materials. The illustrative clinical case was taken from the clinical practice of a contributor's colleague (SR).
Results. We present an algorithm and supportive materials to help guide the care of older adults with LSS, a condition that occurs not uncommonly in those with CLBP. The case illustrates the importance of function-focused management and a rational approach to conservative care.
Conclusions. Lumbar spinal stenosis exists not uncommonly in older adults with CLBP and management often can be accomplished without surgery. Treatment should address all conditions in addition to LSS contributing to pain and disability.
C1 [Fritz, Julie M.] Univ Utah, Dept Phys Therapy, Salt Lake City, UT USA.
[Fritz, Julie M.] Univ Utah, Coll Hlth, Salt Lake City, UT USA.
[Rundell, Sean D.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA.
[Dougherty, Paul; Kochersberger, Gary] Canandaigua VA Med Ctr, Canandaigua, NY USA.
[Dougherty, Paul] New York Chiropract Coll, Dept Res, Seneca Falls, NY USA.
[Dougherty, Paul; Kochersberger, Gary] Univ Rochester, Sch Med & Dent, Div Geriatr, Rochester, NY USA.
[Gentili, Angela] Hunter Holmes McGuire VA Med Ctr, Richmond, VA USA.
[Gentili, Angela] Virginia Commonwealth Univ Hlth Syst, Richmond, VA USA.
[Morone, Natalia E.; Rossi, Michelle I.; Weiner, Debra K.] Vet Affairs Pittsburgh Healthcare Syst, GRECC, Pittsburgh, PA USA.
[Morone, Natalia E.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Ctr Res Hlth Care, Pittsburgh, PA USA.
[Morone, Natalia E.; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Clin & Translat Sci Inst, Pittsburgh, PA USA.
[Rodriguez, Eric; Rossi, Michelle I.; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr Med, Pittsburgh, PA 15213 USA.
[Raja, Srinivasa Naga] Johns Hopkins Univ, Sch Med, Dept Anesthesiol, Baltimore, MD USA.
[Raja, Srinivasa Naga] Johns Hopkins Univ, Sch Med, Crit Care Med, Baltimore, MD USA.
[Raja, Srinivasa Naga] Johns Hopkins Univ, Sch Med, Div Pain Med, Baltimore, MD USA.
[Shega, Joseph] VITAS Healthcare, Miami, FL USA.
[Sowa, Gwendolyn] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA.
[Sowa, Gwendolyn] Univ Pittsburgh, Dept Orthoped Surg, Pittsburgh, PA USA.
[Sowa, Gwendolyn] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA.
[Weiner, Debra K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA.
[Weiner, Debra K.] Univ Pittsburgh, Dept Anesthesiolgoy, Pittsburgh, PA USA.
RP Weiner, DK (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr C,1A-118,Res Off Bldg, Pittsburgh, PA 15240 USA.
EM Debra.Weiner@va.gov
FU Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development, Rehabilitation Research and Development
Service
FX This material is based on work supported by the Department of Veterans
Affairs, Veterans Health Administration, Office of Research and
Development, Rehabilitation Research and Development Service.
NR 46
TC 1
Z9 1
U1 2
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1526-2375
EI 1526-4637
J9 PAIN MED
JI Pain Med.
PD MAR
PY 2016
VL 17
IS 3
BP 501
EP 510
DI 10.1093/pm/pnw011
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA DI8DL
UT WOS:000373731300009
PM 26962233
ER
PT J
AU Billings, CJ
Penman, TM
Ellis, EM
Baltzell, LS
McMillan, GP
AF Billings, Curtis J.
Penman, Tina M.
Ellis, Emily M.
Baltzell, Lucas S.
McMillan, Garnett P.
TI Phoneme and Word Scoring in Speech-in-Noise Audiometry
SO AMERICAN JOURNAL OF AUDIOLOGY
LA English
DT Article
ID MINI-MENTAL-STATE; HEARING-LOSS; ELDERLY LISTENERS; RECOGNITION; AGE;
DIFFICULTIES; PERCEPTION; DEFICITS; MASKING; LEVEL
AB Purpose: Understanding speech in background noise is difficult for many individuals; however, time constraints have limited its inclusion in the clinical audiology assessment battery. Phoneme scoring of words has been suggested as a method of reducing test time and variability. The purposes of this study were to establish a phoneme scoring rubric and use it in testing phoneme and word perception in noise in older individuals and individuals with hearing impairment.
Method: Words were presented to 3 participant groups at 80 dB in speech-shaped noise at 7 signal-to-noise ratios (-10 to 35 dB). Responses were scored for words and phonemes correct.
Results: It was not surprising to find that phoneme scores were up to about 30% better than word scores. Word scoring resulted in larger hearing loss effect sizes than phoneme scoring, whereas scoring method did not significantly modify age effect sizes. There were significant effects of hearing loss and some limited effects of age; age effect sizes of about 3 dB and hearing loss effect sizes of more than 10 dB were found.
Conclusion: Hearing loss is the major factor affecting word and phoneme recognition with a subtle contribution of age. Phoneme scoring may provide several advantages over word scoring. A set of recommended phoneme scoring guidelines is provided.
C1 [Billings, Curtis J.; Penman, Tina M.; Ellis, Emily M.; Baltzell, Lucas S.; McMillan, Garnett P.] Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, Portland, OR 97239 USA.
[Billings, Curtis J.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
RP Billings, CJ (reprint author), Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, Portland, OR 97239 USA.; Billings, CJ (reprint author), Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
EM billings2@va.gov
FU NIH/NIDCD [R03DC10914]; VA/RRD [C4844C, C8006W]
FX This work was supported by grants to the first author (NIH/NIDCD
R03DC10914; VA/RR&D C4844C and C8006W). The contents do not represent
the views of the U.S. Department of Veterans Affairs or the U.S.
Government. Participants provided informed consent, and research was
completed with the approval from the pertinent Institutional Review
Boards. Authors' contributions to this study include study design and
data collection (EE, LB, TP, and CB), analysis and interpretation of
data (GM, CB, and TP), and manuscript preparation (CB, TP, EE, LB, and
GM). The authors thank Melissa Papesh, Angela Eilbes, and Paul
Pendergraft for their contributions. Portions of these data were
presented in 2013 at the AudiologyNow! and the Joint Defense Veterans
Audiology Conference.
NR 32
TC 0
Z9 0
U1 0
U2 4
PU AMER SPEECH-LANGUAGE-HEARING ASSOC
PI ROCKVILLE
PA 10801 ROCKVILLE PIKE, ROCKVILLE, MD 20852-3279 USA
SN 1059-0889
EI 1558-9137
J9 AM J AUDIOL
JI Am. J. Audiol.
PD MAR
PY 2016
VL 25
IS 1
BP 75
EP 83
DI 10.1044/2016_AJA-15-0068
PG 9
WC Audiology & Speech-Language Pathology; Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Otorhinolaryngology
GA DI3VC
UT WOS:000373425600008
PM 26989823
ER
PT J
AU Rinne, ST
Liu, CF
Wong, ES
Hebert, PL
Heidenreich, P
Bastian, LA
Au, DH
AF Rinne, Seppo T.
Liu, Chuan-Fen
Wong, Edwin S.
Hebert, Paul L.
Heidenreich, Paul
Bastian, Lori A.
Au, David H.
TI Organizational Structure for Chronic Heart Failure and Chronic
Obstructive Pulmonary Disease
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID QUALITY-OF-CARE; ACUTE EXACERBATIONS; MATCHING-MICHIGAN; ADHERENCE;
HEALTH; PROGRAM; READMISSIONS; IMPROVEMENT; GUIDELINES; MANAGEMENT
AB Objectives: In contrast to chronic heart failure (CHF), measures of quality of care for chronic obstructive pulmonary disease (COPD) are poor. Our objective was to examine differences in organizational structure available to support quality of care for patients with CHF and COPD.
Study Design: We performed 2 nationwide surveys exploring organizational structure for the management of CHF and COPD. We surveyed the chief of medicine and the chief of cardiology and pulmonary medicine at 120 Veterans Affairs facilities in the United States.
Methods: Analogous questions about organizational structure that enhanced adherence to guideline-based care were compared between CHF and COPD surveys.
Results: We found large and notable differences in the organizational structure for disease management, with systematically less attention given to COPD than CHF. These differences were evident in multiple processes of care. Key differences included fewer facilities: having COPD clinics than CHF clinics (12.7% vs 50.8%; P <. 01), relating performance measures with COPD providers than CHF providers (17.1% vs 70%; P <. 01), and having home monitoring programs for COPD than for CHF (50.5% vs 87.4%; P <. 01).
Conclusions: Despite the growing burden of COPD, less organizational structure existed for COPD than CHF. Lack of organizational structure for COPD likely impedes an organization's abilities to encourage high-quality care and avoid recently implemented hospital readmission penalties. Our results suggest the need to develop a systematic approach for healthcare systems to provide essential organizational structure based on the burden of disease in the population.
C1 [Rinne, Seppo T.; Bastian, Lori A.] VA Connecticut Hlth Care Syst, Dept Vet Affairs, West Haven, CT USA.
[Rinne, Seppo T.] Yale Univ, Sect Pulm & Crit Care, Dept Internal Med, New Haven, CT USA.
[Liu, Chuan-Fen; Wong, Edwin S.; Hebert, Paul L.; Au, David H.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Dept Vet Affairs, Seattle, WA USA.
[Liu, Chuan-Fen; Wong, Edwin S.; Hebert, Paul L.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Au, David H.] Univ Washington, Dept Med, Div Pulm, Seattle, WA USA.
[Au, David H.] Univ Washington, Dept Med, Div Crit Care, Seattle, WA USA.
[Heidenreich, Paul] VA Palo Alto Hlth Care Syst, Hlth Res & Policy, Dept Vet Affairs, Palo Alto, CA USA.
[Bastian, Lori A.] Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT USA.
RP Au, DH (reprint author), 1100 Olive Way,Ste 1400, Seattle, WA 98104 USA.
EM David.Au@va.gov
FU Veterans Affairs clinical research grant [IIR-09-354]
FX Funding for this research was provided by a Veterans Affairs clinical
research grant IIR-09-354. The views expressed here are those of the
authors and do not necessarily reflect the position or policy of the
Department of Veterans Affairs.
NR 33
TC 1
Z9 1
U1 1
U2 2
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD MAR
PY 2016
VL 22
IS 3
BP E82
EP +
PG 8
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA DI5XL
UT WOS:000373573700001
PM 26978239
ER
PT J
AU Szul, T
Bratcher, PE
Fraser, KB
Kong, M
Tirouvanziam, R
Ingersoll, S
Sztul, E
Rangarajan, S
Blalock, JE
Xu, X
Gaggar, A
AF Szul, Tomasz
Bratcher, Preston E.
Fraser, Kyle B.
Kong, Michele
Tirouvanziam, Rabindra
Ingersoll, Sarah
Sztul, Elizabeth
Rangarajan, Sunil
Blalock, J. Edwin
Xu, Xin
Gaggar, Amit
TI Toll-Like Receptor 4 Engagement Mediates Prolyl Endopeptidase Release
from Airway Epithelia via Exosomes
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE protease; Toll-like receptor 4; exosome; cystic fibrosis; pulmonary
ID EXTRACELLULAR-MATRIX DEGRADATION; CELL-DERIVED EXOSOMES;
CYSTIC-FIBROSIS; NEUTROPHILIC INFLAMMATION; PROTEIN SECRETION; VESICLES;
LUNG; MICROVESICLES; TRAFFICKING; BIOGENESIS
AB Proteases are important regulators of pulmonary remodeling and airway inflammation. Recently, we have characterized the enzyme prolyl endopeptidase (PE), a serine peptidase, as a critical protease in the generation of the neutrophil chemoattractant tripeptide Pro-Gly-Pro (PGP) from collagen. However, PE has been characterized as a cytosolic enzyme, and the mechanism mediating PE release extracellularly remains unknown. We examined the role of exosomes derived from airway epithelia as a mechanism for PE release and the potential extracellular signals that regulate the release of these exosomes. We demonstrate a specific regulatory pathway of exosome release from airway epithelia and identify PE as novel exosome cargo. LPS stimulation of airway epithelial cells induces release of PE-containing exosomes, which is significantly attenuated by small interfering RNA depletion of Toll-like receptor 4 (TLR4). These differences were recapitulated upon intratracheal LPS administration in mice competent versus deficient for TLR4 signaling. Finally, sputum samples from subjects with cystic fibrosis colonized with Pseudomonas aeruginosa demonstrate elevated exosome content and increased PE levels. This TLR4-based mechanism highlights the first report of nonstochastic release of exosomes in the lung and couples TLR4 activation with matrikine generation. The increased quantity of these proteolytic exosomes in the airways of subjects with chronic lung disease highlights a new mechanism of injury and inflammation in the pathogenesis of pulmonary disorders.
C1 [Szul, Tomasz; Bratcher, Preston E.; Rangarajan, Sunil; Blalock, J. Edwin; Xu, Xin; Gaggar, Amit] Univ Alabama Birmingham, Dept Med, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA.
[Szul, Tomasz; Bratcher, Preston E.; Tirouvanziam, Rabindra; Blalock, J. Edwin; Xu, Xin; Gaggar, Amit] Univ Alabama Birmingham, Program Protease & Matrix Biol, Birmingham, AL 35294 USA.
[Fraser, Kyle B.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA.
[Kong, Michele] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL 35294 USA.
[Kong, Michele; Xu, Xin; Gaggar, Amit] Univ Alabama Birmingham, Gregory Fleming James Cyst Fibrosis Res Ctr, Birmingham, AL 35294 USA.
[Sztul, Elizabeth; Gaggar, Amit] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL 35294 USA.
[Blalock, J. Edwin; Gaggar, Amit] Univ Alabama Birmingham, Lung Hlth Ctr, Birmingham, AL 35294 USA.
[Tirouvanziam, Rabindra; Ingersoll, Sarah] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA.
[Tirouvanziam, Rabindra; Ingersoll, Sarah] Emory Univ, Emory Childrens Ctr Cyst Fibrosis & Airways Dis R, Atlanta, GA 30322 USA.
[Gaggar, Amit] Birmingham Vet Affairs Med Ctr, Med Serv, Birmingham, AL USA.
RP Gaggar, A (reprint author), Univ Alabama Birmingham, Dept Med, Div Pulm Allergy & Crit Care, Birmingham, AL 35294 USA.
EM agaggar1@uab.edu
FU American Heart Association postdoctoral fellowship; National Institutes
of Health training grant [5T32HL007457]; National Heart, Lung, and Blood
Institute [HL07783, HL090999, HL087824, HL102371]; Veterans
Administration grant [1 I01BX001756]; Ismail Moustapha Scholar Fund;
National Institutes of Health; Family Smoking Prevention and Tobacco
Control Act
FX This work was supported by an American Heart Association postdoctoral
fellowship (T.S.); by National Institutes of Health training grant
5T32HL007457; by National Heart, Lung, and Blood Institute grants
HL07783, HL090999, and HL087824 (J.E.B.) and HL102371 (A.G.); by
Veterans Administration grant 1 I01BX001756 (A.G.); and by the Ismail
Moustapha Scholar Fund (A.G.). Research reported in this publication was
supported by the National Institutes of Health and the Family Smoking
Prevention and Tobacco Control Act. The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the National Institutes of Health or the Food and Drug
Administration.
NR 44
TC 3
Z9 3
U1 2
U2 5
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD MAR
PY 2016
VL 54
IS 3
BP 359
EP 369
DI 10.1165/rcmb.2015-0108OC
PG 11
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA DI7UB
UT WOS:000373706400008
PM 26222144
ER
PT J
AU Herzig, MCS
Zavadil, JA
Street, K
Hildreth, K
Drinkwater, NR
Reddick, T
Herbert, DC
Hanes, MA
McMahan, CA
Reddick, RL
Walter, CA
AF Herzig, Maryanne C. S.
Zavadil, Jessica A.
Street, Karah
Hildreth, Kim
Drinkwater, Norman R.
Reddick, Traci
Herbert, Damon C.
Hanes, Martha A.
McMahan, C. Alex
Reddick, Robert L.
Walter, Christi A.
TI DNA Alkylating Agent Protects Against Spontaneous Hepatocellular
Carcinoma Regardless of O-6-Methylguanine-DNA Methyltransferase Status
SO CANCER PREVENTION RESEARCH
LA English
DT Article
ID LIVER-CANCER; TRANSGENIC MICE; UNITED-STATES; REPAIR;
HEPATOCARCINOGENESIS; RISK; CARCINOGENESIS; MUTAGENESIS; CULTURE; LINES
AB Hepatocellular carcinoma is increasingly important in the United States as the incidence rate rose over the last 30 years. C3HeB/FeJ mice serve as a unique model to study hepatocellular carcinoma tumorigenesis because they mimic human hepatocellular carcinoma with delayed onset, male gender bias, approximately 50% incidence, and susceptibility to tumorigenesis is mediated through multiple genetic loci. Because a human O-6-methylguanine-DNA methyltransferase (hMGMT) transgene reduces spontaneous tumorigenesis in this model, we hypothesized that hMGMT would also protect from methylation-induced hepatocarcinogenesis. To test this hypothesis, wild-type and hMGMT transgenic C3HeB/FeJ male mice were treated with two monofunctional alkylating agents: diethylnitrosamine (DEN; 0.025 mu mol/g body weight) on day 12 of life with evaluation for glucose-6-phosphatase-deficient (G6PD) foci at 16, 24, and 32 weeks or N-methyl-N-nitrosurea (MNU; 25 mg MNU/kg body weight) once monthly for 7 months starting at 3 months of age with evaluation for liver tumors at 12 to 15 months of age. No difference in abundance or size of G6PD foci was measured with DEN treatment. In contrast, it was unexpectedly found that MNU reduces liver tumor prevalence in wildtype and hMGMT transgenic mice despite increased tumor prevalence in other tissues. hMGMT and MNU protections were additive, suggesting that MNU protects through a different mechanism, perhaps through the cytotoxic N7-alkylguanine and N3-alkyladenine lesions which have low mutagenic potential compared with O-6-alkylguanine lesions. Together, these results suggest that targeting the repair of cytotoxic lesions may be a good preventative for patients at high risk of developing hepatocellular carcinoma. (C) 2015 AACR.
C1 [Herzig, Maryanne C. S.; Zavadil, Jessica A.; Hildreth, Kim; Herbert, Damon C.; Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, Mail Code 7762,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
[Street, Karah] Saddleback Coll, Mission Viejo, CA USA.
[Drinkwater, Norman R.] Univ Wisconsin Madison, McArdle Lab Canc Res, Madison, WI USA.
[Reddick, Traci] Duke Univ, Med Ctr, Transgen Mouse Facil, Durham, NC USA.
[Hanes, Martha A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Lab Anim Resources, San Antonio, TX 78229 USA.
[McMahan, C. Alex; Reddick, Robert L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Ctr Longev & Aging Studies, San Antonio, TX 78229 USA.
[Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio Canc Inst, San Antonio, TX 78229 USA.
[Walter, Christi A.] Audie Murphy Hosp, South Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Walter, CA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, Mail Code 7762,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM walter@uthscsa.edu
FU VA Merit grant; CPRIT Research Training Award [RP140105]; [P30
CA014520]
FX These studies were supported by a VA Merit grant to C.A. Walter and
CPRIT Research Training Award (RP140105) to J.A. Zavadil. The
histochemical staining for the G6PD studies was done by the Experimental
Pathology Core of the University of Wisconsin Carbone Cancer Center
Cancer Center supported by Grant P30 CA014520. The Ki67-staining
conducted by the Histology and Immunohistochemistry Laboratory of the
Department of Pathology at University of Texas Health Science Center San
Antonio.
NR 34
TC 0
Z9 0
U1 2
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1940-6207
EI 1940-6215
J9 CANCER PREV RES
JI Cancer Prev. Res.
PD MAR
PY 2016
VL 9
IS 3
BP 245
EP 252
DI 10.1158/1940-6207.CAPR-15-0251
PG 8
WC Oncology
SC Oncology
GA DI4BS
UT WOS:000373445800005
PM 26667451
ER
PT J
AU Inagami, S
Gao, SS
Karimi, H
Shendge, MM
Probst, JC
Stone, RA
AF Inagami, Sanae
Gao, Shasha
Karimi, Hassan
Shendge, Martine M.
Probst, Janice C.
Stone, Roslyn A.
TI Adapting the Index of Relative Rurality (IRR) to Estimate Rurality at
the ZIP Code Level: A Rural Classification System in Health Services
Research
SO JOURNAL OF RURAL HEALTH
LA English
DT Article
DE geography; health services research; index of relative rurality;
observational data; rural classification
ID URBAN; ACCESS; POLICY; AREAS; CARE
AB BackgroundAccurate analysis of health problems facing rural residents depends on how rurality is defined. Health services research relies frequently on the rural urban commuting area (RUCA) codes to estimate rurality at the small area level. We modified the county-level Index of Relative Rurality (IRR) to the ZIP code level (IRRZIP) to create an alternative small-area-level rural classification system. We then compared how the 2 rural classification systems differ in how rural areas and populations are defined and in methodological analysis.
MethodsWe linked data for veterans (n = 37,466) who attended the VA Pittsburgh Healthcare System to 2000 United States Census and the US Department of Agriculture's Economic Research Service data.
ResultsThe RUCA and the IRRZIP do not consistently classify the same ZIP code areas and populations as rural. Using the IRRZIP, each 10th increment in increased rurality was associated with a 2.6 increased odds of receiving primary care at a satellite clinic.
ConclusionsThe IRRZIP is a straightforward measure that is easy to use and interpret and may be a relevant alternative rural classification system that can be used in health services research.
C1 [Inagami, Sanae] VA Pittsburgh Hlth Care Syst, Primary Care Serv Line, Pittsburgh, PA USA.
[Inagami, Sanae] Univ Penn, Dept Gen Internal Med, Pittsburgh, PA USA.
[Gao, Shasha; Stone, Roslyn A.] VA Pittsburgh Hlth Care Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Karimi, Hassan] Univ Pittsburgh, Sch Informat Sci, Pittsburgh, PA USA.
[Probst, Janice C.] Univ S Carolina, Arnold Sch Publ Hlth, Hlth Serv Policy & Management, Columbia, SC 29208 USA.
[Probst, Janice C.] South Carolina Rural Hlth Res Ctr, Columbia, SC USA.
RP Inagami, S (reprint author), VA Pittsburgh Hlth Care Syst, Primary Care Serv Line, Pittsburgh, PA USA.
EM sanae.inagami@va.gov
FU Department of Veterans Affairs [72-047]
FX Support for this paper was provided by Locally Initiated Project 72-047
from the Department of Veterans Affairs.
NR 14
TC 0
Z9 0
U1 3
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0890-765X
EI 1748-0361
J9 J RURAL HEALTH
JI J. Rural Health
PD SPR
PY 2016
VL 32
IS 2
BP 219
EP 227
DI 10.1111/jrh.12148
PG 9
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA DI6MD
UT WOS:000373612100011
PM 26397170
ER
PT J
AU Chao, LL
Reeb, R
Esparza, IL
Abadjian, LR
AF Chao, Linda L.
Reeb, Rosemary
Esparza, Iva L.
Abadjian, Linda R.
TI Associations between the self-reported frequency of hearing chemical
alarms in theater and regional brain volume in Gulf War Veterans
SO NEUROTOXICOLOGY
LA English
DT Article
DE Brain imaging; Cerebral volume; Chemical warfare agents; Gulf War
veterans
ID LOW-LEVEL SARIN; GENOME-WIDE ASSOCIATION; SURFACE-BASED ANALYSIS; HUMAN
CEREBRAL-CORTEX; US ARMY VETERANS; CYCLOSARIN EXPOSURE;
ALZHEIMERS-DISEASE; TOKYO SUBWAY; ORGANOPHOSPHATE PESTICIDES; IDENTIFIES
VARIANTS
AB Background: We previously reported evidence of reduced cortical gray matter (GM), white matter (WM), and hippocampal volume in Gulf War (GW) veterans with predicted exposure to low-levels of nerve agent according to the 2000 Khamisiyah plume model analysis. Because there is suggestive evidence that other nerve agent exposures may have occurred during the Gulf War, we examined the association between the self-reported frequency of hearing chemical alarms sound during deployment in the Gulf War and regional brain volume in GW veterans.
Methods: Ninety consecutive GW veterans (15 female, mean age: 52 +/- 8 years) participating in a VA funded study underwent structural magnetic resonance imaging (MRI) on a 3T scanner. Freesurfer (version 5.1) was used to obtain regional measures of cortical GM, WM, hippocampal, and insula volume. Multiple linear regression was used to determine the association between the self-reported frequencies of hearing chemical alarms during the Gulf War and regional brain volume.
Results: There was an inverse association between the self-reported frequency of hearing chemical alarms sound and total cortical GM (adjusted p= 0.007), even after accounting for potentially confounding demographic and clinical variables, the veterans' current health status, and other concurrent deployment-related exposures that were correlated with hearing chemical alarms. Post-hoc analyses extended the inverse relationship between the frequency of hearing chemical alarms to GM volume in the frontal (adjusted p= 0.02), parietal (adjusted p= 0.01), and occipital (adjusted p = 0.001) lobes. In contrast, regional brain volumes were not significantly associated with predicted exposure to the Khamisiyah plume or with Gulf War Illness status defined by the Kansas or Centers for Disease Control and Prevention criteria.
Conclusions: Many veterans reported hearing chemical alarms sound during the Gulf War. The current findings suggest that exposure to substances that triggered those chemical alarms during the Gulf War likely had adverse neuroanatomical effects. Published by Elsevier Inc.
C1 [Chao, Linda L.; Reeb, Rosemary; Esparza, Iva L.; Abadjian, Linda R.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, 4150 Clement St,114 M, San Francisco, CA 94121 USA.
[Chao, Linda L.; Reeb, Rosemary] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA.
[Chao, Linda L.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
RP Chao, LL (reprint author), 4150 Clement St,114M, San Francisco, CA 94121 USA.
EM linda.chao@ucsf.edu
FU VA grant entitled 'Longitudinal Assessment of Gulf War Veterans with
Suspected Sarin Exposure' [CX000798]
FX The contents of this publication are solely the responsibility of the
authors and do not necessarily represent the official views of the Army,
Department of Defense, or Department of Veterans Affairs. This study
supported by VA grant No. CX000798 entitled 'Longitudinal Assessment of
Gulf War Veterans with Suspected Sarin Exposure'. This material is the
result of work supported with resources and the use of facilities at the
San Francisco Veterans Affairs Medical Center. The authors would like to
thank the Gulf War veterans who participated in these studies.
NR 67
TC 1
Z9 1
U1 3
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0161-813X
EI 1872-9711
J9 NEUROTOXICOLOGY
JI Neurotoxicology
PD MAR
PY 2016
VL 53
BP 246
EP 256
DI 10.1016/j.neuro.2016.02.009
PG 11
WC Neurosciences; Pharmacology & Pharmacy; Toxicology
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology
GA DI3UK
UT WOS:000373423800028
PM 26920621
ER
PT J
AU Johnson, TJ
Hickey, RW
Switzer, GE
Miller, E
Winger, DG
Nguyen, M
Saladino, RA
Hausmann, LRM
AF Johnson, Tiffani J.
Hickey, Robert W.
Switzer, Galen E.
Miller, Elizabeth
Winger, Daniel G.
Margaret Nguyen
Saladino, Richard A.
Hausmann, Leslie R. M.
TI The Impact of Cognitive Stressors in the Emergency Department on
Physician Implicit Racial Bias
SO ACADEMIC EMERGENCY MEDICINE
LA English
DT Article
ID CLINICAL DECISION-MAKING; ASSOCIATION TEST; ACHIEVEMENT GAP; EXPLICIT
ATTITUDES; AFRICAN-AMERICANS; MEDICAL-STUDENTS; UNCONSCIOUS RACE; TIME
PRESSURE; HEALTH-CARE; STEREOTYPES
AB ObjectivesThe emergency department (ED) is characterized by stressors (e.g., fatigue, stress, time pressure, and complex decision-making) that can pose challenges to delivering high-quality, equitable care. Although it has been suggested that characteristics of the ED may exacerbate reliance on cognitive heuristics, no research has directly investigated whether stressors in the ED impact physician racial bias, a common heuristic. We seek to determine if physicians have different levels of implicit racial bias post-ED shift versus preshift and to examine associations between demographics and cognitive stressors with bias.
MethodsThis repeated-measures study of resident physicians in a pediatric ED used electronic pre- and postshift assessments of implicit racial bias, demographics, and cognitive stressors. Implicit bias was measured using the Race Implicit Association Test (IAT). Linear regression models compared differences in IAT scores pre- to postshift and determined associations between participant demographics and cognitive stressors with postshift IAT and pre- to postshift difference scores.
ResultsParticipants (n = 91) displayed moderate prowhite/antiblack bias on preshift (mean SD = 0.50 +/- 0.34, d = 1.48) and postshift (mean +/- SD = 0.55 +/- 0.39, d = 1.40) IAT scores. Overall, IAT scores did not differ preshift to postshift (mean increase = 0.05, 95% CI = -0.02 to 0.14, d = 0.13). Subanalyses revealed increased pre- to postshift bias among participants working when the ED was more overcrowded (mean increase = 0.09, 95% CI = 0.01 to 0.17, d = 0.24) and among those caring for >10 patients (mean increase = 0.17, 95% CI = 0.05 to 0.27, d = 0.47). Residents' demographics (including specialty), fatigue, busyness, stressfulness, and number of shifts were not associated with postshift IAT or difference scores. In multivariable models, ED overcrowding was associated with greater postshift bias (coefficient = 0.11 per 1 unit of NEDOCS score, SE = 0.05, 95% CI = 0.00 to 0.21).
ConclusionsWhile resident implicit bias remained stable overall preshift to postshift, cognitive stressors (overcrowding and patient load) were associated with increased implicit bias. Physicians in the ED should be aware of how cognitive stressors may exacerbate implicit racial bias.
C1 [Johnson, Tiffani J.] Univ Penn, Sch Med, PolicyLab, Div Pediat Emergency Med, Philadelphia, PA 19104 USA.
[Johnson, Tiffani J.] Univ Penn, Sch Med, Childrens Hosp Philadelphia, Ctr Perinatal & Pediat Hlth Dispar Res, Philadelphia, PA 19104 USA.
[Johnson, Tiffani J.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA.
[Hickey, Robert W.; Saladino, Richard A.] Univ Pittsburgh, Dept Pediat, Div Pediat Emergency Med, Pittsburgh, PA 15260 USA.
[Switzer, Galen E.; Hausmann, Leslie R. M.] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA.
[Miller, Elizabeth] Univ Pittsburgh, Dept Pediat, Div Adolescent & Young Adult Med, Pittsburgh, PA 15260 USA.
[Winger, Daniel G.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA 15260 USA.
[Margaret Nguyen] Rady Childrens Hosp San Diego, Dept Emergency Med, San Diego, CA USA.
[Switzer, Galen E.; Hausmann, Leslie R. M.] Ctr Hlth Equ Res & Promot, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Johnson, TJ (reprint author), Univ Penn, Sch Med, PolicyLab, Div Pediat Emergency Med, Philadelphia, PA 19104 USA.; Johnson, TJ (reprint author), Univ Penn, Sch Med, Childrens Hosp Philadelphia, Ctr Perinatal & Pediat Hlth Dispar Res, Philadelphia, PA 19104 USA.; Johnson, TJ (reprint author), Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA.
EM johnsont6@email.chop.edu
FU Agency for Healthcare Research and Quality [T32 HS 017587]; National
Heart, Lung, and Blood Institute [K12 HL109009]; University of
Pittsburgh Clinical and Translational Science Institute (CTSI) through
the National Institutes of Health [UL1-TR-000005]
FX This research was conducted while Dr. Johnson was a fellow at the
Children's Hospital of Pittsburgh and supported by a grant from the
Agency for Healthcare Research and Quality (T32 HS 017587). Data
analysis and manuscript preparation was completed while Dr. Johnson was
funded by the National Heart, Lung, and Blood Institute (K12 HL109009).
The project was also supported by the University of Pittsburgh Clinical
and Translational Science Institute (CTSI) through the National
Institutes of Health through grant UL1-TR-000005. The sponsoring
agencies had no role in the design and conduct of the study; in the
collection, management, analysis, and interpretation of the data; or in
the preparation, review, or approval of the manuscript. The content of
this article is solely the responsibility of the authors and does not
necessarily represent the official views of the sponsoring agencies.
There are no financial disclosures or conflicts of interest to report.
NR 69
TC 5
Z9 5
U1 7
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1069-6563
EI 1553-2712
J9 ACAD EMERG MED
JI Acad. Emerg. Med.
PD MAR
PY 2016
VL 23
IS 3
BP 297
EP 305
DI 10.1111/acem.12901
PG 9
WC Emergency Medicine
SC Emergency Medicine
GA DH9HF
UT WOS:000373106300008
PM 26763939
ER
PT J
AU Ruggiero, NA
Kish, TD
Lee, ML
AF Ruggiero, Nicole A.
Kish, Troy D.
Lee, Mikyung L.
TI Metformin-Induced Hemolytic Anemia in a Patient With Glucose-6-Phosphate
Dehydrogenase Deficiency
SO AMERICAN JOURNAL OF THERAPEUTICS
LA English
DT Article
DE glucose-6-phosphate dehydrogenase deficiency; hemolytic anemia;
metformin
AB Metformin, an oral antidiabetic agent, is considered the preferred first-line therapy for patients with type II diabetes. Between 2010 and 2012, it has been estimated that 14 million Americans were administered an oral antidiabetic agent, suggesting the extensive use of metformin among the diabetic population. There have been few case reports implicating metformin in causing hemolytic anemia. We present a case of a 53-year-old white male who developed hemolytic anemia after the initiation of treatment with metformin 500 mg twice daily. The patient experienced a 1.5 g/dL decrease in hemoglobin from baseline and a 2.8 mg/dL increase in total bilirubin within 1 day of treatment. Laboratory results confirmed that the patient was also glucose-6-phosphate dehydrogenase deficient. The hemolytic anemia resolved on discontinuation of metformin. Although this adverse effect seems to be rare, it is important to consider its seriousness. Clinicians should be advised to closely monitor patients newly started on metformin.
C1 [Ruggiero, Nicole A.; Lee, Mikyung L.] James J Peters VA Med Ctr, Dept Pharm, 130 West Kingsbridge Rd,119, Bronx, NY 10468 USA.
[Kish, Troy D.] Long Isl Univ, Arnold & Marie Schwartz Coll Pharm & Hlth Sci, Brooklyn, NY USA.
RP Ruggiero, NA (reprint author), James J Peters VA Med Ctr, Dept Pharm, 130 West Kingsbridge Rd,119, Bronx, NY 10468 USA.
EM nicole.ruggiero@va.gov
NR 13
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1075-2765
EI 1536-3686
J9 AM J THER
JI Am. J. Ther.
PD MAR-APR
PY 2016
VL 23
IS 2
BP E575
EP E578
DI 10.1097/MJT.0000000000000194
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DG6EX
UT WOS:000372176400032
PM 25756470
ER
PT J
AU Snyder, M
Kish, T
AF Snyder, Mitchell
Kish, Troy
TI Sertraline-Induced Rhabdomyolysis: A Case Report and Literature Review
SO AMERICAN JOURNAL OF THERAPEUTICS
LA English
DT Review
DE depression; psychiatry; SSRIs; sertraline; adverse event report
ID SEROTONIN; DEPRESSION; INHIBITORS; EFFICACY; OVERDOSE
AB The objective of this study is to report a case of sertraline-induced rhabdomyolysis in a female patient with a history of depression. A 25-year-old Hispanic woman with a history of depression reported to the emergency department (ED) with a chief complaint of muscle swelling and soreness and dark urine. The patient's creatine phosphokinase was 15,103 U/L. Despite treatment with IV normal saline, the patient's symptoms persisted and the creatine phosphokinase continued to rise to a peak of 16,778 U/L on day 2. The patient reported completing a strenuous, although routine, exercise the day before arriving at the ED, and her medication history was only significant for sertraline. Of note, 6 weeks before her visit to the ED, sertraline was increased from 100 mg daily to 150 mg daily. The patient's rhabdomyolysis was attributed to sertraline in conjunction with recent exercise. Selective serotonin reuptake inhibitor (SSRI)-induced rhabdomyolysis has been documented in 5 case reports. Similar to most reports, our patient presented with rhabdomyolysis in the presence of both SSRI use and exercise. Unlike the majority of previous reports, our patient was not taking other medications with documented association to rhabdomyolysis and had performed routine exercise before presenting with rhabdomyolysis. Although the mechanism of SSRI-induced rhabdomyolysis is not known, a theory posits that sertraline may have a role in muscle contraction and relaxation, leading to shorter time to contracture and longer time of contraction. The use of sertraline and other SSRIs may be associated with development of rhabdomyolysis, especially in the presence of strenuous exercise.
C1 [Snyder, Mitchell] James J Peters VA Med Ctr, 130 West Kingsbridge Rd 119, Bronx, NY 10468 USA.
[Kish, Troy] Long Isl Univ, Arnold & Marie Schwartz Coll Pharm & Hlth Sci, Brooklyn, NY USA.
RP Snyder, M (reprint author), James J Peters VA Med Ctr, 130 West Kingsbridge Rd 119, Bronx, NY 10468 USA.
EM mitchell.snyder@va.gov
NR 22
TC 0
Z9 0
U1 2
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1075-2765
EI 1536-3686
J9 AM J THER
JI Am. J. Ther.
PD MAR-APR
PY 2016
VL 23
IS 2
BP E561
EP E565
DI 10.1097/MJT.0000000000000196
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DG6EX
UT WOS:000372176400028
PM 25581857
ER
PT J
AU Perlick, DA
Berk, L
Kaczynski, R
Gonzalez, J
Link, B
Dixon, L
Grier, S
Miklowitz, DJ
AF Perlick, Deborah A.
Berk, Lesley
Kaczynski, Richard
Gonzalez, Jodi
Link, Bruce
Dixon, Lisa
Grier, Savannah
Miklowitz, David J.
TI Caregiver burden as a predictor of depression among family and friends
who provide care for persons with bipolar disorder
SO BIPOLAR DISORDERS
LA English
DT Article
DE bipolar disorder; burden; depression; family
ID SERIOUS MENTAL-ILLNESS; TREATMENT ENHANCEMENT PROGRAM; RANDOMIZED
CONTROLLED-TRIAL; EXPRESSED EMOTION; DISEASE CAREGIVERS; SCHIZOPHRENIA;
PEOPLE; IMPACT; SYMPTOMS; INTERVENTION
AB ObjectivesOver one-third of caregivers of people with bipolar disorder report clinically significant levels of depressive symptoms. This study examined the causal relationship between depression and caregiver burden in a large sample of caregivers of adult patients with bipolar disorder.
MethodsParticipants were 500 primary caregivers of persons with bipolar disorder enrolled in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).This study evaluates the strength and direction of the associations between caregiver burden and depressive symptoms at baseline and at six- and 12-month follow-up using cross-lagged panel analyses, controlling for the clinical status of patients and sociodemographic variables.
ResultsHigher levels of overall caregiver burden at baseline were associated with increased levels of depressive symptoms among caregivers at follow-up (F = 8.70, df = 1,290, p < 0.001), after controlling for baseline caregiver depression, gender, race, age, social support, and patients' clinical status. By contrast, caregiver depression at baseline was not significantly associated with caregiver burden at follow-up (F = 1.65, p = 0.20).
ConclusionsCaregiver burden is a stronger predictor of caregiver depressive symptoms over time than the reverse. Interventions that help alleviate caregiver burden may decrease depressive symptoms.
C1 [Perlick, Deborah A.; Grier, Savannah] Vet Affairs Med Ctr, James J Peters Dept, Bronx, NY USA.
[Perlick, Deborah A.; Grier, Savannah] VISN 3 Mental Illness Res Educ & Clin Ctr MIRECC, Bronx, NY USA.
[Perlick, Deborah A.; Grier, Savannah] Icahn Sch Med Mt Sinai, Dept Psychiat, One Gustave L Levy Pl, New York, NY 10029 USA.
[Berk, Lesley] Deakin Univ, Fac Hlth, Mental Hlth & Wellbeing Res Ctr, Geelong, Vic 3217, Australia.
[Berk, Lesley] Univ Melbourne, Dept Psychiat, Parkville, Vic 3052, Australia.
[Kaczynski, Richard] Vet Affairs New England Mental Illness Res Educ &, West Haven, CT USA.
[Kaczynski, Richard] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
[Gonzalez, Jodi] Univ Texas San Antonio, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78284 USA.
[Link, Bruce] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA.
[Dixon, Lisa] Columbia Univ, Dept Psychiat, New York, NY USA.
[Dixon, Lisa] New York State Psychiat Inst & Hosp, Ctr Practice Innovat, New York, NY 10032 USA.
[Miklowitz, David J.] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Semel Inst, Div Child & Adolescent Psychiat, Los Angeles, CA 90095 USA.
RP Perlick, DA (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, One Gustave L Levy Pl, New York, NY 10029 USA.
EM deborah.perlick@mssm.edu
FU National Institute of Mental Health [MH-65015, NIMH-8001]
FX This study was supported by grants MH-65015 and NIMH-8001 from the
National Institute of Mental Health.
NR 59
TC 0
Z9 0
U1 5
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-5647
EI 1399-5618
J9 BIPOLAR DISORD
JI Bipolar Disord.
PD MAR
PY 2016
VL 18
IS 2
BP 183
EP 191
DI 10.1111/bdi.12379
PG 9
WC Clinical Neurology; Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA DH9OB
UT WOS:000373124400010
PM 27004622
ER
PT J
AU Umezaki, Y
Badran, BW
DeVries, WH
Moss, J
Gonzales, T
George, MS
AF Umezaki, Yojiro
Badran, Bashar W.
DeVries, William H.
Moss, Jkeonye
Gonzales, Theresa
George, Mark S.
TI The Efficacy of Daily Prefrontal Repetitive Transcranial Magnetic
Stimulation (rTMS) for Burning Mouth Syndrome (BMS): A Randomized
Controlled Single-blind Study
SO BRAIN STIMULATION
LA English
DT Article
DE Burning mouth syndrome; Repetitive transcranial magnetic stimulation;
Left dorsolateral prefrontal cortex; Chronic pain
ID ALPHA-LIPOIC ACID; TREATMENT-RESISTANT DEPRESSION; CEREBRAL-BLOOD-FLOW;
CHRONIC PAIN; OROFACIAL PAIN; OPEN-LABEL; CORTEX; TMS; TRIAL; FMRI
AB Background: Burning mouth syndrome (BMS) is a burning oral sensation without any corresponding abnormal findings. In some cases, BMS is refractory to pharmacologic treatments. Repetitive transcranial magnetic stimulation (rTMS) over left prefrontal cortex induces analgesic effect in both acute and chronic pain. However, its effect for BMS has not been evaluated.
Objective: The aim of this randomized, controlled, single-blind study was to assess the efficacy of prefrontal rTMS for BMS.
Method: Twenty patients with BMS were recruited and randomized to receive 30,000 pulses in total at 10 Hz TMS (n = 12) or sham TMS (n = 8). We assessed the change of BMS pain condition, functional status and mood until 2 months after the beginning of treatment.
Results: In the real group, the BMS pain intensity decreased 67%, and 75% of the patients reported >50% pain decrease on final assessment compared to baseline, without heavy side effects. There was significant pain reduction in subjects in the real group immediately after 1 week of treatment, whereas there was none in those in the sham group. Similar tendency was confirmed in change of functional status. Mood and the affective aspect of pain were not changed in this study.
Conclusion: BMS pain was significantly improved with 2 weeks of treatment of high frequency rTMS over left DLPFC compared to sham stimulation. Further study is needed to refine and improve TMS as a potential treatment of BMS. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Umezaki, Yojiro; Badran, Bashar W.; DeVries, William H.; Moss, Jkeonye; George, Mark S.] Med Univ S Carolina, Dept Psychiat, Brain Stimulat Lab, 67 President St, Charleston, SC 29425 USA.
[Gonzales, Theresa] Med Univ S Carolina, Coll Dent Med, Div Oral Pathol, 173 Ashley Ave, Charleston, SC 29425 USA.
[George, Mark S.] Ralph H Johnson VA Med Ctr, 109 Bee St, Charleston, SC 29401 USA.
RP Umezaki, Y (reprint author), Med Univ S Carolina, Dept Psychiat, Brain Stimulat Lab, 67 President St, Charleston, SC 29425 USA.
EM umezaki@yahoo.com
NR 55
TC 3
Z9 3
U1 5
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1935-861X
EI 1876-4754
J9 BRAIN STIMUL
JI Brain Stimul.
PD MAR-APR
PY 2016
VL 9
IS 2
BP 234
EP 242
DI 10.1016/j.brs.2015.10.005
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DH5UC
UT WOS:000372856500010
PM 26597930
ER
PT J
AU Philip, NS
Dunner, DL
Dowd, SM
Aaronson, ST
Brock, DG
Carpenter, LL
Demitrack, MA
Hovav, S
Janicak, PG
George, MS
AF Philip, Noah S.
Dunner, David L.
Dowd, Sheila M.
Aaronson, Scott T.
Brock, David G.
Carpenter, Linda L.
Demitrack, Mark A.
Hovav, Sarit
Janicak, Philip G.
George, Mark S.
TI Can Medication Free, Treatment-Resistant, Depressed Patients Who
Initially Respond to TMS Be Maintained Off Medications? A Prospective,
12-Month Multisite Randomized Pilot Study
SO BRAIN STIMULATION
LA English
DT Article
DE Transcranial magnetic stimulation; Maintenance of effect; Long term
outcome; Pilot clinical trial
ID TRANSCRANIAL MAGNETIC STIMULATION; OPEN-LABEL; MAJOR DEPRESSION;
REFRACTORY DEPRESSION; CONTROLLED-TRIAL; DISORDER; THERAPY; SCALE; RTMS;
EFFICACY
AB Background: Repetitive transcranial magnetic stimulation (TMS) is efficacious for acute treatment of resistant major depressive disorder (MDD), but there is little information on maintenance TMS after acute response. Objective/hypothesis: This pilot feasibility study investigated 12-month outcomes comparing two maintenance TMS approaches - a scheduled, single TMS session delivered monthly (SCH) vs. observation only (OBS). Methods: Antidepressant-free patients with unipolar, non-psychotic, treatment-resistant MDD participated in a randomized, open-label, multisite trial. Patients meeting protocol-defined criteria for improvement after six weeks of acute TMS were randomized to SCH or OBS regimens. TMS reintroduction was available for symptomatic worsening; all patients remained antidepressant-free during the trial. Results: Sixty-seven patients enrolled in the acute phase, and 49 (73%) met randomization criteria. Groups were matched, although more patients in the SCH group had failed >= 2 antidepressants (p = .035). There were no significant group differences on any outcome measure. SCH patients had nonsignificantly longer time to first TMS reintroduction, 91 +/- 66 days, vs. OBS, 77 52 days; OBS patients were nonsignificantly more likely to need reintroduction (odds ratio = 1.21; 95% Cl.38-3.89). Reintroduction lasted 14.3 +/- 17.8 days (SCH) and 16.9 +/- 18.9 days (OBS); 14/18 (78%) SCH and 17/27 (63%) OBS responded to reintroduction. Sixteen patients (32.7%) completed all 53 weeks of the study. Conclusions: Maintaining treatment-resistant depressed patients off medications with periodic TMS appears feasible in some cases. There was no statistical advantage of SCH vs. OBS, although SCH was associated with a nonsignificantly longer time to relapse. Those who initially respond to TMS have a strong chance of re-responding if relapse occurs. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
C1 [Philip, Noah S.] Prov VA Med Ctr, Ctr Neurorestorat & Neurotechnol, Providence, RI USA.
[Philip, Noah S.; Carpenter, Linda L.] Butler Hosp, Providence, RI 02906 USA.
[Dunner, David L.] Ctr Anxiety & Depress, Mercer Isl, WA USA.
[Dowd, Sheila M.; Janicak, Philip G.] Rush Univ, Med Ctr, Chicago, IL 60612 USA.
[Aaronson, Scott T.] Sheppard Pratt Hlth Syst, Baltimore, MD USA.
[Brock, David G.; Demitrack, Mark A.] Neuronetics Inc, Malvern, PA USA.
[Hovav, Sarit] Creighton Univ, Univ Nebraska Med Ctr, Omaha, NE 68178 USA.
[George, Mark S.] Med Univ S Carolina, Charleston, SC 29425 USA.
[George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Philip, NS (reprint author), Prov VA Med Ctr, Ctr Neurorestorat & Neurotechnol, Providence, RI USA.; Philip, NS (reprint author), Butler Hosp, Providence, RI 02906 USA.
EM Noah_Philip@Brown.edu
OI Philip, Noah/0000-0002-4889-8775
FU Neuronetics, Inc.
FX Supported by Neuronetics, Inc.
NR 26
TC 3
Z9 3
U1 2
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1935-861X
EI 1876-4754
J9 BRAIN STIMUL
JI Brain Stimul.
PD MAR-APR
PY 2016
VL 9
IS 2
BP 251
EP 257
DI 10.1016/j.brs.2015.11.007
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DH5UC
UT WOS:000372856500012
PM 26708778
ER
PT J
AU Demissei, BG
Valente, MAE
Cleland, JG
O'Connor, CM
Metra, M
Ponikowski, P
Teerlink, JR
Cotter, G
Davison, B
Givertz, MM
Bloomfield, DM
Dittrich, H
van der Meer, P
van Veldhuisen, DJ
Hillege, HL
Voors, AA
AF Demissei, Biniyam G.
Valente, Mattia A. E.
Cleland, John G.
O'Connor, Christopher M.
Metra, Marco
Ponikowski, Piotr
Teerlink, John R.
Cotter, Gad
Davison, Beth
Givertz, Michael M.
Bloomfield, Daniel M.
Dittrich, Howard
van der Meer, Peter
van Veldhuisen, Dirk J.
Hillege, Hans L.
Voors, Adriaan A.
TI Optimizing clinical use of biomarkers in high-risk acute heart failure
patients
SO EUROPEAN JOURNAL OF HEART FAILURE
LA English
DT Article
DE Acute heart failure; Prognosis; Risk stratification; Multimarker
strategy; Time-dependent AUC analysis
ID NATRIURETIC PEPTIDE; ACUTE DYSPNEA; SOLUBLE ST2; MORTALITY;
HOSPITALIZATION; STRATIFICATION; PREDICTION; OUTCOMES; ROLOFYLLINE;
ANTAGONIST
AB AimThe clinical value of single biomarkers at single time-points to predict outcomes in patients with acute heart failure (AHF) is limited. We performed a multimarker, multi-time-point analysis of biomarkers for the prediction of post-discharge clinical outcomes in high-risk AHF patients.
Methods and resultsA set of 48 circulating biomarkers were measured in the PROTECT trial which enrolled 2033 patients with AHF. Associations between baseline levels of biomarkers and outcomes (30-day all-cause mortality, 30-day death or rehospitalization for renal/cardiovascular causes and 180-day all-cause mortality) were evaluated. Prognostic accuracies of baseline, days 2 or 3, 7, and 14 biomarker measurements were estimated and compared utilizing a time-dependent area under the curve (AUC) analysis. Forty-four biomarkers were significantly associated with outcomes, but 42 had limited prognostic value (C-index<0.70). However, multimarker models combining best-performing biomarkers from different clusters had a much stronger prognostic value. Combining blood urea nitrogen (BUN), chloride, interleukin (IL)-6, cTnI, sST-2 and VEGFR-1 into a clinical model yielded a 11% increase in C-index to 0.84 and 0.78 for 30-day and 180-day all-cause mortality, respectively, and cNRI of 0.86 95% CI [0.55-1.11] and 0.76 95% CI [0.57-0.87]. Prognostic gain was modest for the 30-day death/rehospitalization for cardiovascular or renal causes endpoint. Comparative time-dependent AUC analysis indicated that late measurements provided superior accuracy for the prediction of all-cause mortality over 180days, with few exceptions including BUN and galectin-3. However, the predictive value of most biomarkers showed a diminishing pattern over time irrespective of moment of measurement.
ConclusionsMultimarker models significantly improve risk prediction. Subsequent measurements, beyond admission, are needed for majority of biomarkers to maximize prognostic value over time, particularly in the long term.
C1 [Demissei, Biniyam G.; Valente, Mattia A. E.; van der Meer, Peter; van Veldhuisen, Dirk J.; Hillege, Hans L.; Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.
[Demissei, Biniyam G.; Hillege, Hans L.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands.
[Cleland, John G.] Univ London Imperial Coll Sci Technol & Med, London, England.
[O'Connor, Christopher M.] Duke Univ, Med Ctr, Durham, NC USA.
[Metra, Marco] Univ Brescia, Brescia, Italy.
[Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland.
[Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Cotter, Gad; Davison, Beth] Momentum Res, Durham, NC USA.
[Givertz, Michael M.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
[Bloomfield, Daniel M.] Merck Res Labs, Rahway, NJ USA.
[Dittrich, Howard] Univ Iowa, Abboud Cardiovasc Res Ctr, Carver Coll Med, Iowa City, IA 52242 USA.
RP Voors, AA (reprint author), Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.
EM a.a.voors@umcg.nl
RI Ponikowski, Piotr/O-6454-2015
OI Ponikowski, Piotr/0000-0002-3391-7064
FU NovaCardia, a subsidiary of Merck
FX The PROTECT trial was supported by NovaCardia, a subsidiary of Merck.
NR 29
TC 10
Z9 10
U1 2
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1388-9842
EI 1879-0844
J9 EUR J HEART FAIL
JI Eur. J. Heart Fail.
PD MAR
PY 2016
VL 18
IS 3
BP 269
EP 280
DI 10.1002/ejhf.443
PG 12
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DI0BO
UT WOS:000373160000007
PM 26634889
ER
PT J
AU Jaramillo, CA
Eapen, BC
McGeary, CA
McGeary, DD
Robinson, J
Amuan, M
Pugh, MJ
AF Jaramillo, Carlos A.
Eapen, Blessen C.
McGeary, Cindy A.
McGeary, Donald D.
Robinson, Jedediah
Amuan, Megan
Pugh, Mary Jo
TI A cohort study examining headaches among veterans of Iraq and
Afghanistan wars: Associations with traumatic brain injury, PTSD, and
depression
SO HEADACHE
LA English
DT Article
DE headache; traumatic brain injury; posttraumatic stress disorder;
postconcussive symptoms; persistence; veterans
ID POSTTRAUMATIC-STRESS-DISORDER; US SOLDIERS; MILITARY PERSONNEL;
HEAD-INJURY; CONCUSSION; PREVALENCE; SEVERITY; MIGRAINE; PROGRAM; BLAST
AB ObjectivesTo describe the prevalence and persistence of headache and associated conditions in an inception cohort of U.S. veterans of Iraq and Afghanistan wars.
BackgroundIraq and Afghanistan war veterans (IAV) suffer from persistent and difficult-to-treat headaches that have been found to co-occur with traumatic brain injury (TBI) and other deployment related comorbidities.
MethodsThis longitudinal retrospective cohort study used data from the national Veterans Health Administration (VA) data repository for IAV who first received VA care in 2008 (baseline) and also received care each year in 2009, 2010, and 2011. We used ICD-9-CM codes, to identify those treated for headache each year (2008-2011). Individuals with headache diagnosed each year were classified as having persistent headache. We also identified comorbidities that may be associated with baseline headache using algorithms validated for use with ICD-9-CM codes. Comorbidities included TBI, posttraumatic stress disorder (PTSD), depression, and conditions associated with these diagnoses (anxiety, memory/attention/cognition, neck pain, tinnitus/hyperacusis, photosensitivity/photo blurring, insomnia, malaise/fatigue, and vertigo/dizziness). Multivariable logistic regression analysis was used to determine characteristics associated with baseline headache as well as those associated with persistent headache.
ResultsAmong all IAV, 38,426 received their first year of VA care in 2008 and had care each year 2009-2011: 13.7% of these were diagnosed with headache in 2008. Veterans diagnosed with headache in 2008 were more likely than those without a headache diagnosis to also have a diagnosis of TBI alone (adjusted odds ratios [AOR] 6.75; 95% CI 5.79-7.86), TBI+depression (AOR 7.09; 95% CI 5.23-9.66), TBI+PTSD (AOR 10.16; 95% CI 8.96-11.53), TBI+PTSD+depression (AOR 9.40; 95% CI 8.12-10.09), and neck pain (AOR 2.44; 95% CI 2.14-2.77). Among those with headache diagnosis in 2008, 24.3% had a headache diagnosis each of the subsequent years of care (persistent headache). While diagnoses of TBI, PTSD, and/or depression at baseline were not associated with headache persistence, persistence was more likely for individuals with baseline tinnitus/hyperacusis (AOR 1.21; 95% CI 1.02-1.45), insomnia (AOR 1.19; 95% CI 1.02-1.39), and vertigo/dizziness (AOR 1.83; 95% CI 1.30-2.57).
ConclusionsOur results indicate that TBI alone is a strong predictor of headache in the first year of VA care among IAV and that comorbid psychiatric comorbidities increase the likelihood of headache among individuals with TBI. However, among those with baseline headache, only tinnitus, insomnia, and vertigo were baseline clinical predictors of headache persistence. These results suggest that attention to other symptoms and conditions early in the diagnosis and treatment of headaches may be important for understanding prognosis. These comorbidities offer potential targets for intervention strategies that may help address postdeployment headaches.
C1 [Jaramillo, Carlos A.; Eapen, Blessen C.] South Texas Vet Hlth Care Syst, Polytrauma Rehabil Ctr, San Antonio, TX USA.
[Jaramillo, Carlos A.; Eapen, Blessen C.; Robinson, Jedediah] Univ Texas Hlth Sci Ctr San Antonio, Dept Rehabil Med, San Antonio, TX 78229 USA.
[McGeary, Cindy A.; McGeary, Donald D.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
[Amuan, Megan] Edith Nourse Rogers Mem Hosp, CHQOER, Bedford, MA USA.
[Pugh, Mary Jo] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
RP Jaramillo, CA (reprint author), South Texas Vet Healthcare Syst ALMD, Polytrauma Rehabil Ctr, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.
EM jaramilloc3@uthscsa.edu
OI Pugh, Mary Jo/0000-0003-4196-7763
FU VA Health Services Research and Development [DHI 09-237]
FX The study was funded by VA Health Services Research and Development (DHI
09-237).
NR 54
TC 1
Z9 1
U1 1
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0017-8748
EI 1526-4610
J9 HEADACHE
JI Headache
PD MAR
PY 2016
VL 56
IS 3
BP 528
EP 539
DI 10.1111/head.12726
PG 12
WC Clinical Neurology
SC Neurosciences & Neurology
GA DH6HG
UT WOS:000372891000009
PM 26688427
ER
PT J
AU Cadena, J
Thompson, GR
Patterson, TF
AF Cadena, Jose
Thompson, George R., III
Patterson, Thomas F.
TI Invasive Aspergillosis Current Strategies for Diagnosis and Management
SO INFECTIOUS DISEASE CLINICS OF NORTH AMERICA
LA English
DT Article
DE Aspergillosis; Invasive pulmonary aspergillosis; Resistance; Chronic
cavitary aspergillosis; Aspergilloma
ID STEM-CELL TRANSPLANTATION; CRITICALLY-ILL PATIENTS; CHRONIC PULMONARY
ASPERGILLOSIS; RANDOMIZED CONTROLLED-TRIAL; AMPHOTERICIN-B THERAPY;
ANTIFUNGAL THERAPY; FUNGAL-INFECTIONS; HEMATOLOGICAL PATIENTS;
NEUTROPENIC PATIENTS; SERUM GALACTOMANNAN
AB Aspergillosis remains a significant cause of morbidity and mortality in the immunocompromised population. The spectrum of disease is broad, ranging from severe and rapidly fatal infection to noninvasive disease. The diversity of patients and risk factors complicates diagnostic and therapeutic decision-making. Invasive procedures are often precluded by host status; noninvasive diagnostic tests vary in their sensitivity and specificity. Advancements in understanding the pathophysiology of invasive aspergillosis and host genetics in differential risk have also occurred. Future work may assist in therapeutic decision-making and patient prognosis. Voriconazole remains the preferred agent for treatment. Additional alternatives have emerged.
C1 [Cadena, Jose; Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Infect Dis, 7703 Floyd Curl Dr,MSC 7881, San Antonio, TX 78229 USA.
[Cadena, Jose; Patterson, Thomas F.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Thompson, George R., III] Univ Calif Davis, Dept Internal Med, Div Infect Dis, 1 Shields Ave,Tupper Hall,Room 3146, Davis, CA 95616 USA.
RP Patterson, TF (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Infect Dis, 7703 Floyd Curl Dr,MSC 7881, San Antonio, TX 78229 USA.
EM patterson@uthscsa.edu
NR 95
TC 3
Z9 4
U1 1
U2 8
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0891-5520
EI 1557-9824
J9 INFECT DIS CLIN N AM
JI Infect. Dis. Clin. North Am.
PD MAR
PY 2016
VL 30
IS 1
BP 125
EP +
DI 10.1016/j.idc.2015.10.015
PG 20
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DH5UJ
UT WOS:000372857200008
PM 26897064
ER
PT J
AU Anesi, JA
Baddley, JW
AF Anesi, Judith A.
Baddley, John W.
TI Approach to the Solid Organ Transplant Patient with Suspected Fungal
Infection
SO INFECTIOUS DISEASE CLINICS OF NORTH AMERICA
LA English
DT Article
DE Solid organ transplant; Invasive fungal infection; Candida; Aspergillus;
Endemic fungi; Cryptococcus; Mold
ID PNEUMOCYSTIS-CARINII-PNEUMONIA; SURVEILLANCE NETWORK TRANSNET;
ORTHOTOPIC LIVER-TRANSPLANTATION; PRIMARY CUTANEOUS CRYPTOCOCCOSIS;
CENTRAL-NERVOUS-SYSTEM; OF-THE-LITERATURE; BETA-D-GLUCAN;
INVASIVE-ASPERGILLOSIS; RISK-FACTORS; LUNG TRANSPLANTATION
AB In solid organ transplant (SOT) recipients, invasive fungal infections (IFIs) are associated with significant morbidity and mortality. Detection of IFIs can be difficult because the signs and symptoms are similar to those of viral or bacterial infections, and diagnostic techniques have limited sensitivity and specificity. Clinicians must rely on knowledge of the patient's risk factors for fungal infection to make a diagnosis. The authors describe their approach to the SOT recipient with suspected fungal infection. The epidemiology of IFIs in the SOT population is reviewed, and a syndromic approach to suspected IFI in SOT recipients is described.
C1 [Anesi, Judith A.] Univ Penn, Div Infect Dis, 3400 Spruce St,3 Silverstein,Suite E, Philadelphia, PA 19104 USA.
[Baddley, John W.] Univ Alabama Birmingham, Dept Med, 1900 Univ Blvd,229 THT, Birmingham, AL 35294 USA.
[Baddley, John W.] Birmingham VA Med Ctr, Med Serv, 700 South 19th St, Birmingham, AL 35233 USA.
RP Baddley, JW (reprint author), Univ Alabama Birmingham, Dept Med, 1900 Univ Blvd,229 THT, Birmingham, AL 35294 USA.
EM jbaddley@uab.edu
OI Anesi, Judith/0000-0001-6671-4557
NR 149
TC 0
Z9 0
U1 1
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0891-5520
EI 1557-9824
J9 INFECT DIS CLIN N AM
JI Infect. Dis. Clin. North Am.
PD MAR
PY 2016
VL 30
IS 1
BP 277
EP +
DI 10.1016/j.idc.2015.10.001
PG 21
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DH5UJ
UT WOS:000372857200016
PM 26739603
ER
PT J
AU Wiederhold, NP
Najvar, LK
Fothergill, AW
Bocanegra, R
Olivo, M
McCarthy, DI
Fukuda, Y
Mitsuyama, J
Patterson, TF
AF Wiederhold, Nathan P.
Najvar, Laura K.
Fothergill, Annette W.
Bocanegra, Rosie
Olivo, Marcos
McCarthy, Dora I.
Fukuda, Yoshiko
Mitsuyama, Junichi
Patterson, Thomas F.
TI The novel arylamidine T-2307 demonstrates in vitro and in vivo activity
against echinocandin-resistant Candida glabrata
SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
LA English
DT Article
ID FKS MUTATIONS; SUSCEPTIBILITY; CASPOFUNGIN; EFFICACY; ALBICANS
AB Candida species are major causes of invasive mycoses in immunocompetent and immunocompromised hosts. Treatment options are limited in the setting of antifungal resistance and increased rates of echinocandin-resistantCandida glabrata have been reported. The novel arylamidine T-2307 demonstrates potentin vitro antifungal activity againstCandida species. Our objective was to evaluate thein vitro andin vivo activity of T-2307 against resistantC. glabrata.
In vitro activity was determined against 42 clinicalC. glabrata isolates, including 17 echinocandin-resistant strains. Neutropenic ICR mice were inoculated intravenously with an echinocandin-resistantC. glabrata isolate (T-2307; caspofungin MICs a parts per thousand currency sign0.008 and 0.5 mg/L, respectively). Therapy with vehicle control, T-2307 (0.75, 1.5, 3 or 6 mg/kg subcutaneously once daily) or caspofungin (1 or 10 mg/kg intraperitoneally once daily) began 1 day post-challenge. Kidneys were collected on day 8 and fungal burden was assessed by counting cfu.
T-2307 demonstrated potentin vitro activity againstC. glabrata (geometric mean MIC 0.0135 mg/L), which was maintained against echinocandin-resistant isolates (geometric mean MIC 0.0083 mg/L). T-2307 also demonstratedin vivo efficacy in mice infected with echinocandin-resistantC. glabrata. Significant reductions in fungal burden were observed at each dosage level of T-2307 compared with control. Reductions in fungal burden were also observed with high-dose caspofungin.
T-2307 demonstrated potentin vitro activity againstC. glabrata, including echinocandin-resistant isolates, which translated intoin vivo efficacy against invasive candidiasis caused by an echinocandin-resistantC. glabrata strain. These results demonstrate the potential for T-2307 as therapy against echinocandin-resistantCandida.
C1 [Wiederhold, Nathan P.; Najvar, Laura K.; Fothergill, Annette W.; Bocanegra, Rosie; Olivo, Marcos; McCarthy, Dora I.; Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Najvar, Laura K.; Bocanegra, Rosie; Olivo, Marcos; Patterson, Thomas F.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Fukuda, Yoshiko; Mitsuyama, Junichi] Toyama Chem Co Ltd, Toyama, Japan.
RP Wiederhold, NP (reprint author), Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
EM wiederholdn@uthscsa.edu
OI Wiederhold, Nathan/0000-0002-2225-5122
FU National Institute of Allergy and Infectious Diseases, National
Institutes of Health, Department of Health and Human Services
[HHS272201000018I, HHSN272201000038I]
FX This project utilized preclinical services funded by the National
Institute of Allergy and Infectious Diseases, National Institutes of
Health, Department of Health and Human Services, under Contract Nos.
HHS272201000018I and HHSN272201000038I-Task Orders A03 and A13,
respectively.
NR 15
TC 0
Z9 1
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-7453
EI 1460-2091
J9 J ANTIMICROB CHEMOTH
JI J. Antimicrob. Chemother.
PD MAR
PY 2016
VL 71
IS 3
BP 692
EP 695
DI 10.1093/jac/dkv398
PG 4
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA DH7OS
UT WOS:000372984200019
PM 26620102
ER
PT J
AU Fraenkel, L
Lim, J
Garcia-Tsao, G
Reyna, V
Monto, A
AF Fraenkel, Liana
Lim, Joseph
Garcia-Tsao, Guadalupe
Reyna, Valerie
Monto, Alexander
TI Examining Hepatitis C Virus Treatment Preference Heterogeneity Using
Segmentation Analysis Treat Now or Defer?
SO JOURNAL OF CLINICAL GASTROENTEROLOGY
LA English
DT Article
DE patient preferences; hepatitis C; treatment deferral
ID DISCRETE-CHOICE EXPERIMENT; GENOTYPE 1 INFECTION; FUZZY-TRACE THEORY;
RHEUMATOID-ARTHRITIS; INTERFERON THERAPY; KNEE REPLACEMENT;
AFRICAN-AMERICAN; HCV; SOFOSBUVIR; RIBAVIRIN
AB Objective:
To improve our understanding of patients' treatment preferences for chronic hepatitis C (HCV).
Methods:
Subjects with HCV were recruited from 2 VA medical centers. Preferences were ascertained using conjoint analysis. We used segmentation analysis to examine whether there were groups of respondents with similar preferences that were systematically different from the preferences of others. We then measured the associations between treatment preference with subjects' characteristics and their gist principles related to living with HCV and the burden of therapy.
Results:
A total of 199 subjects participated in this study. The segmentation analysis demonstrated that subjects could be classified into 2 distinct groups. The larger group [group 1, n=118 (59%)] opted for current treatment and the other [group 2, n=81 (41%)] preferred to defer. Patients with cirrhosis were less likely to belong to group 2 (prefer to defer) compared with those without cirrhosis (40.5% vs. 21.3%), whereas subjects self-identifying as African American were more likely to belong to group 2 than white subjects (51.3% vs. 30.5%). Members of group 1 had a more positive overall gist principles related to HCV compared with members of group 2 [mean (SD) score=28.63 (3.06) vs. 26.46 (2.79), P < 0.0001]. These gist principles mediated the relationship between race and treatment preference (Sobel test statistic=-2.68, 2-tailed P=0.007).
Conclusions:
Our findings indicate that there are groups of HCV patients with similar preferences that are distinct from other groups' preferences. Patients' gist principles related to the significance of having a chronic viral infection and the burdens of therapy are strongly related to their current treatment decisions. These findings help inform how best to initiate and deliver treatment for patients with HCV.
C1 [Fraenkel, Liana; Lim, Joseph; Garcia-Tsao, Guadalupe] Yale Univ, Sch Med, VA Connecticut Hlth Care Syst, New Haven, CT 06520 USA.
[Reyna, Valerie] Cornell Univ, Dept Human Dev & Psychol, Ithaca, NY USA.
[Monto, Alexander] San Francisco VA Med Ctr, San Francisco, CA USA.
[Monto, Alexander] Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Fraenkel, L (reprint author), Yale Univ, Rheumatol Sect, Sch Med, 300 Cedar ST,TAC Bldg,RM 525,POB 208031, New Haven, CT 06520 USA.
EM liana.fraenkel@yale.edu
FU VA Health Services and Research Department [IIR 10-131]; Abbott;
Achillion; Bristol-Myers Squibb; Gilead; Janssen; Xerox
FX Supported in full by the VA Health Services and Research Department (IIR
10-131). Analyses were performed by Liana Fraenkel. All authors had a
substantial role in the design of the study and writing the manuscript.;
J.L. has served as a consultant for Boehringer-Ingelheim, Bristol-Myers
Squibb, Gilead, Janssen, Merck, and has received research funding from
Abbott, Achillion, Bristol-Myers Squibb, Gilead, and Janssen (paid to
the institution). V.R. has served on including committees of the
National Academy of Sciences, Psychonomic Society, and other nonprofits.
She has been a paid consultant for Xerox. G.G.-T. has served as a
consultant for Abbvie and Fibrogen, is an associate editor for
Hepatology and serves on committees of the American Association for the
Study of Liver Diseases. The remaining authors declare that they have
nothing to disclose.
NR 41
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0192-0790
EI 1539-2031
J9 J CLIN GASTROENTEROL
JI J. Clin. Gastroenterol.
PD MAR
PY 2016
VL 50
IS 3
BP 252
EP 257
DI 10.1097/MCG.0000000000000380
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DH5NT
UT WOS:000372837100012
PM 26166145
ER
PT J
AU Fu, LW
Wei, CC
Powell, PC
Bradley, WE
Ahmad, S
Ferrario, CM
Collawn, JF
Dell'Italia, LJ
AF Fu, Lianwu
Wei, Chih-Chang
Powell, Pamela C.
Bradley, Wayne E.
Ahmad, Sarfaraz
Ferrario, Carlos M.
Collawn, James F.
Dell'Italia, Louis J.
TI Increased fibroblast chymase production mediates procollagen autophagic
digestion in volume overload
SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
LA English
DT Article
DE Volume overload; Cardiac fibroblast; Chymase; Autophagy; Intracellular
procollagen
ID MAST-CELL CHYMASE; MATRIX-METALLOPROTEINASE ACTIVITY; RENIN-ANGIOTENSIN
SYSTEM; EXTRACELLULAR-MATRIX; MITRAL REGURGITATION; NEUTROPHIL ELASTASE;
CARDIAC FIBROBLASTS; FORMING PATHWAYS; HEART-FAILURE; HIGH-GLUCOSE
AB Background: Previous work has identified mast cells as the major source of chymase largely associated with a profibrotic phenotype. We recently reported increased fibroblast autophagic procollagen degradation in a rat model of pure volume overload (VO). Here we demonstrate a connection between increased fibroblast chymase production and autophagic digestion of procollagen in the pure VO of aortocaval fistula (ACF) in the rat.
Methods and results: Isolated LV fibroblasts taken from 4 and 12 week ACF Sprague-Dawley rats have significant increases in chymase mRNA and chymase activity. Increased intracellular chymase protein is documented by immunocytochemistry in the ACF fibroblasts compared to cells obtained from age-matched sham rats. To implicate VO as a stimulus for chymase production, we show that isolated adult rat LV fibroblasts subjected to 24 h of 20% cyclical stretch induces chymase mRNA and protein production. Exogenous chymase treatment of control isolated adult cardiac fibroblasts demonstrates that chymase is internalized through a dynamin-dependent mechanism. Chymase treatment leads to an increased formation of autophagic vacuoles, LC3-II production, autophagic flux, resulting in increased procollagen degradation. Chymase inhibitor treatment reduces cyclical stretch-induced autophagy in isolated cardiac fibroblasts, demonstrating chymase's role in autophagy induction.
Conclusion: In a pure VO model, chymase produced in adult cardiac fibroblasts leads to autophagic degradation of newly synthesized intracellular procollagen I, suggesting a new role of chymase in extracellular matrix degradation. Published by Elsevier Ltd.
C1 [Fu, Lianwu; Wei, Chih-Chang; Powell, Pamela C.; Dell'Italia, Louis J.] Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Wei, Chih-Chang; Bradley, Wayne E.; Dell'Italia, Louis J.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA.
[Fu, Lianwu; Collawn, James F.; Dell'Italia, Louis J.] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL USA.
[Ahmad, Sarfaraz; Ferrario, Carlos M.] Wake Forest Univ, Bowman Gray Sch Med, Div Surg Sci, Winston Salem, NC USA.
RP Dell'Italia, LJ (reprint author), Birmingham VA Med Ctr, 700 South 19th St, Birmingham, AL 35233 USA.
EM louis.dellitalia@va.gov
FU Department of Veteran Affairs for Merit Review [1BX001050-01,
1CX000993-01]; NIH [P01 HL051952]
FX This work was supported by grants from Department of Veteran Affairs for
Merit Review (Grant 1BX001050-01 to C.C.W. and Grant 1CX000993-01 to
L.J.D.) and NIH (Grant P01 HL051952 to CMF and L.J.D.).
NR 46
TC 5
Z9 5
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0022-2828
EI 1095-8584
J9 J MOL CELL CARDIOL
JI J. Mol. Cell. Cardiol.
PD MAR
PY 2016
VL 92
BP 1
EP 9
DI 10.1016/j.yjmcc.2016.01.019
PG 9
WC Cardiac & Cardiovascular Systems; Cell Biology
SC Cardiovascular System & Cardiology; Cell Biology
GA DH9DD
UT WOS:000373095700001
PM 26807691
ER
PT J
AU Veenema, TG
Griffin, A
Gable, AR
MacIntyre, L
Simons, RADMN
Couig, MP
Walsh, JJ
Lavin, RP
Dobalian, A
Larson, E
AF Veenema, Tener Goodwin
Griffin, Anne
Gable, Alicia R.
MacIntyre, Linda
Simons, R. A. D. M. Nadine
Couig, Mary Pat
Walsh, John J., Jr.
Lavin, Roberta Proffitt
Dobalian, Aram
Larson, Elaine
TI Nurses as Leaders in Disaster Preparedness and ResponseA Call to Action
SO JOURNAL OF NURSING SCHOLARSHIP
LA English
DT Editorial Material
DE Competencies; curriculum; disaster; education; nursing; policy;
practice; preparedness; public health emergency; research; scope of
practice
ID VOLUNTEER HEALTH-PROFESSIONALS; PUBLIC-HEALTH; HURRICANE KATRINA;
EARTHQUAKE RELIEF; CORE COMPETENCES; EMERGENCIES; EXPERIENCE;
MANAGEMENT; KNOWLEDGE; EDUCATION
AB PurposeTo develop a vision for the future of disaster nursing, identify barriers and facilitators to achieving the vision, and develop recommendations for nursing practice, education, policy, and research.
Design and MethodsA series of semistructured conference calls were conducted with 14 national subject matter experts to generate relevant concepts regarding national nursing workforce preparedness. An invitational daylong workshop hosted by the Veterans Emergency Management Evaluation Center, U.S. Department of Veterans Affairs, was held in December 2014 to expand and refine these concepts. Workshop participants included 70 nurses, emergency managers, and a broad range of public health professionals. Conference call notes and audiotapes of the workshop were transcribed and thematic analysis conducted to outline a vision for the future of nursing in disaster preparedness and response, and to articulate an agenda for nursing practice, education, policy, and research to achieve that vision.
FindingsThe group developed a vision for the future of disaster nursing, and identified current barriers and opportunities to advance professional disaster nursing. A broad array of recommendations for nursing practice, education, policy, and research, as well as implementation challenges, are summarized in this article.
ConclusionsThis project represents an important step toward enhancing nurses' roles as leaders, educators, responders, policymakers, and researchers in disaster preparedness and response. Nurses and the health and human service organizations that employ them are encouraged to engage in an expansive national dialogue regarding how to best incorporate the vision and recommendations into their individual lives and the organizations for which they work.
Clinical RelevanceNurses comprise the largest healthcare workforce, and opportunities exist to strengthen disaster readiness, enhance national surge capacity, and build community resiliency to disasters.
C1 [Veenema, Tener Goodwin] Johns Hopkins Univ, Johns Hopkins Sch Nursing, Sch Nursing, Dept Community & Publ Hlth, Baltimore, MD USA.
[Veenema, Tener Goodwin] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Refugee & Disaster Response, Baltimore, MD USA.
[Griffin, Anne; Gable, Alicia R.; Dobalian, Aram] US Dept Vet Affairs, Vet Hlth Adm, Off Publ Hlth, Vet Emergency Management Evaluat Ctr, North Hills, CA USA.
[MacIntyre, Linda] Amer Red Cross, Washington, DC 20006 USA.
[Simons, R. A. D. M. Nadine] US Dept Hlth & Human Serv, Off Assistant Secretary Hlth, Reg 9, San Francisco, CA USA.
[Couig, Mary Pat] US Dept Vet Affairs, Off Nursing Serv, Special Projects & Publ Hlth Emergency Preparedne, Emergency Preparedness, Washington, DC USA.
[Walsh, John J., Jr.] Vanderbilt Univ, Sch Med, Vanderbilt Program Disaster Res & Training, 221 Kirkland Hall, Nashville, TN 37235 USA.
[Lavin, Roberta Proffitt] Univ Missouri, Coll Nursing, Acad Programs, St Louis, MO 63121 USA.
[Dobalian, Aram] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA.
[Dobalian, Aram] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA.
[Larson, Elaine] Columbia Univ, Sch Nursing, Res, New York, NY USA.
[Larson, Elaine] Columbia Univ, Sch Nursing, Nursing Res, New York, NY USA.
[Larson, Elaine] Columbia Univ, Mailman Sch Publ Hlth, Epidemiol, New York, NY USA.
RP Veenema, TG (reprint author), Johns Hopkins Sch Nursing, 525 N Wolfe St Off,Room 532, Baltimore, MD 21205 USA.
EM tveenem1@jhu.edu
RI Lavin, Roberta/H-1892-2016
OI Lavin, Roberta/0000-0001-6106-8066
NR 62
TC 2
Z9 2
U1 13
U2 24
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6546
EI 1547-5069
J9 J NURS SCHOLARSHIP
JI J. Nurs. Scholarsh.
PD MAR
PY 2016
VL 48
IS 2
BP 187
EP 200
DI 10.1111/jnu.12198
PG 14
WC Nursing
SC Nursing
GA DG7MH
UT WOS:000372267900010
PM 26869230
ER
PT J
AU Zhang, YQ
Liu, YH
Walsh, M
Bokov, A
Ikeno, Y
Jang, YC
Perez, VI
Van Remmen, H
Richardson, A
AF Zhang, Yiqiang
Liu, Yuhong
Walsh, Michael
Bokov, Alex
Ikeno, Yuji
Jang, Young C.
Perez, Viviana I.
Van Remmen, Holly
Richardson, Arlan
TI Liver specific expression of Cu/ZnSOD extends the lifespan of Sod1 null
mice
SO MECHANISMS OF AGEING AND DEVELOPMENT
LA English
DT Article
DE CuZnSOD; Oxidative stress; Lifespan; Liver-specific transgenic mice
ID MANGANESE SUPEROXIDE-DISMUTASE; SKELETAL-MUSCLE ATROPHY; OXIDATIVE
STRESS; HEPATOCELLULAR-CARCINOMA; HEARING-LOSS; LIPID-PEROXIDATION;
DEFICIENT MICE; AGE; CUZNSOD; LEADS
AB Genetic ablation of CuZn-superoxide dismutase (Sod1) in mice (Sod1(-/-) mice) leads to shortened lifespan with a dramatic increase in hepatocellular carcinoma and accelerated aging phenotypes, including early onset sarcopenia. To study the tissue specific effects of oxidative stress in the Sod1(-/-) mice, we generated mice that only express the human SOD1 gene specifically in the liver of Sod1(-/-) mice (Sod1(-/-)/hSOD1(alb) mice). Expression of hSOD1 in the liver of Sod1(-/-) mice improved liver function, reduced oxidative damage in liver, and partially restored the expression of several genes involved in tumorigenesis, which are abnormally expressed in the livers of the Sod1(-/-) mice. However, liver specific expression of hSOD1 did not prevent the loss of body weight and muscle mass and alterations in the structure of neuromuscular junctions. The expression of hSOD1 in the liver of Sod1(-/-) mice significantly improved the lifespan of Sod1(-/-) mice; however, the lifespan of the Sod1(-/-)/hSOD1(alb) mice was still significantly shorter than wild type mice. Published by Elsevier Ireland Ltd
C1 [Zhang, Yiqiang] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA.
[Liu, Yuhong; Walsh, Michael] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular Biol, San Antonio, TX 78229 USA.
[Liu, Yuhong; Walsh, Michael] Univ Texas Hlth Sci Ctr San Antonio, Dept Biol Struct, San Antonio, TX 78229 USA.
[Bokov, Alex] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol, San Antonio, TX 78229 USA.
[Bokov, Alex] Univ Texas Hlth Sci Ctr San Antonio, Dept Biostat, San Antonio, TX 78229 USA.
[Ikeno, Yuji] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Ikeno, Yuji] South Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA.
[Jang, Young C.] Georgia Inst Technol, Sch Appl Physiol, Atlanta, GA 30332 USA.
[Perez, Viviana I.] Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA.
[Van Remmen, Holly] Oklahoma Med Res Fdn, 825 NE 13th St, Oklahoma City, OK 73104 USA.
[Van Remmen, Holly; Richardson, Arlan] Oklahoma City VA Med Ctr, Oklahoma City, OK USA.
[Richardson, Arlan] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
RP Richardson, A (reprint author), Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
EM LiuY2@uthscsa.edu; walshme125@gmail.com; BOKOV@uthscsa.edu;
youngjang@gatech.edu; Viviana.Perez@oregonstate.edu;
Holly-VanRemmen@omrf.org; arlan-richardson@ouhsc.edu
FU National Institute on Aging [AG-020591]; VA Merit Grants
FX This study was funded as part of a program project grant from the
National Institute on Aging (AG-020591) and VA Merit Grants to HVR and
AR.
NR 37
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0047-6374
J9 MECH AGEING DEV
JI Mech. Ageing Dev.
PD MAR
PY 2016
VL 154
BP 1
EP 8
DI 10.1016/j.mad.2016.01.005
PG 8
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA DH6YN
UT WOS:000372938100001
PM 26839948
ER
PT J
AU Hernandez, SE
Taylor, L
Grembowski, D
Reid, RJ
Wong, E
Nelson, KM
Liu, CF
Fihn, SD
Hebert, PL
AF Hernandez, Susan E.
Taylor, Leslie
Grembowski, David
Reid, Robert J.
Wong, Edwin
Nelson, Karin M.
Liu, Chuan-Fen
Fihn, Stephan D.
Hebert, Paul L.
TI A First Look at PCMH Implementation for Minority Veterans Room for
Improvement
SO MEDICAL CARE
LA English
DT Article
DE primary care; health care delivery; health inequality; disparities;
patient-centered care; health disparities; delivery of health care;
health service research
ID CENTERED MEDICAL HOME; QUALITY-OF-CARE; RACIAL DISPARITIES; NEIGHBORHOOD
ENVIRONMENT; HEALTH-CARE; PATIENT SATISFACTION; OLDER-ADULTS; HOSPITALS;
MORTALITY; BENEFICIARIES
AB Background:
Implementation of Patient Aligned Care Teams (PACT), a patient-centered medical home model, has been inconsistent among the > 900 primary care facilities in the Veterans Health Administration.
Objective:
Estimate if the degree of PACT implementation at a facility varied with the percentage of minority veteran patients at the facility.
Research Design:
Cross-sectional, facility-level analysis of PACT implementation measures in 2012.
Subjects:
Veterans Health Administration hospital-based and community-based primary care facilities.
Measures:
We used a previously validated PACT Implementation Progress Index (Pi(2)) and its 8 domains: access, continuity of care, care coordination, comprehensiveness, self-management support, and patient-centered care and communication, shared decision-making domains, and team functioning. Facilities were categorized as low (< 5.2%, n=208), medium (5.2%-25.8%, n=413), and high (> 25.8%, n=206) percent minority based on the percent of their own veteran population.
Results:
Most minority veterans received care in high minority (69%) and medium minority facilities (29%). In adjusted analyses, medium and high minority facilities scored 0.773 (P=0.009) and 0.930 (P=0.008) points lower on the Pi(2) score relative to low minority facilities. Relative to low minority facilities, both medium and high minority facilities were less likely of having high Pi(2) scores (>= 2) and more likely of having low Pi(2) scores (<=-2). Both medium and high minority facilities had the same 3 domain scores lower than low minority facilities (care coordination, comprehensiveness, and self-management).
Conclusion:
Overall PACT implementation varied with respect to the racial/ethnic composition of a facility, with medium and high minority facilities having a lower implementation scores.
C1 [Hernandez, Susan E.; Grembowski, David; Wong, Edwin; Liu, Chuan-Fen; Hebert, Paul L.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA.
[Hernandez, Susan E.; Taylor, Leslie; Wong, Edwin; Nelson, Karin M.; Liu, Chuan-Fen; Hebert, Paul L.] Seattle Ctr Innovat Vet Ctr & Value Dr Care, Puget Sound Hlth Care Syst, 1660 S Columbian Way S-152, Seattle, WA 98108 USA.
[Reid, Robert J.] Trillium Hlth Partners, Inst Better Hlth, Toronto, ON, Canada.
[Nelson, Karin M.; Fihn, Stephan D.] VA Puget Sound Hlth Care Syst, Gen Internal Med Serv, Seattle, WA USA.
[Nelson, Karin M.; Fihn, Stephan D.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
[Fihn, Stephan D.] Vet Hlth Adm, Off Analyt & Business Intelligence, Washington, DC USA.
RP Hernandez, SE (reprint author), Seattle Ctr Innovat Vet Ctr & Value Dr Care, Puget Sound Hlth Care Syst, 1660 S Columbian Way S-152, Seattle, WA 98108 USA.
EM seh315@uw.edu
FU Agency for Healthcare Research and Quality (AHRQ), US Department of
Health and Human Services [5T32HS013853-7, 5T32HS013853-8, HS023376-01];
VA Health Services Research and Development Career Development Award
[CDA 13-024]; VA
FX This project was funded under Grant Numbers (5T32HS013853-7,
5T32HS013853-8, and HS023376-01) from the Agency for Healthcare Research
and Quality (AHRQ), US Department of Health and Human Services. Data for
this project were developed by the national evaluation team at the PACT
Demonstration Lab Coordinating Center and the VHA Office of Analytics
and Business Intelligence. E.W. is funded by a VA Health Services
Research and Development Career Development Award (CDA 13-024).; E.W.
has previously owned stock in Tenet Healthcare Corp. in the past 3
years. D.G. received support from VA funding for the evaluation of PACT.
L.T., E.W., K.M.N., C.F.-L., S.D.F., P.L.H., and S.E.H. are part of the
national PACT evaluation team. The remaining authors declare no conflict
of interest.
NR 43
TC 1
Z9 1
U1 2
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7079
EI 1537-1948
J9 MED CARE
JI Med. Care
PD MAR
PY 2016
VL 54
IS 3
BP 253
EP 261
DI 10.1097/MLR.0000000000000512
PG 9
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA DH6XM
UT WOS:000372935400006
PM 26871643
ER
PT J
AU Blakeley, JO
Coons, SJ
Corboy, JR
Leidy, NK
Mendoza, TR
Wefel, JS
AF Blakeley, Jaishri O.
Coons, Stephen Joel
Corboy, John R.
Leidy, Nancy Kline
Mendoza, Tito R.
Wefel, Jeffrey S.
TI Clinical outcome assessment in malignant glioma trials: measuring signs,
symptoms, and functional limitations
SO NEURO-ONCOLOGY
LA English
DT Article
DE clinical outcome assessment; clinical trials; endpoints; malignant
glioma
ID QUALITY-OF-LIFE; NEWLY-DIAGNOSED GLIOBLASTOMA; KARNOFSKY PERFORMANCE
STATUS; MODULE EORTC QLQ-BN20; RANDOMIZED PHASE-III; BRAIN-TUMOR MODULE;
HIGH-GRADE GLIOMAS; EUROPEAN-ORGANIZATION; NEUROCOGNITIVE FUNCTION;
COGNITIVE FUNCTION
AB The shared goal of all parties developing therapeutics against malignant gliomas is to positively impact the lives of people affected by these cancers. Clinical outcome assessment (COA) tools, including measures of patient-reported outcome, performance outcome, clinician-reported outcome, and observer-reported outcome, allow patient-focused assessments to complement traditional efficacy measures such as overall survival and radiographic endpoints. This review examines the properties of various COA measures used in malignant glioma clinical trials to date and cross references their content to the priority signs, symptoms, and functional limitations defined through a community survey conducted by the National Brain Tumor Society. The overarching goal of this initiative is to identify COA measures that are feasible and have appropriate psychometric properties for use in this patient population as well as highlight where further development is needed.
C1 [Blakeley, Jaishri O.] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21287 USA.
[Blakeley, Jaishri O.] Johns Hopkins Univ, Dept Neurosurg, Baltimore, MD 21287 USA.
[Blakeley, Jaishri O.] Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21287 USA.
[Coons, Stephen Joel] Crit Path Inst, 1730 E River Rd, Tucson, AZ USA.
[Corboy, John R.] Univ Colorado, Sch Med, Denver Vet Affairs Med Ctr, 12631 East 17th Ave B185, Aurora, CO USA.
[Leidy, Nancy Kline] Evidera, 7101Wisconsin Ave,Suite 1400, Bethesda, MD USA.
[Mendoza, Tito R.; Wefel, Jeffrey S.] Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Bld, Houston, TX 77030 USA.
RP Blakeley, JO (reprint author), Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21287 USA.; Blakeley, JO (reprint author), Johns Hopkins Univ, Dept Neurosurg, Baltimore, MD 21287 USA.; Blakeley, JO (reprint author), Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21287 USA.
EM jblakel3@jhmi.edu
NR 57
TC 0
Z9 0
U1 2
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
EI 1523-5866
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD MAR
PY 2016
VL 18
SU 2
BP 13
EP 20
DI 10.1093/neuonc/nov291
PG 8
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA DH9KO
UT WOS:000373115200002
ER
PT J
AU Singh, S
Rejai, S
Antongiorgi, Z
Gonzalez, N
Stelzner, M
AF Singh, Sumit
Rejai, Sepehr
Antongiorgi, Zarah
Gonzalez, Nestor
Stelzner, Matthias
TI Misconnections in the Critically Ill: Injection of High-Dose Gadolinium
into an External Ventricular Drain
SO A & A CASE REPORTS
LA English
DT Article
ID INTRATHECAL GADOLINIUM; GADOPENTETATE DIMEGLUMINE; ENCEPHALOPATHY;
CISTERNOGRAPHY
AB We report an unfortunate case of accidental administration of intrathecal gadolinium through an external ventricular drain in a postcraniotomy patient during magnetic resonance imaging of the brain. The incident occurred after the venous contrast line was connected mistakenly to the ventricular drainage catheter. The patient subsequently developed confusion, aphasia, and right facial droop with new computed tomography evidence of diffuse cerebral edema and stroke. Review of the magnetic resonance image revealed the inappropriate presence of subarachnoid gadolinium. Despite all interventions, the patient developed irreversible neurologic disability. We address the clinical sequelae, management strategies, and factors contributing to the catheter misconnection that led to this event.
C1 [Singh, Sumit; Rejai, Sepehr; Antongiorgi, Zarah] Univ Calif Los Angeles, Med Ctr, Dept Anesthesiol & Perioperat Med, Los Angeles, CA 90024 USA.
[Gonzalez, Nestor] Univ Calif Los Angeles, Med Ctr, Neurosurg, Los Angeles, CA 90024 USA.
[Stelzner, Matthias] Univ Calif Los Angeles, Med Ctr, VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90024 USA.
RP Singh, S (reprint author), Univ Calif Los Angeles, Dept Anesthesiol & Perioperat Med, 757 Westwood Plaza, Los Angeles, CA 90024 USA.
EM SPSingh@mednet.ucla.edu
OI Gonzalez, Nestor/0000-0002-8277-6317
NR 14
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2325-7237
J9 A A CASE REP
JI A A Case Rep.
PD MAR 1
PY 2016
VL 6
IS 5
BP 121
EP 123
DI 10.1213/XAA.0000000000000230
PG 3
WC Anesthesiology
SC Anesthesiology
GA DH2OT
UT WOS:000372626400004
PM 26462163
ER
PT J
AU Beristianos, MH
Yaffe, K
Cohen, B
Byers, AL
AF Beristianos, Matthew H.
Yaffe, Kristine
Cohen, Beth
Byers, Amy L.
TI PTSD and Risk of Incident Cardiovascular Disease in Aging Veterans
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE PTSD; cardiovascular disease; veterans
ID POSTTRAUMATIC-STRESS-DISORDER; CORONARY-HEART-DISEASE; PERIPHERAL
ARTERIAL-DISEASE; MENTAL-HEALTH PROBLEMS; VIETNAM VETERANS; US VETERANS;
SYMPTOMS; AFGHANISTAN; PREVALENCE; IRAQ
AB Objectives: To determine if late-life posttraumatic stress disorder (PTSD) is associated with cardiovascular disease in a sample of older veterans, and whether the association is independent of medical and psychiatric comorbities. Design: Retrospective cohort study conducted using the Department of Veterans Affairs (VA) National Patient Care Database (2000-2011). Setting: VA medical centers in the United States. Participants: A total of 138,341 veterans 55 years and older without cardiovascular disease at study baseline (2000-2003). Measurements: PTSD and cardiovascular disease (as defined by diagnoses of: cerebrovascular disease [CVD], congestive heart failure [CHF], myocardial infarction [MI], and peripheral vascular disease [PVD]) were identified by ICD-9 codes during study baseline (2000-2003) and follow-up (2004-2011), respectively. Results: 3% of veterans (N = 4,041) had a baseline diagnosis of PTSD. Unadjusted increased risk of incidence of CVD was 80%, CHF was 56%, MI was 82%, and PVD was 60% in veterans with PTSD compared with those without PTSD. After adjustment for demographics, medical comorbidities, substance use, and psychiatric comorbidities, veterans with late-life PTSD were at a 45% increased risk for incident CVD, 26% increased risk for incident CHF, 49% increased risk for incident MI, and 35% increased risk for PVD compared with veterans without late-life PTSD. Conclusions: Findings highlight the longitudinal impact of PTSD on increasing the incidence of cardiovascular disease in older adults. This study implies the need for greater monitoring and treatment of PTSD in older persons, particularly older veterans, to assist in preventing adverse outcomes, such as cardiovascular disease, over the long term.
C1 [Beristianos, Matthew H.; Yaffe, Kristine; Byers, Amy L.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Cohen, Beth] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Beristianos, Matthew H.; Yaffe, Kristine; Cohen, Beth; Byers, Amy L.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Beristianos, Matthew H.] Alliant Int Univ, Calif Sch Profess Psychol, San Francisco, CA USA.
RP Beristianos, MH (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Psychiat, 4150 Clement St,116H, San Francisco, CA 94121 USA.
EM Matthew.Beristianos@ucsf.edu
FU U.S. Department of Defense [W81XWH-11-2-0189]; K24 Midcareer
Investigator Award from the National Institute on Aging [AG031155];
National Heart, Lung, and Blood Institute [K23 HL 094765-0]; American
Heart Association [12CRP11810021]; Takeda, Inc.; National Institute on
Aging
FX This study was funded by U.S. Department of Defense grant
W81XWH-11-2-0189 (principal investigator: Dr. Byers). Dr. Yaffe is
supported in part by a K24 Midcareer Investigator Award from the
National Institute on Aging (AG031155). Dr. Cohen is supported in part
by the National Heart, Lung, and Blood Institute grant K23 HL 094765-0
and grant 12CRP11810021 from the American Heart Association.; Mr.
Beristianos, Dr. Cohen, and Dr. Byers report no financial relationships
with commercial interests. Dr. Yaffe reports having served as a
consultant to Novartis, Inc., and Pfizer for reasons not related to the
current project. She serves on DSMB committees for Takeda, Inc., and a
National Institute on Aging-sponsored study, and also serves on the
Beeson Scientific Advisory Board. The authors have no competing
interests, including specific financial interests or relationships or
affiliations relevant to the subject of this article.
NR 41
TC 7
Z9 7
U1 3
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD MAR
PY 2016
VL 24
IS 3
BP 192
EP 200
DI 10.1016/j.jagp.2014.12.003
PG 9
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA DG8CF
UT WOS:000372309300003
PM 25555625
ER
PT J
AU Diem, SJ
Blackwell, TL
Stone, KL
Yaffe, K
Tranah, G
Cauley, JA
Ancoli-Israel, S
Redline, S
Spira, AP
Hillier, TA
Ensrud, KE
AF Diem, Susan J.
Blackwell, Terri L.
Stone, Katie L.
Yaffe, Kristine
Tranah, Greg
Cauley, Jane A.
Ancoli-Israel, Sonia
Redline, Susan
Spira, Adam P.
Hillier, Teresa A.
Ensrud, Kristine E.
TI Measures of Sleep-Wake Patterns and Risk of Mild Cognitive Impairment or
Dementia in Older Women
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE cognitive aging; sleep disorders; older women; dementia; actigraphy
ID OSTEOPOROTIC FRACTURES; ALZHEIMERS-DISEASE; DECLINE; ADULTS;
FRAGMENTATION; QUESTIONNAIRE; RELIABILITY; ACTIGRAPHY; DURATION; RHYTHMS
AB Objective: Sleep disturbances are common in older adults. Little is known about the sleep of cognitively intact older adults and its relationship to subsequent cognitive impairment. The objective of this study was to examine the association between objective sleep-wake measures and risk of incident cognitive impairment. Methods: In this prospective cohort study encompassing four U.S. sites, 1,245 women (mean age: 82.6 years) without dementia participated in the Study of Osteoporotic Fractures and completed actigraphy at the baseline visit and comprehensive cognitive assessment at follow-up. The association between sleep-wake patterns measured by actigraphy and risk of incident mild cognitive impairment (MCI) and dementia was examined. Results: A total of 473 women (38%) developed cognitive impairment during an average (SD) follow-up of 4.9 (0.6) years; 290 (23.3%) developed MCI and 183 (14.7%) developed dementia. After controlling for multiple potential confounders, women in the lowest quartile of average sleep efficiency (<74%) had a 1.5-fold higher odds of developing MCI or dementia compared with women in the highest quartile of sleep efficiency (>86%) (odds ratio: Q1 versus Q4 1.53; 95% CI: 1.07, 2.19; Wald chi(2) [1, N = 1,223] = 5.34 for p for trend = 0.03). Longer average sleep latency, but not total sleep time, was also associated with higher odds of developing cognitive impairment. Greater variability in both sleep efficiency and total sleep time was associated with an increased odds of developing MCI or dementia. Conclusion: Lower average sleep efficiency, longer average sleep latency, and greater variability in sleep efficiency and total sleep time are associated with increased odds of developing cognitive impairment. Further research is needed to explore the mechanisms underlying these associations.
C1 [Diem, Susan J.; Ensrud, Kristine E.] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA.
[Diem, Susan J.; Ensrud, Kristine E.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN 55415 USA.
[Blackwell, Terri L.; Stone, Katie L.; Tranah, Greg] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA.
[Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA.
[Cauley, Jane A.] Univ Pittsburgh, Dept Epidemiol, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA.
[Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA.
[Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
[Redline, Susan] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, 75 Francis St, Boston, MA 02115 USA.
[Redline, Susan] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.
[Spira, Adam P.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA.
[Hillier, Teresa A.] Kaiser Permanente Ctr Hlth Res, Portland, OR USA.
[Ensrud, Kristine E.] Minneapolis VA Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA.
RP Diem, SJ (reprint author), Univ Minnesota, 1100 Washington Ave S, Minneapolis, MN 55415 USA.
EM sdiem@umn.edu
RI Cauley, Jane/N-4836-2015
OI Cauley, Jane/0000-0003-0752-4408
FU National Institute on Aging [RO1 AG005407, RO1 AR35582, ROA AR35583, RO1
AR35584, RO1 AG005394, RO1 AG027574, RO1 AG027576, KO1 AG033195]
FX The Study of Osteoporotic Fractures is supported by grants RO1 AG005407,
RO1 AR35582, ROA AR35583, RO1 AR35584, RO1 AG005394, RO1 AG027574, RO1
AG027576, and KO1 AG033195 from the National Institute on Aging. The
funding agencies had no direct role in the conduct of the study; the
collection, management, analyses and interpretation of the data; or
preparation or approval of the manuscript. All authors have nothing to
disclose.
NR 49
TC 2
Z9 2
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD MAR
PY 2016
VL 24
IS 3
BP 248
EP 258
DI 10.1016/j.jagp.2015.12.002
PG 11
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA DG8CF
UT WOS:000372309300009
PM 26964485
ER
PT J
AU Schlosser, RJ
Storck, K
Cortese, BM
Uhde, TW
Rudmik, L
Soler, ZM
AF Schlosser, Rodney J.
Storck, Kristina
Cortese, Bernadette M.
Uhde, Thomas W.
Rudmik, Luke
Soler, Zachary M.
TI Depression in chronic rhinosinusitis: A controlled cohort study
SO AMERICAN JOURNAL OF RHINOLOGY & ALLERGY
LA English
DT Article
ID ENDOSCOPIC SINUS SURGERY; QUALITY-OF-LIFE; INVENTORY-II;
DIABETES-MELLITUS; DISEASE SEVERITY; SYMPTOMS; OUTCOMES; HEALTH; IMPACT;
ASSOCIATION
AB Background: Depression in patients with chronic rhinosinusitis (CRS) is underdiagnosed but significantly impacts treatment outcomes and health care utilization.
Objective: To compare undiagnosed depression in a CRS cohort with a healthy, non-CRS control cohort.
Methods: A case-control study of patients with symptomatic CRS and a non-CRS control cohort was performed. Demographic and comorbidity factors were correlated to depression-specific outcomes by using the Beck Depression Inventory II (BDI).
Results: We enrolled 42 patients with CRS and 88 control patients with no history of CRS. Physician-diagnosed depression was equivalent in CRS and control patients (6% and 9%, respectively). BDI-detected depression was higher among patients with CRS compared with controls (31% versus 14.8%, respectively; p = 0.031). BDI scores were higher in patients with CRS even when controlling for comorbid asthma, allergy, and aspirin sensitivity. When examined by polyp status, the patients without polyps had more depression than did the controls (38% versus 14.8%; p = 0.048). The somatic subscale scores of the BDI were worse in patients with CRS (p = 0.004), whereas the cognitive subscale trended toward significance (p = 0.081).
Conclusion: Depression may be more common in CRS than previously recognized, especially in patients without polyps. Somatic subscale scores of the BDI are increased in CRS and may impact future treatment outcomes.
C1 [Schlosser, Rodney J.] Ralph H Johnson VA Med Ctr, Dept Surg, Charleston, SC USA.
[Schlosser, Rodney J.; Storck, Kristina; Soler, Zachary M.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA.
[Cortese, Bernadette M.; Uhde, Thomas W.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Rudmik, Luke] Univ Calgary, Dept Surg, Div Otolaryngol Head & Neck Surg, Calgary, AB, Canada.
RP Schlosser, RJ (reprint author), Med Univ S Carolina, Dept Otolaryngol, 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA.
EM schlossr@musc.edu
FU Flight Attendant Medical Research Institute [ID113042_CIA]; National
Institute on Deafness and Other Communication Disorders, one of the
National Institutes of Health, Bethesda, Maryland [R01 DC005805, R03
DC013651-01]; National Institute of Mental Health [K01 MH090548];
Entellus; IntersectENT; OptiNose
FX Supported by a grant from the Flight Attendant Medical Research
Institute (ID113042_CIA). Z.M. Soler is also supported by grants from
the National Institute on Deafness and Other Communication Disorders,
one of the National Institutes of Health, Bethesda, Maryland (R01
DC005805; R03 DC013651-01). B.M. Cortese is supported by a grant from
the National Institute of Mental Health (K01 MH090548).; Z.M. Soler is a
consultant for Olympus, which is not affiliated with this manuscript,
and has grant support from Entellus and IntersectENT. R.J. Schlosser is
supported by grants from OptiNose, Entellus, and IntersectENT, which are
not associated with this manuscript, and is a consultant for Olympus,
Meda, and Arrinex, which are not affiliated with this study. The
remaining authors have no conflicts of interest pertaining to this
article
NR 33
TC 6
Z9 6
U1 1
U2 3
PU OCEAN SIDE PUBLICATIONS INC
PI PROVIDENCE
PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA
SN 1945-8924
EI 1945-8932
J9 AM J RHINOL ALLERGY
JI Am. J. Rhinol. Allergy
PD MAR-APR
PY 2016
VL 30
IS 2
BP 128
EP 133
DI 10.2500/ajra.2016.30.4290
PG 6
WC Otorhinolaryngology
SC Otorhinolaryngology
GA DG8PL
UT WOS:000372346000019
PM 26980393
ER
PT J
AU Lin, JE
Neylan, TC
Epel, E
O'Donovan, A
AF Lin, Joy E.
Neylan, Thomas C.
Epel, Elissa
O'Donovan, Aoife
TI Associations of childhood adversity and adulthood trauma with C-reactive
protein: A cross-sectional population-based study
SO BRAIN BEHAVIOR AND IMMUNITY
LA English
DT Article
DE Childhood adversity; Adulthood trauma; C-reactive protein; Immune
system; Inflammation
ID POSTTRAUMATIC-STRESS-DISORDER; INTIMATE PARTNER VIOLENCE; EARLY-LIFE
STRESS; ELEVATED INFLAMMATION; MENTAL-HEALTH; CARDIOVASCULAR-DISEASE;
PSYCHIATRIC-DISORDERS; PSYCHOLOGICAL STRESS; GENE-EXPRESSION; RISK
AB Mounting evidence highlights specific forms of psychological stress as risk factors for ill health. Particularly strong evidence indicates that childhood adversity and adulthood trauma exposure increase risk for physical and psychiatric disorders, and there is emerging evidence that inflammation may play a key role in these relationships. In a population-based sample from the Health and Retirement Study (n = 11,198, mean age 69 +/- 10), we examine whether childhood adversity, adulthood trauma, and the interaction between them are associated with elevated levels of the systemic inflammatory marker high sensitivity C-reactive protein (hsCRP). All models were adjusted for age, gender, race, education, and year of data collection, as well as other possible confounds in follow-up sensitivity analyses. In our sample, 67% of individuals had experienced at least one traumatic event during adulthood, and those with childhood adversity were almost three times as likely to have experienced trauma as an adult. Childhood adversities and adulthood traumas were independently associated with elevated levels of hsCRP (beta = 0.03, p = 0.01 and beta = 0.05, p < 0.001, respectively). Those who had experienced both types of stress had higher levels of hsCRP than those with adulthood trauma alone, Estimate = -0.06, 95% CI [-0.003, -0.12], p = 0.04, but not compared to those with childhood adversity alone, Estimate = -0.06, 95% CI [0.03, -0.16], p = 0.19. There was no interaction between childhood and adulthood trauma exposure. To our knowledge, this is the first study to examine adulthood trauma exposure and inflammation in a large population-based sample, and the first to explore the interaction of childhood adversity and adulthood trauma with inflammation. Our study demonstrates the prevalence of trauma-related inflammation in the general population and suggests that childhood adversity and adulthood trauma are independently associated with elevated inflammation. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Lin, Joy E.] Univ Calif San Francisco, Sch Med, 500 Parnassus Ave, San Francisco, CA 94143 USA.
[Neylan, Thomas C.; Epel, Elissa; O'Donovan, Aoife] Univ Calif San Francisco, Dept Psychiat, 500 Parnassus Ave, San Francisco, CA 94143 USA.
[Lin, Joy E.; Neylan, Thomas C.; O'Donovan, Aoife] San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA.
RP Lin, JE (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, 4150 Clement St 116C-1, San Francisco, CA 94121 USA.
EM joy.lin@ucsf.edu; thomas.neylan@ucsf.edu; elissa.epel@ucsf.edu;
aoife.odonovan@ucsf.edu
FU National Institute on Aging [NIA U01AG009740]; National Center for
Advancing Translational Sciences Career Development Award at the
University of California, San Francisco [KL2 TR000143]; Society in
Science-Branco Weiss Fellowship; UCSF Dean's Office Medical Student
Research Program
FX The HRS (Health and Retirement Study) is sponsored by the National
Institute on Aging (grant number NIA U01AG009740) and was conducted by
the University of Michigan. A.O.D. was supported by a National Center
for Advancing Translational Sciences Career Development Award at the
University of California, San Francisco (KL2 TR000143) and a Society in
Science-Branco Weiss Fellowship. J.E.L. was supported by the UCSF Dean's
Office Medical Student Research Program. The authors would like to
acknowledge Tom Metzler for statistical support in preparation of this
manuscript.
NR 79
TC 1
Z9 1
U1 4
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0889-1591
EI 1090-2139
J9 BRAIN BEHAV IMMUN
JI Brain Behav. Immun.
PD MAR
PY 2016
VL 53
BP 105
EP 112
DI 10.1016/j.bbi.2015.11.015
PG 8
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA DG9BJ
UT WOS:000372377500012
PM 26616398
ER
PT J
AU Singh, JA
Ramachandran, R
AF Singh, Jasvinder A.
Ramachandran, Rekha
TI Sex differences in characteristics, utilization, and outcomes of patient
undergoing total elbow arthroplasty: a study of the US nationwide
inpatient sample
SO CLINICAL RHEUMATOLOGY
LA English
DT Article
DE Discharge; Hospital stay; Mortality; Outcomes; Sex; TEA; Total elbow
arthroplasty; Utilization
ID SURGEON PROCEDURE VOLUME; TOTAL KNEE ARTHROPLASTY; UNITED-STATES;
SHOULDER ARTHROPLASTY; HIP-REPLACEMENT; HOME; ASSOCIATION; DISCHARGE;
MORTALITY; SUPPORT
AB The aim of this study was to compare patient characteristics, utilization rates, and outcomes after total elbow arthroplasty (TEA) by sex. We used the nationwide inpatient sample from 1998 to 2011 to study sex-related time trends in patient characteristics, comorbidity, and outcomes after TEA. We used chi-squared test, analysis of variance, and the Cochran-Armitage test to assess differences in utilization rates and characteristics over time by sex and logistic regression to compare mortality, discharge disposition, and the length of hospital stay by sex. Overall TEA utilization 0.45 in 1998 to 0.96 per 100,000 in 2011 (p < 0.0001). The utilization rates were significantly higher in females compared to males throughout the study period: 0.62 vs. 0.29 in 1998 (p < 0.0001) and 1.31 vs. 0.70 in 2011 (p < 0.0001). Compared to males, females undergoing TEA were more likely to be white (79.7 vs. 71.4 %; p < 0.0001), have rheumatoid arthritis (16.7 vs. 8.1 %; p < 0.0001), and have Deyo-Charlson index of 2 or more (11.3 vs. 5.9 %; p < 0.0001) and were older (63.5 vs. 51.4 years; p < 0.0001). Compared to males undergoing TEA, females had significantly lower mortality, 0.1 vs. 0.4 % (p = 0.03); lower proportion were discharged to home, 81.9 vs. 89.6 % (p < 0.0001), and fewer had has index hospital stay above the median, 30.0 vs. 33.0 % (p = 0.01); most differences were significant after multivariable adjustment. TEA utilization in the USA more than doubled in the last 14 years, with rates higher in females than males. Females had better outcomes after TEA than men. Preoperative risk communication should be sex-specific based on these data.
C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA.
[Singh, Jasvinder A.; Ramachandran, Rekha] Univ Alabama Birmingham, Sch Med, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.; Ramachandran, Rekha] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA.
RP Singh, JA (reprint author), Univ Alabama Birmingham, Sch Med, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.; Singh, JA (reprint author), Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.
EM jasvinder.md@gmail.com
FU Agency for Health Quality and Research Center for Education and Research
on Therapeutics (CERTs); National Institute of Arthritis,
Musculoskeletal and Skin Diseases (NIAMS); National Institute of Aging
(NIA); National Cancer Institute (NCI)
FX This material is the result of work supported by the resources and use
of facilities at the Birmingham VA Medical Center, Alabama, USA. J.A.S.
is also supported by grants from the Agency for Health Quality and
Research Center for Education and Research on Therapeutics (CERTs),
National Institute of Arthritis, Musculoskeletal and Skin Diseases
(NIAMS), National Institute of Aging (NIA), and National Cancer
Institute (NCI).
NR 19
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0770-3198
EI 1434-9949
J9 CLIN RHEUMATOL
JI Clin. Rheumatol.
PD MAR
PY 2016
VL 35
IS 3
BP 723
EP 731
DI 10.1007/s10067-014-2778-9
PG 9
WC Rheumatology
SC Rheumatology
GA DG9UJ
UT WOS:000372429000022
PM 25316506
ER
PT J
AU Burge, SK
Katerndahl, DA
Wood, RC
Becho, J
Ferrer, RL
Talamantes, M
AF Burge, Sandra K.
Katerndahl, David A.
Wood, Robert C.
Becho, Johanna
Ferrer, Robert L.
Talamantes, Melissa
TI Using Complexity Science to Examine Three Dynamic Patterns of Intimate
Partner Violence
SO FAMILIES SYSTEMS & HEALTH
LA English
DT Article
DE spouse abuse; battered women; domestic violence; nonlinear dynamics;
longitudinal studies
ID PRIMARY-CARE; LYAPUNOV EXPONENTS; TIME-SERIES; RELIABILITY; SEVERITY;
VALIDITY; SYSTEMS; HEALTH; CHAOS; MOOD
AB Introduction: The partner violence literature describes 3 dominant models of dynamics of partner aggression: cycle of violence, family systems theory, and Duluth model (power and control wheel). Complexity science describes 3 patterns of system dynamics: periodic, chaotic, and random. Are these parallel patterns? In this analysis, investigators calculated dynamic patterns (periodic, chaotic, and random) using 84 daily reports of male-to-female aggression and assessed the "fit" between time-series-derived patterns of male partners' violent behaviors and literature-based models of violence dynamics. Method: Participants were 200 women in moderately violent intimate relationships who completed a telephone survey about their relationships every day for 12 weeks. They also completed baseline and end-of-study surveys and maintained telephone contact with the study team weekly. Of 200 participants, 135 women provided enough data to be assigned to period, chaotic, or random groups. Results: Group membership included 16 women in periodic, 40 in chaotic, and 79 in random groups. Consistent with the cycle of violence, periodic women found violence to be predictable and controllable. Consistent with the Duluth model, women in the random group found violence to be unpredictable and out of their control, occurring with high frequency. The chaotic group had the lowest frequency and severity of violence, lowest stress and arguments, and the highest marital satisfaction. Discussion: The most common dynamic pattern in partner violence is random, which exhibits high frequency and unpredictability of aggression. Complexity science suggests interventions in random systems have unpredictable outcomes, posing great challenges for clinicians who work with victims of violence.
C1 [Burge, Sandra K.; Katerndahl, David A.; Wood, Robert C.; Becho, Johanna; Ferrer, Robert L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, 7703 Floyd Curl Dr,Mail Code 7795, San Antonio, TX 78229 USA.
[Talamantes, Melissa] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Burge, SK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, 7703 Floyd Curl Dr,Mail Code 7795, San Antonio, TX 78229 USA.
EM burge@uthscsa.edu
FU "Dynamics of Human Behavior" program, National Science Foundation
[0525026]
FX This study was funded with a grant from the "Dynamics of Human Behavior"
program, National Science Foundation, Award 0525026. Automated data
collection was provided by the University of Colorado, Department of
Family Medicine Information Services group. We thank Stephanie Mitchell,
Kelli Giacomini, and Wilson Pace for their invaluable assistance with
IVR. We also express appreciation to Norma Cantu and Diandrea Garza for
their commitment to screening and enrolling women for this study.
NR 39
TC 2
Z9 2
U1 1
U2 5
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1091-7527
EI 1939-0602
J9 FAM SYST HEALTH
JI Fam. Syst. Health
PD MAR
PY 2016
VL 34
IS 1
BP 4
EP 14
DI 10.1037/fsh0000170
PG 11
WC Health Care Sciences & Services; Family Studies; Public, Environmental &
Occupational Health
SC Health Care Sciences & Services; Family Studies; Public, Environmental &
Occupational Health
GA DG8WG
UT WOS:000372363700002
PM 26618639
ER
PT J
AU Schulman, JM
Oh, DH
Sanborn, JZ
Pincus, L
McCalmont, TH
Cho, RJ
AF Schulman, Joshua M.
Oh, Dennis H.
Sanborn, J. Zachary
Pincus, Laura
McCalmont, Timothy H.
Cho, Raymond J.
TI Multiple Hereditary Infundibulocystic Basal Cell Carcinoma Syndrome
Associated With a Germline SUFU Mutation
SO JAMA DERMATOLOGY
LA English
DT Article
ID GORLIN SYNDROME; MEDULLOBLASTOMA
AB IMPORTANCE Multiple hereditary infundibulocystic basal cell carcinoma syndrome (MHIBCC) is a rare genodermatosis in which numerous indolent, well-differentiated basal cell carcinomas develop primarily on the face and genitals, without other features characteristic of basal cell nevus syndrome. The cause is unknown. The purpose of the study was to identify a genetic basis for the syndrome and a mechanism by which the associated tumors develop.
OBSERVATIONS Whole-exome sequencing of 5 tumors and a normal buccal mucosal sample from a patient with MHIBCC was performed. A conserved splice-site mutation in 1 copy of the suppressor of fused gene (SUFU) was identified in all tumor and normal tissue samples. Additional distinct deletions of the trans SUFU allele were identified in all tumor samples, none of which were present in the normal sample.
CONCLUSIONS AND RELEVANCE A germline SUFU mutation was present in a patient with MHIBCC, and additional acquired SUFU mutations underlie the development of infundibulocystic basal cell carcinomas. The downstream location of the SUFU gene within the sonic hedgehog pathway may explain why its loss is associated with relatively well-differentiated tumors and suggests that MHIBCC will not respond to therapeutic strategies, such as smoothened inhibitors, that target upstream components of this pathway.
C1 [Schulman, Joshua M.; Oh, Dennis H.; Pincus, Laura; McCalmont, Timothy H.; Cho, Raymond J.] Univ Calif San Francisco, Dept Dermatol, 2340 Sutter St,S431, San Francisco, CA 94115 USA.
[Schulman, Joshua M.; Pincus, Laura; McCalmont, Timothy H.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94115 USA.
[Oh, Dennis H.] San Francisco VA Med Ctr, Dermatol Res Unit, San Francisco, CA USA.
[Sanborn, J. Zachary] NantOmics LLC, Santa Cruz, CA USA.
RP Cho, RJ (reprint author), Univ Calif San Francisco, Dept Dermatol, 2340 Sutter St,S431, San Francisco, CA 94115 USA.
EM chorj@derm.ucsf.edu
FU Well Aging Research Center, Samsung Advanced Institute of Technology;
National Cancer Institute, National Institutes of Health [K08 CA169865]
FX This study was supported by the Well Aging Research Center, Samsung
Advanced Institute of Technology, under the auspices of Sang Chul Park,
MD, PhD, and by grant K08 CA169865 from the National Cancer Institute,
National Institutes of Health (Dr Cho).
NR 15
TC 2
Z9 2
U1 1
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6068
EI 2168-6084
J9 JAMA DERMATOL
JI JAMA Dermatol.
PD MAR
PY 2016
VL 152
IS 3
BP 323
EP 327
DI 10.1001/jamadermatol.2015.4233
PG 5
WC Dermatology
SC Dermatology
GA DH0GH
UT WOS:000372460300019
PM 26677003
ER
PT J
AU Morone, NE
Greco, CM
Moore, CG
Rollman, BL
Lane, B
Morrow, LA
Glynn, NW
Weiner, DK
AF Morone, Natalia E.
Greco, Carol M.
Moore, Charity G.
Rollman, Bruce L.
Lane, Bridget
Morrow, Lisa A.
Glynn, Nancy W.
Weiner, Debra K.
TI A Mind-Body Program for Older Adults With Chronic Low Back Pain A
Randomized Clinical Trial
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID SELF-EFFICACY; PSYCHOMETRIC PROPERTIES; NATIONAL-HEALTH; SCALE;
METAANALYSIS; MINDFULNESS; VALIDATION; MEDITATION; DISABILITY; INTENSITY
AB IMPORTANCE Treatment of chronic low back pain (LBP) in older adults is limited by the adverse effects of analgesics. Effective nonpharmacologic treatment options are needed.
OBJECTIVE To determine the effectiveness of a mind-body program at increasing function and reducing pain in older adults with chronic LBP.
DESIGN, SETTING, AND PARTICIPANTS This single-blind, randomized clinical trial compared a mind-body program (n = 140) with a health education program (n = 142). Community-dwelling older adults residing within the Pittsburgh metropolitan area were recruited from February 14, 2011, to June 30, 2014, with 6-month follow-up completed by April 9, 2015. Eligible participants were 65 years or older with functional limitations owing to their chronic LBP (>= 11 points on the Roland and Morris Disability Questionnaire) and chronic pain (duration >= 3 months) of moderate intensity. Data were analyzed from March 1 to July 1, 2015.
INTERVENTIONS The intervention and control groups received an 8-week group program followed by 6 monthly sessions. The intervention was modeled on the Mindfulness-Based Stress Reduction program; the control program, on the "10 Keys" to Healthy Aging.
MAIN OUTCOMES AND MEASURES Follow-up occurred at program completion and 6 months later. The score on the Roland and Morris Disability Questionnaire was the primary outcome and measured functional limitations owing to LBP. Pain (current, mean, and most severe in the past week) was measured with the Numeric Pain Rating Scale. Secondary outcomes included quality of life, pain self-efficacy, and mindfulness. Intent-to-treat analyses were conducted.
RESULTS Of 1160 persons who underwent screening, 282 participants enrolled in the trial (95 men [33.7%] and 187 women [66.3%]; mean [SD] age, 74.5 [6.6] years). The baseline mean (SD) Roland and Morris Disability Questionnaire scores for the intervention and control groups were 15.6 (3.0) and 15.4 (3.0), respectively. Compared with the control group, intervention participants improved an additional -1.1 (mean, 12.1 vs 13.1) points at 8 weeks and -0.04 (mean, 12.2 vs 12.6) points at 6 months (effect sizes, -0.23 and -0.08, respectively) on the Roland and Morris Disability Questionnaire. By 6 months, the intervention participants improved on the Numeric Pain Rating Scale current and most severe pain measures an additional -1.8 points (95% CI, -3.1 to -0.05 points; effect size, -0.33) and -1.0 points (95% CI, -2.1 to 0.2 points; effect size, -0.19), respectively. The changes in Numeric Pain Rating Scale mean pain measure after the intervention were not significant (-0.1 [95% CI, -1.1 to 1.0] at 8 weeks and -1.1 [95% CI, -2.2 to -0.01] at 6 months; effect size, -0.01 and -0.22, respectively).
CONCLUSIONS AND RELEVANCE A mind-body program for chronic LBP improved short-term function and long-term current and most severe pain. The functional improvement was not sustained, suggesting that future development of the intervention could focus on durability.
C1 [Morone, Natalia E.; Rollman, Bruce L.; Lane, Bridget] Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, Div Gen Internal Med, 230 McKee Pl,Ste 600, Pittsburgh, PA 15213 USA.
[Morone, Natalia E.; Rollman, Bruce L.; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Clin & Translat Sci Inst, Pittsburgh, PA 15213 USA.
[Morone, Natalia E.; Weiner, Debra K.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
[Greco, Carol M.] Univ Pittsburgh, Sch Med, UPMC, Dept Psychiat,Ctr Integrat Med, Pittsburgh, PA 15213 USA.
[Moore, Charity G.] Carolinas HealthCare Syst, Dickson Adv Analyt, Charlotte, NC USA.
[Morrow, Lisa A.; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA.
[Glynn, Nancy W.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA.
[Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15213 USA.
[Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr Med, Pittsburgh, PA 15213 USA.
RP Morone, NE (reprint author), Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, Div Gen Internal Med, 230 McKee Pl,Ste 600, Pittsburgh, PA 15213 USA.
EM moronene@upmc.edu
OI Glynn, Nancy/0000-0003-2265-0162; Moore, Charity/0000-0002-0060-0124
FU National Institutes of Health [R01 AG034078]
FX This study was supported by grant R01 AG034078 from the National
Institutes of Health.
NR 29
TC 13
Z9 13
U1 8
U2 18
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD MAR
PY 2016
VL 176
IS 3
BP 329
EP 337
DI 10.1001/jamainternmed.2015.8033
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA DG7ZP
UT WOS:000372302500010
PM 26903081
ER
PT J
AU Auer, R
Vittinghoff, E
Yaffe, K
Kunzi, A
Kertesz, SG
Levine, DA
Albanese, E
Whitmer, RA
Jacobs, DR
Sidney, S
Glymour, MM
Pletcher, MJ
AF Auer, Reto
Vittinghoff, Eric
Yaffe, Kristine
Kuenzi, Arnaud
Kertesz, Stefan G.
Levine, Deborah A.
Albanese, Emiliano
Whitmer, Rachel A.
Jacobs, David R., Jr.
Sidney, Stephen
Glymour, M. Maria
Pletcher, Mark J.
TI Association Between Lifetime Marijuana Use and Cognitive Function in
Middle Age The Coronary Artery Risk Development in Young Adults (CARDIA)
Study
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID POPULATION-BASED COHORT; HEAVY CANNABIS USERS; SOCIOECONOMIC-STATUS;
DRUG-USE; DECLINE; HEALTH; IQ; INTERFERENCE; EXPOSURE; MIDLIFE
AB IMPORTANCE Marijuana use is increasingly common in the United States. It is unclear whether it has long-term effects on memory and other domains of cognitive function.
OBJECTIVE To study the association between cumulative lifetime exposure to marijuana use and cognitive performance in middle age.
DESIGN, SETTING, AND PARTICIPANTS We used data from the Coronary Artery Risk Development in Young Adults (CARDIA) study, a cohort of 5115 black and white men and women aged 18 to 30 years at baseline from March 25, 1985, to June 7, 1986 (year 0), and followed up over 25 years from June 7, 1986, to August 31, 2011, to estimate cumulative years of exposure to marijuana (1 year = 365 days of marijuana use) using repeated measures and to assess associations with cognitive function at year 25. Linear regression was used to adjust for demographic factors, cardiovascular risk factors, tobacco smoking, use of alcohol and illicit drugs, physical activity, depression, and results of the mirror star tracing test (a measure of cognitive function) at year 2. Data analysis was conducted from June 7, 1986, to August 31, 2011.
MAIN OUTCOMES AND MEASURES Three domains of cognitive function were assessed at year 25 using the Rey Auditory Verbal Learning Test (verbal memory), the Digit Symbol Substitution Test (processing speed), and the Stroop Interference Test (executive function).
RESULTS Among 3385 participants with cognitive function measurements at the year 25 visit, 2852 (84.3%) reported past marijuana use, but only 392 (11.6%) continued to use marijuana into middle age. Current use of marijuana was associated with worse verbal memory and processing speed; cumulative lifetime exposure was associated with worse performance in all 3 domains of cognitive function. After excluding current users and adjusting for potential confounders, cumulative lifetime exposure to marijuana remained significantly associated with worse verbal memory. For each 5 years of past exposure, verbal memory was 0.13 standardized units lower (95% CI, -0.24 to -0.02; P =.02), corresponding to a mean of 1 of 2 participants remembering 1 word fewer from a list of 15 words for every 5 years of use. After adjustment, we found no associations with lower executive function (-0.03 [95% CI, -0.12 to 0.07]; P =.56) or processing speed (-0.04 [95% CI, -0.16 to 0.08]; P =.51).
CONCLUSIONS AND RELEVANCE Past exposure to marijuana is associated with worse verbal memory but does not appear to affect other domains of cognitive function.
C1 [Auer, Reto; Vittinghoff, Eric; Yaffe, Kristine; Glymour, M. Maria; Pletcher, Mark J.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Auer, Reto; Kuenzi, Arnaud] Univ Lausanne, Dept Ambulatory Care & Community Med, Lausanne, Switzerland.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat & Neurol, San Francisco, CA 94143 USA.
[Kertesz, Stefan G.] Birmingham Vet Affairs Med Ctr, Ctr Surg Med & Acute Care Res, Birmingham, AL USA.
[Kertesz, Stefan G.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL USA.
[Levine, Deborah A.] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA.
[Levine, Deborah A.] Vet Affairs Ctr Clin Management Res, Ann Arbor, MI USA.
[Levine, Deborah A.] Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA.
[Levine, Deborah A.] Univ Michigan, Dept Neurol, Ann Arbor, MI USA.
[Levine, Deborah A.] Univ Michigan, Stroke Program, Ann Arbor, MI 48109 USA.
[Albanese, Emiliano] Univ Geneva, Dept Psychiat, Geneva, Switzerland.
[Whitmer, Rachel A.; Sidney, Stephen] Kaiser Permanente, Div Res, Oakland, CA USA.
[Jacobs, David R., Jr.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
RP Auer, R (reprint author), Univ Lausanne, Dept Ambulatory Care & Community Med, Rue Bugnon 44, CH-1011 Lausanne, Switzerland.
EM reto.auer@hospvd.ch
OI Glymour, M. Maria/0000-0001-9644-3081
FU National Heart, Lung, and Blood Institute (NHLBI); University of Alabama
at Birmingham [HHSN268201300025C, HHSN268201300026C]; Northwestern
University [HHSN268201300027C]; University of Minnesota
[HHSN268201300028C]; Kaiser Foundation Research Institute
[HHSN268201300029C]; Johns Hopkins University School of Medicine
[HHSN268200900041C]; Intramural Research Program of the National
Institute on Aging (NIA); NIA [AG0005]; NHLBI [AG0005]
FX The Coronary Artery Risk Development in Young Adults (CARDIA) study is
conducted and supported by the National Heart, Lung, and Blood Institute
(NHLBI) in collaboration with the University of Alabama at Birmingham
(grants HHSN268201300025C and HHSN268201300026C), Northwestern
University (grant HHSN268201300027C), University of Minnesota (grant
HHSN268201300028C), Kaiser Foundation Research Institute (grant
HHSN268201300029C), and The Johns Hopkins University School of Medicine
(grant HHSN268200900041C). The CARDIA study is also partially supported
by the Intramural Research Program of the National Institute on Aging
(NIA) and an intra-agency agreement between the NIA and the NHLBI
(AG0005).
NR 45
TC 13
Z9 13
U1 7
U2 18
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD MAR
PY 2016
VL 176
IS 3
BP 352
EP 361
DI 10.1001/jamainternmed.2015.7841
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA DG7ZP
UT WOS:000372302500014
PM 26831916
ER
PT J
AU Widera, E
Talebreza, S
AF Widera, Eric
Talebreza, Shaida
TI Variability in Hospice Care at the Very End of Life
SO JAMA INTERNAL MEDICINE
LA English
DT Editorial Material
C1 [Widera, Eric] Univ Calif San Francisco, Dept Internal Med, Div Geriatr, San Francisco, CA 94143 USA.
[Widera, Eric] San Francisco VA Med Ctr, 4150 Clement St,Campus Box 181G, San Francisco, CA 94121 USA.
[Talebreza, Shaida] Univ Utah, Sch Med, Dept Internal Med, Div Geriatr, Salt Lake City, UT USA.
[Talebreza, Shaida] George E Wahlen Salt Lake City Vet Affairs Med Ct, Salt Lake City, UT USA.
[Talebreza, Shaida] Inspirat Hosp, Salt Lake City, UT USA.
RP Widera, E (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Campus Box 181G, San Francisco, CA 94121 USA.
EM eric.widera@ucsf.edu
NR 2
TC 2
Z9 2
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD MAR
PY 2016
VL 176
IS 3
BP 370
EP 371
DI 10.1001/jamainternmed.2015.7931
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA DG7ZP
UT WOS:000372302500017
PM 26856885
ER
PT J
AU Kim, TY
Schafer, AL
AF Kim, Tiffany Y.
Schafer, Anne L.
TI Variability in DXA Reporting and Other Challenges in Osteoporosis
Evaluation
SO JAMA INTERNAL MEDICINE
LA English
DT Editorial Material
ID PREVENTION; FRACTURE; THERAPY
C1 [Kim, Tiffany Y.; Schafer, Anne L.] San Francisco VA Med Ctr, Endocrine Res Unit, 1700 Owens St,Room 367, San Francisco, CA 94158 USA.
RP Schafer, AL (reprint author), San Francisco VA Med Ctr, Endocrine Res Unit, 1700 Owens St,Room 367, San Francisco, CA 94158 USA.
EM anne.schafer@ucsf.edu
FU CSRD VA [IK2 CX000549]
NR 7
TC 1
Z9 1
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD MAR
PY 2016
VL 176
IS 3
BP 393
EP 395
DI 10.1001/jamainternmed.2015.7550
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA DG7ZP
UT WOS:000372302500025
PM 26746871
ER
PT J
AU Waltz, P
Luciano, J
Peitzman, A
Zuckerbraun, BS
AF Waltz, Paul
Luciano, Jason
Peitzman, Andrew
Zuckerbraun, Brian S.
TI Femoral Hernias in Patients Undergoing Total Extraperitoneal
Laparoscopic Hernia Repair: Including Routine Evaluation of the Femoral
Canal in Approaches to Inguinal Hernia Repair
SO JAMA SURGERY
LA English
DT Letter
C1 [Waltz, Paul; Luciano, Jason; Peitzman, Andrew; Zuckerbraun, Brian S.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA.
[Zuckerbraun, Brian S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Zuckerbraun, BS (reprint author), Univ Pittsburgh, Dept Surg, VA Pittsburgh Healthcare Syst, F1267 PUH,200 Lothrop St, Pittsburgh, PA 15213 USA.
EM zuckerbraunbs@upmc.edu
NR 4
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6254
EI 2168-6262
J9 JAMA SURG
JI JAMA Surg.
PD MAR
PY 2016
VL 151
IS 3
BP 292
EP 293
DI 10.1001/jamasurg.2015.3402
PG 3
WC Surgery
SC Surgery
GA DG7TI
UT WOS:000372286200024
PM 26558846
ER
PT J
AU Kansagara, D
Chiovaro, JC
Kagen, D
Jencks, S
Rhyne, K
O'Neil, M
Kondo, K
Relevo, R
Motu'apuaka, M
Freeman, M
Englander, H
AF Kansagara, Devan
Chiovaro, Joseph C.
Kagen, David
Jencks, Stephen
Rhyne, Kerry
O'Neil, Maya
Kondo, Karli
Relevo, Rose
Motu'apuaka, Makalapua
Freeman, Michele
Englander, Honora
TI So many options, where do we start? An overview of the care transitions
literature
SO JOURNAL OF HOSPITAL MEDICINE
LA English
DT Review
ID RANDOMIZED CLINICAL-TRIAL; ACUTE CORONARY SYNDROME; HEART-FAILURE;
FOLLOW-UP; HOSPITAL DISCHARGE; SYSTEMATIC REVIEWS; METAANALYSIS; HOME;
INTERVENTIONS; READMISSIONS
AB BACKGROUNDHealth systems are faced with a large array of transitional care interventions and patient populations to whom such activities might apply.
PURPOSETo summarize the health and utilization effects of transitional care interventions, and to identify common themes about intervention types, patient populations, or settings that modify these effects.
DATA SOURCESPubMed and Cochrane Database of Systematic Reviews (January 1950-May 2014), reference lists, and technical advisors.
STUDY SELECTIONSystematic reviews of transitional care interventions that reported hospital readmission as an outcome.
DATA EXTRACTIONWe extracted transitional care procedures, patient populations, settings, readmissions, and health outcomes. We identified commonalities and compiled a narrative synthesis of emerging themes.
DATA SYNTHESISAmong 10 reviews of mixed patient populations, there was consistent evidence that enhanced discharge planning and hospital-at-home interventions reduced readmissions. Among 7 reviews in specific patient populations, transitional care interventions reduced readmission in patients with congestive heart failure and general medical populations. In general, interventions that reduced readmission addressed multiple aspects of the care transition, extended beyond hospital stay, and had the flexibility to accommodate individual patient needs. There was insufficient evidence on how caregiver involvement, transition to sites other than home, staffing, patient selection practices, or care settings modified intervention effects.
CONCLUSIONSSuccessful interventions are comprehensive, extend beyond hospital stay, and have the flexibility to respond to individual patient needs. The strength of evidence should be considered low because of heterogeneity in the interventions studied, patient populations, clinical settings, and implementation strategies. Journal of Hospital Medicine 2016;11:221-230. (c) 2015 Society of Hospital Medicine.
C1 [Kansagara, Devan; Chiovaro, Joseph C.; Kagen, David; Rhyne, Kerry; Freeman, Michele] VA Portland Hlth Care Syst, Dept Med, Portland, OR USA.
[Kansagara, Devan; Chiovaro, Joseph C.; Kagen, David; Rhyne, Kerry; Englander, Honora] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA.
[Kansagara, Devan; O'Neil, Maya; Kondo, Karli; Relevo, Rose; Motu'apuaka, Makalapua; Freeman, Michele] Portland VA Evidence Based Synth Program, Portland, OR USA.
RP Kansagara, D (reprint author), Portland VA Med Ctr, Mailcode RD71,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM kansagar@ohsu.edu
FU Department of Veterans Affairs, Veterans Health Administration (VHA)
[ESP 05-225, 01-0206]; Quality Enhancement Research Initiative,
Department of Veterans Affairs [05-225]
FX The research reported here was supported by the Department of Veterans
Affairs, Veterans Health Administration (VHA) Project ESP 05-225,
VA#01-0206. Dr. Jencks' work on this project was supported in part by a
grant from the Quality Enhancement Research Initiative (05-225),
Department of Veterans Affairs. Dr. Jencks has reported prior consulting
work with the following entities: Inovalon, Care Centrix, Affymax,
Curaspan, Reinforced Care, Health Services Advisory Group, Delmarva
Foundation, Connecticut Peer Review Organization, Maryland Health
Services Cost Review Commission, Institute for Healthcare Improvement,
American Association for Respiratory Care, Monaghan Medical, Iowa
Society for Respiratory Care.
NR 38
TC 6
Z9 6
U1 6
U2 15
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1553-5592
EI 1553-5606
J9 J HOSP MED
JI J. Hosp. Med.
PD MAR
PY 2016
VL 11
IS 3
BP 221
EP 230
DI 10.1002/jhm.2502
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA DG8JQ
UT WOS:000372330500011
PM 26551918
ER
PT J
AU Lyerly, MJ
Wu, TC
Mullen, MT
Albright, KC
Wolff, C
Boehme, AK
Branas, CC
Grotta, JC
Savitz, SI
Carr, BG
AF Lyerly, Michael J.
Wu, Tzu-Ching
Mullen, Michael T.
Albright, Karen C.
Wolff, Catherine
Boehme, Amelia K.
Branas, Charles C.
Grotta, James C.
Savitz, Sean I.
Carr, Brendan G.
TI The effects of telemedicine on racial and ethnic disparities in access
to acute stroke care
SO JOURNAL OF TELEMEDICINE AND TELECARE
LA English
DT Article
DE Teleneurology; tele-stroke; healthcare access; racial minorities; ethnic
minorities; telemedicine
ID TISSUE-PLASMINOGEN ACTIVATOR; AMERICAN-HEART-ASSOCIATION; ACUTE
ISCHEMIC-STROKE; UNITED-STATES; OUTCOMES; CENTERS; TIME;
RECOMMENDATIONS; THROMBOLYSIS; TELESTROKE
AB Racial and ethnic disparities have been previously reported in acute stroke care. We sought to determine the effect of telemedicine (TM) on access to acute stroke care for racial and ethnic minorities in the state of Texas. Data were collected from the US Census Bureau, The Joint Commission and the American Hospital Association. Access for racial and ethnic minorities was determined by summing the population that could reach a primary stroke centre (PSC) or telemedicine spoke within specified time intervals using validated models. TM extended access to stroke expertise by 1.5 million residents. The odds of providing 60-minute access via TM were similar in Blacks and Whites (prevalence odds ratios (POR) 1.000, 95% CI 1.000-1.000), even after adjustment for urbanization (POR 1.000, 95% CI 1.000-1.001). The odds of providing access via TM were also similar for Hispanics and non-Hispanics (POR 1.000, 95% CI 1.000-1.000), even after adjustment for urbanization (POR 1.000, 95% CI 1.000-1.000). We found that telemedicine increased access to acute stroke care for 1.5 million Texans. While racial and ethnic disparities exist in other components of stroke care, we did not find evidence of disparities in access to the acute stroke expertise afforded by telemedicine.
C1 [Lyerly, Michael J.] Univ Alabama Birmingham, Dept Neurol, 1813 6th Ave South,RWUH M226, Birmingham, AL 35294 USA.
[Lyerly, Michael J.] Birmingham Vet Affairs Med Ctr, Stroke Program, Birmingham, AL USA.
[Wu, Tzu-Ching; Grotta, James C.; Savitz, Sean I.] Univ Texas Houston, Mem Hermann Med Ctr, Dept Neurol, Houston, TX USA.
[Mullen, Michael T.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.
[Albright, Karen C.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL 35294 USA.
[Albright, Karen C.] Univ Alabama Birmingham, Hlth Serv & Outcomes Res Ctr Outcome & Effectiven, Birmingham, AL 35294 USA.
[Albright, Karen C.] Univ Alabama Birmingham, Ctr Excellence Comparat Effectiveness Res Elimina, Minor Hlth & Hlth Dispar Res Ctr MHRC, Birmingham, AL 35294 USA.
[Albright, Karen C.] Birmingham Vet Affairs Med Ctr, GRECC, Birmingham, AL USA.
[Wolff, Catherine] Duke Univ, Sch Med, Durham, NC USA.
[Boehme, Amelia K.] Columbia Univ, Dept Neurol, Gertrude Sergievsky Ctr, New York, NY USA.
[Branas, Charles C.] Univ Penn, Dept Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Carr, Brendan G.] Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA.
RP Lyerly, MJ (reprint author), Univ Alabama Birmingham, Dept Neurol, 1813 6th Ave South,RWUH M226, Birmingham, AL 35294 USA.
EM mjlyerly@uab.edu
OI Lyerly, Michael/0000-0003-4236-1018
FU AHRQ HHS [5 T32 HS013852-10]; NIMHD NIH HHS [P60 MD000502, 3 P60
MD000502-08S1]; None [HS013852]
NR 52
TC 3
Z9 3
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1357-633X
EI 1758-1109
J9 J TELEMED TELECARE
JI J. Telemed. Telecare
PD MAR
PY 2016
VL 22
IS 2
BP 114
EP 120
DI 10.1177/1357633X15589534
PG 7
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA DG4XG
UT WOS:000372075900005
PM 26116854
ER
PT J
AU Vedire, K
Joselow, AL
Markham, CM
Raugi, GJ
AF Vedire, Kirtana
Joselow, Andrew L.
Markham, Craig M.
Raugi, Gregory J.
TI Teledermatology-directed surgical care is safe and reduces travel
SO JOURNAL OF TELEMEDICINE AND TELECARE
LA English
DT Article
DE Telemedicine; teledermatology; melanoma; severely dysplastic nevi;
primary care clinicians
ID GENERAL-PRACTITIONERS; MELANOMA; EXCISION; REFERRALS; PROGRAM
AB Methods: We conducted a retrospective chart review and identified 186 Veterans in the VA Corporate Data Warehouse as having malignant melanomas or severely dysplastic nevi during the four-year period of observation from 1 July 2009 to 30 June 2013 and met inclusion and exclusion criteria for analysis.
Results: Three hundred and sixty-six surgical procedures were performed for diagnosis and treatment of these conditions including biopsy and wide-local excision, of which 189 carefully selected cases were performed by primary care clinicians with 2.0% biopsy complication rate and a 7.7% wide-local excision complication rate. Cases not performed by primary care providers were referred to specialists (e.g. dermatologists, general surgeons or specialty surgeons) who had a 2.5% complication rate in biopsies and wide-local excision complication rate of 13.5% in severely dysplastic nevi and pTis and pT1a lesions and a 10.7% complication rate for lesions pT1b and greater.
Discussion: These results show that a significant fraction of surgical procedures for diagnosis and treatment of malignant melanoma and severely dysplastic nevi can be safely performed in rural clinics by trained primary care providers.
C1 [Vedire, Kirtana; Joselow, Andrew L.; Markham, Craig M.; Raugi, Gregory J.] VA Puget Sound Hlth Care Syst, Seattle Div, Washington, DC USA.
[Joselow, Andrew L.] Tulane Univ, Sch Med, 1430 Tulane Ave, New Orleans, LA 70112 USA.
[Raugi, Gregory J.] Univ Washington, Dept Med Dermatol, Seattle, WA 98195 USA.
RP Raugi, GJ (reprint author), VISN20 Teledermatol,Fed Off Bldg,Suite 630, Seattle, WA 98104 USA.
EM gregory.raugi@va.gov
FU US Department of Veterans Affairs; VISN20 Office of Rural Health
Services; Office of Rural Health
FX The author(s) disclosed receipt of the following financial support for
the research, authorship, and/or publication of this article: US
Department of Veterans Affairs, VISN20 Office of Rural Health Services,
and the Office of Rural Health.
NR 17
TC 0
Z9 0
U1 0
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1357-633X
EI 1758-1109
J9 J TELEMED TELECARE
JI J. Telemed. Telecare
PD MAR
PY 2016
VL 22
IS 2
BP 121
EP 126
DI 10.1177/1357633X15589861
PG 6
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA DG4XG
UT WOS:000372075900006
PM 26116856
ER
PT J
AU Moriarty, H
Winter, L
Piersol, C
Vause-Earland, T
Robinson, K
Newhart, B
AF Moriarty, Helene
Winter, Laraine
Piersol, Catherine
Vause-Earland, Tracey
Robinson, Keith
Newhart, Brian
TI Patient-Centered and Family-Centered Outcomes in Intervention Research:
Use of Target Outcomes in a Study with Veterans with Traumatic Brain
Injury and Their Family Members
SO NURSING RESEARCH
LA English
DT Meeting Abstract
C1 [Moriarty, Helene] Villanova Univ, Villanova, PA 19085 USA.
[Winter, Laraine; Robinson, Keith; Newhart, Brian] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Piersol, Catherine; Vause-Earland, Tracey] Thomas Jefferson Univ, Philadelphia, PA 19107 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0029-6562
EI 1538-9847
J9 NURS RES
JI Nurs. Res.
PD MAR-APR
PY 2016
VL 65
IS 2
BP E71
EP E71
PG 1
WC Nursing
SC Nursing
GA DG6SA
UT WOS:000372215200194
ER
PT J
AU Moreno, CC
Mittal, PK
Ghonge, NP
Bhargava, P
Heller, MT
AF Moreno, Courtney Coursey
Mittal, Pardeep K.
Ghonge, Nitin P.
Bhargava, Puneet
Heller, Matthew T.
TI Imaging Complications of Renal Transplantation
SO RADIOLOGIC CLINICS OF NORTH AMERICA
LA English
DT Article
DE Renal transplantation; Complications of renal transplantation; Renal
artery stenosis; Renal vein thrombosis; Collecting system injury;
Lymphocele; Urinoma; Posttransplant lymphoproliferative disorder
ID CHRONIC ALLOGRAFT NEPHROPATHY; DELAYED GRAFT FUNCTION; ARTERY-STENOSIS;
RISK-FACTORS; KIDNEY-TRANSPLANTATION; VASCULAR COMPLICATIONS;
MULTIVARIATE-ANALYSIS; DOPPLER SONOGRAPHY; RESISTIVE INDEX; ACUTE
REJECTION
AB Renal transplant complications are categorized as those related to the transplant vasculature, collecting system, perinephric space, renal parenchyma, and miscellaneous complications including posttransplant lymphoproliferative disorder. Many of these renal transplant complications are diagnosed with imaging. Medical complications including rejection, acute tubular necrosis, and drug toxicity also can impair renal function. These medical complications are typically indistinguishable at imaging, and biopsy may be performed to establish a diagnosis. Normal transplant anatomy, imaging techniques, and the appearances of renal transplant complications at ultrasound, computed tomography, and MR imaging are reviewed.
C1 [Moreno, Courtney Coursey; Mittal, Pardeep K.] Emory Univ, Sch Med, Dept Radiol & Imaging Sci, 1364 Clifton Rd NE, Atlanta, GA 30322 USA.
[Ghonge, Nitin P.] Indraprastha Apollo Hosp, Dept Radiol, Delhi Mathura Rd, New Delhi 110076, India.
[Bhargava, Puneet] Univ Washington, Med Ctr, Dept Radiol, VA Puget Sound Hlth Care Syst, 1959 NE Pacific St,Room BB308,Box 357115, Seattle, WA 98195 USA.
[Heller, Matthew T.] Univ Pittsburgh, Sch Med, Dept Radiol, 200 Lothrop St,Suite 174E PUH, Pittsburgh, PA 15213 USA.
RP Moreno, CC (reprint author), Emory Univ, Sch Med, Dept Radiol & Imaging Sci, 1364 Clifton Rd NE, Atlanta, GA 30322 USA.
EM courtney.moreno@emoryhealthcare.org
OI Mittal, Pardeep/0000-0002-3302-8590
NR 62
TC 2
Z9 2
U1 1
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0033-8389
EI 1557-8275
J9 RADIOL CLIN N AM
JI Radiol. Clin. N. Am.
PD MAR
PY 2016
VL 54
IS 2
BP 235
EP +
DI 10.1016/j.rcl.2015.09.007
PG 17
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA DH4QN
UT WOS:000372770600005
PM 26896222
ER
PT J
AU Backhus, LM
Mulligan, MS
Ha, R
Shriki, JE
Mohammed, TLH
AF Backhus, Leah M.
Mulligan, Michael S.
Ha, Richard
Shriki, Jabi E.
Mohammed, Tan-Lucien H.
TI Imaging in Lung Transplantation Surgical Considerations of Donor and
Recipient
SO RADIOLOGIC CLINICS OF NORTH AMERICA
LA English
DT Article
DE Lung transplant; Transplant evaluation; Transplant surgery; Computed
tomography
ID IDIOPATHIC PULMONARY-FIBROSIS; TRAUMATIC CARDIOPULMONARY ARREST; VOLUME
REDUCTION SURGERY; INTERNATIONAL-SOCIETY; CYSTIC-FIBROSIS; ORGAN
DONATION; FLEISCHNER-SOCIETY; SIZE MISMATCH; BRAIN-DEATH; MANAGEMENT
AB Modifications in recipient and donor criteria and innovations in donor management hold promise for increasing rates of lung transplantation, yet availability of donors remains a limiting resource. Imaging is critical in the work-up of donor and recipient including identification of conditions that may portend to poor posttransplant outcomes or necessitate modifications in surgical technique. This article describes the radiologic principles that guide selection of patients and surgical procedures in lung transplantation.
C1 [Backhus, Leah M.; Ha, Richard] Stanford Univ, Dept Cardiothorac Surg, 300 Pasteur Dr,Falk Bldg, Stanford, CA 94304 USA.
[Mulligan, Michael S.] Univ Washington, Dept Surg, Div Cardiothorac Surg, Seattle, WA 98195 USA.
[Shriki, Jabi E.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA.
[Shriki, Jabi E.] VA Puget Sound Hlth Care Syst, Diagnost Imaging Serv, Seattle, WA USA.
[Mohammed, Tan-Lucien H.] Univ Florida, Coll Med, Dept Radiol, Gainesville, FL 32610 USA.
RP Backhus, LM (reprint author), Stanford Univ, Dept Cardiothorac Surg, 300 Pasteur Dr,Falk Bldg, Stanford, CA 94304 USA.
EM lbackhus@stanford.edu
NR 67
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0033-8389
EI 1557-8275
J9 RADIOL CLIN N AM
JI Radiol. Clin. N. Am.
PD MAR
PY 2016
VL 54
IS 2
BP 339
EP +
DI 10.1016/j.rcl.2015.09.013
PG 16
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA DH4QN
UT WOS:000372770600011
PM 26896228
ER
PT J
AU Bahney, CS
Jacobs, L
Tamai, R
Hu, D
Luan, TF
Wang, MQ
Reddy, S
Park, M
Limburg, S
Kim, HT
Marcucio, R
Kuo, AC
AF Bahney, Chelsea S.
Jacobs, Linsey
Tamai, Robert
Hu, Diane
Luan, Tammy F.
Wang, Miqi
Reddy, Sanjay
Park, Michelle
Limburg, Sonja
Kim, Hubert T.
Marcucio, Ralph
Kuo, Alfred C.
TI Promoting Endochondral Bone Repair Using Human Osteoarthritic Articular
Chondrocytes
SO TISSUE ENGINEERING PART A
LA English
DT Article
ID MESENCHYMAL STEM-CELLS; IN-VIVO; CARTILAGE REPAIR; GENE-EXPRESSION;
OSSIFICATION; HYDROGELS; DEFECTS; CULTURE
AB Introduction: Current tissue engineering strategies to heal critical-size bone defects through direct bone formation are limited by incomplete integration of grafts with host bone and incomplete graft vascularization. An alternative strategy for bone regeneration is the use of cartilage grafts that form bone through endochondral ossification. Endochondral cartilages stimulate angiogenesis and are remodeled into bone, but are found in very small quantities in growth plates and healing fractures. We sought to develop engineered endochondral cartilage grafts using osteoarthritic (OA) articular chondrocytes as a cell source. Such chondrocytes often undergo hypertrophy, which is a characteristic of endochondral cartilages.
Materials and Methods: We compared the ability of unmodified human OA (hOA) cartilage and cartilage grafts formed in vitro from hOA chondrocytes to undergo endochondral ossification in mice. Scaffold-free engineered chondrocyte grafts were generated by pelleting chondrocytes, followed by culture with transforming growth factor-beta 1 (TGF-beta 1) and bone morphogenetic protein 4. Samples derived from either primary or passaged chondrocytes were implanted subcutaneously into immunocompromised mice. Grafts derived from passaged chondrocytes from three patients were implanted into critical-size tibial defects in mice. Bone formation was assessed with histology after 4 weeks of implantation. The composition of tibial repair tissue was quantified with histomorphometry.
Results: Engineered cartilage grafts generated from passaged OA chondrocytes underwent endochondral ossification after implantation either subcutaneously or in bone. Cartilage grafts integrated with host bone at 15 out of 16 junctions. Grafts variably remodeled into woven bone, with the proportion of bony repair tissue in tibial defects ranging from 22% to 85% (average 48%). Bony repair tissue bridged the tibial defects in half of the animals. In contrast, unmodified OA cartilage and engineered grafts formed from primary chondrocytes did not undergo endochondral ossification in vivo.
Conclusions: hOA chondrocytes can adopt an endochondral phenotype after passaging and TGF-beta superfamily treatment. Engineered endochondral cartilage grafts can integrate with host bone, undergo ossification, and heal critical-size long-bone defects in a mouse model. However, additional methods to further enhance ossification of these grafts are required before the clinical translation of this approach.
C1 [Bahney, Chelsea S.; Hu, Diane; Marcucio, Ralph] Univ Calif San Francisco, Orthopaed Trauma Inst, San Francisco Gen Hosp, San Francisco, CA 94121 USA.
[Jacobs, Linsey; Tamai, Robert; Luan, Tammy F.; Wang, Miqi; Reddy, Sanjay; Park, Michelle; Limburg, Sonja; Kim, Hubert T.; Kuo, Alfred C.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, 4150 Clement St,Box 112, San Francisco, CA 94121 USA.
RP Kuo, AC (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, 4150 Clement St,Box 112, San Francisco, CA 94121 USA.
EM kuoac@orthosurg.ucsf.edu
FU National Institute of Arthritis and Musculoskeletal and Skin Disease
(NIAMS) of the National Institutes of Health (NIH) [5F32AR062469];
Musculoskeletal Transplant Foundation; UCSF Graduate Education in
Medical Sciences (GEMS); UCSF Department of Orthopaedic Surgery; San
Francisco Veterans Affairs Medical Center
FX Research reported in this publication was supported by the National
Institute of Arthritis and Musculoskeletal and Skin Disease (NIAMS) of
the National Institutes of Health (NIH) under the following award
numbers: CSB (#5F32AR062469). Additional research support was provided
by the Musculoskeletal Transplant Foundation (CSB: MTF Junior
Investigator Award), the UCSF Graduate Education in Medical Sciences
(GEMS), the UCSF Department of Orthopaedic Surgery, and the San
Francisco Veterans Affairs Medical Center.
NR 31
TC 0
Z9 1
U1 3
U2 8
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
EI 1937-335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD MAR 1
PY 2016
VL 22
IS 5-6
BP 427
EP 435
DI 10.1089/ten.tea.2014.0705
PG 9
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA DH0FL
UT WOS:000372457800005
PM 26830207
ER
PT J
AU Allott, EH
Howard, LE
Aronson, WJ
Terris, MK
Kane, CJ
Amling, CL
Cooperberg, MR
Freedland, SJ
AF Allott, Emma H.
Howard, Lauren E.
Aronson, William J.
Terris, Martha K.
Kane, Christopher J.
Amling, Christopher L.
Cooperberg, Matthew R.
Freedland, Stephen J.
TI Racial Differences in the Association Between Preoperative Serum
Cholesterol and Prostate Cancer Recurrence: Results from the SEARCH
Database
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID AFRICAN-AMERICAN; RISK; MEN; COHORT; ATHEROSCLEROSIS; MORTALITY; IMPACT;
GRADE; CELLS
AB Background: Black men are disproportionately affected by both cardiovascular disease and prostate cancer. Epidemiologic evidence linking dyslipidemia, an established cardiovascular risk factor, and prostate cancer progression is mixed. As existing studies were conducted in predominantly non-black populations, research on black men is lacking.
Methods: We identified 628 black and 1,020 non-black men who underwent radical prostatectomy and never used statins before surgery in the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Median follow-up was 2.9 years. The impact of preoperative hypercholesterolemia on risk of biochemical recurrence was examined using multivariable, race-stratified proportional hazards. In secondary analysis, we examined associations with low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides, overall and among men with dyslipidemia.
Results: High cholesterol was associated with increased risk of recurrence in black [HRper10 (mg/dL) 1.06; 95% confidence interval (CI), 1.02-1.11] but not non-black men (HRper10 mg/dL 0.99; 95% CI, 0.95-1.03; P-interaction = 0.011). Elevated triglycerides were associated with increased risk in both black and non-black men (HRper10 mg/dL 1.02; 95% CI, 1.00-1.03 and 1.02; 95% CI, 1.00-1.02, respectively; P-interaction = 0.458). There were no significant associations between LDL or HDL and recurrence risk in either race. Associations with cholesterol, LDL, and triglycerides were similar among men with dyslipidemia, but low HDL was associated with increased risk of recurrence in black, but not non-black men with dyslipidemia (P-interaction = 0.047).
Conclusion: Elevated cholesterol was a risk factor for recurrence in black but not non-black men, whereas high triglycerides were associated with increased risk regardless of race.
Impact: Significantly contrasting associations by race may provide insight into prostate cancer racial disparities. (C) 2016 AACR.
C1 [Allott, Emma H.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA.
[Allott, Emma H.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
[Howard, Lauren E.] Duke Univ, Sch Med, Dept Biostat & Bioinformat, Durham, NC USA.
[Aronson, William J.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Surg, Urol Sect, Los Angeles, CA USA.
[Aronson, William J.] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA.
[Terris, Martha K.] Vet Affairs Med Ctr, Urol Sect, Augusta, GA USA.
[Terris, Martha K.] Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA.
[Kane, Christopher J.] Univ Calif San Diego Hlth Syst, Dept Urol, San Diego, CA USA.
[Amling, Christopher L.] Oregon Hlth & Sci Univ, Div Urol, Portland, OR 97201 USA.
[Cooperberg, Matthew R.] UCSF Helen Diller Family Comprehens Canc Ctr, Dept Urol, San Francisco, CA USA.
[Freedland, Stephen J.] Cedars Sinai Med Ctr, 8635 West 3rd St,Suite 1070W, Los Angeles, CA 90048 USA.
[Freedland, Stephen J.] Vet Affairs Med Ctr, Div Urol, Durham, NC USA.
RP Freedland, SJ (reprint author), Cedars Sinai Med Ctr, 8635 West 3rd St,Suite 1070W, Los Angeles, CA 90048 USA.
EM stephen.freedland@cshs.org
FU NIH [1K24CA160653, P50CA92131]; University Cancer Research Fund of North
Carolina
FX This study was supported by grants from NIH [1K24CA160653 (to S.J.
Freedland) and P50CA92131 (to W.J. Aronson)] and by the University
Cancer Research Fund of North Carolina (to E.H. Allott).
NR 32
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD MAR
PY 2016
VL 25
IS 3
BP 547
EP 554
DI 10.1158/1055-9965.EPI-15-0876
PG 8
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA DG6EA
UT WOS:000372173900015
PM 26809276
ER
PT J
AU Mackin, RS
Vigil, O
Insel, P
Kivowitz, A
Kupferman, E
Hough, CM
Fekri, S
Crothers, R
Bickford, D
Delucchi, KL
Mathews, CA
AF Mackin, R. Scott
Vigil, Ofilio
Insel, Philip
Kivowitz, Alana
Kupferman, Eve
Hough, Christina M.
Fekri, Shiva
Crothers, Ross
Bickford, David
Delucchi, Kevin L.
Mathews, Carol A.
TI PATTERNS OF CLINICALLY SIGNIFICANT COGNITIVE IMPAIRMENT IN HOARDING
DISORDER
SO DEPRESSION AND ANXIETY
LA English
DT Article
DE hoarding disorder; cognitive impairment; executive dysfunction;
categorization; information processing speed; memory; attention
ID OBSESSIVE-COMPULSIVE DISORDER; SYMPTOM DIMENSIONS; OLDER-ADULTS;
EXECUTIVE FUNCTION; DECISION-MAKING; DEPRESSION; INVENTORY; ATTENTION;
VALIDITY; THERAPY
AB ObjectivesThe cognitive characteristics of individuals with hoarding disorder (HD) are not well understood. Existing studies are relatively few and somewhat inconsistent but suggest that individuals with HD may have specific dysfunction in the cognitive domains of categorization, speed of information processing, and decision making. However, there have been no studies evaluating the degree to which cognitive dysfunction in these domains reflects clinically significant cognitive impairment (CI).
MethodsParticipants included 78 individuals who met DSM-V criteria for HD and 70 age- and education-matched controls. Cognitive performance on measures of memory, attention, information processing speed, abstract reasoning, visuospatial processing, decision making, and categorization ability was evaluated for each participant. Rates of clinical impairment for each measure were compared, as were age- and education-corrected raw scores for each cognitive test.
ResultsHD participants showed greater incidence of CI on measures of visual memory, visual detection, and visual categorization relative to controls. Raw-score comparisons between groups showed similar results with HD participants showing lower raw-score performance on each of these measures. In addition, in raw-score comparisons HD participants also demonstrated relative strengths compared to control participants on measures of verbal and visual abstract reasoning.
ConclusionsThese results suggest that HD is associated with a pattern of clinically significant CI in some visually mediated neurocognitive processes including visual memory, visual detection, and visual categorization. Additionally, these results suggest HD individuals may also exhibit relative strengths, perhaps compensatory, in abstract reasoning in both verbal and visual domains.
C1 [Mackin, R. Scott; Vigil, Ofilio; Kivowitz, Alana; Kupferman, Eve; Hough, Christina M.; Crothers, Ross; Bickford, David; Delucchi, Kevin L.; Mathews, Carol A.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Mackin, R. Scott; Insel, Philip] San Francisco VA Med Ctr, San Francisco, CA USA.
[Fekri, Shiva] Univ Colorado, Dept Psychol, Denver, CO 80202 USA.
RP Mackin, RS (reprint author), Univ Calif San Francisco, Langley Porter Psychiat Inst, Dept Psychiat, 401 Parnassus Ave,Box F-0984, San Francisco, CA 94143 USA.
EM Scott.Mackin@ucsf.edu
RI Hough, Christina/K-2416-2016
OI Hough, Christina/0000-0002-8864-5262
FU NIMH [R21 MH087748, K08 MH081065, R01 0977669]; Patient-Centered
Outcomes Research Institute (PCORI) Award [6000]
FX Contract grant sponsor: NIMH; Grant numbers: R21 MH087748, K08 MH081065,
R01 0977669. The Althea Foundation and a Patient-Centered Outcomes
Research Institute (PCORI) Award; Contract number: 6000.
NR 46
TC 3
Z9 3
U1 6
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1091-4269
EI 1520-6394
J9 DEPRESS ANXIETY
JI Depress. Anxiety
PD MAR
PY 2016
VL 33
IS 3
BP 211
EP 218
DI 10.1002/da.22439
PG 8
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA DG6FY
UT WOS:000372179800005
PM 26474146
ER
PT J
AU Achuko, O
Walker, RJ
Campbell, JA
Dawson, AZ
Egede, LE
AF Achuko, Obinna
Walker, Rebekah J.
Campbell, Jennifer A.
Dawson, Aprill Z.
Egede, Leonard E.
TI Pathways Between Discrimination and Quality of Life in Patients with
Type 2 Diabetes
SO DIABETES TECHNOLOGY & THERAPEUTICS
LA English
DT Article
ID REPORTED RACIAL-DISCRIMINATION; RANDOMIZED CONTROLLED-TRIAL; PERCEIVED
DISCRIMINATION; SOCIAL DETERMINANTS; AFRICAN-AMERICAN; GLYCEMIC CONTROL;
HEALTH-CARE; EVERYDAY DISCRIMINATION; PSYCHOLOGICAL DISTRESS; WEIGHT
DISCRIMINATION
AB Background: Discrimination is a social determinant that has been linked to poor physical and mental health outcomes. This study aimed to examine the pathway whereby discrimination influences quality of life in patients with type 2 diabetes.
Subjects and Methods: Six hundred fifteen patients were recruited from two adult primary care clinics in the southeastern United States. Measures included perceived discrimination, perceived stress, social support, and social cohesion and were based on a theoretical model for the pathways by which perceived discrimination influences mental and physical health. Quality of life was measured using the SF-12 questionnaire.
Results: The final model [chi(2)(106) = 157.35, P = 0.009, R-2 = 0.99, root mean square error of approximation = 0.03, comparative fit index = 0.99] indicates direct effects of higher perceived stress (r = -1.02, P < 0.05) and lower social support (r = 0.36, P < 0.001) significantly related to decreased mental health component score (MCS) of quality of life. Discrimination and social cohesion were not significantly directly related to MCS. However, higher discrimination (r = 0.47, P < 0.001), higher social cohesion (r = 0.14, P < 0.05), and lower social support (r = -0.43, P < 0.001) were significantly directly related to increased stress. No significant paths were found for the physical component score of quality of life.
Conclusions: Perceived discrimination was significantly associated with stress and served as a pathway to influence the mental health component of quality of life (MCS). Social support had a direct and an indirect effect on MCS through a negative association with stress. These results suggest that future interventions should be developed to decrease stress and increase social support surrounding discrimination to improve the MCS of quality of life in patients with diabetes.
C1 [Achuko, Obinna; Walker, Rebekah J.; Campbell, Jennifer A.; Dawson, Aprill Z.; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280, Charleston, SC 29425 USA.
[Walker, Rebekah J.; Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Charleston VA Hlth Serv Res & Dev COIN, Hlth Equ & Rural Outreach Innovat Ctr, Charleston, SC USA.
[Walker, Rebekah J.; Egede, Leonard E.] Med Univ S Carolina, Dept Med, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA.
RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280, Charleston, SC 29425 USA.
EM egedel@musc.edu
FU National Institute of Diabetes and Digestive and Kidney Disease
[K24DK093699-01]
FX This study was supported by grant K24DK093699-01 from the National
Institute of Diabetes and Digestive and Kidney Disease (Principal
Investigator: L.E.E.).
NR 58
TC 1
Z9 1
U1 2
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1520-9156
EI 1557-8593
J9 DIABETES TECHNOL THE
JI Diabetes Technol. Ther.
PD MAR 1
PY 2016
VL 18
IS 3
BP 151
EP 158
DI 10.1089/dia.2015.0305
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DG6HE
UT WOS:000372183700008
PM 26866351
ER
PT J
AU McGinley, KF
Sun, XZ
Howard, LE
Aronson, WJ
Terris, MK
Kane, CJ
Amling, CL
Cooperberg, MR
Freedland, SJ
AF McGinley, Kathleen F.
Sun, Xizi
Howard, Lauren E.
Aronson, William J.
Terris, Martha K.
Kane, Christopher J.
Amling, Christopher L.
Cooperberg, Matthew R.
Freedland, Stephen J.
TI Utilization and impact of surgical technique on the performance of
pelvic lymph node dissection at radical prostatectomy: Results from the
Shared Equal Access Regional Cancer Hospital database
SO INTERNATIONAL JOURNAL OF UROLOGY
LA English
DT Article
DE lymph node excision; prostatectomy; prostatic neoplasms; quality of
health care; robotic surgical procedures
ID MEN; UPDATE
AB ObjectiveTo evaluate performance of pelvic lymph node dissection during radical prostatectomy within an equal access care setting over a period of time, and stratified by prostate cancer risk group and surgical technique.
MethodsWe identified men in the Shared Equal Access Regional Cancer Hospital database who had open or robotic-assisted radical prostatectomy from 2006 to 2013. Univariable logistic regression was used to test the association between age, race, body mass index, total biopsy cores, number of positive biopsy cores, risk group, year, center, surgical volume and surgical technique on pelvic lymph node dissection use. Multivariable logistic analysis was used to examine surgical technique and pelvic lymph node dissection performance. Spearman's correlation examined temporal changes in pelvic lymph node dissection utilization stratified by risk group and surgical technique.
ResultsA total of 1425 men met inclusion criteria; 67% of them underwent pelvic lymph node dissection. On multivariable analysis, robotic-assisted radical prostatectomy was associated with an 92% decreased use of pelvic lymph node dissection in low-risk, 84% decreased in intermediate-risk and 91% decreased in high-risk men (all P < 0.001). In robotic-assisted radical prostatectomy, there was a trend for increased pelvic lymph node dissection utilization over time in high-risk men (Spearman; P = 0.077) reaching similar to 85% in 2012-2013, which was accompanied by increased use in low-risk men (P = 0.016). For open radical prostatectomy, fewer pelvic lymph node dissections were carried out in low-risk men over time, decreasing to similar to 35% (P = 0.047) in 2012-2013, whereas rates remained high for high-risk men throughout (similar to 95%; P = 0.621).
ConclusionRegardless of risk group, pelvic lymph node dissection is carried out significantly less during robotic-assisted radical prostatectomy. For robotic-assisted radical prostatectomy, pelvic lymph node dissection utilization increased over time for high-risk men, but rates also increased for low-risk men. Further attention to the discrepancy between provided and guideline recommended pelvic lymph node dissection performance is required to improve prostate cancer care.
C1 [McGinley, Kathleen F.] Duke Univ, Dept Surg, Div Urol, Durham, NC USA.
[McGinley, Kathleen F.; Sun, Xizi; Howard, Lauren E.; Freedland, Stephen J.] Vet Affairs Med Ctr, Dept Surg, Div Urol, Durham, NC USA.
[Sun, Xizi; Howard, Lauren E.] Duke Univ, Dept Biostat & Bioinformat, Durham, NC USA.
[Aronson, William J.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Surg, Urol Sect, Los Angeles, CA USA.
[Aronson, William J.] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA.
[Terris, Martha K.] Vet Affairs Med Ctr, Urol Sect, Augusta, GA USA.
[Terris, Martha K.] Georgia Regents Univ, Dept Urol, Augusta, GA USA.
[Kane, Christopher J.] Univ Calif San Diego Hlth Syst, Dept Urol, San Diego, CA USA.
[Amling, Christopher L.] Oregon Hlth & Sci Univ, Dept Urol, Portland, OR 97201 USA.
[Cooperberg, Matthew R.] UCSF Helen Diller Family Comprehens Canc Ctr, Dept Urol, San Francisco, CA USA.
[Freedland, Stephen J.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Ctr, Dept Surg, Div Urol, Los Angeles, CA 90048 USA.
RP Freedland, SJ (reprint author), Cedars Sinai Med Ctr, 8635 West 3rd St,Suite 1070W, Los Angeles, CA 90048 USA.
EM stephen.freedland@cshs.org
NR 21
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0919-8172
EI 1442-2042
J9 INT J UROL
JI Int. J. Urol.
PD MAR
PY 2016
VL 23
IS 3
BP 241
EP 246
DI 10.1111/iju.13027
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA DG5YH
UT WOS:000372157100011
PM 26667212
ER
PT J
AU Harwood, NMK
Golden-Mason, L
Cheng, LL
Rosen, HR
Mengshol, JA
AF Harwood, Noah M. K.
Golden-Mason, Lucy
Cheng, Linling
Rosen, Hugo R.
Mengshol, John A.
TI HCV-infected cells and differentiation increase monocyte
immunoregulatory galectin-9 production
SO JOURNAL OF LEUKOCYTE BIOLOGY
LA English
DT Article
DE JFH-1; non-classical monocyte; exosome
ID HEPATITIS-C VIRUS; NATURAL-KILLER-CELLS; IN-VITRO;
HEPATOCELLULAR-CARCINOMA; GLYCAN INTERACTIONS; SIGNALING PATHWAY; TIM-3
EXPRESSION; STRANDED-RNA; IMMUNITY; REPLICATION
AB The lectin galectin-9 may help establish and maintain chronic hepatitis C virus infection. Galectin-9 is elevated in the liver and sera of hepatitis C virus patients, induces apoptosis of hepatitis C virus-specific T cells, and increases inhibitory regulatory T cells. Kupffer cells stain strongly for galectin-9 protein in hepatitis C virus patients. In the current study, we determined stimuli that induce galectin-9 production by monocytes and macrophages in hepatitis C virus infection. With the use of real-time PCR and flow cytometry, we analyzed galectin-9 mRNA and protein from human monocytes cocultured with hepatitis C virus-infected cells or noninfectious hepatitis C virus subgenomic replicon cells. We focused on finding the stimuli for galectin-9 production. Additionally, we measured galectin-9 during monocyte-to-macrophage maturation. Finally, we examined galectin-9 in peripheral monocytes from hepatitis C virus patients using flow cytometry. Galectin-9 mRNA increased 8-fold when primary monocytes were exposed to hepatitis C virus-infected cells. Maximum induction required proximity or contact and did not require IFN-gamma or hepatitis C virus virions. Coculture of monocytes with subgenomic replicon cells increased galectin-9 5-fold, and purified exosomes from infected cells stimulated galectin-9 production. Stimulation of monocyte TLR3, -7, and -8 increased galectin-9 production. Differentiation of monocytes to macrophages increased galectin-9, and nonclassic monocytes from hepatitis C virus patients had the highest levels of galectin-9. Hepatitis C virus-infected cells stimulated monocytes to produce galectin-9 in close proximity, possibly, in part, as a result of exosomes and endosomal TLRs. Differentiation of monocytes to macrophages increased galectin-9. Nonclassic monocytes from hepatitis C virus patients express the highest galectin-9 levels, suggesting they may contribute to elevated galectin-9 and adaptive immune inhibition in hepatitis C virus infection.
C1 [Harwood, Noah M. K.; Golden-Mason, Lucy; Cheng, Linling; Rosen, Hugo R.; Mengshol, John A.] Univ Colorado, Sch Med, Denver VA Med Ctr, Div Gastroenterol & Hepatol, Denver, CO 80220 USA.
RP Mengshol, JA (reprint author), Univ Colorado, Sch Med, Div Gastroenterol & Hepatol, 1055 Clermont St,Box 111E, Denver, CO 80220 USA.
EM andy.mengshol@ucdenver.edu
FU Denver Research Institute; Liver Scholar Award from American Association
for the Study of Liver Disease; U.S. National Institutes of Health
National Institute of Allergy and Infectious Diseases [R21-AI103361];
American Liver Foundation; VA Merit Review Grant
FX J.A.M. is supported by the Denver Research Institute and a Liver Scholar
Award from the American Association for the Study of Liver Disease and
the American Liver Foundation. H.R.R. is funded by U.S. National
Institutes of Health National Institute of Allergy and Infectious
Diseases Grant R21-AI103361 and a VA Merit Review Grant. The authors
thank our leukocyte donors for their generous contribution and Diana Ir
and Katelyn Leahy for tissue-culture work. Additionally, the authors
thank Harsh Pratap for flow cytometry assistance and Ron Bouchard for
immunofluorescence guidance. Amy Stone provided valuable advice
regarding TLR stimulation.
NR 52
TC 1
Z9 1
U1 1
U2 3
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0741-5400
EI 1938-3673
J9 J LEUKOCYTE BIOL
JI J. Leukoc. Biol.
PD MAR
PY 2016
VL 99
IS 3
BP 495
EP 503
DI 10.1189/jlb.5A1214-582R
PG 9
WC Cell Biology; Hematology; Immunology
SC Cell Biology; Hematology; Immunology
GA DG2IO
UT WOS:000371890800012
PM 26475932
ER
PT J
AU Tang, Y
Chang, CCH
Lave, JR
Gellad, WF
Huskamp, HA
Donohue, JM
AF Tang, Yan
Chang, Chung-Chou H.
Lave, Judith R.
Gellad, Walid F.
Huskamp, Haiden A.
Donohue, Julie M.
TI Patient, Physician and Organizational Influences on Variation in
Antipsychotic Prescribing Behavior
SO JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS
LA English
DT Article
ID CARE; RECOMMENDATIONS; ANTIDEPRESSANT; SCHIZOPHRENIA; INFORMATION;
PERFORMANCE; MORTALITY; DIFFUSION; OUTCOMES; IMPACT
AB Background: Physicians face the choice of multiple ingredients when prescribing drugs in many therapeutic categories. For conditions with considerable patient heterogeneity in treatment response, customizing treatment to individual patient needs and preferences may improve outcomes.
Aims of the Study: To assess variation. in the diversity of antipsychotic prescribing for mental health conditions, a necessary although not sufficient condition for personalizing treatment. To identify patient caseload, physician, and organizational factors associated with the diversity of antipsychotic prescribing.
Methods: Using 2011 data from Pennsylvania's Medicaid program, IMS Health's HCOS (TM) database, and the AMA Masterfile, we identified 764 psychiatrists who prescribed antipsychotics to >= 10 patients. We constructed three physician level measures of diversity/concentration of antipsychotic prescribing: number of ingredients prescribed, share of prescriptions for most preferred ingredient, and Herfindahl-Hirschman index (HHI). We used multiple membership linear mixed models to examine patient caseload, physician, and healthcare organizational predictors of physician concentration of antipsychotic prescribing.
Results: There was substantial variability in antipsychotic prescribing concentration among psychiatrists, with number of ingredients ranging from 2-17, share for most preferred ingredient from 16%-85%, and HHI from 1,088-7,270. On average, psychiatrist prescribing behavior was relatively diversified; however, 11% of psychiatrists wrote an average of 55% of their prescriptions for their most preferred ingredient. Female prescribers and those with smaller shares of disabled or serious mental illness patients had more concentrated prescribing behavior on average.
Discussion: Antipsychotic prescribing by individual psychiatrists in a large state Medicaid program varied substantially across psychiatrists. Our findings illustrate the importance of understanding physicians' prescribing behavior and indicate that even among specialties regularly prescribing a therapeutic category, some physicians rely heavily on a small number of agents.
Implications for Health Policies, Health Care Provision and Use: Health systems may need to offer educational interventions to clinicians in order to improve their ability to tailor treatment decisions to the needs of individual patients.
Implications for Future Research: Future studies should examine the impact of the diversity of antipsychotic prescribing to determine whether more diversified prescribing improves patient adherence and outcomes.
C1 [Tang, Yan; Gellad, Walid F.; Donohue, Julie M.] Univ Pittsburgh, Hlth Policy Inst, Ctr Pharmaceut Policy & Prescribing CP3, Pittsburgh, PA 15261 USA.
[Tang, Yan; Donohue, Julie M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, 130 DeSoto St,Crabtree Hall A645, Pittsburgh, PA 15261 USA.
[Chang, Chung-Chou H.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.
[Lave, Judith R.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15261 USA.
[Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Gellad, Walid F.] Univ Pittsburgh, Div Gen Med, Pittsburgh, PA 15261 USA.
[Huskamp, Haiden A.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Cambridge, MA 02138 USA.
RP Tang, Y (reprint author), Univ Pittsburgh, Hlth Policy Inst, Ctr Pharmaceut Policy & Prescribing CP3, Pittsburgh, PA 15261 USA.; Tang, Y (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, 130 DeSoto St,Crabtree Hall A645, Pittsburgh, PA 15261 USA.
EM yan.tang@pitt.edu
FU National Institute of Mental Health [R01MH093359]; Pennsylvania
Department of Human Services; University of Pittsburgh
FX This work was supported in part by grant R01MH093359 from the National
Institute of Mental Health (Drs. Donohue and Huskamp), and by an inter
-governmental agreement between the Pennsylvania Department of Human
Services and the University of Pittsburgh. Dr. Huskamp serves on the
Academic Advisory Committee for the Health Services Research Network at
IMS Health Inc. (uncompensated). The other authors report no conflict of
interest. Some of the findings were presented at the International
Society of Pharmacoeconomics and Outcomes Research 20th Annual
International Meeting, May 16-20, 2015, Philadelphia, PA, USA.
NR 40
TC 0
Z9 0
U1 0
U2 0
PU INT CTR MENTAL HEALTH POLICY & ECONOMICS-ICMPE
PI MILANO
PA VIA DANIELE CRESPI 7, MILANO, 20123, ITALY
SN 1091-4358
J9 J MENT HEALTH POLICY
JI J. Ment. Health Policy Econ.
PD MAR
PY 2016
VL 19
IS 1
BP 45
EP 59
PG 15
WC Health Policy & Services; Psychiatry
SC Health Care Sciences & Services; Psychiatry
GA DG6QP
UT WOS:000372211500005
PM 27084793
ER
PT J
AU Bunpin, JJD
Chapman, S
Blegen, M
Spetz, J
AF Bunpin, Jose J. Dy, III
Chapman, Susan
Blegen, Mary
Spetz, Joanne
TI Differences in Innovative Behavior Among Hospital-Based Registered
Nurses
SO JOURNAL OF NURSING ADMINISTRATION
LA English
DT Article
ID CARE; EMPOWERMENT; AUTONOMY
AB BACKGROUND: The 2010 Institute of Medicine report, 'The Future of Nursing: Leading Change, Advancing Health', advocated for nurses to innovate in their practice, research, and education. However, little is known about the innovative behavior of registered nurses or whether there are differences in innovative behavior among registered nurses. OBJECTIVE: The purpose of this article is to describe the innovative behavior of hospital-based registered nurses and understand the differences in innovative behavior when registered nurses are categorized into various demographic groups. METHODS: A survey of 251 hospital-based registered nurses from 9 hospitals in California was administered to assess demographic characteristics and innovative behavior, measured through Scott and Bruce's Individual Innovative Behavior Scale. RESULTS: Hospital-based registered nurses, on average, reported moderate levels of innovative behavior. There were statistically significant differences in innovative behavior when registered nurses were categorized according to specialty certification, role, level of education, hospital size, and hospital innovativeness. CONCLUSIONS: To support innovative behavior, organizations should provide opportunities for specialty certification and increasing levels of education.
C1 [Bunpin, Jose J. Dy, III] San Francisco VA Med Ctr, Surg & Procedural Care, San Francisco, CA 94121 USA.
[Chapman, Susan] Univ Calif San Francisco, Sch Nursing, Dept Social & Behav Sci, San Francisco, CA 94143 USA.
[Blegen, Mary] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA.
[Spetz, Joanne] Univ Calif San Francisco, Sch Med, Inst Hlth Policy Studies, San Francisco, CA 94143 USA.
RP Bunpin, JJD (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA.
EM jose.dybunpin@va.gov
NR 33
TC 0
Z9 0
U1 7
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0002-0443
EI 1539-0721
J9 J NURS ADMIN
JI J. Nurs. Adm.
PD MAR
PY 2016
VL 46
IS 3
BP 122
EP 127
DI 10.1097/NNA.0000000000000310
PG 6
WC Nursing
SC Nursing
GA DF8BZ
UT WOS:000371583200006
ER
PT J
AU Ikizler, HO
Zelnick, L
Ruzinski, J
Curtin, L
Utzschneider, KM
Kestenbaum, B
Himmelfarb, J
de Boer, IH
AF Ikizler, Halil O.
Zelnick, Leila
Ruzinski, John
Curtin, Laura
Utzschneider, Kristina M.
Kestenbaum, Bryan
Himmelfarb, Jonathan
de Boer, Ian H.
TI Dietary Acid Load is Associated With Serum Bicarbonate but not Insulin
Sensitivity in Chronic Kidney Disease
SO JOURNAL OF RENAL NUTRITION
LA English
DT Article
ID GLOMERULAR-FILTRATION-RATE; METABOLIC-ACIDOSIS; AFRICAN-AMERICANS;
HYPERTENSIVE NEPHROPATHY; UNITED-STATES; OLDER-ADULTS; RESISTANCE; RISK;
PROGRESSION; HUMANS
AB Objective: In chronic kidney disease (CKD), dietary acid may promote metabolic acidosis and insulin resistance, which in turn may contribute to adverse clinical health outcomes. We examined associations between dietary acid load, serum bicarbonate, and insulin sensitivity in CKD.
Design: In a cross-sectional study, we collected 3-day prospective food diaries to quantify dietary acid load as net endogenous acid production (NEAP, the nonvolatile acid load produced by the diet's acid balance) and potential renal acid load (PRAL). We measured urine net acid excretion (NAE) in 24-hour urine samples. Insulin sensitivity was measured by hyperinsulinemic euglycemic clamp.
Subjects: Forty-two patients with CKD Stages 3 to 5 attending nephrology clinics in the Pacific Northwest and 21 control subjects (estimated glomerular filtration rate [eGFR] >= 60 mL/minute/1.73 m(2)).
Main Outcome Measures: Serum bicarbonate and insulin sensitivity (SIclamp).
Results: Mean age was 60.8 +/- 13.6 years, and 54% of participants were men. Mean eGFR and serum bicarbonate concentrations were 34.4 +/- 13.1 mL/minute/1.73 m(2) and 24.1 +/- 2.9 mEq/L for participants with CKD and 88.6 +/- 14.5 mL/minute/1.73 m(2) and 26.3 +/- 1.8 mEq/L for control subjects, respectively. Mean NEAP, PRAL, and NAE were 58.2 +/- 24.3, 9.7 +/- 18.4, and 32.1 +/- 19.8 mEq/day, respectively. Considering all participants, dietary acid load was significantly, inversely associated with serum bicarbonate, adjusting for age, gender, race, eGFR, body mass index, and diuretic use: -1.2 mEq/L per standard deviation (SD) NEAP (95% confidence interval [CI] -1.8 to -0.6, P<.0001); -0.9 mEq/L bicarbonate per SD PRAL (95% CI -1.5 to -0.4, P=.0005); -0.7 mEq/L bicarbonate per SD NAE (95% CI -1.2 to -0.1, P=.01). These associations were similar in participants with and without CKD. However, neither NEAP and PRAL nor NAE was significantly associated with SIclamp. Serum bicarbonate was also not significantly associated with SIclamp.
Conclusions: In CKD, dietary acid load is associated with serum bicarbonate, suggesting that acidosis may be improved by dietary changes, but not with insulin sensitivity. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.
C1 [Ikizler, Halil O.] Univ Vermont, Coll Med, Burlington, VT USA.
[Ikizler, Halil O.; Zelnick, Leila; Ruzinski, John; Curtin, Laura; Kestenbaum, Bryan; Himmelfarb, Jonathan; de Boer, Ian H.] Univ Washington, Kidney Res Inst, Box 359606,325 9th Ave, Seattle, WA 98104 USA.
[Utzschneider, Kristina M.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA.
[Utzschneider, Kristina M.] Univ Washington, Seattle, WA 98195 USA.
[Kestenbaum, Bryan; Himmelfarb, Jonathan; de Boer, Ian H.] Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98195 USA.
[Kestenbaum, Bryan; de Boer, Ian H.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
RP de Boer, IH (reprint author), Univ Washington, Kidney Res Inst, Box 359606,325 9th Ave, Seattle, WA 98104 USA.
EM deboer@u.washington.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
[T32DK007247]; NIDDK [DK087726, DK007247, DK017047]; University of
Washington Diabetes Research Center [P30 DK01704]; University of
Washington Institute of Translational Health Sciences [UL1TR000423];
Department of Veterans Affairs
FX H.O.I. was supported by grant T32DK007247 from the National Institute of
Diabetes and Digestive and Kidney Diseases (NIDDK). The SUGAR study was
supported by NIDDK grants DK087726, DK007247, and DK017047. Support was
also provided by the University of Washington Diabetes Research Center
(P30 DK01704), the University of Washington Institute of Translational
Health Sciences (UL1TR000423), and the Department of Veterans Affairs.
The funding sources had no role in study design, analysis or
interpretation of data, writing of the report, or the decision to submit
this article for publication.
NR 44
TC 4
Z9 4
U1 3
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1051-2276
EI 1532-8503
J9 J RENAL NUTR
JI J. Renal Nutr.
PD MAR
PY 2016
VL 26
IS 2
BP 93
EP 102
DI 10.1053/j.jrn.2015.08.008
PG 10
WC Nutrition & Dietetics; Urology & Nephrology
SC Nutrition & Dietetics; Urology & Nephrology
GA DG4AA
UT WOS:000372011100007
PM 26508542
ER
PT J
AU Molfino, A
Kaysen, GA
Chertow, GM
Doyle, J
Delgado, C
Dwyer, T
Laviano, A
Fanelli, FR
Johansen, KL
AF Molfino, Alessio
Kaysen, George A.
Chertow, Glenn M.
Doyle, Julie
Delgado, Cynthia
Dwyer, Tjien
Laviano, Alessandro
Fanelli, Filippo Rossi
Johansen, Kirsten L.
TI Validating Appetite Assessment Tools Among Patients Receiving
Hemodialysis
SO JOURNAL OF RENAL NUTRITION
LA English
DT Article
ID CHRONIC KIDNEY-DISEASE; HOSPITALIZED-PATIENTS; NUTRITIONAL-STATUS;
ANOREXIA; LEPTIN; INFLAMMATION; ADIPONECTIN; MORTALITY; CACHEXIA; DEATH
AB Objective: To test the performance of appetite assessment tools among patients receiving hemodialysis (HD).
Design: Cross-sectional.
Subjects: Two hundred twenty-one patients receiving HD enrolled in seven dialysis facilities in Northern California.
Intervention: We assessed 5 appetite assessment tools (self-assessment of appetite, subjective assessment of appetite, visual analog scale [VAS], Functional Assessment of Anorexia/Cachexia Therapy [FAACT] score, and the Anorexia Questionnaire [AQ]).
Main Outcome Measures: Reported food intake, normalized protein catabolic rate, and change in body weight were used as criterion measures, and we assessed associations among the appetite tools and biomarkers associated with nutrition and inflammation. Patients were asked to report their appetite and the percentage of food eaten (from 0% to 100%) during the last meal compared to usual intake.
Results: Fifty-eight (26%) patients reported food intake <= 50% (defined as poor appetite). The prevalence of anorexia was 12% by self-assessment of appetite, 6% by subjective assessment of appetite, 24% by VAS, 17% by FAACT score, and 12% by AQ. All the tools were significantly associated with food intake <= 50% (P<.001), except self-assessment of appetite. The FAACT score and the VAS had the strongest association with food intake <= 50% (C-statistic 0.80 and 0.76). Patients with food intake <= 50% reported weight loss more frequently than patients without low intake (36% vs 22%) and weight gain less frequently (19% vs 35%; P = .03). Normalized protein catabolic rate was lower among anorexic patients based on the VAS (1.1 +/- 0.3 vs 1.2 +/- 0.3, P=.03). Ln interleukin-6 correlated inversely with food intake (P = .03), but neither interleukin-6 nor C-reactive protein correlated with any of the appetite tools. Furthermore, only the self-assessment of appetite was significantly associated with serum albumin (P = .02), prealbumin (P = .02) and adiponectin concentrations (P = .03).
Conclusions: Alternative appetite assessment tools yielded widely different estimates of the prevalence of anorexia in HD. When considering self-reported food intake as the criterion standard for anorexia, the FAACT score and VAS discriminated patients reasonably well. (C) 2016 by the National Kidney Foundation, Inc. All rights reserved.
C1 [Molfino, Alessio; Kaysen, George A.; Dwyer, Tjien] Univ Calif Davis, Dept Internal Med, Div Nephrol, Davis, CA 95616 USA.
[Molfino, Alessio; Laviano, Alessandro; Fanelli, Filippo Rossi] Univ Roma La Sapienza, Dept Clin Med, Viale Univ 37, I-00185 Rome, Italy.
[Chertow, Glenn M.] Stanford Univ, Sch Med, Dept Med, Div Nephrol, Palo Alto, CA 94304 USA.
[Doyle, Julie; Delgado, Cynthia; Johansen, Kirsten L.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA.
[Doyle, Julie; Delgado, Cynthia; Johansen, Kirsten L.] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA USA.
RP Molfino, A (reprint author), Univ Roma La Sapienza, Dept Clin Med, Viale Univ 37, I-00185 Rome, Italy.
EM alessio.molfino@uniroma1.it
FU National Institute of Diabetes and Digestive and Kidney Diseases
[N01-DK-7-005, N01-DK-7-5004]; NIDDK [K24DK085153]; Department of
Veterans Affairs, Clinical Science Research and Development Program
[1IK2CX000527-01A2]; National Center for Research Resources; National
Center for Advancing Translational Sciences, National Institutes of
Health, through UCSF-CTSI Grant [UL1 RR024131]
FX This work was supported by contracts N01-DK-7-005 and N01-DK-7-5004 from
the National Institute of Diabetes and Digestive and Kidney Diseases.
K.L.J.'s effort was supported in part by K24DK085153 from NIDDK. C.D.'s
work was supported by the Department of Veterans Affairs, Clinical
Science Research and Development Program under Career Development Award
1IK2CX000527-01A2. Her contribution is the result of work supported with
the resources and the use of facilities at the San Francisco VA Medical
Center. This publication was also supported by the National Center for
Research Resources and the National Center for Advancing Translational
Sciences, National Institutes of Health, through UCSF-CTSI Grant number
UL1 RR024131.
NR 28
TC 1
Z9 1
U1 1
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1051-2276
EI 1532-8503
J9 J RENAL NUTR
JI J. Renal Nutr.
PD MAR
PY 2016
VL 26
IS 2
BP 103
EP 110
DI 10.1053/j.jrn.2015.09.002
PG 8
WC Nutrition & Dietetics; Urology & Nephrology
SC Nutrition & Dietetics; Urology & Nephrology
GA DG4AA
UT WOS:000372011100008
PM 26522141
ER
PT J
AU Mysore, VS
Szablowski, J
Dervan, PB
Frost, PJ
AF Mysore, Veena S.
Szablowski, Jerzy
Dervan, Peter B.
Frost, Patrick J.
TI A DNA-binding Molecule Targeting the Adaptive Hypoxic Response in
Multiple Myeloma Has Potent Antitumor Activity
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID BONE-MARROW ANGIOGENESIS; IN-VIVO; ACTIVATED PRODRUG; INDUCIBLE FACTOR;
CELLS; CANCER; TUMOR; EXPRESSION; TRANSLATION; INHIBITION
AB Multiple myeloma is incurable and invariably becomes resistant to chemotherapy. Although the mechanisms remain unclear, hypoxic conditions in the bone marrow have been implicated in contributing to multiple myeloma progression, angiogenesis, and resistance to chemotherapy. These effects occur via adaptive cellular responses mediated by hypoxia-inducible transcription factors (HIF), and targeting HIFs can have anticancer effects in both solid and hematologic malignancies. Here, it was found that in most myeloma cell lines tested, HIF1 alpha, but not HIF2 alpha expression was oxygen dependent, and this could be explained by the differential expression of the regulatory prolyl hydroxylase isoforms. The anti-multiple myeloma effects of a sequence-specific DNA-binding pyrrole-imidazole (Py-Im) polyamide (HIF-PA), which disrupts the HIF heterodimer from binding to its cognate DNA sequences, were also investigated. HIF-PA is cell permeable, localizes to the nuclei, and binds specific regions of DNA with an affinity comparable with that of HIFs. Most of the multiple myeloma cells were resistant to hypoxia-mediated apoptosis, and HIF-PA treatment could overcome this resistance in vitro. Using xenograft models, it was determined that HIF-PA significantly decreased tumor volume and increased hypoxic and apoptotic regions within solid tumor nodules and the growth of myeloma cells engrafted in the bone marrow. This provides a rationale for targeting the adaptive cellular hypoxic response of the O-2-dependent activation of HIF alpha using polyamides.
C1 [Mysore, Veena S.; Frost, Patrick J.] Greater Los Angeles Vet Adm Healthcare Syst, 11301Wilshire Blvd,Bldg 114,Room 113, Los Angeles, CA 90073 USA.
[Mysore, Veena S.; Frost, Patrick J.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Szablowski, Jerzy; Dervan, Peter B.] CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA.
RP Frost, PJ (reprint author), Greater Los Angeles Vet Adm Healthcare Syst, 11301Wilshire Blvd,Bldg 114,Room 113, Los Angeles, CA 90073 USA.
EM pfrost@ucla.edu
FU MERIT from the United States Department of Veterans Affairs Biomedical
Laboratory Research and Development Service [1I01BX001532]; NIH
[GM051747]
FX This work was supported by a MERIT grant 1I01BX001532 (to P.J. Frost)
from the United States Department of Veterans Affairs Biomedical
Laboratory Research and Development Service and a NIH GM051747 grant (to
P.B. Dervan).
NR 50
TC 0
Z9 0
U1 4
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1541-7786
EI 1557-3125
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD MAR
PY 2016
VL 14
IS 3
BP 253
EP 266
DI 10.1158/1541-7786.MCR-15-0361
PG 14
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA DG3XM
UT WOS:000372004400002
PM 26801054
ER
PT J
AU Li, H
Wheeler, S
Park, Y
Ju, ZL
Thomas, SM
Fichera, M
Egloff, AM
Lui, VW
Duvvuri, U
Bauman, JE
Mills, GB
Grandis, JR
AF Li, Hua
Wheeler, Sarah
Park, Yongseok
Ju, Zhenlin
Thomas, Sufi M.
Fichera, Michele
Egloff, Ann M.
Lui, Vivian W.
Duvvuri, Umamaheswar
Bauman, Julie E.
Mills, Gordon B.
Grandis, Jennifer R.
TI Proteomic Characterization of Head and Neck Cancer Patient-Derived
Xenografts
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; PHASE PROTEIN ARRAY; DRUG DEVELOPMENT;
PANCREATIC-CANCER; GENOMIC CHARACTERIZATION; PREDICTIVE BIOMARKERS;
TUMOR XENOGRAFTS; IN-VITRO; MODELS; MOUSE
AB Despite advances in treatment approaches for head and neck squamous cell carcinoma (HNSCC), survival rates have remained stagnant due to the paucity of preclinical models that accurately reflect the human tumor. Patient-derived xeno-grafts (PDX) are an emerging model system where patient tumors are implanted directly into mice. Increased understanding of the application and limitations of PDXs will facilitate their rational use. Studies to date have not reported protein profiles of PDXs. Therefore, we developed a large cohort of HNSCC PDXs and found that tumor take rate was not influenced by the clinical, pathologic, or processing features. Protein expression profiles, from a subset of the PDXs, were characterized by reverse-phase protein array and the data was compared with The Cancer Genome Atlas HNSCC data. Cluster analysis revealed that HNSCC PDXs were more similar to primary HNSCC than to any other tumor type. Interestingly, while a significant fraction of proteins were expressed similarly in both primary HNSCC and PDXs, a subset of proteins/phosphoproteins were expressed at higher (or lower) levels in PDXs compared with primary HNSCC. These findings indicate that the proteome is generally conserved in PDXs, but mechanisms for both positive and negative model selection and/or differences in the stromal components exist.
C1 [Li, Hua; Egloff, Ann M.; Duvvuri, Umamaheswar; Grandis, Jennifer R.] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA.
[Wheeler, Sarah; Fichera, Michele; Grandis, Jennifer R.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA.
[Park, Yongseok] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA.
[Ju, Zhenlin; Mills, Gordon B.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA.
[Thomas, Sufi M.] Univ Kansas, Med Ctr, Dept Otolaryngol, Kansas City, KS 66103 USA.
[Thomas, Sufi M.] Univ Kansas, Med Ctr, Dept Canc Biol, Kansas City, KS 66103 USA.
[Lui, Vivian W.] Univ Hong Kong, Dept Pharmacol & Pharm, Hong Kong, Hong Kong, Peoples R China.
[Duvvuri, Umamaheswar] Vet Affairs Pittsburgh Healthcare Syst, Univ Dr Campus, Pittsburgh, PA USA.
[Bauman, Julie E.] Univ Pittsburgh, Dept Internal Med Hematol Oncol, Pittsburgh, PA USA.
[Mills, Gordon B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA.
[Grandis, Jennifer R.] Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA 94158 USA.
RP Grandis, JR (reprint author), Univ Calif San Francisco, 1450 3rd St,Room HD200, San Francisco, CA 94158 USA.
EM jennifer.grandis@ucsf.edu
RI Lui, Vivian/I-5458-2016
FU NIH [P50CA097190, K07 CA137140]; American Cancer Society; Department of
Veterans Affairs BLRD; NCI [CA16672]
FX This work was supported by grants NIH P50CA097190 and the American
Cancer Society (to J.R. Grandis), NIH K07 CA137140 (to A.M. Egloff),
Department of Veterans Affairs BLR&D (to U. Duvvuri). RPPA work was
performed in the MDACC CCSG supported core NCI CA16672.
NR 40
TC 4
Z9 5
U1 1
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1541-7786
EI 1557-3125
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD MAR
PY 2016
VL 14
IS 3
BP 278
EP 286
DI 10.1158/1541-7786.MCR-15-0354
PG 9
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA DG3XM
UT WOS:000372004400004
PM 26685214
ER
PT J
AU Martinez-Martin, P
Leentjens, AFG
de Pedro-Cuesta, J
Chaudhuri, KR
Schrag, AE
Weintraub, D
AF Martinez-Martin, Pablo
Leentjens, Albert F. G.
de Pedro-Cuesta, Jesus
Chaudhuri, Kallol Ray
Schrag, Anette E.
Weintraub, Daniel
TI Accuracy of screening instruments for detection of neuropsychiatric
syndromes in Parkinson's disease
SO MOVEMENT DISORDERS
LA English
DT Review
DE Parkinson's disease; neuropsychiatric symptoms; screening; instruments;
accuracy
ID GERIATRIC DEPRESSION SCALE; IMPULSIVE-COMPULSIVE DISORDERS; DRUG-INDUCED
PSYCHOSIS; ANXIETY RATING-SCALES; QUALITY-OF-LIFE; NONMOTOR SYMPTOMS;
HOSPITAL ANXIETY; RECOGNIZING DEPRESSION; COGNITIVE IMPAIRMENT;
REPETITIVE BEHAVIORS
AB Parkinson's disease includes neuropsychiatric manifestations, such as depression, anxiety, apathy, psychosis, and impulse control disorders, which often are unreported by patients and caregivers or undetected by doctors. Given their substantial impact on patients and caregivers as well as the existence of effective therapies for some of these disorders, screening for neuropsychiatric symptoms is important. Instruments for screening have a particular methodology for validation, and their performance is expressed in terms of accuracy compared with formal diagnostic criteria. The present study reviews the attributes of the screening instruments applied for detection of the aforementioned major neuropsychiatric symptoms in Parkinson's disease. A quasi-systematic review (including predefined selection criteria, but not evaluating the quality of the reviewed studies) was carried out on the basis of previous systematic reviews (commissioned by the American Academy of Neurology and the Movement Disorder Society) and made current by conducting a literature search (2005-2014). For depression, 11 scales and questionnaires were shown to be valid for Parkinson's disease screening. The recently developed Parkinson Anxiety Scale and the Geriatric Anxiety Inventory demonstrate satisfactory properties as screening instruments for anxiety, and the Lille Apathy Rating Scale for detection of apathy. No scale adequately screens for psychosis, so a specific psychosis instrument should be developed. The Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease (Questionnaire and Rating Scale) are valid for comprehensive screening of impulse control disorders, and the Parkinson's Disease-Sexual Addiction Screening Test for hypersexuality specifically. (c) 2015 International Parkinson and Movement Disorder Society
C1 [Martinez-Martin, Pablo; de Pedro-Cuesta, Jesus] Carlos III Inst Hlth, Natl Ctr Epidemiol, Avda Monforte de Lemos 5, Madrid 28029, Spain.
[Martinez-Martin, Pablo; de Pedro-Cuesta, Jesus] Carlos III Inst Hlth, CIBERNED, Madrid 28029, Spain.
[Leentjens, Albert F. G.] Maastricht Univ, Med Ctr, Dept Psychiat, NL-6200 MD Maastricht, Netherlands.
[Chaudhuri, Kallol Ray] Kings Coll London, Natl Parkinson Fdn Int Ctr Excellence, London WC2R 2LS, England.
[Chaudhuri, Kallol Ray] South London & Maudsley NHS Fdn Trust, Natl Inst Hlth Res, Mental Hlth Biomed Res Ctr, London, England.
[Chaudhuri, Kallol Ray] South London & Maudsley NHS Fdn Trust, Dementia Unit, London, England.
[Chaudhuri, Kallol Ray] Kings Coll London, London WC2R 2LS, England.
[Schrag, Anette E.] UCL, Inst Neurol, Royal Free Campus, London, England.
[Weintraub, Daniel] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Weintraub, Daniel] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Martinez-Martin, P (reprint author), Carlos III Inst Hlth, Natl Ctr Epidemiol, Avda Monforte de Lemos 5, Madrid 28029, Spain.
EM pmartinez@isciii.es
NR 97
TC 6
Z9 6
U1 5
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
EI 1531-8257
J9 MOVEMENT DISORD
JI Mov. Disord.
PD MAR
PY 2016
VL 31
IS 3
BP 270
EP 279
DI 10.1002/mds.26522
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA DG7SR
UT WOS:000372284500003
PM 26695691
ER
PT J
AU Moelter, ST
Weintraub, D
Mace, L
Cary, M
Sullo, E
Xie, SX
Karlawish, J
AF Moelter, Stephen T.
Weintraub, Daniel
Mace, Lauren
Cary, Mark
Sullo, Elizabeth
Xie, Sharon X.
Karlawish, Jason
TI Research consent capacity varies with executive function and memory in
Parkinson's disease
SO MOVEMENT DISORDERS
LA English
DT Article
DE Parkinson's disease; decision making; capacity; cognitive impairment;
informed consent
ID MILD COGNITIVE IMPAIRMENT; DEMENTIA; TRIAL
AB BackgroundWe examined the association between cognitive domains and research consent capacity in PD. Our hypothesis was that research consent capacity is best predicted by executive function.
MethodsA cohort of 90 PD patients and 30 healthy older adults were administered the MacArthur Competence Assessment Tool for Clinical Research, Dementia Rating Scale-2, and the MoCA. Experts classified patients as either capable or not capable of providing informed consent to participate in two clinical trials.
ResultsMacArthur Competence Assessment Tool for Clinical Research Reasoning scores for both clinical trial types were most associated with executive functions and delayed recall. As scores on these domains improved, the odds of an expert rating of capable of consent increased.
ConclusionsThese results extend our previous findings by demonstrating that memory and executive abilities appear closely associated with capacity when evaluated using either a structured interview or expert judgment of that interview. (c) 2016 International Parkinson and Movement Disorder Society
C1 [Moelter, Stephen T.; Mace, Lauren] Univ Sci, Dept Behav & Social Sci, 600 South 43rd St, Philadelphia, PA 19104 USA.
[Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA.
[Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA.
[Weintraub, Daniel] Univ Penn, Dept Psychiat, Geriatr Psychiat Sect, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Cary, Mark; Xie, Sharon X.] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Sullo, Elizabeth; Karlawish, Jason] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Karlawish, Jason] Univ Penn, Dept Med Eth & Hlth Policy, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Karlawish, Jason] Univ Penn, Leonard Davis Inst Hlth Econ, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Karlawish, Jason] Univ Penn, Alzheimers Dis Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Moelter, ST (reprint author), Univ Sci, Dept Behav & Social Sci, 600 South 43rd St, Philadelphia, PA 19104 USA.
EM s.moelte@usciences.edu
FU National Institute of Neurological Disorders and Stroke [R01NS65087];
Morris K. Udall Center for Parkinson's Disease Research [P50 NS053488,
NS062684]; National Institute on Aging [AG10124]
FX This work was supported by the National Institute of Neurological
Disorders and Stroke (R01NS65087), Morris K. Udall Center for
Parkinson's Disease Research (P50 NS053488 and NS062684), and the
National Institute on Aging (AG10124).
NR 15
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
EI 1531-8257
J9 MOVEMENT DISORD
JI Mov. Disord.
PD MAR
PY 2016
VL 31
IS 3
BP 414
EP 417
DI 10.1002/mds.26469
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA DG7SR
UT WOS:000372284500026
PM 26861463
ER
PT J
AU Brawner, BM
Alexander, KA
Fannin, EF
Baker, JL
Davis, ZM
AF Brawner, Bridgette M.
Alexander, Kamila A.
Fannin, Ehriel F.
Baker, Jillian L.
Davis, Zupenda M.
TI The Role of Sexual Health Professionals in Developing a Shared Concept
of Risky Sexual Behavior as it Relates to HIV Transmission
SO PUBLIC HEALTH NURSING
LA English
DT Article
DE disease prevention; diversity; health promotion; HIV; AIDS; patient
education; prevention; programme planning; public health systems; sexual
behavior
ID INTIMATE PARTNER VIOLENCE; YOUNG-ADULTS; RELATIONSHIP POWER; DOMESTIC
VIOLENCE; ADOLESCENT GIRLS; UNITED-STATES; SELF-EFFICACY; SOUTH-AFRICA;
CONDOM USE; PREVENTION
AB Risky sexual behavior accounts for the majority of new HIV infections regardless of gender, age, geographic location, or ethnicity. The phrase, however, refers to a relatively nebulous concept that hampers development of effective sexual health communication strategies. The purpose of this paper was to propose development of a shared conceptual understanding of risky sexual behavior. We reviewed multidisciplinary HIV/AIDS literature to identify definitions of risky sexual behavior. Both the linguistic components and the social mechanisms that contribute to the concept of risky sexual behaviors were noted. Risky sexual behavior was often defined in a subjective manner in the literature, even in the scientific research. We urge a paradigm shift to focus on explicit behaviors and the social context of those behaviors in determining HIV risk. We also propose a new definition that reduces individual biases and promotes a broader discussion of the degree of sexual risk across a diversity of behavioral contexts. Sexual health professionals can strengthen practice and research initiatives by operating from a concise working definition of risky sexual behavior that is broadly transferable and expands beyond a traditional focus on identity-based groups.
C1 [Brawner, Bridgette M.] Univ Penn, Sch Nursing, Dept Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA.
[Brawner, Bridgette M.; Fannin, Ehriel F.] Univ Penn, Sch Nursing, Ctr Global Womens Hlth, 418 Curie Blvd,Room 419, Philadelphia, PA 19036 USA.
[Alexander, Kamila A.] Johns Hopkins Sch Nursing, Dept Community Publ Hlth, Baltimore, MD USA.
[Fannin, Ehriel F.] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, 418 Curie Blvd,Room 419, Philadelphia, PA 19036 USA.
[Baker, Jillian L.; Davis, Zupenda M.] La Salle Univ, Sch Nursing & Hlth Sci, Dept Urban Publ Hlth & Nutr, Philadelphia, PA 19141 USA.
RP Brawner, BM (reprint author), Univ Penn, Sch Nursing, Ctr Global Womens Hlth, 418 Curie Blvd,Room 419, Philadelphia, PA 19036 USA.; Brawner, BM (reprint author), Univ Penn, Sch Nursing, Ctr Hlth Equ Res, 418 Curie Blvd,Room 419, Philadelphia, PA 19036 USA.
EM brawnerb@nursing.upenn.edu
FU Centers for Disease Control and Prevention [CDC U01PS003304]; National
Institute of Mental Health [NIH/NIMH R25MH087217]; Substance Abuse and
Mental Health Services Administration at American Nurses Association
Minority Fellowship Program [5SM058566-02]; Hampton-Penn Center for
Health Disparities Research [NINR P20NR008361]; Distinguished
Postdoctoral Fellowship; Fontaine Society Fellowship at University of
Pennsylvania; Individual Ruth L. Kirschstein NRSA Predoctoral Fellowship
[F31NR013121]; Ruth L. Kirschstein NRSA Postdoctoral Fellowship; Ruth L.
Kirschstein NRSA Predoctoral Fellowship [5T32NR007100-13]; National
Institute of Child Health & Human Development Diversity Research
Supplement Award [5R01HD061061-03]
FX This article was supported by funding to Dr. Brawner from the Centers
for Disease Control and Prevention (CDC U01PS003304), the National
Institute of Mental Health (NIH/NIMH R25MH087217; PI: B. Guthrie, J.),
the Substance Abuse and Mental Health Services Administration at the
American Nurses Association Minority Fellowship Program (5SM058566-02),
the Hampton-Penn Center for Health Disparities Research (NINR
P20NR008361), and the Distinguished Postdoctoral Fellowship and the
Fontaine Society Fellowship at the University of Pennsylvania. The
article was also supported by the Individual Ruth L. Kirschstein NRSA
Predoctoral Fellowship (F31NR013121) and the Ruth L. Kirschstein NRSA
Postdoctoral Fellowship (T32HDO64428; PI: Campbell) awarded to Dr.
Alexander; the Ruth L. Kirschstein NRSA Predoctoral Fellowship
(5T32NR007100-13; PI: Sommers) awarded to Ms. Ehriel Fannin; and funding
from a National Institute of Child Health & Human Development Diversity
Research Supplement Award (5R01HD061061-03; PI: Jemmott) to Dr. Baker.
NR 74
TC 1
Z9 1
U1 5
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0737-1209
EI 1525-1446
J9 PUBLIC HEALTH NURS
JI Public Health Nurs.
PD MAR-APR
PY 2016
VL 33
IS 2
BP 139
EP 150
DI 10.1111/phn.12216
PG 12
WC Public, Environmental & Occupational Health; Nursing
SC Public, Environmental & Occupational Health; Nursing
GA DG2PW
UT WOS:000371910700007
PM 26184496
ER
PT J
AU Pang, CE
Sarraf, D
Freund, KB
AF Pang, Claudine E.
Sarraf, David
Freund, K. Bailey
TI An Atypical Presentation of Bartonella Neuroretinitis Reply
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Letter
ID MYOPIA
C1 [Pang, Claudine E.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
[Pang, Claudine E.; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY USA.
[Sarraf, David] Univ Calif Los Angeles, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA 90024 USA.
[Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA.
[Freund, K. Bailey] NYU, Sch Med, Dept Ophthalmol, New York, NY USA.
RP Pang, CE (reprint author), Vitreous Retina Macula Consultants New York, New York, NY USA.; Pang, CE (reprint author), Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY USA.
NR 2
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2016
VL 36
IS 3
BP e24
EP e24
DI 10.1097/IAE.0000000000000990
PG 1
WC Ophthalmology
SC Ophthalmology
GA DG1MX
UT WOS:000371833300008
PM 26849457
ER
PT J
AU Weisbord, SD
AF Weisbord, Steven D.
TI Patient-Centered Dialysis Care: Depression, Pain, and Quality of Life
SO SEMINARS IN DIALYSIS
LA English
DT Article
ID STAGE RENAL-DISEASE; RECEIVING CHRONIC-HEMODIALYSIS; MAINTENANCE
HEMODIALYSIS; PSYCHOSOCIAL FACTORS; TRANSPLANT PATIENTS; MORTALITY RISK;
SYMPTOMS; PREVALENCE; ADHERENCE; HOSPITALIZATION
AB Remarkable advancements have been made in the provision of chronic dialysis therapy since its inception decades ago. A series of studies inform current dialysis dosing recommendations, while advancements in strategies to treat mineral and bone disease, acid-base and electrolyte disturbances, and anemia have facilitated the management of these well-recognized complications of ESRD. The collective result has been a model of chronic dialysis care focused principally on the achievement of metabolic and dialysis-related targets. In fact, guidelines such as the Kidney Disease Outcomes Quality Initiative put forth by the National Kidney Foundation recommend metrics that characterize successful dialysis care, including the attainment of specific solute clearance targets; maintenance of hemoglobin, calcium, phosphorous, and parathyroid hormone levels within target ranges; and the preferred use of primary arteriovenous fistulae for vascular access. This focus on serologic and dialysis-specific outcomes has helped renal providers manage the biochemical effects related to the loss of kidney function and has reduced ESRD-related morbidity and mortality. Yet, absent from this model of care is an emphasis on the treatment of bothersome symptoms and the impact of such treatment on quality of life (QOL). Among the many symptoms that affect patients on chronic dialysis, depression and pain are particularly common, strongly associated with decrements in QOL, and potentially treatable. This review discusses key research findings and unanswered questions pertaining to the prevalence, significance, and treatment of depression and pain and the effect of such treatment on QOL in patients dependent on chronic dialysis, with the broad goal of incorporating symptom management strategies into a paradigm of patient-centered dialysis care.
C1 [Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Med Serv Line, Renal Sect, Pittsburgh, PA USA.
[Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA.
[Weisbord, Steven D.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA.
RP Weisbord, SD (reprint author), VA Pittsburgh Healthcare Syst, 7E Room 120,111F U, Pittsburgh, PA 15240 USA.
EM weisbordsd@upmc.edu
NR 47
TC 2
Z9 2
U1 3
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-0959
EI 1525-139X
J9 SEMIN DIALYSIS
JI Semin. Dial.
PD MAR
PY 2016
VL 29
IS 2
BP 158
EP 164
DI 10.1111/sdi.12464
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA DG7SC
UT WOS:000372283000010
PM 26748494
ER
PT J
AU Saby, A
Miller, LS
AF Saby, Adam
Miller, Lawrence S.
TI Functional Assessment in End-Stage Renal Disease: Enhancing Quality of
Life
SO SEMINARS IN DIALYSIS
LA English
DT Article
ID DIALYSIS PATIENTS; HEMODIALYSIS; MORTALITY; HEALTH; FACILITIES;
DISABILITY; CAPACITY; OUTCOMES; FALLS; RISK
AB Why do functional assessments in patients with end-stage renal disease (ESRD) matter? Multiple studies show that new dialysis patients undergo a substantial decline among activities of daily living. Moreover, poor functional status in ESRD patients is associated with early morality. That is why CMS has developed new criteria to assess ESRD patients in regards to their functional, psychologic, and cognitive capabilities. Functional assessments by health providers have been used in field of Rehabilitation Medicine for over 50 years; rehabilitation physicians have found them effective in establishing goals and monitoring improvement. Assessments can provide guidance by identifying the needs and types of intervention most suited for patients. Impairments can be addressed with referrals to physical therapy for gross motor issues, occupational therapy for self-care problems, psychiatry for mental disorders, and neurology for cognitive deficits. The more accurate the assessments over time, the more targeted and effective the therapies become. We believe that the new CMS goals to assess functionality will improve ESRD patient's quality of life, longevity, and long-term healthcare costs.
C1 [Saby, Adam] Univ Calif Los Angeles, David Geffen Sch Med, Greater Los Angeles Vet Adm Hlth Care Syst, Dept Phys Med & Rehabil, Los Angeles, CA 90095 USA.
[Miller, Lawrence S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
RP Saby, A (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Greater Los Angeles Vet Adm Hlth Care Syst, Dept Phys Med & Rehabil, Los Angeles, CA 90095 USA.; Saby, A (reprint author), Dept Phys Med & Rehabil 117, 11301 Wilshire blvd, Los Angeles, CA 90073 USA.
EM asaby@ucla.edu
NR 21
TC 0
Z9 0
U1 2
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-0959
EI 1525-139X
J9 SEMIN DIALYSIS
JI Semin. Dial.
PD MAR
PY 2016
VL 29
IS 2
BP 170
EP 172
DI 10.1111/sdi.12466
PG 3
WC Urology & Nephrology
SC Urology & Nephrology
GA DG7SC
UT WOS:000372283000012
PM 26756940
ER
PT J
AU Sarmiento, K
Rossettie, J
Stepnowsky, C
Atwood, C
Calvitti, A
AF Sarmiento, Kathleen
Rossettie, John
Stepnowsky, Carl
Atwood, Charles
Calvitti, Alan
CA VA Sleep Network
TI The state of Veterans Affairs sleep medicine programs: 2012 inventory
results
SO SLEEP AND BREATHING
LA English
DT Article
DE Access to health care; Health services; Sleep disorders; Veterans
AB The Veterans Health Administration (VHA) represents one of the largest integrated health-care systems in the country. In 2012, the Veterans Affairs Sleep Network (VASN) sought to identify available sleep resources at VA medical centers (VAMCs) across the country through a national sleep inventory.
The sleep inventory was administered at the annual 2012 VA Sleep Practitioners meeting and by email to sleep contacts at each VAMC. National prosthetics contacts were used to identify personnel at VAMCs without established sleep programs. Follow-up emails and telephone calls were made through March 2013.
One hundred eleven VA medical centers were included for analysis. Thirty-nine programs did not respond, and 10 were considered "satellites," referring all sleep services to a larger neighboring VAMC. Sleep programs were stratified based on extent of services offered (i.e., in-lab and home testing, sleep specialty clinics, cognitive behavioral therapy for insomnia (CBT-i)): 28 % were complex sleep programs (CSPs), 46 % were intermediate (ISPs), 9 % were standard (SSPs), and 17 % offered no formal sleep services. Overall, 138,175 clinic visits and 90,904 sleep testing encounters were provided in fiscal year 2011 by 112.1 physicians and clinical psychologists, 100.4 sleep technologists, and 115.3 respiratory therapists. More than half of all programs had home testing and CBT-i programs, and 26 % utilized sleep telehealth.
The 2012 VA sleep inventory suggests considerable variability in sleep services within the VA. Demand for sleep services is high, with programs using home testing, sleep telehealth, and a growing number of mid-level providers to improve access to care.
C1 [Sarmiento, Kathleen; Rossettie, John; Stepnowsky, Carl; Calvitti, Alan] VA San Diego Healthcare Syst, 3350 Jolla Village Dr,111J, San Diego, CA 92161 USA.
[Sarmiento, Kathleen] Univ Calif San Diego, Dept Pulm & Crit Care Med, La Jolla, CA 92093 USA.
[Rossettie, John; Stepnowsky, Carl] Univ Calif San Diego, Dept Med, La Jolla, CA 92103 USA.
[Atwood, Charles] VA Pittsburgh Healthcare Syst, Univ Dr, Pittsburgh, PA 15240 USA.
[Atwood, Charles] UPMC Montefiore, PACCM, Pittsburgh, PA 15213 USA.
RP Sarmiento, K (reprint author), VA San Diego Healthcare Syst, 3350 Jolla Village Dr,111J, San Diego, CA 92161 USA.; Sarmiento, K (reprint author), Univ Calif San Diego, Dept Pulm & Crit Care Med, La Jolla, CA 92093 USA.
EM kfsarmiento@ucsd.edu
NR 1
TC 4
Z9 4
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1520-9512
EI 1522-1709
J9 SLEEP BREATH
JI Sleep Breath.
PD MAR
PY 2016
VL 20
IS 1
BP 379
EP 382
DI 10.1007/s11325-015-1184-0
PG 4
WC Clinical Neurology; Respiratory System
SC Neurosciences & Neurology; Respiratory System
GA DG5ZJ
UT WOS:000372160800058
PM 25924933
ER
PT J
AU Becker, WC
Gordon, K
Edelman, EJ
Kerns, RD
Crystal, S
Dziura, JD
Fiellin, LE
Gordon, AJ
Goulet, JL
Justice, AC
Fiellin, DA
AF Becker, William C.
Gordon, Kirsha
Edelman, E. Jennifer
Kerns, Robert D.
Crystal, Stephen
Dziura, James D.
Fiellin, Lynn E.
Gordon, Adam J.
Goulet, Joseph L.
Justice, Amy C.
Fiellin, David A.
TI Trends in Any and High-Dose Opioid Analgesic Receipt Among Aging
Patients With and Without HIV
SO AIDS AND BEHAVIOR
LA English
DT Article
DE Analgesics; Opioids; Aging; Pain; Chronic; Human immunodeficiency virus
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CORONARY-HEART-DISEASE; CHRONIC NONCANCER
PAIN; HEALTH-CARE-SYSTEM; UNINFECTED PATIENTS; INFECTED ADULTS;
DRUG-DEPENDENCE; UNITED-STATES; RISK-FACTORS; BACK-PAIN
AB Harms of opioid analgesics, especially high-dose therapy among individuals with comorbidities and older age, are increasingly recognized. However, trends in opioid receipt among HIV-infected patients are not well characterized. We examined trends, from 1999 to 2010, in any and high-dose (a parts per thousand yen120 mg/day) opioid receipt among patients with and without HIV, by age strata, controlling for demographic and clinical correlates. Of 127,216 patients, 64 % received at least one opioid prescription. Opioid receipt increased substantially among HIV-infected and uninfected patients over the study; high-dose therapy was more prevalent among HIV-infected patients. Trends in high-dose receipt stratified by three age groups revealed an increasing trend in each age strata, higher among HIV-infected patients. Correlates of any opioid receipt included HIV, PTSD and major depression. Correlates of high-dose receipt included HIV, PTSD, major depression and drug use disorders. These findings suggest a need for appropriate balance of risks and benefits, especially as these populations age.
C1 [Becker, William C.; Gordon, Kirsha; Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven VA Med Ctr, Internal Med, Mail Stop 151B,950 Campbell Ave, West Haven, CT 06516 USA.
[Kerns, Robert D.; Goulet, Joseph L.] VA Connecticut Healthcare Syst, Psychol, West Haven, CT 06516 USA.
[Becker, William C.; Edelman, E. Jennifer; Dziura, James D.; Fiellin, Lynn E.; Justice, Amy C.; Fiellin, David A.] Yale Univ, Sch Med, Internal Med, New Haven, CT USA.
[Kerns, Robert D.; Goulet, Joseph L.] Yale Univ, Sch Med, Psychol, New Haven, CT USA.
[Crystal, Stephen] Rutgers State Univ, Ctr Hlth Serv Res, New Brunswick, NJ 08903 USA.
[Gordon, Adam J.] Univ Pittsburgh, Pittsburgh, PA USA.
[Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
RP Becker, WC (reprint author), VA Connecticut Healthcare Syst, West Haven VA Med Ctr, Internal Med, Mail Stop 151B,950 Campbell Ave, West Haven, CT 06516 USA.; Becker, WC (reprint author), Yale Univ, Sch Med, Internal Med, New Haven, CT USA.
EM william.becker@yale.edu
OI Edelman, E. Jennifer/0000-0002-9375-0489; Fiellin,
David/0000-0002-4006-010X; Justice, Amy/0000-0003-0139-5502; Goulet,
Joseph/0000-0002-0842-804X
FU Veterans Health Administration Health Services Research & Development
Career Development Award [08-276]; VA Health Services Research and
Development Center of Innovation [CIN 13-047]; Society of General
Internal Medicine's Lawrence Linn Award; Robert Wood Johnson Foundation
Clinical Scholars Program; Veterans Aging Cohort study; National
Institute on Alcohol Abuse and Alcoholism [U10 AA 13566]
FX This work was supported by a Veterans Health Administration Health
Services Research & Development Career Development Award (08-276); other
VA support came from VA Health Services Research and Development Center
of Innovation (CIN 13-047). This work was also supported by the Society
of General Internal Medicine's Lawrence Linn Award, the Robert Wood
Johnson Foundation Clinical Scholars Program, and the Veterans Aging
Cohort study, funded by the National Institute on Alcohol Abuse and
Alcoholism (U10 AA 13566). This work was presented at the Northeast
Regional Society of General Internal Medicine Meeting, New Haven, CT,
March 8, 2013 and the Society of General Internal Medicine National
Meeting, Denver, CO, April 25, 2013. The authors would like to thank Dr.
Eugenia Buta for input on statistical analyses.
NR 60
TC 5
Z9 5
U1 2
U2 2
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD MAR
PY 2016
VL 20
IS 3
BP 679
EP 686
DI 10.1007/s10461-015-1197-5
PG 8
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA DF8JA
UT WOS:000371602700020
PM 26384973
ER
PT J
AU Merlin, JS
Tamhane, A
Starrels, JL
Kertesz, S
Saag, M
Cropsey, K
AF Merlin, Jessica S.
Tamhane, Ashutosh
Starrels, Joanna L.
Kertesz, Stefan
Saag, Michael
Cropsey, Karen
TI Factors Associated with Prescription of Opioids and Co-prescription of
Sedating Medications in Individuals with HIV
SO AIDS AND BEHAVIOR
LA English
DT Article
DE HIV; Chronic pain; Opioid; Benzodiazepine; Muscle relaxant
ID QUALITY-OF-LIFE; OVERDOSE DEATHS; UNITED-STATES; PRESCRIBING PRACTICES;
NONMALIGNANT PAIN; INFECTED PATIENTS; SCREENING-TEST; MENTAL-HEALTH;
BENZODIAZEPINES; DISORDERS
AB Opioids are often prescribed for chronic pain, and opioid risks such as overdose and death are heightened when opioids are co-prescribed with other sedating medications. We investigated factors associated with chronic opioid prescription, alone and in combination with benzodiazepines and muscle relaxants, in a clinical cohort of individuals with HIV. We used multivariable logistic regression models to determine participant clinical and demographic characteristics that are associated with chronic prescription of opioids or chronic co-prescription of opioids with sedating medications. Among 1474 participants, chronic prescription of opioids occurred in 253 individuals (17.2 %), and chronic co-prescription occurred in 90 individuals (6.1 %). Age > 50, public insurance as compared to private insurance, and symptoms of depression and anxiety were significantly associated with chronic opioid prescription and chronic co-prescription. Our findings raise concern that opioid prescription and co-prescription of sedating medications occurs disproportionately in patients for whom use is riskier.
C1 [Merlin, Jessica S.; Tamhane, Ashutosh; Saag, Michael] Univ Alabama Birmingham, Dept Med, Div Infect Dis, BBRB 222,1530 3rd Ave S, Birmingham, AL 35294 USA.
[Merlin, Jessica S.] Univ Alabama Birmingham, Div Gerontol Geriatr & Palliat Care, Birmingham, AL 35294 USA.
[Starrels, Joanna L.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA.
[Kertesz, Stefan] Birmingham VA Med Ctr, Birmingham, AL USA.
[Kertesz, Stefan] Univ Alabama Birmingham, Dept Med, Div Prevent Med, Birmingham, AL 35294 USA.
[Cropsey, Karen] Univ Alabama Birmingham, Dept Psychiat, Birmingham, AL 35294 USA.
RP Merlin, JS (reprint author), Univ Alabama Birmingham, Dept Med, Div Infect Dis, BBRB 222,1530 3rd Ave S, Birmingham, AL 35294 USA.; Merlin, JS (reprint author), Univ Alabama Birmingham, Div Gerontol Geriatr & Palliat Care, Birmingham, AL 35294 USA.
EM jmerlin@uab.edu
OI Tamhane, Ashutosh/0000-0002-4475-2760; Kertesz,
Stefan/0000-0001-6101-8421
FU University of Alabama at Birmingham (UAB) Center for AIDS Research, an
NIH [P30 A1027767]; NIAID; NCI; NICHD; NHLBI; NIDA; NIMH; NIA; FIC; OAR;
AHRQ [1K12HS02169401]; NIDA [K23DA027719]; Mary Fisher CARE Fund at UAB
FX This research was supported by the University of Alabama at Birmingham
(UAB) Center for AIDS Research, an NIH funded program (P30 A1027767)
that was made possible by the following institutes: NIAID, NCI, NICHD,
NHLBI, NIDA, NIMH, NIA, FIC, and OAR. JSM was supported by
1K12HS02169401 (AHRQ). JLS was supported by K23DA027719 (NIDA). Funding
was also provided by the Mary Fisher CARE Fund at UAB.
NR 52
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD MAR
PY 2016
VL 20
IS 3
BP 687
EP 698
DI 10.1007/s10461-015-1178-8
PG 12
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA DF8JA
UT WOS:000371602700021
PM 26487298
ER
PT J
AU Korom-Djakovic, D
Canamucio, A
Lempa, M
Yano, EM
Long, JA
AF Korom-Djakovic, Danijela
Canamucio, Anne
Lempa, Michele
Yano, Elizabeth M.
Long, Judith A.
TI Organization Complexity and Primary Care Providers' Perceptions of
Quality Improvement Culture Within the Veterans Health Administration
SO AMERICAN JOURNAL OF MEDICAL QUALITY
LA English
DT Article
DE quality improvement; culture; organizational complexity; primary care;
Veterans Affairs
ID MEDICAL GROUP PRACTICES; IMPLEMENTATION; DELIVERY; STAFF; HOME
AB This study examined how aspects of quality improvement (QI) culture changed during the introduction of the Veterans Health Administration (VHA) patient-centered medical home initiative and how they were influenced by existing organizational factors, including VHA facility complexity and practice location. A voluntary survey, measuring primary care providers' (PCPs') perspectives on QI culture at their primary care clinics, was administered in 2010 and 2012. Participants were 320 PCPs from hospital- and community-based primary care practices in Pennsylvania, West Virginia, Delaware, New Jersey, New York, and Ohio. PCPs in community-based outpatient clinics reported an improvement in established processes for QI, and communication and cooperation from 2010 to 2012. However, their peers in hospital-based clinics did not report any significant improvements in QI culture. In both years, compared with high-complexity facilities, medium- and low-complexity facilities had better scores on the scales assessing established processes for QI, and communication and cooperation.
C1 [Korom-Djakovic, Danijela; Canamucio, Anne; Lempa, Michele; Long, Judith A.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Korom-Djakovic, Danijela; Long, Judith A.] Univ Penn, Philadelphia, PA 19104 USA.
[Yano, Elizabeth M.] VA Greater Angeles Healthcare Syst, Sepulveda, CA USA.
[Yano, Elizabeth M.] UCLA Fielding Sch Publ Hlth, Los Angeles, CA USA.
RP Long, JA (reprint author), Univ Penn, Perelman Sch Med, 1201 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM jalong@mail.med.upenn.edu
FU VA Office of Patient Care Services
FX The authors disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: This work was
undertaken as part of the Veterans Affairs (VA) Patient Aligned Care
Team (PACT) Demonstration Laboratory initiative, supporting and
evaluating VA's transition to a patient-centered medical home. Funding
for the PACT Demonstration Laboratory initiative is provided by the VA
Office of Patient Care Services.
NR 25
TC 2
Z9 2
U1 2
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1062-8606
EI 1555-824X
J9 AM J MED QUAL
JI Am. J. Med. Qual.
PD MAR-APR
PY 2016
VL 31
IS 2
BP 139
EP 146
DI 10.1177/1062860614559743
PG 8
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA DF8VL
UT WOS:000371638300007
PM 25414376
ER
PT J
AU Tanner, NT
Kanodra, NM
Gebregziabher, M
Payne, E
Halbert, CH
Warren, GW
Egede, LE
Silvestri, GA
AF Tanner, Nichole T.
Kanodra, Neeti M.
Gebregziabher, Mulugeta
Payne, Elizabeth
Halbert, Chanita Hughes
Warren, Graham W.
Egede, Leonard E.
Silvestri, Gerard A.
TI The Association between Smoking Abstinence and Mortality in the National
Lung Screening Trial
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE smoking cessation; lung neoplasms; early detection of cancer; tobacco
ID UNITED-STATES; COST-EFFECTIVENESS; CLINICAL-PRACTICE; CANCER-PATIENTS;
PUBLIC-HEALTH; TOBACCO USE; CESSATION; PARTICIPANTS; GUIDELINE;
DIAGNOSIS
AB Rationale: Smoking is the largest contributor to lung cancer risk, and those who continue to smoke after diagnosis have a worse survival. Screening for lung cancer with low-dose computed tomography (LDCT) reduces mortality in high-risk individuals. Smoking cessation is an essential component of a high-quality screening program.
Objectives: To quantify the effects of smoking history and abstinence on mortality in high-risk individuals who participated in the NLST (National Lung Screening Trial).
Methods: This is a secondary analysis of a randomized controlled trial (NLST).
Measurements and Main Results: Measurements included self-reported demographics, medical and smoking history, and lung cancer-specific and all-cause mortality. Cox regression was used to study the association of mortality with smoking status and pack-years. Kaplan-Meier survival curves were examined for differences in survival based on trial arm and smoking status. Current smokers had an increased lung cancer-specific (hazard ratio [HR], 2.14-2.29) and all-cause mortality (HR, 1.79-1.85) compared with former smokers irrespective of screening arm. Former smokers in the control arm abstinent for 7 years had a 20% mortality reduction comparable with the benefit reported with LDCT screening in the NLST. The maximum benefit was seen with the combination of smoking abstinence at 15 years and LDCT screening, which resulted in a 38% reduction in lung cancer-specific mortality (HR, 0.62; 95% confidence interval, 0.51-0.76).
Conclusions: Seven years of smoking abstinence reduced lung cancer-specific mortality at a magnitude comparable with LDCT screening. This reduction was greater when abstinence was combined with screening, highlighting the importance of smoking cessation efforts-in screening programs.
C1 [Tanner, Nichole T.; Kanodra, Neeti M.; Silvestri, Gerard A.] Med Univ S Carolina, Div Pulm Crit Care & Sleep Med, Charleston, SC 29425 USA.
[Tanner, Nichole T.; Gebregziabher, Mulugeta; Halbert, Chanita Hughes; Egede, Leonard E.] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA.
[Gebregziabher, Mulugeta; Payne, Elizabeth] Med Univ S Carolina, Dept Psychiat & Behav Sci, Hollings Canc Ctr, 171 Ashley Ave, Charleston, SC 29425 USA.
[Halbert, Chanita Hughes] Med Univ S Carolina, Dept Radiat Oncol, Charleston, SC 29425 USA.
[Warren, Graham W.] Med Univ S Carolina, Dept Cell & Mol Pharmacol, Charleston, SC 29425 USA.
[Warren, Graham W.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Egede, Leonard E.] Ralph H Johnson Vet Affairs Hosp, Hlth Equ & Rural Outreach Innovat Ctr, Charleston, SC USA.
RP Tanner, NT (reprint author), 96 Jonathan Lucas St, Charleston, SC 29425 USA.
EM tripici@musc.edu
OI Gebregziabher, Mulugeta/0000-0002-4826-481X
FU OneBreath Foundation
FX Supported by OneBreath Foundation.
NR 33
TC 12
Z9 12
U1 2
U2 6
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD MAR 1
PY 2016
VL 193
IS 5
BP 534
EP 541
DI 10.1164/rccm.201507-1420OC
PG 8
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA DG0KI
UT WOS:000371753300014
PM 26502000
ER
PT J
AU Clark, DJ
Neptune, RR
Behrman, AL
Kautz, SA
AF Clark, David J.
Neptune, Richard R.
Behrman, Andrea L.
Kautz, Steven A.
TI Locomotor Adaptability Task Promotes Intense and Task-Appropriate Output
From the Paretic Leg During Walking
SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
LA English
DT Article
DE Electromyography; Rehabilitation; Stroke; Walking
ID COORDINATION; HEMIPARESIS; PERFORMANCE; POSTSTROKE; LENGTH; STROKE
AB Objective: To test the hypothesis that participants with stroke will exhibit appropriate increase in muscle activation of the paretic leg when taking a long step with the nonparetic leg compared to during steady-state walking, with a consequent increase in biomechanical output and symmetry during the stance phase of the modified gait cycle.
Design: Single-session observational study.
Setting: Clinical research center in an outpatient hospital setting.
Participants: Adults with chronic poststroke hemiparesis (N=15).
Interventions: Participants walked on an instrumented treadmill while kinetic, kinematic, and electromyogram data were recorded. Participants performed steady-state walking and a separate trial of the long-step adaptability task in which they were instructed to intermittently take a longer step with the nonparetic leg.
Main Outcome Measures: Forward progression, propulsive force, and neuromuscular activation during walking.
Results: Participants performed the adaptability task successfully and demonstrated greater neuromuscular activation in appropriate paretic leg muscles, particularly increased activity in paretic plantarflexor muscles. Propulsion and forward progression by the paretic leg were also increased.
Conclusions: These findings support the assertion that the nonparetic long-step task may be effective for use in poststroke locomotor rehabilitation to engage the paretic leg and promote recovery of walking. (C) 2016 by the American Congress of Rehabilitation Medicine
C1 [Clark, David J.] Malcom Randall Vet Affairs Med Ctr, Brain Rehabil Res Ctr, Gainesville, FL 32608 USA.
[Clark, David J.] Univ Florida, Dept Aging & Geriatr Res, Gainesville, FL USA.
[Neptune, Richard R.] Univ Texas Austin, Dept Mech Engn, Austin, TX 78712 USA.
[Behrman, Andrea L.] Univ Louisville, Dept Neurol Surg, Louisville, KY 40292 USA.
[Kautz, Steven A.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Kautz, Steven A.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA.
[Kautz, Steven A.] Med Univ S Carolina, Dept Hlth Profess, Div Phys Therapy, Charleston, SC 29425 USA.
RP Clark, DJ (reprint author), Malcom Randall Vet Affairs Med Ctr, Brain Rehabil Res Ctr 151A, 1601 SW Archer Rd, Gainesville, FL 32608 USA.
EM davidclark@ufl.edu
FU National Institutes of Health [HD-46820, GM-109040]; U.S. Department of
Veterans Affairs Rehabilitation Research and Development Service
[B3983R, B4888M, B7176W]
FX Supported by the National Institutes of Health (grant nos. HD-46820 and
GM-109040) and the U.S. Department of Veterans Affairs Rehabilitation
Research and Development Service (Merit Review B3983R and Career
Development Awards B4888M and B7176W). The contents do not represent the
views of the U.S Department of Veterans Affairs or the U.S. government.
NR 10
TC 2
Z9 2
U1 5
U2 6
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0003-9993
EI 1532-821X
J9 ARCH PHYS MED REHAB
JI Arch. Phys. Med. Rehabil.
PD MAR
PY 2016
VL 97
IS 3
BP 493
EP 496
DI 10.1016/j.apmr.2015.10.081
PG 4
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA DG1TJ
UT WOS:000371850100018
PM 26525528
ER
PT J
AU Placzek, AN
Molfese, DL
Khatiwada, S
Di Prisco, GV
Huang, W
Sidrauski, C
Krnjevic, K
Amos, CL
Ray, R
Dani, JA
Walter, P
Salas, R
Costa-Mattioli, M
AF Placzek, Andon N.
Molfese, David L.
Khatiwada, Sanjeev
Di Prisco, Gonzalo Viana
Huang, Wei
Sidrauski, Carmela
Krnjevic, Kresimir
Amos, Christopher L.
Ray, Russell
Dani, John A.
Walter, Peter
Salas, Ramiro
Costa-Mattioli, Mauro
TI Translational control of nicotine -evoked synaptic potentiation in mice
and neuronal responses in human smokers by elF2 alpha
SO ELIFE
LA English
DT Article
ID LONG-TERM POTENTIATION; DOPAMINE NEURONS; BINDING-PROTEIN; IN-VIVO;
HOMEOSTASIS; EXPOSURE; SMOKING; REWARD; DEPRESSION; WITHDRAWAL
AB Adolescents are particularly vulnerable to nicotine, the principal addictive component driving tobacco smoking. In a companion study, we found that reduced activity of the translation initiation factor eIF2 alpha underlies the hypersensitivity of adolescent mice to the effects of cocaine. Here we report that nicotine potentiates excitatory synaptic transmission in ventral tegmental area dopaminergic neurons more readily in adolescent mice compared to adults. Adult mice with genetic or pharmacological reduction in p-eIF2 alpha-mediated translation are more susceptible to nicotine's synaptic effects, like adolescents. When we investigated the influence of allelic variability of the Eif2s1 gene (encoding eIF2 alpha) on reward -related neuronal responses in human smokers, we found that a single nucleotide polymorphism in the Eif2s1 gene modulates mesolimbic neuronal reward responses in human smokers. These findings suggest that p-eIF2 alpha regulates synaptic actions of nicotine in both mice and humans, and that reduced p-eIF2 alpha may enhance susceptibility to nicotine (and other drugs of abuse) during adolescence.
C1 [Placzek, Andon N.; Khatiwada, Sanjeev; Di Prisco, Gonzalo Viana; Huang, Wei; Ray, Russell; Salas, Ramiro; Costa-Mattioli, Mauro] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA.
[Placzek, Andon N.; Khatiwada, Sanjeev; Di Prisco, Gonzalo Viana; Huang, Wei; Ray, Russell; Costa-Mattioli, Mauro] Baylor Coll Med, Memory & Brain Res Ctr, Houston, TX 77030 USA.
[Molfese, David L.; Salas, Ramiro] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Molfese, David L.; Salas, Ramiro] Michael E DeBakey Vet Adm Med Ctr, Houston, TX USA.
[Khatiwada, Sanjeev] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA.
[Sidrauski, Carmela; Walter, Peter] Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem & Biophys, San Francisco, CA USA.
[Krnjevic, Kresimir] McGill Univ, Dept Physiol, Montreal, PQ, Canada.
[Amos, Christopher L.] Dartmouth Coll, Geisel Sch Med, Dept Community & Family Med, Ctr Genom Med, 1 Med Ctr Dr, Lebanon, NH 03756 USA.
[Dani, John A.] Perelman Sch Med, Mahoney Inst Neurosci, Dept Neurosci, Philadelphia, PA USA.
[Placzek, Andon N.] Mercer Univ, Sch Med, Div Basic Med Sci, Macon, GA 31207 USA.
[Sidrauski, Carmela] Calico LLC, San Francisco, CA USA.
RP Costa-Mattioli, M (reprint author), Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA.; Costa-Mattioli, M (reprint author), Baylor Coll Med, Memory & Brain Res Ctr, Houston, TX 77030 USA.
EM costamat@bcm.edu
FU National Institute of Mental Health [MH096816]; National Institute of
Neurological Disorders and Stroke [NS076708, NS21229]; National
Institute on Drug Abuse [DA09411, DA026539, DA09167]; Howard Hughes
Medical Institute; U.S. Department of Veterans Affairs [VHA5101CX000994]
FX National Institute of Mental Health MH096816 Mauro Costa-Mattioli;
National Institute of Neurological Disorders and Stroke NS076708,
NS21229 John A Dani Mauro Costa-Mattioli; National Institute on Drug
Abuse DA09411, DA026539, DA09167 John A Dani Ramiro Salas; Howard Hughes
Medical Institute PW Peter Walter; U.S. Department of Veterans Affairs
VHA5101CX000994 Ramiro Salas
NR 32
TC 3
Z9 3
U1 1
U2 2
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050-084X
J9 ELIFE
JI eLife
PD MAR 1
PY 2016
VL 5
AR e12056
DI 10.7554/eLife.12056
PG 11
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA DG2IA
UT WOS:000371889400001
ER
PT J
AU Liu, M
Blanco-Centurion, C
Konadhode, RR
Luan, LJ
Shiromani, PJ
AF Liu, Meng
Blanco-Centurion, Carlos
Konadhode, Roda Rani
Luan, Liju
Shiromani, Priyattam J.
TI Orexin gene transfer into the amygdala suppresses both spontaneous and
emotion-induced cataplexy in orexin-knockout mice
SO EUROPEAN JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE amygdala; emotion; narcolepsy; orexin; predator odour; sleep
ID HUMAN NARCOLEPSY; NEURONS; SLEEP; RAT; MUTATION; BEHAVIOR; RECEPTOR;
MODELS; BRAIN; ONSET
AB Narcolepsy is a chronic sleep disorder linked to the loss of orexin-producing neurons in the hypothalamus. Cataplexy, a sudden loss of muscle tone during waking, is an important distinguishing symptom of narcolepsy and it is often triggered by strong emotions. The neural circuit underlying cataplexy attacks is not known, but is likely to involve the amygdala, a region implicated in regulating emotions. In mice models of narcolepsy, transfer of the orexin gene into surrogate neurons has been successful in ameliorating narcoleptic symptoms. However, it is not known whether this method also blocks cataplexy triggered by strong emotions. To examine this possibility, the gene encoding mouse prepro-orexin was transferred into amygdala neurons of orexin-knockout (KO) mice (rAAV-orexin; n=8). Orexin-KO mice that did not receive gene transfer (no-rAAV; n=7) or received only the reporter gene (rAAV-GFP; n=7) served as controls. Three weeks later, the animal's sleep and behaviour were recorded at night (no-odour control night), followed by another recording at night in the presence of predator odour (odour night). Orexin-KO mice given the orexin gene transfer into surrogate amygdala neurons had significantly less spontaneous bouts of cataplexy, and predator odour did not induce cataplexy compared with control mice. Moreover, the mice with orexin gene transfer were awake more during the odour night. These results demonstrate that orexin gene transfer into amygdala neurons can suppress both spontaneous and emotion-induced cataplexy attacks in narcoleptic mice. It suggests that manipulating amygdala pathways is a potential strategy for treating cataplexy in narcolepsy.
C1 [Liu, Meng; Blanco-Centurion, Carlos; Konadhode, Roda Rani; Luan, Liju; Shiromani, Priyattam J.] Med Univ S Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA.
[Shiromani, Priyattam J.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA.
RP Liu, M (reprint author), Med Univ S Carolina, Charleston, SC 29425 USA.; Shiromani, PJ (reprint author), Ralph H Johnson VA Med Ctr, Charleston, SC USA.
EM liumen@musc.edu; shiroman@musc.edu
FU Medical Research Service of the Department of Veterans Affairs [I01
BX000798]; NIH [1K01AG041520, NS052287, NS084477, NS079940, HL091363]
FX This study was supported by Medical Research Service of the Department
of Veterans Affairs (I01 BX000798) and NIH grants 1K01AG041520,
NS052287, NS084477, NS079940 and HL091363. We thank Dr Patrick K.
Randall for support with the SPSS statistical analysis program.
NR 34
TC 1
Z9 1
U1 1
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0953-816X
EI 1460-9568
J9 EUR J NEUROSCI
JI Eur. J. Neurosci.
PD MAR
PY 2016
VL 43
IS 5
BP 681
EP 688
DI 10.1111/ejn.13158
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA DG2PN
UT WOS:000371909800009
PM 26741960
ER
PT J
AU Burke, RE
Johnson-Koenke, R
Nowels, C
Silveira, MJ
Jones, J
Bekelman, DB
AF Burke, Robert E.
Johnson-Koenke, Rachel
Nowels, Carolyn
Silveira, Maria J.
Jones, Jacqueline
Bekelman, David B.
TI Can we engage caregiver spouses of patients with heart failure with a
low-intensity, symptom-guided intervention?
SO HEART & LUNG
LA English
DT Article
DE Symptom management; Heart failure; Caregiver; Palliative care; Quality
of life
ID QUALITY-OF-LIFE; INFORMAL CAREGIVERS; PALLIATIVE CARE; TRANSITIONAL
CARE; FAMILY CAREGIVERS; SELF-MANAGEMENT; OLDER-ADULTS; TRIAL; SUPPORT;
METAANALYSIS
AB Objective: Evaluate a pilot intervention to engage caregivers in management of heart failure (HF) patient symptoms.
Background: HF impairs quality of life; caregivers provide an important role in HF management.
Methods: We developed modules to help patients report and caregivers alleviate symptoms of depression, pain, dyspnea, and fatigue. Semi-structured interviews followed by a mixed inductive and deductive, team based analysis were used to evaluate acceptability and feasibility in patients with HF and their caregivers.
Results: Participants (n = 22) expressed significant interest but few used the modules in follow-up. We identified three barriers to acceptability and feasibility: the quality of dyadic relationship, the timing and structure of the intervention, and the patient's perceived control over their illness.
Conclusions: Future interventions should evaluate dyadic relationship dynamics, match the timing and content of the intervention to the patient population, and enroll patients with perceived control over their illness to maximize intervention acceptability and feasibility. Published by Elsevier Inc.
C1 [Burke, Robert E.; Johnson-Koenke, Rachel; Bekelman, David B.] Denver VA Med Ctr, Dept Med, Denver, CO USA.
[Burke, Robert E.; Nowels, Carolyn; Bekelman, David B.] Univ Colorado, Denver Sch Med, Dept Med, Div Gen Internal Med, Anschutz Med Campus, Aurora, CO USA.
[Silveira, Maria J.] Ann Arbor Vet Affairs Med Ctr, Ctr Clin Management Res, Ann Arbor, MI USA.
[Silveira, Maria J.] Univ Michigan, Dept Internal Med, Div Gen Med, Ann Arbor, MI 48109 USA.
[Jones, Jacqueline] Univ Colorado, Coll Nursing, Aurora, CO USA.
RP Burke, RE (reprint author), Denver VA Med Ctr, 1055 Clermont St, Denver, CO 80220 USA.
EM Robert.Burke5@va.gov
FU VA Chronic Heart Failure Quality Enhancement Research Initiative (QUERI)
Locally Initiated Project award; VA [IIR 08-0309]; VA Career Development
Award [08-022]
FX The study was supported by a VA Chronic Heart Failure Quality
Enhancement Research Initiative (QUERI) Locally Initiated Project award
to Drs. Burke and Bekelman. Dr. Silveira was supported by VA IIR
08-0309. Dr. Bekelman was supported by a VA Career Development Award
(08-022). These funding sources had no role in the design,
interpretation, or presentation of results. This report represents the
views of the authors and not necessarily those of the U.S. Department of
Veterans Affairs.
NR 57
TC 0
Z9 0
U1 6
U2 9
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0147-9563
EI 1527-3288
J9 HEART LUNG
JI Heart Lung
PD MAR-APR
PY 2016
VL 45
IS 2
BP 114
EP 120
DI 10.1016/j.hrtlng.2015.12.006
PG 7
WC Cardiac & Cardiovascular Systems; Nursing; Respiratory System
SC Cardiovascular System & Cardiology; Nursing; Respiratory System
GA DG1SL
UT WOS:000371847700006
PM 26831372
ER
PT J
AU Choi, J
Tate, JA
Rogers, MA
Donahoe, MP
Hoffman, LA
AF Choi, JiYeon
Tate, Judith A.
Rogers, Mary Alana
Donahoe, Michael P.
Hoffman, Leslie A.
TI Depressive symptoms and anxiety in intensive care unit (ICU) survivors
after ICU discharge
SO HEART & LUNG
LA English
DT Article
DE Post intensive care unit; Intensive care unit survivors; Depressive
symptoms; Anxiety; Recovery
ID QUALITY-OF-LIFE; PROLONGED MECHANICAL VENTILATION;
RESPIRATORY-DISTRESS-SYNDROME; LONG-TERM OUTCOMES; RANDOMIZED
CONTROLLED-TRIAL; CRITICALLY-ILL PATIENTS; ACUTE LUNG INJURY; CRITICAL
ILLNESS; POSTTRAUMATIC-STRESS; HEALTH
AB Background: The association between intensive care unit (ICU) survivors' psychological sequelae, individual care needs, and discharge disposition has not been evaluated.
Objective: To describe depressive symptoms and anxiety in ICU survivors and explore these symptoms based on individual care needs and discharge disposition for 4 months post-ICU discharge.
Methods: We analyzed data from 39 ICU survivors who self-reported measures of depressive symptoms (Center for Epidemiologic Studies-Depression 10 items [CESD-10]) and anxiety (Shortened Profile of Mood States-Anxiety subscale [POMS-A]).
Results: A majority of patients reported CESD-10 scores above the cut off (>= 8) indicating risk for clinical depression. POMS-A scores were highest within 2 weeks post-ICU discharge and decreased subsequently. Data trends suggest worse depressive symptoms and anxiety when patients had moderate to high care needs and/or were unable to return home.
Conclusion: ICU survivors who need caregiver assistance and extended institutional care reported trends of worse depressive symptoms and anxiety. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Choi, JiYeon; Hoffman, Leslie A.] Univ Pittsburgh, Sch Nursing, Dept Acute & Tertiary Care, Pittsburgh, PA 15261 USA.
[Donahoe, Michael P.] Univ Pittsburgh, Sch Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA.
[Tate, Judith A.] Ohio State Univ, Coll Nursing, Columbus, OH 43210 USA.
[Rogers, Mary Alana] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Hoffman, Leslie A.] Clin & Translat Sci Inst, San Francisco, CA USA.
RP Choi, J (reprint author), Univ Pittsburgh, Sch Nursing, 336 Victoria Bldg,3500 Victoria St, Pittsburgh, PA 15261 USA.
EM jic11@pitt.edu
FU NIH, National Institute of Nursing Research, U.S. Public Health Service
[F32 NR 011271, T32 NR 008857]; Rehabilitation Nursing Foundation
[FEL-0905]; Undergraduate Research Mentorship Program, University of
Pittsburgh School of Nursing
FX Funding was provided by the NIH, National Institute of Nursing Research,
U.S. Public Health Service (F32 NR 011271 and T32 NR 008857) and
Rehabilitation Nursing Foundation, Fellow Research Award (FEL-0905).
Work from Ms. Mary Alana Rogers was supported by the Undergraduate
Research Mentorship Program, University of Pittsburgh School of Nursing.
The authors declare no conflicts of interest.
NR 54
TC 1
Z9 1
U1 3
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0147-9563
EI 1527-3288
J9 HEART LUNG
JI Heart Lung
PD MAR-APR
PY 2016
VL 45
IS 2
BP 140
EP 146
DI 10.1016/j.hrtlng.2015.12.002
PG 7
WC Cardiac & Cardiovascular Systems; Nursing; Respiratory System
SC Cardiovascular System & Cardiology; Nursing; Respiratory System
GA DG1SL
UT WOS:000371847700010
PM 26791248
ER
PT J
AU Blosnich, JR
Bossarte, RM
AF Blosnich, John R.
Bossarte, Robert M.
TI Childhood Abuse and Military Experience-Important Information to Better
Serve Those Who Have Served
SO JAMA PSYCHIATRY
LA English
DT Editorial Material
C1 [Blosnich, John R.] US Dept Vet Affairs, VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Blosnich, John R.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA USA.
[Bossarte, Robert M.] US Dept Vet Affairs, Off Publ Hlth, Washington, DC USA.
[Bossarte, Robert M.] Univ Rochester, Dept Psychiat, Rochester, NY USA.
[Bossarte, Robert M.] Univ Rochester, Dept Publ Hlth Sci, Rochester, NY USA.
RP Blosnich, JR (reprint author), VA Pittsburgh Healthcare Syst, Dept Vet Affairs, Ctr Hlth Equ Res & Promot, Univ Dr C 151C-U,Bldg 30, Pittsburgh, PA 15240 USA.
EM john.blosnich@va.gov
NR 8
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-622X
EI 2168-6238
J9 JAMA PSYCHIAT
JI JAMA Psychiatry
PD MAR
PY 2016
VL 73
IS 3
BP 195
EP 196
DI 10.1001/jamapsychiatry.2015.2736
PG 2
WC Psychiatry
SC Psychiatry
GA DF8NC
UT WOS:000371613500005
PM 26817448
ER
PT J
AU Carter, SP
DiMauro, J
Renshaw, KD
Curby, TW
Babson, KA
Bonn-Miller, MO
AF Carter, Sarah P.
DiMauro, Jennifer
Renshaw, Keith D.
Curby, Timothy W.
Babson, Kimberly A.
Bonn-Miller, Marcel O.
TI Longitudinal associations of friend-based social support and PTSD
symptomatology during a cannabis cessation attempt
SO JOURNAL OF ANXIETY DISORDERS
LA English
DT Article
DE PTSD; Social support; Substance use; Longitudinal study; Military
ID POSTTRAUMATIC-STRESS-DISORDER; SUBSTANCE USE DISORDERS; PSYCHOLOGICAL
DISTRESS; CAREGIVER BURDEN; MENTAL-ILLNESS; VETERANS; SYMPTOMS;
PARTNERS; ABUSE; METAANALYSIS
AB Research supports bidirectional associations between social support and posttraumatic stress disorder (PTSD), whereby social support may buffer against PTSD, and individuals with PTSD may experience decreasing support over time. Research examining contexts that may affect these relations is needed. This study examined the longitudinal associations between PTSD and social support from friends over a 6-month period in 116 veterans with cannabis dependence who had recently initiated an attempt to quit cannabis use. A cross-lagged autoregressive model revealed a significant, negative relation between earlier PTSD symptoms and later support. An exploratory multigroup analysis comparing those with and without a relapse in the first month after their quit attempt revealed that the significant negative association between PTSD and future support was present only in those who relapsed. Although this analysis was limited by a small sample size, results suggest that substance use may be an influential contextual variable that impacts the longitudinal associations between PTSD and support. (c) 2016 Elsevier Ltd. All rights reserved.
C1 [Carter, Sarah P.; DiMauro, Jennifer; Renshaw, Keith D.; Curby, Timothy W.] George Mason Univ, Dept Psychol, 4400 Univ Dr,3F5, Fairfax, VA 22030 USA.
[Babson, Kimberly A.; Bonn-Miller, Marcel O.] VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, 795 Willow Rd, Menlo Pk, CA 94025 USA.
[Babson, Kimberly A.; Bonn-Miller, Marcel O.] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, 795 Willow Rd, Menlo Pk, CA 94025 USA.
[Bonn-Miller, Marcel O.] Philadelphia VA Med Ctr, Ctr Excellence Subst Abuse Treatment & Educ, 3900 Woodland Ave, Philadelphia, PA 19104 USA.
[Bonn-Miller, Marcel O.] Univ Penn, Perelman Sch Med, Dept Psychiat, 3440 Market St,Suite 370, Philadelphia, PA 19104 USA.
RP Carter, SP (reprint author), George Mason Univ, Dept Psychol, 4400 Univ Dr,3F5, Fairfax, VA 22030 USA.
EM scarte18@gmu.edu
FU VA Clinical Science Research and Development (CSR&D) Career Development
Award [CDA-2, 1IK2CX1023-01A1]
FX This work was supported, in part, by a VA Clinical Science Research and
Development (CSR&D) Career Development Award (CDA-2; 1IK2CX1023-01A1)
awarded to Dr. Babson. Data for the parent study were collected as part
of VA CSR&D CDA-2 awarded to Dr. Bonn-Miller.
NR 43
TC 0
Z9 0
U1 3
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-6185
EI 1873-7897
J9 J ANXIETY DISORD
JI J. Anxiety Disord.
PD MAR
PY 2016
VL 38
BP 62
EP 67
DI 10.1016/j.janxdis.2016.01.008
PG 6
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA DF6EQ
UT WOS:000371449100008
PM 26836369
ER
PT J
AU Korte, KJ
Allan, NP
Gros, DF
Acierno, R
AF Korte, Kristina J.
Allan, Nicholas P.
Gros, Daniel F.
Acierno, Ron
TI Differential treatment response trajectories in individuals with
subclinical and clinical PTSD
SO JOURNAL OF ANXIETY DISORDERS
LA English
DT Article
DE PTSD; Posttraumatic stress disorder; Subclinical; Subthreshold;
Military; Veterans; Growth curve modeling
ID POSTTRAUMATIC-STRESS-DISORDER; COVARIANCE STRUCTURE-ANALYSIS; COGNITIVE
PROCESSING THERAPY; CONFIRMATORY FACTOR-ANALYSIS; RANDOMIZED
CONTROLLED-TRIAL; SUBTHRESHOLD PTSD; PRIMARY-CARE; BEHAVIORAL
ACTIVATION; PROLONGED EXPOSURE; MILITARY VETERANS
AB Subclinical presentations of posttraumatic stress disorder (PTSD), wherein patients are one or two symptom criteria short of the full disorder, are prevalent and associated with levels of distress and impaired functioning approximating that of full PTSD. Nonetheless, research examining treatment efficacy for this group is in the nascent stage. The purpose of the present study was to examine whether the sub clinical PTSD group would: (1) show a greater reduction in PTSD symptoms at pre and post treatment in response to an exposure based treatment and (2) show a greater rate of change over the course of treatment, when compared to the full criteria PTSD group. We also examined whether differences would emerge when examining PTSD symptom clusters. Consistent with predictions, the subclinical PTSD group demonstrated a greater reduction in PTSD symptoms at post-treatment (29%) than those with a PTSD diagnosis (14%). Further, the groups had different treatment trajectories, with the subclinical PTSD group showing a marginally greater rate of change during the course of treatment. Findings also varied by symptom cluster with the subclinical group showing a greater rate of change in the intrusions, hyper vigilance, and avoidance symptom clusters. There was not a significant between group difference in the numbing symptom cluster. This study provides preliminary evidence that treating PTSD symptoms at the subclinical level may result in a larger, and more rapid symptom reduction, and thus has implications supporting treatment earlier in the developmental trajectory of the disorder. Published by Elsevier Ltd.
C1 [Korte, Kristina J.; Allan, Nicholas P.; Gros, Daniel F.; Acierno, Ron] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Korte, Kristina J.; Allan, Nicholas P.; Gros, Daniel F.; Acierno, Ron] Med Univ S Carolina, Charleston, SC 29425 USA.
RP Gros, DF (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA.
EM kortek@musc.edu; grosd@musc.edu
FU CSRD VA [IK2 CX000845]; NIAAA NIH HHS [T32 AA007474]
NR 49
TC 0
Z9 0
U1 4
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-6185
EI 1873-7897
J9 J ANXIETY DISORD
JI J. Anxiety Disord.
PD MAR
PY 2016
VL 38
BP 95
EP 101
DI 10.1016/j.janxdis.2016.01.006
PG 7
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA DF6EQ
UT WOS:000371449100012
PM 26874291
ER
PT J
AU Krigbaum, H
Takemoto, S
Kim, HT
Kuo, AC
AF Krigbaum, Henry
Takemoto, Steven
Kim, Hubert T.
Kuo, Alfred C.
TI Costs and Complications of Short Versus Long Cephalomedullary Nailing of
OTA 31-A2 Proximal Femur Fractures in U.S. Veterans
SO JOURNAL OF ORTHOPAEDIC TRAUMA
LA English
DT Article
DE cephalomedullary nail; intertrochanteric femur fracture
ID INTERTROCHANTERIC HIP-FRACTURES; INTRAMEDULLARY NAILS; GAMMA-NAIL; A2
AB Objectives:
In fractures without subtrochanteric extension, the indications for the use of short versus long cephalomedullary nails (CMNs) for intertrochanteric femur fractures are unclear. We hypothesized that long nails would be associated with higher costs and similar complication rates.
Design:
Retrospective comparative study.
Setting:
United States Department of Veterans Affairs Medical Centers.
Participants:
Patients receiving CMNs for OTA 31-A2 pertrochanteric fractures from 2001 to 2010.
Interventions:
Short versus long cephalomedullary nailing.
Main Outcome Measurements:
Costs, perioperative complications, readmissions, surgical failures, and mortality.
Results:
We identified 262 patients with OTA 31-A2 pertrochanteric fractures (125 treated with short CMNs and 137 treated with long CMNs). The 2 cohorts had similar demographic and medical characteristics. There were no significant differences in perioperative complications, readmissions within 30 days, surgical failures within one year, or death within 30 days or one year. The average cost of hospitalization was significantly higher for the cohort treated with long nails (greater than $7000 in actual costs, and greater than $3000 when statistically adjusted for differences in postoperative lengths of stay). Multivariable analyses showed no significant differences in the rates of development of at least one complication, readmission, or death.
Conclusions:
In a cohort of patients with similar characteristics and fracture patterns, the use of long CMNs was associated with similar rates of complications, readmission, and reoperations, but significantly higher costs than with the use of short nails.
Level of Evidence:
Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
C1 [Kuo, Alfred C.] San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Kuo, AC (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA.
EM kuoac@orthosurg.ucsf.edu
FU James O. Johnston resident research grant
FX Supported by the James O. Johnston resident research grant to H.
Krigbaum.
NR 14
TC 2
Z9 2
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0890-5339
EI 1531-2291
J9 J ORTHOP TRAUMA
JI J. Orthop. Trauma
PD MAR
PY 2016
VL 30
IS 3
BP 125
EP 129
DI 10.1097/BOT.0000000000000521
PG 5
WC Orthopedics; Sport Sciences
SC Orthopedics; Sport Sciences
GA DF5IK
UT WOS:000371384900005
PM 26894639
ER
PT J
AU Suhasini, AN
Wang, L
Holder, KN
Lin, AP
Bhatnagar, H
Kim, SW
Moritz, AW
Aguiar, RCT
AF Suhasini, A. N.
Wang, L.
Holder, K. N.
Lin, A-P
Bhatnagar, H.
Kim, S-W
Moritz, A. W.
Aguiar, R. C. T.
TI A phosphodiesterase 4B-dependent interplay between tumor cells and the
microenvironment regulates angiogenesis in B-cell lymphoma
SO LEUKEMIA
LA English
DT Article
ID NON-HODGKIN-LYMPHOMA; MICROVESSEL DENSITY; GENE-EXPRESSION; CYCLIC-AMP;
MURINE LYMPHOMAS; PDE4 INHIBITORS; PROLIFERATION; CANCER; VEGF;
CHEMOTHERAPY
AB Angiogenesis associates with poor outcome in diffuse large B-cell lymphoma (DLBCL), but the contribution of the lymphoma cells to this process remains unclear. Addressing this knowledge gap may uncover unsuspecting proangiogenic signaling nodes and highlight alternative antiangiogenic therapies. Here, we identify the second messenger cyclic-AMP (cAMP) and the enzyme that terminates its activity, phosphodiesterase 4B (PDE4B), as regulators of B-cell lymphoma angiogenesis. We first show that cAMP, in a PDE4B-dependent manner, suppresses PI3K/AKT signals to downmodulate vascular endothelial growth factor (VEGF) secretion and vessel formation in vitro. Next, we create a novel mouse model that combines the lymphomagenic Myc transgene with germline deletion of Pde4b. We show that lymphomas developing in a Pde4b-null background display significantly lower microvessel density (MVD) in association with lower VEGF levels and PI3K/AKT activity. We recapitulate these observations by treating lymphoma-bearing mice with the FDA-approved PDE4 inhibitor, Roflumilast. Lastly, we show that primary human DLBCLs with high PDE4B expression display significantly higher MVD. Here, we defined an unsuspected signaling circuitry in which the cAMP generated in lymphoma cells downmodulates PI3K/AKT and VEGF secretion to negatively influence vessel development in the microenvironment. These data identify PDE4 as an actionable antiangiogenic target in DLBCL.
C1 [Suhasini, A. N.; Wang, L.; Lin, A-P; Bhatnagar, H.; Kim, S-W; Aguiar, R. C. T.] Univ Texas Hlth Sci Ctr San Antonio, Div Hematol & Med Oncol, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
[Holder, K. N.; Moritz, A. W.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Aguiar, R. C. T.] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA.
[Aguiar, R. C. T.] Audie Murphy VA Hosp, South Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Aguiar, RCT (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Hematol & Med Oncol, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM aguiarr@uthscsa.edu
FU CPRIT [RP110200, RP150277]; William and Ella Owens Medical Research
Foundation; Cancer Center support grant [P30 CA054174]
FX We thank the Cancer Therapy and Research Center at UTHSCSA Core
Pathology Tissue Bank for procurement of the primary DLBCL samples. We
acknowledge Patricia Dahia for insightful suggestions during the
execution of this project. This work was supported by CPRIT awards
RP110200 and RP150277 (to RCTA), a grant from the William and Ella Owens
Medical Research Foundation (to RCTA), and a Cancer Center support grant
P30 CA054174.
NR 48
TC 4
Z9 4
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
EI 1476-5551
J9 LEUKEMIA
JI Leukemia
PD MAR
PY 2016
VL 30
IS 3
BP 617
EP 626
DI 10.1038/leu.2015.302
PG 10
WC Oncology; Hematology
SC Oncology; Hematology
GA DF9NR
UT WOS:000371688500011
PM 26503641
ER
PT J
AU Cote, AJ
McLeod, CM
Farrell, MJ
McClanahan, PD
Dunagin, MC
Raj, A
Mauck, RL
AF Cote, Allison J.
McLeod, Claire M.
Farrell, Megan J.
McClanahan, Patrick D.
Dunagin, Margaret C.
Raj, Arjun
Mauck, Robert L.
TI Single-cell differences in matrix gene expression do not predict matrix
deposition
SO NATURE COMMUNICATIONS
LA English
DT Article
ID MESENCHYMAL STEM-CELLS; MARROW STROMAL CELLS; HUMAN ARTICULAR
CHONDROCYTES; BONE-MARROW; IN-VITRO; CHONDROGENIC DIFFERENTIATION;
LINEAGE COMMITMENT; HETEROGENEITY; CARTILAGE; CULTURE
AB Mesenchymal stem cells (MSCs) display substantial cell-to-cell heterogeneity, complicating their use in regenerative medicine. However, conventional bulk assays mask this variability. Here we show that both chondrocytes and chondrogenically induced MSCs exhibit substantial mRNA expression heterogeneity. Single-molecule RNA FISH to measure mRNA expression of differentiation markers in single cells reveals that sister cell pairs have high levels of mRNA variability, suggesting that marker expression is not heritable. Surprisingly, this variability does not correlate with cell-to-cell differences in cartilage-like matrix production. Transcriptome-wide analysis suggests that no combination of markers can predict functional potential. De-differentiating chondrocytes also show a disconnect between mRNA expression of the cartilage marker aggrecan and cartilage-like matrix accumulation. Altogether, these quantitative analyses suggest that sorting subpopulations based on these markers would only marginally enrich the progenitor population for ' superior' MSCs. Our results suggest that instantaneous mRNA abundance of canonical markers is tenuously linked to the chondrogenic phenotype at the single-cell level.
C1 [Cote, Allison J.; McLeod, Claire M.; Farrell, Megan J.; McClanahan, Patrick D.; Dunagin, Margaret C.; Raj, Arjun; Mauck, Robert L.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA.
[McLeod, Claire M.; Farrell, Megan J.; Mauck, Robert L.] Univ Penn, Perelman Sch Med, McKay Orthopaed Res Lab, Dept Orthopaed Surg, Philadelphia, PA 19104 USA.
[McLeod, Claire M.; Mauck, Robert L.] Philadelphia VA Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA 19104 USA.
RP Raj, A; Mauck, RL (reprint author), Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA.; Mauck, RL (reprint author), Univ Penn, Perelman Sch Med, McKay Orthopaed Res Lab, Dept Orthopaed Surg, Philadelphia, PA 19104 USA.; Mauck, RL (reprint author), Philadelphia VA Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA 19104 USA.
EM arjunrajlab@gmail.com; lemauck@mail.med.upenn.edu
OI Raj, Arjun/0000-0002-2915-6960
FU NSF CAREER award [1350601]; NIH New Innovator [1DP2OD008514]; Penn
Center for Musculoskeletal Disorders [P30 AR050950]; NIH [R01 EB008722,
R01 EB02425]; NIH training grant [T32 GM-07229, T32 HL007954]; NSF
Graduate Research Fellowship [DGE-0822]
FX A.R. acknowledges support from an NSF CAREER award (Grant Number
1350601), NIH New Innovator 1DP2OD008514, and a pilot grant from the
Penn Center for Musculoskeletal Disorders P30 AR050950. R.L.M.
acknowledges support from NIH grants R01 EB008722 and R01 EB02425.
A.J.C. was supported by NIH training grant T32 GM-07229. C.M.M. was
supported by NSF Graduate Research Fellowship DGE-0822 and by NIH
training grant T32 HL007954.
NR 70
TC 5
Z9 5
U1 2
U2 18
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAR
PY 2016
VL 7
AR 10865
DI 10.1038/ncomms10865
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DF9WG
UT WOS:000371712300001
PM 26936319
ER
PT J
AU O'Hare, AM
Rodriguez, RA
Bowling, CB
AF O'Hare, Ann M.
Rodriguez, Rudolph A.
Bowling, Christopher Barrett
TI Caring for patients with kidney disease: shifting the paradigm from
evidence-based medicine to patient-centered care
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Review
DE evidence-based medicine; patient-centered care; kidney disease; older
adults; paradigm
ID MULTIPLE CHRONIC CONDITIONS; SHARED DECISION-MAKING; QUALITY-OF-CARE;
CLINICAL-PRACTICE GUIDELINES; STAGE RENAL-DISEASE; OLDER-ADULTS;
UNITED-STATES; HEALTH-CARE; BLOOD-PRESSURE; TRIALS
AB The last several decades have witnessed the emergence of evidence-based medicine as the dominant paradigm for medical teaching, research and practice. Under an evidence-based approach, populations rather than individuals become the primary focus of investigation. Treatment priorities are largely shaped by the availability, relevance and quality of evidence and study outcomes and results are assumed to have more or less universal significance based on their implications at the population level. However, population-level treatment goals do not always align with what matters the most to individual patients-who may weigh the risks, benefits and harms of recommended treatments quite differently. In this article we describe the rise of evidence-based medicine in historical context. We discuss limitations of this approach for supporting real-world treatment decisions-especially in older adults with confluent comorbidity, functional impairment and/or limited life expectancy-and we describe the emergence of more patient-centered paradigms to address these limitations. We explain how the principles of evidence-based medicine have helped to shape contemporary approaches to defining, classifying and managing patients with chronic kidney disease. We discuss the limitations of this approach and the potential value of a more patient-centered paradigm, with a particular focus on the care of older adults with this condition. We conclude by outlining ways in which the evidence-base might be reconfigured to better support real-world treatment decisions in individual patients and summarize relevant ongoing initiatives.
C1 [O'Hare, Ann M.; Rodriguez, Rudolph A.] VA Puget Sound Hlth Care Syst, Hosp & Specialty Med Serv, Seattle, WA USA.
[O'Hare, Ann M.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Innovat, Seattle, WA USA.
[O'Hare, Ann M.; Rodriguez, Rudolph A.] Univ Washington, Dept Med, Seattle, WA USA.
[Bowling, Christopher Barrett] Atlanta VA Med Ctr, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Decatur, GA USA.
[Bowling, Christopher Barrett] Emory Univ, Dept Med, Atlanta, GA 30322 USA.
RP O'Hare, AM (reprint author), VA Puget Sound Hlth Care Syst, Hosp & Specialty Med Serv, Seattle, WA USA.; O'Hare, AM (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Innovat, Seattle, WA USA.; O'Hare, AM (reprint author), Univ Washington, Dept Med, Seattle, WA USA.
EM ann.ohare@va.gov
FU NIH [1U01DK102150-01]; US Department of Veterans Affairs
[1I01HX000961-01, 1IK2CX000856-01A1]; CDC [IAA 14FED1405094-0001];
National Institute on Aging [R03AG042336-01]; T. Franklin Williams
Scholarship Award (Atlantic Philanthropies, Inc.); T. Franklin Williams
Scholarship Award (John A. Hartford Foundation); T. Franklin Williams
Scholarship Award (Association of Specialty Professors); T. Franklin
Williams Scholarship Award (American Society of Nephrology); T. Franklin
Williams Scholarship Award (American Geriatrics Society)
FX A.M.O. receives research funding from the NIH (1U01DK102150-01), the US
Department of Veterans Affairs (1I01HX000961-01) and the CDC (IAA
14FED1405094-0001). She receives an honorarium from UpToDate. C.B.B.
receives funding from the National Institute on Aging (R03AG042336-01)
and the T. Franklin Williams Scholarship Award (funding provided by
Atlantic Philanthropies, Inc., the John A. Hartford Foundation, the
Association of Specialty Professors, the American Society of Nephrology
and the American Geriatrics Society) and the US Department of Veterans
Affairs (1IK2CX000856-01A1).
NR 89
TC 3
Z9 3
U1 6
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931-0509
EI 1460-2385
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PD MAR
PY 2016
VL 31
IS 3
BP 368
EP 375
DI 10.1093/ndt/gfv003
PG 8
WC Transplantation; Urology & Nephrology
SC Transplantation; Urology & Nephrology
GA DF7EU
UT WOS:000371521400007
PM 25637639
ER
PT J
AU Barnett, PG
Jeffers, A
Smith, MW
Chow, BK
McFall, M
Saxon, AJ
AF Barnett, Paul G.
Jeffers, Abra
Smith, Mark W.
Chow, Bruce K.
McFall, Miles
Saxon, Andrew J.
TI Cost-Effectiveness of Integrating Tobacco Cessation Into Post-Traumatic
Stress Disorder Treatment
SO NICOTINE & TOBACCO RESEARCH
LA English
DT Article
ID QUALITY-OF-LIFE; SMOKING-CESSATION; VIETNAM VETERANS; ECONOMIC
EVALUATIONS; CIGARETTE-SMOKING; MENTAL-ILLNESS; FORMER SMOKERS;
HEALTH-CARE; MORTALITY; POPULATION
AB We examined the cost-effectiveness of smoking cessation integrated with treatment for post-traumatic stress disorder (PTSD).
Smoking veterans receiving care for PTSD (N = 943) were randomized to care integrated with smoking cessation versus referral to a smoking cessation clinic. Smoking cessation services, health care cost and utilization, quality of life, and biochemically-verified abstinence from cigarettes were assessed over 18-months of follow-up. Clinical outcomes were combined with literature on changes in smoking status and the effect of smoking on health care cost, mortality, and quality of life in a Markov model of cost-effectiveness over a lifetime horizon. We discounted cost and outcomes at 3% per year and report costs in 2010 US dollars.
The mean of smoking cessation services cost was $1286 in those randomized to integrated care and $551 in those receiving standard care (P < .001). There were no significant differences in the cost of mental health services or other care. After 12 months, prolonged biochemically verified abstinence was observed in 8.9% of those randomized to integrated care and 4.5% of those randomized to standard care (P = .004). The model projected that Integrated Care added $836 in lifetime cost and generated 0.0259 quality adjusted life years (QALYs), an incremental cost-effectiveness ratio of $32 257 per QALY. It was 86.0% likely to be cost-effective compared to a threshold of $100 000/QALY.
Smoking cessation integrated with treatment for PTSD was cost-effective, within a broad confidence region, but less cost-effective than most other smoking cessation programs reported in the literature.
C1 [Barnett, Paul G.] Vet Affairs Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, 795 Willow Rd 152 MPD, Menlo Pk, CA 94025 USA.
[Barnett, Paul G.] Univ Calif San Francisco, Dept Psychiat, Treatment Res Ctr, San Francisco, CA 94143 USA.
[Jeffers, Abra] Stanford Univ, Dept Management Sci & Engn, Stanford, CA 94305 USA.
[Smith, Mark W.] Truven Hlth Analyt, Bethesda, MD USA.
[Chow, Bruce K.] Vet Affairs Cooperat Studies Program Coordinating, Palo Alto, CA USA.
[McFall, Miles; Saxon, Andrew J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[McFall, Miles; Saxon, Andrew J.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
RP Barnett, PG (reprint author), Vet Affairs Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, 795 Willow Rd 152 MPD, Menlo Pk, CA 94025 USA.
EM paul.barnett@va.gov
FU Cooperative Studies Program; National Institute on Drug Abuse [P50
DA09253]
FX This research was supported by the Cooperative Studies Program and grant
P50 DA09253 from the National Institute on Drug Abuse. Trial
registration: http://ClinicalTrials.gov identifier: NCT00118534.
NR 49
TC 0
Z9 0
U1 3
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462-2203
EI 1469-994X
J9 NICOTINE TOB RES
JI Nicotine Tob. Res.
PD MAR
PY 2016
VL 18
IS 3
BP 267
EP 274
DI 10.1093/ntr/ntv094
PG 8
WC Substance Abuse; Public, Environmental & Occupational Health
SC Substance Abuse; Public, Environmental & Occupational Health
GA DF8HP
UT WOS:000371598600006
PM 25943761
ER
PT J
AU Katzman, WB
Vittinghoff, E
Kado, DM
Schafer, AL
Wong, SS
Gladin, A
Lane, NE
AF Katzman, Wendy B.
Vittinghoff, Eric
Kado, Deborah M.
Schafer, Anne L.
Wong, Shirley S.
Gladin, Amy
Lane, Nancy E.
TI Study of Hyperkyphosis, Exercise and Function (SHEAF) Protocol of a
Randomized Controlled Trial of Multimodal Spine-Strengthening Exercise
in Older Adults With Hyperkyphosis
SO PHYSICAL THERAPY
LA English
DT Article
ID COMMUNITY-DWELLING MEN; OSTEOPOROTIC FRACTURES; PHYSICAL PERFORMANCE;
RANCHO-BERNARDO; THORACIC KYPHOSIS; WOMEN; POSTURE; TRUNK; VALIDATION;
GUIDELINES
AB Background. Hyperkyphosis negatively affects health status, physical mobility, and quality of life, but there is no standard protocol for treating people with hyperkyphosis. Treatment options include targeted exercise.
Objectives. This single-site randomized controlled trial (RCT) will determine the efficacy of a targeted multimodal spine-strengthening exercise program, compared with no exercise intervention, among community-dwelling men and women aged >= 60 years, with thoracic kyphosis >= 40
Design. The RCT is a parallel-group design, with 1:1 randomization to exercise and attentional control groups.
Setting. The study will be conducted at one primary site (one academic medical center partnered with one local community medical center).
Participants. One hundred men and women, aged years, with thoracic kyphosis degrees will be randomized.
Intervention. The targeted multimodal spine-strengthening exercise intervention includes exercise and postural training delivered by a physical therapist in a group of 10 participants, 3 times a week for 6 months. Controls receive monthly health education meetings in a group of 10 participants and monthly calls from the study. coordinator to monitor physical activity and any adverse events.
Measurements. The primary outcome is change in Cobb angle of kyphosis measured from lateral spine radiographs at baseline and 6 months. Secondary outcomes include change in physical function (assessed with the modified Physical Performance Test, Timed "Up & Go" Test, timed loaded standing, 4-m walk, and Six-Minute Walk Test) and health-related quality of life (assessed with the modified Scoliosis Research Society instrument [SRS-30] self-image domain and Patient Reported Outcomes Measurement Information System [PROMIS] global health and physical function indexes). Additional secondary outcomes include pain, physical activity level, spinal flexion and extension muscle strength, paraspinal extensor muscle density, and adverse events.
Limitations. Blinding of the participants and instructors providing the intervention is not possible.
Conclusions. The efficacy of a high-quality, adequately powered exercise intervention in men and women with kyphosis degrees will be evaluated to determine whether targeted multimodal spine-strengthening exercise reduces hyperkyphosis in older adults and improves important secondary outcomes of physical function and health-related quality of life.
C1 [Katzman, Wendy B.; Wong, Shirley S.] Univ Calif San Francisco, Dept Phys Therapy & Rehabil Sci, UCSF Box 0625, San Francisco, CA 94143 USA.
[Vittinghoff, Eric; Schafer, Anne L.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Kado, Deborah M.] Univ Calif San Diego, Dept Family Med, San Diego, CA 92103 USA.
[Kado, Deborah M.] Univ Calif San Diego, Dept Publ Hlth, San Diego, CA 92103 USA.
[Kado, Deborah M.] Univ Calif San Diego, Dept Internal Med, San Diego, CA 92103 USA.
[Schafer, Anne L.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Schafer, Anne L.] San Francisco VA Med Ctr, Med Serv, San Francisco, CA USA.
[Gladin, Amy] Kaiser Permanente No Calif, San Francisco Med Ctr, San Francisco, CA USA.
[Lane, Nancy E.] Univ Calif Davis, Dept Internal Med, Davis, CA 95616 USA.
RP Katzman, WB (reprint author), Univ Calif San Francisco, Dept Phys Therapy & Rehabil Sci, UCSF Box 0625, San Francisco, CA 94143 USA.
EM wendy.katzman@ucsf.edu
FU National Institute of Aging [R01-AG028]; US Department of Veterans
Affairs, Veterans Health Administration, Office of Clinical Science
Research and Development [5 IK2 CX000549]
FX The study was funded by National Institute of Aging grant R01-AG028.
Additional support was provided by the US Department of Veterans
Affairs, Veterans Health Administration, Office of Clinical Science
Research and Development, under grant 5 IK2 CX000549 (to Dr Schafer).
NR 36
TC 1
Z9 1
U1 4
U2 5
PU AMER PHYSICAL THERAPY ASSOC
PI ALEXANDRIA
PA 1111 N FAIRFAX ST, ALEXANDRIA, VA 22314 USA
SN 0031-9023
EI 1538-6724
J9 PHYS THER
JI Phys. Ther.
PD MAR
PY 2016
VL 96
IS 3
BP 371
EP 381
DI 10.2522/ptj.20150171
PG 11
WC Orthopedics; Rehabilitation
SC Orthopedics; Rehabilitation
GA DF6FV
UT WOS:000371452200013
PM 26251480
ER
PT J
AU Jain, S
Keys, D
Martin, S
Edelstein, CL
Jani, A
AF Jain, Swati
Keys, Daniel
Martin, Sandra
Edelstein, Charles L.
Jani, Alkesh
TI Protection From Apoptotic Cell Death During Cold Storage Followed by
Rewarming in 13-Lined Ground Squirrel Tubular Cells: The Role of
Prosurvival Factors X-Linked Inhibitor of Apoptosis and PhosphoAkt
SO TRANSPLANTATION
LA English
DT Article
ID POLYCYSTIC KIDNEY-DISEASE; AKT PHOSPHORYLATION; EPITHELIAL-CELLS;
HIBERNATION; INJURY; ISCHEMIA; MITOCHONDRIA; REPERFUSION; PROGRESSION;
METABOLISM
AB Background. Hibernators, such as the 13-lined ground squirrel, endure severe hypothermia during torpor followed by periodic rewarming (REW) during interbout arousal (IBA), proapoptotic conditions that are lethal to nonhibernatingmammals. We have previously shown that 13-lined ground squirrel tubular cells are protected from apoptotic cell death during IBA. To understand the mechanism of protection, we developed an in vitro model of prolonged cold storage (CS) followed by REW, which is akin to the in vivo changes of hypothermia followed by REW observed during IBA. We hypothesized that renal tubular epithelial cells (RTECs) isolated from hibernating ground squirrels would be protected against apoptosis during CS/REW versus nonhibernating mouse RTECs. Methods. Isolated hibernating ground squirrel and mouse RTECs were subjected to CS at 4 degrees C for 24 hours followed by REW to 37 degrees C for 24 hours (CS/REW). Results. Ground squirrel RTECs had significantly less apoptosis compared to mouse RTECs when subjected to CS/REW. Next, we hypothesized that the mechanism of protection was related to the antiapoptotic proteins X-linked inhibitor of apoptosis (XIAP), phospho-Akt (pAkt), and phospho-BAD. There was a significantly increased pAkt and pBAD expression in ground squirrel versus mouse RTECs subjected to CS/REW. The XIAP expression was maintained in ground squirrel RTECs but was significantly decreased in mouse RTECs after CS/REW. Ground squirrel RTECs in which gene expression of Akt1 and XIAP was silenced lost their protection and demonstrated increased apoptosis and cleaved caspase-3 expression after CS/REW. Conclusions. Our findings suggest that ground squirrel RTECs are protected against apoptosis during prolonged CS/REW by the "prosurvival" factors XIAP and pAkt.
C1 [Jain, Swati; Keys, Daniel; Martin, Sandra; Edelstein, Charles L.; Jani, Alkesh] Univ Colorado, Denver, CO 80202 USA.
[Edelstein, Charles L.; Jani, Alkesh] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Jani, A (reprint author), Univ Colorado Denver, Div Renal Dis & Hypertens, 12700 East 19th Ave,C281, Aurora, CO 80045 USA.
EM Alkesh.jani@ucdenver.edu
FU NIH [1 R03 DK96151-01]; VA Merit Award [1I01BX001737]
FX This work was supported by NIH 1 R03 DK96151-01 and a VA Merit Award
1I01BX001737.
NR 33
TC 0
Z9 0
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0041-1337
EI 1534-6080
J9 TRANSPLANTATION
JI Transplantation
PD MAR
PY 2016
VL 100
IS 3
BP 538
EP 545
DI 10.1097/TP.0000000000000937
PG 8
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA DF8BR
UT WOS:000371582400025
PM 26457601
ER
PT J
AU Treuting, PM
Snyder, JM
Ikeno, Y
Schofield, PN
Ward, JM
Sundberg, JP
AF Treuting, P. M.
Snyder, J. M.
Ikeno, Y.
Schofield, P. N.
Ward, J. M.
Sundberg, J. P.
TI The Vital Role of Pathology in Improving Reproducibility and
Translational Relevance of Aging Studies in Rodents
SO VETERINARY PATHOLOGY
LA English
DT Article
DE aging; pathology; health span; life span; longevity; necropsy;
histopathology; rodent; mouse model; animal model; cause of death
ID GENETICALLY HETEROGENEOUS MICE; OF-DEATH ASSIGNMENT; EXTENDS LIFE-SPAN;
CHRONIC DISEASE; INTERIM-REPORT; ANIMAL-MODELS; MOUSE MODELS;
DATA-CAPTURE; RAPAMYCIN; LONGEVITY
AB Pathology is a discipline of medicine that adds great benefit to aging studies of rodents by integrating in vivo, biochemical, and molecular data. It is not possible to diagnose systemic illness, comorbidities, and proximate causes of death in aging studies without the morphologic context provided by histopathology. To date, many rodent aging studies do not utilize end points supported by systematic necropsy and histopathology, which leaves studies incomplete, contradictory, and difficult to interpret. As in traditional toxicity studies, if the effect of a drug, dietary treatment, or altered gene expression on aging is to be studied, systematic pathology analysis must be included to determine the causes of age-related illness, moribundity, and death. In this Commentary, the authors discuss the factors that should be considered in the design of aging studies in mice, with the inclusion of robust pathology practices modified after those developed by toxicologic and discovery research pathologists. Investigators in the field of aging must consider the use of histopathology in their rodent aging studies in this era of integrative and preclinical geriatric science (geroscience).
C1 [Treuting, P. M.; Snyder, J. M.] Univ Washington, Sch Med, Dept Comparat Med, Seattle, WA 98195 USA.
[Ikeno, Y.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst, San Antonio, TX 78229 USA.
[Ikeno, Y.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Ikeno, Y.] South Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX USA.
[Ikeno, Y.] South Texas Vet Hlth Care Syst, Audie L Murphy VA Hosp, Geriatr Res & Educ Clin Ctr, San Antonio, TX USA.
[Schofield, P. N.] Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge, England.
[Schofield, P. N.; Sundberg, J. P.] Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.
[Ward, J. M.] Global VetPathol, Montgomery Village, MD USA.
RP Treuting, PM (reprint author), Univ Washington, Comparat Pathol, Dept Comparat Med & Histol & Imaging Core, Sch Med, 1-458,Box 357340, Seattle, WA 98195 USA.
EM treuting@uw.edu
FU BLRD VA [I01 BX001023]; NCI NIH HHS [CA34196, P30 CA034196]; NIA NIH HHS
[AG13319, AG25707, P01 AG001751, P01AG01751, P30 AG013280, P30 AG013319,
P30 AG025707, P30AG013280]; NIH HHS [R25 OD010450, R25OD010450]
NR 81
TC 3
Z9 3
U1 4
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0300-9858
EI 1544-2217
J9 VET PATHOL
JI Vet. Pathol.
PD MAR
PY 2016
VL 53
IS 2
BP 244
EP 249
DI 10.1177/0300985815620629
PG 6
WC Pathology; Veterinary Sciences
SC Pathology; Veterinary Sciences
GA DF8PO
UT WOS:000371620500003
PM 26792843
ER
PT J
AU Jarlenski, M
Baller, J
Borrero, S
Bennett, WL
AF Jarlenski, Marian
Baller, Julia
Borrero, Sonya
Bennett, Wendy L.
TI Trends in Disparities in Low-Income Children's Health Insurance Coverage
and Access to Care by Family Immigration Status
SO ACADEMIC PEDIATRICS
LA English
DT Article
DE access to care; disparities; health insurance; immigrant
ID UNINSURED CHILDREN; UNITED-STATES; EXPANSIONS; MEDICAID; PARENTS; IMPACT
AB OBJECTIVE: To examine time trends in disparities in low-income children's health insurance coverage and access to care by family immigration status.
METHODS: We used data from the National Survey of Children's Health in 2003 to 2011-2012, including 83,612 children aged 0 to 17 years with family incomes <200% of the federal poverty level. We examined 3 immigration status categories: citizen children with nonimmigrant parents; citizen children with immigrant parents; and immigrant children. We used multivariable regression analyses to obtain adjusted trends in health insurance coverage and access to care..
RESULTS: All low-income children experienced gains in health insurance coverage and access to care from 2003 to 2011-2012, regardless of family immigration status. Relative to citizen children with nonimmigrant parents, citizen children with immigrant parents had a 5 percentage point greater increase in health insurance coverage (P = .06), a 9 percentage point greater increase in having a personal doctor or nurse (P < .01), and an 11 percentage point greater increase in having no unmet medical need (P < .01). Immigrant children had significantly lower health insurance coverage than other groups. However, the group had a 14 percentage point greater increase in having a personal doctor or nurse (P < .01) and a 26 percentage point greater increase in having no unmet medical need (P < .01) relative to citizen children with nonimmigrant parents.
CONCLUSIONS: Some disparities in access to care related to family immigration status have lessened over time among children in low-income families, although large disparities still exist. Policy efforts are needed to ensure that children of immigrant parents and immigrant children are able to access health insurance and health care.
C1 [Jarlenski, Marian] Univ Pittsburgh, Dept Hlth Policy & Management, Grad Sch Publ Hlth, 130 DeSoto St,A647, Pittsburgh, PA 15261 USA.
[Jarlenski, Marian; Borrero, Sonya] Univ Pittsburgh, Ctr Womens Hlth Res & Innovat, Pittsburgh, PA USA.
[Baller, Julia] Math Policy Res, Washington, DC USA.
[Borrero, Sonya] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA USA.
[Borrero, Sonya] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Bennett, Wendy L.] Johns Hopkins Univ, Sch Med, Div Gen Internal Med, Baltimore, MD USA.
[Bennett, Wendy L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Populat Family & Reprod Hlth, Baltimore, MD USA.
RP Jarlenski, M (reprint author), Univ Pittsburgh, Dept Hlth Policy & Management, Grad Sch Publ Hlth, 130 DeSoto St,A647, Pittsburgh, PA 15261 USA.
EM marian.jarlenski@pitt.edu
OI Jarlenski, Marian/0000-0001-6907-5447
NR 37
TC 1
Z9 1
U1 2
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1876-2859
EI 1876-2867
J9 ACAD PEDIATR
JI Acad. Pediatr.
PD MAR
PY 2016
VL 16
IS 2
BP 208
EP 215
PG 8
WC Pediatrics
SC Pediatrics
GA DF5AK
UT WOS:000371364000016
PM 26329016
ER
PT J
AU Kranzler, HR
Armeli, S
Wetherill, R
Feinn, R
Tennen, H
Gelernter, J
Covault, J
Pond, T
AF Kranzler, Henry R.
Armeli, Stephen
Wetherill, Reagan
Feinn, Richard
Tennen, Howard
Gelernter, Joel
Covault, Jonathan
Pond, Timothy
TI Self-efficacy mediates the effects of topiramate and GRIK1 genotype on
drinking
SO ADDICTION BIOLOGY
LA English
DT Article
DE GRIK1; mediated moderation; personalized treatment; pharmacogenetics;
self-efficacy; topiramate
ID ALCOHOL DEPENDENCE; 12-STEP; EXPECTATIONS; MODERATION; DRINKERS;
PROGRAMS; OUTCOMES
AB Previous studies indicate that topiramate reduces alcohol use among problem drinkers, with one study showing that the effect was moderated by a polymorphism (rs2832407) in GRIK1, the gene encoding the GluK1 kainate subunit. We examined whether the interactive effect of medication and genotype (1) altered the association between daily self-efficacy and later-day drinking; and (2) had an indirect effect on drinking via self-efficacy. In a 12-week, placebo-controlled trial of topiramate, we used daily interactive voice response technology to measure self-efficacy (i.e. confidence in avoiding heavy drinking later in the day) and drinking behavior in 122 European-American heavy drinkers. Topiramate's effects on both self-efficacy and drinking level were moderated by rs2832407. C-allele homozygotes treated with topiramate showed higher levels of self-efficacy and lower levels of nighttime drinking across the 12-week trial. Further, the interactive effect of topiramate and genotype on mean nighttime drinking levels was mediated by mean levels of self-efficacy. By modeling topiramate's effects on nighttime drinking across multiple levels of analysis, we found that self-efficacy, a key psychologic construct, mediated the effect of topiramate, which was moderated by rs2832407 genotype. Thus, it may be possible to use an individualized assessment (i.e. genotype) to select treatment to optimize the reduction in heavy drinking and thereby provide a personalized treatment approach.
C1 [Kranzler, Henry R.; Wetherill, Reagan; Pond, Timothy] Univ Penn, Dept Psychiat, Ctr Studies Addict, Perelman Sch Med, 3900 Chestnut St, Philadelphia, PA 19104 USA.
[Kranzler, Henry R.] Philadelphia VA Med Ctr, MIRECC VISN4, Philadelphia, PA USA.
[Armeli, Stephen] Fairleigh Dickinson Univ, Dept Psychol, Teaneck, NJ USA.
[Feinn, Richard] Quinnipiac Univ, Frank Netter Sch Med, Dept Med Sci, Hamden, CT USA.
[Tennen, Howard] Univ Connecticut, Sch Med, Dept Community Med & Healthcare, Farmington, CT USA.
[Covault, Jonathan] Univ Connecticut, Dept Psychiat, Sch Med, Alcohol Res Ctr, Farmington, CT 06107 USA.
[Gelernter, Joel] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
[Gelernter, Joel] Vet Affairs Connecticut Healthcare Ctr, West Haven, CT USA.
RP Kranzler, HR (reprint author), Univ Penn, Dept Psychiat, Ctr Studies Addict, Perelman Sch Med, 3900 Chestnut St, Philadelphia, PA 19104 USA.
EM kranzler@mail.med.upenn.edu
FU National Institutes of Health [P60 AA03510, K24 AA13736]
FX Supported by National Institutes of Health grants P60 AA03510 and K24
AA13736. Staff members of the Clinical Research and Evaluation Unit of
the University of Connecticut Alcohol Research Center and the Center for
Studies of Addiction of the University of Pennsylvania Perelman School
of Medicine were instrumental in the conduct of the study.
NR 31
TC 7
Z9 9
U1 4
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1355-6215
EI 1369-1600
J9 ADDICT BIOL
JI Addict. Biol.
PD MAR
PY 2016
VL 21
IS 2
BP 450
EP 459
DI 10.1111/adb.12207
PG 10
WC Biochemistry & Molecular Biology; Substance Abuse
SC Biochemistry & Molecular Biology; Substance Abuse
GA DF2CW
UT WOS:000371148700020
PM 25496338
ER
PT J
AU Clarke, TK
Smith, AH
Gelernter, J
Kranzler, HR
Farrer, LA
Hall, LS
Fernandez-Pujals, AM
MacIntyre, DJ
Smith, BH
Hocking, LJ
Padmanabhan, S
Hayward, C
Thomson, PA
Porteous, DJ
Deary, IJ
McIntosh, AM
AF Clarke, Toni-Kim
Smith, Andrew H.
Gelernter, Joel
Kranzler, Henry R.
Farrer, Lindsay A.
Hall, Lynsey S.
Fernandez-Pujals, Ana M.
MacIntyre, Donald J.
Smith, Blair H.
Hocking, Lynne J.
Padmanabhan, Sandosh
Hayward, Caroline
Thomson, Pippa A.
Porteous, David J.
Deary, Ian J.
McIntosh, Andrew M.
TI Polygenic risk for alcohol dependence associates with alcohol
consumption, cognitive function and social deprivation in a
population-based cohort
SO ADDICTION BIOLOGY
LA English
DT Article
DE Alcohol dependence; cognition; environment; genetics; polygenic; social
deprivation
ID EXECUTIVE FUNCTIONS; FAMILY HEALTH; OLD-AGE; CHILDREN; INTELLIGENCE;
ADOLESCENCE; CHILDHOOD; EDUCATION; CORTEX; ABUSE
AB Alcohol dependence is frequently co-morbid with cognitive impairment. The relationship between these traits is complex as cognitive dysfunction may arise as a consequence of heavy drinking or exist prior to the onset of dependence. In the present study, we tested the genetic overlap between cognitive abilities and alcohol dependence using polygenic risk scores (PGRS). We created two independent PGRS derived from two recent genome-wide association studies (GWAS) of alcohol dependence (SAGE GWAS: n=2750; Yale-Penn GWAS: n=2377) in a population-based cohort, Generation Scotland: Scottish Family Health Study (GS:SFHS) (n=9863). Data on alcohol consumption and four tests of cognitive function [Mill Hill Vocabulary (MHV), digit symbol coding, phonemic verbal fluency (VF) and logical memory] were available. PGRS for alcohol dependence were negatively associated with two measures of cognitive function: MHV (SAGE: P=0.009, =-0.027; Yale-Penn: P=0.001, =-0.034) and VF (SAGE: P=0.0008, =-0.036; Yale-Penn: P=0.00005, =-0.044). VF remained robustly associated after adjustment for education and social deprivation; however, the association with MHV was substantially attenuated. Shared genetic variants may account for some of the phenotypic association between cognitive ability and alcohol dependence. A significant negative association between PGRS and social deprivation was found (SAGE: P=5.2x10(-7), =-0.054; Yale-Penn: P=0.000012, =-0.047). Individuals living in socially deprived regions were found to carry more alcohol dependence risk alleles which may contribute to the increased prevalence of problem drinking in regions of deprivation. Future work to identify genes which affect both cognitive impairment and alcohol dependence will help elucidate biological processes common to both disorders.
C1 [Clarke, Toni-Kim; Hall, Lynsey S.; Fernandez-Pujals, Ana M.; MacIntyre, Donald J.; McIntosh, Andrew M.] Univ Edinburgh, Div Psychiat, Edinburgh EH10 5HF, Midlothian, Scotland.
[Hayward, Caroline; Thomson, Pippa A.] Univ Edinburgh, Western Gen Hosp, Ctr Genom & Expt Med, Inst Genet & Mol Med, Edinburgh EH10 5HF, Midlothian, Scotland.
[Hayward, Caroline; Porteous, David J.] Univ Edinburgh, MRC Human Genet, MRC IGMM, Edinburgh EH10 5HF, Midlothian, Scotland.
[Thomson, Pippa A.; Porteous, David J.; Deary, Ian J.; McIntosh, Andrew M.] Univ Edinburgh, Ctr Cognit Ageing & Cognit Epidemiol, Edinburgh EH10 5HF, Midlothian, Scotland.
[Deary, Ian J.] Univ Edinburgh, Dept Psychol, Edinburgh EH10 5HF, Midlothian, Scotland.
[Smith, Andrew H.; Gelernter, Joel] Yale Univ, Sch Med, Dept Psychiat, Div Human Genet, West Haven, CT 06516 USA.
[Smith, Andrew H.; Gelernter, Joel] VA CT Healthcare Ctr, West Haven, CT USA.
[Smith, Andrew H.] Yale Univ, Sch Med, Med Scientist Training Program, West Haven, CT 06516 USA.
[Smith, Andrew H.] Yale Univ, Sch Med, Interdept Neurosci Program, West Haven, CT 06516 USA.
[Gelernter, Joel] Yale Univ, Sch Med, Dept Genet & Neurobiol, West Haven, CT 06516 USA.
[Kranzler, Henry R.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Kranzler, Henry R.] Philadelphia VA Med Ctr, MIRECC VISN4, Philadelphia, PA USA.
[Farrer, Lindsay A.] Boston Univ, Sch Med & Publ Hlth, Dept Med, Boston, MA 02215 USA.
[Farrer, Lindsay A.] Boston Univ, Dept Neurol, Sch Med & Publ Hlth, Boston, MA 02215 USA.
[Farrer, Lindsay A.] Boston Univ, Dept Ophthalmol, Sch Med & Publ Hlth, Boston, MA 02215 USA.
[Farrer, Lindsay A.] Boston Univ, Dept Biomed Genet, Sch Med & Publ Hlth, Boston, MA 02215 USA.
[Farrer, Lindsay A.] Boston Univ, Dept Epidemiol, Sch Med & Publ Hlth, Boston, MA 02215 USA.
[Farrer, Lindsay A.] Boston Univ, Dept Biostat, Sch Med & Publ Hlth, Boston, MA 02215 USA.
[Smith, Blair H.] Univ Dundee, Populat Hlth Sci, Dundee DD1 4HN, Scotland.
[Hocking, Lynne J.] Univ Aberdeen, Div Appl Hlth Sci, Aberdeen AB9 1FX, Scotland.
[Padmanabhan, Sandosh] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow G12 8QQ, Lanark, Scotland.
RP Clarke, TK (reprint author), Univ Edinburgh, Royal Edinburgh Hosp, Div Psychiat, Kennedy Tower, Edinburgh EH10 5HF, Midlothian, Scotland.
EM toni.clarke@ed.ac.uk
RI ; Padmanabhan, Sandosh/S-3963-2016
OI Smith, Blair/0000-0002-5362-9430; McIntosh, Andrew/0000-0002-0198-4588;
MacIntyre, Donald J/0000-0001-6963-1335; Clarke,
Toni-Kim/0000-0002-7745-6351; Farrer, Lindsay/0000-0001-5533-4225;
Hocking, Lynne J/0000-0002-2414-2826; Padmanabhan,
Sandosh/0000-0003-3869-5808
FU Chief Scientist Office of the Scottish Government; Scottish Funding
Council; Scottish Government Health Department, Chief Scientist Office
[CZD/16/6]; National Institutes of Health [N01-HG-65403, RC2 DA028909,
R01 DA12690, R01 DA12849, R01 DA18432, R01 AA11330, R01 AA017535, P50
AA12870, MSTP T32GM07205, CTSA 8UL1TR000142]; Study of Addiction:
Genetics and Environment (SAGE) was provided through the NIH Genes,
Environment and Health Initiative [GEI] [U01 HG004422]; GENEVA
Coordinating [U01 HG004446]; Collaborative Study on the Genetics of
Alcoholism (COGA) [U10 AA008401]; Collaborative Genetic Study of
Nicotine Dependence (COGEND) [P01 CA089392]; Family Study of Cocaine
Dependence (FSCD) [R01 DA013423]; Johns Hopkins University Center for
Inherited Disease Research; NIH GEI [U01HG004438]; National Institute on
Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; NIH
[HHSN268200782096C]; Dr Mortimer and Theresa Sackler Foundation;
Biotechnology and Biological Sciences Research Council (BBSRC); Medical
Research Council (MRC); Wellcome Trust [104036/Z/14/Z]
FX The Chief Scientist Office of the Scottish Government and the Scottish
Funding Council provided core support for Generation Scotland. GS:SFHS
was funded by a grant from the Scottish Government Health Department,
Chief Scientist Office (No. CZD/16/6). Genotyping services for a part of
the Yale GWAS study were provided by the Center for Inherited Disease
Research (CIDR) and Yale University (Center for Genome Analysis). CIDR
is fully funded through a federal contract from the National Institutes
of Health to The Johns Hopkins University (Contract No. N01-HG-65403).
The publicly available datasets used for the analyses described in this
manuscript were obtained from dbGaP at
http://www.ncbi.nlmnih.gov/projects/gap/cgi-bin/studycgi?study_id=phs000
092.vl.p1 through dbGaP accession number phs000092.vl.p. Funding support
for the Study of Addiction: Genetics and Environment (SAGE) was provided
through the NIH Genes, Environment and Health Initiative [GEI] (U01
HG004422). SAGE is one of the genome-wide association studies funded as
part of the Gene Environment Association Studies (GENEVA) under GEL
Assistance with phenotype harmonization and genotype cleaning, as well
as with general study coordination, was provided by the GENEVA
Coordinating Center (U01 HG004446). Assistance with data cleaning was
provided by the National Center for Biotechnology Information. Support
for collection of datasets and samples was provided by the Collaborative
Study on the Genetics of Alcoholism (COGA; U10 AA008401), the
Collaborative Genetic Study of Nicotine Dependence (COGEND; P01
CA089392) and the Family Study of Cocaine Dependence (FSCD: R01
DA013423). Funding support for genotyping, which was performed at the
Johns Hopkins University Center for Inherited Disease Research, was
provided by the NIH GEI (U01HG004438), the National Institute on Alcohol
Abuse and Alcoholism, the National Institute on Drug Abuse, and the NIH
contract 'High throughput genotyping for studying the genetic
contributions to human disease' (HHSN268200782096C). The authors TKC and
AN NI acknowledge with gratitude the financial support received for this
work from the Dr Mortimer and Theresa Sackler Foundation. PAT, DTP, IJD
and AMM are members of Hie University of Edinburgh Centre for Cognitive
Ageing and Cognitive Epidemiology, part of the cross council Lifelong
Health and Wellbeing Initiative (MR/K026992/1). Funding from the
Biotechnology and Biological Sciences Research Council (BBSRC) and
Medical Research Council (MRC) is gratefully acknowledged, supported in
part by National Institutes of Health grants RC2 DA028909, R01 DA12690,
R01 DA12849, R01 DA18432, R01 AA11330, R01 AA017535, P50 AA12870, MSTP
T32GM07205 and CTSA 8UL1TR000142. This work is supported by the Wellcome
Trust through a Strategic Award, reference 104036/Z/14/Z.
NR 47
TC 3
Z9 5
U1 1
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1355-6215
EI 1369-1600
J9 ADDICT BIOL
JI Addict. Biol.
PD MAR
PY 2016
VL 21
IS 2
BP 469
EP 480
DI 10.1111/adb.12245
PG 12
WC Biochemistry & Molecular Biology; Substance Abuse
SC Biochemistry & Molecular Biology; Substance Abuse
GA DF2CW
UT WOS:000371148700022
PM 25865819
ER
PT J
AU Heath, B
Bernhardt, J
Michalski, TJ
Crnich, CJ
Moehring, R
Schmader, KE
Olds, D
Higgins, PA
Jump, RLP
AF Heath, Barbara
Bernhardt, Jaime
Michalski, Thomas J.
Crnich, Christopher J.
Moehring, Rebekah
Schmader, Kenneth E.
Olds, Danielle
Higgins, Patricia A.
Jump, Robin L. P.
TI Results of a Veterans Affairs employee education program on
antimicrobial stewardship for older adults
SO AMERICAN JOURNAL OF INFECTION CONTROL
LA English
DT Article
DE Antimicrobial stewardship; Professional education; Nursing home;
Registered nurses; Asymptomatic bacteriuria; Aged
ID CARE FACILITIES; NURSES
AB We describe a course in the Veterans Affairs (VA) Employee Education System designed to engage nursing staff working in VA long-term care facilities as partners in antimicrobial stewardship. We found that the course addressed an important knowledge gap. Our outcomes suggest opportunities to engage nursing staff in advancing antimicrobial stewardship, particularly in the long-term care setting. Published by Elsevier Inc. on behalf of the Association for Professionals in Infection Control and Epidemiology, Inc.
C1 [Heath, Barbara; Higgins, Patricia A.; Jump, Robin L. P.] Geriatr Res Educ & Clin Ctr, Cleveland, OH USA.
[Bernhardt, Jaime; Michalski, Thomas J.] Louis Stokes Cleveland Vet Affairs Med Ctr, Employee Educ Syst, Cleveland, OH USA.
[Crnich, Christopher J.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA.
[Crnich, Christopher J.] Univ Wisconsin, Madison, WI USA.
[Moehring, Rebekah; Schmader, Kenneth E.] Durham Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Durham, NC USA.
[Moehring, Rebekah; Schmader, Kenneth E.] Duke Univ, Durham, NC USA.
[Olds, Danielle] Louis Stokes Cleveland Vet Affairs Med Ctr, Qual Scholars Program, Cleveland, OH USA.
[Higgins, Patricia A.] Case Western Reserve Univ, Frances Payne Bolton Sch Nursing, Cleveland, OH 44106 USA.
[Jump, Robin L. P.] Case Western Reserve Univ, Dept Med, Div Infect Dis & HIV Med, Cleveland, OH 44106 USA.
[Jump, Robin L. P.] Louis Stokes Cleveland Vet Affairs Med Ctr, Div Med, Infect Dis Sect, Cleveland, OH USA.
RP Jump, RLP (reprint author), Louis Stokes Cleveland VA Med Ctr, GRECC 111C W,10701 East Blvd, Cleveland, OH 44106 USA.
EM robin.jump@va.gov
FU AHRQ HHS [K08 HS023866]
NR 10
TC 1
Z9 1
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-6553
EI 1527-3296
J9 AM J INFECT CONTROL
JI Am. J. Infect. Control
PD MAR 1
PY 2016
VL 44
IS 3
BP 349
EP 351
DI 10.1016/j.ajic.2015.09.026
PG 3
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA DF4CS
UT WOS:000371295500024
PM 26553404
ER
PT J
AU Safdar, N
Codispoti, N
Purvis, S
Knobloch, MJ
AF Safdar, Nasia
Codispoti, Nicolette
Purvis, Suzanne
Knobloch, Mary Jo
TI Patient perspectives on indwelling urinary catheter use in the hospital
SO AMERICAN JOURNAL OF INFECTION CONTROL
LA English
DT Article
DE Patient perspectives; Catheter-associated urinary tract infections
ID TRACT-INFECTIONS
AB Urinary tract infections are one of the most common hospital-acquired infections, with 70%-80% resulting from catheter-associated urinary tract infections (CAUTIs). We undertook a qualitative study to assess patient perspectives of indwelling urinary catheters using a semistructured interview. We found that patient awareness and patient engagement regarding indwelling urinary catheters and their consequences could be improved in the hospital setting. Implementing educational programs incorporating patient preferences for both health care workers and patients is likely to increase the involvement of patients in decision-making regarding urinary catheters and may lead to a decline in CAUTIs. Published by Elsevier Inc. on behalf of Association for Professionals in Infection Control and Epidemiology, Inc.
C1 [Safdar, Nasia; Knobloch, Mary Jo] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
[Safdar, Nasia] Univ Wisconsin, Sch Med & Publ Hlth, Infect Dis, Dept Med, Madison, WI USA.
[Codispoti, Nicolette] Univ Wisconsin, Madison, WI USA.
[Purvis, Suzanne] Univ Wisconsin Hosp & Clin, Geriatr, Madison, WI 53792 USA.
RP Safdar, N (reprint author), MFCB 5221,1685 Highland Ave, Madison, WI 53705 USA.
EM ns2@medicine.wisc.edu
OI Purvis, Suzanne/0000-0001-5977-5984
FU Agency for Healthcare Research and Quality [R03HS023791]
FX Supported by the Agency for Healthcare Research and Quality (grant no.
R03HS023791).
NR 11
TC 2
Z9 2
U1 1
U2 5
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-6553
EI 1527-3296
J9 AM J INFECT CONTROL
JI Am. J. Infect. Control
PD MAR 1
PY 2016
VL 44
IS 3
BP E23
EP E24
DI 10.1016/j.ajic.2015.10.011
PG 2
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA DF4CS
UT WOS:000371295500003
PM 26698670
ER
PT J
AU Nair, BG
Horibe, M
Neradilek, MB
Newman, SF
Peterson, GN
AF Nair, Bala G.
Horibe, Mayumi
Neradilek, Moni B.
Newman, Shu-Fang
Peterson, Gene N.
TI The Effect of Intraoperative Blood Glucose Management on Postoperative
Blood Glucose Levels in Noncardiac Surgery Patients
SO ANESTHESIA AND ANALGESIA
LA English
DT Article
ID INDEPENDENT RISK-FACTOR; VASCULAR-SURGERY; PERIOPERATIVE PERIOD;
COLORECTAL SURGERY; INSULIN INFUSION; GLYCEMIC CONTROL; CARDIAC-SURGERY;
SITE INFECTION; HYPERGLYCEMIA; OUTCOMES
AB BACKGROUND:
Postoperative hyperglycemia has been associated with poor surgical outcome. The effect of intraoperative glucose management on postoperative glucose levels and the optimal glycemic threshold for initiating insulin are currently unknown.
METHODS:
We performed a retrospective cohort study of surgery patients who required intraoperative glucose management with data extracted from electronic medical records. In patients who required glucose management, intraoperative glucose levels and insulin therapy were compared against postoperative glucose levels during 3 periods: first postoperative level within 1 hour, within the first 12 hours, and 24 hours of the postoperative period. Logistic regression models that adjusted for patient and surgical factors were used to determine the association between intraoperative glucose management and postoperative glucose levels.
RESULTS:
In 2440 patients who required intraoperative glucose management, an increase in mean intraoperative glucose level by 10 mg/dL was associated with an increase in postoperative glucose levels by 4.7 mg/dL (confidence interval [CI], 4.1-5.3; P < 0.001) for the first postoperative glucose measurement, 2.6 mg/dL (CI, 2.1-3.1; P < 0.001) for the mean first 12-hour postoperative glucose, and 2.4 mg/dL (CI, 2.0-2.9; P < 0.001) for the mean first 24-hour postoperative glucose levels (univariate analysis). Multivariate analysis showed that these effects depended on (interacted with) body mass index and diabetes status of the patient. Both diabetes status (regression coefficient = 12.2; P < 0.001) and intraoperative steroid use (regression coefficient = 10.2; P < 0.001) had a positive effect on elevated postoperative glucose levels. Intraoperative hyperglycemia (> 180 mg/dL) was associated with postoperative hyperglycemia during the first 12 hours and the first 24 hours. However, interaction with procedure duration meant that this association was stronger for shorter surgeries. When compared with starting insulin for an intraoperative glucose threshold of 140 mg/dL thus avoiding hyperglycemia, initiation of insulin for a hyperglycemia threshold of 180 mg/dL was associated with an increase in postoperative glucose level (7 mg/dL; P < 0.001) and postoperative hyperglycemia incidence (odds ratio = 1.53; P = 0.01).
CONCLUSIONS:
A higher intraoperative glucose level is associated with a higher postoperative glucose level. Intraoperative hyperglycemia increases the odds for postoperative hyperglycemia. Adequate intraoperative glucose management by initiating insulin infusion when glucose level exceeds 140 mg/dL to prevent hyperglycemia is associated with lower postoperative glucose levels and fewer incidences of postoperative hyperglycemia. However, patient- and procedure-specific variable interactions make the relationship between intraoperative and postoperative glucose levels complicated.
C1 [Nair, Bala G.; Newman, Shu-Fang; Peterson, Gene N.] Univ Washington, Dept Anesthesiol & Pain Med, BB 1469 Hlth Sci Bldg,Mail Box 356540, Seattle, WA 98195 USA.
[Horibe, Mayumi] VA Puget Sound Hlth Care Syst, Dept Anesthesiol, Seattle, WA USA.
[Neradilek, Moni B.] Mt Whisper Light Stat LLC, Seattle, WA USA.
[Peterson, Gene N.] Virginia Commonwealth Univ, Dept Anesthesiol, Richmond, VA USA.
RP Nair, BG (reprint author), Univ Washington, Dept Anesthesiol & Pain Med, BB 1469 Hlth Sci Bldg,Mail Box 356540, Seattle, WA 98195 USA.
EM nairbg@uw.edu
FU Patient Safety Innovation Program Grant by the University of Washington
FX This research was partly supported by a Patient Safety Innovation
Program Grant provided by the University of Washington.
NR 25
TC 1
Z9 1
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD MAR
PY 2016
VL 122
IS 3
BP 893
EP 902
DI 10.1213/ANE.0000000000001100
PG 10
WC Anesthesiology
SC Anesthesiology
GA DE2FL
UT WOS:000370441900010
PM 26599793
ER
PT J
AU Grubaugh, AL
Clapp, JD
Frueh, BC
Tuerk, PW
Knapp, RG
Egede, LE
AF Grubaugh, Anouk L.
Clapp, Joshua D.
Frueh, B. Christopher
Tuerk, Peter W.
Knapp, Rebecca G.
Egede, Leonard E.
TI Open trial of exposure therapy for PTSD among patients with severe and
persistent mental illness
SO BEHAVIOUR RESEARCH AND THERAPY
LA English
DT Article
DE Severe mental illness (SMI); Posttraumatic stress disorder (PTSD);
Trauma; Exposure therapy; Prolonged exposure
ID POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-BEHAVIORAL TREATMENT;
QUALITY-OF-LIFE; SCHIZOAFFECTIVE DISORDER; PSYCHOMETRIC PROPERTIES;
DSM-IV; SCHIZOPHRENIA; TRAUMA; VETERANS; ADULTS
AB Objective: There are few empirical data regarding effective treatment of trauma-related symptoms among individuals with severe mental illness (SMI; e.g., bipolar disorder, schizophrenia). This under examined clinical issue is significant because rates of trauma and PTSD are higher among individuals with SMI relative to the general population, and there are sufficient data to suggest that PTSD symptoms exacerbate the overall course and prognosis of SMI.
Method: 34 veterans with SMI received prolonged exposure (PE) for PTSD using an open trial study design.
Results: Data suggest that PE is feasible to implement, well-tolerated, and results in clinically significant decreases in PTSD severity in patients with SMI. Mean CAPS scores improved 27.2 points from baseline to immediate post [95% CI for mean change: -44.3, - 10.1; p = 0.002, paired t-test, and treatment gains were maintained at 6 months [mean change from baseline to 6-months, W-16.1; 95% CI: -31.0, -1.2; p = 0.034, paired t-test].
Conclusions: The current data support the use of exposure-based interventions for PTSD among individuals with SMI and highlight the need for rigorous randomized efficacy trials investigating frontline PTSD interventions in this patient population. (C) 2015 Published by Elsevier Ltd.
C1 [Grubaugh, Anouk L.; Tuerk, Peter W.] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, 109 Bee St, Charleston, SC 29401 USA.
[Grubaugh, Anouk L.; Tuerk, Peter W.] Med Univ S Carolina, Dept Psychiat & Behav Sci, 109 Bee St, Charleston, SC 29401 USA.
[Clapp, Joshua D.] Univ Wyoming, Dept Psychol, 1000 E Univ Ave, Laramie, WY 82071 USA.
[Frueh, B. Christopher] Menninger Clin, Houston, TX USA.
[Frueh, B. Christopher] Univ Hawaii, Dept Psychol, 200 W Kawili St, Hilo, HI 96720 USA.
[Knapp, Rebecca G.] Med Univ S Carolina, Dept Publ Hlth Sci, 135 Cannon St, Charleston, SC 29403 USA.
[Egede, Leonard E.] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, 135 Rutledge Ave,POB 250593, Charleston, SC 29425 USA.
[Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, 135 Rutledge Ave,POB 250593, Charleston, SC 29425 USA.
RP Grubaugh, AL (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, POB 250861, Charleston, SC 29425 USA.
EM grubaugh@musc.edu
NR 58
TC 1
Z9 1
U1 6
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0005-7967
EI 1873-622X
J9 BEHAV RES THER
JI Behav. Res. Ther.
PD MAR
PY 2016
VL 78
BP 1
EP 12
DI 10.1016/j.brat.2015.12.006
PG 12
WC Psychology, Clinical
SC Psychology
GA DF5DX
UT WOS:000371373100001
PM 26797658
ER
PT J
AU Jordan, TH
Talarico, RH
Schuberth, JM
AF Jordan, Thomas H.
Talarico, Ross H.
Schuberth, John M.
TI Letter Regarding: The Fate of the Fixed Syndesmosis Over Time
SO FOOT & ANKLE INTERNATIONAL
LA English
DT Letter
C1 [Jordan, Thomas H.] Kaiser Permanente Med Grp, Santa Rosa, CA USA.
[Talarico, Ross H.] Podiat Surg Sect, San Francisco, CA USA.
[Talarico, Ross H.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Schuberth, John M.] Kaiser Fdn Hosp, Dept Orthoped Surg, Foot & Ankle Surg, San Francisco, CA USA.
RP Schuberth, JM (reprint author), Kaiser Fdn Hosp, Dept Orthoped Surg, Foot & Ankle Surg, San Francisco, CA USA.
EM jmfoot@aol.com
NR 2
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1071-1007
EI 1944-7876
J9 FOOT ANKLE INT
JI Foot Ankle Int.
PD MAR
PY 2016
VL 37
IS 3
BP 344
EP 344
DI 10.1177/1071100715627352
PG 1
WC Orthopedics
SC Orthopedics
GA DF4JS
UT WOS:000371314500015
PM 26921312
ER
PT J
AU Klingaman, EA
Hoerster, KD
Aakre, JM
Viverito, KM
Medoff, DR
Goldberg, RW
AF Klingaman, Elizabeth A.
Hoerster, Katherine D.
Aakre, Jennifer M.
Viverito, Kristen M.
Medoff, Deborah R.
Goldberg, Richard W.
TI Veterans with PTSD report more weight loss barriers than Veterans with
no mental health disorders
SO GENERAL HOSPITAL PSYCHIATRY
LA English
DT Article
DE Veterans; Post-traumatic stress disorder; Weight management; MOVE
ID POSTTRAUMATIC-STRESS-DISORDER; PHYSICAL-ACTIVITY; SELF-EFFICACY;
BEHAVIORAL ACTIVATION; ANXIETY DISORDERS; MILITARY SERVICE;
HEART-DISEASE; RISK-FACTOR; DEPRESSION; MORTALITY
AB Objective: This study characterized and compared Veterans of the United States Armed Forces with posttraumatic stress disorder ( PTSD) to Veterans with no mental health disorders on self-reported measures of factors that influence success in weight management programs.
Method: We examined the relation of PTSD diagnosis with weight loss plan, reasons for overweight/obesity and barriers to dieting and physical exercise among 171,884 Veterans. Statistically significant variables in chi-square tests (P<.05) with at least a small effect size were then compared via multivariate logistic regression analyses.
Results: Both groups reported high ratings of importance and confidence regarding changing weight loss behaviors and were preparing or actively engaging in efforts to manage their weight. Compared to Veterans without mental health disorders, more Veterans with PTSD endorsed 27 of the 28 barriers to changing eating and physical habits.
Conclusions: The results of this study help to explain the lower rates of success of Veterans with PTSD in weight loss programs. Results suggest that a comprehensive, integrated approach to promoting weight loss in Veterans with PTSD is needed. Published by Elsevier Inc.
C1 [Klingaman, Elizabeth A.; Aakre, Jennifer M.; Medoff, Deborah R.; Goldberg, Richard W.] US Dept Vet Affairs, Capitol Healthcare Network, Mental Illness Res Educ & Clin Ctr, 10 North Greene St,Annex Suite 720, Baltimore, MD 21201 USA.
[Klingaman, Elizabeth A.; Aakre, Jennifer M.; Medoff, Deborah R.; Goldberg, Richard W.] Univ Maryland, Sch Med, Dept Psychiat, 737 West Lombard St, Baltimore, MD 21201 USA.
[Hoerster, Katherine D.] VA Puget Sound Healthcare Syst, Seattle Div, Mental Hlth Serv, 1660 South Columbian Way S-116, Seattle, WA 98108 USA.
[Hoerster, Katherine D.] Univ Washington, Dept Psychiat & Behav Sci, 1959 Northeast Pacific St,Box 356560,Room BB1644, Seattle, WA 98195 USA.
[Viverito, Kristen M.] Cent Arkansas Vet Healthcare Syst, Hlth Serv Res & Dev Serv, Mental Healthcare & Outcomes Res, North Little Rock, AR 72114 USA.
[Viverito, Kristen M.] Univ Arkansas Med Sci, Inst Psychiat Res, Div Hlth Serv Res, 4301 West Markham,554, Little Rock, AR 72205 USA.
RP Klingaman, EA (reprint author), Baltimore VA Med Ctr, VA Maryland Healthcare Syst, 10 North Greene St,Annex Suite 720, Baltimore, MD 21201 USA.
EM elizabeth.klingaman@va.gov; Katherine.hoerster@va.gov;
jennifer.aakre@va.gov; Kristen.viverito@va.gov;
dmedoff@psych.umaryland.edu; richard.goldberg@va.gov
FU Department of Veterans Affairs (VA) Office of Academic Affiliations
Advanced Fellowship Program in Mental Illness Research and Treatment; VA
Health Services Research and Development Fellowship; VA Career
Development Award (HSRD) [CDA 12-263]; VA Capitol Healthcare Network
Mental Illness Research, Education and Clinical Center; Central Arkansas
Veterans Healthcare System Center for Mental Healthcare and Outcomes
Research
FX This research is supported by the Department of Veterans Affairs (VA)
Office of Academic Affiliations Advanced Fellowship Program in Mental
Illness Research and Treatment and the VA Health Services Research and
Development Fellowship. Dr. Hoerster is supported by VA Career
Development Award (HSR&D CDA 12-263). It is the result of work supported
with resources and the use of facilities at the VA Capitol Healthcare
Network Mental Illness Research, Education and Clinical Center and the
Central Arkansas Veterans Healthcare System Center for Mental Healthcare
and Outcomes Research. Special thanks to Susan Raffa, Ken Jones and Tony
Rogers for their contributions to this manuscript.
NR 51
TC 4
Z9 4
U1 2
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0163-8343
EI 1873-7714
J9 GEN HOSP PSYCHIAT
JI Gen. Hosp. Psych.
PD MAR-APR
PY 2016
VL 39
BP 1
EP 7
DI 10.1016/j.genhosppsych.2015.11.003
PG 7
WC Psychiatry
SC Psychiatry
GA DF3KY
UT WOS:000371244000001
PM 26719103
ER
PT J
AU Swenson, ER
AF Swenson, Erik R.
TI Reply to Drs. Teppema and Berendsen
SO JOURNAL OF APPLIED PHYSIOLOGY
LA English
DT Letter
ID CARBONIC-ANHYDRASE INHIBITION; VENTILATORY RESPONSES; AMMONIUM-CHLORIDE;
ACETAZOLAMIDE; HYPOXIA; HUMANS; ACIDOSIS
C1 [Swenson, Erik R.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
RP Swenson, ER (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
EM erik.swenson@va.gov
NR 10
TC 0
Z9 0
U1 2
U2 2
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 8750-7587
EI 1522-1601
J9 J APPL PHYSIOL
JI J. Appl. Physiol.
PD MAR 1
PY 2016
VL 120
IS 5
BP 565
EP 565
DI 10.1152/japplphysiol.00872.2015
PG 1
WC Physiology; Sport Sciences
SC Physiology; Sport Sciences
GA DF6CN
UT WOS:000371442900011
PM 26933003
ER
PT J
AU Urayama, A
Grubb, JH
Sly, WS
Banks, WA
AF Urayama, Akihiko
Grubb, Jeffrey H.
Sly, William S.
Banks, William A.
TI Pharmacologic manipulation of lysosomal enzyme transport across the
blood-brain barrier
SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
LA English
DT Article
DE Blood-brain barrier; beta-glucuronidase; enzyme replacement therapy;
brain uptake; mannose 6-phosphate receptor
ID MANNOSE 6-PHOSPHATE RECEPTOR; MUCOPOLYSACCHARIDOSIS TYPE-VII;
ALPHA-MANNOSIDOSIS MICE; REPLACEMENT-THERAPY; MEDIATED TRANSPORT;
BETA-GLUCURONIDASE; MOUSE MODEL; LIGAND INTERACTIONS; INSULIN TRANSPORT;
PERMEABILITY
AB The adult blood-brain barrier, unlike the neonatal blood-brain barrier, does not transport lysosomal enzymes into brain, making enzyme replacement therapy ineffective in treating the central nervous system symptoms of lysosomal storage diseases. However, enzyme transport can be re-induced with alpha-adrenergics. Here, we examined agents that are known to alter the blood-brain barrier transport of large molecules or to induce lysosomal enzyme transport across the blood-brain barrier ((+/-)epinephrine, insulin, retinoic acid, and lipopolysaccharide) in 2-week-old and adult mice. In 2-week-old adolescent mice, all these pharmacologic agents increased brain and heart uptake of phosphorylated human beta-glucuronidase. In 8-week-old adult mice, manipulations with (+/-)epinephrine, insulin, and retinoic acid were significantly effective on uptake by brain and heart. The increased uptake of phosphorylated human b-glucuronidase was inhibited by mannose 6-phosphate for the agents (+/-)epinephrine and retinoic acid and by L-NG-nitroarginine methyl ester for the agent lipopolysaccharide in neonatal and adult mice. An in situ brain perfusion study revealed that retinoic acid directly modulated the transport of phosphorylated human beta-glucuronidase across the blood-brain barrier. The present study indicates that there are multiple opportunities to at least transiently induce phosphorylated human beta-glucuronidase transport at the adult blood-brain barrier.
C1 [Urayama, Akihiko] Univ Texas Med Sch Houston, Dept Neurol, Houston, TX USA.
[Grubb, Jeffrey H.] Ultragenyx Pharmaceut Inc, Lysosomal Res, Novato, CA USA.
[Grubb, Jeffrey H.; Sly, William S.] St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO USA.
[Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
[Banks, William A.] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA.
RP Urayama, A (reprint author), Univ Texas Med Sch Houston, Dept Neurol, Houston, TX USA.
EM Akihiko.Urayama@uth.tmc.edu
FU Sanfilippo Syndrome Medical Research Foundation; Veterans Affairs Merit
Review; National Institutes of Health [NS050547, AG029839]; National
Institutes of Health Grant [GM34182]
FX The author(s) disclosed receipt of the following financial support for
the research, authorship, and/or publication of this article: This study
was supported by The Sanfilippo Syndrome Medical Research Foundation
(WAB and WSS), Veterans Affairs Merit Review (WAB), National Institutes
of Health Grants NS050547 and AG029839 (to WAB), and National Institutes
of Health Grant GM34182 (to WSS).
NR 40
TC 1
Z9 1
U1 1
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0271-678X
EI 1559-7016
J9 J CEREBR BLOOD F MET
JI J. Cereb. Blood Flow Metab.
PD MAR
PY 2016
VL 36
IS 3
BP 476
EP 486
DI 10.1177/0271678X15614589
PG 11
WC Endocrinology & Metabolism; Hematology; Neurosciences
SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology
GA DF4ER
UT WOS:000371301100004
PM 26661222
ER
PT J
AU Winchester, RJ
Williams, JS
Wolfman, TE
Egede, LE
AF Winchester, Rhonda J.
Williams, Joni S.
Wolfman, Tamara E.
Egede, Leonard E.
TI Depressive symptoms, serious psychological distress, diabetes distress
and cardiovascular risk factor control in patients with type 2 diabetes
SO JOURNAL OF DIABETES AND ITS COMPLICATIONS
LA English
DT Article
DE Diabetes; Diabetes distress; Depressive symptoms; Serious psychological
distress; Cardiovascular disease risk factor
ID CLINICAL DEPRESSION; GENERAL-POPULATION; GLYCEMIC CONTROL; SCREENING
SCALE; MENTAL-ILLNESS; MORTALITY; HEALTH; ADULTS; K6
AB Objective: This study examined the association between cardiovascular disease (CVD) risk factor control and elevated depressive symptoms (EDS), serious psychological distress (SPD), and diabetes distress (DD) in patients with type 2 diabetes (T2DM).
Methods: This was a cross-sectional study of adults seen at an academic medical center and Veterans Affairs Medical Center in the southeastern US. Linear regression models were computed using CVD risk factors as clinically meaningful outcomes (glycosylated hemoglobin A1c (HbA1c); systolic (SBP) and diastolic (DBP) blood pressure; and low-density lipoprotein cholesterol (LDL-C)); EDS, SPD, and DD were primary independent variables. Covariates included sociodemographics and comorbidities.
Results: The sample consisted of 361 adults. Correlation analyses showed significant relationships between DD and HbA1c, DBP, and LDL-C. Adjusted linear regression models showed DD to be significantly associated with HbA1c and LDL-C, and SPD to be significantly associated only with LDL-C. In the fully adjusted model, DD remained significantly associated with HbA1c ((beta = 4349; 95% CI (-0.649, 2.222)).
Conclusions: In this sample of adults with T2DM, DD and SPD were significantly associated with CVD risk factors; however, after controlling for covariates, only DD was shown to be significantly associated with poor glycemic control.
Practice implications: Strategies are warranted to examine the relationship between DD and CVD risk factor control in patients with T2DM. Published by Elsevier Inc.
C1 [Winchester, Rhonda J.; Williams, Joni S.; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,POB 250593, Charleston, SC 29425 USA.
[Williams, Joni S.; Wolfman, Tamara E.; Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Dept Med, 96 Jonathan Lucas St,Suite 803,MSC 623, Charleston, SC 29425 USA.
[Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Hlth Equ & Rural Outreach Innovat Ctr, 109 Beet St, Charleston, SC 29401 USA.
RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, Hlth Equ & Rural Outreach Innovat Ctr, 135 Rutledge Ave,Room 280G,POB 250593, Charleston, SC 29425 USA.
EM runwithjane@gmail.com; stromjl@musc.edu; wolfmant@musc.edu;
egedel@musc.edu
FU National Institute of Diabetes and Digestive and Kidney Disease
[K24DK093699]
FX Funding Source: This study was supported by Grant K24DK093699 from The
National Institute of Diabetes and Digestive and Kidney Disease (PI:
Leonard Egede). The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
NR 30
TC 0
Z9 0
U1 9
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1056-8727
EI 1873-460X
J9 J DIABETES COMPLICAT
JI J. Diabetes Complications
PD MAR
PY 2016
VL 30
IS 2
BP 312
EP 317
DI 10.1016/j.jdiacomp.2015.11.010
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DF2SW
UT WOS:000371195100022
PM 26657725
ER
EF